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Abstracts
1 | What Does Replicable and Robust Non‐
Randomized Database Evidence Look Like?
Shirley Wang1; Jeremy Rassen2; Simone Pinheiro3; Jesse Berlin4;
Sebastian Schneeweiss1
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
2Aetion, Inc, New York, NY; 3US Food and Drug Administration, Silver
Springs, MD; 4Johnson & Johnson, Philadelphia, PA
Background: ‘Real world’ data analyses (non‐randomized administra-
tive and clinical healthcare databases) have become a vital tool, provid-
ing key insights for regulators, payers, and other healthcare decision
makers. However, the credibility of database analyses suffers when 1)
the results are not reproducible, 2) conflict with results from other data-
base studies addressing the same question or 3) diverge from random-
ized clinical trial (RCT) results. Conducting causal inference in
database studies can be complex. Implementation of a database study
can involve a great deal of data manipulation to create appropriately
temporally anchored analytic cohorts from data that were not collected
for research purposes. The many subtle design and analysis decisions
made during study implementation, have left some stakeholders con-
cerned about selective reporting of study specifications that arrive at
a favorable result. Healthcare decision‐makers have emphasized the
need greater transparency in research that make secondary use of data-
bases. The REPEAT Initiative has embarked on several projects aimed at
improving transparency, reproducibility and validity of database
research. These projects include large scale replication of 150 published
database studies, evaluation of the robustness of results for 50 studies
to alternative design and implementation parameters, and development
of a structured reporting template with design visualization to increase
transparency of reporting and minimize misinterpretation.
Objectives: This symposium will ask the following questions: What
does replicable and robust database evidence look like and how can
we achieve it? Will structured reporting with design visualization help?
How can we clearly communicate design and analytic choices, as well
as results, when there are numerous sensitivity analyses? How do we
interpret results from different database studies or sensitivity analyses
that address the same PICOTS (Patients, Intervention, Comparator,
Outcome, Time Horizon, Setting) but have discordant findings?
Description: The symposium panel agenda will include: 1. Presenta-
tion of empirical results from replication of 150 published database
studies (Wang 25 min) 2. Structured reporting of design details with
visualization (Rassen 15 min) 3. FDA perspective (Pinheiro 10 min) 4.
Industry perspective (Berlin 10 min) 5. Moderator and audience ques-
tions (Schneeweiss) (20 min).
2 | How Do We Assess When Electronic
Health Records or ClaimsDatabases Are Fit for
a Specific Research or Regulatory Purpose?
Cynthia J. Girman1; Mary E. Ritchey2; David Martin3; Wei J. Zhou4;
Nancy J. Dreyer5
1CERobs Consulting, LLC, Chapel Hill, NC; 2RTI Health Solutions,
Durham, NC; 3Food & Drug Administration, Silver Springs, MD; 4Merck &
Co., Inc, North Wales, PA; 5 IQVIA, Cambridge, MA
Background: There is escalating interest in the use of real‐world data
(RWD) not only for safety but also for effectiveness evaluation. FDA
released a framework for public comment at the end of 2018 which
focused on randomized trials in clinical practice, potential observational
designs, and data quality aspects for the use of real world evidence
(RWE) in regulatory and clinical contexts. There is no ‘one size fits all’
approachtoqualifyingadatasourceforbroadresearchor regulatorypur-
poses as the feasibility of using RWDdepends on how the results will be
used, the anticipated effect size and the quality of the data for the study
components critical to addressing the specific research question.
Objectives: To review the FDA framework on RWD and provide a new
structured study‐specific context by which to assess the feasibility of
using RWD for a specific research question or regulatory purpose
(new indication or expanded labeling). This should be of interest to all
pharmacoepidemiologists and researchers involved in the design and
conduct of real world studies for potential regulatory or other purposes.
Description: Accuracy and reliability of data (including extent of miss-
ing data) to define specific components of the research question, such
as the population, intervention, comparator, and outcome), fundamen-
tally drive whether RWD in electronic health record or claims data-
bases can be useful for a specific envisioned study. The adequacy of
ascertainment of these components along with sample size and antic-
ipated treatment effect size leads to a practical structured approach
for assessing utility of RWD in the context of the specific research
question. Discussion will consider the perspective of the use of
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RWD for regulatory labeling or new indications, as well as for other
research purposes.
Dr. Zhou will introduce the concepts of data quality, relevance and
validation based on the FDA Framework followed by Dr. Ritchey pre-
senting a new practical approach to assess RWD feasibility in the con-
text of the specific research question. Dr. Martin and Dr. Girman will
review the utility of this study‐specific contextual approach for
assessing feasibility of RWD for fit‐for‐regulatory purposes and for
general research studies, respectively. A 20‐minute discussion led by
Dr. Dreyer, involving audience participation with the speaker panel,
will conclude the session.
3 | When Artificial Intelligence Meets
Pharmacoepidemiology
Dorothee B. Bartels1; Jim Slattery2; Antoine Pariente3; John Rigg4
1BI X GmbH, Ingelheim, Germany; 2EMA, Amsterdam, Netherlands;
3Univ Bordeaux Centre Régional de Pharmacovigilance de Bordeaux,
Bordeaux, France; 4 IQVIA, Ingelheim, United Kingdom
Background: The rapidly growing use of Artificial Intelligence (AI), in
particular machine learning (ML) across both research and clinical set-
tings is challenging epidemiologists' traditional choice of methods and
indeed their very role with many epidemiologists unsure of the impli-
cations of AI for their profession. AI is increasingly being used to con-
tribute to both, traditional and emerging epidemiological areas:
traditional areas include, for instance, identification of risk factors
and quantification of treatment effects. New areas stem from the
increasing adoption of analytics‐enabled technologies in clinical prac-
tice. While AI has already brought genuine innovation, most notably
in the ability to accurately predict clinical events in data which is com-
plex and often high dimensional, it could be argued that its greatest
potential for novel insights lies in the ability to meaningfully link data
in a world that is becoming increasingly digitized. However, all is not
rosy. There are instances where AI algorithms have shown clear biases
and inaccuracies, e.g. ML based real world analytics have been biased
because of the lack of using inception cohorts and a clear time zero or
conditioning on outcomes (Avati et al. 2018).
Objectives: The symposium will cover industry, research, regulatory
and educational perspectives for various stakeholders around what is
required to maximize the potential utility and impact of applying AI
in pharmacoepidemiological research.
Description: The symposium will describe current AI approaches,
including ML and neural networks, and provide examples where AI
has brought clear added value. It will highlight uncertainties inherent
in the approach and propose solutions as to how these might be man-
aged. From a regulatory perspective if AI outputs are to find accept-
ability, a clear framework defining best practice is required. The
session will discuss what such a framework could incorporate and in
particular how pharmacoepidemiology can bring critical rigor to ana-
lytics supported by AI, e.g. advice on suitable study designs, the defi-
nition of metrics for assessing the quality and appropriateness of
data sources, providing principles for transparency of reporting espe-
cially over time in the context of learning algorithms, and creating clear
pathways for validation. From a research and education perspective,
the session will discuss on the implications of the potential integration
of AI in the pharmacoepi toolbox in terms of teaching/learning for
trainees and professionals.
4 | Pregnancy Registries and Pregnancy
Outcome Studies in Healthcare Databases:
Trends and Complementary Research
Approaches.
Steve Gao1; Krista Huybrechts2; Leyla Sahin3; John Seeger2;
Daina Esposito4; Christina D. Chambers5
1Regeneron Pharmaceuticals Inc., Tarrytown, NY; 2Havard University,
Boston, MA; 3Food and Drug Administration, Silver Spring, MD; 4Boston
University, Boston, MA; 5University of California, San Diego, CA
Background: National drug regulatory authorities, such as the FDA,
may require manufacturers to evaluate the risk of adverse pregnancy
and infant outcomes associated with a new drug in the real‐world set-
ting as part of the post marketing requirements (PMRs) of a drug
approval. Recently, some pregnancy outcome studies have required
prolonged follow up for infant outcomes (e.g., through the first five
years of life) and some PMRs have included both a prospective preg-
nancy registry and retrospective database‐based study.
Objectives: The symposium objectives are (1) to discuss trends in
safety requirements for the real‐world and long‐term data of safety
in pregnancy and infant outcomes from industry, academia, regulators,
and researchers poised to carry out these types of studies and (2) to
provide an overview of methodologies in pregnancy registry studies,
multi‐database studies, and using the common data model to carry
out these PMRs.
Description: The proposed symposium will offer a variety of perspec-
tives on the pregnancy registries and database studies to obtain ade-
quate post‐marketing safety information in drugs used during
pregnancy. The regulatory, industry, and academic perspectives will
be presented. Case examples of pregnancy studies and related PMRs
will be shared to illustrate regulatory trends, challenges that the phar-
maceutical industry may face, and knowledge and experience that can
help in the planning and design of future post‐marketing require-
ments. The perspectives shared from the case examples from different
research organizations will provide the audience an overview of the
PMRs with in‐depth discussion of methodology, the pros and cons,
and how the different approaches complement each other for a more
thoughtful consideration of the scientific designs to better understand
safety in pregnancy. Audience participation in the discussion is
encouraged. Krista Huybrechts and Steve Gao will serve as the moder-
ators of the symposium. The agenda will include: 1) introduction of the
topic (Krista Huybrechts, Harvard Medical School); 2) regulatory per-
spective on post‐approval safety studies in pregnant women (Leyla
Sahin, FDA); 3) a database perspective on post‐approval safety studies
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in pregnant women (John Seeger, Optum/Harvard or Daina Esposito,
Boston University/Ciconia); (4) navigating a multi‐database environ-
ment in pregnancy studies (Daina Esposito or John Seeger); 5) registry
vs database: when is one plus one more than two (Christina Chambers,
University of California, San Diego); 6) audience participation and
Q&A; 7) closing comments (Steve Gao, Regeneron).
5 | Drugs and Germs: Dirty Details about
Pharmacoepidemiology and the Microbiome
Daniel B. Horton1; Peter J. Turnbaugh2; Scott E. Plevy3;
Soko Setoguchi1; Tobias Gerhard1; James D. Lewis4
1Rutgers University, New Brunswick, NJ; 2University of California San
Francisco, San Francisco, CA; 3 Janseen, Spring House, PA; 4University of
Pennsylvania, Philadelphia, PA
Background: The human microbiome is inhabited by trillions of micro-
organisms (microbiota such as bacteria, fungi, and viruses) that perform
a variety of critical homeostatic functions, including production of
energy, vitamins, and neurotransmitters, and immune regulation. Nota-
bly, gut microbiota possess enzymes that influence drug effects by, for
example, regulating pharmacokinetics (e.g., digoxin) and producing
toxic metabolites (e.g., NSAIDs). Furthermore, drugs such as antibiotics
can alter microbiota in ways that may affect downstream process,
including pharmacodynamic profiles (e.g., PD‐1 inhibitors) or predispo-
sition to certain diseases (e.g., childhood obesity). Microbiota may
explain heterogeneity of treatment effects not explained by
pharmacogenomic or other factors. Additionally, microbiota may be
used to treat certain diseases (e.g., fecal microbiota transplantation
for recurrent Clostridium difficile colitis). Better understanding about
the roles and functions of microbiota in diseases and their effects on
drugs may ultimately lead to novel, safer, more effective, personalized
strategies for disease treatment and prevention.
Objectives: To educate attendees about (1) the basic ecology, func-
tion, and regulators of the microbiome, (2) the role of the microbiome
in drug pharmacokinetics and pharmacodynamics, (3) approaches for
studying drugs that affect or are affected by the microbiome, and (4)
the development and monitoring of microbiome‐based therapies such
as fecal microbiota transplantation. This symposium is geared towards
trainees, researchers, and members of industry and regulatory bodies
interested in better understanding or performing microbiome‐related
pharmacoepidemiologic research.
Description: This symposium will feature speakers from academia and
industry with experience in basic science, translational, and
pharmacoepidemiologic research involving the microbiome, drugs, and
short‐ and long‐term outcomes. Following the talks will be a 25‐minute
panel discussion addressing questions from the audience and future
directions.
Speakers:Horton ‐ Introduction on the microbiome (5 minutes).
Turnbaugh ‐ A primer on pharmacomicrobiomics and how the
microbiome mediates therapeutic variability (20 minutes). Horton ‐
Methodologic considerations for pharmacoepidemiologic studies of
microbiome‐related drugs (10 minutes). Plevy ‐ Strategies and chal-
lenges to developing live biotherapeutic products (15 minutes). Lewis
‐ Monitoring the safety of live biotherapeutic products (15 minutes).
6 | Scientific Evidence Supporting Benefits
of Novel Therapeutic Agents Approved by
the US Food and Drug Administration, 2015–
2017
James Heyward1; G. Caleb Alexander1,2; Thomas J. Moore3,4
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Johns Hopkins Medicine, Baltimore, MD; 3 Institute for Safe Medication
Practices, Alexandria, VA; 4George Washington University Milken
Institute of Public Health, Washington, DC
Background: The US Food and Drug Administration (FDA) exercises
flexibility in the requirement that new drugs provide substantial evi-
dence of benefit under the Food, Drug and Cosmetic Act. Provisions
in law and policy provide numerous exceptions to the historical scien-
tific standard of 2 or more controlled clinical trials demonstrating sta-
tistically significant evidence of benefit.
Objectives: To examine implementation of the FDA requirement for
“substantial evidence” of benefit among a large group of recently
approved new molecular entities (NMEs).
Methods: We used FDA annual drug approval reports to derive a list
of approved NMEs between 2015 and 2017 and their approval path-
ways (e.g. breakthrough, accelerated approval). Trial data were
obtained from FDA documents at drugs@fda, the clinicaltrials.gov
web site, and the peer reviewed literature. The scientific standards
of interest were: (1) reproducible results—defined as 2 or more clinical
trials providing evidence of benefit; (2) randomized design‐a trial with
patients randomized to treatment, active drug or placebo comparison
groups; (3) clinical scale or benefit‐a measurable effect on the patient's
health rather than a biomarker or surrogate endpoint; and (4) 100 or
more patients treated with active drug‐to assess biological variability
and identify adverse effects.
Results: We identified 225 pivotal trials cited as evidence of benefit
for the FDA approval of 101 new therapeutic agents from 2015 to
2017. Expedited pathways and incentives were common. Overall, 36
of 101 products (36%) met all 4 standards, and 3 drugs meet none
of them. We identified 14 drugs (14%) approved on the basis of a sin-
gle, uncontrolled trial, including 5 drugs with fewer than 100 patients
treated. Extent of scientific evidence also varied by therapeutic area:
all 4 standards were met by all the dermatological products (n = 9),
respiratory products (n = 3) and 2 of 3 ophthalmological drugs. Oncol-
ogy drugs (n = 29) varied the most, with 2 agents meeting all 4 stan-
dards but 8 meeting only 1 standard. Drugs approved under the
orphan drug incentive (n = 43) included all 3 drugs meeting none of
the standards and 16 of 20 drugs (80%) without a controlled trial.
Conclusions: FDA approval of new molecular entities now reflects a
body of scientific evidence of benefit that varies from an uncontrolled
trial in a few patients to randomized comparative trials enrolling
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thousands. Without randomized controls, the scientific evidence of
benefit is without protection against conscious or unconscious bias,
atypical patient selection, and unmeasured confounding.
7 | Cost‐Effectiveness of First Line Tyrosine
Kinase Inhibitor Initiation Strategies for
Chronic Myeloid Leukemia
Joehl T. Nguyen1; Ashley L. Cole1,2; Ashley A. Leech3;
William A. Wood4; Stacie B. Dusetzina3,5
1University of North Carolina at Chapel Hill Eshelman School of
Pharmacy, Chapel Hill, NC; 2Cecil G. Sheps Center for Health Services
Research, Chapel Hill, NC; 3Vanderbilt University School of Medicine,
Nashville, TN; 4University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill, NC; 5Vanderbilt‐Ingram Cancer Center, Nashville,
TN
Background: First‐line tyrosine kinase inhibitors (TKI) for chronic mye-
loid leukemia (CML) have demonstrated similar overall survival in clin-
ical trials but differ in treatment costs and adverse event profiles.
Understanding the relative cost‐effectiveness of first‐line TKIs may
help identify the optimal treatment strategy for newly diagnosed adult
patients with CML.
Objectives: To evaluate the one year cost‐effectiveness of TKI initia-
tion strategies for newly diagnosed adult patients with CML from a
US Payer's perspective.
Methods: We constructed a decision analytic model to compare TKI
initiation with imatinib, dasatinib, or nilotinib among a hypothetical
cohort of newly diagnosed patients with CML. We assumed optimal
TKI adherence among patients. Outcomes included quality‐adjusted
life years (QALYs), healthcare costs, net‐monetary benefit, and incre-
mental cost‐effectiveness ratios. We used medical expenditures, TKI
treatment patterns, and safety outcomes observed among patients
with CML identified in the Truven Health MarketScan Commercial
Claims and Medicare Supplemental database to inform model param-
eters. To calculate TKI costs, we used the Federal Supply Schedule
estimates and median observed time on first‐line TKIs. We evaluated
cost‐effectiveness under a willingness to pay threshold of 100,000
USD/QALY. We conducted deterministic and probabilistic sensitivity
analyses using 10,000 Monte Carlo simulations to assess the model's
sensitivity to uncertainty around probability, cost, and utility input
values.
Results: In the base case analysis, imatinib was the favored initiation
strategy and was associated with lower per patient costs compared
to both dasatinib and nilotinib. Imatinib remained the favored strategy
after deterministic variations in branded imatinib uptake, TKI costs
(including assumed rebates for second generationTKIs), TKI switching,
QALYs, adverse event risk, and CML progression to accelerated phase.
Under a 100,000 USD/QALY threshold, imatinib dominated dasatinib
and nilotinib in 63% and 10% of probabilistic simulations, respectively.
With respect to net monetary benefit, imatinib was cost‐effective at a
lower threshold at 90,000 USD/QALY. Dasatinib and nilotinib were
cost‐effective in 50% of simulations at thresholds of approximately
205,000–215,000 USD/QALY.
Conclusions: Imatinib initiation was the favored strategy in this cost‐
effectiveness simulation of newly diagnosed patients with CML.
Generic entry of imatinib may provide additional economically attrac-
tive treatment opportunities for patients with CML.
8 | Healthcare Resource Use and
Expenditures in Patients Newly Diagnosed
with Paroxysmal Supraventricular
Tachycardia in the United States
Naomi C. Sacks1,2; Katie Everson1; Philip L. Cyr1; Madison T. Preib1;
David R. Wood3; Sean D. Pokorney4
1Precision Health Economics, Boston, MA; 2Tufts University School of
Medicine, Boston, MA; 3Milestone Pharmaceuticals, Montreal, QC,
Canada; 4Duke University Medical Center, Durham, NC
Background: Paroxysmal Supraventricular Tachycardia (PSVT) can be
challenging to diagnose, however once diagnosed, PSVT can be
treated medically or with ablation procedures. Little is known about
healthcare resource use (HRU) or costs before and after PSVT
diagnosis.
Objectives: To characterize HRU and costs in the three years before
and after index PSVT diagnosis in patients < age 65.
Methods: Retrospective longitudinal study that used data from the
Truven Health MarketScan® database. Study patients were newly
diagnosed with PSVT (ICD‐9: 427.0; ICD‐10: I47.1) from January 1,
2011 to December 31, 2014 and observable three years before and
after index diagnosis. Propensity matched controls were identified
through the same database. Outcome measures included change in
mean annual per patient HRU and costs paid by insurers pre‐ versus
post‐diagnosis.
Results: Of 13,092 newly diagnosed patients, 62.7% were female sex;
mean age was 47.6 years (SD: 13.67). Mean annual costs per patient
were $7,634 in the third year before index diagnosis (i.e., 36 to
25 months pre‐diagnosis) and rose significantly to $11,212 in the year
immediately preceding index diagnosis (i.e., 12 to 0 months pre‐diag-
nosis; P < 0.0001). In the year following index diagnosis, costs
increased to $22,958 per patient (P < 0.0001). Costs were significantly
lower in each of the next 2 years (13–24 months post index: $11,377;
25–36 months post‐index: $11,607; P < 0.0001) but did not return to
earlier spending levels. Emergency Department (ED) visit rates
increased in the pre‐diagnosis years, from 0.26 per patient, on aver-
age, in the third year before diagnosis, to 0.45 in the year before
and 0.51 in the year after diagnosis. Hospitalization rates also rose,
from 0.09 in the third year pre‐diagnosis to 0.11 in the year before
diagnosis and 0.28 in the year (P < 0.0001). ED visit and hospitaliza-
tion rates were significantly lower in the second and third years after
diagnosis (both years: ED: 0.35; IP: 0.1). PSVT diagnoses accounted for
71% of cost increase in the year after diagnosis ($8,362/$11,746;
71%); cardiac ablations were 41% of this increase ($4,846/$11,746).
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Spending and HRU over the 6‐year observation window were stable
for control patients.
Conclusions: Healthcare costs rise in the year immediately preceding
PSVT diagnosis, consistent with the challenges in PSVT diagnosis.
ED visit and hospitalization rates also increase, suggesting patients
are seeking care for an undiagnosed condition. The increase in HRU
and costs post diagnosis may reflect the high costs of monitoring
and treatment.
9 | The Economic Impact of the Introduction
of Infliximab‐Biosimilar: Preliminary Results
from a Study on Rheumatologic Patients in
Tuscany, Italy
Valentina Lorenzoni1; Leopoldo Trieste1; Marta Mosca2;
Irma Convertino3; Marco Tuccori4,5; Ersilia Lucenteforte3;
Sara Ferraro3; Luca Leonardi3; Giuseppe Roberto6; Nicoletta Luciano2;
Corrado Blandizzi3,5; Rosa Gini6; Giuseppe Turchetti1
1Scuola Superiore Sant'Anna, Pisa, Italy; 2University Hospital of Pisa,
Pisa, Italy; 3University of Pisa, Pisa, Italy; 4University Hospital of Pisa,
Pisa, Italy; 5Tuscan Pharmacovigilance Centre, Pisa, Italy; 6Agenzia
Regionale di Sanità della Toscana, Florence, Italy
Background: The introduction of biosimilars can be a chance to signif-
icantly impact on the sustainability of National Healthcare Systems;
however the real economic impact still needs to be clarified.
Objectives: To assess the economic impact of the use of biosimilar
infliximab (BI) considering rheumatoid arthritis (RA) patients and Tus-
cany (Italy) as case study, benefiting from the “counterfactual” set in
2015 when the Tuscan Health Authority encouraged physicians to
switch patients from originator infliximab (OI) to BI.
Methods: We estimated the economic impact of the introduction of
BI in Tuscan rheumatoid arthritis (RA) patients from the perspective
of the Regional Health System and valuing direct costs related to bio-
logics (infliximab and other treatment), emergency room visits, hospi-
talizations and specialist visits using data from Tuscan healthcare
administrative databases. We performed two analyses on: 1) patients
naïve to infliximab from January 1st, 2012 to December 31st, 2016,
treated with OI before 2015 and with OI or BI after 2015; 2) prevalent
infliximab users from January 1st, 2013 to December 31st, 2013
(before the BI recommendation) and from January 1st, 2015 to
December 31st, 2015 (post the BI recommendation). We evaluated
costs up to 1 year in the first analysis and up to 2 years in the second
one.
Results: The mean annual direct costs related to infliximab (OI or BI)
among naïve patients (n = 214) decreased from 9,823 ± 5,308 Euro
in 2012 to 7,406 ± 4,406 Euro in 2016 (p = 0.025), similarly for the
mean overall direct costs related to the disease management that
decreased of about 4,000 Euro from the first (13,793 ± 6,222 Euro
per patient/year) to the last observation year (9,989 ± 5,729 Euro
per patient/year, p = 0.004). We also observed a decrease of both
direct costs related to infliximab and overall direct costs by comparing
prevalent infliximab RA patients in the pre‐recommendation group
(n = 354) to patients in the post‐recommendation group (n = 334). In
particular, mean costs related to infliximab over 2 years were
15,315 ± 9,843 Euro per patient among those treated with OI and
12,383 ± 9,141 Euro per patient among those treated with either OI
or BI (p < 0.001); similarly, 2 years mean overall direct costs were
20,622 ± 9,712 Euro per patient and 18,414 ± 9,441 Euro per patient,
respectively (p = 0.003).
Conclusions: The introduction of BI produced a reduction of direct
costs for the management of RA patients. This template analysis can
be repeated whenever a new biosimilar drug enters the market. Causal
mechanisms underlying the economic impact warrant further analysis.
10 | Antithrombotic Stewardship
Albert Dreijer1; Marieke J.H.A. Kruip1; Jeroen Diepstraten2;
Suzanne Polinder1; Rolf Brouwer2; Nanne Croles1; Esther Kragten2;
Frank W.G. Leebeek1; Patricia van den Bemt1
1Erasmus University Medical Center, Rotterdam, Netherlands; 2Reinier de
Graaf ziekenhuis, Delft, Netherlands
Background: Although the benefits of antithrombotic drugs are indis-
putable, they carry a high risk for patient safety. Studies on the imple-
mentation and (cost‐) effectiveness of a hospital‐based
multidisciplinary antithrombotic team on bleeding and thrombotic out-
comes are scarce.
Objectives: Main aim is to investigate the effect of implementing a
hospital‐based multidisciplinary antithrombotic team on the efficacy
and safety of antithrombotic therapy during and after hospitalization.
Secondary aims are to determine the effect of the multidisciplinary
team on severity of bleeding, all‐cause mortality and length of
hospitalization.
Methods: Design: Prospective, observational multicenter cohort
study. Setting: Patients admitted to Erasmus University Medical Cen-
ter and Reinier de Graaf Hospital between October 2015 and Decem-
ber 2017, using one or more therapeutically dosed anticoagulants.
Intervention: Implementation of a hospital‐based multidisciplinary
antithrombotic team. Primary outcome: proportion of patients with a
composite end point consisting of ≥1 bleeding or ≥ 1 thrombotic
event from hospitalization until 3 months after hospitalization. Sec-
ondary outcomes: proportion of patients with a major and non‐major
bleeding event, all‐cause mortality and length of hospitalization before
and after implementation of the multidisciplinary antithrombotic team.
Statistical analysis: For analysis of the primary outcome we used seg-
mented regression analysis for the interrupted time series data. For
the secondary outcomes logistic regression analysis was used. T‐Test
analysis was performed for the length of hospitalization.
Results: 941 patients were included in the usual care period and 945
patients in the intervention period. Introduction of the multidisciplin-
ary antithrombotic team led to a significant reduction in the propor-
tion of patients with the primary outcome (−1.83% (95% CI: −2.58%;
−1.08%). Lower all‐cause mortality (odds ratio [OR] 0.71, 95%
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confidence interval [95% CI] 0.53–0.95) was observed after introduc-
tion of the multidisciplinary antithrombotic team. No significant effect
of the intervention was found for the severity of bleeding and mean
length of hospital stay.
Conclusions: Introducing a multidisciplinary antithrombotic team con-
tributes to patient safety.
11 | Privacy versus Public Good: The
Methodological Approach of the Belgian
Healthdata.be Platform to Protect Individual
Privacy in Health Research
Kaatje Bollaerts1; Maria Alexandridou1; Simeon Wanyama2;
Kris Vranken2
1P95 Epidemiology and Pharmacovigilance, Leuven, Belgium; 2Sciensano,
Brussels, Belgium
Background: Healthdata.be was developed by Sciensano, (a federal
public health research institute), to facilitate data exchange between
healthcare professionals, patients and researchers according to the
‘only once’ principle and the re‐use of data to advance public health
science and support health care policy.
Objectives: To develop guidelines and statistical methodology compli-
ant with the European General Data Protection Regulation (GDPR) that
allow accessing data on the Healthdata.be platform for research pur-
poses while protecting the privacy of patients and healthcare profes-
sionals (HCPs).
Methods: A review of existing guidelines and methods on sharing
confidential data was carried out. We then developed a methodol-
ogy to a) assess the risk of identity disclosure, b) assess the impact
of a potential disclosure and c) reduce this risk through the imple-
mentation of disclosure control measures, trading‐off disclosure
risk/impact with the importance of the research. The statistical mea-
sures K‐anonymity and M‐sensitivity were used to assess the disclo-
sure risk and impact, respectively. The ‘data access request (DAR)
and privacy impact assessment (PIA)’ templates were developed,
with the ‘DAR’ to be completed by the researcher requesting data
access and the ‘PIA’ to be completed by an independent impact
assessment assessor. The methodology was piloted with the Belgian
Cystic Fibrosis Register (BCRF) and feedback was solicited from
external experts.
Results: The initial risk of identity disclosure of BCRF patients was
high: 90.7% of the samples violated 2‐anonymity. Using a ‘leave‐
one‐out procedure’ suggested that the highest reductions would be
achieved by reducing details on year of birth, patient's residence,
and anonymizing the treating physician. After applying data transfor-
mation steps, the 2‐anonymity reduced to 3.7% and the M‐sensitiv-
ity was above the critical value of 95% for 5.8% of the patients but
restricted to 5 variables. The external expert committee agreed with
the proposed methodology.
Conclusions: The developed template standardizes the ‘PIA’ and facil-
itates the disclosure risk/impact versus research importance trade‐off
discussion between the researcher and independent assessor. The
methodology is currently routinely implemented.
12 | Infant Infections after Maternal Anti‐
TNF Treatment in Pregnancy
Gabriella Broms1; Helle Kieler1; Anders Ekbom1; Mika Gissler2;
Karin Hellgren1; Maarit K. Leinonen2; Lars Pedersen3;
Marcus Schmitt‐Egenolf4; Henrik Toft Sørensen3; Fredrik Granath1
1Karolinska institutet, Stockholm, Sweden; 2THL National Institute for
Health and Welfare, Helsinki, Finland; 3Aarhus University Hospital,
Aarhus, Denmark; 4Umeå University, Umeå, Sweden
Background: Agents that inhibit tumor necrosis factor (anti‐TNF)
increase the susceptibility to infections and most of them are trans-
ferred across the placenta in late pregnancy. There are limited data
on the rate of infections in infants after maternal exposure.
Objectives: To assess the risk of infant infections in the first three
years of life after maternal anti‐TNF treatment during pregnancy.
Methods: A nation‐wide population‐based study including all births in
Denmark, Finland and Sweden 2006–2013 based on the patient regis-
ters and medical birth registers. We identified women with diseases
for which anti‐TNF treatment is indicated; rheumatoid arthritis, psori-
asis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel
disease. The frequency of hospital admissions for infection and antibi-
otic prescriptions in the first three years of life in infants born to
women treated with anti‐TNF was compared to women of the general
population and to women treated with non‐biologic systemic treat-
ment. Adjustments were made for maternal age, parity, smoking,
BMI, country and calendar year.
Results: Among 1,633,909 births, 1,027 infants were born to women
treated with anti‐TNF and 9,399 to women with non‐biologic sys-
temic treatment. Compared with the general population, women with
anti‐TNF treatment and women with non‐biologic systemic treatment
had a higher rate of first year hospitalization for infection, odds ratio
1.5 (1.3–1.8) and 1.2 (1.1–1.2), respectively. For individual anti‐TNF
agents, the ratio was 1.4 (1.0–2.0) for adalimumab, 1.4 (1.0–1.8) for
etanercept and 1.6 (1.2–2.2) for infliximab. The overall odds ratio
decreased over time and was 0.9 (0.5–1.5) for anti‐TNF treatment in
the third year and 1.0 (0.8–1.1) for non‐biologic systemic treatment.
The result was similar whether treatment was in early pregnancy only,
or also in late pregnancy. For antibiotic use, the odds ratios were 1.1
(1.0–1.3) and 1.1 (1.1–1.2) for year 1, respectively, and similar for year
2 and 3.
Conclusions: Anti‐TNF treatment during pregnancy may increase the
rate of hospital admissions for infection in the first year of life, and
slightly for antibiotic use. However, treatment with anti‐TNF and
non‐biologic systemic treatment were both associated with infant
infections, regardless of treatment timing in pregnancy, implying that
the association does not solely depend on the third trimester trans-
fer of anti‐TNF agents across the placenta and may be influenced by
biases such as surveillance and confounding by indication.
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13 | The Association between Atopic
Eczema and Cancer in England and Denmark:
Two Cohort Studies
Kathryn E. Mansfield1; Sigrún A. Jóhannesdóttir Schmidt2;
Bianka Darvalics2; Amy Mulick1; Katrina Abuabara3; Angel Wong1;
Henrik Toft Sørensen2; Liam Smeeth1; Krishnan Bhaskaran1;
Isabel dos Santos Silva1; Richard J. Silverwood4; Sinéad M. Langan1
1London School of Hygiene and Tropical Medicine, London, United
Kingdom; 2Aarhus University Hospital, Aarhus, Denmark; 3University of
California, San Francisco, CA; 4London School of Hygiene and Tropical
Medicine, London, United Kingdom
Background: The association between eczema and cancer risk is con-
troversial, with two competing theories: immune surveillance (reduced
risk) and immune stimulation (increased risk).
Objectives: To determine if eczema is associated with all‐site cancer
and with specific cancers, and if any increased/reduced risk is depen-
dent on eczema severity.
Methods: We undertook two cohort studies in England (1998–2016)
and Denmark (1982–2016) using data from English primary care prac-
tices contributing to the Clinical Practice Research Datalink and
nationwide Danish registry data. We used stratified Cox regression
to estimate hazard ratios (HR) for the association between eczema
and cancer, to compare risk of new‐onset cancer in those with eczema
(England: ≥18 years; Denmark: no age restriction) to matched (age,
sex, general practice [England only], and calendar period) cohorts of
individuals without eczema. We also explored whether the association
differed by eczema severity.
Results: In England we identified a cohort of 472,065 with eczema
and 2,240,524 without (mean follow up 6 years, SD 5). In Denmark
we identified 44,945 with eczema matched to 445,673 without (mean
follow up 14 years, SD 9).
Lymphoma (excluding cutaneous lymphoma) risk was raised in those
with eczema compared to those without (England: adjusted for calen-
dar period, deprivation, implicitly adjusted for age, sex, cohort‐entry
date, and practice HR 1.22, 99% CI 1.11–1.33; Denmark: implicitly
adjusted for age, sex and cohort‐entry date HR 1.33, 99% CI 0.86–
2.05), with evidence in England (Denmark underpowered) of a dose–
response relationship (HR [99% CI]) compared to those with no
eczema: mild 1.11 [0.95 to 1.16]; moderate 1.28 [1.08 to 1.51]; severe
2.08 [1.46 to 2.98]).
In England we found a small increased all‐site cancer risk in those with
eczema compared to those without (adjusted HR 1.04, 99% CI 1.02–
1.06), which attenuated (HR 1.02, 99% CI 0.99–1.04) upon further
adjustment for potential mediators (harmful alcohol use, smoking,
body mass index). Findings were similar in Denmark.
We found no strong evidence for associations between eczema and
the following site‐specific cancers: prostate, leukemia, multiple mye-
loma, breast, pancreas, central nervous system or melanoma.
Conclusions: Our findings do not support an association between
eczema and risk of most site‐specific cancers. However, there appears
to be an association between eczema and lymphoma that increases
with eczema severity. Further work should explore underlying mecha-
nisms and seek to understand the implications for treating severe
eczema with existing and novel immunosuppressive treatment.
14 | The Association between Partner
Bereavement and Incident Psoriasis or Atopic
Dermatitis: A Matched Cohort Study
Angel Y.S. Wong1; Harriet J. Forbes1; Amy Mulick1;
Kathryn Mansfield1; Richard J. Silverwood1; Henrik T. Sørensen2;
Liam Smeeth1; Sigrún A.J. Schmidt2; Sinéad M. Langan1
1London School of Hygiene and Tropical Medicine, London, United
Kingdom; 2Aarhus University Hospital, Aarhus, Denmark
Background: Psychological stress is commonly reported as an impor-
tant risk factor for psoriasis and atopic dermatitis. However, epidemi-
ological evidence for the relationship is limited by small sample sizes
and difficulty measuring stress.
Objectives: To investigate the association between partner bereave-
ment (an extreme life stressor) and psoriasis or atopic dermatitis.
Methods: We conducted a matched cohort study using routinely col-
lected clinical data from the United Kingdom Clinical Practice
Research Datalink between 01/01/1997 and 31/07/2017. We identi-
fied heterosexual couples using an existing algorithm. Among eligible
couples, we matched up to 10 non‐bereaved people to each bereaved
person on age, sex and general practice. Outcomes were the first diag-
nosis of psoriasis or atopic eczema. We excluded people with a history
of the relevant outcome. We used Cox regression stratified by
matched set to estimate hazard ratios (HR) (complete case analysis),
adjusted for Charlson Comorbidity Index, smoking status, body mass
index, alcohol consumption and socioeconomic status. We further
examined such associations by time since bereavement (0–30 days,
0–90 days, 0–365 days, 0–1095 days).
Results: For psoriasis, we identified 144,873 bereaved people and
1,211,218 without bereavement after excluding people with a history
of psoriasis. For atopic dermatitis, there were 127,477 bereaved and
946,178 non‐bereaved after excluding people with a history of atopic
dermatitis. We found no evidence that bereavement was associated
with psoriasis (HR: 0.97; 95% CI: 0.92–1.03) or atopic dermatitis
(HR: 1.01; 95% CI: 0.98–1.04) during the entire follow‐up. However,
in analyses by time since bereavement, we saw a possible increase in
risk in the first 90 days following bereavement for both psoriasis
(HR: 1.14; 95% CI: 0.91–1.45) and atopic dermatitis (HR: 1.16; 95%
CI: 1.00–1.33). For atopic dermatitis, the increased risk persisted in
the first year (HR in 0–365 days: 1.13; 95% CI: 1.05–1.21) but atten-
uated in the 3 years following bereavement (HR in 0–1095 days: 1.06;
95% CI: 1.01–1.11). We found no evidence of an increased risk of
psoriasis or atopic dermatitis in other periods following bereavement.
Conclusions: We found evidence that partner bereavement might be
associated with a short‐term increased risk of atopic dermatitis and
psoriasis. Understanding psychological stress associated with recent
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psoriasis and atopic dermatitis episodes could inform prevention and
improve clinical care.
15 | Risk of Liver Disease in Patients with
Psoriasis, Psoriatic Arthritis, and Rheumatoid
Arthritis Treated with Methotrexate
Joy Wan1; He Zhang2; Alexis Ogdie3; Alexander Egeberg4;
Joel M. Gelfand1
1University of Pennsylvania Perelman School of Medicine, Philadelphia,
PA; 2Copenhagen University Hospital Gentofte, Gentofte, Denmark;
3University of Pennsylvania Perelman School of Medicine, Philadelphia,
PA; 4Copenhagen University Hospital Gentofte, Gentofte, Denmark
Background: Methotrexate (MTX) is a first‐line treatment for psoriasis
(PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). Serious
liver complications are a concern with chronic MTX use. It has been
suggested that patients with PsO are more susceptible to MTX toxic-
ity than those with RA despite limited direct comparative data.
Objectives: To determine the risk of liver disease in patients with PsO,
PsA, versus RA who received MTX.
Methods: Using national registry data, we performed a longitudinal
cohort study of Danish patients with PsO, PsA, or RA diagnosis during
1/1/1997–12/31/2015 who received a prescription for MTX. Main
outcome measures were mild liver disease, moderate‐to‐severe liver
disease, cirrhosis, and hospitalization due to cirrhosis, as derived from
ICD‐10 codes. The start date was the latter of earliest diagnosis or
earliest treatment by MTX, and the end date was the earliest of date
of liver outcome, death, migration, or end of study. Cox regression
analysis was performed to compare the risk of each liver outcome
among PsO, PsA, versus RA, adjusted for age, sex, smoking, alcohol
abuse, diabetes, hyperlipidemia and statin use, year of study inclusion,
Charlson Comorbidity Index (without liver disease and RA), and aver-
age weekly MTX dose.
Results: A total of 5,687, 6,520, and 28,030 patients with PsO, PsA,
and RA, respectively, received MTX. The average weekly MTX dose
was similar across the groups but the duration and cumulative dose
of MTX was greatest in RA, followed by PsA, then PsO. Drug survival
was longest for patients with RA (50% discontinuation after
80 months), then PsA (50% discontinuation after 54 months), and
shortest for PsO (50% discontinuation after 26 months). In adjusted
analyses, patients with PsO had significantly increased risks for mild
liver disease (HR 2.22, 95% CI [1.81–2.72]), moderate‐to‐severe liver
disease (1.56 [1.05–2.31]), cirrhosis (3.38 [2.44–4.68]), and cirrhosis‐
related hospitalization (2.25 [1.37–3.69]) compared to patients with
RA. Patients with PsA also had significantly greater risk of mild liver
disease (HR 1.27 [1.01–1.60]) and cirrhosis (1.63 [1.10–2.42]) com-
pared to RA.
Conclusions: Among MTX users, patients with psoriatic disease were
more likely to develop liver disease than those with RA and relative
risk differences were greatest for those with PsO, suggesting effect
modification by disease indication. Further work is needed to dissect
the drivers of these differences among PsO, PsA, and RA. These data
demonstrate the need for careful monitoring of liver complications in
patients receiving MTX for psoriatic disease.
16 | Prediction of Cardiovascular Events in
Rheumatoid Arthritis Patients Using Protein
Biomarkers and Clinical Factors
Jeffrey R. Curtis1; Fenglong Xie1; Lang Chen1; Eric Sasso2;
Elena Hitraya2; Jerry S. Lanchbury2; Darl Flake2; Alexander Gutin2;
Cheryl Chin3; Cynthia Crowson4
1University of Alabama at Birmingham, Birmingham, AL; 2Crescendo
BioScience, Salt Lake City, UT; 3Crescendo BioScience, South San
Francisco, CA; 4Mayo Clinic, Rochester, MN
Background: The ACC/AHA recommends preventive strategies for
patients with a high‐predicted risk of atherosclerotic cardiovascular
disease (CVD). RA patients are at higher risk for CVD events, yet the
role of systemic inflammation and the influence of traditional CVD risk
factors are unclear with respect to risk prediction in RA.
Objectives: A simple and accurate algorithm for predicting CVD event
risk that considers systemic inflammation might help risk assessment
for RA patients and optimize preventive care.
Methods: We derived a cohort of RA patients by linking multi‐bio-
marker disease activity (MBDA) test data to Medicare claims requiring
≥1 yr Medicare coverage prior to 1st MBDA test (baseline). Exclusions
were past MI, stroke, or cancer. Follow‐up ended at the earliest of 1)
CVD event; 2) death; 3) loss of coverage; or 4) 12/31/16. CVD events
defined as: incident MI, stroke or fatal CVD event, and were identified
using validated algorithms (PPV ≥80%). The leptin‐adjusted MBDA
score (Curtis et al., Rheumatol 2018) and its 12 protein biomarkers were
evaluated as predictors of CVD events, as were demographics,
healthcare utilization, CVD‐related comorbidities/medications, and
RA‐related features (e.g. DMARD/biologic use, steroid use). The cohort
was randomly split 2:1 to use 2/3 patients for training and 1/3 for vali-
dation. Cox proportional hazard regression with LASSO was used for
variable selection based on minimization of 10‐fold cross‐validated
error + 1 SE. Model calibration (observed vs. expected) and discrimina-
tion were assessed for predicted CVD events at 3 yrs. Analyses are
ongoing; model performance results are reported for the cross‐vali-
dated training data.
Results: Eligible RA patients (26,261) were analyzed; mean (SD) age
68.6 (10.2) yrs, 80% female, 73% white, 23% diabetes, 43% statin
use, 56% methotrexate, 44% on biologics/tofacitinib, 55% steroids,
and median (IQR) adjusted MBDA score 40 (32–49). A total of 477
CVD events occurred over mean (SD) follow‐up time of 1.7 (1.2) yrs
yielding a CVD incidence rate of 16.5 (95% CI 15.0–18.0)/1000py.
The most important predictors in the LASSO‐selected models were
age, beta‐blocker use, sex, diabetes, adjusted MBDA score and a sub-
set of MBDA biomarkers. The best performing model had a cross‐val-
idated area under the receiver operator curve of 0.70 and good
observed: expected prediction at 3 yrs.
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Conclusions: Preliminary results from this approach suggest a simple
algorithm consisting of a limited number of protein biomarkers and
clinical measures can provide an accurate method to predict short‐
term CVD risk in RA.
17 | Induction Immunosuppression Practices
in Liver Transplantation Are Variable and
Predict Post‐Transplant Outcomes
Therese Bittermann1; Rebecca A. Hubbard2; James D. Lewis1;
David S. Goldberg1
1University of Pennsylvania, Philadelphia, PA; 2University of
Pennsylvania, Philadelphia, PA
Background: Induction therapy is potent immunosuppression (IS) given
prior to transplantation. Its benefits remain uncertain in liver transplant
(LT) recipients, though its use has significantly increased over time.
Objectives: 1) To evaluate transplant center practice variability in the
use of induction IS; 2) to assess the effectiveness of lymphocyte
depleting (thymoglobulin, alemtuzumab, rituximab) and non‐depleting
(daclizumab, basiliximab) induction in a large sample of LT recipients.
Methods: This was a retrospective cohort study using the United Net-
work for Organ Sharing national transplant database. All adult liver
alone recipients between 1/1/05–1/31/18were included. Center prac-
tice variability in induction use/type was described. The proportion of
variance in the receipt of either induction type attributed to center
was obtained through mixed‐effects logistic regression. Induction IS
as a categorical exposure (no induction, non‐depleting induction
[NDI], depleting induction [DI]) was evaluated as a predictor of graft fail-
ure or death using multivariable Cox proportional hazards models. Its
association with estimated glomerular filtration rate (eGFR) at 6 months
post‐LT was assessed using multivariable mixed‐effects linear
regression.
Results: 69,349 recipients were transplanted at 114 centers during the
study period: 27% received induction (60.8%NDI, 39.2%DI). 85 centers
used no induction in ≥50% of LT recipients, while 19 and 6 centers
favored NDI and DI, respectively. 65.7% of the variance in the receipt
of induction was attributed to transplant center, independent of recipi-
ent and donor factors. Receipt of NDI andDIwere associatedwith a sig-
nificantly lower adjusted hazard of death/graft failure: HR 0.90 (95%CI:
0.86–0.95) and 0.91 (95%CI: 0.85–0.97), respectively (p < 0.001). Base-
line eGFR at LT was an effect modifier of the association of induction
and eGFR6months post‐LT: patientswith lower eGFR at LT had greater
predicted gains in post‐LT eGFR with NDI and DI. At mean baseline
eGFR, NDI was associated with an adjusted gain in eGFR of 2.62 mL/
min/1.73m2 (95% CI: 1.72–3.53), and DI of 2.48 mL/min/1.73m2
(95% CI: 1.25–3.71; p < 0.001 overall).
Conclusions: Marked variability in induction practices exists with cen-
ter being a major determinant. Both NDI and DI are associated with
significant improvements in death/graft failure and post‐LT renal func-
tion. Given its marked increase in use, consensus guidance on induc-
tion IS for LT is needed.
18 | Comparative Safety of Antiepileptic
Drugs and Risk of Major Congenital
Malformations
Jacqueline M. Cohen1; Maarit K. Leinonen2; Silje Alvestad3;
Marte‐Helene Bjørk3; Carolyn E. Cesta4; Kristjana Einarsdóttir5;
Anders Engeland1,3; Mika Gissler2,6,4; Óskar Hálfdánarson5;
Øystein Karlstad1; Helle Kieler4; Kari Klungsøyr1,3; Mette Nørgaard7;
Lars Pedersen7; Randi Selmer1; Helga Zoega5,8; Kari Furu1
1Norwegian Institute of Public Health, Oslo, Norway; 2National Institute
for Health and Welfare, Helsinki, Finland; 3University of Bergen, Bergen,
Norway; 4Karolinska Institutet, Stockholm, Sweden; 5University of
Iceland, Reykjavik, Iceland; 6University of Turku, Turku, Finland; 7Aarhus
University, Aarhus, Denmark; 8UNSW Sydney, Sydney, Australia
Background: The teratogenic potential of antiepileptic drugs (AEDs)
has been recognized for decades but many patients require continued
treatment during pregnancy. Direct comparison between AEDs will aid
treatment decisions.
Objectives: To determine which AEDs are associated with an
increased risk of any major congenital malformation (MCM), compared
to lamotrigine monotherapy which has the most evidence for safety in
pregnancy and is used for a range of epilepsy types and other AED
indications.
Methods:We carried out a cohort study using linked data from Nordic
birth and prescription registries from Denmark 1997–2017, Finland
1996–2014, Iceland 2003–2012, and Norway 2004–2017. We
included singleton live births with prescription data covering 3 months
before the last menstrual period (LMP) until birth. First trimester AED
use was defined as ≥1 prescription fill from LMP to LMP + 97 days.
We compared monotherapy of carbamazepine, valproate, pregabalin,
oxcarbazepine, levetiracetam, gabapentin, and topiramate to
lamotrigine. MCMs were identified by ICD‐9/10 codes mainly
recorded within one year of birth. We estimated RRs and 95% confi-
dence intervals, adjusted for maternal age, year of birth, opioids, ben-
zodiazepines/z‐drugs, and antidepressants. We combined estimates
from each country with fixed‐effects meta‐analyses. Iceland was only
included in crude analyses due to small numbers.
Results: The baseline prevalence of MCM in over 3 million births with
no first trimester AED exposure ranged from 2.7% in Finland to 4.5%
in Denmark. In total, n = 4385 births were exposed to lamotrigine
monotherapy and n = 6323 exposed to monotherapy of the other
AEDs of interest. Lamotrigine exposed births had an elevated risk of
MCM compared with the baseline (pooled RR: crude 1.3, 95% CI
1.2–1.5). Compared to lamotrigine, there was an increased risk of
MCM associated with valproate (n = 1494, pooled RRs: crude 1.8,
1.5–2.3; adjusted 1.6, 1.1–2.1) and topiramate (n = 306, pooled RRs:
crude 1.5, 1.0–2.3, adjusted 1.5, 0.7–2.2) with stronger estimates
when we required at least 2 filled prescriptions. We found no differ-
ences for carbamazepine (n = 1739, crude RR 1.0, 0.7–1.3), pregabalin
(n = 717, RR 1.2, 0.9–1.7), oxcarbazepine (n = 1053, RR 0.9, 0.6–1.3),
or gabapentin (n = 474, RR 1.1, 0.7–1.6). Levetiracetam was associated
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with a lower risk (n = 540, pooled RRs: crude 0.7, 0.5–1.2, adjusted
0.7, 0.3–1.1).
Conclusions: Among the most commonly used AEDs, use of valproate
and topiramate in pregnancy are associated with the highest risk of
malformations, whereas levetiracetam is associated with the lowest
risk compared to lamotrigine.
19 | Use of Oral Fluconazole during
Pregnancy and Risks of Spontaneous
Abortion, Stillbirth and Major Congenital
Malformation: An International, Multi‐Centre
Cohort Study
Colin Dormuth1; Brandace Winquist2; Anat Fisher1; Fangyun Wu3;
Pauline Reynier4; Matthew Dahl5; Zhihai Ma6; Xinya Lu7;
Jianguo Zhang6; Colette Raymond5; Kristian B. Filion8;
Robert W. Platt8; Carolina Moriello4; J. Michael Paterson3;
CNODES Investigators9
1University of British Columbia, Victoria, BC, Canada; 2University of
Saskatchewan, Saskatoon, SK, Canada; 3 ICES, Toronto, ON, Canada;
4 Jewish General Hospital, Montreal, QC, Canada; 5University of
Manitoba, Winnipeg, MB, Canada; 6University of Calgary, Calgary, AB,
Canada; 7Saskatchewan Health Quality Council, Saskatoon, SK, Canada;
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Background: Vaginal candidiasis is common during pregnancy.
Although intravaginal formulations of topical azole antifungals are
first‐line treatment, oral fluconazole is frequently prescribed, despite
safety concerns. Currently, Health Canada recommends that oral
non‐prescription fluconazole products not be used when women are
pregnant or trying to become pregnant, and that they talk with their
doctor before using prescription fluconazole.
Objectives: To study the association between oral fluconazole expo-
sure during pregnancy and risks of spontaneous abortion (SA), stillbirth
(SB), and major congenital malformation (CM).
Methods:We undertook an international, multi‐centre cohort study of
women aged 12–55 y who had a pregnancy event (SA, induced abor-
tion, SB, or live birth) between April 2002 and March 2016 recorded in
administrative data from 5 Canadian provinces, the US MarketScan
database, and the UK Clinical Practice Research Datalink. Our primary
outcome measure was fetal death defined as a composite of SA or SB.
Secondary outcomes were the components of the composite and CM.
To minimize confounding by indication, exposure to oral fluconazole
was compared with exposure to topical azoles. We estimated hazard
ratios (HR) and odds ratios (OR) using high dimensional propensity
score‐adjusted proportional hazards regression and logistic regression,
as appropriate, with time‐dependent drug exposures. Sensitivity anal-
yses excluded pregnancy losses during the first 6 w, 20 w gestation;
considered exposures during 4–10 w gestation; and studied the first
pregnancy per woman. Site‐level results were pooled using random‐
effects models.
Results: Among the 63,346 pregnancies exposed to oral fluconazole,
14.2% resulted in fetal death vs 4.8% of 107,212 exposed to topical
azoles. Just 20% of fluconazole‐exposed women received a cumula-
tive dosage greater than 300 mg during pregnancy. After adjustment,
fluconazole exposure during pregnancy was associated with signifi-
cantly increased risks of fetal death (HR 1.30, 95% CI 1.24–1.35), SA
(HR 1.31, 1.22–1.41), and SB (HR 1.48, 1.29–1.69). It was not associ-
ated with an increased risk of major birth defects (OR 0.90, 0.75–
1.09). Results of sensitivity analyses were consistent with those of
the primary analyses.
Conclusions: In this large, multi‐centre cohort study, use of oral flu-
conazole during pregnancy was associated with significantly increased
risks of fetal death, SA, and SB relative to use of topical azoles. Oral
fluconazole should be prescribed cautiously during pregnancy.
20 | Oral Fluconazole Use in Pregnancy and
the Risk of Birth Defects
Yanmin Zhu1; Brian T. Bateman1,2; Sonia Hernandez‐Diaz3;
Kathryn J. Gray4; Helen Mogun1; Krista F. Huybrechts1
1Brigham and Women's Hospital and Harvard Medical School, Boston,
MA; 2Brigham and Women's Hospital and Harvard Medical School,
Boston, MA; 3Harvard T. H. Chan School of Public Health, Boston, MA;
4Brigham and Women's Hospital and Harvard Medical School, Boston,
MA
Background: Prior studies suggest a possible increased risk of oral
clefts and tetralogy of Fallot associated with oral fluconazole use dur-
ing the first trimester. An FDA safety review further suggests maternal
chronic high‐dose use may be associated with musculoskeletal
defects, but limited evidence is available regarding the potential risk
at common therapeutic doses.
Objectives: To evaluate the effect of oral fluconazole use during the
first trimester on the risk of congenital malformations.
Methods: We performed a cohort study using the nationwide Medic-
aid Analytic eXtract for 2000–2013, including pregnant women
enrolled in Medicaid from ≥3 months before the last menstrual period
(LMP) to ≥1 month after delivery and infants enrolled for ≥3 months
after birth unless they died sooner. We ascertained oral fluconazole
exposure as having ≥1 prescription filled between LMP and LMP + 90
and no filled prescription for other oral antifungal agents between
LMP‐90 and LMP + 90. We further classified the exposed into 3
cumulative dose groups: 150 mg, 150‐300 mg and > 300 mg. The ref-
erence group included patients with topical azoles filled between LMP
and LMP + 90 and no fills of any oral antifungal agents between LMP‐
90 and LMP + 90. Primary outcomes were musculoskeletal defects,
tetralogy of Fallot and oral clefts diagnosed within 90 days after birth.
Propensity score fine stratification was used to control for confound-
ing and relative risks (RRs) were estimated using log‐binomial models.
Results: Among 1,811,062 pregnancies, 34,025 (1.9%) were exposed
to oral fluconazole, and 76,229 (4.2%) to topical/vaginal azoles. Over-
all, 220 (0.6%) oral fluconazole exposed and 363 (0.5%) topical azoles
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exposed infants were diagnosed with musculoskeletal defects. The
absolute risks of tetralogy of Fallot and oral clefts among the flucona-
zole exposed vs. controls were 0.04% vs. 0.05%, and 0.09% vs. 0.11%
respectively. The adjusted RR for musculoskeletal defects was 1.29
(95% CI, 1.09–1.52). Compared to topical azoles, the magnitude of
the increased risk for musculoskeletal defects was similar across the
fluconazole dose groups [adjusted RR, 150 mg: 1.32 (1.09–1.59),
150 mg ‐ 300 mg: 1.30 (0.97–1.75), >300 mg: 1.24 (0.82–1.89)]. For
tetralogy of Fallot, the adjusted RR was 0.62 (0.34–1.15) while the
adjusted RR for oral clefts was 0.88 (0.58–1.32).
Conclusions: Oral fluconazole use during the first trimester was not
associated with tetralogy of Fallot and oral clefts, but was associated
with a 30% increased risk for musculoskeletal defects independent
of cumulative dose. Given the observed risk, oral fluconazole should
be prescribed with caution during the first trimester.
21 | The Impact of In‐Utero Prescription
Opioid Exposure on Congenital
Malformations
Loreen Straub1; Krista F. Huybrechts1; Sonia Hernandez‐Diaz2;
Helen Mogun1; Brian T. Bateman1,3
1Brigham and Women's Hospital and Harvard Medical School, Boston,
MA; 2Harvard T.H. Chan School of Public Health, Boston, MA; 3Brigham
and Women's Hospital and Harvard Medical School, Boston, MA
Background: Prescription opioid use during pregnancy is widespread in
the US. Prior studies suggest an association between opioid exposure
and certain congenital malformations, but data are few and conflicting.
Objectives: To evaluate the risk of 1st trimester (T1) in‐utero opioid
exposure with respect to malformations previously suggested to be
associated with such exposure: major malformations overall, cardiac
malformations overall, ventricular septal defects (VSD), secundum atrial
septal defects (ASD), central nervous system (CNS) malformations, neu-
ral tube defects (NTD), gastroschisis, club foot, and oral clefts.
Methods: We conducted a cohort study of pregnant women and their
liveborn infants nested in the nationwide Medicaid Analytic eXtract
database for 2000–2013. Exposure was defined based on ≥2 dispens-
ings for any opioid during T1, on the assumption that if a woman is
refilling the medication, she is likely to be taking it. Claims‐based algo-
rithms were used to define the malformations of interest. Relative
risks (RR) were estimated using generalized linear models with propen-
sity‐score stratification to adjust for potential confounders including
demographics, pain conditions, concomitant drug exposure, comorbid-
ities, and measures of healthcare utilization.
Results: Of the 1,686,121 included pregnancies, 53,029 (3.1%) were
exposed to any opioid (≥ 2 dispensings) during T1. Overall, there were
2,443 (4.6%) cases of malformations in the opioid exposed and 60,337
(3.7%) in the unexposed. The unadjusted RR was 1.25 (95% confi-
dence interval [CI], 1.20–1.30) for malformations overall, 1.27 (1.17–
1.38) for cardiac malformations, 1.18 (1.04–1.34) for VSD, 1.29
(1.08–1.55) for ASD, 1.12 (0.93–1.36) for CNS malformations, 0.94
(0.59–1.50) for NTD, 1.31 (0.99–1.73) for gastroschisis, 1.32 (1.09–
1.59) for club foot, and 1.56 (1.27–1.92) for oral clefts. The adjusted
RR was 0.99 (0.96–1.03) for malformations overall, 1.00 (0.92–1.09)
for cardiac malformations, 0.96 (0.84–1.08) for VSD, 0.92 (0.77–
1.11) for ASD, 1.01 (0.84–1.22) for CNS malformations, 0.64 (0.40–
1.02) for NTD, 1.19 (0.90–1.57) for gastroschisis, 1.05 (0.87–1.26)
for club foot, and 1.20 (0.97–1.47) for oral clefts.
Conclusions: After adjusting for relevant confounders, we observed
no increase in the risk for malformations overall, cardiac
malformations overall, VSD, ASD, CNS malformations, NTD, or club
foot. Risk estimates were slightly increased for gastroschisis and oral
clefts, but with relatively wide CI that intersect the null. Further eval-
uation of the impact of opioid type, dose, and duration of treatment
on these outcomes is needed.
22 | Risk of Neonatal Abstinence Syndrome
Following Prenatal Exposure to Methadone vs
Buprenorphine
Mollie Wood1; Milada Mahic2; Marte Handal2; Svetlana Skurtveit2;
Ingunn Olea Lund2; Sonia Hernandez‐Diaz1
1Harvard TH Chan School of Public Health, Boston, MA; 2Norwegian
Institute of Public Health, Oslo, Norway
Background: Rising rates of opioid addiction mean that pregnant
women are more often on opioid maintenance therapy (OMT), necessi-
tating a clinical choice between methadone and buprenorphine. In
observational studies maternal methadone use has been associated
with a 20% higher risk of neonatal abstinence syndrome (NAS), com-
pared to buprenorphine. However, residual confounding may explain
this, as women on methadone often have a more severe addiction.
Objectives: To estimate the risk of NAS in methadone vs.
buprenorphine exposed pregnancies, with additional adjustment for
addiction severity.
Methods: We used Norwegian National Registries data collected from
2009–2015 to identify a cohort of pregnantwomenonOMTat concep-
tion and identify newborns with NAS diagnoses. We used two defini-
tions of exposure. Exposure in early pregnancy reflects the time at
which a clinical decision is made to use methadone or buprenorphine
during the pregnancy. Late pregnancy exposure is the more biologi-
cally‐relevant exposure window for NAS.We used log‐binomial regres-
sion to assess the risk ratio of NAS in methadone vs. buprenorphine
exposed pregnancies and adjusted for confounders with inverse proba-
bility of treatment weights. In a sample linked to specialized addiction
services data we further adjusted for additional addiction severity.
Results: 180 women were on OMT during pregnancy. The risk of NAS
in the newborn was 77% in the 53 exposed to methadone in early
pregnancy and 68% in the 106 exposed to buprenorphine in early
pregnancy, with similar risks in the 83 women linked to the specialized
addiction services data. Women on methadone vs those on
buprenorphine more often reported heroin use, depression or anxiety,
and switching OMT within the last 5 years. However, the risk ratio
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only changed from 1.13 to 1.14 (95% CI 0.91 to 1.43) after adjust-
ment. The crude and adjusted risk ratios for exposure in the 30 days
before delivery were 0.96 and 1.04 (95% CI 0.86 to 1.24),
respectively.
Conclusions: We found a slightly higher NAS risk for methadone than
for buprenorphine treatment in early pregnancy but not near delivery,
although confidence intervals were wide and overlapping thus chance,
selection bias or residual confounding could explain these findings.
However, we did not find evidence to support that the higher risk of
NAS among methadone users early in pregnancy was explained by
severity of addiction.
23 | Paternal Exposure to Finasteride ‐
Before and during Pregnancy
Jon T. Andersen1,2; Thomas B. Jensen1; Henrik Horwitz1;
Stine S. Clausen1
1Copenhagen University Hospital Bispebjerg, København NV, Denmark;
2University of Copenhagen, Copenhagen, Denmark
Background: Finasteride is used for the treatment of hair loss in men
of reproductive age. The consumption is increasing. Administration of
high oral doses of finasteride in female animals, has resulted in con-
genital malformations in male fetuses, but there is a general lack on
human data concerning possible teratogenic effects of paternal expo-
sure. This has caused concern among doctors and users of finasteride.
Objectives: The objective of this study was to examine the fetal risk of
paternal exposure to finasteride between 90 days before pregnancy
and during the first trimester.
Methods: We conducted a nationwide register‐based cohort study
consisting of all registered pregnancies in Denmark between 1997–
2016. Births were identified from the Medical Birth Registry, and mis-
carriages and abortions from the National Hospital Register. Finaste-
ride‐exposure were identified from the National Prescription Registry.
Results: We identified 1,478,912 registered pregnancies with known
paternityofwhom903pregnancieswereof finasteride‐exposedfathers.
Among these, 69 (7.6%) ended as a miscarriage compared to 131,221
(8.9%)amongunexposed.Thehazardratio forexperiencingamiscarriage
in pregnancies with paternal finasteride‐exposure was 0.89 (CI95%
0.70–1.12). Therewasno increased riskofhavinganoffspringdiagnosed
withamajorcongenitalmalformation ingeneral (OR=0.65 (CI95%0.40–
1.05)),malformationof thegenitalorgansoranyotherspecificmalforma-
tion group, according to the EUROCAT classification system. Further-
more, there were no increased risk of congenital malformations in
children to fathers specificly exposed to finasteride in the three months
period before pregnancy or specificly in the first trimester.
Conclusions: We did not find an increased risk of miscarriage or
malformations in pregnancies with paternal exposure to finasteride.
Although, the study has low power of detecting very rare
malformations, paternal finasteride should not be of major concern.
24 | Modeling Effect Heterogeneity in the
Presence of Heterogeneous Confounding: A
Plasmode Simulation
Mitchell M. Conover; Virginia Pate; Michele Jonsson Funk
Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC
Background: Standard methods for identifying treatment effect het-
erogeneity (e.g. single interaction term) may be biased when covariate
effects differ by subgroup (e.g. sex).
Objectives: Evaluate bias and precision of alternative modeling
approaches when treatment and covariate effects differ by sex.
Methods: We simulated 1,000 plasmode cohorts, each with n = 6,000
sampled with replacement from NHANES respondents, 1999–2014,
age 40–79, with labs and no statin use (n = 6,063). We simulated
statin initiation as a function of demographic and cardiovascular risk
factors such that covariate‐exposure relationships differed by sex.
We simulated outcomes as a function of exposure and 10‐year
ASCVD risk score, which differs by sex, thereby inducing heteroge-
neous confounding. Simulated treatment effects differed by sex
(RRwomen = 0.35, RRmen = 0.69). We produced estimates using conven-
tional outcome models, g‐computation, inverse‐probability‐of‐treat-
ment weighting (IPTW), and doubly‐robust estimators. We evaluated
various model forms to control for covariates including: main effects
only, treatment‐sex interaction, covariate‐sex interactions, or full
stratification. We report median absolute bias (log‐scale) and 95%
confidence interval widths (CIW) based on the 2.5th and 97.5th
percentiles.
Results: Confounding was stronger in women, RR = 0.93 (bias = 0.97,
CIW = 0.71), than men, RR = 0.94 (bias = 0.31, CIW = 0.55), with no
evidence of heterogeneity in the crude. Three models without sex‐
specific covariate parameters were biased: 1) outcome model with
covariate main effects and treatment‐sex interaction (biaswomen = 0.16,
CIW = 0.81; biasmen = −0.07, CIW = 0.58); 2) g‐computation with main
effects (biaswomen = 0.17, CIW = 0.85; biasmen = −0.05, CIW = 0.638);
and 3) IPTW with main effects for covariates fit in the pooled cohort
(biaswomen = 0.29, CIW = 0.89; biasmen = −0.19, CIW = 0.95). (The last
also failed to detect statistically significant effect heterogeneity.) All
other model forms produced adjusted estimates with minimal bias
(<0.1). Among these, models with treatment‐sex and covariate‐sex
interactions were more precise. Sex‐stratified g‐computation models
failed to converge in 0.6% of simulations for women and < 0.1% of
iterations for men.
Conclusions: Various methods can be used for modeling effect het-
erogeneity, so long as the model form flexibly allows for confounding
relationships to also differ (i.e. stratifying by subgroup or using covar-
iate‐subgroup interactions). G‐computation produced precise, unbi-
ased estimates but occasional non‐convergence may indicate
infeasibility in small studies.
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25 | A Little off the Sides: Propensity Score
Trimming in the Presence of Heterogeneity
Michael Webster‐Clark1; Robert Glynn2; Til Stürmer1
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Harvard T.
H. Chan School of Public Health, Boston, MA
Background: Past simulation studies assessed bias and precision of
types of propensity score trimming in the presence of uniform treat-
ment effects. How this trimming affects estimates in populations with
heterogeneous treatment effects is unknown.
Objectives: Assess change in average treatment effect in the treated
(ATT) and average treatment effect in the untreated (ATU) after 5%
asymmetric trimming (AT), 10% Crump trimming (CT), and 30%/70%
preference score trimming (PT) given heterogeneous treatment
effects.
Methods: We simulated 500 studies of the safety of treatment X for an
outcomeY for 50,000 people in the presence of four independent con-
founders, three binary and one continuous, all associated logistically
with X and log‐linearlywithY. In thosewith nomodifiers X had no effect
on Y. One binary confounder (C1) was a contraindication (treatment
odds ratio (OR): 0.25) while another (C2) was a compelling indication
(treatment OR: 4.00); both were present in 15% of participants. Mar-
ginal probability of treatmentwas 26%.We considered scenarioswhere
1) treatment X had a RR for Y of 2.0 when C1 = 1, 2) treatment X had a
RR for Y of 0.60 when C2 = 1, and 3) both C1 and C2 modified treatment
effect. Propensity score models were correctly specified and included
all confounders. We trimmed each population, re‐estimated propensity
score, and estimated ATT and ATU after weight‐based standardization.
We calculated true RRs in ATT and ATU populations to compute bias
and change from untrimmed estimates.
Results: Median C statistic for the propensity score model across all
replicates was 0.70. Weighting estimated ATT and ATU RRs in the
trimmed populations without bias. Trimmed estimates were within
90–110% of pre‐trimming estimates except ATU estimates in scenario
1 (untrimmed RR: 1.31, AT: 1.10, CT: 1.11, PT: 1.11) and scenario 3
(untrimmed RR: 1.20, AT: 0.99, CT: 0.98, PT: 1.00) and some ATT esti-
mates in scenario 2 (untrimmed RR: 0.81, AT: 0.88, CT: 0.81, PT: 0.91).
With AT and PT, when treatment effect modifiers predicted exposure
logically (factors increasing exposure were associated with improved
effects and factors decreasing it were associated with worse effects),
ATT estimates typically moved upward after trimming and ATU esti-
mates moved downward.
Conclusions: In these simulations, changes in ATT and ATU RRs
after trimming were modest and in predictable directions despite
potent modifiers strongly associated with exposure; estimates gener-
ally moved towards the RR in those with no modifiers. These find-
ings may help limit concerns about treatment effects in target
populations when trimming is deemed necessary to improve con-
founding control.
26 | Propensity Score Trimming ‐ Lessons
from a Study of Antipsychotic Augmentation
for Depression
Tobias Gerhard1; Daniel Horton1; Mark Olfson2; T. Scott Stroup2;
Soko Setoguchi1; Brian L. Strom1
1Rutgers University, New Brunswick, NJ; 2Columbia University, New
York, NY
Background: Propensity Score (PS) trimming has been suggested as a
promising approach to reduce bias from unmeasured confounding.
Objectives: To evaluate the effects of PS trimming choices in a study
examining the mortality risk of second generation antipsychotic (SGA)
augmentation for adult depression.
Methods: Using near‐national US Medicaid data (2001–2010), we
examined all‐cause mortality in a cohort of non‐elderly adults (25–
64 years) with depression who, after ≥3 months of antidepressant
(AD) monotherapy, initiated either a SGA or a second AD. Patients
with alternative SGA indications, e.g., schizophrenia or bipolar disor-
der, were excluded. PSs were calculated from >100 claims‐based
demographic, clinical, and healthcare utilization variables. Inverse
probability of treatment (IPT)‐weighted Cox models were used to
assess all‐cause mortality risk of SGA vs. AD augmentation before
and after asymmetric PS trimming with 2.5th(treated) and
97.5th(untreated) percentiles as cut points. PS trimming was
prespecified in the study protocol due to concerns regarding strong
unmeasured confounding in the PS tails. (1) High tail: SGAs being
withheld from patients with confounding factors unmeasured in claims
data, such as obesity, that predispose to known SGA‐associated
adverse events as well as mortality. (2) Low tail: SGAs prescribed pref-
erentially to patients with particularly severe depressive symptoms,
that increase mortality risk but are not captured in claims data. To
evaluate the impact of the protocol‐specified approach on our study
results, we separately estimated treatment effects in the PS tails and
within deciles of the trimmed cohort. Other cut points and stratifica-
tion approaches were examined in sensitivity analysis (not shown).
Results: We estimated IPT‐weighted HRs for mortality of 1.45
(1.02–2.06) in the trimmed cohort (N = 39,582) and 1.21 (0.87–
1.69) in the untrimmed cohort (n = 44,301). PS‐stratified analyses
indicated reasonably homogenous mortality risk across PS deciles
in the trimmed cohort with HRs ranging from 0.84 (0.26–2.75) to
2.52 (0.73–8.64). In contrast, stronger heterogeneity was apparent
in the trimmed PS tails, with HRs of 0.30 (0.12–0.74) in the high tail
and 6.96 (0.72–66.9) in the low tail.
Conclusions: PS trimming substantially affected study findings. The
heterogeneous and counterintuitive SGA effects observed in the PS
tails (greatly decreased mortality risk in the high tail; greatly increased
mortality risk in the low tail) are compatible with strong uncontrolled
confounding in the PS tails. These analyses provide empirical support
for the utility of PS trimming.
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27 | Residual Confounding and Treatment
Effect Heterogeneity: An Applied Example
Mitchell M. Conover; Virginia Pate; Michele Jonsson Funk
Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC
Background: Typical methods to assess treatment effect heterogene-
ity rely on balancing the marginal distribution of covariates for con-
founding control. If covariate effects differ between subgroups of
interest, previously reported theoretical findings suggest that resid-
ual confounding may obscure or induce apparent treatment effect
heterogeneity. The real‐world impact of this bias has not been
reported.
Objectives: Evaluate the impact of residual confounding due to the
use of a pooled propensity score model versus age‐ and sex‐ spe-
cific models in an analysis of statin effects on 2‐year all‐cause
mortality.
Methods:We used Medicare claims to select patients with an outpa-
tient visit, 2007–2013. We restricted the cohort to patients
≥66 years with continuous enrollment and no prior statin prescrip-
tion fills in the past year. We limited the cohort to patients at ele-
vated cardiovascular risk without major statin contraindications. We
classified patients with a statin claim in the 14 days after the index
visit as exposed (otherwise unexposed) and assessed all‐cause mor-
tality over 2‐years of follow‐up. Covariates included demographic,
clinical, and selected lab values based on level II CPT codes (low‐
density lipoprotein, HbA1C, blood pressure). We estimated propen-
sity scores using a single model including all eligible patients or strat-
ified by age and sex. We produced estimates of the risk ratio and
risk difference in the target population of patients initiating a statin
using standardized mortality ratio weights (SMRW) with 1% asym-
metric trimming.
Results: Among n = 646,394 patients, estimates based on a pooled
propensity score model indicated strong treatment effect heterogene-
ity by age but not by sex (RRmen ≤ 75 = 0.89, 95%CI: 0.81–0.97;
RRmen > 75 = 0.79, 95%CI: 0.74–0.85); (RRwomen ≤ 75 = 0.89, 95%CI:
0.82–0.97; RRwomen > 75 = 0.76, 95%CI: 0.72–0.80). Estimates based
on the age‐ and sex‐ specific propensity score models moved towards
the null for both men and women >75 and away from the null for
those ≤75. The resulting estimates indicated that treatment effects
were similar among men regardless of age (RRmen ≤ 75 = 0.85,
95%CI: 0.78–0.93; RRmen > 75 = 0.87, 95%CI: 0.81–0.93), and differ-
ences between women were greatly attenuated (RRwomen-
75 = 0.82, 95%CI: 0.76–0.89; RRwomen > 75 = 0.79, 95%CI: 0.75–0.33).
Conclusions: Reliance on a pooled propensity score model created
the appearance of strong treatment effect heterogeneity by age,
largely due to residual confounding. These findings indicate that
modeling confounding within categories of suspected effect modi-
fiers may have important impacts on estimates and conclusions.
28 | Novel Approaches for Defining Binary
Confounders in Claims Data: A Simulation
Study.
John G. Connolly; Sebastian Schneeweiss; Robert J. Glynn;
Joshua J. Gagne
Brigham and Women's Hospital, Boston, MA
Background: When investigators have two claims‐based definitions
for the same binary confounder, it is unclear whether to prefer the
more sensitive or specific definition. Utilizing both definitions may
result in improved confounding control.
Objectives: To compare adjusting for the sensitive or specific defini-
tion alone versus two novel approaches: 1) a “two‐algorithm indica-
tor” approach, and 2) a “two‐algorithm restriction” approach.
Methods: Each simulated patient had a binary exposure, outcome,
and confounder. We randomly assigned the confounder to 25% of
the cohort and used logistic regression models to generate the
exposure and outcome conditional on the confounder. The true
exposure effect was null. We created two misclassified versions
of the confounder based on validated definitions of heart failure.
The “sensitive” definition had a sensitivity of 0.98 and a specificity
of 0.83, while the “specific” definition had a sensitivity of 0.77 and
a specificity of 0.99. Patients were classified into 3 groups: those
who did not meet the sensitive or specific definition (Group 1),
those who met the sensitive but not specific definition (Group 2),
and those who met both the sensitive and specific definition
(Group 3). The two‐algorithm indicator approach adjusted for indi-
cators for Groups 2 and 3, while the two‐algorithm restriction
approach excluded patients in Group 2 and adjusted for an indica-
tor for Group 3. Odds ratios (ORs) for exposure were estimated
using logistic regression models after adjusting using each approach.
Each 10,000 patient dataset was recreated and reanalyzed 2,000
times.
Results: The crude OR was 1.33 (95%CI: 1.07, 1.63). Using the sen-
sitive or specific definitions alone resulted in partially adjusted ORs
of 1.14 (95%CI: 0.91, 1.40) and 1.09 (95%CI: 0.87, 1.35), while the
two‐algorithm indicator method resulted in an OR of 1.07 (95%CI:
0.86, 1.33). The two‐algorithm restriction approach resulted in the
least biased OR of 1.02 (95%CI: 0.79, 1.29) but excluded 20% of
the cohort. Across sensitivity analyses varying the validated defini-
tions and confounder prevalence, the indicator approach always
removed at least as much bias as the better of the two component
definitions and was sometimes the least biased approach overall,
particularly when covariate prevalence was high and overall mea-
surement was poor.
Conclusions: Using two definitions can improve confounding adjust-
ment in claims data. We recommend the two‐stage indicator approach
because it performed as well as the best component definition without
any loss in sample size.
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29 | An Empirical Evaluation of a Propensity
Score Stratification Based Weighting
Approach in Settings of More Than Two
Treatment Groups
Rishi J. Desai; Kazuki Yoshida; Krista Huybrechts; Jessica Franklin
Harvard Medical School/Brigham & Women's Hospital, Boston, MA
Background: Propensity‐score (PS) stratification based weighting has
recently been shown to perform well with respect to bias and variance
when comparing two treatment groups; however, the performance of
this approach has not been tested when comparing >2 groups
simultaneously.
Objectives: To compare covariate balance and treatment effect esti-
mates after confounding adjustment with a novel weighting
approach based on simultaneous stratification on a multinomial PS
with matching weights and standardized mortality ratio weights
(SMRW) in the setting of >2 treatment groups.
Methods: A cohort of early rheumatoid arthritis (RA) patients initiat-
ing tumor necrosis factor inhibitors (TNFi), hydroxychloroquine,
methotrexate, or other non‐biologic DMARDs, was followed for
the outcome of incident hyperlipidemia. A multinomial logistic
regression model provided 3 non‐redundant PSs based on 18 covar-
iates, one for each treatment except for TNFi, the reference group.
For each PS, we trimmed regions of non‐overlap and stratified (5
or 10 strata) based on the PS distribution in exposed patients
followed by a simultaneous stratification procedure using all three
strata indicators (resulting in 53 and 103 potential strata). All expo-
sure groups were reweighted according to the number of TNFi
exposed patients in their stratum. A weighted Cox proportional haz-
ards model with robust variance estimation was used to calculate
the hazard ratio (HR) and confidence intervals (CI).
Results: A total of 17,143 patients were included (6% TNFi, 36%
hydroxychloroquine, 46% methotrexate, 12% other non‐biologics).
Standardized differences were slightly higher for all comparisons in
the decile‐based stratification compared to other approaches. HR
(95% CI) for hydroxychloroquine, methotrexate, and other non‐bio-
logics vs. TNFi, respectively were comparable for quintile‐based
stratification (0.61 [0.41–0.91], 0.78 [0.55–1.12], 1.04 [0.64–1.68]),
matching weights (0.65 [0.43–0.97], 0.75 [0.52–1.06], 1.06 [0.67–
1.67]), and SMRW (0.64 [0.43–0.96], 0.76 [0.53–1.08], 1.07 [0.67–
1.7]); but decile‐based stratification resulted in numerically different
estimates with higher variance (0.47 [0.29–0.74], 0.75 [0.5–1.12],
0.92 [0.53–1.61]).
Conclusions: PS‐based simultaneous stratification approach may pro-
vide an alternative confounding adjustment approach in settings with
>2 treatment groups. However, with many treatment groups, multi‐
dimensional stratification quickly results in a very large number of strata
and highly variable estimates.
30 | Use of Stimulants in Adults and Risk of
Cardiovascular Events: A Multi‐Design
Approach
Mina Tadrous1; Simon Greaves2; Michael Paterson2; Jennifer Watt1;
David N. Juurlink2; Diana Martins1; Muhammad M. Mamdani1;
Tara Gomes1
1St. Michael's Hospital, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada
Background: Use of prescription stimulants (ex. methylphenidate) is
known to elevate blood pressure and heart rate. The associated risks
of cardiovascular (CV) events have been established in children, how-
ever, have not been rigorously studied in older adults. With the rising
use of stimulants in older adults, the risks of CV events are considerable
and require further study. Previous studies applying differing study
designs have produced conflicting results, likely due to potential selec-
tion bias and the use of drug trials.
Objectives: To investigate whether stimulant use is associated with an
increased risk of CV events among older adults.
Methods: We conducted a multi‐design observational study among
patients ≥66 years old dispensed a prescription stimulant between
January 1, 2002‐ December 31, 2015. We used a multi‐design
approach applying a matched cohort, nested case–control, and case‐
crossover designs. We matched on age, sex, and comorbidities in the
case–control design (matched 1:1) and matched using a high‐dimen-
sional propensity score in the cohort design (4 non‐users:1 user).
The primary outcome was a composite of hospitalization or emer-
gency room visit for myocardial infarction, stroke, or arrhythmia. For
both the nested case–control and case‐crossover designs the look‐
back period was defined as 30 days from the event date. Conditional
logistic regression was used for the case–control and case‐crossover
design. A Cox proportional hazard model was used for the cohort
and assessed the risk of events at 30, 60, and 90 days after initiation.
Results: A total of 665 CV events occurred among 6,457 stimulants
users. We found that stimulant use was not associated with an
increased risk of CV events in both the case–control (Odds Ratio [OR]
0.9; 95% Confidence Interval [CI] 0.6–2.0) and case‐crossover (OR
0.8; 95% CI 0.6–1.2) designs. The cohort design did find a significant
association at 30‐days after initiation (Hazard Ratio (HR) 1.4; 95% CI
1.1–1.8). This finding was not significant at the 60‐(HR 1.2; 95% CI
0.9–1.5) and 90‐day (HR 1.0; 95% CI 0.6–1.8) after index. Post‐Hoc
analysis found that the significant finding in the cohort design is largely
due to a higher risk of arrhythmias (HR 3.0; 95% CI 1.1–8.7).
Conclusions: Overall, these results support previous studies that long‐
term stimulant use may not lead to more CV events among older adults.
Theremaybeanimmediateriskatinitiation,largelyassociatedwithtachy-
cardia. Applying a multi‐design approach allowed the ability to contrast
results in a scenariowhere competing biasmay greatly influence results.
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31 | Mirabegron and the Risk of Arrhythmias:
A Population‐Based Cohort Study
Mina Tadrous1; Rano Matta2; Simon Greaves3; David N. Juurlink3;
Muhammad Mamdani1; Tara Gomes1
1St. Michael's Hospital, Toronto, ON, Canada; 2University of Toronto,
Toronto, ON, Canada; 3 ICES, Toronto, ON, Canada
Background: Mirabegron, a ß‐3 adrenoreceptor agonist, used to treat
overactive bladder (OAB) has been shown in clinical trials to produce a
minor increase in resting heart rate, blood pressure, and QTc interval.
More patients are being prescribed mirabegron, owing to its limited
adverse effects relative to antimuscarinic OAB drugs. However, there
is a lack of cardiovascular safety data in older patients and those with
existing cardiovascular disease.
Objectives: We aimed to evaluate the risk of cardiac arrhythmias and
other adverse cardiovascular events in older patients using mirabegron
relative to other OAB agents.
Methods: We conducted a population‐based cohort study of patients
≥66 years oldwhowere newusers ofOAB drugs between June 1, 2015
and March 31, 2017 in Ontario, Canada. We followed patients for one
year after starting themedication or until they discontinued or switched
treatment. The primary outcome was a composite of hospitilization or
emergencyroomvisitforarrhythmiaandtachycardiaevents.Thesecond-
ary outcome was myocardial infarction (MI) or stroke. Patients taking
mirabegron were matched to subjects taking other OAB agents on age,
sex, date of initiating medication, and a high‐dimensional propensity
score. The primary analysis usedCox proportional hazards regression.
Results: Wematched16,948mirabegron users to 21,870 users of other
OABdrugs.Themedianageof thecohortwas76 (Interquartile range71–
83), andmostwere female (N= 25,189, 64.9%). A large proportionof the
cohort had hypertension (N = 30,393, 78.3%) and diabetes (N = 13,757,
35.4%).Overall, 624 (1.6%)patientsexperiencedanarrhythmiaor tachy-
cardia event and 480 (1.2%) experienced an MI or stroke. The 1‐year
cumulative incidence of arrhythmia or tachycardia events was 3.3% in
themirabegron group and3.5% in the otherOABdrugs group (adjusted?
Hazard Ratio [HR] 0.93; 95% Confidence Interval [CI] 0.80–1.09).
Mirabegron was not associated with an increased risk of MI or stroke
compared to other OAB drugs (HR 1.06; 95%CI 0.89–1.27).
Conclusions: In a population‐based cohort of older patients, use of
mirabegron was not associated with an increased risk of arrhythmia
or other cardiovascular events compared to other OAB drugs. These
results are supportive of current prescribing trends and give a bal-
anced view of the real‐world safety of this treatment option.
32 | Risk of Major Cardiovascular Events
Associated with Varenicline and Nicotine
Replacement Therapy: An Australian
Population‐Based Study
Alys Havard1; Stephanie K.Y. Choi1; Clara K. Chow2; Duong T. Tran1;
Kristian B. Filion3
1UNSW Sydney, Sydney, Australia; 2The University of Sydney, Sydney,
Australia; 3McGill University, Montreal, QC, Canada
Background: There are inconsistent reports that use of varenicline and
nicotine replacement therapy (NRT) for smoking cessationmay be asso-
ciatedwith an increased risk of cardiovascular events. However, current
evidence is insufficient to determine whether these concerns are valid.
Objectives: Todeterminewhether varenicline andnicotine replacement
therapy (NRT) are associated with an increased risk of major cardiovas-
cular events relative to bupropion, another smoking cessation therapy.
Methods: A new user, active comparator cohort study in New South
Wales,Australia, using linkedpharmaceutical dispensing, hospital admis-
sion, and death data. We identified individuals dispensed varenicline,
NRT patch, or bupropion for the first time during the study period
(2008–2016 for varenicline, 2011–2016 forNRT).Wedefinedexposure
usinganapproachanalogous to intention‐to‐treat, and followedpatients
for amaximumof 6months. The primary outcomeswere acute coronary
syndrome (ACS), ischaemic stroke, cardiovascular death, and a compos-
iteof these (referred toasmajor cardiovascular events).Weused inverse
probability of treatmentweightingwithpropensity scores to account for
differences between treatment groups. We used Cox proportional haz-
ardmodels to estimate adjusted hazard ratios (HR) and event rates, both
with 95% confidence intervals (CI).
Results: Among the cohort of 346,473 varenicline users and 16,449
bupropion users, there was no difference in the rate of major cardiovas-
cular events (7.12 versus 8.15, per 1000 person‐years [PY]; HR = 0.85
[95%CI: 0.64, 1.12]). Varenicline was also not associatedwith increased
risk of the individual outcomes (ACSHR=0.81 [95%CI: 0.60, 1.10], isch-
aemic stroke HR = 2.17 [95% CI: 0.65, 7.24], cardiovascular death
HR = 0.76 [95% CI: 0.38, 1.55]). Among the 110,294 NRT users and
8,065 bupropion users, there was no difference in the rate of major car-
diovascular events (12.31 versus 19.12, per 1000 PY; HR = 0.67 [0.40,
1.13]). However, NRTwas associated with a significant reduction in risk
of ACS (8.19 versus 17.35, per 1000 PY; HR = 0.48 [0.27, 0.87]) in com-
parisontobupropion.Therewasno increasedrisk incardiovasculardeath
associatedwithNRTuse (HR=0.79 [95%CI:0.23,2.74]),while the riskof
ischaemic stroke could not be estimated due to the low event rate.
Conclusions: Our results suggest there is no increased risk of any
major cardiovascular events associated with varenicline relative to
bupropion. Compared with bupropion, NRT is associated with a lower
risk of ACS but not associated with other major cardiovascular events.
33 | Cardiovascular Safety of Prucalopride
for Chronic Constipation: A Multinational
Population‐Based Cohort Study
Alicia Gilsenan1; Joan Fortuny2; Miguel Cainzos‐Achirica2;
Oscar F. Cantero3; Robert W.V. Flynn4; Luis Garcia‐Rodriguez3;
Abenah Harding1; Bianca Kollhorst5; Pär Karlsson6; Love Linnér6;
Thomas M. MacDonald4; Ingvild Odsbu6; Estel Plana2;
Ana Ruigómez3; Tania Schink5; Ryan Ziemiecki1;
Elizabeth B. Andrews1
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Background: The serotonin 5‐HT4 receptor agonist prucalopride is
approved in the European Union (EU) for the treatment of chronic con-
stipation, thus providing opportunity to include real‐world observa-
tional data on cardiovascular safety to support approval of
prucalopride in the United States.
Objectives: To estimate the pooled adjusted incidence rate ratio (IRR)
for major adverse cardiovascular events (MACE, defined as hospitali-
zation for non‐fatal acute myocardial infarction or stroke, and in‐hos-
pital cardiovascular death) in adult initiators of prucalopride compared
with initiators of polyethylene glycol 3350 (PEG) treated for chronic
constipation, following a common protocol.
Methods: Thepooledanalysesfromthisobservational,population‐based
cohort study (EUPAS9200) included data from the Clinical Practice
Research Datalink (CPRD), The Health Improvement Network (THIN),
andtheInformationServicesDivision(ISD)ofScotlandintheUnitedKing-
dom,andtheSwedishNationalRegisters(SNR)inSweden.Upto5PEGini-
tiatorswereselected foreachprucalopride initiator,matchedbyage, sex,
andyearoffirstprucaloprideorPEGprescriptionordispensing.Standard-
izedincidencerates(SIRs)andIRRsofMACEwerederivedusingpropensity
score stratification. Sensitivity analyses explored the impact of exposure
definition,outcomecategories,cancer,andunmeasuredconfounding.
Results: The pooled analyses included 5,715 initiators of prucalopride
and 29,372 initiators of PEG. Average duration of use was 175 days
for prucalopride and 82 days for PEG. The pooled SIR per 1,000 per-
son‐years (95% confidence interval) of MACE was 6.57 (3.90–10.39)
for patients initiating prucalopride and 10.24 (6.97–14.13) for PEG.
The pooled adjusted IRR for MACE was 0.64 (0.36–1.14), and results
were consistent for individual MACE components. Sensitivity analyses
yielded results consistent to the main analysis, with IRRs for first epi-
sode of use only, extension to 30 days of risk, and past use of 0.69
(0.34–1.42), 0.65 (0.38–1.09), and 0.65 (0.45–0.92), respectively.
Inclusion of out‐of‐hospital cardiovascular deaths in the MACE defini-
tion yielded an IRR of 0.43 (0.25–0.73) and inclusion of probable cases
yielded an IRR of 0.75 (0.27–2.05). Adjustment for hypothetical addi-
tional confounding factors under various assumptions did not change
the direction of the associations observed in the main analyses.
Conclusions: Results suggest no increased risk of MACE above the
prespecified safety threshold of 3.00 in patients with chronic consti-
pation using prucalopride as compared with PEG.
34 | Cardiotoxicity of Aromatase Inhibitors
in Post‐Menopausal Women with Breast
Cancer: A Population‐Based Cohort Study
Farzin Khosrow‐Khavar1; Nathaniel Bouganim2; Kristian B. Filion1;
Samy Suissa1; Laurent Azoulay1
1McGill University and Lady Davis Institute, Montreal, QC, Canada;
2McGill University, Montreal, QC, Canada
Background: Hormone‐receptor positive breast cancer comprises 75%
of all diagnoses of breast cancer. Recent changes in guidelines in
North America and Europe recommend extended treatment of
patients with hormone‐receptor positive breast cancer with aromatase
inhibitors (AIs) or tamoxifen for up to ten years. However, randomized
controlled trials have suggested that AIs may be associated with
adverse cardiovascular events.
Objectives: Toexamine this safety concern,weconducted a study in the
real‐world setting to determinewhether AIs, in comparisonwith tamox-
ifen, are associatedwith increased risk ofmyocardial infarction, ischemic
stroke, congestive heart failure, and cardiovascular‐death.
Methods: We conducted a population‐based cohort study using the
United Kingdom Clinical Practice Research Datalink linked to Hospital
Episode Statistics hospitalization data and Office for National Statistics
vital statistics. The study population consisted of post‐menopausal
women newly‐diagnosed with breast cancer and newly‐treated with
either AIs or tamoxifen between April 1, 1998 and February 29, 2016.
Cox proportional hazards model with inverse probability of treatment
and censoring weights were used to estimate hazard ratios (HRs) with
95% confidence intervals (CIs) comparing AIs with tamoxifen for each
of the studyoutcomes. Secondaryanalysiswasconductedby typeofAIs.
Results: The study cohort included 8,139 and 9,783 patients newly‐
treated with AIs and tamoxifen, respectively. The patients were
followed for a mean of 1.9 (SD: 1.7) years. Compared with tamoxifen,
AIs were associated with a trend towards an increased risk of myocar-
dial infarction (incidence rate: 51 vs 22 per 10,000 person‐years, HR:
1.38; 95% CI: 0.93–2.07), ischemic stroke (incidence rate: 64 vs 35
per 10,000 person‐years, HR: 1.23; 95% CI: 0.86–1.76), congestive
heart failure (incidence rate: 167 vs 60 per 10,000 person‐years, HR:
1.29; 95% CI: 0.79–2.12), and a significantly increased risk of cardio-
vascular‐death (rate: 95 vs 47 per 10,000 person‐years, HR: 1.44;
95% CI: 1.06–1.95). The results were consistent by type of AIs.
Conclusions: In this large real‐world setting study, AIs were associated
with increased cardiovascular mortality compared with tamoxifen.
There were also trends towards increased, though non‐significant,
risks of myocardial infarction, ischemic stroke, and congestive heart
failure with AIs compared with tamoxifen. Further research is needed
to ascertain whether the observed increased risks are due to deleteri-
ous effects of AIs or cardioprotective effects of tamoxifen.
35 | Diagnosis of Immune Checkpoint
Inhibitor Associated Myocarditis: A
Systematic Review of Case Reports and
Observational Studies
Richeek Pradhan1; Amit Nautiyal2; Sonal Singh3
1McGill University, Montreal, QC, Canada; 2Albany Medical College,
Albany, NY; 3University of Massachusetts Medical School, Worcester, MA
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Background: Immune checkpoint inhibitors cause a variety of immune
mediated reactions, and myocarditis is a rare but severe adverse event
associated with these drugs with a high case fatality rate. However little
is known about the value of diagnostic tests to evaluate this condition.
Objectives: To characterize the diagnostic approaches to myocarditis
associated with immune checkpoint inhibitors.
Methods: The systematic review was carried out according to the
PRISMA protocol (PROSPERO CRD42018097247). We searched
Medline and Embase on 10th June, 2018 for case reports, case series
and observational studies published in journal articles or presented
as conference abstracts that describe patients on any immune check-
point inhibitor who developed myocarditis after therapy. Two
reviewers independently and in duplicate screened citations and
extracted data. We evaluated the completeness of information in the
case reports and case series using the checklist provided by the Inter-
national Society of Pharmacoepidemiology and the risk of bias in the
observational studies using the New Castle Ottawa checklist. We
pooled data from the case reports and case series to contrast these
with findings from the controlled observational study.
Results: After a review of 2326 citations, we included 89 cases of
myocarditis associated with immune checkpoint inhibitors (54 cases
of in the case reports and case series and 35 cases in the observational
study). Serum troponin was elevated in 95% of the case reports and
94% of participants in the observational study. ST changes including
ST elevation were present in almost a third of case reports. Echocardi-
ography revealed preserved left ventricular ejection fraction in 32% of
case reports and 51% of cases in the observational study; however,
preserved systolic function did not predict greater survival. On cardiac
magnetic resonance imaging, late gadolinium enhancement was
absent in 31% of case reports and 26% of participants in the observa-
tional study. Acute myocardial ischemia was ruled out in all cases
(n = 31) when the diagnostic workup included coronary angiography.
Limitations of the case report include incomplete reporting of clinical
features, dose of the drug, and concomitant medications among.
Conclusions: Immune checkpoint inhibitor associated myocarditis is
associated with elevation of cardiac troponin levels and non‐specific
electrocardiographic changes. Early coronary angiography may distin-
guish it from myocardial ischemia or myocardial infarction.
36 | Effects of Bisphosphonate Use on Knee
Osteoarthritis Progression: An Analysis of the
Osteoarthritis Initiative Study
Kaleen N. Hayes; Vasily Giannakeas; Andy Kin On Wong
University of Toronto, Toronto, ON, Canada
Background: Knee osteoarthritis (KOA) is a debilitating condition
which is prevalent in older adults. Bisphosphonates (BP) have been
explored for treating KOA; however, little data exist on effects of
today's more potent BPs on radiographic disease progression.
Objectives: To determine if the use of BP is protective against 2‐year
radiographic progression of KOA in Osteoarthritis Initiative (OAI)
cohort patients. Secondary objectives were to explore cumulative BP
exposure effects and time to incident narcotic analgesic use.
Methods: The OAI is an 11‐year longitudinal US cohort study which
recruited men and women aged 45–75 from 2004–2006. Patients
were enrolled into the progression (existing symptomatic KOA), inci-
dence (high risk of developing symptomatic KOA), or healthy control
sub‐cohorts. We linked publicly available demographic, imaging, and
clinical OAI datasets to identify incidence and progression patients
at enrollment (baseline) with at least 1 follow‐up visit. We excluded
patients with other osteoporosis drug, corticosteroid, or narcotic anal-
gesic use; missing or severe radiograph readings for both knees; and
conditions which may impact bone. Patients were followed until first
radiographic KOA progression in a non‐prosthetic knee (1‐unit change
in Kellgren and Lawrence [KL] grade), or data were censored (first
missed visit or end of 2‐year follow‐up). Discrete time logistic models
were used to estimate hazard ratios between baseline BP users versus
non‐users by baseline KL grade. Models were adjusted for time‐invari-
ant (sex, age, enrollment date, race, symptomatic KOA diagnosis,
Charlson score, smoking status, body mass index, vitamin D use, mul-
tivitamin use [healthy user proxy]) and time‐varying (OA medication/
analgesic use, fractures, falls) confounders.
Results: We identified 3,566 eligible patients (28% symptomatic KOA,
56% women, mean age 61 ± 9 years, 9% BP users [71% alendronate]).
N = 564 patients experienced the primary outcome, and N = 308 were
censored. BP users with KL grade < 2 were protected against progres-
sion (HRadj 0.46 [95% CI 0.23, 0.95]), while BP use was not associated
with radiographic progression in those with KL grade ≥ 2 (HRadj 1.06
[95% CI 0.73, 1.53]). Years of BP use at baseline had no significant
effect on progression, though sample size was limited. BP use did
not affect time to narcotic analgesic use.
Conclusions: BP may be protective against radiographic KOA progres-
sion in early‐stage patients, but less so for those with advanced dis-
ease. More study of the effects of BP type, cumulative dose, and
potential confounding by indication is needed.
37 | The Effect of Beta Blocker Use on Bone
Outcomes in the Framingham Osteoporosis
Study
Christine W. Lary1; Kathleen Nevola2; Alexandra C. Hinton1;
Theresa I. Shireman3; Katherine Motyl4; Karen L. Houseknecht5;
Frances L. Lucas1; Sarah Hallen6; Andrew R. Zullo3; Sarah D. Berry7;
Douglas P. Kiel7
1Maine Medical Center, Portland, ME; 2Tufts University, Boston, MA;
3Brown University School of Public Health, Providence, RI; 4Maine
Medical Center Research Institute, Scarborough, ME; 5University of New
England, Biddeford, ME; 6Maine Medical Center, Portland, ME; 7Harvard
Medical School, Boston, MA
Background: Beta Blockers (BBs) have shown positive effects on bone
mineral density (BMD) and fracture outcomes in several studies, with
some but not all finding increased effect for Beta‐1 selective BBs. It
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is unresolved how Beta‐1 selectivity influences this effect and how
the effect varies by skeletal site.
Objectives: Test the hypotheses that 1) BB use and 2) Beta‐1 selective
BB use are associated with greater hip and spine BMD and lower inci-
dence of osteoporotic fractures.
Methods: We used data from the Offspring (2nd generation) cohort of
the FraminghamHeart Study (N = 2,803), a prospective study of cardio-
vascular outcomes. BB use and Beta‐1 selective BB use and covariates
were assessed between2005–2008,whichwas the index date. Femoral
neck (FN), trochanter, total femur, and lumbar spine (L2‐L4) BMDwere
measured using dual energy x‐ray absorptiometry in cohort members
willing to return for a call back visit (N = 1662). Occurrence of an osteo-
porotic fracture between the index date and the end of follow‐up
(August 2013) was noted. Covariates were age, height, weight, current
smoking, cigarettes per day, prior cardiovascular disease, current treat-
ment for diabetes, hypertension, hyperlipidemia, and menopause and
hormone therapy for women. Analyses were done for the full cohort
and stratified by sex, and models were adjusted for covariates using lin-
ear or logistic regression for BMD or fracture.
Results: Of the 1,662 who participated in the Osteoporosis study visit
(53.1% female, average age 66), BB were used by 418 (25.2%) individ-
uals, 358 (85.6%) of which were B1‐selective users, with atenolol and
metoprolol being the most common medications. FN BMD was signif-
icantly higher in BB users vs. non‐users in crude and adjusted sex‐
combined models (0.019 g/cm2 greater; 95% CI 0.003–0.035,
p = 0.0171 in adjusted model). The effect of Beta‐1 selective agents
was similar (0.017 g/cm2 greater; 95% CI 0.001–0.033, p = 0.0399).
Sex‐stratified models showed similar trends but were not significant.
Other BMD sites showed significant results in crude but not adjusted
models. Of the full cohort of 2,803, 204 (7.3%) had an osteoporotic
fracture, 61 (8.4%) for BB users and 143 (6.9%) for non BB‐users.
There was no significant association between BB use and fracture in
either crude or adjusted models (odds ratio of 1.09; p = 0.6758 in
adjusted model).
Conclusions: BB use and B1‐selective BB use were significantly asso-
ciated with higher BMD of the hip, but there was no reduction in risk
for incident fractures among users. This may due to insufficient influ-
ence of BMD to reduce fracture risk, or because BBs may affect other
fracture risk factors such as falls.
38 | Sodium‐Glucose Co‐Transporter 2
Inhibitors and the Risk of Fractures among
Patients with Type 2 Diabetes
Devin Abrahami1,2; Antonios Douros1,2; Hui Yin2; Oriana H.Y. Yu2,3;
Laurent Azoulay1,2
1McGill University, Montreal, QC, Canada; 2Lady Davis Institute, Jewish
General Hospital, Montreal, QC, Canada; 3Division of Endocrinology,
Jewish General Hospital, Montreal, QC, Canada
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors are
novel drugs used to manage type 2 diabetes. While they are favorably
prescribed, there are concerns that their use may increase the risk of
fractures. Indeed, large cardiovascular outcome trials have generated
conflicting findings, and few real‐world studies have been conducted
to assess this association. As type 2 diabetes largely affects the
elderly, and fracture incidence in this vulnerable population is associ-
ated with increased mortality, there is an urgent need to address this
safety issue in the natural setting of clinical practice.
Objectives: To determine whether the use of SGLT2 inhibitors is asso-
ciated with an increased fracture risk in patients with type 2 diabetes.
Methods: Using the UK Clinical Practice Research Datalink, we identi-
fied a cohort of 73,178 patients newly‐treated with antihyperglycemic
drugs between January 1, 2013 and December 31, 2017, followed
until March 31, 2018. Time‐dependent Cox proportional hazards
models were used to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs) of incident fractures associated with use of SGLT2
inhibitors overall, and according to specific types (dapagliflozin,
empagliflozin and canagliflozin), when compared with use of dipeptidyl
peptidase‐4 inhibitors, a clinically relevant comparator. Models were
adjusted for age, sex, smoking status, body mass index, alcohol‐related
disorders and markers of diabetes severity. We also assessed whether
the risk was modified by history of fracture, osteoporosis, age or sex.
We conducted several sensitivity analyses, including a marginal struc-
tural model and high‐dimensional disease risk score, to assess the
robustness of the findings.
Results: During 153,179 person‐years of follow‐up, there were 1,973
incident fracture events (incidence rate: 12.9/1,000 per year). Overall
use of SGLT2 inhibitors was not associated with an increased risk of
fracture (HR: 0.97, 95% CI: 0.79–1.19) when compared with
dipeptidyl peptidase‐4 inhibitors. Similar findings were observed when
stratifying on specific SGLT2 inhibitors, with non‐significant HRs rang-
ing between 0.67 and 1.42. The risk was not modified by history of
fracture, osteoporosis, age or sex. Sensitivity analyses yielded highly
consistent findings.
Conclusions: The results of this large population‐based study suggest
that use of SGLT2 inhibitors is not associated with fracture incidence
in patients with type 2 diabetes. This finding should provide reassur-
ance on the safety of this new drug class.
39 | Immunosuppression, Fractures, and
Post‐Kidney Transplant Outcomes among
Older Recipients
Mara McAdams DeMarco; Megan Salter; Sunjae Bae; Nadia Chu;
Dorry Segev
Johns Hopkins, Baltimore, MD
Background: Older kidney transplant (KT) recipients are living longer
with a functioning graft, and are at risk for age‐related adverse events
including fractures. However, fracture risk may be elevated in this
population due to the life‐long reliance on immunosuppression (IS),
which often includes classes of medications, like steroids, that increase
fracture risk in older adults. Understanding which IS agents elevate
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fracture risk may help identify optimal IS regimens for older recipients
to reduce adverse outcomes like graft loss and mortality.
Objectives: To estimate the risk of incident post‐KT fractures associ-
ated with induction and maintenance IS and the risk of subsequent
death‐censored graft loss (DCGL) and mortality.
Methods: This was a cohort study of 47,815 patients aged 55 years
and older who received KT (1/1/1999–12/31/2014). We linked data
from the national registry of KT recipients to Medicare claims through
the United States Renal Data System. Induction (none, ATG, IL2
receptor antagonist, alemtuzumab, other) and maintenance IS (steroid
use, calcineurin inhibitors [tacrolimus, cyclosporin, none], and antime-
tabolites [MMF, mTOR, azathioprine, other, none]) at discharge was
gleaned. We estimated the cumulative incidence of post‐KT fractures
and association between IS and post‐KT fractures using adjusted com-
peting risks models. We estimated risk of DCGL and mortality after
fracture using adjusted Cox proportional hazards models treating frac-
tures as time‐varying.
Results: The 5‐year incidence of post‐KT hip, vertebral, and extremity
fracture for those aged 65–69 was 3.8%, 1.6%, and 3.1%, respectively.
No induction IS agents were associated with post‐KT fractures. mTOR
was associated with a 1.31‐fold (95% CI: 1.07–1.59) increased risk of
hip fracture compared to MMF. Lack of a calcineurin inhibitor was
associated with 1.42‐fold (95% CI: 1.05–1.91) increased risk of verte-
bral fracture compared to tacrolimus; and steroid use was associated
with a 1.19‐fold (95% CI: 1.04–1.35) increased risk of extremity frac-
ture compared to no use. DCGL and mortality risk were higher after
hip (DCGL aHR = 4.94, 95%CI:4.48–5.44; mortality aHR = 2.32,
95%CI:2.15–2.51), vertebral (DCGL aHR = 5.31, 95%CI:4.51–6.26;
mortality aHR = 2.84, 95%CI:2.51–3.24), and extremity (DCGL
aHR = 4.37, 95%CI:3.92–4.88; mortality aHR = 2.12, 95%CI:1.93–
2.32) fracture.
Conclusions: Maintenance IS regiments that included mTOR and ste-
roids but not calcineurin inhibitors, may increase the risk of post‐KT
fractures leading to mortality and graft loss and should be avoided
among older recipients.
40 | Benzodiazepines and Risk of Fractures
in Young People
Greta A. Bushnell1; Tobias Gerhard2; Stephen Crystal2; Mark Olfson1,3
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2Rutgers University, New Brunswick, NJ; 3Columbia University Irving
Medical Center, New York, NY
Background: Benzodiazepine (BZD) treatment has been associated
with falls and fractures in older adults. BZD side effects such as slowed
reaction time and dizziness could also lead to accidental falls in youth,
including falls from heights or during athletic activities. Whether BZD
treatment increases fracture risk in youth remains unknown.
Objectives: To determine if privately insured youth with anxiety disor-
ders initiating a BZD have an increased risk of fractures compared to
youth initiating an SSRI.
Methods: In a commercial claims database (2007–2016), we identified
privately insured children (6–17 years) and young adults (18–24) with
a recent anxiety disorder diagnosis, who newly initiated BZD or SSRI
treatment (one‐year washout). Following treatment initiation, youth
were followed until fracture, treatment discontinuation or switching,
insurance disenrollment, end of data, or 6‐months. The endpoint was
defined by ICD‐9 and ICD‐10 codes for long‐bone fractures. We esti-
mated separate propensity scores in children and young adults and
applied one percent trimming. We then estimated crude and inverse‐
probability of treatment weighted fracture rates and adjusted hazard
ratios (aHRs).
Results: The cohort included 12,840 child BZD initiators (107,875
SSRI initiators) and 57,684 young adult BZD initiators (122,084 SSRI
initiators). Overall, BZD treatment was shorter than SSRI treatment:
5% of BZD initiators and 40% of SSRI initiators remained on treatment
after 6 months. The crude fracture rate during treatment in children
was 32.6 per 1000 person‐years (PYs) in BZD initiators and 23.5/
1000 PYs in SSRI initiators [HR = 1.29 (95%CI = 0.93–1.78); rate dif-
ference (RD) = 9.1/1000 PYs]. In the weighted cohort, the fracture
rate was 38.7/1000 PYs and 23.5/1000 PYs in BZD vs. SSRI child ini-
tiators, respectively [aHR = 1.54 (0.91–2.58), RD = 15.2/1000 PYs]. In
young adults, fracture rates were lower than in children with a
weighted fracture rate during BZD treatment of 7.9/1000 PYs and
of 8.5/1000 PYs during SSRI treatment [aHR = 0.94 (0.65–1.36), RD = ‐
0.6/1000 PYs].
Conclusions: Initial findings suggest a potentially clinically relevant
heightened rate of fractures in children with anxiety disorders initiat-
ing BZD treatment compared to SSRI treatment, but not in young
adults. Increased caution in the weeks after BZD initiation in children
with anxiety disorders may be warranted.
41 | Long‐Term Budesonide Treatment and
Risk of Osteoporotic Fractures in Patients
with Microscopic Colitis
Mette Reilev1; Ole K. Bonderup2; Gunnar L. Nielsen3; MartinT. Ernst1;
Jesper Hallas1
1University of Southern Denmark, Odense, Denmark; 2Aarhus University,
Odense, Denmark; 3Aalborg University, Aalborg, Denmark
Background: Due to a substantial first pass metabolism of oral
budesonide the systemic bioavailability is low compared to other oral
corticosteroids. This may lead to a low risk of adverse effects normally
related to long‐term use of corticosteroids.
Objectives: We aimed to determine whether use of oral budesonide is
associated with osteoporotic fractures in patients with microscopic
colitis.
Methods: Applying data from the Danish nationwide health registries,
we conducted a case–control study nested within patients with a his-
tologically verified diagnosis of microscopic colitis from 2004 to 2012.
Cases were individuals with a first‐occurrence of a fracture likely
caused by osteoporosis i.e., fracture of hip (ICD‐10: S72), wrist
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(S525) or spine (S220 & 320). Cases were matched to controls by risk
set sampling in a ratio of 1:3. We estimated odds ratios (ORs) for the
association between ever use of budesonide and any osteoporotic
related fractures, and for hip‐, wrist and spinal fractures indepen-
dently. Further, we investigated dose–response associations and asso-
ciations for subgroups at suspected high or low risk of fractures.
Potential confounding was adjusted for by risk set sampling and
regression analyses.
Results: ResultsWeidentified485caseswitha firstoccurrenceofafrac-
ture as defined above. The majority were women (86%) and the median
age was 78 years. After adjustment for confounding, a modestly
increasedadjustedORwasobserved for theoverall associationbetween
use of budesonide and osteoporotic fractures (OR 1.39, CI: 1.09–1.76).
Stratification by type of fracture revealed the highest risk of spinal frac-
tures (2.15, CI: 1.09–4.25), followed hip‐, and wrist fractures (OR 1.34
(CI: 0.94–1.93) and OR 1.26 (CI: 0.87–1.83), respectively). No dose–
response association was evident (OR for doubling of cumulative dose
1.03 (CI: 0.91–1.16). When addressing differences across subgroups,
we generally foundmoderately increased ORs (1.28–1.97).
Conclusions: Our results suggest a moderately increased risk
increased risk of osteoporotic fractures related to use of budesonide
among individuals with microscopic colitis. However, no dose–
response association could be demonstrated.
42 | The Ascension of Real‐World Evidence:
Can (and Should) We Establish Thresholds for
Validity?
Nicolle M. Gatto1; Cynthia Girman2; Stephan Lanes3; David Martin4;
Robert F. Reynolds1; Sebastian Schneeweiss5; Jim Slattery6
1Pfizer, New York, NY; 2CERobs, Chapel Hill, NC; 3HealthCore,
Wilmington, DE; 4U.S. Food and Drug Administration, Silver Spring, MD;
5Brigham and Women's Hospital, Boston, MA; 6European Medicines
Agency, London, United Kingdom
Background:While real‐world data (RWD) have been used to evaluate
medicine safety for decades, interest in appropriate use of real‐world
evidence (RWE) for regulatory decision making has grown rapidly
due to the potential benefits associated with accelerated clinical
development and the potential harm due to misleading evidence.
The regulatory utility of RWE will likely depend on the extent to which
researchers can demonstrate certainty about validity. To do so,
researchers need methods and tools that are flexible, and easy to
communicate.
Objectives: To understand current approaches to evaluating (a priori
and post hoc) biases in real‐world studies intended for regulatory deci-
sion making, identify key gaps in methods or tools that aid these eval-
uations, and to discuss the feasibility of setting thresholds for
regulatory quality evidence. This symposium will be of interest to
those involved in the design, implementation, or interpretation of
comparative effectiveness/safety studies using RWD for regulatory
decision‐making.
Description: Internal validity (bucketed under “relevance”) is a critical
component of the recently released FDA RWE Framework. Much is
known about the potential effects of biases in observational studies
and there is comprehensive guidance to assess the validity of a com-
pleted study (e.g. GRACE Principles) or minimize bias through design
(e.g. ENCePP). Sensitivity analyses (especially pre‐specified) may help
increase confidence in the robustness of results but are not applied
systematically, and acceptable level of uncertainty around imperfect
confounding control and misclassification (e.g. a sensitivity or speci-
ficity of <100% for a key inclusion diagnosis or primary outcome)
is not well characterized. Acceptability may depend on the size of
the treatment effect, seriousness of the outcome and other factors.
In this symposium, researchers and decision makers will describe
the current state of bias evaluation, and will discuss how ongoing
validation studies, RCT replication projects and other supportive pro-
jects will look to derive principles within and across projects. The
panel will discuss the current gaps in knowledge and tools, and the
feasibility of establishing requirements for validity in regulatory
guidance.
Structure (approx. times):
Introduction ‐ 5 min (NG).
Current state: Evaluation of endpoint validity ‐ 15 min (SL).
Current state: Evaluation of confounding control ‐ 15 min (SS).
FDA led/sponsored validation projects ‐ 15 min (DM).
EMA perspective ‐ 10 min (JS).
Building validation into RWE generation platforms ‐ 10 min (RR).
Summary ‐ 5 min (CG).
Panel discussion −20 min.
43 | Heterogeneity and Validity in National
and International Multi‐Database
Pharmacoepidemiologic Studies (MPES):
Lessons Learned in North America, Europe,
and Asia
Edward Chia‐Cheng Lai1; Kenneth Man2; Darren Toh3; Robert Platt4;
Jesper Hallas5; Soko Setoguchi6
1National Cheng Kung University, Tainan, Taiwan; 2UCL School of
Pharmacy, London, United Kingdom; 3Harvard University, Boston, MA;
4McGill University, Montreal, QC, Canada; 5National Cheng Kung
University, University of Southern Denmark, Denmark; 6Rutgers
University, New Brunswick, NJ
Background: Multi‐Database pharmacoepidemiologic studies (MPES)
can assess safety and effectiveness of medications with greater statis-
tical power and identify treatment variations within a country and/or
across countries. However, observed heterogeneity among databases
can be due to genetic, cultural, and behavioral differences in the pop-
ulations but also can arise from differences in clinical practice or tech-
nical issues in coding or mapping across databases.
Objectives: This symposium will share experiences in the US, Canada,
Europe, and Asia to provide important lessons for those who want to
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learn about and/or conduct national and international multi‐database
studies. The objectives are:
1. To describe how to recognize heterogeneity and how they affect
the validity of national and international MPES. 2. To start forming
consensus on recommendations on the best practices to address/
reveal measured and unmeasured heterogeneity across databases. 3.
To discuss when to aggregate the results from multiple databases
and conclude the study appropriately.
Description: After a brief introduction of the topic (Setoguchi S), four
presenters will present:
1.MPES of various databases within one country ‐ the US FDA Senti-
nel System (Toh D.; 15 mins) 2.MPES of Province‐based databases
within one country ‐Canadian Network for Observational Drug Effect
Studies (CNODES) (Platt R.;15 mins) 3.MPES of country‐based data-
bases within one union ‐ experience from European network (Man
K.; 15 mins) 4.MPES of country‐based databases within Asia ‐the
Asian Pharmacoepidemiology Network (AsPEN) (Lai E.; 15 mins).
Panel discussion (Setoguchi S. and Hallas J.; 30 mins): The session will
end with panel discussion addressing the questions below to bring the
audiences and panelists towards consensus on the best practices for
MPES regarding understanding and managing heterogeneity: A. How
to recognize and prevent technical issues related to coding, mapping
and common data models. B. How to recognize heterogeneity and
other related validity issues. C. Suggestions on valid analytic
approaches for dealing with the heterogeneity. D. When it is appropri-
ate to aggregate the results from multiple databases. E. Consensus on
practical guides to maintain transparency and increase producibility
for a standard report in MPES.
44 | Thinking Globally While Acting Locally:
Developing Time‐on‐Treatment Data in
International Settings
Judith C. Maro1; Kristian B. Filion2; Achim Wolf3; Kevin Haynes4;
Michael D. Nguyen5
1Harvard Medical School and Harvard Pilgrim Health Care Institute, Inc.,
Boston, MA; 2McGill University, Montreal, QC, Canada; 3Medicines and
Healthcare Products Regulatory Agency, London, United Kingdom;
4HealthCore, Wilmington, DE; 5U.S. Food and Drug Administration, Silver
Spring, MD
Background: Correct classification of exposed time is critical and chal-
lenging when integrating data streams. Differences in exposure mea-
surement represent an important source of heterogeneity that needs
to be considered in design and analysis of studies.
Objectives: Time‐on‐treatment information may be sourced from dis-
parate data streams such as prescribing, dispensing and medication
administration information. Prescribing data can identify clinical intent,
but lacks assurance of use. Dispensing data is more widely used, but
may not capture inpatient information or out‐of‐pocket payment.
Finally, medication administration may lack needed granularity. How-
ever, as common data models and querying tools enable efficient
use of multiple data sources, many are faced with decisions regarding
how to define time‐on‐treatment within and across data sources. This
symposium addresses approaches to these issues and identifies poten-
tial limitations when conducting multi‐site research using disparate
data streams to define exposure. We focus on illustrative examples
including direct acting oral anticoagulants, Vitamin K antagonists,
sodium glucose cotransporter (SGLT2) inhibitors, and selected
antibiotics.
Description: 1. Comparisons in dispensing data in the Canadian Net-
work for Observational Drug Effect Studies (CNODES) and the US
Sentinel System. With common data models and querying tools, Cana-
dian and US dispensing data are compared for a range of therapies.
(15 min, Maro) 2. Integrating prescribing data into CNODES:
CNODES has included UK Clinical Practice Research Datalink (CPRD)
prescribing data in common‐protocol studies to increase precision and
leverage clinical data to examine residual confounding. (15 min, Filion)
3. US dispensing vs. US prescribing data in the Patient‐Centered Clin-
ical Research Network (PCORnet). Data linkage within
PCORnet allowed comparison of antibiotic prescribing and dispensing
for the same patient, highlighting differences across multiple systems.
(15 min, Haynes) 4. UK CPRD experience with prescribing data for-
matted to the Sentinel Common Data Model (SCDM). Translation of
the UK CPRD's Aurum database into the SCDM required creation
and population of a prescribing data table for routine querying. Sample
queries highlight differences between the UK CPRD and other data
sources. (15 min, Wolf) 5. Regulatory Impact: The US Food and Drug
Administration reflects on the use of heterogeneous treatment data
from international collaborators in advancing the science of drug
safety. (15 min, Nguyen) 6. Discussion (15 min, All).
45 | Machine Learning to Improve Causal
Inference in Pharmacoepidemiology
Jason Roy1; Nandita Mitra2
1Rutgers University, Piscataway, NJ; 2University of Pennsylvania,
Philadelphia, PA
Background: Machine learning methods have largely been developed
for prediction, but increasingly they are being used within a causal
inference framework.
Objectives: To review some causal inference and machine learning
methods. To describe ways in which causal inference methods can
benefit from specific machine learning methods. To have a guided dis-
cussion on the use of machine learning methods in
pharmacoepidemiology. To learn how to implement the methods in
R. Researchers wanting additional information about modern causal
inference methods should benefit by attending.
Description: This workshop will begin with a brief review of some
popular causal inference methods, such as inverse probability of treat-
ment weighting and g‐computation. Opportunities will be identified
for making these approaches more robust with the use of machine
learning methods. As examples, two machine learning methods will
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be introduced: super learner and Bayesian additive regression trees
(BART). Illustrations of how these machine learning methods can be
used in conjunction with standard causal inference methods will be
presented. After each causal inference/machine learning combination
is introduced and discussed in the context of specific
pharmacoepidemiology studies, there will be a guided, interactive dis-
cussion. The workshop will include implementation of these methods
in R, along with comparisons with more familiar regression versions
of the methods. There will be a discussion of some of the benefits
and limitations of these methods, especially in the context of EHR
and claims database research.
46 | Measuring, Mapping, and Meshing of
Genotype and Phenotype Data across Large
Datasets: Challenges of Combining and
Mining Genotype and Phenotype Data
Leah Sansbury1; Meg Ehm1; Marylyn Richie2; Amalia Issa3;
Colin Palmer4; Edgar Simard1
1GlaxoSmithKline, Collegeville, PA; 2University of Pennsylvania,
Collegeville, PA; 3Univeristy of the Sciences, Philadelphia, PA; 4University
of Dundee, Collegeville, PA
Background: Large datasets containing genetic information are uti-
lized to understand mechanisms of disease and to identify therapeutic
targets. Linking of numerous data sources facilitates broad phenotypic
explorations and enhances our understanding of the target disease
mechanisms. However, due to different data collection methods
researchers face numerous challenges mapping concepts across
datasets and merging disparate information.
Objectives: To discuss the various data resources available for
conducting translational genotype and phenotype studies, including
genetic and real‐world data for translational research. The presenters
will outline examples of the newest methods to define phenotypes
and assess association with genetic data. Furthermore, the panelists
will discuss opportunities that are emerging (e.g. the option to
engage patients to get more phenotypic data). Finally, the presenters
will discuss challenges associated with methods, data, and interpreta-
tion of large datasets that have combined genotype and phenotype
data.
Description: With the convergence of greater access to large, deep,
genetic datasets that also contain phenotypic insights (e.g. 23andMe,
UK BioBank, FinnGen), and advances in analytic capabilities, our ability
to merge and generate genotypic and phenotypic insights has greatly
increased. Presenters will outline how we are using genetics for drug
discovery and how to leverage the advantages of each dataset. In
addition, presenters will provide examples of conducing PheWAS
and the use of methods to derive phenotypes. Additionally, the pre-
senters will provide examples of use of EHRs to understand
pharmacogenic associations. Finally, there will be a focus on
implementing complex methods, including polygenic risk score
analysis.
47 | Using Negative Control Outcomes to
Assess the Comparability of Osteoporosis
Treatment Groups
Leah J. McGrath1; Leslie Spangler2; Jeffrey R. Curtis3;
Vera Ehrenstein4; Henrik Toft Sørensen4; Bradley Saul1;
Sara Levintow1; M. Alan Brookhart1; Brian D. Bradbury2
1NoviSci, Durham, NC; 2Amgen, Thousand Oaks, CA; 3University of
Alabama at Birmingham, Birmingham, AL; 4Aarhus University Hospital,
Aarhus, Denmark
Background: Comparative safety and effectiveness estimates for oste-
oporosis (OP) treatments can be biased due to confounding by indica-
tion. The extent of bias can be assessed with negative control
outcomes that are expected to have no plausible association with
the biologic effects of OP medications.
Objectives: Using negative control outcomes selected by an expert
panel, we evaluated whether women initiating different OP treat-
ments were comparable after controlling for potential confounders.
Methods: We used the MarketScan Commercial and Medicare Sup-
plemental claims data to identify OP treatment‐naïve women aged
55 years or older initiating denosumab, intravenous (IV) zoledronic
acid (ZA), or an oral bisphosphonate (BP) (risedronate, alendronate,
or ibandronate) from October 1, 2010 through September 30, 2015.
We required at least 12 months of continuous enrollment in a
healthcare plan before initiation and excluded patients with history
of Paget's disease or cancer. We compared individual oral BPs, as well
as denosumab with ZA and with all oral BPs, with respect to 11 neg-
ative control outcomes grouped into three domains, defined by the
expected source of bias: functional status, healthy user/adherer, and
access to healthcare. We estimated the 12‐month cumulative risk dif-
ference (RD) of each outcome, using inverse probability of censoring
and treatment weights to control confounding by baseline demo-
graphics, healthcare utilization, comorbidities, and comedications. Indi-
vidual RDs within each domain were pooled using inverse‐variance
weights.
Results: Among 148,587 eligible women, 53% were 55–64 years old,
10% had a history of fracture, and 30% had a history of corticosteroid
use. Alendronate was the most common osteoporosis treatment
(57%), followed by ibandronate (12%), ZA (11%), risedronate (10%),
and denosumab (10%). Nearly all exposure comparisons indicated no
meaningful association between treatment choice and negative con-
trol outcomes. Exceptions were comparisons of either denosumab or
ZA with oral BPs on the healthy user/adherer domain. The pooled
RD per 1,000 women was 9.1 (95% CI: 3.5, 14.7) comparing
denosumab with oral BPs and 6.5 (95% CI: 1.8, 11.2) comparing ZA
with oral BPs.
Conclusions: After adjustment, there was minimal evidence of residual
bias for most negative control outcomes among women initiating OP
treatments, supporting the potential for non‐experimental compara-
tive safety research. Caution is warranted when comparing injectable
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versus oral medications and in extending these results to other popu-
lations, such as older adults with comorbidities.
48 | Can Adjustment Fail? Confounder
Misclassification in Single‐Arm Studies with
Real World Comparators
Michael Webster‐Clark; Mitchell Conover; Michele Jonsson‐Funk;
Til Stürmer
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Hybrid studies comparing outcomes in those on experi-
mental therapy to untreated patients from real‐world data (RWD)
are becoming more common. These single‐arm studies control for
confounding with statistical methods, but it is unclear when these
methods fail to reduce bias in the setting of confounder
misclassification.
Objectives: Explore changes in bias after weighting by a confounder
measured differently in two treatment arms using illustrative quantita-
tive examples.
Methods: We considered treatment X with no effect on outcome Y,
confounder C affecting X and Y, and C′ representing measured C.
We held fixed effect of C on Y (RR = 5.0), sensitivity (0.60) and spec-
ificity (0.99) of C in the experimental arm (i.e. when X = 1), and prev-
alence of X (0.1) when C = 0. We varied prevalence of C, effect of C
on X, and sensitivity and specificity for measurement of C in the
RWD arm (i.e. when X = 0). We used prevalence and sensitivity
parameters for smoking from the literature (10% prevalence, RWD
sensitivity of 0.15, RWD specificity of 0.99) in situations where
smoking tripled (scenario 1) or divided by 3 (scenario 2) probability
of X. We also examined two generic scenarios with near‐perfect sen-
sitivity (0.99) of C when X = 1: scenario 3 where rare C (10% preva-
lence) tripled probability of X with low specificity (0.60) in the RWD;
and scenario 4 where common C (80% prevalence) divided by 3 prob-
ability of X with low sensitivity (0.60) in the RWD arm. We then used
inverse probability of treatment weighting (IPTW) to adjust for C′ and
also performed separate analyses stratified by C′.
Results: In scenario 1, the unadjusted RR (RRunadj) was 1.52 vs an
IPTW RR of 1.17 (bias decrease versus the true null effect). In scenario
2 the RRunadj was 0.762 vs an IPTW RR of 0.757 (minor bias increase).
In scenarios 3 and 4, bias increased more substantially: in scenario 3
the RRunadj was 1.65 vs an IPTW RR of 2.05; in scenario 4 the RRunadj
was 0.756 vs an IPTW RR of 0.723. Weaker effects of C on X or larger
gaps in measurement error between the two arms increased bias. Even
when the IPTW RR was less biased than the RRunadj, estimates in at
least one subgroup were often biased.
Conclusions: If there is differential misclassification of and confound-
ing by C, collider bias from conditioning on C′ may increase bias com-
pared to a crude estimate. The larger the gap in classification between
treatment arms and the weaker the true confounder‐exposure associ-
ation, the more easily partial control for C is overwhelmed by this col-
lider bias. Single‐arm studies may need to consider methods (e.g.
imputation) to remedy differential misclassification of confounders
by treatment.
49 | Confounding by Indication in Drug‐
Cancer Association Studies: A Nested Case–
Control Study of the Association between
Calcium Channel Blockers and Renal Cell
Carcinoma
Kasper Bruun Kristensen1; Laurel A. Habel2; Joshua J. Gagne3;
Søren Friis4; Jesper Hallas1; Klaus Kaae Andersen4; Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Kaiser Permanente
Northern California, Oakland, CA; 3Brigham and Women's Hospital and
Harvard Medical School, Boston, MA; 4Danish Cancer Society,
Copenhagen, Denmark
Background: Use of calcium channel blockers (CCBs) and other anti-
hypertensive drugs has been associated with increased risk of renal
cell carcinoma. Since hypertension is a risk factor for renal cell carci-
noma, confounding by indication is a potential explanation for the
association.
Objectives: To examine whether CCB use was associated with an
increased risk of renal cell carcinoma and provide a framework for
addressing confounding by indication in drug‐cancer association
studies.
Methods: We conducted a nested case–control study using Danish
demographic and health registries. We identified all renal cell cancer
cases in Denmark between 2005–2015 and selected ten controls for
each case matched on age and sex. Using conditional logistic regres-
sion, we estimated odds ratios (ORs) with 95% confidence intervals
(CI) for long‐term (≥ 1000 defined daily doses) vs. never use of CCBs
associated with renal cell carcinoma. We addressed confounding by
indication in several analyses including (i) adjusting for severity of
hypertension and concurrent antihypertensive drug use; (ii) evaluating
dose–response patterns; (iii) estimating ORs for other antihyperten-
sive drugs associated with renal cell carcinoma, and (vi) restricting to
new users of antihypertensives and selecting long‐term use of other
first‐line antihypertensive drugs as a referent.
Results: We included 5502 renal cell carcinoma cases of whom 16.4%
were long‐term users of CCBs. The corresponding proportion among
controls was 9%, yielding a crude OR of 2.23 (95%CI 2.05 to 2.42).
The association was attenuated upon adjusting for hypertension
severity and use of other antihypertensives (OR 1.45, 95%CI 1.31 to
1.60). The OR increased with increasing cumulative dose in adjusted
models (ptrend < 0.001). Long‐term use of ACE‐inhibitors, thiazides,
and furosemide showed similar associations with renal cell carcinoma,
including dose–response patterns. When restricting to new‐users and
using long‐term use of other first‐line antihypertensive drugs as refer-
ent, the adjusted OR was 1.68 (95%CI 1.47 to 1.91).
Conclusions: Long‐term use of CCBs was associated with increased
risk of renal cell cancer. We used a range of methods to address con-
founding by indication and demonstrated a smaller association when
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adjusting for severity of hypertension and similar associations with
other commonly used antihypertensive drugs. However, confounding
by indication does not appear to fully explain the association between
CCBs and renal cell carcinoma.
50 | Visualization Tool of Variable Selection
for Inverse Probability Weighted Estimator in
High‐Dimensional Covariates
Ya‐Hui Yu1; Ashley I. Naimi2; Lisa M. Bodnar2; Kristian B. Filion1;
Robert W. Platt1
1McGill University, Montreal, QC, Canada; 2University of Pittsburgh,
Pittsburgh, PA
Background: Inverse probability weighting (IPW) is a commonly used
confounder adjustment method in pharmacoepidemiological studies
and there is a need to adjust for a high‐dimensional set of confounders
in administrative datasets. Adjusting for all confounders may reduce
bias, but at the expense of increased variance resulting in (near) posi-
tivity violations and unstable IPWs.
Objectives: We developed a SAS macro to generate plots displaying
the impact of each confounder on the bias and variance of IPW esti-
mates, propensity‐matched estimates, and propensity score overlap.
Methods: Mean squared error (MSE) was used as a summary statistic
for bias and variance of the IPW‐weighted estimate. We presumed
that the estimate from the fully adjusted model was the unbiased esti-
mate. We calculated bias as the deviance between this unbiased esti-
mate with the estimate from the model excluding certain confounders.
We also showed the estimates from IPW truncation as a comparison
to the approach of removing certain confounders. Among the two out-
put plots, the first showed risk ratios (RRs) with 95% confidence inter-
val from models that excluded the variable shown on the y‐axis. The
second plot showed the distribution of propensity scores of exposed
and non‐exposed groups from the corresponding models. These plots
were sorted by MSE of the outcome model. We showed how our
macro can visualize the impact of problematic confounders in two sce-
narios: (1) an empirical study examining the association between pre‐
pregnancy obesity and stillbirth in a cohort of linked birth and death
records in Pennsylvania; (2) a plasmode simulation study to mimic a
pharmacoepidemiologic study with high‐dimensional covariates. We
used data from the Clinical Practice Research Datalink and simulated
the known effect of statin use post‐myocardial infarction on one‐year
all‐cause mortality keeping the original associations among covariates.
Results: In our empirical study examining pre‐pregnancy obesity and
stillbirth, we identified 35 confounders. Adjusting for all confounders
led to RR = 1.37 (95% CI: 1.01, 1.90). After applying our macro, we
identified one confounder (prior gestational weight gain) that
increased MSE 3‐fold compared to full model. Removing this con-
founder from the propensity score model resulted in RR = 1.68 (95%
CI: 1.43, 1.99) and better propensity score overlap. The detailed
results from the plasmode simulation will be demonstrated in a series
of plots.
Conclusions: Our results suggest careful consideration of the analytic
impact of all confounders should be made when fitting IPW and pro-
pensity‐matched estimators.
51 | A General Propensity Score for Signal
Detection Using Tree‐Based Scan Statistics
Shirley V. Wang1; Joshua J. Gagne1; Judith C. Maro2;
Sushama Kattinakere1; Danijela Stojanovic3; Efe Eworuke3;
Elande Baro3; Rita Ouellet‐Hellstrom3; Michael Nguyen3;
Sandra DeLuccia2; Ella Pestine2; Martin Kulldorff1
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
2Harvard Pilgrim Health Care Institute and Harvard Medical School,
Boston, MA; 3US Food and Drug Administration, Silver Spring, MD
Background: Tree‐based scan statistics (TBSS) appropriately adjust p‐
values for multiple testing of correlated hypotheses when screening
thousands of potential adverse events for signal detection studies.
Simulation has demonstrated the promise of TBSS with a propensity
score (PS) matched cohort design. However, it is unclear which vari-
ables to include in the PS for applied signal detection studies of drug
safety to adjust for confounding across thousands of potential
outcomes.
Objectives: To develop a general PS applicable to different active‐
comparator cohorts and thousands of outcomes.
Methods: We selected 3 drug pairs with established safety profiles
where few, if any signals were expected. For each pair, we evaluated
5 candidate PS that included different combinations of: predefined
general covariates (demographics, comorbidity, frailty, utilization),
empirically identified covariates (via high‐dimensional PS algorithm)
and covariates tailored to the drug pair. We identified 1:1 matched
cohorts in MarketScan data using each PS, ran TBSS, ranked potential
adverse events by log likelihood ratio (LLR) and set a threshold for
alerting of p ≤ 0.01.
Results: For each drug pair (N > 290,000 each), the top ranked out-
comes were similar across PS matched cohorts. There were ≤ 2
unique alerts observed per example. Outcomes that met the threshold
for alerting were expected or explainable. For example, when compar-
ing macrolides versus fluoroquinolones, the top ranked outcome for
each PS‐matched cohort was hypertension complication in pregnancy.
This was explainable by channeling of azithromycin (a macrolide) to
pregnant women. Pregnancy was not a covariate in the predefined
PS, the outcome hypertension in pregnancy had p ≤ 0.01. When preg-
nancy was included as empirical and/or tailored covariates, the p‐
values were between 0.13–0.43. However, fewer pregnant patients
were in the matched cohorts, achieving better balance but reduced
power.
Conclusions: Including empirical covariates may provide better proxy
coverage of confounders for numerous outcomes than predefined
covariates alone, but could increase variance. Unlike covariates tai-
lored to exposures, empirical and predefined general covariates can
be applied “out of the box” for signal detection with different active‐
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comparator cohorts. Other than pregnancy, covariates tailored to
exposure did not appreciably impact screening results in our examples.
Potential signals should be followed up with pharmacoepidemiologic
assessment where confounding control is tailored to the specific out-
come(s) under investigation.
52 | Approaches to Overcome the
Immeasurable Time Bias in Cohort Studies:
Beta‐Blockers and Risk of Mortality in
Patients with Heart Failure
In‐sun Oh1; Han Eol Jeong1; Kristian B. Filion2; Ju‐Young Shin1
1SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Republic of
Korea; 2McGill University, Montreal, QC, Canada
Background: Immeasurable time bias, which occurs due to the lack of
inpatient drug data in many databases, may exaggerate drug benefits
in pharmacoepidemiologic studies. However, the optimal approach of
minimizing this bias remains unclear.
Objectives: To compare different methodological approaches at
reducing immeasurable time bias using the case study of β‐blocker
use and mortality among heart failure (HF) patients.
Methods: We conducted a propensity‐score matched, new‐user
cohort of patients with incident HF between 2003 and 2013 using
Korea's nationwide healthcare database. Exposure to β‐blockers was
treated as time‐varying, and patients were followed until death or
end of the study period. We estimated the gold standard hazard ratio
(HR) and its 95% confidence interval (CI) using both in‐ and outpatient
drug data. To assess methodological approaches to reduce immeasur-
able time bias, we used outpatient drug data only and conducted nine
trimming and five weighting analyses: trimming those with cumulative
hospitalization durations ≥90% of follow‐up, decreasing in 10% inter-
vals, weighting the number of observed days by 1) each exposed‐ and
unexposed durations, and 2) unexposed duration. Proportional dura-
tion, defined as observed days divided by the total duration of fol-
low‐up, was also used for weighting by 3) each exposed‐ and
unexposed durations, and 4) unexposed duration. An approach was
considered successful when the 95% CI of the estimated HR over-
lapped with the 95% CI of the gold standard HR.
Results: From our matched cohort of 14,774 patients, the gold stan-
dard's HR for mortality associated with β‐blocker use was 0.80 (95%
CI 0.73–0.89). After assessing a total of 45 approaches, trimming with
weighting by proportional durations was successful in minimizing the
bias while trimming with weighting by observed days was not. The
approach closest to the gold standard was trimming those hospitaliza-
tion ≥10% of follow‐up with weighting by each proportional durations
(0.71, 0.59–0.86). Using trimming cutoffs of ≥20% (0.65, 0.55–0.78)
and ≥ 30% (0.64, 0.53–0.76) were also successful approaches, while
a cutoff of ≥50% (0.55, 0.48–0.63) was not. When weighting by pro-
portional unexposed duration, only a trimming cutoff of ≥10% (0.69,
0.60–0.79) mitigated the bias whereas trimming cutoffs of ≥20%
(0.65, 0.57–0.72) and ≥ 30% (0.59, 0.52–0.67) did not.
Conclusions: The magnitude of the immeasurable time bias was sub-
stantial in our real‐world example. Trimming with weighting by pro-
portional durations seem to be optimal for reducing the impact of
immeasurable time bias.
53 | Risk of Pregnancy Loss in Patients
Exposed to Mycophenolate Compared to
Azathioprine: A Retrospective Cohort Study
Thuy N. Thai1; Amir Sarayani1; Xi Wang1; Yasser Albogami1;
Sonja Rasmussen2,3; Almut G. Winterstein1,3
1College of Pharmacy, University of Florida, Gainesville, FL; 2College of
Medicine, University of Florida, Gainesville, FL; 3College of Medicine and
College of Public Health and Health Professions, University of Florida,
Gainesville, FL
Background: Mycophenolate is one of the most commonly used
immunosuppressant medications. Although it is not recommended
for use during pregnancy due to its teratogenicity risk, the evidence
is limited to case series and one transplant registry study.
Objectives: To evaluate the relative risk (RR) of pregnancy loss associ-
ated with the use of mycophenolate (MPA) versus azathioprine (AZA)
during early pregnancy.
Methods: We conducted a retrospective cohort study using the IBM
MarketScan commercial claims databases from January 1st, 2005 to
June 31st, 2015. Pregnant patients had continuous enrollment
≥132 days before conception until the pregnancy end date. Concep-
tion was estimated using a claims‐based algorithm created from preg-
nancy‐related diagnoses and procedures codes. Patients with ≥1 MPA
dispensing were compared with AZA users during the first trimester.
The composite endpoint was pregnancy loss including stillbirth and
spontaneous abortion. Potential confounders included age, drug indi-
cations, comorbidities, use of other teratogenic medications, and ges-
tational age at first MPA or AZA prescription fill. The relative risk of
pregnancy loss was estimated using a generalized estimating equation
model with inverse probability of treatment weighting. In sensitivity
analyses, we varied the exposure assessment window (6 weeks before
conception to the end of first trimester and 6 weeks before concep-
tion to pregnancy end date), and the pregnancy loss definition (still-
birth, spontaneous, and induced abortions).
Results: A total of 108 and 445 pregnancies were exposed to MPA
(mean [SD] age of 33.3 [9.41]) and AZA (mean [SD] age of 32.6
[5.61]), respectively. In the MPA group, 50 pregnancies resulted in
pregnancy loss (46.3%) including 3 (2.8%) stillbirth and 47 (43.5%)
spontaneous abortions. In the AZA group, 100 pregnancies had preg-
nancy loss (22.5%) including 5 (1.1%) stillbirth and 95 (21.4%) sponta-
neous abortions. The unadjusted RR of pregnancy loss for MPA was
2.06 (95% CI 1.56–2.67) and the adjusted RR was 2.08 (95% CI,
1.58–2.70) compared to AZA. In the sensitivity analyses, we observed
similar adjusted RRs.
Conclusions: Exposure to MPA during pregnancy is associated with a
significantly increased risk of pregnancy loss. Our results support the
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recommendations for pregnancy prevention and use of alternative
treatment options at least 6 weeks before planned pregnancy.
54 | Exposure to Antidepressants during
Pregnancy and the Risk of Attention Deficit
Hyperactivity Disorder in Offspring: Findings
from a Nationwide Cohort Study with and
without Sibling Design
Buket Öztürk; Lars Pedersen; Vera Ehrenstein; Henrik T. Sørensen
Aarhus University Hospital, Aarhus, Denmark
Background: Attention deficit hyperactivity disorder (ADHD) is a seri-
ous disease. Recent studies have suggested an association between
maternal use of antidepressants during pregnancy and elevated risk
of ADHD in offspring. However, the findings may be confounded by
unmeasured socioeconomic or genetic factors.
Objectives: To examine the association between maternal use of anti-
depressants during pregnancy and the risk of ADHD in offspring by
using a classical cohort design and a sibling design.
Methods: We included all singleton live‐born infants in Denmark in
1997–2016. In a classical cohort design, we examined the association
by applying three models with increasing number of confounders
included for control: 1) a crude model (no adjustment), 2) a model con-
trolling for birth‐ and disease‐related factors, and 3) a model with addi-
tional control for socioeconomic factors. In a sibling design, we
compared the outcome in exposure‐discordant siblings, thus removing
confounding by shared risk factors. In addition, we adjusted for covar-
iates that could vary among siblings. As sensitivity analyses we per-
formed former vs. current user comparison and unconditional sibling
comparison. In addition, as a negative control analysis we performed
paternal exposure analysis. In all analyses, we used Cox regression to
calculate hazard ratios (HRs) for the risk of ADHD in offspring con-
trasting those with vs. those without exposure to antidepressants dur-
ing gestation.
Results: The overall population consisted of 1,223,201 live‐born sin-
gletons. The sibling population consisted of 30,578 siblings discordant
for maternal use of antidepressants. The three models in the cohort
design resulted in HRs of 2.09 (95% CI 1.92; 2.26), 1.46 (95% CI
1.32; 1.61) and 1.47 (95% CI 1.32; 1.65), respectively. The adjusted
model in the sibling design resulted in a HR of 1.20 (95% CI 0.93;
1.54). The sensitivity analysis of former vs. current user comparison
resulted in a HR of 1.19 (95% CI 1.06; 1.33) and the unconditional sib-
ling comparison in 1.20 (95% CI 1.00; 1.45). The negative control
paternal exposure analysis resulted in a HR of 1.17 (95% CI 1.05;
1.29).
Conclusions: There was an association between maternal use of anti-
depressants during pregnancy and the risk of ADHD in offspring in the
classical cohort design. This association was attenuated when a sibling
design was used, suggesting presence of uncontrolled confounding.
The sensitivity and negative control analyses supported this
conclusion.
55 | Does the Type of Antihypertensive
Medication Used in Pregnancy Affect Risk of
Pre‐Eclampsia?
Sascha Dublin1; Mary A. Akosile1; Lu Chen1; Lyndsay A. Avalos2;
T. Craig Cheetham3; Thomas Easterling4; Victoria L. Holt4;
Sylvia E. Badon2; Romain S. Neugebauer2; Kristi Reynolds5;
Rod L. Walker1; Susan M. Shortreed1
1Kaiser Permanente Washington, Seattle, WA; 2Kaiser Permanente
Northern California, Oakland, CA; 3Chapman University, Irvine, CA;
4University of Washington, Seattle, WA; 5Kaiser Permanente Southern
California, Pasadena, CA
Background: Hypertensive disorders are common in pregnancy and
increase the risk of adverse maternal outcomes including pre‐eclamp-
sia. Several medications are used to treat hypertension in pregnancy,
but it is unclear whether any are superior for preventing adverse
outcomes.
Objectives: To compare the risk of pre‐eclampsia with use of different
antihypertensive medications in pregnancy.
Methods: We conducted a retrospective cohort study of women with
a singleton live or stillbirth from 2005–2014 in 3 US healthcare sys-
tems: Kaiser Permanente Washington, Northern California and South-
ern California. Data came from electronic medical records and linked
birth certificate data. We identified women with chronic or gestational
hypertension using ICD‐9 diagnosis codes, medication dispensings,
and blood pressure values. We restricted the cohort to women who
filled an antihypertensive medication during pregnancy after their first
prenatal visit and before 35 weeks 6 days gestation, including new and
prevalent users. The first medication fill in this time period was consid-
ered the index fill. We required women to have at least 150 days of
enrollment and to be free of pre‐eclampsia in this pregnancy before
the index fill. Exposure category (specific medication used) was
defined from the index fill. Pre‐eclampsia was identified from inpatient
ICD‐9 diagnosis codes from 20 weeks gestation through 28 days after
delivery, an algorithm with high positive predictive value in a valida-
tion study. We used logistic regression to compare the risk of pre‐
eclampsia with use of labetalol, methyldopa, nifedipine, or other beta
blockers, adjusting for covariates including blood pressure before the
index fill through propensity scores and inverse probability of treat-
ment weighting.
Results: Among 6349 births to women treated for hypertension, there
were 3019 (48%) with an index fill for labetalol, 1834 (29%) for meth-
yldopa, 1106 (17%) for nifedipine and 390 (6%) for other beta
blockers. Mean maternal age was 34 years and mean gestational age
at the index fill was 18 weeks. 86% of women had chronic hyperten-
sion, and 66% were Hispanic or nonwhite. The incidence of pre‐
eclampsia was 33% for women using labetalol, 29% for methyldopa,
31% for nifedipine and 23% for other beta blockers. Compared to
use of labetalol, the adjusted odds ratio for pre‐eclampsia with use
of methyldopa was 1.01 (95% CI 0.87–1.17), for nifedipine 1.01
(0.86–1.19), and for other beta blockers 1.02 (0.74–1.04).
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Conclusions: In women with hypertension in pregnancy, the risk of
pre‐eclampsia did not differ by type of antihypertensive medication
used.
56 | Prenatal Antidepressant Exposure and
Perinatal Outcomes: An Analysis Utilizing
Longitudinal Clustering Methods
Gretchen Bandoli1; Christina Chambers1; Kristin Palmsten1,2
1University of California San Diego, San Diego, CA; 2HealthPartners
Institute, Minneapolis, MN
Background: Studies of antidepressant safety in pregnancy typically
do not address complex patterns of use, precluding assessment of
how changes in dose, timing of use, and coverage gaps affect the
pregnancy.
Objectives: The objective of this study was to quantify patterns of
antidepressant exposure in pregnancy, and test whether exposure pat-
terns were associated with perinatal outcomes.
Methods: The study analyzed data from OptumLabs® Data Ware-
house, which includes de‐identified claims data from commercially
insured individuals in the US. After enforcing continuous enrollment
requirements, 226,932 singleton, live‐births were identified between
2012–2016. All antidepressant dispensings between last menstrual
period (LMP) and 35 weeks' gestation were converted into fluoxetine
equivalents. We performed k‐means longitudinal modeling to identify
similar antidepressant utilization patterns. Multivariable log‐linear
regression with a Poisson distribution and robust standard errors
was used to estimate risk ratios (RR) and 95% confidence intervals
(CI) of preterm birth, low birth weight, neonatal respiratory distress,
and postpartum hemorrhage. Models were adjusted for maternal
demographics, diagnosis of depression, anxiety, pain or other mental
health disorders, benzodiazepine or antipsychotics claims between
LMP and 35 weeks' gestation.
Results: We identified 15,041 (6.6%) pregnant women with an antide-
pressant dispensing. Antidepressant exposure was best summarized
into 5 trajectories: very low (average of 4 mg/day, n = 7,622), low
sustained (18 mg/day n = 3,170), medium with first trimester discon-
tinuation (12 mg/day, n = 1,907), medium sustained (38 mg/day,
n = 1,918), and high sustained exposure (75 mg/day, n = 424). When
compared with the lowest trajectory, medium sustained and high
sustained trajectories were both associated with an increased risk of
preterm birth [RR 1.31, 95% CI (1.16, 1.49); RR 1.78, 95% CI (1.48,
2.14)], low birth weight [RR 1.27 95% CI (1.10, 1.47); RR 1.65 95%
CI (1.33, 2.04)], and postpartum hemorrhage [RR 1.35, 95% CI
(1.03,1.78); RR 2.51, 95% CI (1.69, 3.71)]. All four trajectories
increased the risk of neonatal respiratory distress: e.G. medium
discontinued RR 1.23, 95% CI (1.05, 1.44); high sustained RR 2.23,
95% CI (1.83, 2.77) relative to the lowest trajectory.
Conclusions: Although these findings may reflect indication severity,
they demonstrate the nuanced exposure assessment that longitudinal
cluster analysis affords. Additional attention to women who require
medium to high sustained antidepressant use across gestation is
warranted.
57 | Incident Exposure to Benzodiazepine in
Early Pregnancy and the Risk of Spontaneous
Abortion
Odile Sheehy; Anick Bérard; Jin‐Ping Zhao
CHU Sainte‐Justine Centre de Recherche, Montreal, QC, Canada
Background: Studies show that benzodiazepine use in early preg-
nancy is associated with an increased risk of spontaneous abortion.
However, no one has examined the association between specific
benzodiazepine agent exposures and the risk of spontaneous
abortion.
Objectives: To quantify the risk of spontaneous abortion associated
with gestational benzodiazepine incident use as a class as well as by
duration of action, and by specific benzodiazepine agents.
Methods: We conducted a nested case–control study within the Que-
bec Pregnancy Cohort, which includes all pregnancies covered by the
Quebec Prescription Drug plan from 01/01/1998 to 31/12/2015.
Conditional logistic regression models were used to calculate ajusted
odds ratios (aOR), and 95% confidence intervals (CI). We defined
spontaneous abortion as a pregnancy loss before the 19th completed
week of gestation. Each case of spontaneous abortion was randomly
matched on gestational age at the time of the event with up to five
controls. We defined incident benzodiazepine exposure as ≥1 filled
prescription between the first day of the last menstrual period (LMP)
and the index date (date of spontaneous abortion) without prior
LMP exposure. Benzodiazepine exposure was categorized as 1) any
benzodiazepine use, 2) long‐acting or short‐acting, and 3) by specific
benzodiazepine agents; non‐use of benzodiazepine was the reference
category.
Results: A total of 375 (1.4%) of the 27,149 pregnancies ending with
a spontaneous abortion were exposed to benzodiazepine in early
pregnancy, as compared to 788 (0.6%) of the 134,305 matched con-
trols (crude OR, 2.39; 95%CI, 2.10–2.73). Adjusting for potential
confounders including maternal mood and anxiety disorders before
pregnancy, and compared to non‐use, early pregnancy benzodiaze-
pine exposure was associated with an increased risk of spontaneous
abortion (aOR, 1.85; 95%CI, 1.61–2.12). The risk of spontaneous
abortion was similar among pregnancies exposed to short‐acting
(aOR 1.81, 95%CI 1.55–2.12; 284 exposed cases) and long‐acting
benzodiazepines (aOR 1.73, 95%CI 1.31–2.28; 98 exposed cases).
Specifically, early pregnancy exposure to diazepam, temazepam,
bromazepam, alprazolam, clonazepam, lorazepam and oxazepam
were all independently associated with an increased risk of sponta-
neous abortion (aOR from 3.43 to 1.48).
Conclusions: An increased risk of spontaneous abortion was
observed among early pregnancies with incident exposure to short
or long‐acting benzodiazepines, as well as to any benzodiazepine
types.
32 ABSTRACTS
58 | Ondansetron Use in Early Pregnancy
and Miscarriage
Elizabeth A. Suarez1; Kim Boggess2; Stephanie M. Engel1;
Jennifer L. Lund1; Til Stürmer1; Michele Jonsson Funk1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2School of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC
Background: Ondansetron is commonly used to treat nausea and
vomiting in pregnancy despite inconclusive evidence of its safety. Pre-
vious studies have reported no increase in risk of miscarriage but
relied on non‐user comparators or methods that failed to account
for gestational weeks at risk.
Objectives: To evaluate the risk of miscarriage among women with
orders for ondansetron versus alternative antiemetics during the first
20 weeks of pregnancy.
Methods: A pregnancy cohort was created using electronic health
record (EHR) data from the UNC Health Care system in North Car-
olina, USA. Pregnancies were identified at the date of first record of
the pregnancy in the EHR and followed until miscarriage, induced
abortion, loss to follow‐up (last record with evidence of pregnant
status), or 140 days of gestation. Miscarriage was defined as spon-
taneous fetal loss before 140 days of gestation. Antiemetic expo-
sure status was defined by first antiemetic ordered (ondansetron
or comparators, metoclopramide and promethazine) in the first
140 days of gestation; pregnancies with orders for both antiemetic
groups on the same day were excluded. Sensitivity analyses defined
exposure using only administered (inpatient or intravenous) orders.
Cumulative incidence of miscarriage was estimated on the gesta-
tional age timescale. Pregnancies were censored at gestational age
of loss to follow‐up or 140 days, whichever was first, and induced
abortions were analyzed as competing events. We report adjusted
risk differences (RD), risk ratios (RR), and 95% confidence intervals
(CI). Confounding by antiemetic indication, maternal age, race, eth-
nicity, insurance status, smoking status, comorbidities, and medica-
tion use was controlled using stabilized inverse probability of
treatment weights.
Results: We identified 2730 eligible pregnancies with antiemetic
orders; 66% had first ondansetron order and 34% had first comparator
antiemetic order. The median gestational age of first order was 64 and
67 days in the ondansetron and comparator groups, respectively. The
crude risk of miscarriage was 13.1% (95% CI: 9.9, 17.4) in the
ondansetron group and 12.1% (95% CI: 8.8, 16.7) in the comparator
group. After covariate adjustment, there was no difference in risk of
miscarriage for ondansetron users (RD 0.3%, 95% CI ‐5.8, 5.6; RR
1.02, 95% CI 0.63, 1.62). Sensitivity analyses with administered orders
included 967 ondansetron users and 462 comparator users, and simi-
lar results were observed (RD 0.1%, 95% CI ‐9.5, 9.6; RR 1.01, 95% CI
0.56, 2.09).
Conclusions: We observed no increase in the risk of miscarriage for
pregnancies exposed to ondansetron versus comparator antiemetics.
59 | Use of Psychotropic Drugs in Children
and Adolescents with Tic Disorders in
Denmark: A Nationwide Drug‐Utilization
Study
Lotte Rasmussen1; Julie M. Thrane1; Niels Bilenberg2;
Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Odense University
Hospital, Odense, Denmark
Background: The pharmacological treatment of tic disorders, including
Tourette syndrome and chronic tic disorders, is complex and mainly
based on treating comorbid psychiatric disorders. Due to limited evi-
dence, treatment mostly relies on clinical experience and preferences
of the individual prescriber.
Objectives: To describe the use of psychotropics in children and ado-
lescents with tic disorders in Denmark, including overall utilization pat-
terns, regional variation, how psychiatric comorbidities affect use
patterns, and the effect of the introduction of the European clinical
guideline in 2011.
Methods: Based on the Danish National Patient Registry, we identi-
fied three cohorts of children and adolescents 6–17 years old with a
recent (within 2 years) hospital diagnosis of a tic disorder in 2008
(n = 1662), 2012 (n = 2816), and 2016 (n = 2862; median age 11 years,
interquartile range 8–13; 77% boys). Data on drug use was obtained
from the Danish National Prescription Registry.
Results: The psychotropics most commonly used were ADHD medica-
tions (2008: 26%; 2012: 30%; and 2016: 25%), antipsychotics (2008:
21%; 2012: 16%; and 2016: 9%), melatonin (2012: 12%; 2016: 15%),
and antidepressants (2008: 8%; 2012: 6%; and 2016: 5%). Medication
use was more common in Tourette syndrome (47% used at least one
psychotropic during 2016) and chronic tic disorders (45%) compared
to transient tic disorder (34%) or other/unspecified tic disorders
(23%). In Tourette syndrome, use of psychotropics followed recorded
psychiatric comorbidity, e.g. use of ADHD medication in 62% of those
with comorbid ADHD compared to 18% overall, and use of antide-
pressants among those with obsessive–compulsive disorder was 32%
compared to 6% overall. Comparing the five Danish regions, differ-
ences in use were observed for ADHD medication (in 2016 highest
vs. lowest one‐year prevalence proportion 42% vs. 18%) and melato-
nin/hypnotics (23% vs. 12%) while no variation was seen for antipsy-
chotics or antidepressants. In 2008 and 2012, risperidone accounted
for the majority of antipsychotic use (46–57% of antipsychotic pre-
scriptions) while in 2016, aripiprazol accounted for 40% and risperi-
done accounted for 34%.
Conclusions: The use of psychotropics among children and adoles-
cents with tic disorders is considerable, in particular for Tourettes syn-
drome and chronic tic disorders, and is heavily influenced by
psychiatric comorbidity. Regional variation is seen for use of ADHD
medication and melatonin/hypnotics. Contrary to the 2011 European
recommendations, antipsychotic use has shifted from risperidone to
aripiprazol.
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60 | Patterns of Drug Utilization over Age in
Asthmatic Children
Esmé Baan1; Astrid Heeremans2; Leila Karimi1; Hettie M. Janssens3;
Miriam Karimi4; Johan C. de Jongste5; Lies Lahousse2;
Katia Verhamme1
1Erasmus MC, Rotterdam, Netherlands; 2Ghent University, Ghent,
Belgium; 3Erasmus University Medical Center – Sophia Children's
Hospital, Rotterdam, Netherlands; 4University Medical Center Utrecht,
Utrecht, Netherlands; 5Erasmus University/Sophia Children's Hospital,
Rotterdam, Netherlands
Background: Children start using drugs for asthma treatment at differ-
ent ages, and many stop using these after different periods of time.
Objectives: To study patterns of asthma drug utilization by age using
group‐based trajectory models in children, and investigate risk factors
for different trajectories.
Methods: A retrospective cohort study (2007–2016) in asthmatic chil-
dren, 5–17 years old in 2 primary care databases: IPCI (NL) and THIN
(UK). Asthma was defined as ≥1 asthma disease code and ≥ 2 pre-
scriptions of respiratory drugs in 1 year. Prescriptions were retrieved
by ATC code from patient records. We used group‐based trajectory
analysis to model 4 trajectories of drug use of any asthma drug (ATC
code R03) over age. Drug use was defined as ≥30 days covered by
a prescription in a year. Patient characteristics at baseline were com-
pared between trajectory groups using chi‐square test.
Results: In total 24,276 children from the IPCI database and 138,734
children from the THIN databases were included. In both databases
we found trajectories of ‘late users’ (22 and 20% of the patients in
theTHIN and IPCI database), ‘late moderate users’ (28 and 29%), ‘early
users’ (26 and 20%) and ‘early moderate users’ (25 and 30%), with a
median age of asthma onset 11, 13, 7 and 8 years, respectively. ‘Early
users’ were significantly more often boys (65 and 63%, vs 41–49% in
the two databases), had more often eczema (48 and 41% vs 25–44%)
and gastro‐oesophageal reflux disease (2 and 4% vs 1–3%) though less
often rhinitis, depression or obesity compared to the other groups.
Conclusions: We found 4 different trajectories of asthma drug utiliza-
tion in primary care databases. These groups had distinct patient char-
acteristics, suggesting different asthma phenotypes by age of onset.
61 | Methylphenidate Treatment during
Childhood Is Continued in Adulthood in Half
of the Study Population
Chii Chyi Cheung1; Katia M. Verhamme1; Ron M.C. Herings2;
Loes E. Visser1; Bruno HCh Stricker1
1Erasmus University Medical Center, Rotterdam, Netherlands; 2PHARMO
Institute for Drug Outcomes Research, Utrecht, Netherlands
Background: Until the beginning of 2018, methylphenidate was only
approved in the Netherlands for children between 6 and 18 years
old, because of the cardiovascular risk in adults. Despite the fact that
it was not approved for use in adults, there was a considerable degree
of off‐label use in this group.
Objectives: To estimate the number of patients who started methyl-
phenidate during childhood and continued treatment beyond the age
of 18 and to study the determinants that may be associated with con-
tinuing treatment.
Methods: It is a nested case–control study in a cohort of methylphe-
nidate users. The study population consisted of all patients with active
follow‐up during the study period between 1 January 1996 until 1
January 2017. Data were obtained from a longitudinal primary care
database containing medical records from more than 450 general
practitioners (GPs) throughout the Netherlands. Patients were
included if they started methylphenidate before the age of 18 years
and if they reached the age of 19 years (to guarantee at least 1 year
of follow‐up during adulthood) before the end date of the study.
Potential determinants related to continued use of methylphenidate
(sex, age, medication possession ratio (MPR), previous use of other
psychostimulants and other psychotropic drugs and the presence of
any potential contraindications). Cases were defined as users of meth-
ylphenidate who continued treatment beyond the age of 18 year,
while controls were users who were treated with methylphenidate
during childhood or adolescence but discontinued treatment before
the age of 18 years. Logistic regression analyses were performed to
assess the association between potential determinants and continua-
tion with methylphenidate treatment after the age of 18 years.
Results: 53% of all methylphenidate users (n = 1,020) continued their
treatment after the age of 18 years. Patients were more likely to con-
tinue treatment with methylphenidate if they started treatment at the
age of 15 to 17 years than those starting at the age of 11 and younger
(ORadj: 5.84, 95%CI: 1.56–21.81), if they had a MPR between 0.80 and
1.00 compared to a lower MPR (ORadj: 1.63, 95%CI: 1.04–2.54) or if
they had a history of a psychiatric disorder (contraindication)
(ORadj:1.69, 95%CI: 1.24–2.30).
Conclusions: Methylphenidate treatment initiated during childhood
was continued in half of the study population when reaching the age
of 18. Adolescents were more likely to continue treatment than young
children and patients with a history of a psychiatric disorder prior to
methylphenidate initiation, were also more likely to continue
treatment.
62 | Unintended Consequences of a National
Policy Intervention to Curb Inappropriate
Alprazolam Prescribing in Australia
Andrea L. Schaffer1; Nicholas A. Buckley2; Sallie Pearson1,3
1UNSW Sydney, Sydney, Australia; 2University of Sydney, Sydney,
Australia; 3University of Sydney, Sydney, Australia
Background: Regulators and payers aim to promote evidence‐based
prescribing to reduce harm. Alprazolam, which is recommended for
short‐term use only, is subsidized on Australia's Pharmaceutical
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Benefits Scheme (PBS) with prescribing requiring prior approval. In
February 2017, the PBS de‐listed 2 mg tablets, eliminated repeat pre-
scriptions and listed a 10‐tablet pack to curb long‐term use.
Objectives: To quantify the impact of these changes on patterns of
alprazolam prescribing and dispensing in naïve and previously‐treated
individuals.
Methods: Interrupted time series analysis and a retrospective cohort
study of alprazolam‐treated people using dispensings and prescribing
approvals for a 10% sample of Australians (2014–2018). We used
autoregressive regressiontoquantifychanges inuseover time,and logis-
tic regression to compare patterns of use pre‐ and post‐intervention.
Results: Overall, alprazolam prescribing approvals increased by 27.1%
(95% CI 21.8 to 32.7%) yet dispensing rates fell by 25.2% (95% CI ‐
30.3 to −19.8%). In the year post‐intervention, 2976 people were dis-
pensed alprazolam (63.6% female, median age 57 years), of which
20.9% were alprazolam‐naïve in the 2 years prior to February 2017.
Compared to people initiating pre‐intervention, alprazolam‐naïve peo-
ple post‐intervention were more likely to initiate according to subsidy
restrictions with pack sizes ≤10 (20.8% vs 2.2%, adjusted Odds Ratio
(aOR) = 11.85, 95% CI 7.65–18.36) and no second dispensing up to
180 days after initiation (28.4% vs 42.9%, aOR = 0.53, 95% CI 0.43–
0.66). However, a subset of alprazolam‐naïve people were also more
likely to initiate on pack sizes >50 tablets post‐intervention (23.3%
vs 5.4%, aOR = 5.35, 95% CI 3.85–7.43). In people previously alpraz-
olam‐treated, post‐intervention dispensings were more likely to be for
>100 tablets (16.3% vs 4.2%, aOR = 4.63, 95% CI 3.85–5.57), less
likely to be for ≤50 tablets (38.4% vs 72.3%, aOR = 0.24, 95% CI
0.22–0.26), and more likely to be for >100 mg (13.6% vs 10.8%,
aOR = 1.37, 95% CI 1.17–1.60) compared to pre‐intervention.
Conclusions: Alprazolam dispensing decreased post‐intervention, but
we observed two divergent effects on adherence to subsidy restric-
tions. Some patients were prescribed smaller pack sizes at initiation,
but most were still receiving treatment outside restrictions, notably
increased pack sizes to overcome the lack of repeats. While elimi-
nating repeat prescriptions may facilitate increased monitoring of
patients, it places a greater burden on prescribers and the health
system, and for many may not reduce inappropriate long‐term use.
63 | Prescribing Systemic Steroids for Acute
Respiratory Tract Infections in US Outpatient
Settings
Kueiyu Joshua J. Lin1; Evan Dvorin2; Aaron S. Kesselheim1
1Brigham and Women's Hospital, Boston, MA; 2Ochsner Health System,
Jefferson Parish, LA
Background: Evidence and clinical guidelines do not support use of
systemic steroids for acute respiratory tract infections (ARTIs), but
such practice may be common in the US. Detailed utilization patterns
and predictors of such practice have not been evaluated.
Objectives: To describe prescribing pattern of systemic steroids for
ARTI and determine its predictors.
Methods: We used a large US national commercial claims database,
the IBM MarketScan, to identify all patients aged 18–65 with an ARTI
diagnosis (acute bronchitis, sinusitis, pharyngitis, otitis media, acute
upper respiratory infections, allergic rhinitis, influenza, and pneumonia)
recorded in an ambulatory visit from 2007 to 2016. We excluded
those with systemic steroid use in the prior year and an extensive list
of steroid‐indicated conditions, including asthma, chronic obstructive
pulmonary disease, and many autoimmune diseases. We estimated
the proportion of the cohort receiving systemic steroids within 7 days
of the ARTI diagnosis. We used multivariate logistic regression to
assess the association between systemic steroid use and 55 factors,
including patient demographics and an extensive list of co‐morbidities.
Results: Among 11,192,974 patients with an eligible ARTI encounter,
11.6% were prescribed systemic steroids (45.8% parenteral, 47.6%
oral, and 6.6% both). Among systemic steroid users with detailed med-
ication information (53.7% of all users), 46.0% were prescribed predni-
sone equivalents <20 mg, 23.6% 20‐39 mg, and 30.4% ≥40 mg. Most
(84.4%) were prescribed a steroid prescription of 7 days or fewer,
15.1% 8–29 days, and 0.5% ≥30 days. All ARTI diagnoses but influ-
enza were predictive of receiving systemic steroids. There was
remarkable geographical variability: the adjusted odds ratio (aOR) of
receiving parenteral steroids was 14.48 (95% confidence interval
[CI]: 14.25–14.72) comparing southern vs northeastern US. The corre-
sponding aOR was 1.67 (95% CI: 1.65–1.68) for oral steroids. After
multivariate adjustment, other positive predictors for prescribing
included emergency department (ED) or urgent care settings (vs. regu-
lar office), otolaryngologist/ED doctors (vs. primary care), fewer co‐
morbidities, and older patient age. There was an increasing trend from
2007 to 2016 (aOR 1.91 [95% CI: 1.90–1.93] comparing 2016 to
2007).
Conclusions: Systemic steroid use in ARTI is common with great geo-
graphical variability. These findings call for an effective national edu-
cation program about this non‐evidence based practice.
64 | Characteristics of Febuxostat and
Allopurinol Initiators and Utilization Patterns
in Real‐World Settings
Marie Bradley1; Efe Eworuke1; Austin Cosgrove2; Laura Hou2;
Darren Toh2
1Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School and Harvard Pilgrim Health Care Institute, Boston, MA
Background: The Cardiovascular Safety of Febuxostat and Allopurinol
in Patients with Gout (CARES) trial reported an increase in cardiovascu-
lar and all‐cause mortality in febuxostat users compared to allopurinol
users. TheCARES trial included a population enriched for cardiovascular
disease (CVD), raising concerns about the generalizability of the findings
to users of urate‐lowering therapies (ULT) in real‐world settings.
Objectives: To determine if patients and utilization of ULTs in the
CARES trial reflect the gout population and ULT utilization in real‐
world settings.
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Methods: A retrospective cohort study was conducted among patients
with a new diagnosis of gout in the Sentinel Distributed Database
(SDD), from January 1, 2009 to September 30, 2016. New initiators of
ULT (febuxostat, allopurinol, pegloticase and probenecid) were identi-
fied. Characteristics of new initiators and the cumulative duration and
switching patterns for febuxostat and allopurinol use were examined.
Findings from SDD were compared to the CARES population.
Results: Allopurinol was the most commonly initiated ULT
(n = 1,049,462) in SDD and febuxostat use was comparatively rare
(n = 80,083). ULT users in CARES were younger than in SDD, with only
48.9% febuxostat and 51.3% allopurinol users aged 65+, compared to
66.0% and 64.2% in SDD, respectively. There were more male ULT
users in CARES, with 84.1% and 83.8% in the febuxostat and allopurinol
arms, respectively, compared to 62.6% and 65.1% in SDD. As expected,
patients in the CARES trial had more CVD and chronic kidney disease
(CKD). Although the prevalence of CVD indicators was lower in SDD,
distributions were similar between ULT initiators. For example; 38.6%
and 39.8% of febuxostat and allopurinol users, respectively, in CARES
had a history of myocardial infarction, compared to 1.5% of each in
SDD. ULT users in CARES had more severe gout than those in SDD,
indicated by tophi in 21.6% and 21.0% of febuxostat and allopurinol
users, compared to 14.8% and 8.6% in SDD. Median duration of ULT
use was longer among febuxostat and allopurinol users in CARES at
728 days and 719 days, respectively, compared to 210 days and
334 days in SDD. The proportion of ULT initiators in SDD that switched
between ULTs during follow‐up was low (generally <10%) and the larg-
est proportion of switches occurred from allopurinol 100mg to 300mg.
Conclusions: Compared to users in real‐world settings, ULT users in
CARES were younger, more adherent to ULTs, more likely to be male,
had more severe gout and had a higher prevalence of both CVD and
CKD. These differences need to be considered in interpreting the
results of the CARES study.
65 | Analysis of Sodium‐Glucose‐
Cotransporter‐2 Inhibitor Use in Patients with
Type‐1 Diabetes Mellitus and Rates of
Diabetic Ketoacidosis
Christian Hampp1; Richard Swain1; Casie Horgan2; Elizabeth Dee2;
Yandong Qiang1; Sarah Dutcher1; Andrew Petrone2;
Rong Chen Tilney2; Judith C. Maro2; Catherine A. Panozzo2
1Office of Surveillance and Epidemiology, Center for Drug Evaluation and
Research, Food and Drug Administration, Silver Spring, MD; 2Department
of Population Medicine, Harvard Medical School and Harvard Pilgrim
Health Care Institute, Boston, MA
Background: Sotagliflozin is the first sodium‐glucose cotransporter‐2
inhibitor (SGLT2i) seeking approval for type‐1 diabetes mellitus
(T1DM). Preapproval clinical trials detected increased rates of diabetic
ketoacidosis (DKA), compared with placebo.
Objectives: To estimate real‐world off‐label utilization of approved
SGLT2i (only indicated for T2DM) in patients with T1DM, estimate
rates of DKA, and compare observed and expected counts of DKA
during off‐label use of approved SGLT2i in patients withT1DM, based
on DKA rates observed in sotagliflozin clinical trials.
Methods: Using claims data from 17 Sentinel System Data Partners (3/
2013–6/2018), we identified new users of canagliflozin, empagliflozin,
and dapagliflozin withT1DM‐broad (> 50% of DM diagnosis codes dur-
ing days [−365, −5] relative to index dispensing were specific toT1DM)
or T1DM‐narrow (T1DM‐broad with ≥1 prescription for short‐ or
rapid‐acting insulin and no oral antidiabetic drug dispensing other than
metformin). DKA was identified using inpatient and emergency depart-
ment claims. Standardized incidence ratios (SIRs) were calculated using
age‐ and sex‐specific follow‐up time in Sentinel and pooled age‐ and
sex‐specific DKA rates from sotagliflozin trials 309, 310, and 312.
Results: Among 475,527 initiators of SGLT2i, 0.92% met criteria for
T1DM‐broad and 0.50% met criteria for T1DM‐narrow across all age
categories. Patients with T1DM‐broad comprised 11.3%, 7.28%,
1.84%, 0.90%, and 0.68% of SGLT2i initiators ages 12–18, 19–24,
25–44, 45–64, and ≥ 65 years, respectively. Rates of DKA were 7.3
per 100 person‐years among T1DM‐narrow patients and 4.5 per
100‐person‐years among T1DM‐broad patients using SGLT2i, across
all age categories. Rates of DKA were highest among T1DM‐narrow
patients age 25–44, especially females age 25–44, who had a DKA
rate 19.7 per 100 person‐years. More DKA events were observed in
T1DM‐narrow patients during off‐label use of approved SGLT2i in
Sentinel than would be expected based on sotagliflozin clinical trials
(SIR = 1.83; 95% CI, 1.45–2.28). The SIR was 2.57 among patients
ages 25–44 and decreased with increasing age.
Conclusions: Real‐world off‐label use of SGLT2i in patients with
T1DM was relatively rare in the overall study population but more fre-
quent in younger patients. The risk for DKA during off‐label use was
notable, especially among patients under the age of 45. Although
real‐word rates of DKA exceeded the expectation based on clinical tri-
als, results should be interpreted with caution due to differences in
study methods, patient samples, and study drugs.
66 | Clinical Outcomes in Patients with Type
2 Diabetes Newly Initiating SGLT2 or DPP4
Inhibitors
Sruthi Adimadhyam; Danielle Isaman; Andrew Weckstein;
Emma Payne; Edward Yu; Anthony Louder; Shannon L. Reynolds
Aetion, Boston, MA
Background: Real world evidence on comparative effectiveness of
sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) is limited to car-
diovascular outcomes. Other clinical outcomes indicating adequacy
of glycemic control have not yet been assessed.
Objectives: To determine the time to diabetes‐related hospitalization
and to treatment intensification following initiation of SGLT2i relative
to dipeptidyl peptidase‐4 inhibitors (DPP4i).
Methods: We conducted a retrospective cohort study using the de‐
identified Optum® Clinformatics® Data Mart (2000–2017) database.
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Patients with Type 2 Diabetes aged 18 years or older newly initiating
SGLT2i or DPP4i between April 2013 and May 2017 were included in
the cohort. Patients were required to have continuous enrollment dur-
ing a 365‐day baseline period and those with prior insulin use or renal
impairment were excluded. Outcomes were hospitalization for diabe-
tes‐related complications and treatment intensification. Treatment
intensification was defined as addition of insulin to index medication.
Patients were matched 1:1 on propensity score and followed from the
date of first dispensing of SGLT2i or DPP4i until the earliest occurrence
of outcomes, treatment discontinuation, death, disenrollment, or end of
data (December 2017). Cox Proportional Hazards models were used to
estimate Hazard Ratios (HR) and 95% Confidence Intervals (CI).
Results: There were 130,486 patients that met our selection criteria.
After 1:1 propensity score matching, there were 32,646 comparable
patients in each treatment group. The average age in the matched
cohort was 56.8 (±12) years; 44% were female; 42.8% had at least 1
complication of diabetes. Patients were followed for a median 192
(64–399) days over which 1.3% were hospitalized for diabetes and
3.8% intensified treatment. The median time to a diabetes‐related
hospitalization was 181 (65–405) days overall and 169 (64–374) in
those initiating SGLT2i vs. 187 (67–413) in those initiating DPP4i.
The median time to treatment intensification was 124 (41–297) days
overall and 116 (36–297) in those initiating SGLT2i vs. 127 (44–297)
in those initiating DPP4i. Initiation of treatment with SGLT2i was
associated with a 22% decrease in risk of diabetes‐related hospitaliza-
tion (HR: 0.78 [0.68–0.90]) and a 38% decreased risk of treatment
intensification (HR: 0.61 [0.57–0.67]) relative to DPP4i.
Conclusions: Initiation of treatment with SGLT2i was associated with
better clinical outcomes relative to DPP4i in this large cohort of com-
mercially insured adults with Type 2 Diabetes in the United States.
67 | Incidence Rate of Fournier's Gangrene
in Type‐2 Diabetic Patients Using Second‐
Line Anti‐Diabetic Drugs
Sara Eapen1; Sebastian Schneeweiss2; Aditya Rajan1;
Natalia Petruski‐Ivleva1; Saira A. Jan3,4
1Aetion, Boston, MA; 2Brigham and Women's Hospital and Harvard
Medical School, Boston, MA; 3Horizon Blue Cross Blue Shield of New
Jersey, Newark, NJ; 4Rutgers State University of New Jersey, New
Brunswick, NJ
Background: On August 29, 2018, the FDA issued a warning that
cases of a rare but serious infection called Fournier's gangrene (FG)
have been reported with sodium‐glucose cotransporter‐2 inhibitors
(SGLT‐2i).
Objectives: To evaluate the safety signal in longitudinal claims data in
a population of patients with type 2 diabetes mellitus (T2D).
Methods: We used administrative claims data from Horizon Blue
Cross Blue Shield of New Jersey from 2014 through 2017 to esti-
mate incidence rates of FG (ICD‐9 code of 608.4 or ICD‐10 of
N49.3) or necrotizing fasciitis of the perineum (NF, ICD‐9: 728.86
or ICD‐10: M72.6) among patients treated with a second‐line antidi-
abetic drug (SGLT‐2i, DPP4i, GLP‐1 and Sulfonylureas [SU]). We
used the combined endpoint (FG or NF) due to our sample size
and very low incident rate of FG. Patients were censored at time
of switch therapy. For the comparative analysis, we restricted
cohorts to new users (no exposure in the prior 180 days) and con-
ducted four pairwise comparisons (SGLT‐2i vs. DPP4i; SGLT‐2i vs.
GLP‐1; SGLT‐2i vs. SU; SGLT‐2i vs all other). Potential confounders
(baseline UTI, hospitalization for bacterial infections, prior immune‐
modulating or ‐suppressing drug use, HIV, obesity, and others) were
balanced using 1:1 propensity score (PS) matching. Analyses were
performed using the Aetion Evidence Platform, version 3.0.
Results: We identified 68,004 patients receiving second‐line antidia-
betic medication. The incidence rate per 1,000 person‐years (95%
CI) for FG or NF among SGLT‐2is, DPP‐4i, GLP‐1, and SU users were
0.77 (0.25–1.79), 0.87 (0.44–1.29), 0.98 (0.12–3.56), and 1.21 (0.80–
1.61), respectively. The unadjusted rate ratios of FG or NF in patients
initiating SGLT‐2i compared to DPP‐4i, GLP‐1, and SU were 0.88
(0.38–2.05), 0.78 (0.15–4.01), and 0.63 (0.25–1.62), respectively. In
the PS‐matched comparative analyses, the rate ratios (95% CI) for
FG or NF in SGLT‐2i users compared to DPP‐4i and GLP‐1 users were
0.89 (0.13–6.34) and 1.42 (0.13,15.7), respectively. There were no
events among SU users after PS‐matching.
Conclusions: In a population‐based analysis of T2D patients using
claims data, we found very low incidence rates of FG or NF. We
found no indication of an increased risk among SGLT‐2i users com-
pared to similar patients treated with other second‐line antidiabetic
medications. However, the small number of events yielded wide
confidence intervals that cannot rule out a six‐fold increase.
68 | SGLT‐2 Inhibitors and the Risk of
Community‐Acquired Pneumonia in Patients
with Type‐2 Diabetes
Vanessa Brunetti1,2; Pauline Reynier2; Laurent Azoulay1,2;
Oriana H.Y. Yu1,2; Pierre Ernst1,2; Robert W. Platt1,2;
Kristian B. Filion1,2
1McGill University, Montreal, QC, Canada; 2Lady Davis Institute, Jewish
General Hospital, Montreal, QC, Canada
Background: Sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors are
a novel class of antidiabetic drugs whose use has increased dramati-
cally since their entry into the market. However, the US Food and
Drug Administration announced labeling changes related to infections
associated with their use, possibly due bacterial proliferation. It is pos-
sible that SGLT‐2 inhibitors may act on receptors in the lung, possibly
leading to respiratory infections such as community‐acquired pneumo-
nia (CAP). In contrast, the DECLARE‐TIMI trial found a smaller number
of bronchitis events with the SGLT‐2 inhibitor dapagliflozin than with
placebo, suggesting a possible protective effect on respiratory infec-
tions. To our knowledge, the risk of CAP with SGLT‐2 inhibitors has
not been investigated previously in a real‐world setting.
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Objectives: To compare the rate of CAP among patients with type 2
diabetes prescribed SGLT‐2 inhibitors compared to that in patients
prescribed dipeptidyl peptidase‐4 (DPP‐4) inhibitors.
Methods: We used data from the United Kingdom's Clinical Practice
Research Datalink linked to Hospital Episodes Statistics hospitalization
data and Office for National Statistics vital statistics data. Patients
entered the study cohort upon a prescription for a newantidiabetic drug
between 2013 (the year SGLT‐2 inhibitors entered the market) and
2018. Patients were excluded if they were aged less than 18 years,
had a diagnosis of CAP or were hospitalized in the 30 days prior to
cohort entry or had cancer any time before cohort entry. Current expo-
sure was modeled using a time‐varying approach and defined by the
prescription duration + a 30‐day grace period. The primary endpoint
was incident CAP, defined by an inpatient or outpatient diagnosis. We
used time‐dependent Cox proportional hazards models to compare
the rate of CAP with current use of SGLT‐2 inhibitors versus current
use of DPP‐4 inhibitors.
Results: A total of 30,237 patients entered the study cohort. In all,
728 CAP events were observed over an average follow‐up duration
of 1.8 years (SD: 1.2), representing an overall event rate of 13.7
(95% confidence interval [CI]:12.7–14.7) per 1,000 person‐years.
Incidence rates for SGLT‐2 and DPP‐4 inhibitor users were 5.8
(95% CI: 3.5–9.6) and 17.6 (95% CI: 15.2–20.5) per 1000 person‐
years, respectively. After adjustment, current use of SGLT‐2 inhibi-
tors was associated with a decreased rate of CAP compared to cur-
rent use of DPP‐4 inhibitors (hazard ratio: 0.54, 95% CI: 0.32, 0.93).
Conclusions: Use of SGLT‐2 inhibitors is associated with a decreased
risk of CAP compared to use of DPP‐4 inhibitors in patients with type
2 diabetes.
69 | Risk of Inflammatory Bowel Disease
with Sodium Glucose Co‐Transporter‐2
Inhibitors Compared to Dipeptidyl Peptidase‐
4 Inhibitors in Patients with Type 2 Diabetes
Ghadeer K. Dawwas; Steven M. Smith
University of Florida, Gainesville, FL
Background: Recent reports to the Food and Drug Administration
Adverse Event Reporting System suggested a higher risk of inflamma-
tory bowel disease (IBD) with sodium glucose co‐transporter‐2 inhibi-
tors (SGLT2‐i) but the risk remains uncertain.
Objectives: We aimed to assess the risk of IBD with SGLT2‐i com-
pared to dipeptidyl peptidase‐4 inhibitors (DPP‐4i) among patients
with type 2 diabetes.
Methods: A retrospective cohort analysis usingTruvenHealthCommer-
cial and Medicare Supplemental database was conducted among
patients with a diagnosis of type 2 diabetes (ICD‐9: 250.x0 or 250.x2)
between January 2014 and December 2017. New‐users of SGLT2‐i or
DPP‐4iwhohadnoprioruseforat least twelvemonthsprior totreatment
initiation (index‐date) were included. Patients with a diagnosis of type 1
diabetes or end‐stage renal during the pre‐index period were excluded.
The risk of IBDwas compared between SGLT2‐i and DPP‐4i. Follow‐up
continued until the first occurrence of IBD, end of enrollment, switch to
the comparator, or end of study period. Cox‐proportional hazard model
after propensity score matching (PSM) was used to obtain hazard ratios
(HR) and 95% confidence intervals (CI). Heterogeneity of treatment
effectwas examined in selected subgroups including patientswith base-
line chronic kidney disease (CKD).
Results: A total of 103,917 new‐users of SGLT2‐i (mean age, 54 years,
54% male, 2% CKD) and 103,916 new‐users of DPP‐4i (mean age
54 years, 53% male, 2% CKD) were identified. Incidence rates of
IBD were 6 and 5 per 1000 person‐years in the SGLT2‐i and the
DPP‐4i groups, respectively. After PSM, a 10% increased risk of IBD
was observed with SGLT2‐i compared to DPP‐4i (HR, 1.10; 95% CI,
1.01, 1.21). Subgroup analysis found no statistically significant differ-
ence in the risk of IBD between SGLT2‐i and DPP‐4i in patients with
CKD (HR, 1.28; 95% CI, 0.73, 2.23).
Conclusions: In this population‐based analysis, SGLT2‐I use was asso-
ciated with a modestly higher risk of IBD compared to DPP‐4i use. We
found no evidence of heterogeneity among the small number of
patients with prior CKD.
70 | Sodium‐Glucose Co‐Transporter 2
Inhibitors and the Risk of Venous
Thromboembolism in Patients with Type 2
Diabetes: A Cohort Study
Niklas Schmedt1; Dirk Enders1; Felix Müller1; Jochen Walker1;
Edeltraut Garbe2; Antonios Douros3,4,5
1 InGef – Institute for Applied Health Research Berlin, Berlin, Germany;
2University of Bremen, Bremen, Germany; 3Lady Davis Institute,
Montreal, QC, Canada; 4McGill University, Montreal, QC, Canada;
5Charité ‐ Universitätsmedizin Berlin, Berlin, Germany
Background: Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i)
induce glycosuria and diuresis and are known to increase hematocrit
values. Thus, there are concerns that their use could be associated
with a higher risk of venous thromboembolism (VTE).
Objectives: To assess the risk of VTE associated with use of SGLT2i
compared with use of dipeptidyl peptidase‐4 inhibitors (DPP4i) in
patients with type 2 diabetes in Germany.
Methods: We used the InGef database to conduct a cohort study with
nested case–control analysis in new users of non‐insulin antidiabetic
drugs with type 2 diabetes between 12 November 2012 (date of first
SGLT2i launch) and 30 June 2018. VTE cases were selected based on
ambulatory diagnoses in combination with prescriptions of oral antico-
agulants or hospital discharge diagnoses. For each case, up to 40 con-
trols were randomly selected using risk‐set sampling. We applied
conditional logistic regression to estimate confounder adjusted odds
ratios (OR) with 95% confidence intervals (CI) of VTE comparing cur-
rent use of SGLT2i (alone or in combination with other antidiabetic
drugs, but not DPP4i) and current use of DPP4i (alone or in
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combination with other antidiabetic drugs, but not SGLT2i). In second-
ary analyses, we stratified by individual SGLT2i, age, sex, VTE history
and use of loop diuretics. In sensitivity analyses we excluded patients
with cancer and used current use of glucagon‐like peptide‐1 receptor
agonists (GLP1ra) instead of DPP4i as reference.
Results: The cohort comprised 219,538 newusers of non‐insulin antidi-
abetic drugswith ameanageof62.9years (40%females). Thecrude inci-
dence rate of VTEwas 3.7 cases per 1,000 person‐years. For the nested
case–control analysis, 2,152 VTE cases were matched to 85,104 con-
trols. Overall, no increased risk of VTE was observed when comparing
current use of SGLT2i to DPP4i in the crude analysis (OR: 0.70; 95% CI:
0.56–0.88) and confounder adjusted analysis (OR: 0.75; 95% CI: 0.59–
0.94). Similar results were found for current use of individual SGLT2i,
(dapagliflozin OR: 0.77; 95% CI: 0.57–1.03/empagliflozin OR: 0.71;
95%CI:0.52–0.98), andnoeffectmodificationwasobserved in theother
secondary analyses. In addition, no increased risk ofVTEwas foundafter
excluding cancer patients (OR: 0.74; 95% CI: 0.58–0.95) or when com-
paring current use of SGLT2i to GLP1ra (OR: 0.83; 95%CI: 0.60–1.14).
Conclusions: Our study suggests that SGLT2i are not associated with
an increased risk of VTE compared to DPP4i in patients with type 2
diabetes. The observed protective effects for SGLT2i require further
evaluation.
71 | Association of Aripiprazole with the
Risk of Psychiatric Hospitalization, Self‐Harm,
or Suicide
François Montastruc1,2,3; Rui Nie1; Simone Loo1; Soham Rej4;
Sophie Dell'Aniello1; Joelle Micallef5; Samy Suissa1,6;
Christel Renoux1,6,7
1Centre for Clinical Epidemiology ‐ Lady Davis Institute ‐ Jewish General
Hospital, Montreal, QC, Canada; 2Service de Pharmacologie Médicale et
Clinique, Centre Midi‐Pyrénées de PharmacoVigilance,
Pharmacoépidémiologie et d'Informations sur le Médicament, Centre
Hospitalier Universitaire, Faculté de Médecine, Toulouse, France; 3Unité
clinique de Pharmacologie psychiatrique, Faculté de Médecine, Centre
Hospitalier Universitaire, Toulouse, France; 4Geri‐PARTy Research Group,
Department of Psychiatry ‐ Jewish General Hospital, McGill University,
Montreal, QC, Canada; 5Aix Marseille Univ, APHM, INSERM, Inst
Neurosci Syst, Marseille, France; 6Department of Epidemiology and
Biostatistics, McGill University, Montreal, QC, Canada; 7Department of
Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
Background: Aripiprazole is a frequently used antipsychotic because of
its reduced metabolic side effects. However, concerns have emerged
regarding a potential psychiatric worsening associated with first‐time
use of aripiprazole in patients already treated with other antipsychotic
drugs.
Objectives: To assess whether switching to or adding aripiprazole is
associated with serious psychiatric worsening compared with
switching to or adding another antipsychotic drug in patients previ-
ously exposed to antipsychotic médications.
Methods: This population‐based cohort study was conducted using
the United Kingdom Clinical Practice Research Datalink. Within a base
cohort of new users of antipsychotic drugs between 2000 and 2015,
we identified a study cohort of all patients prescribed aripiprazole or
another oral antipsychotic drug (switch or add‐on to the previously
used antipsychotic) on or after January 1, 2005 (the year aripiprazole
was licensed in the UK). Each patient starting aripiprazole was
matched 1:1 to a patient starting another antipsychotic on calendar
year of cohort entry, time since first antipsychotic prescription, psychi-
atric disease history (schizophrenia, bipolar disorder, depression, other
psychiatric diseases, unknown), age and time‐conditional propensity
score. Patients were considered exposed to the antipsychotic pre-
scribed at study cohort entry until the end of follow‐up (maximum
one year). Cox proportional hazards models were used to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs) of serious psy-
chiatric worsening (a composite of psychiatric hospitalizations, self‐
harm, or suicide) associated with switching to or adding aripiprazole
compared with other antipsychotic drugs.
Results: The cohort included 1,643 patients starting aripiprazole pro-
pensity‐matched to 1,643 patients starting another antipsychotic.
During 2,692 person‐years of follow‐up, 391 incident serious events
of psychiatric worsening occurred, with a crude incidence rate of
14.52 (95% CI 13.16–16.04) per 100 person‐years. First‐time use of
aripiprazole was not associated with an increased rate of psychiatric
treatment failure (HR 0.87; 95% CI 0.71–1.06), psychiatric hospitaliza-
tions (HR 0.85; 95% CI 0.69–1.06), or self‐harm/suicide (HR 0.96; 95%
CI 0.68–1.36) compared with starting another antipsychotic drug.
Results were consistent across several sensitivity analyses.
Conclusions: Compared with other antipsychotics, initiating
aripiprazole use, after a previous antipsychotic exposure was not asso-
ciated serious psychiatric worsening.
72 | Changes in the Population
Characteristics of U.S. Youth Receiving
Psychotropic Polypharmacy: 1996 to 2016
Chengchen Zhang1; O'Mareen Spence1; Gloria Reeves2;
Susan dosReis1
1University of Maryland School of Pharmacy, Baltimore, MD; 2University
of Maryland School of Medicine, Baltimore, MD
Background: Novel therapies, such as selective serotonin reuptake
inhibitors and second generation antipsychotics, had rapid uptake in
youth. This contributed to the rise of psychotropic polypharmacy
among US youth over the past 20 years. Few studies have investi-
gated if the demographic and clinical characteristics of youth who
receive psychotropic polypharmacy have changed over time.
Objectives: To determine the associations between the growth in psy-
chotropic polypharmacy over the past 21 years among US youth and
a) changes in psychiatric diagnoses, b) change in the severity of mental
health impairment, and c) expansion in prescribing to very young chil-
dren and females.
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Methods: The 1996–2016 Medical Expenditure Panel Survey was
used to identify youth ≤18 years old who received psychotropic
polypharmacy, defined as ≥3 psychotropic classes reported in at least
one interview in a year. The 21‐years were divided into three periods:
before (1996–2004), during (2005–2010), and after (2011–2016) the
emergence of novel therapies. The dependent variables were binary
measures of a) <5 years old; b) female; c) psychiatric diagnosis: mood
disorder (bipolar disorder or depression), attention‐deficit/hyperactiv-
ity disorder, schizophrenia/psychoses, anxiety; and d) severe mental
health impairment, defined as a Columbia Impairment Scale total
score ≥ 16. Survey weights generated nationally representative esti-
mates and 95% confidence intervals. Logistic regression models esti-
mated the trend in change across periods for each dependent variable.
Results: The total number of youth reporting psychotropic
polypharmacy increased from 109,381 in 1996–2004 to 292,110 in
2011–2016. Psychotropic polypharmacy for youth <5 years old was
not reported until 2011–2016 (1.1%). Females, as a proportion of
youth with psychotropic polypharmacy, increased from 30%
(95%CI = 19.4, 40.5) in 1996–2004 to 38% (95%CI = 25.8, 49.2) in
2011–2016, but this trend was not significant [OR: 1.03 (95%CI = 1.00,
1.08)]. The trend for mood disorders as a proportion of youth with
psychotropic polypharmacy was significant [OR: 1.13 (95%CI = 1.04,
1.22)], increasing from 9% (95%CI = 2.9, 15.8) to 49% (95%CI = 40.5,
57.7) to 60% (95%CI = 50.0, 69.3), in each respective period. The pro-
portion with severe mental health impairment increased from 73%
(95%CI = 64.5, 82.1) in 1996–2004; 72% (95%CI = 63.1, 80.3) in
2005–2010; and 84% (95%CI = 76.5, 91.6) in 2011–2016. This trend
was significant [OR: 1.04 (95%CI = 1.01, 1.08)].
Conclusions: Growth in psychotropic polypharmacy among US youth
was associated with mood disorders and severe mental health
impairment.
73 | Trends in Antipsychotic‐Related
Polypharmacy among U.S. Youth from 1996
to 2016
Chengchen Zhang1; O'Mareen Spence1; Gloria Reeves2;
Susan dosReis1
1University of Maryland School of Pharmacy, Baltimore, MD; 2University
of Maryland School of Medicine, Baltimore, MD
Background: Antipsychotics are often prescribed to youth concomi-
tantly with other psychotropics, despite the concerns over the meta-
bolic side effects of second generation antipsychotics. While a few
reports of single US state experiences show less antipsychotic use in
recent years, it is unclear if antipsychotic‐related polypharmacy has
decreased nationally in light of the safety concerns.
Objectives: To evaluate 21‐year trends in antipsychotic‐related
polypharmacy among US youth.
Methods: The 21‐year trend in antipsychotic use was derived from
the 1996–2016 Medical Expenditure Panel Survey. Psychotropic use
was based on reported use in at least one interview in the year. We
identified three mutually exclusive antipsychotic user groups, a) anti-
psychotic‐related polypharmacy (≥3 concomitant psychotropic clas-
ses, of which one was an antipsychotic), b) dual‐therapy
(antipsychotic with one other psychotropic) and c) monotherapy (sole
use of an antipsychotic). We collapsed years into three periods: 1996–
2004 (emergence of SGAs); 2005–2010 (emergence of safety con-
cerns); 2011–2016 (post‐safety warnings). We estimated the popula-
tion prevalence among all youth ≤18 years old and changes of
prevalence across periods for each antipsychotic user group. We used
survey weights to derive nationally representative estimates and 95%
confidence intervals, and linear regression to estimate the annual
prevalence change within each period.
Results: Antipsychotic‐related polypharmacy prevalence overall
increased from 0.05% (95%CI = 0.03, 0.07) to 0.20% (95%CI = 0.15,
0.25) to 0.29% (95%CI = 0.14, 0.42) in 1996–2004, 2005–2010, and
2011–2016, respectively. Antipsychotic dual‐therapy increased from
0.07% (95%CI = 0.05, 0.09) to 0.27% (95%CI = 0.21, 0.33) to 0.32%
(95%CI = 0.24, 0.41) in each respective period. The overall prevalence
of antipsychotic monotherapy increased from 0.01% (95%CI = 0.00,
0.02) to 0.06% (95%CI = 0.02, 0.09) to 0.19% (95%CI = 0.16, 0.52)
in each respective period. Within the 1996–2004 period, antipsy-
chotic‐related polypharmacy increased 0.02% (95%CI = 0.01, 0.03)
per year, antipsychotic dual‐therapy 0.03% (95%CI = 0.01, 0.05) per
year, and antipsychotic monotherapy 0.005% (95%CI = 0.00, 0.01)
per year. Prevalence change plateaued for all groups in 2005–2010.
Antipsychotic monotherapy prevalence revealed a significant increase
within the 2011–2016 period: 0.03% (95%CI = 0.01, 0.05) per year.
Conclusions: Antipsychotic monotherapy continued to increase over
time at faster rate than antipsychotic‐related polypharmacy.
74 | Off‐Label Use of Antipsychotics among
US Commercially‐Insured Youth
Kyungwan Hong; O'Mareen Spence; Susan dosReis
University of Maryland, Baltimore, MD
Background: In the US, antipsychotics are FDA approved in youth for
bipolar disorder, schizophrenia, and autism. All other use is considered
off‐label. Recent evidence shows that off‐label antipsychotic use has
increased among youth with attention‐deficit/hyperactivity disorder
(ADHD). It is unclear if antipsychotics are used more often in youth
with ADHD who have comorbid disruptive behavior disorders (DBD).
Objectives: The goal of this study was to assess the prevalence of
concomitant antipsychotic + stimulant use among US youth with
ADHD, with and without a comorbid DBD.
Methods: IQVIA™ PharMetrics Plus adjudicated claims were used to
identify US commercially‐insured youth ≤18 years‐old who were
diagnosed with ADHD anytime between 2007 and 2015
(n = 169,433). Youth with an FDA antipsychotic indicated condition
were excluded. We created four comorbidity subgroups: a) ADHD
only, b) ADHD+DBD only (i.e. conduct disorder, oppositional defiant
disorder, and impulse disorder), c) ADHD+other disorders (i.e.
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depression, anxiety, adjustment disorder, and PTSD), and d) ADHD
+DBD + other disorders. The primary outcome was the use of a regi-
men including an antipsychotic + stimulant or all other use. Descriptive
analysis estimated the cross‐sectional, annual prevalence of antipsy-
chotic + stimulant use from 2007 to 2015, overall and within each
comorbidity subgroup. Generalized estimating equations (GEE), for
repeated measures, estimated the odds of antipsychotic + stimulant
use in 2015 versus 2007 and across each subgroup. We also tested
the interaction between comorbidity subgroup and year.
Results: The overall prevalence of antipsychotic + stimulant decreased
from 3.5% in 2007 to 2.3% in 2015 (OR = 0.89; 95%CI = 0.81–0.99).
Relative to 2007, antipsychotic + stimulant use in 2015 significantly
decreased in youth with ADHD only (OR = 0.63; 95%CI = 0.56–
0.72) and ADHD+DBD + other disorders (OR = 0.73; 95%CI = 0.53–
0.99). Antipsychotic + stimulant use among youth with ADHD+DBD
only and ADHD+other disorders did not change significantly in 2015
versus 2007. When comparing comorbidity subgroup, the odds of
antipsychotic + stimulant use was significantly lower in youth with
ADHD only (OR = 0.26; 95%CI = 0.24–0.29), ADHD+DBD only
(OR = 0.76; 95%CI = 0.68–0.85), and ADHD+other disorders
(OR = 0.50; 95%CI = 0.45–0.55) compared to youth with ADHD
+DBD + other disorders. The interaction between comorbidity sub-
group and year was not statistically significant.
Conclusions: Among youth with ADHD, off‐labeled antipsychotic
use is more likely among youth with complex comorbidities. Anti-
psychotic + stimulant use has decreased among youth with ADHD
only.
75 | Risk of Psychosis with Amphetamine
versus Methylphenidate in Attention Deficit
Hyperactivity Disorder
Lauren V. Moran1; Dost Ongur1; John Hsu2; Victor M. Castro2;
Roy H. Perlis2; Sebastian Schneeweiss3
1McLean Hospital, Belmont, MA; 2Massachusetts General Hospital,
Boston, MA; 3Brigham and Women's Hospital, Boston, MA
Background: The use of prescription stimulants amphetamine and
methylphenidate for the treatment of attention deficit hyperactivity
disorder (ADHD) is increasing. In 2007, the US Food and Drug Admin-
istration mandated changes to stimulant prescribing labels based on
findings of new‐onset psychosis in patients without pre‐existing dis-
ease. Although these changes were mandated over 10 years ago, there
has been no systematic study of the comparative risk of psychosis
between amphetamine and methylphenidate.
Objectives: We sought to compare the risk of psychosis in adoles-
cents and young adults with ADHD who are new users of amphet-
amine versus methylphenidate.
Methods: This is a cohort study of patients 13–25 years old with an
outpatient diagnosis of ADHD from two commercial insurance claims
databases (Optum Clinformatics and IBM Marketscan) who started
taking amphetamine or methylphenidate between January 1, 2004
and September 30, 2015. The outcome was a diagnosis of psychosis
requiring treatment with an antipsychotic medication within 60 days
of initial psychosis diagnosis. We used 1:1 propensity score (PS)
matching to match patients on a set of 50 covariates measuring
ADHD severity, psychiatric comorbidity, psychotropic medication
use, substance use and healthcare utilization. For the pre‐specified pri-
mary analysis, we estimated hazard ratios (HR) in PS‐matched patients
and then pooled results across the two databases using fixed effects
meta‐analysis.
Results: A total of 221,846 participants in the propensity score
matched subsets with 143,286 person‐years of follow‐up experienced
343 psychotic events (2.4 per 1,000 person‐years). Use of amphet-
amine tripled over the study period with preferential prescribing of
amphetamine to older patients. The majority of patients were pre-
scribed stimulants by family/internal medicine physicians, who had
the highest prescribing rates of amphetamine (72.5%) compared to
pediatricians (51.6%) and psychiatrists (63.7%). Use of amphetamine
was associated with an increased risk of psychosis based on 237 psy-
chotic events in amphetamine users and 106 psychotic events in
methylphenidate users (HR 1.65, 95% CI 1.31 to 2.09).
Conclusions: Amphetamine use is associated with an increased risk of
treatment‐emergent psychosis compared to methylphenidate among
adolescents and young adults with ADHD.
76 | The Occurrence of Suicide‐Related
Outcomes among Patients Initiating
Tegaserod in Routine Clinical Practice
John D. Seeger; Sherry G. Quinn; Heather Norman; Judy Wong
Optum, Boston, MA
Background: Irritable bowel syndrome with constipation (IBS‐c), while
not life‐threatening, is a painful condition that is associated with anx-
iety, depression and suicidal ideation. Tegaserod is a 5‐HT4 serotonin
receptor agonist that relieves IBS‐c by increasing gastrointestinal
motility. Approved in 2002 for treatment of IBS‐c, an indication that
was later expanded to include chronic idiopathic constipation.
Tegaserod was withdrawn from the US market in 2007, although a
recent FDA advisory committee voted in favor of resuming marketing
of tegaserod.
Objectives: The objective of this study was to assess the effect of
tegaserod initiation on the occurrence of suicide‐related outcomes.
Methods: This cohort study identified tegaserod initiators from 2002
through 2006 within the Optum Research Database (ORD), a commer-
cial US health insurance claims database. These tegaserod initiators
were matched to a contemporaneous cohort of patients who had sim-
ilar patterns of healthcare services but who did not initiate tegaserod.
Matching was on the basis of propensity scores that incorporated over
200 characteristics associated with tegaserod initiation. Suicide‐
related outcomes (self‐injury and death) were identified by ICD‐9
codes for self‐injury along with all‐cause and cause‐specific mortality.
Follow‐up for outcomes included screening for claims codes along
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with review of medical records to confirm outcomes. Members of
each cohort were followed for up to 6 months from cohort entry for
the occurrence of an outcome or censoring.
Results: There were 52,229 tegaserod initiators and 52,229 compara-
tors, and the mean follow‐up was 5.1 months. There were 25 claims‐
based self‐injury events among the tegaserod initiators and 34 among
the comparators (HR = 0.74, 95% CI 0.44–1.25). There were 83
deaths among the tegaserod initiators and 72 among the comparators
(HR = 1.01, 95% CI 0.73–1.39). Additionally, there were 13 potential
self‐injury events during current use of tegaserod and 33 during
non‐use time (RR = 0.81, 95% CI 0.42–1.53). There were 38 potential
deaths during current tegaserod use and 72 during non‐use (RR = 1.14,
95% CI 0.77–1.68). Medical record confirmation (available for 85% of
initiators and 84% of non‐users) were largely consistent with the
claims‐based analysis and suggest that there is no increased risk of sui-
cide‐related outcomes among the tegaserod initiators.
Conclusions: Suicidal ideation may be a consequence of IBS‐c and
may be influenced by medications used for treatment. This study sug-
gests that tegaserod does not increase the risk of suicide or self‐injury.
77 | Cholesterol‐Lowering Medication and
Breast Cancer Recurrence in Postmenopausal
Women Treated with Adjuvant Aromatase
Inhibitors: A Danish Population‐Based Cohort
Study
Karl S. Harborg1; Uffe Heide‐Jørgensen2; Thomas P. Ahern3;
Maj‐Britt Jensen4; Marianne Ewertz5; Deirdre Cronin‐Fenton2;
Signe Borgquist1
1Aarhus University Hospital, Aarhus, Denmark; 2Aarhus University,
Aarhus, Denmark; 3University of Vermont, Burlington, VT; 4Danish Breast
Cancer Group, Copenhagen, Denmark; 5University of Southern Denmark,
Odense, Denmark
Background: Observational studies suggest that cholesterol‐lowering
medication (CLM) use is associated with longer recurrence‐free sur-
vival in breast cancer patients. Since 2007, aromatase inhibitors (AIs)
have been guideline treatment for estrogen receptor positive (ER+)
postmenopausal breast cancer. AI therapy is associated with increased
cholesterol levels.
Objectives: To investigate the association of CLM use and breast can-
cer recurrence rate in patients treated with AIs.
Methods: We included a cohort of all postmenopausal women diag-
nosed with stage I‐III ER+ breast cancer from 2007–2016, treated
with AI in the adjuvant setting, and registered in the Danish Breast
Cancer Group database and Danish Cancer Registry. We ascertained
incident CLM exposure (≥1 prescription post‐diagnosis) from the
Danish National Prescription Registry and modeled CLM as a time‐
varying exposure lagged by 6 months. Follow‐up began 6 months after
diagnosis and continued to the first event of recurrence, death, emi-
gration, 5 years, (and 10 years in overall follow‐up), or 25th September
2018. We estimated incidence rates (IR) of recurrence at 5 years and
overall, and used Cox regression models to compute crude and
adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI),
comparing CLM exposure with non‐exposure.
Results: We enrolled 12,947 eligible patients. Median follow‐up was
4.6 years. During the first 5 years, there were 35 recurrences in 3,290
person‐years of follow‐up for CLM exposed, and 525 recurrences in
46,590 in the unexposed group (IR per 1000 person‐years: 10.64
[95% CI: 7.41–14.80] and 11.27 [95% CI:10.33–12.28], respectively).
Overall, there were 646 recurrences in 56,171 total person‐years in
the unexposed group and 64 recurrences in 5,246 total person‐years
of follow‐up in the CLM exposed group (IR per 1,000 person years:
11.50 [95% CI: 10.63–12.42] and 12.20 [95% CI: 9.40–15.58], respec-
tively). There was some evidence of a reduced risk of recurrence associ-
ated with CLM exposure during the first 5 years of follow‐up (adjusted
HR: 0.76 [95% CI: 0.52–1.12], but this was not evident during overall
follow‐up (adjusted HR: 0.90 [95% CI: 0.68–1.20].
Conclusions: CLM use was not associated with a substantially reduced
risk of breast cancer recurrence among AI users.
78 | Association between
Hydrochlorothiazide Exposure and Skin, Lip
and Oral Cancer: A Series of Population‐
Based Nested Case–Control Studies
Daniel R. Morales1; Alexandra Pacurariu2; Xavier Kurz2; Jim Slattery2
1University of Dundee, Dundee, United Kingdom; 2European Medicines
Agency, London, United Kingdom
Background: Hydrochlorothiazide (HCTZ) exposure has been associ-
ated with non‐melanoma skin cancer in recent studies from Denmark.
The proposed mechanism is photosensitivity increasing the risk of skin
cancer from UV exposure.
Objectives: The aim of the studies presented in this report was to
attempt to replicate these associations in a different population and
data source, and to assess the impact of adjusting for missing con-
founders of smoking and body mass index (BMI).
Methods: The UK THIN database was used to perform five nested
case control studies assessing the association between HCTZ expo-
sure and squamous cell carcinoma, basal cell carcinoma, melanoma,
lip cancer and oral cancer matching up to 20 controls using risk set
sampling. Oral cancer was included as a negative control outcome.
The exposures analyzed included ever use and cumulative use of
HCTZ stratified into dose categories as per the original studies. Fur-
ther adjustment for smoking status and BMI was undertaking follow-
ing multiple imputation of missing data values.
Results: The crude incidence of each outcome in the adult population
per 100,000 person years was: 1.1 for lip cancer; 11.7 for squamous
cell carcinoma; 137.5 for basal cell carcinoma; 17.9 for melanoma;
and 5.7 for oral cancer. An increased relative incidence of lip cancer
was observed for high‐dose cumulative HCTZ exposure but this was
not statistically‐significant in standard analysis (IRR 2.23, 95%CI
0.54–9.16). When the lag‐time for HCTZ exposure was increased
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from 2 to 5 years, a statistically significant association with lip cancer
was observed (IRR 2.85, 95%CI 1.32–6.15). Statistically significant
associations were observed with high‐dose cumulative HCTZ expo-
sure for squamous cell carcinoma (IRR 2.93, 95%CI 1.85–4.62) and
basal cell carcinoma (IRR 1.30, 95%CI 1.03–1.65) but not melanoma
(IRR 0.90, 95%CI 0.33–2.45). No association was observed with HCTZ
exposure and oral cancer (IRR 0.84, 95%CI 0.56–1.26). The associa-
tions following adjustment for smoking and BMI were similar to the
main results.
Conclusions: Statistically significant associations with high‐dose
cumulative hydrochlorothiazide exposure and non‐melanoma skin
cancer and lip cancer were replicated in a UK population and data
source. Adjustment for smoking and BMI did not material change
the size of the observed associations.
79 | Voriconazole and Cutaneous Squamous
Cell Carcinoma Risk among Lung Transplant
Recipients
Monica D'Arcy1; Ruth Pfeiffer1; Donna R. Rivera1; Sarah Aaron2;
Elizabeth Yanik3; Isaac Brownell4; Edward Cowen4;
Matthew Triplette5; Greg Hess6; Eric A. Engels1
1National Cancer Institute, National institute of Health, Rockville, MD;
2University of California at San Francisco, San Francisco, CA;
3Washington University, St. Louis, MO; 4National Institute of Arthritis,
Musculoskeletal and Skin Diseases, National institute of Health, Bethesda,
MD; 5University of Washington, Seattle, WA; 6University of
Pennsylvania, Philadelphia, PA
Background: Solid organ transplant recipients have greatly elevated
risk of cutaneous squamous cell carcinoma (SCC), an aggressive skin
cancer. Voriconazole (vori) is used to prevent and treat invasive asper-
gillosis in lung transplant recipients. It can cause phototoxicity and has
been associated with increased SCC risk in modestly sized studies.
Objectives: Investigate the association between voriconazole (vori)
use and cutaneous SCC among lung recipients.
Methods: The Scientific Registry of Transplant Recipients (SRTR) was
used to identify White lung recipients in the US (2008–2016). Phar-
macy claims for immunosuppressants and antifungals (vori,
itraconazole [itra], posaconazole [posa], other) were linked from a
nationwide claims data warehouse. SCC was ascertained from the
SRTR. Follow‐up began at transplantation and ended at the earliest
of SCC, transplant failure/retransplant, death, loss to follow‐up or
12/31/2016. Person‐time was divided into 30‐day intervals, with
medication exposure assessed at the start of each interval. We
excluded all persons missing >25% of immunosuppressant interval
coverage. Intervals lacking an immunosuppressant or antifungal claim
were assigned unknown exposure status. Antifungal use was treated
as a time varying exposure. Cox models adjusted for sex, age, trans-
plant reason and number, induction therapy, smoking history, total
ambient ultraviolet exposure, and other antifungal use were used to
assess the association between vori and SCC.
Results: We evaluated 9,738 lung recipients (median age 59 years,
interquartile range [IQR] 48–65), of whom 59% were male. Median
follow‐up was 3.0 years (IQR 1.4–5.0), and recipients had immunosup-
pressant medication data for 75% (IQR 51%–90%) of 30‐day intervals.
There were 1,031 SCCs observed over 32,064 person‐years (PY) (inci-
dence 322 per 10,000 PY). Overall, 41%, 26%, and 13% of recipients
had a claim for vori, itra, and posa, respectively. Compared to individ-
uals with no observed vori use, those with 1–3, 4–7, 8–15,
and > 15 months of vori experienced increasingly elevated SCC risk:
adjusted hazard ratio (aHR) 1.1 (95%CI 0.9–1.3), 1.4 (1.2–1.7), 2.0
(1.7–2.5), and 3.0 (2.4–3.9). For each 30‐day vori use, SCC risk
increased 5% (aHR 1.05, 95%CI 1.04–1.06). There was no association
between other antifungals and SCC.
Conclusions: In a dose–response manner, vori was associated with
increased cutaneous SCC risk in a large population‐based sample of
lung recipients. Vori may play a role in the etiology of skin cancer,
and high‐risk lung recipients (e.g., fair skin) should be counseled on
the potential adverse effects of vori prior to initiation.
80 | Detection of Prevalent Cancer among
New Users without Routine Care
Monica D'Arcy; Til Stürmer; Michele Jonsson Funk
University of North Carolina, Chapel Hill, NC
Background: Elevated incidence rates of algorithm‐identified cancers
shortly after treatment initiation are common in new‐user studies,
but are unlikely to be real.
Objectives: To characterize features that may be driving high inci-
dence rates after initiation within a new‐user study.
Methods: We performed a new‐user, cohort study using a 20% ran-
dom sample of Medicare beneficiaries (2007–2014), aged 66+ initiat-
ing an antihypertensive (AHT), exclusive of betablockers. The outcome
was colorectal cancer (CRC), and was identified with ≥2 ICD‐9 CRC
diagnosis codes within 60 days. The diagnosis date was the date of
the 1st observed CRC claim. Cohort members had ≥2 claims,
≥360 days of continuous Medicare (A/B) enrollment, no evidence of
CRC prior to AHT initiation, and ≥ 180 days of part D enrollment with
no AHT claim. Person‐time/cases began accrual after the 2nd pre-
scription. CRC rates were calculated and stratified by time. We calcu-
lated the number of office visits (OV) in the 60–360 days prior to
initiation and stratified users into those with 0, 1, 2–3 or ≥ 4 OVs.
We calculated CRC incidence stratified by time (0–90, 91–180, 181–
365, 366–730, 731+ days) and strata of OV. Among cases, we identi-
fied claims post initiation that suggested prevalent CRC (history of
colon or rectal cancer) or incident CRC (physical symptoms, pathol-
ogy). We calculated the number and proportion of these events strat-
ified by time since initiation and number of office visits.
Results: There were 417,458 AHT initiators and 2,127 cases identified
over 683,097 person years (incidence 311 per 100,000). Incidence
was highest in the 0–90 days post initiation and varied by the number
of office visits (0:758, 1:475, 2–3:456, ≥4:414). Incidence for all OV
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strata dropped in the 91–180 days post initiation, stabilizing after
180 days. The decrease was most pronounced in those with 0 OVs.
The proportion of probable prevalent cases was higher in the 0–
90 days (7.5%) after initiation than in all other time strata (91‐180d
4.0%; 181‐365d 2.4%; 366‐730d 3.9%; ≥731d 2.9%). The proportion
did not vary by strata of OVs. The proportion of probable incident
cases did not vary substantially by time since initiation or by the num-
ber of OV.
Conclusions: Individuals with no office visits in the 60–360 days prior
to medication initiation have markedly higher CRC incidence in the 0–
90 days post initiation and drive much of the observed high incidence
in the cohort overall. Compared with cases diagnoses after 90 days, a
higher proportion of cases diagnosed within 90 days of initiation
appear to be prevalent cases. Induction periods after drug initiation
reduce misclassification of prevalent as incident cancers.
81 | Automatic Detection of Drug–Drug
Interactions in Cancer Patients: A French
Population‐Based Cohort Study
Camille Morival1; Clément Mathieu2; Antoine Pariente1;
Mathieu Molimard1; Amandine Gouverneur1; Pernelle Noize1
1Bordeaux Population Health Research Center, Team
Pharmacoepidemiology, UMR1219, University of Bordeaux, Inserm/
Clinical Pharmacology, Bordeaux University Hospital, Bordeaux, France;
2Bordeaux Population Health Research Center, Team
Pharmacoepidemiology, UMR1219, University of Bordeaux, Inserm,
Bordeaux, France
Background: Risk management and appropriateness of care are public
health priorities. Promoting optimal oncological care pathways
requires an analysis of risk situations and contexts of use of anticancer
drugs, especially since oncological care are switching to the outpatient
setting.
Objectives: This study aimed at estimating the prevalence of outpa-
tient potential drug–drug interactions (DDI) in the French population
with cancer to identify situations requiring actions to prevent or pro-
mote the appropriate use of drugs.
Methods: A retrospective cohort was conducted using reimbursement
data from the national health insurance system (Echantillon Généraliste
de Bénéficiaires). All patients aged 18 and over with a new cancer diag-
nosis between January 1st, 2009 and December 31st, 2014 were
included. Potential DDI were identified during the year following can-
cer diagnosis according to the national thesaurus published by the
French Medicines Agency (September 2016). Potential DDI were
defined as the dispensing within a period of 15 days of drugs that
could interact and were automatically detected using the Thériaque®
database. Potential DDI were described according to i) nature of drugs
involved, ii) mechanism and iii) severity.
Results: A total of 18,614 patients were included in the cohort
(median age: 67 years; 50% female). During the one‐year follow‐up,
11,249 patients (60.4%) had at least one potential DDI; the prevalence
was 6.1% for contraindicated potential DDI and 16.0% for potential
DDI that should be avoided. The contraindicated potential DDI most
frequently observed concerned biguanides and contrast media. Among
the cohort, 4,335 patients (23.3%) had anticancer drug dispensings
(median age: 67 years; 59.5% female). In this population, 2,802
patients (64.6%) had at least one potential DDI during the one‐year
follow‐up. The most frequent severe potential DDI (contraindicated
and that should be avoided) involving anticancer drugs concerned folic
acid analogues (methotrexate). Among less severe potential DDI (that
should be taken into account) involving anticancer drugs, those
concerning protein kinase inhibitors and proton pump inhibitors were
the most frequent.
Conclusions: This study provides a global description of outpatient
DDI in the French population with cancer that enables to consider
preventive actions. A further analysis of the clinical consequences of
specific potential DDI would be of interest in this population.
82 | Treatment Pattern and Real World
Effectiveness on Non Small Cell Lung Cancer
Patients Harboring Major Single and Double
EGFR Mutations
W. Venus So1; Xing Yang1; Mathias Leddin2; Lin‐Chi Chen1;
Yvonne A. Nagel2
1Roche Innovation Center New York, New York, NY; 2Roche Innovation
Center Basel, Basel, Switzerland
Background: Although the clinical outcome of EGFR‐positive
advanced non‐small cell lung cancer (aNSCLC) patients has been well
studied, the analysis of real world treatment effectiveness on specific
mutation combinations is lacking to direct drug development for
enhancing personalized healthcare.
Objectives: To characterize treatment and effectiveness on aNSCLC
patients with the most common EGFR mutations using electronic
health records (EHR) real world data (RWD).
Methods: Patients with aNSCLC diagnosed between 2011 and Nov
2018, who were tested EGFR mutation‐positive were identified from
the Flatiron Health EHR‐derived database. Those with the common
single mutations, exon 19 deletion (del19) and L858R (LR); and
T790 M (TM) acquired from EGFR‐targeted tyrosine kinase inhibitors
(TKI) were studied for treatment pattern and overall survival. Cohorts
for survival comparison were balanced using standardized mortality
ratio weighting. Median overall survival (mOS) was estimated using
Kaplan–Meier curve and hazard ratios (HR) using Cox proportional
hazards.
Results: The study included 4489 EGFR‐positive aNSCLC patients
(median age 69 years old: 1909 with del19, 1504 with L858R and
660 with T790 M). Among them, 23 had both del19 and LR, 231 had
the double mutation TMLR, 338 had TMdel19 and 6 had triple muta-
tion (TMLRdel19). De novo TM mutation was detected in 4.4% (182/
4129) NSCLC patients with biopsy dates before first/second genera-
tion TKIs. Usage of these TKIs as first line for LR and del19 mutations
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peaked in 2014 at ~80% of all treatment categories, and dropped to
~25% in 2018, in which ~50% were treated with first line osimertinib.
Among patients who acquired theTM mutation after first lineTKIs, the
TMLR double mutation resulted in worse OS (HR 1.57, p = 0.007),
with mOS of 30.4 months (95% CI: 26.9–32.9) from start of first line
treatment, compared to TMdel19 (mOS 41.5 months, 95% CI: 35.0–
53.4). In this study, mOS of LR patients (double‐mutation patients
excluded) was 19.8 months (95% CI: 18.0–21.5) and that of del19
was 22.5 months (20.7–23.9, HR 1.14 [p = 0.05]).
Conclusions: The large number of NSCLC patients in the Flatiron
Health EHR‐derived database allowed a more comprehensive retro-
spective study of patients with specific mutations. Patients withTMLR
mutations had worse OS than TMdel19 after first line first/second
generation TKIs. This difference is more prominent in patients harbor-
ing double mutations than those with single mutations. More data on
recent osimertinib treatment is needed to see its real world effective-
ness on the different double mutation patients.
83 | Impact of a Two‐Tier Intervention on
Statin Prescribing and Adherence Levels
among Latino Patients with Diabetes
Toney Duong
Texas A&M Irma Lerma Rangel College of Pharmacy, College Station, TX
Background: Type 2 Diabetes Mellitus (T2DM) is a risk factor for car-
diovascular disease (CVD), the leading cause of death in the United
States. To increase primary and secondary prevention of major cardio-
vascular events (CVE), current guidelines recommend starting diabetic
patients ≥40 years of age on a statin. Unfortunately, there is lack of
consensus among primary care physicians (PCPs) to prescribe, and
poor patient adherence to comply with statin therapy for CVE prophy-
laxis. Repercussions of PCP noncompliance and poor patient adher-
ence could adversely affect the benefits of the statin therapy among
diabetic patients, especially among those with a high prevalence of
T2DM and a high incidence of CVE, such as the Latino group.
Objectives: The objectives for this study are: 1) Estimate the preva-
lence of diabetes in a group of Latino patients; 2) Calculate the pro-
portion of diabetic beneficiaries ≥40 years age receiving a
prescription for a statin during the study period; 3) Determine diabetic
beneficiaries adherence level to statin therapy.
Methods: This study follows a descriptive design using data from bene-
ficiaries of a Latino based pharmacy benefit manger (PBM) with contin-
uous enrollment from January 1, 2018 to October 31, 2018. Diabetes
beneficiaries were defined as those with at least two generic product
identifiers (GPIs) for a diabetic agent during the study period. GPIs for
statin products were used to the estimate the prevalence of statin pre-
scribing among diabetic beneficiaries. Proportion of days covered (PDC)
was used to estimate diabetic beneficiaries' adherence to the statin
therapy.
Results: The prevalence of diabetes among beneficiaries of the PBM
aged 40–75 was 6% (6,243/111,572). The mean age for the diabetic
beneficiaries was 55 (SD ± 7), and 53% were males. A total of 3,401
(54%) diabetic beneficiaries received at least one prescription for a
statin during the study. Among those diabetic beneficiaries who
received at least one prescription for a statin during the study period,
1,932 (57%) had PDC ≥ 80%.
Conclusions: Although treatment guidelines recommend placing dia-
betic patients≥40 years of age on a statin, this study found suboptimal
prescribing among Latino diabetic patients. In addition, among those
Latino diabetic patients who received at least one prescription for a
statin, the adherence levels to the statin pharmacotherapywas subopti-
mal. Therefore, prompting a bigger issue addressing poor adherence by
means of intervention through educating physicians and patients.
84 | Secondary Adherence to Oral
Anticoagulants. Preliminary Results of a
Systematic Review and Meta‐Analysis of
Real‐World Studies
Clara L. Rodríguez‐Bernal; Salvador Peiró; Anibal García‐Sempere;
Gabriel Sanfélix‐Gimeno
FISABIO, Valencia, Spain
Background: Since the release of the first non‐vitamin K antagonist
oral anticoagulant (NOAC), several observational studies have been
carried out to estimate adherence to oral anticoagulants (OAC), many
of them, being funded by NOAC marketers. There are no studies sum-
marizing systematically the available evidence on secondary adher-
ence in the real world using pharmacy claim databases or atrial
fibrillation registers and taking into account potential biases.
Objectives: To describe secondary adherence to OACs, to compare
adherence between OACs and to analyze potential biases in OAC sec-
ondary adherence studies using databases.
Methods: We searched on PubMed, SCOPUS and Web of Science
databases to identify longitudinal observational studies reporting days'
supply adherence measures to OAC in patients with AF from claims
databases or AF registers. The main study endpoint was the percent-
age of patients exceeding the 80% threshold in proportion of days
covered (PDC80) with 12 months follow‐up. We used random‐effects
meta‐analysis to pool study estimates, stratified by the presence of
conflict of interest (CoI; defined by funding or authorship).
Results: We found 22 studies reporting PDC80 (or MPR80) at
12 months (from 2013 to 2018) fulfilling inclusion criteria, reporting
data from 30 cohorts, 19 without CoI and 11 with CoI (all related with
Rivaroxaban marketers). Total PDC80 pooled estimates by drug were:
59% (Warfarin), 62% (Dabigatran), 67% (Rivaroxaban) and 71%
(Apixaban). In studies without CoI, adherence estimates increased for
Warfarin (63%), Apixaban (75%) and Dabigatran (64%) without
changes for Rivaroxaban. In the opposite direction, in studies with
CoI adherence estimates were clearly reduced for Warfarin (from
63% to 53%) and Apixaban (from 75% to 68%).
Conclusions: Conflict of interest bias is a relevant factor in studies
assessing adherence to OAC in AF patients.
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85 | Persistence and Adherence to Biologics
in Patients with Psoriasis: A Nation‐Wide
New User Cohort Study
Yanfang Liu1; Yu‐Huei Huang2; Choo Hua Goh3; Chia‐Li Chang4;
Hong Qiu5; Chao‐Hsiun Tang4
1 Janssen Research & Development LLC, Titusville, NJ; 2Department of
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Administration, Taipei Medical University, Taipei, Taiwan; 5Global
Epidemiology, Janssen Research & Development LLC, Titusville, NJ
Background: Adalimumab, etanercept and ustekinumab are biologics
approved to treat moderate‐to‐severe psoriasis in patients who fail to
respond to conventional topical and systemic agents or phototherapy
inTaiwan. Persistence on the biologics can be a proxy of effectiveness
inTaiwan, where reimbursement is only provided with clinical improve-
ment evaluated every 6 months. No population‐based studies have
evaluated how biologics are used for the treatment of psoriasis in Asia.
Objectives: To describe characteristics of new users of biologics and
to evaluate treatment persistence and adherence to biologics using
the National Health Insurance Research Database in Taiwan.
Methods: New users of biologics aged at least 18 years with a con-
firmed diagnosis of psoriasis (ICD‐9 code 696.1) from 1 November
2014 to 31 December 2015 were identified. Exclusion criteria
were < 12months duration in the database prior to the diagnosis, malig-
nancy, activeTB, active hepatitis B and/or Cwithin 6months before the
index date. Patients were followed up until 31 December 2016. Persis-
tence was defined as time (consecutive days) from treatment initiation
until discontinuation. Discontinuation was defined as a treatment gap
of at least 90 days for etanercept and adalimumab, and 180 days for
ustekinumab. A sensitivity analysis assessed 30‐, 60‐, 90‐, and 120‐
day treatment gaps. A Kaplan–Meier analysis estimated the proportion
of patients who remained persistent on the index biologic following the
index date throughout the follow‐up period. We used a log‐rank test to
compare persistence between groups. Confounding factors; gender,
age, co‐medications were adjusted.
Results: There were 811 patients with psoriasis who were new users of
biologics, of whom 558 (study population) had no other co‐morbidities
that required treatment with biologics. The mean age was 44.9 years
(SD 13.5) and 76.2% were male. The persistence rate in psoriasis
patients without co‐morbidities at 1 year was 68.8%, 81.2% and
93.4% for patients taking etanercept, adalimumab, and ustekinumab,
respectively (p < 0.0001). Results were consistent (p < 0.0001) in a sen-
sitivity analysis conducted using different treatment gaps to define per-
sistence. The adherence rate (i.e., the correct quantity of drug
prescribed) at 12 months was 67.2% for etanercept, 62.8% for
adalimumab and 94.7% for ustekinumab (p < 0.0001). Adherence at
18 months was 64.3%, 47.3%, and 91.4%, respectively (p < 0.0001).
Conclusions: Drug persistence and adherence was highest in patients
with psoriasis treated with ustekinumab.
86 | Investigating the Impact of Statin
Intensity on Patients' Discontinuation of
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Francisco de Assis Acurcio7; Alec Morton1; Amanj Kurdi1
1University of Strathclyde, Glasgow, United Kingdom; 2Federal University
of Ouro Preto, Ouro Preto, Brazil; 3NHS National Services Scotland,
Edinburgh, United Kingdom; 4Karolinska Institutet, Stockholm, Sweden;
5The Scottish Government, Edinburgh, United Kingdom; 6NHS Greater
Glasgow & Clyde, Glasgow, United Kingdom; 7Federal University of Minas
Gerais, Belo Horizonte, Brazil
Background: Statins are among the most widely prescribed drugs in
many countries. Current treatment guidelines in the UK recommend
high‐intensity statin therapy (atorvastatin 80 mg) for secondary pre-
vention of cardiovascular disease (CVD). However, information
regarding the impact of recommending this high statin dose on treat-
ment discontinuation is limited.
Objectives: To evaluate the impact of high‐intensity therapy on statin
discontinuation in patients in Scotland.
Methods: Retrospective cohort study using the Scottish prescribing
dataset linked with hospitalization records, comprising patients (≥
18 years) initiating statins between January 2010 and December
2015; statin intensity was defined as high, moderate or low based on
current National Institutes for Health and Care Excellence classifica-
tions. Discontinuation was calculated using the refill‐gap method;
Kaplan–Meier and Cox proportional hazard models, adjusted for age,
sex, comorbidity and whether statins were used for primary or second-
ary prevention, were used to determine differences in discontinuation.
Results: A total of 73,716 patients (mean age 61.4 years [SD 12.6])
were identified. Overall, 62.9% of patients discontinued treatment;
the majority of these however re‐initiated treatment. Discontinuation
rates varied among intensity levels, being lowest among high intensity
(50.9%) and highest among low intensity statins (75.5%). Furthermore,
rates differed between patients with a diagnosis of ischaemic heart
disease, angina, myocardial infarction or stroke (secondary preven-
tion), and those without (primary prevention) ‐ ranging from 36.3%
(high intensity) to 58.8% (low intensity) among the former, and from
55.9% (high) to 76.3% (low) among the latter. Similarly, median time
to discontinuation was shortest among low intensity (207 days, 95%
confidence interval (CI) 168–244), and longest among high intensity
statins (911 days, 95% CI 843–1007). Adjusted hazard ratios (HR)
for high intensity treatment, as compared to moderate intensity, were
0.43 (95% confidence interval (CI) 0.34–0.55) and 0.80 (95% CI 0.74–
0.86) among patient with and without prior CVD, respectively.
Conclusions: Compared to moderate and low intensity, high‐intensity
statin therapy was associated with lower discontinuation rates. How-
ever, the clinical impact of these differences in discontinuation needs
further investigation.
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87 | Does Single‐Tablet Regimen Improve
Adherence to Antiretroviral Therapy in Brazil?
A Group‐Based Trajectory Modeling Analysis
of Patients Switching Regimens
Simone Santos1; Micheline R. Silveira1; Celline C. Almeida‐Brasil2;
Juliana O. Costa1,3; Marcio Cruz1; Edna Reis1; Francisco Acurcio1;
Maria das Graças B. Ceccato1
1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; 2Research
Institute of the McGill University Health Centre, Montreal, QC, Canada;
3University of New South Wales, Sidney, Australia
Background: CombinationAntiretroviral Therapy (cART) in a single‐tab-
let regimen (STR)was adopted inBrazil in 2015. The simplification of the
therapeutic regimen is one of the factors that influence patients'
adherence.
Objectives: We evaluated if this simplification strategy impacted on
adherence and clinical outcomes.
Methods: We conducted a retrospective cohort study of 1206 patients
using efavirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg in
multiple‐tablet regimenwho switched to a STR containing the same for-
mulation between March and June 2015. We obtained data from the
Brazilian Ministry of Health electronic databases. The index date was
defined as the day of the switch (i.e. the date of the first prescription fill
for the STR). Adherence was measured by the proportion of days cov-
ered (PDC) and patients were followed for 18 months prior (pre‐switch
period) and after (post‐switch period) the switch. We calculated the
cumulative and monthly PDC considering 95% of adherence as thresh-
old. Adherence patterns to cART regimen over time for each period
(pre‐ and post‐switch) were identified using group‐based trajectory
modeling. We also identified predictors of each trajectory group.
Results: We observed an increase of 14% in the proportion of adherent
patients after switching to STR (p < 0.001). Therewas also an increase in
the number of patients with CD4 count >500cells/μl (6.2%, p < 0.001;
N = 490). The proportion of patients with undetectable viral load after
the switch remained similar (96.4 vs. 96.7%; p = 0.871; N = 699). The
group‐based trajectory analysis revealed four groups of adherence
probability: 1) early non‐ adherence; 2) insufficient adherence; 3) slow
increase in adherence; and 4) nearly‐always adherence. After the
switch, the trajectory patterns were more uniform as the adherence
probabilities have remained more constant over time. Moreover, we
observed a migration of patients towards a group representing a higher
probability of adherence after the switch, where 55% of the patients
shifted to a group with a higher level of adherence, 40% remained at
the same level and only 5% shifted to a group with lower adherence
level. Patients belonging to the group with the worst chance of adher-
ence were more likely to be women, have lower education, or longer
time on cART than the nearly‐always adherent patients.
Conclusions: The strategy of introducing STR in Brazil for HIV treat-
ment had a positive impact on adherence and clinical outcomes.
Patients belonging to different adherence patterns over time may war-
rant different types of clinical interventions.
88 | Risk Factors for Non‐Persistence with
Antiplatelet Agents in Patients after a
Transient Ischemic Attack
Martin Wawruch; Gejza Wimmer Jr; Jan Murin
Comenius University, Faculty of Medicine, Bratislava, Slovakia
Background: Antiplatelet medication represents an important tool of
secondary prevention in patients after a transient ischemic attack (TIA).
Objectives: The study was aimed at evaluating non‐persistence with
antiplatelet medications in patients after a TIA and identifying patient‐
related characteristics influencing the probability of non‐persistence.
Methods: Data for our study were collected from the database of the
General Health Insurance Company, the largest health insurance pro-
vider of the Slovak Republic. Our study cohort included 1298 patients
(62.1% of them women), in whom antiplatelet therapy was initiated
between 1 January 2010 and 31 December 2010. Patients were
followed for three years from the index date. Patients with a treatment
gap were classified as non‐persistent. A treatment gap was defined as a
6‐month period without any antiplatelet medication prescription. The
Cox proportional hazardsmodelwas used to identify patient‐associated
characteristics influencing the patient's risk for non‐persistence.
Results: Attheendof the follow‐upperiod,647 (49.8%)of1298patients
were identified as non‐persistent with antiplatelet agents. Older




Conclusions: The results of our study indicate that inTIA patients aged
<65 years and those without certain comorbid conditions special
attention should be paid to the improvement of their persistence with
antiplatelet medications. Funding: This study was funded by grant of
the Scientific Grant Agency of the Ministry of Education, Science,
Research and Sport of the Slovak Republic VEGA 1/0112/17.
89 | Treatment Patterns and Adherence in a
UK Primary Care Migraine Population
Eleanor Yelland1; Rebecca Ghosh1; Tarita Murray‐Thomas1;
Alison Williams2; Victoria Hacking2
1Medicines and Healthcare products Regulatory Agency, London, United
Kingdom; 2Novartis Pharmaceuticals UK, Frimley, Surrey, United Kingdom
Background: Migraine is estimated to affect 7.6% of men and 18.3%
of women in England but use of preventive therapies is reported to
be low. There is limited evidence on adherence to such treatments.
Objectives: To estimate cumulative migraine incidence and describe
prophylactic treatment patterns and adherence in 2015.
Methods: Patients ≥18 years old in the Clinical Practice Research
Datalink with incident migraine during 01/01/2007–31/12/2017.
Cumulative incidence of migraine was estimated, and cohort factors
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described. Treatments were categorized as none, acute only, prophy-
lactic only, acute and prophylactic. 12‐month treatment patterns were
described in patients initiating prophylactic treatment with amitripty-
line, propranolol or topiramate in 2015. These were classified as con-
tinuous use (<90 days between prescriptions), augmentation (new
treatment ≥57 days after index treatment & before end of index
treatment), switching (new treatment ≤56 days before end of index
treatment & ≤90 days after end of index treatment) or discontinua-
tion (≥91 days between prescriptions). Adherence was defined as
the proportion of days covered (PDC) (days in possession/365) and
medication possession ratio (MPR) (days in possession/days on treat-
ment). Patients were ‘adherent’ if their PDC or MPR was ≥0.80.
Results: 89,442 patients had incident migraine. Mean age at diagnosis
was 40 years [SD 15]; 76.6% were females. Mean follow‐up after diag-
nosis was 1666 days [SD 927]. The cumulative incidence of migraine
was 25.8/10,000 person‐years [95%CI:25.6–26.0]. Common comor-
bidities included depression [19.2%], asthma [19.7%] and anxiety
[16.5%]. 26% of patients received acute treatment only, 86.7% received
prophylactic and/or acute treatment; 37.6% and 20.1% received ≥2
and ≥ 3 different prophylactic treatments during follow‐up, respec-
tively. 1,636 patients initiated prophylactic treatment in 2015. Propran-
olol (47.8%) and amitriptyline (47.4%) were most commonly prescribed.
79% of propranolol users and 83% of amitriptyline users discontinued
treatment within 12 months; mean time to discontinuation was 92.2
and 82.7 days, respectively. The discontinuation rate for topiramate
was 69.2% and mean time to first change was 99.5 days. Median MPR
was 1.00 and median PDC was 0.31. Using MPR, 80–85% of patients
were adherent while on treatment, though only 20–30% continued
treatment up to 12 months.
Conclusions: Most migraine patients receive one or more treatments.
Despite being adherent while on treatment, most discontinue prophy-
lactic treatment within 12 months. Reasons for discontinuation and
strategies to reduce this should be explored.
90 | The Impact of Reduced Copay for
Hormonal Therapy on Primary and Secondary
Non‐Adherence for Breast Cancer Medicare
Patients
Aaron N. Winn; Nicole Fergestrom; Joan M. Neuner
Medical College of Wisconsin, Milwaukee, WI
Background: Several large randomized controlled trials have clearly
documented the survival benefit of hormonal therapy (HT); however,
manywomenwith breast cancer fail to initiate (primary non‐adherence)
and among those who are initiate, many fail to remain adherent to HTs
(secondary non‐adherence). Prior studies have found that costs impact
secondary non‐adherence to medications, but have failed to examine
primary non‐adherence.
Objectives: To estimate how primary and secondary adherence was
impacted by reducing copays for medications by the introduction of
generic HTs.
Methods: We examined monthly adherence to HT after active treat-
ment ceased using the proportion of days covered (PDC) for women
diagnosed with stage 1–3 breast cancer between 2008–2009 using
SEER‐Medicare data. We followed patients for up to five year or until
they were censored due to insurance disenrollment or having evi-
dence of cancer recurrence. We examined adherence for 1 year
before and up to 4 years after generic HT was available. We compare
women whose copays would change and those whose copays would
not due to the receipt of cost‐sharing subsidies. To examine primary
and secondary non‐adherence we use a multi‐state model with 4
states (Never used, Low adherence (PDC < 0.80), Adherent
(PDC ≥ 0.80), and Former User). Additionally, we used the model to
simulate the expected time a person is adherence to the drug, effec-
tively combining the results for the primary and secondary adherence
components. We implemented the multi‐state model using a clock for-
ward approach and used a Cox proportional hazard model adjusting
for demographic and clinical factors.
Results: We identified 38,626 women with breast cancer. We find that
reduced copays results in faster initiation of treatment (hazard ratio
(HR) = 1.11; 95%CI = 1.04–1.19; p‐value <0.01). Among adherent indi-
viduals, reduced copays results in being less likely tomove to having low
adherence (HR=0.68; 95%CI = 0.62–0.75; p‐value <0.01) and less likely
to stop taking medication adherent (HR = 0.49; 95%CI = 0.42–0.57; p‐
value <0.01). Among individuals with low adherence, they are less likely
to stop taking the HT (HR = 0.65; 95%CI = 0.57–0.82; p‐value <0.01).
However, if a patient stops using the HT, those with low copays are less
likely to reinitiate HT (HR = 0.48; 95%CI = 0.42–0.57; p‐value <0.01).
Simulations document that lower copays increase the amount of time
a person is using and adherent to HT.
Conclusions: This study finds that both primary and secondary non‐
adherence were positively impacted by reduced copays.
91 | Uncertain Association between
BenzodiazepineUse and the Risk of Dementia:
Population‐Based Matched Cohort Study
Yeon‐Hee Baek1; Hyesung Lee1; Woo Jung Kim2; Jee‐Eun Chung3;
Nicole Pratt4; Lisa K. Ellett4; Ju‐Young Shin1
1SKKU Pharmacoepidemiology, School of Pharmacy, Sungkyunkwan
University, Suwon, Republic of Korea; 2Myongji Hospital, Hanyang
University College of Medicine, Goyang, Republic of Korea; 3Hanyang
University, Ansan, Republic of Korea; 4University of South Australia,
Adelaide, Australia
Background: Controversy exists regarding the increased risk of
dementia associated with benzodiazepine use. The Asian population
may be at a higher risk of benzodiazepine‐induced dementia due to
the genetic variation in CYP2C19.
Objectives: To examine the association between benzodiazepine use
and the risk of dementia.
Methods: We conducted a retrospective cohort study using a nation-
wide healthcare database from 2007 to 2016 in South Korea. Study
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subjects included new‐users aged 50 years or older without having a
prior prescription record of benzodiazepines or a history of dementia
within the 5‐year eligibility period, 2002–2006. Outcome was defined
as an incident dementia with pre‐specified algorithms using diagnosis
andprescription recordswith theapplicationof5‐year lag time.Weused
multivariable cox proportional hazard models to estimate hazard ratio
(HR) and their 95% confidence interval (CI). Comorbidities and co‐med-
ications were treated as time‐varying variables on 90 day unit. Active
comparatorwas used to control for bias fromconfounding by indication.
Results: Our final subjects included 612,256 patients, after propensity
score estimation and matching in 1:1 ratio. We observed a 23%
increased risk of dementia associated with the use of benzodiazepine,
as compared with non‐users, over a mean follow‐up of 5.5 years
(HR = 1.23, 95% CI = 1.14–1.32). Consistent finding was observed
with varying the lag‐time duration, but close to the null association
with 7‐year lag time (HR = 1.17, 95% CI = 1.04–1.30). Contrary to this,
repeated analyses with active comparator produced no increased risk
in benzodiazepine users.
Conclusions: While we found a significant association between the
use of benzodiazepine and the risk of dementia, null or negative
results produced by the longer duration of lag‐time and use of active
comparator meant the absence of causal association.
92 | Risk of Cardiovascular Adverse Events
and Domperidone Use: A Case‐Crossover
Study
Sun Mi Shin; Junqing Li; Hye‐Jun Kim; Hyesung Lee; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Republic of
Korea
Background: Recent epidemiological studies have suggested that
domperidone may increase the risk of severe cardiac arrhythmias, and
new safety concerns regarding other cardiovascular (CV) disease also
exists.
Objectives: The aim of this study is to investigate whether the use of
domperidone increases the risk of cardiovascular adverse events,
including arrhythmias, hypertension, myocardial infarction, ischemic
stroke and heart failure.
Methods: We conducted a case‐crossover study using the Sample
Cohort data from the National Health Insurance Service in South Korea
from 2002 to 2015. From a total of 254,840 incident patients with CV
events, our final case series included 60,783 patients with a prior pre-
scription for domperidone or metoclopramide. Exposure to
domperidone in a 7‐day hazard period prior to each patient's CV event
was compared with domperidone use in an earlier 7‐day control period.
We conducted conditional logistic regression analysis to estimate odds
ratios (ORs) and 95% confidence interval. Also, the risk was estimated
for each category of average daily domperidone dose (≤30 mg
and > 30 mg) and whether co‐medication of CYP3A4 inhibitors or QT
prolonging drugs with domperidone. We produced repeated analysis
with the use of metoclopramide as an active comparator.
Results: The odds ratio for overall CV events was 1.57 (95% CI 1.46–
1.69) versus non‐use, and 0.59 (95% CI 0.50–0.70) versus
metoclopramide use. Myocardial infarction showed the highest odds
ratio (OR 2.86, 95% CI 1.21–6.76) versus non‐use, followed by ische-
mic stroke (OR 2.33, 95% CI 1.72–3.14), hypertension (OR 1.53, 95%
CI 1.42–1.66), arrhythmias (OR 1.45, 95% CI 1.13–1.85) and heart fail-
ure (OR 1.44, 95% CI 0.94–2.21). A higher CV risk was observed in
patients taking the higher daily dose of domperidone (>30 mg, OR
2.54, 95% CI 1.74–3.72), and those who were co‐exposed with
CYP3A4 inhibitors (OR 2.69, 95% CI 2.31–3.12) or QT prolonging
drugs (OR 2.87, CI 2.53–3.24). However, no increased risk was
observed for specific outcome with respect to metoclopramide.
Conclusions: Our results suggested that domperidone use was associ-
ated with overall CV events, with a suggestion of high risk for myocar-
dial infarction, ischemic stroke and hypertension not only for
arrhythmias. However, no increased risk in comparison of
metoclopramide imply the absence of causal relationship between
domperidone and CV risk.
93 | A Multi‐Institutional Health Screening
Records Database (HSRD) of Korea:
Evaluation of Its Characteristics and
Representativeness
Yunha Noh1; Han Eol Jeong1; Hye‐Jun Kim1; Hanju Ko2;
Eun‐Hee Nah3; Ju‐Young Shin1
1SKKU Pharmacoepidemiology, School of Pharmacy, SungKyunKwan
University, Suwon, Republic of Korea; 2 IT Development & Support Office,
Korea Association of Health Promotion, Seoul, Republic of Korea; 3Health
Promotion Research Institute, Korea Association of Health Promotion,
Seoul, Republic of Korea
Background: The Health Screening Records Database (HSRD) is the
largest multi‐institutional health screening records derived from an
organization of 16 hospitals in Korea. Although laboratory data from
health screenings may be extensively used for medical studies, repre-
sentativeness of such data have yet to be evaluated.
Objectives: To evaluate the characteristics and representativeness of
the HSRD for its use as a reliable data source for medical studies.
Methods: This comparative study used data from HSRD and Korea's
National Health Insurance Service‐National Health Screening Cohort
(NHIS‐HEALS) database, on 2015. The NHIS‐HEALS is a 10% sample
cohort randomly extracted from nationwide health screening pro-
gramme participants of 5,150,000. Common variables from both
databases were selected, which included gender, age group, labora-
tory results, personal and family disease history, risk factors (ciga-
rette smoking, alcohol, obesity, physical activity), and cognitive and
mood function. Gender‐based analyses were conducted for each var-
iables included in the study, in which the mean or proportion, where
appropriate, were used for comparison. The NHIS‐HEALS was con-
sidered to be the gold standard. The HSRD was considered to have
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statistical resemblance if the mean or proportion of the NHIS‐HEALS
lied within the mean or proportion's 95% confidence interval of the
HSRD.
Results: The HSRD contained additional clinical information compared
to NHIS‐HEALS such as, personal disease history, lower body function
and laboratory results (bone mineral density). The HSRD included less
elderly participants (18.5% vs 30.9%) but more females (53.2% vs
41.3%) than NHIS‐HEALS. On the contrary, participants' insurance
type distributions were similar between HSRD and NHIS‐HEALS. All
variables except diastolic blood pressure were determined to have
clinical resemblance, with fasting blood glucose, serum creatinine,
and hemoglobin having statistical resemblance as well.
Conclusions: The HSRD had more clinical information and a wider age
population than NHIS‐HEALS, while showing high level of clinical
resemblance with NHIS‐HEALS. The HSRD may serve as an alterna-
tive database by providing a comprehensive range of clinical data for
medical studies.
94 | The Association between Use of Opioid
Analgesics and Benzodiazepines and the Risk
of Death: A Population‐Based Case‐
Crossover Study
Junqing Li1; Bo Ram Yang2; Ha‐Lim Jeon1; Ju‐Young Shin1
1SungKyunKwan University, Suwon, Republic of Korea; 2Seoul National
University Hospital, Seoul, Republic of Korea
Background: A number of previous studies examined the association
between concomitant use of opioids and benzodiazepines and the risk
of death; however, it is still unclear.
Objectives: The aim of study is to investigate whether co‐prescription
of benzodiazepines and opioids increased the risk of death in a popu-
lation‐based crossover setting.
Methods: Weconductedacase‐crossover studyusingaNationalHealth
Insurance Service‐National SampleCohort (NHIS‐NSC) database. In this
design, cases served as their own controls.We introduced a 30‐day haz-
ard period preceding the onset of death and consecutive 3 previous 30‐
daycontrol periodsalongwith30‐daywashoutperiod.Exposures toopi-
oid analgesics and benzodiazepine during the hazard period were com-
pared with those of 3 control periods. Odds ratios (ORs) and 95%
confidence intervals (CIs) were estimated using conditional logistic
regression analyses and adjusted for time varying comedication.
Results: A total of 11,097 individualswith the prior record of benzodiaz-
epine or opioid analgesics and death were included in the study. We
found the highest risk of all‐cause mortality in the concurrent use of
two medications (aOR: 1.79, 95% CI: 1.68–1.91), as compared with
non‐use of two medications. In the subgroup analyses, increased risks
were observed in patients with respiratory disease (aOR: 1.48, 95% CI:
1.35–1.61) and in patients less than 20 years old (aOR: 3.74, 95% CI:
1.89–7.43).
Conclusions: Co‐prescription of opioid analgesics and benzodiaze-
pines was associated with an increased risk of mortality, especially in
the young age group (< 20 years old). This results may strengthen
the previous hypothesis of higher mortality in patients used two med-
ications concomitantly, and will give evidence on cautious use of opi-
oids and benzodiazepines which can be prescribed simultaneously in
the clinic.
95 | Comparative Mortality Risk of
Antipsychotic Medications in Elderly Patients
with Stroke: Adjusting for Unmeasured
Confounders with Stroke Registry Database
Using Propensity Score Calibration
Chien‐Chou Su1,2; Edward Chia‐Cheng Lai1,3,2; Cheng‐Yang Hsieh4;
Chih‐Hung Chen5; Huey‐Juan Lin6; Sheng‐Feng Sung7; Yu‐Wei Chen8;
Yea‐Huei Kao Yang1,3,2
1 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan, Taiwan; 2Health
Outcome Research Center, National Cheng Kung University, Tainan,
Taiwan; 3School of Pharmacy, College of Medicine, National Cheng Kung
University, Tainan, Taiwan; 4Department of Neurology, Tainan Sin Lau
Hospital, Tainan, Taiwan; 5Department of Neurology, College of
Medicine, National Cheng Kung University, Tainan, Taiwan; 6Department
of Neurology, Chi Mei Medical Center, Tainan, Taiwan; 7Division of
Neurology, Department of Internal Medicine, Ditmanson Medical
Foundation Chiayi Christian Hospital, Chiayi, Taiwan; 8Department of
Neurology, Taiwan Landseed Hospital, Taoyuan, Taiwan
Background: Elderly patients are at risk for developing psychosis after
stroke. According to previous guidelines, antipsychotics are the first‐
line pharmacological intervention for psychosis. However, studies
examining mortality risk associated with antipsychotic use in post
stroke elderly patients remain inconclusive.
Objectives: To evaluate comparative mortality risk of antipsychotic
use in elderly patients after a stroke by using an active comparator
and new user design with an external adjustment method.
Methods: Design and setting: We conducted a retrospective cohort
study using the Multi‐Center Stroke Registry (MCSR) and retrieving
patients aged above 65 years old admitted for stroke in the National
Health Insurance Database (NHID) from 2002 to 2014. These patients
were not prescribed antipsychotics before their discharge date and
were followed until they started to receive antipsychotic treatment.
The date of antipsychotic use was set as the index date. The covari-
ates were retrieved from claims during the one‐year period prior to
the index date. We then linked the MCSR with the NHID to retrieve
additional variables, including smoking history, BMI, National Institute
of Health Stroke Scale, the Barthel index, and the modified Rankin
Scale. Exposure: Antipsychotics. Main outcome: One‐year all‐cause
mortality. Statistical analysis: To compare antipsychotics with respect
to risk of all‐cause mortality, we performed Cox proportional hazard
models using the propensity score calibration (PSC) method to adjust
for unmeasured confounders in order to estimate the relative risk
among antipsychotics in elderly stroke patients.
50 ABSTRACTS
Results: We selected the antipsychotics, including quetiapine, haloper-
idol and risperidone, which were prescribed for post‐stroke psychosis
treatment, and compared themortality risk among these antipsychotics.
In the PSC‐adjusted intent to treat analyses, haloperidol [adjusted haz-
ard ratio (aHR) = 1.22; 95% confidence interval (CI) 1.18–1.27] and ris-
peridone (aHR = 1.31; 95% CI 1.24–1.38) users had a higher mortality
risk as compared to quetiapine users. Haloperidol and risperidone
exhibited a dose–response related to mortality risk after controlling
for confounders. The sensitivity analyses assessing the influence of
the study population showed similar patterns.
Conclusions: The significant variations in the differences in mortality
risk among antipsychotic agents suggests that antipsychotic selection
and dosing may affect survival in elderly stroke patients.
96 | Trend of Isoniazid Prophylaxis and TB
Infection for Rheumatoid Arthritis Patients
Receiving TNF Inhibitors: A Nationwide
Population‐Based Analysis
Hsun‐Yin Liang1; Meng‐Yu Weng2; Wei‐I Huang1; Pi‐Hui Chao1;
Wen‐Wen Chen1; Yea‐Huei Kao Yang3; Edward Chia‐Cheng Lai3,4
1Taiwan Drug Relief Foundation/Taiwan National ADR Reporting Center,
Taipei, Taiwan; 2Department of Internal Medicine, Division of Allergy,
Immunology, and Rheumatology, National Cheng Kung University Medical
College and Hospital, Tainan, Taiwan; 3School of Pharmacy, Institute of
Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine,
National Cheng Kung University, Tainan, Taiwan; 4Department of
Pharmacy, National Cheng Kung University Hospital, Tainan, Taiwan
Background: The Taiwan Food and Drug Administration issued a risk
management plan (RMP) for tumor necrosis factor inhibitor (TNFi) in
2012, requiring isoniazid (INH) prophylaxis regimen in latent tubercu-
losis infection (LTBI) patients receiving TNFi.
Objectives: To evaluate the trend of INH prophylaxis regimen and the
incidence of TB infection in patients with rheumatoid arthritis (RA)
receiving TNFi before and after RMP implementation.
Methods: We used the Taiwan National Health Insurance Database
(NHID) from 2000–2016 for the study. Study cohort included RA
patients aged 20+ years who newly received TNFi. Cases of TB infec-
tionwere identified by both ICD‐9 diagnosis code and the use of at least
three kinds of anti‐TB drugs within one year after TNFi initiation. We
compared the incidence of TB infection and the rate of INH prophylaxis
among our study cohort before and after RMP implementation.We also
explored the utilization pattern of INH prophylaxis including duration
and adherence which evaluated by medication possession ratio (MPR).
Results: We identified a cohort of 10,430 patients with mean age of
55.2 (SD 12.8) and 81% of them were female. The incidence rate of
TB infection before RMP implementation ranged from 7.65 to 14.52
cases per 1,000 person‐years (PYs); then the rate decreased after
RMP was implemented (ranged from 4.47–5.27 cases per 1,000
PYs). Only 5% of the study population received INH prophylaxis,
which was lower than estimated LTBI rate (18%) in similar population
in Taiwan. Annual rate of INH prophylaxis increased from 4% to 8%
after RMP was implemented. The trends of duration (median:
274 days) and adherence (median MPR: 89%) of INH prophylaxis were
stable over years.
Conclusions: The findings suggested that TB incidence rate among RA
patients receiving TNFi has decreased and INH prophylaxis rate has
increased after RMP implementation; however the prophylaxis rates
remained lower than our expectation. The study provided strong
grounds for the enforcement of RMP implementation to prevent TB
infection among patients receiving TNFi.
97 | Risk of Neuroleptic Malignant
Syndrome among Patients Exposed to
Antipsychotics
Esther W. Chan1; Shijian Lao1; Jiaxi Zhao1; Josephh E. Blais1;
Ian C.K. Wong1; Frank M.C. Besag2; W.C. Chang1; David J. Castle3
1LKS Faculty of Medicine, The University of Hong Kong, Hong Kong,
Hong Kong; 2School of Pharmacy, UCL, London, United Kingdom;
3University of Melbourne, Melbourne, Australia
Background: Antipsychotics are associated with neuroleptic malignant
syndrome (NMS), a rare but serious adverse reaction. However, the
epidemiology and risk estimation of NMS among antipsychotic users
is unknown.
Objectives: To determine the risk of NMS associated with exposure to
any antipsychotic, and four antipsychotics commonly implicated in
cases of NMS: haloperidol, olanzapine, quetiapine, and risperidone.
To characterize the incidence and case fatality risk of NMS in patients
taking antipsychotics.
Methods: This study was a population‐based cohort and case‐cross-
over study analyzing health records from the Hong Kong Hospital
Authority. Among 297,647 antipsychotic users identified from January
1st, 2004 toDecember 31st, 2016, 328 patients had their incident diag-
nosis of NMS during the same period. We further extended the NMS
identification period to November 30th, 2017 and analyzed data for a
total of 336 eligible patients. In the primary analysis, the use of antipsy-
chotics was compared during day 1 to 30 (case period) and day 91 to
120 (reference period) preceding the diagnosis of NMS to estimate
the risk of NMS associated with any antipsychotic, haloperidol,
olanzapine, quetiapine, and risperidone (case‐crossover study).We also
calculated the incidence and case fatality risk of NMS (cohort study).
Results: In the case‐crossover study, 336 patients were diagnosed
with NMS (210 males [62.5%]; mean age, 49.7 years; case fatality risk
6.0%). After adjustment for time trends in exposure, concurrent med-
ications, and medical conditions, diagnosis of NMS was associated
with exposure to any antipsychotic (OR, 4.77; 95% CI, 1.95–11.66),
haloperidol (OR, 4.40; 95% CI 1.97–9.81), and quetiapine (OR, 4.32;
95% CI, 1.70–10.97), while there was no observed association for ris-
peridone (OR, 2.00; 95% CI, 0.93–4.32) or olanzapine (OR, 1.23; 95%
CI, 0.47–3.18). In the cohort of patients exposed to antipsychotics,
NMS occurred with an incidence of 1.10 per 1000 persons.
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Conclusions: Antipsychotics are associated with an acutely increased
risk ofNMS.Patients had statistically significant increased oddsof expo-
sure to, haloperidol and quetiapine but not risperidone or olanzapine,
during the 30 days prior to the diagnosis of NMS, as compared with the
earlier reference period. Clinicians who prescribe antipsychotics should
weigh the acutely increased risk of NMS with the potential benefits of
antipsychotic therapy, especially for haloperidol and quetiapine.
98 | The Use of Long‐Acting Insulin
Analogues and the Risk of Colorectal Cancer
in Patients with Type 2 Diabetes Mellitus
Richeek Pradhan1; Hui Yin2; Oriana HoiYun Yu2; Laurent Azoulay1
1McGill University, Montreal, QC, Canada; 2Lady Davis Institute,
Montreal, QC, Canada
Background: The long‐term safety of long‐acting insulin analogues is
controversial, with some studies reporting a possible association with
colorectal cancer. However, these studies had important methodolog-
ical limitations. Thus, additional studies with long‐term follow‐up are
needed to investigate this possible association.
Objectives: To examine whether the use of long‐acting insulin ana-
logues is associated with an increased risk of colorectal cancer, when
compared with use of intermediate‐acting insulins in patients with
type 2 diabetes.
Methods: We used the United Kingdom Clinical Practice Research
Datalink to identify patients, at least 40 years of age, newly‐treatedwith
either insulin analogues (glargine, detemir, degludec) or intermediate‐
actinghuman insulins (neutral protamineHagedorn, lente) betweenSep-
tember 1, 2002 and March 31, 2017, with follow‐up until March 31,
2018. All patients were required to have at least one year of follow‐up,
necessary to account for a minimum cancer latency. Cox proportional
hazardsmodelswereused to estimatehazard ratios (HRs)with 95%con-
fidence intervals (CIs) of colorectal cancer, comparingoverall useof long‐
acting insulin analogues with intermediate‐acting insulin, adjusted for
high‐dimensional propensity score deciles. We also assessed for the
presence of a duration‐response relationship using restricted cubic
splines and whether the association varied according to specific type of
analogue.
Results: A total of 17,378 patients initiated their insulin treatment with
long‐acting analogues versus 9703 patients with intermediate‐acting
insulin, with the cohorts followed for up to 16 years. Overall, long‐acting
analogues were not associated with an increased risk of colorectal can-
cer, when compared with intermediate‐acting insulin (2.2 (95% CI: 1.9–
2.6) vs 1.9 (95% CI: 1.4–2.4) per 1000 person‐years, respectively; HR:
1.27, 95% CI: 0.91–1.78). There was no clear duration‐response rela-
tionship in restricted cubic splines. Furthermore, no single long‐acting
analogue was associated with colorectal cancer, although the HR was
elevated for glargine (glargine: HR: 1.35, 95% CI 0.96–1.91; detemir:
HR: 0.91, 95% CI: 0.53–1.56; degludec: no events).
Conclusions: The results of this population‐based study indicate that
long‐term use of long‐acting insulin analogues is not associated with
an overall increased risk of colorectal cancer.
99 | Methodologic Considerations for Data
Source Selection and Study Design of Non‐
Interventional Studies Comparing the Safety
and Effectiveness of Biosimilars and
Reference Biologics: Insulin Glargine Products
as a Case Example
Nancy D. Lin1; Jaclyn L.F. Bosco2; Cynthia H. Holmes3;
Catherine M. Lockhart4; John D. Seeger1
1Optum Epidemiology, Boston, MA; 2 IQVIA, Cambridge, MA; 3Abbvie,
North Chicago, IL; 4Biologics and Biosimilars Collective Intelligence
Consortium, Alexandria, VA
Background: Careful consideration of the features of real world data
(RWD) systems and study design options for non‐interventional stud-
ies (NIS) of biosimilar and reference biologic safety and effectiveness
is critical to ensuring generation of robust real world evidence (RWE)
to support clinical and policy decision making related to biosimilars.
Objectives: To establish an organizing framework and set of best prac-
tice recommendations to support planning and critical evaluation of
non‐interventional comparative safety and/or effectiveness research
(CSR/CER) studies of biosimilars and their reference biologics.
Methods: The Biologics and Biosimilars Collective Intelligence Consor-
tium convened a multi‐stakeholder Workgroup consisting of research
scientists and practicing clinicians from payers, industry, and academia
to establish a framework for the design and conduct of non‐interven-
tional biosimilar‐to‐reference biologic CSR/CER studies. The
Workgroup members participated in 5 teleconferences between June
2018 and November 2018 to discuss specific topics and build consen-
sus recommendations. Insulin glargine products was used as a case
example to illustrate selected aspects of the framework.
Results: The Workgroup developed a data source and study design
selection framework to help guide the planning and evaluation of
biosimilar‐referencebiologicCSR/CERstudies,highlightingspecificcon-
siderations and recommendations regarding: (1) relative strengths and
limitations of selected types of RWD systems (claims, electronic health
records, registries, and linked data) vis a vis significant general features
of reference biologics and biosimilars, and specific features relevant to
insulin glargine products, that influence study design choice and (2)
methodologic considerations for design and analytic options including
cohort, case only, and 2 quasi‐experimental approaches ‐ cohort design
with instrumental variable analysis and interrupted time series analysis.
Conclusions: This framework and set of recommendations may be
helpful in supporting a systematic approach to assess methodologic
considerations and approaches to mitigate potential sources of bias
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in the design and conduct of post‐marketing NIS of biosimilars and
reference biologics.
100 | Adherence and Discontinuation for
Infliximab Biosimilar and Originator Drugs
Covered by Public Provincial Insurance in
Canada
Cristiano S. Moura1; Waqqas Afif2; Talat Bessissow2; Gilles Boire3;
Vivian P. Bykerk4; Denis Choquette5; Peter Lakatos2;
Walter P. Maksymowych6; Larry Svenson7; Laura Targownik7;
Carter Thorne8; Sasha Bernatsky2
1McGill University Health Center, Montreal, QC, Canada; 2McGill
University, Montreal, QC, Canada; 3Sherbrooke University, Sherbrooke,
QC, Canada; 4Hospital for Special Surgery, New York, NY; 5University of
Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada;
6University of Alberta, Edmonton, AB, Canada; 7University of Manitoba,
Winnipeg, MB, Canada; 8Southlake Regional Health Centre, Newmarket,
ON, Canada
Background: In 2014, Inflectra® (biosimilar infliximab, INF‐B) was
approved for inflammatory arthritis and inflammatory bowel disease
in Canada. However, no population‐based comparisons of patterns
of use for Inflectra and its originator product Remicade® (INF‐O) are
available.
Objectives: To compare infusion‐based adherence and discontinua-
tion among initiators of INF‐B and INF‐O, in the context of public pro-
vincial insurance in Canada.
Methods: We analyzed National Prescription Drug Utilization Infor-
mation System (NPDUIS) claims data from provincial drug plans across
Canada (except Quebec). We studied infliximab‐naïve patients
(≥18 years) with at least 2 infliximab infusions from January–Decem-
ber 2016. Adherence was defined as having more than 4 infusions
over a 6‐month follow‐up period. We used two discontinuation mea-
sures: a) time to first missing dose (according to scheduled infusions of
0, 2, and 6 weeks and every 8 weeks thereafter); b) complete discon-
tinuation of therapy, defined as a ≥ 90‐day gap between infusions
without restarting therapy until the end of follow‐up. Descriptive anal-
ysis included age, sex, province, and prior biologic/systemic steroid
use. We used logistic regression to compare INF‐B and INF‐O sers
in terms of adherence and Cox regression to compare time to discon-
tinuation. All models adjusted for age, sex, prior use of biologic/sys-
temic steroid, and province (Ontario versus other provinces).
Results: We studied 2118 infliximab‐naïve patients, 188 (9%) INF‐B
and 1930 INF‐O (91%) users; half were women and the mean age
was 45 ± 17 years. Most patients were from Ontario (32%), and
87% were biologic‐naïve. Adherence at 6 months was 56% among
INF‐B users and 40% among the INF‐O group (95% confidence inter-
val, 95%CI for the difference = 5% to 26%). During follow‐up, 14% of
all patients missed at least one infusion, 8% for INF‐B and 14% for
INF‐O (95%CI for the difference = 2% to 10%). Only 3% of patients
had a complete discontinuation of therapy. Comparing INF‐B to INF‐
O, the adjusted odds ratio, OR was 1.27, (95%CI = 0.78–2.09) for
adherence. Hazard ratios (INF‐B versus INF‐O) were 0.66 (95%CI
0.38–1.15) for time to first missing dose and 1.12 (95%CI 0.39–3.20)
for complete discontinuation.
Conclusions: Canadian public drug plan beneficiaries initiating INF‐B
and INF‐O had similar rates of adherence and discontinuation. The
decision to prescribe INF‐B vs. INF‐O and the cause for
nonadherence/treatment gaps are not available in claims data. These
issues should be explored in future investigations.
101 | Abatacept in Rheumatoid Arthritis and
the Risk of Cancer: A Disproportionality
Analysis in Vigibase
Sibylle De Germay1,2; Haleh Bagheri1,2; Vanessa Rousseau1,2;
François Montastruc1,2
1Service de Pharmacologie Médicale et Clinique, Centre de
PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le
Médicament, Centre Hospitalier Universitaire, Faculté de Médecine,
Toulouse, France; 2UMR 1027 INSERM Pharmacoepidemiology,
assessment of drug utilization and drug safety ‐ University Paul Sabatier,
Toulouse, France
Background: Two recent cohort studies found an increased risk of
cancer overall and particularly non‐melanoma skin cancer (NMSC)
when comparing abatacept as a first or second line of biologic dis-
ease‐modifying antirheumatic drugs (bDMARDs) in the treatment of
rheumatoid arthritis (RA) with other bDMARDs. These studies were
performed in two different data sources, the Swedish Rheumatology
Register and the Truven MarketScan US database. As these results
need to be corroborated, we investigated the risk of cancer with
abatacept using a different data source, the WHO's global database
of individual case safety reports, Vigibase®.
Objectives: To assess whether abatacept used in patients for RA,
when compared to other bDMARDs, is associated with an increased
risk of reporting overall cancer and specific cancer, including breast,
cervical, lung, lymphoma, melanoma and NMSC.
Methods: We performed a pharmacovigilance study within Vigibase®,
from 2007 to 2017 to compare the cases of cancer (and specific can-
cers) reported in RA patients exposed to abatacept with those
reported in RA patients exposed to other bDMARDs. We conducted
disproportionality analyses allowing the estimation of reporting odds
ratios (ROR) with their 95% confidence interval (CI) of the exposure
odds among spontaneous reporting of cancer (and specific cancer) to
the exposure odds among reported other adverse effects.
Results: We identified 15,846 adverse effects reported in RA patients
who received abatacept and 290,568 adverse effects reported in RA
patients treated with other bDMARDs. Compared with other
bDMARDs, the use of abatacept was associated with an increased risk
of reporting cancer overall (931 reports for abatacept and 14,915 for
other bDMARDs (ROR 1.13; 95% CI 1.05, 1.21). The analysis by spe-
cific cancer sites showed a significantly increased ROR of NMSC (1.31
ABSTRACTS 53
95% CI 1.12, 1.53) and melanoma (1.68 95% CI 1.27, 2.34), but no sig-
nificant difference for other specific cancer sites.
Conclusions: Compared with other bDMARDs, exposure to abatacept
in patients treated for RA was associated with a slight increased risk
of reporting cancer overall and particularly skin cancers.With a different
data source and a different method, this study corroborated previous
results from two large cohort studies. The increased risk of NMSC and
melanoma is consistent with the pharmacodynamic properties of
abatacept (analog of the cytotoxic T‐lymphocyte‐associated protein 4,
CTLA‐4) since it has an opposite action than ipilimumab, an antibody
that blocks CTLA‐4 and approved for the treatment of malignant
melanoma.
102 | Predictors of Infection in Rheumatoid
Arthritis Patients Using Anti‐Tumor Necrosis
Factor Agents
Tasia Liu1; Aisling R. Caffrey1,2,3
1University of Rhode Island, College of Pharmacy, Kingston, RI; 2Veterans
Affairs Medical Center, Institutional Review Board and Infectious Diseases
Research Program and Center of Innovation in Long Term Services and
Supports, Providence, RI; 3Brown University School of Public Health,],
Providence, RI
Background: Rheumatoid arthritis (RA) is an incurable autoimmune dis-
ease that can cause permanent joint damage and loss of function. Anti‐
tumor necrosis factor (anti‐TNF) agents inhibit the function of tumor
necrosis factor (TNF), which leads to a reduction in the progression of
joint damage. However, an increased risk of serious infections in RA
patients using anti‐TNF agents has been observed in previous studies.
Objectives: To determine predictors of hospitalized infection among
patients with RA who were prescribed anti‐TNF agents (adalimumab,
etanercept, or infliximab).
Methods: A nested case–control study was conducted using de‐iden-
tified Clinformatics™ DataMart (OptumInsight, Eden Prairie, MN) data
from January 1, 2010 to December 31, 2013. Patients were included
based on ≥1 RA diagnosis, age, enrollment eligibility, number of RA
diagnoses, exposure to an anti‐TNF agent, and excluded based on cer-
tain comorbidities. A follow‐up period of 1‐year was selected to iden-
tify serious infections requiring hospitalization. Cases and controls
were matched 1:1 based on gender, region, and RA cohort entry date
(quarter, year). Predictors were identified from multivariable condi-
tional logistic regression from which odds ratios (ORs) and 95% confi-
dence intervals (CI) were calculated.
Results: In a cohort of 15,181 RA patients, 255 eligible cases and
matched controls were identified. Predictors of hospitalized infection
within the 1‐year after anti‐TNF exposure included prednisone use
in the 90 days prior to hospitalization (OR 1.87, 95% CI 1.02–3.46);
diabetes in the 90 days prior to hospitalization (OR 2.96, 95% CI
1.44–6.08); chronic obstructive pulmonary disease (COPD) in the
90 days prior to hospitalization (OR 9.23, 95% CI 2.76–30.95); and
previous history of infection within 12 months of the RA cohort entry
date (OR 8.98, 95% CI 1.90–42.60). No associations were observed
with specific anti‐TNF agents (adalimumab, infliximab, or etanercept)
or incident/prevalent anti‐TNF use.
Conclusions: Recent prednisone use, diabetes, COPD, and previous his-
tory of infection increased the risk of hospitalization for an infection
among those treated with anti‐TNF agents. The use of specific anti‐
TNF agents was not independently associated with an increased risk
of hospitalized infection in RA patients. Efforts to mitigate risk of infec-
tion amongRApatientswith these characteristics should be considered.
103 | Blood Utilization among U.S. Elderly
Medicare Beneficiaries in the Institutional
Outpatient Setting, during 2007–2018
Mikhail Menis1; Barbee I. Whitaker1; Yixin Jiao2; Madeline Swarr2;
An‐Chi Lo2; Jiemin Liao2; Thomas E. MaCurdy2; Jeffrey A. Kelman3;
Steven A. Anderson1; Richard A. Forshee1
1FDA, Silver Spring, MD; 2Acumen LLC, Burlingame, CA; 3Centers for
Medicare & Medicaid Services, Washington, DC
Background: As the elderly use most of transfused blood in the United
States, population‐based assessments of blood utilization are needed
to assure adequate national blood supply and safety.
Objectives: To evaluate blood use among the U.S. elderly in the insti-
tutional outpatient setting during 2007–2018.
Methods: This retrospective study used large Medicare administrative
databases from January 2007 through October 2018 to evaluate blood
components and number of units transfused, including percentage of
leukoreduced (LR) components,overall andannually, among institutional
outpatient elderly Medicare beneficiaries ages 65 years and older. We
used revenue center and procedure codes to identify transfused blood
components. Blood utilization trendswere assessed by total units trans-
fused andmean units per visit using linear time series models.
Results: Among 51,611,023 elderly Medicare beneficiaries during
2007–2018, 1,869,251 (3.6%) had transfusion of blood in the institu-
tional outpatient setting, with a total of about 5.6 million transfusion
visits and 12 million units of blood transfused, for an average of
2.2 units per transfusion visit. Blood use significantly declined over
time: from 1,008,777 units in 2007 to 876,575 units in 2017, a 13%
decline (p = 0.015), and from 2.3 to 2.0 units per visit (p < 0.01),
respectively. Of all transfusion visits: 4.1 million visits (74%) had LR
Red Blood Cells (RBCs) only transfused, 513,501 (9.2%) had LR Plate-
lets only, 377,180 (6.7%) had non‐LR RBCs only, and 327,739 visits
(5.8%) had LR Platelets and RBCs. Overall, 95.4% of all platelet com-
ponents transfused were leukoreduced, ranging from 93.9% in 2007
to 97.3% in 2018; and similarly, 91.0% of all RBCs components were
leukoreduced, ranging from 83.3% in 2007 to 96.2% in 2018. Immu-
nocompromised recipients comprised 46.4% of all transfused elderly
and had 67.8% of total units transfused and 65.8% of all transfusion
visits, with an average of 4.25 transfusion visits per person.
Conclusions: Our investigation shows a significant decline in blood use
among U.S. elderly in the institutional outpatient setting during study
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period. LR RBCs was identified to be the most frequently transfused
component, followed by LR Platelets. The study suggests a substantially
increased proportion of LR blood components transfused, with virtually
all platelets and RBCs leukoreduced in 2018. Although comprising less
than a half of transfused elderly, immunocompromised used most of
transfused blood and required most transfusion visits, thus suggesting
the importance of monitoring blood use and safety in this population.
104 | Identification of Exposure to
Reference Biologics and Biosimilars ‐ Use of
Medical Claim National Drug Code and
Healthcare Common Procedure Coding
System Code Modifier
Jie Zhang1; Kevin Haynes1; Aaron B. Mendelsohn2; James Marshall3;
Charlie Barr4; Cara McDermott5; Annemarie Kline6; James Kenney7;
Katelyn J. King2; Cynthia Holmes8; Huifeng Yun9; Kai Yeung10;
Cate Lockhart5
1HealthCore, Inc., Wilmington, DE; 2Harvard Pilgrim Health Care
Institute, Boston, MA; 3Harvard Pilgrim Health Care Institute, Bostone,
MA; 4Biologics and Biosimilars Collective Consortium, Alexandria, VA;
5Biologics and Biosimilars Collective Intelligence Consortium, Alexandria,
VA; 6Aetna, Informatics, Hartford, CT; 7Harvard Pilgraim Health Care,
Boston, MA; 8Abbvie, Chicago, IL; 9University of Alabama at Birmingham,
Birmingham, AL; 10Kaiser Permanente Washington Health Research
Institute, Seattle, WA
Background: Optimal post‐approval surveillance of biologics (refer-
ence and biosimilar) requires accurate identification of the specific
product used from administrative claims databases when billed using
Not Otherwise Specified (NOS) HCPCS codes or HCPCS codes that
are not specific to a single product (e.g., biosimilars of the same refer-
ence biologic administered by a healthcare provider between 1/1/
2016 and 3/31/2018).
Objectives: To assess the capture of biologic dispensings in the claims
databases of the Biologics and Biosimilars Collective Intelligence Con-
sortium (BBCIC) Distributed Research Network (DRN) partners, with a
focus on the utilization of medical claim National Drug Code (NDC), a
novel data field, and HCPCS modifiers.
Methods: A cross‐sectional observational study was conducted among
patients with medical and pharmacy benefits enrolled in participating
insurance plans of the BBCIC DRN between 1/1/2013 and 9/30/
2017. We calculated the proportion of medical claims with ≥1 NDC
code. For select biologics (insulin glargine, anti‐inflammatory biologics,
erythropoiesis‐stimulating agents, granulocyte colony‐stimulating fac-
tors, and biosimilars), dispensings were identified using 4 different
approaches: 1) specific HCPCS alone, 2) specific HCPCS and NDC, 3)
NOS HCPCS with NDC, and 4) HCPCS with modifiers (applicable to
biosimilars). Numbers of dispensings were calculated for each biologic
by the approach and by select patient and health plan characteristics.
Results: More than 1.5 million eligible participants contributed
approximately 4 million person‐years of data, including 1.2 billion
medical claims. The proportion of medical claims with ≥1 NDC
increased from 1.2% in 2013 to 3.0% in 2017. Medical claim NDC
code and NOS HCPCS code identified 2,074 dispensings of
vedolizumab in 2014 and 2015 (FDA approved vedolizumab in
2014), accounting for 39% and 28% of all vedolizumab dispensings
identified from the claims during the two years. Out of 26,381 dis-
pensings of filgrastim biosimilars (Zarxio) identified from medical
claims, 51% had a HCPCS modifier and an additional 12% had a med-
ical claim NDC code. We identified 1,244 dispensings of infliximab
biosimilars from medical claims; the manufacturer was confirmed for
38% of the biosimilar dispensings using HCPCS modifier, and an addi-
tional 3% using NDC code.
Conclusions: Use of medical claim NDC codes and HCPCS modifiers
improves identification of exposure to select biologics that do not
have a product‐specific HCPCS code.
105 | Batch‐Level Pharmacovigilance
Following Manufacturing Change of
Biological Products
Ayad K. Ali1; John D. Ayres2
1Eli Lilly and Company, Indianapolis, IN; 2Pharma Safety Solutions, LLC,
Noblesvills, IN
Background: Protamine sulfate is produced from trout and salmon milt
and used as a heparin antagonist and as an excipient in insulin formu-
lations to prolong insulin action. As a result of the March 2011 Japan
earthquake and subsequent tsunami, the fishing industry was unable
to maintain operations in the former Honshu fishing grounds. To
ensure an adequate protamine supply, the fishing grounds for wild
chum salmon were moved to the Hokkaido Island region.
Objectives: To describe a batch‐specific pharmacovigilance program
for protamine‐containing insulin products following the introduction
of a manufacturing change in the source of protamine sulfate.
Methods: Side‐by‐side Proportional Reporting Ratio (PRR)
disproportionality analyses were performed on the manufacturer‐
maintained database of adverse event reports for insulin suspensions.
Batch‐level analyses included Hokkaido‐sourced protamine batches
for reports submitted between May 2013–January 2018 (new); Hon-
shu‐sourced batches for reports between January 2007–December
2008 (historic); and Honshu‐sourced batches for reports between Jan-
uary 2010–January 2018 (concurrent). MedDRA PT of interest
included changes in insulin effect and hypersensitivity (including
immunogenicity and injection site reactions). New batches were com-
pared to concurrent and historic batches separately. Concurrent
batches were also compared to historic batches to minimize signal
drift due to ripple‐effect. Drug‐event combinations with PRR ≥ 2.0
are considered potential signals that warrant further review.
Results: A total of 14,103 reports for new batches were compared to
5,999 reports for historic batches; 14,093 reports for new batches
were compared to 5,672 reports for concurrent batches; and 5,810
reports for concurrent batches were compared to 5,999 reports for
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historic insulin batches. Signal detection resultswere: lack of drug effect
(new vs. historic, PRR = 1.0; new vs. concurrent, PRR = 0.93; concurrent
vs. historic, PRR = 1.06); increased drug effect (new vs. historic,
PRR = 0.86; new vs. concurrent, PRR = 1.04; concurrent vs. historic,
PRR=0.83); andhypersensitivity reactions (newvs. historic, PRR=0.82;
new vs. concurrent, PRR = 0.66; concurrent vs. historic, PRR = 1.26).
Conclusions: No signal has been identified implicating a worsening of
glycaemic control or hypersensitivity in usersofHokkaido‐sourcedprot-
amine‐containing insulin suspensions. Batch‐level pharmacovigilance
provides an objective assessment of biological product comparability
before and after changes in themanufacturing process.
106 | Evidence of Residual Confounding in
Healthcare Database Studies of Oseltamivir
and Influenza Complications
Phyo T. Htoo1; Gregory Measer2; Robert Orr2; Justin Bohn1;
Alfred F. Sorbello2; Henry Francis2; Sarah K. Dutcher2;
Sengwee Darren Toh1; Noelle M. Cocoros1
1Harvard Pilgrim Health Care Institute and Harvard Medical School,
Boston, MA; 2US Food and Drug Administration, Silver Spring, MD
Background: Oseltamivir is recommended for treatment and preven-
tion of influenza. It has been shown to reduce influenza symptoms
but its effects on complications are less certain. Observational studies
report conflicting findings and no study has explicitly examined the
presence of residual confounding.
Objectives: To evaluate whether there is evidence of residual con-
founding in healthcare database studies of the relationship between
oseltamivir and influenza complications (pneumonia and all‐cause
hospitalizations).
Methods: Using MarketScan® Databases during the 2014–15 influ-
enza season (Oct ‐ May), we identified enrollees aged ≥18 with new
outpatient influenza diagnosis claims after a 90‐day washout, during
which there was no claim for influenza diagnosis in any care settings
or outpatient influenza antivirals. We compared those initiating
oseltamivir with those not initiating on the influenza diagnosis date
(index date) with respect to incident pneumonia and all‐cause hospital-
izations. Follow up started from the day after the index through day
30, censoring for death and disenrollment (primary risk period).
Assuming oseltamivir only has short term effects, the 2nd and 3rd
months following index diagnosis served as negative control risk
periods during which estimates away from the null suggest residual
confounding. We estimated hazard ratios (HR) and 95% confidence
intervals (CI) after 1:1 matching on propensity scores predicting
oseltamivir initiation, conditional on baseline covariates.
Results: Oseltamivir initiators (n = 149,530) and non‐initiators
(n = 84,940) had similar baseline characteristics. During the 1st month
after influenza diagnosis, oseltamivir was protective against pneumo-
nia (HR: 0.84, 95% CI: 0.77, 0.91) and hospitalization (HR: 0.65, 95%
CI: 0.59, 0.72). During negative control periods, estimates moved
closer to the null, though still suggesting some residual confounding:
HRs of 0.86 (95% CI: 0.68, 1.09) and 0.77 (95% CI: 0.57, 1.02) for
2nd and 3rd months respectively for pneumonia. For hospitalization,
HRs were 0.93 (95% CI: 0.80, 1.08) and 0.90 (95% CI: 0.76, 1.05) for
2nd and 3rd months respectively, suggesting less residual confounding.
Conclusions: Our study suggests the evidence of some residual con-
founding in studies of the relationship of oseltamivir and influenza
complications: pneumonia and to a lesser extent, hospitalizations.
Residual confounding could be due to unmeasured influenza severity
and frailty. Next step is to evaluate residual confounding in the Senti-
nel System after stratifying on age and influenza test status.
107 | Use of Statins and Risk of Acute
Exacerbations in Patients with Chronic
Obstructive Pulmonary Disease
Chia‐Hsuin Chang1; Zhe‐Wei Zhan2; Yaa‐Hui Dong2
1National Taiwan University Hospital, Taipei, Taiwan; 2National Yang‐
Ming University, Taipei, Taiwan
Background: Chronic obstructive pulmonary disease (COPD) poses a
substantial disease burden worldwide. A number of observational
studies have reported that statins may decrease risk of acute exacer-
bations in patients with COPD. However, most of these studies
applied a “prevalent user, non‐user comparison approach”, which
may have methodological concerns of “healthy user bias” and compa-
rability between treatment groups leading to overestimation of clinical
effectiveness of statins.
Objectives: We aimed to examine the effectiveness of statins in
reducing acute exacerbations in patients with COPD using a new user,
active‐comparison cohort design.
Methods: We identified patients with COPD who initiated a statin or a
fibrate in theTaiwanNationalHealth InsuranceDatabase. Patientswere
followed up to the earliest of hospitalization due to acute exacerbations
(i.e., outcome of interest), treatment change or discontinuation, death,
or the end of the data. Stratified Cox regression models were used to
estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of acute
exacerbations comparing statins versus fibrates after variable‐ratio pro-
pensity score (PS) and high‐dimensional PS (hd‐PS) matching,
respectively.
Results:We identified a total of 134,909 eligible patients (110,726 ini-
tiating statins and 24,183 initiating fibrates); 8,326 experienced acute
exacerbations during follow‐up. The HRs were 1.09 (95% CI, 0.94–
1.26) after PS matching and 1.03 (95% CI, 0.89–1.20) after hd‐PS
matching. The results did not differ materially by patient characteris-
tics or statin types.
Conclusions: This large‐scale, population‐based study did not show
use of statins was associated with reduced risk of acute exacerbations
in patients with COPD using state‐of‐the‐art pharmacoepidemiologic
methods. The findings emphasize the importance of methodology
issues in observational studies.
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Treated with Oral Anticoagulants for
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Onyekachukwu Illoh1; Yuqin Wei2; Margie R. Goulding1;
Yoganand Chillarige2; Mary Ross Southworth1; Thomas E. MaCurdy2;
Jeffrey A. Kelman3
1US Food and Drug Administration, Silver Spring, MD; 2Acumen LLC,
Burlingame, CA; 3Centers for Medicare & Medicaid Services, Washington,
DC
Background: Non‐vitamin K antagonist oral anticoagulants (NOACs)
are alternatives to warfarin in patients with nonvalvular atrial fibrilla-
tion. Randomized trials compared NOACs to warfarin, but none have
compared individual NOACs against each other for safety and
effectiveness.
Objectives: To compare each of the NOACs (dabigatran, rivaroxaban,
and apixaban) with warfarin, and with each other, for the outcomes of
thromboembolic stroke, intracranial hemorrhage, major extracranial
bleeding, and all‐cause mortality.
Methods: We performed a retrospective new‐user cohort study of
patients with nonvalvular atrial fibrillation enrolled in US Medicare
who initiated warfarin (n = 183,318), or a standard dose of dabigatran
(150 mg twice‐daily; n = 86,198), rivaroxaban (20 mg once‐daily;
n = 106,389) or apixaban (5 mg twice‐daily; n = 73,039) between
October 2010 and September 2015. Multinomial logistic regression
was used to estimate stabilized inverse probability of treatment
weights for the warfarin and individual NOAC cohorts. For each out-
come, a single weighted Cox proportional hazards regression model
with robust estimation was used to estimate adjusted hazard ratios
(HR) and 95% confidence intervals (CI), comparing each NOAC with
warfarin, and with each other NOAC.
Results: Compared with warfarin, each NOAC was associated with
reduced risks of thromboembolic stroke (20%–29% reduction;
P = 0.002 [dabigatran], P < 0.001 [rivaroxaban, apixaban]), intracranial
hemorrhage (35%–62% reduction; P < 0.001 [each NOAC]), and mor-
tality (19%–34% reduction; P < 0.001 [each NOAC]). The NOACs
were similar for thromboembolic stroke but rivaroxaban was associ-
ated with increased risks of intracranial hemorrhage (vs. dabigatran:
HR = 1.71; 95% CI 1.35–2.17), major extracranial bleeding (vs.
dabigatran: HR = 1.32, 95% CI 1.21–1.45; vs. apixaban: HR = 2.70,
95% CI 2.38–3.05), and death (vs. dabigatran: HR = 1.12, 95% CI
1.01–1.24; vs. apixaban: HR = 1.23, 95% CI 1.09–1.38). Dabigatran
was associated with reduced risk of intracranial hemorrhage
(HR = 0.70; 95% CI 0.53–0.94) and increased risk of major extracranial
bleeding (HR = 2.04; 95% CI 1.78–2.32) compared with apixaban.
Conclusions: Among patients treated with standard dose NOAC for
nonvalvular atrial fibrillation and warfarin users with similar baseline
characteristics, dabigatran, rivaroxaban, and apixaban were associated
with a more favorable benefit‐harm profile than warfarin. Among
NOAC users, dabigatran and apixaban were associated with a more
favorable benefit‐harm profile than rivaroxaban.
109 | Replication of Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of
Stroke and EmbolismTrial in Atrial Fibrillation
in a Cohort Study Using Electronic Primary
Care Database
Turki A.I. Althunian1; Anthonius de Boer2; Rolf H.H. Groenwold3;
Katrien O. Rengerink3; Patrick C. Souverein3; Olaf H. Klungel3
1Saudi Food and Drug Authority/Utrecht University, Riyadh, Saudi
Arabia; 2Utrecht University/Dutch Medicines Evaluation Board, Utrecht,
Netherlands; 3Utrecht University, Utrecht, Netherlands
Background: Imitating the design of a randomized controlled trial in an
observational study is one of the recent methodological approaches
that has been developed to improve the usefulness of observational
studies in assessing drug effectiveness (efficacy of drugs in routine
clinical care); however, the usefulness of this approach has not been
investigated from non‐inferiority perspective.
Objectives: To imitate the design of the ROCKET AF (Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation) non‐inferiority trial in an observational study.
Methods: A retrospective cohort study was conducted using the Brit-
ish Clinical Practice Research Datalink (CPRD). Applying the eligibility
criteria of the trial, patients who were diagnosed with non‐valvular
AF and were prescribed either rivaroxaban or warfarin (incident users)
from October 2008 were included and followed to the end of the
study period (December 2017). Non‐inferiority of rivaroxaban to war-
farin in the prevention of the composite endpoint of stroke or sys-
temic embolism was assessed using a non‐inferiority margin of
hazard ratio (HR) 1.46 (the margin that was used in the triak). Cox‐pro-
portional hazards regression was used to estimate the study outcomes
adjusting for time‐fixed and time‐varying confounders.
Results: We included 25,473 incident users of rivaroxaban (n = 4,008)
orwarfarin (n = 21,465). Similar to the trial, non‐inferiority in the primary
outcomewas demonstrated: HR1.04 (95% confidence interval [CI] 0.84
to 1.30) in the intention‐to‐treat population and in another two analysis
populations. The target population of the trial is mostly treated in the
real‐world settings (i.e. the proportion of patients who did not meet
the exclusion criteria was small), thus affecting the precision of analysis
in the latter. Finally, the event rate of the primary outcome in warfarin
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group was lower compared with that in the trial and this may affect the
applicability of the trial's non‐inferiority margin in our study.
Conclusions: imitating the design of a non‐inferiority trial in observa-
tional study led to consistent results with that of the trial in similar
patient population, however, an adjustment for the trial's non‐inferior-
ity margin is needed to take into account the variation in the effect of
the active comparator in observational settings.
110 | Carboplatin‐Based Chemotherapy (C)
versus Immunotherapy (IO) in Metastatic
Urothelial Carcinoma (MUC)
Emily Feld1; Joanna Harton1; Neal J. Meropol2; Blythe Adamson2;
Ravi Parikh1; Matthew D. Galsky3; Aaron Cohen2; Vivek Narayan1;
John Christodouleas1; David J. Vaughn1; Rebecca A. Hubbard1;
Ronac Mamtani1
1Hospital of the University of Pennsylvania, Philadelphia, PA; 2Flatiron
Health, New York, NY; 3Tisch Cancer Institute, Mount Sinai, New York, NY
Background: There are limited data comparing first‐line (1 L) C versus
IO in cisplatin‐ineligible mUC patients. The primary evidence guiding
treatment decisions was a May 2018 Food and Drug Administration
(FDA) safety alert based on early review of two ongoing phase III trials,
reporting shorter survival in PD‐L1 negative patients receiving IO rel-
ative to chemotherapy. Final results from these trials are unknown and
may not be applicable to a real‐world cohort.
Objectives: To compare the effectiveness of C versus IO in first‐line
cisplatin‐ineligible mUC patients.
Methods: We conducted a retrospective cohort study of mUC
patients receiving 1 L C or IO from January 1, 2011 to May 18,
2018 using the Flatiron Health electronic health record‐derived data-
base. The primary outcome was overall survival (OS) from start of
1 L treatment to date of death. We compared 12‐ and 36‐month
OS, and hazard ratios before and after 12 months. Propensity
score‐based inverse probability of treatment weighting (IPTW) was
used to address confounding in Kaplan–Meier (KM) and Cox multi-
variable regression model estimates of comparative‐effectiveness.
Results: Of 2,243 patients (median age 76, 73% male, 74% white, 73%
smokers, 7% PD‐L1 tested), 562 received IO and 1,681 received C.
Baseline characteristics were balanced between IO and C initiators,
with exception of IO initiators having a worse ECOG performance sta-
tus (ECOG ≥2: 22% vs 12%) and mean Elixhauser comorbidity score
(2.28 vs 1.07). IPTW‐adjusted KM curves showed 12‐month and 36‐
month OS rates were 40.7% and 29.1% in IO and 46.4% and 13.7%
in C initiators. In the first 12 months, IO was associated with an
increased hazard of death compared to C (HR 1.38, 95% CI 1.16–
1.66). Among patients who survived one year, survival was improved
with IO compared to C (HR 0.50, 95% CI 0.27–0.92).
Conclusions: In routine clinical practice, 1 L IO was associated with
inferior 12‐month OS relative to C, but superior OS beyond
12 months. Clinicians and patients should carefully consider how to
balance the early benefit of C against the late benefit of IO. Currently
pending trial results will contribute additional evidence to inform
treatment decision making.
111 | Optimal Duration of Anticoagulant
Thromboprophylaxis in Total Hip
Arthroplasty ‐ New Evidence in 55,540
Patients with Osteoarthritis from the Nordic
Arthroplasty Register Association (NARA)
Group
Alma Pedersen1; Ina Trolle Andersen1; Søren Overgaard2;
Anne Marie Fenstad3; Stein Atle Lie4; Jan‐Erik Gjertsen3; Ove Furnes3
1Aarhus University Hospital, Aarhus, Denmark; 2Odense University
Hospital, Odense, Denmark; 3Haukeland University Hospital, Bergen,
Norway; 4University of Bergen, Bergen, Norway
Background: The recommended optimal duration of the
thromboprophylaxis treatment among total hip arthroplasty (THA)
patients has been a matter of debate for years.
Objectives: We examined the association between short (1–5 days),
standard (6–14 days) and extended (> = 15 days) duration of
thromboprophylaxis, with regards to the risk of VTE, major bleeding,
and death in unselected THA patients.
Methods: We performed a cohort study using prospectively collected
data from the population‐based hip arthroplasty registries, prescrip-
tion databases and patient administrative registries in Denmark and
Norway. We included primary THA patients with osteoarthritis (OA)
(n = 55,540).
Results: The 90‐day cumulative incidence of VTE was 1.0% for
patients with standard treatment (reference), 1.1% for those with
short‐term treatment (adjusted hazard ratio (aHR) of 1.1, 95%
confidence interval (CI) 0.8–1.5) and 1.0% for those with extended
treatment (aHR of 0.9, CI 0.8–1.2). The aHRs for major bleeding
were 1.1 (CI 0.8–1.6) for short and 0.8 (CI 0.6–1.1) for extended
vs. standard treatment. In addition, patients with short and
extended treatment had aHRs for death of 1.2 (CI 0.8–1.8) and
0.8 (95% CI 0.5–1.1) vs. standard treatment, respectively. Patients
who started short treatment postoperatively had aHR for death of
1.8 (CI 1.1–3.1) and absolute risk difference of 0.2%, whereas
patients who started short treatment preoperatively had aHR for
death of 0.5 (CI 0.2–1.2) and absolute risk difference of 0.3%
compared to patients with standard treatment post and preopera-
tively start, respectively.
Conclusions: In routine clinical practice, we observed no overall clin-
ically relevant difference in the risks of VTE and major bleeding
within 90 days of THA with respect to thromboprophylaxis duration.
However, our data indicates that short‐term thromboprophylaxis
started postoperatively is associated with increased 90‐day mortal-
ity. The significance of these data should be explored further.
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112 | Causal Inference Modeling in
Comparative Effectiveness Research for
Antiplatelet Agents
Nicholas Belviso1; Herbet Aronow2; Ashley Buchanan1;
Stephen Kogut1; Aisling Caffrey1; Marilyn Barbour1; Xuerong Wen1
1University of Rhode Island, Kingston, RI; 2BrownUniversity, Providence, RI
Background: Because the randomized controlled trials (RCT) have
shown significant benefits of ticagrelor in preventing ischemic end-
points when compared to clopidogrel, time‐varying confounding and
informative censoring pose a challenge in real‐world data studies.
Objectives: To apply causal modeling to quantify the effect of anti-
platelet agents on preventing ischemic events by addressing time‐
varying confounding and selection bias due to informative loss to fol-
low‐up.
Methods: This study included patients who underwent percutaneous
coronary intervention (PCI) due to an acute coronary syndrome
(ACS) from 2011 to 2015 captured by the Optum Clinformatics™
database. Patients were excluded with a contraindication to either
agent, fibrinolytic therapy, oral anticoagulation, or concomitant use
with P‐450 inducers or inhibitors. Five methodologies were employed:
PP, ITT, AT, time‐varying exposure (TD), intention to treat (ITT‐CW)
and time‐varying exposure (TD‐CW) both with censoring weights.
The primary outcome was composite incident myocardial infarction
(MI), ischemic stroke, or death. Patients were followed until the event,
one calendar year, or end of insurance eligibility. We used marginal
structural Cox models fit with inverse probability treatment and cen-
sor weighting to adjust for time‐varying confounding and censoring
and with a robust sandwich variance estimator to account for the
within‐cluster correlation.
Results: There were 17,344 patients initiated on clopidogrel and 2,457
initiated on ticagrelor with no difference in unadjusted rates of MI,
stroke, or death (T: 5% vs C: 6%). Patients initiated on ticagrelor were
younger (64.8 years vs 65.6 years), more male (68% vs 62%), had
higher rates of hypertension (77% vs 72%), hyperlipidemia (73% vs
66%), medication switching (25% vs C: 3%), and loss of eligibility
(47% vs 39%) than those on clopidogrel. The PP (HR: 1.0, 95%CI:
0.69–1.5), ITT (HR: 0.93, 95%CI: 0.77–1.1), AT (HR: 1.1, 95% CI:
0.87–1.3) approaches showed no difference in MI, stroke, or death
between clopidogrel and ticagrelor groups. The TD and CW methods
showed a 9%–13% reduction in risk (TD HR: 0.89, 95%CI: 0.73–1.1;
ITT‐CW HR: 0.91, 95%CI: 0.75–1.1; TD‐CW HR: 0.87, 95%CI: 0.71–
1.1), which are more consistent with the RCT results although did
not achieve statistical significance.
Conclusions: Informative censoring should be considered when artifi-
cial censoring and imbalances of loss to follow‐up occur between com-
parison groups. Accounting for time‐varying confounding due to
unbalanced drug switches can lead to improvements in the accuracy
of effect estimates.
113 | Comparing the Safety of Apixaban,
Rivaroxaban and Dabigatran: Indirect
Treatments Comparisons Using Real‐World
Studies
Carlos Alves1,2; Diogo Mendes1; Francisco Batel Marques1,2
1AIBILI ‐ Association for Innovation and Biomedical Research on Light
and Image, Coimbra, Portugal; 2School of Pharmacy, University of
Coimbra, Coimbra, Portugal
Background: According to the direct comparisons from observational
studies using real‐world evidence, the risk of bleeding is lower with
apixaban compared to rivaroxaban and dabigatran, when used to pre-
vent stroke in patients with atrial fibrillation.
Objectives: This study is aimed at comparing the risk of bleeding of
apixaban with rivaroxaban and dabigatran, through adjusted indirect
treatment comparisons.
Methods: A literature search was conducted to identify real‐world
data studies assessing the safety of apixaban, rivaroxaban and
dabigatran to prevent stroke in patients with atrial fibrillation, using
warfarin as control. Outcome measures included major bleeding, gas-
trointestinal bleeding and intracranial bleeding. Relative risks and
95% confidence intervals were estimated. Adjusted indirect treatment
comparisons were performed using STATA 13.0.. Chi‐square test
assessed between‐studies heterogeneity, identified when p < 0,05.
Results: Twenty‐one studies were included. Apixaban reduced the risk
of major bleeding compared with rivaroxaban (RR 0,53; 95%CI 0,44 ‐
0,63; heterogeneity: p < 0,0001) and dabigatran (RR 0,58; 95%CI
0,44‐0,76; heterogeneity: p < 0,0001). The risk of gastrointestinal
bleeding is low with apixaban when compared with rivaroxaban (RR
0,46; 95%CI 0,33‐0,65; heterogeneity: p < 0,0001) and dabigatran
(RR 0,31; 95%CI 0,20‐0,49; heterogeneity: p < 0,0001). For intracra-
nial bleeding, no risk differences were identified between apixaban
and the other two anticoagulants.
Conclusions: The results of this adjusted indirect treatment compari-
son are in line with the evidence from direct comparisons, where
apixaban demonstrated to be safer than rivaroxaban and dabigatran
in real‐world clinical practice. However, between studies heterogene-
ity was identified in the risk estimates.
114 | Statin Use and Fall‐Related
Hospitalizations among Residents of Long
Term Care Facilities: A Case–Control Study
Kate N. Wang1; J. Simon Bell1; Edwin C.K. Tan2;
Julia F.M. Gilmartin‐Thomas1; Michael J. Dooley1; Jenni Ilomäki1
1Monash University, Melbourne, Australia; 2University of Sydney, Sydney,
Australia
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Background: Statins are associated with muscle‐related adverse
events but few studies have investigated the possible association with
fall‐related hospitalizations among residents of long‐term care facili-
ties (LTCFs).
Objectives: To investigate whether statin use is associated with fall‐
related hospitalizations among residents of LTCFs.
Methods: A case–control study was conducted among residents aged
≥65 years admitted to hospital from 2013–2015. Cases were resi-
dents admitted for falls and fall‐related injuries. Controls were resi-
dents admitted for infections. Cases and controls were matched 1:1
by age (±2 years), index date of admission (±6 months) and sex.
Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were
estimated using conditional logistic regression for statin use in resi-
dents admitted for falls compared to infections. Models were adjusted
for history of falls, hypertension, dementia, functional comorbidity
index, polypharmacy (nine or more regular pre‐admission medications)
and falls risk medications. Unmatched sub‐analyses were performed
for residents with and without dementia, and comparing high vs
low/moderate intensity statin use.
Results: Overall, 32% of cases and 22% of controls used statins. Statin
use was associated with fall‐related hospitalizations (aOR = 2.34,
95%CI 1.27–4.33). After stratifying by dementia status, statin use
was only associated with fall‐related hospitalizations among residents
with dementia (aOR = 3.27, 95%CI 1.26–8.47). There was no associa-
tion between statin intensity and fall‐related hospitalizations
(aOR = 2.19, 95%CI 0.75–6.40).
Conclusions: Statin use is associated with fall‐related hospitalizations
from LTCFs, particularly among residents with dementia. However,
there is minimal evidence for a dose‐dependent relationship between
statin intensity and fall‐related hospitalizations.
115 | Risk of Culpable Traffic Accident by
Frailty in Drivers with Advanced Age
Sun‐Young Jung1; Byungkwan Hwang2; Bo RamYang3; Mi‐Sook Kim3;
Ye‐Jee Kim4; Nam‐Kyong Choi5; Byung‐Joo Park6; JoongYub Lee7
1Chung‐Ang University, Seoul, Republic of Korea; 2Texas Tech University
Health Science Center, Lubbock, TX; 3Seoul National University Hospital,
Seoul, Republic of Korea; 4Asan Medical Center, Seoul, Republic of Korea;
5Ewha Womans University, Seoul, Republic of Korea; 6Seoul National
University College of Medicine, Seoul, Republic of Korea; 7 Inha University
Hospital, Incheon, Republic of Korea
Background: Although older drivers has been increasing, medical
screening of older drivers is not evidence based.
Objectives: This study was conducted to evaluate the influence of the
frailtymeasured from claims data on the risk of culpable traffic accident.
Methods: Setting: We extracted the data of drivers who died of motor
vehicle crashes (MVCs) during 2010–2014 from the Korean Traffic
Accident Analysis System and linked it to the Korean National Health
Insurance database. Main outcome measures: We calculated the
responsibility score of an accident to quantify the driver's culpability
using the responsibility analysis method, which will categorize drivers
into culpable drivers (responsibility score < 12) or non‐culpable driver
(responsibility score ≧ 12). Exposures: Frailty score using ICD‐10
codes was calculated to categorize driver's frailty into low risk (frailty
score < 5), intermediate risk (frailty score 5 to 15), and high risk (frailty
score ≧ 15). Statistical analysis: Logistic regression analysis was used
to evaluate the influence of frailty on the culpability of drivers,
adjusting for age, sex and medications which were known to be
related to traffic accidents.
Results: We found 8,881 deaths during the study period, among
whom 8,828 were successfully linked to the national insurance data.
Among them, 2,081 drivers were categorized into the culpable group
and 6,747 into non‐culpable group. The mean age of the participants
was 48.9 (±17.7), and 8,169 (92.5%) were males. Culpable drivers
had more frequent prescription of hypnotics, narcotics, muscle relax-
ants, and antispasmodics 1 year prior to the traffic accidents. When
adjusted for demographic factors and medications, high frailty (odds
ratio 1.224: 95% confidence interval 1.030–1.454) was significantly
related to the culpable crashes. Interestingly, age older than 65 was
protective against culpable accidents (0.995: 0.992–0.998).
Conclusions: High frailty score measured using claims data was asso-
ciated to the culpable traffic accident which could be attributed to
the fault of driver. Methods to screen drivers with advanced age using
frailty score will help preventing traffic accident related to aging of
drivers.
116 | Multidose Drug Dispensing and
Longitudinal Changes in Psychotropic
Prescribing Patterns among Older Adults:
National Matched Cohort Study
Lucas Morin1; Samuel Hawley2; Jonas W. Wastesson1;
Kristina Johnell1; Daniel Prieto‐Alhambra2
1Karolinska Institutet, Stockholm, Sweden; 2University of Oxford, Oxford,
United Kingdom
Background: An increasing number of frail andmultimorbid older adults
are dispenseddrugs inmachine‐packeddisposable pouches that contain
all the drugs that are intended for a given dose occasion (‘multidose’). It
has been suggested that multidose may promote psychotropic overuse.
Objectives: We aimed to compare the use of psychotropic drugs
before and after the transition to multidose drug dispensing among
older adults in Sweden.
Methods: Matched cohort study using individual‐level drug dispensing
data with national coverage in Sweden. Older adults (≥65 years) who
initiated multidose drug dispensing between 1 January and 31 Decem-
ber 2013, matched 1:2 on sex, age and index date with older adults
who remained on manually dispensed medications. Initiation of
multidose dispensing was assessed using a 5‐year washout period.
Study participants were followed from 24 months before until
24 months after the index date, with censoring at time of death or
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emigration. Main outcome was psychotropic polypharmacy (≥3 drugs
acting on the CNS).
Results: A total of 31,612 cases and 63,224 controls were included.
Mean age at index date was 83.9 (7.4) years. The prevalence of psy-
chotropic polypharmacy increased substantially among multidose initi-
ators, from 15.1% two years before the transition, to 37.5% the month
after, up to 43.7% two years after. This psychotropic polypharmacy
was fueled by a dramatic increase in the incident use of long‐acting
benzodiazepines (e.g. clonazepam), Z‐drugs (e.g. zopiclone), strong opi-
oids, antipsychotics, antidepressants, and ‐ to a lesser extent ‐
antidementia drugs. For instance, the incidence rate of benzodiazepine
initiation increased from 0.70 per 1000 person‐month 12 months
before multidose initiation to 4.78 per 1000 during the first month
after. No change was observed among controls.
Conclusions: Older adults who switch to multidose drug dispensing
are at high risk of adverse drug‐related events due to a sustained
increase in exposure to substantial psychotropic polypharmacy.
117 | Danish Health Care Professionals'
Attitudes towards Deprescribing in Older
Patients with Limited Life Expectancy: A
Qualitative Focus Group Study
Carina Lundby1; Trine Graabæk1; Jesper Ryg1; Jens Søndergaard2;
Anton Pottegård1; Dorthe Susanne Nielsen1
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark
Background: Deprescribing may be particularly relevant in older
patients with limited life expectancy as many preventive medications
can no longer be expected to provide clinical benefit at this point in
life. In order to effectively carry out deprescribing in this population,
it is important to understand the perspectives of health care profes-
sionals involved in the management of these patients' medication.
Objectives: To explore different health care professionals' attitudes
towards deprescribing in older patients with limited life expectancy.
Methods: Six focus group interviews were conducted, using a semi‐
structured approach, with a) health care assistants (n = 5), b) nurses
(n = 6), c) clinical pharmacists (n = 6), d) geriatricians (n = 5), e) general
practitioners (n = 5), and f) clinical pharmacologists (n = 5). Interviews
were audio recorded and transcribed verbatim. Results were analyzed
using systematic text condensation.
Results: The analysis elicited three themes related to health care pro-
fessionals' attitudes towards deprescribing in older patients with lim-
ited life expectancy, namely 1) how different health care
professionals approach deprescribing in this population, 2) how differ-
ent health care professionals perceive their own as well as others
responsibility/role in the deprescribing process, and 3) how collabora-
tion and recognition between different health care professionals
impact the deprescribing process.
The participants recognized the importance of deprescribing and con-
sidered it as being an essential aspect of providing good care for older
patients with limited life expectancy; however, they also considered
several characteristics related to the patient population to complicate
the deprescribing process. Although the general practitioners generally
were seen as those being primarily responsible for such deprescribing
initiatives, a general perception was that all health care professionals
have an important role to play in the deprescribing process. Despite
this, the participants also considered some groups of health care pro-
fessionals to be lacking in taking the necessary responsibility as well as
not acknowledging other groups' skills/competencies.
Conclusions: Our results imply that Danish health care professionals
recognize the importance of deprescribing among older people with
limited life expectancy. However, uncertainty about how to approach
deprescribing in this population as well as lack of responsibility and
acknowledgement may complicate or hinder deprescribing initiatives.
118 | Frailty and Use of Psychotropic
Medications in Long‐Stay Nursing Home
Residents
Yiyang Yuan; Kate L. Lapane; Christine M. Ulbricht
University of Massachusetts Medical School, Worcester, MA
Background: Frailty, characterized by decline of physical function and
physiologic reserve, affects 30–89% of older adults in nursing homes
(NH) and may also predict adverse health outcomes. Psychotropic
medication is extensively used in older adults in NHs and is associated
with higher risk of falls, hospitalization, and mortality.
Objectives: To examine use of psychotropic medication by frailty sta-
tus in long‐stay NH residents in the U.S.
Methods: The Minimum Data Set (MDS) 3.0 assessment is mandated
for all Medicare/Medicaid‐certified NHs. Using MDS 3.0 data from
2015, we identified 265,101 newly‐admitted, long‐stay NH residents.
Frailty was defined by FRAIL‐NH, a scale with MDS 3.0 items on
fatigue, resistance, ambulation, incontinence, weight loss, nutrition
approach, and help with dressing. At baseline and at the 90‐day
assessment, residents were categorized as non‐frail (0–5), pre‐frail
(6–7) and frail (8–14) based on their FRAIL‐NH score at baseline. Psy-
chotropic medication use was measured by the receipt of antipsy-
chotic, antianxiety, antidepressant and hypnotic medications in the
past 7 days.
Results: At admission, 34% were aged 75–84 years, 44% were 85 or
older, and 66% were women. Fifty‐nine percent had moderate and
20% had severe impairments in activities of daily living. Most were
cognitively impaired; 29% had moderate and 39% had severe cogni-
tive impairment. Depression diagnosis was present in 39% of resi-
dents. At admission, 28% were pre‐frail, of whom 31% were frail at
the 90 assessment. Of the 56% of the residents with frailty at admis-
sion, 82% remained frail at the 90 assessment. Similar rates at admis-
sion and the 90‐day assessment were observed for receipt of
antipsychotic (20%), antianxiety (20%) and hypnotic (4%) medications,
with no substantial variation across frailty levels. Receipt of antide-
pressants in all residents increased from 46% at admission to 53%
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by 90 days, with the highest increase in those who were frail, from
47% to 54%. In residents with frailty, 61% were on at least one psy-
chotropic medication at admission, which increased to 67% at the 90
assessment.
Conclusions: Psychotropic medication use is high at admission, regard-
less of frailty status, but appears to increase in residents with frailty in
the first 90 days of a NH stay. Additional research is needed to assess
if psychotropic medication use in NH is appropriate and the extent to
which the presence of frailty places residents at higher risk for adverse
health outcomes associated with psychotropic medications.
119 | Meaningful Measurement Matters:
How to Best Define Potentially Inappropriate
Medication Use to Target Cognitive
Outcomes
Ashley I. Martinez1; Erin A. Abner2,3; Daniela C. Moga1,2,3
1University of Kentucky College of Pharmacy, Lexington, KY; 2University
of Kentucky College of Public Health, Lexington, KY; 3Sanders‐Brown
Center on Aging, Lexington, KY
Background: Deprescribing in the geriatric population is often focused
on improving clinical outcomes, such as preventing cognitive or func-
tional decline (CFD). Clinicians may consider polypharmacy or consult
explicit lists of potentially inappropriate medications (PIM) when
deprescribing. However, the association between measures of PIM
use and CFD has not been well established.
Objectives: In this study, we aim to 1) estimate the prevalence of PIM
use for those with and without cognitive or functional impairment
(CFI), and 2) identify the PIM measure that best predicts risk of CFD
after one year.
Methods: We used 2005–2017 data from adults aged≥65 years com-
piled by the National Alzheimer's Coordination Center. First, in a cross‐
sectional study, we assessed the prevalence of CFI (Clinical Dementia
Rating [CDR] global score≥ 0.5) and PIM use at enrollment.We consid-
ered eight PIM definitions based on polypharmacy (≥4 and ≥ 5 total
medications) and the number of medications present in existing explicit
criteria (≥1,≥4, and≥ 5medications in Beers' 2015 and STOPP). Then,
in a retrospective cohort study, we investigated which definition of PIM
use at enrollment best predictedCFD (defined as an increase in the CDR
sum of boxes score after one year). We used Poisson regression to cal-
culate risk ratios (RR) and 95% confidence intervals (CI) adjusted for
baseline clinical and demographic characteristics.
Results: We assessed PIMs and CFI prevalence at enrollment for
24,522 subjects (56.0% female; mean age 75.8 [SD 6.9] years).
62.7% of subjects had some degree of CFI. PIM prevalence ranged
from 58.5% (STOPP) to 74.2% (polypharmacy, ≥4 medications). In
the cohort study, 16,354 subjects experienced CFD after one year.
There were no clinically significant correlations between the CFD risk
and the PIM definitions of polypharmacy or ≥ 1 medication in either
criteria. However, subjects who reported ≥4 or ≥ 5 medications in
the Beers' criteria or ≥ 5 medications in STOPP at enrollment had a
higher risk of CFD compared to patients who reported no such medi-
cations (RR [CI] 1.33 [1.08–1.64] and 1.46 [1.12–1.89] respectively for
Beers'; 1.41 [1.14–1.74] for STOPP).
Conclusions: The results of this study indicate that neither
polypharmacy nor ≥1 medication in Beers' and STOPP criteria predict
CFD well. Clinicians may consider focusing their deprescribing efforts
on the total burden of PIMs (using Beers' or STOPP) to decrease CFD
risk in the geriatric population. Further research into the clinical rele-
vance of existing tools used to identify PIM use is warranted.
120 | Angiotensin Converting Enzyme
Inhibitors, Angiotensin Receptor Blockers,
and the Risk of Suicide: A Nested Case
Control Study
Mina Tadrous1; Tony Antoniou1; Tara Gomes1; Simon Greaves2;
Selina Manji1; David N. Juurlink2; Sidney H. Kennedy3;
Muhammad M. Mamdani1
1St. Michael's Hospital, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada; 3University Health Network, Toronto, ON, Canada
Background: Angiotensin converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) are widely used to lower blood
pressure. Both drug classes have central effects which include modu-
lation of neurotransmitter release and may influence mood and mental
health. Recent studies suggest ARBs, but not ACEIs, may increase the
risk of suicide.
Objectives: The objective of this study was to examine the association
between suicide and uste of ARBs relative to ACEIs among older
adults.
Methods: Weconductedapopulation‐basednestedcase–control study
among over 2.3 million residents of Ontario, Canada aged 66 years and
older from January 1st, 1995 to December 31st, 2013. Cases were
patients who died of suicide within 100 days of receiving a prescription
for an ACEI or ARB. Cases were matched 4:1 using on age, sex, and pre-
vious diagnoses of hypertension and diabetes. We compared baseline
characteristics of cases and controls and used multivariable conditional
logistic regression to generate odds ratios (ORs) and 95% confidence
intervals (CIs), adjusting for potential confounders.
Results: Over the 18‐year study period, we matched 820 cases to
3,280 controls exposed to either an ACEI or ARB within 100 days
prior to the index date. In the primary analysis, relative to ACEIs,
ARB exposure was associated with a higher risk of suicide (adjusted
odds ratio = 1.73; 95% CI = 1.38–2.17).
Conclusions: We found that ARBs were associated with a higher risk
of suicide relative to ACEIs. The mechanisms explaining how ARBs
or ACEIs might have differential risks of suicide are unknown. Our
findings should be considered preliminary and need to be replicated
in future studies. Given the high prevalence of use of these medica-
tions, the outcome severity, and the interchangeability of these drug
classes for the same indications clinicians may opt for preferential
use of ACEIs over ARBs where possible.
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121 | Impact of a new pharmaceutical care
model on polymedication and potentially
inappropriate medications in long term care
facilities in Canada
Carolina Tisnado‐Garland1,2; Line Guénette3,4,5; Edeltraut Kröger3,2;
Rachel Rouleau5,3; Caroline Sirois1,2
1Laval University, Quebec, QC, Canada; 2Centre of Excellence on Aging
of Quebec, Quebec, QC, Canada; 3Laval University, Quebec, QC, Canada;
4Research Centre of the CHU de Quebec, Quebec, QC, Canada; 5CIUSSS
de la Capitale Nationale, Quebec, QC, Canada
Background: Polypharmacy and potentially inappropriate medications
(PIMs) are known to be predominant in long‐term care (LTC) facilities
and are associated with morbidity. A new pharmaceutical care model
based on inter‐professional collaboration and pharmacists' expanded
scope of practice might improve pharmacotherapy in LTC facilities.
Objectives: The purpose of this study was to determine the impact of
a new model on (1) the number of medications prescribed and the pro-
portion of individuals exposed to excessive polypharmacy (at least 10
medications) and (2) the proportion of individuals receiving at least
one PIM, in elderly living in LTC facilities.
Methods:We performed a quasi‐experimental study. Eligible patients
were aged 65 and over living in 2 LTC facilities exposed to the phar-
maceutical care model (±359 beds) and 2 non‐exposed LTC facilities
(±241 beds). The new model was implemented during 12 months
through educational sessions offered to all health care professionals.
The new model proposed to take advantage of pharmacists'
expanded scope of practice and thorough medication reviews to
empower pharmacists and nurses in collaborating for a more effi-
cient resolution of pharmacotherapy problems among residents. Data
on medications and clinical information was obtained through elec-
tronic records. We computed all active prescriptions at a specific
day at 0, 3, 6, 9 and 12 months following the beginning of imple-
mentation to assess (1) the average number of prescribed medica-
tions per resident and the proportions of seniors exposed to
excessive polypharmacy and 2) the proportion of seniors receiving
at least one PIM, according to the 2015 Beers criteria. We compared
exposed and non‐exposed groups before and after implementation.
Results: The total number of prescriptions per patient went from
11.53 ± 4.83 to 9.49 ± 4.25 (exposed group) and from 13.59 ± 5.24
to 13.15 ± 5.14 (non‐exposed group). The average number of regular
prescriptions per patient went from 9.17 ± 4.02 to 7.05 ± 3.42 drugs
(exposed group) and from 9.56 ± 3.96 to 8.85 ± 3.88 (control group).
The proportion of elderly receiving excessive polypharmacy went from
63.4% to 45.7% (exposed group) and from 76.9% to 76.0% (non‐
exposed group). The proportion of seniors receiving at least one PIM
went from 60% to 56% (exposed group) and from 73% to 69% (non‐
exposed group).
Conclusions: Although PIM use decreased in both groups, the pharma-
ceutical care model led to the reduction of excessive polypharmacy and
overall medication consumption. The impact of suchmedication burden
reduction on health outcomes has to be evaluated.
122 | Abstract Withdrawn
123 | How to estimate long‐term treatment
effects in multiple sclerosis registry studies
Arthur Allignol1; Tim Spelman2; Jonatan Freilich3; Meritxell Sabidó1;
Alan Gillett4; Jan Hillert2; Emmanuelle Boutmy1
1Merck KGaA, Darmstadt, Germany; 2Karolinska Institute, Stockholm,
Sweden; 3Parexel International, Stockholm, Sweden; 4EMD Serono, Inc., a
business of Merck KGaA, Darmstadt, Germany
Background: Analysis of long‐term treatment effects in patients with
relapsing–remitting multiple sclerosis (MS) can be challenging, particu-
larly as patients may discontinue treatment or switch disease‐modify-
ing treatments (DMTs) over time. The main issue is to define long‐
term effects regarding exposure, outcome, and models, and to deter-
mine which estimand is most relevant.
Objectives: To assess effects of treatment change over time, adjusting
for other confounders, with different estimands and models, using
data from the Swedish MS register.
Methods: Between 1997–2014, patients initiating subcutaneous (sc)
interferon‐beta (IFNβ)‐1a (n = 1413) or intramuscular (im) IFNβ‐1a
(n = 2378) were followed from first prescription until death, conver-
sion to secondary progressive MS, or loss to follow‐up, whichever
occurred first. Main outcome was time to disability progression. We
considered two populations: 1) discontinuous exposure ‐ patients
remained exposed regardless of treatment changes over time, and 2)
continuous exposure ‐ patients censored at treatment discontinuation.
Analyses with Cox cause‐specific models and Fine & Gray models
were compared considering discontinuous and continuous exposure
definitions. Depending on populations considered, death and treat-
ment discontinuation were competing risks. For discontinuous expo-
sure, Cox Marginal Structural Models (MSM) adjusted for post‐
baseline treatments and relapseswereused. All models were adjusted
for baseline confounders.
Results: For discontinuous exposure, the risk of disability progression
was significantly higher, except with MSM, for im IFNβ‐1a exposure
vs. sc IFNβ‐1a exposure, with an adjusted hazard ratio (aHR) of 1.23
(95% Confidence Interval [95%CI; 0.98–1.53]) in the MSM, 1.28
[95%CI 1.04–1.57] in the Cox model, and 1.28 [95%CI 1.04–1.56] in
the Fine & Gray model. For continuous exposure, the risk of disability
progression was not significant differently between DMTs with an
aHR for im IFNβ‐1a vs. sc IFNβ‐1a of 1.06 [95%CI 0.78–1.43] in the
Cox model and 1.24 [95%CI 0.92–1.68] in the Fine & Gray model.
Conclusions: Magnitudes of aHR were similar in all models, except for
continuous exposure in the Cox model. Discontinuous exposure might
better capture treatment effects in day‐to‐day practice with gaps and
ABSTRACTS 63
switches. This study supports the use several exposure definitions to
assess the impact of treatment changes on the relative benefit attrib-
utable to DMTs. Estimand frameworks proved useful in navigating
through the nuances of interpretation from different exposure popula-
tions and models.
124 | Recommendations for
disproportionality analysis in small databases
Ola Caster1; Yasunori Aoki1,2; Lucie Gattepaille1; Birgitta Grundmark1
1Uppsala Monitoring Centre, Uppsala, Sweden; 2National Institute of
Informatics, Tokyo, Japan
Background: Disproportionality analysis (DA) is the most common
quantitative approach to guide signal detection in collections of spon-
taneous reports. Yet, little is known about when DA can be expected
to be robust. Such knowledge would be useful for countries and other
organizations with newly set up pharmacovigilance systems, and for
signal detection software users.
Objectives: To determine safe lower limits on the number of reports
for performing DA in (i) general subsets of larger databases, and (ii)
country‐specific databases.
Methods: 500 subsets each of sizes between 500 and 100,000
reports were randomly sampled from VigiBase, the WHO Global
Database of ICSRs, as of 31st December 2017. In addition, each sub-
set of reporting country of origin was studied. For each subset, a
permutation analysis was performed to determine the rate of spuri-
ous DA associations: first, the number of drug‐event combinations
with a positive lower endpoint of a 95% credibility interval for the
Information Component measure (IC025 > 0) was computed. Then,
the drugs of each report were paired with the events of a randomly
selected report, and the IC analysis was repeated on this permuted
version of the subset. The spurious rate was then computed as the
ratio between the number of associations in the permuted data
and the number of associations in the original data. If there were
fewer than 5 associations in the original data, the subset was
excluded from analysis.
Results: The spurious rate converged to a value of about 10% with
growing subset size, both for the random and the country‐specific
subsets. 21 countries were excluded because of too few associa-
tions, all of which had fewer than 500 reports. Among the remain-
ing 110 countries, the median spurious rate was 7.0% (range
0.0%–14%), with only 7 countries exceeding a spurious rate of
10%. For the random subsets of sizes between 500 and 2,000
reports, the median spurious rate was low (0.0%–7.2%), but vari-
ability was considerable: consistently, more than 1/5 of the data
sets exhibited a spurious rate above 10%. For subset sizes
between 3,000 and 5,000 reports, this proportion varied roughly
between 1/8 and 1/20, and for subsets of 7,500 reports or more,
it was close to zero.
Conclusions: For DA in generically constructed subsets of data-
bases of spontaneous reports, we recommend a lower subset size
of about 3,000–5,000 reports. For DA in country‐specific data-
bases, we recommend at least 500 reports. However, while DA
may produce robust results in very small databases, its utility is
likely to be minor as few associations will be generated. Signal
detection based on case‐by‐case assessment is likely to be more
effective in such cases.
125 | Missing data techniques in longitudinal
epidemiologic research: A case study
Valerie Strezsak; Jin‐Liern Hong; Paul Dolin
Takeda Pharmaceutical Company Limited, Cambridge, MA
Background: Missing data are pervasive in observational research,
particularly in longitudinal studies. Researchers often exclude
patients with missing outcome data when calculating treatment
response rates, but this results in loss of statistical power and may
impact validity. There are several alternative approaches for address-
ing missing data and the choice of method can have a profound
impact on interpretation of results.
Objectives: To present alternative imputation methods for the han-
dling of missing outcome data and to compare their impact on calcu-
lation of treatment response rates.
Methods: These analyses used real world data from a prospective
cohort study of patients receiving drug therapy for a non‐fatal chronic
disease. The primary outcome was proportion of patients in remission
after 6, 12, 24, and 36 months of drug therapy. At each time point, a
patient could be in remission, not in remission, or have missing out-
come data. As alternatives to excluding patients with missing outcome
data (Complete Case Analysis), the following imputation methods
were applied to the data: (1) assuming all missing observations were
remission [responder imputation], (2) assuming all missing observa-
tions were not remission [non‐responder imputation], (3) last observa-
tion carried forward [LOCF], (4) multiple imputation [MI], and (5)
inverse probability weighting [IPW].
Results: At 6 months follow‐up, 30.5% of patients were missing out-
come data. Remission rates were: Complete Case Analysis, 61.0%;
responder imputation, 72.9%, and non‐responder imputation 42.4%.
At 36 months, 20.7% of patients were missing outcome data. Remis-
sion rates were: Complete Case Analysis, 36.9%; responder imputa-
tion, 50.0%, and non‐responder imputation 29.3%. MI and IPW
analyses yielded remission rates similar to Complete Case Analysis
except at 36 months, where MI was lower (33.7%), while LOCF find-
ing were consistently lower than Complete Case analysis.
Conclusions: Consideration needs to be given to the analysis of miss-
ing data and how this impacts interpretation of treatment response
rates. For transparency, a range of imputation methods should be
included in a standard analysis. Although inherently biased, responder
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and non‐responder imputations are simple to calculate and useful in
providing upper and lower estimates of the unknown true remission
rate. In this case study, Complete Case, MI and IPW analyses yielded
similar results, suggesting that outcome data were missing completely
at random.
126 | Prospective testing of hypothesis‐free
signal detection utilizing a disturbance
algorithm: Nifedipine use case
Jamie Geier; Qing Liu; Stephen E. Schachterle; Kenneth Petronis;
Manfred Hauben; Vladyslav Bykoriz; Andrew Bate
Pfizer Inc, New York, NY
Background: Hypothesis‐free signal detection within Longitudinal
Observational Databases (LODs) is an emerging field of
pharmacovigilance research with no consensus on best practice.
Methodologic developments and evaluations are, however, of interest
to regulators, academics and pharma. The chronograph has shown
promise in pharmacovigilance work; however, manual review can be
time consuming. The prospective application of a disturbance algo-
rithm filter may be an effective tool for triaging clinical reviews. A
methodological study was initiated to evaluate the feasibility for
hypothesis‐free signal detection in LODs.
Objectives: To develop and test a systematic approach for hypothesis‐
free signal detection equipped to highlight signals of disproportionate
recording (SDRs) for integration into existing signal management sys-
tems and processes.
Methods: .A process model was developed via team consensus to
ensure study reproducibility and integration with routine signal detec-
tion processes. Nifedipine data within the Truven MarketScan data-
base (2010–2015) were evaluated and chronographs were generated
for 1,461 pre‐identified drug‐event pairs. An ARIMA‐based distur-
bance algorithm was applied to each chronograph to identify chrono-
graphs that contained clear indications of an increase in Information
Component scores that might be indicative of SDRs. The subsequent
data matrix was analyzed and outliers were compiled for clinical
review and SDR determination.
Results: Following data logic checks, 87% (n = 1,275) of the drug‐
event pairs were excluded because signals either occurred prior to
drug exposure or were in a negative direction. A total of 186
drug‐event pairs were eligible for pattern review. Of those, approxi-
mately 54% (101 of 186) were excluded as non‐SDRs leaving 85
drug‐event pairs for clinical review. Following clinical review, 30
drug‐event pairs were conditionally validated as SDRs, 33 were not
considered SDRs and 22 were known or labeled events associated
with nifedipine. Difficulties determining the timing of drug exposure
relative to maternal and neonatal events were, however, noted. The
review extended over a 3 hour period with the support of a clinician
and 2 epidemiologists.
Conclusions: Hypothesis‐free signal detection in LODs is tractable and
aligns with routine signal detection processes. Although limited signal
detection capability enhancement was seen with nifedipine, the data
suggest that signal detection in LODs may have a complementary role
to signal detection in spontaneous reports and other data sources
from a process‐driven perspective.
127 | Toxicity latent classes in
chemotherapy‐refractory, metastatic
colorectal cancer patients treated with anti‐
epidermal growth factor receptor monoclonal
antibody: Latent class analysis of clinical trial
data
Lidija Latifovic1; Wei Xu1; Rayjean Hung2; Geoffrey Liu1
1University Health Network, Toronto, ON, Canada; 2Sinai Health System,
Toronto, ON, Canada
Background: Cancer patients experience concurrent and inter‐related
toxicities. Little is known about the clinical factors that predict these
toxicities.
Objectives: To identify, among metastatic colorectal cancer patients
(mCRC) receiving anti‐epidermal growth factor receptor (EGFR) mono-
clonal antibody, subgroups of patients with similar toxicities and to
asses their association with clinical characteristics.
Methods: There were 660 participants randomized to treatment with
anti‐EGFR monoclonal antibody. We selected 14 toxicity indicators
for the latent class analysis. Six patient‐reported toxicities, graded
according to NCI's Common Terminology Criteria at grade > 3 and
prevalence of >5%: fatigue, pain, dyspnea, rash, infection, and
anorexia and eight laboratory tests: granulocyte count (<1.5x109/L),
platelet count (<75x109/L), hemoglobin (<80 g/L), total bilirubin
(>1.5X upper limit of normal (ULN) or 2.0X ULN with liver metastasis),
ALT and AST (>2.5X ULN or 5.0X ULN with liver metastasis), serum
creatinine (>1.5X ULN) and magnesium (<0.5 mmol/L). Latent class
analysis was implemented using a Bayesian stabilizing prior to handle
sparseness and adjusting estimates for clustering by study center.
Optimal number of latent classes was determined using Bayesian
Information Criterion (BIC). The relation between age, sex, primary site
of tumor, and liver metastasis and latent class membership was
examined.
Results: We identified three classes: all low toxicity (75.1%), all high
toxicity (18.7%) and high renal toxicity (6.2%). Age, sex and liver
metastasis predicted class membership (p < 0.01). Odds ratios (OR)
were estimated relative to the all low toxicity class. For every year
increase in age the odds of all high toxicity class membership
increased by 1.01 (95% confidence interval [CI]: 1.00, 1.02) and
the odds of renal toxicity class membership by 1.01 (95%CI: 1.00,
1.02), male sex was associated with decreased odds of all high tox-
icity class membership (OR: 0.80 (95%CI: 0.72, 0.89) and renal toxic-
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ity class membership (OR: 0.82, 95%CI: 0.68, 0.98). The presence of
liver metastasis was predictive of all high toxicity class membership
(OR: 5.95, 95%CI: 3.43, 10.30) but not renal toxicity class member-
ship (OR: 0.27, 95%CI: 0.23, 0.32).
Conclusions: Three toxicity latent classes were identified that may
help guide more individualized toxicity interventions in mCRC patients
given anti‐EGFR monoclonal antibodies.
128 | Identifying risk factors for 30‐day
hospital readmissions among heart failure
patients using machine‐learning techniques
Joseph Menzin; Jordan Menzin; Mark Friedman; Anna Watzker
BHE, Boston, MA
Background: Understanding patients most at risk for hospital readmis-
sion is of great interest to clinicians and policymakers. Heart failure
(HF) patients are known to have a substantial risk for early hospital read-
mission, but prior studies show fairly low predictive accuracy. For exam-
ple, a recent machine‐learning (ML) analysis using data from a single US
hospital had an AUC of 0.64 (Kutyifa, 2018, Cardiology Journal).
Objectives: The objective of this study was to identify risk factors for
30‐day readmissions among HF patients using an ML approach.
Methods: This single cohort retrospective analysis used the
HealthCore Integrated Research Database (HIRD), an administrative
claims database with over 50 million members. The study cohort
consisted of patients with a first‐listed diagnosis of HF between 1/
1/08 and 3/31/15, one year of eligibility prior to the HF hospitaliza-
tion (“Index”), and at least 30 days of eligibility following
discharge from the index stay. A priori defined features included
patient characteristics, index stay characteristics, and
baseline resource use. Additional features were generated empirically
based on the frequency of medications, diagnoses, and procedures
summarized to a CCS or Multum level for the year prior to index
and during the index stay. An ML model using XGBoost with all fea-
tures and a 15% holdout with a 75%/25% train/validation split was
used. The most important features were described. The analysis was
undertaken using the Instant Health Data (IHD) platform (BHE, Bos-
ton, MA, USA).
Results: A total of 112,653 HF patients were identified (median age:
70 years; 47% female), of whom 19.9% were readmitted within
30 days. The ML model's performance was: Accuracy: 71.7%, AUC:
67.3%, Recall: 60.0%, Precision: 36.5% and F1: 0.45. Important fea-
tures identified included patient demographic characteristics (eg, age,
region), discharge status, admission through the emergency depart-
ment (ED), baseline resource use (eg, number of inpatient visits, num-
ber of ED visits), select clinical characteristics (eg, cardiovascular,
ophthalmic, and infectious diagnoses), and cardiovascular and infec-
tion‐related medication use (eg, beta‐blockers, macrolides). The
Quan‐Charlson and Elixhauser Comorbidity Indexes and the LACE
index were identified as important predictors as well.
Conclusions: In this cohort of HF patients, our ML approach identified
risk factors for 30‐day readmission that were similar to a previous
study, with a slightly higher AUC. Further testing and evaluation
would be useful in varied databases with additional information from
clinical notes.
129 | Replication of risk characterization in a
cohort with women with advanced ER+/
HER2‐ breast cancer using a new analytic tool
Xiaofeng Zhou1; Cynthia de Luise1; Patricia Prince2; Rongjun Shen1;
Kaiyi Luo2; Anthony Louder2; Nicolle M. Gatto1
1Pfizer Inc., New York, NY; 2Aetion Inc., New York, NY
Background: Estrogen receptor positive (ER+)/human epidermal
growth factor receptor 2 negative (HER2‐) breast cancer (BCa) is
the most common subtype of BCa. Identifying a cohort of women
with advanced ER+/HER2‐ BCa using real world data (RWD) allows
for risk characterization and contextualization of potential safety
concerns in this population. There is an increasing interest to
improve the speed of safety analyses.
Objectives: Use a rapid‐cycle analytic tool to 1) identify a cohort of
women with advanced ER+/HER2‐BCa to estimate incidence rates
(IRs) for selected safety outcomes of interests (SOIs), and
2) compare results obtained from traditional de novo SAS
programming.
Methods: A retrospective cohort of women with advanced ER+/
HER2‐ BCa during 1/1/2007 and 7/1/2017 was identified from
Optum EHR data using Aetion Evidence Generation Platform
(AEP), a rapid‐cycle analytic tool. An a priori algorithm using clin-
ical insight was applied, consisting of females aged 55+ at 1st
diagnosis of BCa or > 18 on the treatment index date of hor-
monal or other ER+/HER2‐ therapy, with ≥6 months of enroll-
ment. IRs and 95% confidence intervals (CIs) were estimated for
10 SOIs: neutropenia, febrile neutropenia, leukopenia, anemia,
thrombocytopenia, pulmonary embolism (PE), other venous throm-
bosis and embolism (VTE), embolism and thrombosis of unspeci-
fied (ETN), diabetes mellitus, and hyperglycemia. ICD‐9/10 codes,
NDC codes, and unstructured data were used to identify the
cohort and SOIs.
Results: A total of 14255 women with advanced ER+/HER2‐ BCa
were identified using the AEP, providing a 100% match with SAS
programming. IRs and 95% CIs per 100 person years for Anemia,
neutropenia, leukopenia, thrombocytopenia, hyperglycemia, other
VTE, diabetes mellitus, febrile neutropenia, PE, and ETN were
24.9 [24.2, 25.6], 15.2 [14.8, 15.7], 13.0 [12.6, 13.4], 5.3 [5.1,
5.6], 3.5 [3.3, 3.7], 3.0 [2.9, 3.2], 2.9 [2.7, 3.1], 1.7 [1.6, 1.8], 1.5
[1.4, 1.6], and 0.1 [0.1, 0.2] respectively. All IRs were near equal
to results using SAS. Cohort generation and safety analysis using
AEP took approximately 4 weeks, compared to up to 8 weeks using
traditional SAS programming.
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Conclusions: Rapid‐cycleanalyticswithAEPenabled rapid replicationof
a cohort with advanced ER+/HER2‐ BCa and IR calculation for several
safety endpoints. The results verified against traditional SAS program-
mingwerenear identical. Rapid‐cycle analytics can serve as an important
method for rapidly responding to potential safety concerns and leverag-
ing RWD for drug safety surveillance.
130 | Consistency between prescription
symmetry sequence analysis and symmetry
analysis cohort design: Study using claims
data in Japan
Kiyoshi Kubota1; Seiya Suzuki2; Yuki Kinoshita2; Nobuhiro Ooba3;
Yasuo Ohashi2
1NPO Drug Safety Research Unit Japan, Tokyo, Japan; 2Chuo University,
Tokyo, Japan; 3Nihon University School of Pharmacy, Chiba, Japan
Background: Since Hallas advocated the prescription sequence
symmetry analysis (sometimes called simply as “symmetry analysis”
(SA)) in 1996, SA has been used mainly to raise signals of possible
adverse drug reactions from the database. With slight modification
of SA, a “symmetry analysis cohort design” (SACD) was proposed
by Kubota (PDS, 2016) as a method suitable in the study involving
the primary data collection without a comparator group.
Objectives: In the current study, we examined whether SACD can
provide results compatible with those by SA.
Methods: We used claims data (Medi‐Scope) between May 2013 and
April 2018 covering 1.3 million persons provided by corporate insur-
ance plans in Japan. We used positive and negative events in the study
by Wahab (PDS 2013) which was conducted to test SA. The rate ratio
(RR) was estimated by SA (RR (SA)) and SACD (RR (SACD)) by analyzing
the data after 6‐month run‐in period using 12‐month time‐window.
We estimated the sensitivity and specificity for SA and SACD.We con-
ducted functional relationship analysis (Kendall, 1979) to know the
relationship between SA and SACD. The study was approved by the
ethics committee of Nihon University School of Pharmacy.
Results: We found a total of 52,722 (man: 43.0%, age: 46.0 ± 13.9 years
old) and10,743 (man:43.8%, age: 53.2±11.5yearsold) patientswho ini-
tiated a causative drug and had an outcome for 37 positive and 60 nega-
tive events, respectively. The sensitivity was 22% (8/37) with SA and
19% (7/37) with SACD. The specificity was 98% (59/60) with both SA
andSACD.ThefunctionalrelationshipanalysisrevealedRR(SACD)=βRR
(SA) where β = 0.960 (95% confidence interval: 0.950–0.969). Though
the specificity was similar between our study using SA (98%) and that
byWahab (93%), the sensitivity in our studyusingSA (22%)was substan-
tially smaller than that in the study byWahab (61%).
Conclusions: The rate ratio by SACD was close to that by SA. The sen-
sitivity in our study was substantially smaller than that by Wahab
potentially due to the difference of age structure of study population
and treatment pattern with drugs used as a surrogate of the outcome
occurrence.
131 | To censor or not to censor: Impact of
death censoring in estimating excess length
of stay in relation to nosocomial infection
Tomomi Kimura1; Toshifumi Sugitani1; Stephen Stanhope2
1Astellas Pharma Inc., Tokyo, Japan; 2Astellas Pharma US Inc.,
Northbrook, IL
Background: Nosocomial infection can prolong length of stay (LoS).
Death is a competing risk for discharge and key component for esti-
mating excess LoS due to nosocomial infection.
Objectives: To assess the impact of death censoring in estimating
excess LoS attributable to a nosocomial infection.
Methods: Using a large Japanese hospital‐based administrative data-
base, all hospitalizations during April 2008 to March 2017 for patients
≥18 year‐old were extracted. Clostridioides (Clostridium) difficile
infection (CDI) during the hospitalization was identified by treatment
plus diagnosis or immunoassay positive result. Hospitalization with
CDI was matched to a hospitalization without CDI at the timing of
the onset using the propensity score. Excess LoS was calculated in
each matched pair by subtracting days after matching. In order to
assess the impact of censoring, Kaplan Meier methods were applied
to excess LoS with and without regarding transfer to other hospital
and hospital death as censoring events.
Results: In total, 11,722 hospitalizationswere associatedwith the noso-
comial infection. In thematchedcohort,21.5%hospitalizationwith infec-
tion resulted in death while it was 14.6% in hospitalization without the
infection. Median excess LoS attributable to CDI was 3 days (interquar-
tile range:−14,22),withoutcensoring transfer tootherhospital ordeath.
Itwas4days (3,14)whencensoringonlytransferand16days (4,77)when
both transfer and deathwere censored.
Conclusions: In this study, the excess LoS was largely varied by cen-
soring based on the type of event that terminated the hospitalization.
Which estimand to choose should depend on the objective of the
study. If the estimated excess LoS is to be used in a purely economic
context, death might be reasonably used as an event that terminates
the stay. However, if excess LoS is to be considered in a broader con-
text with death being the burden of the infection, discharge with
death may be better regarded as censoring.
132 | Codelist proximity analysis ‐ an
innovative, data driven, semi‐automated
system, underpinned by neural networks on
the Thin database, to create candidate clinical
Codelists for cohort extraction and data
exploration
Alison Bourke; Timothy Reason
IQVIA, London, UK
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Background: Constructing a specific clinical coding list to extract a
patient cohort from an Electronic Medical Records (EMR) database is
essential to high quality research. Compiling code lists is usually time
consuming and requires input from experts in the specific database
design, coding system, and medical speciality. We sought to make the
process less resource intensive using innovative data driven methods.
Objectives: To create a semi‐automated system to produce a set of
candidate clinical codes for searching an EMR database for patients
with specific medical conditions.
Methods: In order to explore and document the relationship
between clinical codes in the Health Improvement Network (THIN)
database of over 12 million UK primary care patient records, a neu-
ral network was fitted to patient medical histories to produce a vec-
tor for each READ clinical code encountered throughout patients'
medical histories. Cosine similarity was used to measure “associa-
tion” between codes based on how often they appeared together
in each patient record. A web application was then built to allow
any researcher, on inputting a specific READ code of interest, to
view the top 200 clinical codes with the highest association to the
original code. A comparison was made of traditionally prepared code
lists and the semi‐automatic method described here and named
Codelist Proximity Analysis.
Results: There was a close comparison between code selections
derived from Codelist Proximity Analysis and pre‐existing compiled
clinical code lists created using the traditional method of examination
of the coding dictionary by both free text and hierarchy. The Codelist
Proximity Analysis system was found to have a high user acceptance
being intuitive, fast, & needing less expert input than traditional code
list generation.
Conclusions: Neural Networks represent one of the many techniques
in the machine learning field. This application of the method to EMR
has been used to create a system to reduce the costs, time and exper-
tise needed to extract cohorts. This new approach can also be used to
explore clinical and therapeutic relationships providing further
research insights in a data driven way.
133 | Variation in grace period used to
define exposure to anticoagulants impacts
incidence rates of major bleeding in patients
with atrial fibrillation
Liliya Sinyavskaya1; Christel Renoux2; Madeleine Durand1
1Université de Montréal, Montréal, QC, Canada; 2McGill University,
Montréal, QC, Canada
Background: While direct oral anticoagulants (DOACs) are prescribed
at fixed doses, warfarin requires frequent dose adjustments by physi-
cians. Pharmaceutical dispensing data are therefore less likely to
reflect the true duration of warfarin supply compared with DOACs.
The use of fixed grace periods to define episodes of drug exposure
may lead to differential misclassification of exposure to DOACs and
warfarin.
Objectives: To assess whether the length of the grace period used to
define use of oral anticoagulants has a differential impact on the inci-
dence rates of major bleeding associated with warfarin and DOACs.
Methods: Using the administrative healthcare databases of Québec,
we formed the cohort of all patients with atrial fibrillation newly dis-
pensed warfarin, dabigatran, or rivaroxaban between 2010 and
2016. First, in an as‐treated approach, patients were followed from
treatment initiation until drug discontinuation. Second, we used a
time‐varying exposure definition, in which each day of follow‐up was
classified as exposed or unexposed to anticoagulants. In both scenar-
ios, current use of oral anticoagulant was defined by the duration of
each prescription plus a grace period of 0, 3, 7, 30 and 60 days. We
estimated the crude incidence rates (IRs) of major bleeding associated
with each oral anticoagulant and each grace period based on a Poisson
distribution.
Results: The cohort included 55,220 patients newly treated with anti-
coagulants. Using the as‐treated approach, the mean follow‐up varied
from 0.27 year with 0‐day grace period to 1.65 year with 60‐day grace
period. The highest IRs were observed with 0‐day grace period (warfa-
rin 18.2, dabigatran 10.7, rivaroxaban 16.5 per 100 person‐years). IRs
attenuated with longer grace periods (60‐day grace period, warfarin
11.3, dabigatran 7.3, rivaroxaban 11.0). Using the time‐varying
approach, the mean follow‐up was 2.71 years. Conversely to the pat-
tern observed using the as treated definition, for all drugs, IRs were
lowest with 0‐day grace period (warfarin 10.6, dabigatran 6.7,
rivaroxaban 10.1) and highest with 60‐day grace period (warfarin
11.2, dabigatran 7.2, rivaroxaban 10.4).
Conclusions: Varying the length of the grace period to define expo-
sure to oral anticoagulants did not have a differential impact on IRs
of major bleeding for DOACs and warfarin. However, for all drugs,
the length of the grace period had an opposite effect on the IRs esti-
mated using as‐treated and time‐varying definition of exposure, prob-
ably related to depletion of susceptibles and protopathic bias.
134 | Big data and real world evidence:
Rapid cycle analysis capability via emerging
analytic tools ‐ insights in atopic dermatitis
and lessons for wider adoption
Xiaofeng Zhou; Jamie Geier; Rongjun Shen; Richard Gong;
Nicolle M. Gatto; Andrew Bate
Pfizer Inc, New York, NY
Background: Several analytic tools have emerged to meet increasing
demands for rapid real world evidence generation on real world data
(RWD). It is well appreciated that RWD vary enormously and underly-
ing population characteristics (across regions or even data sources) can
differ greatly, often requiring access to multiple data sources to pro-
vide a range of background rates for risk characterization. There is
an increasing need to improve the speed of such analyses.
Objectives: To explore how a range of tools and data sources can pro-
vide rapid insights into Atopic Dermatitis (AD) population risk
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characterization, and further our understanding of disease population
variation in general.
Methods: Four analytic tools licensed from different vendors
(SÆfetyWorks, Aetion, IHD, and E360) were used to understand the
demographic characteristics of patients with AD and the incidence
rates (IRs) of 2 endpoints of interest: herpes zoster (HZ) and mela-
noma. A total of 684,928,490 patients with at least 2 AD diagnostic
codes aged ≥12 from 13 distinct healthcare databases across 8 unique
countries (United States (US), Canada, United Kingdom (UK), Italy,
France, Germany, Belgium, Australia) comprised the study's base pop-
ulation. IRs and incidence proportions (IPs) of HZ and melanoma dur-
ing 2012–2017 were calculated. A ≥ 6 month washout period prior to
the 1st diagnosis of each endpoint was applied.
Results: 525,489 and 74,742 AD patients across 5 US and 8 non‐US
databases were identified. IRs of HZ and melanoma per 1000 person
years (PYs) are 0–10.17 and 0–1.89 for all databases and tools:
7.51–10.17 and 1.21–1.89 for US claim data; 7.40–7.67 and 1.15–
1.16 for US EHR data (same data source); 0 for US hospital based data;
and 6.11 and 0.31 for UK EMR data. IPs of HZ and melanoma (%) are
0‐ < 2.57 and 0–0.46 for all databases and tools: 0–2.46 and 0–0.46 in
US; 1.74 and 0 in Canada; 1.32 and 0 in Australia, and 0.45‐ < 2.57
and 0–0.92 in EU respectively. It took ~5 hours to execute all analy-
ses. Variability per tool was observed, but was primarily driven by dif-
ferences in data in each tool.
Conclusions: Analytic tools enabled rapid analyses for risk characteri-
zation for AD using a vast amount data. Variation in results under-
scores the importance of access and use of a wide range of RWD to
further our understanding of disease outcomes in real world settings.
Rapidity facilitates iterative learning and the opportunity to develop
data‐driven and more complex follow up analyses as needed. These
tools provide great potential for leveraging real world data for proac-
tive and rapid drug safety surveillance.
135 | Application of machine learning
algorithms to a large primary care database
analysis: Random Forest in evaluation of body
weight and other characteristics as predictors
of antidepressants prescribing
Svetlana Puzhko1; Gillian Bartlett1; David Barber2; Tibor Schuster1
1McGill UniversityMontreal, QC, Canada; 2Queen's University, Kingston,
ON, Canada
Background: Antidepressants medications (AD) can cause weight gain,
and patients with excess weight may have poor response or non‐
response to AD treatment. Therefore, patient's body weight needs
to be considered when prescribing AD. As a first step to optimize
pharmacological treatment of depression in obese and overweight
patients, it is important to evaluate whether weight is a prominent
predictor of AD prescribing. Electronic medical records (EMR) contain
data on multiple factors, including patient's body weight and pre-
scribed medications. Advanced machine learning algorithms have
promising potential to be more efficient than conventional statistical
models when analyzing complex data.
Objectives: Using a large primary care database, to apply a Random
Forest (RF) machine learning algorithm to evaluate patient's body
weight and other socio‐demographic and health characteristics in pre-
diction of AD prescribing, and to compare performance of RF model to
an existing approach (multivariable binary logistic regression model).
Methods: Source: EMR from the national Canadian Primary Care Sen-
tinel Surveillance Network (CPCSSN) for 2011–2016; adult patients
(18 years of age and older) with depression. Measure: Prescribing of
at least one AD (outcome), body mass index to categorize patients into
weight groups (primary exposure); age, sex, network identification
number (ID), and comorbidities (secondary exposure variables). Analy-
sis: RF classification model with the number of trees set to 300 and
multivariable binary logistic regression (MLR) were used to evaluate
weight and other patient characteristics as predictors of AD
prescribing.
Results: Among 61699 patients with depression, 41389 were pre-
scribed AD. Five most important predictors of AD prescribing with
RF were ranked as follows: network ID (Mean Decrease Accuracy
[MDA] = 77.8%), age (MDA = 32.3%), epilepsy (MDA = 31.5%), hyper-
tension (MDA = 21%), and weight (MDA = 13.8%). In the RF model,
out‐of‐bag prediction error = 34%; sensitivity = 93.4%, specific-
ity = 11.6%. Areas Under the Curve were 57.2% and 58.5% for the
RF and the MLR, respectively.
Conclusions: RF model showed high sensitivity but low specificity, and
its performance was not superior as compared to the MLR model;
however, applying RF to analyze large primary care database allowed
to determine the importance of socio‐demographic and health charac-
teristics in prediction of AD prescribing. Weight was ranked among
the most important predictors of AD prescribing.
136 | Reproducibility of a population‐based
cohort study characterizing newly diagnosed
multiple myeloma patients in the UK using an
EHR database
Anouchka Seesaghur1; Victoria Banks1; Joe Maskell1;
Natalia Petruski‐Ivleva2; Jocelyn Ruoyi Wang2; Pattra W. Mattox2;
David Neasham1; Shannon L. Reynolds2; George Kafatos1
1Amgen Ltd, Uxbridge, UK; 2Aetion, Boston, MA
Background: The recent abundance of real‐world evidence from stud-
ies using large databases, including electronic health records (EHR),
has resulted in increasing efforts to improve the reproducibility of
research by promoting transparency of the analytical decisions and
replicating studies using the same data.
Objectives: To evaluate the reproducibility of a study characterizing
newly‐diagnosed multiple myeloma (NDMM) patients within a UK‐
based EHR database.
Methods: A large population‐based EHR, from general practices (GP)
within the primary care settings in the UK, the Clinical Practice
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Research Datalink (CPRD), was used. We identified NDMM patients
between January 1, 2006 through December 31, 2016; follow‐up
period extended to December 31, 2017. The study cohort included
patients ≥18 years with NDMM, no history of solid tumors, and a reg-
istration at the GP for at least two years prior to diagnosis. Baseline
demographics and clinical characteristics were assessed prior to, and
including the day of, MM diagnosis. A common study protocol and sta-
tistical analysis plan were deployed to evaluate reproducibility using
the Aetion Evidence Platform (AEP), a rapid‐cycle analytics tool. Tradi-
tional programming using SAS was carried out independently and in
parallel as a gold standard method. The reproducibility of study results
was evaluated by calculating the absolute difference in prevalence
between SAS (original) and AEP (reproduced) data, with an absolute
difference of 0.0 representing exact concordance.
Results: Both approaches yielded near‐identical number of eligible
patients diagnosed with NDMM during the study period (N = 2,646
in AEP versus N = 2,648 in SAS). We observed exact concordance
on the distribution of gender and median age, and high agreement
for clinical characteristics including osteopenia, osteoporosis, osteoar-
thritis, gout, CKD, CVD, and hypertension (absolute difference in
prevalence range 0.0 to 0.3). Distribution by age categories was
slightly discordant, due to varying methods for imputing incomplete
dates (i.e. missing month or day). We observed exact agreement in
prevalence for record of bone pain (combined and site‐specific) as well
as skeletal‐related events.
Conclusions: In this direct replication study evaluating early signs and
symptoms of NDMM within a UK‐based EHR, a rapid‐cycle analytics
tool achieved near‐exact reproduction of findings obtained using tra-
ditional SAS programming. Transparency of the study design and oper-
ational choices shared by independent investigators was critical to this
reproducibility.
137 | Using SNOMED to automate clinical
concept mapping
Shaun Gupta; Daniel Homola; Frederik B.C. Dieleman; Adam Webber;
Orla Doyle; Nadejda Leavitt; John A. Rigg
IQVIA, London, UK
Background: The International Classification of Disease (ICD) is a
widely used diagnostic ontology for the classification of health disor-
ders. However, it poses several challenges: (i) it is an evolving ontology
and complete cross‐walks do not exist between previous versions (e.g.
ICD‐9 to ICD‐10) resulting in the need for custom mappings and (ii)
performing analytics on a code level directly results in a highly sparse
representation which is difficult to interpret.
Objectives: Clinical knowledge can be employed to map ICD codes to
aggregated medical concepts, however, this process can be highly
time‐consuming and costly. We propose an automated solution to
these challenges that does not sacrifice the accuracy of the results.
Methods: Our solution leverages the SNOMED ontology whereby
medical concepts are organized in a directed acyclic graph. This
performs two functions, (i) provides a mapping between ICD‐9 and
ICD‐10 by associating codes to concepts closely related on the
SNOMED graph and (ii) for any graph/tree‐based ontology, our cus-
tom rollup algorithm groups together codes/concepts into higher
level, more easily interpretable features. To assess impact, the perfor-
mance of a Gradient Boosted tree (XGBoost [1]), developed to classify
patients with Exocrine Pancreatic Insufficiency (EPI) disorder, was
compared when using features constructed by our solution vs clini-
cally‐driven methods. Data were extracted from US prescription and
open‐source medical claims reserving a held‐out set for testing.
Results: The data set comprised 23,204 EPI patients and 277,324
non‐EPI patients. Preliminary results showed 62% and 25% precision
at 25% and 50% recall, respectively, when using the clinically defined
mapping. Our algorithmically defined SNOMED features performed
comparably.
Conclusions: Our ontology agnostic rollup algorithm could be used
to automatically incorporate clinical domain knowledge into an
empirically‐orientated approach without comprising the accuracy of
the solution and obviating the need for time‐consuming manual
mapping.
138 | How to imply the needs of marginal
structural model to clinicians: An application
in Parkinson's disease ‐ from a junior
Statistician's aspect ‐
Shih‐Wei Chiu; Takuhiro Yamaguchi
Division of Biostatistics, Tohoku University Graduate School of Medicine,
Sendai, Japan
Background: J‐FIRST was a large‐scale observational study for non‐
motor symptoms (NMs) and treatment in patients with PD in Japan.
One of the antiparkinsonian medications, Istradefylline (adenosine
A2A receptor antagonist), was first approved as in Japan 2013. In
order to estimate the treatment effect for NMs, we planed different
kinds of analysis including marginal structural models (MSMs). But
the results did not have dramatical differences between MSMs, either
to the conventional regression model. Although MSM is widely used
to deal with time‐varying problems, to nonfamiliar clinicians, it may
be confused and questionable: What had MSM exactly done? Can
we just use a simple method?
Objectives: The aim was to demonstrate how to explain the needs of
MSM to clinicians in a smooth way.
Methods: We followed the next steps to construct MSMs.1.Decide
the causal directed acyclic graph (DAG) and choose the possible
time‐fixed and time‐varying confounders by clinical opinions. 2. Test
the time‐dependent nature of confounders. 3. Use the selected covar-
iates to conduct MSMs and compare the weights and distribution of
confounders. 4. Estimate the treatment effect by MSMs. After meet-
ings with clinicians, we pick up 4 frequently asked question. And try
to answer the questions by the interim results which already existed
in our steps.
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Results: The 4 questions and answers are described as below. Q1.
What do the results of pseudo population mean? Q2. Is it ok to not
to adjust all unbalanced covariates? Q3. After adjusting the con-
founders, why the results were not change dramatically? Q4. Can we
just use the conventional regression model? A1. Use DAG to demon-
strate the relationship between covariates, treatment, and outcome.
A2. Show the testing result of time‐dependent nature to point out
which covariates are really predicted by prior exposures or influenced
next outcome. A3. Emphasize the goal is to adjust confounders not
the outcome. Also Illustrate the balance of confounders after
adjusting. A4. Among A1–3, the time‐dependent confounders were
indeed existed in our study, and the treatment is also time‐varying.
It's exactly why we need MSM to estimate the total effect of time‐
varying treatment on outcome without bias in the presence of time‐
dependent confounders.
Conclusions: MSM method can be easily performed by statistical
packages nowadays. Without further understanding and attention,
the results may be mistaken and lead to the wrong conclusion. Follow-
ing some necessary steps, MSM can be conducted efficiently. And
each step is also the material to sharpen clinicians' understanding.
139 | The feasibility of federated analysis for
multi‐site real world evidence studies
Fiona Grimson1; Nicolas Niklas2; Ruben Hermans1; Lorena Cirneanu1;
Benedikt Maissenhaelter2; Joseph Kim1,3
1 IQVIA, London, UK; 2 IQVIA, Frankfurt, Germany; 3London School of
Hygiene & Tropical Medicine, London, UK
Background: In the generation of real‐world evidence for rare dis-
eases, there may be no single site with a sufficiently large patient pop-
ulation for generating statistically meaningful results. Consequently,
there has been a great demand for studies that pool information from
multiple sites. One approach to multi‐site analysis is to pool individual
patient data (IPD) from multiple sites. However, this has become
increasingly challenging due to newly imposed restrictions on data pri-
vacy, such as, the EU General Data Protection Regulation (GDPR).
Another approach involves a meta‐analysis of site‐level statistics
which can be less informative as information contained in IPD is
ignored. We propose the method of federated analysis (FA), an analyt-
ical technique to obtain results mathematically equivalent to pooling
IPD that fully preserves data privacy as IPD is never shared outside
the host site. In FA, a global statistical model is fit over a centralized
network of contributing sites. Each site independently computes a
model update based on local IPD and communicates this update to a
central server where all updates are aggregated to a new global model.
Objectives: To explore the feasibility, advantages, and limitations of
FA for multi‐site real world evidence studies.
Methods: A literature review of FA methodologies and case studies
was undertaken to summarize the advantages and limitations of FA
as a means to conduct studies in a privacy preserving manner in
pharmacoepidemiology. IQVIA's European Oncology Evidence
Network (E‐OEN) was used as a case study to explore the feasibility
of executing federated studies on research databases.
Results:FA performed on a research database network could poten-
tially accelerate research timelines as the analysis is performed consis-
tently and simultaneously across the network. Several technical
challenges remain with FA, such as developing and validating robust
software solutions. Additionally, the epidemiological limitations of
IPD pooled analyses and use of harmonized data are not avoided in
FA. For instance, electronic medical records (EMR) are typically col-
lected to facilitate treatment not research. As such, methods of data
collection vary across sites which may result in the loss of nuanced
information in harmonized data.
Conclusions: Increasing concerns on data privacy, new legislation, and
potential gains in efficiency and statistical power has led to a demand
for FA in real world EMR databases. In rare diseases where single sites
have only a small number of patients, one needs to combine the ana-
lytical power of pooled analyses while fully preserving data privacy.
140 | A simulation‐based comparison of
confounding adjustment methods in
observational studies of administrative data
Imane Benasseur1; Jason R. Guertin1; Madeleine Durand2;
Anne Holbrook3; Alexis Matteau2; Brian J. Potter2; Christel Renoux4;
Mireille Schnitzer2; Jean‐Éric Tarride3; Denis Talbot1
1Université Laval, Quebec CityQC, Canada; 2Université de Montréal,
MontréalQC, Canada; 3McMaster University, Hamilton, ON, Canada;
4Lady Davis Institute for Medical ResearchJewish General Hospital,
Montreal, QC, Canada
Background: Propensity score (PS) methods are common for control-
ling for confounding bias when estimating the effect of an exposure
on an outcome using observational data. However, when analyzing
administrative data, the application of PS methods raises questions
regarding how to select confounders and the risk of unmeasured
confounding.
Objectives: To compare different methods for confounding adjust-
ment in the context of observational studies based on administrative
data.
Methods: Four methods for selecting confounders were compared
using simulation studies: high‐dimensional PS (hdPS), Outcome‐adap-
tive Lasso (OAL), Bayesian Causal Effect Estimation algorithm (BCEE)
and scalable collaborative targeted maximum likelihood (SCTMLE).
For hdPS and OAL, four PS adjustment approaches were considered:
1:1 greedy matching on the logit of the PS with a 0.2 SD caliper,
covariate adjustment in the outcome model using cubic splines,
matching weights and inverse probability of treatment weighting
(IPTW). BCEE and SCTMLE are doubly robust approaches that com-
bine PS with outcome modeling. Two simulations based on syntheti-
cally generated data with 1000 observations and 100 potential
confounders have been realized. In Simulation 1, covariates are uncor-
related, whereas correlations between 0.1 and 0.2 were present in
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Simulation 2. More simulations are underway, including simulations
with unmeasured confounders. Approaches were compared according
to relative bias, mean squared error (MSE) and proportion of 95% con-
fidence intervals (CI) that included the true effect over 1000 replica-
tions of each scenario.
Results: BCEE performed best, with very low bias and MSE and CI
that included the true effect close to 95% of the time. SCTMLE per-
formed as well as BCEE in terms of bias and MSE, but its CI included
the true effect 80–85% of the time. For OAL and hdPS approaches,
IPTW produced the best results, followed in order by covariate adjust-
ment in the outcome model, matching weights and matching. In Simu-
lation 1, both hdPS and OAL eliminated almost all bias and CI included
the true effect around 95% of the time. In Simulation 2, where con-
founders are correlated, only OAL yielded adequate results; substan-
tial bias remained for hdPS after adjustment and CI included the true
effect only 15–35% of the time.
Conclusions: BCEE and OAL are interesting approaches for selecting
confounders in high dimension settings, such as administrative data-
bases. While hdPS is a popular approach, our results indicate potential
for substantial residual bias when confounders are correlated, which is
likely in most real‐life situations.
141 | A real‐world evidence study of BRCA
mutations and survival in HER2‐negative
breast cancer
Tapashi Dalvi1; Kimmie McLaurin1; Josefa Briceno1; Beth Nordstrom2;
James Bennett3; Robert Hettle3; Brian Murphy2; Jenna Collins2;
Susan McCutcheon3
1AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD; 2Evidera,
Waltham, MA; 3AstraZeneca, Cambridge, UK
Background: Limited data exist on the natural history (treated with
standard of care) of metastatic breast cancer (mBC) characterized by
germline breast cancer susceptibility gene mutations (gBRCAm).
Objectives: To evaluate clinical characteristics and overall survival
(OS) among gBRCAm, gBRCA wild type (wt) and gBRCA unknown mBC.
Methods: Patients (pts) with human epidermal growth factor receptor
2 negative (HER2‐) mBC diagnosed from January 2013–August 2017
were retrospectively selected from the Flatiron Health Oncology elec-
tronic medical record database. Pts were classified as having
gBRCA1m, gBRCA2m, or gBRCAwt disease. Those who did not receive
genetic testing or who had equivocal results were classified as gBRCA
unknown. OS was calculated from first diagnosis of mBC, and from the
start of first‐ and second‐line therapy for metastatic disease. Lines of
therapy included both hormonal and systemic therapies. Kaplan–
Meier analyses provided median OS with 95% confidence interval
(CI). Unadjusted log‐rank tests compared OS between gBRCA1m and
gBRCA2m, and between overall gBRCAm and gBRCAwt.
Results: Of 8,080 pts selected, mean age at first mBC diagnosis was
64 years, 98.7% were female, and 82.0% had evidence of hormone
receptor positive disease. gBRCA status was known for 1,852
(22.9%) of pts, of whom 89 (4.8%) had gBRCA1m, 152 (8.2%) had
gBRCA2m, and 8 (0.4%) had both gBRCA mutations. Pts with known
gBRCA status were younger, with mean ages of 52 years for gBRCAm,
55 years for gBRCAwt, and 67 years for gBRCA unknown. Hormone
receptor positive disease was less common among pts with known
gBRCA status (71.9% for gBRCAm and 77.2% gBRCAwt) as compared
to unknown gBRCA status (83.6%). Median (95% CI) OS from mBC
diagnosis was 22 (14–26) months for gBRCA1m and 30 (27–37)
months for gBRCA2m (p = 0.01), though numbers were small by the
median timepoint. Overall gBRCAm disease was associated with
median OS of 28 (25–32) months, compared to 32 (30–35) months
for gBRCAwt (p = 0.07); OS was similar between groups for the first
24 months but declined thereafter in the gBRCAm group. Similar pat-
terns were observed for OS after the start of first‐ and second‐line
therapy, although no comparisons showed statistically significant dif-
ferences. Further analyses will present adjusted results and compari-
sons with outcomes for the pts with gBRCA unknown.
Conclusions: This real‐world study of pts receiving care in largely com-
munity oncology clinics suggests that OS after diagnosis of mBC is
reduced in pts with gBRCA1m compared to gBRCA2m and may be
reduced in gBRCAm mBC overall. Effective treatments targeted for
gBRCAm subtypes of mBC appear to be warranted.
142 | Racial disparities in survival among
women who have HER2+ metastatic breast
cancer: A systematic review and meta‐
analysis
Emily Patry; Ami Vyas
University of Rhode Island, Kingston, RI
Background: Non‐Hispanic Black women have a lower incidence rate
of breast cancer than non‐Hispanic white women, yet have higher
mortality rates. Several well studied disparities contribute to worse
outcomes among Black women. These disparities include diagnosis at
a later stage, specific molecular sub‐type of breast cancer, and delayed
initiation or under utilization of first line therapeutic treatments.
Objectives: To determine whether Black women with HER2+ meta-
static breast cancer experience shorter survival times than non‐His-
panic white women.
Methods: A systematic review and meta‐analysis was conducted using
individual studies identified from PubMed, WorldCat, EBSCOHOST,
Embase, and Proquest published until April, 2018. Conference
abstracts from the San Antonio Breast Cancer Symposium were also
searched. Studies which included female patients with metastatic
HER2+ breast cancer which was either HR+ or ‐, or HR unspecified
and a sub group analysis of survival outcomes between non‐Hispanic
white, and non‐Hispanic Black patients were included. A meta‐analysis
was completed in RevMan; hazard ratios (HR) were pooled and the
95% confidence interval (CI) for survival at 12 months was calculated.
I2 statistic was calculated to determine heterogeneity between
included studies.
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Results: Four retrospective cohort studies were identified and
included in the meta‐analysis. Overall survival and breast cancer spe-
cific survival significantly favors non‐Hispanic white women with
HER2+ metastatic breast cancer over non‐Hispanic Black women with
the same diagnosis. In the adjusted (HR: 1.53, CI: 1.23–1.90, p‐value:
0.0002)model for overall survival Black women were 53% more likely
to die during the follow up period than non‐Hispanic white women.
And in the the adjusted model for breast cancer specific survival
(HR: 1.44, CI: 1.18–1.76, p‐value: 0.0004) Black women were 44%
more likely to die during the same period.
Conclusions: Black women with HER2+ breast cancer have poorer
overall survival and breast cancer specific survival, despite lower inci-
dence. Opportunities exist for identifying the factors affecting these
disparities in survival and also developing and implementing targeted
interventions aimed at improving survival in this disparate group.
143 | Metastatic breast cancer sub‐type
classification using biomarker and treatment
information in electronic health records
Christopher Craggs1; Evelyn M. Flahavan2; Andy Surinach3;
Matthew Kent3; Thibaut Sanglier1
1Hoffman‐La Roche, Basel, Switzerland; 2Roche Products Limited,
Welwyn Garden City, UK; 3Genesis Research, Hoboken, NJ
Background: Correctly classifying metastatic breast cancer (mBC) sub‐
types (estrogen receptor, ER; progesterone receptor, PR; and human
epidermal growth factor receptor 2, HER2) is important when identify-
ing disease cohorts in electronic databases. Classification difficulties
can arise due to timing or missing‐ness of biomarker and treatment
information.
Objectives: To characterize biomarker testing and estimate the con-
cordance in between classified sub‐type and the type of treatment ini-
tiated for mBC in EHR.
Methods: Using Flatiron Health EHR‐derived data (data records
between 2011–2018) on ER, PR, and HER2 testing and corresponding
treatment information were obtained for mBC patients over 18 years
old. Various mBC sub‐type classifications were explored at mBC and
primary BC according to ER, PR and HER2 test timings, and their con-
cordance with HER2 targeted therapies, endocrine therapies, or che-
motherapies‐only in the metastatic setting was investigated. Patients
with positive tests +/−90 days around primary or metastatic diagnosis
were considered positive for the respective biomarker at that time‐
point; patients with concurrent negative tests for ER, PR, and HER2
were classified as TNBC. Applicable biomarker test results were evalu-
ated by looking at the first, last, closest test to diagnosis date, and
applying a hierarchical selection (‘+’ >’‐‘>’equivocal’ >’unknown’).
Kappa, sensitivity (SE), and specificity (SP) values were calculated to
estimate concordance between test results and treatment types
received.
Results: Of N = 13,899 mBC patients, 19% of patients received at
least one HER2 targeted therapy (10% HER2+/HR+; 9% HER2+/
HR‐), 63% at least one endocrine therapy, and 18% chemotherapy
only in the metastatic setting. Among patients with initial mBC diagno-
sis, the concordance estimates between tests at mBC diagnosis date
(K, SE, SP) were 0.7, 0.6 and 0.99 for HER2+/HR‐; 0.7, 0.9 and 0.92
for HER2+/HR+; 0.8, 0.96 and 0.8 for HER2‐/HR+; and 0.7, 0.6 and
0.99 for TNBC. For patients with an initial eBC diagnosis, the concor-
dance estimates (K, SE, SP) were 0.7, 0.6 and 0.99 for HER2+/HR‐;
0.6, 0.7 and 0.96 for HER2+/HR+; 0.7, 0.94 and 0.8 for HER2‐/HR+;
and 0.6, 0.6 and 0.97 for TNBC.
Conclusions: Overall, mBC test results showed good concordance
with targeted therapies in the metastatic setting. The poorer concor-
dance for TNBC biomarker and treatment, highlights a limitation of
the validity of classifications based on treatment only e.g. in claims
data. In this dataset, oral (endocrine) therapies are abstracted manu-
ally, so there may be some under‐recording.
144 | Derivation of anthropometric‐based
equations to predict lean body mass
composition of cancer patients
Macarius Donneyong; Autumn B. Carey; Ashley S. Felix; Jared Huling;
James Odei; Christopher Coss
The Ohio State University, Columbus, OH
Background: The lean bodymass (LBM) composition of cancer patients
is a significant predictor of chemotherapy‐related adverse events. How-
ever, there are currently no validated measures of LBM that can easily
be implemented in routine oncologic settings. “Gold standard” LBM
measures such as dual‐energy x‐ray absorptiometry (DXA) are expen-
sive and not frequently used in routine oncologic settings.
Objectives: Therefore, we aimed to derive and validate anthropomet-
ric equations that can estimate the LBM of cancer patients in routine
oncologic settings.
Methods: Eight cycles of the National Health and Nutrition Examina-
tion Survey (NHANES) 1999–2014 were analyzed to build predictive
models given the presence of anthropometric and DXA measures in
this national data sample. A population of participants with self‐
reported physician diagnosis of cancer was randomly divided into
training (75%) and validation (25%) sets. First, we utilized the training
data to predict DXA measures of LBM using a combination of 8 differ-
ent common anthropometric measures ‐ height, weight, circumference
measures (arm, waist, thigh, and calf), and skinfold (subscapular and tri-
ceps). Next, the best fitting and most parsimonious models were uti-
lized to estimate the predicted LBM of the validation group.
Absolute differences and correlation coefficients between DXA mea-
sured LBM and predicted LBM were used to validate the equations.
Last, we tested how well predicted LBM predicts mortality status of
the sample population. Models were stratified by sex and adjusted
for race and age to account for anatomical differences. The fit of
models were measured as R2.
Results: Predictive models were derived from a sample of 682 adult
(≥18 years old) participants (representing 3,763,122 persons in the
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US)with self‐reported cancer diagnosis andwhohad completeDXAand
anthropometric measures. Overall, a combination of anthropometric
variables accurately predicted the LBM composition of cancer patients
(R2 = 0.95). The model predicted LBM better among male (R2 = 0.94)
than among female (R2 = 0.86) cancer patients. The predicted LBM dis-
criminated death to the same magnitude as direct LBM measures from
DXA scans, C‐statistics: 0.76.
Conclusions: Anthropometric measures can be used to accurately esti-
mate the LBM of cancer patients and help optimize chemotherapy
dosing. Our next step is to apply these derived equations to measure
LBM thresholds associated with the risk of chemotherapy adverse
events.
145 | Characterizing active multiple
myeloma populations identified by published
claims‐based algorithms
Laura L. Hester1; Frank J. DeFalco2; Dina M. Gifkins2
1 Janssen Research & Development, Titusville, NJ; 2 Janssen Research &
Development, Raritan, NJ
Background: The smoldering and active phases of multiple myeloma
(MM) have different progression, treatment, and outcomes; however,
distinguishing the phases is difficult in claims data since both are
assigned the same diagnosis code. Published algorithms combine rules
with treatment, diagnostic tests, and CRAB symptoms (hypercalcemia,
renal insufficiency, anemia, bone lesions) to distinguish active from
smoldering MM. However, overlap in populations defined by these
algorithms is poorly characterized.
Objectives: To describe the overlap in the size and characteristics of
active MM populations defined by published claims‐based algorithms.
Methods: Using Optum© De‐Identified Clinformatics® Data Mart
Extended Socioeconomic data, we found patients aged 18+ with
an index MM diagnosis (SNOMED 109989006/ICD‐10 C90.0)
between 01/2016–08/2018 that was preceded 30–180 days by
the 1st MM diagnosis and ≥ 365 days continuous enrollment. As
done in the literature, 4 algorithms were added to the base popula-
tion to identify active MM: 1) 1+ MM treatment in 180 days after
1st diagnosis; 2) 2+ protein electrophoresis and 1+ immunoglobulin
tests 180 days before the 1st diagnosis; 3) 1+ bone marrow biopsy
or 2+ diagnostic tests before the 1st diagnosis with 2+ MM diagno-
ses 90 days before both; 4) 1+ diagnosis code for CRAB symptoms
180 days before the 1st diagnosis. We explored overlap between
populations and compared standardized differences (SD) ≥0.2 in
the proportion of prior diagnoses, drugs, procedures, and
measurements.
Results: Of 10,387 patients in the base MM population, 10% had no
active MM rule suggesting potential smoldering MM, 21% met only
1 active MM rule, and 10% met all active MM rules. The base pop-
ulation and the population defined by protein electrophoresis and
immunoglobulin tests were similar, with SD <0.2 between all covar-
iates. Populations defined by bone marrow biopsies/multiple
diagnostic tests had a higher proportion receiving chemotherapies
before the 2nd diagnosis than the base population. Populations
defined by symptoms had more inpatient visits and condition codes,
such as renal disease, but less treatment or diagnostic tests than the
base population. There was little overlap between populations
defined by bone marrow biopsy/early diagnostic tests and by CRAB
symptoms.
Conclusions: Treatment, tests, and symptoms are proxies for
distinguishing active from smoldering MM in claims but identify differ-
ent underlying MM populations. When combining algorithms to iso-
late active MM, researchers should ensure that they are not
integrating populations with different clinical characteristics.
146 | Association of in‐Hospital Bleeding
Events with subsequent infection and
mortality among patients undergoing cancer‐
directed surgeries in English inpatient
hospitals
Stephen Johnston1; Jing Yuan1; Nadine Jamous2; Sameer Mistry2;
Simran Jain3; Gaurav Gangoli2; Walter Danker2; Eric Ammann4;
Kingsley Hampton5
1 Johnson & Johnson, New Brunswick, NJ; 2Ethicon, Johnson & Johnson,
Somerville, NJ; 3Mu Sigma, Bangalore, India; 4 Janssen, Johnson &
Johnson, Titusville, NJ; 5The University of Sheffield, Sheffield, UK
Background: Patients undergoing cancer‐directed surgeries are at risk
for bleeding events.
Objectives: To evaluate the incidence of in‐hospital bleeding events,
and their association with subsequent in‐hospital infection and in‐hos-
pital mortality, among patients undergoing cancer‐directed surgeries
in English inpatient hospitals.
Methods: We conducted a retrospective, observational cohort study
using hospital discharge data from English hospitals (Hospital Episode
Statistics [HES] database) linked to electronic health records (Clinical
Practice Research Datalink [CPRD]). We selected patients aged
≥18 years who underwent selected cancer‐directed surgeries between
January 2010 and February 2016: hysterectomy, low anterior resection
(LAR, rectal), lung (transplant & resection), mastectomy, and prostate
(prostatectomy & resection). The primary independent variable was
occurrence of in‐hospital bleeding events (diagnosis of hemorrhage
and haematoma complicating a procedure or reopening/re‐exploration
and surgical arrest of postoperative bleeding). The primary outcomes
were in‐hospital infection (composite of wound infection, cellulitis, sep-
sis, transfusion‐related infection, urinary tract infection, and pneumo-
nia) and in‐hospital mortality, each occurring during or after the
surgery.We carried outmultivariable logistic regressionmodels to com-
pare the study outcomes between patients with vs. without bleeding
events, adjusting for baseline patient and procedural characteristics.
Results: The study included 26,438 cancer‐directed surgeries (hyster-
ectomy: 6,092; LAR: 2,957; lung: 1,539; mastectomy: 12,806; prostate:
3,044). Incidence proportions of bleeding events varied by surgical site
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(hysterectomy: 1.9%; LAR: 2.9%; lung: 1.8%; mastectomy: 1.5%; pros-
tate: 1.0%; overall: 1.7%).Overall, the incidence proportions of infection
and mortality were higher among patients with bleeding events (infec-
tion: 12.67% vs. 3.36%, p < 0.0001; death: 2.89% vs. 0.37%,
p < 0.0001) as compared with those without bleeding events. In multi-
variable analyses, bleeding events were associated with higher odds of
subsequent infection (adjusted odds ratio [AOR] = 3.50, 95% Confi-
dence Interval [CI] = 2.55–4.83) and mortality (AOR = 6.25, 95%
CI = 3.39–11.53).
Conclusions: Among patients undergoing cancer‐directed surgeries,
bleeding events were associated with increased risks of subsequent
infection and mortality, and therefore the prevention and manage-
ment of such events may lead to improved patient outcomes.
147 | The incidence of hematologic cancers
after breast cancer. A 35‐year population‐
based cohort study in Denmark
Cathrine Fonnesbech Hjorth1; Dora Kormentine Farkas1;
Lidia Schapira2; Suzanne Tamang2; Mark Cullen2;
Henrik Toft Sørensen1,2; Deirdre Cronin‐Fenton1
1Aarhus University Hospital, Aarhus, Denmark; 2Stanford University,
Stanford, CA
Background: Breast cancer survivors may have increased risk of new
primary hematologic cancer, due to shared risk factors or breast can-
cer‐directed treatments.
Objectives: To examine the incidence of hematological cancers
among breast cancer survivors compared with the general population.
Methods: We used the Danish Cancer Registry to ascertain a cohort
of all Danish women aged 18 years or older who were
diagnosedwith incident non‐metastatic breast cancer between 1978
and 2013 and who were alive and cancer free four months after
their breast cancer diagnosis (n = 93,620 women). We followed
the women until first new primary cancer of any type, death, emigra-
tion, or end of follow‐up (30 November 2013). We computed stan-
dardized incidence ratios (SIRs) with corresponding 95% confidence
intervals (95% CI) as measures of the relative risk of hematologic
cancers comparing hematologic cancers observed in breast cancer
survivors with that expected in the general population.
Results: Overall, we observed 607 cases of hematologic cancer com-
pared with an expected 575 cases corresponding to a SIR of 1.06
(95% CI 0.97–1.14) in a median follow‐up of 6.4 years. We observed
increased risk of myeloid leukemia (SIR 1.60; 95% CI 1.32–1.91), evi-
dent from one year after breast cancer diagnosis and persisting until
10 years of follow‐up. The increased risk of myeloid leukemia was
highest in women aged 18–49 years (SIR 2.36; 95% CI 1.54–3.46).
Risk of myeloid leukemia was increased irrespective of chemotherapy
or radiotherapy but was highest among women treated with chemo-
therapy (SIR = 2.54, 95% CI 1.64–3.75). The risk of non‐Hodgkin lym-
phoma, the most frequently observed hematologic cancer, was similar
to that in the general population (SIR 1.03; 95% CI 0.92–1.14), but the
risk of lymphoid leukemia was lower in breast cancer survivors (SIR
0.75; 95% CI 0.59–0.92).
Conclusions: Our observed increased risk of myeloid leukemia among
breast cancer survivors may be partly due to adverse effects of breast
cancer‐directed treatment. The potential mechanism underlying the
decreased risk of lymphoid leukemia in breast cancer survivors is
intriguing and warrants further investigation.
148 | Safety event rates in large claims‐
based cohorts of advanced/metastatic cancer
patients after initiation of systemic therapy
and immunotherapy
Daniel C. Beachler1; Francois‐Xavier Lamy2; Leo J. Russo3; Jade Dinh1;
Devon H. Taylor1; Ruihua Yin1; Aziza Jamal‐Allial1; Patrice Verpillat2;
Stephan Lanes1
1HealthCore Inc., Wilmington, DE; 2Merck KgGA, Darmstadt, Germany;
3Pfizer Inc., Collegeville, PA
Background: Healthcare claims databases are a source for real‐
world evidence and safety evaluation in oncology, but their use
has been limited by lack of clinical information, such as cancer
stage. We previously used claims data linked to cancer registries
and machine learning methods to build and validate algorithms to
predict advanced or metastatic (a/m) stage in five cancer types. In
this study we aim to assess rates of pre‐defined safety events in
a population of a/m cancer patients identified based on these
algorithms.
Objectives: To estimate safety event rates in five cohorts of a/m stage
cancer: ovarian cancer (OC), urothelial carcinoma (UC), gastric adeno-
carcinoma (GC), Merkel cell carcinoma (MCC), and non‐small cell lung
cancer (NSCLC).
Methods: This cohort study was conducted in the HealthCore Inte-
grated Research Database (HIRD), which contains claims data from
across the US restricted to 2010–2018. We applied the previously
defined algorithms to the HIRD to define five cohorts of a/m cancer.
Cohort characteristics were described at a/m diagnosis and incidence
of 62 pre‐specified, fatal and non‐fatal safety events were described
after initiation of any systemic anticancer therapy including
immunotherapy.
Results: Algorithm‐defined a/m patients resulted in the following
cohorts: 12,659 OC, 1,401 UC, 6,253 GC, 625 MCC and 38,451
NSCLC patients. The majority of patients in each cohort were de novo
a/m, but a subset was diagnosed at early stage and progressed to a/m
stage: from 3.3% for OC to 23.1% for UC with a mean time to a/m
ranging from 245 to 470 days. Between 35% (MCC, UC) and 60–
65% (GC, OC, and NSCLC) of patients received any systemic antican-
cer therapy during follow‐up (most commonly alkylating agents). Most
frequent safety events, regardless of causality to treatment, included
infusion‐related reactions, serious infections, nausea and vomiting,
abdominal pain, and anemia (nearly all >20 events per 100 person‐
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years in all cohorts). In the subgroups of patients initiating immuno-
therapy (>5,000 overall) rates were similar or varied modestly com-
pared with those after any anticancer therapy.
Conclusions: Using large cohorts of a/m cancer patients identified
through predictive algorithms in claims data, this study found high rates
of safety events, as expected in this population. The rates of selected
safety events did not differ widely for users of immunotherapy com-
pared to any systemic therapy.
149 | Association of Continuity of Care &
Mortality for breast cancer patients with
comorbidities
Ning Cheng1; Jingjing Qian1; Joel Farley2; Peng Zeng1;
Chiahung Chou1; Richard Hansen1
1Auburn University, Auburn, AL; 2University of Minnesota, Minneapolis,
MN
Background: Breast cancer patients with comorbidities have high mor-
tality risk and need to see multiple healthcare providers.
Objectives: To examine the association of continuity of care (COC) &
mortality for breast cancer patients with comorbidities.
Methods: A retrospective cohort study of newly diagnosed female
breast cancer patients (n = 57,578) with comorbidities (hypertension,
hyperlipidemia, and diabetes) was conducted using SEER‐Medicare
data (2006–2014). The primary outcome was all‐cause mortality
(assessed annually for up to 5 years). COC index, a validated measure
accounting for both the frequency and dispersion of healthcare pro-
vider visits, was measured yearly with a scale of 0 (dispersed) to 1
(concentrated) in five ways: Specialty COC (unique specialist groups:
Primary Care Physicians (PCP), Oncologists, and Other specialists
(Other)), Individual COC (all individual providers regardless of spe-
cialty), PCP COC (all individual PCP), Oncologist COC (all individual
Oncologists), and Other COC (all individual Other). Cox proportional‐
hazards models estimated the hazard ratio (HR) of all‐cause mortality
associated with COC quartile.
Results: The average scores increased slightly across the study
period for all five COC Indices (p < 0.05) Patients with stage IV
breast cancer had the highest Specialty COC, Individual COC, and
Oncologist COC than others (p < 0.05). Patients with 3 comorbidi-
ties had the highest PCP COC than others. Patients' crude mortality
rate decreased with survival time and negatively associated with
advanced tumor stages and more comorbidities (p < 0.05). Patients
had high continuity of care based on Specialty COC (4th vs. 1st quar-
tile, HR 1.45, 95%CI 1.33–1.58) and Oncologist COC (3rd vs. 1st
quartile, HR 1.50, 95%CI 1.27–1.78) had higher mortality risks com-
pared with those who had low COC. However, patients had high
continuity of care based on Individual COC (4th vs. 1st quartile, HR
0.54, 95%CI 0.50–0.59), PCP COC (4th vs. 1st quartile, HR 0.35,
95%CI 0.31–0.39), and Other COC (4th vs. 1st quartile, HR 0.37,
95%CI 0.33–0.42) had lower mortality risks compared with those
who had low COC.
Conclusions: This study examined the association between COC and
mortality risk for breast cancer patients. Higher Individual, PCP, and
Other COC levels were related to lower mortality risk. Higher Spe-
cialty and Oncologist COC levels were related to higher mortality
risk, which might be confounded by uncontrolled disease severity
factors. COC should be considered carefully when building the
models of coordinated care and may help to improve the quality of
care for cancer survivorship.
150 | The association between partner
bereavement and first diagnosis and mortality
of melanoma: Population‐based cohort study
Angel Y.S. Wong1; Lara Dearing1; Harriet J. Forbes1; Amy Mulick1;
Kathryn Mansfield1; Richard J. Silverwood1; Henrik T. Sørensen2;
Liam Smeeth1; Sigrún A.J. Schmidt2; Sinéad M. Langan1
1London School of Hygiene and Tropical Medicine, London, UK; 2Aarhus
University Hospital, Aarhus, Denmark
Background: Partnership status may be important in the early detec-
tion of melanoma, and consequently in improved survival. However,
we do not know whether the death of a partner affects the incidence
and mortality of melanoma.
Objectives: To evaluate the association between partner bereavement
and 1) first diagnosis of melanoma and 2) mortality in patients with
melanoma.
Methods: We conducted two cohort studies using routinely collected
data from Clinical Practice Research Datalink between 01/01/1997
and 31/07/2017. Study 1: A matched cohort study comparing inci-
dence of first melanoma diagnosis between bereaved and matched
(on age, sex and general practice) non‐bereaved subjects. We used
Cox regression, stratified by match set to estimate hazard ratios (HR).
Study 2: A cohort of individuals withmelanomawhowere part of a cou-
ple andwere eligible for linkagewithOffice for National Statistics (ONS)
death registration data. We used Cox regression to estimate the risk of
death (melanoma‐specific and all‐cause mortality) in those whose part-
ner died compared to those whose partner was alive (partner bereave-
ment defined as a time‐varying variable). As a sensitivity analysis, we
repeated the analysis in Study 2 for all‐cause mortality without
restricting to those with ONS linkage. All analyses were adjusted for
Charlson Comorbidity Index, smoking status, body mass index, alcohol
consumption and socioeconomic status. Missing data were handled by
complete case analysis.
Results: In Study 1, we included 150,547 bereaved and 1,306,385
matched non‐bereaved subjects. We observed a lower risk of incident
melanoma (HR: 0.86; 95% CI: 0.79–0.94) post‐bereavement in the
bereaved compared with non‐bereaved during the entire follow‐up. In
Study 2, we included 3,233 patients with melanoma. We found some
evidence of an increased risk of all‐cause mortality (HR: 1.23; 95% CI:
0.98–1.54) but little evidence of any increased risk ofmelanomamortal-
ity (HR: 1.28; 95% CI: 0.88–1.86) associated with bereavement, possi-
bly due to limited power. In the sensitivity analysis, we confirmed the
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increase in all‐cause mortality associated with bereavement (HR: 1.31;
95% CI: 1.15–1.50) among 8,373 patients with melanoma.
Conclusions: We found a decreased risk of melanoma diagnosis,
but increased mortality associated with partner bereavement.
These findings may be partly explained by delayed detection as
a result of the bereaved not having a partner to notice skin
changes. Results from a parallel study using Danish registries,
including information on melanoma stage, are pending and will
be presented.
151 | Incidence and trends of melanoma skin
cancer in the United States, 1999–2016
Phuong Le1; Chi Le2; Chi Truong3; Hoa Le4
1University of Toronto, Mississauga, ON, Canada; 2School of Medicine,
Vanderbilt University, Nashville, TN; 3MedCodeWorld LLC, Chapel Hill,
NC; 4PAREXEL, Durham, NC
Background: Cutaneous melanoma is the sixth most common malig-
nancy in U.S. While data from the Surveillance, Epidemiology and
End Results (SEER) program are essential to incidence estimations of
melanoma, under‐reporting and delays in reporting have remained
major limitations. Surveillance is hindered by the absence of mela-
noma on states' reportable disease list and possible omission of outpa-
tient diagnoses from hospital registries. Thus, the exact incidence of
melanoma has not been accurately known.
Objectives: To determine melanoma incidence and trends from 1999
to 2016 in a nationally representative sample of the US.
Methods: New melanoma cases among adults aged ≥20 years were
identified from the National Health and Nutrition Examination Sur-
vey (NHANES), 1999–2016. Crude and age‐adjusted incidences
of melanoma and 95% CIs were estimated by survey year cohorts
(1999–2006 and 2007–2016) based on the 2000 US standard pop-
ulation. Sex and age‐stratified longitudinal trends were evaluated in
age and sex‐adjusted regression models. Statistical analyses
accounted for complex survey design, including examination sample
weight, and adjusted for nonresponse. Sensitivity analyses included
unadjusted modeling and modeling adjusted for sex, age or different
age groups. A 2‐sided p‐value of.05 was used to determine statistical
significance.
Results: Among 47,172 adults and 21,192 non‐Hispanic whites from
1999–2016, the overall age‐standardized incidences of melanoma per
100000 persons were 76.9 (95% CI: 46.2–107.7) and 97.6 (95% CI:
56.0–139.3), respectively. The median age at first melanoma diagnosis
was 70.7 (mean = 67.1, IQR = 57.6–79.6 years). The incidence was
higher in men than in women (94.3 vs 50.5 per 100000 persons,
p = .04) and increased with older age (p < .001). Between 1999–2006
and 2007–2016, the incidence of melanoma was significantly higher
in those older than 70, 75, and 80 (p ≤ .02). Growths in incidence were
also observed in overall population, men, women, and by approximately
40% among those older than 70. The results of sensitivity analyses
showed similar increasing trends.
Conclusions: Our incidence rates for all melanoma were high, partic-
ularly in the elderly. Our findings of risk factors for melanoma con-
firmed findings of previous studies. From 1999 to 2016, melanoma
incidence substantially increased among those older than 70, a
concerning observation given the aging US population. As under-
standing susceptible groups help tailor public health interventions,
our study provided an updated depiction of melanoma incidence
and trends in U.S.
152 | Characteristics of patients with small
cell lung cancer in the real‐world setting: A
systematic review
Asieh Golozar1; Mareva Faure2; Aurore Bergamasco3; Kevin Chen2;
Teigna Arredondo‐Bisonó3; Yola Moride4
1AstraZeneca, Gaithersburg, MD; 2YOLARX Consultants, Montreal, QC,
Canada; 3YOLARX Consultants, Paris, France; 4YOLARX Consultants and
Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada
Background: Patients with poor performance status (PS) ≥2 are gen-
erally underrepresented in clinical trials. Describing patients' charac-
teristics outside clinical trials setting would help better characterize
unmet needs.
Objectives: To systematically review and describe characteristics of
SCLC patients, overall and according to sub‐types; extensive stage
(ES) and limited stage (LS).
Methods: A systematic review of observational studies was conducted
using MEDLINE and Embase databases between January 1998 and
October 2018. Pragmatic searches of the gray literature were con-
ducted to identify additional sources. Studies reporting
epidemiological data on SCLC were independently screened, adjudi-
cated and data were abstracted by two assessors, with conflicts
resolved by a third.
Results: Of the 2,418 sources identified, 394 were reviewed in
depth and 140 were retained. An additional 28 sources were
identified through pragmatic searches yielding a total of 168.
Median age at diagnosis (reported in 32 studies) ranged from 54
to 74 years. Sex distribution was reported in 86 studies, with a
male predominance irrespective of stage. Eastern Cooperative
Oncology Group PS was reported in 30 studies. The majority of
studies were hospital‐based (n = 28, 93%) and data mainly origi-
nated from medical records or chart review (22, 73%). PS was
assessed at baseline or at the time of diagnosis in 26 studies.
Twenty‐three (77%) studies reported poor PS status for >25% of
the SCLC population, with six reporting poor PS in ≥50% of the
SCLC population. The proportion of SCLC patients with poor PS
ranged from 14% to 88%. Findings were heterogeneous across
studies due to the variability in thresholds used to define the cate-
gories, study setting and inclusion of both LS‐ and ES‐SCLC patients
for reporting. For studies reporting PS by stage (n = 4), the propor-
tion of patients with poor PS ranged from 13% to 53% in ES‐SCLC
and 11% to 12% in LS‐SCLC.
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Conclusions: A significant percentage of patients with SCLC outside
clinical trials present with a poor PS. LS‐SCLC patients have a better
PS. Prevalence of poor PS was higher for ES‐SCLC and the reported fig-
ures are higher compared to non‐small cell lung cancer.
153 | Incidence estimates and trends of non‐
melanoma skin cancer in the United States,
1999–2016
Chi Le1; Phuong Le2; Chi Truong3; Hoa Le4
1School of Medicine, Vanderbilt University, Nashville, TN; 2University of
Toronto, Mississauga, ON, Canada; 3MedCodeWorld LLC, Chapel Hill,
NC; 4PAREXEL International, Durham, NC
Background: As themost commonmalignancy in theUnited States, skin
cancer is associated with significant morbidity and healthcarecosts.
Non‐Melanoma Skin Cancer (NMSC), including basal cell carcinoma
and squamous cell carcinoma, accounts for the majority of skin cancer
cases. Due to sparse reporting to national cancer registries, the exact
incidence of NMSC is unknown. Recent estimates primarily relied on
county‐specific electronic medical records and Medicare databases,
posing limitations to application to the general US population.
Objectives: To investigate the incidence and trends of NMSC
from 1999 to 2016 in a US nationally representative sample.
Methods:WeidentifiednewNMSCcases amongadults aged≥20years
in the National Health and Nutrition Examination Survey (NHANES).
The crude and age‐adjusted incidences of NMSC and 95% CIs were
estimated. Further analyses stratified incidence by sex, race/ethnicity,
age groups, and survey year cohorts (1999–2008 and 2009–2016)
based on the 2000 US standard population. Age and sex adjusted
regression models were applied to investigate longitudinal trends.
Race/ethnicity was also examined for race‐specific patterns. Statistical
analyses were accounted for the complex survey design including
examination sampling weights, which adjusted for nonresponse, and a
2‐sided p‐value of.05 for statistical significance. Sensitivity analyses
including unadjustedmodeling,modeling adjusted for sex only, age only,
modeling with different age groups, and a stricter NMSC definition
were performed.
Results: Among 47,172 adults and 21,192 non‐Hispanic whites from
1999–2016, the overall age‐standardized incidence of NMSC per
100000 persons was 319.5 (95% CI: 248.3–390.7) and 423.3 (95% CI:
327.1–519.5), respectively. The incidence in men was significantly
higher compared to that in women (394.1 vs 258.5, p = .02). In all
groups, incidence rose with age (p < .001). From 1999–2008 to 2009–
2016, the overall incidence of NMSC significantly increased from
232.2 to 414.5 (p = .01). Rising incidence was also observed among
women and those above 70, 75, and 80 years of age (p ≤ .02). Similar
trends were also found through sensitivity analyses (p < 0.05).
Conclusions: Over the study period 1999–2016, the incidence of
NSMC nearly doubled in all adults, non‐Hispanic whites, women, and
among those 70 years and older, a concerning observation given the
aging population. Our study findings provided an updated understand-
ing of NMSC incidence in the US general population and susceptible
subgroups. The observed rising incidence called for greater improve-
ment in prevention.
154 | Real world treatment patterns, adverse
events and healthcare resource utilization and
costs among chronic lymphocytic leukemia
(CLL) patients in the US
Shaum Kabadi1; Temitope O. Olufade1; Lisa Le2;
Stacey Dacosta Byfield2
1AstraZeneca LP, Gaithersburg, MD; 2Optum, Eden Prairie, MN
Background: Treatment options for CLL have expanded in recent
years, but few studies provide real‐world data on treatment patterns
and outcomes associated with these agents.
Objectives: To evaluate treatment patterns, adverse events (AEs),
healthcare resource utilization (HCRU), and costs associated with
CLL‐directed therapy in patients with CLL.
Methods: This retrospective study used medical and pharmacy claims
from the Optum Research Database to identify commercially insured
and Medicare Advantage (MA) enrolled adults. Patients included had
CLL (≥ 2 medical claims ≥7 days apart between July 1, 2012 to May
31, 2017), at least 1 claim for systemic CLL‐directed therapy and con-
tinuous enrollment for 12 months prior to (baseline period)
and ≥ 1 month after the first observed CLL‐directed therapy (index
date). Patients receiving CLL therapy in the baseline period or stem cell
transplantation in the entire study period were excluded. Up to 3 lines
of therapy (LOT) were captured. Cohorts based on the most common
regimens received, regardless of LOT sequence, were created. Poten-
tial treatment‐related AEs were identified by ICD‐9 and ICD‐10 diag-
nosis codes on claims. All‐cause and AE‐related healthcare resource
utilization and costs (per patient per month (PPPM)) were examined.
All analyses were descriptive.
Results: A total of 3292 patients with CLL met all study criteria (65%
MA enrollees; 35% commercially insured). Mean age was 71 years
(SD 11) with a baseline Charlson comorbidity index score of 3.5
(SD 1.9). Overall, 31% of patients had ≥2 LOTs and 10% had ≥3
LOTs. The most common regimens (excluding rituximab (R) mainte-
nance therapy) observed by LOT were; bendamustine + R (23%) in
LOT1, ibrutinib (22%) in LOT2 and ibrutinib (17%) in LOT3. Overall,
4,509 LOT periods (LOT1‐LOT3) were observed, 3177 of these were
the 5 most common treatment regimens: R (excluding maintenance
therapy) (30%); bendamustine + R (28%); ibrutinib (20%);
obinutuzumab ± chlorambucil and chlorambucil only (14%); and
cyclophosphamide + fludarabine + R (8%). The most common AEs
associated with these treatments were anemia (34%), hypertension
(33%) and infection (32%). AEs associated with the highest mean
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PPPM costs were renal failure ($14,237), stroke ($8,037), myocardial
infarction ($6,976) and neutropenia ($6,787).
Conclusions: This study shows that occurrence of AEs in patients with
CLL receiving systemic therapy in the real‐world setting is substantial
and associated with significant healthcare cost. The economic burden
associated with AEs underscores the need for treatments with fewer
AEs.
155 | Risk of primary urological and genital
cancers following incident breast cancer: A
Danish population‐based cohort study
Jens Sundbøll1; Dóra Farkas1; Lidia Schapira2; Suzanne Tamang2;
Mette Nørgaard1; Mark Cullen2; Deirdre Cronin‐Fenton1;
Henrik T. Sørensen1
1Aarhus University, Aarhus, Denmark; 2Stanford University, Stanford, CA
Background: Screening programs and improved treatments have
increased the prevalence of long‐term breast cancer survivors.
Chemotherapy, radiation, and anti‐hormonal therapies for breast
cancer may increase the risks of subsequent urological and genital
cancers.
Objectives: To examine the risk of primary urological and genital
cancers in patients with a history of breast cancer and to compare
this cancer risk with that of the general population.
Methods: Using population‐based Danish medical registries, we
conducted a nationwide population‐based cohort study of female
patients (>18 years) diagnosed with primary breast cancer and
restricted to patients with localized cancer or regional spread dur-
ing 1978–2013. We followed them for any subsequent urological
or genital cancer registered in the Danish Cancer Registry. We
computed cumulative incidences, accounting for the competing risk
of death. As relative risk measure, we computed standardized inci-
dence ratios (SIRs) with 95% confidence intervals (CIs) as the
observed number of cancers relative to the expected number
based on national incidence rates by age (5‐year intervals) and cal-
endar year (5‐year intervals).
Results: Among 96,374 female patients with a history of breast cancer
(median age 61 years), we observed 1397 genital cancers and 538 uro-
logical cancers during a median follow‐up of 6.1 years. The cumulative
incidence was 1.3% for any genital cancer and 0.4% for any urological
cancer after 10 years of follow‐up. SIRs were increased for cancers of
the uterus (1.27, 95% CI: 1.17–1.37) and ovary (1.39, 95% CI: 1.27–
1.51), but approximated unity for cancers of the external female gen-
italia (0.97, 95% CI: 0.73–1.28), vagina (1.31, 95% CI: 0.80–2.02), cer-
vix (0.78, 95% CI: 0.66–0.92), kidney (0.98, 95% CI: 0.83–1.15), renal
pelvis (1.20, 95% CI: 0.86–1.64), ureter (0.92, 95% CI: 0.42–1.76),
and urinary bladder (1.13, 95% CI: 1.02–1.26). The SIR estimates
remained largely unchanged when restricting to cancers occurring
after 12 months of follow‐up for all types of cancer.
Conclusions: Breast cancer survivors had higher risks of cancers of the
uterus and ovary than expected, possibly related to tamoxifen therapy
or the BRCA genotype. Although the absolute risks were relatively low,
our findingsmerit increased attention to these cancer types during clini-
cal follow‐up of patients with a history of breast cancer.
156 | Hysterectomy utilization among newly
diagnosed endometrial cancer patients by
body mass index category: A real‐world
analysis using a claims and electronic health
record database
Ellen Thiel; Debra Irwin
IBM Watson Health, Ann Arbor, MI
Background: For endometrial cancer (EC), laparoscopic hysterectomy
(LH) is an effective, minimally invasive surgical treatment; however, this
approachmay not be recommended for obese patients due to increased
risk for complications.
Objectives: The aim of this study was to measure the rates of LH and
subsequent ER visits and rehospitalizations among EC patients strati-
fied by body mass index (BMI) categories.
Methods: This retrospective study utilized insurance claims linked to
electronic health record (EHR) data contained in the IBM MarketScan
Explorys Claims‐EHR Data Set. Newly diagnosed EC patients (1/1/
2007–6/30/2017)with continuous enrollmentduring a12‐monthbase-
line and 6‐month follow‐up period were selected. Patients were strati-
fied into four BMI subgroups based on baseline BMI on the EHR:
normal or underweight (BMI <25), overweight (BMI 25‐ < 30), obese
(BMI 30‐ < 40), morbidly obese (BMI >40), and were required to have
had a hysterectomywithin the follow‐up period. Emergency room visits
and rehospitalization within 30 days of hysterectomyweremeasured.
Results: A total of 1,090 newly‐diagnosed EC patients met the selec-
tion criteria, of whom, 16% were normal/underweight, 19% were
overweight, 39% were obese, and 26% were morbidly obese. The pro-
portion of patients receiving LH increased as BMI category increased:
53% among normal/underweight, 59% among overweight, 59%
among obese, and 63% among the morbidly obese. Among those
who received LH, rates of ER visits or rehospitalizations were lower
than those receiving non‐LH hysterectomy across all BMI strata,
including the obese (11% in LH vs. 19% in non‐LH) and morbidly
obese (9% in LH vs. 15% in non‐LH).
Conclusions: This real‐world analysis shows that LH is utilized in a high
proportion of morbidly obese EC patients, despite that it is frequently
deemed infeasible in this patient population. Although the rate of ER
visits and rehospitalization is lower among LH patients than those
undergoing traditional hysterectomy across all BMI strata, the rates
for these costly rehospitalizations are still burdensome and further
research is needed to determine the optimal patient population to
receive LH.
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157 | Risk of cancer in patients with
psoriasis/psoriatic arthritis: A population‐
based study in the province of British
Columbia
J. Antonio Avina‐Zubieta1; Alyssa Dominique2; Teresa A. Simon2;
Hamid Tavakoli1
1Arthritis Research Canada, Richmond, BC, Canada; 2Bristol‐Myers
Squibb, Princeton, NJ
Background: Psoriasis (PsO) is a relapsing chronic autoimmune disease
of the skin. Up to one‐third of patients (pts) also develop inflammatory
arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms
of chronic inflammatory arthritis, are often associated with complica-
tions such as cardiovascular disease and infections. However, data on
the risk of cancer in pts with PsO/PsA at population level are limited.
Objectives: To assess the risk of cancer in pts with newly diagnosed
PsO/PsA at the population level.
Methods: We created a population‐based matched retrospective
cohort of pts with PsO/PsA diagnosed between January 1, 1997 and
December 31, 2012 using administrative health data from British
Columbia, Canada. We identified all incident cases of PsO/PsA and
an equal number of controls matched on sex, age and calendar year.
PsO/PsA cases met ≥1 of the following: 1 diagnostic code for PsO/
PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for
PsO/PsA, ≥2 months apart in a 2‐year period by a non‐rheumatolo-
gist/dermatologist; or ≥ 1 hospitalization with diagnostic code for
PsO/PsA. We evaluated incident cancers during follow‐up from the
Cancer Registry in both cohorts. Adjusted risk of cancers was esti-
mated using a generalized estimating equation extension of multivari-
ate Poisson regression models.
Results: We identified 81,568 incident cases of PsO/PsA (mean age
48.5 years [SD 17.8], 51.5% female). Individuals with PsO/PsA were
at significantly higher risk of being diagnosed with 8/41 types of
cancer examined, including eye and orbit (4 fold; incidence rate ratio
[IRR] 4.25 [95% CI: 1.21, 14.91]); female genital other than cervix
uteri, corpus uteri and ovary (3 fold; IRR 2.57 [95% CI: 1.55,
4.25]); non‐melanoma skin (2 fold; IRR 1.82 [95% CI: 1.54, 2.14]);
and prostate (males; 1.1 fold; IRR 1.12 [95% CI: 1.01, 1.25]). Inci-
dence of rectal (IRR 0.79 [95% CI: 0.64, 0.98]) and colon (IRR 0.84
[95% CI: 0.72, 0.99]) cancer was lower among pts with PsO/PsA rel-
ative to the non‐PsO/PsA cohort.
Conclusions: This general population‐based study demonstrates that
pts with PsO/PsA have an increased risk of several types of cancer,
and a decreased risk of rectal and colon cancer. This association high-
lights the need to further explore potential risk factors and pathways
that contribute to these complications.
Original abstract (c) EULAR/BMJ. First presented at EULAR 2018 and
published in Ann Rheum Dis (OP0130). Any reprints, promotional
options, education material etc have to be done through the original
source (ARD/BMJ).
158 | Epidemiology of cholangiocarcinoma in
adults with type 2 diabetes in the United
Kingdom clinical practice research datalink
Ayad K. Ali1; Syed W. Hassan2
1Eli Lilly and Company, Indianapolis, IN; 2Eli Lilly and Company, Erl Wood
Manor, UK
Background: Cholangiocarcinoma (CCA) and other bile duct tumors
are rare malignancies; however, CCA accounts for 10–20% of all liver
cancers and 3% of all gastrointestinal cancers. Recently, metabolic
syndrome has been considered as a risk factor for CCA, but the epide-
miology of CCA in patients with type 2 diabetes mellitus (T2DM) is not
well characterized.
Objectives: To calculate the incidence and prevalence rates of CCA in
adults withT2DM compared to general population without diabetes in
the U.K.
Methods: Electronic medical records of >17 million adults (≥18 years
old) enrolled in the U.K. Clinical Practice Research Datalink (CPRD)
between January 2007 and April 2018 were used to calculate the inci-
dence (per 100,000 person‐years) and prevalence (in %) of CCA
among adults with T2DM and adults without diabetes. Read diagnosis
codes were used to define CCA and T2DM. Results were stratified by
gender, age groups, and body mass index (BMI) categories of (in kg/
m2) <18.5 (underweight); 18.5–24.9 (healthy weight); 25.0–29.9
(overweight); 30.0–34.9 (obese); 35.0–39.9 (severely obese);
and ≥ 40.0 (morbidly obese).
Results: During the analysis period, a total of 502,615 adults with
T2DM and 16,628,872 adults without diabetes were followed.
The incidence rate (per 100,000 person‐years) of CCA among
patients with T2DM was 11.0 (95%CI = 10.0–13.0), and in those
without diabetes was 1.0 (95%CI = 1.0–2.0). Corresponding prev-
alence rates were 0.13% and 0.02%, respectively. There was no
difference in the epidemiology of CCA between men and women
with T2DM. The rates were increasing with age: incidence (18–
44 years, 2.0; 45–54 years, 6.0; 55–64 years, 8.0; 65–74 years,
20; and ≥ 75 years, 17); prevalence (18–44 years, 0.02%; 45–
54 years, 0.05%; 55–64 years, 0.08%; 65–74 years, 0.18%;
and ≥ 75 years, 0.16%). Unlike general population, where rates
increased by BMI, the rates were bimodal among those with
T2DM, where higher rates observed in underweight and over-
weight patients: incidence (underweight, 20; healthy weight, 10;
overweight, 12; obese, 10; severely obese, 10; and morbidly
obese, 10); prevalence (underweight, 0.34%; healthy weight,
0.16%; overweight, 0.14%; obese, 0.11%; severely obese, 0.10%;
and morbidly obese, 0.09%).
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Conclusions: Compared to general population, patients with T2DM
have markedly higher incidence and prevalence rates of CCA.
159 | Risk of primary gastrointestinal
cancers following incident breast cancer: A
Danish population‐based cohort study
Kasper Adelborg1; Dóra K. Farkas1; Lidia Schapira2; SuzanneTamang2;
Deirdre C. Fenton1; Mark Cullen2; Henrik T. Sørensen1
1Aarhus University Hospital, Aarhus, Denmark; 2Stanford University, Palo
Alto, CA
Background: Development of new primary malignancies among breast
cancer patients may be a public health problem, as the number of
breast cancer survivors is growing.
Objectives: To examine the risk of primary gastrointestinal cancers in
female patients (>18 years) with breast cancer and to compare this
cancer risk with that of the general population. Such data may provide
insight into the clinical course following breast cancer and inform
screening guidelines for this population.
Methods: Data from the Danish Cancer Registry were used in this
nationwide population‐based cohort study of all patients with pri-
mary breast cancer with localized cancer or regional spread
(1978–2013). The outcome measures were subsequent occurrence
of gastrointestinal cancers. We calculated absolute cancer risks,
accounting for the competing risk of death. As a measure of rela-
tive risk, we computed standardized incidence ratios (SIRs), as the
observed number of cancers relative to the expected number based
on national incidence rates by age (5‐year intervals) and calendar
year (5‐year intervals).
Results: A total of 96,374 female patients with breast cancer
(median age, 61 years) were identified. During a median follow‐up
of 6.1 years, 2,205 new primary gastrointestinal cancers were
recorded. The cumulative incidence of any gastrointestinal cancer
was 0.1% after 6 months, increasing to 1.9% after 10 years. There
were weak positive associations with esophageal cancer [SIR, 1.19,
95% confidence interval (CI): 0.96–1.47], stomach cancer [SIR,
1.35, 95% CI: 1.17–1.55], cancer of the small intestine (SIR, 1.19,
95% CI: 0.81–1.69), and anal cancer (SIR, 1.24, 95% CI: 0.92–1.65).
No meaningful associations were found with colon cancer (SIR,
1.04, 95% CI: 0.98–1.11), rectal cancer (SIR, 1.06, 95% CI: 0.97–
1.17), pancreatic cancer (SIR, 1.07, 95% CI: 0.96–1.20), or bladder
and biliary tract cancers (SIR, 0.92, 95% CI: 0.73–1.15). Slightly
reduced risk was observed for liver cancer (SIR, 0.68, 95% CI:
0.50–0.90). The SIR estimates were largely unchanged when
restricting to cancers occurring beyond 1 year.
Conclusions: Breast cancer was not associated with increased risk of
gastrointestinal malignancies and thus no additional screening is war-
ranted for breast cancer survivors.
160 | International comparison of cancer
burden and Medicaloutcomes between 11
Asian countries and 23 cancer types(2018): A
linear Mutilevel model analysis
Joanne Lo1,2
1 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan, Taiwan; 2School of
Pharmacy, College of Medicine, National Cheng Kung University, Tainan,
Taiwan
Background: Cancer is the most serious of the global burden of dis-
ease, and it is becoming the top of the leading causes of death. Under-
standing the current state of the cancer epidemic in a country's region
benefits the rational resource allocation of health care in the country.
However, only a few studies have explored the variation of cancer dis-
ease burden and medical outcomes between countries and cancer
types in Asia.
Objectives: Focusing on countries in Asia, this study aims to explore
the diversities of the cancer epidemics between countries, and the
associations between economic/geographical factors these cancer
epidemics. In addition, we also analyzed the variations of the cancer
epidemics between cancer types by using both descriptive and infer-
ential statistics.
Methods: The epidemic data of 23 cancer types among 11 Asian coun-
tries was acquired from Cancer Today, part of GLOBOCAN 2018 pro-
ject, produced by the International Agency for Research on Cancer
(IARC). We collected the prevalence (represent the disease burden)
and calculated the mortality to incidence ratios (MIRs) (represent the
medical outcomes). Descriptive statistic and the box plot were applied
to show the variations of prevalence and MIRs between countries and
cancer types. Linear Multilevel Model (LMM) was used to estimate the
associations between multilevel factors (gender, cancer types, geo-
graphic area and economy level) and disease burden and medical
outcomes.
Results: Among Asian countries, South Korea and Singapore had the
largest variations in cancer prevalence and MIR. High‐income coun-
tries (Japan, Korea, Singapore) had lower MIRs significantly, while no
significant association between economic level and prevalence was
found. Both prevalence and MIRs were not much different between
geographic areas. Among all cancer types, endocrine cancer had the
largest variation in prevalence, and head and neck cancers had the
greatest variation in MIRs. The prevalence was significantly higher
for digestive and reproductive cancers, and the MIRs of respiratory
cancers were significantly higher.
Conclusions: This study compared the differences between Asian
countries by analyzing the latest cancer epidemiological data in the
world, and explored the correlation between cross‐level factors and
disease burden/medical outcomes. The results can be used as a
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reference for future national cancer prevention and treatment related
policy planning and development.
161 | Use of claims and electronic medical
data to describe care pathway for newly‐
diagnosed colorectal cancer patients
Juliane Mills1; Shady Gendy1; Deepa Kumar1; Bettina K. Rillmann2;
Margaret S. Richards3; Jane Quigley1
1PRA Health Sciences, Blue Bell, PA; 2PRA Health Sciences, Mannheim,
Germany; 3PRA Health Sciences, South Kingston, RI
Background: Real‐world data sources can be used to assess the feasi-
bility of a proposed study design and inform changes that could mini-
mize disruptions and burden to participating patients and investigators.
Objectives: The primary objective is to evaluate the use of real‐world
data to describe the care pathway of newly‐diagnosed colorectal can-
cer (CRC) patients from colonoscopy to first treatment (eg., chemo-
therapy, surgery). The secondary objective is to assess for a
correlation with time to first treatment and severity of disease.
Methods: This research analyzed a combination of disparate but
linkable data sources to describe the care pathway from the time of
colonoscopy to first treatment for adult CRC patients diagnosed
within the US. The study utilized an encrypted anonymized patient
key that links the patient activities across all data sources to ensure
individual patient‐level data is anonymous and protected consistent
with US HIPAA rules. US outpatient medical and prescription data
linked to electronic medical records were used. Patients age 18 or
older who were diagnosed with CRC in the period June 2015 to June
2018 as defined by diagnosis codes for colorectal cancer diagnosis and
with colonoscopy prior to or at diagnosis and a treatment post diagno-
sis were included. First treatment was defined as first recorded claim/
prescription for any of first‐line chemotherapy or surgical intervention.
The care pathway was described in terms of type of procedures done
concurrently with colonoscopy and types of treatment at time colo-
noscopy and within subsequent weeks.
Results: Over 9000 patients with evidence of CRC diagnosis were
identified within the claims and medical data set. Of these patients,
a final dataset of 1865 patients were selected based on evidence of
endoscopy within 6 mos prior to diagnosis, availability of data for first
line of treatment, and excluded patients without a diagnosis date or
with Stage III or IV disease without prescription data. Within the final
dataset, 6 care pathways characterizing types of tests and surgical
procedures were identified from time of diagnosis to first treatment
among Stage I ‐ IV patients.
Conclusions: Using a combination of US claims and medical data from
a discrete population of patients with colorectal cancer identified
based on data completeness and diagnosis and procedures codes, it
is possible to identify and define care pathways based on disease
stage. This information can be used to optimize real‐world protocols
that maximize the likelihood of identifying eligible patients and mini-
mize the burden of study participation to patients and investigators.
162 | Lymphovascular invasion: Strong
factor in AA
Yesenia Rodríguez
Institute of Health Technology Assessment and Research (IETSI), Lima,
Peru
Background: Although node‐negative disease is the major prognostic
factor for survival in ampullary adenocarcinoma (AA), a subgroup of
patients experience cancer death. There is strong evidence that the
presence of lymphovascular invasion (LVI) can suggest occult
micrometastases and therefore could identify at risk node‐negative
patients in gastric and colon cancers, however its importance in AA
still unknown.
Objectives: To assess the hazard of LVI in overall survival (OS) of
patients who underwent duodenopancreatectomy (PD) for a node‐
negative AA.
Methods: We performed a retrospective multicenter study of patients
who underwent PD for node‐negative AA between 2002 and 2011 in
Lima, Peru. Pathological reports were reviewed for all patients. Sur-
vival curves were calculated using the Kaplan–Meier method form
post‐surgery until the death for any cause and the relation with ILV
presence. Bivariate and multivariable analysis was performed using
Cox regression analysis. Crude and adjusted Hazard Ratios (HR) con
95% Confidence Intervals (CI) were computed.
Results: 144 patients were included from the most important national
hospitals in Peru. LVI was present in 54 patients (37%). Demographic
and pathologic characteristics were similar between patients with
and without LVI. Risk of LVI increased with T stage (T1, 14%; T2,
31%; T3, 47% and T4, 73%; p = 0.002). Patients with LVI had a shorter
median OS (31 months) in comparison with patients without LVI
(60 months; p < 0.001). On multivariable analysis, LVI (HR = 2.54,
95% CI 1.37–4.571; p = 0.003) was significantly associated with
instantaneous risk of death.
Conclusions: In this study, LVI was a factor associated with higher
instantaneous risk of death in patients who underwent PD for a
node‐negative AA. This result represents a potential evidence that
LVI could identify node‐negative AA patients with shorter survival
who could benefit from adjuvant therapy.
163 | Survival and prognostic factors in
patients with small cell lung cancer: A
systematic review of observational studies
Mareva Faure1; Asieh Golozar2; Aurore Bergamasco3; Kevin Chen1;
Teigna Arredondo‐Bisonó3; Yola Moride4
1YOLARX Consultants, MontrealQC, Canada; 2AstraZeneca,
Gaithersburg, MD; 3YOLARX Consultants, Paris, France; 4YOLARX
Consultants and Faculty of Pharmacy, University of Montreal, Montreal,
QC, Canada
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Background: With limited advances in the management of small cell
lung cancer (SCLC) within the past thirty years, SCLC still imposes a
substantial burden. Identification of prognostic factors will help to
optimize the development of appropriate treatment strategies.
Objectives: To systematically review and describe survival and prog-
nostic factors in SCLC.
Methods: A systematic review of observational studies was conducted
using MEDLINE and Embase over the period 01 January 1998–17
October 2018. Pragmatic searches of the gray literature, including
conference abstracts and proceedings, were also conducted to iden-
tify additional sources. Search outputs were independently screened,
adjudicated and abstracted by two assessors independently, with con-
flicts resolved by a third.
Results: Of the 2,418 sources identified in the literature, 394 were
retained for full text review, out of which 140 were included. In addi-
tion, 28 were identified through pragmatic searches yielding a total of
168 sources. Data mainly originated from Asia‐Pacific (51; 42.2%),
North America (30; 24.8%) and Europe (29; 24%). Eight different mea-
sures of survival were used across 121 studies (102 overall, 40 limited
stage [LS]‐SCLC and 42 extensive stage [ES]‐SCLC): median overall
survival (OS) was the most commonly reported, followed by 1‐ and
5‐year survival rates. A total of 71/102 (69.6%) studies on SCLC,
19/40 (47.5%) on LS‐, and 17/42 (40.5%) on ES‐SCLC reported
median OS. In SCLC, the median OS ranged from 4.6 to 29.1 months,
while it ranged from 10 to 47 months in LS‐SCLC and from 4 to
14.2 months in ES‐SCLC. Survival trend was reported in three studies
using data from SEER registries with a general trend towards an
increase in survival rate when 2‐ and 5‐year survival rates were
reported. When reported (one source), no improvement in OS trend
was noted. Chemotherapy, radiation therapy, prophylactic cranial irra-
diation, performance status, age and sex were among prognostic fac-
tors identified in both stages of SCLC.
Conclusions: SCLC survival rate is low yet variable with significantly
lower rates in ES‐SCLC and minimal changes in survival trend. Signifi-
cant variability exists in measurement and reporting SCLC survival and
survival trend, thus hampering comparability of findings, syntheses of
findings and clinical decision‐making.
164 | Trends and factors associated with
asthma among U.S. prostate cancer patients
in 2007–2014
Nan Huo1; Jingjing Qian1; Kimberly B. Garza1; Chiahung Chou1;
Zeng Peng2
1Auburn University Harrison School of Pharmacy, Auburn, AL; 2Auburn
University, Auburn, AL
Background:
Objectives: To examine trends in the prevalence of and identify fac-
tors associated with asthma among prostate cancer patients, and
treatment patterns among patients with concurrent asthma and pros-
tate cancer.
Methods: A retrospective, cohort analysis was used to identify newly
diagnosed prostate cancer patients (n = 107,285) from the 2007–2014
Surveillance, Epidemiology, and End Results (SEER)‐Medicare data-
base. Prostate cancer patients were identified as primary site cancer
by using ICD‐9 code (185) and ICD‐O site code (619). Asthma was
identified using ICD‐9 codes (493) in 12 months before the initial
prostate cancer (index date) and the ‘Asthma First Ever Occurrence
Date’ flag in the master beneficiary summary file among prostate can-
cer patients and non‐cancer patients (comparison group). Prostate
cancer and asthma treatments were examined in 12 months post‐
index period. Simple linear regression models were applied to test
annual prevalence trends in asthma among prostate cancer patients
and non‐cancer comparison group. Multivariable logistic regression
model was used to identify factors associated with asthma among
prostate cancer patients. Statistical significance was set at P < 0.05.
Results: Annually, about 17% of prostate cancer patients had asthma
comparing with 15% in non‐cancer patients from 2007 to 2014. The
annual trend in prevalence of asthma was stable (trend P = 0.61).
The top three prostate cancer management strategies in the 1st year
after cancer diagnosis were Active Surveillance (14.01% vs. 17.15%),
ADT only (29.74% vs. 24.01%), and ADT plus surgery (8.91% vs.
11.74%) among prostate cancer patients with and without asthma,
respectively. The most frequently used asthma treatment was inhaled
corticosteroids (65.58% vs. 79.23%) among asthma patients with and
without prostate cancer, respectively. Prostate cancer patients who
also had comorbid asthma were more likely to be associated with
older age, non‐Hispanic black, not married, in stage IV prostate cancer,
and with two or more comorbidities.
Conclusions: This study identified a stable trend in comorbid asthma
among U.S. prostate cancer patients. Treatment patterns for prostate
cancer were similar between prostate cancer patients with and with-
out asthma. Understanding burden of and factors associated with
asthma helps practitioners better identify patient's needs and improve
clinical decision making in treatment selection for prostate cancer
patients with comorbidities. Future studies need to investigate how
cancer and asthma treatments affect clinical outcomes for patients
with prostate cancer and comorbid asthma.
165 | Age and race as determinants for
surgical treatment of fibroids: A retrospective
analysis of a large United States electronic
health record database
Georgios Varsos; Fred W. Peyerl; Kunal Lodaya; Meng Shen;
Laxmi Gannu; Apeksha Shenoy; David K. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Fibroids are benign, often asymptomatic tumors of the
uterus that occur in about 80% of women in the United States by
the age of 50, with age and race being important epidemiological risk
factors. Apart from medications, treatment options may include sur-
gery based on severity of symptoms.
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Objectives: The objective of the present study was to assess said risk
factors in fibroid patients and their impact, if any, on surgical rates.
Methods: This retrospective study examined data from aU.S. electronic
health record database (Cerner Health Facts®). All visits, including inpa-
tient (females, age≥ 18 years), between 2012 and 2016with a principal
ICD9/10 diagnosis of fibroids were included in the analysis. Surgical
procedures were identified based on relevant ICD‐9 and CPT codes.
Results: The study included 364,384 fibroid‐related patient visits.
Intramural fibroids were present in 9.3% of visits, while 5.1% had sub-
mucosal fibroids. Majority of visits were in the age group of ‘36–
65 years’ (81.1%), while 45.7% were Caucasian, closely followed by
African‐American (38.5%). However, when compared to the total
patient visits in the database for each race, African‐American women
had a higher number of fibroid‐related visits as compared to Caucasian
women (0.8% vs. 0.2%). As for surgical rates, 15.9% of visits
underwent surgery with rates differing slightly across age groups
(12.1% in the 18–36 age group, 16.7% in the 36–65 age group, and
14.2% in the >65 age group). From the subset of patients undergoing
surgery, 21.2% were Caucasian, followed by Hispanic (13.5%).
Conclusions: The results of the study show a higher prevalence of
fibroid‐related visits in African‐American women compared to other
races. Surgical rates were similar across different age groups, with
Caucasian women showing a higher surgical treatment rate as com-
pared to other races.
166 | Dynamic assessment of stroke risk
among patients with atrial fibrillation in Japan
‐ evidence from J M D C Inc database
Rahul Jain; Lu Zhang; Catherine Richards; Joseph Menzin
Boston Health Economics Inc, Boston, MA
Background: Stroke risk scores, often used to guide stroke prevention
therapy among patients with atrial fibrillation (AF), may vary over time.
A recent study among newly‐diagnosed AF patients in a Taiwanese
population found the 1‐, 2‐, and 7‐year cumulative incidence of an
increase in CHA2DS2‐VASc scores among both men and women to
be approximately 16%, 25%, and 49%, respectively (Chao et al., Ann
Intern Med. 2019). The generalizability of these findings to other
Asian populations is unknown.
Objectives: To investigate the incidence of an increase in CHA2DS2‐
VASc scores to ≥1 (men) or ≥ 2 (women) among newly‐diagnosed
AF patients in Japan.
Methods: This retrospective study used claims data from the JMDC
Inc. database between 1/1/2005 and 5/31/2018. OAC treatment
naïve adults (≥18 years) with ≥1 AF diagnosis between 1/1/2007
and 5/31/2017 were identified. The first day of the month (index
month) of the AF diagnosis was set as the index date. Patients were
required to have ≥12 months of continuous enrollment and no diag-
nosis of AF prior to the index date. Baseline CHA2DS2‐VASc scores
were calculated using all observable records from 1/1/2005 until the
end of the index month; only patients with a score of 0 (men) or 1
(women) were retained. Patients were followed from the index date
until an observed incident score increase or were censored at the start
of OAC therapy or the end of eligibility/data, whichever came first.
Cumulative incidence curves for the increase in CHA2DS2‐VASc
scores were estimated for men and women separately using the
Kaplan–Meier method. All statistical analyses were performed using
the Instant Health Data platform (BHE, Boston, MA, USA).
Results: A total of 1,768 newly‐diagnosed AF patients met all inclu-
sion and exclusion criteria. The mean (SD) age was 44.6 (11.4) years
and 31.1% were female. The mean duration of follow‐up was
27 months. Among men, the cumulative incidence of an increase in
CHA2DS2‐VASc scores at 1, 2 and 7 years was 31% (95%CI: 29%–
34%), 45% (42%–48%), and 74% (70%–78%), respectively. Among
women, corresponding estimates at 1, 2 and 7 years were 22%
(95%CI: 18%–25%), 32% (28%–36%), and 60% (50%–68%). The
cumulative incidence of an increase in stroke risk was higher among
men (log‐rank test p < 0.0001).
Conclusions: Japanese patients with newly‐diagnosed AF experienced
increases in CHA2DS2‐VASc scores over time, with the largest
increases occurring among men. The increase in risk observed in this
study exceeded those found in a Taiwanese AF cohort in the prior
analysis. Our results confirm that the re‐evaluation of stroke risk
among AF patients should be carried out regularly.
167 | Incident unrecognized myocardial
infarction among people with Dysglycemia:
An opportunity for prevention
Janice C. Zgibor; Markku Malmi
University of South Florida College of Public Health, Tampa, FL
Background: Up to 45% of initial myocardial infarctions (MI) are
unrecognized (UMI), which is problematic since they are asymptomatic
and are often only detected during a routine electrocardiogram (ECG),
post‐event. This delayed diagnosis may postpone necessary medical
management of risk factors for the prevention of future MI. The risk
for subsequent events following UMI is similar to MI placing these
individuals at particularly high risk. This is especially problematic
among people with diabetes and prediabetes who are already at high
risk for these events.
Objectives: Our objective was to determine if there was a difference
in the incidence of UMI between those with diabetes or prediabetes
and their subsequent treatment for cardiovascular (CVD) risk factors,
specifically hypertension and hyperlipidemia.
Methods: Data from two cohort studies, the Atherosclerosis Risk in
Communities (ARIC) and the Cardiovascular Health Studies (CHS),
were pooled and analyzed (n = 17623 people with diabetes or predia-
betes). Thirteen years of follow‐up data were available. CHS was an
observational study in adults 65 years or older undergoing annual
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exams from 1989–1999 with subsequent phone follow‐up. ARIC indi-
viduals were aged 45–64 and were examined every three years
through 2013. Definitions: UMI was determined according to Minne-
sota Codes on ECG, prediabetes: fasting glucose 100–125 mg/dL, dia-
betes > = 126 mg/dL or treatment for diabetes, hypertension:
> = 140/90 mmHg, and hyperlipidemia: LDLc> = 100 mg/dL.
Results: The population consisted of 9,567 (54%) with diabetes and
8,056 (46%) with prediabetes. The mean age was 64 and 55 years
respectively. Approximately half the population in both groups were
female and three‐fourths were white. There were 210 UMI events:
0.88% of those with diabetes had UMI while 1.56% of people with
prediabetes experienced UMI. Significant predictors of UMI were pre-
diabetes, male sex, older age, and history of hypertension. Among
those who did not experience UMI, but had a history of hypertension
or hyperlipidemia, people with diabetes were 60% more likely to be
treated for hypertension and 68% more likely to be treated for hyper-
lipidemia compared with people with prediabetes. These treatment
differences were statistically significant (p < 0.0001).
Conclusions: Despite the higher risk for UMI among prediabetes,
those with diabetes were more likely to be treated for hypertension
and hyperlipidemia. This may indicate a lack of awareness for the high
risk for UMI in prediabetes and the need for risk factor treatment for
primary prevention of coronary events in this population.
168 | Sex disparities in cardiovascular risk
and risk factor Management in Type 2
diabetes: A population‐based study of the
clinical practice research datalink
Alison K. Wright1; Evangelos Kontopantelis1; Richard Emsley2;
Iain Buchan3; Mamas A. Mamas4; Naveed Sattar5;
Darren M. Ashcroft1; Martin K. Rutter1,6
1University of Manchester, Manchester, UK; 2King's College London,
London, UK; 3University of Liverpool, Liverpool, UK; 4Keele University,
Stoke‐on‐Trent, UK; 5University of Glasgow, Glasgow, UK; 6Manchester
University NHS Foundation Trust, Manchester, UK
Background: Historically, women developing type 2 diabetes (T2DM)
have experienced a 27–50% greater increase in their risk for cardio-
vascular disease (CVD) than men developing T2DM.
Objectives: With recent changes in UK clinical practice for diabetes
care, we aimed to determine if this gender disparity persists in con-
temporary data and if any disparity could be explained by gender
biases in diabetes management.
Methods: Using the Clinical Practice Research Datalink (CPRD) linked
to hospital admission and death data, we identified 79,985 people with
incident T2DM between 2006–2013 and 386,547 age‐sex‐practice‐
matched controls without diabetes. The primary endpoint was the first
record of fatal and non‐fatal myocardial infarction, stroke or cardiovas-
cular death, identified from primary care, hospital and death records.
Sex‐stratified Cox models were used to assess cardiovascular risk.
Results: Compared to women without T2DM, women withT2DM had
a higher cardiovascular event risk (adjusted HR 1.20 [95% CI 1.12–
1.28]) with similar corresponding data in men (HR 1.12 [1.06–1.19])
leading to a non‐significant 7% excess relative risk in women (risk ratio
1.07 [0.98–1.17]). However, some important sex differences in the
management of risk factors were observed. Compared to men with
T2DM, women withT2DMwere more likely to be obese, hypertensive
and have hypercholesterolaemia but were less likely to be prescribed
statins and ACE inhibitors, especially if they had CVD. In T2DM sub-
groups with CVD, women were less likely to receive antiplatelet
agents than men.
Conclusions: Compared to men developingT2DM, women withT2DM
do not have a significantly higher relative increase in CVD risk, but
ongoing sex disparities in prescribing should prompt heightened
efforts to improve the standard and equity of diabetes care. Particular
attention is required for women with abnormal cardiovascular risk fac-
tors, who may be receiving suboptimal preventative care.
169 | Trend in 3‐day, 7‐day and 30‐day heart
failure readmission rates from 2010 To2015
in the Nationwide readmissions database
Phuong N. Pham; Joshua Brown
College of Pharmacy, University of Florida, Gainesville, FL
Background: Thirty‐day readmission among heart failure patients has
been used as a quality measure in the Hospital Readmission Reduction
Program (HRRP) and are tied to financial penalties for hospitals by the
Centers for Medicare and Medicaid Services (CMS). Although 30‐day
readmission rates have been widely used to evaluate hospital perfor-
mance, there have been many concerns about the validity of the met-
ric, including the choice of the 30‐day interval.
Objectives: This analysis evaluated the trends in 3‐day, 7‐day, and 30‐
day readmissions for heart failure in Medicare beneficiaries between
2010 to 2015 to determine how this policy has influenced hospital
quality.
Methods: The Nationwide Readmission Database (NRD) from 2010 to
2015 was used which contains a national sample of hospital discharges
and readmissions. Patients aged≥65 years‐old with a primary diagnosis
of HF and Medicare insurance during January to November each year
were included.We excluded patientswho died during index hospitaliza-
tion, were transferred, discharged against medical advice, and with
missing data. The measures of interest were 3‐day, 7‐day, and 30‐day
unplanned, all‐cause readmissions as a proportion of index admissions.
Multiple index admissions per patient were considered but could have
only one readmission. The second outcome of interest was the relative
reduction in the proportion of readmissions. Adjusted readmission rates
were calculated for each year controlling for patient demographic, hos-
pital, and clinical characteristics between years using hierarchical logis-
tic regression models. Cochran‐Armitage Trend Tests were used to
assess the trend in adjusted readmission rates between years.
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Results: Overall trends showed a decreased readmission rate between
2010 and 2015 and was statistically significant for trend (P < 0.001)
for each readmission interval: 23.1% to 20.8% (30‐day); 7.6% to
6.6% (7‐day); and 3.4% to 2.9% (3‐day). Relative percent reduction
in readmission rates in 2015 versus 2010 were 9.9% for 30‐day inter-
val, which was a lower reduction compared to 13.9%, and 14.9% for
7‐, and 3‐day intervals.
Conclusions: We found that shorter readmission intervals (3‐day and
7‐day) had larger relative reductions since the introduction of financial
penalties compared to 30‐day readmissions. The findings support the
assertion that hospitals may be disincentivized by metrics they cannot
influence or that further innovation is needed to differentiate and
intervene on factors that drive shorter versus longer term
readmissions.
170 | Incidence of post‐operative acute
myocardial infarction among adults
undergoing elective spinal fusion, Total hip
and Total knee arthroplasty
Kui Huang; Patrick Arena; Xiaofeng Zhou; Qing Liu; Richard Gong;
Sundaresan Murugesan; Jingping Mo
Pfizer Inc, New York, NY
Background: Acute myocardial infarction (AMI) is one of most serious
complications after elective spinal fusion surgery (SF), total hip
arthroplasty (THA), and total knee arthroplasty (TKA). There is scarce
data on the incidence of AMI in these populations, particularly in
high‐risk sub‐populations and after 30 days post‐operation.
Objectives: To estimate incidence rates (IRs) of AMI among adults
undergoing elective SF, THA, and TKA in different post‐operative
periods and characterize high‐risk sub‐populations in the United
States.
Methods: We conducted a retrospective cohort study using a longitu-
dinal EHR database (Optum EHR) from January 1, 2007 to June 30,
2018. Patients aged 18 to 85 years undergoing elective SF, THA, or
TKA were identified. ICD codes were used to identify SF, THA, TKA,
AMI, and selected clinical characteristics. IRs and 95% confidence
intervals (CIs) were estimated in the following windows: surgical hos-
pitalization, 10, 30, 90, 180, and 365 days post‐operation.
Results: 67,327 SF patients, 88,284 THA patients, and 168,785 TKA
patients were eligible for the study. There were more whites (>88%)
across all surgical types, more females undergoing THA (53%) and
TKA (59%), and more males undergoing SF (57%). The median age
at the index date was 59, 65, and 66 years for SF, THA, and TKA,
respectively. The IR of AMI after SF, THA and TKA per 1000 per-
son‐years decreased consistently from 295.96, 280.37, and 231.85
during surgical hospitalization to 12.77, 11.61, and 10.20 ≤ 365 days
post‐operation, respectively. The IR of AMI was higher among
patients who were older, male, with longer hospital stays (LHS),
had a history of MI, and had a history of diabetes across three types
of surgery at each widow. The LHS could be a result of AMI. Racial
differences were also observed. The IR of AMI was higher among
blacks in TKA at each window and in SF up to the 90 days post‐
operation while the IR of AMI was higher among whites in THA at
each window. Additionally, SF and TKA patients with the same day
revisional surgery had higher IRs of AMI at each window and during
surgical hospitalization, respectively. Patients with exiting perma-
nently implanted devices/prostheses had a higher IR of AMI in
THA and TKA at each window.
Conclusions: Our study showed the IRs of AMI in patients undergoing
elective SF, THA, or TKA were highest during surgical hospitalization
and attenuated over 365 days post‐operative periods. Furthermore,
we identified some high‐risk sub‐populations. Further studies are war-
ranted to confirm these findings by controlling confounding and iden-
tifying effect modifiers.
171 | Evaluating the Charlson and Elixhauser
comorbidity index to predict acute
cardiovascular disease survival for 1 to
5 years in Korean National Health Insurance
Cohort
Hee‐Jin Kim1; Mi‐sook Kim2,3; Young‐Jin Ko2; Sang‐shin Park4;
Nam‐kyong Choi1
1Department of Health Convergence, College of Science & Industry
Convergence, Ewha Womans University, Seoul, Korea, Republic of;
2Department of Preventive Medicine, Seoul National University College of
Medicine, Seoul, Korea, Republic of; 3Medical Research Collaborating
Center, Seoul National University Hospital, Seoul, Korea, Republic of;
4Graduate School of Urban Public Health, University of Seoul, Seoul,
Korea, Republic of
Background: The Charlson comorbidity index (CCI) and Elixhauser
comorbidity index (ECI), which are commonly used as adjusting
methods for Korean comorbidity, have been developed for specific
patients and diseases in the United States and Canada. Therefore, it
would not be appropriate for the Korean population and disease
structure.
Objectives: To identify the survival aspects of acute myocardial infarc-
tion (AMI) or Stroke patients for 1 to 5 years according to the comor-
bidity levels and evaluate whether the Charlson comorbidity index
(CCI) and Elixhauser comorbidity index (ECI) is a good predictor com-
pared to other predict factors in Korean claims database.
Methods: This study identified 11,281 patients aged 20 or older who
were diagnosed with acute myocardial infarction (AMI) or stroke
between 2006 and 2010 in korean national health insurance cohort.
Using the Kaplan Meier Curve, we described the survival aspects of
patients according to comorbidity index level of CCI and ECI. And
we selected key variables for predicting survival well among 10 factors
including CCI and ECI through the hazard ratio (HR) of cox regression.
The factors are age, sex, inpatient course, insurance type, inpatient
history, hospital level, operation status, severity of disability,
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medication use for cardiovascular, CCI or ECI. We evaluate model dis-
crimination by the area under the receiver‐operating curve (AUC).
Results: Age, medication use for cardiovascular and comorbidity index
were selected as the 3 key variables that affect to survival prediction.
In the 1‐year survival, a base model (age, sex) AUC was 0.660, and
after the addition of CCI, discrimination was increased but did not out-
perform(0.686). On the other hand, the significant increase occurred
after adding the medication use(0.747) on base model. In the 5‐year
survival, AUC was also increased over the base model(0.715) after
addition of CCI(0.737), but addition of medication use on the base
model made a much greater increase(0.772). This result was almost
near to the model discrimination with 3 major predictors and
sex(0.786) or with all 10 predict factors(0.780). The ECI result patterns
were similar to above and the discrimination was slightly higher than
CCI but not significantly different.
Conclusions: The CCI and ECI are not sufficient to predict survival in
Korean claims database. Especially it needs to be improved for better
predicting the short‐term survival within 1‐year.
172 | Identification of incident atrial
fibrillation patients using health claims
database
Rahul Khanna1; Robert Nicholas D'angelo2; Laura Goldstein3;
Iftekhar Kalsekar1; Stephen Marcello1; Robert Yeh2;
Peter J. Zimetbaum2
1 Johnson and Johnson, New Brunswick, NJ; 2Beth Israel Deaconess
Medical Center, Boston, MA; 3Johnson and Johnson, Irvine, CA
Background: Atrial fibrillation (AF) is the most common arrhythmia
among adults in the United States (US).
Objectives: To examine variation in treatment associated with differ-
ent approaches to incident AF identification using health claims
database.
Methods: We used the 2010–2016 IBM MarketScan® Commercial
Database. We used multiple approaches to identify incident AF, and
examined variation in treatment use in the first year post‐diagnosis.
The approaches differed in terms of the underlying diagnosis criteria
(i.e., identification using multiple visits versus single visit), prior phar-
macotherapy (i.e., identification with prior oral anti‐coagulant use ver-
sus without prior oral anticoagulant use), and baseline pre‐incident
diagnosis period (i.e., one year versus two‐year). For the first
approach, patients aged 20–64 years with at least two visits with pri-
mary diagnosis of AF (with the first visit classified as ‘index diagnosis’)
within three months and continuous enrollment for a least one‐year
pre‐index and post‐index visits were included. Patients who had a pri-
mary or secondary diagnosis of AF or had filled an AAD in the
12 months pre‐index period were excluded. For the second approach,
we included patients aged 20–64 years with at least one primary diag-
nosis of AF and continuous enrollment for a least 24 months pre‐index
and 12 months post‐index diagnosis. Patients who had any diagnosis
of AF or had filled an AAD or an oral anticoagulant in the 24 months
pre‐index period were excluded.
Results: For the first approach for AF identification, 77,207 patients
met inclusion criteria. Mean age was 53.9 years, 66.8% were male.
Almost 30.0% of patients had been trialed on at least one anti‐arrhyth-
mic drug (AAD) and 46.3% on an oral anticoagulant, 24.4% had been
cardioverted, and 7.1% of patients underwent ablation in the 12‐
months post‐incident diagnosis period. For the second approach for
AF identification, 87,758 patients were identified. The mean age was
53.2 years and 61.1% were male. Almost 22% of patients had been
trialed on AAD and 28% on an oral anticoagulant, 16.0% had been
cardioverted, and 4.5% had ablation in the 12‐months post‐incident
diagnosis period.
Conclusions: Variation in inclusion/exclusion by diagnosis criteria,
baseline enrollment, and baseline pharmacotherapy led to variation
in outcomes assessment. The rate of treatment was lower for patients
in the second approach, which could be because of identification of
transient AF patients, as this approach relied on identification using
single medical visit. Further research is needed to better understand
AF phenotyping using health claims database.
173 | Incidence and prevalence of systolic
and diastolic heart failure among obese
patients with type 2 diabetes in the United
States
Ayad K. Ali; Yu‐Jing Huang
Eli Lilly and Company, Indianapolis, IN
Background: Obesity and diabetes are known risk factors for heart
failure; however, the epidemiology of heart failure by type in obese
patients is not well characterized, especially among patients with type
2 diabetes mellitus (T2DM).
Objectives: To estimate the incidence and prevalence of heart failure
by type among obese patients with and without T2DM.
Methods: Between 2007–2017, an analysis of the U.S. Truven Health
MarketScan claims database was performed to calculate the incidence
and prevalence rates of heart failure in obese T2DM patients com-
pared to obese general population without diabetes. Rates were strat-
ified by type of heart failure, including systolic (with reduced ejection
fraction__HFrEF) and diastolic (with preserved ejection
fraction__HFpEF). Obesity, diabetes, and heart failure were defined
by corresponding inpatient and outpatient ICD‐9/10‐CM diagnosis
codes.
Results: During the analysis period, >12 million obese patients were
included (mean age 43 years; 63% females), corresponding to >2 mil-
lion with T2DM (mean age 53 years; 58% females), and > 9 million
without diabetes (mean age 40 years; 65% females). Incidence (per
100 person‐years) and prevalence rates of heart failure for corre-
sponding populations were: overall (112.7; 6.1%); T2DM (238.7;
15.7%); and general population (76.9; 3%). Corresponding rates for
HFrEF: overall (29.9; 1.4%); T2DM (59.9; 3.9%); and general
ABSTRACTS 87
population (19.2; 0.6%), and for HFpEF: overall (43.8; 1.8%); T2DM
(92.8; 5.3%); and general population (24.4; 0.7%). Obese men with
T2DM had higher rates of heart failure than women (incidence = 164.2
vs. 89.1; prevalence = 7.3% vs. 5.4%). Incidence rates of both heart
failure types were higher in obese men with T2DM compared to
women (HFpEF, 53.9 vs. 39.1; HFrEF, 50.1 vs. 20.4). There was no dif-
ference in prevalence rates (HFpEF, 1.9% vs. 1.8%; HFrEF, 2.1% vs.
1.1%). The rates of any heart failure were increasing with age among
obese T2DM patients (18–44 years old, 47.9 and 1.9%; 45–54 years
old, 120.6 and 5.7%; 55–64 years old, 188.2 and 10%; 65–74 years
old, 287.5 and 20.7%; and ≥ 75 years old, 444.2 and 37.1%). Corre-
sponding rates by race were: any heart failure (Whites, 128.2 and
11.7%; Blacks, 118.3 and 10.8%; and Hispanics, 50.7 and 2.6%);
HFpEF (Whites, 54.9 and 3.8%; Blacks, 56.3 and 3.8%; and Hispanics,
23.5 and 0.8%); and HFrEF (Whites, 30.2 and 2.6%; Blacks, 36.2 and
2.9%; and Hispanics, 11.8 and 0.6%).
Conclusions: Incidence and prevalence rates of heart failure, especially
diastolic (HFpEF) type, were higher in obese patients withT2DM com-
pared to obese general population.
174 | Risk factors for post‐ablation early and
late symptomatic recurrence of atrial
fibrillation: Findings from a real world
database study
Shumin Zhang1; Iftekhar Kalsekar1; Ge Lin1; Sashi Yadalam1;
Lee Ming Boo2; Nader Ghaly3; Rahul Khanna1
1 Johnson & Johnson, New Brunswick, NJ; 2 Johnson & Johnson, Irvine, CA;
3 Johnson & Johnson, Diamond Bar, CA
Background: Catheter ablation is a mainstay treatment for drug
refractory atrial fibrillation (AFib), but recurrence can occur after ini-
tially successful ablation. Identifying risk factors for post‐ablation
recurrence may help develop effective strategies to reduce
recurrences.
Objectives: To identify risk factors for early and late symptomatic
recurrence in real‐world settings.
Methods: A retrospective cohort study was conducted in patients
undergoing cardiac ablation for AFib during 2011–2016 using the
MarketScan® Commercial Database. Symptomatic recurrence was
defined as a composite of AFib‐related inpatient readmission, cardio-
version and repeat ablation in an inpatient or outpatient setting. Mul-
tivariable logistic regression was used to evaluate the association
between patient characteristics (assessed in the year pre‐index abla-
tion [baseline]) and risk of early symptomatic recurrence during the
first 3 months post‐index ablation. Multivariable Cox models were
used to evaluate the association for late symptomatic recurrence (4–
12 months).
Results: Of the 14,239 study patients (median age, 57 years; male,
74%), 18% had early symptomatic recurrence post ablation. In multi-
variable analyses, baseline characteristics that were significantly asso-
ciated with a lower risk of early symptomatic recurrence were
age < 50 years, inpatient service setting, presence of AFib and other
arrhythmia, use of antiarrhythmic drugs, and later calendar years of
index ablation. Baseline characteristics that were significantly related
to a higher risk of early symptomatic recurrence were hypertension,
sleep apnea, obesity, valvular heart disease, cardiomyopathy, and use
of ≥2 (vs 1) different anticoagulants. Freedom from early symptomatic
recurrence during the first 3 months and baseline characteristics
including later calendar years of index ablation, presence of AFib and
other arrhythmia, and Northeast/South regions were significantly
related to a lower risk of late symptomatic recurrence. The hazard
ratio comparing patients without vs with symptomatic recurrence dur-
ing the first 3 months was 0.42 (95% confidence interval: 0.39–0.46)
for late symptomatic recurrence. Baseline inpatient service setting,
valvular heart disease, use of ≥2 (vs 1) different anticoagulants, and
North Central region were significantly related to a higher risk of late
symptomatic recurrence.
Conclusions: Cardiometabolic comorbidities were associated with risk
of early and late symptomatic recurrence. Early symptomatic recur-
rence was strongly related to late symptomatic recurrence.
175 | Epidemiology of non fatal major
adverse cardiovascular events in children
with diabetes
Ayad K. Ali; Mark C. Lakshmanan
Eli Lilly and Company, Indianapolis, IN
Background: Unlike adult population, the epidemiology of non‐fatal
major adverse cardiovascular events (MACE) in children with diabetes
is not well characterized.
Objectives: To estimate the incidence and prevalence rates of non‐
fatal MACE in children with diabetes.
Methods: Records of patients enrolled inTruven MarketScan database
between 2015–2016 were analyzed for children (aged <18 years) with
and without diabetes. The primary outcome of non‐fatal MACE was
measured as a composite of myocardial infarction (MI), stroke, hospi-
talization for transient ischemic attack (TIA), hospitalization for unsta-
ble angina (UA), or revascularization procedures (RP). Prevalence rates
in percentages and incidence rates per 100 person‐years (PY) were
estimated and stratified by age, gender, and diabetes type (T1D and
T2D) and compared to those without diabetes.
Results: During the analysis year, >6 million children were identified,
including 32,256 with diabetes (T1D = 16,959 and T2D = 7,963),
and 6,697,362 without diabetes. Children with diabetes had 3‐times
the prevalence and twice the incidence of MACE than those without
diabetes (prevalence, 0.3% vs. 0.1%; incidence, 0.12 vs. 0.05 per 100
PY). Children with T2D had higher rates than those with T1D (preva-
lence, 0.4% vs. 0.2%; incidence, 11 vs. 2.79 per 100 PY). There was
no difference in prevalence by gender, but boys with diabetes had
higher incidence (0.14 vs. 0.1 per 100 PY). Children with diabetes
<6 years had higher rates (prevalence, 0.9%; incidence, 0.44 per 100
PY) than those aged 6–12 years (prevalence, 0.2%; incidence, 0.08
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per 100 PY) or 13–17 years (prevalence, 0.3%; incidence, 0.11 per 100
PY). Stroke contributed to the majority of MACE, with rates in children
with T2D higher than those with T1D (prevalence, 0.3% vs. 0.1%; inci-
dence, 5.51 vs. 2.03 per 100 PY). Adults with diabetes had MACE
prevalence and incidence of 6.6% and 3.89 per 100 PY.
Conclusions: Children with diabetes, particularly T2D, are at risk for
non‐fatal MACE; however, less than adult counterpart population.
Therefore, cardiovascular outcome studies in pediatrics might not be
feasible.
176 | Embolic events and unmet
Therapeutical need for coronary and
peripheral arterial disease
Elisabeth Smits1; Edith M. Heintjes1; Fernie J.A. Penning1;
M. van den Bosch2; Ron M.C. Herings1
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands;
2Bayer BV, Mijdrecht, Netherlands
Background: Despite a decline in vascular mortality over past decades,
atherosclerosis remains the number one cause of death worldwide.
Objectives: To assess prevalence of coronary and peripheral arterial
disease (CAD and PAD) in the Netherlands, embolic event rates and
risk factors.
Methods: Within a cohort of patients diagnosed with CAD and/or
PAD prior to July 2015, embolic event rates after diagnosis were
assessed using data from the PHARMO Database Network. Further-
more, a nested case–control study was performed to assess risk fac-
tors for embolic events.
Results: Of 41,163 patients, 26,306 had CAD‐only, 11,518 PAD‐only
and 3,339 polyvascular disease. In 2015, respective prevalences
were 27, 12 and 3.7 per 1000 persons. Comparing embolic event
rates in the first year after diagnosis with next years, rates
declined from 34 to 20 per 1000 person years (PY) for CAD‐only
and 73 to 35 per 1000 PY for PAD‐only. Most frequent embolic
events were myocardial infarction, stroke, transient ischaemic attack
and acute limb ischaemia. Risk factors for embolic events included
history of embolic events, time between diagnosis and event,
smoking, diabetes and revascularisation. Anti‐thrombotic drugs were
preserved for patients with highest risk.
Conclusions: The decreasing risk of embolic events after diagnosis
confirms what is already known and indicates that treatment
reduces risk over time. Nevertheless, the association between spe-
cific drugs and embolic events shows that current treatment options
are insufficient to eliminate excess risk. To lower the risk of
embolic events among patients with CAD and/or PAD this unmet
medical need has to be addressed.
177 | Glycemic control from 2013 to 2016
among US adults with type 2 diabetes: A
National Estimate Stratified on age, eGFR
category and comorbidities
Yuzhi Xi1; Tongtong Wang2; Carol Koro2
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Merck &
Co, Inc, Kenilworth, NJ
Background: The adequacy of adherence to ADA's guidelines, as
reflected in glycemic control, has not been assessed among US adults
with type 2 diabetes (T2D) by different risk factors, such as age, car-
diovascular diseases (CVD), obesity and chronic kidney disease (CKD).
Objectives: To assess glycemic control (measured by HbA1C) among
US adults with T2D, overall and stratified by age, eGFR categories
and presence/absence of overweight/obesity and CVD.
Methods: Using the National Health and Nutrition Examination Survey
(NHANES) 2013–2016 data, we conducted a cross‐sectional analysis of
an adult sample with T2D, aged≥18 years. T2D was defined as diag-
nosed T2D (self‐reported provider diagnosis) and undiagnosed T2D
(FPG ≥126 mg/dL or HbA1c ≥ 6.5% without self‐reported diagnosis).
Participants who started insulin within a year of T2D diagnosis, or were
pregnant at the time of interview were excluded. CVD was defined
based on self‐reported interview data on a broad range of health condi-
tions—congestive heart failure, coronary heart disease, angina, stroke,
or heart attack. GFR categories were based on eGFR, calculated using
the CKD‐EPI equation. The classification of overweight/obesity was
based on measurement of Body Mass Index. HbA1c measures were
aggregated to 4 levels: <7%, 7‐ < 8%, 8‐ < 9%, and≥ 9%. Glycemic con-
trol rates were calculated as the proportion of T2D patients within each
pre‐specified HbA1c levels, overall and in each pre‐specified subgroup.
Appropriate sample weights were used to provide a national estimate.
Results: The NHANES 2013–2016 sample included a total of 1,705
adults with T2D, yielding a national projected population estimate of
27.1 million. The overall glycemic control rate, defined as HbA1c < 7%,
was 51.9%. AmongT2D aged 45–64 years, 46.6% had an HbA1c < 7%;
while 60.3% of T2D aged ≥75 years had an HbA1c < 7%. Among T2D
with renal impairment, the glycemic control rate was similar across
eGFR categories, remaining at above 50%. AmongT2D with comorbid-
ities, glycemic control rate ranged from 48.5% for those with both obe-
sity and CVD to 69.5% for those with CVD only. It is worth noting that
14.8%of T2Dhad anHbA1c≥ 9%,with 22.7% among aged 18–44 years
and 20.3% among those with eGFR >90 ml/min/1.73m2.
Conclusions: Our findings provide national estimates of glycemic con-
trol from 2013–2016 among US adults with T2D by different risk fac-
tors. Despite the approval of many new anti‐diabetic medications, the
proportion of patients achieving glycemic control targets has not
improved, with only about 50% at HbA1c goal of <7%, ranging from
47–70% depending on risk factors.
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178 | Variation in polycystic ovary syndrome
patient characteristics by body mass index: A
real‐world analysis using a claims and
electronic health record linked database
Ellen R. Thiel; Debra E. Irwin
IBM Watson Health, Ann Arbor, MI
Background: Polycystic ovary syndrome (PCOS) is characterized by
hormonal imbalances which often manifest as both endocrine and
metabolic‐related comorbidities, including obesity.
Objectives: The aim was to describe PCOS patients in terms of clinical
characteristics, medication utilization, and healthcare costs stratified
by body mass index (BMI) categories.
Methods: This retrospective, observational study utilized claims linked
to electronic health record (EHR) data contained in the IBMMarketScan
Explorys Claims‐EHR Data Set. Patients with at least one diagnosis for
PCOS (ICD‐9‐CM 256.4; ICD‐10: E282; SNOMED: 69878008) from
1/1/2007 through 6/30/2017 were selected. Patients were required
to be continuously enrolled in the database, and with no evidence of
pregnancy, during the 12‐month observation period (6 months before
and after the PCOS diagnosis). Clinical characteristics, medication utili-
zation, lab results and all‐cause healthcare costs were described.
Patients were stratified into four BMI subgroups: normal or under-
weight, overweight, obese, and morbidly obese.
Results: A total of 4,142 PCOS patients met the selection criteria, of
whom, 16% were normal or underweight, 17% were overweight,
40% were obese and 27% were morbidly obese. The mean age was
32 years. Approximately 22% of morbidly obese patients were diag-
nosed with type 2 diabetes, compared to 13%, 7% and 3% in the
obese, overweight and normal/underweight subgroups, respectively.
Acne was more often diagnosed in the lower weight patient sub-
groups (normal/underweight 22%; overweight 15%; obese 11%; mor-
bidly obese 6%). Cardiovascular conditions were rare. Oral
contraceptives were more commonly utilized in the lower BMI catego-
ries, while opioids and nonsteroidal anti‐inflammatory drugs were
more common in higher BMI categories. HbA1c levels did not differ
between BMI categories. Mean and median total healthcare costs
were highest in the morbidly obese patients.
Conclusions: This descriptive analysis provides real‐world evidence of
the variation in the clinical and economic burden of PCOS based on
the presence of comorbid obesity. Further research is needed into
the impact of obesity on comorbidity disease management, treatment
and healthcare costs among women with PCOS.
179 | A comparison of the burden and
characteristics of incident type 2 diabetes
mellitus cases in HIV and non‐HIV cohorts
within a US claims database
Harriet Dickinson1; Myriam Drysdale2; Cassidy Henegar3;
Marianne Cunnington1; Leigh Ragone3; Vani Vannappagari3
1GSK, Stevenage, UK; 2GSK, Uxbridge, UK; 3GSK, RTP, NC
Background: Antiretroviral therapy (ART) has been associated with
increased risk for glucose metabolism disorders, including Type 2 dia-
betes mellitus (T2DM). However, the burden of T2DM in HIV vs
non‐HIV patients is not well studied. Additionally, comorbidities and
comedications may also contribute to T2DM onset or complicate
T2DM management, and merit further study.
Objectives: To compare the incidence of T2DM between HIV and
non‐HIV cohorts. Comorbidities, comedications, and treatment of inci-
dent T2DM cases were compared. Additionally, ART use in the HIV
cohort was studied.
Methods: This is a retrospective, longitudinal study using Optum™
Clinformatics™ claims data from 1/1/2012 to 12/31/2016. Estimates
of annual T2DM incidence were calculated using HIV vs non‐HIV age
and gender 1:3 matched cohorts. Demographics, comorbidities, and
comedications were evaluated in the 12 months prior to an incident
T2DM claim. T2DM complications and medication, as well as ART
use were evaluated 0–90 days after an incident T2DM claim. A GSK
funded study.
Results: Commercially insured patients with HIV had a higher inci-
dence of T2DM during years 2012–2016 (n = 1,121, range 3.2–5.6
cases per 100 person‐years), compared to those without HIV
(n = 3,363, range 2.2–2.7 cases per 100 person‐years). In the
12 months prior to T2DM diagnosis, HIV patients were more likely
to have chronic liver disease (2.2% vs 0.6%, p < 0.0001), chronic kid-
ney disease (3.5% vs 0.9%, p < 0.0001), hepatitis B (5.1% vs 0.1%,
p < 0.0001) and hepatitis C (4.4% vs 0.2%, p < 0.0001), while non‐
HIV patients were more likely to be classified as obese (16.4% vs.
7.3% p < 0.0001), and have hypertension (34.9% vs. 26.8%,
p < 0.0001) compared to HIV patients. In the 90‐day period after
T2DM diagnosis, no significant differences were observed between
the proportions of HIV vs non‐HIV patients receiving diabetes therapy
(58.5% vs, 60.8%, p = 0.2), but HIV patients were more likely to expe-
rienceT2DM complications (39.5% vs 33.6%, p = 0.0004). Among HIV
patients with incident T2DM, 86.8% had received treatment with ART
prior to T2DM diagnosis and 83.3% were being treated with ART 0–
90 days after diagnosis.
Conclusions: The incidence of T2DM was higher in HIV patients than
non‐HIV patients, and similar proportions of these incident T2DM
cases received diabetes therapy in both cohorts. T2DM patients with
HIV had a higher prevalence of chronic conditions, such as chronic
liver and kidney disease, and/or infectious diseases, such as hepatitis
B. In contrast, T2DM patients without HIV were more likely to have
comorbidities reflecting lifestyle risk factors.
180 | Potassium trajectories and predictors
for repeated hyperkalemia in high‐risk
patients: A population‐based cohort study
Sia Kromann Nicolaisen1; Kasper Adelborg1; Pål Hasvold2;
Eirini Palaka3; Lars Pedersen1; Reimar Wernich Thomsen1
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1Department of Clinical Epidemiology, Aarhus, Denmark; 2AstraZeneca
Nordic, Medical Department, Etterstad, Oslo, Norway; 3AstraZeneca,
Global Payer Evidence, Cambridge, UK
Background: Hyperkalemia (HK, defined as blood potassium
>5.0 mmol/L) is associated with cardiac arrhythmias and increased
mortality. HK is often considered a transient condition, but some
patients may be susceptible to repeated HK.
Objectives: To examine potassium trajectories and predictors for
repeated HK among high‐risk patients after a first HK event.
Methods: We used Danish population‐based registries to identify all
patients with first‐time renin angiotensin system inhibitor (RASi) pre-
scription, chronic kidney disease (CKD), or chronic heart failure
(CHF) in Northern Denmark (population, 1.8 million), during 2000–
2012. For patients with a first HK event, potassium trajectories over
the following 6 months were examined. Predictors associated with
repeated HK (defined as a second potassium test >5.0 mmol/L
within 6 months after the first HK event) were assessed.
Results: Overall 262,375 first‐time RASi users, 157,283 incident
CKD patients, and 14,600 incident CHF patients were included. Of
these 41,818 (16%), 43,845 (28%), and 5,634 (39%) patients, respec-
tively, had a subsequent HK event. Of patients with a first HK
event, repeated HK within 6 months occurred in 37% of RASi users,
40% with CKD, and 49% of patients with CHF. Predictors of
repeated HK included severe HK at baseline, low baseline eGFR, dia-
betes, and spironolactone use. In all cohorts, the median potassium
levels declined over 2–4 weeks after a first HK event, but reverted
to levels higher than before the first HK event in those who had
repeated HK, with the highest 10% of recorded potassium measure-
ments each week staying above 5.0 mmol/L.
Conclusions: Repeated HK was common among the explored patients.
The potassium values in the trajectory for patients with repeated HK
were markedly higher than the values in the trajectory for patients
with only a single HK event. The first HK event was an indicator of
subsequent increased median potassium levels. Repeated HK predic-
tors may identify patients likely to benefit from intensified monitoring
and intervention for HK.
181 | Prevalence and Management of
Dyslipidaemias in adult renal transplant
recipients attending nephrology Clinic at a
Tertiary Hospital in Kenya
Esbon W. Njau Dr; Sylvia A. Opanga; Peter N. Karimi
University of Nairobi, Nairobi, Kenya
Background: Dyslipidemia is a common cause of cardiovascular mor-
bidity and mortality among renal transplant recipients. Management
of dyslipidemia in these patients is complicated by concerns over
safety of statins due to drug interactions.
Objectives: This study aimed to assess the predictors and manage-
ment of dyslipidemia in Renal Transplant recipients attending clinic
in a tertiary hospital in Kenya.
Methods: A cross‐sectional study was conducted a Kenyatta National
Hospital, a leading referral hospital in Nairobi, Kenya. Adults (≥
18 years) patients who had received a renal transplant at least
3 months before the date of recruitment into the study and on follow
up at the renal transplant clinic were eligible for the study. Those who
met the inclusion criteria were consecutively selected and interviewed
using a structured questionnaire and data was abstracted from their
medical files. Descriptive, bi‐variable analysis and logistic regression
was done using STATA version 13.
Results: 110 adult renal transplant recipients were recruited into the
study. The mean age of the participants was 43.4 ± 13.4 with a male
gender predominance at 64% (n = 70). The prevalence of dyslipidemia
was 72%. The most prevalent types were elevated LDL‐C and elevated
non‐HDL‐C each at 44%. Only 12% of the participants were on a statin
and atorvastatin was the most commonly used at 10%. Lifestyle modifi-
cation strategies used by participants included dietary modification
(30%), physical activity (64%), weight reduction (58%), smoking cessa-
tion/abstinence (99%) and limitation of alcohol intake (99%). Weight
gain (P = 0.003), dietary modification (P = 0.001) and physical activity
(P = 0.04) were significantly associated with dyslipidemia. Dietary mod-
ification (P = 0.004) was the only independent predictor of dyslipidemia.
Conclusions: The prevalence of dyslipidemia was high and the most
prevalent types were elevated LDL‐C and Elevated non‐HDL‐C. The
use of statins and Lifestyle modification strategies for the management
of dyslipidemia was low.Dietary modification, physical activity, obesity
weight gain and time on dialysis before transplant were significant pre-
dictors of dyslipidemia.
182 | Temporal trajectories of complications
of type 2 diabetes mellitus
Eugene Jeong; Namgi Park; Chan Min Park; Dukyong Yoon
Ajou University, Suwon‐si, Republic of Korea
Background: Type 2 diabetes mellitus (T2DM) is rapidly becoming a
global pandemic. Moreover, people with T2DM are at increased risk
of many complications, such as hypertension, dyslipidemia, and cardio-
vascular diseases, due to their interconnected mechanisms. While
many studies have examined complications of T2DM, few attempts
have been made to understand complication trajectories over time.
Objectives: To analyze temporal patterns of T2DM complication pro-
gression, we constructed diagnosis trajectories using data from the
National Health Insurance Service (NHIS) cohort, which sampled
approximately 2% of the Korean population from 2002 to 2013.
Methods: We classified patients as having T2DM if they had one rel-
evant ICD‐10 code (E11‐E14). To account for confounding factors,
controls (without T2DM) were matched according to age, gender,
and hospital discharge week in a ratio of one case to four controls.
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We constructed T2DM trajectories using the following steps: (1) we
used the relative risk (RR) and p‐value from Fisher's exact test to mea-
sure the significance of first complications of T2DM (T2DM→ D1); (2)
associations with second and third complications were defined simi-
larly and we combined pairs with overlapping diagnoses (i.e.,
T2DM → D1 → D2 and T2DM → D2 → D3 were combined to yield
T2DM → D1 → D2 → D3); and (3) finally, we identified the frequency
and duration of the progression of each trajectory.
Results: The NHIS sample cohort contained 1,111,007 patients and
23,829,621 incidence cases. Overall, 214,817 patients were consid-
ered to have T2DM and there were 859,207 matched controls. There
were 1,393 distinct complications after T2DM, of which only 96 had a
significant temporal relationship with T2DM (T2DM → D1). From the
T2DM patient dataset, we identified 133,632 pairs (D1→ D2) of diag-
noses, of which 16,268 were significant. These directional pairs were
then combined into longer trajectories consisting of four diagnoses,
including T2DM (T2DM → D1 → D2 → D3). The top 50 most fre-
quent trajectories include highly reliable patterns, such as “Type 2 dia-
betes mellitus → Polyneuropathy in diseases classified elsewhere →
Retinal disorders in diseases classified elsewhere → Gastro‐esopha-
geal reflux disease”, which confirms that our trajectories reflected
the complications after T2DM in temporal terms.
Conclusions:We constructed dependableT2DM trajectories that have
predictive potential for future research, should contribute to achieving
precision medicine, and will uncover many links among complications
that hitherto have been unclear.
183 | Incidence and prevalence of
gastrointestinal stenosis and obstruction in
patients with diabetes in the United States
Ayad K. Ali; Brian J. DeGuire
Eli Lilly and Company, Indianapolis, IN
Background: The epidemiology of gastrointestinal (GI) stenosis and
obstruction in patients with diabetes mellitus (DM) is not well charac-
terized in the medical literature.
Objectives: We estimated the incidence and prevalence of GI stenosis
and obstruction in this population in US.
Methods: TheTruven Health MarketScan database was used to create
2 person‐time cohorts of adults (≥18 years) with DM and general pop-
ulation between 2015–2016. Diagnosis and procedure codes denoting
to GI stenosis and obstruction were used to identify the condition of
interest. Patients with GI obstruction events related to neoplasms,
neonatal, congenital, pregnancy, foreign body, or food were excluded.
Point prevalence (%) and incidence (per 100 person‐years) rates were
estimated for both cohorts, and stratified by age, gender, and (for DM
cohort) by DM type (T1DM and T2DM).
Results: During the study period, >4 million patients with DM were
identified (2% T1DM and 43% T2DM). Patients with DM have 3‐times
the rates of GI stenosis and obstruction compared to general popula-
tion (prevalence = 9.3% vs. 2.8%; incidence [95%CI] = 1.97 [1.96–
1.99] vs. 0.71 [0.70–0.71]). Patients withT2DM have higher rates than
those with T1DM (prevalence = 8.4% vs. 2.6%; incidence
[95%CI] = 4.05 [3.99–4.10] vs. 0.57 [0.51–0.63]). Compared to men,
women with T2DM have higher prevalence rates; however, incidence
rates of GI stenosis and obstruction do not appear to be much differ-
ent (prevalence = 7.7% vs. 9.1%; incidence [95%CI] = 4.11 [4.03–4.19]
vs. 3.99 [3.91–4.07]). Rates in those with T1DM did not show differ-
ences between genders, and all patients were in 18–44 years age
group. Among patients with T2DM, prevalence rates appear to signif-
icantly increase with age, albeit incidence rates showed modest rise.
The highest prevalence rates were observed in the elderly (18–
44 years = 4.5%; 45–54 years = 6.4%; 55–64 years = 8.0%; 65–
74 years = 12.1%; and ≥ 75 years = 16.1%).
Conclusions: Patients with DM, especially T2DM, have high rates of
GI stenosis and obstruction and should be considered as a comorbidity
during T2DM management.
184 | A snapshot of characteristics recorded
in electronic medical Records of Women with
polycystic ovary syndrome in TriNetX within
two years of diagnosis
Jayashri Desai1; Brian Buysse2; Jessica Albano1
1Syneos Health, Morrisville, NC; 2Syneos Health, Farnborough, UK
Background: Polycystic ovary syndrome (PCOS) is a multifactorial dis-
order that affects approximately 10% of women of childbearing age.
There is considerable interindividual variation in presentation thus
making the condition difficult to diagnose.
Objectives: To describe demographic characteristics, medications, and
labs in electronic medical records of women with PCOS in the United
States within two years of diagnosis.
Methods: TriNetX, a global federated research network, which con-
tains electronic medical record data of up to 47 million US patients
in 39 large healthcare organizations, predominately in [the USA] was
used to identify women with PCOS (ICD‐10 code E28.2) and gather
descriptive statistics on associated variables within two years of a
PCOS diagnosis. The analytics associated with this abstract were per-
formed on February 07, 2019.
Results:Of the 24,801,671 women on the network, there are 164,709
(0.66%) with PCOS with a mean age of 35 years. Sixty‐four percent
are white, 11% are black, 3% are Asian and the other are of unknown
race. The top 3 diagnoses recorded were: 1) factors influencing health
status and contact with health services (47%), which included encoun-
ters for special examinations (n = 49,233), 2) endocrine, nutritional and
metabolic disorders, (46%), which included diabetes (n = 10,872) and
obesity (n = 27,710), and 3) symptoms, signs, and abnormal clinical
findings, not elsewhere classified (38%), which included malaise/
fatigue(n = 9,313) and headache (n = 8,390). Top 3 medication classes
prescribed were: hormones/synthetics (n = 57,842; 38%), central ner-
vous system medications (n = 48,125; 32%), and dermatological agents
(n = 43,983; 29%). The most prescribed medications under these
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respective classes were: blood glucose regulation agents (n = 25,916;
17%), analgesics (n = 32,870; 22%) and sodium chloride (n = 18,659;
12%). Lab procedures performed included: hemoglobin (n = 45,558;
30%), creatinine (n = 45,449; 30%), hematocrit (n = 43,076; 28%),
erythrocyte mean corpuscular volume (n = 42,699; 28%) and platelets
(n = 42,151; 28%). Body Mass Index (BMI) was also measured
(n = 57,229; 38%). The mean BMI was 35.03 kg/m2 with a standard
deviation of 9.54.
Conclusions: Characteristics and diagnoses within 2 years of a PCOS
diagnosis in women include: white race, diabetes, obesity, fatigue
and taking blood regulation agents. These characteristics and lab pro-
cedures such as hemoglobin and creatinine can aid physicians on diag-
nosing women with PCOS when taking into account other factors in
relation to a woman's health.
185 | Comparison of health outcomes in
diabetic and non diabetic patients undergoing
maintenance Haemodialysis
Savitha R. Sanathan1; Libina Thomas1; Manjunath S. Shetty2;
K.K. Kiran2
1 JSS College of Pharmacy, JSS Academy of Higher Education & Research,
Mysore, India; 2 JSS Medical College & Hospital, JSS Academy of Higher
Education & Research, Mysore, India
Background: End stage renal disease and diabetes are diseases that
are associated with significant decrease in health related quality of life.
Epidemiological studies have shown that combination of ESRD and
diabetes leads to increased risk of cardiovascular events and shorter
life expectancy in this group of patients.
Objectives: The aim of this study was to compare the HRQoL in dia-
betic and non diabetic patients undergoing MHD, to provide compre-
hensive patient education and assess the effect of patient education
on HRQoL, and to assess the factors affecting HRQoL in diabetic
and non diabetic patients undergoing MHD.
Methods: This eight months prospective interventional study con-
ducted in the dialysis unit included maintenance hemodialysis patients.
The kidney disease quality of life (KDQoL™‐36) questionnaire was
administered to the patients at the baseline, first follow up and second
follow up. Comprehensive patient education was provided at baseline
and re‐in forced at third month and at sixth month during the study
period. Responses of the patient to the questionnaire were compared
between baseline and two follow ups for all patients and between dia-
betic and non diabetic patients. KDQoL mean scores were compared
using student's t test andthe factors affecting the QoL were assessed
by using chi square test.
Results: A total of 89 patients were enrolled into this study and 69
were followed up. Males comprised majority of the patient population
where diabetics were 87% and non diabetics were 79%. The mean age
of the study population was 46 ± 12 years. It was observed non dia-
betic patients had better HRQoL than diabetic patients undergoing
MHD. An improvement in HRQoL during the follow up period was
observed in the patients after providing with patient education com-
pared to the baseline scores. Male gender (p = 0.032), education less
than or equal to high school (p = 0.049), presence of history of
smoking and alcoholism (p = 0.031) and less than three years of dialy-
sis history (p = 0.035) were the factors found to have significant influ-
ence on the HRQoL. Other factors found associated with lower
HRQoL scores were presence of comorbid diabetes mellitus, age more
than 50 years, unemployment and more than five medications.
Conclusions: Non diabetic patients had better HRQoL when com-
pared to diabetic patients undergoing MHD. Implementation of clinical
pharmacy services in dialysis units can improve HRQoL among the
patients undergoing MHD. Better patient care can be provided by
health care professionals focusing on the factors contributing to lower
HRQoL among patients undergoing MHD.
186 | Identification of medical complications
and real‐life Care of Familial and
Multifactorial Chylomicronaemia Syndromes:
The Esthym study
Manon Belhassen1; Eric Van Ganse1,2; Marine Ginoux1; Maeva Nolin1;
Hanane Bada3; Eric Bruckert4; Michel Krempf5; Vinciane Rebours6;
René Valéro7; Philippe Moulin8
1PELyon, PharmacoEpidemiology Lyon, Lyon, France; 2HESPER 7425,
Health Services and Performance Research, University Claude Bernard
Lyon 1; PELyon, PharmacoEpidemiologie Lyon; Respiratory Medicine,
Croix Rousse University Hospital, Lyon, France; 3Louis Pradel University
Hospital, Hospices Civils de Lyon, INSERM UMR 1060 Carmen, Lyon,
France; 4Pitié Salpêtrière University Hospital, APHP, Paris, Paris, France;
5Nantes University Hospital, Nantes, France; 6BEAUJON University
Hospital, APHP, Clichy, France; 7APHM University Hospital, Marseille,
France; 8Louis Pradel University Hospital, Hospices Civils de Lyon,
INSERM UMR 1060 Carmen, Claude Bernard Lyon 1 University, Lyon,
France
Background: The absolute risk of complication and the health impact
of multifactorial hyperchylomicronemia (MCS) and familial
hyperchylomicronemia (FCS) syndromes are poorly understood in real
life, whereas conventional treatments are poorly effective.
Objectives: To understand the management of FCS and MCS and to
identify the occurrence of complications.
Methods: 30 FCS and 124 MCS patients, with genetic documentation,
followed between 2006 and 2016 in France, were identified in hospi-
tal records. Individual hospital data were linked to the national claims
data (SNDS, health care utilization). Disease management and occur-
rence of complications were described during a median follow‐up time
of 9.8 years, leading to 1509 patient year of follow‐up.
Results: Mean age was higher in the MCS group (45.0 ± 12.4 years)
than in the FCS group (34.1 ± 13.3 years, p < 0.0001). The sex ratio
was towards females in the FCS group (0.67), while it was towards
males in the MCS group (2.1) (p = 0.049). During the study period,
50.0% of FCS patients had ≥1 acute pancreatitis, compared with
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20.2% in the MCS group (p < 0.0001). In addition, the mean number of
hospitalizations for acute pancreatitis was 9.3 in the FCS group, com-
pared to 2.1 in the MCS group (p < 0.0001). By contrast, hospitaliza-
tions for cardiovascular conditions were more frequent in MCS than
in FCS patients (25.0% versus 6.7%, p = 0.03).
Conclusions: The incidence of acute pancreatitis was higher in FCS
than in MCS patients. The incidence of ischemic cardiovascular condi-
tions was higher in MCS. These data illustrate the severity of these
two orphan conditions (prevalence of about 2/106 for FCS and 1/
104 for MCS).
187 | Thyroid disease: A retrospective
analysis of a large United States electronic
health record database
Georgios Varsos; Fred W. Peyerl; Xavier Marinaro; Halit Yapici;
Matharishwan Naganbabu; Laxmi Gannu; David K. Hayashida;
Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Thyroid is an endocrine (ductless) gland that secretes
Thyroid hormone, which enables various metabolic reactions. Disrup-
tions to this secretion, either over or under secretion are the hall-
marks of Thyroid disease. Approximately 20MM Americans are
reported to have a thyroid disease, with more than 12% of the U.
S. population estimated to develop a thyroid condition during their
lifetime.
Objectives: The objective of the present study was to identify types of
thyroid disorders and asses comorbid conditions presented in this
population.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All patient visits
(age ≥ 18 years) between 2014–2018 with an ICD9/10 diagnosis of
thyroid disease were included in the analysis. Thyroid disorder types
were defined based on ICD9/10 diagnosis codes (Thyroid cancer,
Hypothyroidism, Hyperthyroidism, Goiter, Other thyroid diseases) fol-
lowing medical review. Comorbid conditions were identified by corre-
sponding ICD9/10 diagnosis codes.
Results: Over 1.1MM patients with thyroid disorders were identified
in the database, with a total number of 2.8MM visits. Hypothyroid-
ism (64.1%) and Goiter (20.2%) were the most commonly seen types
of thyroid disorders. Most patients were females (78.9%), with 9 out
10 thyroid patients over 36 years old. Several comorbidities were
presented in the study population, with dyslipidemia (20.0%) and
cardiovascular conditions such as atrial fibrillation (5.6%) and coro-
nary heart disease (4.6%) being the most prominent.
Conclusions: This real‐world large database analysis provides insights
on different types of thyroid disorders, patient demographics and
comorbid conditions presented in thyroid patients.
188 | Prevalence of chronic kidney diseases
in patients with diabetes mellitus in the
Middle East: A systematic review and meta‐
analysis
Abdallah Y. Naser1; Hassan Alwafi2
1Al‐Isra University, Amman, Jordan; 2Umm Alqura University, Mecca,
Saudi Arabia
Background: Diabetes mellitus is a major risk factor for chronic kidney
diseases (CKDs). Chronic kidney diseases increase the risk of morbid-
ity and mortality as a result of cardiovascular complications and may
progress to end‐stage renal diseases. The prevalence of CKDs in
patients with diabetes mellitus in the Middle East region is unclear.
Objectives: This review aims to review the existing literature on the
prevalence of CKDs in patients with diabetes mellitus in the Middle
East region.
Methods: Medline, EMBASE and Cochrane Review databases were
searched for relevant studies up to January 2019. The search strategy
was conducted using both keywords and MeSH terms. Following
PRISMA guidelines, two reviewers independently screened articles,
extracted data and assessed the quality of the included studies. Ran-
domized controlled trials (RCTs) and observational studies including
patients from all age groups, and any study design related to the prev-
alence of CKDs in patients with diabetes mellitus were included in the
review. Pooled estimate for the prevalence of CKDs in patients with
diabetes were calculated using random effect models with 95% confi-
dence intervals (CI).
Results: A total of 489 citations were identified of which only 3 stud-
ies matched our inclusion criteria and were included in this review.
The three studies were of an observational study design (two retro-
spective and one prospective study), covering a total of 57,122
patients with type 2 diabetes mellitus aged 25 years and above. The
pooled estimate of the prevalence of CKDs in patients with diabetes
mellitus was 25.4% (95% CI, 8.1–42.8).
Conclusions: The findings of this review highlighted that there is a lack
of studies on the prevalence of CKDs in patients with diabetes
mellitus in the Middle East region. Further epidemiological studies
are required to investigate the prevalence of CKDs among patients
with diabetes mellitus.
189 | Incidence and time course of surgical
complications by cancer stage and site among
Medicare patients undergoing elective
colorectal resection for cancer: An analysis of
the SEER‐Medicare database
Stephen Johnston1; Eric Ammann2; Akhil Nayak3; Deborah Nagle4;
Anuprita Patkar4; Mary Charlton5
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Background: Anastomotic leak, infection, and bleeding are serious sur-
gical complications among patients undergoing resection for colorectal
cancer which may initially present during hospitalization or after
discharge.
Objectives: We describe the incidence and time course of these com-
plications by cancer stage and site among Medicare patients undergo-
ing elective resection for colorectal cancer.
Methods: We selected stage 1–4 colorectal cancer patients diagnosed
in 2009–2013 from the Surveillance, Epidemiology, and End Results
(SEER)‐Medicare Database who were aged ≥66 years, admitted for
elective resection of the primary site (considered the index admission)
and enrolled in fee‐for‐serviceMedicare Part A&B for 1 year before sur-
gery. By cancer stage and site (colon, rectum), we used the Kaplan–
Meier method to calculate unadjusted cumulative incidence propor-
tions of the complications for the period spanning from the index admis-
sion through 90 days post‐discharge. We used multivariable Cox
regression to quantify the association of cancer stage and site with
the rate of each complication, adjusting for patient and provider/hospi-
tal characteristics.
Results: The eligible study sample included 16,997 patients (median
age = 76 yr; 53.3% female). The 90d unadjusted cumulative incidence
proportions of complications were as follows: anastomotic leak (stage
1–4: 14.9%, 14.1%, 14.9%, 15.4%; colon = 14.0%, rectum = 18.3%);
infection (stage 1–4: 10.0%, 10.5%, 11.7%, 14.8%; colon = 9.8%, rec-
tum = 18.0%); bleeding (stage 1–4: 14.1%, 17.1%, 17.3%, 16.1%;
colon = 15.3%, rectum = 20.7%). With respect to timing, across the
stages and sites 74–85% of 90d anastomotic leak was diagnosed during
the index admission, 34–45% for infection, and 65–71% for bleeding. In
multivariable analyses, cancer stage was not significantly associated
with anastomotic leak; however, stage 4 cancer was associated with
the highest rate of infection (HR = 1.26 vs. stage 3, P < 0.01), whereas
stage 1 cancer was associated with the lowest rate of bleeding
(HR = 0.85 vs. stage 3, P < 0.01); rectal resection was significantly asso-
ciated a higher rate of anastomotic leak (hazard ratio [HR] = 1.26,
P < 0.01), infection (HR = 1.64, P < 0.01), and bleeding (HR = 1.25,
P < 0.01) in comparison with colon resection.
Conclusions: Among Medicare patients undergoing colorectal resec-
tion for cancer, anastomotic leak rates were high regardless of anatomic
site, and significant complications continue to accrue over time for colo-
rectal cancer patients after the index surgery.
190 | Relative Hazard of chronic kidney
disease among patients with inflammatory
bowel disease varies by age
Ravy K. Vajravelu1; Lawrence Copelovitch2; Mark T. Osterman1;
Ronac Mamtani1; Frank I. Scott3; James D. Lewis1;
Michelle R. Denburg4
1University of Pennsylvania, Philadelphia, PA; 2Children's Hospital of
Philadelphia, Philadelphia, PA; 3University of Colorado Denver, Denver,
CO; 4Children's Hospital of Philadelphia and University of Pennsylvania,
Philadelphia, PA
Background: The risk of chronic kidney disease (CKD) among patients
with inflammatory bowel disease (IBD) is uncertain, with prior studies
inconsistently demonstrating increased risk and association with 5‐
aminosalicylates (5‐ASAs).
Objectives: To calculate the relative hazard of IBD for development of
CKD and to determine whether IBD medications are associated with
estimated glomerular filtration rate (eGFR) decline.
Methods: This retrospective cohort study analyzed patients enrolled in
the United Kingdom'sThe Health Improvement Network. Patients who
were diagnosed with IBD during follow‐up were matched to up to 4
age‐, sex‐, and practice‐matched controls. The relative hazard of IBD
for CKD was calculated using a Cox model adjusted for risk factors for
CKD (smoking, coronary artery disease, hypertension for at least two
years, peripheral artery disease, stroke, diabetes, and systemic lupus
erythematosus) and number of healthcare visits. The outcome of CKD
was ascertained using eGFR measurements and diagnostic codes.
Because themanifestations of IBD change with age, an interaction term
between IBD and age was incorporated into the Cox model using qua-
dratic splines with a knot at age 60. In a second analysis, medication risk
factors for eGFR decline among patients with IBDwere evaluated using
a longitudinal model fit through a generalized estimating equation.
Patients were considered exposed to a medication if they received it
in the 60 days prior to eGFR measurement.
Results: 17,807 patientswith IBDduringwere identified, and theywere
matched to 66,929 controls. The age‐standardized incidence rateswere
131.4 per 100,000 person‐years (95% CI 123.0–140.2) and 104.6 per
100,000 person‐years (95% CI 100.7–108.7) for persons with IBD and
controls respectively. After controlling for risk factors associated with
CKD, IBD was associated with development of CKD from ages 16 to
81, with the adjusted hazard ratio declining monotonically from aHR
7.61 (95%CI 2.51–23.00) to aHR 1.15 (95%CI 1.02–1.31) with increas-
ing age. In the longitudinal analysis of eGFR change among patientswith
IBD, exposure to 5‐ASAs andmethotrexatewere not associatedwith an
increase or decline in eGFR (−0.04mL/min/1.73m2, 95%CI ‐0.17 ‐ 0.09
and 0.29 mL/min/1.73 m2, 95% CI ‐0.07‐0.66, respectively). Azathio-
prine was associated with small improvement in eGFR (0.32 mL/min/
1.73 m2, 95% CI 0.16–0.48).
Conclusions: The hazard ratio of IBD for development of CKD declines
with increasing age and common IBD medications are not associated
with declines in eGFR. The mechanism of the IBD‐CKD association
should be the subject of future research.
191 | Risk and prognosis of primary liver,
gallbladder, bile duct, and pancreatic cancer
after a negative CT scan: A Danish
population‐based Nationwide cohort study
Frederikke S. Troelsen; Rune Erichsen; Anne Ording; Dóra K. Farkas;
Deirdre C. Fenton; Henrik T. Sørensen
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Background: Computed tomography (CT) scans play a key role in
ruling out and detecting primary liver, gallbladder, bile duct, and pan-
creatic (LGBP) cancers. The sensitivity of CT scans for detecting
LGBP cancers is proven to be high. However, the risk of a LGBP
cancer diagnosis after a negative CT scan remains unknown.
Objectives: We aimed to investigate the risk of LGBP cancers detected
after a negative CT scan compared with the risk of these cancers in the
general population and to evaluate the prognosis among patients with
post‐CT detected LGBP cancers compared with patients whose LGBP
cancers were diagnosed during a first‐time CT scan.
Methods: We conducted a nationwide population‐based cohort
study during 2002–2013 using Danish health registries. We identi-
fied all patients with a first‐time abdominal contrast‐enhanced CT
scan who were not diagnosed with a LGBP cancer during the three
months following this scan. We then followed these patients from
three months post‐scan until a first diagnosis of post‐CT detected
LGBP cancer, death, emigration, or for three years. As an absolute
risk measure, we computed cumulative incidence proportions consid-
ering death as a competing risk. We then calculated age‐, sex‐, and
calendar‐period standardized incidence ratios (SIRs) for a LGBP can-
cer as a measure of the relative risk. We evaluated survival among
all patients with a CT scan and a diagnosis of a LGBP cancer regard-
less of the timing of the diagnosis. Patients were followed from their
diagnosis of a LGBP cancer to death, emigration, or end of study.
We calculated survival probabilities and crude and adjusted mortality
rate ratios (MRRs), comparing LGBPs detected after a scan with
LGBPs diagnosed at the time of a scan.
Results: We observed 687 post‐CT detected LGBP cancers among
154,405 patients recorded as having a contrast‐enhanced CT scan of
the abdomen. The absolute risk of LGBP cancers among patients with
a negative CT scan was 0.44% [95% confidence interval (CI):0.40–
0.48] during three years of follow‐up, corresponding to a relative risk
of 2.11 (95% CI:1.83–2.43). The relative risk was substantially
increased during the first three to six months after the CT scan
[SIR = 9.46 (95% CI: 8.05–11.04)]. Five‐year survival was 9.5% (95%
CI:6.8–12.7) for post CT‐detected LGBP cancers and 6.4% (95%
CI:5.2–7.8) for cancers diagnosed at a first‐time scan. The adjusted
MRR was 0.88 (95% CI:0.80–0.97).
Conclusions: Although the absolute risk was low, patients with a neg-
ative CT scan had an increased relative risk of a LGBP cancer. Progno-
sis was poor regardless of diagnosis time.
192 | Progression from metabolic syndrome
to non‐alcoholic fatty liver disease: Analyses
in an E.M.R‐claims database
Brenna L. Brady; Debra E. Irwin
IBM Watson Health, Bethesda, MD
Background: Non‐alcoholic fatty liver disease (NAFLD), the most com-
mon cause of chronic liver disease, is increasing alongside known risk
factors like metabolic syndrome (METS).
Objectives: This study used the IBM MarketScan Explorys Claims‐
EMR Dataset to explore progression to NAFLD in METS patients.
Methods: Adults with METS (ICD‐9:277.7; ICD‐10:E88.1) were identi-
fied and stratified by NAFLD risk. The first METS diagnosis served as
the index date; continuous eligibility for 6 months prior and 24 months
following index was required. Patients with baseline diagnoses of
NAFLD or diagnoses of alcohol dependence, hepatitis, liver or meta-
static cancer,or biliary cirrhosis at any time were excluded. High (HR)
and low (LR) NAFLD risk groups were defined at index based on evi-
dence of any of the following: BMI > = 25, AST or ALT > = 30, diabe-
tes, a liver biopsy, or bariatric surgery. Clinical characteristics and the
incidence of NAFLD were compared between groups.
Results: The sample included 21,186 patients with METS; 40% of the
sample (8,518) was classified as having a high risk of NAFLD. HR
patients were older (54.9 v. 50.7) and more likely to be male (43.4% v.
37.8%) compared to LR patients, p < 0.001. A higher proportion of HR
patients (6.9% v. 3.9%) progressed to NAFLD and within a shorter time
(253 v. 316 days) than LR patients. Clinically, progressors were more
likely to have elevated liver enzymes, low HDL, hypertension, hyperlip-
idemia, diabetes, and obesity at baseline compared to non‐progressors.
Progression to NAFLD also resulted in a ~3‐fold increase in annual
healthcare costs over the study period compared to METS alone.
Conclusions: Within a population of METS patients, some patients
remain at higher risk of NAFLD. Identification and treatment of METS
patients with elevated NAFLD risk may help to delay the onset of
chronic liver disease, improve outcomes, and mitigate increasing costs
of care.
193 | Epidemiology and characteristics of
patients with hepatocellular carcinoma and
Care in the United States
Huifen Wang; Ping Sun; Binbing Yu; Iksha Herr; Yunes Doleh
AstraZeneca, Gaithersburg, MD
Background: The incidence of liver and intrahepatic bile duct cancer,
of which hepatocellular carcinoma (HCC) accounts for 72.7%, has dou-
bled from 1992 to 2014 in the United States (US).
Objectives: This non‐interventional, cross‐sectional study aimed to
examine the latest epidemiology of HCC by analyzing 2 large US
databases.
Methods: The IBMMarketScan (IBM‐MS) and Surveillance, Epidemiol-
ogy, and End Results‐National Program of Cancer Registries (SEER‐
NPCR) databases were analyzed separately. Patients (age ≥ 18 years)
with HCC as the primary cancer who were covered by employer‐pro-
vided commercial or Medicare supplemental insurance were identified
from the IBM‐MS database using International Classification of Dis-
eases, Ninth and Tenth Revision (ICD‐9/10) codes. Index diagnosis
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was defined as the first eligible HCC diagnosis within the study period
(Jan 2012‐Sep 2017) and no other HCC diagnosis in the prior
12 months. Comorbidities, performance status, distribution of
patients, and treatments received were described. In SEER‐NPCR
(Jan 2010‐Dec 2014), a nationally representative patient sample was
analyzed to describe the incidence and mortality of patients with HCC.
Results: A total of 8150 and 119,927 patients were identified in IBM‐
MS and SEER‐NPCR, respectively. Patients were predominately male
in both databases (IBM‐MS: 72%; SEER‐NPCR: 75%). The HCC inci-
dence rates among the IBM‐MS cohort were 5.9, 5.5, 4.9, and 4.7 per
100,000 person‐years in 2013, 2014, 2015, and 2016, respectively.
The downward trend in the HCC incidence rate post‐2013 for this pop-
ulation coincided with the drop in HCC incidence rate from 2013 to
2014 in SEER‐NPCR. Among the IBM‐MS cohort, 6%, 36%, and 59%
of patients had hepatitis B, hepatitis C, and cirrhosis at index diagnosis,
respectively.Most patients (88%)were considered to have good perfor-
mance status (defined as without any hospice, hospital bed, oxygen use,
etc.) at index diagnosis. Embolization and chemo/targeted therapies
were the most common treatments received by patients irrespective
of the disease stage (31% and 12%, respectively) and in patients with
metastatic HCC (19% and 18%, respectively). Approximately 44% of
the index HCC diagnosis occurred in hospital outpatient settings, 31%
in inpatient settings, and 23% in physician offices.
Conclusions: This study identified the recent epidemiologic changes in
patients with HCC and characterized their comorbidities in a commer-
cially insured and a US representative population. These epidemiologic
data may be important considerations for US payers making coverage
policies for patients with HCC.
194 | SALT‐II: Study of acute liver
transplantation in France
Severine Lignot‐Maleyran; Sinem‐Ezgi Gulmez; Sophie Micon;
Regis Lassalle; Jeremy Jove; Patrick Blin; Cécile Droz‐Perroteau;
Nicholas Moore
Bordeaux PharmacoEpi, Bordeaux, France
Background: A previous study (SALT) looked at all liver transplanta-
tions in 7 countries in Europe over 3 years (2005–2007). SALTII is a
continuation of SALT, in France, over 2008–2013.
Objectives: To estimate the event rates for drug‐associated acute liver
failure leading to registration for transplantation (ALFT).
Methods: All ALFT without identified clinical cause were retrieved
from the 22 French liver transplant centers from 2008 to 2013. Clin-
ical information and previous drug exposure were abstracted by
trained assistants and validated by the Centre director. Previous expo-
sure was considered within 30 days before onset of liver symptoms.
Cases were classified in acute drug overdose (voluntary or not),
drug‐exposed, or non‐exposed ALFT. Exposed cases were compared
to national exposure data from EGB, the 1/97thpermanent represen-
tative sample of SNDS, the National healthcare database system.
Rates are given as cases per million patients (MPt) and per million
patient‐years (MPY).
Results: Over 6 years in 66 million persons, 246 cases of ALFT were
identified, of which 132 were acute drug overdoses, 82 had been
exposed to non‐overdose drugs, and in 32 no drug exposure was
found. Cases were female for 73, 55 and 59% respectively, mean
age was 37, 44, and 42 respectively, and 59%, 77% and 87% were
transplanted. The drug most commonly found in overdose was para-
cetamol (96%), followed by anxiolytics (33%), antidepressants (22%),
hypnotics 15%, as well as opioids and antipsychotics. 43% of paracet-
amol overdoses were non‐intentional. For non‐overdose ALFT, the
most commonly found drugs were paracetamol (43%),
antimycobacterials (AMB, 20%), direct acting antiretrovirals (ARV,
15%), antidepressants (16%), anxiolytics (13%), antiepileptics (13%),
as well as NSAIDs (10%), lipid‐lowering agents (10%), and antithrom-
botic agents (10%). Event rates were highest for AMB with 75/MPt
and 63 per MPY, followed by ARV (2.5/MPt, 1.65/MPY). Non‐over-
dose paracetamol was 0.74/MPt, 0.22/MPY, NSAIDs 0.2/MPt, 0.07/
MPY; Antiepileptics were 2/MPt, 0.88 per MPY, antidepressants
1.15/MPt and 0.44/MPY.
Conclusions: Most drug‐associated ALFT were related to overdoses,
especially of paracetamol. The highest ALFT risk for non‐overdose
drugs was by very far with antimycobacterials, followed by ARV, anti-
epileptics and antidepressants. Paracetamol was present in 43% of
non‐overdose ALFT. These results parallel those for hospital admis-
sions for non‐transplant acute liver injury (EPIHAM), presented else-
where in this meeting.
195 | Blood lipids and risk of dementia in a
cohort of 1.8 million people followed over
two decades
Nawab Qizilbash1,2; Masao Iwagami3; John Gregson2; Stuart Pocock2
1OXON Epidemiology, Madrid, Spain; 2London School of Hygiene &
Tropical Medicine, London, UK; 3University of Tsukuba, Tsukuba, Japan
Background: The association between lipids and dementia is
inconsistent.
Objectives: To investigate the association between lipid measure-
ments and the incidence of dementia,
Methods: We conducted a retrospective cohort study using data from
the UK Clinical Practice Research Datalink (CPRD). We included peo-
ple aged > = 40 years old with a first total cholesterol (TC) measure-
ment between 1992 and 2009 we also identified a subset of people
with measurements of triglycerides (TGs) and high‐density lipoprotein
cholesterol (HDL‐C) while low‐density lipoprotein cholesterol (LDL‐C)
was calculated. We excluded people with a prior record of dementia
diagnosis. Patients were followed until a record of dementia diagnosis
death, change of general practice, or last data collection. Using
Poisson regression, we estimated rate ratios to compare five catego-
ries of each lipid fraction, adjusting for age, sex, calendar year, smoking
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and alcohol status, body mass index, a history of diabetes, cardiovas-
cular diseases, COPD, and antihypertensives and lipid‐lowering agents
overall and by age at first measurement (<65 or ≥ 65 years old) and
length of follow‐up (<10 years or ≥ 10 years).
Results: In our cohort of 1,853,954 eligible people with a first TC mea-
surement (median baseline age 59 years, male sex 48.9%, median fol-
low‐up 7.4 years), 49,416 people received a recorded diagnosis of
dementia during follow‐up, providing an incidence rate of 3.5 per
1,000 person‐years. Overall, there was no association between TC
level and dementia. In a patients with TC measurement in midlife (i.e.
at <65 years old) and follow‐up >10 years, there was a strong positive
association between TC level and dementia: adjusted rate ratios (95%
CIs) were 1.26 (1.01–1.58), 1.36 (1.09–1.68), 1.48 (1.19–1.85), and
1.53 (1.22–1.93) in the 2nd, 3rd, 4th, and highest group, respectively.
A similar pattern was observed for LDL‐C, while there was no associ-
ation between TGs or HDL and dementia. Simulation accounting for
the influence of unmeasured apoE4 variant did not materially change
the estimates.
Conclusions: This single large study explains the conflicting results of
previous studies on the association between lipid measurements and
risk of dementia. TC and LDL measured in midlife were associated
with the incidence of dementia after 10 years.
196 | Suicidal behaviors in patients
diagnosed with multiple sclerosis (MS): A
study in the UK clinical practice research
datalink (CPRD) GOLD
Rebecca Persson1; Sally Lee2; Neil Minton2; Steve Niemcryk2;
Anders Lindholm2; Susan Jick1,3
1Boston Collaborative Drug Surveillance Program, Lexington, MA;
2Celgene Corporation, Summit, NJ; 3Boston University School of Public
Health, Boston, MA
Background: Suicides among multiple sclerosis (MS) patients, though
rare, are more common than among non‐MS patients. However, there
is limited information on other suicidal behaviors (including attempts
and ideation) among MS patients.
Objectives: To estimate the prevalence and incidence of suicidal
behavior in patients with MS and compare them to matched non‐MS
patients.
Methods: We conducted a cohort study in the UK Clinical Practice
Research Datalink (CPRD) GOLD. Each MS patient diagnosed from
2001–2015 with ≥1 year of pre‐diagnosis history was matched with
non‐MS patients of comparable age, sex, general practice and record
history length before cohort entry (MS diagnosis or matched date)
and general practice. We compared prevalence of suicidal behaviors
and risk factors before cohort entry using chi‐square tests. Using
Byar's method, we calculated incidence rates (IRs) and incidence rate
ratios (IRRs) with 95% confidence intervals (CIs) of suicidal behaviors
after cohort entry.
Results: 6932 MS patients were identified and compared with 68,526
non‐MS patients (female, 70%; median age at cohort entry, 43 years).
Before cohort entry, 113 (1.6%) MS patients and 934 (1.4%) non‐MS
patients had a history of suicide attempt or ideation (p = 0.07). 279
(4.0%) MS patients and 2570 (3.8%) non‐MS patients had a history
of intentional self‐harm or drug overdose (p = 0.25). During a median
follow‐up of 5 years, 5 MS patients and 41 non‐MS patients died by
suicide or made suicide attempts. The IRs per 10,000 person‐years
(PY) of any suicidal behavior (suicide death, attempt or ideation) were
11.4 (8.4–15.1) for MS patients and 7.8 (7.0–8.8) for non‐MS patients
[IRR 1.45 (1.04–1.97)]. Among patients with no history of suicidal
behavior or risk factors before cohort entry, the IRs of suicidal behav-
iors were 8.9 (6.3–12.4) for MS patients and 5.3 (4.6–6.1) for non‐MS
patients [IRR 1.67 (1.14–2.38)]. IRs and IRRs were higher among males
and patients age < 40 years in both analyses.
Conclusions: In the UK CPRD GOLD, MS patients had a similar prev-
alence of suicidal behavior before MS diagnosis as matched non‐MS
patients before their matched date. After MS diagnosis or matched
date, suicide and suicide attempts were rare. Rates of any suicidal
behavior were increased in MS compared to non‐MS patients after
diagnosis, with the strongest risk among males and patients age less
than 40.
197 | Incidence of venous thromboembolic
events among amyotrophic lateral sclerosis
patients in a United States health insurance
claims database
Varant Kupelian; Emma Viscidi; Susan Hall; Li Li; Susan Eaton;
Anne Dilley; Nicolas Currier; Toby Ferguson; Laura Fanning
Biogen, Cambridge, MA
Background: Reduced mobility in ALS patients is hypothesized to
increase risk of venous thromboembolism (VTE), consisting of deep
vein thrombosis (DVT) and pulmonary embolism (PE). Few small, sin-
gle‐center studies have investigated the risk of VTE in ALS patients.
Given the high morbidity and mortality associated with VTE, further
understanding of risk in ALS may inform clinical care.
Objectives: Estimate the incidence of VTE in amyotrophic lateral scle-
rosis (ALS) patients compared to non‐ALS controls.
Methods: Patients were identified from a US health insurance claims
database, Truven Health MarketScan®, between 2012 and 2018.
ALS was defined as patients age ≥ 18 years with ≥2 ALS claims
≥27 days apart with ≥1 claim(s) from a neurologist visit or ≥ 1 ALS
claim(s) and a prescription for Riluzole or Edaravone. Each ALS case
was matched to 5 controls without ALS on age and gender. VTE was
defined as ≥1 claim(s) for VTE and ≥ 1 anticoagulant prescription(s)
or VTE related procedure(s) within 7 days of VTE claim date. Incidence
rates were reported per 1,000 person‐years (PYs). Hazard ratios (HR)
and 95% confidence intervals (95% CIs) were estimated using Cox's
proportional hazards model.
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Results: Among 3,078 ALS subjects and 15,390 controls, incident VTE
occurred in 70 ALS subjects (2.3%) and 47 controls (0.3%). Incidence
rates of VTE were 18.2 per 1,000 PYs in ALS cases versus 2.5 in con-
trols with a HR of 7.1 (95% CI: 4.9, 10.2). Median time from initial ALS
claim to first VTE was 7 months (range: 0.4, 58 months).
Conclusions: Consistent with previous studies, a higher incidence of
VTE was observed in a large sample of ALS patients from across the
US compared to matched controls. The markedly increased risk under-
scores the importance of preventive efforts and careful monitoring for
DVT and PE in ALS patients.
198 | Risk factors for suicide and suicide
attempts among patients with treatment
resistant depression: A population based
nested case–control study
Philip Brenner1; Therese M.‐L. Andersson1; Antti Tanskanen2;
Allitia DiBernardo3; Gang Li3; Lena Brandt1; Johan Reutfors1
1Karolinska Institutet, Stockholm, Sweden; 2University of Eastern
Finland, Kuopio, Finland; 3 Janssen Global Services, Titusville, NJ
Background: The risk for suicide is markedly elevated in treatment
resistant depression (TRD) compared to other patients with depres-
sion. However, risk factors for suicide and attempted suicide have
not been investigated in this clinical population.
Objectives: To investigate risk factors for suicide and attempted sui-
cide in TRD, utilizing a pharmacoepidemiological definition of TRD
for use in Swedish health register data.
Methods: A cohort of 119,407 antidepressant treated patients
>18 years diagnosed with depression in specialized health care
2006–2014 were identified in Swedish register data. Patients who
started a third sequential AD treatment during the same depressive
episode were classified withTRD. Among these, a nested case–control
study was performed, where each identified case of suicide or
attempted suicide were matched to three controls by age, sex, time
from depression diagnosis to TRD and time since TRD.
Sociodemographic and clinical risk factors from the literature were
assessed using univariable and multivariable conditional logistic
regression analyses.
Results: Of the 15,631 patients identified with TRD (58% women),
178 (1.1%) died by suicide and 1,242 (7.9%) experienced a suicide
attempt during follow‐up. In multivariable analyses, a suicide attempt
was associated with an elevated risk of suicide within 1 year (aOR
8.8, 95% CI 4.5–16.9), and if over a year ago (aOR 3.6, 95% CI 1.9–
6.7). Higher education increased the suicide risk compared to lower
education (aOR 1.7, 95% CI 1.02–2.8). Factors associated with
attempted suicide were: previous suicide attempt (aOR 5.1, 95% CI
4.0–6.5 within 1 year; aOR 2.5, 95% CI 2.0–3.1 over a year ago), sub-
stance use (aOR 2.6, 95%CI 2.2–3.1), anxiety disorder (aOR 1.3, 95%
CI 1.1–1.5), personality disorder (aOR 1.9, 95% CI 1.5–2.3), recurrent
depression (aOR 1.2, 95% CI 1.01–1.5 within 1 year; aOR 1.4, 95%
CI 1.1–1.7 thereafter), and somatic comorbidity (aOR 1.4, 95% CI
1.2–1.7). Results were similar when stratified by age and sex. In a sep-
arate analysis performed only on the 93 suicide cases without any his-
tory of suicide attempts in the registers, substance use emerged as an
independent risk factor (aOR 2.1, 1.2–3.6).
Conclusions: Suicide attempts, especially if recent, are strong risk fac-
tors for completed suicide in TRD. Several established risk factors for
suicide attempts among patients with MDD were identified also in
TRD.
199 | Early signs of bipolar disorder in a UK
primary care patient cohort
Catharine Morgan1; Darren M. Ashcroft1; Roger T. Webb1;
Carolyn A. Chew‐Graham2; Anya Francis1; Alison R. Yung1
1The University of Manchester, Manchester, UK; 2Keele University, Keele,
UK
Background: Bipolar Disorder (BD) is a serious mental illness charac-
terized by mood instability. Delay in diagnosis is typically between
6–10 years with many experiencing persistent untreated symptoms
and potentially poorer outcomes such as poor social adjustment and
high prevalence of coexisting cardiovascular, endocrine/metabolic or
neurological conditions. There is no agreed strategy for improving
early identification and treatment of BD.
Objectives: To identify signs of emerging Bipolar Disorder, including
prior mental illness symptomatology and diagnoses, psychotropic
medication prescribing and health service engagement.
Methods: The Clinical Practice Research Datalink (CPRD) is an
anonymised primary care electronic patient record database with link-
age to secondary data. Adult incident BD diagnoses made during years
2010–2017 inclusive were extracted using Read and ICD‐10 codes.
Matching by age, gender and GP practice was applied using 1:20 ratio
of case:comparators without BD. Extracted health events prior to
index date included other mental illness diagnoses, prescriptions (anti-
depressants, antipsychotics, benzodiazepines, Z‐drugs, mood stabi-
lizers, pregabalin, gabapentin, strong opioids), substance abuse, self‐
harm/suicidal ideation, mood swings, sleep disturbance and service
interactions (face‐to‐face consultations, missed appointments, A&E
presentations, referral to mental health services). Annual episode inci-
dence for cases and comparators and odds ratios of cases presenting
with each health event prior to index date were reported.
Results: There were 2,366 incident BD cases and 47,138 comparators
(median age 40 years, 60.5% females). Cases had higher incidence of
depression, schizophrenia, personality and anxiety disorders even
10 years before BD diagnosis compared to non BD comparators.
Cases were 8 times more likely to have received 3 different categories
of prescription 6 years prior to index date (OR: 8.4 [95% CI 6.8, 10.6];
p < 0.001). The number of face‐to‐face consultations was higher in all
years prior to index date, with a median [IQR] of 8[15] for cases vs
4[9] for comparators, p < 0.001. At 5 years prior to BD diagnosis, cases
were 5 times more likely to miss 6 scheduled appointments in a year
compared to comparators.
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Conclusions: Potentially useful signals to raise awareness in primary
and specialist care include more than three psychiatric drug prescrip-
tions during the same year, multiple GP attendances in one year,
increasing frequency of non‐attendance of scheduled appointments.
Knowledge about these signs could aid earlier detection of the illness,
leading to more timely and appropriate care.
200 | Parkinson disease psychosis
prevalence, associated comorbidities, and
mortality in the Medicare population
Daniel Weintraub1; Allison W. Willis1; Pilar Torres2; Keith Liu3;
Andrew Shim2; Doral Fredericks2; George Demos2
1Perelman School of Medicine, University of Pennsylvania, Philadelphia,
PA; 2ACADIA Pharmaceuticals, San Diego, CA; 3ACADIA
Pharmaceuticals, Princeton, NJ
Background: Parkinson disease psychosis is characterized by halluci-
nations or delusions, has a lifetime prevalence of over 50% among
Parkinson disease (PD) patients, and is a leading cause of disability
and nursing home placement. Unfortunately, studies have yielded con-
flicting results around the comorbidities and risk factors for PDP. This
analysis evaluates one of the largest populations of PDP patients and
determines the factors and outcomes associated with PDP.
Objectives: To characterize PDP patients in the Medicare database,
determine comorbidities associated with the disease, and evaluate
mortality compared with PD without psychosis.
Methods: A retrospective study evaluated the full Medicare claims
database during a 4‐year period from January 1, 2012, to December
31, 2015. PD patients were identified as patients having at least 1
claim for a diagnosis of PD and another confirmatory claim for PD at
some point during the study period. PDP patients were identified as
those with at least 1 psychosis diagnosis claim during the study period
and at least 2 PD diagnosis claims, with at least 1 of those occurring
before the first psychosis diagnosis.
Results: Overall, 106,893 PD patients were identified: 68,821 PD
patients without psychosis (64.4%) and 38,072 PDP patients
(35.6%). The PDP cohort was older, with a mean age of 81.9 years
vs 78.7 years in the PD cohort (P < 0.001), and prevalence of PDP
increased with age. The PDP cohort had more comorbidities, with a
mean Charlson Comorbidity Index score of 4.14 vs 2.46 in the PD
cohort (P < 0.001). The most common comorbidities in the PDP cohort
with a prevalence greater than twice that of the PD cohort included:
urinary tract infection, dementia, congestive heart failure, depressive
symptoms, stroke, and pneumonia. Age‐standardized mortality in the
PDP cohort was also significantly higher than in the PD cohort, 28.2
vs 7.3 deaths per 100 patient years, respectively.
Conclusions: As patients with PD age, their likelihood of experiencing
symptoms of psychosis increases. The increased patient morbidity and
mortality associated with PDP, along with the increased prevalence of
comorbidities in this population, suggests the need for the utilizations
of treatments that can control these symptoms without worsening the
other concurrent comorbid conditions experienced by these patients.
201 | The incidence of stroke among
patients undergoing elective open posterior
lumbar fusion procedures with multilevel
instrumentation: A retrospective cohort study
Patrick Arena; Jingping Mo; Charu Sabharwal; Elizabeth Begier;
Alejandra Gurtman; Xiaofeng Zhou; Qing Liu; Rongjun Shen;
Charles Wentworth; Kui Huang
Pfizer Inc, New York, NY
Background: Stroke is a rare but life‐threatening complication of spi-
nal surgery occurring in approximately 0.2% of adults undergoing pos-
terior lumbar fusion procedures. However, data on the incidence of
stroke among adults undergoing complex instrumented spinal surgery
are limited.
Objectives: To estimate the incidence of stroke among adults under-
going elective open posterior lumbar fusions procedures with multi-
level instrumentation (EOPLFPMI) in the United States.
Methods: A retrospective cohort study using a longitudinal electronic
health record (EHR) database, Optum EHR, from January 1, 2007 to
June 30, 2018 was performed. Patients aged 18 to 85 years with
≥183 days of enrollment in the database prior to undergoing
EOPLFPMI were identified. EOPLFPMI, stroke, and selected clinical
characteristics used for stratifications were defined based on Interna-
tional Classification of Disease codes. Patients were followed from the
index date (i.e. the date of EOPLFPMI surgery) until the occurrence of
stroke, death, loss to follow‐up, or end of study period. Descriptive
statistics were performed to describe patients' demographic and clini-
cal characteristics; incidence proportions (IPs), incidence rates (IRs),
and 95% confidence intervals (CIs) were estimated in the following
risk windows: surgical hospitalization, 10, 30, 90, 180, and 365 days
post‐operation.
Results: A total of 43,287 patients were eligible for the study. The IP
of stroke following EOPLFPMI ranged from 0.30% (95% CI: 0.25%,
0.35%) during surgical hospitalization to 1.14% (95% CI: 1.04,
1.24) ≤ 365 days post‐operation; the IR of stroke following
EOPLFPMI per 1000 person‐years (PYs) decreased consistently from
227.99 (95% CI: 191.73, 271.12) during surgical hospitalization to
13.88 (95% CI: 12.70, 15.17) ≤ 365 days post‐operation. Stratified
analyses revealed that older patients and those with longer hospital
stays had a higher incidence of stroke. However, the longer hospital
stays could be a consequence of stroke. Racial differences were
observed too (e.g., the IR of stroke ≤365 days post‐operation per
1000 PYs was 20.86 among black patients and 13.48 among white
patients).
Conclusions: The stroke incidences observed in our study are slightly
higher than those reported in the literature; however, this discrepancy
may be due to differences in the study population (e.g., complex
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instrumented surgeries), follow‐up period, and data source between
our study and those in the literature.
202 | Incidence of depression, anxiety and
self‐directed violence in women with uterine
fibroids
Stephanie E. Chiuve1; Carrie Huisingh1; Whitney S. Krueger1;
Deepa Chand1; Ryan D. Kilpatrick1; Lauren A. Wise2
1AbbVie, Inc, North Chicago, IL; 2Boston University School of Public
Health, Boston, MA
Background: Depression and anxiety are commonly reported among
women with uterine fibroids (UF). Further, women with depressive
symptoms and diagnosed depression have a greater risk of UF than
women without. Few studies have quantified the incidence of depres-
sion, anxiety and self‐directed violence in women with UF.
Objectives: To evaluate the incidence of mental health disorders and
self‐directed violence in diagnosed UF patients.
Methods: Women aged 18–50 years with UF (N = 317,055) were
identified in the Optum Clinformatics™ claims database from May 1,
2000 through March 31, 2018. UF was defined as ≥2 diagnosis claims
for UF (ICD9 codes 218.X or ICD10 code D25.X; N = 89,066, 28%) or
1 claim preceded by ultrasonography 30 days prior (N = 227,989,
72%). Women with UF were age‐matched 1:2 to women without
UF, who had a claim for a general medical exam (N = 635,183).
Depression and anxiety were defined by ICD9 and ICD10 diagnosis
codes and/or prescription fills for antidepressants or antianxiety med-
ications, respectively. In sensitivity analysis, these outcomes were
defined using diagnosis codes only. Self‐directed violence (suicide, sui-
cide attempt, and intentional self‐inflicted injury or self‐harm) was
defined by ICD9 and ICD10 diagnosis codes. Women with claims for
depression, anxiety, self‐directed violence or prescription fills for anti-
depressants and antianxiety medications at baseline were excluded.
Cox proportional hazards models estimated the hazard ratio (HR)
and 95% confidence interval (CI) between UF and each outcome,
adjusting for demographics and comorbidities at baseline.
Results: Overall, the mean age was 41 (SD: 6) years. Women with UF
compared to women without were more likely to be African‐American
(20% v 9%), have a history of hypertension (20% v 16%), infertility
diagnosis (5% v 3%), and prior hysterectomy (4% v 1%) at baseline.
The crude incidence rate (per 1000 patient‐years) for depression
(58.1 vs. 55.3), anxiety (75.6 vs. 64.4) and self‐directed violence (0.6
vs. 0.4) were higher for women with UF compared to women without.
The adjusted HRs (95% CI) comparing women with UF to women
without were 1.06 (1.05–1.08) for depression, 1.16 (1.15–1.17) for
anxiety, and 1.40 (1.24–1.58) for self‐directed violence. The HRs were
not appreciably different when depression and anxiety were defined
by diagnosis codes only.
Conclusions: Women with diagnosed UF have an elevated risk of
diagnosed depression, anxiety, and self‐directed violence. Because
comorbid mental illness may affect treatment strategies, identifying
women at risk may improve patient‐centered care.
203 | A landmark approach to estimate the
incidence of malignancies in patients treated
for multiple sclerosis
Mette Nørgaard1; Emmanuelle Boutmy2; Katalin Veres1;
Caroline Foch2; Melinda Magyari3; Meritxell Sabidó2
1 Institute of Clinical Medicine, Aarhus University Hospital, Aarhus,
Denmark; 2Merck KGaA, Darmstadt, Germany; 3Danish Multiple
Sclerosis Center and The Danish Multiple Sclerosis Registry, Copenhagen
University Hospital, Rigshospitalet, Copenhagen, Denmark
Background: Long‐term effect of drugs on malignancy risk is difficult
to characterize due to the time lag between drug initiation and event
onset. Considering the methodological challenge involved in the
dynamic nature of the exposure period, a landmark approach allows
to consider different exposure time.
Objectives: Implement a landmark approach for estimating the inci-
dence of any malignancies (excluding non‐melanoma skin cancer) in
MS patients (pts) initiating immunomodulators (IM) or immunosup-
pressants (IS).
Methods: Data from the Danish Multiple Sclerosis Registry linked to
the Danish Cancer Registry were used to identify adult pts with a
diagnosis of MS between 1995–2015, at least one prescription for
an IM or IS between 1995–2016 (first prescription as the index date),
and ≥ 1 year of database history prior to the index date. Pts were
followed until the first occurrence of: any malignancy, death, end of
data collection or 31‐Dec‐16. Groups were categorized first based
on drug taken at index, secondly based on drug taken continuously
during 12, 24 or 48 months (landmark periods) with gaps less than
90 days allowed. The incidence rate (IR) of any malignancy per
100,000 person‐years, with 95% confidence interval (95% CI), was cal-
culated in each exposed group.
Results: At index, respectively 6,739, and 1,329 were identified in the
IM only and IS only groups. By IM only at index, IR per 100,000 PY
(95% CI) was 329.1 (284.8–373.4), median (q1‐q3) follow‐up (FU) of 9
(5–13) years. After landmark periods of 12, 24, 48months, duringwhich
patients were continuously exposed to IM only, IR estimates respec-
tively ranged from 337.0 (289.0–385.0), 359.2 (305.0–413.4), to
403.5 (334.1–472.8). As the landmark duration increased, the number
of patients decreased, respectively 6,275, 5,531, and 4,264 pts. By IS
only at index, IR per 100,000 PY (95% CI) was 383.5 (189.4–577.5),
median (q1‐q3) FU of 2 (1–3) years. After selecting pts continually
exposed to IS only during landmarks of 12, 24 and 48 months, IR esti-
mates respectively ranged from 478.7 (207.9–749.6), 382.1 (76.4–
687.9), to 689.7 (137.8–1,241.6). Number of patients decreased for
each increase in landmark duration: 1,077, 616 and 187 pts,
respectively.
Conclusions: With various exposure duration and across treatment
groups, the IR estimates overlapped. However, due to the lower
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number of patients, the estimates in the IS groups were less precise. A
strength of this method is the ability to obtain IR estimates for variable
length of continuous exposure. A limitation is the decrease of the
number of patients, while the duration of the landmark increased,
especially in the IS group.
204 | Description of treatment resistant
depression in France, from the French
Nationwide claims database
Pauline Bosco‐Lévy1; Angela Grelaud1; Patrick Blin1; Bernard Astruc2;
Bruno Falissard3; Pierre‐Michel LLorca4,5; Dominique Schaetz6;
Marie‐Agnès Bernard1; Régis Lassalle1; Nicholas Moore1;
Cécile Droz‐Perroteau1
1Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux,
Bordeaux, France; 2Psychiatrist, Paris, France; 3Centre de recherche en
épidémiologie et santé des populations (CESP)/Institut national de la
santé et de la recherche médicale (INSERM) U1018, Maison de Solenn,
Paris, France; 4CMP B CHU, Clermont‐FerrandUniversité Clermont
Auvergne, EA 7280 Clermont‐Ferrand, France; 5Fondation FondaMental,
Créteil, France; 6 Janssen, Issy les Moulineaux, France
Background: Treatment Resistant Depression (TRD) is a serious health
hazard worldwide, which results in significant impairment, increased
morbidity and high costs for society. To date, the global epidemiolog-
ical situation and the clinical characteristics of TRD patients are poorly
understood, especially in France.
Objectives: To estimate annual incidence and prevalence of TRD in
France, and patient characteristics, from the nationwide claims data-
base SNDS (“Système National des Données de Santé”).
Methods: We identified all adult patients (≥ 18 years) with aTRD epi-
sode between January 1, 2012 and December 31, 2014 in EGB
(“Échantillon généraliste des bénéficiaires”), the 1/97 permanent random
sample of SNDS. After exclusion of any psychotic disorders, Parkinson's
disease, dementia or bipolar affective disorders, a TRD episode was
defined as the succession of 3 sequences of different antidepressants
(AD), or a combination of an ADwith a potentiator (lithium, antiepileptic
drugs, antipsychotic drugs or thyroid hormones) over a period of
3months, with at least 3weeks of treatment between eachAD andwith
a Medication Possession Ratio ≥ 80%. TRD patients should not have
had any AD dispensing or hospitalization for depression within the
6months preceding the first AD dispensing (i.e. initiation date). The inci-
dence rate was estimated yearly from 2012 to 2014 then averaged. The
prevalence was estimated according to a Gamma parametric function
using treatment duration and a 30‐year prediction.
Results: Between 2012 and 2014, 700 patients were identified in EGB
with a TRD episode. The mean age was 47.4 years; 52.7% were
women, 694 had only one episode and 6 had 2 episodes. The median
duration of a completed TRD episode was 5.4 months. The annual
incidence of TRD was estimated at 5.8 per 10 000 persons, and the
annual prevalence at 25.8 per 10 000 persons.
Conclusions: From the event rates we found, TRD may be amenable
itself to further analyses, including analysis of treatment trajectories
and comparative effectiveness in the full national database.
205 | Revisiting multiple sclerosis prevalence
in the 21st century: Exploration based on a
large representative real‐world cohort in the
United States
Allison Bryant; Michael Behling; Shannon Cerf; Richard Gliklich
OM1, Inc, Boston, MA
Background: Recent estimates from claims databases more than dou-
ble the widely reported prevalence of multiple sclerosis (MS) in the
United States (estimated at 400,000 or approximately 123 per
100,000), prompting the creation of a national surveillance registry.
In the meantime, quantifying the disease burden and characteristics
of patients with MS is critical for the diagnosis and management of
this heterogeneous, debilitating disease.
Objectives: To estimate the prevalence of MS in the US using a large,
representative database of patients with linked electronic medical
record (EMR) and claims data.
Methods: The OM1 Data Cloud collects, links, and leverages struc-
tured and unstructured data, including extensive clinical and claims
data on patients from multiple payers seen in a variety of provider
practice types across the US with data from 2013 through the present.
An ongoing, continuously enrolling cohort of MS patients who are pro-
spectively followed was developed using a conservative case defini-
tion for MS based on diagnosis and medication codes. Prevalence
was estimated based on the number of adult patients ≥18 years in
the MS cohort over the total adult patients in the OM1 Data Cloud
from 2013 to 2018.
Results: Of the 195 million adult patients in the OM1 Data Cloud,
approximately 591,000 patients met the case definition for MS and
were included in the MS cohort for a prevalence of 303 per
100,000 patients. The average age of patients was 55 years (SD
13.8) and 75% of patients were female. Prevalence was higher in
the Midwest and North census regions (339 and 319 per 100,000,
respectively) than in the West and South (293 and 286 per
100,000, respectively). Approximately 30% of patients had a history
of treatment with at least one disease‐modifying therapy (DMT) and
5% had more than one. Of patients overall, the most common DMTs
were glatiramer acetate (10%), interferon beta 1a (7%), and dimethyl
fumarate (6%).
Conclusions: The prevalence of MS in the OM1 Data Cloud is more
than double commonly referenced estimates. This finding is important
for planning the provision of healthcare services and motivating the
development of novel therapies. Given that less than one‐third of
patients received DMTs, further investigation into patterns of treat-
ment use to understand unmet clinical need is warranted.
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206 | Odds of discharge to substance abuse
treatment or psychiatric care after
hospitalization for alcohol or drug poisonings,
Maryland 2016
Aida Kuzucan; Sean Fleming; Linda Simoni‐Wastila
University of Maryland, Baltimore, MD
Background: Hospitalizations involving alcohol‐ and drug‐ related poi-
sonings continue to be a pressing public health issue. Poisonings, par-
ticularly those associated with suicide, often indicate a need for
additional psychiatric or substance related care.
Objectives: To identify the predictive variables for discharge to psy-
chiatric or substance use care following hospitalizations involving alco-
hol‐ and drug‐related poisonings.
Methods: This cross‐sectional study identified alcohol and drug‐
related poisoning hospitalizations from a 100% sample of 2016
Maryland Health Services Cost Review Commission (HSCRC) data.
Alcohol and drug‐related poisonings were defined as events with
ICD‐10‐CM diagnostic codes for poisonings involving alcohol, heroin,
opioids, marijuana, cocaine, psychotropics, and hallucinogens. Chi‐
square tests compared demographic characteristics among individ-
uals who were and were not discharged to psychiatric or substance
use rehabilitation facilities after alcohol or drug‐related poisonings.
Adjusted logistic regression was used to determine the association
of predictive variables with discharge to psychiatric or substance
use treatment facilities among individuals with alcohol or drug‐
related hospitalizations.
Results: In 2016, 9,952 of the 622,397 hospitalizations in Maryland
involved alcohol‐ or drug‐ related poisonings; 518 (5.2%) of hospitali-
zations involving alcohol and drug‐related poisoning were discharged
to psychiatric or substance use facilities. Relative to alcohol and
drug‐related poisoning individuals not discharged to these facilities,
poisoned individuals who did receive this additional care were youn-
ger (mean 43.6 vs. 55.4 years, p < 0.01), single (80.3% vs. 76.2%,
p < 0.01), and white (74.3% vs. 62.4%, p < 0.01). In our adjusted
model, events involving suicidal intent had increased odds of discharge
to psychiatric or substance use care (OR: 20.38 (95% CI: 16.1–25.2)
compared to individuals with unintentional or not otherwise stated
(NOS) intent.
Conclusions: Care after hospitalization plays an important role in
preventing recurrent alcohol‐ and drug‐ related harms across the
lifespan. More research regarding discharges to psychiatric or sub-
stance abuse treatment facilities and its effect on outcomes overall
and among vulnerable groups is warranted.
207 | Visit adherence and visual acuity in
wet macular degeneration
Brian L. VanderBeek; Meera S. Ramakrishnan; Y.U. Yinxi
Scheie Eye Institute/Univeristy of Pennsylvania, Philadelphia, PA
Background: The effect of missed appointments for anti‐VEGF treat-
ment for age‐related macular degeneration (AMD) on visual acuity
(VA) is unknown. We performed a secondary analysis of the Compar-
ison of Age‐Related Macular Degeneration Treatment Trial (CATT)
study to evaluate the association between patient's visit adherence
to clinical trial visits and VA in AMD patients.
Objectives: To determine if visit adherence is related to visual out-
comes in wet AMD patients.
Methods: The publicly available CATT data files were reviewed to
characterize visit adherence. The 2‐year CATT study protocol required
a visit every 4 weeks (every 28–35 days, 26 total). Visit adherence was
measured in 4 ways: average number of days (avg days) between each
visit, longest duration in days between visits, total number of missed
visits, and visit constancy (the tally of 3‐month periods with at least
1 visit attended). Average and maximum days between visits were also
categorized as being “on time”(28–35 days), “late”(36–60 days), and
“very late”(>60 days). The primary outcome was change in ETDRS
visual acuity (VA) between the baseline study visit and the last visit.
Nonparametric univariate tests, linear and multivariate regression
models were applied to analyze the association between visit adher-
ence parameters and change in VA, controlling for age, gender, and
baseline VA.
Results: 1,173 CATT patients had complete visit data. Mean (standard
deviation [SD]) number of missed visits was 2.7(±3.7). 1,088(93%)
patients had complete visit constancy over the length of the study
period. Avg days between visits were 38.2[SD ± 31.8] days; when cat-
egorized, 966(82.3%) patients were classified as “on time,” 125
(10.7%) were “late,” and 82 (7.0%) were “very late.” These groups
averaged +3.0, −1.1, and − 0.9 letter change in vision, respectively.
The longest duration between two visits ranged from 29 to 667 days
(84.8[±118.6] days).Increasing number of missed visits and longest
duration between visits were significantly associated with decreasing
final visual acuity(p < 0.02 for both). Patients whose average visit
interval were “late” and “very late” were also more likely to have worse
vision(p < 0.001). This remained true even after controlling for base-
line vision, gender, age, drug, and treatment frequency in multivariate
regression modeling. Visit constancy and avg days between visits were
not associated with VA.
Conclusions: Visit adherence contributes to visual acuity outcomes in
AMD.
208 | Do Parents' mental disorders affect
child behaviour via home environments, and/
or Parents' education? A mediation analysis
Md Jamal Uddin1,2; Claus Thorn Ekstrøm2; Merete Nordentoft3
1Shahjalal University of Science and Technology, Sylhet, Bangladesh;
2University of Copenhagen, Copenhagen, Denmark; 3Mental Health
Centre, Copenhagen, Denmark
Background: Children of parents with mental disorders, e.g. schizo-
phrenia (SZ), bipolar disorder (BP), are exposed to numerous
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environmental risk factors and may face different developments and
behavioral problems. These problems may also link to their home envi-
ronments (HEnv) and/or parents' education (PEdu) that act as media-
tors. Classical statistical methods (e.g. linear regression) are widely
applied to study such problems in psychiatric epidemiology. However,
research on this area using mediation analyses is not widely studied.
Objectives: We aimed to investigate the association of parents' men-
tal disorders and child behaviour when home environments and/or
parents' education act as mediators.
Methods: We used data from the Nationwide Danish High Risk and
Resilience Study ‐ VIA7 cohort. The study sample was 522 in which
202 7‐year‐old children living with their parents diagnosed with SZ,
120 children living with their BP parents and 200 control children liv-
ing with their parents who did not have a diagnosis of SZ or BP. The
outcome was considered as child behaviour checklist school‐age ver-
sion (CBCL) and the HEnv and PEdu were considered as mediators.
We analyzed data using different statistical models including parallel
and serial mediation models and the analyses were also stratified by
sex of the children.
Results: Our mediation analyses showed that the total effects of par-
ents' mental disorder, BP and SZ, as compared to the control group on
the CBCL was 6.50 [2.15, 10.85] and 9.96 [6.22, 13.69], respectively.
When considering both mediators simultaneously (serial mediation
model), there was a significant indirect effect of SZ and BP vs. control
on the CBCL through HEnv and PEdu. Here, 34% total effects for BP
and 43% total effects for SZ on the CBCL were accounted by both
mediators. For male children, the mediators could account for 32%
and 39% of the total effect of the BP and SZ on the CBCL and for
female children, they accounted for 42% and 59% of the total effect
of the BP and SZ on the CBCL, respectively.
Conclusions: Our analyses show that the mediation analysis is an
essential tool to find out actual causal association in a complex study
in psychiatric epidemiology. Hence, we conclude that an adequate
home environments and/or parents' education are significant mediat-
ing factors for child behaviour, which is more vital when either one
of the parents is mentally sick.
209 | Epidemiology of radiation retinopathy
in the United States
Wenzhen Ge; Lei Chen; Kimberly Reed; Steve Gao
Regeneron Pharmaceuticals Inc., Tarrytown, NY
Background: Radiation retinopathy (RR) can cause devastating vision
loss in patients undergoing radiation for head and neck malignancies.
Incidence, prevalence, and patient characteristics of RR have not
been well established in the general population of the United States
(US).
Objectives: To estimate incidence and prevalence of RR in a represen-
tative US patient population using large commercial medical claims
databases, and to describe the demographic and clinical characteristics
of patients at first RR diagnosis.
Methods: A cohort of adult patients were retrieved from the Truven
MarketScan Commercial and Medicare Supplemental Database during
2013/01/01–2017/12/31. To be eligible for the study, patients must
be enrolled for at least 6 months during the study period. Cases of RR
were ascertained through an integrated algorithm that is composed of
a sequence diagnosis of head and/or neck cancer; treatment with radi-
ation; and diagnosis of retinopathy. Only the first occurrence of RR
was counted. Age‐sex stratified prevalence was calculated and directly
standardized to the 2017 US population. Incidence rate was defined
and calculated as the number of new cases divided by person‐years.
Demographics, treatment characteristics and comorbidities among
RR patients were described.
Results: A total of 52,865,903 patients were eligible for the analysis,
with a median age of 43 years (range: 18–119 years) and females com-
prised 53% of the total. Among these patients, 3,171 (6.00/100,000)
patients were identified as RR cases. The age‐sex standardized preva-
lence of RR by the US Census population was 7.74/100,000 in 2017.
The incidence rate of RR was 3.37/100,000 person‐years. The median
age at RR diagnosis was 60 years and 60% were males. The median
interval between the first oncology radiation treatment and the first
occurrence of RR was 4.3 months. Patients had received an average
of 11 radiation treatment before the first occurrence of RR. Among
the RR patients, the most common comorbidities were diabetes
(13.2%), chronic pulmonary disease (12.8%), cerebrovascular or cardio-
vascular disease (11.1%), and liver disease (4.0%).
Conclusions: This study characterized the epidemiology of RR patients
using a large medical claims database in the US. The MarketScan data-
bases include employer‐sponsored active employees, dependents, and
retirees and therefore may not be representative of the national pop-
ulation. The algorithm for RR identification was developed based on
claims data and clinician experience; however, future studies with
medical chart review are needed to further validate this algorithm.
210 | Eye color and risk of ocular melanoma
in patients with glaucoma ‐ a Swedish register
study combining data from the Swedish
police Authority's register on passport
applications and National Health Registers
David Hägg; Ingegärd Anveden Berglind; Helle Kieler; Marie Linder;
Ingvild Odsbu
Karolinska Institutet, Centre for Pharmacoepidemiology, Stockholm,
Sweden
Background: Data on the association between glaucoma and risk of
ocular melanoma (OM) are scarce with conflicting results. Individuals
with light eye color are at higher risk of developing OM. However,
the association between eye color and OM in individuals with glau-
coma have not previously been studied. Topical prostaglandins might
increase the risk of OM, but studies show conflicting results. In previ-
ous studies data on eye color have been obtained by visual inspection
of the eye. The availability in Sweden of register data on eye color that
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can be linked via the personal identifier to other national health regis-
ters makes it possible to study the association between eye color and
OM in a real‐world setting.
Objectives: To examine the association between light eye color and
OM in patients with glaucoma.
Methods: A case–control study using linked data from national health
registers and the Swedish Police Authority's register with information
on passport applications. The study population consisted of individuals
filling at least one prescription of topical drugs for glaucoma treatment
during the period 1 July 2006–2012. Individuals who developed OM
were selected as cases. Controls without OM were selected from
the general population. Cases and controls were matched (1:3) on
age, sex and region of residency. Data on eye color were manually
retrieved from passport applications during the period 1964–1989.
Eye color was categorized as light (blue, gray) and other (green, mixed,
brown). Adjusted odds ratio (aOR) with 95% confidence interval (CI)
was calculated by a conditional logistic regression, adjusted for sun
exposure (geographical region).
Results: We identified 44 cases and 132 controls, and obtained data
on eye color for 78% of the individuals. Among the cases, 73% had
light colored eyes, 16% had other eye colors, while 11% had no infor-
mation on eye colors (no passport application in the available period).
For the controls, 58% had light colored eyes, 16% had other eye colors
and 26% had no information on eye colors. The aOR for the risk of
OM was 1.95 (95% CI 0.92–4.11) when comparing light colored eyes
with other eye colors.
Conclusions: We found a slightly and imprecise increased risk of OM
associated with light colored eyes in patients with glaucoma. The
study confirmed that linkage to the Swedish Police Authority's register
was possible and that information on eye color could be obtained for a
high proportion of the individuals.
211 | Incidence of depression, anxiety and
self‐directed harm in women with
endometriosis
Carrie Huisingh1; Stacey A. Missmer2; Natalia Petruski‐Ivleva3;
Whitney S. Krueger1; Ryan D. Kilpatrick1; Deepa Chand1;
Stephanie E. Chiuve1
1AbbVie, Inc, North Chicago, IL; 2Michigan State University, Grand
Rapids, MI; 3Aetion,Inc, Boston, MA
Background: In cross‐sectional studies, women with endometriosis
(EM) have a high prevalence of anxiety and depression. However, pro-
spective studies assessing the relationship between EM and subse-
quent comorbidities are limited.
Objectives: To evaluate the incidence of diagnosed mental health dis-
orders and self‐harm in women with clinically recognized EM.
Methods: Women aged 18–50 years with EM (N = 2,101) were iden-
tified in the Optum Clinformatics™ commercial insurance claims data-
base from May 1, 2000 through March 31, 2018. EM was defined as
≥2 diagnosis claims (ICD9 codes 617.X or ICD10 codes N80.X; 10%)
or 1 claim preceded by laparoscopy 30 days prior (90%). Women with
EM were age‐matched 1:2 to women without EM but had a claim for a
general medical exam (N = 4,232). Depression and anxiety were
defined by ICD9 and ICD10 diagnosis codes and/or prescription fills
for antidepressants or antianxiety medications, respectively. In sensi-
tivity analysis, these outcomes were defined using diagnosis codes
only. Self‐directed violence (suicide, suicide attempt, and intentional
self‐inflicted injury or self‐harm) was defined by ICD9 and ICD10 diag-
nosis codes. Women with claims for depression, anxiety, self‐directed
violence or prescription fills for antidepressants and antianxiety med-
ications at baseline were excluded. Cox proportional hazards models
estimated the hazard ratio (HR) and 95% confidence interval (CI)
between EM and each outcome, adjusting for demographics and
comorbidities at baseline.
Results: The mean age was 38 (SD: 7) years and 63% of women were
Caucasian. Women with EM compared to women without were more
likely to have a history of opioid use (65% v 36%), hysterectomy (49%
v 1%), infertility diagnosis (13% v 5%), low back pain (27% v 20%),
migraines (9% v 6%) and asthma (10% v 7%) at baseline. The incidence
rate (per 1,000 patient‐years) among women with EM was 81.8 for
depression, 98.5 for anxiety and 1.0 for self‐harm, using diagnosis
and/or prescription claims and 39.2 for depression and 35.7 for anxi-
ety, using diagnosis claims only. The adjusted HRs (95% CI) comparing
women with EM to women without were 1.6 (1.4–1.8) for depression,
1.7 (1.5–1.9) for anxiety, and 2.1 (0.6–7.6) for self‐directed harm.
Results were similar when outcomes were defined using diagnosis
claims only.
Conclusions: Women with clinically recognized EM were more likely
to develop depression and anxiety than women without EM. Rates
of self‐directed harm were low but higher among EM patients.
Because comorbid mental illness may affect treatment strategies,
identifying women at risk may improve patient‐centered management.
212 | Epidemiology of acute medical events
in a cohort with a rare neurodegenerative
disease, progressive Supranuclear palsy, after
diagnosis
Denise M. Oleske1; Joan Holman1; Jorge Zamudio1; Robert Diegidio1;
Günter U. Höglinger2
1AbbVie, North Chicago, IL; 2Technical University of Munich, Munich,
Germany
Background: Acute medical events in persons with Progressive
Supranuclear Palsy (PSP), a rare debilitating neurodegenerative disease,
have not been systematically examined outside small clinic samples.
Understanding their incidences occurring in a real world setting and risk
factors help inform strategies to improve patients' quality of life.
Objectives: To determine the frequency, onset, and potential risk fac-
tors for select acute medical events after a diagnosis of PSP.
Methods: This cohort study included patients with a first diagnosis of
PSP [ICD‐10 G23.1], within the interval 1/1/2010 to 12/31/2017,
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aged ≥40 years, both sexes, within electronic medical records data-
bases sourced by Disease Analyzer (IQVIA) from general practitioners
and internists providing community care in Germany, and having at
least 365 days of observation before diagnosis. Five acute medical
events were selected, based on the age and disability present in this
patient population, determined from at least one day after the PSP
diagnosis. Rates were examined by sex, age group (<65, 65+ years)
and a prior diagnosis of Parkinson's disease (PD) (yes/no). Person‐time
in years was computed from the PSP diagnosis date to the first date of
each acute medical event or to the last activity in the database divided
by 365.25 days. Incidence rates, 95% confidence intervals, time to
event probabilities calculated with the product‐limit method, and their
significance were computed using SAS.
Results: The cohort of 115 patients had mean age at diagnosis of
73.7 years, were 54.8% male, and 63.5% had prior diagnosis of
Parkinson's disease (PD). After the diagnosis of PSP, the overall inci-
dence rates of acute respiratory infection (ARI), falls, hospitalization
for any cause, suicidality, and thrombosis were 15.5, 23.8, 26.1, 3.0,
and 3.0 per 100 person‐years, respectively. In subgroup analysis, the
relative risk (RR) of ARI was higher among those with a prior PD diag-
nosis (RR = 2.33, 95% CI: 1.01–5.95, p = 0.05) compared to those
without a prior PD diagnosis. The RR of suicidality among males was
higher than females (RR = 4.76, 95% CI: 0.66–113.4, p = 0.069).
Suicidality is seen in males with approximately 5% probability within
one year after diagnosis. Age group did not predict any of the acute
medical events.
Conclusions: The rates of selected acute medical events after a PSP
diagnosis are high. While some of these acute medical events, such
as falls, could be a symptom of the disease itself, prior diagnosis of
PD or gender could influence their occurrence. Awareness of the rates
of these events may inform strategies for their prevention.
213 | Predictors of in‐hospital psychiatric
care among alcohol‐ and drug‐ related
hospitalizations in Maryland, 2016
Sean Fleming; Aida Kuzucan; Linda Simoni‐Wastila
University of Maryland Baltimore, Baltimore, MD
Background: Alcohol‐ and drug‐ related hospitalizations continue to
be a pressing public health issue. Psychiatric disorders are of concern
among patients involved in alcohol‐ or drug‐ related hospitalizations,
as they are associated with increased risk for substance‐related
adverse events, including overdose.
Objectives: To identify the predictive variables for receiving psychiat-
ric care during alcohol‐ and drug‐related hospitalizations.
Methods: This cross‐sectional study identified alcohol‐ and drug‐
related hospitalizations from a 100% sample of 2016 Maryland Health
Services Cost Review Commission (HSCRC) data. Alcohol and drug‐
related hospitalizations were defined as events with ICD‐10‐CM diag-
nostic codes for abuse, dependence, or poisonings involving alcohol,
heroin, opioids, marijuana, cocaine, psychotropics, and hallucinogens.
Chi‐square tests compared demographic characteristics among indi-
viduals who did and did not receive in‐hospital psychiatric care.
Adjusted logistic regression was used to determine the association
of predictive variables with receipt of in‐hospital psychiatric care.
Results: In 2016, 77,293 of the 622,397 hospitalizations in Maryland
involved alcohol or drugs; 14,404 (18.6%) received in‐hospital psychi-
atric care. Those who received in‐hospital psychiatric services, relative
to individuals not receiving psychiatric care were younger (mean 39 vs.
50 years, p < 0.01), single (86.1% vs. 74.1%, p < 0.01), and associated
with a principal diagnosis of mental or behavioral disorder (98.6% vs.
17.3%, p < 0.01). In our adjusted model, events involving adults older
than 25 had decreased odds of receiving psychiatric care (OR range:
0.38 (95% CI: 0.2–0.7) age 26–34 to 0.09 (95% CI: 0.04–0.2) age 65
and older) compared to individuals 18 or younger (age 19–25 non‐sig-
nificant OR 0.78 (95% CI: 0.4–1.5). Events involving patients who
were married have 0.5 times (0.4–0.7) the odds of psychiatric care
compared to those involving single patients. Gender and race were
found to be non‐significant with males having 1.0 times (95% CI:
0.8–1.3) the odds and African Americans having 1.2 times (95% CI:
0.8–1.5) the odds of psychiatric care compared to females and to
whites, respectively.
Conclusions: Mental health plays an important role in recurrent alco-
hol‐ and drug‐ related harms across the lifespan, but especially in
younger patients. More research regarding in‐hospital psychiatric
intervention and its effect on outcomes overall and among vulnerable
groups is warranted.
214 | Identifying psychosis in patients with
dementia: Not a hallucination or delusion, the
challenge really exists
Joan Forns1; J. Bradley Layton2; Mary E. Ritchey2
1RTI Health Solutions, Barcelona, Spain; 2RTI Health Solutions, Research
Triangle Park, NC
Background: Psychosis is common in advanced Parkinson's disease
and in some dementias, such as Alzheimer's disease. Antipsychotics
are commonly used to treat psychosis associated with dementia,
although the FDA issued a black box warning of mortality risk in these
patients. Assessing the risk of mortality associated with antipsychotics
requires correct identification of patients with psychosis, which may
be challenging, particularly in automated health care databases where
diagnosis code algorithms are used.
Objectives: To identify coding algorithms used to identify patients
with psychosis associated with dementia in recent literature.
Methods: A targeted literature review, from 2008 to date, was con-
ducted in PubMed to identify code algorithms used to identify psy-
chosis associated with dementia in studies assessing the mortality
risk among these patients treated with antipsychotics.
Results: Of 324 records identified in our search strategy, 32 articles
were selected for review. Of them, 28 articles were excluded because
they relied on medication use and 2 were excluded because they
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identified psychosis using patient‐reported questionnaires. Two
included studies conducted in the US identified psychosis using the
following ICD‐9‐CM codes: 293.81–2, 297.0–3, 297.8–9, 298.0–4,
298.8–9, 368.16, and 780.1. We expanded our search by conducting
a literature search in PubMed to identify studies assessing the epide-
miology of psychosis in dementia. We identified 3 additional articles:
1 US study defined psychosis with the presence of one of the follow-
ing ICD‐9‐CM codes: 780.1, 292, 292.1, 293.81–2, 297, 298.3–4,
301.0. Another study conducted in Taiwan identified psychosis with
ICD‐9 codes 295.00–298.9, and 299.10–11. A third US study used
the definition: ≥ 1 medical claim with a diagnosis of psychosis
(298.0, 298.1, 298.4–298.9), hallucinations (293.82, 368.16, 780.1),
or delusions (293.81, 297.1).
Conclusions: The majority of studies analyzing mortality in patients
with dementia treated with antipsychotics did not identify psychosis
with diagnosis codes, and most did not account for delirium or agita-
tion. Only five studies used coding algorithms to identify psychosis
in patients with dementia. Most of these studies used similar codes
to identify hallucinations (293.82 and 780.1) and delusions (293.81
and 297). However, these studies also included different, including
nonspecific, codes to identify psychosis. A validated coding algorithm
updated to ICD‐10‐CM to identify psychosis related with dementia
is recommended.
215 | Sociodemographic and clinical risk
factors of treatment‐resistant depression: A
Danish populations‐based study
Frederikke H. Gronemann1; Martin B. Jorgensen2;
Merete Nordentoft2,3; Per K. Andersen4; Merete Osler1,5
1Center for Clinical Research and Prevention, Frederiksberg, Denmark;
2Mental Health Centre Copenhagen, Copenhagen, Denmark; 3Lundbeck
Foundation Initiative for Integrative Psychiatric Research iPsych,
Copenhagen, Denmark; 4Department of Public Health, Section of
Biostatistics, University of Copenhagen, Copenhagen, Denmark;
5Department of Public Health, Section of Epidemiology, University of
Copenhagen, Copenhagen, Denmark
Background: Knowledge of risk factors of Treatment‐Resistant
Depression (TRD) contribute to understanding the underlying mecha-
nisms and to identify patients at risk. Several studies have investigated
this matter, however, there are still caveats in our current understand-
ing of how different risk factors associate with TRD.
Objectives: To determine how potential sociodemographic and clinical
risk factors associates with TRD.
Methods: We included all citizens in Denmark diagnosed first time
with depression at a hospital, either as in‐ or outpatient, between 1
January 1996 and 31 December 2014. The patients were identified
in the Danish National Patient Registry using the international Classi-
fication of Diseases, Tenth Revision (ICD‐10 codes), codes F32 and
F33. We excluded patients with either a comorbid diagnosis of manic
episode (ICD‐10: F30), bipolar disorder (ICD‐10: F31), persistent mood
disorder (ICD‐10), other or unspecified mood (affective) disorders
(ICD‐10: F38 and F39) or a comorbid schizophrenia spectrum disorder
(ICD‐10: F20). A total of 208,625 patients were followed for develop-
ment of TRD within 12 months after diagnosis. TRD was defined as
two shifts in antidepressant treatment. Patients' redemption of pre-
scriptions for antidepressant medication were identified in the Danish
National Prescription Registry by Anatomic Therapeutic Chemical
(ATC) classification system codes (N06A). Potential sociodemographic
and clinical risk factors were identified in nation‐wide registries. Data
were analyzed using Cox Proportional Hazard Regression and Fine‐
Gray model for competing mortality risk.
Results: 14.1% of patients developed TRD corresponding to an inci-
dence rate of 164.31 per 1,000 person years (95% CI, 162.5–166.2).
Indicators of disease severity (type of depression, depression severity,
type of patient, type of contact) were the strongest risk factors. Disad-
vantaged socioeconomic conditions, stressful life events, comorbid
anxiety (adjusted HR 1.21 (CI 95%, 1.14–1.30)), insomnia (adjusted
HR 1.29 (CI 95%, 1.08–1.55)) and migraine (adjusted HR 1.40 (CI
95%, 1.14–1.71)) as well as use psychotropic drugs were also associ-
ated with higher rates of TRD.
Conclusions: We tracked patients who did not benefit from standard
treatment, and showed that besides indicators of disease severity,
other important risk factors are those related to social conditions,
stressful life events as well as anxiety, insomnia, migraine and the
use of psychotropic drugs.
216 | Confounding variable capture in large
healthcare administrative claims databases: A
trend analysis in the sentinel system
Wei Liu1; Austin Cosgrove2; Sarah K. Dutcher1; Justin Bohn2
1Division of Epidemiology, Office of Surveillance and Epidemiology, CDER,
FDA, Silver Spring, MD; 2Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Boston, MA
Background: Several variables such as smoking, obesity, and drug
abuse are traditionally considered important confounders in post‐mar-
keting observational studies, yet are often underreported due to limi-
tations of administrative claims data.
Objectives: To conduct a trend analysis to determine how well
selected confounding variables are captured in the Sentinel Distrib-
uted Database (SDD), from 2007 through 2017.
Methods: We analyzed healthcare billing data from 17 Data Partners
contributing to the SDD. Descriptive analyses were conducted to
examine the prevalence and incidence of five confounding conditions,
including smoking, obesity, overweight, alcohol abuse or dependence,
and drug abuse or dependence, identified by diagnosis, procedure, and
dispensing codes. Eligible members were required to be continuously
enrolled in health plans with medical and pharmacy coverage for
≥365 days before the date of first recording of a confounder of inter-
est during the study time. For incidence estimates, eligible members
cannot have evidence of the confounder of interest in the prior
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365 days. The proportion of enrollees with at least 1 claim for each
confounder was calculated, stratified by age, sex, and calendar year.
Results: The number of eligible beneficiaries in the SDD increased
from 15 million in 2007 to the highest of 67 million in 2016. During
2007–2017, the estimated prevalence of obesity increased 1.9‐fold
from 69 to 197 per 10,000 eligible members, paralleled by a 2.5‐fold
increase in overweight from 22 to 78 per 10,000. The prevalence of
smoking increased 82% from 65 to 118 per 10,000. For alcohol abuse
or dependence, this increase was 50%, from 14 to 21 per 10,000. The
prevalence of drug abuse and dependence increased 67% (from 6 to
10 per 10,000) over the same time. Similar increasing trends were
noted in the incidence of confounding condition estimates. The transi-
tion of the ICD coding system in 2015 does not seem to change the
increasing trend of prevalence and incidence estimates. For smoking,
obesity, and overweight, prevalence and incidence increased as a
function of age. For alcohol and drug abuse, the highest prevalence
and incidence were observed among subjects aged 44–64 and 18–
43 years.
Conclusions: A continuous increase in the recording of confounding
conditions in claims data was observed; though low prevalence sug-
gests these conditions remain inadequately documented in US claims.
Future studies should evaluate whether this represents an actual
improved recording of these conditions or an increase in the underly-
ing prevalence of these conditions or a combination of these factors.
217 | The comparison of medical records and
claims for Oral anti cancer agents
Manvi Sharma1; Michael L. Johnson2; Sharon H. Giordano3;
Holly M. Holmes4
1The University of Mississippi, University, MS; 2University of Houston,
Houston, TX; 3The University of Texas MD Anderson Cancer Center,
Houston, TX; 4McGover Medical School, The University of Texas Health
Science Center, Houston, TX
Background: Healthcare claims databases like Medicare Part D are
increasingly being used for drug utilization research. Such use of
administrative claims data for pharmacoepidemiologic studies of oral
anti‐cancer agents may be affected by misclassification bias due to
disagreement between administrative claims and electronic medical
records.
Objectives: To determine the rate of concordance between electronic
medical records and Medicare Part D claims for use of oral anti‐cancer
agents.
Methods: Medicare Part D claims were linked with electronic medi-
cal records for selected patients treated at The University of Texas
MD Anderson Cancer Center (MDACC), Houston, Texas via the
Texas Cancer registry. Patients aged 65 or more treated at MDACC
with at least 1 Medicare Part D claim and continuous enrollment in
Medicare for at least 12 months during the study period of Jan
2007 to Dec 2012 were included in the study. The use of any oral
anti‐cancer agent was extracted from the MDACC electronic health
record (EHR) through retrospective chart review of clinic notes,
medication lists, and pharmacy records. The Medicare Part D event
files were used to identify claims for oral anti‐cancer drugs for each
patient. EHR and Part D concordance rates were ascertained after
matching drug name and requiring overlapping treatment dates.
Results: The study sample consisted of 419 medication records for
170 patients. There were 23 different oral anti‐cancer drugs evalu-
ated. Bicalutamide, anastrozole and capecitabine were the most fre-
quently used drugs. The overall percent agreement between the two
datasets was 67.5%, where 106 claims were yes/yes and 177 claims
were no/no for both datasets. The percent disagreement was 32.5%,
where (n = 75) 17.9% claims found in Part D were not in the EHR
and (n = 61)14.6% drugs were found in the EHR and not in Part D.
The kappa statistic was found to be 0.33, with 95% confidence limits
of 0.24 to 0.43.
Conclusions: There was moderate concordance between electronic
medical records and Medicare Part D event files for oral anti‐cancer
agents. This has important implications for the ability to use Medicare
Part D data to identify oral anti‐cancer utilization and study toxicity
patterns. A limitation of this study was the inability to measure the
reasons for disagreement. Missing claims for the drug may be due to
use of drug discount programs or obtaining medications from a source
other than Part D. Missing medical records may be due to incorrect
medication documentation or treatment outside of MDACC. Further
work is needed to verify concordance for individual anti‐cancer agents
in specific populations.
218 | UK electronic health records (EHR)
databases: Expanding primary care coverage
with clinical practice research datalink (CPRD)
aurum
Achim Wolf; Daniel Dedman; Jennifer Campbell; Helen Booth;
Darren Lunn; Jennifer Chapman; Puja Myles
Medicines and Healthcare products Regulatory Agency (MHRA), London,
UK
Background: For 30 years, CPRD has been collecting General Practice
(GP) primary care data for public health research from practices using
one GP EHR system in the UK (contributing to the CPRD GOLD data
resource). To expand sample size, geographical coverage, and repre-
sentativeness, CPRD has begun collecting data from practices using
an additional GP IT system, and participating practices contribute to
a new data resource, CPRD Aurum.
Objectives: To characterize the patients and GP practices in
CPRD Aurum. To describe the data available in CPRD Aurum and
standard linkages to additional national health and socioeconomic
databases.
Methods: We describe the full cohort of patients available in CPRD
Aurum, using the September 2018 build. In particular, we report the dis-
tribution of gender, age, geographical region, deprivation, and follow‐
up, for both current (alive and registered at actively contributing
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practices) and all patients (including dead and transferred‐out), and
describe the types of data recorded.
Results: As of September 2018, CPRD Aurum contained routinely‐
collected data from 738 primary care GP practices in England. This
included records for over 19 million patients, of whom 7 million
were current. Current patients had a median follow‐up of 9.1 years,
of whom a quarter had over 20 years of follow‐up (Interquartile
range: 3.3–20.1) and were broadly representative of the English pop-
ulation in terms of age, gender, and deprivation (compared to Office
for National Statistics data). Routinely collected data in CPRD Aurum
includes information on demographics, diagnoses, symptoms, pre-
scriptions, referrals, immunisations, lifestyle factors, and tests
recorded by GPs or other practice staff. These are entered using
nationally approved coding systems (Read, SNOMED, dm + d). Stan-
dard linkages to CPRD Aurum data include Hospital Episode Statis-
tics (HES) databases as well as national mortality, cancer, mental
health, and deprivation databases.
Conclusions: CPRD Aurum's strengths are its sample size (corre-
sponding to 13% of the population of England), longitudinal follow‐
up, representativeness, and standard linkages to additional data
resources.
219 | Leveraging heterogeneity of European
healthcare data sources to estimate validity
of case‐finding algorithms in multi‐database
studies where a true gold standard is lacking:
Strategy from the Emif project
Giuseppe Roberto1; Maria Garcia‐Gil2; Talita Duarte‐Salles2;
Paul Avillach3; Elisabeth Smits4; Sulev Reisberg5; Alessandro Pasqua6;
Lars Pedersen7; Lara Tramontan8; Miguel A. Mayer9; Ron Herings4;
Miriam Sturkenboom10; Peter Rijnbeek11; Rosa Gini1
1Agenzia Regionale di Sanità della Toscana, Florence, Italy; 2Primary Care
Research Institute Jordi Gol, Barcelona, Spain; 3Department of
BIomedical Informatics, Harvard Medical School & Children's Hospital
Informatics Program, Boston Children Hospital, Boston, MA; 4PHARMO
Institute for Drug Outcomes Research, Utrecht, Netherlands; 5Quretec,
Software Technology and Applications Competence Center, University of
Tartu, Tartu, Estonia; 6 Italian College of General Practitioners and
Primary Care, Florence, Italy; 7Department of Clinical Epidemiology,
University Hospital, Aahrus, Denmark; 8Arsenal.IT Consortium, Veneto's
Research Center for eHealth Innovation, Treviso, Italy; 9Hospital del Mar
Medical Research Institute (IMIM) and Universitat Pompeu Fabra,
Barcelona, Spain; 10P95 Epidemiology and Pharmacovigilance, Hervelee,
Belgium; 11Department of Medical Informatics, Erasmus University
Medical Center, Rotterdam, Netherlands
Background: European healthcare databases are heterogeneous in
coding terminology, language, underlying health policies and data
provenance. Some collect diagnoses from primary care practices
(PC), others from inpatient care (INP) and/or death registries (DEATH).
In multi‐database studies, heterogeneity is commonly considered as a
weakness.
Objectives: Leveraging heterogeneity of healthcare databases to esti-
mate case‐finding algorithms' sensitivity (SE) and positive predictive
values (PPV) when a gold standard is not available.
Methods: We measured the incidence of acute myocardial infarction
(AMI) as a test case. Five databases were considered: SIDIAP (Spain),
HSD, ARS (Italy), PHARMO (Netherlands) and AUH (Denmark). HSD
provided diagnoses from PC, SIDIAP and PHARMO from PC and
INP, ARS and AUH from INP and DEATH. The Unified Medical Lan-
guage System was used to project the AMI concept to local termi-
nologies (ICD9CM, ICD10, ICPC, READ). Three standardized AMI‐
finding algorithms, PC, INP and DEATH, were created. In each data-
base, cases were retrieved using all available algorithms. Cumulative
incidence (CI) of AMI was estimated in 2012 among subjects aged
45+, with ≥2 years of look‐back. Results were compared within
and across databases. Based on previous validation studies: PPV of
INP was 100% in AUH, and PPV of PC in HSD was 96.6%. To esti-
mate the algorithms' SE and PPV in all databases, we made three
assumptions: PPV = 100% for INP, SE = 100% for the combination
INP or DEATH, cases retrieved from PC were true positives only if
also found in INP.
Results: Study population was about 4 million subjects. CI (cases/
10,000 persons) ranged between 7.8 and 24.8 for PC, 30.3 and
47.3 for INP and 8.9 and 9.4 for DEATH. Cases identified from
two provenances overlapped partially. INP identified 28.9% and
30.5% of DEATH in ARS and AUH, and 44.7% and 44.1% of PC in
SIDIAP and PHARMO, respectively. Based on our assumptions, con-
servative estimates of SE of INP were 83.4% in ARS and 77.5% in
AUH; PPV of PC was 44.1% in PHARMO and 44.7% in SIDIAP.
Assuming that SE of INP in SIDIAP and PHARMO was the average
between ARS' and AUH's (80.5%), then conservative estimates of
SE of PC in PHARMO and SIDIAP were 26.7% and 29.4%, respec-
tively. The average between those two estimates, 28.1%, could be
assumed to be SE of PC in HSD.
Conclusions: In multi‐database studies, when de novo validation is not
possible, existing information and assumptions can be exploited to
provide a range of validity estimates and adjust study results to
account for event misclassification.
220 | Use of claims profile review to guide
retrieval of medical Records in an
Observational Cohort Study
Suvapun Bunniran; Libby Horter; Yihua Xu; Claudia Uribe;
Brandon T. Suehs
Humana, Louisville, KY
Background: Medical record review provides clinical information that is
not available in administrative claims data, and is commonly used to val-
idate claims‐based methods to identify outcomes. Limitations of
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medical record review may include incomplete information obtained
from a single site and low rate of response to record requests.
Objectives: Create a stepwise process to optimize case retrieval rate
and completeness of clinical information necessary to adjudicate
potential cancer cases identified using administrative claims data.
Methods: Cancer cases occurring between 10/1/2012 and 12/31/
2017 were identified for a historical cohort study of patients 18–
90 years of age receiving treatment for overactive bladder. A claims
profile was created for each patient, consisting of a chronological
listing of cancer‐related encounters −30 days to +90 days of the first
observed diagnosis. Using the claims profile, a nurse experienced in
medical record review ranked up to three sites using criteria of phy-
sician specialty, place of treatment, and procedures performed. Next,
the identified sites were outreached with medical record requests,
with the highest priority site being the site most likely to have a
record that could serve to validate the cancer (e.g., an
oncologist encounter). Information from the medical records were
consolidated into a single abstraction form reflecting relevant clinical
information necessary for a panel of oncologists to adjudicate the
case.
Results: A total of 1,100 cancer cases were identified for adjudica-
tion. After claims profile review, 2,960 sites were prioritized for
medical record retrieval, and 65% (N = 1,931) of requested charts
were retrieved. At least one chart was retrieved for 84% (N = 925)
of cases identified from claims. Mean (SD) number of charts received
for cases with at least one chart retrieved was 2.1 (0.4). Of the 925
patients, 74% (N = 683) had a physician note in their medical
records confirming cancer and 62% (N = 569) had a biopsy or
pathology report retrieved. Chart obtain rates were 69% (837/
1,219) for charts assigned priority 1, 65% for priority 2 (627/960),
and 60% (467/781) for priority 3.
Conclusions: The use of claims profile review and the identification
of multiple sites for medical record retrieval resulted in a high overall
case retrieval rate. The site prioritization resulted in retrieval of
charts with relevant clinical information needed to adjudicate the
case. This study benefited from use of an integrated team to
design claims profiles and chart prioritization methodology as well
as concise chart abstraction forms to organize key clinical
information.
221 | The potential of German claims data to
characterize real‐world treatment patterns in
cancer patients ‐ the example of Crizotinib
Sarina Schwarz1; Katja Anita Oppelt1; Ulrike Haug1,2
1Leibniz Institute for Prevention Research and Epidemiology ‐ BIPS,
Bremen, Germany; 2University of Bremen, Bremen, Germany
Background: As clinical trials are conducted under very controlled
conditions (including highly selective populations), they often face
problems of generalizability and only little is known about real‐world
treatment patterns after marketing approval. Claims data might be
useful to characterize oncologic drug utilization in clinical practice.
Objectives: To explore the potential of German claims data for charac-
terization of real‐world treatment patterns in oncology, exemplified by
patients treated with crizotinib which was approved for the 2nd or later
line therapy of anaplastic lymphoma kinase positive non‐small cell lung
cancer in 2012 and for the respective 1st line therapy in 2015.
Methods: We used claims data from the German Pharmacoepid-
emiological Research Database (GePaRD) to identify patients with at
least one crizotinib dispensation. Each individual was followed as long
as possible, longest 2004 until 2015. We defined first line therapy as
the first antineoplastic therapy (inpatient or outpatient) after a lung
cancer diagnosis (ICD‐10 C34) was coded. The subsequent therapies
were then defined as second or later line therapy. We described
patients with regards to age, sex, diagnosis codes for lung cancer
and metastases, number of crizotinib prescriptions, as well as
sequence of oncologic therapies.
Results: In total, 229 crizotinib patients were identified. The mean age
at first crizotinib prescription was 58.1 years and 54.2% were women.
Lung cancer was diagnosed in 96.5% of the patients and 87.8% of
these patients had diagnosis codes for metastases within 6 months
after the first lung cancer diagnosis recorded in GePaRD. The mean
time between the first lung cancer diagnosis and the first
crizotinib prescription was 16.9 months. The mean number of crizo-
tinib prescriptions a patient received was 7.4. The minority of the
patients (18.3%) received crizotinib as first line therapy, whereas the
remaining ones (81.6%) received crizotinib as second or later line ther-
apy. Overall, 83% of the patients received at least one other chemo-
therapy prescription during the study period. Only 13.5% of patients
received another chemotherapy after crizotinib discontinuation.
Conclusions: Using GePaRD we found treatment patterns regarding
crizotinib consistent with other studies and could provide detailed
information on its utilization. The results underline the potential of
German claims data for monitoring real‐world oncologic drug
utilization.
222 | Data sources for drug utilization
research in Latin American (LatAm) countries
Luciane Cruz Lopes1; Maribel Salas2; Claudia G.S. Osorio‐de‐Castro3;
Angela Acosta4; Maruja Crisante5; André O. Baldoni6; Anahi Dreser7;
Lucila I. Castro‐Pastrana8; Juan C. Sánchez‐Salgado9;
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Background: Cross‐national comparisons (CNC) of drug use have been
recognized as important in Drug Utilization Research (DUR). However,
valid CNC studies can only be performed if data sources are available,
accessible, and can deliver valid information to describe and measure
the pattern, extent, and determinants of drug exposure in each indi-
vidual country.
Objectives: To develop an inventory of available national drug utiliza-
tion data in the Latin American (LatAm) region as potential data
sources for DUR.
Methods: A network of health experts from 10 countries at the
LatAm region (Argentina, Bolivia, Brazil, Chile, Colombia, Equator,
Mexico, Nicaragua, Peru, Uruguay conducted a) a website search
from government, academic, and private institutions and b) liaising
with national data providers and academic experts in
Pharmacoepidemiology (via on‐line survey). Researchers indepen-
dently screened eligible data sources. Possible divergences were
analyzed by a third researcher. The data sources were characterized
for accessibility, coverage (national, regional, municipality, organiza-
tion multi‐site) data provider (public health, private sector, both),
type of data sources (wholesaler, pharmacy records, electronic health
records, other) and setting (ambulatory, hospital, both). Descriptive
analysis was performed.
Results: As a preliminary result, we identified 85 data sources for
DUR in 10 LatAm countries. Brazil, Colombia and México leaded
the available national. Fifteen (17%) out of the 85 data sources were
publicly and conveniently accessible;49 (57%) were accessible with
limitations (32 with access restricted by country specific legislation
and 17 only accessible after a priori authorisation), and 21 (25%)
lacked clear rules for data access. About coverage, 77 (90%)
portrayed national data, 65 (76%) were of public sector origin, 30
(35%) were sourced from pharmacy records and 63 (74%) came from
a hospital or ambulatory setting ‐ with possible access to individual
patient‐level data.
Conclusions: Those preliminary findings show that although a
great number and a variety of data sources for DUR are available
in LatAM,the accessibility is a major challenge. The procedures for
researcher access to DUR data, should be transparent,
feasible, affordable, protocol‐driven. Linkage of DUR data to out-
come data at the patient level could substantially improve gover-
nance of health care. Data collection is being undertaken in other
LatAm countries in order to expand the inventory.
223 | Enrollment patterns and health in
claims data for the commercially insured US
population
Dana Y. Teltsch1; Elizabeth Cheever1; Dawn G. Albright1;
Monica Gierada1; Richard Wyss2
1Aetion, New York, NY; 2Brigham and Women's Hospital and Harvard
Medical School, Boston, MA
Background: It is often stated that duration of enrollment in adminis-
trative claims data ‐ a correlate of duration of exposure and follow‐up
in medication safety or effectiveness studies ‐ is potentially associated
with patients' underlying health status. Such associations could result
in limited representativeness of studied populations and biased esti-
mates when clinical conditions and enrollment duration define cohort
eligibility.
Objectives: To study if enrollment duration is associated with patients'
health status in a commercial US healthcare claims database.
Methods: We used the IBM® MarketScan® Research Databases data
from 2003–2016. We conducted a preliminary analysis among 16mil
randomly sampled enrollees to evaluate enrollment patterns such as
median duration, time trends, gaps, pharmacy benefits, and primary
subscriber versus dependent. Then, to study the association of health
status with enrollment length, we defined cohorts from the full dataset
in specific calendar periods. Individuals entered the cohorts on com-
pletion of 6 months of continuous enrollment. We assessed demo-
graphics (year, age, insurance plan type, gender), clinical
characteristics (diabetes with/without complications, coronary artery
disease, renal disease), key health status measurements including
Charlson Comorbidity index (CCI), and resource utilization (hospitaliza-
tions, office visits, dispensings) during a 6 m baseline period. We used
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multivariable Cox models to estimate the association of enrollment
duration with the measured characteristics.
Results: Nearly 90% of enrollees had only one enrollment period
(median 947d). 8.8% had 2 periods of eligibility, the 1st was longer
(medians length 517 and 426 d respectively), with a median gap of
1y. Results were similar for an allowable enrollment gap of 0d or
31d. In the multivariate analysis (estimates based on 04/2012 cohort),
use of any drug (hazard ratio (HR) of enrollment discontinuation with
95% CI, 1.12 (1.12–1.13)), ER visit (1.09 (1.08–1.10)), and a CCI of
either 3+ (1.17 (1.09–1.25)) or a CCI of 2+ (1.08 (1.02–1.13)) were
associated with shorter enrollment. Older age, female gender, and out-
patient visits were associated with longer enrollment durations. Mod-
erately elevated health status was associated with longer enrollment
in the univariate, but not in the multivariate models.
Conclusions: The association of certain non‐severe diseases with
enrollment duration varied across subgroups and was confounded by
other factors. While these results should not be interpreted as a causal
relationship, they serve to caution against assuming a simple
association.
224 | Characterizing disease registries
utilized for drug safety evaluation
Jeeyun Kim1; Rashedul Hasan2; Alfred Sorbello2; Jacqueline M. Major1
1Office of Surveillance and Epidemiology/FDA, Silver Spring, MD; 2Office
of Translational Sciences/FDA, Silver Spring, MD
Background: Under the 21st Century Cures Act of 2016, the U.S.
Food and Drug Administration began a program for evaluating use
of real‐world data (including registries) for real‐world evidence gen-
eration fit for regulatory purposes. Characterizing disease registries
provides the opportunity to better understand and optimize their
use for regulatory safety surveillance.
Objectives: To characterize disease registries and unique contribu-
tions across three publicly available data sources used for identifying
disease registries.
Methods: Studies that used existing disease registries to evaluate
outcomes of patients receiving a drug and systematically collect
adverse event data were identified through December 2018 using
publicly available resources: PubMed, Embase, and ClinicalTrials.
gov. Disease registries that examined drug safety among pregnant
women were excluded. Registries were further restricted to those
with U.S. participating sites. Studies were characterized using a stan-
dardized approach to assess pre‐specified study and registry‐level
elements following manual extraction of information from qualifying
registries. Using a semi‐automatic approach, we applied open source
natural language processing (NLP) tools to determine whether iden-
tified registries were included in existing drug labels archived in
DailyMed.
Results: Of 36 studies (26 distinct disease registries) identified in
the initial search, 11 (31%) used disease registries that included
international populations in addition to US sites; one identified study
was found in drug labels using NLP. Most studies (94%) were
based on disease registries with clear objectives. Nearly all
identified studies had additional objectives beyond drug safety; one
evaluated safety as its sole objective. Forty‐seven percent of
studies comprised populations that had rare conditions. Over 80%
of identified studies ascertained baseline health status,
concomitant medications, and presented clear follow‐up strategies.
Adequate analysis plans and consideration of relevant covariates
were described in greater than 20 studies; however, only 44% of
studies indicated measures to account for missing data due to
potential loss to follow‐up. We observed variations in data com-
pleteness and type/granularity of information reported within each
data source.
Conclusions: Initial results suggest that clear objectives, follow‐up
strategies, and inclusion of key covariates contribute to the utility
of disease registries. This review highlights the need to improve
patient retention efforts in studies and transparency of information
for registries across resources.
225 | Non‐small cell lung cancer (ALK+/
EGFR+) data sources in Europe and Canada: A
landscape study
Aurore Bergamasco1; Thalia Nikoglou2; Michael Lees2;
Yola Moride1,3,4
1YOLARX Consultants, Paris, France; 2Takeda Pharmaceuticals
International AG, Zurich, Switzerland; 3YOLARX Consultants, Montreal,
QC, Canada; 4Faculty of Pharmacy, Université de Montréal, Montreal,
QC, Canada
Background: Non‐small cell lung cancer (NSCLC) accounts for the
majority of lung cancer cases. Targeted treatments are in development
for the ALK+/EGFR+ subtypes.
Objectives: This study aimed to identify and characterize fit‐for‐pur-
pose ALK+/EGFR+ NSCLC data sources for the generation of real‐
world evidence.
Methods: A literature search using MEDLINE and Embase (01 Jan.
2012–23 Apr. 2018) as well as pragmatic searches of web sources
were conducted. Data sources were identified using, as the search
strategy, data requirements for real‐world studies in this disease
(e.g., diagnostic procedures, treatments, safety and effectiveness
outcomes). For each data source identified, metadata were
abstracted in a standardized data extraction form, including: avail-
ability of mandatory and optional data elements, codification, infra‐
structure and access policies, linkage capabilities with administrative
claims databases. To obtain further information, an online question-
naire was administered to database custodians.
Results: A total of 74 unique data sources on ALK+ and/or EGFR+
NSCLC were identified: 72 covered ALK+ NSCLC patients, of which
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40 also included data on EGFR+ NSCLC patients. Questionnaire to
custodians led to the identification of two additional EGFR+ data
sources, resulting in a total of 42 databases for EGFR+ NSCLC
patients. Of the 72 ALK+ NSCLC sources, the majority
originated from Europe (n = 65, 90.3%), followed by Canada
(n = 5, 6.9%), and two (2.8%) covered both Europe and Canada.
Most sources consisted of cohorts with ad hoc data collection
(n = 23, 31.9%) or medical records (n = 11, 26.4%, 10 electronic
and 1 paper‐format). More than three quarter (n = 55, 76.4%)
ascertained ALK+ diagnosis through genetic testing. Of the 42
EGFR+ NSCLC sources, 34 were disease‐specific (81.0%) while the
remaining (n = 8, 19.0%) covered the general population. For most
sources, data collection was ongoing at the time of evaluation
(n = 32, 76.2%). Linkage to medical charts or administrative claims
were possible for 16 sources (38.1%). Based on the number of
patients and the interest of custodians for potential collaboration,
41 data sources were considered fit‐for‐purpose for ALK+/EGFR+
NSCLC: 32 (78.1%) would allow the conduct of drug utilization stud-
ies and 29 (70.7%) provide longitudinal data on clinical outcomes
allowing for the conduct of safety and effectiveness studies.
Conclusions: Several real‐world data sources on ALK+/EGFR+ NSCLC
have been identified throughout Europe and Canada. A formal feasibil-
ity assessment will need however to be undertaken prior to the imple-
mentation of a study and common data models.
226 | Assessment of the use of synthetic
data to support the generation of real‐world
evidence in cancer in England
Ali Abbasi1,2; Ruben Hermans1; Fiona Grimson1; Joseph Kim1,3;
Benjamin Bray1,4; Deborah Layton1,5; Adam Reich1
1 IQVIA, London, UK; 2University Medical Centre Groningen, Groningen,
Netherlands; 3London School of Hygiene and Tropical Medicine, London,
UK; 4King's College London, London, UK; 5University of Keele, Keele,
Newcastle, UK
Background: Real‐world data (RWD) are commonly used to support
drug development and to understand patients' characteristics and
clinical effectiveness of care. Whilst the use of RWD in cancer is
increasing, data sources remain subject to operational challenges
related to data access and patient confidentiality. In England, a syn-
thetic oncology dataset “Simulacrum” was developed to overcome
these core challenges and make the data collected by the National
Cancer Registration and Analysis Service (NCRAS) more accessible
to researchers.
Objectives: To explore the potential of using the Simulacrum to refine
real‐world evidence (RWE) generation from the cancer data collected
by NCRAS in England.
Methods: In 2018, we enhanced a process that employs the Simula-
crum to conduct exploratory analyses and test methodological
approaches. Our analytical queries were programmed in R using Simu-
lacrum data. We tested, refined and validated R codes before being
applied to the national cancer registry data. The distribution of
patients and tumors were described.
Results: In our exploratory studies (on breast and lung cancers) run
via this process, we extracted counts and tested queries in Simula-
crum. Between 2013 and 2015, the Simulacrum included 1.45 mil-
lion tumors (of which 136,249 [9.4%] were breast cancers) and
1.37 million patients with ≥1 cancers (of whom 132,800 [9.7%]
were those with a breast cancer). When our code was applied to
the real data, the national cancer registry database identified 1.46
million tumors (137,656 [9.4%] breast cancers) and 1.37 million
patients with ≥1 cancers (133,627 [9.7%] patients with a breast can-
cer). All results from the actual data were certified as anonymous,
and aggregated results were generated with no risk of patient
identification.
Conclusions: Synthetic datasets, like Simulacrum, can be used as a
framework to test and refine analytical codes and to support the
generation of RWE in oncology, leveraging the data collected by
NCRAS in England without the risk of patient identification. How-
ever, it should be noted that Simulacrum cannot be used as a
standalone resource to generate scientific evidence.
227 | Health indicator recording in UK
primary care electronic health records: Key
implications for handling missing data
Irene Petersen1; Catherine A. Welch2; Irwin Nazareth1; Kate Walters1;
Louise Marston1; Richard W. Morris3; James R. Carpenter4;
Tim P. Morris5; Tra My Pham5
1University College London, London, UK; 2University of Leicester,
Leicester, UK; 3University of Bristol, Bristol, UK; 4London School of
Hygiene and Tropical Medicine, London, UK; 5MRC Clinical Trials Unit at
UCL, London, UK
Background: Clinical databases are increasingly used for health
research; many of them capture information on common health
indicators including height, weight, blood pressure, cholesterol level,
smoking status, and alcohol consumption. However, these are often
not recorded on a regular basis; missing data are ubiquitous.
Objectives: We described the recording of health indicators in
UK primary care and evaluated key implications for handling missing
data.
Methods: We examined the recording of health indicators in The
Health Improvement Network (THIN) UK primary care database over
time, by demographic variables (age and sex) and chronic diseases (dia-
betes, myocardial infarction, and stroke). Using weight as an example,
we fitted linear and logistic regression models to examine the associa-
tions of weight measurements and the probability of having weight
recorded with individuals' demographic characteristics and chronic
diseases.
Results: In total, 6,345,851 individuals aged 18–99 years contributed
data to THIN between 2000 and 2015. Women aged 18–65 years
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were more likely than men of the same age to have health indicators
recorded; this gap narrowed after age 65. About 60–80% of individ-
uals had their height, weight, blood pressure, smoking status, and
alcohol consumption recorded during the first year of registration.
In the years following registration, these proportions fell to 10%–
40%. Individuals with chronic diseases were more likely to have
health indicators recorded, particularly after the introduction of a
General Practitioner incentive scheme. Individuals' demographic
characteristics and chronic diseases were associated with both
observed weight measurements and missingness in weight.
Conclusions: Missing data in common health indicators will affect
statistical analysis in health research studies. A single analysis of pri-
mary care data using the available information alone may be mis-
leading. Multiple imputation of missing values accounting for
demographic characteristics and disease status is recommended but
should be considered and implemented carefully. Sensitivity analysis
exploring alternative assumptions for missing data should also be
evaluated.
228 | Quantifying the completeness of
hospital episode information recorded in
primary Care in England Using THIN‐HES
Rosalind Polya; Suvi Hokkanen; Deborah Layton
IQVIA, London, UK
Background: The Health Improvement Network ‐ Hospital Episode
Statistics (THIN‐HES) is an Electronic Medical Record (EMR) data-
base containing linked, patient‐level General Practice (GP) and hospi-
tal data from National Health Service patients in England. Hospital
episodes, especially events like hospitalization and Accident & Emer-
gency (A&E) visits, are often used as proxy for secondary care infor-
mation within observational studies using primary care medical
records.
Objectives: To quantify the completeness of recording of hospital
episode information in primary care by comparing the distribution
of A&E attendances and hospitalization between primary and sec-
ondary care.
Methods: In this retrospective EMR cohort study, completeness of pri-
mary care records was quantified for 01/01/2016–12/31/2016. The
study population were patients in the THIN‐HES database
(N = 2,292,443; 162 GP practices), including both active (i.e. registered
with a GP contributing data to THIN) and historic patients that passed
data quality checks. Descriptive statistics on hospitalization and A&E
records in primary and secondary care were calculated. Events were
defined usingTHIN Read codes and HES variables. The following mea-
sures were reported: total number of records, number (%) of patients
with a record in THIN‐HES, mean number of records per patient, and
mean number of records per patient with a record. As each patient had
aTHINandaHES record, theMcNemar's test of difference inpairedpro-
portionswas used to compare theproportionof patientswith a record in
primary and secondary care.
Results: In primary and secondary care, the total number of records
were reported for hospitalization [48355 vs. 786709, respectively]
and A&E events [99372 vs. 759700, respectively]. The number of
patients in primary and secondary care with records was also calcu-
lated for hospitalization [24738 vs. 336220, respectively] and A&E
events [57720 vs. 454649, respectively]. The proportion of patients
in THIN‐HES with an A&E record was significantly lower in primary
than secondary care (p < 0.001), [2.5% (n = 57720) vs 19.8%
(n = 454649), respectively]. The proportion of patients in THIN‐
HES with a record for hospitalization was also significantly lower in
primary than secondary care (p < 0.001): [1.1% (n = 24738) vs
14.6% (n = 336220), respectively].
Conclusions: The THIN primary care records did not accurately cap-
ture HES hospitalization and A&E events. Research should not rely
on secondary care information recorded in primary care. Rather,
robust secondary care data sources should be sought.
Recording practices may have changed since 2016.
229 | Development of an integrated research
network to facilitate non‐interventional
research
Stephanie Reisinger1; Ariel Berger2; Donny Chen3; Steve Chick1;
Lee Kallenbach1; Brad Vernon1; Krista Payne4
1Veradigm, Chicago, IL; 2Evidera, Waltham, MA; 3Evidera, Morrisville,
NC; 4Evidera, St.‐Laurent, QC, Canada
Background: Key success factors for high quality and timely research
include methods for rapid identification, recruitment, and enrollment
of “protocol‐specified” patients, and engagement of study sites reflec-
tive of usual care community practice.
Objectives: To describe development of a research network based on
an electronic health record (EHR) technology platform that connects
providers and patients to researchers.
Methods: The potential scale of the research network comprises
approximately 30,000 practitioners from small private US
practices who collectively treat about 18 M patients (mostly
“research naïve”). Practitioners are approximately evenly split
between primary care physicians and specialists, and the network
is compliant with the Health Insurance Portability and Accountability
Act (HIPAA) of 1996. Care rendered by providers is entered into
EHRs using commonly accepted US coding conventions (e.g., ICD‐
10 for diagnoses, SNOMED codes, national drug codes [NDCs]); pro-
viders and support staff can also be contacted via EHRs to partici-
pate in research. Study‐specific questions also can be added to the
EHRs to collect additional data (e.g., quality‐of‐life, patient
preference).
Results: The number of patients (or clinicians) who meet prespecified
selection criteria operationalizable through EHRs can be ascertained
rapidly (<5 days), with invitations for participation then sent to clini-
cians who treat “qualifying” patients (or who themselves qualify,
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depending on study focus). Clinicians who opt in are contracted to
participate in the research, and their qualifying patients are asked
to provide informed consent. For patients who provide consent,
their EHRs can be queried to develop “baseline” histories. Their
EHRs can also be used to collect information during the study,
thereby reducing the burden of participation on qualifying patients
and their clinicians and minimizing the chance of data collection/
transcription errors.
Conclusions: Our EHR‐based research network represents real‐world
experience at small private practices that capture a relatively large
segment of the US population. Three potential applications of the
network have been identified for evaluation: (1) natural history stud-
ies; (2) risk evaluation and mitigation strategy (REMS) programs and
evaluations; and (3) disease and product registries. Key parameters
to evaluate will include response rates, time to identify and enroll
patients and/or physicians, EHR‐ and participant‐reported data qual-
ity and completeness, and study timelines and costs (versus non‐net-
work studies).
230 | Rare disease epidemiology: A Danish
population‐based program
Jon Fryzek1; Lauren C. Bylsma2; Henrik T. Sørensen3
1EpidStrategies, A Division of ToxStrategies, Inc., Rockville, MD;
2EpidStrategies, A Division of ToxStrategies, Inc., Ann Arbor, MI; 3Aarhus
University Hospital, Aarhus, Denmark
Background: The epidemiologic study of rare diseases is limited by dif-
ficulty in identifying sufficiently large cohorts of patients to evaluate
demographic, clinical, or treatment characteristics or to determine out-
comes or adverse events.
Objectives: To describe the system of large, longitudinal, population‐
based medical databases and biobanks in Denmark, which have been
successfully utilized to investigate the prevalence of rare diseases as
well as the health care resource use and clinical course of patients
with rare diseases.
Methods: We provide an overview of Danish administrative and
medical data sources that permit the identification and quantification
of rare diseases and their outcomes. Examples of the capabilities of
these data resources are illuminated through a listing of recent
publications.
Results: In Denmark a tax‐supported healthcare system guarantees
medical care for residents. A unique identifier, assigned to all Danish
residents at birth or immigration since 1968, allows linkage of
national registry data on all hospital diagnoses, pathology and labora-
tory reports, and nearly 200 other health registries under the aus-
pices of the Danish government. Virtually all Danish residents are
included in these registries. Important variables include ICD diagno-
sis codes, treatments, examinations, prescriptions, laboratory tests,
hospital outcomes, and vital status. The Danish population‐based
databases are essentially complete, and data entry is integrated into
clinical practice with on‐going quality control procedures in place,
supporting long‐term and multi‐generational epidemiological
research. The DNA of all persons born after 1981 is stored in the
Danish National biobank, making it possible to study the impact of
early biomarkers over the lifespan. Examples of cohorts created
using linked datasets to examine disease prevalence, disease sever-
ity, health resource use, treatment patterns, outcomes (including
thromboembolic events), and vital status include Prader‐Willi Syn-
drome, systemic mastocytosis, X‐linked hypohidrotic ectodermal dys-
plasia, and cold agglutinin disease among many others.
Conclusions: The nationwide Danish health care system incorporates
uniform registration and coding, allowing for near‐complete cohort
ascertainment, including identification and complete follow‐up of
rare disease patient cohorts. The Danish research infrastructure is
an exceptionally valuable resource for evaluating the epidemiology,
demographic and clinical characteristics, treatments, outcomes, and
prognosis of patients with rare diseases.
231 | The Zuellig pharma Korea consortium
database ‐ an on‐site drug wholesales
database for Pharmacoepidemiological
studies using real‐world data
Han Eol Jeong1; In‐Sun Oh1; Junqing Li1; Erwan Vilfeu2;
Sang A. Ryuu2; Ju‐Young Shin1
1SKKU Pharmacoepidemiology, School of Pharmacy, SungKyunKwan
University, Suwon, Korea, Republic of; 2Zuellig Pharma Korea, Seoul,
Korea, Republic of
Background: Drug wholesales data are collected on‐site, allowing for
its quicker release for research and minimizing the drug use latency
issue when compared to health insurance claims data. However, rep-
resentativeness of drug wholesaler data have yet to be evaluated.
Objectives: To assess the value and representativeness of the Zuellig
Pharma Korea Consortium (ZPK‐C) database, which contains drug
wholesales data collected in a weekly interval, for its prospective
use as a data source for pharmacoepidemiology studies.
Methods: We conducted a descriptive drug utilization study by com-
paring the ZPK‐C database to South Korea's nationwide health
insurance claims database between 1 January 2016 and 30 Septem-
ber 2017. Therapeutic areas of interest were 13 antidiabetic and 10
antihypertensive products. Product‐based analyses were conducted
for each of the 17 provincial‐level administrative regions of South
Korea. For standardized comparison, the defined daily dose (DDD)
was used to calculate DDDs per 100,000 inhabitants per day
(DID). For each product, the DID proportion was calculated by divid-
ing each provincial‐level region's DID over the total DID of South
Korea. The nationwide claims database was considered to be the
gold standard. The ZPK‐C database was considered to have regional
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concordance and representativeness if the DID proportion of the
health insurance claims database lied within the DID proportion's
95.0%, 97.5% or 99.0% confidence interval of the ZPK‐C database.
Results: We found regional concordance between the ZPK‐C and
nationwide claims database in 12 and 13 regions (out of 17) for anti-
diabetic and antihypertensive products, respectively, of which, con-
cordance was higher in rural regions than metropolitan regions. For
the 13 antidiabetic products at the 95.0% confidence level (CL), ≥
11/13 products showed concordance in three regions. Especially,
at both 97.5% and 99.0% CLs, one region showed complete concor-
dance for all 13 products. As for 10 antihypertensive products, six
regions, double that of antidiabetic products, ≥ 8/10 products
showed concordance, with three regions showing complete concor-
dance in all 10 products. Throughout all CLs (95.0% to 99.9%), all
10 antihypertensive products showed concordance in three regions.
Conclusions: In particular regions of South Korea, the ZPK‐C data-
base was found to have very high regional concordance and there-
fore, representativeness. Thus, with further evaluation in other
therapeutic areas, the ZPK‐C database has shown potential as a
valuable data source for future research.
232 | Real world evidence multi‐database
research in Europe: The EU‐ADR Alliance
Natasha Yefimenko
SYNAPSE Research Management Partners, Barcelona, Spain
Background: The EU‐ADR Alliance was established in 2013 built on
the results of the project “Exploring and Understanding Adverse Drug
Reactions by Integrative Mining of Clinical Records and Biomedical
Knowledge”. The network is based on the concept of federated data-
bases, non‐competition with its members, independence and scientific
interest.
Objectives: The EU‐ADR Alliance is a network of EU‐based
researchers and databases set up to conduct real‐world evidence stud-
ies to evaluate drug safety in clinical practice, the effectiveness and
safety of drugs in specific populations, drug utilization, and health out-
comes research.
Methods: Initially, there were eight research centres from five EU
countries (the Netherlands, UK, Denmark, Italy and Spain) participat-
ing in the EU‐ADR Alliance, and the network is progressively
expanding to new databases and countries. Source data are routinely
collected data from electronic health records (primary care data-
bases, dispensing records and hospital linkage) and additional linked
data sources. The EU‐ADR Alliance databases include over 21 million
of active patients, enabling us to access a broad range of partici-
pants including pediatric populations. All databases comply with
European Union guidelines on the use of medical data for medical
research and have been validated for pharmacoepidemiologic
research. Since 2013, eight observational studies have been
conducted in the respiratory, musculoskeletal and cardiovascular
fields, resulting in several publications and conference presentations.
The methodological challenges encountered during the course of
these studies were recently analyzed during a bespoke workshop
organized by the EU‐ADR Alliance network.
Results: The studies follow a standardized structured process which
has been validated during more than five years of experience. A num-
ber of tools and methods have been developed for data curation and
analysis. The EU‐ADR Alliance researchers actively explore methodo-
logical opportunities and challenges that arise in this distributed
pharmacoepidemiology network.
Conclusions: The EU‐ADR Alliance provides an unprecedented amal-
gamation of expertise with a solid governance structure and tested
working methods allowing to run centralized powered studies and
produce clinically meaningful results, thus generating valid and reli-
able evidence. The network has a capacity to investigate challenges
for methods research in pharmacoepidemiology using distributed
data. Given the recent incorporation of new databases and increased
request for the research questions, the need for methodological
innovations will continue to grow.
233 | Does adding claims to Emr data
improve comorbidity burden capture:
Concerto health AI definitive oncology
dataset and symphony linkage study
William Wong1; Navdeep Pal1; Ning Wu1; Danny Sheinson1; Li Chen2;
Laura Chu1
1Genentech, Inc, South San Francisco, CA; 2Concerto HealthAI, Boston,
MA
Background: Current commercially available oncology electronic
medical record (EMR) databases typically have limited data on
patient comorbidities which may limit the ability to accurately
include/exclude these patients or adjust for these factors in health
outcomes research.
Objectives: The objective of this study was to investigate the impact
of identifying comorbidities using both EMR and claims data.
Methods: The Concerto Health AI Definitive Oncology Dataset is a
deeply curated cohort of patients (pts) derived from a wide range
of oncology practices throughout the United States. Concerto Health
AI has a co‐exclusive partnership with ASCO CancerLinQ and
collects data from multiple other sources. These data were determin-
istically linked to US Symphony Health's (SH) Integrated Dataverse,
an anonymized, HIPAA‐compliant data set. Advanced (stage IIIb/IV)
non‐small cell lung cancer (aNSCLC) pts with data curated via
manual review by nurse practitioners and diagnosed after 2011 were
included. Comorbidities within 1 year prior to advanced diagnosis
were categorized using the Charlson Comorbidity Index (CCI). The
impact of the claims linkage on inclusion/exclusion (I/E) criteria
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was assessed by applying criteria from the IMpower150 clinical
study and exploring changes to survival estimates, as calculated
using Kaplan–Meier method.
Results: A total of 11,373 aNSCLC pts were identified, of which
7,887 pts were linked to SH. Using only Concerto, 278 pts (3.5%)
had a CCI score ≥ 1, whereas 3,033 pts (38.4%) had a CCI score-
1 using linked Concerto and SH. After applying I/E criteria from
IMpower150 using available data elements from Concerto only, 88
pts were identified matching the trial criteria, with a median survival
of 15.8 mths (95% CI: 14.4, 21.0). When leveraging Concerto and
SH, 8 (9.1%) more patients were excluded (n = 80) based on comor-
bidities (6 pts) and oral medications (2 pts), with a median survival of
16.6 mths (95% CI: 14.6, 23.4).
Conclusions: The addition of claims to EMR enhanced the ability to
identify patient comorbidities given the longer history and broader
physician specialty of claims data. Future real‐world studies should
explore linkages across datasets to better capture comorbidities for
patient selection and adjustment.
234 | Data enhancement through linkage:
Health plan linkage with PCORnet clinical
data research network
Kevin Haynes1; P.I. Lin2; Juliane Reynolds2; Qian Shi1;
L. Charles Bailey3; Hanieh Razzaghi3; Jason Block2
1HealthCore, Inc., Wilmington, DE; 2Harvard Pilgrim Health Care, Boston,
MA; 3Children's Hospital of Philadelphia, Philadelphia, PA
Background: Electronic medical record data (EMR) contains prescrip-
tions written and administrative claims data contains prescriptions dis-
pensed. Linked data across these common pharmacoepidemiology
data sources can close gaps in evidence. We linked data from a Health
Plan Research Network (HealthCore) and a Clinical Research Network
(PEDSnet) within PCORnet.
Objectives: The objective of the health plan linkage was to utilize
privacy preserving record linkage (PPRL) methods to link health plan
claims data to EMR data in the PCORnet Common Data Model and
to explore data on medication dispensings compared to prescriptions
to measure the impact on missing data from the PCORnet Antibi-
otics and Childhood Growth Study (ABX).
Methods: We utilized PPRL methods which included the generation of
anonymous hashed linkages to determine the population that over-
lapped between the two organizations. We linked populations of
patients aged0–2yearsusing thePPRLanonymoushasheswith theCol-
orado University Record Linkage (CURL) method. We used descriptive
analysis to summarize the number of patients from PEDSnet by sex and
race and compared characteristics of patients who had a HealthCore
health plan linkage to all patients included in the main ABX study. We
then described antibiotics use among patients with a health plan linkage
bycounting the total numberofpatientswhohad1) bothprescribingand
dispensing records (yPyD); 2) no prescribing or dispensing records
(nPnD;3)prescribingbutnodispensing records (yPnD); and4)dispensing
but no prescribing records (nPyD). We then compared 10‐day prescrib-
ing and dispensing episodes by performing bi‐directional matching and
presented the proportion of episodes with and without corresponding
matching.
Results: The PEDSnet‐HealthCore linkage found a total of 4,792
patients with linked records. The linked population was similar with
regard to sex to the original ABX cohort with a greater proportion
of whites in the linked population. 42.6% and 20.6% of the linked
population were true positive (yPyD) and true negative (nPnD) in
terms of their antibiotic exposure status, respectively. 23.5% of the
linked population had dispensing records not captured by prescrip-
tion records. There were 13.3% had prescribing records but no dis-
pensing records.
Conclusions: Data linkage can close gaps in data to improve the abil-
ity for real world data to generate real world evidence. Prescriptions
from EMRs may not be filled and prescriptions may be written from
outside organizations leading to additional exposure data capture.
235 | Data enhancement through linkage:
Health plan linkage with Pcornet patient
powered research networks
Abiy Agiro1; Xiaoxue Chen1; Elizabeth B. Clark2; Cristina Burroughs2;
W. Benjamin Nowell3; Sara Loud4; Kalen Young5; Antoine G. Sreih6;
Robert McBurney4; Rebecca Sutphen2; Jeffrey R. Curtis7;
Peter A. Merkel6; Kevin Haynes1
1HealthCore‐New England Research Institute, Wilmington, DE;
2University of South Florida, Tampa, FL; 3Global Healthy Living
Foundation, Upper Nyack, NY; 4Accelerated Cure Project, Waltham, MA;
5Vasculitis Foundation, Kansas City, MO; 6University of Pennsylvania,
Philadelphia, PA; 7University of Alabama at Birmingham, Birmingham, AL
Background: Linking digital patient data to health plan claims can pin-
point opportunities for patient participation in patient‐centered out-
comes research (PCOR) such as drug safety and comparative
effectiveness research. Compared to administrative claims data,
patient‐generated disease data as reported by patients joining a
PCOR‐net Patient‐Powered Research Networks (PPRNs) can serve
as a “silver standard” to validate claims based computable phenotypes.
We developed a privacy‐preserving record linkage (PPRL) process
method to conduct data linkage between PPRNs and health plans.
Objectives: The aims were 1) to implement PPRL, 2) to validate claims
based computable phenotypes, and 3) to quantify the selection bias on
which patients join a PPRN and then participate in patient‐centered
research.
Methods: We used PPRL to link members from 4 PPRN registries to
enrollees of 14 commercial health plans. Non‐linked health plan
enrollee cohort who met computable phenotypes of interest
were compared to linked PPRN members using bivariate analysis.
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Self‐reported diagnoses by PPRN members were compared
with claims‐based computable phenotypes to calculate confirmation
rates (study outcome) across varying durations of health plan
coverage.
Results: Data for 21,616 PPRN members were hashed. Of these,
4,487 (21%) members were linked, regardless of any expected over-
lap with the fourteen health plans. A total of 3,546 (16%) PPRN
members were commercially insured, and had available data permis-
sions for analysis. Compared to non‐linked health plan cohort
(N = 1,825,115), those who joined PPRNs (N = 3,546) were younger
(48 vs 56 years), more likely to be female (92% vs 76%) and had
fewer all cause hospitalizations (26% vs 35%) or ED visits (36% vs
43%). Members who joined PPRNs and participated in research also
showed similar differences compared to the non‐linked health plan
cohort. For members with ≥5 years of continuous health plan enroll-
ment, the confirmation rates were 93% (95% confidence interval
[CI], 87% ‐ 97%) for multiple sclerosis; 91% (95% CI, 82% ‐ 96%)
for breast or ovarian cancer; 80% (95% CI, 67%‐ 90%) for vasculitis;
and 67% (95% CI, 60% ‐ 73%) for rheumatoid arthritis, psoriatic
arthritis or psoriasis.
Conclusions: This study demonstrated that PPRN membership and
health plan data can be successfully linked using PPRL methodology,
and used to confirm claims based phenotypes. The selection bias on
who joins a PPRN as a member is similar to the bias on who ultimately
joins a PPRN research opportunity. Linkage is important for future
work related to collection of patient reported outcomes in
pharmacoepidemiology research.
236 | CIDACS‐RL: A novel search engine‐
based record linkage system for huge
datasets with high accuracy and scalability
George C.G. Barbosa1; Mohamed S. Ali1,2; Bruno Araujo1;
Maria Y. Ichihara1; Sandra Reis1; Samila Sena1; Julia M. Pescarini1;
Rosemeire L. Fiaccone1,3; Leila D. Amorim1,3; Robespierre Pita1;
Marcos E. Barreto1,3,4; Liam Smeeth2; Mauricio L. Barreto1,3
1Centre for Data and Knowledge Integration for Health (CIDACS),
Salvador, Brazil; 2 London School of Hygiene and Tropical Medicine,
London, UK; 3Federal University of Bahia (UFBA), Salvador, Brazil;
4University College London, London, UK
Background: Several open source and commercial record linkage
tools, used for identifying and combining records of the same individ-
ual from two or more different data sources, are available. However,
the volume and complexity of data sets being linked pose a challenge.
Hence, designing an efficient linkage tool with reasonably high accu-
racy and scalability was required.
Objectives: To describe the design and performance of CIDACS‐RL
(Centre for Data and Knowledge Integration for Health ‐ Record
Linkage).
Methods: We developed CIDACS‐RL: an iterative deterministic
record linkage algorithm based on search engine indexing for scoring
and comparing potential matches. A gold standard dataset was cre-
ated using two Brazilian administrative data sources: the Mortality
Information System (SIM) and the Live Birth Information System
(SINASC) using exact matching. The case study comprises data from
two governmental databases: the Unified Registry for Social
Programmes of the Federal Government (CadUnico) and tuberculosis
data (SINAN‐TB) from the Information System for Notifiable Dis-
eases (SINAN). All data sets contain individual‐level. The following
attributes were used for linkage: name, mother's name, date of birth,
municipality and sex. A simulated cohort was used to evaluate scal-
ability and execution time both in single core and 8‐core settings.
We assessed the accuracy of the linkage with standard metrics: sen-
sitivity, specificity, positive predictive value (PPV), and area under
the ROC curve (AUC).
Results: 3,013,228 from SINASC and 1,293,219 from SIM related to
2015 were used to construct the gold standard dataset, by exact
match, adding up to 3,028 records. In this dataset, the sensitivity,
specificity, and positive predictive value for the CIDACS‐RL algo-
rithm were 99.87%, 99.94%, and 99.93%, respectively. In the case
study, the CadUnico had 114,008,179 individual records and SINAN
included 1,182,777 reported tuberculosis cases from 2001–2013,
after data cleaning for linkage. After a manual review, 17,355 pairs
of records were identified as true matches and 12,461 as false
matches. Applying an optimal cut‐off point (0.896), the sensitivity,
specificity, and AUC were 92.5 [95% confidence interval; 92.07,
92.99], 93.5% [93.08, 93.8], 97.2% [96.97, 97.35], respectively. In
the simulated cohort, the distributed execution was about four times
faster than the serial setting when using a database with 20 million
records.
Conclusions: CIDACS‐RL algorithm is an innovative linkage tool for
huge data sets, with high accuracy, improved scalability, and substan-
tially shorter execution time.
237 | Use of ICD codes and physician notes
from electronic medical records to identify
cases of a rare disease
Lisa Vinikoor‐Imler1; Nasha Wang1; Henry Krzywy1; Anne Dilley2
1Biogen, Research Triangle Park, NC; 2BiogenCambridge, MA
Background: Use of electronic medical records (EMR) is increasingly
important in the field of pharmacoepidemiology. A component of
EMR, physician notes, can provide additional value as a source of
information.
Objectives: To determine whether physician notes would identify
additional cases of a rare disease, trigeminal neuralgia (TN), that were
not identified solely using ICD codes.
Methods: This study was performed using a general population
cohort from the Optum© deidentified electronic health records
118 ABSTRACTS
dataset including data from 2007‐March 2018. Individuals enrolled
in integrated delivery networks for at least 6 continuous months
were included. Indications of a TN diagnosis were identified using
two methods: 1) ICD‐9 and ICD‐10 codes for TN (350.1 and
G50.0, respectively) and 2) keywords from physician notes. To be
considered as TN using the physician notes, the keyword “trigeminal
neuralgia” or “tic douloureux” needed to be present. Subjects were
not counted as having a TN diagnosis based on physician notes if
additional information in the notes was unsupportive of the diagno-
sis. The number of individuals captured using ICD codes and/or phy-
sician notes was determined and basic descriptive statistics were
examined.
Results: Approximately 27 million individuals in this cohort had at
least 6 months of continuous enrollment. Of these individuals,
109,192 had at least one indication of TN (ICD code and/or key-
word). It is standard practice in database studies to require two
codes with a specific length of time in‐between. When we applied
this standard definition of two codes at least 27 days apart to the
TN‐related ICD codes, 34,726 individuals were identified. When
employing this same standard definition using keywords from the
physician notes, 31,948 individuals were identified. Of these,
17,952 were already captured using the standard definition for ICD
codes but an additional 13,996 individuals were retrieved that had
not met the standard definition using ICD codes or had no TN‐
related ICD codes at all, resulting in a total of 48,722 identified
cases.
Conclusions: While the majority of individuals withTN were identified
using the traditional approach of ICD diagnosis codes recorded in the
EMR (71%), in this example the addition of keywords from physician
notes adds a meaningful number of individuals. Although the effort
required to search physician notes is substantially greater than that
for searching ICD codes, in rare diseases where increasing the number
of patients available for a study is particularly important, this effort
may prove to be worthwhile.
238 | Enhancing SEER data through public
health reporting of pharmacy claims for
precision cancer surveillance
Donna Rivera1; Kathleen A. Cronin1; Kevin C. Ward2;
Jennifer Stevens3; Nicola Schussler3; Linda Coyle3; David Angelaszek3;
Lynne Penberthy1
1National Cancer Insitute, Rockville, MD; 2Department of Epidemiology,
Emory University Rollins School of Public Health, Atlanta, GA;
3 Information Management Services, Inc., Calverton, MD
Background: The National Cancer Institute Surveillance, Epidemiology,
and End Results (SEER) Program is a coordinated system of population‐
based cancer registries representing 34% of the US population. SEER
registries currently collect the first course of treatment, with a gap in
longitudinal, detailed treatment data needed to conduct clinically rele-
vant cancer surveillance. SEER is establishing collaborations to expand
treatment data collection, including an initial study establishing
reporting of oral oncologic treatment through retail pharmacy claims
to the Georgia State Cancer Registry (GCR).
Objectives: This initial collaboration seeks to a) facilitate automated
capture of oral oncologic agents to fulfill legally mandated
public health reporting and b) evaluate enhanced treatment data (e.
g. representativeness and coverage) and expand ability to provide
relevant cancer health statistics (e.g. patterns of care, health
outcomes).
Methods: Oncology Pharmacy Claims (OPC) were securely matched
to GCR data as part of legally mandated reporting requirements for
cancer. OPC were identified using strict rules to ensure each drug
had a specific indication for cancer treatment or treatment‐related
symptom management. A retrospective analysis was conducted
among female patients identified in GCR with Hormone Receptor
(HR+) Invasive Breast Cancer (BC), as a single primary neoplasm,
between 2013–2016 and matched with OPC (2013–2017) to evalu-
ate representativeness of the data and hormonal therapy treatment
patterns among patients with OPC. Aromatase Inhibitor and
SERM drug utilization was assessed. Demographic, socioeconomic,
and clinical characteristics of patients were evaluated using descrip-
tive statistics. Treatment outcomes evaluated include time to treat-
ment initiation, treatment duration, and adherence using proportion
of days covered.
Results: Among the HR+ BC cohort analyzed, 5,364 cases (30%) had
an OPC for hormonal therapy; 68% white, 29% black, and 3% iden-
tified as another race. The mean age at diagnosis for patients
with hormonal OPC was 58 years. Among the hormonal therapy
OPC, patients received anastrozole (51%), exemestane (14%),
letrozole (27%), and tamoxifen (34%). Additional utilization
patterns, treatment characteristics, and adherence measures will be
provided.
Conclusions: The addition of pharmacy claims data within cancer reg-
istries represents a novel first step towards obtaining more compre-
hensive treatment data to enhance cancer surveillance (eg. case
ascertainment, additional courses of therapy) and evaluate longitudinal
patient treatment patterns.
239 | The comorbid burden of gout on
health outcomes: Results from linking
electronic health records to patient‐reported
outcomes
Stephanie Huynh1; Dena Jaffe2; Carey Strader3; Tom Haskell4
1Kantar Health, New York, NY; 2Kantar Health, Tel Aviv, Israel; 3Kantar
Health, St Louis, MO; 4Kantar Health, Horsham, PA
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Background: The comorbid burden among gout patients is associ-
ated with higher serum uric acid (sUA) and recurring attacks, which
may result in greater costs and poorer health‐related quality of life
(HRQoL). Linked self‐reported survey and clinical data from elec-
tronic health records provide valuable insights into this relationship.
Objectives: To examine the prevalence of gout and related comor-
bidities using two nationally‐representative surveys, and
further characterize patient subgroups according to sUA levels
through the linkage of survey data to electronic health records
(EHR).
Methods: Data from two cross‐sectional, nationally‐representative
US surveys were used: Patient‐Centered‐Research (PaCeR) (2015–
2018; annual sample ~75,000) and National Health and
Nutrition Examination Survey (NHANES) (2015–2016; annual sample
9,971). PaCeR data was linked in a HIPAA‐compliant methodology
to a large US ambulatory EHR database. Respondents with gout
and gout‐related comorbidities were identified through self‐reported
diagnosis, and NHANES estimates were weighted to the
general population. Linked PaCeR‐EHR respondents were identified
as those with 1+ sUA tests in the EHR within 18 months of survey
completion (n = 231). Outcomes included patient‐reported
HRQoL and health status using the SF‐36v2. Descriptive
and bivariate analyses used ANOVAs and Pearson's correlation
coefficients.
Results: Among adults (≥18 years), the annual prevalence of gout
was 4.8% in PaCeR‐EHR and 4.0% in NHANES. The average age
and percent male patients were similar in both data sources
(PaCeR‐EHR: 64.7 ± 10.8 years, 64.4% male; NHANES:
62.0 ± 12.7 years, 63.7% male). Highly prevalent comorbidities
among gout patients included hypertension (PaCeR‐EHR = 75.6%;
NHANES = 74.0%), coronary heart disease (CHD) (PaCeR‐
EHR = 19.0%; NHANES = 13.0%), and obesity (PaCeR‐EHR = 55.3%;
NHANES = 54.8%). Average sUA in gout patients was 5.6 (±1.4) mg/
dL, and sUA was positively correlated with number of comorbidities
(r = 0.20, p < 0.005). HRQoL also decreased as number of comorbid-
ities increased. For example, the SF‐36v2 physical component score
was lower for gout patients with one (46.7 ± 10.2), two
(42.5 ± 10.0), or three (36.7 ± 15.9) comorbidities compared with
patients with no hypertension, CHD, or obesity (52.2 ± 6.6)
(p's < 0.001).
Conclusions: Large‐scale population‐based survey data provide valu-
able prevalence information. Further, linking survey data with EHR
allows for a more comprehensive view of disease burden by delin-
eating the relationship between clinical characteristics and patient‐
reported burden.
240 | Linking genomic and longitudinal real‐
world data: Applications to drug development
and Pharmacoepidemiology research
Ali Abbasi1,2; Fiona Grimson1; Joanne M. Hackett3;
Sudhir Venkatesan1; Valeria Lascano1; Yoshiko T. Cook1;
Benjamin Bray1,4; Deborah Layton1,5; Joseph Kim1,6
1 IQVIA, London, UK; 2University Medical Centre Groningen, Groningen,
Netherlands; 3Genomics England, London, UK; 4King's College London,
London, UK; 5University of Keele, Keele, Newcastle, UK; 6London School
of Hygiene and Tropical Medicine, London, UK
Background: The increasing use of linked genomic and real‐world data
(RWD) can provide insights for targeted therapies or predicting treat-
ment response. Since 2013 Genomics England has been working in
partnership with theNHS in England, Scotland,Wales andNorthern Ire-
land to complete the 100,000 Genomes Project; an initiative that has
sequenced 100,000 whole genomes from individuals with rare diseases
and cancers. We investigated an infrastructure that allow the linkage
between genomic and Hospital Episode Statistics (HES) data.
Objectives: To generate initial insights into the patient cohorts included
in the 100,000 Genomes Project and to describe how the linkage can
support analytic processes and evidence generation.
Methods: This was an exploratory assessment to describe
the linked genomic and RWD. Privacy‐protected and de‐identified
HES data were linked to genomic data from patients with a diagnosis
of at least one condition from the 100,000 Genomes
Project. Summary descriptive statistics on patient counts
were calculated in each cohort. We described the type of studies that
the linked genomic and HES data could support.
Results: An exploratory analysis showed that the 100,000
Genomes Project included genomic data from several types of solid
tumors (like colorectal, n =2,880; lung, n=2,009and sarcoma,n=1,030),
hematological cancers (n = 454), childhood tumors (n = 143) and many
different rare diseases (like cystic kidney disease, n = 1,516 and familial
hypercholesterolaemia, n = 501). Using the linkage, comorbid pheno-
types and clinical outcomes of patients with cancer or rare disease were
defined in the HES data.
Conclusions: Our investigation shows that the systematic application of
large scale genomics to RWD is now feasible. Technological infrastruc-
ture of the NHS allows to generate linked clinical‐genomic datasets for
research under rigorous governance processes and privacy protection.
Further scientific work is needed to investigate applications of linked
genomic‐RWD to provide genomic‐based evidence for predicting effi-
cacy or safety of drugs, biomarker testing or stratifying patients.
120 ABSTRACTS
241 | Burden and concordance of
information on CYP2D6, CYP2C19, AND
CYP2C9 related substrate and inhibitor co‐
prescriptions from the lifelines cohort: the
Pharmlines initiative
Muh. Akbar Bahar1; Jens H.J. Bos1; Sander D. Borgsteede2;
Aafje Dotinga3; Rolinde A. Alingh3; Bob Wilffert1; Eelko Hak1
1Groningen Research Institute of Pharmacy, University of Groningen,
Groningen, Netherlands; 2Health Base Foundation, Houten, Netherlands;
3Lifelines Cohort Study, Groningen, Netherlands
Background: Drug–drug interactions (DDI) are one of the major con-
tributors to adverse drug reactions.
Objectives: We aimed to estimate the burden of substrate and inhib-
itor of CYP2D6‐, CYP2C19‐, and CYP2C9‐mediated co‐prescriptions
that may lead to potentially clinically relevant DDIs in the LifeLines
cohort. Further, the concordance of questionnaire and prescription
database was assessed.
Methods: Data on the prevalence of substrate and inhibitor of
CYP2D6, CYP2C19, and CYP2C9 co‐prescriptions were collected
from the LifeLines participants and linked by Statistics Netherlands
to the pharmacy database IADB.nl, as a part of the PharmLines Initia-
tive project. Data analysis were performed at fifth level of ATC codes
for all potentially clinically relevant CYP2D6‐, CYP2C19‐, and
CYP2C9‐mediated DDIs. The co‐prescriptions were divided based on
the duration of use of prescribed medications i.e. regularly used med-
ication (RM) and RM combination, RM‐non regularly used medication
(NRM) combination and NRM‐NRM combination. To measure the
level of agreement, Cohen's kappa statistics was used and the results
were stratified by time windows, sex, and age.
Results: At entry, of all 80,837 medicine users, about two per hun-
dred LifeLines participants were exposed to a CYP2D6/2C19/2C9‐
mediated potentially clinically relevant DDI. Most of the potential
DDIs were mediated by CYP2C19 (1,120 patients), followed by
CYP2D6 (590 patients) and CYP2C9 (255 patients). Using an over-
lapping time window of three months, kappa values were moderate
at 0.53, 0.56, and 0.43 for CYP2D6, CYP2C19, and CYP2C9‐medi-
ated DDIs, respectively. Subgroup analysis by the type of medication
indicated that the potential DDIs between RM‐RM and RM‐NM
combination mostly had better kappa values than NRM‐NRM. The
influence of gender on the concordance values was different for dif-
ferent CYPs. Among older persons agreement levels were higher for
all CYPs‐mediated potentially clinically relevant DDIs than among
the younger population.
Conclusions: CYP2D6/2C19/2C9‐mediated potentially clinically rele-
vant DDIs were frequently observed in the LifeLines cohort. The
agreement between the LifeLines cohort data and the prescription
data is moderate. Future pharmaco‐epidemiological studies should
preferably combine the two data sources to achieve the highest accu-
racy of drug exposure rates.
242 | Do Oral antineoplastic treatment data
differ between EMR & Claims: Concerto
Health AI Definitive Oncology Dataset &
Symphony Linkage Study
Laura Chu1; Nayan Chaudhary1; Li Chen2; William Wong1
1Genentech, Inc, South San Francisco, CA; 2Concerto HealthAI, Boston,
MA
Background: Electronic Medical Records (EMRs) are increasingly
being used for health outcomes research because they contain
a rich array of clinical data. Oral medications are captured via
structured medication order fields or abstracted from the clinical
notes; however, it's unknown how these correspond with
dispensations.
Objectives: The objective of this study was to better understand how
oral antineoplastic orders captured from an EMR database compare to
dispensations from pharmacy claims.
Methods: The Concerto Health AI Definitive Oncology Dataset is a
deeply curated cohort of patients (pts) derived from a wide range
of oncology practices throughout the United States. Concerto Health
AI has a co‐exclusive partnership with ASCO CancerLinQ & collects
data from multiple other sources. These data were deterministically
linked to US Symphony Health's (SH) Integrated Dataverse, an
anonymized, HIPAA‐compliant data set. Only advanced (stage IIIb/
IV) non‐small cell lung cancer (aNSCLC) pts with curated data via
manual review by nurse practitioners & oral antineoplastics pre-
scribed for lung cancer were included in this analysis. Among a sub-
set of pts that had a dispensation within 90 days of their 1st EMR
order, treatment duration was calculated as time from 1st to last
order/claim (before a 30‐day gap) plus 30 days supply, for EMR &
claims, respectively.
Results: Of 19,175 aNSCLC pts from Concerto, 8,864 pts were linked
to SH. Among linked pts, there were 2,057 pt‐drug instances; 750
(36.5%) were in both Concerto and SH, 1,160 (56.4%) in Concerto
but not SH, and 147 (7.1%) in SH but not Concerto. Median time from
1st order in Concerto to 1st dispensation in SH was 16 days (interquar-
tile range (IQR): 6, 78), with 76% of pt‐drug instances having a dispen-
sation within 90 days of 1st Concerto order. Median treatment
duration was 44 (IQR: 30, 125) and 93 (IQR: 41, 241) days based on
Concerto and SH, respectively.
Conclusions: Concerto EMR orders identified more pts treated with
oral antineoplastics, though treatment durations were longer using
SH claims. Limitations of this analysis include use of orders from
EMR instead of abstracted start and end dates and use of open
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claims with limited specialty pharmacy data. Linked datasets may
provide more robust capture of orals data and warrant further
research.
243 | Combining a prospective registry with
a retrospective medical chart review
Sandrine Leroy; Monika Brand; Daniel Rosenberg; Graham Wetherill;
Adele Morganti
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Background: The OPsumit® USers Registry (OPUS) provides real‐
world data on the use and safety profile of Opsumit, an endothelin
receptor antagonist indicated for the treatment of pulmonary arte-
rial hypertension (PAH), a rare and severe condition. The OPUS reg-
istry was an FDA post‐marketing requirement focusing on the class‐
effect of hepatotoxicity. The OPsumit® Historical USers (OrPHeUS)
medical chart review study complemented OPUS, to achieve the
requested sample size of 5000 patients newly treated with Opsumit
within 5 years in the combined analysis.
Objectives: To evaluate the appropriateness of combining OPUS and
OrPHeUS data.
Methods: The studies were designed to be as similar as possible.
Exploratory heterogeneity assessment on key variables was per-
formed, with bootstrap 95%CI, using PAH patients who represented
the majority of patients.
Results: The combined OPUS (n = 2086) and OrPHeUS (n = 2984)
dataset included 4072 (80.3%) PAH patients; 96 (61.9%) of 155 par-
ticipating sites contributed to both studies. The median (range)
Opsumit initiation year was 2016 (2014–2018) in OPUS and 2015
(2013–2016) in OrPHeUS; median (95%CI) age was 62 (61, 63)
and 61 (60, 62) years, respectively. For patients with a WHO func-
tional class (FC) assessment ≤3 months from Opsumit initiation
(OPUS 71.7% and OrPHeUS 21.9%), the proportion (95%CI) in
WHO FC I/II was similar: 39.2% (36.5, 41.9) and 36.1% (32.0,
40.1). The median (95%CI) Opsumit exposure time in OPUS was
11.9 (11.1, 12.7) and in OrPHeUS was 15.6 (14.7, 16.4) months,
and annual visit rate (95%CI) was 3.6 (3.5, 3.7) and 3.3 (3.2, 3.4)
visits/year, respectively. The annual liver test (LT) rate (95%CI) was
lower in OPUS (1.8 [1.7, 1.9]) than in OrPHeUS (2.2 [2.1, 2.4]), as
was the proportion of patients with a liver test. This might have
been related to the hepatotoxicity concern in the first years after
Opsumit launch in Oct 2013, which may have lessened after daily
care experience.
Conclusions: The similarities between OPUS and OrPHeUS studies
enabled combined analyses. The higher rate of liver tests in
OrPHeUS may have induced a detection bias, potentially leading
to more liver test abnormalities being detected. However, this did
not change the overall conclusion about the (hepatic) safety of
Opsumit.
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245 | Building an integrated real‐time data
ecosystem to enhance care delivery for
asthma patients in Singapore
Shao Wei Sean Lam1,2; Sumitra Shantakumar3,2; Dave Webb4;
Cheng Hian Ang5; Hao Sen Andrew Fang1,6; Yaoxian Alwin Zhang1;
Sudha Harikrishnan1; See‐Hwee Yeo3; Pei Yee Tiew1;
Ngiap Chuan Tan6; Eng Hock Marcus Ong1,2,7; Julian Thumboo1,2,7;
Des Burke4; Chian Min Loo1,2,7; Siyue Mariko Koh2,7;
David Bruce Matchar1,2
1Singapore Health Services, Singapore, Singapore; 2Duke‐NUS Medical
School, Singapore, Singapore; 3GlaxoSmithKline, Singapore, Singapore;
4GlaxoSmithKline, London, UK; 5 Integrated Health Information Systems,
Singapore, Singapore; 6SingHealth Polyclinics, Singapore, Singapore;
7Singapore General Hospital, Singapore, Singapore
Background: Asthma affects an estimated 273 million people world-
wide, with Singapore having one of the highest asthma prevalence
rates. The real‐time capture, aggregation and analysis of real‐world
electronic clinical data provides important information for improving
the care of asthma patients in Singapore.
Objectives: To develop an asthma real‐world data ecosystem (RWDE)
for a large academic medical centre in Singapore through a public‐pri-
vate partnership with Singapore Health Services (SingHealth), Duke‐
NUS Medical School and GlaxoSmithKline. This abstract describes
the data linkages, source data verification and validation steps in the
creation of the RWDE.
Methods: Multiple clinical data sources such as the electronic medical
records and clinical measurement result system, were linked using the
SingHealth enterprise data warehouse (EDW). To ensure accurate
data transfers, back‐end data retrieved from the EDW was matched
with the front‐end data captured at the point of care. The data quality
assurance includes a gated stepwise process to ensure the correct
integration of data from various sources. As part of the data validation
process, demographics and clinical information were retrospectively
extracted for asthma patients visiting the Singapore General Hospital
(SGH) from October 2012 to October 2017, and exploratory descrip-
tive analyses (EDA) performed.
Results: Testing of the RWDE yielded satisfactory results. Descriptive
statistics of key variables were checked to ensure that the extracted
data were of high veracity. In our EDA, a total of 621 asthma patients
from SGH were included. Mean age of the cohort was 55.1 years and
43.0% were males. 21.3% were smokers or ex‐smokers. Common
comorbidities include allergic rhinitis and gastro‐esophageal reflux dis-
ease. 58.6%, 19.3%, 16.1% and 6.0% were of Chinese, Indian, Malay
and other ethnicities, respectively. The majority had their Asthma
Control Test scores (83.9%) and spirometry results (62.6%) docu-
mented. 58.0% and 60.4% of the patients were provided with a
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Written Asthma Action Plan and had their inhaler technique assessed,
respectively. Overall, results from the EDA are concordant with other
studies on asthmatics conducted at SGH.
Conclusions: The development and application of an asthma RWDE in
SGH enables real‐time access and analysis of large‐volume tertiary
level data to facilitate clinical research, and to support the future
design of clinical decision support systems to improve patient out-
comes. The next step will be to incorporate public primary care data
from the network of SingHealth polyclinics. FUNDING:
GlaxoSmithKline.
246 | Initiation of an innovative study
combining digital patient generated data with
health records to evolve understanding of
Back pain
Alison Bourke1; Shaun O'Hanlon2; Toby Helliwell3; Matthew Cooper4;
Mick Mullane4; Stephanie Meleck5; Josh Hiller1; Jaskiran Dhanjal1
1 IQVIA, London, UK; 2EMIS, Leeds, UK; 3Keele University, Keele, UK;
4National Institute of Health Research (NIHR) Clinical Research Network
National Coordinating Centre, Leeds, UK; 5uMotif, London, UK
Background: Back pain affects up to 80% of the population and is one
of the most common reasons for long term sickness. Therefore it is
important to understand more about sufferers and to quantify the
economic and social burden of the condition and pain management
from a patient centric view.
Objectives: To utilize electronic health records (EHR) combined with
digital health data from patients to i) assess quality of life (QoL) over
time for patients with back pain, and the variation in pain, ii) investi-
gate the epidemiology of back pain, and iii) quantify the economic bur-
den of back pain.
Methods: A collaboration was established between IQVIA, uMotif,
EMIS Health, and NIHR and a study was initiated to recruit patients
with a diagnosis of acute or chronic low back pain from UK Primary
Care. The study utilized a novel, efficient recruitment application
called AppScript embedded into the General Practitioner's EMIS prac-
tice management software. Patients used a mobile app, uMotif, to pro-
vide informed consent and collect information on QoL, work
productivity, physical, and mental impacts of the back pain. The
patient reported data was combined with retrospective EHR data to
provide broader insights from both the health team and the patient.
Results: A study kick‐off meeting ensured that the sponsor, chief
investigators, facilitators and app providers were aligned on study
goals, roles and methods. Study materials, including the patient
eSurvey, were developed and Ethics Committee approval was
obtained. General Practitioners were recruited and trained. Patient
recruitment has begun with the aim of recruiting 150–200 patients
with at least 3 months' chronic or acute back pain who will be in the
study for 3 months providing data via the mobile app.
Conclusions: This novel use of digital technology reduces the burden
of recruitment and data collection from clinicians. Collecting direct
patient generated data has the promise of shortening the time needed
to complete a study, reducing costs, improving quality of research data
and reducing recall bias, while still being acceptable to patients. Hav-
ing the ability to collect timely patient generated insights and link this
to routine healthcare data represents a new approach to driving
insights and understanding of common and impactful conditions such
as back pain.
247 | Does NA‐NSAID use reduce the
mortality among endometrial cancer patient?
Cecilie D. Sperling1; Freija Verdoodt1; Gitte L. Aalborg1;
Christian Dehlendorff1; Søren Friis1,2; Susanne K. Kjaer1,2
1Danish Cancer Research Center, Copenhagen, Denmark; 2University of
Copenhagen, Copenhagen, Denmark
Background: An anti‐neoplastic effect of non‐aspirin non‐steroidal
anti‐inflammatory drugs (NA‐NSAIDs) has been suggested, mainly
through suppression of cyclooxygenase, isoform 2 (COX‐2). Elevated
levels of COX‐2 in malignant endometrial cells have led to the hypoth-
esis that NA‐NSAID can improve the prognostic outcome among
endometrial cancer patients.
Objectives: To examine whether post‐diagnostic use of NA‐NSAIDs is
associated with reduced cancer mortality in a large nationwide regis-
try‐based cohort of endometrial cancer patients.
Methods: From the Danish Cancer Registry we retrieved all women
with a diagnosis of endometrial cancer. Women who were diag-
nosed between 2000 and 2012, aged 30–84 years, who had no his-
tory of cancer (except non‐melanoma skin cancer) and were alive
one year after cancer diagnosis were eligible for the study. NA‐
NSAID use was defined as one or more prescriptions after date
of diagnosis and was further characterized by cumulative amount,
intensity and duration of use, and COX‐2 selectivity. Follow‐up
started one year after diagnosis and continued until death, emigra-
tion, or end of study, whichever came first. Primary outcome was
endometrial cancer specific mortality. Using Cox regression models,
adjusted hazard ratios (HRs) and 95% confidence intervals (CIs)
were estimated for the association between post‐diagnosis NA‐
NSAID use and endometrial cancer mortality with NA‐NSAID use
included as time‐varying variable. In pre‐defined sensitivity analyses
to test the robustness of the results and to account for the influ-
ence of time‐varying confounders, drug use was treated as a
time‐fixed variable with follow‐up starting at 1 year and 5 years
after diagnosis, respectively. The potential impact of competing
events was tested by Fine and Gray's proportional subdistribution
hazard model.
Results: The study population comprised 6,694 endometrial cancer
patients and during follow‐up 753 died from endometrial cancer.
NA‐NSAID use was associated with a HR of 1.07 (95% CI 0.91–
1.26) for endometrial cancer mortality. Neither the selective COX‐2
inhibitors (HR 1.05, 95% 0.84–1.32) nor nonselective NA‐NSAIDs
(HR 1.10, 95% CI 0.90–1.35) were associated with a reduced
ABSTRACTS 123
endometrial cancer mortality. The analyses on the time‐fixed expo-
sures and subdistribution hazards yielded similar results.
Conclusions: In conclusion, NA‐NSAID use was not associated with
endometrial cancer mortality among Danish patients.
248 | Inhibition of the renin‐angiotensin
system and survival in patients with
pancreatic cancer
Jakob Kirkegård; Deirdre Cronin‐Fenton
Aarhus University Hospital, Aarhus, Denmark
Background: The renin‐angiotensin system may mediate tumor
growth in pancreatic cancer. Drugs inhibiting this system may
therefore be associated with survival in patients with pancreatic
cancer.
Objectives: To examine the association between prediagnostic use of
angiotensin converting enzyme inhibitors (ACEi) or angiotensin recep-
tor blockers (ARB) and survival in pancreatic cancer patients.
Methods: A population‐based cohort study of all patients aged over
18 years diagnosed with pancreatic ductal adenocarcinoma in Den-
mark during 1997–2016. Patients were followed for a maximum of
three years from date of diagnosis until death or end of follow‐up
(23 May 2018). Patients were classified as ACEi‐users or ARB‐users
if they had filled a prescription for one of these drug types in the year
before pancreatic cancer diagnosis. Patients with no prescriptions of
either drug type were classified as non‐users. We computed median
survival with associated interquartile range (IQR) according to expo-
sure status and crude and adjusted hazard ratios (HRs) and associated
95% confidence intervals (95% CI) using Cox proportional hazards
regression model, adjusting for age, sex, year of diagnosis, Gagne
comorbidity score, and cardiovascular disease. We conducted sensitiv-
ity analyses comparing ACEi users with ARB users and excluding
patients exposed to both drugs (n = 116); and second, extending the
exposure period to two years before pancreatic cancer diagnosis. In
the latter analyses, we restricted to patients with prescription drug
data available for the period of interest.
Results: Of 11,662 pancreatic cancer patients, 1,289 (11.2%) were
ACEi‐users, 983 (8.5%) were ARB‐users, and 116 (1.0%) were exposed
to both drug types. Median age was lower in non‐users (67 years)
compared with ACEi (70 years) and ARB (71 years) users. There were
no differences in tumor stage at diagnosis according to drug exposure.
ACEi‐users had more comorbidity than ARB‐users and non‐users.
Median survival was 4.3 (IQR: 1.6–10.4) months in ACEi‐users, 5.0
(IQR: 1.7–11.2) months in ARB‐users, and 4.6 (IQR: 1.8–10.8) months
in non‐users. Compared with non‐users, neither ACEi (adjusted HR:
1.00; 95% CI: 0.94–1.07) nor ARB use (adjusted HR: 0.97; 95% CI:
0.91–1.05) was associated with survival. The sensitivity analyses had
only little effect on the HRs.
Conclusions: Exposure to antihypertensive drugs acting on the renin‐
angiotensin system before pancreatic cancer diagnosis was not associ-
ated with survival in patients with pancreatic cancer.
249 | Real‐world assessment of clinical
outcomes among first‐line (1 L) Sunitinib
patients with metastatic renal cell carcinoma
(MRCC) by the international Mrcc database
consortium (IMDC) risk group
Lynn Huynh1; Marie‐France Savard2; J. Connor Wells2;
Jeffrey Graham3; John Steinharter4; Bradley McGregor4;
Frede Donskov5; Georg A. Bjarnason6; Ulka Vaishampayan7;
Aaron Hansen8; Marco Iafolla8; Giovanni Zanotti9; Catherine Nguyen1;
Rose Chang1; Mei S. Duh1; Daniel Y.C. Heng2
1Analysis Group, Inc, Boston, MA; 2University of Calgary, Calgary, AB,
Canada; 3CancerCare Manitoba, University of Manitoba, Winnipeg, MB,
Canada; 4Dana‐Farber Cancer Institute, Boston, MA; 5Aarhus University
Hospital, Aarhus, Denmark; 6Sunnybrook Health Sciences Centre,
Toronto, ON, Canada; 7Karmanos Cancer Institute, Detroit, MI; 8Princess
Margaret Cancer Centre, Toronto, ON, Canada; 9Pfizer, Inc, New York,
NY
Background: Sunitinib is a standard treatment for 1 L mRCC. Find-
ings from several clinical trials suggest that clinical outcomes of
mRCC patients treated with 1 L sunitinib may vary across prognos-
tic risk groups (i.e., favorable, intermediate, poor risk), defined by
IMDC criteria. A gap in the literature on the effectiveness of 1 L
sunitinib by IMDC prognostic risk group in the real‐world setting
exists.
Objectives: This study assesses clinical outcomes and provide bench-
marks for mRCC patients treated with 1 L sunitinib in the real‐world to
provide contemporary benchmarks for outcomes and survival.
Methods:Clear cell mRCCpatients≥18 years of agewho initiated suni-
tinib as 1 L therapy between 2010–2018 at select IMDC clinical sites
were included in this real‐world retrospective database study. Kaplan
Meier analysis was used to estimate median time to treatment discon-
tinuation (TTD) and overall survival (OS) by IMDC risk groups based
on Karnofsky Performance Status <80%, diagnosis to treatment inter-
val < 1 year, anemia, neutrophilia, hypercalcemia and thrombocytosis.
Results: Among 1,769 1 L sunitinib patients with clear cell in this real‐
world clinical dataset, 318 (18%) had favorable, 1,031 (58%) had inter-
mediate and 420 (24%) had poor IMDC risk. Across the favorable, inter-
mediate, and poor risk groups, patients had similar mean age in years,
gender distribution, and year of sunitinib initiation (age: 63.8, 62.9 and
62.6; male: 74%, 75%, and 72%; sunitinib initiation year of 2010–
2013: all 71%). In the favorable risk group, 99% received nephrectomy
vs 88% in intermediate and 66% in poor risk group. Median TTD was
15.0, 8.5, and 4.2 months (mos) in the favorable, intermediate, and poor
risk groups, respectively, and was 7.1 mos in the combined intermedi-
ate/poor risk groups. Median OS was 52.1, 31.5, and 9.8 mos in the
favorable, intermediate, and poor risk groups, respectively, and was
23.2 mos in the combined intermediate/poor risk groups.
Conclusions: This real‐world study based on a contemporary cohort of
1 L sunitinib mRCC patients found a median OS of 52 mos which sets
a new benchmark for clear cell mRCC in the favorable risk group. OS
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in the intermediate and poor risk groups are similar to previous
reports. This affects patient counseling and clinical trial design.
250 | Antihistamines and survival from
ovarian cancer: A population‐based cohort
study and in vitro cell viability study
Christian Dehlendorff1; Freija Verdoodt1; Marja Jäättelä1;
Robert Strauss1; Anton Pottegård2; Jesper Hallas2; Susanne K. Kjaer3;
Søren Friis4
1Danish Cancer Society Research Center, Copenhagen, Denmark;
2Clinical Pharmacology and Pharmacy, Department of Public Health,
University of Southern Denmark, Odense, Denmark; 3Danish Cancer
Society Research Center & Department of Gynecology, Rigshospitalet,
University of Copenhagen, Copenhagen, Denmark; 4Danish Cancer
Society Research Center & Department of Public Health, University of
Copenhagen, Copenhagen, Denmark
Background: Epithelial ovarian cancer is associated with poor progno-
sis, since it is often diagnosed in a late stage and often becomes resis-
tant to chemotherapy. A subclass of antihistamines with cationic
amphiphilic drug (CAD) characteristics have been associated with
improved cancer outcomes, in pre‐clinical and observational studies.
In this study, we evaluate the potential of these antihistamines to
improve survival after ovarian cancer.
Objectives: To assess whether CAD antihistamines improves the sur-
vival in ovarian cancer patients.
Methods: We performed a cohort study including all 1‐year survivors
of epithelial ovarian cancer between 2000 and 2015 aged 30–
84 years. Information on filled prescriptions of antihistamine, use of
other drugs, comorbid conditions and socioeconomic parameters was
retrieved from nationwide prescription, medical and demographic reg-
istries. By means of Cox proportional hazards models, we computed
hazard ratios (HRs) and 95% confidence intervals (CIs) for use of
CAD antihistamines and ovarian cancer mortality. The underlying
timescale was time since 1 year after diagnosis. Use of antihistamines
was defined as filling at least one prescription between 6 months
before and 12 months after diagnosis. We used an active comparator
approach comparing CAD‐antihistamine users with users of non‐CAD
antihistamines. In secondary analysis we moved the baseline to three
years after diagnosis and defined use of antihistamines as use within
three years after diagnosis. Finally, we tested the effect of clinically
relevant CAD and non‐CAD antihistamines on cell viability in three
serous ovarian cancer cell lines, including OVCAR‐3, UWB1.289, and
ovc316. Separate one‐way ANOVA was used to evaluate cell death
according to dose for each antihistamine in each of the three cell lines.
Results: We identified 5075 1‐year survivors after ovarian cancer and
of these 484 patients used antihistamines between 6 months before
and 1 year after diagnosis. Of the 484 users of antihistamines 148
were classified as CAD users. Use of CAD antihistamines was associ-
ated with a HR of 0.74 (95% CI: 0.51–1.06) compared to use of
non‐CAD in 1‐year survivors, whereas the HR was 0.63 (95% CI:
0.40–0.99) for 3‐year survivors among 145 CAD antihistamine users
and 292 non‐CAD users. Similar results were seen when comparing
to patients not using antihistamine. Cell viability experiments showed
consistent dose–response relationships with cell death for all CAD
antihistamines, but not for non‐CAD antihistamines.
Conclusions: Use of CAD antihistamines may improve survival after
ovarian cancer.
251 | Response and adherence to Nilotinib in
daily practice (RAND‐study): An in‐depth
observational study of patients with chronic
myeloid leukemia treated with Nilotinib
Christel C.L.M. Boons1; Lonneke Timmers1; Jeroen J.W.M. Janssen1;
Peter E. Westerweel2; Eleonora L. Swart1; Harry Hendrikse1;
Jacqueline Hugtenburg1
1Amsterdam UMC locatie VUMC, Amsterdam, Netherlands; 2Albert
Sweitzer Medical Center, Dordrecht, Netherlands
Background: In chronic myeloid leukemia (CML), oral treatment needs
to be taken indefinitely in the majority of patients and specifically for
nilotinib, the necessity of a twice daily, fasted schedule is an extra bur-
den. Non‐adherence to CML treatment may influence plasma levels
and has been recognized as a determinant of treatment failure in CML.
Objectives: To gain insight into adherence with the use of nilotinib in
daily clinical practice and its influence on exposures and treatment
outcome.
Methods: A multicentre prospective observational study conducted
between August 2013–April 2017. CML patients treated with nilotinib
were followed for twelve months. Achievement of a major molecular
response (MMR) within the first twelve months of nilotinib treatment
was assessed. Adherence was measured by three methods: medication
event monitoring system (MEMS) (proportion of days covered [PDC]),
pill count (adherence rate [AR]), and self‐reported Medication Adher-
ence Report Scale (MARS‐5). Nilotinib trough plasma concentrations
were measured at baseline, three, six, and twelve months.
Results: Sixty‐eight patients (57.0 ± 15.0 years;48% female) partici-
pated. At baseline, 29 patients were newly starting nilotinib (subpopu-
lation‐A) and 39 were already on treatment with nilotinib
(subpopulation‐B) with a median treatment duration of 39 months
(range 3–92). The overall 1‐year MMR rate ranged from 44–75%.
Median PDC and AR were 99.6 and 100.2 in subpopulation‐A and
97.6 and 98.1 in subpopulation‐B, respectively. Three and five
patients, respectively, had PDC and AR <90%. The percentage of
patients reporting any non‐adherence behaviour (MARS‐5) increased
in subpopulation‐A from 8% at three months to 26% at twelve
months, and remained steady in subpopulation‐B at 23–30%. Average
trough plasma concentration was 1084 ± 556 ug/L (range 196–2540).
Six patients (9.8%) had a plasma concentration below the therapeutic
target level (<490 ug/L) at any time. There was no association
between nilotinib trough level or nilotinib adherence and MMR at
twelve months.
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Conclusions: Substantial non‐adherence (<90%) to nilotinib was rare
and nilotinib blood levels were above the therapeutic target in 90%
of patients. Achievement of MMR on nilotinib was not related to
nilotinib non‐adherence or inadequate blood levels. However, inciden-
tal non‐adherence increases over time to a quarter of patients, empha-
sizing the importance of continuous support of medication adherence
in CML care.
252 | Comparative efficacy and safety of
immune checkpoint inhibitors for untreated
and treated advanced non‐small cell lung
cancer: Meta‐analysis and meta‐regression
analysis
Jason C. Hsu1; Yen‐Tzu Chen1; Joanne Lo1; Szu‐Chun Yang2;
Yang‐Cheng Lee3; Peng‐Chan Lin1
1National Cheng Kung University, Tainan, Taiwan; 2National Cheng Kung
University Hospital, Tainan, Taiwan; 3Tainan Municipal Hospital, Tainan,
Taiwan
Background: In recent years, more and more randomized clinical trials
and observational studies have been conducted and demonstrated
that many Immune checkpoint inhibitors (ICIs) can significantly
improve the survival rate of advanced non‐small cell lung cancer
(NSCLC). Many meta‐analyses studies have been conducted to
address possible inconsistencies in clinical trial results, and to achieve
comprehensive conclusions. However, only a few studies have
explored the efficacy and safety of ICIs for advanced NSCLC in detail
by subgroup analyses.
Objectives: This meta‐analysis systematically and quantitatively evalu-
ated the efficacy and safety of ICIs compared with chemotherapy
treatment for untreated advanced NSCLC.
Methods: Following the Preferred Reporting Items for Systematic
Reviews and Meta Analyses (PRISMA) and the Cochrane Collaboration
guidelines, electronic databases (PubMed, Embase, Web of Science
and Cochrane Library) were searched for all clinical trials and observa-
tional studies in NSCLC using ICIs. Data about overall survival (OS),
progression free survival (PFS), all‐grade adverse events (AEs) and
high‐grade (3–5) AEs were pooled. Meta‐regression was performed
for further subgroup analyses.
Results: A total of 10 trails with 5,277 patients (3 with nivolumab; 3
with pembrolizumab; 3 with atezolizumab; and 1 with durvalumab)
were included in this meta‐analysis. We demonstrated that ICIs thera-
pies significantly improved OS (HR = 0.67, 95% CI 0.62–0.72,
P < 0.05) and PFS (0.74, 0.64–0.86, P < 0.05) in treated advanced
NSCLC, while the results were not always significant in untreated
advanced NSCLC: OS (0.84, 0.63–1.14, P = 0.265) and PFS (0.66,
0.47–0.91, P = 0.012). In terms of safety, ICIs had a significantly lower
risk of any all‐grade AEs (OR = 0.48, 95% CI 0.33–0.71, P < 0.05) and
high‐grade AEs (0.27, 0.14–0.51, P < 0.05) in treated advanced
NSCLC; while the results were not always significant in untreated
advanced NSCLC: any all‐grade AEs (0.54, 0.21–1.38, P = 0.198) and
high‐grade AEs (0.57, 0.17–1.84, P = 0.341). The results of meta‐
regression also showed that OS, PFS, all‐grade and high‐grade AEs
were better for patients with squamous histology and higher PD‐L1
expression.
Conclusions: In conclusion, compared with chemotherapy, ICIs
improve OS and PFS in advanced NSCLC with fewer all and higher‐
grade adverse effects in treated patients, but not always in untreated
patients. Especially, ICIs as a prefer treatment option for patients with
squamous histology and higher PD‐L1 expression.
253 | Lifestyle factors and systemic breast
cancer treatment‐ a cross‐sectional UK study
Jessie O. Oyinlola; Eleanor Yelland; Puja Myles; Rachael Williams
Clinical Practice Research Datalink (CPRD), London, UK
Background: Differences exist in how patients are allocated systemic
breast cancer treatment based on their body mass index (BMI). How-
ever, there is limited evidence regarding whether other lifestyle fac-
tors (e.g. smoking status and alcohol consumption) also play a role in
treatment allocation for such patients.
Objectives: To assess whether a patient's lifestyle factors (BMI,
smoking status and alcohol intake) are associated with the treatment
administered.
Methods: This was a cross‐sectional study using linked UK data from
CPRD (CPRD GOLD primary care, Hospital Episode Statistics Admit-
ted Patient Care, NCRAS Cancer Registration Data and the newly
available NCRAS Systemic Anti‐Cancer Therapy dataset). Cases
included women with incident breast cancer registered between
2013–2015 based on the London Breast Cancer Alliance (LCA) defini-
tions. The latest BMI, smoking status and alcohol status recorded in
the patient's primary care record prior to diagnosis were extracted.
The primary outcome was whether a patient was treated with a sys-
temic treatment (epirubicin, doxetaxcel, flourouacil, paclitaxel or
trastuzumab). Descriptive analysis of the outcomes of interest strati-
fied by exposure and other covariates was undertaken. Logistic regres-
sion was used to generate odds ratios (OR) with 95% confidence
intervals (95% CI).
Results: 3,791 female patients with incident breast cancer were
included with a mean age of 60.6 (standard deviation 13.8). Of
those, 26% were obese, 12% were current smokers and 72% were
current drinkers. In total, 906 (24%) had systemic treatment
recorded. Due to relatively small numbers, confidence intervals
were wide, and some results were not statistically significant. How-
ever, obese patients had similar odds of receiving systemic treat-
ment compared to underweight/healthy weight cases (unadjusted
OR 0.98; 95%CI 0.76–1.26) while current smokers had higher odds
of receiving treatment (unadjusted OR 1.37; 95%CI 1.02–1.84)
compared to never smokers. Current drinkers had slightly higher
odds of receiving treatment (unadjusted OR 1.12; 95%CIs 0.86–
1.46) compared to never drinkers. Adjusted analyses will be pre-
sented at the conference.
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Conclusions: These results suggest that there may be differences in
treatment allocation for breast cancer patients based on lifestyle fac-
tors. Given that prognosis has been shown to vary by treatment, fur-
ther research in larger patient populations and/or a longer study
period is warranted.
254 | Can we modulate response to
preoperative therapy in rectal cancer patients
by ACE inhibitors?
Anouk J.M. Rombouts1; Niek Hugen1; Rob A.H. Verhoeven2;
Josephina G. Kuiper3; Philip M.P. Poortmans1; Hans J.H.W. de Wilt1;
Iris D. Nagtegaal1
1Radboud University Medical Centre, Nijmegen, Netherlands;
2Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands;
3PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands
Background: Only 50% of the rectal cancer patients respond to preop-
erative treatment and some patients even show progression during
treatment. Therefore, it is important to identify factors that could
influence tumor response to preoperative chemoradiation in rectal
cancer.
Objectives: The aim of this study was to assess the effect of angioten-
sin‐converting‐enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) on tumor response to preoperative chemoradiation
for rectal cancer.
Methods: Data on patients who received chemoradiation prior to sur-
gery for rectal cancer between 2010–2015 were retrieved from link-
age between the PHARMO Database Network, Dutch Pathology
Registry and Netherlands Cancer Registry. Pathological complete
response rates (pCR) were compared between patients who did or
did not use ACEIs/ARBs during treatment. Multivariable analysis was
performed using logistic regression.
Results: Out of 345 patients, 92 patients (26.7%) used ACEIs/ARBs
during treatment. Median age was 65 years (range 30–85). Older
and male patients were more likely to use ACEIs/ARBs. pCR
(ypT0N0) was observed in 17.4% of patients using ACEIs/ARBs com-
pared to 14.6% of patients who did not use ACEIs/ARBs (p = 0.595).
A good response (ypT0–1 N0) was observed in 21.7% of ACEIs/
ARBs patients versus 19.4% of patients who did not use ACEIs/
ARBs (p = 0.724). Multivariable analysis, taking into account back-
ground variables and co‐medication, showed increased pCR in
patients using beta‐blockers (odds ratio 2.34, 95% confidence inter-
val 1.01–5.41).
Conclusions: In this retrospective cohort, the use of ACEIs/ARBs was
not associated with tumor response to preoperative chemoradiation in
rectal cancer patients. Thereby, the suggested potentiating effect of
ACEIS/ARBs could not be confirmed in our study. Further research
could be directed to investigate a possible benefit of beta‐blockers
or other anti‐hypertensive drugs.
255 | Effectiveness of Bevacizumabin
metastatic colorectal cancer: The
observational cohort study in Indonesia
Erna Kristin Dr.1; Dwi Endarti Dr.2; Woro Rukmi Pratiwi Dr.1;
Dwi ArisAgung Nugrahaningsih Dr.1; Alfi Yasmina Dr.3;
Ratih Puspita Febrinasari Dr.4
1Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia;
2Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia;
3Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin,
Indonesia; 4Faculty of Medicine, Universitas Sebelas Maret, Surakarta,
Indonesia
Background: Bevacizumab is a well‐established first‐line treatment
for metastatic colorectal cancer. However, there is scarce evidence
in the literature about its effectiveness in clinical practice in
Indonesia.
Objectives: The objective of the this cohort study was to compare the
overall survival (OS), Progression free survival (PFS) and cost of treat-
ment in patients with mCRC treated with bevacizumab + chemother-
apy (B + CT) compared to chemotherapy only (CT) in an Indonesian
clinical practice setting.
Methods: Design: Cohort retrospective Setting: Hospital‐based
medical records 2009–2017 Exposures or interventions:
Bevacizumab + chemotherapy (B + CT) compared to chemotherapy
only (CT) Main outcome measures: Overall survival (OS), Progres-
sion free survival (PFS), Percentage of each combination therapy,
cost of combination therapy Incident patients with mCRC were
identified during the period 2009–2017 from four hospital‐based
medical record in Indonesia. Cases were linked to health care utili-
zation databases to obtain the entire spectrum of health services
provided to each patient. Patients starting a first‐line treatment
with B + CT or CT alone from the diagnosis were included in the
study cohort.
Results: Of 139 patients with mCRC included in the study cohort,
69.1% received first‐line B + CT, and 30.9% received CT. Patients
receiving B + CT were underwent surgery more frequently. The
median OS was 12.5 and 8.8 months for B + CT and CT, respec-
tively (p = .011). The median PFS was 10.0 and 5.7 months for
B + CT and CT, respectively (p = .011). Patients with B + CT
received combination therapy in the following: bevacizumab +
oxaliplatin + capecitabine (45.8%, cost 201,610,508 IDR),
bevacizumab + oxaliplatin + leucovorin +5FU (40.6%, cost
276,481,952 IDR), bevacizumab + irinotecan + leucovorin +5FU
(13.5%, cost 280,273,593 IDR). Patients with CT received combina-
tion therapy in the following: oxaliplatin + leucovorin +5FU (46.5%,
cost 176,051,373 IDR), oxaliplatin + capecitabine (39.5%, cost
104,336,179 IDR), irinotecan + leucovorin +5FU (14.0%, cost
252,833,552 IDR).
Conclusions: In this Indonesian real‐world setting of unselected
mCRC, the OS of patients treated with B + CT was similar compared
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with CT. Definitive evidence of an improvement in OS cannot be
drawn. The cost of combination therapy in patients with B + CT higher
than with C + T.
256 | Performance of Abiraterone and
enzalutamide in metastatic castration‐
resistant prostate cancer men: A head to head
comparison based on a 2014–2017 French
population study
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Fabien Despas4; Sébastien Vincendeau5; Frédéric BALUSSON3;
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Background: Considering clinical data published since 2011 as regard
the metastatic castration resistant prostate cancer (mCRPC) treat-
ment, in patients where chemotherapy is not yet needed, clinicians
should consider two per os therapeutic options, abiratérone (ABI) or
enzalutamide (ENZ), two next‐generation androgen receptor‐targeted
agents (AR).
Objectives: Using the French national health insurance database
(SNDS), the aim of this study was to compare effectiveness of ABI
and ENZ as first line treatment in mCRPC men with a direct
comparison.
Methods: Thanks to the SNDS (Système National des Données de
Santé), new users of ABI and ENZ were included between January
2014 and Decemeber 2015, and followed by December 2017. Main
outcome was overall survival (OS). With an “intent‐to‐treat” principle,
a survival analysis was performed, estimating hazard ratio with Cox
proportional hazard model and using a propensity score (SIPTW
method). ABI was the reference group.
Results: Between 2014 and 2015, among 4783 patients without his-
tory of chemotherapy, 83% and 17% were new users of ABI and
ENZ, respectively. The mean age was similar in groups, around
78 years. Crude incidence rate of death was 26.0 for 100 PA
[95%CI: 24.9–27.1]) for ABI and 23.8 for 100 PA [95%CI: 21.5–
26.4] for ENZ. Survival analysis showed a significant benefice of
ENZ compared to ENZ: adjusted HA 0.86 [95%CI: 0,77–0.96].
Conclusions: In a direct comparison, our population‐based study in
almost 5000 French mCPRC patients showed a significant OS increase
with ENZ compared to ABI.
257 | Comparative effectiveness of
Efavirenz and protease inhibitors in patients
with human immunodeficiency virus ‐ a meta‐
analysis
Sabina O. Nduaguba; Chinyere Okoh; Jamie C. Barner; Kentya C. Ford;
James P. Wilson; Kenneth Lawson; James N. Barnes;
Tasha N. Beretvas
The University of Texas at Austin, Austin, TX
Background: In many parts of the world, non‐nucleoside reverse tran-
scriptase inhibitor‐ and protease inhibitor‐based regimens (NNRTIs
and PIs) continue to be used in the management of patients with
HIV. The World Health Organization recommends efavirenz as the
NNRTI of choice for initiating HIV treatment.
Objectives: To determine the relative effectiveness of efavirenz and
PIs using a meta‐analytic approach.
Methods: Data was obtained through a systematic review of ran-
domized controlled trials (RCTs) conducted between 1987 and
2018 comparing efavirenz with PIs. The review was conducted by
searching Embase, PubMed, Cochrane, and clinicaltrials.gov data-
bases using the PICO (Population‐Intervention‐Comparator‐Out-
come) search strategy and following a sequence from title screen
to abstract screen and then full‐text screen. The publications assem-
bled for the study consisted of RCTs of treatment naïve HIV
patients aged 13 and older initiating treatment with an efavirenz‐
based vs a PI‐based highly active antiretroviral therapy (HAART) reg-
imen. RCTs including patients with hepatitis or tuberculosis co‐infec-
tion were excluded. Included publications were assessed for
potential bias using the Cochrane risk of bias tool. The main out-
come of interest was the proportion of patients who were virologi-
cally suppressed. Random‐effects meta‐analysis was conducted
using the robust variance estimation approach.
Results: Fifteen studies met the inclusion and exclusion criteria. The
trials totaled 7,186 patients of which 1,700 (23.7%) were females.
Follow‐up ranged from 24 weeks to 144 weeks. Average age ranged
from 33 years to 44 years. Average baseline CD4 count ranged from
32 cells/mL to 557 cells/mL while average baseline viral load ranged
from log10 4.5 copies/mL to log10 5.5 copies/mL. Virological sup-
pression (<50 copies/mL) at 48 weeks was 56%–100% vs 51–100%
for EFV vs PI, respectively (Odds ratio (OR) range = 0.76–2.10).
Meta‐analysis showed that patients receiving efavirenz‐based regi-
mens had 37% higher odds of virological suppression compared to
PI‐based regimens OR = 1.37, 95% CI = 1.06–1.77, p = 0.02). The
Egger test suggested the presence of publication bias (B = 0.927,
t = 2.214, p = 0.033). The main threat to the quality of evidence
was attrition bias.
Conclusions: Regarding virological suppression, efavirenz was more
effective than protease inhibitors and, therefore, might be ideal for
the management of treatment naïve patients with HIV in settings
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where NNRTIs and PIs are used. Publication bias, however, suggests
caution in interpretation of results.
258 | Comparative effect of four antimalarial
treatments on hematocrit in children in
Southwest Nigeria
Zacchaeus F. Olofin1; Adebola E. Orimadegun1; Catherine O. Falade1,2
1University of Ibadan, Ibadan, Nigeria; 2University College Hospital,
Ibadan, Nigeria
Background: Anemia in malaria has both central (dyserythropoiesis)
and peripheral causes (phagocytosis of both infected and uninfected
erythrocytes and haemolysis). However, it is often difficult to disen-
tangle the anemia effect of malaria from its treatments.
Objectives: To compare the change in hematocrit following four anti-
malarial treatments among children of microscopically‐confirmed Plas-
modium falciparum infection.
Methods: Data were extracted from 313 case record forms of children
thatmet the eligibility criteria aged 3–119months enrolled in antimalar-
ial clinical trials in Southwest Nigeria between 1998 and 2014. Study
participants were followed up over a 28 day period according to the
World Health Organization recommendation for treatment of malaria
research participants. Enrollment criteria included symptoms compati-
ble with acute uncomplicated malaria, including parasite density of at
least 1000/μL and absence of chronic illness or danger signs of severe
malaria. Change in hematocrit level frombaseline through the treatment
period and 28 days post treatment were compared among children
treated with artemether‐lumefantrine (82), artovaquone‐proguanil
(41), artesunate‐amodiaquine (156) and chloroquine (34). Repeated
measures analysis was done by fitting a general linear model (GLM).
Results:Themedianageof thestudypopulationwas25monthsand54%
were males. The mean differences (95% CI) in hematocrit from baseline
were4.7 (95%CI =3.6, 5.8), 4.4 (95%CI =2.7, 6.0), 3.8 (95%CI =3.0, 4.7)
and 2.4 (95% CI = 0.5, 4.4), for artemether‐lumefantrine, artovaquone‐
proguanil and artesunate‐amodiaquine and chloroquine, respectively.
Using the general lineal model, repeated measure analysis showed that
there were significant differences in the mean hematocrit level over the
28‐day follow‐up among the four treatment groups (p<0.05).
Conclusions: All children experienced increases in hematocrit after
treatment, with artesunate‐amodiaquine appearing to result in a
greater increase in hematocrit than other antimalarial drugs.
259 | Continuous cefazolin infusion versus
cefazolin plus probenecid for the ambulatory
treatment of uncomplicated cellulitis: A
retrospective cohort study
Daniel Landry1; Sherif Eltonsy2; Luc P. Jalbert1; Gabriel Girouard1;
Jonathan Couture1; Mathieu Belanger3
1Vitalité Health Network, Moncton, NB, Canada; 2University of
Manitoba, Winnipeg, MB, Canada; 3Universite de Sherbrooke,
Sherbrooke, QC, Canada
Background: The preferred ambulatory IV therapy for cellulitis is often
once‐daily cefazolin combined with once‐daily oral probenecid (C + P).
However, due to a national probenecid drug shortage in 2011, our
centre developed a replacement protocol for the administration of
cefazolin continuous infusion (CCI) using elastomeric infusers.
Objectives: Our goal was to compare treatment efficacy, duration of
IV therapy, and recurrence rates associated with CCI and C + P using
data from a hospital centre.
Methods: We conducted a non‐inferiority single‐centre retrospective
cohort study using the emergency department medical records.
Patients received either C + P (cefazolin 2 g IV once daily + probenecid
1 g PO once‐daily) or CCI (cefazolin 2 g IV loading dose, followed by
cefazolin 6 g IV via continuous infusion over 24 hours, via an elasto-
meric infuser). Treatment efficacy, duration of IV therapy, and recur-
rence rates were compared.
Results: A total of 203 patients were analyzed, with 107 included in
the CCI arm and 96 in the C + P arm. Overall, CCI users and C + P
users were comparable in their sociodemographic and clinical variables
measured at admission. Increased odds of achieving successful treat-
ment was observed among the CCI group, however it did not reach
statistical significance (OR, 95% CI: 2.25, 0.84–6.07). Recurrence rates
were similar between both groups (1.91, 0.32–11.31). The average
duration of IV therapy was similar between groups (p = 0.6).
Conclusions: With results suggesting that CCI was non‐inferior to
C + P, and that both approaches required similar treatment durations,
CCI could represent an acceptable alternative to C + P for the ambu-
latory IV treatment of cellulitis.
260 | Factors associated with viral
suppression among HIV‐positive Kenyan gay
and bisexual men who have sex with men
Colin P. Kunzweiler
Analysis Group, Boston, MA
Background: The UNAIDS 90–90‐90 target has prioritized achieving
high rates of viral suppression.
Objectives: We identified factors associated with viral suppression
among HIV‐positive gay, bisexual, and other men who have sex with
men (GBMSM) in Kisumu, Kenya.
Methods: HIV‐positive participants in the Anza Mapema study were
offered antiretroviral therapy (ART) regardless of CD4 count. HIV viral
load was assessed at baseline and after 6 and 12 months of follow‐up.
Viral suppression was defined as <1,000 copies/mL.
Sociodemographic, sexual behaviors, and psychosocial characteristics
were assessed via audio computer‐assisted self interview. We used
generalized estimating equations to estimate the associations
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between baseline and time‐dependent predictors and viral suppres-
sion at 6 and 12 months.
Results: Seventy‐five HIV‐positive men were enrolled in the Anza
Mapema study, of which 63 had at least one viral load measured dur-
ing follow‐up. Among 52 men with a viral load measure at month 6, 37
(71%) were on ART and virally suppressed. Among 59 men with a viral
load measure at month 12, 37 (63%) were on ART and virally sup-
pressed. In the final multivariable model, men who reported receptive
or versatile sexual position during anal intercourse with a male partner
had reduced odds of viral suppression (aOR = 0.20; 95% CI: 0.08–
0.50). Greater levels of coping self‐efficacy were associated with
increased odds of viral suppression (aOR = 1.10; 95% CI: 1.03–1.16).
Conclusions: Despite extensive initiation, retention, and adherence
support, the rate of viral suppression in this population did not meet
the UNAIDS 90–90‐90 target (81% for individuals aware of their
HIV status). Pervasive stigma against male‐malesex, especially men
who practice receptive anal sex, may underlie our findings, which high-
light the need for advocacy and stigma reduction efforts. Because
coping self‐efficacy was a protective factor, efforts to promote resil-
ience in addition to healthy sexual identity development may lead to
improved care outcomes among GBMSM in this area.
261 | Predicting relapse episodes in patients
with multiple sclerosis treated with disease
modifying therapies in a large representative
real‐world cohort in the United States
Michael Behling; Allison Bryant; Tom Brecht; Shannon Cerf;
Richard Gliklich; Zhaohui Su
OM1 Inc, Boston, MA
Background: A relapse of multiple sclerosis (MS) interferes with a
patient's ability to function at home and at work. Early and accurate
identification of patients at risk of relapses improves quality of life
and reduces cost of care.
Objectives: To use advanced analytics to predict relapses among MS
patients treated with disease modifying therapies (DMTs) identified
from a large, representative database of linked EMR and claims data.
Methods: The OM1 Data cloud collects, and links structured and
unstructured data, including extensive clinical and claims data on
patients from a variety of provider practice types across the US. The
study includes data from January 2015–June 2018. MS patients
treated with a DMT prior to Dec 31, 2017 (index date) and had no evi-
dence of relapse in the 30 days prior to the index were included in this
analysis. Relapse was defined as an MS‐related inpatient stay, emer-
gency room visit, or outpatient visit with documented MS and a corti-
costeroid prescription within 7 days. The outcome of interest was
whether the patient experienced a relapse within 6 months post index.
Random forests, classification and regression trees were used to iden-
tify pre‐index predictors. Models were built in a training set with ran-
domly selected 80% of patients and validated in the remaining 20% of
patients. The cutoff value for high‐risk patients was determined based
on optimal model performance.
Results: This study included 18,137 patients, 7.8% of whom had
relapses; median age was 54 (IQR: 45–62) years. In the validation
set, the model correctly identified relapse outcomes in 84% of
patients. Among the most significant predictors were the number of
relapses in the previous 12 months, antiemetic medication use, skele-
tal muscle relaxants, and MS‐related fatigue symptoms. The area
under the curve for both the training and validation sets were above
0.70. Among patients identified as high‐risk (14% of patients), 20.3%
experienced a relapse, and among patients identified as low‐risk by
the model, 5.8% experienced a relapse.
Conclusions: We developed a predictive model for relapse using data
elements routinely collected in electronic medical records and insur-
ance claims among DMT‐treated MS patients. The patients identified
at high risk had nearly a 4‐fold relapse rate than patients identified
at low risk.
262 | Edaravone utilization and outcomes
within a nationally integrated health system
Michelle Vu; Kathryn Tortorice; Jeanne Tuttle; Xiang‐Ming Wei;
Diane Dong; Jennifer Zacher; Peter Glassman; Francesca Cunningham
Department of Veterans Affairs, Hines, IL
Background: The Veterans Health Administration (VA) provides care
for over 4,000 Veterans with amyotrophic lateral sclerosis (ALS).
Edaravone was approved for ALS in 2017, and the VA has imple-
mented a national prior authorization process for edaravone, approved
for approximately 10% ALS Veterans. Given limited real‐world data,
the VA initiated a surveillance effort to monitor the safe and appropri-
ate use of edaravone in Veteran patients.
Objectives: This pharmacovigilance initiative evaluated the patient
characteristics, utilization, safety and effectiveness of edaravone use.
Methods: A descriptive cohort analysis was conducted. Diagnoses,
procedure, demographics, prescription and death data were obtained
from prescription databases, corporate data warehouse and the vital
statistics files. Patients with ALS receiving at least one cycle of
edaravone from 8/1/2017 to 12/31/18 were included. Veteran char-
acteristics included demographics, service connection, and comorbidi-
ties. Utilization measures included, edaravone use/discontinuation and
concomitant riluzole use. Outcomes included mortality, emergency
department (ED)/hospitalization visits and functional status as identi-
fied by surrogate markers such as mechanical ventilation, gastric func-
tion, and durable medical equipment (DME) use. Safety and
effectiveness outcomes were compared at baseline and at 6‐month
follow‐up. Descriptive statistics summarized characteristics, utilization,
and outcomes. Outcomes were compared at baseline and follow‐up
using McNemar's tests with p less than 0.05 as statistically significant
for ED/hospitalization and descriptive statistics for functional status
outcomes.
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Results: Out of 272 Veterans who received edaravone, mean age was
65 years, 93% were male, 67% white, 75% service connected, and
5.5% had a listed comorbidity. Veterans received a mean 6.5 cycles
of edaravone, with 40% discontinuation, and 61% received riluzole
in combination with edaravone. Overall mortality was 10%. Outcomes
at follow‐up were not significantly different from baseline for any ED/
hospitalization (38% vs. 36%, p = 0.36). Functional status markers
were increased from baseline for tracheostomy (0% vs. 3.0%),
mechanical ventilation (0.6% vs. 2.4%), and PEG placement (2.4% vs.
4.2%), and decreased for DME use (5.4% vs. 2.4%).
Conclusions: Evaluations to date suggest that the effectiveness of
edaravone may be associated with surrogate markers of functional
status. Future outcome evaluations will also utilize chart reviews. Uti-
lization and outcome monitoring will be continued to evaluate access,
safety and effectiveness of edaravone.
263 | Using artificial intelligence and real‐
world data to identify drugs to repurpose for
Parkinson's disease
Sharon Hensley Alford1; Naomi P. Visanji2; Alix M.B. Lacoste1;
Piyush Madan3; Italo Buleje4; Yanyan Han5; Connie Marras2
1 IBM Watson Health, Cambridge, MA; 2Toronto Western Hospital,
University of Toronto, Toronto, ON, Canada; 3 IBM Research, Cambridge,
MA; 4 IBM Research, Miami, FL; 5 IBM Research, San Jose, CA
Background: About 7–10 million people worldwide are living with
Parkinson's Disease (PD). Currently there is no cure or treatment to
slow disease progression. As electronic medical data continues to
expand, opportunities for novel analyses for long standing problems
become feasible. We have used machine learning to identify drugs that
may have a diseasemodifying effect in PD and analyzed real‐world data
to investigate the effect of exposure on PD risk modification.
Objectives: To test antihypertensives for potential influence on the
risk of PD diagnosis.
Methods: Using IBMWatson for Drug Discovery we identified antihy-
pertensives as a class of drugs that may have a disease modifying effect
in PD. Using the IBMMarketScan Research Databases, we constructed
a cohort of individuals with incident hypertension (HTN). Exposure to
HTN medications was classified as single agent, double agent or 3+
agents. Drugs were collapsed into major drug categories, including
alpha‐blockers (AB), beta‐blockers (BB), ACE inhibitors (ACEi), angioten-
sin receptor blockers (ARBs), Renin Inhibitors (RI), dihydropyridine cal-
cium channel blockers (DHP‐CCB), non‐dihydropyridine CCB (CCB)
and diuretics. We conducted univariate and multivariate Cox Propor-
tional Hazards Ratios with exposure assessment as a time‐dependent
covariate. Exposure categories were individual drug categories, paired
drug categories, 3 or more drug categories, and no drug exposure.
Diuretics were used as the referent group in all analyses.We consider 3
or more and no drug exposures to be of limited value due to difficulty in
interpretation and so do not report their results. Age at HTN diagnosis,
sex, and several comorbidities were included in multivariate analyses.
Results: In univariate analyses we found that compared to diuretics
alone, ACEi with diuretics, ARBs with DHP‐CCB, ARBs with diuretics,
DHP‐CCBs alone, andDHP‐CCBswith diureticswere significantly asso-
ciated with decreased risk of diagnosis of PD. In multivariate analyses,
ACEi with diuretics remained significant (hazard ratio = 0.60, p‐value
<0.01) as did ARBs plus DHP‐CCBs (hazard ratio = 0.55, p‐value <0.01).
Conclusions: We show that DHP‐CCB with ARBs, as well as ACEi
with diuretics, show the most promise for a potential decrease in risk
of PD diagnosis. Our analysis was unique in that we were able to ana-
lyze single and combination therapies, which to our knowledge has not
been done before. As more clinical data becomes available and larger
datasets emerge, there is promise for the application of data mining
to tackle questions that could not previously have been addressed.
264 | Efficacy and safety of interventions
used for Management of Diabetic
Neuropathy Pain: A frequentist network
meta‐analysis
Dipika Bansal; Mir Mahmood Asrar
National Institute of Pharmaceutical Education and Research, Mohali,
India
Background: Diabetic neuropathy (DNeP) is associated with a wide
range of clinical manifestations, accounting for a massive amount of
economic burden to healthcare system.
Objectives: The purpose of this study was to assess efficacy and
safety of pharmacological interventions used in managing DNeP.
Methods: A comprehensive search strategy in PubMed, Embase and
Cochrane Library was built to identify randomized controlled trials
involving the treatment of DNeP. The studies satisfying pre‐defined
eligibility criteria was included in network meta‐analysis, direct and
indirect comparison evidence for the estimation of the mean differ-
ence and odd ratios. The efficacy end point include 30% pain reduction
from baseline.
Results: A total of 45 trials consist of 10511subjects were included
in the Random effect mixed treatment comparison. 16 and 44 trials
reported 30% pain reduction and withdrawal outcomes respectively.
NMA of 30% pain reduction reported least efficacy of placebo com-
pared to all other treatments (Lamotrigine, duloxetine Carbamaze-
pine, duloxetine 120 mg, duloxetine 60 mg). For safety outcome,
Pregabalin 300 mg, pregabalin 150 mg, pregabalin/duloxetine,
gabapentin were at greater risk for withdrawal from study com-
pared to sodium valproate, OR, CI: 1.17 (0.15; 8.96), 1.18 (0.15;
9.60), 1.28 (0.16; 9.99), 1.26 (0.15; 10.59) respectively. After con-
sidering both efficacy and safety outcomes, pregabalin/duloxetine
and carbamazepine exhibited highest probability compared to
others.
Conclusions: This NMA suggests Pregabalin 600 mg, Gabapentin
3000 mg, arbamazepine, venlafaxine, Lamotrigine were most effica-
cious in pain relief and Oxcarbazapine and pregabaline 600 mg were
safer drugs in adult patients with DNeP.
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265 | A systematic review of ketamine for
treatment‐resistant depression
Reshmee Patel; Feng‐Hua Loh
Touro College of Pharmacy, New York, NY
Background: Healthcare professionals often prescribe ketamine as a
treatment for immediate relief of depression and in some cases,
treatment of suicide ideation. Ketamine may be beneficial for
patients who did not respond positively to other treatments for
depressive symptoms in major depressive disorder (MDD).
Objectives: To compare the effectiveness of ketamine on treatment‐
resistant depression based on the dosages.
Methods: This is a systematic review comparing the effectiveness
of ketamine given for treatment‐resistant depression for 3 different
dosages (0.25 mg/kg, 0.50 mg/kg, and 0.75 mg/kg). We searched
Pubmed and EBSCOhost for trials completed in 2010–2018 from
any country, using the search words “ketamine” and “depression.”
Inclusion criteria includes adult population (age 18+), diagnosis of
depression (MDD) and use of ketamine. Studies were appraised
for quality using the Mixed Methods Appraisal Tool. This literature
included randomized clinical trials, systematic reviews, case series,
and case reports, focusing primarily on clinical trials and case
reports.
Results:Thissystematicreviewidentifiedeighteligiblestudieswhicheval-
uated the beneficial effect of ketamine on depression in terms of dosage
and comparison with anti‐depressant medications. Researchers found
that the higher dose of 0.75mg/kgwasmore effective; however a bolus
dose of 0.5 mg/kg was more effective than infusion and no differences
werefoundintheeffectivenesswhen0.75mg/kgwasadministeredusing
adifferentmethodofadministration.
Conclusions: Ketamine is very effective in patients who have not
responded well to other medications for treatment of depression.
Ketamine has a rapid‐onset compared to other antidepressant medica-
tions ‐‐ even when given in small doses for treatment‐resistant
depression and has minimal severe side effects. Most patients tend
to experience dizziness, nausea, or anxiety, which can be relieved with
bed rest.
266 | Investigating the potential role of
BDNF and PRL genotypes on antidepressant
response in depression patients: A
prospective inception cohort study
Taichi Ochi1; Natalya M. Vyalova2; Innokentiy S. Losenkov2;
Lyudmila A. Levchuk2; Anton J.M. Loonen1,3; Fokko J. Bosker1;
German G. Simutkin5; Nikolay A. Bokhan2; Bob Wilffert1;
Svetlana A. Ivanova2,5
1University of Groningen, Groningen, Netherlands; 2Mental Health
Research Institute, Tomsk, Russian Federation; 3GGZ Westelijk,
Halsteren, Netherlands; 4National Research Tomsk State University,
Tomsk, Russian Federation; 5National Research Tomsk Polytechnic
University, Tomsk, Russian Federation
Background: Two‐thirds of patients with major depressive disorder
(MDD) do not respond optimally to antidepressant medication.
Brain‐derived neurotrophic factor (BDNF) has been associated with
the response to antidepressant drugs in mood and anxiety disorders
and prolactin (PRL) is a pituitary hormone with behavioral effects
which may be involved in the antidepressant pharmacological
response acting as a neurotrophic factor within the brain.
Objectives: To investigate the relationship between BDNF and PRL
genotypes with short‐term antidepressant drug response in drug‐
naïve patients with a major depressive disorder.
Methods: In a prospective inception cohort design, we included 186
Russian participants (28 men and 158 women) of 18–70 years clin-
ically diagnosed with depressive disorder who initiated antidepres-
sant medication, including SSRIs and TCAs. These patients had not
been treated with antidepressant drugs in the preceding three
months with 54.5% never been treated with antidepressant drugs.
DNA polymorphisms were genotyped for rs1341239 within PRL
and for rs6265 and rs7124442 within BDNF. We measured the pri-
mary clinical outcome by differences in scores using the Hamilton
Depression Rating Scale (ΔHAMD) between baseline and week
two, and week two and week four. Higher ΔHAMD score denotes
better clinical outcome. Paired‐sample t‐tests determined the statis-
tical significance between ΔHAMD between the two time‐points.
Independent T‐Test determined the statistical significance between
polymorphisms and ΔHAMD in baseline and week two, and week
two and week four.
Results: Comparisons between genotypes did not reveal any signif-
icant differences in scores during the first two weeks of treatment
(all p‐values >0.05). For the latter two weeks, homozygous C BDNF
rs7124442 responded significantly worse (5.60 ± 3.64) in compari-
son to homozygous T during this period (8.51 ± 4.26). Further anal-
ysis of homozygous C BDNF rs7124442 revealed significance in all
women (5.60 ± 3.64) and post‐menopausal (≥ 50 years) women
(4.90 ± 4.06) but not in pre‐menopausal (< 50 years of age) women
(7.00 ± 2.34) in comparison to homozygous T.
Conclusions: PRL rs1341239 genotype did not affect HAMD score
differences in patients. Difference in HAMD scores for BDNF
rs6265 genotypes were not found to be significant in most
patients. Homozygous C BDNF rs712442 patients were found to
respond significantly worse in the last two weeks of treatment, with
the exception of pre‐menopausal women. This work was in part
supported by the Russian Foundation for Basic Research, grant
#17–29‐02205.
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267 | Identification of weekly or every‐
other‐week administration schedules for
Cetuximab in the treatment of metastatic
colorectal cancer in US claims data
Michael Batech; Emmanuelle Boutmy; Francois‐Xavier Lamy;
Philippe Ronga; Shaista Salim; Patrice Verpillat
Merck KGaA, Darmstadt, Germany
Background: After an initial dose of 400 mg/m2, cetuximab (CET) at a
dose of 250 mg/m2 in combination with chemotherapy (CT) is
approved for once‐weekly (q1w) use in the treatment of metastatic
colorectal cancer (mCRC). In clinical practice, off‐label use of CET
500 mg/m2 administered every other week (q2w) has been reported.
To study the comparative effectiveness and safety of q1w and q2w
CET using US claims data, we first aimed to assess a method of classi-
fying q1w and q2w schedules where administration schedules of anti-
cancer therapy infusions are not available.
Objectives: To describe the accuracy of the method used to identify
CET administration schedules.
Methods: Using IBM MarketScan, we identified a cohort of patients
with mCRC treated with CET + CT between 2010 and 2016. Patients
were required to have ≥1 CRC diagnosis, no other cancer diagnoses,
and ≥ 2 consecutive CET infusions in combination with a CT claim
within ±28 days. Administration schedules were derived from the
median observed days between each subsequent CET infusion during
follow‐up. Patients with a median duration of 4 to 10 days between
CET claims were classified as q1w; patients with a median duration
of 11 to 18 days were classified as q2w. The root mean squared error
(RMSE) and mean absolute difference (MAD) of observed durations
between claims were assessed by comparing them with theoretical
values: 7 days for q1w and 14 days for q2w.
Results: A total of 2,869 patients with mCRC exposed to CET were
identified; 1,865 were classified in the q1w group (65.0%) and 1,004
in the q2w group (35.0%). Mean age of patients was 60.1 ± 11.7 years
for q1w and 58.1 ± 11.1 years for q2w. Most patients were male:
57.5% and 60.8% in q1w and q2w, respectively. There were 28,478
and 8,248 total claims in the q1w and q2w groups, respectively, with
mean durations between claims of 8.1 ± 3.8 days (first and third quar-
tile [Q1‐Q3]: 7–7) and 15.0 ± 4.8 days (Q1‐Q3: 14–14). In the q1w
group, 75.6% of durations between 2 consecutive claims were exactly
7 d, and in the q2w group, 65.5% of durations were exactly 14 d.
Comparison of observed data points with theoretical values suggests
small differences for both schedules: the RMSE was 1.86 days in the
q1w group and 2.01 days in the q2w group; the MAD was 1.17 days
in the q1w group and 1.33 days in the q2w group.
Conclusions: In this large US claims database, the method defined to
derive different administration schedules for CET based on observed
durations between claims was shown to be accurate as the observed
durations between consecutive claims were close to the expected
durations for each considered schedule.
268 | Treatment patterns and outcomes of
159 Ibrutinib‐treated MCL patients in the US:
A retrospective electronic medical record
database and chart review study
Jeff Sharman1; Shaum Kabadi2; Jamyia Clark3; E. Susan Amirian3;
David J. Andorsky4
1US Oncology Research, Willamette Valley Cancer Institute, Eugene, OR;
2AstraZeneca LP, Gaithersburg, MD; 3McKesson Specialty Health, The
Woodlands, TX; 4Rocky Mountain Cancer Centers, US Oncology
Research, Boulder, CO
Background: Ibrutinib, a Bruton tyrosine kinase inhibitor, was
approved in the US for the treatment of relapsed/refractory mantle
cell lymphoma (MCL) in 2013. However, real‐world data on ibrutinib
use is limited.
Objectives: To examine ibrutinib use, dosages, and reasons for treat-
ment discontinuation among MCL patients treated in a community
oncology practice setting.
Methods: The study population consisted of adult MCL patients
treated with ibrutinib between November 1, 2013 and October 31,
2016, who were not enrolled in a clinical trial and had ≥2 visits to a
US Oncology Network (USON) clinic. Patients with other primary can-
cers were excluded. Patient data were sourced from USON's elec-
tronic health records system, iKnowMed (iKM)™, which provided
demographics and clinical and treatment characteristics. Manual chart
review confirmed ibrutinib treatment patterns. Duration of ibrutinib
therapy (DOT), overall survival (OS), and progression‐free survival
(PFS) from treatment initiation were estimated using Kaplan–Meier
methods. Patients were censored if their treatment was ongoing for
DOT. Censors for OS and PFS were patients lost to follow up or those
who did not experience a failure event.
Results: Overall, 159 eligible MCL patients were identified through
iKM: 88.7% were Caucasian (n = 141), 76.1% were male (n = 121),
and 73.6% were diagnosed with Stage IV disease (n = 117). Median
follow‐up was 16.1 months. Approximately 7.5% (n = 12) of patients
received ibrutinib as first‐line therapy (1 L), compared with 54.1%
(n = 86) in 2 L and 38.4% (n = 61) in 3 L+. Median ibrutinib dose at ini-
tiation was 560 mg (range: 140–700). During ibrutinib treatment,
16.4% (n = 26) of patients experienced a dose reduction. Dose holds
occurred in 30.2% (n = 48), 66.7% (n = 32) due to toxicities. The overall
discontinuation rate was 83.6%. The primary reasons for discontinua-
tion were disease progression (n = 46, 34.6%) and toxicities (n = 34,
25.6%). Median DOT was higher for patients initiating treatment in
3 L+ (14.9: 95% CI 8.8–17.1) vs other lines. Median PFS was
19.6 months (95% CI: 16.5–24.3) for the overall population and
median OS was 25.8 months (95% CI: 19.9‐not reached).
Conclusions: Our real‐world findings on survival are consistent with
clinical trials on ibrutinib in relapsed/refractory MCL, although our dis-
continuation rate (~84%) was higher vs the trials (~58%), which had a
similar median follow‐up (16.1 vs 15.3 months, respectively). Our
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findings provide additional data on MCL treatment patterns and
patient outcomes in clinical practice.
269 | Factors associated with receipt and
overall survival of concurrent
Chemoradiotherapy versus single modality
therapy in Unresectable stage III NSCLC
Maral DerSarkissian1; Kellie Ryan2; Mei Sheng Duh1; Ambika Satija1;
Priyanka J. Bobbili1; Jorge E. Gomez3
1Analysis Group, Inc, Boston, MA; 2AstraZeneca, Gaithersburg, MD;
3 Icahn School of Medicine at Mt. Sinai, New York, NY
Background: While concurrent chemoradiotherapy (cCRT) is standard
of care for patients with unresectable stage III non‐small cell lung can-
cer (NSCLC), some patients receive single modality therapy, i.e., sys-
temic therapy or radiotherapy.
Objectives: This study aimed to identify predictors of type of therapy
received, and differences in overall survival (OS) by therapy type in a
Medicare population.
Methods: This retrospective study used Surveillance, Epidemiology
and End Results ‐ Medicare data (2009–2014). Stage III NSCLC
patients aged ≥65 yrs, with ≥1 claim for systemic therapy (chemo-
therapy or targeted therapy) or radiotherapy within 90 days of diagno-
sis were included. cCRT patients had overlapping claims for
chemotherapy and radiotherapy ≤90 days from start of therapy;
remaining patients were grouped by first therapy received. Sequential
CRT patients and those with surgical resection of tumor were
excluded from this analysis. Logistic regression was used to analyze
predictors of cCRT. Multivariable Cox proportional hazards models
were used to compare OS between therapies.
Results: Of 4,544 patients identified, 51% received cCRT, 21% sys-
temic therapy, and 27% radiotherapy. Across groups, cCRT patients
were likely younger (p < 0.001), White (p < 0.001), male
(p = 0.015), and with a good predicted performance status (PS)
(p < 0.001). After adjustment, patients with a higher Charlson
Comorbidity Index (CCI) were less likely to receive cCRT vs. single
modality therapy (odds ratio [OR]: 0.93, 95% CI: 0.90–0.97,
p < 0.001), as were patients with stage IIIB vs. IIIA NSCLC (OR:
0.84, 95% CI: 0.73–0.96, p = 0.008). Good predicted PS was asso-
ciated with increased odds of receiving cCRT (OR: 1.75, 95% CI:
1.52–2.01, p < 0.001). Older age and Black race were significantly
predictive of not receiving cCRT, while sex was not predictive of
therapy type. Median OS was 14.7 months (mo) for cCRT vs.
10.9 mo for systemic therapy (adjusted hazard ratio [HR]: 1.36,
95% CI: 1.24–1.49, p < 0.001) vs. 7.8 mo for radiotherapy (adjusted
HR: 1.55, 95% CI: 1.42–1.69, p < 0.001).
Conclusions: Only 51% of patients received cCRT. Younger age,
White race, having stage IIIA NSCLC, a favorable PS, and lower CCI
were predictive of receiving cCRT. Given the survival benefit, physi-
cians should be encouraged to pursue cCRT in patients with
unresectable stage III NSCLC. Further efforts to develop less morbid
therapies are critical in this population.
270 | Comparison of real‐world treatment
patterns, persistence, healthcare resource
utilization (HRU) and costs between
octreotide and Lanreotide for the treatment
of neuroendocrine tumors (NET)
Lynn Huynh1; Beilei Cai2; Dominique Lejeune1; Mu Cheng1;
Angie Lax1; Mei S. Duh1; Wendy Cheng1; Michelle K. Kim1
1Analysis Group, Boston, MA; 2Novartis Pharmaceuticals Corporation,
East Hanover, NJ
Background: There has been limited research assessing differences
between somatostatin analogues (SSAs) as treatments for NET.
Objectives: This study aims to assess treatment pattern, persistence,
HRUs and costs among patients (pts) with NET receiving long‐acting
octreotide vs lanreotide.
Methods: Retrospective claims data from Symphony Health Solutions
were analyzed for NET pts who initiated octreotide or lanreotide
(index date) between 01/2015–11/2017 for ≥90 days. Pts with con-
tinuous clinical activity (≥180 pre and ≥ 90 days post index date) and
no prior non‐surgical NET treatment were included. A 1:1 propensity
score matched sample was used to compare the two SSA groups with
respect to treatment persistence (time to treatment discontinuation
[TTD] using Kaplan–Meier) and to all cause and NET related HRUs
and costs (provider charges for medical services and insurance pay-
ments for prescription drugs) using adjusted rate ratio (RR) and
adjusted mean cost difference (CD) with 95% bootstrap confidence
interval (CI), respectively.
Results: Among 2,043 NET pts identified, a balanced matched cohort
of octreotide and lanreotide pts (N = 543 each) was achieved. In both
cohorts, mean age was 65 years and baseline Charlson Comorbidity
Index was 5.7. Approximately 80% of matched pts initiated monother-
apy; others used SSAs in combination with chemo‐, targeted or liver‐
directed therapy as first line therapy. Median TTD was directionally
longer but did not reach statistical significance among octreotide vs
lanreotide (19.2 vs 17.5 months, p = 0.6). Numerically lower and
non‐statistically significant hospitalization rates were observed among
octreotide than lanreotide pts (RR [CI]: all cause = 0.87 [0.73, 1.05];
NET related = 0.85 [0.63, 1.15]). Statistically significantly fewer NET
related outpatient visits (1.05 vs 1.10 per pts per month [PPPM]; RR
[CI]: 0.95 [0.92, 0.99]) and lower total mean healthcare costs PPPM
were observed for octreotide than lanreotide (CD [CI]: all cause = −
$3,701 [−$5,205, −$2,355]; NET related = −$3,752 [−$4,948, −
$2,455]).
Conclusions: This study shows similar treatment patterns and per-
sistence between SSA cohorts. Octreotide appeared to be associ-
ated with less HRU and total healthcare costs compared with
lanreotide.
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271 | Predictors of granulocyte Colony
stimulating factor administration among
metastatic colorectal cancer patients
Chinelo C. Orji1; Carolyn M. Brown1; Russell J. Hoverman2;
Kristin M. Richards1
1University of Texas at Austin, Austin, TX; 2Texas Oncology, Austin, TX
Background: Despite the widespread success of chemotherapy in
treating various forms of cancer, it's use is limited by certain toxic-
ities such as neutropenia. When used for prophylaxis, colony stimu-
lating factors (CSF) are useful in preventing neutropenia, as well as
reducing its duration and severity. Current American Society of
Clinical Oncology (ASCO) guidelines recommend chemotherapy dose
reduction as a viable alternative to CSF administration. Understand-
ing the factors associated with CSF use may help decrease exces-
sive utilization of CSF, which may result in cost savings and
enhanced clinical practice.
Objectives: To determine patient characteristics that predict CSF
administration in a cohort of metastatic colorectal cancer patients
who received chemotherapy.
Methods: In this retrospective observational study, we utilized data
from the electronic health records of metastatic colorectal cancer
patients who received care at a multi‐center oncology practice net-
work between July 2013 to December 2014. Logistic regression
models were employed to explore the demographic (age, gender),
clinical (disease, year of diagnosis) and therapeutic (febrile neutrope-
nia [FN] risk, line of therapy, duration of treatment) factors associ-
ated with CSF administration. Adjusted odds ratios (OR) with 95%
confidence intervals (CI) were estimated. All statistical analyses
were performed using SAS 9.4 and alpha was set at 0.05.
Results: There were 2541 chemotherapy regimens corresponding to
2131 patients. 344 (13.5%) of the regimens had at least one CSF
administration. The CSF administered was pegfilgrastim. In the multi-
variate analysis, age, gender, FN risk, duration of treatment, and line
of therapy were significantly associated with CSF administration.
Patients who received CSF administration were significantly more
likely to be younger (ORs range: 0.24–0.85), be female (OR = 1.39;
95% CI = 1.08–1.39), have higher FN risk (OR = 1.86; 95% CI = 1.34–
2.52), have a duration of treatment between 13–23months (OR = 1.57;
95% CI = 1.09–2.10), and be on their 2nd line of therapy (OR = 1.51;
95% CI =1.09–2.10).
Conclusions: CSFs were moderately utilized in this population. Our
results demonstrate significant demographic and therapeutic varia-
tion in CSF administration. Most of the associations are consistent
with recommendations for dose reduction. Targeting the factors
associated with CSF use can help with education regarding appro-
priate use of dose reduction in lieu of CSF for this population.
272 | Contemporary chemotherapy
treatment patterns in non‐small cell lung
cancer patients: An analysis of an Optum
claims data
Dongmu Zhang; Jerzy E. Tyczynski; Bruce A. Bach
AbbVie, North Chicago, IL
Background: The NSCLC treatment landscape has changed signifi-
cantly with the addition of new targeted drugs and combination
therapies.
Objectives: The aim of this study was to assess the most recent treat-
ment patterns in a health care claims data base stratified by lines of
therapy (LoT).
Methods: This was a retrospective cohort study based on Optum
claims database. Patients who met the following criteria were
included: At least two diagnosis claims at different dates for lung can-
cer during 2015 to 2017; Age ≥ 18 years at the lung cancer diagnosis;
No other cancer diagnosis or chemotherapy within six months prior to
the earliest diagnosis; Secondary malignancy after the primary diagno-
sis; At least one systemic treatment after the primary diagnosis; Con-
tinuous health plan enrollment for at least 6 months prior to the
primary diagnosis until at least 28 days after the chemotherapy initia-
tion; No SCLC‐related treatments. Patients were followed from the
chemotherapy initiation date until discontinuous enrollment, death,
or end of database. First LoT was defined as all chemotherapy drugs
a patient filled during 28 days after the earliest chemotherapy date.
If a patient initiated a different drug after 1st LoT, the initiation date
of that new drug was defined as the initiation date of 2nd LoT. All che-
motherapy drugs the patient filled during 28 days after the initiation
date of 2nd LoT were defined as 2nd LoT. The same definition was
for 3rd LoT and so on.
Results: The study cohort consisted of a total number of 5,082
patients (52% males). Approximately 61% of patients were over
70 years of age, with the mean age of 70.9 years (SD = 8.7). In 1st
LoT, nearly 40% of patients received platinum plus taxane combination
(39.3%) with similar proportion of patients receiving platinum‐based
mono‐ or combination therapy (39.1%). The most frequent 1st LoT reg-
imen was carboplatin plus paclitaxel (31.9%), followed by carboplatin
plus pemetrexed (17.7%), pembrolizumab (5.8%) and erlotinib (4.5%).
33% of patients received 2nd LoT. The most frequently used treatment
in 2nd LoT was nivolumab (42% of patients who received the 2nd line),
followed by pembrolizumab (7.6%) and carboplatin plus pemetrexed
(5.1%). 8% of patients received 3rd LoT. The most frequent treatment
used in 3rd LoT was nivolumab (33.5%), followed by docetaxel mono-
therapy (15.6%) and gemcitabine (6.2%). The median duration of 1st
LoT, 2nd LoT, and 3rd LoT was 92, 83, and 78 days, respectively.
Conclusions: The IO drugs were most frequently used treatment reg-
imens in 2nd and 3rd LoTs documenting significant role of targeted
treatment regimens in NSCLC.
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273 | Trends in the promotion and utilization
of programmed death Receptor‐1 blocking
antibodies
Shelley Jazowski1; Stacie Dusetzina2
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Vanderbilt
University Medical Center, Nashville, TN
Background: Immune checkpoint inhibitors have experienced rapid
uptake across patients with cancer, especially in older adults ‐ a pop-
ulation underrepresented in immunotherapy clinical trials. Receipt of
pharmaceutical manufacturer payments has been associated with
higher rates of prescribing; however, the role of such payments on
the adoption of immunotherapies among older Americans with cancer
remains unknown.
Objectives: To identify trends in pharmaceutical manufacturer promo-
tion and Medicare Part D utilization of programmed death receptor‐1
(PD‐1) blocking antibodies: pembrolizumab (Keytruda®) and
nivolumab (Opdivo®).
Methods: We used General Payments files (2014–2016) from the
Centers for Medicare and Medicaid (CMS) Open Payments Data-
base and Part D Prescriber files (2014–2016) from the CMS Medi-
care Providers Utilization and Payment Data. We identified
healthcare providers who received a promotional payment or wrote
prescriptions (≥11) for anti‐PD‐1 immunotherapies. Descriptive sta-
tistics were used to assess payment patterns and utilization trends.
Results: Healthcare providers received 89,876 general payments total-
ing more than $22 million for anti‐PD‐1 agents. Pembrolizumab repre-
sented 58% ($12,878,426) of promotional spending, while nivolumab
comprised 68% (61,480) of all payments. A total of 3,147Medicare Part
D claims were filed, with 14% (435) of prescriptions filled for
pembrolizumab and 86% (2,712) of prescriptions filled for nivolumab.
Despite higher promotional spending on pembrolizumab in both 2014
(94% or $1,499,586) and 2016 (60% or $7,504,985), Part D utilization
of pembrolizumab lagged behind nivolumab, only comprising 22%
(155) and 11% (267) of prescriptions in 2015 and 2016, respectively.
Conclusions:Despitebeingoutspentbypembrolizumab'smanufacturer,
annual growthof nivolumab'smarket share outpaced that of its compet-
itor. Use of pembrolizumabmay have been limited due tominimal PartD
health plan coverage; physician preference for and experience with
nivolumab (resulting from earlier Food and Drug Administration
approval of expanded indications); or observed trends not being reflec-
tive of a provider's patient population or overall prescribing habits.
274 | Patterns and predictors of first‐line
targeted therapy utilization among older
adults diagnosed with metastatic renal cell
carcinoma
Blánaid Hicks1; Danielle Chun2; Sharon peacock Hinton2;
Christine Hsu2; Hung‐Jui Tan2,3; Jennifer Lund2
1Queen's University Belfast, Belfast, UK; 2University of North Carolina,
Chapel Hill, NC; 3UNC Lineberger Comprehensive Cancer Center, Chapel
Hill, NC
Background: The management of patients with metastatic renal cell
carcinoma has changed dramatically with the approval of targeted
therapies. While these therapies demonstrate benefit in the setting
of clinical trials, their utilization among older adults, aged 66+ years,
in real world settings is largely unknown.
Objectives: This study aimed to examine patterns and predictors of
first‐line targeted therapy utilization among older adults diagnosed
with metastatic renal cell carcinoma.
Methods: We conducted a cohort study using the SEER‐Medicare
database. Patients aged 66+ years old with a primary diagnosis of met-
astatic renal cell carcinoma were identified from 2007 through 2013.
The primary outcome was initiation of first‐line targeted therapy
within four months of diagnosis. Descriptive statistics summarized
targeted therapy utilization, the prevalence of specific agents, and
temporal trends. Multivariable logistic regression yielded adjusted
odds ratios (ORs) and 95% confidence intervals (CIs) for predictors
of targeted therapy versus no targeted therapy initiation.
Results: Of the 1,643 patients diagnosed with metastatic renal cell
carcinoma, 28.9% received first‐line targeted therapy, 4.6% received
non‐targeted therapies, and 66.5% received no treatment within four
months of diagnosis. Among those initiating target therapy, the most
commonly agents included sunitinib (57.6%), temsirolimus (17.9%)
and pazopanib (13.5%). Overall, use of first‐line targeted therapy
among older patients with metastatic kidney cancer increased over
time, from 25.9% in 2007 to 36.3% by 2013. Patients with clear cell
histology and distant metastases were more likely to receive first‐line
targeted therapy, while those aged 85+ (OR = 0.33 95%CI 0.20, 0.55)
or with a high frailty score (>50% OR = 0.22 95%CI 0.10, 0.49) were
less likely to receive first‐line targeted therapies.
Conclusions: Overall, use of first‐line targeted therapy among older
metastatic renal cell carcinoma patients has increased over time.
Age, frailty, and tumor characteristics appeared to be key drivers for
therapy initiation.
275 | Demographics, clinical characteristics
and treatment sequencing in stage 3
Unresectable non‐small cell lung cancer
patients: A Cancerlinq cohort
Alyssa B. Klein1; Iksha Herr1; Sharon MacLachlan2; Danielle Potter1
1AstraZeneca, Gaithersburg, MD; 2Evidera, London, UK
Background:
Objectives: To describe the demographics, clinical characteristics and
treatment sequencing among a real‐world cohort of stage III
unresectable non‐small cell lung cancer (NSCLC) treated with chemo-
radiation therapy (CRT) in the US.
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Methods: Cancerlinq Discovery Database (CLQ), launched by the
American Society of Clinical Oncology (ASCO) in 2016. CLQ consists
of longitudinal, demographically and geographically diverse data
aggregated from oncology practice Electronic Health Record (EHR)
databases in the US. This retrospective cohort comprises 324 stage
III unresectable NSCLC patients who received concurrent, platinum‐
based chemoradiation between January 1, 2007 and December 31,
2017 (study period). A patient was considered unresectable if s/he
did not have surgery within 6 months of the stage III diagnosis date
(study index date). A patient's follow up period was defined as the
study index date until the end of the study period, patient death, or
loss to follow up, whichever event occurs first.
Results: The cohort was mostly male, white, with a mean age of
66.86 years at index. Nearly all of the cohort (93.57%) had an initial
diagnosis of stage III (75.31% IIIA, 2.78% IIIB); 2.47% had an initial
stage I diagnosis and 4.00% had an initial diagnosis of stage II. The
most common histology was squamous cell carcinoma (46.61%),
followed by adenocarcinoma (41.05%). Curation related to clinical
characteristics (eg ECOG status, smoking status and other comorbidi-
ties) are ongoing, so they are largely missing at this time. During the
mean 26.64 months of follow up time, the cohort received 1.60 lines
of therapy. The most common treatment sequence during the follow
up period consisted of platinum therapy +CRT (82.72%); almost 10%
of patients received platinum+CRT, followed by immuno‐oncology
(IO) therapy. Approximately 38.30% of patients progressed to line of
therapy 2 (LOT2) and 29.84% progressed to line of therapy3 (LOT3),
with nearly 18% of patients receiving immuno‐oncology (IO) therapy
during LOT2 or LOT3.
Conclusions: This exploratory analysis of a stage III unresectable
NSCLC cohort is descriptive in nature and suggests that the CLQ Dis-
covery Database can be used to construct generalizable cancer
cohorts. Future analyses will focus on validation of CLQ as a real‐
world data source, using findings from other retrospective, observa-
tional studies conducted by AstraZeneca as a benchmark.
276 | Chemotherapy patterns, survival and
healthcare resource utilization among
patients with advanced small cell lung cancer
in Indiana state
Jinghua He1; Changxia Shao1; Siu Hui2; Zuoyi Zhang2; Jarod Baker2;
Paul Dexter2; Sumesh Kachroo1; Fan Jin1
1Merck & Co., Inc, Kenilworth, NJ; 2Regenstrief Institute, Indianapolis, IN
Background: Small Cell Lung Cancer (SCLC) is often diagnosed at an
advanced stage.
Objectives: To investigate real‐world chemotherapy patterns, overall
survival, and HealthCare Research Utilization (HCRU) for patients
diagnosed with advanced SCLC.
Methods: We linked an Indiana electronic health record (EMR) data-
base and Indiana State Cancer Registry to identify adult SCLC
patients. Eligible patients were either initially diagnosed with stage
III/IV SCLC or progressed to metastasis during 2005–2015. Patients
were followed from their advanced SCLC index date until the earliest
date of last visit, death or end of the study period. A line of therapy
(LOT) started from the first date of receiving a SCLC chemotherapy
agent and ended upon receipt of a new treatment, a treatment gap
≥90 days or end of follow‐up, whichever occurred first. Time‐to‐
event analyses were performed using the Kaplan–Meier method for
duration of treatment (DOT), time‐to‐next‐treatment (TTNT), and
overall survival (OS).
Results: A cohort of 498 advanced SCLC patients were identified,
including 429 initially diagnosed with advanced disease and 69 with
chart‐confirmed metastasis. Median overall survival was 10.1 months
from first‐line chemotherapy, and 7.7 months from second‐line che-
motherapy. First‐line chemotherapy was received by 464 (93.2%)
patients, including 127 (27.4%) cisplatin‐based regimens and 240
(51.7%) carboplatin‐based regimens. Carboplatin plus etoposide
was the most commonly observed, received by 217 (46.8%)
patients, followed by cisplatin plus etoposide (27.4%). Median
DOT was 2.2 months. Median TTNT was 8.9 months. The mean
number of healthcare visits during first‐line treatment was 3.0 per
patient per month, including 2.8 outpatient visits, 0.2 inpatient visits
and 0.1 emergency visits. Ninety‐five (19.1%) patients continued
with second‐line chemotherapy, including 25 (26.3%) carboplatin‐
based regimens, 20 (21.0%) topotecan based regimens, and 15
(15.8%) paclitaxel‐based regimen. Topotecan monotherapy (20%)
was the most commonly used regimen, followed by carboplatin plus
etoposide (15%). Median DOT was 2.6 months and median TTNT
was 6.3 months. During second‐line treatment, the mean number
of healthcare visits was 3.5 per months, including 3.2 outpatient
visits, 0.1 inpatient visits and 0.1 emergency visits.
Conclusions: Patients with advanced SCLC had short life expectancy.
Most patients received chemotherapy with short DOT and TTNT.
The study highlighted high unmet medical need among advanced
SCLC patients.
277 | Use of electronic healthcare data to
study the real‐world utilization of target
therapy and immunotherapy for the
treatment of lung cancer: A systematic review
Andrea Spini1,2; Giulia Hyeraci3; Francesco Pellicano1;
Sandra Donnini1; Silvano Giorgi2; Claudia Bartolini3; Rosa Gini3;
Marina Ziche1,2; Giuseppe Roberto3
1University of Siena, Siena, Italy; 2Azienda Ospedaliera Universitaria
Senese, Siena, Italy; 3Agenzia Regionale di Sanità Toscana, Florence,
Italy
Background: During the last decade, pharmacotherapy of lung cancer
has evolved rapidly due to the authorization of novel anticancer drugs
as target‐ and immunotherapies for patients with advanced stage non
small cell lung cancer (NSCLC). In this contest, the re‐use of routinely
collected electronic healthcare data (EHD) can complement evidence
ABSTRACTS 137
from clinical trial providing information on the real‐world use of drugs
in large and unselected populations.
Objectives: To retrieve and describe published studies that, through
the analysis of routinely collected EHD, provided information on
the real‐world utilization of target‐ and immunotherapies for lung
cancer.
Methods: A systematic review of PubMed database was performed to
identify all retrospective, observational studies published from 2016
to March 2018. Only studies based on routinely collected EHD provid-
ing information on the real world use of novel anticancer drugs used
for lung cancer were included.
Results: A total of 131 publications were found of which 19 met
the inclusion criteria. Only 1 study was performed in Europe while
11 were performed in the United States. Ten studies used data
from record linkage of administrative, medical records and cancer
registry data. In 4 cases, an hospital‐based cohort, ranging from
85 to 16,413 subjects, was analyzed. The remaining studies were
population‐based with a study population from 164 to 77,756
patients). Six studies only, provided information on the molecular
characterization of lung cancer. Performance status was reported
in 4 studies. Eight out of 19 studies, described the pharmacother-
apy for locally advanced/metastatic NSCLC: the study period
ranged between 2006 and 2016 and the percentage of patients
treated with platinum regimens and tyrosine kinase inhibitors (TKI)
ranged from 52 to 85 and from 6 to 32, respectively. Only 1 study
concerned immunotherapy with 17% of patients receiving
nivolumab.
Conclusions: This systematic review highlighted the paucity of pub-
lished studies on the topic. Notably, only 1 study was performed in
Europe. Record linkage of administrative data, medical records and
cancer registries was the most used approach. Information on molec-
ular characterization of tumors and performance status of patients,
which are often fundamental for the appropriate use of target‐ and
immunotherapies, were reported in few studies only. Only a minority
of advanced stage NSCLC patients currently receive novel antineo-
plastic drugs, particularly immunotherapy.
278 | Relapsed/refractory primary
mediastinal large B‐cell lymphoma: A
structured review of epidemiology, treatment
guidelines, and real‐world treatment practices
Monika Raut1; Rebekah Borse1; Arun Balakumaran1; Jitender Takyar2;
Manu Sehgal2
1Merck & Co., Inc, Kenilworth, NJ; 2PAREXEL International, Chandigarh,
India
Background: Relapsed or refractory primary mediastinal large B‐cell
lymphoma (rrPMBCL) after first‐line therapy confers a challenging clin-
ical situation and poor prognosis. Trial data and treatment guidelines
for rrPMBCL are scarce, and management is largely based on clinical
experience.
Objectives: To determine the incidence, prevalence, and mortality
rates associated with rrPMBCL, and identify clinical practice guidelines
and real‐world patterns of care.
Methods: Electronic literature databases (time frame: 1997–2017) and
specialist conferences (time frame: 2015–2017) were searched for lit-
erature reviews or studies unpublished as full‐text, respectively. Inclu-
sion criteria were adults (≥ 18 years) with rrPMBCL from studies in
Australia, Canada, European nations, Japan, Korea, and the United
States, published in English, with no restrictions on interventions/
comparators used. Screening and data extraction steps were per-
formed by separate reviewers.
Results: Ten epidemiology studies reported on PMBCL as the primary
patient group or as a subgroup. Of these, one study reported on
rrPMBCL. PMBCL had higher prevalence among females than males
(61% versus 39%) and in Caucasians (79%). Between 10–30% of
patients with PMBCL still experience progression or relapse. Despite
availability of high‐dose therapy followed by autologous stem cell
transplantation for rrPMBCL, progression‐free survival (PFS) is 27%
at 5 years. Twelve published treatment guidelines on PMBCL were
identified, of which 4 provided recommendations for rrPMBCL. Six-
teen studies provided data on real‐world treatment, most were retro-
spective, single‐center studies with small patient numbers.
Chemotherapy/immunochemotherapy (with or without radiotherapy),
followed by high‐dose treatment and stem cell transplantation, was
the mainstay of salvage therapy. In most cases, real‐world care
followed published treatment guidelines, with deviations in the spe-
cific chemotherapy agents used.
Conclusions: To our knowledge, this is the first structured review to
assess real‐world treatment patterns in rrPMBCL, attempt to define
its epidemiologic characteristics, and determine the management rec-
ommendations in treatment guidelines. The results highlight the pau-
city of epidemiologic data and evidence‐based recommendations
available. Large prospective and retrospective studies are needed to
improve the available evidence.
279 | Association between regular use of
aspirin and prevalence of melanoma in males:
Findings from the 2015 US National Health
Interview Survey
Ching‐Yuan Chang1; Chung‐Hsuen Wu2
1College of Pharmacy, University of Florida, Gainesville, FL; 2College of
Pharmacy, Taipei Medical University, Taipei, Taiwan
Background: Melanoma is more common in men (29.8 new cases per
100,000 persons) than in women (17.7 new cases per 100,000 per-
sons). Focus of the melanoma research has shifted from therapy to
prevention, especially for the males, due to the poor prognosis and
health burden. Studies had suggested that regular use of aspirin might
decrease the risk of developing some types of cancer, but protective
effect of aspirin for melanoma in males was contradictory and
inconsistent.
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Objectives: We examined whether self‐reported regular use of aspirin
was associated with the prevalence of melanoma in a national sample
of the United States (US) male adults.
Methods: This cross‐sectional study included a nationally representa-
tive of US male adults from the 2015 National Health Interview Sur-
vey. Regular aspirin users were those who self‐reported regularly
taking aspirin at least 3 times per week in the survey year. Melanoma
was measured by participants' self‐report. We used a weighted multi-
variable logistic regression model to examine the association between
regular use of aspirin and melanoma adjusting for sociodemographic
and health status factors (e.g., smoking). Adjusted odds ratios (aORs)
with 95% confidence interval (95%CI) were reported.
Results: Among eligible 108,884,206 participants in 2015, 21.0% were
regular aspirin users, and they were more likely to be older, Whites,
lower educated, insured, having smoke and alcohol, and receiving skin
check than non‐regular aspirin users. The prevalence of melanoma
was higher for regular aspirin users (1.8%) than that for non‐regular
aspirin users (0.5%, p < 0.001). However, in a multivariable analysis,
regular aspirin users (aOR = 1.7, 95% CI = 0.67–4.46) were not asso-
ciated with a decreased prevalence of melanoma.
Conclusions: Regular aspirin use was not associated with a lower self‐
reported prevalence of melanoma among US male adults in 2015.
Healthcare providers should have a more conservative attitude toward
the protective effect of aspirin for melanoma in males before further
clinical trials and longitudinal studies.
280 | Comparison of availability and
accessibility of Immuno‐oncology (IO) drugs
for cancer treatment among Japan, Korea,
China and Taiwan
Joanne Lo1,2
1 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan City, Taiwan; 2School
of Pharmacy, College of Medicine, National Cheng Kung University,
Tainan City, Taiwan
Background: Cancer immunotherapies are prosperously developed
and brought to markets. Up to present, five drugs of cancer
immuno‐oncology therapy categorized as immune checkpoint have
been approved and marketed in many Asian countries, which are
ipilimumab, nivolumab, pembrolizumab, atezolizumab and
durvalumab. Availability and accessibility of immuno‐oncology thera-
pies are two of the crucial elements for drug utilizations in cancer
treatments.
Objectives: This study aims to compare 5 immune‐oncology therapies'
availability and accessibility between 4 Asian countries, Japan, South
Korea, China and Taiwan, by their approval time and indications,
health insurance coverage and reimbursement limitation.
Methods: The approval time and indications (availability) of the 5 cancer
immunotherapies across the 4 Asianmarkets will be acquired by from the
database of PMDA, KFDA, CFDA and TFDA. The accessibility of those
along with price settings will be obtained from the authorities' health
insurance system database primarily. Taiwan will be taken as the
reference country to which, the availability and accessibility of the five
cancer immunotherapies among three other countries will be compared.
Results: Only 2 of the 5 immuno‐oncology drugs, nivolumab and
pembrolizumab, are approved and launched in all the 4 target markets.
Compared to Taiwan, the approval time of nivolumab and
pembrolizumab appear to be in a lag in China by 25 months and
26 months respectively, while those are in a more advanced manner
in Korea by 15 months for both. The indications for different cancer
types approved by TFDA in Taiwan are of the most extensive among
the 4 countries for pembrolizumab, nivolumab and atezolizumab while
those are only selectively approved for certain cancer types by PMDA,
KFDA and CFDA. In terms of accessibility of the 5 immune‐oncology
drugs, Korea and Taiwan are the only 2 countries listing nivolumab
and pembrolizumab, and ipilimuamb in the national health insurance
system respectively.
Conclusions: From availability perspective, the indications approved
for various cancer types are the most extensive in Taiwan while the
accessibility of nivolumab and pembrolizumab are so far only present
in Korea. The 2 drugs are being covered by the health insurance under
Risk Sharing Agreement (RSA) with different scope and occasions of
the applications. Ipilimumab is currently the only immuno‐oncology
drug listed in the national health insurance system in Taiwan at a
NHI price similar to the market price in Japan.
281 | Treatment trends for localized prostate
cancer: A comparison of androgen
deprivation therapy and curative treatments
in the linked SEER‐Medicare database, 2004–
2013
Kate Gelperin1; Steven T. Bird1; Armen Avagyan2; Jiemin Liao2;
Yang‐Min Max Ning1; Elaine Chang1; Daniel Suzman1; Paul Kluetz1;
Hai Lyu2; Yixin Jiao2; Thomas MaCurdy2,3; Jeffrey A. Kelman4;
David J. Graham1
1Food and Drug Administration, Silver Spring, MD; 2Acumen, LLC,
Burlingame, CA; 3Stanford University, Stanford, CA; 4Centers for
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Background: Initial management of localized prostate cancer (PCa)
includes therapies with curative intent (prostatectomy, radiation) or
expectant management (active surveillance, watchful waiting). Imme-
diate androgen deprivation therapy (ADT) alone using gonadotropin‐
releasing hormone (GnRH) analogs has sometimes been administered
as initial therapy, particularly in older patients who may be poor candi-
dates for radiation or surgery, but there is little evidence supporting
this approach.
Objectives: We characterized initial treatment trends among U.S.
Medicare beneficiaries diagnosed with localized PCa from 2004 to
2013 and investigated changes in ADT treatment trends by PCa risk
over time.
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Methods: Men ≥65 years old, enrolled in Medicare Fee‐for‐Service,
with incident non‐metastatic PCa between 2004 and 2013 in the
SEER (Surveillance, Epidemiology, and End Results) registry were iden-
tified. SEER cancer cases were linked with Medicare records, with
patients' cancer risk (low, intermediate, high) characterized based on
the National Comprehensive Cancer Network guidelines. Patients
were followed up to 21 months after diagnosis to identify initial treat-
ments, categorized into four mutually exclusive groups: ‘prostatec-
tomy’, ‘radiation’, ‘ADT alone’, or ‘expectant management’.
Results: There were 103,242 men ≥65 years old with localized PCa
including: 29,331 with low‐risk; 40,720 with intermediate‐risk; and
33,191 with high‐risk disease. During the 10‐year study period, most
high‐risk patients received curative‐intent therapy with radiation
(49%) or prostatectomy (15%). In 2004, initial treatment with ADT
alone was common (29%) among high‐risk patients, but declined
steadily to 14% in 2013. The small proportion of low‐ and intermedi-
ate‐risk patients who received ADT alone also declined, from 6%
and 10%, respectively, in 2004, to 2% and 3%, in 2013. The proportion
of low‐risk patients receiving expectant management increased
sharply during this time, from 22% to 50%.
Conclusions: Although most patients with localized PCa were treated
with expectant management or curative‐intent therapies, some
received initial treatment with ADT alone using GnRH‐analog drugs,
despite unclear benefit and known risks. Our data show that treat-
ment of localized PCa with ADT alone declined steadily in all risk
groups during the 10‐year period of study.
282 | Potential inappropriate Underdosing in
patients initiating non‐vitamin K Oral
anticoagulants: Findings from the French
National Healthcare Database
Géric Maura1; Cécile Billionnet1; Jérôme Drouin1; Alain Weill1;
Anke Neumann1; Antoine Pariente2,3
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Background: Post‐marketing data have raised concerns about poten-
tial inappropriate underdosing associated with non‐vitamin K oral anti-
coagulants (NOAC) in atrial fibrillation (AF) patients but mostly based
on field and registry studies with small sample sizes.
Objectives: To describe potential inappropriate underdosing in NOAC
at treatment initiation in patients with AF using the large national
French National Healthcare databases (50 million beneficiaries).
Methods: A population‐based cohort study included patients with
AF initiating NOAC therapy in 2015–2016. Potential inappropriate
underdosing with NOACs was defined as initiation of NOAC therapy
in patients at risk of stroke in whom reduced doses of NOAC were
prescribed with no identified clinical justification. The proportion of
AF patients initiating reduced‐dose NOAC (dabigatran 75 or
110 mg; rivaroxaban 10 mg or 15 mg and apixaban 2,5 mg) with
an HAS‐BLED score < 3 among all NOAC new users with a
CHA2DS2‐VASc score ≥ 2 was used as proxy to quantify potential
inappropriate underdosing in NOAC new users. Due to the nature
of data used with no access to medical data such as patient's weight,
glomerular filtration rate and exact alcohol consumption and, to bet-
ter identify patients at risk of stroke, analyses were replicated in
patients i) with CHA2DS2‐VASc score ≥ 4 and ii) aged 75 and over
with a history of arterial thromboembolic events (ATE).
Results: A total of 127,841 new users of NOAC therapy with AF
were identified in 2015–2016 (mean age: 74.1 ± 11.6; 50.1%
women). Reduced doses were prescribed in 40.0% of NOAC new
users. Among the 116,391 NOAC new users with AF with a
CHA2DS2‐VASc score ≥ 2, 29.1% (N = 33,845) were prescribed a
reduced dose although they had an HAS‐BLED score < 3
(dabigatran: 46.3%; rivaroxaban: 27.2%; apixaban: 28.3%). This pro-
portion was 33.4% (N = 24,281) and 14.5% (N = 1,379) when con-
sidering patients with a CHA2DS2‐VASc score ≥ 4 (N = 72,608) and
aged 75 and over with a history of ATE (N = 9,503), respectively.
Among patients with a CHA2DS2‐VASc score ≥ 2 and HAS‐
BLED<3, differences in baseline characteristics were observed
according to the type of NOAC dose prescribed, e.g. patients with
reduced‐dose NOAC were older and frailer than those with stan-
dard‐dose NOAC.
Conclusions: Taken together with results of US, Japanese and Euro-
pean registries, these data suggest that inappropriate underdosing
might be a common issue in NOAC new users with AF. Regulators
and physicians should carefully consider this emerging NOAC pattern
of use for which increased risk for adverse outcomes has been
shown.
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Background:Diabetes and cardiovascular diseases are often coexistent,
with many diabetes patients suffering from cardiovascular complica-
tions. Oral anticoagulant medications (OACs) are widely prescribed for
the prevention and treatment of cardiovascular diseases.
Objectives: To explore the prescribing pattern ofOACs inType 2Diabe-
tesMellitus (T2DM) in the United Kingdom between 2001 and 2015.
Methods: An observational drug utilization study was conducted using
electronic health records in The Health Improvement Network (THIN)
primary care database. Patients with T2DM aged >18 and registered
within the THIN database between 2001 and 2015 were identified
using the Read Codes. Oral anticoagulant medications were catego-
rized into three groups: warfarin, DOACs and other anticoagulant
medications including acenocoumarol, pentosan polysulfate and
phenindione. The prevalence rate of OACs presented per 100 patients
with 95% confidence interval (CI) was calculated and stratified by age,
gender, and therapeutic classifications annually between 2001 and
2015. All analyses were performed using SAS version 9.4 (SAS Insti-
tute, Cary, NC, USA).
Results: A total of 361,635 individuals with T2DM were identified, of
which 36,570 were prescribed OACs from 2001 to 2015. The preva-
lence of OAC prescribing increased by 50.8% [from 4.4 (95% CI 4.2–
4.6) in 2001 to 6.6 (95% CI 6.5–6.7) in 2015 per 100 patients]. The
prevalence of warfarin prescribing decreased by 13.9% [from 98.9
(95% CI 98.4–99.4) in 2001 to 85.1 (95% CI 84.6–85.7) in 2015 per
100 patients]. This corresponded with an increased prescribing of
direct oral anticoagulants (DOACs) [from 0.1 (95% CI 0.08–0.23) in
2010 to 17.6 (95% CI 17.1–18.2) in 2015 per 100 patients] during
the same period.
Conclusions: Prescribing of OACs in patients with T2DM increased
from 2001 to 2015. Since the introduction of DOACs there has been
a clear shift in prescribing toward these agents. Future studies are
needed to assess the safety of the co‐administration of oral anticoag-
ulant medications and antidiabetic therapy among patients with
T2DM.
284 | Trends in utilization and predictors for
initiation of non‐aspirin non‐steroidal anti‐
inflammatory drugs in patients with
cardiovascular contraindications
Anton Pottegård1; Morten Schmidt2,3
1University of Southern Denmark, Odense, Denmark; 2Aarhus University
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Background: Non‐aspirin non‐steroidal anti‐inflammatory drugs
(NSAIDs) are widely used for pain, fever, and inflammation. Clinical
guidelines advice against NSAID use in patients with cardiovascular
disease. It is unknown to what extent the increased awareness of car-
diovascular risks of NSAIDs have translated into decreased use in
patients with cardiovascular disease.
Objectives: To study temporal trends in use of NSAIDs among patients
with cardiovascular disease and to determine predictors for initiation.
Methods: From the Danish National Patient Registry, we identified
patients with a first ever inpatient diagnosis between 1996 and
2016 for the following cardiovascular diseases: myocardial infarction
(overall and according to ST‐segment elevations in the ECG), stable
angina pectoris, atrial fibrillation or flutter, heart failure, ischemic
stroke, venous thromboembolism, valvular heart disease, and infective
endocarditis. The cohorts were identified separately (i.e., a patient may
be included in more than one cohort). Using the Danish National Pre-
scription Registry, we mapped 1‐ and 5‐year prevalence of NSAID use
after cohort entry over time, standardizing to the year 2000 age com-
position. Predictors of NSAID initiation was estimated using logistic
regression.
Results: Overall, the use of NSAIDs showed a slight decline through-
out the study period. The 1‐year prevalence initially increased from
1996 (19%) to 2002 (23%) after which it declined until 2016 (14%).
The 5‐year prevalence followed a similar trajectory, from 39% in
1996, over 43% in 2002 to 29% in 2012. Identical patterns were seen
across cardiovascular contraindications, except for an even stronger
relative decline among patients with ischemic heart disease (1‐year
prevalence among patients with myocardial infarction declined from
18% in 2002 to 10% in 2016). The majority of NSAID use was ibupro-
fen (57% of all NSAID users during the study period) followed by
diclofenac (25%). However, over time, the use of ibuprofen increased
alongside a decline in the use of diclofenac and etodolac, and a marked
drop in use for coxibs. Users of individual NSAIDs were generally com-
parable in terms of baseline comorbidity. The strongest predictors of
NSAID use was osteoarthritis, rheumatoid arthritis, obesity and sleep
apnoea. Further, younger age predicted use of ibuprofen, naproxen
and diclofenac, while older age predicted use of etodolac and coxibs.
Conclusions: Although declining, NSAID use remains considerable in
patients with cardiovascular contraindications.
285 | Oral anticoagulant (OAC) prescribing
for stroke prevention in older people (aged
75+) with atrial fibrillation (AF) in the UK
Anneka Mitchell1,2; Margaret C. Watson1; Tomas Welsh3,4,5;
Julia Snowball1; Anita McGrogan1
1University of Bath, Bath, UK; 2University Hospital Southampton,
Southampton, UK; 3Research Institute for the Care of Older People
(RICE), Bath, UK; 4Royal United Hospitals, Bath, UK; 5University of
Bristol, Bristol, UK
Background: Although international guidelines recommend OACs be
considered for individuals ≥75 years with AF, they are underused in
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this patient population. Direct OACs (DOACs) (dabigatran,
rivaroxaban, apixaban, edoxaban) were introduced as alternatives to
warfarin (WAR) in 2011; utilization patterns comparing OACs in older
patients have not been described. We hypothesized that there would
be differences in the characteristics of older patients prescribed
DOACs compared to warfarin.
Objectives: To describe OAC utilization in UK primary care for older
people with AF (OPwAF) from 2011–2017. To examine time on index
OAC and switching between OACs during the study period. To com-
pare baseline characteristics of new OAC users.
Methods: A cohort of OAC users aged ≥75 years, newly started on
WAR or DOAC between 2011 and 2017 were extracted from the
Clinical Practice Research Datalink (a UK database containing data
from primary care). Users required a Read code for AF before index
date or within 1 month (1/12) and ≥ 1 year free of OAC. Exclusion
criteria were valvular AF, other indication for OAC, or ≥ 2 OACs
prescribed on index date. Follow‐up continued until date of last
OAC script. We abstracted demographic, prescription and co‐mor-
bidity data and calculated stroke risk score (CHA2DS2‐VASc, ↑
score = ↑ stroke risk). Time on OAC was defined as time from
index to last script for the index OAC. Switching was defined as
having a script for a different OAC ≤ 3/12 from last index OAC
script.
Results: Our final cohort included 24409 patients (15393 WAR,
9016 DOAC). DOACs comprised 3.2% of new OAC users in 2012
but increased to 84.7% in 2017. Rivaroxaban and apixaban were
the most frequently prescribed DOACs (47% and 43% of all DOAC
users, respectively). The median time on index OAC was shorter for
DOACs than WAR (307 vs 624 days). Risk of failure on DOAC was
23% higher than WAR (HR 1.23, 95% CI 1.18–1.29). Ten percent of
patients switched OAC during the study period (76% from WAR to
DOAC, 5% DOAC to WAR, 19% DOAC to DOAC). There were no
significant differences in demographics between patients prescribed
WAR or DOAC. Mean CHA2DS2‐VASc scores suggest similar stroke
risk per group (WAR 4.28, DOAC 4.31); more DOAC patients had
history of stroke/TIA/thromboembolism (50% vs. 45%).
Conclusions: DOACs are now prescribed in preference to WAR for
OPwAF in UK general practice. Demographics and stroke risk for
OPwAF commenced on DOACs are broadly similar to those started
on WAR; investigation of other factors that influence OAC choice is
warranted. OPwAF switch predominantly from WAR to DOAC: rea-
sons for switching require further investigation.
286 | Sex differences in Cardiometabolic
treatment among patients with type 2
diabetes
Petra Denig1; Sieta T. Vries de1; Eugène Puijenbroek van2;
Peter G.M. Mol1
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Background: Treatment recommendations for patients with type 2
diabetes are similar for males and females. Sex differences in adverse
drug reactions of cardiometabolic treatment have been observed,
which may lead to differences in prescribing.
Objectives: To assess sex differences in prescribing of cardiometabolic
treatment among patients with type 2 diabetes.
Methods: Cohort study using the Groningen Initiative to AnalyzeType
2 diabetesTreatment (GIANTT) database, which includes general prac-
tice data from almost all adult patients with type 2 diabetes in the
province of Groningen, the Netherlands. We assessed (1) level, (2)
type, and (3) dose of glucose‐lowering, blood pressure‐lowering and
lipid‐lowering treatment in 2013, after an update of the treatment
guidelines. Level was defined according to the step‐wise treatment
recommendations; type was defined by ATC codes; dose was assessed
for 9 commonly prescribed drugs and categorized in classes. Sex dif-
ferences were assessed using logistic regression analyses, adjusting
for age, diabetes duration, body mass index, comorbidity, and baseline
level of the related risk factor.
Results: Of the 27,172 included patients, 50% were females and the
population was on average 67 years old. Females were less likely to
receive glucose‐lowering (0.85, 95%CI 0.76–0.94) and lipid‐lowering
(0.89; 95%CI 0.82–0.98) drug treatment than males. They were less
likely to receive metformin (0.77; 95%CI 0.71–0.84), sulfonylureum
derivatives (0.90; 95%CI 0.83–0.97), but more likely to receive insulin
(1.16; 95%CI 1.04–1.29). They were less likely to receive ACE‐inhibi-
tors (0.67; 95%CI 0.62–0.72), calciumblockers (0.84; 95%CI 0.77–
0.91) but more likely to receive ARBs (1.27; 95%CI 1.17–1.38) and
diuretics (1.32; 95%CI 1.22–1.43). Furthermore, they were less likely
to receive high doses of metformin, glimepiride, enalapril, rosuvastatin
but no significant differences were seen for dosing of gliclazide, pio-
glitazone, losartan, metoprolol, simvastatin.
Conclusions: Adjusting for potential confounders, such as age and
comorbidity, we showed several sex differences in the treatment
of patients with type 2 diabetes. Females received lower levels of
glucose‐lowering and lipid‐lowering treatment and different types
of blood pressure‐lowering drugs. Further studies are needed to
assess the reasons for these differences and whether treatment
guidelines should include more sex‐specific recommendations.
287 | Beta‐blocker choice and
exchangeability in patients with heart failure
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Background: Current clinical guidelines suggest that for patients with
heart failure (HF) and concurrent chronic obstructive pulmonary dis-
ease (COPD), metoprolol/bisoprolol/nebivolol should be preferred.
Nevertheless, studies suggest a high proportion of carvedilol usage
that is in opposition to above‐mentioned recommendations.
Objectives: This study aims to investigate beta‐blocker exchangeabil-
ity and the predictors of carvedilol choice in patients with HF and
COPD that were naïve to carvedilol, metoprolol, bisoprolol, and
nebivolol.
Methods: Caserta Local Health Unit databases (Italy) were used as
data sources. The study outcome was the odds ratio (OR) of receiving
carvedilol versus other beta‐blockers. Age, sex, year of inclusion in the
study population, chronic comorbidities according to the Elixhauser
Comorbidity Index and the 500 most prevalent potential predictors
for carvedilol choice were included in a logistic regression model to
assess predictors of carvedilol choice. Kernel density estimations
(KDE) were used to assess the overlap in propensity scores (PS) and
preference scores (PFS) distributions for receiving carvedilol. Beta‐
blocker exchangeability is assumed if half of the distributions of the
PFS is between 0.3 and 0.7.
Results: The study population included 10091 patients of which 2011
exposed tocarvedilol. Themeanagewas77.7years.Theestimatedover-
lapping area of two KDE of PS among beta‐blockers was 57%. Accord-
ingly, the exchangeability according to the PFS criteria was not
reached. Atrioventricular block (AB) (OR 8.20; 95%Confidence Interval,
95%CI 1.30–51.80), cerebrovascular thrombosis (CT) (OR 7.06; 95%CI
1.14–43.68), chronic kidney disease (CKD) (OR 4.32; 95%CI 1.16–
16.02), andacuteHF (OR1.97;95%CI1.28–3.03)hospitalizationswithin
two years prior to the first beta‐blocker prescription were statistically
significantly associatedwith carvedilol choice.Analogously, the redemp-
tion of human insulin (OR 3.00; 95%CI 1.24–7.24), fondaparinux (OR
2.47; 95%CI 1.17–5.21) or strontium ranelate (OR 2.03; 95%CI 1.06–
3.90) within one year prior to the beta‐blocker prescription was signifi-
cantly associated with a higher odd of receiving carvedilol.
Conclusions: This study suggests absence of exchangeability between
carvedilol and metoprolol/bisoprolol/nebivolol users and a preferential
choice of carvedilol in patients with HF, COPD and concurrent CKD,
AB, CT, acute HF or redeeming human insulin, fondaparinux or stron-
tium ranelate.
288 | Patterns of use of P2Y12 inhibitors in
patients with acute coronary syndrome in
routine clinical practice
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Background: Acute coronary syndrome (unstable angina, elevated ST‐
segment myocardial infarction (STEMI), and non‐STEMI) is associated
with significant morbidity and mortality. Antiplatelet therapy remains
a mainstay for managing ACS patients, particularly those undergoing
percutaneous coronary intervention (PCI). Few studies have evaluated
how ACS patients are managed in clinical practice, particularly after
the introduction of several new P2Y12 inhibitors (P2Y12i).
Objectives: To evaluate the patterns of P2Y12i use in patients with
ACS who underwent PCI in various clinical settings.
Methods: Patients aged≥18 who had an emergency room visit and/or
were hospitalized with newly diagnosed ACS (index date), had continu-
ous observation from at least one‐year before to 30 days after the index
date,anddidnot receivecoronaryarterybypasssurgery30daysafter the
index date were eligible for the study. Proportions of P2Y12i use
(clopidogrel, prasugrel, ticagrelor) with first dispense within 30 days of
the index diagnosis were evaluated for 3‐time periods: 01/01/2007 to
12/31/2011 (P1), 01/01/2012 to 12/31/2016 (P2); and on or after
01/01/2017 (P3), using 4 healthcare databases in the US: IBM
MarketScan® (Commercial (CCAE), Multi‐State Medicaid (MDCD), and
Medicare Supplemental (MDCR)) and Optum© De‐Identified
Clinformatics®DataMart Database ‐ Socio‐Economic Status (Optum).
Results: During the study period from 1‐1‐2007 to 12‐31‐2017, about
235,000 ACS patients undergoing PCI were identified. The propor-
tions of P2Y12i use varied across study periods and databases. For
CCAE, MDCR, and Optum, the proportions of P2Y12i use were 88%,
81%, and 81% for P1; 82%, 76%, and 69% for P2; and 86%, 77%,
and 68% for P3, respectively. It was observed that since the approval
of prasugrel (2009) and ticagrelor (2011), the use of clopidogrel has
declined: from 74% (Optum) to 78% (CCAE) in P1 down to 34%
(CCAE) to 49% (MDCR) in P3, in part due to the uptake of other
P2Y12 therapies, mainly ticagrelor: from 8% (Optum) to 14% (CCAE)
in P2 to 20% (Optum) to 40% (CCAE) in P3. For MDCD, the propor-
tion of P2Y12 use was notably lower regardless of the study period:
48% in P1 and 37% in P2 (no data available for P3).
Conclusions: Despite evidence from clinical trials that prasugrel and
ticagrelor are associated with a greater reduction in major cardiovas-
cular events compared to clopidogrel, adoption of these newer
P2Y12 inhibitors appears moderate, with greater uptake in younger,
commercially insured patients. Studies may be needed to further eval-
uate why P2Y12 therapies are generally underutilized in Medicaid
patients with ACS undergoing PCI.
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angiotensin‐II receptor blockers products in
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Background: In 2018, probable human carcinogens ‐ N‐
nitrosodimethylamine (NDMA) and N‐nitrosodiethylamine (NDEA)
were discovered in valsartan‐containing products. The US Food and
Drug Administration coordinated a voluntary recall of these products
that subsequently expanded to include irbesartan and losartan‐con-
taining products. Current data suggest contaminated products were
introduced as early as 2010. Ongoing characterization of use of these
products is crucial for future pharmacoepidemiologic safety
assessments.
Objectives: To assess the utilization of NDMA/NDEA‐contaminated
angiotensin II‐receptor blocker (ARBs) in the Sentinel Distributed
Database.
Methods: Between 01/01/2010 and 06/30/2018, we identified
patients at least 18 years old, newly treated (365‐days washout
period) with an ARB. Using NDCs, valsartan products were catego-
rized as NDMA‐positive, NDMA/NDEA‐positive, NDMA/NDEA‐neg-
ative based on FDA's testing of finished drug products (FDPs) and
manufactured recalled products lots. Exposure episode lengths were
defined using days supplied, allowing a gap of 15 days or less to create
continuous treatment. Follow‐up began on the dispensing date until
the first occurrence of: disenrollment, end of data, end of the expo-
sure episode, switching to any of the comparator exposure groups,
or death. Only the first valid exposure episode that occurred during
the study period was included.
Results: A total of 3,909,866 new ARB initiators, except valsartan
were identified. Among the valsartan users, 102,083 patients were
exposed to an affected product (28,838 NDMA‐ or NDMA/
NDEA‐positive and 73,245 recalled products). Prevalence of new
initiators was highest in 2016 and 2015, respectively. There were
141,261, and 860,275 patients in the NDMA‐negative and other
valsartan product categories, respectively. The majority of exposure
episodes were censored at the end of continuous treatment. The
median follow‐up time from index dispensing to end of follow‐up
ranged from 0.7 years (for NDMA ‐positive) to 2.4 years (for
NDMA‐negative products).
Conclusions: Exposure to NDMA/NDEA‐contaminated products
appears to be low with follow‐up time that is notably right‐censored
for cancer outcomes. An updated analysis expanded to other ARBs
is planned when more data become available and the testing of the
FDPs is completed.
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Background: Although the efficacy and safety of existing therapies of
heart failure (HF) have been demonstrated in clinical trials in the last
35 years, little is known about the treatment patterns of HF in clinical
practice, especially in France.
Objectives: To describe the treatment initiation patterns and the sub-
sequent treatment changes among HF patients, in the first year fol-
lowing an incident hospitalization for HF, in a French real‐world
setting.
Methods: A cohort of patients aged 40 years old and older, with an
incident hospitalization for HF between January 1, 2008 and Decem-
ber 31, 2013, was identified in the EGB, a 1/97 permanent random
sample of the French nationwide claims database. All patients who
died during the index hospitalization or with a period of at least 3 con-
secutive months with no healthcare dispensing recorded were
excluded. All included patients were followed one year. HF drugs of
interest were: beta blockers (BB), angiotensin‐converting enzyme
inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone
antagonists (AA), diuretics, digoxin or ivabradine. Drug exposure was
assessed quarterly using a Proportion of Days Covered >66% (>
60 days out of the 90 days of the quarter covered by the treatment
of interest), by considering HF drugs individually or in combination.
Drug changes were assessed between each quarter over the first year
of follow‐up.
Results: Between 2008 and 2013, 7,387 patients from the EGB were
included in the cohort study. The mean age at baseline was 77.7 years
(±12.0 years) and 51.6% were women. During the follow‐up, 24.4% of
patients died and 20% did not receive any HF treatment. During the
first quarter following initial hospitalization, 42.7% of patients had
diuretics, 26.0% had BB, 25.7% had or ACEI, 7.4% had ARB, 7.6%
had AA, 4.7% had digoxin and 1.3% had ivabradine. The most frequent
combination was BB/ACE/ARB (23.4%). These proportion remained
globally constant over the follow‐up. The main change occurred
between the first and the second quarter and concerned 53.1% of
the initially untreated patients; by the second quarter, 22.2% of them
initiated a BB/ACEI/ARB combination, 13% a diuretic alone, 7.4% a
BB and 4.9% a BB/ACEI/ARB/AA combination.
Conclusions: This study provides precious information on treatment
patterns after an initial hospital admission for heart failure at a time
when new treatments for heart failure are emerging.
291 | Non‐aspirin non‐steroidal anti‐
inflammatory drug use in the Nordic countries
2000–2016 from a cardiovascular risk
perspective: A drug‐utilization study
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Anton Pottegård1; Jonas W. Wastesson4; Helga Zoega5;
Morten Schmidt6
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selective COX‐2 inhibitors ‐ has accumulated during the last decade.
Objectives: To examine whether the use of NSAIDs in the Nordic
countries changed as evidence on the cardiotoxicity of specific
NSAIDs accumulated.
Methods: We conducted a drug‐utilization study using nationwide
wholesale statistics and prescription registries in Denmark, Finland,
Iceland, Norway, and Sweden 2000–2016. Our main outcome mea-
sures were yearly total sales expressed as defined daily doses (DDD)
sold per 1,000 inhabitants per day and yearly prevalence of prescrip-
tion use as prescription users per 1,000 inhabitants.
Results: Total sales of NSAIDs increased in all countries and were
highest in Iceland with 74.3 DDDs/1,000 inhabitants/day sold in
2016, followed by Finland (73.9), Sweden (54.4), Norway (43.8), and
Denmark (33.1 in 2015). Diclofenac use declined after 2008 in all
countries, but remained the most widely prescribed NSAID in Norway
with 63 prescription users/1000 inhabitants in 2016. Diclofenac sales
also remained high in Iceland (12.7 DDD/1,000 inhabitants/day), Nor-
way (8.1), and Sweden (7.8). Since its introduction in 2003, the use of
etoricoxib, a newer selective COX‐2 inhibitor, increased in all coun-
tries except Denmark, with highest sales in Finland (6.7 DDD/1,000
inhabitants/day in 2016).
Conclusions: Given existing evidence on the cardiovascular risks asso-
ciated with use of diclofenac and etoricoxib, the persistent high use of
diclofenac in Iceland, Norway, and Sweden and increasing use of
etoricoxib in most of the Nordic countries pose a cardiovascular health
concern.
292 | Trends in prescription of thiazide and
thiazide‐like diuretics in the UK
Tatiana V. Macfarlane; Amy Rogers; Robert W.V. Flynn;
Steven V. Morant; Isla S. Mackenzie; Thomas M. MacDonald
University of Dundee, Dundee, UK
Background: Hypertension is an important public health problem,
and effective treatment reduces the cardiovascular complications
such as stroke, myocardial infarction, heart failure and early death.
National Institute for Health and Clinical Excellence (NICE) guidelines
for the management of hypertension 2011 suggested using
indapamide in preference to bendroflumethiazide in cases when a
diuretic is to be initiated or changed. A recent systematic review
highlighted a lack of studies on comparative efficacy of monotherapy
with bendroflumethiazide versus indapamide.
Objectives: The aim of the study was to describe trends in the pre-
scriptions of thiazide and thiazide‐like diuretics overall and as first‐line
monotherapy after a diagnosis of hypertension in the UK and to inves-
tigate the impact of the publication of NICE guideline (CG127) in 2011
on prescribing patterns.
Methods: Information on prescriptions was obtained from Informa-
tion Services Division (ISD) Scotland, OpenPrescribing.net and the
Clinical Practice Research Datalink (CPRD). Choice of anti‐hyperten-
sive therapy was described by age and time period (before and after
the guidelines). Thiazide and thiazide‐like diuretic prescriptions were
described by year, age of patient and geographical area. Logistic
regression and interrupted time series regression modeling were
used in data analysis.
Results: Prescribing of thiazide and thiazide‐like drugs as first‐line
monotherapy for hypertension decreased throughout the UK
between the period 1990 and 2017. The thiazide diuretic,
bendroflumethiazide remained the most prescribed drug of this class
despite an increase in prescription of the thiazide‐like drug,
indapamide, since 2011. There was variation within the UK in the
prescribing of thiazide and thiazide‐like diuretics. Patients with a his-
tory of diabetes prior to their first prescription for hypertension
were more likely (P < 0.001) to be prescribed indapamide in
1990–2010 compared to 2011–2016. Patients were more likely to
be prescribed indapamide if they had established cardiovascular dis-
ease or a high ratio of indapamide versus bendroflumethiazide use
within their medical practice, for both time periods, thus confirming
the influence overall practice policy in addition to patient
characteristics.
Conclusions: The NICE 2011 Hypertension Guidelines were associ-
ated with an increase in the use of indapamide and a reduction in
the use of bendroflumethiazide. However, the proportion of
indapamide used remains much lower than bendroflumethiazide, par-
ticularly in some regions. This suggests that adoption of the advice
in the guideline has been limited.
293 | Temporal changes in the prevalence of
cardiovascular drugs use in persons with and
without Alzheimer's disease, a retrospective
cohort study
Mai Vu1; Marjaana Koponen1; Heidi Taipale1,2,3; Antti Tanskanen2,3,4;
Jari Tiihonen2,3; Raimo Kettunen1; Sirpa Hartikainen1;
Anna‐Maija Tolppanen1
1University of Eastern Finland, Kuopio, Finland; 2Karolinska Institutet,
Stockholm, Sweden; 3Niuvanniemi Hospital, Kuopio, Finland; 4National
Institute for Health and Welfare, Helsinki, Finland
Background: Both cardiovascular diseases and Alzheimer's disease
(AD) are common in aging populations. There is little information
about the use of cardiovascular (CV) drugs in relation to AD diagnosis.
Objectives: To investigate the changes in prevalence of CV drug use in
relation to AD diagnosis, and compare the prevalence to a matched
cohort without AD.
Methods:Our study is based on the retrospective register‐based Med-
icationUse andAlzheimer's disease (MEDALZ) cohort which includes all
community dwellers who received a clinically verified AD diagnosis dur-
ing 2005–2011 in Finland. Point prevalence of CV drug use during a
two‐week observation period was counted every six months, from five
years before to five years after AD diagnosis. Each person in the AD
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cohort was matched with one comparison person without AD by age,
sex, and region of residence on the date of AD diagnosis (index date).
Use of CV drugs was extracted from the Prescription Register by Ana-
tomical Therapeutic Chemical‐classification system codes C* (excluding
C04 and C05) and modeled with PRE2DUP method. Longitudinal asso-
ciations between AD and CV drug use were studied with generalized
estimating equations (logistic regression).
Results: On the index date, the use of CV drugs was equally common
among persons with and without AD (approximately 70% in both
cohorts). The differences in CV drug categories were also relatively
small. Beta blockers were the most commonly used in both AD
(44.2%) and non‐AD cohort (43.9%), followed by statins, with approx-
imately one third of both groups (AD 33.6% and non‐AD 31.5%). Cal-
cium channel blockers were used more commonly in the non‐AD
cohort (20.2% and 22.9% in AD and non‐AD cohorts, respectively).
Angiotensin converting enzyme inhibitors (AD 22.2%; non‐AD 20.9%)
were more commonly used than angiotensin II receptor blockers drugs
(AD 13.9%; non‐AD 16.9%). Loop diuretics were somewhat more com-
mon among persons with AD (17.9% in the AD cohort; 17.1% in the
non‐AD). Overall, the trajectories of use were divergent for different
CV drugs, but the common trend was that the prevalence of the use
increased before the AD diagnosis among both groups (for example,
for any CV drug RR:1.05 95% CI 1.03–1.08). After AD diagnosis the
prevalence began to decline among persons with AD (for any CV drug
RR:0.60 95% CI 0.59–0.62).
Conclusions: The prevalence of CV drug use was similar in persons
with and without AD until the AD diagnosis. After that, the prevalence
of CV drug began to decline among persons with AD compared to
non‐AD. Further studies are needed to determine the difference in
CV treatment practices.
294 | Characteristics of NOAC users aged
less than 65 years in the sentinel system
Marie C. Bradley1; Emily C. Welch2; Efe Eworuke1; Rongmei Zhang;
Elande Baro1; David J. Graham1; Mayura Shinde2
1Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School and Harvard Pilgrim Health Care Institute, Boston, MA
Background: A number of studies comparing non‐vitamin K antagonist
oral anticoagulants (NOACs) have reported differential benefits and
harms among those over age 65 years with atrial fibrillation (AF). How-
ever, little information is available on the benefit‐harm profiles in
those under age 65.
Objectives: To inform the feasibility of a similar safety study in those
under age 65 we examined characteristics of and utilization among
NOAC initiators for all indications in that age group in the Sentinel
Distributed database (SDD).
Methods: New users of NOACS (rivaroxaban, apixaban, dabigatran)
aged between 18 and 64 years from October 2010 to September
2015 were identified in SDD. New use was indicated by no use of
any NOAC or warfarin in the 183 days prior to the index dispensing.
Patients were categorized according to NOAC type and strength.
Characteristics of each NOAC exposure group were assessed includ-
ing: age, sex, health service utilization and potential indications for use.
Results: There were 128,954 NOAC initiators under age 65 during the
study period. The mean age was 55 years and 72.0% of users were
aged between 51–64 years. Males accounted for 61.0% of new users;
however, rivaroxaban 10 mg and apixaban 2.5 mg users tended to
have slightly more female initiators. The most frequently initiated
NOAC was rivaroxaban 10 mg (40,197 new users) followed by
rivaroxaban 20 mg (36,874 new users), and dabigatran 150 mg
(21,260 new users). Atrial fibrillation (40.9%) appeared to be the most
common potential indication for use followed by joint replacement
(19.5%) and knee surgery (11.6%). Around 39% of all NOAC users
had no history of AF, pulmonary embolism (PE) or deep vein thrombo-
sis (DVT) as did 70.7% of apixaban 2.5 mg and 94.7% of rivaroxaban
10 mg users. History of surgery was most common in new users of
rivaroxaban 10 mg (56.3% joint replacement, 35% knee surgery and
19% hip surgery) and apixaban 2.5 mg users (38.6% joint replacement,
23.1% knee surgery 13.2% hip surgery). Initiators of dabigatran
150 mg (88.4%), dabigatran 75 mg (78.6%), rivaroxaban 20 mg
(59.8%), and apixaban 5 mg (78.2%) commonly had a history of AF
and no history of PE or DVT.
Conclusions: Rivaroxaban was the most commonly prescribed NOAC
in those under age 65 in the Sentinel System. Safety assessments, sim-
ilar to those conducted in patients over 65 years old, are therefore
warranted. Since many NOAC initiators had AF, future safety studies
in those under age 65 could exclude rivaroxaban 10 mg and apixaban
2.5 mg users as they appear to be used for indications other than AF.
295 | Impact of serious infection on
continuation of chronic disease medications
Kanya K. Shah1; Aisling R. Caffrey1; Vrishali Lopes2
1University of Rhode Island, College of Pharmacy, Kingston, RI; 2Veterans
Affairs Medical Center, Providence, RI
Background: There have been over 50 studies in the past 15 years eval-
uating the protective effects of statins among patients with infections,
but the collective results of these studies have been inconclusive. The
definition of statin exposure varies greatly between studies, including
periods of initiation and continuation in relation to the onset of infec-
tion, which is likely responsible for the unexplained heterogeneity.
Objectives: The objective of this study was to assess the effects of
serious infections on statin utilization patterns in Veterans Affairs
(VA) patients hospitalized between 2002 and 2015 with Staphylococ-
cus aureus bacteremia.
Methods: Our national retrospective cohort study assessed statin
exposures, focusing on statin drug, dose, and duration of use, among
patients who were cultured and admitted to a VA hospital on the same
day. The collection date of the blood culture served as the index date
and exposure mapping was used to identify statin exposures in the
30 days before and after culture (total 61 days).
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Results:We included 6,109 patients with S. aureus bacteremia exposed
to statins. About one third of patients received the same statin drug and
dose for the duration of the observation period (30.9%). Change in
statin dose, but not drug, was observed in 5.2% of patients, and 1.9%
changed their statin drug and dose at least once during the observation
period. Statin medication was initiated during the observation period in
10.5% of patients, and 28.9% of the initiations occurred within the
5 days before or 5 days after the admission/culture. Statin discontinua-
tion, without later reinitiating, occurred in 10.3% of patients, with
11.8% of discontinuations occurring within the 5 days before or 5 days
after the admission/culture. Statins were discontinued on hospital
admission day, creating a gap in therapy, in 1.2% of included patients.
Prior to admission, 51.4% of patients took a statin every day for the
30 day period, and 7.9%of patient did not take a statin until after admis-
sion. Simvastatin was the most common statin (75.7%) and the most
common doses were 20 mg (17.8%), 40 mg (17.5%), and 80 mg (9.6%).
Conclusions: Two‐thirds of patients experienced a change in statin
therapy, either as a discontinuation, gap in therapy, or change in
drug/dose. This study identified more accurate definitions of statin
utilization among those with precipitating events, and provides an
example of how to use exposure mapping for improving operational
definitions of exposure.
296 | Variation in patient characteristics in
atrial fibrillation treatment: A real‐world
assessment of contact force and Cryoballoon
technology
Scott J. Pollak1; Laura Goldstein2; Mehmet Daskiran3;
Iftekhar Kalsekar4; Rahul Khanna4
1Advent Health, Orlando, FL; 2 Johnson and Johnson, Irvine, CA;
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Background: Catheter ablation is an effective treatment for patients
with atrial fibrillation (AF) who are drug refractory or intolerant to drugs.
Objectives: To compare characteristics among AF patients undergoing
ablation using a contact force (CF) radiofrequency catheter
(THERMOCOOL SMARTTOUCH® Catheter) versus a cryoballoon
(CB) catheter (Arctic Front™/Arctic Front Advance™ Catheter).
Methods: Patients aged 18 years and above with AF who had an elec-
tive ablation procedure between January 1, 2014 and June 30, 2017
were identified. Patients who underwent catheter ablation, surgical
ablation, valvular procedures, or left atrial appendage occlusion during
the 12‐month pre‐index admission were excluded. Patients with AF
who underwent catheter ablation using either the CF THERMOCOOL
SMARTTOUCH® Catheter or the Arctic Front™/Arctic Front
Advance™ CB Catheter without any additional point‐to‐point catheter
use during an inpatient or outpatient hospital admission were identi-
fied. Characteristics of patients in the two catheter groups were com-
pared using student t‐test or chi‐square test.
Results: A total of 3,715 patients were in the final sample, with 1,409
in the CF THERMOCOOL SMARTTOUCH® Catheter group and
2,306 in the Arctic Front™/Arctic Front Advance™ CB Catheter group.
The average age of patients in the CF group was lower than patients in
the CB group (63.21 ± 10.21 vs 64.52 ± 10.76, p = 0.0002). When
examining clinical characteristics, a significantly higher proportion of
patients in the CF group had sleep apnea (26.90% vs 20.69%,
p < 0.0001), obesity (16.96% vs 9.24%, p < 0.0001), chronic pulmonary
disease (16.18% vs 13.57%, p = 0.0287), renal disease (6.10% vs
4.55%, p = 0.0379), congestive heart failure (19.87% vs 15.57%,
p = 0.0007), atrial flutter (32.65% vs 18.86%, p < 0.0001), valvular dis-
ease (18.45% vs 14.44%, p = 0.0012), and cardiomyopathy (7.38% vs
4.90%, p = 0.0018) as compared to patients in the CB group. The aver-
age Charlson Comorbidity Index (CCI) score was significantly higher
(p = 0.0002) in the CF group (0.90 ± 1.18) as compared to the CB
group (0.75 ± 1.12).
Conclusions: In this real‐world study, patients undergoing ablation
using the CF THERMOCOOL SMARTTOUCH® Catheter had higher
comorbidity burden as compared to those who had ablation using
the Arctic Front™/Arctic Front Advance™ CB Catheter. Further
research is needed to better understand differential in outcomes
among patients with high comorbidity status undergoing ablation
using a CF Catheter versus the CB Catheter.
297 | Real‐world DOAC and VKA use: The
PHARMO‐anticoagulation cohort
Elisabeth Smits; Jelle Evers; Fernie J.A. Penning‐ van Beest;
Ron Herings; Irene D. Bezemer
PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands
Background: Anticoagulation with vitamin K antagonists (VKAs),
including acenocoumarol, phenprocoumon and warfarin, has been
the standard of care for more than 60 years, but has been associated
with drug use‐related hospital admissions due to bleeding events.
Dosing requires close monitoring of therapeutic levels. Direct oral
anticoagulants (DOACs), which have been on the market since
10 years, do not require close monitoring. DOACs include factor II
inhibitors (dabigatran) and factor Xa inhibitors apixaban, rivaroxaban
and edoxaban).
Objectives: To create a real‐world dynamic cohort of patients using
DOACs or VKAs with the aim to set a basis for safety and efficacy
outcome monitoring.
Methods: Patients with recorded dispensings of DOAC or VKA
between 2008 and 2017 were selected from the Out‐patient Phar-
macy Database of the PHARMO Database Network, resulting in the
PHARMO‐ anticoagulation cohort. Outcome data are available from
hospital admission records and for a subset of the patients, detailed
patient information from the GP Database is available.
Results:During 2008–2017 a total of 77,189 patients usingDOACs and
249,210 patients using VKAs were identified; 22,512 were in both
groups. DOAC users were 69.9 ± 12.1 years at the time of first use;
44% used rivaroxaban, 30% dabigatran, 17% apixaban, 3% edoxaban
and 7% had used multiple DOACs over time. VKA users (74% used
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acenocoumarol, 21% phenprocoumon and 5% used both over time)
were 70.6 ± 14.1 years at the time of first dispensing in the study period;
this is a mix of new and prevalent users. For about 25% of the popula-
tion detailed medical information from GP records is available.
Conclusions: The PHARMO‐anticoagulation cohort provides real‐
world information on DOAC and VKA use in the Netherlands and
delivers comprehensive insights in anticoagulation‐related safety, effi-
cacy and resource utilization.
298 | Trends in cardiovascular drug use and
cardiovascular disease mortality in Serbia
Ana D. Tomas Petrović; Olga Horvat; Zdenko Tomić; Ana Sabo
University of Novi Sad, Novi Sad, Serbia
Background: CVD drugs are biggest drivers of pharmaceutical expen-
diture in Serbia, but there is limited data about the impact this high uti-
lization has had on the mortality of CVD.
Objectives: The aim of this study was to determine the trends in car-
diovascular drug use and mortality in Serbia.
Methods: The data on utilization of cardiovascular drugs expressed in
in defined daily doses per 1000 inhabitants per day (DID) (from 2006–
2016) was retrieved from the Medicines and Medical Devices Agency
of Serbia. The WHO database was searched for the mortality data
(ASDR per 100 000 inhabitants, from 2006 to 2015).
Results: Utilization of CVD drugs in Serbia showed a steady increasing
trend (from 399.79 DID in 2006 to 632.80 DID in 2016, 58.3% rela-
tive increase). There was an increase in the beta‐blocking agents (by
56%) and calcium channel blockers (by 81%), while use of nitrates
showed a decreasing trend overtime. ACE inhibitors were the most
commonly used drugs in all years analyzed (≈39% of group C), but
patterns of use of changed. Biggest changes were obsreved in the
use of angiotensin receptor blockers (ARB, 0.06 to 11.3 DID) and fixed
combinations. Fixed combinations of ACE inhibitors and thiazide
diuretics were used almost 7 times more in 2016 (73 DID), than
2006 (11.9 DID), while steady increasing trend was also observed
for ARB and thiazide combinations (0.1 in 2006, 1.7 in 2012 and
16.7 DID in 2016). Fixed combinations accounted for 14% of total uti-
lization in 2016, compared for just 3% in 2006. The use of lipid mod-
ifying agents (ATC group C10) doubled during the observed period
(from 12.74 to 25.8 DID, relative increase 102.5%), mostly on the
account of increase in use of atorvastatin, whose utilization increased
5 times over the study period. Overall mortality from diseases of the
circulatory system was significantly lower in 2016 (329) than in
2006 (424). Significant decrease in mortality from ischemic heart dis-
eases (100.7 to 60.9) and cerebrovascular diseases (121.3 to 75.3)
was noted. However, mortality from hypertensive diseases increased
(23.4 in 2006 to 35.9 in 2016). A.
Conclusions: The increasing trends in use of CVD and a decrease in
mortality from ischemic heart diseases and cerebrovascular diseases
was observed in this study. Biggest increase was noted in the use of
antihypertensive fixed combinations and statins.
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comparative drug utilization study
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Background: Despite a tremendous increase in prescribing of direct
oral anticoagulants (DOACs) in recent years limited data is available
on prescribers' adherence to registered indications (ICs), contraindica-
tions (CIs), special warnings/precautions (SW/PCs), and potential
drug–drug interactions (pDDIs).
Objectives: The aim of this study was to assess in six European
databases prescribers' adherence to the Summary of Product Char-
acteristics (SmPC) of three DOAC compounds (dabigatran,
rivaroxaban, and apixaban) with a special focus on IC, CI, SW/PC,
and pDDI.
Methods: This retrospective cohort study was conducted in databases
covering regionally/nationally representative populations in five Euro-
pean countries (Denmark, Germany, Spain, the Netherlands, and
United Kingdom). The study cohort consisted of adult patients
(≥18 years) initiating dabigatran, rivaroxaban or apixaban between
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2008 and 2015. ICs, CIs, SW/Ps and pDDIs as registered in the SmPC
of the DOACs were mapped to respective coding systems.
Results: 407,576 patients initiated DOACs during the study period
(rivaroxaban: 240,985 [59.1%], dabigatran: 95,303 [23.4%],
apixaban: 71,288 [17.5%]). In 2015, non‐valvular atrial fibrillation
was the most common IC registered, representing more than 60%
of incident DOAC users in most databases. For the whole study
period, a substantial variety between the databases was found
regarding the proportion of patients with at least one CI (inter‐
database range [IDR]: 8.2% to 55.7%), with at least one SW/PC
(IDR: 35.8% ‐ 75.2%), and with at least one pDDI (22.4% to
54.1%). In 2015, the most frequent CI was ‘malignant neoplasm’
(IDR: 0.7% ‐ 21.3%) whereas the most frequent SW/Pc were ‘pre-
scribing to the elderly (75 years or older)’ with an IDR from
25.0% to 66.4%. The most common single compound class pDDI
was ‘concomitant use of nonsteroidal antinflammatory drugs’ with
an IDR between 3.0% to 25.3%.
Conclusions: CIs, SW/Ps, and pDDIs were present in a significant
number of new DOAC users. Differences between all databases might
be related to ‘true’ differences in prescription behaviour, but could
also be partially due to differences in database characteristics.
300 | Adherence to prescription guidelines
and achievement of treatment goals among
persons with coronary heart disease ‐ a cross‐
sectional study
Elisabeth Pedersen1; Beate H. Garcia1; Anne Elise Eggen1;
Kjell H. Halvorsen1; Henrik Schirmer1,2,3; Marit Waaseth1
1UiT The Arctic University of Norway, Tromsø, Norway; 2University of
Oslo, Oslo, Norway; 3Akershus University Hospital, Lørenskog, Norway
Background: Adherence to clinical practice guidelines in coronary
heart disease (CHD) patients has been shown to reduce morbidity,
mortality and overall treatment costs.
Objectives: To describe adherence to prescription guidelines for med-
ical treatment of CHD and explore factors associated with treatment
goal achievement for blood pressure, cholesterol and glycated hemo-
globin (HbA1c).
Methods: We have analyzed data from the seventh wave of the
Tromsø Study, a population‐based prospective health study con-
ducted in 2015–16, inviting all inhabitants in the municipality of
Tromsø, Norway, aged ≥40 years. We included all participants
reporting myocardial infarction, angina, percutaneous coronary inter-
vention and/or coronary artery bypass surgery (n = 1481). Self‐
reported medication use and treatment goal measures (blood pressure,
low‐density lipoprotein (LDL)‐cholesterol and HbA1c) were compared
to the European Guidelines on cardiovascular disease prevention in
clinical practice (version 2012), which were prevailing in Norway in
2015–16.
Results: The prevalence of medical CHD treatment was 66.1% for
acetylsalicylic acid, 70.9% for blood pressure lowering medicines and
76.4% for lipid lowering drugs (LLDs), while 48.5% used all three med-
ication groups. The blood pressure target (<140/90 mmHg, <140/
80 mmHg if diabetic) was achieved by 58.0%, LDL‐cholesterol target
(<1.8 mmol/l) by 9.3%, and HbA1c target in diabetics (HbA1c of
<7%, n = 199) by 41.2% of the participants. Among participants using
blood pressure lowering medicines, 54.7% reached the blood pressure
target, compared with 66.1% among the non blood pressure medicine
users. Equivalent proportions for cholesterol was 12.1% among partic-
ipants using LLDs and 1.0% for non‐users. We are investigating poten-
tial associations between low treatment goal achievement and factors
like time since diagnosis, specific medication use, demography, health
(co‐morbidity/co‐medication), and lifestyle.
Conclusions: Our preliminary results show that treatment goal
achievement among CHD‐patients is low, especially for lipid manage-
ment. The connection between treatment guidelines and reaching the
recommended treatment goals is unsatisfactory, but this can be due to
underlying factors that we will present at the conference.
301 | Antihypertensive drug combinations to
optimize blood pressure control in black
patients
Onyinye Akunne1; Aduragbenro D.A. Adedapo2; Kayode S. Adedapo3
1University of the Western Cape, Bellville, South Africa; 2University of
Ibadan, Ibadan, Nigeria; 3University College Hospital, Ibadan, Nigeria
Background: Guidelines on the treatment and management of hyper-
tension stipulate the use of combination therapy containing either a
calcium channel blocker (CCB) or diuretic for the treatment of hyper-
tension in blacks.
Objectives: We compared the effectiveness of combination drug ther-
apy containing diuretics and/or CCBs in controlling blood pressure (BP).
Methods:This cross‐sectional researchwas carriedout at theoutpatient
clinics in a tertiary institution in south‐west Nigeria. Prescription of
hypertensive patients that i). were above18years old ii). containedmore
than one antihypertensive medication iii). had been on a combination
for>1month iv). had recorded BP readingwas evaluated. The treatment
group was classified as prescriptions containing i.) CCB + diuretics ii.)
CCB + angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin
receptor blocker (ARB) iii.) CCB + diuretics + ACEI or ARB iv.) Diuretics
+ ACEI or ARB. The effectiveness of drug combinations to lower BP to
acceptable thresholds (<140/90mmHg)was studied. Presenceof diabe-
tes mellitus (DM), cardiovascular disease (CVD) and chronic kidney dis-
ease (CKD) and antihypertensive medication prescribed in these
conditions were evaluated. Effect of age, sex, number/combination of
antihypertensive medication prescribed and concomitant disease on
BP control was assessed. Chi‐square and Pearson's correlation in SPSS
Version 23 was used to test for associations.
Results: Nine hundred and eighty‐six prescriptions were included in
the final analysis. The mean age of patients was 61 ± 11 (30–85)
years, Females = 55%. The most prescribed drug combination was
diuretics + CCB + ACEI or ARB (331 (33.6%)). Diuretics + ACEI or
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ARB, CCB + diuretics and CCB + ACEI or ARB was prescribed to
225 (22.8%), 222 (22.5), 209 (21.2%) of the patients respectively.
Diuretics + ACEI or ARB was prescribed to 45.9% of hypertensive
patients with CVD. CCB + diuretics was prescribed to 65.6% and
38.5% of patients with DM and CKD respectively. BP control was
observed in 431 (43.7%) of the patients. BP control was significantly
higher in patients on either Diuretics + ACEI or ARB (57.5%) or
CCB + Diuretic (51.6%) (χ2, p < 0.01). The number of drugs pre-
scribed correlated with BP control (r = 0.084, p < 0.01). Patients
receiving 3 drugs had the worst BP control. The number of health
problems did not correlate with BP control. Patients having cardio-
vascular disease had significantly worse BP control than patients
with other complications (r = −0.084, p < 0.01).
Conclusions: BP control was less than average. Patients receiving a
fewer number of drugs and on diuretics had better blood pressure
control.
302 | Sacubitril/Valsartn (Entresto)
utilization and prescribing patterns in
Northern Ireland: A repeated, cross‐sectional
study
Pamela Boyed1; Amanj Kurdi1,2
1Strathclyde Institute of Pharmacy and Biomedical Science, University of
Strathclyde, 161 Cathedral/University of Strathclyde, Glasgow, UK;
2Hawler Medical University, Erbil, Iraq
Background: In April 2016, the National Institute of Clinical Excellence
(NICE) approved the new chronic heart failure medication (CHF)
Entresto (sacubitril/valsartan) for treating symptomatic CHF, giving
patients the right for full access. Although, Entresto has been accepted
for use by the Northern Ireland (NI) Manged Entry Process, it is not
listed on the NI formulary not it is first line for CHF therapy. The uti-
lization pattern of Entresto is unclear.
Objectives: To evaluate the utilization pattern and uptake of
Entresto in the primary care setting in NI and identify any regional
variations.
Methods: Repeated, cross‐sectional study using the Prescription Cost
Analysis (PCA) data from November 2016 to October 2017. PCA pro-
vides information on number of items, quantity, strength and cost of
all the prescriptions dispensed in the community setting in NI.
Monthly utilization pattern was measured using number of items dis-
pensed, number of defined daily doses (DDD)/1000 inhabitant/day,
and net ingredient costs. Number of DDD/1000/day was stratified
regions to identify any regional variation. The cost of Entresto as a
percentage of all heart failure medications was also calculated. Data
were analyzed used descriptive statistics and liner regression to test
any trend change over time.
Results: Overall, there was insignificant increase in the prescribing of
Entresto over the study period. The number of dispensed items fluc-
tuated during the study period, with insignificant increase of 21.7%
from 143 items in November‐2016 to 174 items in October‐2017
(p > 0.05). Similar pattern was observed with number of DDD/
1000/day, with insignificant increase of 31% from 0.0008 DDD/
1000/day to 0.0011. Likewise, the monthly cost increased by
36.9% from £11,438 to £51,660 in October‐2017. By the end of
the study period, Entresto accounted for only about 4.4% of the
total cost of all heart failure medications. Significant regional varia-
tions were observed among the 5 Irish regions, with Belfast as the
only region which showed steady increase in number of DDD/
1000/day.
Conclusions: The utilization and uptake of Entresto was low and slow
in NI which reflects the current NI formulary. This might highlights the
issue of securing enough resources to fund this expensive medications
given the financial pressure on the Irish healthcare system. However,
the observed regional variations highlights the need for further
research to explore the factors associated with this variations.
303 | Pain relief and function restoration
after primary Total knee arthroplasty: An
evaluation using knee injury and
osteoarthritis outcome score in real world
data
Zhenna Huang; Jill Webster Ruppenkamp; Chantal E. Holy
Johnson and Johnson Inc., New Brunswick, NJ
Background: Knee Injury and Osteoarthritis Outcome Score (KOOS) is
currently used by Centers for Medicare and Medicaid Service to
instruct value‐based payment programs. However, so far, few studies
attempted to use KOOS score in real world data to evaluate pain relief
and function restoration after TKA.
Objectives: This study aims to evaluate changes in KOOS score (scale
0–100) after TKA surgery, including all five subscales: pain, other
symptoms, function in daily living (ADL), function in sport and recrea-
tion (Sport/Rec) and knee‐related quality of life (QOL).
Methods: Through data partnership with Mercy‐Technology‐Ser-
vice, patients who underwent primary TKA surgery and with
available KOOS score were extracted from 2011–2018 Mercy
electronic health records, which is one of the most comprehen-
sive real‐world databases including preoperative and intraoperative
information. Baseline KOOS was determined by the most recent
measurement three‐months before surgery. Due to the sparse dis-
tribution of follow‐up KOOS measurement, we analyzed the fol-
low‐up KOOS scores 30–180 days after surgery. The higher
increase in KOOS scores indicates greater function restoration
or pain relief. Mean difference and 95% CI were estimated using
paired‐t‐test. Total KOOS score was calculated by averaging the
five subscales. Factors associated with total KOOS score change
30‐days after surgery were investigated using multiple linear
regression.
Results: In total, 230 (0.9%) out of 24,830 TKA patients were iden-
tified with both baseline and follow‐up KOOS scores 30–180 days
after surgery (Age median 65y (IQR: 60.0–72.8); 64% female; 59%
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commercial insured; median day of follow‐up measurement after sur-
gery: 58d (IQR: 43–101)). The mean score difference of follow‐up to
baseline for pain, other symptoms, ADL, Sport/Rec and QOL were
23.4 (95% CI: 20.6–26.3), 20.9 (95% CI: 18.0–23.9), 24.6 (95% CI:
21.6–27.7), 9.8 (95% CI: 6.7–13.0), and 26.7(95% CI: 23.6–29.8),
respectively. Higher baseline KOOS score (β = −0.65, p < 0.001),
longer OR time (β = −0.18, p = 0.009), and elder age (β = −0.36,
p = 0.004) were significantly associated with lower KOOS increase
30–180 days after surgery.
Conclusions: TKA patients in this study reported significant improve-
ment in pain, other symptoms, ADL, function in sport and recreation
and QOL 30–180 days after surgery. Further studies with larger sam-
ple size and longer follow‐up measurement are warranted.
304 | Knee injury and osteoarthritis outcome
score availability evaluation in real world data
Zhenna Huang; Jill Webster Ruppenkamp; Chantal E. Holy
Johnson and Johnson Inc., New Brunswick, NJ
Background: Knee Injury and Osteoarthritis Outcome Score (KOOS) is
currently used by Centers for Medicare and Medicaid Service to
instruct value‐based payment programs. However, little is known
about its availability in real world databases.
Objectives: To evaluate the availability of KOOS score after TKA sur-
gery in real world data and investigate factors associated with KOOS
measurement availability.
Methods: Through data partnership with Mercy Technology Ser-
vices (the IT arm of St. Louis‐based Mercy health system), patients
who underwent primary TKA surgery were extracted from 2011–
2018 Mercy electronic health records, which is one of the most
comprehensive real‐world databases including preoperative and
intraoperative information. Patients with at least one KOOS mea-
surement were identified. A descriptive analysis was performed to
compare patients who ever had KOOS reported and those who
were without any KOOS measurement. Preoperative and intraoper-
ative variables associated with KOOS availability (p < 0.2) in the
crude analysis were included in the multivariable logistic regression
development. Manual backward selection was used to obtain the
final model.
Results: In this study TKA population, 1,615 out of 24,830 (6.5%)
patients were with reported KOOS measurement. Patients who
were older (10‐year increment: aOR: 1.09, 95% CI: 1.01, 1.16,
mean (SD): 66.7(9.8) vs 65.5 (9.8)), being current smoker (aOR:
1.42, 95% CI: 1.15, 1.77), having higher BMI (aOR: 1.04, 95% CI:
1.03, 1.05) and higher number of hypertension prescription prior
to surgery (10‐ increment: aOR: 1.46, 95% CI: 1.07, 2.01) were sta-
tistically significantly associated with increased odds of unavailable
KOOS measurement. Baseline pain level (scale 0–10) (aOR: 0.97,
95% CI:0.94, 0.99), number of opiate prescription prior to surgery
(10‐increment aOR: 0.71, 95% CI:0.57, 0.88), number of
anticoagulation prescription prior to surgery (10‐ increment aOR:
0.2, 95% CI:0.12, 0.34), and recovery room time (10‐minutes incre-
ment: aOR: 0.94, 95% CI:0.93, 0.95) were factors that statistically
significantly associated with decreased odds of unavailable KOOS
measurement.
Conclusions: KOOS availability in real world database was poor
(6.5%). More efforts are needed to increase KOOS measurement in
TKA population, especially among patients who are with lower base-
line pain level. When making conclusions using KOOS score,
researchers should consider potential bias brought by non‐random
KOOS missing. Future studies using other real‐world data sources
are warranted.
305 | Evaluation of three database‐derived
comorbidity measures to predict infections,
extended length of stay and readmissions
after Total knee replacement
Abhishek S. Chitnis1; Zhenna Huang1; Shreya Murthy2;
Chantal E. Holy1
1 Johnson and Johnson, New Brunswick, NJ; 2Mu Sigma, Banglore, India
Background: The three database‐derived comorbidity measures,
Charlson, Elixhauser and Functional comorbidity measures have been
used as risk‐adjustment tools in quality and safety data. However,
there is no data on their performance in patients that undergo total
knee replacement (TKR).
Objectives: To evaluate the discriminative ability of the Charlson,
Elixhauser and Functional comorbidity measures for predicting infec-
tions, extended length of stay (LOS) and readmissions after TKR.
Methods: Patients who underwent total knee replacement between
January 1, 2010 and December 31, 2017 in IBM Commercial database
were identified. The outcomes of interest were (1) infection within
three months post‐TKR, (2) extended LOS defined as ≥3 days of stay
for TKR (3) all‐cause readmissions within three months post‐TKR. For
each outcome, four multivariable logistic regression models were con-
structed. One base model that included age, gender and year of sur-
gery and three models with the variables in the base model and a
comorbidity measure, Charlson, Elixhauser or Functional. The predic-
tive performance of the Charlson, Elixhauser and Functional comor-
bidity measures was assessed using the area under the receiver
operating characteristic curve (AUC) derived from these regression
models.
Results: A total of 200,396 patients with TKR were identified. The
mean (SD) age of the cohort was 56.7 (5.4) years and most were
females (59.7%). For infection, AUC of base, Charlson, Elixhauser
and Functional comorbidity measure models were 0.570 (95% CI,
0.566–0.575), 0.599 (95% CI, 0.594–0.603), 0.608 (95% CI, 0.604–
0.612) and 0.608 (95% CI, 0.604–0.613), respectively. For extended
LOS, AUC of base, Charlson, Elixhauser and Functional comorbidity
measure models were 0.6044 (95% CI, 0.601–0.608), 0.622 (95% CI,
0.618–0.625), 0.626 (95% CI, 0.623–0.630) and 0.621 (95% CI,
0.617–0.624), respectively. Finally, for readmissions, AUC of base,
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Charlson, Elixhauser and Functional comorbidity measure models
were 0.528 (95% CI, 0.523–0.532), 0.551 (95% CI, 0.547–0.556),
0.570 (95% CI, 0.566–0.575) and 0.565 (95% CI, 0.560–0.569),
respectively.
Conclusions: The discriminative ability of the Charlson, Elixhauser and
Functional comorbidity measure was poor (all AUC <0.7) in predicting
infections, extended LOS and readmissions after TKR. Of the three
comorbidity measures, Elixhauser models had better discriminative
ability. Future research developing comorbidity measures with
improved discriminative ability for outcomes after TKR would be of
value.
306 | Association between early diagnosis of
post‐surgical infection and reoperation
following Total knee arthroplasty
Abhishek S. Chitnis1; Piyush Nandwani2
1 Johnson and Johnson, New Brunswick, NJ; 2Mu‐Sigma, Bangalore, India
Background: Post‐surgical infection (PSI) is significantly associated
with increased risk for reoperation after total knee arthroplasty
(TKA). However, little is known about the timing of diagnosis of PSI
and rate of reoperations. Early diagnosis of PSI may help surgeons
select appropriate strategy mostly with an antibiotic therapy and min-
imal surgical intervention.
Objectives: To evaluate the association between early diagnosis of
any and deep PSI and reoperations after TKA.
Methods: This was a retrospective cohort study of patients undergo-
ing TKA between 2014 and 2017 using IBM® MarketScan® Com-
mercial, Multi‐State Medicaid and Medicare Supplemental
databases. Patients were included if they had a diagnosis of PSI
within six months after TKA and continuous enrollment six months
prior to and two years after TKA. Early diagnosis of any PSI and
deep PSI were defined as any claim for PSI and deep PSI, respec-
tively within 11 days of TKA. Two separate multivariable logistic
regressions controlling for patient demographic and clinical charac-
teristics were developed to examine the association between an
early diagnosis of any PSI and deep PSI and reoperation within
two years after TKA.
Results: A total 3,398 patients with any PSI were identified, of
which 1401 (41.2%) patients had deep PSI. The mean (standard
deviation, SD) age of the cohort was 63.0 (10.7) years with 62.4%
females and the mean (SD) Elixhauser score was 2.0 (1.9). The top
three comorbidities were hypertension (64.1%), diabetes (24.9%)
and obesity (21.0%). The rates of reoperations within two years of
TKA were 6.4% for any PSI and 12.4% for deep PSI. The adjusted
models showed that there were 43.0% lower odds of reoperation
[odds ratio (OR), 0.57, 95% confidence interval (95% CI), 0.39–
0.84] with an early diagnosis of any PSI and 41.0% lower odds of
reoperation (OR, 0.59, 95% CI, 0.38–0.90) with an early diagnosis
of deep PSI compared to the delayed diagnosis of any PSI or deep
PSI, respectively (both p < 0.01).
Conclusions: This study found that the early diagnosis of any PSI and
deep PSI was significantly associated with a lower risk of reoperation
as compared to delayed diagnosis of PSI following TKA. Patients with
delayed diagnosis of PSI may have a biofilm developed on the implant
surface by the infecting organisms that may reduce the effectiveness
of antibiotic treatment thereby requiring aggressive surgical strategy
involving reoperation.
307 | Early diagnosis of post‐surgical
infection and reoperation following Total hip
arthroplasty
Abhishek S. Chitnis1; Piyush Nandwani2; Chantal E. Holy1
1 Johnson and Johnson, New Brunswick, NJ; 2Mu Sigma, Bangalore, India
Background: Post‐surgical infection (PSI) is significantly associated
with morbidity and increased risk for reoperation after total hip
arthroplasty (THA). The timing of diagnosis of PSI is crucial in deter-
mining the subsequent medical and surgical management. Early diag-
nosis of PSI especially deep infection may have a lower risk of
reoperations as compared to PSI diagnosed late as with the latter
there may be formation of the biofilm on the implant surface by
the infecting organisms that reduce susceptibility to antibiotic treat-
ment thus requiring aggressive surgical strategy including
reoperation.
Objectives: To evaluate the association between early diagnosis of
any and deep PSI and reoperation after THA.
Methods: This was a retrospective cohort study of patients undergo-
ing THA between 2014 and 2017 using IBM® MarketScan® Com-
mercial, Multi‐State Medicaid and Medicare Supplemental
databases. Patients were included if they had a diagnosis of PSI
within six months after THA and continuous enrollment six months
prior to and two years after THA. Early diagnosis of any and deep
PSI were defined as any claim for PSI and deep PSI, respectively
within 11 days of THA. Two separate multivariable logistic regres-
sions controlling for patient demographic and clinical characteristics
were developed to examine the association between an early diag-
nosis of any PSI and deep PSI and reoperation within two years
after THA.
Results: A total 1,883 patients with any PSI were identified, of
which 882 (46.8%) were deep PSI. The mean (standard deviation,
SD) age of the cohort was 65.0 (13.7) years with 57.5% females
and the mean (SD) Elixhauser score was 2.0 (2.1). The top three
comorbidities were hypertension (60.1%), diabetes (20.1%) and
chronic pulmonary disease (19.0%). The rate of reoperation within
two years of THA was 21.5% for any PSI and 25.1% for deep PSI.
The adjusted models showed that there were 34.0% lower odds of
reoperation [odds ratio (OR), 0.66, 95% confidence interval (95%
CI), 0.49–0.90] with an early diagnosis of any PSI and 42.0% lower
odds of reoperations (OR, 0.58, 95% CI, 0.38–0.88) with an early
diagnosis of deep PSI compared to a delayed diagnosis of any PSI
or deep PSI, respectively (both p < 0.01).
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Conclusions: This study found that the early diagnosis of PSI and more
so deep PSI was significantly associated with a lower risk of reopera-
tion as compared to delayed PSI diagnoses following THA. Early diag-
nosis of PSI may help surgeons select appropriate strategy to possibly
retain the implant without reoperations.
308 | Similar epidemiologic trends on
arthroplasty‐related adverse outcomes
suggest common modifying role of sex/race‐
related patient factors in various
arthroplasties
Yasameen Azarbaijani; Yelizaveta Torosyan
FDA, Silver Spring, MD
Background: As part of translational research for predictive evaluation
of real‐world performance, we are developing new evidentiary
approaches incorporating putative patient‐related risk predictors and
outcome modifiers. Our previous research (as reported at ICPE
2015–2017) revealed sex/race‐related modifying effects on adverse
outcomes in hip arthroplasty.
Objectives: This project is focused on overall sex/race‐associated
trends in implant‐related adverse outcomes in various arthroplasties.
Methods: Data from the Nationwide Inpatient Sample of the Agency
for Healthcare Research & Quality (2010–2014) were used for a retro-
spective analysis of arthroplasty related discharges with or without
adverse outcomes, as identified by ICD9 codes. The main outcomes
of interest were Mechanical Loosening, Dislocation, Periprosthetic
Fracture, Periprosthetic Osteolysis, and Articular Bearing Surface
Wear. The arthroplasties were grouped as Hip, Knee, and Other (i.e.,
prosthetic procedures for shoulder, finger/wrist, elbow, and ankle).
Using SAS v.9.3 (Proc Logistic: unadjusted and adjusted for interac-
tions among age, race, and arthroplasty status), the occurrence of
adverse outcomes was compared in the sex/race‐stratified subpopula-
tions with various arthroplasties.
Results: Per our analysis of inpatient population, arthroplasty proce-
dures in general were found to be more frequent among females.
As shown by overall analyses on the sex/race‐stratified discharges
associated with various arthroplasties, Dislocation and
Periprosthetic Fracture were more prevalent among females, while
Periprosthetic Osteolysis and Wear were more prevalent among
males. Race/ethnicity had additional, mostly independent, modifying
effects, e.g., risk increases for Periprosthetic Osteolysis and Articular
Bearing Surface Wear among White males with different
arthroplasties, or for Mechanical Loosening among Black Males with
Knee arthroplasty.
Conclusions: Epidemiologic evidence on various arthroplasties
strongly suggests that arthroplasty‐related adverse outcomes share
similar sex/race‐related modifying effects, suggesting possible role of
genetic background and other patient‐related factors, regardless of
device type. Further studies on the sex/race‐stratified subpopulations
are expected to elucidate the underlying genetic and non‐genetic
causes and thereby benefit development of health care measures
addressing the outcome heterogeneity and health disparities in the
growing population of patients with arthroplasties.
309 | Surgical stapler malfunctions: A
systematic review of the literature
Ilynn Bulatao1; Brian Man2; George Gibeily1; Nilsa Loyo‐Berrios1;
Dongyi (Tony) Du1
1Food and Drug Administration, Silver Spring, MD; 2University of
Pittsburgh, Pittsburgh, PA
Background: Surgical staplers are complex medical devices that
have been on the market for decades. They are used in sur-
gery for resection or transection of organs, and for
anastomoses.
Objectives: This systematic review was conducted to describe the
occurrence of surgical stapler malfunctions, describe the types of
malfunctions, and identify the consequences associated with surgical
stapler malfunctions reported in the literature.
Methods: The PubMed and EMBASE electronic databases were
searched from the dates of surgical stapler inception to 30 May
2018 using terms related to surgical stapler malfunction. The search
was limited to English language, and human only papers, and we
excluded conference abstracts. Eligible studies included clinical trials,
observational studies, systematic reviews and case reports. The search
yielded 378 unique records after removing duplicates. Of these, 49
articles were retained after screening titles and abstracts, and
underwent full‐text review. 40 articles were retained for data
extraction.
Results: Surgical procedures performed were open, laparoscopic or
robotic surgeries involving the kidneys, lungs, liver, or gastrointesti-
nal system. Surgical stapler malfunctions were reported in 0% to
19.2% (median, 1.8%) of surgeries involving surgical staplers and
0.1% to 5.2% of stapler deployments. In surveys of surgeons
conducting surgeries with surgical staplers, up to 73% reported per-
sonal experience of, and 86% reported knowing of, someone
experiencing stapler misfire or malfunction during surgery. The most
common device malfunctions were malformed staples or staple line,
and missing staples. Most of the studies did not report the conse-
quences of malfunction, or only reported that the intraoperative
complications produced by stapler malfunction were managed by
repeated stapling or with suturing (uneventful outcomes). In studies
reporting complications arising from stapler malfunction, bleeding
and conversion to open surgery/altering of surgical plan were the
most reported consequences. Laparoscopic surgeries sustaining sta-
pler technical failures had higher likelihood of conversion to open
surgery, higher odds of transfusion and higher odds of death and
morbidity, compared to surgeries with no stapler failure. Variability
in reported frequencies of malfunctions may be due to the difficulty
of determining if this is due to surgeon experience or error, or due
to technical failure.
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Conclusions: The results of the systematic review indicate that surgi-
cal stapler malfunction may not be uncommon and may produce
adverse outcomes such as conversion to open surgery, bleeding, and
morbidity.
310 | Safety and effectiveness of
intrauterine devices: Gynecological history
and sexual behaviour of study participants
from the European active surveillance study
on LCS12
Christine Hagemann; Anja Bauerfeind; Klaas Heinemann
ZEG ‐ Berlin Center of Epidemiology and Health Research, Berlin,
Germany
Background: Intrauterine contraceptive methods, such as Mirena and
CU‐IUDs, have a high contraceptive efficacy. LCS12 (Jaydess) is a
new IUS containing Levonorgestrel, with lower initital release rates
per day compared to Mirena (14 μg vs. 20 μg). LCS12 is indicated
for contraception for up to 3 years use. Data from routine clinical
practice comparing the contraceptive effectiveness of LCS12, Mirena
and CU‐IUDs is not available so far.
Objectives: The primary outcome of the “European Active Surveil-
lance Study on LCS12” (EURAS‐LCS12) study is contraceptive failure
in users of LCS12, Mirena or any CU‐IUD. Secondary outcomes are
risk of ectopic pregnancies, pelvic inflammatory disease (PID), and
uterine perforation.
Methods: Large, prospective, controlled, non‐interventional, long‐term
cohort study with active surveillance of approximately 48,000 study
participants in ten European countries (Austria, Czech Republic, Fin-
land, France, Germany, UK, Poland, Spain, Italy, and Sweden). Women
are enrolled by health care providers and complete a questionnaire
including questions on their socio‐economic status and individual sex-
ual behavior. Patients receive 5 follow‐up quest'res within 3 years. All
patient‐reported outcomes of interest are validated with the treating
physician.
Results: Until end of August 2018, 46,242 women were enrolled by
the prescribing HCPs, thereof 5,239 (11%) LCS12 users, 23,461
(51%) Mirena users and 15,097 (33%) CU‐IUD users. LCS12 users
were considerably younger than users of other IUDs (mean age
26.9 years vs. 36.2 years in Mirena and 30.8 years in CU‐IUD users).
65% of LCS12 users were nulliparous compared to 11% of Mirena
and 25% of CU‐IUD users. Overall, 10% of study participants were
breastfeeding at time of insertion: 10% of Jaydess users, 9% of Mirena
and 13% of CU‐IUD users. Participants were asked for the number of
sexual partners in the 12 months preceding the IUD insertion: 74% of
LCS12 users had one partner, compared with 87% of Mirena and 80%
of CU‐IUD users; and 20% of LCS12 users had 2–5 partners, com-
pared with 7% and 15% in Mirena and CU‐IUD users, respectively.
Of those participants with a new partner in the 12 months before
the IUD insertion, 60% of LCS12, 37% of Mirena and 56% of CU‐
IUD users used a condom.
Conclusions: In the EURAS‐LCS12 study, the three user cohorts show
substantial differences regarding age and gynecological history, as well
as showing large differences between the countries. Further sensitiv-
ity analysis, including the influence of associated factors, will be done
after recruitment is completed.
311 | Accuracy of molecular diagnostic tests
for drug‐resistant tuberculosis detection in
China: A systematic review
Yixin Sun1; Le Gao1; Hui Xia2; Zhirong Yang3; Yanlin Zhao2;
Shitong Huan4; Siyan Zhan1
1Department of Epidemiology and Biostatistics, Peking University School
of Public Health, Beijing, China; 2National Center for Tuberculosis Control
and Prevention, Chinese Center for Disease Control and Prevention,
Beijing, China; 3Primary Care Unit, University of Cambridge, Cambridge,
UK; 4Bill and Melinda Gates Foundation, Beijing Office, Beijing, China
Background: To face the major challenge in the management of drug‐
resistant tuberculosis (TB) across the world, molecular diagnostic tests
have been recommended as a rapid and effective way to detect pat-
terns of drug resistance, which is critical to promote proper treat-
ments, improve patient outcomes, and reduce further spread.
Objectives: This systematic review evaluated the accuracy of molecu-
lar diagnostics for the detection of drug‐resistant TB in Chinese
patients.
Methods: Three English databases (EMBASE, PUBMED, and the
Cochrane Library) and four Chinese databases (CNKI, SinoMed,
WanFang, and VIP) were searched for eligible studies that evaluated
the accuracy of molecular diagnostics against drug susceptibility test-
ing (DST) for detecting drug resistance in Chinese TB patients. Two
researchers independently screened the literature according to the
inclusion and exclusion criteria, extracted data and assessed the qual-
ity of each study with QUADAS‐2. A bivariate random‐effects meta‐
analysis was conducted to pool sensitivity and specificity by index test
and drug‐resistance type.
Results: A total of 159 studies were included, focusing on four molec-
ular tests: Xpert assay, Line Probe assay (LPA), Genechip assay, and
MeltPro assay. Comparing with DST reference standard, Xpert can
diagnose rifampicin‐resistant TB accurately, with a pooled sensitivity
and specificity of 92% (90%, 94%) and 98% (97%, 98%), respectively.
LPA also performed well for rifampicin resistance, with a pooled sen-
sitivity of 91% (88%, 93%) and specificity of 98% (96%, 99%), but
not for isoniazid and second‐line drugs due to lower sensitivity (under
80%). The pooled sensitivities of Genechip for rifampicin, isoniazid,
and multidrug resistance were 89% (86%, 91%), 79% (75%, 82%),
and 79% (73%, 84%), respectively, and the specificities were all above
97%. Similarly, MeltPro had better sensitivity and specificity for first‐
line drugs, varying from 87% to 89% and 97% to 98%, respectively,
than for second‐line drugs.
Conclusions: The Xpert assay, LPA, Genechip assay, and MeltPro
assay are credible methods with high accuracy for rifampicin
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resistance detection, but they may not be appropriate for other anti‐
TB drugs due to low sensitivity. Since discordance still exists between
phenotypic DST and molecular diagnostics, we recommend molecular
assays as an early guide for TB treatment until DST results can be
administered.
312 | Comparing detection of medical device
recalls using quality control and
disproportionality analyses methods of
spontaneous complaint reports
Gary Chung; Amer Ghanem; Paul Coplan
Johnson & Johnson, New Brunswick, NJ
Background: Device spontaneous report data sources include FDA's
adverse event database (MAUDE), complaints, and recently, the Inter-
national Medical Device Database (IMDD). Evidence from higher qual-
ity data sources can take months or yea rs and are often costly,
therefore structured contemporaneous assessment of spontaneous
reports is a necessary component of proactive surveillance. However,
current literature on signal detection in spontaneous reports for
devices is sparse.
Objectives: We compared statistical trending methods from
pharmacovigilance and manufacturing quality control on recalled
devices across two groups by indicated use (per IMDD) by examining
corresponding spontaneous reports (per MAUDE). We measured time
to detection of a signal and false positive/negative rates.
Methods: We searched the IMDD device roster (Dec 19 2018) for
classifications and cross‐referenced against MAUDE (2009‐’18) using
fuzzy keyword matching. Two IMDD classifications, “Dental” and
“Neurological”, were selected with 380 reports across two devices
and 29,682 reports across 4 devices, respectively. Known signal
periods were identified using IMDD recall dates and compared
against prior time periods. Non‐signal periods were also assessed
as negative controls. Analysis assumes continuous monthly review.
Statistical algorithms assessed include 3 quality control (QC) algo-
rithms, x‐bar chart, CUSUM, SPRT, and 3 disproportionality (DPA)
algorithms, PRR, GPS, and BCPNN. Two counting methods were
considered. Analysis was in R 3.5.2 using the mds and mdsstat
packages.
Results: A total of 6 and 16 analyses (combination of signal periods
and counting methods) were assessed for each algorithm for dental
and neurological, respectively. In dental, where the data are low vol-
ume (0 to 10 events per month) and just one comparable device exists,
DPA algorithms had lower sensitivity but higher specificity. QC algo-
rithms had higher sensitivity but lower specificity. In neurological,
where the data are higher volume (20 to hundreds per month) with
3 comparable devices, the opposite was true where DPA algorithms
had high sensitivity/low specificity while QC had low sensitivity/high
specificity.
Conclusions: This study reviews tradeoffs of trending algorithms used
in medical device surveillance in spontaneous reports. Algorithm
performance is highly dependent on available comparable devices,
time under surveillance, parameters, data quantity and quality. Due
to these complexities, care is needed when selecting appropriate
trending methodologies for a given context.
313 | Physician adjudication of angioedema
in patients with heart failure on angiotensin‐
converting enzyme inhibitor therapy
Eric S. Johnson1; Micah L. Thorp1; Alan S. Go2; Mingsum S. Lee3;
Albert Y.J. Shen3; Ken J. Park1; Katarzyna Budzynska4;
Abraham Markin4; Sue H. Sung2; Jamie H. Thompson1; Xiuhai Yang1;
Jaejin An5; Kristi Reynolds5; Douglas W. Roblin6;
Andrea E. Cassidy‐Bushrow7; Raymond Schlienger8; Sigrid Behr8;
David H. Smith1
1Kaiser Permanente, Portland, OR; 2Kaiser Permanente, Oakland, CA;
3Kaiser Permanente, Los Angeles, CA; 4Henry Ford Hospital, Detroit, MI;
5Kaiser Permanente, Pasadena, CA; 6Kaiser Permanente, Rockville, MD;
7Henry Ford Health System, Detroit, MI; 8Novartis Pharma AG, Basel,
Switzerland
Background: Angioedema, a potentially fatal adverse event of angio-
tensin‐converting enzyme inhibitor (ACEI) therapy, occurs more often
in patients with heart failure. Cohort studies conducted with
healthcare databases can identify possible angioedema events during
ACEI therapy using International Classification of Diseases (ICD) diag-
nosis codes. Few studies have undertaken physician adjudication of
events to confirm angioedema and estimate the positive predictive
value (PPV) of diagnosis codes.
Objectives: Our objective was to calculate the PPV of ICD‐9 and 10
diagnosis codes for angioedema according to physicians' confirmation
of events after reviewing the text of health records.
Methods: We included patients from five health plans in the United
States (US) that contribute to the Cardiovascular Research Network
(CVRN): Kaiser Permanente (KP) Northern California, KP Southern Cali-
fornia, KPNorthwest,KPMid‐Atlantic States and theHenryFordHealth
System. We assembled a cohort of patients with heart failure based on
diagnostic criteria. We identified incident users of ACEIs between July
2006andDecember 2017.We followedpatients until the first diagnosis
of angioedema or censoring: (1) discontinuation of ACEI therapy; (2) ini-
tiation of a different renin‐angiotensin‐aldosterone system (RAAS)
blocking therapy; (3) completion of 365 days of ACEI therapy; (4)
disenrollment from the health plan; (5) death; or, (6) end of the study on
December 31, 2017. We identified angioedema using ICD‐9 code
995.1 (Angioneurotic edema not elsewhere classified) or ICD‐10 codes
in the T78.3 series (Angioneurotic edema). Physicians reviewed coded
angioedema events against the text of the electronic health record. To
confirm a diagnosis, we required the documentation of signs or symp-
toms consistent with angioedema (e.g., facial swelling). We calculated
the PPV as the number of confirmed events divided by all events with a
diagnosis code. When an event could not be confirmed because of
incomplete documentation, we classed the event as unconfirmed.
ABSTRACTS 155
Results: We observed 141 possible angioedema events in 45,483
patients (26,039 patient‐years). Physicians confirmed 119 events.
Twenty‐two events were not confirmed, including 13 events with
incomplete documentation. The PPV was 0.84 (95% confidence inter-
val, 0.78 to 0.90).
Conclusions: The PPV of an ICD‐9 or 10 code for angioedema was
high. Our cohort's PPV is consistent with a previous US cohort
study‐‐conducted 20 years earlier‐‐of patients on ACEI therapy, which
adjudicated events with similar clinical criteria.
314 | Validity of low birth weight and small
for gestational age in the Medicaid analytic
extract database
Xi Wang1; Joshua Brown1; Hong Xiao1; Ellen M. Zimmermann2;
Almut G. Winterstein1
1College of Pharmacy, University of Florida, Gainesville, FL; 2College of
Medicine, University of Florida, Gainesville, FL
Background: The accuracy of low birth weight (LBW) and small for
gestational age (SGA) in administrative healthcare records is critical
for perinatal pharmacoepidemiology studies, however, data on the
validity of these diagnoses is scarce.
Objectives: To assess the validity of LBW and SGA diagnoses in the
Medicaid Analytic eXtract (MAX) database.
Methods: Using 1999–2010 MAX linked to birth certificates (BC) in
Florida (FL), Texas (TX), and New Jersey (NJ), we identified live births
where mothers and infants were enrolled ≥30 days from birth in Med-
icaid. We included linked deliveries with both valid gestational age
(GA) and birth weight (BW) on the BC. We identified deliveries with
LBW based on presence of an in‐ or outpatient encounter for mother
or infant in the first 30 days after delivery and grouped them based on
ICD‐9‐CM into: < 500 grams, 500–999, 1000–1499, 1500–1999,
2000–2500 grams. The same approach was used to obtain SGA
(ICD‐9‐CM codes 656.5, 656.51, 656.53, 764.0x, 764.1x, 764.9x).
We considered GA and BW on BC as the gold standard and flagged
infants with BW below the 10th percentile of the U.S. reference for
a given GA week as SGA. We calculated the sensitivity (SE), specificity
(SP), and positive/negative predictive value (PPV/NPV) of MAX‐based
LBW groups and SGA and stratified by gender for evaluating the per-
formance of SGA diagnosis code.
Results: We identified 1,533,881 live births, including 548,741 in FL,
972,027 in TX, and 13,113 in NJ. All five LBW groups had low SEs
(<60%), high SPs (>99.0%) and NPVs (>99.0%), whereas PPVs varied.
Infants with BW 2000–2500 grams had the highest PPV (92.1%,
95% CI 91.9%–92.4%), followed by 1500–1999 grams (87.5%,
87.0%–88.0%), 500–999 grams (38.7%, 37.7%–39.80%), 1000–
1499 (34.6%, 33.9%–35.4%), and < 500 grams (5.5%, 4.8%–6.3%).
Among 53,216 deliveries with SGA diagnoses determined based
GA/BW from the BC, SE of the SGA ICD‐9‐CM codes was 16.3%;
SP was 99.1%; PPV was 77.3% (76.9%, 77.6%); NPV was 86.3%
(86.2%, 86.3%). PPV of the SGA diagnosis code was 82.5% (82.1%,
83.0%) for male infants, and was 69.6% (69.0%, 70.2%) for females.
Conclusions: Identification of LBW and SGA infants using ICD‐9‐CM
code from administrative healthcare records had low SE but high SP
and NPV. PPVs may be acceptable for LBW infants greater than
1500 grams and SGA.
315 | Validity of diagnosis‐based case
definitions for chronic kidney disease in a
Japanese database
Tomomi Kimura1; Robert Snijder2
1Astellas Pharma Inc., Tokyo, Japan; 2Astellas Pharma Europe BV, Leiden,
Netherlands
Background: Chronic Kidney Disease (CKD) is a silent condition with
no specific treatment. The CKD stage can be determined by estimated
Glomerular Filtration Rate (eGFR), derived from serum creatinine (SCr)
values, but the laboratory test results are usually limited in administra-
tive databases. Therefore, it is challenging to identify CKD patients in
administrative databases.
Objectives: To assess the validity of diagnosis‐based case definitions
for CKD in a Japanese claims database.
Methods: An insurance claims database linked to annual health
checkup data were used. All subjects aged 18–74 years old with >1
valid SCr values in 2015–2016 were extracted. CKD stage was deter-
mined based on the eGFR value derived from two consecutive SCr
values at least 3 months apart. Patients on dialysis or post‐kidney
transplantation were excluded. The usage pattern of pre‐specified,
CKD‐related Japan‐specific standardized diagnosis codes during 1 year
of follow‐up period were reviewed and some were combined. Then,
the diagnosis codes (individual or combined) that were used for >5%
of patients in at least one of the CKD stages were selected. Sensitivity
and positive predictive value (PPV) to identify CKD stage G3a or
above, G3b or above, G4 or G5 and G5 were estimated against
eGFR‐defined CKD.
Results: In total, 452,818 subjects in CKD stage 1 or 2 and 16,779
patients in stage G3a or above were identified. Median age was
45 years and 71.1% were male. 95% (14,992/15,776) of stage
G3a patients did not have any of the pre‐specified CKD‐related
diagnosis codes while 73.3% (110/150) and 95.9% (47/49) of stage
G4 and G5, respectively, had one or more of the pre‐specified diag-
nosis codes. The most frequently used diagnosis codes were
“chronic renal failure”, “CKD”, and “diabetic nephropathy”. In stage
G4 and G5, “CKD stage 4”, “CKD stage 5” and “End Stage Renal
Failure” were also used. Case definition using any of the pre‐spec-
ified CKD‐related diagnosis codes resulted in sensitivity of 7.1%,
41.0%, and 78.9% and PPV of 26.5%, 9.1%, and 3.5% to distinguish
CKD stage G3a or above, G3b or above and G4 or G5 from all the
other subjects, respectively. For stage G5, “End Stage Renal Failure”
gave 42.9% sensitivity and 72.4% PPV while combination of “End
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Stage Renal Failure” or “CKD Stage 5” gave 51.0% sensitivity and
69.4% PPV.
Conclusions: Identification of CKD patients using diagnosis‐based
case definitions did not result in high sensitivity and PPV in this
setting. Subjects aged >75 years and females were under‐repre-
sented and the results may not be generalizable. eGFR‐based defi-
nition would be preferable to investigate CKD patients in this
database.
316 | Development of computable
phenotypes to identify heart failure patients
with preserved ejection fraction
Sarah S. Cohen1; Veronique L. Roger2; Susan A. Weston2;
Ruoxiang Jiang2; Naimisha Movva3; Akeem Yusuf4;
Alanna M. Chamberlain2
1EpidStrategies, Cary, NC; 2Mayo Clinic, Rochester, MN; 3EpidStrategies,
Rockville, MD; 4Amgen, Inc., Thousand Oaks, CA
Background: Patients with heart failure (HF) with preserved ejection
fraction (HFpEF) currently have limited therapy options. A better
understanding of the HFpEF population is needed to develop targeted
treatments. Research using claims databases is often conducted to
characterize demographics and prevalence of conditions as well as to
assess market need and uptake of treatments, but careful identifica-
tion of the condition of interest is needed and is often limited by data
availability in claims databases.
Objectives: To develop and validate computable phenotypes for
HFpEF using data elements available in claims databases in a cohort
of Framingham criteria‐validated HF patients as the gold standard.
Methods: Using resources from the Rochester Epidemiology Project
(REP), this retrospective study utilized an existing cohort of Olmsted
County, Minnesota residents meeting the Framingham criteria for
HF. Adults aged ≥20 years diagnosed with HF between January
2007 and December 2015 with an available measure of left ventricu-
lar ejection fraction (LVEF) were included. The gold standard definition
of HFpEF included meeting the validated Framingham criteria for HF
and having a LVEF ≥50%. Computable phenotypes of claims‐type
data elements in the REP (including ICD9 and ICD10 diagnostic codes
and lab test codes) both individually and in combinations were
assessed in terms of sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) with respect to the gold
standard.
Results: 2,035 Olmsted County residents had Framingham‐validated
HF with 1,172 (58%) meeting the gold standard definition for HFpEF
(LVEF ≥50%). One in‐patient or two out‐patient diagnosis codes of
ICD9 428.3X or ICD10 I50.3X had 46% sensitivity, 88% specificity,
84% PPV, and 54% NPV. The addition of 1 BNP/NT‐proBNP lab test
code reduced sensitivity to 32% while increasing specificity to 91%
(PPV = 84%, NPV = 50%). Broadening the diagnostic codes to ICD9
428.0, 428.3X and 428.9 or ICD10 I50.3X and I50.9 increased the
sensitivity at the expense of decreasing specificity (diagnostic code‐
only model: 87% sensitivity, 8% specificity, 56% PPV, 30% NPV; diag-
nostic code and BNP model: 54% sensitivity, 51% specificity, 60%
PPV, 45% NPV).
Conclusions: Measures widely available in claims databases have
potential for identifying the subset of HF patients with preserved
ejection fraction. Although prone to some misclassification, we identi-
fied computable phenotypes that may be used in commercially avail-
able claims databases to gain a deeper understanding of the
characteristics of the HFpEF population.
317 | Validity of claims‐based algorithms to
identify acute kidney injury, acute liver injury,
severe complications of urinary tract
infections, breast cancer, and bladder cancer
among patients with type 2 diabetes: A pilot
study
Cindy Ke Zhou1; Jade Dinh1; Heather E. Danysh2;
Catherine Johannes2; Lia Gutierrez2; Rita Schmid3; Alejandro Arana2;
James A. Kaye2; Manel Pladevall‐Vila2; Xabier Garcia‐Albeniz2;
Kelsey Gangemi1; Ruihua Yin1; Javier Cid Ruzafa4; Alicia Gilsenan2;
Daniel C. Beachler1
1HealthCore, Inc, Wilmington, DE; 2RTI Health Solutions, Research
Triangle Park, NC; 3South Bend Clinic, Granger, IN; 4Evidera/PPD,
Barcelona, Spain
Background: The validity of coding algorithms using diagnostic and/or
procedural codes to identify acute kidney injury (AKI), acute liver
injury (ALI), severe complications of urinary tract infections (UTI),
breast cancer or bladder cancer is not well studied.
Objectives: To estimate the positive predictive value (PPV) of the cod-
ing algorithm for each outcome in a pilot validation study among
patients with type 2 diabetes newly initiating anti‐diabetic drugs dur-
ing 2014–2017.
Methods: We identified provisional cases for each outcome using pre‐
defined coding algorithms in the HealthCore Integrated Research
Database (HIRD). Among provisional cases, we randomly sampled
250 patients hospitalized for AKI, 96 hospitalized for ALI, and 250
who visited the emergency department or had an inpatient hospitali-
zation for severe complications of UTI (i.e., pyelonephritis or
urosepsis). We also sampled patients with at least two diagnoses
within 60 days apart during outpatient, inpatient, or physician office
visits for invasive female breast cancer (n = 100) or invasive/in situ
bladder cancer (n = 20). Two clinicians blinded to information on study
drugs, independently reviewed available medical records and adjudi-
cated the case status according to pre‐defined clinical criteria. When
there was disagreement, final case status was decided by a committee
with a third reviewer. PPVs and 95% confidence intervals (CI) of the
coding algorithms were estimated.
Results: Among 125 AKI, 45 ALI, and 125 UTI provisional cases
reviewed, 48 AKI, 19 ALI, 71 UTI cases were confirmed. After review,
39 AKI, 10 ALI, and 28 UTI cases remained provisional due to
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insufficient information in selected medical records. Restricting to
confirmed cases and non‐cases yielded corresponding PPVs of 56%
(95%CI, 45%, 66%) for AKI, 54% (95%CI, 38%, 71%) for ALI, and
73% (95%CI, 64%, 82%) for UTI. Among 50 breast and 12 bladder can-
cer provisional cases reviewed, 41 breast and 9 bladder cancers were
confirmed. Restricting to confirmed cases and non‐cases yielded cor-
responding PPVs of 84% (95%CI, 73%, 94%) for breast and 90%
(95%CI, 71%, 100%) for bladder cancer after respectively excluding
one breast and two bladder cancer provisional cases without sufficient
information for adjudication.
Conclusions: This pilot study suggests that our coding algorithms have
high PPVs to capture breast and bladder cancer cases, but lower PPVs
for AKI, ALI and severe complications of UTI. Further evaluation of the
algorithms for acute outcomes is needed.
318 | Standardizing EMR lab data for
improved safety surveillance
Irene Cosmatos; Jamie Reifsnyder; Michael Bulgrien; Rich Murray
United BioSource, Blue Bell, PA
Background: The clinical details in electronic medical record (EMR)
data are increasingly critical for active safety surveillance of marketed
drugs. Many of FDA's Sentinel queries were unsuccessful because
claims data were ‘insufficient’ due to lack of laboratory results.
Objectives: Our objective was to standardize laboratory data from US
and non‐US EMR databases into a common structure to enable active
safety surveillance analyses to be conducted and compared across
data sources that do not use a standardized coding system, such as
Logical Observation Identifiers Names and Codes (LOINC).
Methods: UBC developed an approach to transform source data into a
cohesive and accurate database of lab results based on standardized
units and test names, while minimizing loss of data. Steps included 1)
performing an algorithmic search using keywords from the FDA's Sen-
tinel test definitions to select appropriate lab names; 2) review and
acceptance by UBC European and US clinicians of test names, test
specimen type, and units; and 3) verification of unit matching or con-
version of units to a single valid unit for each test type. The initial
effort focused on 3 liver function tests (LFTs) that are important for
safety assessment: alanine aminotransferase (ALT), aspartate amino-
transferase (AST), and Total Bilirubin. Three EMR databases were
included: 2 US and 1 EU.
Results: Across the three databases, the algorithmic search discovered
107 unique test names that represented LFTs (Step 1). However,
slightly more than half of these initial matches (62 test names, 58%)
were excluded from the final LFT group based on clinician review (Step
2). Reasons for exclusion included: incorrect initial classification by the
algorithm (26%); test name indicated a different clinical measurement
such as ‘direct bilirubin’ rather than ‘total bilirubin’ (14%); non‐accept-
able specimen type, such as urine vs. blood (13%); or other reasons
(0.9%). The 45 clinically approved LFT names were associated with
149 unique units in the lab results (e.g., Total Bilirubin measured in
mmol/L or mg/dL). After removing test results with units that could
not be matched or converted to the standard (Step 3), our transformed
LFT database contained 260 million records. Importantly, only 1.1% of
the original LFT records could not be included as a valid LFT result.
Conclusions: Diverse and ‘messy’ lab data found in real‐world EMR
databases can be successfully converted into a standardized data
model. However, close clinical scrutiny and unit conversions are criti-
cal to enable efficient and meaningful safety evaluations involving
lab results from multiple databases.
319 | Suitability of administrative claims
databases for bariatric surgery research
Xiaojuan Li; Sengwee Toh
Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA
Background: Claims databases are often considered a suboptimal data
source for obesity research due to the lack of information on body
mass index (BMI). Due to insurance reimbursement requirement, the
validity of BMI‐related diagnoses in claims databases may be sufficient
to permit comparative effectiveness and safety research of bariatric
procedures.
Objectives: To assess the validity of BMI‐related diagnosis codes in
claims data for patients who underwent bariatric surgery.
Methods: We identified a retrospective cohort of patients aged
18+ who had bariatric surgeries using the OptumLabs® Data Ware-
house (2007–2018), which contains linked de‐identified claims and
electronic health record (EHR) data. Eligible patients had at least
1 BMI (kg/m2) recorded in the EHR in the 6‐month baseline period
preceding the index procedure. We evaluated the performance of
the BMI‐related ICD‐9‐CM and ICD‐10‐CM diagnosis codes for
two major measures: (1) the presence of a baseline BMI ≥ 35 (an
important cohort selection criterion; classified as a binary variable);
(2) the last baseline BMI prior to surgery (an important baseline
confounder; classified as a categorical variable). We used patients'
BMI in the EHR as the gold standard to estimate the sensitivity,
specificity, positive predictive value (PPV), and negative predictive
value (NPV) of the BMI‐related diagnosis codes in the claims
database.
Results: Among 4842 eligible patients, 218 (4%) had adjusted gastric
banding, 2314 (48%) Roux‐en‐Y gastric bypass, and 2310 (48%)
sleeve gastrectomy. The population was largely female (74%) with
a mean age of 50 years. BMI‐related codes were present for 4431
(92%) patients and slightly more prevalent in the ICD‐10‐CM than
ICD‐9‐CM coding era (93% vs 91%). Compared to patients with
codes, those without codes were more likely to be male, older and
had a lower BMI. In the subcohort of 4431 patients with codes,
the diagnosis codes for the presence of a baseline BMI ≥ 35 had
a sensitivity 99.5%, specificity 62.0%, PPV 98.2% and NPV 84.9%.
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When classifying the last baseline BMI into broad categories, the
sensitivity of BMI‐related diagnoses codes for underweight
(BMI ≤ 19), normal weight (BMI 20‐ < 25), overweight (BMI
25‐ < 30) and obesity (BMI ≥30) was 100%, 48.9%, 40.4% and
99.8%; the PPV was 71.8%, 79.3%, 74.2% and 99.1%, respectively.
Categorizing using finer BMI categories increased sensitivity to
above 60% for most BMI categories for morbid obesity (e.g. BMI
35‐ < 40, 62.6%; 40‐ < 45, 63.8%).
Conclusions: It is feasible to use claims databases for obesity‐related
research, especially among patients where BMI‐related coding is
required for insurance reimbursement.
320 | Description of bariatric surgery coding
in the UK clinical practice research datalink
and hospital episodes statistics
Theresa Burkard1,2; Marlene Rauch1,2; Susan S. Jick3,4;
Christoph R. Meier1,2,3
1University of Basel, Basel, Switzerland; 2University Hospital Basel, Basel,
Switzerland; 3Boston Collaborative Drug Surveillance Program, Lexington,
MA; 4Boston University School of Public Health, Boston, MA
Background: Bariatric surgical procedures (BS, weight loss surgeries)
are performed in hospital and recorded ambiguously with codes not
separable from surgeries treating gastric cancer/ulcer and pyloric valve
malfunctioning. To date, consistency between BS codes in the UK
Clinical Practice Research Datalink (CPRD) and Hospital Episodes Sta-
tistics (HES) has not been assessed.
Objectives: To assess consistency of BS entries in CPRD and HES.
Methods: We conducted a descriptive study in all patients in UK‐
based CPRD linked to HES (April 1998–March 2017). We estimated
sensitivity, specificity, positive and negative predictive values (PPV/
NPV) of BS codes in the CPRD compared to HES overall and sepa-
rately in patients eligible only from a first obesity entry until occur-
rence of a differential indication for BS (gastric cancer/ulcer, pyloric
valve malfunctioning) or the patient record end (referred to as valid
patients). We considered primary BS codes (potential first‐time sur-
geries) only for sensitivity and PPV estimations and primary and sec-
ondary BS codes (e.g. maintenance) for specificity and NPV
estimations. Furthermore, we described primary BS counts in CPRD
and HES yearly from April to March overall and in valid patients
only.
Results: Among 7,357,007 patients in CPRD‐linked HES, we identified
14,874 BS entries in either CPRD and/or HES. BS entries yielded a
sensitivity and specificity of 33.2% and 99.9%, respectively, and a
PPV and NPV of 52.2% and 99.8%, respectively. Among 1,191,219
valid patients, we identified 5662 BS entries in either CPRD and/or
HES. BS codes yielded a sensitivity and specificity of 71.0% and
99.8%, respectively, and a PPV and NPV of 52.2% and 99.9%, respec-
tively. Yearly primary BS counts plateaued between 1998/99 and
2003/04 at around 180 HES and 250 CPRD entries overall, and at
around 25 entries in both HES and CPRD in valid patients, before
increasing to a peak of 953 HES and 709 CPRD entries overall, and
to 415 HES and 531 CPRD entries in valid patients between 2010
and 2012. Subsequently until 2016/17, BS counts in HES decreased
slightly and in CPRD strongly to 883 and 234 entries overall, and in
valid patients, to 140 HES and 180 CPRD entries.
Conclusions: Restricting the study population to obese patients free
of BS differential indications, compared to the overall population, BS
became less frequently recorded in HES than in the CPRD, sensitivity
of BS doubled to 71% (i.e. 29% of BS entries in HES not referred back
to CPRD), PPV of BS remained at 52% (i.e. 48% of BS entries in the
CPRD not supported by HES) and due to general low BS prevalence,
specificity and NPV remained at almost 100%.
321 | Development and validation of a
predictive model for incident heart failure in
subjects under 65 years old with newly
diagnosed atrial fibrillation
Joel Swerdel1,2,3; Patrick Ryan1,4,3; Elizabeth Marshall2;
George Rhoads2; William Kostis5
1 Janssen Pharmaceuticals, Titusville, NJ; 2Rutgers School of Public
Health, Piscataway, NJ; 3Observational Health Data Sciences and
Informatics (OHDSI), New York, NY; 4Columbia University, New York, NY;
5Rutgers Robert Wood Johnson School of Medicine, Piscataway, NJ
Background: The incidence of both atrial fibrillation (AF) and heart
failure (HF) have been increasing in the US. Negative outcomes includ-
ing stroke, myocardial infarction, and death are experienced at a
higher rate in those with both conditions compared to those with only
one of the conditions. It is important to understand the factors that
make patients with one of the disorders prone to the development
of the other disease.
Objectives: The objective of this study was to use machine learning to
develop a model for predicting the probability of developing any HF,
HF with Reduced (HFrEF) and Preserved (HFpEF) Ejection Fraction
in patients under 65 years old with newly diagnosed AF.
Methods: We used administrative claims data from the Optum© De‐
Identified Clinformatics® Data Mart Database (Optum) and IBM®
MarketScan® Commercial Claims and Encounters Database (CCAE)
datasets from 2000–17. The target populations were subjects under
65 years old with newly diagnosed AF and the outcome populations
were subjects who developed HF at 3–12 months (M) and 12–36 M
after AF. Using regularized logistic regression, we included covariates
for condition occurrence, drug exposure, and clinical observations
and measurements within 365 days of the index date (AF). Internal
validation of the models was performed by applying the model devel-
oped on 75% of the CCAE data to the remaining 25%. External valida-
tion of the models was performed by applying the model developed
on CCAE to Optum.
Results: At 3–12 M after AF, for internal validation the areas under
the Receiver Operating Curves (AUCs) (95% CI) were 0.732 (0.727,
0.737), 0.719 (0.714, 0.724), and 0.760 (0.755, 0.765) for developing
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any HF, HFrEF, HFpEF, respectively, indicating good discrimination.
For external validation, the AUCs (95% CI) were 0.746 (0.742,
0.750), 0.717 (0.713, 0.721), and 0.757 (0.753, 0.761) for developing
any HF, HFrEF, HFpEF, respectively, indicating good external general-
izability. We found similar model performance at 12–36 M. The
models predicted associations with HFrEF development for factors
such as cardiomyopathy, ischemic heart disease, and high‐ceiling
diuretics. The model predicted associations with HFpEF development
for factors such as diabetes, edema, and polyneuropathy.
Conclusions: These models provide a tool to help clinicians develop
a more effective treatment plan for their patients. Patients may be
more likely to adhere to treatment after understanding their per-
sonal risk of HF.
322 | Validity of chemotherapy procedure
codes in the Danish National Patient Registry:
A validation study
Martin Oskar Broe1; Thea Otto Mattsson2; Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Odense University
Hospital, Odense, Denmark
Background: The chemotherapy procedure codes in the Danish
National Patient Registry is used for administrative purposes and is a
potentially valuable resource for pharmacoepidemiological research.
The validity of chemotherapy procedure codes has, however, only
been evaluated in one smaller study.
Objectives: To assess the validity of chemotherapy procedure codes
in the Danish National Patient Registry for patients with colorectal
cancer by estimating the positive predictive value (PPV) and
sensitivity.
Methods: We identified 440 random patients in the Region of South-
ern Denmark with a diagnose of colorectal cancer. All chemotherapy
procedure codes and medical records between May 2016 and May
2018 were obtained. Duplicates on the same calendar day in the Dan-
ish National Patient Registry were excluded. We systematically exam-
ined all patient records and recorded all chemotherapies the patient
received. Using the medical record as the gold standard, we computed
the positive predictive value and sensitivity of chemotherapy proce-
dure codes in the Danish National Patient Registry.
Results: We identified 2830 treatments. The overall PPV was 0.94
(95% CI, 0.93–0.95), and the overall sensitivity was 0.91 (95% CI,
0.90–0.92). Considering single chemotherapy regimens, the PPV of
FOLFOX‐regimen (5‐FU/folinic acid and oxaliplatin) was 0.95, (95%
CI, 0.92–0.97), although oxiplatin was only given in 76.7% of the treat-
ments, while the sensitivity was 0.93 (95% CI, 0.89–0.95). The PPV for
FOLFIRI‐regimen (5‐fluorouracil, leucovorin, and irinotecan) was 0.97,
(95% CI, 0.92–0.99) and the sensitivity was 0.80 (95% CI, 0.73–0.86).
The PPV for bevacizumab was 0.93, (95% CI, 0.86–0.96) and the sen-
sitivity was 0.97 (95% CI, 0.94–0.99). The PPV for cetuximab was
0.98, (95% CI, 0.95–1.00) and the sensitivity was 0.87 (95% CI,
0.82–0.91).
Conclusions: The validity of the chemotherapy procedure codes
recorded in the Danish National Patient Registry is very high,
supporting their use in pharmacoepidemiological studies.
323 | Validation of an algorithm to predict
treatment discontinuation status in electronic
health records
Jessica Davies1; Thibaut Sanglier2; Jinjoo Shim2; Alexa Hibbert3;
Michael D. Taylor4; Ken Carson3
1Roche Products, Ltd, Welwyn Garden City, UK; 2F. Hoffman La Roche,
Basel, Switzerland; 3Flatiron Health, New York, NY; 4Genentech, Inc,
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Background: Treatment duration (TD) may serve as a proxy measure
for treatment tolerability and effectiveness, which can inform the clin-
ical management of patients. Cohorts derived from EHRs provide an
opportunity to understand TD from a broad group of patients and
understand how a treatment is administered in routine clinical prac-
tice. To estimate TD, it is essential to be able to accurately identify
patients that have discontinued therapy at a particular time point. A
patient's treatment end date of a systemic anti‐cancer therapy regi-
men is not readily collected in a structured format in EHRs. To address
this limitation a stepwise algorithmic approach based on data readily
available in the EHR was developed to predict if a patient had
discontinued intravenous treatment.
Objectives: To evaluate the accuracy of predicting treatment discon-
tinuation status in an EHR cohort based on a last treatment adminis-
tration (LTA) algorithm.
Methods: A cohort of 1,000 advanced non‐small cell lung cancer
patients with exposure to at least 1 cycle of a cancer immuno-
therapy (CIT) agent (atezolizumab, nivolumab, or pembrolizumab)
were selected for abstraction. A patient's discontinuation status
was both abstracted from medical notes (gold standard) and pre-
dicted from the LTA algorithm. Briefly, the LTA algorithm defined
a discontinuation or censor on treatment according to the
observed absence of the exposure of interest (without visit inter-
ruption) or the presence of death recorded, within a pre‐defined
observation period (OP) following LTA. The sensitivity (SE), speci-
ficity (SP), positive predictive value (PPV), and negative predictive
value (NPV) of a patient's discontinuation status based on the
LTA algorithm against the gold standard abstracted data were esti-
mated. Sensitivity analyses were conducted that varied the OP
within the LTA algorithm.
Results: 877 patients had confirmed treatment exposure and 68%
were considered to have discontinued treatment based on abstrac-
tion. Validation metrics varied by CIT and OP ranging from 74% to
94%, 42% to 98%, 82% to 99%, 41% to 91% for SE, SP, PPV and
NPV.
Conclusions: The LTA algorithm adequately identified patients that
have discontinued intravenous treatment based on data readily
available in the EHR. OP assumption, follow‐up time and
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discontinuation rate impacts accuracy estimates. Clinical and phar-
macological relevance of the OP should be considered when
applying such an algorithm and should be considered in sensitivity
analyses.
324 | The predictive value of acute
cerebrovascular codes in the BIFAP primary
care database
Elisa Martin‐Merino; Luz María León‐Muñoz;
Arturo Alvarez‐Gutierrez; Mar Martín‐Pérez;
Dolores Montero‐Corominas; Consuelo Huerta
Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid,
Spain
Background: In primary care (PC) databases, operational definitions to
identify cerebrovascular accidents (CVA) are required for observa-
tional research.
Objectives: To estimate the positive predictive value of the CVA type
recorded among initiators of oral anticoagulant drugs (OAC) inThe Pri-
mary Care Database For Pharmacoepidemiological Research (BIFAP) in
Spain.
Methods: In this cohort study, patients in BIFAP aged 18 years were
includedwhen initiatingOAC during 2008–2016. Individuals were then
followed up until a first International Classification of Primary Care
(ICPC) or Diseases (ICD‐9) code for ischaemic stroke (IS), haemorrhagic
stroke (HS), unspecified CVA (uCVA without mention to stroke or tran-
sient) or transient ischaemic attack (TIA), the end of available data,
death, or the study ended. The gold‐standard was the recorded evi-
dence of confirmed CVA in the clinical profiles. Anonymized profiles
were manually reviewed to retrieve recorded evidence for diagnosis
confirmation: including a CVA mentioned as final diagnosis in a dis-
charge letter from hospital, specialist (neurologist, internal, etc.) or
CAT/MRI unit, or as a PC physician's free text comment (including
CVA diagnosed in hospital, as cause of death, or “stroke code” activa-
tion). ‘Possible CVA’ status was assigned when there were only signs
or symptoms recorded, a diagnosis written as doubtful, not clear differ-
ential diagnosis or no additional information available. ‘Discarded CVA’
were past episodes or an alternative diagnosis.
Results: Out of 51023 OAC initiators, 1930 had a recorded CVA,
including 592 IS, 254 HS, 485 UCVA, and 605 TIA [6 patients had
>1 CVA records]. The confirmation was 60.6% of IS, 71.7% of HS,
50.3% of uCVA and 31.4% of TIA, while 34.1%, 24.8%, 40.8% and
67.3% were the respective figures for possible CVA, and 5.2%, 3.5%,
8.9% and 1.3% for discarded CVA, respectively. A quarter of the IS,
HS and uCVA while 39% of TIA did not include additional information
or included only signs or symptoms. The recorded type of CVA was
misclassified in 0.4% of HS, 3.4% of IS and 3.4% of TIA. A final spec-
ified CVA type was mentioned in 34.4% of uCVA. mentioned in
34.4% of uCVA.
Conclusions: In BIFAP, the HS recording had the highest confirmatory
evidence and the lowest misclassification of the CVA type versus
other CVA. Contrarily, TIA had the lowest confirmation proportion
since only signs or symptoms without any stronger evidence to fill
the confirming criteria were available in most of them. This might be
explained by the severity of the event. A third of uCVA records had
further evidence of the ischemic, hemorrhagic or transient nature of
the episode.
325 | Identifying active hepatitis C and
tuberculosis infection cases using United
States medical claims data
Katrina Wilcox Hagberg1; Rebecca Persson1;
Catherine Vasilakis‐Scaramozza1; Susan S. Jick1,2
1Boston Collaborative Drug Surveillance Program (BCDSP), Lexington,
MA; 2Boston University School of Public Health, Boston, MA
Background: New and reactivated hepatitis C (HepC) and tuberculosis
(TB) infections are important outcomes in studies of DMARDs and
biologic drugs to treat psoriasis and psoriatic arthritis (PsA). Active
HepC and TB infections are contraindications for many DMARD and
biologic treatments; thus, patients are screened for these infections
at the time of treatment initiation or change. In US claims data, HepC
and TB diagnostic codes are recorded as the indication for screening
tests without knowledge of active infection status. Furthermore, fol-
lowing an active infection event, diagnostic codes are typically
recorded repeatedly thereafter, regardless of current infection status.
Therefore, it is difficult to distinguish between routine care, an inci-
dent infection, and a new reactivation event in patients with a history
of HepC or TB. Thus, to avoid case misclassification, it is important to
understand claims data recording practices to accurately identify inci-
dent or reactivated HepC and TB infections.
Objectives: To identify new or reactivated HepC and TB infections
among patients with treated psoriasis or PsA using MarketScan claims
data.
Methods: We identified patients with treated psoriasis or PsA
between March 2014 and December 2016. We identified all patients
with at least one HepC or TB diagnosis during follow‐up and then
evaluated the presence, duration, and timing of HepC or TB treatment.
Our final HepC and TB case definitions included patients who
received a diagnostic code and at least 60 days of HepC or TB treat-
ment within 15 days of a diagnosis code. We stratified the results by
HepC and TB history status to evaluate differences in identifying
new versus reactivated infections.
Results: We identified 124,714 patients with treated psoriasis or PsA.
There were 688 patients who received at least 1 HepC diagnostic
code, of which 177 (26.5%) also received a HepC treatment during fol-
low‐up. The final case series consisted of only 141 patients, or 20.5%
of the 688 identified based on the presence of HepC diagnoses alone.
We identified 369 patients who received at least 1 TB diagnostic
code, of which 88 (23.8%) also received a treatment for TB during fol-
low‐up. The final TB cases series consisted of only 56 patients, or
15.2% of the 369 patients identified based on having a TB diagnosis
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alone. The proportion of cases retained in the final case series differed
by prior HepC or TB history status.
Conclusions: This study suggests that when using claims data careful
consideration of timing of HepC and TB diagnoses, receipt of and
duration of treatment, and a patient's infection history is necessary
to minimize case misclassification.
326 | Identification of patients with suicidal
ideation or attempt in electronic health
record data
Monica L. Bertoia1,2; William M. Spalding3; Cynthia M. Bulik4;
Karen S. Yee3; Li Zhou1,2; Hantao Cheng1,2; Nan Liu1,2;
John D. Seeger1,2
1Optum Epidemiology, Boston, MA; 2Optum Epidemiology, Ann Arbor,
MI; 3Takeda, Lexington and Cambridge, MA; 4University of North
Carolina, Chapel Hill, NC
Background: Although International Classification of Diseases, 9th
Revision (ICD‐9) codes for suicidal ideation (SI) and suicide attempt
(SA) exist, these are likely to under‐capture the true number of events.
Natural language processing (NLP) of full text clinical notes may pro-
vide an opportunity to identify missed SI and SA events.
Objectives: To develop and validate SI and SA algorithms using a com-
bination of ICD‐9 codes and NLP data within an electronic health
record (EHR) database.
Methods: In the context of a study of binge‐eating disorder, patients
with SI and SA were identified using NLP of clinical notes within
Optum's EHR database. The NLP created unique fields, including con-
cept (e.g., suicide precautions), note section (e.g., plan), fact type (e.g.,
positive), modifiers (e.g., active), and sentiment (e.g., deny). An algo-
rithm was created using combinations of NLP fields (e.g., active sui-
cidal ideation) to identify SI and SA patients between January 2009
and September 2015. Chronologic sequences of NLP concepts and
modifiers extracted from the clinical notes were reviewed for a sample
of patients at each iteration of the SI and SA algorithms. After the
algorithms had been refined, a sample of de‐identified clinical notes
was sought from 50 patients with SA, many of whom also had SI (total
of 568 clinical notes) and manually reviewed to assess algorithm per-
formance. An emergency medicine physician reviewed the clinical
notes and adjudicated the presence of SI and SA. Adjudication results
led to a final iteration of the algorithms. Adjudication results were also
used to assess performance characteristics: the positive predictive
value (PPV) for each algorithm was calculated as the number of con-
firmed SI/SA patients divided by the total number of algorithm‐identi-
fied SI/SA patients.
Results: A total of 545 (96%) clinical notes were received with at least
one note for each of the 50 patients. The PPVs were 75% (95% CI 43
to 95%) for suicidal ideation and 27% (95% CI 6 to 61%) for suicide
attempt.
Conclusions: Using combinations of SI‐ and SA‐related NLP terms in
an EHR database led to an algorithm for SI identification that was
reasonable in terms of predictive value. However, the SA algorithm
did not perform as well and overestimated the number of SA events.
327 | The recording and incidence of
inflammatory bowel disease in Girls' primary
care medical Records in Spain
Elisa Martin‐Merino1; Javier Molina Infante2; Mar Martín‐Pérez1;
Dolores Montero‐Corominas1
1Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid,
Spain; 2University Hospital of San Pedro de Alcántara, Cáceres, Spain
Background: An implication of the human papillomavirus vaccination
on the development of Inflammatory Bowel Disease (IBD) in girls has
been suggested.
Objectives: To validate the IBD recording in the Spanish Primary Care
Database For Pharmacoepidemiological Research (BIFAP), for evalua-
tion of that association, and estimate the IBD incidence.
Methods:Thecohort studywasmadeof girls aged9–19years registered
in BIFAP in 2002–2016 with at least one year of primary care (PC)
records. The date when those inclusion criteria were met was the start
date to follow‐up to a recorded IBD, 19 years of age or died, endof infor-
mation, or 31/12/2016. IBDwas recorded through International Classi-
fication of Primary Care (ICPC) or Diseases (ICD‐9) codes or free‐text in
specialist referrals fields. Anonymized PC records were reviewed to
retrieve diagnosis confirmation (a positive colonoscopy or biopsy, a spe-
cialist letter or PC physician's free‐text comments mentioning it) or
discarding (negativeprocedureresults, alternativediagnosisor reference
to family history) information. Prescriptions of intestinal anti‐inflamma-
tory agents (aminosalicylic acid, local corticosteroids, azatioprine and
mercaptopurine) and systemic glucocorticoids within 2 years were col-
lected. The IR of IBD per 105 girls‐years was estimated.
Results: Out of 480,634 girls in the study cohort, 323 had a first ever
recorded IBD. Among them, 38.7% (N = 125) ‘confirmed incident’ IBD
cases, 1.5% (N = 5) ‘confirmed at a prevalent date’ and 21.4% (N = 64)
discarded IBD were identified. Information about IBD was missing in
129 patients (39.9%) that we categorized as ‘possible IBD’. Sixty out
of 64 discarded were referrals to specialist either related only to family
history (N = 44) or confirming an alternative diagnosis (N = 9) or neg-
ative IBD results (N = 7). The median age at IBD was 15.2 years. Anti‐
inflammatory agents were prescribed in 89.60% of confirmed incident,
80.0% of prevalent, 3.1% of discarded, and 58.1% of possible IBD, as
was azatioprine in 48.8%, 20.0%, 0.0%, and 27.1% respectively, and
mercaptopurine in 1.6% of discarded and 2.3% of possible IBD. The
IR was 6.74 ‘confirmed incident’ IBD diagnosis increasing up to
13.69 per 105 girls‐years when including ‘possible’ IBD.
Conclusions: A third of the girls with a recording IBD included special-
ist evidence confirming the diagnosis while most of those with missing
evidence, had treatment indicated for IBD. Both recording patterns
may be useful for IBD research in BIFAP. The IR of IBD was higher
than previously published although methodological differences should
be considered.
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328 | Validity of atrial fibrillation in
electronic medical records: A Single
University hospital experience in Japan
Masato Takeuchi; Koji Kawakami
Kyoto University, Kyoto, Japan
Background: Large healthcare databases offer unique research oppor-
tunities in cardiovascular medicine, despite concern regarding the
accuracy of data. The validity of diagnosis of atrial fibrillation (AF) in
healthcare databases was examined in several studies decades earlier,
without reporting the modern risk score for thromboembolism (ie,
CHADS2/CHA2DS2‐VASc scores).
Objectives: To assess the accuracy of diagnosing AF, AF‐related
comorbidity, and CHADS2/CHA2DS2‐VASc scores in an electronic
medical record (EMR) in a single university hospital in Japan.
Methods: Eligible patients were those who received medical services
at Kyoto University Hospital in 2014 at inpatient and/or outpatient
settings. Up to 300 patients were enrolled to create each of the fol-
lowing cohorts: inpatients with AF, those without AF, outpatients with
AF, and those without AF. The accuracy of these diagnoses and scores
in the EMR was calculated using medical chart records as the refer-
ence standard. Metrics were reported as sensitivity, specificity, the
positive predictive value (PPV), and the negative predictive value
(NPV) for diagnosis of AF and its comorbidity, and as correlation coef-
ficient for CHADS2/CHA2DS2‐VASc scores.
Results: The sensitivity, specificity, PPV, and NPV were 97%–99%,
92%–99%, 92%–99%, and 97%–99% for diagnosis of AF, and 73%,
95%, 77%, and 94% for bleeding episodes, respectively. Correlation
statistics were 0.46–0.59 for the CHADS2 score and 0.64–0.73 for
the CHA2DS2‐VASc score.
Conclusions: The diagnosis of AF and AF‐related comorbidity in an
EMR were highly accurate, but correlation for the CHADS2/
CHA2DS2‐VASc score was modest in our setting. Despite a single‐cen-
ter experience, our findings will be helpful to interpret the reliability of
diagnosing AF and related conditions in research using EMRs.
329 | Identification of transfused individuals
in electronic health records and claims
databases utilizing different coding systems
Kinnera Chada1; Graça Dores1; Joyce Obidi1; Joann Gruber1;
Barbee Whitaker1; Emily Storch1; Alan Williams1; Juan M. Banda2;
Saurabh Gombar2; Deepa Balraj2; John Price3; Jarrah Hamer3;
Thomas Falconer4; Karthik Natarajan4; Eldar Allakhverdiiev5;
Sara Dempster6; Nerissa Williams7; Christian Reich6; Azadeh Shoaibi1
1Food and Drug Administration, Silver Spring, MD; 2Stanford University,
Stanford, CA; 3Regenstrief Institute, Indianapolis, IN; 4Columbia
University, New York, NY; 5Odysseus Data Services Inc., Cambridge, MA;
6 IQVIA, Cambridge, MA; 7 IQVIA, Fairfax, VA
Background: The FDA Center for Biologics Evaluation and Research
started the Biologics Effectiveness and Safety Initiative (BEST) in 2017
toenhance itshemovigilance(HV)capability, incollaborationwith IQVIA,
and the Observational Health Data Sciences and Informatics Consor-
tium. Identification of transfused individuals (TI) with blood components
can informHVactivitiesandtransfusionguidelines.Health insurancebill-
ing (administrativeclaims),andelectronichealthrecordsmayproviderich
data sources to support safety monitoring of blood transfusions. In the
United States, billing systems for blood components include the ICD9/
ICD10‐PCS, HCPCS Level I and II, and revenue codes. Currently all US
blood banks and hospitals use the Information Standard for Blood and
Transplant (ISBT128), a standardized global coding systemfor identifica-
tion and labeling of human origin medical products.
Objectives: Assess and compare the capability of billing and ISBT128
coding systems to identify recipients of blood components.
Methods: A TI is defined as a person receiving at least one blood com-
ponent (RBC, platelet, plasma) regardless of the unit number, in a
specified year using billing codes or ISBT128 codes. TI were identified
using billing and ISBT128 codes categorized to identify red blood cells
(RBC), platelets, and plasma. We used billing and ISBT128 data from
three data sites of the BEST: Columbia University, Stanford University,
and Regenstrief Institute. The Observational Medical Outcomes Part-
nership Common Data Model standardized vocabulary version 5.0.1
was used to identify TI during the period January 1, 2010 to Decem-
ber 31, 2017.
Results: We were able to identify TI with specific blood components
using both billing and ISBT128 codes. The number of TI identified using
the ISBT128codes remainedrelatively stableover timeafterAABBstan-
dardization to ISBT128 in 2012–2013, irrespective of the component or
site. For platelet and plasma exposures, TI reflected in billing codes
matched those from ISBT128codes for limitedperiodsof timeat a single
data site, but formostobservationyears at each site, billing codesgreatly
under‐estimated TI (compared to ISBT128) by a varying range. The vari-
ation in number of identified TI across the sites is more prominent using
the billing codes compared to ISBT codes.
Conclusions: Overall, billing codes underestimated the number of TI
compared to ISBT128 codes regardless of component type although
the estimates varied across sites. The ISBT128 coding system is a better
means for HV activities and captures a larger proportion of transfusions.
330 | Systematic review of algorithms used
for identifying acute myocardial infarction,
ischemic heart disease and stroke in Italian
administrative healthcare databases
Giulia Hyeraci1; Andrea Spini2; Rosa Gini1; Claudia Bartolini1;
Ersilia Lucenteforte3; Giovanni Corrao4; Federico Rea4;
Giuseppe Roberto1
1Agenzia Regionale di Sanità Toscana, Florence, Italy; 2Università degli
Studi di Siena, Siena, Italy; 3Università di Pisa, Pisa, Italy; 4National
Centre for Healthcare Research & Pharmacoepidemiology, Milan, Italy
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Background: Acute myocardial infarction (AMI), ischemic heart dis-
eases (IHD) and stroke are serious and potentially fatal cardiovas-
cular diseases (CVDs) which may lead to hospitalizations, require
periodical medical monitoring and life‐long drugs use, thus having
an high impact on both public health and Healthcare Service
expenditure. In this contest, Italian administrative databases (IAD),
which routinely collect patient‐level information on healthcare ser-
vices reimbursed by the National Healthcare Service, are increas-
ingly used for identifying and monitoring the occurrence of these
CVDs.
Objectives: To identify and describe case‐finding algorithms used in
the past 10 years for the identification of AMI, IHD and stroke in
IAD.
Methods: A systematic literature review was performed. PubMed
database was searched to retrieve all articles published between
2007 and 2017 describing algorithms used for the identification of
AMI, IHD and stroke in IAD. The 1st part of the search string was dis-
ease‐specific, while the 2nd concerned the use of IAD. Among all per-
tinent papers, data were extracted only from papers describing
algorithms used to identify: i)disease occurrence, ii)disease‐based
cohorts,iii)outcomes.
Results: A total of 17 original algorithms for AMI, 5 for IHD and 27 for
stroke were found. Moreover, we identified 3 algorithms for ST eleva-
tion myocardial infarction, 3 for Non‐ST elevation myocardial infarc-
tion, 8 for ischemic stroke and 3 for hemorrhagic stroke. Hospital
discharge diagnoses (HDD) were used in all algorithms. For each of
the three CVDs, a difference of ≥1 ICD9CM code was always
observed across different algorithms. In few cases, diagnoses from
co‐payment exemption registry, drug prescriptions (DP) and death cer-
tificates (DC) were used as additional algorithm components. External
validation was performed only in one case: primary HDD of AMI
(ICD9CM code 410) was reported to have a positive predictive value
between 86% and 52.7%, according to diagnostic criteria used as the
gold standard.
Conclusions: HDD represent the main source of data for the iden-
tification of AMI, IHD and stroke in IAD. However, a remarkable
heterogeneity, in terms of both data sources and codes used, was
observed across algorithms aimed to identify the same event and
for the same objective. This was likely due to the lack of evidence
on algorithms' validity. Finally, although DC,emergency room
records, DP and exemption from co‐payment can be leveraged to
refine AMI,IHD and stroke identification,these data sources are still
underutilized.
331 | Validation of major cardiovascular
events in a multi‐database post‐authorization
safety study of Prucalopride
Miguel Cainzos‐Achirica1; Ana Ruigómez2; Thomas M. MacDonald3;
Luis García‐Rodríguez2; Joan Fortuny1; Robert W.V. Flynn3;
Estel Plana1; Ryan Ziemiecki4; Elizabeth B. Andrews4; Alicia Gilsenan4
1RTI Health Solutions, Barcelona, Spain; 2Centro Español de Investigación
Farmacoepidemiológica, Madrid, Spain; 3University of Dundee, Dundee,
UK; 4RTI Health Solutions, Research Triangle Park, NC
Background: A post‐authorization safety study (PASS) was conducted
to assess the cardiovascular safety of prucalopride, comparing the
occurrence of major adverse cardiovascular events (MACE, a compos-
ite of hospitalization for acute myocardial infarction [AMI], hospitaliza-
tion for stroke, and in‐hospital cardiovascular death) among initiators
of prucalopride and among a matched comparator cohort. The study
was conducted in five data sources from three European member
states: the United Kingdom (UK), Germany and Sweden.
Objectives: To report the validation process of MACE endpoints con-
ducted for the prucalopride multi‐database PASS in the UK data
sources: Clinical Practice Research Datalink (CPRD), the Health
Improvement Network (THIN), and the Information Services Division
(ISD) Scotland.
Methods: Potential MACE events were identified using an automated
algorithm based on previous studies. Validation was conducted per the
common validation plan, which included (1) direct confirmation via link-
age to hospital records (CPRD only); (2) requests for additional clinical
information through questionnaires (CPRD), free text (THIN), or original
hospital case records (ISD); (3) patient profile review by study investiga-
tors (CPRD/THIN) to rule out non‐cases; and (4) event adjudication by
three clinicians, all blinded to exposure, for all potential endpoints not
previously confirmed or determined as non‐case. Cases were assigned
final status of definite, probable, possible, or non‐cases.
Results: The electronic algorithms identified 260 potential MACE
events, of which 38 cases were considered confirmed via linkage to
hospital records (CPRD only), 91 were considered non‐cases after pro-
file review (CPRD and THIN), and 13 were not available for adjudica-
tion (THIN and ISD). Of the remaining 118 potential cases, 62 were
adjudicated as definite, 10 adjudicated as probable, 13 as possible,
and 33 as non‐cases. The general practitioner questionnaire response
rate in CPRD was 79%, free text was available for all potential cases
from THIN, and all but three requested hospital case records from
ISD were retrieved. This was the first observational study in Scotland
in which access to hospital case records was granted.
Conclusions: A common validation protocol, with local adaptations
based on the types of clinical information available in each data
source, allowed for the validation of MACE endpoints in the
prucalopride multi‐database PASS in three UK data sources.
332 | How accurate are ICD‐10 codes in
identifying cases of syphilis?
Yenling A. Ho1; Saurabh Rahurkar2; Janet N. Arno3,4; Jane Wang2;
Andrea A. Broyles2; Brian E. Dixon1,2
1 Indiana University Richard M. Fairbanks School of Public Health,
Indianapolis, IN; 2Regenstrief Institute, Indianapolis, IN; 3 Indiana
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Background: International Classification of Diseases (ICD) codes are
used to identify cases of syphilis in administrative claims. To date, no
study has validated the use ICD codes for syphilis identification.
Objectives: To examine the validity of ICD‐10 codes for identifying
cases of syphilis.
Methods: We constructed a retrospective cohort of patients between
10/1/2015 and 12/31/2016 using the Indiana Network for Patient
Care (INPC), the nation's oldest and most comprehensive community
health information exchange. Included patients were between 13 and
44 years old and received either ICD‐10 diagnosis for syphilis (A51.x,
A52.x and A53.x) or laboratory testing for syphilis. For validation, the
INPC was queried to obtain a list of all medical record numbers and
dates of ICD diagnosis and laboratory test results for all potential cases.
If a case hadmultiple syphilis ICD diagnoses, only the first was assessed.
ICD results were evaluated by comparing to syphilis laboratory tests
within 60 days of the ICD diagnosis date. Each case was categorized
as one of the following: true positive (TP), ICD diagnosis of syphilis
and positive syphilis test; false positive (FP), syphilis ICD code and no
positive syphilis test; false negative (FN), no syphilis ICD code and a pos-
itive syphilis test; and true negative (TN), no syphilis ICD code and a neg-
ative syphilis test. Validity of ICD diagnoses were measured by
calculating sensitivity and positive predictive value.
Results: A total of 31,787 patients received either an ICD diagnosis or
were tested for syphilis. Of the 31,787 patients, 87 were TP, 56 FP,
616 FN, and 31,028 wereTN. Among the cases with an ICD diagnosis,
31.5% had no testing, 60.8% tested positive for syphilis, and 7.8%
tested negative for syphilis. Positive predictive value (PPV) was found
to be 60.8% (95% CI: 60.7%–61.0%) and sensitivity was 12.4% (95%
CI: 12.3%–12.4%).
Conclusions: ICD codes are not recommended to identify cases of
syphilis in administrative claims. This study, using a population‐based
cohort, demonstrated low PPV and utilization of syphilis ICD codes.
Possible reasons for the low PPV and sensitivity could be clinicians
diagnosing patients solely on symptoms or delaying diagnosing
patients until laboratory test results are available without updating
the electronic health record.
333 | Validation of a complex algorithm for
the diagnosis of metastatic castration‐
resistant prostate cancer within a claims
database
Nicolas Thurin1,2,3; Magali Rouyer1; Marine Gross‐Goupil3;
Michel Soulié4; Sylvestre Le Moulec5; Ludovic De Beaucoudrey6;
Stéphanie Lamarque1; Emmanuelle Bignon1; Jeremy Jové1;
Cécile Droz‐Perroteau1; Nicholas Moore1,2,3; Patrick Blin1
1Bordeaux PharmacoEpi, CIC1401, Université de Bordeaux, Bordeaux,
France; 2 INSERM U1219, Bordeaux, France; 3CHU de Bordeaux,
Bordeaux, France; 4CHU deToulouse, Toulouse, France; 5Clinique Marzet,
Pau, France; 6 Janssen, Issy les Moulineaux, France
Background: An algorithm was developed in the French nationwide
claims database (SNDS) to identify cases of metastatic castration‐
resistant prostate cancer (mCRPC). The usual way to validate such
an algorithm is reviewing patients' medical charts. An alternative
within a irreversible pseudonymised database is to use all healthcare
use information to identify diagnosis and/or treatment of prostate
cancer, then resistant and metastatic stage.
Objectives: To assess and validate mCRPC algorithm using the wealth
of data available in SNDS.
Methods: 100 of 14 050 mCRPC patients identified by the algorithm
and 100 of 372 273 non‐mCRPC patients were randomly selected
within SNDS. The 6‐year medical history of each of these 200 patients
was reconstituted (Long term disease registration [LTD], drug dispens-
ings, procedure codes, hospitalizations, lab tests). These 200 cases
were randomly divided into 2 groups of 100 cases. Two groups of
independent experts including an urologist and an oncologist each
adjudicated blindly the mCRPC status of 100 cases. In case of dis-
agreement within a pair of experts, the 4 experts collegially assessed
the case. Positive (PPV) and negative (NPV) predictive values of the
algorithm were calculated.
Results: 92 out of 100 mCRPC cases and 93 out of 100 non‐mCRPC
cases were concordant between the experts and the algorithm,
resulting in an algorithm PPV of 0.92 and a NPV of 0.93.
Conclusions: Thewealth of data available in the SNDSmakes it possible
to implement algorithms to detect complex diseases, and to validate
them via the reconstitution of medical history. The present results show
goodperformanceof thealgorithmfor the identificationofmCRPCinthe
SNDS. In addition, the validation study detected some parameters that
could be used to optimize the algorithm's performance.
334 | A validation exercise: Identifying
hospitalizations for heart failure among
patients with COPD in the CPRD
Nuria Saigi‐Morgui1; Cristina Rebordosa1; Christine Bui2;
Jaume Aguado1; Estel Plana1; Javier Nuevo3; Sami Z. Daoud4;
Alejhandra Lei5; Susana Perez‐Gutthann1; Elena Rivero‐Ferrer1
1RTI Health Solutions, Barcelona, Spain; 2RTI Health Solutions, RTP, NC;
3Global Medical Affairs, AstraZeneca, Madrid, Spain; 4Global Clinical
Lead, AstraZeneca, Gaithersburg, MD; 5Patient Safety RIA, AstraZeneca,
Barcelona, Spain
Background: The validity of algorithms to identify hospitalizations for
heart failure (HF) among patients with chronic obstructive pulmonary
disease (COPD) in the Clinical Practice Research Datalink (CPRD) in
the United Kingdom has not been described.
Objectives: To validate potential cases (including deaths) of hospitali-
zation for HF in patients with COPD in the CPRD.
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Methods: Hospitalizations for HF in a cohort of new users of selected
COPD medications (September 2012–June 2017) were identified
electronically through: (1) primary and secondary discharge diagnosis
for HF in the Hospital Episode Statistics (HES), (2) HF recorded as
cause of death in the Office for National Statistics (ONS) and a code
for hospitalization within 30 days before in the CPRD General Practi-
tioner Online Database (GOLD), and (3) HF diagnosis and a record for
hospitalization within 30 days in the CPRD‐GOLD when linkage to
HES/ONS was not available. A questionnaire (Qx) was sent to the gen-
eral practitioners (GPs) to confirm diagnosis. For cases with conflicting
information from Qx, adjudication was performed through manual
clinical review of the patient profiles. The positive predictive value
(PPV) was calculated as an indicator of the validity of HF diagnosis.
Results: There were 2,283 potential HF cases identified in 51,319
individuals with COPD aged ≥40 years. A Qx was sent to the GPs
for 1,176 potential HF cases identified from active practices. The
response rate was 69.7%. Among the Qx received, 656 Qx (55.8%)
included evaluable information. Of these 656 potential cases, 434
were confirmed (PPV = 66.2%). The cases confirmed were 97 of 102
cases (PPV = 95.1%) identified through HES primary discharge diagno-
sis, 168 of 350 cases (PPV = 48.0%) identified through HES secondary
discharge diagnoses, and 169 of 204 cases (PPV = 82.8%) identified
through CPRD GOLD diagnosis code and a hospitalization code. PPVs
were similar among patients with or without prior history of hospital-
ization for HF.
Conclusions: Among patients with COPD, the algorithms used to iden-
tify hospitalizations for HF through HES primary discharge diagnosis
and through GOLD HF diagnosis and hospitalization codes had a high
PPV. The algorithm that identified cases through secondary discharge
diagnosis had a lower PPV but contributed to a high proportion of the
total cases confirmed.
335 | Psychotropic co‐medication in Dutch
children and adolescents using psycho‐
stimulants; a prescription sequence symmetry
analysis
Alexis M.A. Blaauwhof; Eelko Hak; Jens H.J. Bos;
Catharina C.M. Schuiling‐Veninga
University of Groningen, Groningen, Netherlands
Background: Psychiatric side effects like anxiety, depression, psy-
chotic symptoms and hallucinations are frequently reported after the
initiation of psycho‐stimulant treatment. However, co‐morbidities
present in ADHD children include behavioral disorders, anxiety,
autism, bipolar, depression and sleeping problems, making it difficult
to disentangle possible side‐effects from these co‐morbidities.
Objectives: Assess a possible association between the initiation of
psycho‐stimulants and psychiatric side‐effects in children and
adolescents.
Methods:We performed a symmetry analysis, with a study period from
January 1, 2008 to December 31, 2017, using the IADB.nl prescription
database. We included all children and adolescents (<20 years) who
received a first prescription of both a psycho‐stimulant and another
psychotropic drug within 12 months (not on same date). A sequence
ratio, adjusted for prescribing time trends, was calculated.
Results: In total, 3462 patients (mean age 14.0 years; 69% male) were
incident users of both psycho‐stimulants and other psychotropic med-
ications with 12 months: 2451 received first a prescription for a psy-
cho‐stimulant whereas 1011 were first prescribed another
psychotropic drug. The adjusted sequence ratio (ASR) was 1.45
(95%CI: 1.05–1.84) for all psycho‐stimulants and all groups of psycho-
tropic medications together. When stratifying the data, no increased
ratios were obtained between initiating methylphenidate and psycho-
tropic medications whereas significant increased ratios were found
between the initiation of atomoxetine and antidepressants (ASR = 1,62
CI95% (1.20–2,04)), hypnotic and sedative drugs (ASR = 1,42, CI95%
(1,03‐1,81)) and antipsychotic drugs (ASR = 1,81, CI95% (1.37–2.26)).
Conclusions: We found an association between the initiation of psy-
cho‐stimulant treatment and the risk of being prescribed other psy-
chotropic medications. Stratified analyses suggest that this
association may especially exist between initiation of atomoxetine
treatment and antidepressants and antipsychotics, whereas the risk
of psychiatric side effects in patients initiating methylphenidate treat-
ment seems not to be increased.
336 | Utilization of neuromuscular blocking
agents and their reversal agents among
children: A Cerner database study
Wenjun Zhong1; Sarah Liu1; Lori Bash2; Carol Koro1
1Merck, North Wales, PA; 2Merck, Rahway, NJ
Background: Sugammadex (BRIDION) was approved by the US FDA
in December 2015 for the reversal of neuromuscular block (NMB)
induced by rocuronium and vecuronium in adults undergoing surgery
and approved for use in both adults and children in the EU in 2008.
Sugammadex use in children has been reported in the US, but to what
extent is not clear.
Objectives: Describe the utilization pattern of NMB agents
(rocuronium and vecuronium) and factors associated with the use of
reversal agents (neostigmine and sugammadex) in US hospitalized
children.
Methods: Cross‐sectional study of pediatric hospital stays including
exposure to rocuronium/vecuronium between 2015 and 2017 within
the Cerner database, a hospital‐based EMR database across 600 facil-
ities in US. Logistic regression estimated factors associated with the
use of sugammadex vs neostigmine.
Results: A total of 21,845 pediatric hospital stays were exposed to
rocuronium (76%), vecuronium (18%), or both (6%). Among them,
43% were girls; 48% white; 33% 0–1 year and 38% 12–17 years. In
this population, 32% received neostigmine for reversal in 2015 (before
sugammadex approval); in 2017 28% received neostigmine and 8%
received sugammadex. A total of 642 children received sugammadex
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in 2016–2017. Compared to neostigmine users (n = 3862),
sugammadex users tend to be older (mean age: 13 vs 11 years), more
likely to be in teaching hospitals (80% vs 70%), with longer stays
(2017, IQR was (1, 4) vs (1, 3) days). Appendicitis was the most com-
mon primary diagnosis for both sugammadex (11%) and neostigmine
(14%) users, though primary diagnoses were largely missing (23%
and 43% among sugammadex and neostigmine, respectively). Multi-
variable logistic regression (including calendar year, patient demo-
graphics, hospital status, admission source, and the use of
vecuronium vs rocuronium) suggested that children who were older
(age 12–17 years vs 0–1 year: OR 1.96, 95% CI 1.36–2.83), Hispanic
or Latino (OR 2.03, 95% CI 1.55–2.67), in teaching hospitals (OR
1.26, 95% CI 1.00–1.59), or admitted through emergency departments
(OR 1.65, 95% CI 1.06–2.58) were more likely to receive sugammadex
than neostigmine.
Conclusions: In Cerner 2015–2017, among children rocuronium was
more commonly used than vecuronium, and sugammadex use was
observed since 2016. Sugammadex and neostigmine users varied by
demographic, clinical, and site level characteristics. Limitations of the
database should be noted, specifically limited participating hospitals,
a substantial amount of missing data, and observations may not be
generalizable to pediatric populations not included in Cerner.
337 | Temporal trends in opioid prescription
dispensing among commercially insured
children and adolescents undergoing
outpatient surgery in the United States,
2000–2015
Shahar Shmuel1; Virginia Pate1; Jennifer L. Lund1; Marisa A. Ryan2
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2 Johns Hopkins University School of
Medicine, Baltimore, MD
Background: Children who undergo invasive surgical procedures in
the outpatient setting are often prescribed post‐operative opioids
for pain management to be administered by a caregiver. As these
patients are not monitored post‐operatively in a clinical setting, they
are at an increased risk of opioid‐related adverse events that are not
readily caught and addressed by healthcare professionals.
Objectives: We sought to describe temporal patterns of opioid pre-
scription dispensing among children and adolescents undergoing out-
patient surgeries in the United States (US) using a large, national
sample of privately insured individuals and their dependents with
fee‐for‐service plans.
Methods: Using IBM's MarketScan Commercial Claims and Encoun-
ters Database (2000–2015), we estimated annual proportions and
95% confidence intervals (CIs) of pediatric outpatient surgeries that
had an associated short‐acting opioid prescription claim. Results
were stratified by age, sex, geographic region, body system, and
whether the opioid was codeine. Changes in annual proportions of
each opioid type (e.g., codeine, dihydrocodeine, hydrocodone,
fentanyl, hydromorphone, meperidine, morphine, oxycodone,
oxymorphone, pentacozine, propoxyphene, tapentadol, and tramadol)
were examined. Using weight from the CDC growth chart, we
explored changes in dosing (based on weight‐adjusted morphine
equivalents).
Results: We identified 16,366,646 unique outpatient pediatric sur-
geries from 2000–2015, of which 7.6% (n = 1,241,956) had an asso-
ciated short‐acting opioid prescription claim. Compared to surgeries
without an associated opioid claim, those with an associated opioid
claim were more common among individuals who were 12–17 years
old, male, and resided in the US South. There was an overall decline
in the annual proportion of outpatient pediatric surgeries with an
associated opioid prescription claim (from 0.095 (95% CI: 0.093,
0.097) in 2000 to 0.057 (95% CI: 0.057, 0.058) in 2015). Over the
study period, we observed that non‐codeine opioid dispensing
stayed fairly stable, while codeine dispensing declined. As the rela-
tive proportion of codeine declined, those of hydrocodone, oxyco-
done, and tramadol increased.
Conclusions: Given the known risks associated with opioid use in chil-
dren, the decline in surgery‐associated opioid claims is reassuring;
however, continued monitoring of opioid trends is needed. Our results
suggest that safe opioid use education targeted at healthcare profes-
sionals treating certain subpopulations could have greater impact.
338 | Psychotropic prevalence among a US
commercially‐insured youth: 2007–2015
Kyungwan Hong; O'. Mareen Spence; Susan dos Reis
University of Maryland, Baltimore, MD
Background: The prevalence of psychotropic use among youth in the
US started to rise in the early 2000s. This led to concerns about over-
use of certain therapeutic classes (i.e., antipsychotics) and use in some
patient subgroups (i.e., very young). Research on psychotropic preva-
lence among commercially insured youth is limited and warrants inves-
tigation to better understand the distribution of psychotropic use in
this population.
Objectives: The goal of this study was to establish the prevalence of
psychotropic use among commercially insured youth in the US.
Methods: The IQVIA™ PharMetrics Plus adjudicated claims data-
base was used to estimate the annual (2007–2015) cross‐sectional
population prevalence of six psychotropic classes. The psychotropic
classes were: stimulants, antidepressants, antipsychotics, anxiolytics,
mood stabilizers, and sedatives. We identified all individuals
≤18 years with at least one month of prescription coverage in each
study year. Psychotropic class use was defined as at least one dis-
pensing of the six psychotropic classes during the year. We esti-
mated the overall and class‐specific population prevalence for the
entire sample and stratified by gender and age group (<5; 5–9;
10–14; 15–18). Generalized estimating equations (GEE) were used
to assess significant changes in prevalence, comparing 2015 to
2007.
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Results: Overall psychotropic prevalence significantly increased by
0.06% per year from 5% in 2007 to 7% in 2015. Compared with
2007, the odds of psychotropic class use increased: 45%
(95%CI = 1.42–1.48) for stimulants, 94% (95%CI = 1.90–1.99) for
antidepressants, 23% (95%CI = 1.19–1.28) for antipsychotics, 29%
(95%CI = 1.26–1.32) for anxiolytics, and 14% (95%CI = 1.09–1.19)
for mood stabilizers in 2015. Overall psychotropic prevalence
increased in 2015 compared to 2007 in both genders (female:
OR = 1.43; 95%CI = 1.40–1.45 and male: OR = 1.72; 95%CI = 1.69–
1.75). Relative to 2007, the odds of overall psychotropic use in 2015
decreased by 15% (OR = 0.85; 95% CI = 0.80–0.90) among those
aged <5 years. Significant increases were observed in all other age
groups; 5–9 (OR = 1.39; 95%CI = 1.34–1.44), 10–14 (OR = 1.36;
95%CI = 1.34–1.39), and 15–18 (OR = 1.58; 95%CI = 1.54–1.60).
The observed increases were largely due to significant increases in
stimulants and antidepressants use among those aged 5–9 and stim-
ulants, antidepressants, antipsychotics, and anxiolytics use among
those aged 10–14 and 15–18.
Conclusions: Psychotropic use in commercially‐insured youth demon-
strated growth in most therapeutic classes, with the exception of
youth aged <5.
339 | Cough and cold medicine
recommendations for children in the United
States, 2002–2015
Daniel B. Horton1; Tobias Gerhard1; Brian L. Strom2
1Rutgers University, New Brunswick, NJ; 2Rutgers University, Newark, NJ
Background: In 2008 the Food and Drug Administration (FDA) recom-
mended that children under age 2 not use over‐the‐counter (OTC)
cough and cold medicines (CCM) given concerns about efficacy and
safety. Manufacturers also voluntarily re‐labeled CCM for children
≥4, and the American Academy of Pediatrics recommended avoiding
CCM in children <6. Subsequent studies through 2010 showed equiv-
ocal impact on CCM use.
Objectives: To study trends in physicians' recommendations for tradi-
tional CCM and, for comparison, antihistamines in the US pediatric
population.
Methods: We used the National Ambulatory Medical Care Surveys
(2002–2015) and National Hospital Ambulatory Medical Care Surveys
(2002–2015, outpatient/emergency department), US‐representative
surveys of office‐ and hospital‐based ambulatory settings, respec-
tively. The study sample consisted of all visits for children <18. We
measured all visits with recommendations for traditional CCM (drugs
containing antitussives, decongestants, or expectorants), sub‐classified
by the presence of opioid ingredients (codeine or hydrocodone). We
included codeine monotherapy for visits for respiratory diagnoses.
Separately, we studied single‐agent antihistamines for acute respira-
tory infections. To compare age‐specific trends before and after the
advisory, we conducted logistic regression with a 3‐way interaction
between elapsed time ([survey year‐2002]/14), era (2002–2008 vs.
2009–2015), and age group. Analyses were adjusted for sex, insur-
ance, race/ethnicity, clinical setting, and region, incorporating visit
weights, clustering, and strata for the complex survey design.
Results: In a sample representing 3.1 billion pediatric visits over
14 years, US physicians ordered approximately 95.7 million CCM, of
which 12.0% (95% CI 10.0%, 14.3%) contained opioids. During the
study period, recommendations for opioid‐containing and non‐opioid
CCM declined substantially, while recommendations for antihista-
mines rose. After 2008, compared to older children (adjusted odds
ratio [aOR] 0.7–1.3), the trend in recommendations for non‐opioid
CCM appeared to decline more strongly among children <2 (aOR
0.3, 95% CI 0.1, 1.01), and among children <6 for opioid‐containing
CCM (aOR 0.1). In contrast, the trend in recommendations for antihis-
tamines increased in all age groups after 2008.
Conclusions: Physicians' recommendations for traditional CCM have
steadily declined in the US since 2002. These declines seemed to
accelerate in young children after the FDA's 2008 public health advi-
sory, with possible replacement by increasing recommendations for
off‐label antihistamines.
340 | Pediatric antibiotic use: A Nationwide
observational study
Githa Fungie Galistiani1; Maria Matuz1; Balazs Babarczy2;
Renata Papp3,4; Agnes Hajdu2; Szabolcs Szigeti5; Laszlo Korosi6;
Ria Benko1
1University of Szeged, Szeged, Hungary; 2National Public Health Center,
Budapest, Hungary; 3National Healthcare Services Center, Budapest,
Hungary; 4University of Pécs, Pécs, Hungary; 5World Health Organization
Country Office, Budapest, Hungary; 6National Health Insurance Fund,
Budapest, Hungary
Background: Antimicrobial resistance (AMR) is a major public health
concern worldwide. One of the key strategies to contain AMR is the
prudent use of antimicrobials. The burden of infectious diseases in
childhood is substantial with consequent frequent antibiotic prescrib-
ing. The scale and pattern of pediatric antibiotic use has been found
suboptimal previously. To plan targeted interventions, a more in‐depth
analysis is needed.
Objectives: To describe antibiotic use among children in relation to
prescribers' age and seasonality.
Methods: Systemic antibiotics (ATC: J01) prescribed at ambulatory
visits in 2017 were retrieved from the database of the National Health
Insurance Fund. Data were stratified by age‐groups (patient and pre-
scriber) and gender (patients). Analysis was focused on children aged
0–19 years. Prescribers were categorized into 3 age groups (<40 yrs,
40–65 yrs, >65 yrs). Antibiotic use was expressed as number of pre-
scriptions and standardized as number of prescriptions per 100 chil-
dren inhabitant per year and per month. Population data were
derived from Eurostat. For quality assessment, the proportion of nar-
row‐spectrum (N) beta‐lactams and macrolides, as defined by the
European Centre for Disease Prevention and Control, was calculated.
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Results: In total, approximately 6.8 million antibiotic prescriptions
were redeemed at pharmacies in 2017. Almost one‐third of these pre-
scriptions were issued for children, in majority (66%) by doctors aged
40–64 yrs. 108.3 antibiotic prescriptions per 100 children per year
was issued. Co‐amoxiclav (J01CR02) was the most frequently pre-
scribed antibiotic for children, however its relative proportion differed
greatly by age‐group of prescribers (<40 yrs: 41.3%, 40–65 yrs: 31.0%,
>65 yrs: 27.5%). Younger doctors tended to prescribe less narrow‐
spectrum antibiotics than older doctors (N% <40 yrs: 2.6%, N% 40–
65 yrs: 3.5%, N% >65 yrs: 5.8%). Antibiotic prescribing peaked in Jan-
uary with 16.6 prescriptions per 100 children per month, while lowest
use was detected in July (4 prescriptions per 100 children per month).
No patient gender differences were observed in the seasonality
pattern.
Conclusions: Antibiotic prescription patterns differ by prescribers' age
group. Our results may suggest that interventions should primarily
focus on middle‐aged and young prescribers as they issue most pre-
scriptions and tend to prescribe less narrow‐spectrum agents.
341 | Drug‐induced hearing disorders in
children
Adrien Gainville1; Vanessa Rousseau1; Florentia Kaguelidou2;
Leila Chebane1; Jean‐Louis Montastruc1; Geneviève Durrieu1
1Faculty of Medicine, Toulouse, France; 2Robert Debré Hospital, Paris,
France
Background: Around 34 million children worldwide have disabling
hearing loss. Damage to the auditory system limits quality of life of
patients, leading to serious consequences especially for psychosocial
development of children. It can have a negative impact on communica-
tion, with significant vocational, educational and social consequences.
Drugs is one of the causes of a hearing disorders.
Objectives: The objective of our study was to characterize drug‐
induced hearing disorders in a pediatric population.
Methods: Reports of Adverse Drug Reactions (ADR) registered under
the MedDRA term “hearing disorders” until December 2018 in pediat-
ric population (< 18 years).were extracted from the French
PharmacoVigilance Database (FPVD). We performed a retrospective
and descriptive analysis of ADR reports. Characteristics of patients
(age, gender, medical history), characteristics of ADRs (Lowest Level
Term = LLT MedDRA term of ototoxic adverse reactions, seriousness)
and “suspected drugs” (ATC classification system 2nd and 5th levels)
were analyzed.
Results: A total of 68 ADR reports were identified, involving adoles-
cents (n = 34, 5%), children (n = 29, 42.6%) and infant (n = 5, 7.3%).
Overall, 38 notifications (55.9%) involved girls. A total of 51 reports
(75%) were “serious” (n = 51). The most frequent hearing disorders
(LLT MedDRA term) were: deafness (n = 31, 45.6%), hypoacusis
(n = 20, 29.4%), bilateral deafness (n = 6, 8.8%), auditory disorders
(n = 4, 5.9%), and vertigo (n = 4, 5.9%). The most involved ATC 2nd
level were antibacterials for systemic use (n = 30, 29.4%),
antineoplastic agents (n = 25, 20.6%), vaccines (n = 12, 16.2%), analge-
sics (n = 3, 4.4%), antiepileptics (n = 3, 4.4%), corticosteroids for sys-
temic use (n = 3, 4.4%) and immunosuppressants (n = 3, 4.4%).
Suspected drugs (ATC 5th level) were: amikacin (n = 10, 14.7%), cis-
platin (n = 8, 11.8%), doxorubicin (n = 4, 5.9%), vincristine (n = 4,
5.9%), ceftriaxone (n = 3, 4.4%), clarithromycin (n = 3, 4.4%), isotreti-
noin (n = 3, 4.4%), MMR vaccine (n = 3, 4.4%), and vancomycin
(n = 3, 4.4%).
Conclusions: This study shows that 75% of drug‐induced hearing
disorders in pediatric population were “serious”, deafness being the
most frequent ADR reported. As expected, the most frequently
suspected drugs were antibacterials for systemic use (amikacin,
clarithromycin) and antineoplastic agents (cisplatin, vincristine).
Moreover, if it is difficult to conclude for doxorubicine, ceftriaxone
and MMR vaccine due to an association with an ototoxic drug or
known hearing loss risk factors. More interestingly, this review sug-
gests that ototoxicity of vancomycin and isotretinoin needs further
research.
342 | Prescribing patterns of antiasthma
medication in children and adolescents in
primary Care in France
Isabelle Naiim1; Florence Tubach2; Sylvie Guillo2; Aya Ajrouche2;
Veronique Houdouin1; Yann De Rycke2; Florentia Kaguelidou3
1Department of Pediatric Pneumology, Hôpital Robert Debré, APHP,
Paris, France; 2 INSERM, IPLESP UMR‐S1136, CIC 1421, AP‐HP, Hôpital
Pitié‐Salpêtrière, Département Biostatistique Santé Publique et
Information Médicale, Centre de Pharmacoépidémiologie, Céphépi,
Sorbonne Université, Paris, France; 3Department of Pediatric
Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP;
Université Paris VII Diderot ‐ Pres Sorbonne Paris Cité; INSERM CIC1426,
Paris, France
Background: Little is known about the short and long‐term therapeu-
tic management of asthmatic children.
Objectives: The aim of this study was to assess the prescribing pat-
terns of antiasthma drugs in primary care.
Methods: This is a retrospective cohort study performed between
January 2011 and December 2017 using the EGB (Echantillon
Généraliste de Bénéficiaires) database, a 1/97th sample of the French
national healthcare insurance system. Claims data for all individuals
aged from 5 to 18 years' old who had received at least one antiasthma
drug in the study period without any delivery in the previous
24 months and with 24 months of follow‐up after first delivery, were
analyzed.
Results: A total of 7,680 children and adolescents (68.6% aged 5–11,
31.4% aged 12–18 years) were delivered at least one antiasthma drug
(ATC code R03) during study period. The majority (66%) did not
redeem another prescription in the following year (occasional users),
when 18.4% redeemed prescriptions twice (low users) and 15.6% ≥3
times (high users). Most users (67%) were delivered only one class of
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R03 per dispensing in the first year and short‐acting β2‐agonists was
the most frequently dispensed antiasthma drug class (46% of drugs
dispensed). However, 33.4% of users were not prescribed short‐acting
β2‐agonists and 42% were delivered antibiotics concomitantly to R03
drugs. During the second year, only 27% of first‐year users redeemed
R03 prescriptions: 15.8% among occasional users, 35.5% of low users
and 64.7% of high users. Short‐acting β2‐agonists was still the most
frequently dispensed antiasthma drug class (42.3%) among second‐
year users and only 0.1% of R03 users were prescribed long‐acting
β2‐agonists in monotherapy. However, among low and high first‐year
users who redeemed R03 drugs during the second year, 39.7% did not
use inhaled corticoids alone or in association to long‐acting β2‐
mimetics.
Conclusions: A significant proportion of children and adolescents that
used antiasthmatic drugs, even on a regular basis, did not redeem pre-
scriptions of these drugs in the long term. This finding may correspond
either to the widespread use of antiasthmatic drugs in indications
other than asthma or to an undertreatment of asthmatic children
and adolescents.
343 | Application of Phevaluator for
assessment of pediatric phenotype algorithms
for type 1 diabetes mellitus using diagnostic
predictive modeling in observational claims
databases
Jill Hardin; Rupa Makadia; Joel Swerdel
Janssen Research and Development, Titusville, NJ
Background: This study explores the utility of different phenotype
algorithms (PAs) for identification of subjects ≤18 years of age with
type 1 diabetes mellitus (T1DM) in administrative claims data. All data
in a subject's record, including inpatient/outpatient diagnosis codes,
clinical observations, and prescriptions, were used to inform the diag-
nostic predictive model.
Objectives: To use a tool (PheValuator) to assess seven pediatric PAs
for T1DM.
Methods: We used three administrative claims datasets: Optum©
De‐Identified Clinformatics® Data Mart Database‐ Socio‐Economic
Status (OPTUM); IBM® MarketScan® Multi‐State Medicaid
(MDCD) and Commercial Claims and Encounters (CCAE) from
2010–18. Using PheValuator involves 1) creating a diagnostic pre-
dictive model for T1DM, 2) applying the model to 2 M randomly
selected subjects, and 3) comparing each subject's T1DM predicted
probability to inclusion/exclusion in PAs. Predicted probability is
used as a measure to classify positive/negative cases. Seven PAs
for pediatric T1DM, including ≥1‐time diagnosis (dx) in a hospital
inpatient setting (≥1X‐IP); ≥1‐time dx in a hospital outpatient set-
ting (≥1X‐OP); ≥2 dx in a hospital outpatient setting (≥2X‐OP);
≥1‐time dx and insulin (INS) prescription (≥1X + INS); ≥1‐time dx
and glucagon prescription (≥1X + glucagon); ≥1‐time dx and no
metformin (MET) prescription (≥1X + no MET); ≥1‐time dx and
INS and no MET prescriptions (≥1X + INS + no MET) were
examined.
Results: The PA ≥1X‐OP showed the highest sensitivity (98.2%
(OPTUM), 98.0% (CCAE), 94.1% (MDCD) from all PAs. ≥1X + gluca-
gon had the highest PPVs (98.8% (CCAE), 97.8% (OPTUM), 96.3%
(MDCD)) with lower sensitivities (80.2%, 80.1%, 79.2%). The lowest
sensitivities and PPVs were observed for PA ≥1X + no MET (sen-
sitivity/PPV: 5.8%/77.9% (CCAE), 5.5%/69.6% (OPTUM), 14.9%/
77.1% (MDCD)). The PAs with prescriptions for INS, ≥1X + INS
and ≥ 1X + INS + no MET had higher sensitivities than the PA
≥1X + glucagon (93.4% (CCAE), 94.6% (OPTUM), 88.4% (MDCD)
≥1X + INS; 88.4% (CCAE), 89.7% (OPTUM), 76.5% (MDCD)
(≥1X + INS + no MET) vs. 80.2% (CCAE), 80.1% (OPTUM),
79.2% (MDCD) (≥1X + glucagon). Specificities were high for all
PAs (> 99%).
Conclusions: Using PheValuator we evaluated seven pediatric
PAs for T1DM and determined the ≥1X‐OP PA had the
highest sensitivity and the PA ≥1X + INS + no MET had
the highest PPV. Understanding the performance characteristics
of PAs is critical for improving the accuracy of research using
observational data.
344 | Annual number of pediatric inpatient
orthopedic and neurological surgeries in the
United States using different data sources
Iona Munjal; Jasmina Ivanova; Bing Cai; Birol Emir; Deepa Malhotra
Pfizer, New York, NY
Background: Surgical site infections are associated with significant
morbidity. Reliable baseline epidemiology data is needed to estimate
the population at risk. This study aimed to estimate the number of
pediatric inpatient orthopedic and neurological surgeries in the US
from different data sources, and the percentage of surgeries which
are elective, a potential target population for interventional
strategies.
Objectives: Estimate the annual number of pediatric inpatient
orthopedic and neurological surgeries and percentage of elective
surgeries in the US using de‐identified claims data for commercially
insured (Optum® Clinformatics® Data Mart, OCDM) and Medicaid
insured (Truven MarketScan Multi‐state Medicaid database, MM)
children and compare the estimates of select inpatient surgeries
to weighted national estimates from the HCUP Kids' Inpatient
Database (KID).
Methods: Inpatient orthopedic and neurologic surgeries in 2012
among children ages 0–17 years were identified using ICD‐9‐CM
procedure codes from the OCDM, MM, and KID. The surgery rates
from claims data were calculated as the number of surgeries divided
by the number of children with medical coverage for at least one
month in 2012. To project the number of surgeries in the US, the
rate was multiplied by the number of children in the US in 2012.
Elective surgeries were identified from the OCDM and defined as
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surgeries with elective admission type and where patients were not
transferred from another institution or admitted through the emer-
gency room (admission type/channel not available in MM or KID).
Results: The number of pediatric inpatient orthopedic and neuro-
logic surgeries per 100,000 persons in 2012 was 116 in OCDM
and 130 in MM corresponding respectively to projected 85,365
and 95,595 surgeries in the US. 46% of these surgeries were elec-
tive. The 3 most common sub‐categories with high percentage of
elective surgery were: ortho bone osteotomy (OCDM: 38 surgeries
per 100,000 persons [27,706 surgeries in the US], 65% elective;
MM: 23 [16,956]; KID: 79 discharges per 100,000 [57,996 dis-
charges in the US]); plastic/ortho surgery (OCDM:16 [11,603],
54% elective; MM: 15 [11,304]; KID: 35 [26,113]); and fusion
(OCDM:13 [9,617], 71% elective; MM: 16 [12,014]; KID: 18
[13,049]).
Conclusions: The OCDM and MM databases tended to have similar
surgical rates by sub‐category type but the KID was higher, possibly
due to the survey of discharge codes rather than surgeries. It may be
helpful to use multiple databases to estimate, validate, or verify esti-
mates of pediatric surgeries in order to reliably asses the target
population.
345 | Safety and effectiveness of
piperacillin/Tazobactam (Zosyn®) for
treatment of hospital acquired pneumonia
(HAP): Novel approach to assessment of drug
safety in children
Brian T. Fisher1; Brittany Haltzman‐Cassenti1; Muhammad Younus2;
Margaret Tawadrous2; Jennifer Faerber1; Amy Stein3; Hal Tucker2;
Jesse Blumenstock1; Michele Wible2; Muida Menon1; Kevin Downes1;
Ellen Kratz1; Rasheeda Lawler4; Silke S. Harmeyer5; John Bradley6;
Inci Yildirim7; Laila Hussani7; Andrea Hahn8; Joanna Thomson9;
Jason Newland10; Cindy Terrill10; Philip Zachariah11
1Children's Hospital of Philadelphia, Philadelphia, PA; 2Pfizer Inc,
Collegeville, PA; 3 IQVIA, Austin, TX; 4Children's Hospital of Philadelphia,
Philadelphia, PA; 5Pfizer UK Ltd, Walton Oaks, UK; 6Rady Children's
Hospital, San Diego, CA; 7Emory University, Atlanta, GA; 8Children's
National Health System, Washignton, DC; 9Cincinnati Children's Hospital
Medical Center, Cincinnati, OH; 10St. Louis Children's Hospital, St. Louis,
MO; 11Columbia University Irving Medical Center, New York, NY
Background: US legislation formalized requirements for investigations
to produce pediatric‐specific data on pharmaceutical agents. However,
the reticence to enroll children in prospective studies remains a barrier
to completing studies in a timely manner. Novel approaches are
needed to efficiently and accurately produce pediatric data.
Objectives: This study aimed to assemble a cohort of children with
hospital acquired pneumonia (HAP) to estimate risk of serious
adverse events (SAEs) and assess effectiveness of piperacillin/tazo-
bactam (P/T) compared to other HAP antibiotics (i.e., ticarcillin‐
clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin).
Methods: This was a multicenter retrospective cohort study of
patients treated for the indication of HAP between 2003 and 2016
in 7 US hospitals. Data on medications and diagnosis codes from the
Pediatric Health Information System (PHIS) were screened to identify
possible HAP patients. Subsequent medical chart review was per-
formed to confirm HAP diagnosis, and to determine HAP therapy,
occurrence of SAE, and clinical outcomes. A multivariable Poisson
regression model inclusive of propensity score weights was developed
to compare SAE rates between groups.
Results: Of 1899 admissions with possible HAP identified in PHIS
screening, 407 (21.4%) met study inclusion criteria. 141 patients
were in the P/T group and 266 patients were in the comparator
group. An adjusted comparison showed similar SAE rates between
P/T and comparator group (incidence rate ratio: 0.85, 95% confi-
dence interval [CI]: 0.26, 2.75). A comparable proportion of patients
in both groups were categorized as clinically improved within 14 days
of HAP therapy initiation: 90.78% in P/T and 91.73% in the compar-
ator group. Mortality rates within 30‐days from HAP treatment initi-
ation was 3.6% in P/T and 4.5% in comparator group.
Conclusions: This novel multistep methodology using administrative
and medical record data was successful in efficiently completing a
safety and effectiveness study of P/T in children. SAE rates and clini-
cal outcomes were similar between P/T and comparator group.
346 | Estimating patient age to support EMA
pediatric investigation plans in the UK clinical
practice research database (CPRD)
David J. Webb1; Harriet A. Dickinson1; Rachael Williams2;
John W. Logie1
1GlaxoSmithKline R&D, Uxbridge, UK; 2Clinical Practice Research
Datalink, London, UK
Background: New drug applications to the European Medicines
Agency (EMA) require a Pediatric Investigation Plan (PIP) to describe
the potential for drug exposure in children. Although PIPs expect
reporting in specific age‐classes, including neonates (0–27 days), accu-
rate age classification is often difficult in data sources where the date
of birth (DOB) is redacted for anonymisation. The CPRD offers the
potential to better assess age, as the data contain month of birth for
children aged under 16 years. However, it remains unclear if this level
of detail is sufficient to classify accurately age at first registration date
(FRD) using the EMA mandated age‐classes.
Objectives: To assess the potential of the CPRD to estimate patient
age in children to support EMA Pediatric Instigation Plans, with an
emphasis on neonates.
Methods: A cohort of patients first registered from 2012 to 2017, and
within 1 month of their known month of birth (MOB), was identified.
Estimated DOBs (eDOBs) were derived using all available data for chil-
dren and, where available, their algorithmically linked mothers. Full
details of these methods are not provided on the request of CPRD's
Information Governance Team. The age (in days) at FRD was
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estimated comparing the eDOB with a “default” method calculated
using only the mid‐point of the CPRD‐provided MOB. The number
of patients classified as neonates at FRD using eDOB and the default
DOB is reported. All analyses were based on estimated age and
reported at an aggregate level to protect patient confidentiality. This
is a GSK funded study, approved by the Independent Scientific Advi-
sory Committee, and conducted in collaboration with CPRD's internal
Observational Research Team.
Results: Of 228,868 patients registered within one month of their
known MOB, 88% had information available to generate an eDOB.
The mean absolute difference in age at FRD between the eDOB and
“default” DOB was 7.7 (SD = 4.39) days. The proportion of the cohort
classified as neonates at FRD using eDOB was (73% n = 166,243) vs.
default (68% n = 155,854).
Conclusions: The results suggest important misclassification of neo-
nates when using only the MOB information provided by CPRD. This
has implications for PIPs and other studies of neonates where accu-
rate assessment of age is required. Ethical considerations, and strate-
gies to better assess age in collaboration with ISAC and CPRD's
research team are discussed.
347 | Prevalence and incidence of
antiasthma medication use in children: A
Nationwide prescription study in France
Isabelle Naiim1; Florence Tubach2; Sylvie Guillo2; Aya Ajrouche2;
Veronique Houdouin1; Yann De Rycke2; Florentia Kaguelidou3
1Department of Pediatric Pneumology, Hôpital Robert Debré, APHP,
Paris, France; 2Département Biostatistique Santé Publique et Information
Médicale, Centre de Pharmacoépidémiologie, Céphépi, Sorbonne
Université, INSERM, IPLESP UMR‐S1136, CIC 1421, AP‐HP, Hôpital Pitié‐
Salpêtrière, Paris, France; 3Department of Pediatric Pharmacology and
Pharmacogenetics, Hôpital Robert Debré, APHP; Université Paris VII
Diderot ‐ Pres Sorbonne Paris Cité; INSERM CIC1426, Paris, France
Background: Use of antiasthmatic medications has increased over the
years worldwide.
Objectives: The aim of this study was to describe the pediatric use of
antiasthma drugs in children in France.
Methods: Data were retrieved from the permanent sample (1/97th) of
the French national healthcare database ‐ the Système National des
Données de Santé (SNDS) for all individuals aged from 5 to 18 years
old (n = 143,909) from 1 January 2011 to 31 December 2017. Preva-
lence and incidence rate of antiasthmatic dispensing were calculated.
Volume of use was assessed as total number of prescriptions dis-
pensed. All analyses were stratified by calendar year, age (5–11, 12–
18 years) and gender. Users were classified as occasional if they were
dispensed antiasthmatic drugs only once during the year, low users if
they were dispensed twice and high users if they were dispensed
three or more times in the calendar year.
Results: The annual prevalence of antiasthmatic drug use varied
between 12 (2011) and 11 (2017) per 100 persons and incidence var-
ied between 4.3 (2013) and 3.8 (2017) per 100 PYs. Prevalence and
incidence of use were highest in children aged between 5–11 years
and in boys. In 2017, the most prescribed antiasthmatics were short‐
acting β2‐agonists (41.8% of drugs dispensed) mainly salbutamol,
followed by fixed associations of inhaled corticoids and long‐acting
β2‐agonists (20.9%) mainly salmeterol‐fluticasone, inhaled corticoids
alone (18.6%) mainly fluticasone, and leukotriene antagonists
(17.2%). However, differences were observed in most dispensed drugs
with regards to age groups. Most users were occasional (53%) and
only one third redeemed deliveries on a regular basis (high users:
28%). No trend was observed in the percentages over time or with
regards to gender and age group.
Conclusions: Use of antiasthmatic drugs in France is higher than
previously described in other European countries. Prevalence of
use is also higher than the prevalence of asthma as assessed in epi-
demiological national studies indicating that these drugs are over‐
prescribed.
348 | Pediatric codeine prescriptions in
outpatient and inpatient settings in Korea
Dajeong Kim; Inmyung Song; Dongwon Yoon; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Korea,
Republic of
Background: Codeine has long been used for children as an analgesic
and antitussive agent. Using codeine to children under 12 years is
increasingly being restricted in many countries owing to safety con-
cerns, though it is still widely used.
Objectives: To examine the patterns of prescribing codeine for chil-
dren under 12 years and to identify characteristics associated with
pediatric codeine prescriptions in outpatient and inpatient setting in
Korea.
Methods: A retrospective observational study was conducted to
examine codeine prescriptions and patients' characteristics. We used
the Korea Health Insurance Review and Assessment Service‐
National Patient Sample database. The study participants were
patients who were prescribed codeine as inpatients or outpatients
between 2011 and 2016. The study drugs contained codeine phos-
phate as the only analgesic and antitussive agent and codeine com-
bination products that contain acetaminophen or ibuprofen as an
active ingredient. Pediatric codeine use was defined as codeine pre-
scribed at least once for a child under 12 years old. The frequency
and proportion of pediatric codeine users were analyzed by age
group (0–2, 3–6, 7–11 years), sex, year, region, diagnosis, type of
medical institution, and co‐prescribed medication. Logistic regression
analyses were performed to identify characteristics associated with
pediatric codeine users.
Results: Of all patients younger than 12 years old, 512 816 (55.2%)
and 16 541 (1.7%) were treated with codeine in outpatient and
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inpatient settings, respectively, (p < .0001). The mean age of these
users was 5.6 and 6.3 years, respectively. The most frequent diagno-
ses for pediatric codeine users were acute bronchitis (40.2%) and
acute upper respiratory infection (27.1%) in out‐ and in‐patient set-
tings, respectively. Odds of pediatric codeine prescriptions were
highest for outpatients at general hospitals (adjusted Odds Ratio,
aOR = 7.85; 95% Confidence Interval, CI, 7.20–8.55) and clinics
(aOR = 7.44; 95% CI, 6.84–8.11) and for inpatients at tertiary hospi-
tals (aOR = 4.77; 95% CI, 4.29–5.31) and general hospitals
(aOR = 4.24; 95% CI, 3.81–4.71). The proportion of pediatric
patients treated with codeine showed little change in the temporal
trend. There appears to be seasonality for the proportion of outpa-
tient codeine users.
Conclusions: Codeine was frequently prescribed for children in
Korea compared to the U.S. and the U.K., especially in general hos-
pitals and clinics. Efforts to limit codeine use in children are
required to prevent the occurrence of codeine‐related adverse
events.
349 | Characteristics of pediatric patients
prescribed sertraline: Insights from the
sertraline pediatric registry for the evaluation
of safety
Francesca Kolitsopoulos1; Sara Ramaker2; Scott Compton3;
Samuel Broderick3; John Orazem1; Yuliya Lokhnygina3; Phil Chappell4
1Pfizer, New York, NY; 2Pfizer, Collegeville, NY; 3Duke Clinical Research
Institute, Durham, NC; 4Pfizer, Groton, CT
Background: Sertraline has been used to treat various psychiatric con-
ditions in children and adolescents in clinical practice. It is unknown
whether sertraline users differ from non‐users in baseline disease
characteristics and if long‐term sertraline use impacts pediatric growth
and development.
Objectives: To describe the baseline disease characteristics of patients
enrolled in the Sertraline Pediatric Registry for the Evaluation of
Safety (SPRITES).
Methods: SPRITES is an open‐label, post marketing study of outcomes
in pediatric patients treated with sertraline compared to psychother-
apy (for up to 3 years) in clinical settings in the United States. Patients
were prescribed sertraline at baseline (or within 45 days prior) or psy-
chotherapy. Baseline data included demographics, psychiatric history,
concomitant psychiatric medications. Primary outcomes were: 1) mea-
sures of cognitive and emotional development (Trails B, BRIEF), phys-
ical development (height and weight), and pubertal status. Data were
also collected on present/lifetime risk of suicide‐related events using
the Columbia‐Suicide Severity Rating Scale.
Results: Study enrollment occurred April 2012 to July 2017. SPRITES
enrolled 941 patients between the ages of 6 to 17 years. Patients'
baseline mean age was 11.9 years, 57.2% were female, and 81.2%
were white. Most patients (78.4%) had an anxiety disorder and
15.6% were diagnosed with OCD. Mean age of onset at first mental
illness was 7.91 years, and the most frequently reported family history
of mental illness was depressive and anxiety disorders (63.2%, 60.5%,
respectively). When compared to the no pharmacologic treatment
group, a higher percentage of sertraline‐treated patients received
prior: psychotherapy (59.0% versus 34.4%), psychotropic medications
for a psychiatric disorder (14.1% vs 3.3%), and non‐sertraline selective
serotonin reuptake inhibitors (SSRIs) (8.6% vs 1.2%). Most patients
were moderately ill on Clinical Global Impressions‐Severity scale, and
a higher percentage of sertraline‐treated patients had a moderate to
severe mental impairment score (73.0% versus 57.8%, respectively).
The sertraline‐treated group also reported higher levels of lifetime
and baseline suicidal ideation/behavior compared to the no pharmaco-
logic treatment group.
Conclusions: SPRITES is the first study to examine the long‐term
safety of sertraline or any SSRI in pediatric patients with follow‐up
consistent with usual practice. Baseline data suggest patients pre-
scribed sertraline are reflective of a more mentally ill study population.
350 | Prevalence of kabuki syndrome in
Europe: A literature review and database
analysis
Shreya Dave; Chao Chen
Takeda Pharmaceuticals International Co., Cambridge, MA
Background: Kabuki syndrome is a rare congenital disorder character-
ized by distinctive facial features, intellectual disability, abnormal stat-
ure, and other physical abnormalities. There is a paucity of data on
prevalence of Kabuki syndrome in Europe.
Objectives: To review available data on prevalence of Kabuki syn-
drome (KS) in Europe,and calculate prevalence of KS in United King-
dom (UK) primary care.
Methods: Key words and text words for KS were combined to
search for relevant European studies published to date, using com-
puterized databases. A study to assess prevalence of KS in the UK
using the Clinical Practice Research Datalink (CPRD), a large pri-
mary care database, was conducted. The numerator for the CPRD
analysis included all patients with a clinical code for KS in their
medical history who were registered with a general practice and
who were alive on 31 December 2017. The denominator included
all eligible patients in the CPRD registered and alive on 31 Decem-
ber 2017.
Results: Five published studies reporting European prevalence data
for KS were found. The DYSCERNE pilot project, a Europe‐wide
study, found the prevalence of KS (n = 3) in 2010–2012 was esti-
mated to range between 0.1 and 0.9 per 10,000. An Italian study
using data from the Tuscany Registry of Congenital Anomalies
and the Tuscany Registry of Rare Diseases found the prevalence
of KS was 0.195 per 10,000 (95% CI 0.063–0.455) births (n = 5
KS cases and 256,256 live births in Tuscany between years 2006
to 2013). A study in the Italian province of Sassari in Sardinia
found a prevalence of KS among 9–20 year olds of 0.86 per
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10,000 (n = 5 KS patients). A study in the Spanish province of
Badajoz reported a prevalence of 0.2 per 10,000 persons between
1988 and 1990 (n = 5 KS cases, catchment area approximately
250,000 persons). The 2018 Orphanet Report Series reported the
prevalence of KS in Europe was estimated to be 0.31 per 10,000
persons. The analysis using the UK CPRD indicated a prevalence
of KS in the UK of 0.08 per 10,000 persons (95% CI 0.06–0.10;
n = 48/6,258,143).
Conclusions: Some of the studies reviewed included relatively small
samples, and varied in their methodology and patient populations.
While there was some heterogeneity in the available data on preva-
lence of KS in Europe, estimates were consistently below 1 per
10,000. Improvements in the definition of specific diagnostic criteria
for KS as well as wider availability of genetic testing, and better
awareness about the condition will help enhance the detection rate
moving forwards. Hence prevalence estimates should be updated
over time.
351 | Does geographic access to providers
matter for pediatric ADHD treatment
engagement and medication adherence?
Navneet Upadhyay1; Rajender Aparasu1; Paul J. Rowan2;
Marc L. Fleming1; Rajesh Balkrishnan3; Hua Chen1
1University of Houston, Houston, TX; 2University of Texas School of
Public Health, Houston, TX; 3University of Virginia School of Medicine,
Charlottesville, VA
Background: ADHD management requires frequent provider visits
that may put a significant travel burden on families of children with
ADHD.
Objectives: To examine the impact of geographic access to providers
on ADHD treatment engagement and medication adherence in chil-
dren and adolescents with newly diagnosed ADHD.
Methods: A retrospective cohort study was conducted using the
2013–2016 claims data from a Medicaid Managed Care plan active
in the area around Houston. Individuals aged 4–18 years with an
incident ADHD diagnosis were identified. Geographic access mea-
sures used were: a) Travel distance to the provider who made
ADHD diagnosis/initiated the treatment, defined as the shortest
route calculated from Google Maps®. b) Primary care providers
(PCP) density per 10,000 residents within a 5‐mile travel distance
radius from the population center of each patient's zip code; and
c) mental health specialist density. Density was calculated by geo-
graphic information system based floating catchment method using
ArcGIS®. Patients were followed for 3 months post‐index ADHD
diagnosis to assess the treatment engagement defined as receiving
≥2 sessions of psychotherapy for ADHD, ≥2 ADHD prescriptions
or both. Among those who were engaged in pharmacotherapy,
treatment adherence was assessed using proportion of days
covered (PDC) within 300 days post‐index prescription. Multivariate
logistic regression was conducted to test the association between
the geographic access measures and the odds of treatment engage-
ment and medication adherence.
Results: A total of 10,206 cases with an incident ADHD diagnosis
were identified, of which 62% had access to 5 PCPs and 82% had
access to ≥1 specialist within 5 miles of travel distance. PCPs initiated
the treatment in ~70% cases and nearly a half traveled 5 to 15 miles to
the providers who initiated their ADHD treatment. The treatment
engagement rate was 55% and the mean PDC was 0.54 (±0.24) among
those engaged in treatment. None of the geographic access measures
were significantly associated with ADHD treatment engagement and
treatment adherence (e.g. effect of travel distance on treatment
engagement: 5–15 miles vs <5 miles: OR = 1.17, 95% CI [0.93–
1.47]; >15 miles vs <5 miles: OR = 1.19, 95% CI [0.93–1.52] and effect
of PCP density on treatment engagement: 5–10 PCP vs < 5 PCP:
OR = 0.96, 95% CI [0.72–1.27]; >10 PCP vs < 5 PCP: OR = 1.18,
95% CI [0.90–1.54]).
Conclusions: Different from the treatment for pediatric depression, a
significant geographic access barrier was not found in the care for
pediatric ADHD. This may be due to PCPs' in‐depth participation in
ADHD diagnosis and treatment.
352 | Proactive risk assessment of
intrathecal chemotherapy in pediatric
oncology at referral Hospital in Kenya: A
cross sectional study
Major Nyamai1; Eric Guantai2; Pegotty Mutai2; Irene Weru3;
Sylvia Opanga4
1Embu Level 5 Hospital, Embu, Kenya; 2School of Pharmacy, University
of Nairobi, Nairobi, Kenya; 3Kenyatta National Hospital, Nairobi, Kenya;
4School of Pharmacy, University of Nairobi, Nairobi, Kenya
Background: Chemotherapeutic agents are classified as high alert
medications due to their high toxicity, narrow therapeutic range
and potential for medication related problems. Intrathecal chemo-
therapy is associated with potentially fatal but preventable medica-
tion errors.
Objectives: To determine the prevalence of intrathecal chemotherapy
and the associated hazards in pediatric oncology patients at Kenyatta
National Hospital.
Methods: Patient demographics, diagnosis and indication for intra-
thecal chemotherapy data was obtained retrospectively from medi-
cal records of pediatric patients on chemotherapy admitted
between January and December 2015. Data was collected between
October and December 2016 and analyzed descriptively and by
logistic regression. To identify the potential hazards associated with
the prescribing, dispensing, preparation and administration of intra-
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thecal chemotherapy, a multidisciplinary team of nine members
working in pediatric oncology was interviewed. The Healthcare
Failure Mode and Effect Analysis was used to identify potential
failure modes, which were subjected to hazard and decision tree
analyses.
Results: A total of 281 patient records were retrieved and 198
patients were on chemotherapy. Out of the thirty three patients
(16.7%) on intrathecal chemotherapy, 23 were males while 10 were
females. A total of 151 intrathecal doses were administered. The
study identified 54 failure modes. Ten failure modes were deemed
to have a sufficient likelihood of occurrence and severity to warrant
control measures. These include; inability to determine the date the
preceding intrathecal dose was administered and dispensing unla-
beled medication for intrathecal administration. Seven failure modes
were identified as single point weaknesses whose occurrence would
lead to process failure. These include; generation of an incorrect
medication order from a prescription, and errors in intrathecal dose
determination.
Conclusions: The current practice of intrathecal chemotherapy does
not provide adequate safeguards to ensure patient and provider
safety. Key recommendations were made in the form of computerized
prescribing and ordering, induction training and regular competence
assessment and adequate supply and availability of equipment and
materials.
353 | Antibiotics utilization in pediatric
respiratory tract infections at tertiary care
hospitals in an Indian City
Deepthi Chinthakindhi; Rahamath Khanam; Afzal Unissa;
Srividya Kudikala; Kalpana Swain
Talla Padmavathi College of Pharmacy, Warangal, India
Background: Respiratory tract infections (RTIs) are the most com-
mon medical emergencies in children, especially during the first
years of life and account for 25% of deaths among children (aged
below 5 years) in developing countries possibly owing to poor
understanding of antibiotic drug utilization patterns. Appropriate
and rational usage of antibiotic is the key to manage RTIs which
may lead to decreased mortality. Hence, the present study was
undertaken to explore the drug utilization pattern of antibiotics in
the treatment of respiratory tract infections in pediatrics (Aged
below 15 years).
Objectives: To assess the antibiotic drug utilization in pediatric
population suffering with respiratory tract infections which
include upper respiratory tract infection (URTI), lower respiratory
tract infection (LRTI) and recurrent respiratory tract infection
(RRTI).
Methods: The study undertaken was a prospective descriptive cross‐
sectional study carried out at two tertiary care hospitals for a
duration of six months from April, 2018 to September, 2018). Pedi-
atric out patients with respiratory tract infection were enrolled in
the study and relevant data were collected and recorded in data col-
lection form which includes various sections of important informa-
tion like demographics, present complaints, diagnosis, prescribed
medications (dose, route, total quantity, duration and cost), and
investigations. All the relevant and necessary data were collected
from patient's prescriptions; interviewing the patient care takers
and diagnostic laboratory reports.
Results: Out of 1082 patients (Mean age‐6.8 years) enrolled in the
study, majority of patients were males (62%), and in them most of
the patients were infants (aged 1 month to 2 years; 58%) and
young children (2 years to 6 years; 27%). The study population
included a higher proportion of patients from urban area (59%)
compared to rural area (41%). The study results indicated a higher
incidence (76%) of LRTI followed by URTI (15%) and RRTI (10%).
It was found that β‐ lactams (71%) were highly prescribed in the
respiratory tract infections followed by macrolides (19%),
fluoroquinolones (4%) and aminoglycosides (3.5%). Among various
macrolides, azithromycin was highly prescribed drug (69%) espe-
cially in RRTIs.
Conclusions: In conclusion the study indicated that the cephalospo-
rins were highly prescribed in pediatric RTIs. But, in the treatment of
recurrent respiratory tract infections, macrolides were preferred over
other classes of antibiotics.
354 | Comorbidities and treatments in
United States youth with chronic
musculoskeletal pain
Matthew T. Taylor1; Daniel B. Horton2
1Sidney Kimmel Medical College, Thomas Jefferson University,
Philadelphia, PA; 2Rutgers University, New Brunswick, NJ
Background: Chronic musculoskeletal (MSK) pain has been associated
with other chronic illnesses, including mental illness, and with high
rates of pain medication use. Few studies have investigated treatment
patterns and comorbidities associated with chronic MSK pain in youth
across the US.
Objectives: To identify comorbidities and treatments associated
with chronic MSK pain in a nationally representative sample of US
youth.
Methods: We used the National Ambulatory Medical Care Survey
(2002–2015) and outpatient National Hospital Ambulatory Medical
Care Survey (2002–2011), which contain national cross‐sectional,
visit‐level data on demographics, reasons for visit (RFV), diagnoses,
and drugs ordered in outpatient US clinics. The study included all
visits for youth age 8–24, excluding those with MSK pain whose
duration could not be determined. We identified visits for chronic
(≥3mo) or acute (<3mo) MSK pain based on the main RFV. We
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compared comorbidities and drugs ordered in visits for chronic
MSK pain with visits for either acute MSK pain or any reason
besides chronic MSK pain, using chi‐square tests and logistic
regression, adjusting for age, sex, race, ethnicity, insurance, and set-
ting of care.
Results: Chronic and acute MSK pain accounted for 1.2% and 4.0%
of all visits, respectively. Compared to visits for acute MSK pain,
visits for chronic MSK pain were more commonly accompanied by
diagnoses of a chronic illness (39.5% vs. 20.3%, adjusted odds ratio
[AOR] 1.9, 95% CI 1.4, 2.5). Mental disorders (14.9% vs. 4.4%, AOR
2.7, 95% CI 1.7, 4.5) and prescribed psychotropic drugs (25.3% vs.
10.9%, AOR 1.8, 95% CI 1.1, 3.0) were also more common in visits
for chronic MSK pain than in visits for acute MSK pain. In contrast,
the prevalence of mental disorders and psychotropic drug orders
was lower in visits for chronic MSK pain than in visits for other
reasons. Opioids (28.0% vs. 15.9%, AOR 1.5, 95% CI, 1.01, 2.1)
and gastrointestinal drugs (9.9% vs. 4.0%, AOR 2.4, 95% CI 1.1,
5.2) were more commonly ordered for chronic MSK pain than for
acute MSK pain; nonsteroidal anti‐inflammatories (NSAIDs) were
less commonly ordered for chronic pain (36.4% vs. 37.7%, AOR
0.70, 95% CI 0.55, 0.89), and muscle relaxants were ordered at sim-
ilar rates in visits for chronic and acute MSK pain.
Conclusions: Compared to those with acute MSK pain, youth with
chronic MSK pain in the US are more likely to have other chronic con-
ditions, including mental illness, and be prescribed psychotropic drugs
and opioids, but less likely to receive NSAIDs. Further research in lon-
gitudinal settings will help clarify the temporality of these relationships
and associated clinical outcomes.
355 | Stevens‐Johnson syndrome and toxic
epidermal necrolysis with antiepileptic drugs
in pediatric patients
Eric P. Borrelli; Erica Y. Lee; Aisling R. Caffrey
University of Rhode Island College of Pharmacy, Kingston, RI
Background: Stevens‐Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are severe dermatologic adverse reactions.
Although these reactions are rare in incidence, they have been
associated with antiepileptic drugs (AEDs), along with certain other
medication classes. Though AEDs are used in children, studies eval-
uating SJS/TEN in pediatric populations exposed to AEDs studies
are limited.
Objectives: To quantify the reporting odds ratio (ROR) and propor-
tional reporting ratio (PRR) of SJS/TEN in children exposed to
AEDs.
Methods: A disproportionality analysis of the Food and Drug
Administration Adverse Event Reporting System (FAERS) was per-
formed for a 42‐month period (July 2014–December 2017).
Exclusion criteria consisted of follow up reports, missing age,
and patients ≥18 years old. A search was conducted using the
medical dictionary for regulatory activities (MedRA) terms “Ste-
vens‐Johnson syndrome” and “toxic epidermal necrolysis” and
reports were reviewed for inclusion. The ROR, PRR, and 95%
confidence intervals (CI) were calculated for each medication
compared to non‐AEDs, as well as for the entire class, using
OpenEpi.
Results: There was a total of 95,221 reactions reported for pediatric
patients during the study period with 5,831 (6%) consisting of AEDs.
There were 148 reports of SJS/TEN within the study period, with
AEDs having the most reports of any medication class (n = 42,
28%), followed by nonsteroidal anti‐inflammatories (NSAIDS;
n = 23, 16%). Of the 34 AEDs assessed, 24% (n = 8) had at least
1 report of SJS/TEN: carbamazepine (n = 1), clonazepam (n = 5),
diazepam (n = 1), lamotrigine (n = 27), levetiracetam (n = 3),
oxcarbazepine (n = 2), rufinamide (n = 1), and valproic acid (n = 2).
AEDs as a class had a ROR of 6.1 (CI 4.3–8.7) and a PRR of 6.1
(CI 4.3–8.7). Only 4 AED medications had statistically significant risk
estimates with rufinamide having a ROR of 46.8 (CI 6.2–353.6) and
a PRR of 44.4 (CI 6.5–301.8), clonazepam with a ROR 38.3 (CI 15.3–
95.7) and a PRR of 36.7 (CI 15.2–88.2), lamotrigine with a ROR of
36.0 (CI 23.4–55.3) and a PRR of 34.6 (CI 22.8–52.4), and
oxcarbazepine with a ROR of 11.3 (CI 2.8–46.2) and a PRR of
11.2 (CI 2.8–44.8).
Conclusions: AEDs as a class had approximately a 6‐fold increased
risk of SJS/TEN compared to all other non‐AED medications. A sig-
nificant disproportionality signal for SJS/TEN was observed with
rufinamide, clonazepam, lamotrigine, and oxcarbazepine. Proper con-
sultation should be given to patients when initiating these agents to
alert their parents of early warning signs for this potentially fatal
adverse reaction.
356 | Efficacy of Pidotimod in children: A
systematic review
Qui‐sha Yi1,2,3; Chun‐song Yang1,2; Li‐nan Zeng1,2; Li‐na Chen1;
Li‐na Qiao1; Liang Huang1,2; Hao‐xin Song1,2,3; Mao Lin1,2,3;
Wen‐rui Li1,2,3; Xue Mi1,2,3; Ling‐li Zhang1,2
1West China Second University Hospital, Sichuan University, Chengdu,
China; 2Ministry of Education, Chengdu, China; 3Sichuan University,
Chengdu, China
Background: As the only marketed drug with oral bioactive immune
promoter, pidomide is widely used in children with respiratory tract
and urinary tract infections and low immune function. However, the
research results are inconsistent, and its effectiveness is controver-
sial and there is still a lack of systematic evaluation to evaluate its
effectiveness.
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Objectives: To systematically evaluate the efficacy of pidotimod in
children, and provide evidence of evidence‐based medicine for clinical
treatment.
Methods: Databases including Pubmed, The Cochrane Library,
EMbase (Ovid), CNKI, CBM, VIP and WanFang Database were
searched from inception to January 2018,to collect randomized con-
trolled trials (RCTs) about pidotimod in children. Two reviewers
independently screened literature, extracted data, evaluate the qual-
ity of included studies,and meta‐analysis was performed by RevMan
5.3.
Results: 318 RCTs involving 27500 children were included. The
result of meta‐analysis showed that compared with the control
group, the pidotimod group could significantly reduce the number
of respiratory tract infection[MD = −2.79, 95%CI(−3.12, −2.46),
P < 0.05],the time of respiratory tract infection[MD = −4.15,
95%CI(−4.72, −3.58),P < 0.05], the time of
fever[MD = −1.47,95%CI(−1.77,‐1.17),P < 0.05] in recurrent respira-
tory tract infection. And pidotimod could reduce the time of fever
[MD = −0.25,95%CI(−0.38,‐0.11),P < 0.05] in mycoplasma
pneumoniae pneumonia, the time of fever
[RR = 1.163,95%CI(1.043,1.297,P < 0.05)] in hand‐foot‐mouth dis-
ease,incidence of anaphylactoid purpura followed up for
6 months[RR = 0.370,95%CI(0.215, 0.636),P < 0.05] in anaphylac-
toid purpura,but there was no significant difference between the
pidotimod group and the control group in the incidence of asthma
followed up for 1 year[RR = 0.80,95%CI(0.60, 1.06),P > 0.05]in
asthma.
Conclusions: Current evidence shows that, Pidotimod may be effec-
tive for respiratory tract infection,asthma,hand‐foot‐mouth disease,
could reduce disease relapse and relieve symptoms related to ill-
ness. Due to limited quality included studies more strict designed
and multicenter clinical researches are needed to verify the above
conclusion.
357 | Antibiotics prescribing among children
under five at a tertiary healthcare facility
south East Nigeria
Charles C. Ezenduka
University of Nigeria Enugu Campus, Enugu, Nigeria
Background: Inappropriate use of antibiotics especially in children
undermines treatment goals constituting significant danger to the
development of the child. Local monitoring of prescribing in relation
to diagnosis is essential for enhanced prescription practices.
Objectives: The study aimed to describe use pattern of antibiotics
among children under five at a university teaching hospital south east
Nigeria.
Methods: A cross‐sectional observational study was conducted in a
university teaching hospital in south eastern Nigeria, selected based
on availability of reliable data and consent to participate in the
study. Data were retrospectively collected from patient folders
and prescription records over the period of January to June 2016,
using a customized form for relevant information. Only cases pre-
scribed antibiotics were included for analysis while incomplete data
were excluded. The antibiotics were categorized according to the
Anatomical Therapeutic Chemical (ATC) classification system and
analyzed to include the Daily Defined Dose (DDD) per patient
pay day.
Results: A total of 286 children folders were reviewed out of which
208 were prescribed antibiotics. Only one antibiotic was prescribed
in 78% of encounters while up to three were prescribed per patient
in 6% of cases. Most (57%) of prescribed antibiotics were through oral
route while 47% were prescribed for parenteral administration. Ceph-
alosporins (47%) followed by penicilins (42%) were the most pre-
scribed classes of the antibiotics, with amoxicillin (16%) as the most
commonly prescribed agent. Gastrointestinal disorders (32%),
followed by malaria (24%) were the most commonly diagnosed
conditions.
Conclusions: Findings suggest significant rational prescribing of antibi-
otics in the study facility. However, there appears to be an overuse of
penicilins and cephalosporins mostly among children aged below one
year, with limited laboratory investigations. There is scope for
enhanced adherence to guidelines to help prevent antibiotic resistance
and improved child health outcomes.
358 | Appropriateness of postoperative
analgesic doses among pediatric surgical
patients in a teaching Hospital in Northwest
Nigeria
Kazeem Adeola Oshikoya1; Ibrahim Abayomi Ogunyinka2;
Comfort Adamaigbo2; Christopher Suiyel Lukong2;
Ahmed Olowo‐Okere2; Adekunle Azeez Adebayo1
1Lagos State University College of Medicine, Ikeja, Lagos, Nigeria;
2Usmanu Danfodiyo University, Sokoto, Nigeria
Background: Inappropriate uses of analgesics and suboptimal treat-
ment are a global problem and concerning to healthcare manage-
ment of postoperative pain, particularly in children. Information
relating to the management of postoperative pain in children is
generally limited, particularly in low and middle income countries.
Such information is, however, unavailable from the Northwest
Nigeria.
Objectives: To describe the types of analgesic drugs used postopera-
tively for children and evaluated the appropriateness of their doses
to ensure best practices. Factors predicting the risk of underdosed
analgesic drugs were also determined.
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Methods: We performed a retrospective chart review of patients
administered analgesic drugs after surgery between 1 January
2015 and 31 December 2017. Exposures were categories of analge-
sic drug doses (underdose, normal dose, and overdose). Simple
descriptive and comparative statistical analyses were performed.
Logistic regression was used to build analgesic underdose risk pre-
diction model.
Results: A total of 194 patients received 281 analgesic drugs. Sum-
marily, 112 (57.67%), 77 (39.7%), and 5 (2.76%) patients received
single, double and triple analgesic drugs, respectively. Paracetamol
(148; 52.7%) and pentazocine (77; 27.54%) were the most com-
monly used analgesic drugs. Of the 7 different analgesic drugs,
overdosing (64; 22.8%) and underdosing (89; 31.7%) were recorded.
There was a statistically significant association between analgesic
drug types and categories of dose appropriateness; p less than
0.001. None of the patients' demographics or the number of anal-
gesic drugs used predicted the risk of underdosing.
Conclusions: Inappropriate use of analgesic drugs (overdosing or
underdosing) is common and cuts across all analgesic drug types and
all age groups. A substantial number of children underdosed with the
analgesic drugs suggested pain under‐treatment.
359 | Observation versus prophylactic
antibiotics in late preterm infants with
premature rupture of membranes: A
pragmatic randomized controlled trial
Linan Zeng; Lingli Zhang
West China Second University Hospital, Sichuan University, Chengdu,
China
Background: This study aimed to compare the effect of expectant
observation versus prophylactic antibiotics in the prevention and
treatment of infections in late preterm infants born to mothers with
premature rupture of membranes (PROM).
Objectives: This study aimed to compare the effect of expectant
observation versus prophylactic antibiotics in the prevention and
treatment of infections in late preterm infants born to mothers with
premature rupture of membranes (PROM).
Methods: Design A pragmatic randomized controlled trial. Setting
NICU of West China Second University Hospital (WCSUH). Patients
Infants between 34 and 36 weeks gestation weighting ≥1500 grams
born to mothers with PROM. Interventions Infants were randomized
to either prophylactic antibiotic group (cefuroxime, 30 mg/kg q12h,
48 hours) or expectant observation group. Main outcome measures
The incidence of sepsis and the incidence of systemic bacterial infec-
tion during hospitalization.
Results: A total of 120 infants were enrolled (n = 60/group), 113
of whom were followed during follow‐up. There was no significant
difference in terms of sepsis or systemic bacterial infections
between the 2 groups during hospitalization (RR 0.25, 95% CI
0.01 to 5.66, P = 0.48; RR 0.80, 95% CI 0.23 to 2.84, P = 0.73).
Twelve (20.0%) infants in the expectant observation group received
antibiotics during hospitalization. No death or fungal infection
occurred in the two groups. The risk of readmission due to infec-
tion seemed to be higher in expectant group, but without statisti-
cally significant difference (8.3% vs 1.7%, RR 5.10, 95%CI 0.58 to
45.12, P = 0.14).
Conclusions: Expectant observation strategy could be considered in
late preterm infants born to mothers with PROM to reduce unneces-
sary consumption of antibiotics. Future study with sufficient sample
size should compare the long term outcomes following these two
approaches.
360 | Drug‐related problems in pediatric
patients with respiratory disease hospitalized
in Rionegro Antioquia, Colombia
Jefferson Antonio Buendia1; Juanita Rivas2
1University of Antioquia, Medellin, Colombia; 2UNIREMINGTON,
Medellin, Colombia
Background: Drug related problems (DRP) are common cause of
morbidity and mortality worldwide. The evidence about incidence
of DRP in the pediatric population, in developing countries is
scarce.
Objectives: The objective of this study was to determine and charac-
terize the frequency of problems related to medications in patients
with respiratory pathology.
Methods: Cross‐sectional and analytical study. A stratified random
sampling of 110 clinical records of patients hospitalized in the pediat-
ric service was analyzed, whose main reason for hospitalization was
some diagnosis of respiratory pathology. Nursing records and medica-
tion administration were additionally reviewed.
Results: 110 patients were studied, with an age (median) of
30.5 months, mainly of females 79% (n = 87). The most frequent
diagnoses among the patients studied were bronchiolitis 39%
(n = 43), pneumonia 34.55% (n = 38) and asthmatic crisis 20.91%
(n = 23). The estimated incidence density of DRP was 10.62 cases
per year. The DRP most frequently encountered were prescription‐
prescription problems (81%), followed by problems of therapeutic
duplicity (11%) and adverse drug events (7%). 79% of the indica-
tion‐prescription problems occurred in patients with bronchiolitis
mainly related to the use of bronchodilators or hypertonic solution.
83% of duplicity problems were noted in asthmatic crisis mainly
simultaneous use of two inhaled corticosteroids or antimuscarinics.
The most frequently reported adverse event was epistaxis due to
the use of oxygen or nebulized medication.
Conclusions: This is the first study in the pediatric population focused
on respiratory pathology in our country. It is necessary to establish
educational and computer tools that prevent and warn this type of
medical errors.
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361 | Assessment of clinical Care for Infants
with neonatal abstinence syndrome in an
electronic health record database
Kelesitse Phiri; Michael Doherty; Robin Clifford; Yuan Fan;
John Seeger
Optum, Boston, MA
Background: Administrative claims data are increasingly being used
in observational studies of medication exposure and safety in preg-
nancy. However, certain research questions may not be adequately
addressed using claims information alone due to limitations in ascer-
tainment or clinical granularity. As an example, studies of treatment
and outcomes among infants exhibiting neonatal abstinence syn-
drome (NAS) following in‐utero exposure to opioids may depend
on assessment tools and treatments (both pharmacologic and non‐
pharmacologic) that do not result in specific claims. Other data
sources, such as electronic health records (EHR) databases may pro-
vide this information either as a standalone resource or through link-
age to claims.
Objectives: To present a real‐world view of pharmacological and
non‐pharmacological management and measures among neonates
with NAS using an EHR database. Two individual cases of NAS clin-
ical characteristics and management based on the Finnegan scoring
system illustrate the findings.
Methods: A random sample of 100 neonates with clinical notes that
indicate NAS was identified within the Optum EHR database. We
excluded those with missing activity dates to arrive at 74 for whom
we generated a chronological listing of clinical notes. Manual review
of these listings was conducted to evaluate the presence of
Finnegan scores and characterize those available.
Results: From the 74 neonates with NAS mention in clinical notes,
36 (49%) had Finnegan scores, most showing repeat measurements
over the course of the hospital stay. Out of the 74, 43 (58%) had
pharmacotherapy consisting of morphine (30), methadone (25), phe-
nobarbital (16), clonidine (3) and buprenorphine (11), as either mono-
therapy or in combination. Non‐pharmacological care was observed
in the clinical notes for 25 (34%), and included mentions of calming
(18), swaddling (1), holding (3) and use of breast pump (10). One
newborn female with an initial Finnegan score of 16, received a
combination of morphine, methadone, phenobarbital and
buprenorphine, and was discharged with a Finnegan score of 4 after
13 days of inpatient treatment. A newborn male without Finnegan
mention in the clinical notes was treated with buprenorphine,
calming, holding and use of a breast pump. The infant was
discharged after 6 days of inpatient stay.
Conclusions: The availability of EHR databases allows for a more com-
plete clinical picture to be developed among neonates with NAS. Cer-
tain research questions may benefit from the use of EHR, and this data
source should be considered when conducting a
pharmacoepidemiology study.
362 | Antimicrobial prescribing in infants in
Indonesia
Jarir At Thobari1; Cahya Dewi Satria1; Yohanes Ridora1; Jullie Bines2;
Jim Buttery3; Yati Soenarto1
1Faculty of Medicine, Publich Health and Nursing, Universitas Gadjah
Mada, Yogyakarta, Indonesia; 2Murdoch Children's Research Institute,
University of Melbourne, Melbourne, Australia; 3Monash University,
Melbourne, Australia
Background: Antimicrobial resistance has become a global health
emergency and is mainly caused by inappropriate antibiotic use in clin-
ical and community setting.
Objectives: to evaluate the antimicrobial prescribing pattern in infant
in Indonesia.
Methods: A cohort analysis was conducted in 1621 participants from
Rotavirus Vaccine RV3BB Phase IIb trial conducted in Indonesia
from January 2013 through July 2016. The concomitant medication
recorded all medications, including antibiotics until the 18 months
of follow‐up. Information's regarding antibiotic prescribing including
the frequency, duration of usage, formulation, classes, indications,
and their association with the vaccine trial were evaluated, including
prophylactic antibiotic and perinatal.
Results: Of 1621 participants, 551 (33.99%) received at least one
antibiotic for treatment of infections during the 18 months observa-
tion period. The number of illness episodes were significantly associ-
ated with the incidence of antibiotic prescribing (p‐value<0.05). A
total of 951 antibiotic were prescribed during 18 months follow
up, with some (7.57%) were antimicrobial combination. The average
duration of antibiotic course was 4.77 days, and no significant asso-
ciation with the RV3‐BB vaccine was observed. Penicillin and
sulphonamides were the most common antibiotic classes prescribed
(39.01% and 24.60%, respectively). Among illness that were treated
by antibiotic, 84.78% of prescribed for upper respiratory tract infec-
tion, non‐bloody diarrhea 74.85%. Prophylactic antibiotics were pre-
scribed in 1244 (76.74%) participants and antibiotic prescribed in
235 mothers of participants (14.50%) during perinatal period.
Conclusions: The prescribing rate suggested need an improvement
of antimicrobial stewardship implementation in our setting. The
overuse of antibiotic in URTIs and non‐bloody diarrhea was still a
major problem. Different classes of antibiotic were also inappropri-
ately prescribed and may risk development of antimicrobial
resistance.
363 | Pharmacist‐conducted review
prevents potential prescribing errors of
neonatal parenteral nutrition: A cross
sectional study
Sara Hazem1; Mohamed K. Gomaa2; Khalid Rashid2;
Mohammad Zaitoun1
ABSTRACTS 179
1Pharmacy Department, Armed Forces Hospitals Southern Region,
Khamis Mushayt, Saudi Arabia; 2Neonatal Intensive Care Unit, Armed
Forces Hospitals Southern Region, Khamis Mushayt, Saudi Arabia
Background: Parenteral nutrition [PN] Preparations are considered as
high alert medications per the Institute For Safe Medication Practices
[ISMP]. Thus, medication errors involving PN bear heightened risk to
patients especially for vulnerable populations as neonates. Previous
studies highlighted pharmacists' contribution to PN prescribing, moni-
toring, prevention of medication errors and education of other health
care professionals.
Objectives: The purpose of this study was to assess the impact of
pharmacist‐conducted PN order review on the prevention of potential
prescribing errors.
Methods: A pharmacist reviewed all PN orders of neonatal intensive
care unit [NICU] patients of King Faisal military hospital, Khamis
Mushait, Saudi Arabia. Pharmacist's recommendations were communi-
cated to the prescribers for appropriate action. A cross sectional study
was conducted to detect prescribing errors prevented due to Pharma-
cist's recommendations since January 2017 till December 2017. Med-
ication errors were categorized by two pharmacists and a
neonatologist per the Pharmaceutical Care Network Europe (PCNE)
drug related problem classification v 8.02.
Results: During the study period, 2350 PN orders were reviewed by
Pharmacist, 214 prescribing errors were detected and prevented in
199 orders (8.47% of orders). Dosing errors and omission errors con-
stituted the highest percentage of errors prevented (69.6% and
22.4% respectively). Sub‐therapeutic doses were found in 44.4% of
errors while Supra‐therapeutic doses were detected in 25.2% of them.
The remaining 7.9% of prescribing errors were due to incomplete
patients' data. More than 96% of prescribing errors involved eight
components of PN orders; Dextrose (17.1%), lipids and fat soluble
vitamins (16.6%), Heparin (15.5%), Magnesium Sulphate (10.9%),
Sodium Chloride (10.4%), Amino Acids (9.9%), Phosphate (9.3%) and
Potassium Chloride (7.3%).
Conclusions: Pharmacist‐conducted review of PN orders seems to
have significant role in prevention of prescribing errors.
364 | Outpatient and inpatient use of
ribavirin among children under 14 years old in
Yinzhou District, Ningbo, China
Lu Xu1; Hailong Li2; Houyu Zhao1; Hongbo Lin3; Cuili Liu4;
Peng Shen3; Siyan Zhan1
1School of Public Health, Peking University, Beijing, China; 2West China
Second University Hospital, Sichuan University, Chengdu, China; 3Yinzhou
District Center for Disease Control and Prevention, Ningbo, China;
4Center for Drug Revaluation, CFDA, Beijing, China
Background: Ribavirin is a synthetic nucleoside antiviral drug. The
number of adverse drug reaction (ADR) reports of ribavirin has
increased significantly, and the common types of ADRs at home and
abroad are different.
Objectives: To explore the clinical use of ribavirin among children
under 14 years of age in Yinzhou district, Ningbo, China.
Methods: Outpatient and inpatient records from 2010 to 2016 in
Yinzhou healthcare information database were used. We extracted
patient identification number, birth date, gender, International Classifi-
cation of Diseases code version 10 (ICD‐10), medical institution code,
prescription date, generic name, dosage form and route of administra-
tion from the database to analyze the clinical use of ribavirin. SQL was
used to clean original data and R software was used to analyze the
data. The main statistical indicator is the number of prescriptions.
Results: (1) Outpatient use: The number of prescriptions for children
aged 14 and under accounted for 50.56% of the total prescriptions.
For ribavirin injection, the proportion of prescriptions for children
aged 14 and under was 50.40% of the total ribavirin injection prescrip-
tions and the main reason for ribavirin injection use was acute upper
respiratory tract infection. For ribavirin granules and tablets, the pro-
portion of prescriptions for children aged 14 and under was 77.19%
and the main reason for use was acute upper respiratory tract infec-
tion. For Ribavirin eye drops, the proportion of prescriptions for chil-
dren aged 14 and under was 28.97% and the main reason for use
was conjunctival disorders. For ribavirin aerosol, the proportion of pre-
scriptions for children aged 14 and under was 99.12% and the main
reason for use was viral infection of skin and mucosal lesions. For riba-
virin oral solution, the proportion of prescriptions for children aged 14
and under was 52.61% and the main reason for use was acute upper
respiratory tract infection. (2) Inpatient use: The number of prescrip-
tions for children aged 14 and under accounted for 9.15% of the total
prescriptions. For ribavirin injection, the proportion of prescriptions
for children aged 14 and under was 9.84% of the total ribavirin injec-
tion prescriptions and the main reason for ribavirin injection use was
acute respiratory tract infection. For Ribavirin eye drops, the propor-
tion of prescriptions for children aged 14 and under was 9.37% and
the main reason for use was keratitis.
Conclusions: Irrational ribavirin use still existed in China. Medical insti-
tutions at all levels should strengthen the monitoring and control of
ribavirin use to promote rational use of ribavirin.
365 | The association between antipsychotic
polypharmacy and potential ADEs in pediatric
psychiatric patients
Soo‐Min Jeon; Susan Park; Sena An; Hae‐Young Park; Jin Won Kwon
Kyungpook National University, Daegu, Republic of Korea
Background: A number of studies on antipsychotic polypharmacy
(APP) have exhibited increasing trend of APP prevalence among pedi-
atric patients, especially for Western countries. Polypharmacy is
closely related with inappropriate drug use and consequently induces
potential adverse drug events (ADEs). However, APP in pediatrics is
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inadequately understood in Asian countries and the study on associa-
tion between APP and ADEs has been rare.
Objectives: The aim of this study was to investigate the prevalence of
APP and to explore the association between APP and potential ADEs
in Korean psychiatric patients aged 2–19 years.
Methods: We used Health Insurance Review and Assessment Service
‐ Pediatric Patients Sample (HIRA‐PPS), which consists of nationally
representative claim data. We selected psychiatric patients aged 2–
19 years with F codes (ICD‐10) from 2012 to 2016 (2012,
n = 38,724; 2013, n = 34,836; 2014, n = 33,721; 2015, n = 33,195;
2016, n = 33,714). Potential ADEs was defined according to the list
of ICD‐10 codes by Stausberg J & Hasford J. The incidence of the
ADEs was assessed from July to December in patients without the
ADEs history from January to June in each year. Antipsychotics were
classified according to the drug classifications of the Korea Food and
Drug Administration (KFDA). APP was defined as the prescription of
an average of two or more antipsychotic active ingredients per day
for 6 months from January to June in each year. Descriptive statistics
and logistic regressions were conducted to explore prescription pat-
terns and risk factors associated with pediatric polypharmacy.
Results: The prevalence of pediatric APP was increasing in recent
5 years, which were 1.4%, 1.6%, 1.7%, 2.0%, and 2.2% in 2012,
2013, 2014, 2015, and 2016, respectively. When we explore the prev-
alence of APP according to age groups, the APP prevalence was higher
in adolescents (aged 14–19 years: 2.6%) than preschool children (aged
1–7 years: 0.2%) and school aged children (aged 8–13 years: 1.4%).
The proportion of potential ADEs was elevated with increasing daily
mean of polypharmacy, especially for adolescents (without APP:
2.5% vs. with APP: 7.2). After adjustment for socio‐demographics
and admission history, the pediatric psychiatric patients with APP
was 2.5 times higher risk of potential ADEs with statistical significance
in multivariate logistic regression analysis.
Conclusions: Pediatric psychiatric patients with APP experienced a
greater risk of potential ADEs. This result suggests that the introduc-
tion of a medication review system for pediatric psychiatric patients
with APP is needed to reduce the potential ADEs.
366 | Determinants of aminoglycoside
trough levels among pediatric patients in a
large referral Hospital in Kenya: A prospective
cohort study
Zaietuni Mulaa1; Margaret Oluka1; Faith Okalebo1; Sylvia Opanga1;
Anastasia Guantai1; Loice Achieng1; Amanj Ismael Baker Kurdi2,3;
Brian Godman2; Marion Bennie2
1University of Nairobi, Nairobi, Kenya; 2Strathclyde Institute of
Pharmacy and Biomedical Science, University of Strathclyde, 161
Cathedral, Glasgow, UK; 3Hawler Medical University, Erbil, Iraq
Background: Aminoglycosides antibiotics used in pediatrics for the
management of severe infections. Routine measurement of aminogly-
coside levels is required to monitor efficacy and toxicity; however this
is not routinely done in resource limited settings and dosing is largely
empiric.
Objectives: To determine aminoglycoside trough levels and factors
affecting trough levels in pediatric patients at the Kenyatta National
Hospital (KNH).
Methods: A prospective descriptive cohort study was conducted in
the pediatric wards of the Kenyatta National Hospital between May
and September 2018. All pediatric patients aged 5 < years receiving
amikacin or gentamicin treatment were recruited. Patient records
were reviewed daily by the principal investigator and aminoglycoside
trough levels were determined on day three before the third dose of
aminoglycosides. Patients' baseline characteristic and kidney function
were also collected. The main outcome variable was aminoglycoside
serum trough levels and this was used to stratify participants accord-
ing to dosing. Linear and logistic regression was used to analyze the
data; patients were categorized in the sub therapeutic range or other-
wise. Ethical and institutional approval was obtained from KNH/UON
Ethics and Research Committee.
Results:Overall, 140 pediatric patients were recruited into the study.
The prevalence of aminoglycoside use was 57.12%. The most com-
mon indication for use was pneumonia 117 (83.45%). One hundred
and ten patients were treated with gentamicin with a median dose
of 53 mg [IQR: 21,70]/kg body weight for a duration of 7 days.
Thirty patients were on amikacin with a median dose of 105 [IQR:
85,210] for a duration of 7 days. Nearly all the patients on amikacin
(90%) had serum levels below the therapeutic range (<3.4 micro-
gram/ml) in contrast to only 30 patients on gentamicin (27%) (>2
microgram/ml). The predictors for sub‐therapeutic levels were
age < 18 months (adjusted OR 0.36, 95% CI: 0.14–0.92), and
weight < 10kgs (adjusted OR 0.2, 95% CI: 0.07–0.53).
Conclusions: There was a high prevalence of under dosing in pediat-
ric patients who received aminoglycosides particularly for amikacin;
therefore there is need to review and update the existing aminogly-
coside use protocols to include therapeutic drug monitoring.
367 | The effect of antipsychotic
polypharmacy on seizure incidence in
pediatric psychiatric patients
S.O.O.M.I.N. JEON; Susan Park; Sena An; Hae‐Young Park;
Jin‐Won Kwon
Kyungpook, National University, Daegu, Korea, Republic of
Background: Seizure has been reported the one of important side
effect due to both typical and atypical antipsychotics. Considering this,
antipsychotic polypharmacy (APP) can more elevate the risk of anti-
psychotic‐related seizure (ARS) in psychiatric patients. However, the
study on the effect of APP on ARS has been rare in pediatric patients.
Objectives: The main purpose of this study was to explore the associ-
ation between APP and ARS in Korean psychiatric patients aged 2–
19 years.
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Methods: We used nationally representative claim data known as
Health Insurance Review and Assessment Service ‐ Pediatric Patients
Sample (HIRA‐PPS). Psychiatric patients was defined using F codes
(ICD‐10) from 2012 to 2016 (2012, n = 38,724; 2013, n = 34,836;
2014, n = 33,721; 2015, n = 33,195; 2016, n = 33,714). The case of
seizure was defined according to the ICD‐10 codes of G40 (Epilepsy
and recurrent seizures) and R56 (Convulsions, not elsewhere classi-
fied). In a merged data of 5 years from 2012 to 2016, the incidence
of seizure was identified from July to December in patients without
the seizure history from January to June in each year. Antipsychotics
were determined based on the drug classifications of the Korea Food
and Drug Administration (KFDA). The APP was assessed only in
6 months from January to June in each year and it was defined when
two or more antipsychotic active ingredients were prescribed per day,
averagely. Multiple logistic regression as statistical analysis was
performed.
Results: The proportions of seizure incidence were similar in recent
5 years, which were 1.5%, 1.4%, 1.6%, 1.7%, and 1.7% in 2012,
2013, 2014, 2015, and 2016, respectively. When we explore the inci-
dence case of seizure according to APP exposure level, the incidence
rate of seizure was higher in pediatric patients prescribed more than
2 antipsychotic medications (3.9%) than in patients without antipsy-
chotic medication (1.7%). The seizure case was frequently observed
in the pediatric patients with younger age (age 1–7 years), medical
aid beneficiary, and admission history. After adjustment other related
factors, Odds Ratio (OR) of APP in developing seizure was 1.7
(95%CI = 1.40–2.07) .
Conclusions: Pediatric psychiatric patients with APP exhibited the
higher risk of seizure incidence. These results suggest that the APP
may be a significant risk factor of possible ARS in pediatric patients.
The further investigations using long‐term follow‐up data are needed
to confirm the association between APP and ARS.
368 | Data‐driven identification of adverse
event reporting patterns for Japan in the
WHO global database
Rika Wakao1; Henric Taavola2; Lovisa Sandberg2; Eiko Iwasa1;
Rebecca E. Chandler2; G. Niklas Norén2
1Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; 2Uppsala
Monitoring Centre, Uppsala, Sweden
Background: Adverse event (AE) reporting patterns vary between
countries, given differences in reporting culture, clinical practice and
underlying patient populations. Japan collects over 50,000 domestic
AE reports yearly and shares serious reports with VigiBase, the
WHO global database of individual case safety reports. Understanding
these reports in the global context could be helpful for regulators
worldwide and aid hypothesis‐generation for Japanese‐specific vul-
nerabilities to adverse drug reactions.
Objectives: To explore differences in the reporting of AEs between
Japan and other countries contributing to VigiBase.
Methods: vigiPoint is a method for data‐driven exploration in
pharmacovigilance. It outlines data subsets, pinpoints key features
and facilitates expert review, using odds ratios subjected to statistical
shrinkage to distinguish one data subset from another. Here, we com-
pared 260,000 Japanese reports in VigiBase to 2.5 million reports
from the rest of the world (RoW; of which 51% from US). This
included reports in E2B format classified as serious and received
between 2013 and 2018. Reporting patterns for which the 99% cred-
ibility interval of a shrunk log‐odds ratios were above 0.5 or below
−0.5 were flagged as key features. The shrinkage was set to the
vigiPoint default (1% of the Japanese data subset).
Results: There were higher reporting rates in Japan from physicians
(83% vs 39%) and pharmacists (17% vs 10%). It was also more com-
mon to see reports with more than five drugs per report (22% vs
14%) and reports with a single adverse event (72% vs 45%). More than
half of the Japanese reports had a vigiGrade completeness score
above 0.8 compared to about 1 in 5 in RoW. There were more reports
than expected for patients aged 70–90 years and fewer reports for
adults aged 20–60 years.
AEs reported more often in Japan included interstitial lung disease,
hepatic function abnormal, platelet count decreased, neutrophil count
decreased and drug eruption. AEs reported less often included death,
fatigue, dyspnoea, fatigue and headache. Drugs reported more often
in Japan included prednisolone, methotrexate and peginterferon alfa‐
2b. Drugs reported less often included rosiglitazone, adalimumab as
well as blood substitutes and perfusion solutions.
Conclusions: Analysis of Japanese AE reports in global context has
revealed key features that may reflect possible pharmaco‐ethnic vul-
nerabilities in the Japanese, as well as differences in AE reporting
and clinical practice. This knowledge is essential in the global collabo-
ration of signal detection afforded by the WHO Programme for Inter-
national Drug Monitoring.
369 | The utilization of a new tool in signal
management ‐ who drug standardized drug
groupings
Rebecca E. Chandler; Olof Lagerlund
Uppsala Monitoring Centre, Uppsala, Sweden
Background: Screening of large databases of spontaneous reports of
suspected adverse drug reactions (ADR) is performed by
disproportionality analyses at the level of single drug ‐ ADR pairs. Sub-
sequent signal refinement may include exploration of additional clini-
cally relevant concepts within the MedDRA hierarchy and potential
drug class effects within the Anatomical Therapeutic Classification
(ATC). WHODrug Standardized Drug Groupings (SDG) are specific
classifications of drugs of interest, grouped according to properties
such as their pharmacological effect or metabolic pathway.
Objectives: To demonstrate the utility of an SDG in the refinement of
a signal nintedanib ‐ colitis identified by statistical screening of
Vigibase.
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Methods: Disproportionality analysis was performed on 13 February
2019 in VigiBase, the global database for individual case safety
reports; the combination of nintedanib ‐ colitis (MedDRA PT) was
highlighted with an IC025 of 0.96. An initial clinical review was under-
taken to determine the need and/or direction of signal refinement
within VigiBase data. Disproportionality analyses were performed for
relevant adjacent terms in the MedDRA dictionary, as well as for drug
groupings using both the ATC and SDG.
Results: Clinical review revealed nintedanib to be a small molecule
tyrosine kinase (TK) inhibitor blocking vascular epithelial growth factor
(VEGF), fibroblast GF and platelet‐derived GF receptors. A mouse
model reveals VEGF inhibition to be associated with regression of cap-
illaries in intestinal villi, and gastrointestinal perforation is included in
the Summary of Product Characteristics. Subsequent exploration of
adjacent MedDRA PTs revealed IC025 of 0.02 for “colitis ischaemic”
and 2.22 for “gastrointestinal perforation”. Nintedanib is in ATC code
LO1XE “protein kinase inhibitors” and in the SDG “Antiangiogenic
drugs with antagonistic effect on the VEGFR, inhibiting actions on
VEGF or VEGFR TKs”. Respective disproportionality at ATC level
was IC025 0.04 for “colitis ischaemic” and IC025 2.34 for “gastrointesti-
nal perforation”; at the SDG level was IC025 1.23 and IC025 5.37.
Conclusions: Standardized drug groupings are a useful tool in the sig-
nal management process. Refinement of the signal “nintedanib‐colitis”
using an SDG provided stronger evidence of a potential causal rela-
tionship compared to ATC. Exploration of potential drug class effects
in during signal assessment may be improved by use of WHODrug
SDG.
370 | Identifying signals of drug–drug
interactions involving direct‐acting Oral
anticoagulants: A translational biomedical
informatics approach
Meijia Zhou1; Lei Wang2; Charles E. Leonard1; Colleen M. Brensinger1;
Warren B. Bilker1; Stephen E. Kimmel1; Todd E. Hecht1; Lang Li2;
Sean Hennessy1
1Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA; 2Ohio State University, Columbus, OH
Background: Drug–drug interactions (DDIs) with oral anticoagulants
are associated with increased risk of serious bleeding. Few studies
have examined DDIs involving direct‐acting oral anticoagulants
(DOACs).
Objectives: To systematically identify which potentially interacting
drugs are most likely to affect the rate of hospital presentation for
serious bleeding when taken concomitantly with DOACs, using real
world clinical data.
Methods: We identified all oral medications (i.e. precipitants) fre-
quently co‐prescribed with dabigatran, rivaroxaban, apixaban, and
edoxaban within OptumInsight Clinformatics Data Mart, 2010–2016.
First, we performed physiologically based pharmacokinetic (PBPK)
modeling based on the inhibition of cytochromes P450s to predict
which potential interacting drugs are likely to affect the rate of serious
bleeding. Second, we conducted a high‐throughput
pharmacoepidemiologic screening study using self‐controlled case
series design and Optum claim data. We included adults with at least
one dispensed DOAC prescription and at least one hospital presenta-
tion for serious bleeding. Conditional Poisson regression was used to
estimate rate ratios and 95% confidence intervals comparing precipi-
tant exposed vs. unexposed time for each DOAC‐precipitant pair. To
minimize within‐person confounding by indication for the precipitant
and to distinguish a DDI from an inherent effect of the precipitant
on bleeding risk, we used pravastatin as a negative control object drug.
Multiple estimation was adjusted using Semi‐Bayes shrinkage.
Results:We predicted one moderate DDI (apixaban and clonidine) and
one weak DDI (apixaban and fluconazole) based on PBPK modeling.
We identified 45, 36 and 28 precipitants associated with increased
rate of serious bleeding when used concomitantly with dabigatran,
rivaroxaban and apixaban, respectively. Using pravastatin as the nega-
tive control, there were 23, 12 and 16 precipitants associated with
elevated rate of serious bleeding for dabigatran, rivaroxaban, and
apixaban, respectively. Among these DDI signals, 38 (75%) were not
documented in DDI knowledge databases Lexicomp and/or
Micromedex. The results of PBPK prediction and
pharmacoepidemiologic screening were poorly correlated.
Conclusions: The identified potential DDI signals need further exami-
nation in future studies. In this example, combining the pharmacoki-
netic prediction and pharmacoepidemiologic screening did not
significantly improve the ability to identify DDI signals.
371 | Knowledge attitudes and perceptions
on adverse drug events reporting among
patients and healthcare providers in rural
Uganda
Dan Kajungu1; Helen Ndagije2; Victoria Nambasa2;
Edward Galiwango1
1Makerere University Centre for Health and Population Research
(MUCHAP), Kampala, Uganda; 2National Drug Authority, Kampala,
Uganda
Background: Drug regulators promote patient safety by monitoring
adverse drug reactions. The reporting rate of suspected adverse drug
reactions in Uganda is below the average for a well‐performing
system.
Objectives: To describe patient and healthcare worker knowledge,
attitude and practice about adverse drug events and reporting at the
community level.
Methods: A cross‐sectional survey among respondents from randomly
selected households and healthcare workers in Iganga Mayuge HDSS
(IMHDSS) in Eastern Uganda.
Results: Of the 1034 community members, 59% sought treatment
from private drug shops, 37% from either private clinics, health cen-
ters or hospitals while 4% sought treatment from herbalists, friends
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or relatives. Over half of the respondents (56%) were aware that
drugs can have negative effects, 57% expressed willingness to report
an ADE while 43% did not know what to do in case an ADE
occurred. Almost half (46%) could not differentiate between an
ADE and the disease, and for those who could, the majority (76%)
were willing to report an ADE in case it occurred. However, only
34% had ever reported an ADE when it actually occurred to them.
For respondents who reported, 43% had their drugs changed, 31%
were counseled while 11.5% continued on the same medication.
For healthcare providers, 95% knew about an ADE but only 35%
(n = 116) have ever reported. Some reasons for not reporting were
fear of being victimized or sued upon reporting (35%), reported lack
of adequate knowledge about ADE (26%) while 20% thought it
would disappear shortly and 14% did not find it necessary to report
the reaction.
Conclusions: Patients would want to report an ADE, but they do not
have adequate knowledge about ADEs. Healthcare workers do not
report because of fear and subjectivity. Dedicated pharmacovigilance
interventions at the community level would improve community mem-
bers' knowledge and hence ADE reporting.
372 | Identifying patients at risk of adverse
outcomes from inappropriate polypharmacy
Nashwa Masnoon1; Sepehr Shakib2; Lisa Kalisch‐Ellett3;
Gillian Caughey4
1Royal Adelaide Hospital, University of South Australia, Adelaide,
Australia; 2Royal Adelaide Hospital, University of Adelaide, Adelaide,
Australia; 3University of South Australia, Adelaide, Australia; 4University
of Adelaide, Royal Adelaide Hospital, University of South Australia,
Adelaide, Australia
Background: Polypharmacy is defined as the use of five or more med-
icines, which does not help distinguish clinically appropriate from inap-
propriate polypharmacy. Whilst there are various polypharmacy
assessment tools, none of them combine the different aspects of med-
ication rationalization to identify patients at risk of adverse events.
Objectives: To develop a score‐based polypharmacy tool to identify
patients at risk of adverse events.
Methods: A systematic review of existing polypharmacy tools and
their validation against patient outcomes was undertaken. Expert
doctors and pharmacists in the Quality Use of Medicines (QUM)
were surveyed regarding their use of existing validated tools and
important factors during polypharmacy assessment. Important medi-
cation‐related factors identified from the literature and survey find-
ings were subsequently tested against the outcomes of drug‐
related hospitalisations (DRH), emergency hospitalisations and mor-
tality within one year of discharge from an outpatient multimorbidity
clinic using binary logistic regression, before combining them into a
final formula for the polypharmacy tool. Medicines on discharge
were used for patients aged 65 years or over, discharged from the
clinic between January 2010 to February 2017.
Results: The systematic review identified 42 polypharmacy tools, with
31.0% (n = 13) validated against outcomes. Experts in QUM (n = 22)
revealed low use of validated polypharmacy tools and stated that
whilst the number of medicines is important, medication‐related fac-
tors such as drug–drug interactions, taking sedatives and anticholiner-
gics, opioids and systemic corticosteroids are also important in
polypharmacy assessment. The median age of the 601 patients
included was 80.0 years (interquartile range or IQR 73.0–85.0 years),
with patients taking a median of 12.0 medicines (IQR 8.0–16.0). The
prevalence of drug–drug interactions was 76.4% (n = 459), sedatives
and anticholinergics was 49.1% (n = 295), opioids was 18.0%
(n = 108) and systemic corticosteroids was 8.3% (n = 50). Opioids pre-
dicted DRH, systemic corticosteroids predicted DRH and emergency
hospitalisations and sedatives and anticholinergics predicted mortality.
The number of medicines predicted emergency hospitalisations.
Conclusions: The prevalence of drug–drug interactions and sedatives
and anticholinergics reflects the complexity of care for older
multimorbid patients with polypharmacy. Whilst polypharmacy is
defined using the number of medicines, this study shows that specific
drug classes need to be additionally considered to identify patients at
risk of adverse events.
373 | Integrating hypothesis‐free signal
detection with real‐world data into existing
signal management systems: A prospective
evaluation of potential impact
Qing Liu; Manfred Hauben; Kenneth Petronis; Stephen Schachterle;
Sundaresan Murugesan; Rongjun Shen; Hannah Sheardown;
Jamie Geier; Andrew Bate
Pfizer Inc., New York, NY
Background: Electronic Health Records are potentially useful data
sources for the drug safety signal detection. Novel analysis methods
and visualization tools can generate signals of disproportionate
recording (SDRs) in longitudinal observational data but there is limited
prospective testing.
Objectives: The overarching objective of this work was to develop and
test a systematic approach equipped to highlight and review SDRs
that was scalable and could be integrated into existing signal manage-
ment systems.
Methods: Temporal patterns between drug claims and health out-
comes were studied in the Truven MarketScan database (Jan 2010 ‐
Jun 2015) by generating chronographs for 3 approved therapies:
pregabalin (Lyrica), atorvastatin (Lipitor) and varenicline (Chantix).
271 event‐drug pairs were identified for this study. All 271 drug‐event
pairs were screened via Self‐Control Case Series, High‐Dimensional
Propensity Score methods, and findings from Pfizer Spontaneous
Reporting System data. Lower bounds of the 95% CI of the test statis-
tics for any drug‐event pair >1 were treated as potential SDRs for fur-
ther investigation and then visually evaluated via chronograph
(graphical display of observed and expected counts). Potential SDRs
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were reviewed by 3 subject matter experts. A chronograph was deter-
mined “positive” if it showed a clear upward trend after prescription
compared to before prescription according to pre‐defined criteria. Fol-
lowing the review, output was classified further as true positives, true
negatives, false positives and false negative using clinical and label‐
based information.
Results: Among the 136 drug‐event pairs reviewed, about 15%
(n = 21) were labeled events. Only 26 (19%) chronographs are identi-
fied as positive of which 81% (n = 21) were false positives. The posi-
tive predictive value (PPV) ranged from 0.16 to 0.33; the negative
predictive value (NPV) ranged from 0.65 to 0.98. The sensitivity
ranged from 0.08 to 0.50 whereas specificity ranged from 0.66 to
0.96.
Conclusions: Signal detection methods/tools need to permit time‐
efficient discovery and assessment of underlying drug‐event pairs.
The triage approach produced 136 chronographs that required
review from 271 drug‐event pairs. Temporal pattern discovery of
these data showed moderate‐to‐high NPV and specificity but poor
PPV and sensitivity. Given the poor PPV, and that visual review of
chronographs is time consuming, a need to more effectively filter
the number of chronographs for manual review was identified for
a subsequent analysis.
374 | Application of natural language
processing techniques to extract insights for
pharmacovigilance from published literatures
Shinichi Matsuda; Takumi Ohtomo
Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
Background: In pharmacovigilance (PV), scientific literatures are
important source not only to identify individual case safety reports
of adverse events for specific drugs but also to understand research
trends including possible emerging safety issues. Because reviewing
literatures manually is a time‐consuming process, recently developing
natural language processing (NLP) techniques may become help to
provide insights. As a case study, we have tried to identify character-
istics on literatures of rheumatoid arthritis (RA) where therapeutic
breakthroughs including approvals of biologics have occurred in recent
years.
Objectives: To understand the characteristic contents of literatures
using NLP techniques.
Methods: PubMed was searched (1 January 2013 to 31 December
2017), and we collected literature abstracts regarding RA. Several sub-
sets of abstracts were created based on the tags that enabled us to fil-
ter them with PV information; those are comprised of abstracts about
adverse drug reactions, safety, autoimmune diseases often related
with RA (e.g. systemic lupus erythematosus, Sjogren's syndrome) and
pregnancy/pregnancy outcomes. Similarly, this research also used
the tags about epidemiology information to filter abstracts with epide-
miologic study methods. After pre‐processing each set of abstracts'
texts (e.g. removing stop words), TF‐IDF analysis was performed to
identify characteristic words in each set. In addition, Latent Dirichlet
Allocation (LDA) was performed to find out 20 specific topics from
the texts with epidemiology information. All analysis was carried out
using R statistical software for text‐mining.
Results: We identified 2064 abstracts regarding RA. Overall, the most
frequently appearing words were RA (3021 appearances), patients
(2683), arthritis (1627), disease (1450), rheumatoid (1418) and treat-
ment (985). Some characteristic words could be identified by
reviewing words that have relatively high TF‐IDF scores in PV infor-
mation; interestingly, certolizumab‐pegol was found because it is the
first tumor necrosis factor‐alpha inhibitor approved in Europe for
medication available for women with RA during pregnancy in 2018.
Additionally, LDA revealed some research topics such as cancer genet-
ics, cardiovascular outcomes, efficacy of biologics, life styles and dis-
ease activities.
Conclusions: Analyzing literatures using NLP techniques can be help-
ful to efficiently explore insights including what kinds of safety‐related
events exist and how diseases are investigated by
pharmacoepidemiologic studies.
375 | Applying prescription sequence
symmetry analysis to detect unknown
adverse drug reactions in a Chinese claims
database
Yinchu Cheng1; Yuansheng Huang2; Siyan Zhan2
1Peking University Third Hospital, Beijing, China; 2Peking University
Health Science Center School of Public Health, Beijing, China
Background: Many adverse drug reaction (ADR) warning systems are
based on current knowledge. Thus, signal detection methods that
can identify unknowns ADRs are needed.
Objectives: To explore ways of detecting unknown ADRs using pre-
scription sequence symmetry analysis (PSSA) in a Chinese national
claims database.
Methods: We applied PSSA to determine which drugs might have
hepatotoxicity in the database of National Basic Medical Insurance
for Urban Employees (NBMIUE). Several liver‐protective drugs were
chosen as marker drugs of liver injury. All the patients with at least
one prescription of these marker drugs between 01/01/2015 and
31/12/2015 were included in the study and all of their records were
extracted from the data source. 4‐digit and 5‐digit codes of the Ana-
tomical Therapeutic Chemical (ATC) Classification System were used
respectively to classify all the prescribed drugs in the study population
and each drug category identified was used as an index drug for fur-
ther PSSA analysis. Crude sequence ratios (CSR) were calculated. CSRs
with lower limits of confidence interval bigger than 1 were considered
positive PSSA results. These positive results were then interpreted as
known ADRs, false positive results induced by bias or unknown ADRs,
based on drug labels, literature review, knowledge base searching and
expert consultation. Descriptive statistics were used to summarize
each type of the results.
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Results: A total of 57,008 liver protective drug users were included.
They used altogether 661 classes of drug identified by 5‐digit ATC
codes, among which 133 positive signals were found by PSSA
(20.1%). After interpretation, 97 positive signals were considered as
known ADRs (72.9%), 34 false positive signals (25.6%) and 2 unknown
ADRs (1.5%). Positive predictive value based on this interpretation
was 74.4% (95%CI, 66.4%–81.1%) in all drugs and was 100% in tradi-
tional Chinese medicine drugs.
Conclusions: PSSA proves to be effective in detecting potential
unknown ADR signals in the NBMIUE database. The unknown signals
detected in this study need further investigation. Future studies are
expected to test the method in patients with longer follow‐up period,
and also to optimize the process of deciding known ADR and potential
bias to improve the efficiency of PSSA in detecting unknown ADRs.
376 | Safety‐signal detection for liver
dysfunction associated with a drug by
utilizing MID‐NET®: Results from pilot
studies
Sono Sawada1; Yoshiaki Fujmura2; Michio Kimura3; Koichiro Murata4;
Naoki Nakashima5; Masaharu Nakayama6; Kazuhiko Ohe7;
Takao Orii8; Eizaburo Sueoka9; Takahiro Suzuki10; Hideto Yokoi11;
Chieko Ishiguro1; Kaori Yamada1; Maori Itoh1; Yoshiaki Uyama1
1Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan;
2Tokushukai Information System Incorporated, Osaka, Japan;
3Hamamatsu University Hospital, Hamamatsu, Japan; 4Kitasato
University Hospital, Sagamihara, Japan; 5Kyushu University Hospital,
Fukuoka, Japan; 6Tohoku University Graduate School of Medicine,
Sendai, Japan; 7The University of Tokyo Hospital, Tokyo, Japan; 8NTT
Medical Center Tokyo, Tokyo, Japan; 9Saga University Hospital, Saga,
Japan; 10Chiba University Hospital, Chiba, Japan; 11Kagawa University
Hospital, Kanagawa, Japan
Background: The Medical Information Database (MID‐NET®) was for-
mally launched in April 2018. One of the notable features of MID‐
NET® is that it makes many laboratory test results available for anal-
ysis. The Pharmaceutical and Medical Devices Agency (PMDA) has
conducted pilot studies in different scenarios to examine the potential
applicability of the MID‐NET® to safety‐signal detection.
Objectives: To assess advantages and limitations of the MID‐NET® as
a safety‐signal detection tool.
Methods: We have conducted two pilot cohort studies with two cou-
ples of target drugs and comparison drugs (amiodarone vs. nifekalant,
and alogliptin vs. vildagliptin) to assess the applicability of MID‐NET®
by examining the recognized risks: the amiodarone‐induced liver dys-
function and the alogliptin‐induced liver dysfunction. Each of the stud-
ies includes subjects who met the following criteria: 1) who initiated
their medication with the target drug or the comparison drug between
April 2009 and September 2016; 2) whose first data in the MID‐NET®
was recorded more than 180 days before initiating the target drug or
the comparison drug; 3) whose levels of liver function were within the
normal range during the 180‐day period before the date on their first
prescription, and 4) who did not have concomitant medications of the
target drug and the comparison drug on the date of their first prescrip-
tion. The liver dysfunction was defined as more than five‐fold increase
in ALT, AST, or/and ALP from the baseline. Every 6 months from 1st
April 2009, we calculated the non‐adjusted incidence rate ratio and
the adjusted incidence rate ratio (aRR), in which subjects in each target
drug group were 1:1 matched to subjects in its comparison group,
based on sex, age, and the date of the first prescription.
Results: In the study of the first pair (amiodarone vs. nifekalant), the
number of subjects was 613 for the amiodarone and 160 for the
nifelakant. The aRR indicated a higher risk in the amiodarone com-
pared to the nifekalant (aRR:20.60, 95%CI: 4.92–86.20) after the 6th
observational point (March 2012). In the other study, the number of
subjects was 4,155 for the alogliptin and 7,472 for the vildagliptin.
The aRR indicated a lower risk in the alogliptin compared to the
vildagliptin (aRR: 0.76, 95%CI: 0.59–0.98) at the final observational
point (September 2016).
Conclusions: Although more careful analysis would be necessary, the
MID‐NET® has huge potential to detect a safety signal of the liver
dysfunction. To properly use MID‐NET® in pharmacovigilance, it is
essential to extend a range of investigations in other drugs with similar
protocols.
377 | Adverse reaction signal detection for
statins in a Chinese regional healthcare
database using tree based scan statistic
method
Hailong Li1,2; Lingli Zhang1; Siyan Zhan2
1Evidence‐Based Pharmacy Center, West China Second Hospital, Sichuan
University, Chengdu, China; 2Peking University Health Science Center,
Beijing, China
Background: With increasing availability, the use of healthcare data-
bases as complementary data source for drug safety signal detection
has been explored to cover the limitations of spontaneous reporting.
The tree‐based scan statistic (TreeScan) is a statistical data mining tool
that has been used for drug safety signal detection.
Objectives: To apply TreeScan method for detecting adverse effect
signals of statins and evaluate the performance of TreeScan in Chinese
Regional Healthcare Database.
Methods: Our study used the Yinzhou healthcare database, a linked
primary and secondary care database, in Ningbo city, China, from
2010 to 2016. Patients older than 18 years with diagnosis of hyper-
tension were included. We identified statin users according to the pre-
scription information of out/in‐patient. The Adverse Events (AEs)
were defined using ICD‐10 codes of out/in‐patient diagnosis. We first
detect the safety signals of statins by using the TreeScan method. In
order to better evaluate the performance of the method, we
established a set of reference signals by referring to a set of ICD‐10
codes to identify AEs. Gold standard for these signals was constructed
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by searching published Meta‐analysis and systematic reviews and
package inserts of statins. By comparing the signals to reference sig-
nals, we could compute measures of diagnostic test, including sensitiv-
ity, specificity, positive predictive value (PPV), negative predictive
value (NPV), accuracy, youden index and area under the curve (AUC).
Results: A total of 224,187 patients were finally enrolled and divided
into two groups (85,758 statin users and 138,429 nonusers). We
built a reference set of 126 AEs (ICD‐10) including 13 positive sig-
nals and 113 negative signals. TreeScan generated 30 positive sig-
nals (P < 0.05), and 9 of them were known adverse effects. The
sensitivity, specificity, PPV, NPV, accuracy, youden index and AUC
were 69%, 82%, 31%, 96%, 81%, 52%, 75%, respectively.
Conclusions: TreeScan can be applied as a signal detection method in
Chinese Regional healthcare database for drug safety surveillance,
simultaneously evaluating small and large number of potential AEs
(subsets of diagnosis codes) and adjusting for multiple testing inherent
in many overlapping groups evaluated. Comparative evaluation study
should be conducted to further evaluate its performance and explore
its proper application condition.
378 | High dimensional empirical Bayes
screening (ideas) in north American claims
and VA electronic medical records
Jill E. Lavigne1; Kwan Hur2; Bharat Thakkar3; John J. Mann4;
Robert D. Gibbons5
1Department of Veterans Affairs, Canandaigua, NY; 2Department of
Veterans Affairs, Hines, IL; 3Department of Veterans Health Affairs,
Hines, IL; 4Columbia University, New York, NY; 5University of Chicago,
Chicago, IL
Background: Suicide is the 10th leading cause of death in the US, and
the rate has been rising for 16 years. Most suicide decedents have
psychiatric disorders and are actively receiving healthcare, yet the
effects of medications on suicidal behavior is intensely debated.
Objectives: To develop a statistical surveillance method based on pop-
ulation claims data and electronic medical records to identify drugs
associated with increased or decreased risk of suicide attempts.
Methods: Design: Within‐person incident‐user cohort to simulta-
neously assess 923 drugs and suicide attempts. Setting: MarketScan
(MS) claims for commercially insured patients and medical records of
Veterans in the VA Corporate Data Warehouse from 2003–2014. Par-
ticipants: 198,652 subjects with a suicide attempt and days' supply of
any medication in either MarketScan (MS) (n = 923) or VA electronic
medical records (n = 513). Exposure: First filled prescription of each of
923 drugs in MS data, 513 of which were also documented in VA elec-
tronic medical records.Main Outcome: Suicidal behavior (ICD‐9 codes
E950‐E959). Statistical analysis: Mixed‐effects logistic regression was
used to estimate empirical Bayes (EB) odds ratios (ORs) and 95% confi-
dence intervals (CIs) adjusted formultiple comparisons for the individual
drug effects. The EB OR is interpreted as the increased or decreased
likelihood that the adverse event will occur following drug exposure.
Results: This new statistical surveillance system found 24 drugs with
increased and 36 with reduced risk of suicidal behavior. In both popu-
lations (VA and MS), 7 drugs were associated with increased and 20
with decreased risk. The strongest increased risk signals occurred in
alprazolam (OR 1.83 (1.57–2.12) (MS), OR 1.70 (1.34–2.16) (VA)), diaz-
epam (OR 1.36 (1.09–1.70)(MS), OR 1.74 (1.42–2.13) (VA)), and
hydromorphone (1.72 (1.07–2.79)(MS) and 1.79 (1.21–2.64) (VA)).
Among the potentially most protective drugs were folic acid (OR
0.37 (0.25–0.56) (MS), OR 0.56 (0.51–0.62)), mirtazapine (OR 0.37
(0.31–0.45) (MS), OR 0.75 (0.67–0.83) (VA)) and naltrexone (OR 0.43
(0.30–0.60) (MS), OR 0.70 (0.57–0.87)). Of those with decreased risk
signals, 22 of 36 (61.1%) are approved psychotropic medications, pro-
viding both a degree of validation of the method and reassurance to
clinicians about the effectiveness and safety of these drugs in suicidal
patients.
Conclusions: High‐dimensional empirical Bayes screening for drug
safety surveillance is feasible and generates statistically and clinically
significant signals of possible risks and benefits of drugs on risk of sui-
cide behavior.
379 | Characterization of drug interaction
related signals leading to Eu regulatory action
and a methodological review of novel drug
interaction signal detection methods in the
post‐marketing setting
Debabrata Roy1,2; Lorna Hazell1,2; Vicki Osborne1,2; Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK
Background: A growing rise in polypharmacy is often attributed to an
aging population and associated co‐morbidities. In patients with com-
plex therapeutic regimens, this increases the potential of harmful drug
interactions (DI's) which may result in unexpected adverse drug reac-
tions. Current signal detection methods used to identify DI‐related
signals may not be sufficient. Novel methods utilizing big data sets,
machine learning or algorithmic techniques may have a crucial role in
DI‐related signal detection.
Objectives: The aim of this study is to assess current and novel
methods used to identify DI‐related safety signals in the post‐market-
ing setting.
Methods: Current methods used to detect DI‐related signals will be
reviewed using publicly available information from the European Med-
icines Agency (EMA) on signals leading to post‐marketing regulatory
action between July 2012 and December 2018. A review of the pub-
lished literature will also be conducted to identify novel methods used
to detect DI‐related signals which may have utility in the post‐market-
ing setting. A systematic approach will be used to assess the perfor-
mance of novel DI signal detection methods based on predefined
criteria including, for example, sensitivity, precision and applicability.
Results: Data collection, identification of valid data sources and meth-
odological review are currently in progress. So far, one DI‐related
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signal which led to post‐marketing regulatory action has been identi-
fied from the search whereby dehydration was associated with an
interaction between tolvaptan (vasopressin antagonist used to treat
inappropriate antidiuretic hormone secretion) and diuretic use. This
DI‐related signal was identified in 2012 based on 16 spontaneous
reports. The identification of this signal resulted in an update to prod-
uct information, regarding a possible interaction between tolvaptan
and diuretic use and the risk of renal dysfunction.
Conclusions: The final results of this study will identify whether the
majority of DI‐related signals in the post‐marketing setting are identi-
fied from individual case safety and spontaneous reports. Novel
methods, utilizing big data sets and advancements in machine learning
and computational power, have the potential to identify previously
unknown and unexpected DI‐related signals.
380 | Using innovative automation to author
development safety update reports and
enhance cost‐effectiveness
Jennifer Cichone; Krystle Pianka; Nipa Parikh; Beth Pulaski;
Akshay Vashist; Mirza Rahman
Otsuka Pharmaceutical Development and Commercialization, Inc.,
Princeton, NJ
Background: Development Safety Update Reports (DSUR) present a
comprehensive review and analysis of pertinent safety information
related to investigational drugs collected during specified periods. Pro-
ducing a quality DSUR is costly, time‐consuming, resource‐intensive,
and requires effective communication across many different
stakeholders.
Objectives: Develop an electronic DSUR authoring platform to auto‐
populate a text‐based business template that reduces writing efforts
without compromising quality or compliance to save time and money.
Methods: Using data analytics operating model, source documenta-
tion was gathered and mapped to 2 relevant text‐based templates.
The first template included keys which auto‐populate via content
extraction from various uploaded source documents. The second tem-
plate served as a framework of text to be submitted in the final draft.
Pre‐defined fixed product attributes also directed population of
optional content. Using expert and text rules as well as natural lan-
guage processing, data and text were merged without manual inter-
vention. User interfaces were designed on a computerized
collaboration platform for answering queries, uploading source docu-
mentation, and testing. Multiple feedback cycles mined and scanned
relevant source data according to natural language processing logic.
Outcomes measured included average hours (h) and costs saved per
DSUR.
Results: Twenty‐one of the 31 DSUR sections were either fully (n = 9)
or partially (n = 12) automated (e.g. marketing approval status, clinical
and post‐market exposure, executive summary, introduction). In 2017,
5 DSURs were developed with the platform and 2 with manual inter-
vention. Automation saved 26 h/DSUR (182 h total) with cost‐savings
realized at $7000/report ($35000/year). In 2018, automation saved
$49,000. Compliance was maintained at 100% and no decrease in
quality was observed.
Conclusions: Automation harmonizes DSUR production and removes
human error through consistent use of templates, data sources, and
process. Of the 10 sections which could not be currently automated,
5 sections required analysis of safety data. Thus, time saved allowed
more time to focus on safety analysis during authoring. Overall, the
tool enhanced the potential of the organization to generate large vol-
umes of quality DSURs with limited resources in a timely manner, with
improved quality and consistency. It transformed a resource heavy
and time‐consuming process to a more streamlined and cost effective
process.
381 | Impact analyses of European
pharmacovigilance interventions on public
health burden
Samantha Lane1; Elizabeth Lynn1,2; Jim Slattery3; Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK; 3European Medicines Agency, London, UK
Background: Since implementation of the 2012 pharmacovigilance
(PV) legislation in the EU, monitoring the success of PV has become
commonplace; however impact of PV regulatory interventions on pub-
lic health remains mostly unquantified. There is a need for research to
identify the best technique for measuring impact of these actions, and
guidelines on reporting impact analyses. The overall aim of this study
is to quantify the impact of EU marketing authorisation withdrawal,
revocation or suspension (“PV regulatory interventions”) in terms of
morbidity changes.
Objectives: Interim analysis to assess the feasibility of predictive
modeling techniques for estimation of public health impact of PV reg-
ulatory interventions.
Methods: Prescription products used in primary care whose marketing
authorisations were withdrawn, revoked or suspended in France, Ger-
many and the UK between 2012 and 2016 were previously identified.
Annual product utilization figures for the year prior to PV action were
estimated using IMS France, IMS Germany and the British Health
Improvement Network (THIN) electronic health record databases. Sys-
tematic searches of PubMed/MEDLINE, and European Medicines
Agency and national competent authority websites and documents
were conducted to identify quantitative studies for the product and
adverse drug reaction (ADR) of interest, allowing risks to be calculated.
The public health impact of the intervention was estimated in terms of
morbidity reduction due to product withdrawal, revocation or suspen-
sion by modeling of usage figures and risk of each ADR. Work con-
tinues to obtain background risk data to establish the actual
reduction in morbidity attributable to removal of the product from
market in this territory.
Results: 18 products were considered for impact analysis; 9 were
excluded as no quantitative studies were identified for the respective
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ADRs. This interim analysis focused on ketoconazole, metoclopramide
and domperidone, and provided a prediction of the number of ADRs
avoided per year as a result of marketing authorisation withdrawal,
revocation or suspension, and an estimation of the public health
impact of each PV action using changes in morbidity as an indicator.
Conclusions: This interim analysis tested a method for predicting pub-
lic health impact of PV interventions on a subset of products based on
drug utilization data and expected changes in morbidity. Results sug-
gest the method could be useful in determining public health impact
of future PV actions. The predictive modeling method will be further
evaluated prior to completion of this study.
382 | Adverse event report forecasting from
custom engagement programs
Qing Liu; Robert Davenport; Phillip Eichorn; Quazi Ataher;
Andrew Bate
Pfizer Inc., New York, NY
Background: New data streams for potential Pharmacovigilance (PV)
use are increasing. Pfizer's Customer Engagement Programs (CEPs)
annually generate over 150,000 adverse event reports (AERs). Quanti-
tative assessment of AERs from completed CEPs may help predict
overall value of individual CEPs in enhancing PV and patient safety.
Objectives: Identify differences in characteristics between completed
CEPs that produced AERs and those that did not, and develop a model
to predict average monthly AER volume (AMV, calculated as total vol-
ume/CEP duration) for a planned CEP.
Methods: We used data on CEP programs and associated AERs
between 1/1/2014 to 9/30/2017. Descriptive analysis generated
mean (SD), median (range) for continuous variables, frequency and
proportion for categorical variables, overall and stratified by CEPs with
or without AERs. Multiple linear regression was performed with AMV
as dependent variable and CEP characteristics (e.g., country, size, com-
munication channel, etc.) as explanatory variables. Models were fit on
original data scale and log transformed scale. Stepwise selection based
on F‐statistics defined the final model.
Results: Among the 8533 CEPs, AMV of AER ranged 0–5311 (mean
5.52, median 0, SD 68.33). 77.1% CEPs had no AERs. Limited differ-
ences were seen between CEPs with and without AERs: CEPs without
AER had lower baseline program complexity scores (21.2% vs 4.8%
with high scores), tended to be the ones that closed receipt of further
AERs upon program end (85.6% vs 92.0%) and had more missing infor-
mation on PV Levels of the products under the program (23.1% vs
38.7%). The final model (F (35, 6760) = 11.78, p < 0.0001) explained
6% of the variance (R2 = 0.06) with 10 predictors: country, whether
it is a nurse program, type of program (e.g., PSP, MRP), subject type
(e.g., patient/consumer, HCP, etc.), size, focus of program(e.g., specific
drug versus unbranded disease area), type of communication, number
of contacts per subject, type of medical condition, and ‘special risk cir-
cumstances’. Confidence intervals of the predicted AMV values were
very wide due to the heterogeneous nature and other limitations of
the data such as the need to combine some variable categories to
facilitate model fitting, the clear existence of outlier CEP programs,
lack of precise subject numbers, and lack of normality in the data.
Conclusions: While some insights can be drawn from the analysis, the
vast heterogeneity across the CEPs and the limited number of AERs in
the majority of CEPs prevented very accurate AMV forecasting. A
more systematic standardization of design and collection of CEP data
may make more accurate prediction of AER in the future.
383 | Evaluating the process of standardizing
investigational drug substance names
reported to the United States Food and Drug
Administration adverse event reporting
system
Maggie Fung; Sonja Brajovic; Nitin Patel; Sherry Chang
US Food and Drug Administration, Silver Spring, MD
Background: The US Food and Drug Administration (FDA) Adverse
Event Reporting System (FAERS) Product Dictionary (FPD) indexes
pre‐ and post‐market suspect drug products to facilitate retrieval of
Individual Case Safety Reports (ICSRs) for internal review. Investiga-
tional drug (IND) substances are initially identified in ICSRs and FPD
by proprietary codes from the sponsor, which may evolve into stan-
dardized substance names established by the US Adopted Names
(USAN) Council and WHO‐International Nonproprietary Names
(WHO‐INN) Expert Group. The FDA Global Substance Registration
System (G‐SRS) incorporates the USAN/INN into its database as pre-
ferred names, which FPD utilizes to update IND substance codes. IND
substance codes that have yet to establish a USAN/INN are grouped
under an “Investigational Product” category within FPD to be manu-
ally reappointed to their respective USAN/INN once established.
Objectives: To evaluate the process for standardizing IND substances
in the FAERS Product Dictionary.
Methods: Synonyms grouped under the “Investigational Product”
category in FPD were retrieved up to October 2018. IND substance
codes were referenced against G‐SRS to determine the existence of
their preferred names. Substances with preferred names that did not
pre‐exist in FPD were added. All substance preferred names had
their respective codes reclassified as synonyms so that cases
reporting the codes are redirected to the preferred names. IND sub-
stances identified only by a code remained in the “Investigational
Product” category.
Results: The “Investigational Product” category of FPD retrieved 359
IND substance codes of which 257 remained unchanged as IND codes
and 102 corresponded to existing G‐SRS preferred substance names.
Of these, 41 IND substance codes were reclassified to 36 unique G‐
SRS preferred names that were already incorporated in FPD, and 61
IND codes were reclassified to 54 unique preferred names that
required the creation of new FPD entries. All 102 IND substance
codes were reclassified as synonyms to their respective preferred sub-
stance names. These updates affected 611 ICSRs in FAERS.
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Conclusions: The current process of manually updating IND sub-
stances in FPD is insufficient, leading to inconsistencies with coding
safety reports as sponsors utilize different synonyms to report the
same IND substance, and as an IND code matures to a preferred sub-
stance name. An automated process is necessary to track IND sub-
stances during development to streamline FPD updates as substance
standardization occurs.
384 | Monitoring of medicinal products
authorized based on a single‐arm trial: The
case of a CAR‐T cell therapy
Torbjorn Callréus1; Maurizio Sessa1; Tarec El‐Galaly2;
Mats Jerkeman3; Morten Andersen1
1Department of Drug Design and Pharmacology, University of
Copenhagen, Copenhagen, Denmark; 2Roche, Basel, Switzerland;
3Department of Oncology, Lund University, Lund, Sweden
Background: For several reasons, scientific progress is now translating
into new therapies that are less likely to have been investigated in tra-
ditional randomized clinical trials (RCT). Hence, alternative approaches
to evidence generation are evolving thereby also impacting post‐
authorisation monitoring strategies.
Objectives: With a recently authorized chimeric antigen receptor T
(CAR‐T) cell therapy as an example (axicabtagene ciloleucel), the aim
of the present study is to estimate the power over calendar time of
detecting significant deviations in terms of effectiveness and safety
when data accrue in health care databases and a single‐arm study is
used as a reference.
Methods: We performed simulations of different scenarios to explore
the temporal patterns of power (1‐β) when different assumptions
were made with regard to source population and the clinically relevant
effects (Δ). As a reference, we used a published pivotal single‐arm trial
of axicabtagene ciloleucel in patients with diffuse large B‐cell lym-
phoma (DLBCL). We assumed a yearly enrolment rate of 2 patients
per million source population. As an effectiveness end‐point we chose
overall survival at 6 months (reference: 21%) and as a safety end‐point
we chose aphasia grade 3 occurring after the CAR‐T cell infusion (ref-
erence: 7%). The type I error rate (α) was set at 5% (one‐sided) and a
chi‐square test was assumed to be used for significance testing.
Results: Assuming amarket introduction in 2019, with a source popula-
tionof5million, the timetoreachapowerof80%todetectaclinically rel-
evant 10%‐point increase of mortality at 6 months was 2025. By
increasing the source population to 15or 25million, this time as reduced
to 2023 and 2022, respectively. The corresponding estimates for a 5%‐
point increase with source populations of 5, 15 and 25 million were
2038,2036and2035, respectively.Withasourcepopulationof5million,
the timeto reachapowerof80%todetectaclinically relevant10%‐point
increase of aphasia grade 3 was 2022. By increasing the source popula-
tion to 15 or 25million, this time as reduced to 2020 and 2020. The cor-
respondingestimates for a 5%‐point increasewith sourcepopulationsof
5, 15 and 25million were 2028, 2026 and 2026, respectively.
Conclusions: When historical controls on ethical grounds are used for
a monitoring program, simulations of various monitoring scenarios can
provide insights into when important deviations in terms of effective-
ness and safety may be detected.
385 | Evaluation of reported adverse drug
reactions: A study from a regional
spontaneous database in Saudi Arabia
Khaledah A. Alenzi1; Ali F. Altebainawi2; Abdulrahman Ghalelah1;
Thamir M. Alshammari2,3
1Ministry of Health, Tabuk, Saudi Arabia; 2Medication Safety Research
Chair, King Saud University, Riyadh, Saudi Arabia; 3Saudi Food and Drug
Authority, Riyadh, Saudi Arabia
Background: A spontaneous regional database of adverse drug reac-
tions (ADRs) is considered an essential source for post‐market autho-
rization safety information that may lead to the early detection of
ADRs.
Objectives: To assess the type, severity, seriousness, causality, com-
pleteness of ADRs among a spontaneous regional database.
Methods: A cross‐sectional study was conducted to assess all ADRs
reports that were submitted to a cluster of hospitals in Saudi Arabia
in the period between 2014 and 2018. The database was structured
based on the fields of Saudi ADRs form which is similar to the
Medwatch® ADRs from. The data included were patient demo-
graphics, drug information, event information, relatedness informa-
tion, laboratory and outcome information, and reporter information.
The Naranjo algorithm was used to assess the causality of the ADRs.
Furthermore, the completeness was assessed by reviewing the com-
ponents of the ADRs fields, and how many fields were completed.
All data were analyzed by using the Statistical Analysis Software
(SAS), version 9.4.
Results: A total number of 209 ADRs reports were reported during
the study period. Around 29% of these ADRs reports were received
from consumers/patients, while, the rest were submitted by
healthcare professionals (HCPs), (71%). As for an ADRs reports com-
pletion, it was found that the completion of the information in these
reports was 87% for patients and 67% for HCPs (P < 0.05). All age
groups were represented in these ADRs reports with the most age
group that been affected by ADRs were between age of 25–34 years.
Female gender was slightly more than male gender as gender distribu-
tion (54% vs 46%). A spontaneity reported (209) cases with (249)
suspected drugs and (516) reactions. The most reported medication
group as suspected drugs had ADRs was Antimicrobial (38.5%),
followed by cardiovascular medications (15.8%) (p < 0.05). The most
severe events were associated with ciprofloxacin, oxytocin, and
imipenem‐cilastatin. As results from Naranjo assessment for causality,
it was found that neurologic events (7%) has high score (≥ 9) of been
causal relationship with the suspected drugs followed by cardiovascu-
lar and respiratory events (5%). Peginterferon was associated with
serious ADR and Lehexol lead to life threating cases.
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Conclusions: Consumer reports are considered of a very essential
source for ADR reporting. In addition, regional spontaneous reports
database is a valuable source for signaling. Commonly used medication
groups are associated with a higher risk of developing severe and seri-
ous events.
386 | Patterns of adverse drug reactions
reported to a hospital‐ based
pharmacovigilance Centre in Bhutan. ‐ a case
series study
Choki Dorji Mr1; Pramote Tragulpiankit Dr2
1 Jigme Dorji Wangchuk National Referral Hospital, Thimphu, Bhutan;
2Mahidol University, Bangkok, Thailand
Background: Adverse Drug Reactions (ADRs) are leading causes of
morbidity and mortality in the hospitalized patients. Approximately
15–20% of hospital budgets are spent on treating ADRs and drug
related problems in Europe. Identifying a suspected drugs and type
of reactions will help clinicians in signal detection.
Objectives: To identify the common drugs and types of reactions
reported to a hospital‐based pharmacovigilance centre (JDWNRH) in
Bhutan and generate hypotheses to inform further studies on ADR
signals detection.
Methods: We conducted a descriptive case series study of individual
case safety reports (ICSR) reported to the JDWNRH
pharmacovigilance centre from 2010–2018. Data extracted were
analyzed to evaluate the pattern of ADRs characterized by patient's
socio‐demographic information; suspected anatomical therapeutic
chemical (ATC) drug classification, council for international organiza-
tions of medical science (CIOMS) classification of ADR, and out-
come. A causal relation between suspected drug and reaction was
assessed using Naranjo's Algorithm. Data management and statistical
analyses were conducted using SPSS (v.21).
Results: We identified 109 ICSR reports among which 56 (51.4%)
were in females and 24 (22.0%) were in persons 21–30 years of
age. The youngest affected patient was a 15‐day‐old infant. There
were 12 (11.0%) reports in children age < 1 year old. Forty‐nine
(44.9%) were due to anti‐infective drugs with 25 (51.0%) of the
reactions being urticaria/angioedema rashes. Ten (20.4%) of the
hypersensitivity reports were due to Amoxicillin. Twenty (18.3%)
reactions were continuing and 67 (61.5%) of the reactions were
reported to be serious, of which 45 (67.0%) of reactions were con-
sidered to be life threatening and 16(24.0%) reaction resulted in a
prolonged hospitalization. Naranjo's causality assessment identified
77(70.6%) reports as probable and 6 (5.5%) as definite.
Conclusions: ADRs have occurred in wide range of age groups
starting from neonate to a geriatric population. Urticarial rashes
attributed to anti‐infective drugs were the most common ADRs
reported along with other category of drugs.
387 | Increased risk of allergic reactions
associated with Xiyanping injection: A
prescription sequence symmetry analysis
Yixin Sun1; Yifan Zhou1; Siyan Zhan1; Yinchu Cheng2;
Shuangqing Gao3; Lang Lv4
1Department of Epidemiology and Biostatistics, Peking University School
of Public Health, Beijing, China; 2Department of pharmacy, Peking
University Third Hospital, Beijing, China; 3Beijing Medical Health
Economics Research Centre of North China, Beijing, China; 4State Key
Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou,
China
Background: Prescription sequence symmetry analysis (PSSA) is an
effective signal detection method for adverse drug events based on
electronic medical databases. Due to its easy application and effective
control of time‐invariant confounders, it can be used to identify unin-
tentional drug effects of traditional Chinese medicine injections, such
as estimating the association between xiyanping use and allergic
reactions.
Objectives: To investigate the risk of allergic reactions associated with
the use of xiyanping in a real‐world setting. And to evaluate the feasibil-
ity of using PSSA to detect drug safety signal in a nationwide medical
database in China.
Methods: A retrospective PSSA study was conducted by using data
from the Chinese Basic Medical Insurance Database in 2015. The
patients newly initiating both xiyanping (index drug) and antiallergic
drugs (marker drug) were identified and selected as study subjects. Anti-
histamines, glucocorticoids, calcium gluconate and adrenaline were
selected as the proxy of allergic reactions. The washout period was set
as one mouth and the interval period was set as 3 days. Adjusted
sequence ratios (ASR) were calculated as the ratio of patients initiating
xiyanping first (causal group) over those initiating an antiallergic first
(non‐causal group) adjusted for time trends in prescribing, which to
investigate the potential association between xiyanping use and allergic
reactions.
Results: There were 6 629 patients who newly initiated both xiyanping
and an antiallergic drug in our study period. The ASR was 2.45 (95%CI:
2.33–2.59), which indicated an increased risk of allergic infections asso-
ciated with the use of xiyanping. Signals were detected by each of the
four kinds of antiallergic drugs.
Conclusions: The results of PSSA showed that there was a potential
association between xiyanping use and allergic reactions. This signal
detection method may be a fast and effective method in drug safety
evaluation and can be used in the Chinese Basic Medical Insurance
Database.
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388 | Adverse drug reactions monitoring at
the Brazil's pharmacovigilance system from
2008 to 2013
Daniel M. Mota1; Álvaro Vigo2; Ricardo de S. Kuchenbecker2
1Brazilian Health Regulatory Agency (Anvisa), Brasília, Brazil; 2 Federal
University of Rio Grande do Sul, Porto Alegre, Brazil
Background: The Adverse Event Reporting System (Notivisa‐drug) is
the primary national surveillance database of the Brazilian Health Regu-
latory Agency (Anvisa) for identifying postmarketing drug
safety problems. Notivisa‐drug has been replaced since December
2018 by VigiMed ‐ an adapted version of the VigiFlow system of the
World Health Organization. VigiMed will allow, for example, the crea-
tion of more accurate reports on the reporting of adverse drug
reactions.
Objectives: The aim of this study was to analyze suspected adverse
drug reactions (ADR) reported in the Brazil's pharmacovigilance system
(Notivisa‐drug) between 2008 and 2013.
Methods: A descriptive study whose database analysis units were
reports of ADR and reports of pairs of drug‐adverse reaction. We ana-
lyzed all reports of suspected ADR submitted to the Anvisa from the
inception of the Notivisa‐drug database from 2008 to 2013 with
respect to reporting rate (RR), patient characteristics, type and severity
of the ADR.
Results: 26,554 reporting were identified in the study period, resulting
in a RR of 22.8 per million inhabitants/year. The female sex prevailed
(60.5%), as well as the white race (58.1%). Age ranged between 0 to
112 years old (median = 46 years). Almost 1/3 (32.5%) of the suspected
ADR reported affected the most vulnerable populations (i.e. elderly and
children). 54,288 pairs of drug‐adverse reaction were assessed, 59.2%
being characterized as severe, especially those that resulted in a clini-
cally important effect (83.1%). Themost frequently drug group in severe
ADRwere L‐Antineoplastic and ImmunomodulatingAgents (32,1%) and
J‐Anti‐infectives for Systemic Use (27.0%), while themost affected Sys-
tem‐organ‐class was skin diseases and similar conditions (23.7%).
Conclusions: This is a pioneer study assessing Brazil's
pharmacovigilance reporting system that resulted in a RR of 22.8
per million inhabitants/year. This RR is far below reported rates of
middle‐ and high‐income countries such as New Zealand,
Swiss, Sweden and Australia, that reported more than 300
reports per million inhabitants/year or South Africa, with 77 reports
per million inhabitants/year.
389 | Mapping Meddra to ICD 9 for signal
detection with longitudinal electronic data
Stephen E. Schachterle; Qing Liu; Kenneth Petronis; Eric Hung;
Sundaresan Murugesan; Richard Gong; Manfred Hauben; Jamie Geier;
Andrew Bate
Pfizer Inc., New York, NY
Background: Longitudinal Observational Databases (LOD), such as
those from health insurance claims, may provide a source of data for
drug safety signal detection. However disease terminologies used in
LOD were not designed for this purpose and may be insufficient to
accurately describe safety concepts. Mapping between the Medical
Dictionary for Regulatory Activities (MedDRA), which was designed
for drug safety, and LOD terminologies could facilitate signal detec-
tion with LOD by appropriately describing drug safety concepts for
signal detection.
Objectives: Develop a method for mapping MedDRA terms to the
International Classification of Disease, Version 9 (ICD‐9) system and
assess the utility of the conversion for signal detection with an Infor-
mation Component Temporal Pattern Discovery (ICTPD) analysis.
Methods: Design: Four conversion tables for the MedDRA to ICD
mapping were used in sequence to map Designated Medical Events
(DME) for a calcium channel blocker (CCB) to ICD‐9 codes. The four
conversion tables were from the: (1) Observational Health Data Sci-
ences and Informatics (OHDSI), (2) Internal Auto Encoding Tool, (3)
MedDRA v.12 dictionary, and (4) UBC Inc. conversion algorithm from
Safety Works® V.6.5.0.
Setting: Patients who were analyzed with the ICTPD were identified
among CCB users in the Truven MarketScan® Insurance Claims data-
base which includes US patients with commercial insurance.
Interventions: The conversions produced groups of ICD‐9 codes that
represented specific MedDRA concepts which, in turn, were assessed
with the ICTPD method.
Main outcome measures: Outcome measures included the proportion
of MedDRA terms that could be converted to ICD‐9 and the number
of signals of disproportional recording (SDRs) generated with the
ICTPD.
Statistical analysis: Proportions of converted terms and SDRs from the
ICTPD analysis were calculated.
Results: Of the 2848 MedDRA DMEs recorded for the CCB, 52%
(n = 1461) could be matched with all 4 of the available conversion
tables. In the ICTPD analysis, 12.7% (n = 186) of the 1461 MedDRA
concepts that were mapped to ICD‐9 produced SDRs.
Conclusions: We were able successfully map 52% of the DMEs for a
CCB from MedDRA to ICD‐9 with 4 separate conversion tables, which
allowed an analysis of the DMEs in LOD. Conversion between
MedDRA and ICD‐9 facilitated the integration of signal detection in
LOD and may improve the performance of signal detection systems;
however, further research is needed to improve conversion between
ICD‐9 and ICD‐10 to MedDRA as well comparative studies that assess
the impact of coding system on signal detection in LOD performance.
390 | Prevalence of colorectal neoplasms
and mortality among new users of low‐dose
aspirin with lower gastrointestinal bleeding
Frederikke S. Troelsen; Dóra K. Farkas; Anne Ording; Rune Erichsen;
Henrik T. Sørensen
Aarhus University Hospital, Aarhus N, Denmark
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Background: Aspirin use is associated with reduced risk of colorectal
cancer (CRC), though the clinical pathway is incompletely understood.
Aspirin inhibits platelet function and may therefore accelerate early
bleeding from premalignant colorectal polyps. The bleeding may
increase detection and removal of polyps before cancer development.
Objectives: To investigate polyp and CRC detection rates and mortal-
ity among new aspirin users with lower gastrointestinal bleeding
(LGIB) compared with non‐users with LGIB.
Methods: We used Danish nationwide population‐based health regis-
tries to conduct this prevalence study during 2006–2013. We identi-
fied all new aspirin users with a diagnosis of LGIB during the study
period. We matched each new user to five non‐users with LGIB.
Matching was based on gender and age on the LGIB diagnosis date.
We computed prevalence and crude and adjusted prevalence ratios
(PRs) for colorectal polyps and CRC, and crude and adjusted mortality
ratios within six months following LGIB, comparing new aspirin users
with non‐users.
Results: We identified 1,038 new users of low‐dose aspirin with LGIB
and 5,190 matched non‐users with LGIB. Among new users and non‐
users, 220 and 950 had endoscopically detected polyps, respectively
[PR = 1.16 (95% CI: 1.01–1.32)]. After restricting the analysis to histo-
logically examined polyps, new aspirin users had a higher prevalence
of conventional polyps [PR = 1.28 (95% CI: 1.06–1.55)] and serrated
polyps [PR = 1.31 (95% CI: 0.95–1.80)]. Stratification by polyp location
showed an increased prevalence of proximal colonic polyps among
new aspirin users compared with non‐users [PR = 1.72 (95% CI:
1.06–2.80)]. New users and non‐users had a similar prevalence of
overall CRC [PR = 1.04 (95% CI: 0.77–1.39)]. However, after stratify-
ing by CRC location, we observed a lower prevalence of proximal
colonic [PR = 0.71 (95% CI: 0.35–1.43)] and rectal tumors [PR = 0.85
(95% CI: 0.53–1.38)] and a higher prevalence of distal colonic tumors
[PR = 1.47 (95% CI: 0.89–2.44)] among new users compared with non‐
users. No difference in mortality was observed [mortality ratio = 1.05
(95% CI: 0.89–1.23)].
Conclusions: The observation that low‐dose aspirin is associated with
increased polyp detection might indicate that bleeding from proximal
polyps leads to earlier detection and removal of polyps before cancer
development.
391 | Testosterone replacement therapy and
the risk of prostate cancer in men with late‐
onset hypogonadism
Christina Santella1; Christel Renoux1; Hui Yin2; Oriana Yu3;
Laurent Azoulay1
1McGill University, Montreal, QC, Canada; 2Lady Davis Institute,
Montreal, QC, Canada; 3 Jewish General Hospital, Montreal, QC, Canada
Background: The association between the use of testosterone
replacement therapy (TRT) and prostate cancer remains uncertain,
with studies assessing this safety concern having important methodo-
logical limitations.
Objectives: The objective of this population‐based study was to
determine whether TRT is associated with an increased risk of pros-
tate cancer in men with late‐onset hypogonadism.
Methods: We used the United Kingdom Clinical Practice Research
Datalink to assemble a cohort of 12,779 men, at least 45 years of
age, newly‐diagnosed with hypogonadism between 1 January 1995
and 31 August 2016, with follow‐up until 31 August 2017. Time‐
dependent Cox proportional hazards models were used to estimate
adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of
prostate cancer associated with use of TRT, compared with non‐use.
Exposure to TRT was lagged by 1 year to account for cancer latency.
Secondary analyses assessed the association by TRT formulation,
number of prescriptions received, and time since initiation. We also
conducted a propensity score‐matched cohort analysis to further
assess the impact of residual confounding.
Results: A total of 215 patients were newly‐diagnosed with prostate
cancer during 58,224 person‐years of follow‐up, generating an inci-
dence rate of 3.7 per 1,000 person‐years. Compared with non‐use,
use of TRT was not associated with an overall increased risk of pros-
tate cancer (3.8 ν 3.4 per 1,000 person‐years, respectively; adjusted
HR, 0.97; 95% CI, 0.71 to 1.32). Results remained consistent in sec-
ondary and sensitivity analyses, as well as in the propensity score‐
matched cohort analysis (HR, 0.87; 95% CI, 0.56 to 1.36).
Conclusions: The use of TRT was not associated with an increased risk
of prostate cancer in men with late‐onset hypogonadism. These find-
ings should provide some reassurance on the long‐term safety of
TRT among men with late‐onset hypogonadism.
392 | Angiotensin converting enzyme
inhibitors and risk of lung cancer: A nested
case–control study
Kasper Bruun Kristensen1; Blánaid Hicks2; Laurent Azoulay3;
Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Queen's University
Belfast, Belfast, UK; 3McGill University, Montreal, QC, Canada
Background: Use of ACE inhibitors (ACEIs) has recently been associ-
ated with an increased risk of lung cancer.
Objectives: To examine whether ACEIs are associated with lung can-
cer compared to use of angiotensin receptor blockers (ARBs) overall,
and to examine whether the association varies with duration of use
and lung cancer histology.
Methods: We conducted a nested case–control study with a new
user, active comparator approach. Cases included all persons with inci-
dent, histologically‐confirmed lung cancer in Denmark from 2005 to
2015, selected from a cohort of patients who had initiated antihyper-
tensive treatments between 1996 and 2015. Each case was matched
to 20 controls on age, sex, and year of initiation of antihypertensive
therapy. We used conditional logistic regression to estimate odds
ratios (ORs) for lung cancer associated with ever‐use of ACEIs com-
pared to ever‐use of ARBs. We examined additional categories of
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duration of use (< 5, 5–10, and > 10 years of use) and tested for a lin-
ear trend with duration of use as a continuous variable. As covariates,
we included selected comorbid conditions (e.g. diabetes and COPD),
use of NSAIDs, use of statins, number of different drug classes used
the year before study start, and highest achieved education. Since
ARBs have been suggested to decrease lung cancer risk, we repeated
the analyses with use of ever‐use of thiazides as reference.
Results: A total of 19,298 cases (median age of 70 years; 53% men)
were matched to 385,804 controls. Of the cases, 43% were diagnosed
with adenocarcinoma, 23% squamous cell carcinoma, 17% small cell
carcinoma, and 17% other types. Compared with ever‐use of ARBs,
ever‐use of ACEIs was associated with an increased risk of lung cancer
in the unadjusted model (crude OR 1.08, 95%CI 1.01–1.14), which
weakened after adjustment (OR 1.05, 95%CI 0.98–1.11). However,
the OR increased with increasing cumulative duration (ptrend < 0.001),
generating ORs for 5–10 years of use of 1.06 (95% CI 0.96–1.18) and
for ≥10 years of 1.16 (95% CI 1.05–1.29). The positive association
with ≥10 years of use was strongest for squamous cell carcinomas
(OR 1.24, 95%CI 0.99–1.55) and small‐cell carcinomas (OR 1.22,
95%CI 0.93–1.59) and weaker for adenocarcinomas (OR 1.12, 95%
CI 0.96–1.31). When using thiazides as an alternate reference group,
we observed ORs of similar magnitude and direction.
Conclusions: Long‐term use of ACEIs was associated with an
increased risk of lung cancer, most notably for squamous cell and
small‐cell carcinomas, with evidence of a duration‐response pattern.
However, the magnitude of the association was small and only signif-
icant for 10 or more years of use.
393 | Low dose aspirin use and colorectal
cancer risk
Hui‐Min Diana Lin1,2; Kinwei Arnold Chan1,2; Pareen Vora3;
Montse Soriano Gabarro3
1National Taiwan University Hospital, Taipei, Taiwan; 2Health Data
Research Center, National Taiwan University, Taipei, Taiwan; 3Bayer AG,
Berlin, Germany
Background: Large scale epidemiology studies and post‐hoc analysis
of randomized trials among non‐Asian populations showed that long
term low dose aspirin (ASA) use was associated with lower risk of
colorectal cancer (CRC).
Objectives: To evaluate the association between low dose ASA use
and CRC risk in a predominantly ethnic Chinese population.
Methods: We carried out a nationwide nested case control analysis
within a study cohort of low dose (most common daily dosage was
100 mg, 150 mg at max) ASA initiators aged 40 or older and age‐sex
frequency matched nonusers from 2002 until 2010. They were identi-
fied from the Taiwan National Health Insurance data and followed
through the end of 2015. CRC cases were ascertained from Taiwan
Cancer Registry. Controls were randomly selected through risk‐set
sampling, matched on age and gender at 1:4 ratio to the cases. We
defined long term current use (at least 3 years, ≥70% drug‐day
coverage over 3 years, within 1 year of recency), episodic (less than
3 years, <70% coverage over 3 years, or past use, beyond 1 year of
recency), and non‐use according to low dose ASA prescriptions prior
to CRC diagnosis. After the study protocol was written and upon
review of recently published reports, we repeated the analysis in a
sub‐cohort of subjects who initiated low dose ASA between age 40
to 59 years. Odds ratio (OR) and 95% confidence interval (CI) were
estimated by conditional logistic regression to evaluate the association
between low dose ASA use and CRC risk. Clinical attributes and
healthcare utilization were adjusted as potential confounders.
Results: In a cohort of 4,710,504, mostly ethnic Chinese aged 40 or
older, we identified 79,095 CRC cases and 316,380 controls. Median
age was 71 years at the time of CRC diagnosis and 59% were men.
For long term low dose ASA use, crude OR was 1.08 (95%CI 1.04–
1.13) and adjusted OR was 0.89 (95%CI 0.85–0.93). Similar level of
risk reduction was observed among episodic low dose ASA users
(adjusted OR 0.88; 95%CI, 0.86–0.89). In the sub‐cohort of
1,496,073 subjects who initiated low dose ASA between age 40 and
59 and were frequency matched, 18,349 CRC cases and 73,396 con-
trols were identified (median age was 60 at time of CRC diagnosis
and 61% were men). Crude OR was 0.93 (95%CI 0.86–1.02) and a
30% risk reduction was observed among long term low dose ASA
users (adjusted OR 0.69 [95% 0.63–0.76]). Similar magnitude of risk
reduction was observed for those with episodic low dose ASA use
(adjusted OR 0.64 [95% 0.61–0.67]).
Conclusions: Long term and episodic low dose ASA use were associ-
ated with lower CRC risks in Taiwan. A stronger CRC risk reduction
effect was observed among those who initiated ASA between age
40 and 59.
394 | Low‐dose aspirin use and endometrial
cancer mortality ‐a Nationwide cohort study
Cecilie D. Sperling1; Freija Verdoodt1; Gitte L. Aalborg1;
Christian Dehlendorff1; Søren Friis1,2; Susanne K. Kjaer1,2
1Danish Cancer Research Center, Copenhagen, Denmark; 2University of
Copenhagen, Copenhagen, Denmark
Background: Accumulating evidence suggests that aspirin use may
improve survival in cancer patients. This is of high interest as aspirin
is typically inexpensive and has a favorable safety profile. For endome-
trial cancer however, only few observational studies exist and results
are inconsistent.
Objectives: To examine whether post‐diagnostic use of low‐dose aspi-
rin is associated with reduced mortality among endometrial cancer
patients.
Methods: From the Danish Cancer Registry, we identified all women
in Denmark aged 30–84 years with a histologically verified diagnosis
of primary endometrial cancer during 2000–2012. Data on drug use,
mortality and potential confounding factors were retrieved from
nationwide registries. Low‐dose aspirin use was defined as a minimum
of one filled prescription after cancer diagnosis. Follow‐up started one
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year after cancer diagnosis and the patients were followed until endo-
metrial cancer mortality, other cause mortality, emigration, or end of
study, whichever came first. Endometrial cancer mortality was the pri-
mary outcome of interest. Using time‐dependent Cox regression
models, adjusted hazard ratios (HRs) and 95% confidence intervals
(CIs) were estimated for the association between post‐diagnosis low‐
dose aspirin use and endometrial cancer mortality. We examined asso-
ciations according to patterns of use (intensity of use and cumulative
amount), and evaluated effect measure modification by tumor charac-
teristics (tumor histology and clinical stage). The exposure was also
modeled as a time‐fixed variable in exposure windows of one year
and five years to account for potential time‐dependent confounding.
We evaluated the potential impact of competing events by Fine and
Gray's proportional subdistribution hazards model.
Results: The study population comprised 6,694 endometrial cancer
patients who were followed for a median of 4.5 years (interquartile
range: 1.9–8.1). Low‐dose aspirin use was associated with a HR of
1.10 (95% CI: 0.90–1.33) for endometrial cancer mortality. Estimates
did not vary substantially according to either pattern of use or tumor
characteristics. The analyses on the time‐fixed exposures and
subdistribution hazards yielded similar results.
Conclusions: In conclusion, we found no indication that low‐dose aspi-
rin use was associated with reduced mortality of endometrial cancer.
Rather, the majority of risk estimates were above one, which may raise
a concern for increased mortality with post‐diagnostic low‐dose aspi-
rin use.
395 | Low‐dose aspirin use and risk of head
and neck cancer ‐ a population‐based case–
control study
Cecilie D. de la Cour1; Freija Verdoodt1; Gitte L. Aalborg1;
Christian von Buchwald2; Søren Friis1,3; Christian Dehlendorff1;
Susanne K. Kjær1,2
1Danish Cancer Society Research Center, Copenhagen, Denmark;
2Rigshospitalet, Copenhagen, Denmark; 3University of Copenhagen,
Copenhagen, Denmark
Background: Long‐term regular use of aspirin has been associated
with reduced risk of several types of cancer. However, the epidemio-
logical evidence on low‐dose aspirin use and risk of head and neck
cancer (HNC) is limited and equivocal.
Objectives: To assess the association between low‐dose aspirin use
and risk of HNC, and to evaluate the association according to patient
characteristics and anticipated association with human papillomavirus
(HPV).
Methods: We performed a case–control study nested in the Danish
population. All cases with a histologically verified first diagnosis of
HNC between 2000 and 2015 and aged 30–84 years were included.
Based on prior evidence, cases were categorized into four groups of
anticipated HPV‐association: strong (oropharynx), moderate (oral
cavity), no/weak (ear, sinus, other pharynx), and uncertain (larynx).
Population‐based controls matched on age and sex were selected
by risk‐set‐sampling in a 1:15 ratio. Information on filled prescrip-
tions of low‐dose aspirin (75–150 mg), use of other drugs, comorbid
conditions and socioeconomic parameters was retrieved from
nationwide prescription, medical and demographic registries. By
means of conditional logistic regression, we computed odds ratios
(ORs) and 95% confidence intervals (CIs) for HNC associated with
low‐dose aspirin use (2 or more prescriptions). The association was
evaluated according to patterns of use (i.e. recency, duration, inten-
sity and continuity of use), age, sex, and anticipated HPV‐
association.
Results: Among 12,389 HNC cases and 185,835 controls, there was
no association between overall use of low‐dose aspirin and HNC
(OR: 1.03, 95% CI: 0.97–1.10). Similar neutral results were found
when analyzing patterns of use. In stratified analyses based on antici-
pated HPV‐association, overall low‐dose aspirin use appeared to
slightly increase the risk of HNC with moderate HPV‐association
(OR: 1.16, 95% CI: 1.04–1.30), while there remained no association
with risk of HNC with strong, no/weak or uncertain HPV‐association.
The risk of HNC was increased in the young age group (30–60 years
of age, OR: 1.18, 95% CI: 1.05–1.31), primarily due to increased risk
of HNC with moderate HPV‐association.
Conclusions: We did not observe an association between overall low‐
dose aspirin use and risk of HNC overall, regardless of patterns of use.
However, low‐dose aspirin use appeared to be associated with a
slightly increased risk of HNC with moderate HPV‐association (oral
cavity). This finding has not previously been reported and should be
interpreted with caution. Further investigation is thus warranted.
396 | Does use of nonaspirin non‐steroidal
anti‐inflammatory drugs reduce the risk of
head and neck cancer in a population‐based
case–control study?
Cecilie D. de la Cour1; Christian Dehlendorff1; Gitte L. Aalborg1;
Christian von Buchwald3; Søren Friis1,3; Freija Verdoodt1;
Susanne K. Kjær1,2
1Danish Cancer Society Research Center, Copenhagen, Denmark;
2Rigshospitalet, Copenhagen, Denmark; 3University of Copenhagen,
Copenhagen, Denmark
Background: Head and neck cancer (HNC) is a common malignancy
with great mortality and morbidity and hence there is a need for iden-
tification of preventive factors. Preclinical and observational studies
report antineoplastic effects of non‐aspirin non‐steroidal anti‐inflam-
matory drugs (NSAIDs), but previous observational studies assessing
non‐aspirin NSAID use and risk of HNC are sparse and with inconsis-
tent results.
Objectives: To estimate the association between use of non‐aspirin
NSAIDs and risk of HNC, and examine whether this association differs
with patient characteristics or anticipated association with human
papillomavirus (HPV).
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Methods: We conducted a register‐based case–control study nested
in the Danish population. Cases comprised all patients aged 30–
84 years with a histologically verified first diagnosis of HNC during
2000–2015. Based on the literature, cases were categorized into four
groups of anticipated HPV‐association: strong (oropharynx), moderate
(oral cavity), no/weak (ear, sinus, other pharynx), and uncertain (lar-
ynx). For each case, 15 age‐ and sex‐matched population‐based con-
trols were selected by risk‐set‐sampling. We obtained information
on filled prescriptions of non‐aspirin NSAIDs, other drug use, comor-
bid conditions and socioeconomic parameters from nationwide regis-
tries. Conditional logistic regression analysis was performed to
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for risk
of HNC associated with use of non‐aspirin NSAIDs (2 or more pre-
scriptions). We evaluated the associations according to patterns of
use (i.e. recency, cumulative amount and consistent use), age, sex,
and anticipated HPV‐association.
Results: A total of 12,389 HNC cases and 185,835 controls were
included in the study. Overall use of non‐aspirin NSAIDs was not asso-
ciated with risk of HNC after adjustment for potential confounders
(OR: 0.99, 95% CI: 0.95–1.03). However, long‐term consistent use
for 5 years or longer was associated with a 25% reduction in HNC risk
(OR: 0.75, 95% CI: 0.62–0.90). We found an inverse association
between non‐aspirin NSAID use and HNC in the oldest age group
(71–84 year old). The stratified analyses by sex or anticipated HPV‐
association showed no material differences in estimates.
Conclusions: Overall use of non‐aspirin NSAIDs was not associated
with the risk of HNC with no apparent influence on the estimates by
the anticipated HPV‐association. However, long‐term consistent use
may be associated with a reduced risk of HNC and merits further
investigation.
397 | Statin use and risk of liver cancer:
Evidence from two population‐based studies
Kim Tu Tran1; Úna McMenamin1; Helen Coleman1; Chris Cardwell1;
Peter Murchie2; Lisa Iversen2; Amanda Lee2; Aaron Thrift3
1Queen's University Belfast, Belfast, UK; 2University of Aberdeen,
Aberdeen, UK; 3Baylor College of Medicine, Houston, TX
Background: Epidemiological studies of statin use and liver cancer risk
have produced conflicting results. Results from recent systematic
reviews and meta‐analyses show that individuals using statins have
40%–50% lower risk of liver cancer compared with non‐users of
statins. However, another study indicated that the decreased associa-
tion of statins and liver cancer attenuated after adjusting for indication
and contraindication of statins that have not been well adjusted in
previous studies.
Objectives: We therefore examined the association between statin
use and risk of primary liver cancer in two large independent study
populations taking account of important covariates and main indica-
tions of statins such as high cholesterol and chronic liver disease.
Methods: We performed a nested case–control study within the Scot-
tish Primary Care Clinical Informatics Unit (PCCIU) database. Five con-
trols were matched to cases with primary liver cancer and we used
conditional logistic regression to calculate odds ratios (ORs) and 95%
confidence intervals (CIs) for associations with statin use. We also
conducted a prospective cohort study within the UK Biobank using
self‐reported statin use and cancer‐registry recorded primary liver
cancer outcomes. Cox regression was used to calculate hazard ratios
(HRs) and 95% CIs.
Results: In the PCCIU case–control analysis, 434 liver cancer cases
were matched to 2,103 controls. In the UK Biobank cohort, 182 out
of 475,768 participants developed incident liver cancer. Statin use
was associated with 39% lower risk of liver cancer in the PCCIU
(adjusted OR 0.61, 95% CI 0.43–0.87). When we examined specific
subtypes of liver cancer in the UK Biobank, statin use was associated
with lower risk of hepatocellular carcinoma (HCC) (adjusted HR, 0.48;
95% CI, 0.24–0.94) but not intrahepatic bile duct carcinoma (IBDC)
(adjusted HR, 1.09; 95% CI, 0.45–2.64).
Conclusions: We found a consistent inverse relationship between
statin use and risk of primary liver cancer which was only seen for
HCC but not IBDC.
398 | Safety of menopausal hormone
therapy in older breast cancer survivors: A
systematic review and meta‐analysis
Godfrey H. Mudhune; Mike Armour; Kate A. McBride
Western Sydney University, Sydney, Australia
Background: Due to the higher incidence of hormone responsive
tumors in women >50, the safety of hormone replacement therapy
(HRT) in older breast cancer survivors may differ from younger age
groups.
Objectives: The primary outcome in this review was the risk of tumor
recurrence and secondary outcome the relationship with breast can-
cer‐related mortality.
Methods: Medline, CINAHL, Cochrane, Google Scholar and EMBASE
databases were searched through August 2018 for studies reporting
exposure to HRT in survivors ≥50 at primary diagnosis. Random
effects models were used to estimate the combined relative risk (RR)
of tumor recurrence and breast cancer‐related mortality using the
Mantel–Haenszel method and the GRADE quality of evidence deter-
mined for the primary outcome.
Results: Overall, nine studies (four cohort, one case–control, four
RCTs; n = 16,002) were included. Very low quality evidence from
observational studies demonstrated no adverse effect on tumor recur-
rence with HRT use (RR 0.80, 95% CI 0.53 to 1.19; I2 = 66%;
n = 11,984), while moderate quality evidence from RCTS demon-
strated an adverse effect (RR 1.46, 95% CI 1.20 to 1.77; I2 = 17%;
n = 4,108). Similarly, observational studies demonstrated no adverse
effect on breast cancer‐related mortality (RR 0.32, 95% CI 0.21 to
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1.49; I2 = 0%, n = 2,182), while RCTs demonstrated a non‐significant
higher risk (RR 1.07, 95% CI 0.77 to 1.49; I2 = 0%; n = 3,918).
Conclusions: Ultimately, despite conflicting findings, evidence of suffi-
cient quality suggests that HRT may increase the risk of tumor recur-
rence in older survivors. However, adverse effect on mortality is
unlikely. Caution with HRT use in survivors is further advised.
399 | Clinical outcomes associated with
drug–drug interactions of Oral
chemotherapeutic agents: A comprehensive
evidence‐based literature review
Manvi Sharma1; Aisha Vadhariya2; Soumya Chikermane2;
Suma Gopinathan2; Mariana Chavez‐MacGregor3;
Sharon H. Giordano3; Michael L. Johnson2; Holly M. Holmes4
1The University of Mississippi, University, MS; 2University of Houston,
Houston, TX; 3The University of Texas M D Anderson Cancer Center,
Houston, TX; 4McGovern Medical School, The University of Texas Health
Science Center, Houston, TX
Background: Oral chemotherapy use is increasing due to new drug
approvals as well as the convenience of administration of oral drugs.
This increased oral chemotherapy use raises the concern of drug–drug
interactions (DDIs) with concomitantly administered drugs, which may
result in loss of therapeutic effect, decreased tolerability, and/or
increased toxicity.
Objectives: The objective of this study was to review existing evi-
dence of clinical impact of DDIs with oral chemotherapeutic agents.
Methods: A comprehensive search of literature using PubMed was
conducted in April 2018 and updated in October 2018 for studies of
DDIs associated with oral chemotherapy. Included studies were in
English. The types of studies that were included were randomized clin-
ical trials, observational studies, and case reports evaluating a DDI
between any oral chemotherapy drug and any other drug. Included
studies needed to have at least one outcome of clinical relevance
potentially attributed to the DDI, for example, effects on survival or
toxicity. The quality of the articles was assessed using published met-
rics appropriate for the study design.
Results: There were 2,626 studies identified in the initial search, of
which 35 met all the eligibility criteria. These included 15 retrospec-
tive cohort studies, 16 case reports or case series and 4 post hoc anal-
yses of clinical trials. Among these, DDIs contributed to a statistically
significant change in a clinical outcome in 12 studies. Eight of these
studies evaluated either overall or progression free survival and found
that the presence of the DDI was associated with reduced survival.
The most frequently evaluated DDIs in the included studies were (a)
concomitant use of acid suppressing agents with tyrosine kinase inhib-
itors (n = 10) and (b) warfarin with oral anticancer agents (n = 7).
Conclusions: Our findings suggest that more real‐world studies evalu-
ating the association between oral chemotherapy DDIs and clinical
outcomes are needed. The adverse clinical outcomes due to DDIs
may be a reason for treatment failures and therapy discontinuation.
400 | Nonsteroidal anti‐inflammatory drug
use and breast cancer risk in a prospective
cohort study of postmenopausal women
Manon Cairat1; Marie Al Rhamoun2; Marc Gunter1; Gianluca Severi2;
Laure Dossus1; Agnes Fournier2,1
1 International Agency for Research on Cancer, Lyon, France; 2Centre for
Research in Epidemiology and Population Health (CESP) Health Across
Generations, Gustave Roussy, Villejuif, France
Background: Nonsteroidal anti‐inflammatory drugs (NSAIDs), a class
of drugs commonly used to treat pain, fever, and inflammation, have
been suggested to reduce breast cancer risk through the inhibition
of the cyclooxygenase‐2 (COX‐2) enzymes. However, prospective
studies of the association between NSAIDs and breast cancer risk
have yielded inconsistent results.
Objectives:We investigated the association between NSAID use and
breast cancer incidence in the French E3N prospective cohort.
Methods: E3N includes 98,995 French women born between 1925
and 1950 and insured by a health insurance plan that covers mostly
teachers. Self‐reported information on lifestyle, anthropometric,
reproductive factors and medical history were collected biannually
by questionnaires and matched with data from a drug reimburse-
ment database pertaining to years 2004–2014. Women with self‐
reported NSAID current use in the questionnaires (2000 or 2002)
or at least two reimbursements in a 3‐month period since 2004
were defined as exposed to NSAIDs. Considering exposure as
time‐varying, multivariable Cox regression models were used to esti-
mate hazard ratios (HRs) for the association of NSAID exposure with
breast cancer risk, overall and by breast cancer subtypes.
Effect modification by breast cancer risk factors and
comorbidities that might be associated with NSAID use was
assessed.
Results: In the current analysis, 62,390 postmenopausal women
were followed between 2004 and 2014 (9 years on average, starting
at a mean age of 63 years; 2,887 breast cancers). Of them, 6% had
been exposed to aspirin, 13% to ibuprofen and diclofenac, 10% to
ketoprofen and piroxicam, 8% to selective COX‐2 inhibitors and
19% to other non‐selective NSAIDs during follow‐up. In multivari-
able models, there was no statistically significant
association between NSAIDs overall and breast cancer risk [HR = 1.00
(0.94–1.09)]. The results were the same by types of NSAIDs
[HRaspirin = 1.00 (0.82–1.22), HRibuprofen = 0.93 (0.80–1.07),
HRketoprofen = 1.01 (0.87–1.19), HRdiclofenac = 1.02 (0.88–1.18),
HRpiroxicam = 1.04 (0.90–1.21), HRcox‐2 inhibitors = 0.98 (0.84–1.15),
HRother‐NSAIDs = 1.01 (0.91–1.11)]. The NSAID‐breast cancer associa-
tions did not differ by breast cancer subtypes, risk factors and
comorbidities, nor by duration, dose, intensity of use, or time since
first or last use.
Conclusions: NSAID use was not associated with breast cancer risk in
this large, prospective cohort of postmenopausal women with up to
10 years of follow‐up.
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401 | Bile acid Sequestrants and the risk of
cancer: A cohort study in the clinical practice
research datalink
Youjin Wang1; Madhav Thambisetty2; Vijay Varma2;
Shahinaz Gadalla1
1National Cancer Institute, Bethesda, MD; 2National Institute on Aging,
Bethesda, MD
Background: Bile acid sequestrants (BAS), a group of lipid‐modifying
treatments (LMTs), bind to bile acids in the gut and lower their blood
level. Evidence from animal models suggested that bile acids may play
a role in carcinogenesis.
Objectives: To calculate the risk of overall and site‐specific cancer
associated with the use of BAS compared with other LMT
(including fibrates, nicotinic acid derivatives, bis‐phenol
antioxidant and ezetimibe), in a large cohort of new users of either
medication.
Methods: We used the UK Clinical Practice Research Datalink to
identify individuals 18 years or older without prior cancer history and
who were newly prescribed BAS (n = 10,658) or other LMT
(n = 34,058) between 1997 and 2017. All individuals were required
to have at least 12 months of continuous registration prior to
index date. For each BAS users, we selected up to 5 LMT
users matched on gender, year of birth and clinic
registration, year of first use, and practice region. Follow‐up started
at the age at first BAS or LMT prescription, and ended at age of first
cancer diagnosis, death, last registration or clinic transfer out. We
used Cox proportional hazards models to calculate
the hazardratio (HR) and 95% confidence interval (CI) of cancer
overal and by anatomic site, in BAS users versus users of other
LMT.
Results: During a median follow‐up of 5.2 years (range = less than
1–23.4 years), 3254 incident cancers (n = 612 in BAS users;
n = 2642 in LMT users) were reported. Most frequently reported
cancers were cancers of the breast (n = 102 for BAS; n = 382 for
LMT), prostate (n = 59 for BAS; n = 293 for LMT) and lung (n = 50
for BAS and n = 291 for LMT). In analyses adjusted for smoking,
gender, prior use of aspirin, metformin or statins, the risk of any can-
cer in BAS users was significantly higher than LMT users (adjusted
HR = 1.22, 95%CI = 1.07–1.40); however, differences by cancer
anatomic site was noted. Specifically, the data suggested a possible
risk reduction in colorectal cancer (HR = 0.75, 95%CI = 0.48–1.19),
but higher risk in female breast (HR = 1.25, 95%CI = 0.87–1.78)
and pancreatic cancer (HR = 2.85, 95%CI = 1.18–6.84) in BAS users
compared with users of other LMT.
Conclusions: Our results suggest that BAS use may modulate risk of
certain cancers. Further studies are warranted to elucidate underly-
ing biological mechanisms.
402 | Intensive safety surveillance of anti‐
cancer medicines subject to additional
monitoring: A pilot study
Diogo Mendes1,2; Graça Rigueiro3,2; Rui Sousa Silva3,2;
Ana Penedones1,4,2; Carlos Alves1,4,2; Gabriela Sousa3,2;
Francisco Batel Marques1,4,2
1AIBILI ‐ Association for Innovation and Biomedical Research on Light
and Image, Coimbra, Portugal; 2DruSER.Net – Drug Safety and
Effectiveness Research Network, Coimbra, Portugal; 3 IPO‐C – Instituto
Português Oncologia de Coimbra Francisco Gentil, E. P. E, Coimbra,
Portugal; 4School of Pharmacy, University of Coimbra, Coimbra, Portugal
Background: Chemotherapy‐related adverse drug reactions (ADRs)
are frequent and often serious. Although spontaneous reporting allow
identifying unknown and serious ADRs, underreporting is a limitation.
The European legislation foresees the conduction of structured post‐
authorization safety studies (PASS) and the implementation of a public
list of medicines under additional monitoring in order to improve drug
safety surveillance.
Objectives: The aim of this study was to test the feasibility and the
usefulness of an intensive safety surveillance program to identify
adverse drug reactions (ADRs) for medicines under additional monitor-
ing that are used to treat cancer patients within a Portuguese oncol-
ogy hospital.
Methods: This pilot intensive safety surveillance program was a 3‐
month prospective, observational study. Patients undergoing treat-
ment with one of the following medicines were included: nivolumab,
olaparib, palbociclib, pembrolizumab, pertuzumab, ramucirumab,
ribociclib, trastuzumab emtansine, or trifluridine/tipiracil. Potential eli-
gible patients were identified by pharmacists based on prescription
data. Clinicians used proper paper‐based reporting forms to record
ADRs. Clinical secretariats sent those reports through an electronic
platform to the pharmacovigilance department for analysis.
Results: Seventy‐five patients were on treatment with selected medi-
cines. Of those, 33 (44%) experienced ADRs: 23 (69.7%) cases were
serious and 5 (15.2%) unexpected. Considering the number of patients
exposed to each medicine and the number of patients experiencing
ADRs, trifluridine/tipiracil (72.7%; 8/11) was associated with the
highest rate of toxicity, followed by olaparib (66.7%; 2/3), trastuzumab
emtansine (50.0%; 3/6), pertuzumab (47.8%; 11/23), pembrolizumab
(45.5%; 5/11), palbociclib (25.0%; 1/4), and nivolumab (18.8%; 3/16).
A total of 59 ADRs were identified (i.e. 1.8 ADRs/patient), mainly gas-
trointestinal disorders (n = 15; 25.4%), and blood and lymphatic sys-
tem disorders (n = 14; 23.7%).
Conclusions: This intensive safety surveillance program was feasible
and allowed identifying serious and unexpected ADRs, adding value
to pharmacovigilance and therefore contributing to improve patient
safety. Further research is needed to confirm the findings of this pilot
study.
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404 | Impact of antidiabetic medication use
on breast cancer diagnostic characteristics
Shahariar Mohammed Fahim1; Chiu‐Hsieh Hsu2; Jingjing Qian1;
Chiahung Chou1,3
1Auburn University, Auburn, AL; 2Mel and Enid Zuckerman College of
Public Health, The University of Arizona, Tucson, AZ; 3China Medical
University Hospital, Taichung, Taiwan
Background: Literature suggests that the presence of diabetes
increases both the risk and severity of breast cancer. However,
knowledge regarding different antidiabetic medication use patterns
at baseline and their impact on breast cancer diagnosis remains
limited.
Objectives: To identify and compare different antidiabetic medication
use patterns among female patients prior to their breast cancer diag-
nosis and evaluate if different antidiabetic medication use was associ-
ated with the breast cancer stage at diagnosis.
Methods:Design Longitudinal, retrospective cohort study. Settings
This study used the linked Surveillance, Epidemiology and End
Results (SEER)‐Medicare database in 2007–2013. Newly diagnosed
breast cancer patients were identified in 2008–2013 and were con-
tinuously enrolled in Medicare Parts A, B, and D for 12 months
before cancer diagnosis (n = 49,255). Exposure Use of antidiabetic
medications, overall and by drug class, during one year prior to
breast cancer diagnosis. Outcome Stage at diagnosis which was fur-
ther categorized as early (stages 0‐II) and advanced (stages III‐IV).
Statistical Analysis Chi‐square tests were used to compare breast
cancer patient characteristics (all were categorical variables: race/
ethnicity, geographic region, marital status, and comorbidities)
between antidiabetic medication user and non‐user groups. For each
antidiabetic medication group, logistic regression models were fitted
to examine the effects of different antidiabetic medication use on
cancer stage at diagnosis while controlling for patient's
characteristics.
Results: A total of 1,719 female breast cancer patients used antidia-
betic medications during one‐year period prior to their breast cancer
diagnosis while 6,084 patients were identified as non‐antidiabetic
users. Although more antidiabetic users (20.36%) had advanced breast
cancer compared to the non‐user group (14.46%), regression model
showed that antidiabetic medication users had similar likelihood (odds
ratio [OR] 0.97, 95% CI 0.83–1.14) in getting advanced breast cancer
compared to the non‐user group. Insulin users were more likely to be
in the advanced stage (OR 1.62, 95% CI 1.10–2.40) compared to the
metformin‐users. Pure metformin users, those who used metformin
only during this period, had lower likelihood (OR 0.63, 95% CI 0.43–
0.91) compared to non‐users.
Conclusions: The relationship between antidiabetic medication use
and breast cancer diagnostic characteristics were complex in nature.
Considering diabetes severity, exposure to different antidiabetic
medications may pose different risks in breast cancer stage at
diagnosis.
405 | Inverse association between digoxin
and cancers derived from real world data
Satoshi Yokoyama; Yasuhiro Sugimoto; Chihiro Nakagawa;
Kouichi Hosomi; Mitsutaka Takada
Faculty of Pharmacy, Kindai University, Higashi‐osaka city, Osaka, Japan
Background: Pharmacoepidemiologic studies demonstrated that car-
diac glycosides including digoxin may improve survival in cancer
patients. Yet, other studies suggest they exacerbate cancer risk.
Digoxin can bind estrogen receptors and may increase the risk of
estrogen‐sensitive breast and uterine cancers. The association
between digoxin and cancer remains controversial.
Objectives: We investigated the real world data including claims data-
base and spontaneous reports database and bioinformatics databases
to clarify the relationships between digoxin and cancers.
Methods: We performed retrospective data mining study with an inte-
grative approach using real world data and bioinformatics databases.
The Japan Medical Data Center (JMDC) claims database (2005–2015)
was used to evaluate adjusted sequence ratios (ASRs) by sequence sym-
metry analysis. Further, the US Food and Drug Administration Adverse
Event Reporting System (FAERS, 2004–2016) were used to evaluate
reporting odds ratios (ROR) and information component (IC) by
disproportionality analysis. For the ASR and ROR, an inverse signal
was defined if the upper limit of the 95% two‐sided confidence interval
was less than 1. For the IC, an inverse signal was defined if the upper
limit of the 95% confidence interval was less than 0. Functional relation-
ships between digoxin and cancers were investigated using BaseSpace
Correlation Engine (BSCE) to access bioinformatics databases. Microar-
ray gene expression profiles were extracted from the BSCE database
and subjected to pathway enrichment analysis.
Results: The number of JMDC claims pertaining to digoxin during the
study period was 52,828. Among 3,035 digoxin users, 1,297 incident
users who received their first digoxin prescription were identified. In
the FAERS database, a total of 300,541 drug‐reaction pairs for digoxin
were found. Claims and FAERS database analyses suggested a signifi-
cant inverse association between digoxin and four cancers: gastric,
colon, prostate and hematological malignancy. Pathway enrichment
analysis based on BSCE suggested digoxin may exert an anticancer
effect via peroxisome proliferator‐activated receptor alpha and apo-
ptotic caspase cascade pathways.
Conclusions: Database analysis revealed the possibility repositioning
digoxin for use in select cancers.
406 | Effect of a clinical pharmacist
intervention on the emergency department
revisits: A randomized controlled trial
Matias F. Martinez; Luis Herrada; Ana Munoz; Camila Chavez;
Tamara Sandoval; Marcela Jiron
University of Chile, Santiago, Chile
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Background: Revisiting the Emergency Department (ED) for a compli-
cation or an unresolved health problem is a lack of quality indicator
and a public health problem, affecting patients and healthcare centers.
Effect of clinical pharmacist intervention on an ED revisit is still
unclear.
Objectives: To determine the effect of a clinical pharmacist interven-
tion on the risk of ED revisit.
Methods: A randomized controlled trial was conducted in patients
who received at least one medication before or during an ED visit at
a teaching hospital in Santiago, Chile. We randomly assigned patients
in a 1:1 ratio to receive standard care in the ED (control =501) and
intervention group (n = 500) received clinical pharmacist recommenda-
tions to the clinical staff on pharmacological treatments (medication
review, drug selection, doses, drug–drug interactions, adverse drug
effects and monitoring), and at discharge the intervention also
includes patient/caregiver education on drug treatment and therapeu-
tic goals. The primary outcome was the risk of an ED revisit within 30
post‐discharge due to a complication or an unresolved health problem
related to the previous ED visit. The association between intervention
and time to event was examined using multivariable Cox proportional
hazards regression models adjusted by sex, age, educational level, rea-
son for ED visit, type of health insurance, polypharmacy (5+ drugs) and
customer satisfaction. Statistical significance was determined using
two‐sided 5% significance level. All statistical analyses were per-
formed using Stata 15.0.
Results: A total of 1001 patients were recruited between April and
December 2015, most of them were female (611; 61.5%), the mean
age was 50.5 ± 19.5 years. A 19,4% presented polypharmacy and
the mean reason of consultation was related to General symptoms
and signs (23,4%). There were 47 patients who had an ED revisit
within 30 days post‐discharge related to the previous ED visit (15
cases in the intervention group versus 32 patients in the control
group). The Kaplan–Meier curves show a difference between arms
(logrank p = 0.011). The analysis of time to the event shows a decrease
of more than a half in the instantaneous hazard of having a re‐consul-
tation to the same center (adjusted HR = 0.45; 95%CI 0.24–0.83).
Conclusions: Our study shows that a clinical pharmacist intervention
based on recommendations to the healthcare team on drug selection
and drug use; patient and caregiver education on drug treatment and
therapeutic goals over time, is an effective health strategy to reduce
unnecessary ED use within 30 days post‐discharge through proactive
interventions.
407 | Efficacy gap between phase 2 and
subsequent phase 3 trials in oncology
Rick Vreman1,2; Ana Teresa M. Mota1; Svetlana V. Belitser1;
Anke M. Hövels1; Wim G. Goettsch1,2; Kit C.B. Roes3;
Hubert G.M. Leufkens1; Aukje K. Mantel‐Teeuwisse1
1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht
Institute for Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 2National Health Care Institute (ZIN), Diemen, Netherlands;
3Department of Biostatistics and Research Support, Julius Center for
Health Sciences and Primary Care, University Medical Center Utrecht,
Utrecht, Netherlands
Background: As the most promising medicines are selected based on
phase II trials, the subsequent phase III trials are on average expected
to perform worse than phase II trials, due to regression to the mean.
There is an increasing trend of new medicines being approved based
on phase II trials only. Therefore, it is necessary to investigate the con-
sistency and quantitative impact of this effect.
Objectives: This research aimed to quantify efficacy differences
between drug development phases for oncology products. Specifically,
the gap between efficacy found in phase II and phase III trials was inves-
tigated. Additionally, explanatory variables for efficacy differenceswere
assessed.
Methods: All oncology drugs approved by the European Medicines
Agency between 2007 and 2016 were included in this retrospective
study. Each indication was included separately. Phase II and phase III
trials were retrieved through electronic database searches and
matched based on trial and patient characteristics. Effect estimates
for objective response rate (ORR), median progression‐free survival
(PFS) and median overall survival (OS) were included. Analysis was
through weighted mixed‐effects regression with previous treatment,
treatment regimen, blinding, randomization, marketing authorization
type and cancer type as fixed effects and the combination of drug
and indication as random effect.
Results: 82 phase II‐phase III drug‐indication groups were identified
including 263 individual trials. Mean (SD) ORR, weighted for the size
of the trials, was 41.2% (23.0) for phase II and 37.0% (24.8) for phase
III. For median PFS and OS, means (SD) were 8.2 (4.2) and 14.7 (6.3)
months for phase II and 10.3 (8.6) and 14.3 (6.7) months for phase III,
respectively. No significant difference was found between phase II
and III results for any of the three efficacy outcomes. However, other
trial characteristics that were included in the analyses were associated
with outcomes, with significance depending on the outcome assessed.
Conclusions: Overall, effect estimates in this dataset of trials measuring
objective response rate andmedian progression free and/or overall sur-
vival did not differ between phase II and phase III trials. These results
may encourage decision‐makers such as regulators or health technology
assessment bodies to look at the overall body of clinical evidence,
including patient population characteristics and patient outcomes,
instead of differentiating between different phases of clinical
development.
408 | Feasibility of using electronic health
records to identify patients with chronic
obstructive pulmonary disease to enroll into
pragmatic trials
AchimWolf1; Daniel Dedman1; Rachael Williams1; Jennifer Campbell1;
Tarita Murray‐Thomas1; Jennifer Quint2; John Logie3;
Jeanne Pimenta3
1CPRD, London, UK; 2 Imperial College, London, UK; 3GSK, London, UK
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Background: Pragmatic trials may use electronic health records to
assess effectiveness of interventions in routine practice. The Clinical
Practice Research Datalink (CPRD) conducts such studies in UK pri-
mary care practices contributing via different GP software to the
CPRD GOLD and, more recently, CPRD Aurum observational data-
bases. Using both databases increases national coverage, but differ-
ences in geographical location, data structure and coding raise
questions of comparability.
Objectives: To assess the feasibility of using CPRD GOLD and Aurum
to identify chronic obstructive pulmonary disease (COPD) patients for
a pragmatic trial. Specifically, to estimate the number of COPD
patients, establish whether they meet minimum necessary trial criteria,
and assess whether patients and data differ between GOLD and
Aurum.
Methods: Patients with a GP recorded COPD diagnosis, aged
≥35 years and registered for >1 year on a hypothetical trial enrolment
date (31/12/17) were included. Patient characteristics were described
overall and in practices active in interventional research.
Results: 56,813 patients in CPRD GOLD and 266,178 in CPRD Aurum
met the COPD inclusion criteria; 29,027 (51%) and 174,545 (66%)
were from practices active in interventional research. For patients
meeting the COPD inclusion criteria, characteristics were comparable
across GOLD and Aurum respectively: median age (70, 68 years), pro-
portions male (50, 52%), deprived (50, 49% in top two quintiles), cur-
rent smokers (38, 40%), and overweight/obese (60, 59%).
Proportions of patients with a history of respiratory conditions (e.g.
asthma (43, 38%), bronchiectasis (5, 5%), pneumonia (8, 10%)) and dis-
ease severity (e.g. MRC grades 3–5 (25, 24%), GOLD grades 3–4 (17,
16%), median FEV1/FVC (63, 67)) were also comparable. However,
geographical distribution differed substantially: 39% of patients in
GOLD were registered with English practices (28% Scotland, 25%
Wales, 9% Northern Ireland), compared to 100% in Aurum. Patients
from practices active in interventional research were comparable to
the total COPD population.
Conclusions: A substantial number of patients with COPDwere poten-
tially eligible for a pragmatic trial using CPRD. CPRDAurum significantly
increased the patient pool, especially among practices active in inter-
ventional research, and increased geographical representativeness.
Patients and data from the twodatabaseswere shown to be comparable
across key aspects relevant to a COPD trial. A pragmatic trial using
CPRD to recruit patients with COPD is scientifically feasible.
409 | Globalization of clinical trials: Variation
in estimated regional costs of pivotal trials,
2015–2016
Yao Qiao1; G. Caleb Alexander1; Thomas Moore2
1 Johns Hopkins University, Baltimore, MD; 2 Institute for Safe Medication
Practices, Alexandria, VA
Background: Despite the increasing globalization of clinical trials, little
is known regarding how the trial site costs vary around the world.
Objectives: We quantified the geographical distribution and regional
cost differences for the clinical trials that established the benefits for
new therapeutic drugs approved by the U.S. Food and Drug Adminis-
tration (FDA) in 2015 and 2016.
Methods: We included all pivotal clinical trials for 59 new molecular
entities approved by the U.S. FDA in 2015and 2016 that included as
least one site in North America. We derived cost estimatesfrom
IQVIA's CostPro, a global clinical trial cost estimating tool used by
pharmaceutical sponsors. We assessed the patient and site allocation
of these trials across eight geographic regions. To quantify the
regional cost differences we conducted a within‐trial comparison by
expressing the estimated regional cost for the sites in each global
region as a percent of the cost in North America. We also estimated
the percentage breakdown of regional cost components (pass‐
through, site management, regulatory, and study conduct costs) for
each trial, for all endpoints reported the median and interquartile
range (IQR).
Results: Overall, 127 pivotal clinical trials enrolled 91,415 patients from
13,264 sites. Most patients (60.3%) and sites (57.3%) were outside
North America. A median of 66% (IQR 60–72%) of the total estimated
trial costs were regional, with the largest share (53.3%) of regional costs
going directly to trial sites with the remainder going to other regional
trial management tasks. Differences were greatest in four lower‐cost
regions: Africa, with an estimated regional cost per site a median of
49% (IQR 44% ‐ 56%) of North America, Central Europe (50%, IQR
41–63%), Middle East (53%, IQR 42–64%)and Latin America (59%,
IQR50–70%). Overall, 90 (71%) of the 127 pivotal trials had a total of
3,160 sites in these lower‐cost regions. In contrast, savings were more
limited inWestern Europe, Oceania, and Asia, where estimated regional
costs were a median of 78% (IQR 67–89%) of North America. One‐
quarter of the trials with sites in Asia and Oceana did not achieve
cost‐savings in those regions relative to North American costs.
Conclusions: Among this sample of pivotal trials for recently approved
FDA products, most patients and sites enrolled were outside of North
America, with selection of regional sites having a significant impact on
total trial costs.
410 | The pragmatic trial: Still a rising star, or
old news?
Margaret S. Richards1; Juliane K. Mills1; Bettina Rillmann2
1PRA Health Sciences, Blue Bell, PA; 2PRA Health Sciences, Mannheim,
Germany
Background: In the early years of the 21st century, pragmatic trials
seemed to be everywhere. The number of trials in Citeline including
the term ‘pragmatic’ in their title or as a design attribution peaked in
2012. Since then, the number of such trials has declined even as the
total number of registered trials has increased. We undertook a
descriptive summary and overlay of the pragmatic trials presenting in
both Citeline's TrialTrove and Clinical Trials. Gov (CT.Gov) in order to
look for trends in the employment of this design.
ABSTRACTS 201
Objectives: To provide a descriptive summary of registered pragmatic
trials and to look at trends over time in the terminology used (‘prag-
matic’ vs. ‘practical’ vs. ‘naturalistic’ vs. ‘large simple’, vs. ‘cluster ran-
domized’ trials or studies.) To compare and contrast the body of
work in TrialTrove versus in CT.Gov.
Methods: TrialTrove and CT. Gov were searched separately for trials
that included the terms ‘pragmatic’, ‘practical’, ‘naturalistic’, ‘large sim-
ple’, or ‘cluster randomized’ in either the protocol title or study design
field as available. Descriptive data were exported into Excel spread-
sheets and using SAS 9.2, listings were sorted, deduplicated and fur-
ther attributed in order to create two databases of potential
pragmatic designs. Data were then summarized and contrasted by
source regarding year of study start, trial phase, therapeutic area, indi-
cation, sponsor type, and a number of other variables.
Results: There are 2411 unique ‘pragmatic’ trials registered in
Citeline's TrialTrove and 3816 unique such trials in CT. Gov through
the end of 2018. Counts of these studies in TrialTrove peak in 2012
then decline, whereas in CT. Gov, the numbers of trials steadily
increases through 2018. The term ‘pragmatic’ (63%) is most often used
followed by ‘cluster randomized’ (30%), with far less frequent use of
the terms ‘naturalistic’ or ‘large simple’ (7% for both). Therapeutic
areas (TA) were similarly emphasized in both registers, with CNS the
most common TA followed by metabolic/endocrine, cardiovascular,
autoimmune/inflammatory, and infectious disease.
Conclusions: An important difference betweenTrialTrove and CT. Gov
is that whereas Citeline is generally limited to trials involving
biopharma or device products, CT. Gov is more general and includes
studies that may consist of behavioral interventions (such a counseling
or hypnosis) only. We will explore further if pragmatic studies are not
necessarily declining in use, but may be shifting to include more non‐
product interventions and/or if they are giving way to real‐world
observational study designs.
411 | Data‐driven identification of indication
for treatment in electronic medical records
using cluster analysis in combination with a
self‐controlled cohort analysis
Tomas Bergvall1; Birgitta Grundmark1; Alison Bourke2; Niklas Norén1
1Uppsala Monitoring Centre, Uppsala, Sweden; 2 IQVIA, London, UK
Background: When analyzing drug utilization or drug safety in elec-
tronic medical records, it is valuable to be able to separate different
treatment indications. These may not be explicitly recorded.
Objectives: Develop and evaluate a methodology that identifies
patients with similar indication for treatment based on medical events
recorded prior to treatment initiation.
Methods: Analyses were performed for a range of drugs inThe Health
Improvement Network (THIN). We focus here on etoricoxib. THIN
contains primary health care data from the UK, and in this study we
used data for 10 million patients available in May 2015. Non‐adminis-
trative Read codes within 30 days before a first‐in‐patient prescription
of etoricoxib were included. Latent class cluster analysis was per-
formed using a probabilistic mixture model for the registration of med-
ical events in the 30‐day period. A hundred such analyses were then
combined through consensus clustering which grouped together any
two patients that were co‐clustered in at least 80 of the 100 individual
analyses. For each consensus cluster, a calibrated self‐controlled
cohort analysis (ICΔ) was used to highlight medical events occurring
more often in the 30‐day period than expected based on the relative
frequency of that medical event within the same patients in two sep-
arate control periods: 6–12 months and 1–3 years before the first
prescription.
Results: Our analysis identified 41 clusters from the 25,000 patients
prescribed etoricoxib. Among the ten largest, three were dominated
by single medical event terms: Pain in joint, Gout and Knee pain; while
seven clustered patients with a variety of terms, e.g. a back‐pain clus-
ter of 1800 records gathering Pain in lumbar spine (in 33% of the
patients), C/O ‐ low back pain (27%), Back pain without radiation NOS
(23%), Sciatica (22%) and Backache (7%). As an illustration of the impact
of the self‐controlled cohort analysis, it kept e.g. Osteoarthritis and
allied disorders (22%) and Enthesopathy of the ankle and tarsus (16%)
while eliminating e.g. Clearance of external auditory canal (22%) and
Otalgia (10%) for a cluster of 470 records relating to osteoarthritis.
Conclusions: Data‐driven identification of treatment indication in
electronic medical records is feasible. Cluster analysis gathered medi-
cal events into clinically coherent indication groups and the calibrated
self‐controlled cohort analysis successfully eliminated medical events
with high background rates, which are less likely to reflect treatment
indications. Combining the two methods gave added value.
412 | Evaluation framework to guide model
selection and cohort definition in causal
inference
Yishia Shimoni1; Sivan Ravid1; Ehud Karavani1; Peter Bak1; Marie Ng2;
Sharon Hensley Alford2; Denise Meade2; Ya'ara Goldschmidt1
1 IBM Research, Haifa, Israel; 2 IBM Watson Health, Cambridge, MA
Background: Clinical and cost outcomes from real‐world data contain
selection bias due to formulary management and provider and patient
influences impacting treatment assignment. Causal inference allows
learning from real‐world data by using observed treatment with corre-
sponding response and adding predicted outcomes given alternative
(non‐factual) treatments while adjusting for bias and confounding.
We sought to develop causal inference models and a framework for
evaluating their performance using rheumatoid arthritis (RA) as a use
case.
Objectives: To demonstrate the utility of causal inference models in
real‐world data and develop a framework for evaluating the perfor-
mance of causal inference in objectively assessing treatment response.
Methods: We used the IBM MarketScan Commercial and Medicare
Claims database (2010–2017) to build causal inference models for
RA clinical (emergency room visits, outpatient visits, hospitalizations)
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and per‐patient per‐month (PPPM) cost outcomes. We analyzed 27
outcomes for 10 biologic therapies and for conventional therapies as
a single treatment group. To evaluate the models, we created 6 visuals
that exhibit model precision, consistency, calibration, propensity distri-
bution, covariate balancing, and accuracy.
Results: Using the evaluation framework we were able to detect pos-
itivity issues in the data, and construct robust and reliable outcome
predictions by: identifying and removing treatment predictions that
were not comparable (by calibration plot); modifying models that were
too weak for predicting outcomes; discarding methods that were
incompatible with causal inference analysis (e. g. random forests);
and identifying outcomes for which there wasn't sufficient predictive
power. In the context of rheumatoid arthritis, we identified multiple
sub‐populations that could benefit from a specific treatment over
other treatment. For example, we identified that for the population
over the age of 65 Etanercept provides the lowest risk of anemia,
while Infliximab provides the lowest overall risk for multiple outcomes
while also accruing relatively low cost.
Conclusions: Our approach allows multiple directions of analysis to
find the best treatment per population, the best responding popula-
tion for a treatment, as well as clusters of patients that respond simi-
larly across multiple treatments. By analyzing adjusted predictors of
treatment response within a disease, formulary decisions can be made
to optimize coverage and manufacturers could gain novel insights into
which patient populations may best respond to their treatment.
413 | A R‐based application to perform
distributed regression analysis with vertically
partitioned data
Qoua Her1; Yuji Samizo2; Thomas Kent2; Mia Gallagher1;
Aleksandra Slavkovic2; Sengwee Toh1
1Harvard Pilgrim Health Care Institute, Boston, MA; 2Penn State
University, University Park, PA
Background: In medical product safety and effectiveness studies,
important variables such as exposures, outcomes, and confounders
may be collected across multiple databases, requiring researchers to
link across multiple data sources. Physical linkage of these so‐called
vertically partitioned databases raises numerous pragmatic concerns,
including the risk of compromising patient privacy. Privacy‐protecting
analytical methods that do not require physical pooling of disparate
databases have been developed to mitigate this concern.
Objectives: To develop an algorithm to perform distributed regression
analysis (DRA), a privacy‐protecting analytical method that performs
multivariable‐adjusted regression analysis with only summary‐level
information, with vertically partitioned data and evaluate its precision
and operational performance.
Methods: We developed an R‐based algorithm to perform distributed
linear and logistic analysis with vertical partitioned data. We used
PopMedNet, a data sharing application, to securely transfer sum-
mary‐level information between the data sites. We evaluated the
precision and operational performance of the algorithm with a test
case (n = 98,162) in a simulated vertically partitioned data environ-
ment, where one data source held the outcome variable and another
data partner held 41 covariates. We considered the algorithm success-
ful if the DRA results were precise compared to results from the
pooled patient‐level data analysis (to at least 10−6). We extracted time
stamps from PopMedNet and computed the total execution time.
Results: Distributed linear and logistic regression analysis with verti-
cally partitioned data can be performed using a secure matrix multipli-
cation algorithm to compute the off‐diagonal blocks of the covariance
matrix. The algorithm produced precise regression parameter and
standard error estimates to those from the pooled patient‐level analy-
sis. For linear regression, a closed form solution exists, while logistic
regression requires iterations of summary‐level information exchanges
between the data sites until the model converges. On average, it took
12.9 minutes to complete one data exchange cycle. The file transfer
process accounted for 97% of the data exchange cycle time. Linear
regression in our test case required 64 minutes to compute DRA
results, while logistic regression required 251 minutes.
Conclusions: We successfully created a DRA algorithm based in R for
vertically partitioned data. Additional work is required to improve
operational performance of the algorithm.
414 | Privacy‐protecting estimation of
adjusted risk ratios using modified Poisson
regression in multi‐center studies
Di Shu; Jessica G. Young; Sengwee Darren Toh
Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA
Background: Multi‐center studies have been increasingly conducted
to generate powerful and generalizable evidence using healthcare
information collected from a variety of data sources. Privacy consider-
ations and legal restrictions often make it impossible to pool individ-
ual‐level data across data‐contributing sites. With binary outcomes,
privacy‐protecting distributed algorithms to conduct logistic regres-
sion analyses have been previously developed. However, the risk ratio
often provides a more transparent measure of exposure‐outcome
associations than the odds ratio. There are currently no existing dis-
tributed algorithms to estimate an adjusted risk ratio while avoiding
sharing of individual‐level data from data partners.
Objectives: The major objectives of this paper are twofold. First, we
propose a new method for making valid and privacy‐protecting infer-
ence on adjusted risk ratios in multi‐center studies. Instead of sharing
individual‐level data, our method only requires sharing of aggregated
information to produce results as if the individual‐level data were
pooled across data‐contributing sites. Second, we provide replication
R code of our simulated data example, which can be easily modified
by interested readers for their own multi‐center analyses.
Methods: Modified Poisson regression was previous proposed to
directly estimate the risk ratio and give confidence intervals with the
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correct nominal coverage when individual‐level data are available. By
leveraging the Newton–Raphson procedures, we adapted the modi-
fied Poisson approach to estimate the risk ratio using only summary‐
level information shared from each site. The proposed method was
illustrated using both simulated and real data examples.
Results: Our method is guaranteed to produce the same risk ratio esti-
mates and standard errors as the pooled individual‐level data analysis
without the need for sharing potentially identifiable individual‐level
data across data‐contributing sites.
Conclusions: We propose distributed Modified Poisson regression
algorithms for valid and privacy‐protecting estimation of the risk ratio
in multi‐center studies. Replication R code is available online.
415 | Relying on RE‐LY to transport effect
estimates to patients in routine care
Michael Webster‐Clark; Til Stürmer; Jessie K. Edwards; Charles Poole;
Ross Simpson; Jennifer L. Lund
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: The RE‐LY trial compared dabigatran to warfarin in atrial
fibrillation (AF) patients. It is unknown how its findings apply to real‐
world AF populations with other distributions of effect modifiers
(EMs). Further, trial intention‐to‐treat (ITT) analyses are difficult to
compare with studies that require participants remain on treatment.
Objectives: Estimate 2‐year as‐treated (AT) risk differences (RDs) for
dabigatran versus warfarin on ischemic stroke (IS), gastrointestinal
bleed (GIB), and death using inverse odds of sampling weights (IOSW)
to reweight the RE‐LY trial to resemble trial‐eligible initiators of
dabigatran or warfarin in routine care.
Methods: We estimated AT RDs in the RE‐LY participants over 65 via
a weighted Aalen‐Johansen estimator for risks and bootstraps to esti-
mate RD standard errors using inverse odds of censoring weights to
account for potential bias from censoring. We identified target popu-
lations with under 15% predicted probability of frailty from 1)
dabigatran new users and 2) warfarin new users in a Medicare 20%
random sample from January 2010 through October 2015. We esti-
mated odds of sampling onto RE‐LY for these users based on EMs,
assigned RE‐LY participants IOSW from marginal odds of sampling
divided by EM‐conditional odds, and repeated AT analyses in
weighted RE‐LY participants.
Results: RE‐LY‐eligible Medicare patients included 8,500 dabigatran
new users and 50,090 warfarin new users. There were 10,018 RE‐LY
participants over 65 in the 150 mg BID and warfarin arms. RE‐LY par-
ticipants were younger with fewer cardiovascular comorbidities (e.g.
diabetes RE‐LY prevalence 23% vs. Medicare dabigatran 29% and
warfarin 31%). AT 2‐year trial RD estimates for IS (−0.81%, 95% CI ‐
1.40%, −0.21%), death (−0.62%, 95% CI ‐1.60%, 0.36%), and GIB
(1.53%, 95% CI 0.78%, 2.27%) were similar to ITT results. IOSW
weighting to dabigatran users increased risk of all outcomes but
showed similar RDs for IS (−0.74%, 95% CI ‐1.61%, 0.13%), death
(−0.59%, 95% CI ‐1.98%, 0.81%) and GIB (1.75%, 95% CI 0.56%,
2.94%). IOSW weighting to warfarin users increased variance and
pushed the RD for death closer to null (−0.19%, 95% CI ‐1.95%,
1.57%).
Conclusions: As‐treated analyses in the RE‐LY trial suggest benefits
and harms in line with past work. Attenuation of estimated effect on
mortality from a number needed to treat of 162 to 527 when
weighting to warfarin users may indicate effect heterogeneity. Despite
the large set of possible modifiers that differed between RE‐LY and
Medicare and an increase in event rates after weighting, weighted trial
estimates suggest similar absolute effects in dabigatran initiators in
routine care.
416 | An online tool for correcting risk ratio
or cumulative incidence estimates for bias
due to outcome misclassification
Gillian C. Hall1; Stephan Lanes2; Kaatje Bollaerts3; Xiaofeng Zhou4;
Vinay Mehta5; Germano Ferreira6; Rosa Gini7
1Gillian Hall Epidemiology Ltd, London, UK; 2HealthCore Inc, Wilmington,
DE; 3P95 Epidemiology and Pharmacovigilance, Leuven, Belgium; 4Pfizer,
New York, NY; 5Merck & Co. Inc, Kenilworth, NJ; 6Consultant, Parada,
Portugal; 7Agenzia Regionale di Sanità della Toscana, Florence, Italy
Background: Insurance claims and electronic medical records data-
bases are not designed for research, and case identification is subject
misdiagnosis, miscoding, and recording errors. For any particular study,
there is rarely sufficient basis for assuming the magnitude or direction
of outcome misclassification bias. Although many researchers
acknowledge the possibility of outcome misclassification, its impact
on study results is rarely assessed.
Objectives: To develop a user‐friendly, open access, web application
to correct risk ratio (RR) and cumulative incidence point and interval
estimates for bias due to outcome misclassification.
Methods: We used Brenner and Gefeller's methodology (Am J
Epidemiol 1993;138:1007–15) to develop a tool to correct RR and
confidence interval (CI) estimates for differential or nondifferential
outcome misclassification and extended their approach for use with
cumulative incidences. The corrected RR uses positive predictive
value (PPV) and sensitivity (Se) estimates in exposed (1) and unex-
posed (0) and is computed as: RRcorrected = RRobserved x (PPV1/
PPV0) x (Se0/Se1).
Results: The tool (http://apps.p‐95.com/ISPE/) provides corrected
point estimates and CIs based on input of the PPV and Se in each
comparison group. For example, given an observed RR of 2.00
(95%CI 1.80 2.20) and assuming non‐differential Se, a PPV of 75% in
the unexposed and 85% in the exposed gives a corrected RR of 2.27
(2.04, 2.49); a PPV of 85% in the unexposed and 75% in the exposed
gives a corrected RR of 1.76 (1.59, 1.94); while the RR remains the
same if the PPV is equal in both exposed and unexposed strata. The
tool offers a graphic presentation of the corrected RR estimates for
a range of hypothetical Se values with specified PPVs and allows users
to download graphs and the data sheets.
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Conclusions: If Se and PPV are the same across exposure strata, the
RR will be unbiased, regardless of its magnitude. With equal Ses across
strata, bias depends on the ratio of PPVs across strata. Therefore, val-
idation studies should estimate PPVs in each exposure strata. The
practice of seeking PPV across strata with a value above a certain
threshold is insufficient to assess bias unless there are no false posi-
tive errors. The online tool helps researchers to understand the poten-
tial impact of disease misclassification on results.
417 | Clopidogrel drug interactions and
serious bleeding: High‐throughput screening
using the self‐controlled case series design
Charles E. Leonard; Meijia Zhou; Colleen M. Brensinger;
Warren B. Bilker; Samantha E. Soprano; Thanh Phuong Pham Nguyen;
Young Hee Nam; Jordana B. Cohen; Sean Hennessy
University of Pennsylvania, Philadelphia, PA
Background: Drug–drug interactions (DDIs) are a major source of var-
iability in systemic concentrations of clopidogrel. Yet, few population‐
based studies have examined bleeding associated with clopidogrel
DDIs.
Objectives: We aimed to identify medications (i.e., precipitant drugs)
taken concomitantly with clopidogrel (i.e., an object drug) that
increased rates of hospital presentation for serious bleeding.
Methods: We conducted high‐throughput screening of 2000–2015
Optum commercial health insurance claims from the United States.
We identified DDI signals by performing confounder‐adjusted self‐
controlled case series studies for clopidogrel + precipitant pairs, exam-
ining associations with hospital presentation for gastrointestinal
bleeding or intracranial hemorrhage. To help distinguish native bleed-
ing effects of a precipitant from a DDI involving clopidogrel, we
reexamined associations using pravastatin as a negative control object
drug. We used conditional Poisson regression to generate rate ratios
(RRs) with 95% confidence intervals (CIs) and accounted for multiple
estimation via semi‐Bayes shrinkage.
Results: We identified 431 precipitants frequently co‐prescribed with
clopidogrel and with pravastatin as object drugs. In confounder‐
adjusted models, 28 (6.5%) clopidogrel + precipitant pairs were statis-
tically significantly positively associated with serious bleeding after
semi‐Bayes shrinkage and therefore suggestive of a DDI; precipitants
included drugs in commonly‐used therapeutic classes, such as anti‐
infectives, cardiovascular, central nervous system, endocrine/meta-
bolic, gastrointestinal, and nutritional agents. Confounder‐adjusted
ratios of RRs ranged from 1.13 (95% CI: 1.01–1.26) to 3.94 (1.69–
9.20). Among these pairs, 13 (46%) were predictable given that precip-
itants alone increased and/or were harbingers of serious bleeding. The
remaining 15 (54%) pairs constituted DDI signals, none (0%) of which
are currently reported in the Micromedex or Lexicomp DDI knowledge
bases.
Conclusions: We identified numerous previously undescribed and/or
unappreciated potential clopidogrel DDIs associated with serious
bleeding. It may be prudent for clinicians to monitor for signs and
symptoms of bleeding, adjust clopidogrel dose, adjust precipitant dose,
and/or consider therapeutic alternatives in patients concomitantly
exposed to clopidogrel‐precipitant drug interaction signals identified
herein.
418 | Statins and risk of venous
thromboembolism
Nils Skajaa1; Szimonetta K. Szépligeti1; Erzsébet Horváth‐Puhó1;
Waleed Ghanima2,3; John B. Hansen4,5; Henrik T. Sørensen1
1Aarhus University Hospital, Aarhus, Denmark; 2University of Oslo, Oslo,
Norway; 3Østfold Hospital, Kalnes, Norway; 4The Arctic University of
Norway, Tromsø, Norway; 5University Hospital of North Norway, Tromsø,
Norway
Background: Statins possess anti‐inflammatory and anti‐thrombotic
effects, but their role in the primary prevention of venous thrombo-
embolism (VTE) is not well‐established.
Objectives: To examine the risks of first‐time VTE in a cohort of
patients initiating statin treatment and in a matched general popula-
tion comparison cohort.
Methods: We conducted a nationwide, population‐based, matched
cohort study based on prospectively recorded data from Danish
health registries. The study period was from 1 January 2005 to 31
December 2015. We identified a cohort of first‐time statin initiators
without a history of VTE, myocardial infarction, and ischemic stroke
and a sex‐, age‐, and calendar year‐matched (1:3) general population
comparison cohort consisting of individuals without a history of
statin use, VTE, myocardial infarction, and ischemic stroke. We com-
puted cumulative risks of VTE during follow‐up (11 years) and sex‐,
age‐, and comorbidity‐adjusted hazard ratios (HRs) using Cox pro-
portional hazard regressions. To examine a potential healthy user
effect, we also computed risks and HRs for myocardial infarction
and ischemic stroke as secondary endpoints.
Results: Among 601,011 statin initiators and 1,803,033 matched
population cohort members during 2005–2015, the cumulative risk
after 11 years of follow‐up was 2.8% for VTE (both cohorts), 4.7%
vs. 2.9% for myocardial infarction, and 7.1% vs. 5.2% for ischemic
stroke. After adjustment, however, first‐time statin use was associ-
ated with a slightly decreased risk of VTE (adjusted HR: 0.95 [95%
CI: 0.92–0.97]), driven by a reduced risk of unprovoked VTE
(adjusted HR: 0.92 [95% CI: 0.88–0.95]). Expectedly, the adjusted
HRs were elevated for myocardial infarction and ischemic stroke.
The reduced risk of unprovoked VTE was more pronounced in
men than in women and in patients of older age than of younger
age. Statin potency did not modify the associations, and the risks
of deep vein thrombosis and pulmonary embolism were similar.
Conclusions: Statin use was associated with a moderately reduced
risk of VTE, and there were no indications of a healthy user effect.
Statins may be considered as an adjunctive therapy in the preven-
tion of VTE.
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419 | Antithrombotic treatment preceding
ischemic stroke, intracranial hemorrhage, and
gastrointestinal bleeds and mortality in
patients with atrial fibrillation
Joris J. Komen1; Tomas Forslund2; Aukje K. Mantel‐Teeuwisse1;
Olaf H. Klungel1; Björn Wettermark2; Paul Hjemdahl2
1Utrecht University, Utrecht, Netherlands; 2Karolinska Institute,
Stockholm, Sweden
Background: Anticoagulation treatment reduces the risk of stroke but
increases the risk of bleeding in atrial fibrillation (AF) patients. There is
little data on survival after a stroke or a severe bleed.
Objectives: To analyze 90‐day mortality in AF patients after an ische-
mic stroke, an intracranial hemorrhage (ICH), or a gastrointestinal
bleed (GIB) and assess associations with the type of antithrombotic
treatment preceding the event.
Methods: From the Stockholm Healthcare database (n = 2.3 million
inhabitants) we selected all AF patients suffering from an ischemic
stroke, an ICH, or a GIB requiring acute hospital care between July
2011 and August 2018 and assessed 90‐day mortality rates. We
assessed current use of warfarin, non‐vitamin K oral anticoagulants
(NOAC), or antiplatelet agents at time of the event. We used a
Cox regression to calculate hazard ratios (HRs), adjusting for compo-
nents of the Charlson Comorbidity Index, the CHADsVASc score,
the HAS‐BLED score, and comedication, to assess the
association between treatment preceding the event and mortality.
In addition, propensity score matched analyses were performed.
We used an asymmetrically trimmed propensity score matched anal-
yses and an array approach for unmeasured confounding as sensitiv-
ity analyses.
Results: Of 105 313 patients with AF, 6 017 were included after an
ischemic stroke, 3 006 after an ICH, and 4 291 after a GIB. 90‐day
mortality rates were 25.1%, 31.6% and 16.2%, respectively. After
ICH, there was a significantly increased risk of mortality in warfarin
compared to NOAC treated patients (aHR: 1.41 CI: 1.10–1.81).
Patients receiving antiplatelets or no treatment had statistically
higher mortality rates compared to patients on NOAC treatment,
both after an ischemic stroke and a GIB, but there was no significant
difference comparing NOACs to warfarin (aHR 0.87 CI: 0.67–1.13
after stroke, aHR 0.96 CI: 0.72–1.29 after GIB). Asymmetrically
trimmed propensity score matching yielded similar results. The array
approach showed that an unmeasured confounder with a relative
risk of 3.0 had to be present in 40% of the warfarin and 10% of
the NOAC patients to explain the association after ICH.
Conclusions: Mortality is high in AF patients suffering from an ische-
mic stroke, an ICH, or a GIB. NOAC treatment was associated with a
lower 90‐day mortality after ICH than warfarin, but no such associ-
ation was found after ischemic stroke or GIB. After ischemic stroke
and GIB, mortality rates were higher in antiplatelet treated and
untreated patients compared to NOAC treated patients.
420 | Pharmacoepidemiologic screening of
potential Oral anticoagulant drug interactions
and thromboembolic events
Meijia Zhou; Charles E. Leonard; Colleen M. Brensinger;
Warren B. Bilker; Stephen E. Kimmel; Todd E. Hecht; Sean Hennessy
Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA
Background: Drug–drug interactions (DDIs) with oral anticoagulants
may lead to reduced anticoagulant effect and thus increased risk
of thromboembolic events. Warfarin is susceptible to numerous
DDIs while few studies have examined DDIs involving direct‐acting
oral anticoagulants.
Objectives: To identify medications associated with an increased
rate of hospitalization of thromboembolic events when taken con-
comitantly with oral anticoagulants.
Methods: We conducted a high‐throughput pharmacoepidemiologic
screening study using OptumInsight Clinformatics Data Mart,
2000–2016. We performed self‐controlled case series studies among
adult oral anticoagulant users (warfarin, dabigatran, rivaroxaban,
apixaban, and edoxaban) with at least one hospitalization for throm-
boembolic events (stroke and/or venous thromboembolism). Among
eligible patients, we identified all oral medications frequently co‐pre-
scribed with oral anticoagulants as potential interacting precipitants.
Conditional Poisson regression was used to estimate rate ratios (RR)
and 95% confidence intervals comparing precipitant exposed time
vs. precipitant unexposed time for each anticoagulant‐precipitant
pair. Use of antiplatelet agents and nonsteroidal anti‐inflammatory
drugs were adjusted as time‐varying covariates. To control for
within‐person confounding by indication for the precipitant and to
distinguish a DDI from a native effect of the precipitant on throm-
boembolism risk, we used pravastatin as a negative control object
drug. We calculated the ratio of RRanticoagulant + precipitant vs. anticoagu-
lant to RRpravastatin + precipitant vs. pravastatin for precipitants identified
in both anticoagulant and pravastatin users. Multiple estimation
was adjusted using semi‐Bayes shrinkage.
Results: We screened 1,622 oral anticoagulant‐precipitant drug pairs
and identified 261 (16%) drug pairs associated with a statistically sig-
nificantly elevated risk of thromboembolism. Using pravastatin as the
reference group, we identified 81 potential DDI signals that
were associated with statistically significantly elevated ratio of
RRs (32 for warfarin, 13 for dabigatran, 22 for rivaroxaban and 14
for apixaban). Among these signals, 40 (49%, 9 for warfarin, 10 for
dabigatran, 11 for rivaroxaban and 10 for apixaban) were not
documented in DDI knowledge databases Lexicomp and/or
Micromedex.
Conclusions: We reproduced some previously documented DDIs,
which demonstrated the validity of our approach. The newly
identified potential DDI signals need to be examined in future
studies.
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421 | Non‐vitamin K antagonist Oral
anticoagulants and angioedema: A cohort and
case‐crossover study
John Connolly; Sebastian Schneeweiss; Robert J. Glynn;
Joshua J. Gagne
Brigham and Women's Hospital, Boston, MA
Background: Patients taking non‐vitamin K antagonist oral anticoagu-
lants (NOACs) such as dabigatran, rivaroxaban, and apixaban have
reported experiencing angioedema in both randomized trials and rou-
tine care.
Objectives: To quantify the association between NOACs and angio-
edema relative to warfarin among routinely treated patients with atrial
fibrillation using a cohort study. In order to contextualize the results
from the active comparator cohort study, we also compared warfarin
users to non‐users in a case‐crossover study.
Methods: Both designs drew eligible patients from the Truven Health
MarketScan Commercial database, the Optum© Clinformatics® Data
Mart, and Medicare. Eligible patients must have been previously diag-
nosed with atrial fibrillation and must not have had a prior dispensing
for an angiotensin‐converting enzyme inhibitor, angiotensin II receptor
blocker, or aliskiren. In the cohort study, we compared the 6‐month
relative rate of angioedema among new users of NOACs (dabigatran,
rivaroxaban, apixaban) and new users of warfarin. Patients contributed
person time while they were exposed to the index medication. We
estimated hazard ratios (HRs) and 95% confidence intervals (CIs)
within each database after adjusting for confounders using propensity
score stratification, and meta‐analyzed the database‐specific HRs
using a random‐effects model. In the case‐crossover study, we
restricted the study period to the time prior to the introduction of
NOACs in October 2010 and pooled cases from each database. We
estimated an odds ratio (OR) for the association between warfarin
and angioedema by comparing the odds of a warfarin prescription in
the 30‐day hazard window immediately prior to the case versus an
earlier 30‐day reference window.
Results: In the cohort study, we observed 249 incident angioedema
events among 267,684 NOAC initiators and 281,145 warfarin initia-
tors during a mean follow‐up of 89 days across all databases. The
absolute incidence rate across all databases was 1.9 per 1,000 per-
son‐years. The meta‐analyzed HR for angioedema comparing any
NOAC versus warfarin was 0.98 (95%CI: 0.76, 1.27). In the case‐cross-
over design, the OR for the association between warfarin and angio-
edema relative to non‐use was 0.91 (95%CI: 0.68, 1.21) based on
431 cases.
Conclusions: Despite suggestions from the pre‐approval trials and
post‐approval individual case safety reports, our estimates were
inconsistent with substantial short‐term relative increases in the rate
of angioedema among NOAC initiators compared to warfarin initiators
or among warfarin initiators compared to non‐users.
422 | Exposure to Dicloxacillin and
Flucloxacillin during warfarin use and risk of
ischemic stroke and systemic embolism
Maja Hellfritzsch1; Lars Christian Lund1; Zandra Ennis2;
Tore B. Stage1; Mette Bliddal2; Peter B. Jensen1; Daniel P. Henriksen2;
Martin T. Ernst1,2; Morten S. Olesen1; Anne Broe1;
Kasper B. Kristensen1; Per Damkier1,2; Jesper Hallas1;
Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Odense University
Hospital, Odense, Denmark
Background: The isoxazolyl penicillins dicloxacillin and flucloxacillin
induce cytochrome P450 catalyzed metabolism of warfarin leading
to decreased anticoagulant effect as measured by the international
normalized ratio. The clinical importance of this drug–drug interac-
tion is unknown.
Objectives: To explore the association between exposure to
dicloxacillin or flucloxacillin and risk of ischemic stroke and systemic
embolism during warfarin use.
Methods: Using the nationwide Danish registries, we identified all
patients receiving warfarin due to atrial fibrillation or mechanical
heart valves during 1995–2018 (n = 114,383). Within this popula-
tion, we performed an active comparator, propensity‐score matched
cohort study comparing the frequency of ischemic stroke/systemic
embolism 7 to 28 days following initiation of dicloxacillin/
flucloxacillin to that among initiators of phenoxymethylpenicillin.
Hazard ratios (HR) with 95% confidence intervals were estimated
using Cox regression. Using the same population of warfarin users,
the association was also explored using an untreated comparator
(random index dates) and by analyzing the data using a case‐cross-
over design.
Results: A total of 49,392 episodes of dicloxacillin/flucloxacillin use
were matched 1:1 to episodes of phenoxymethylpenicillin use.
The frequency of ischemic stroke/systemic embolism during the
respective episodes were 2.3/1000 episodes and 1.1/1000 episodes,
corresponding to a HR of 2.1 (95% CI 1.5–2.9) and a number
needed to harm of 833. Results were consistent across patient sub-
groups. The association was stronger for use of dicloxacillin (HR 2.2;
95% CI 1.6–3.0) than flucloxacillin (HR 1.2; 95% CI 0.5–2.9). Use of
an untreated comparator strengthened the association (HR 2.7; 95%
CI 1.9–3.9). Finally, the case‐crossover analysis gave results
similar to the main analysis (Odds Ratio 1.9; 95% CI 1.4–2.6).
Conclusions: Use of dicloxacillin in warfarin users with atrial fibrilla-
tion or mechanical heart valves was associated with a clinically
relevant increased short‐term risk of ischemic stroke and
systemic embolism. The absolute risk was, however, low.
Dicloxacillin should be used with caution in patients receiving
warfarin.
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423 | Comparative performance of CIDACS‐
RL using administrative data sources
George C.G. Barbosa1; Mohamed S. Ali1,2; Bruno Araujo1;
Maria Y. Ichihara1; Sandra Reis1; Samila Sena1; Julia M. Pescarini1;
Rosemeire L. Fiaccone1,3; Leila D. Amorim1,3; Robespierre Pita1;
Marcos E. Barreto1,3,4; Liam Smeeth2; Mauricio L. Barreto1,3
1Centre for Data and Knowledge Integration for Health (CIDACS),
Salvador, Brazil; 2 London School of Hygiene and Tropical Medicine,
London, UK; 3Federal University of Bahia (UFBA), Salvador, Brazil;
4University College London, London, UK
Background: Record linkage has been a common tool to conduct
cohort studies using administrative data sources. Despite the develop-
ment of several linkage tools, availability of datasets of huge volume
and complexity still pose a huge challenge in record linkage. Recently,
CIDACS‐RL has been developed to meet these challenges in building
“the 100 Million Brazilian cohort”.
Objectives: To evaluate the performance of CIDACS‐RL (Centre for
Data and Knowledge Integration for Health ‐ Record Linkage) com-
pared to four other linkage tools (AtyImo, Febrl, FRIL, and RecLink).
Methods: We created a gold standard dataset using exact matching of
two administrative data sources from the Brazilian Ministry of Health:
the Mortality Information System (SIM) and the Live Birth Information
System (SINASC). In addition, the Unified Registry for Social
Programmes of the Federal Government (CadUnico) and tuberculosis
from the Information System for Notifiable Diseases (SINAN‐Tubercu-
losis) from 2001–2013. All datasets contained individual‐level data
with five attributes in common and were used for linkage: name,
mother name, date of birth, municipality and sex. We assessed the
accuracy of linkage with standard metrics: sensitivity, specificity, pos-
itive predictive value (PPV), and area under receiver operating charac-
teristic (ROC) curve (AUC). To minimize potential implicit bias due to
significant differences in several technical choices among the tools,
we considered the optimal settings for each method.
Results: Overall, CIDACS‐RL algorithm had a superior performance:
positive predictive value (99.93% versus AtyImo 99.30%, RecLink
99.5%, Febrl 98.86%, and FRIL 96.17%) and sensitivity (99.87% versus
AtyImo 98.91%, RecLink 73.75%, Febrl 90.58%, and FRIL 74.66%).
Both AtyImo, RecLink, Febrl and FRIL achieved their best performance
by using blocking techniques, nevertheless the CIDACS‐RL
outperformed them in terms of accuracy and execution time. How-
ever, Febrl and FRIL could not be run in this setting hence comparison
was not possible with all the tools.
Conclusions: CIDACS‐RL algorithm is an innovative linkage tool with
higher accuracy, improved scalability, and substantially shorter exe-
cution time compared to other existing linkage tools. Also,
CIDACS‐RL can be deployed for huge datasets on standard com-
puters without the need for high‐speed processors and distributed
infrastructures.
424 | Swedish National Registries versus
electronic medical records: Comparing the
completeness of systemic therapy data using
data from the SCAN‐LEAF study
Pia Horvat1; Anne Mette‐Kejs2; Quratul Ann1; Valeria Lascano1;
Benjamin Bray1; Dony Patel1; Simon Ekman3; Laure Lacoin4;
Ariadna Juarez‐Garcia5; Joseph Kim1
1 IQVIA, London, UK; 2 IQVIA, Copenhagen, Denmark; 3Karolinska
Institutet/University Hospital, Stockholm, Sweden; 4Bristol‐Myers Squibb,
Braine‐l'Alleud, Belgium; 5Bristol‐Myers Squibb, London, UK
Background: Few studies have examined the completeness of drug
treatment data in Swedish national registries.
Objectives: The aim was to assess the completeness of systemic
anti‐cancer therapy (SACT) data in Swedish national heath
registries through linkage with hospital electronic medical
records (EMR) using data from the SCAN‐LEAF study, a retrospec-
tive cohort of Non‐Small Cell Lung Cancer (NSCLC) patients in
Scandinavia.
Methods: EMRs from 2 major Swedish university hospitals,
Karolinska and Uppsala, were linked with the Swedish National Can-
cer Register (NCR), the National Patient Register (NPR), and the Pre-
scribed Drug Register (PDR) forming a cohort of adult patients
diagnosed with NSCLC from 2012 to 2015, and followed up until
31 December 2016. Patients with a cancer history were excluded.
Ascertainment of systemic therapy in registries was based on proce-
dure (KVÅ) or drug codes (WHO ATC). For PDR which includes
community dispensed prescriptions, completeness was assessed for
oral SACT only. We calculated sensitivity, specificity and predicted
values separately for NPR and PDR, using EMR as the reference
standard.
Results: A total of 2,779 NSCLC patients were included. Median age
at diagnosis was 70 years (22–96 years); 49% of patients were
male, 58% were diagnosed with stage IIIB‐IV disease, and 71% had
a non‐squamous histology. In the NPR, only 265 (9.5%) out of
1,527 patients (55%) identified as SACT‐treated in EMR had SACT
data. Another 26% (713) of these patients had no SACT data in reg-
istries, whereas only 61 patients with SACT data in registries had no
SACT data in EMR. NPR had low sensitivity (0.15 [95% CI 0.14–
0.17]). This result was not associated with disease stage (I‐IIIA vs.
IIIB‐IV). By contrast, PDR had high sensitivity (0.95 [95% CI 0.91–
0.97]), with 230 patients with oral SACT identified in both PDR
and EMR.
Conclusions: We observed significant under‐reporting of SACT in
the Swedish NPR, whereas completeness of oral SACT data in
the PDR was high. Investigators using Swedish national health
registries to study drug treatment data should exercise caution.
Linkage with hospital EMR may overcome some of the limitations
of registry‐only studies of drug treatment in cancer patients.
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425 | Validation of diagnostic algorithms to
detect type 1 diabetes mellitus disease using
administrative data from a general population
from southern Italy
Ylenia Ingrasciotta1; Andrea Fontana2; Valentina Ientile3;
Salvatore Crisafulli3; Maria Paola Bertuccio1; Maurizio Pastorello4;
Vincenzo Provenzano5; Alessandro Scorsone5; Gianluca Trifirò1,3
1University of Messina, Messina, Italy; 2Casa Sollievo della Sofferenza,
San Giovanni Rotondo, Foggia, Italy; 3A.O.U. Policlinico “G. Martino”,
Messina, Italy; 4Palermo Local Health Unit, Palermo, Italy; 5Civic
Hospital, Partinico, Palermo, Italy
Background: In Italy, type 1 diabetes mellitus (T1DM), the most com-
mon form of DM among children, is about 2–3% of all known cases of
diabetes, with an incidence of about 10–11*100,000 persons/year,
increasing every year.
Objectives: To validate diagnostic algorithms which allow
distinguishing betweenT1DM and T2DM patients in a general popula-
tion from Southern Italy, using administrative data from Palermo Local
Health Unit (LHU) during 2011–2017. As gold standard, certain diag-
noses of T1DM/T2DM in a sample of diabetic patients for whom reg-
istries of diabetes ambulatories could be linked to claims data from the
same catchment area.
Methods: Among 1.4 million inhabitants from Palermo LHU, 127,590
(9.4%) users of antidiabetic drugs (AD) during the years 2011–2017
in the claims database were identified. Confirmed diagnoses of
T1DM/T2DM (gestational diabetes was excluded) were available for
a subpopulation of AD users, for whom claims data and registries of
diabetes ambulatories could be linked. The first date of AD dispensing
during the study period was the Index Date (ID). Age and insulin dis-
pensing at ID and DM‐related ICD9‐CM codes (T1DM: 250*1/
250*3; T2DM: 250*0/250*2) as primary/secondary causes of hospital
admissions any time prior to ID were the variables considered for
T1DM coding algorithms development. While one algorithm was
defined by the user, the other one was based on Recursive
PArtitioning and Regression Tree method. Sensitivity (Sn), specificity
(Sp), accuracy as well as positive (PPV) and negative (NPV) predicted
values were estimated. Such algorithms were then applied to all claims
database to identify T1DM.
Results: Among 34,926 AD users with a certainT1DM/T2DM diagno-
sis, 793 (2.3%) were affected by T1DM. The user‐defined algorithm
was based on age (i.e., age < 30 years) OR insulin dispensing OR 1 spe-
cific T1DM code and showed high Sn (94.2%), Sp (84.0%), accuracy
(84.2%), NPV (99.8%), but low PPV (12.0%). The statistical algorithm,
based only on age (i.e., age < 22.5 years) and insulin dispensing,
showed lower Sn (37.8%), but higher Sp (99.5%), accuracy (98.1%),
NPV (98.6%) and PPV (64.1%) than the user algorithm. Applying the
two algorithms in the whole sample of 127,590 claims AD users,
22,606 (21.5%) and 1,070 (0.8%) T1DM patients would be identified,
respectively. The statistical algorithm was more accurate and achieved
high predictive values.
Conclusions: Demographic characteristics in combination with drug‐
utilization patterns can be used to identify T1DM. Advanced statistical
methods may help for a more accurate distinction of T1DM from
T2DM.
426 | Validity of claims‐based definitions for
rheumatoid arthritis, selected cancers and
infectious diseases in Japan: Results from
VALIDATE ‐ J study
Cynthia de Luise1; Haoqian Chen2; Edward Nonnenmacher2;
Naonobu Sugiyama3; Ryota Hase4,5; Mitsuyo Kinjo6; Daisuke Suzuki7;
Kayoko Katayama8; Takakazu Higuchi9; Sadao Jinno10;
Yoshiya Tanaka11; Toshitaka Morishima12; Soko Setoguchi2,13
1Pfizer, New York, NY; 2Rutgers, the State University of New Jersey, New
Brunswick, NJ; 3Pfizer, Tokyo, Japan; 4Kameda Medical Center, Chiba
Prefecture, Japan; 5 Japanese Red Cross Narita Hospital, Chiba, Japan;
6Okinawa Chubu Hospital, Okinawa, Japan; 7Fujita Health University,
Aichi, Japan; 8Kanagawa Cancer Center Research Institute, Kanagawa,
Japan; 9Dokkyo Medical University Saitama Medical Center, Saitama,
Japan; 10Kobe University School of Medicine, Yokohama, Kanagawa,
Japan; 11University of Occupational and Environmental Health,
Kitakyushu, Japan; 12Osaka International Cancer Institute, Osaka, Japan;
13Robert Wood Johnson Medical School, New Brunswick, NJ
Background: The National Claims Database (NDB) was launched for
research use in 2011. Interest among Japanese academia, industry
and government to use the NDB and other large databases is mount-
ing, especially with the increasing interest in real world data and evi-
dence. However, little evidence exists to support the validity of
claims‐based diagnoses in Japan.
Objectives: To assess the validity of claims‐based diagnoses for rheu-
matoid arthritis (RA), selected cancers and infectious diseases (ID) in
Japan.
Methods: We designed a multi‐institutional validation study using
hospital claims data as identifying and linking patients from large
claims databases are prohibited in Japan. We developed various
claims‐based algorithms for RA, selected cancers and ID: herpes zoster
(HZ), Mycobacterium tuberculosis (MTB), non‐Mycobacterium tuberculo-
sis (NTB), and pneumocystis jiroveci pneumonia (PJP), and identified
claims‐based cases from two large hospitals in Japan between 1/
2012–12/2016. The gold standard definitions and standard abstrac-
tion forms for RA and ID were developed by a steering committee
of Japanese clinical and methods experts. All RA and ID cases were
independently reviewed by an adjudication committee. We calculated
positive predictive values (PPV) for RA and ID, and PPV, sensitivity
and specificity for cancer.
Results: We collected and analyzed data from one hospital. We iden-
tified 2,009 RA, 2,272 HZ, 161 MTB, 405 NTB, 162 PJP, and 15,860
cancers. Mean age and % female for RA, all ID, and any cancer were
62; 73%; 64; 54%, and 66; 53%, respectively. PPVs (95% confidence
intervals) were RA = 82% (77–88); HZ = 76% (64–88); MTB = 92%
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(84–99); NTB = 80% (69–91); PJP = 32% (19–44); Colorectal = 87%
(84–90); Breast = 88% (86–89); Lung = 91% (88–93); Pancreas = 90%
(85–94); Gastric = 91% (89–94); Melanoma = 46% (28–65); Lym-
phoma = 82% (78–86); Any malignancy = 84% (83–85). Sensitivity
analyses using alternative algorithms in the subsets for RA and ID pro-
duced PPVs that were 7–10% higher than those in the main analyses.
Conclusions: PPVs for claims‐based algorithms for RA were similar to
those reported in US data whereas several cancers had better PPVs
than those reported in the US (87% to 91% (Japan) vs 60% to 82%
(US)); results for most ID conditions are some of the first ever
reported. All algorithms will be invaluable for future claims‐based
pharmacoepidemiology research in Japan. As the Pharmaceuticals
and Medical Device Agency continues to encourage validation studies
to support the validity of database research for postmarket surveil-
lance, VALIDATE‐J will serve as a model.
427 | ICD‐9 to ICD‐10 mapping for research
in biologics and Biosimilars using
administrative healthcare data
Mengdong He1; Adrian J. Santiago Ortiz1; James Marshall2,3;
Aaron B. Mendelsohn2,3; Jeffrey R. Curtis4; Charles E. Barr5;
Catherine M. Lockhart5; Seoyoung C. Kim1,3
1Brigham and Women's Hospital, Boston, MA; 2Harvard Pilgrim Health
Care Institute, Boston, MA; 3Harvard Medical School, Boston, MA;
4University of Alabama at Birmingham, Birmingham, AL; 5Biologics and
Biosimilars Collective Intelligence Consortium, Alexandria, VA
Background: As of October 1st, 2015, the Centers for Medicare and
Medicaid Services (CMS) mandated the transition from ICD‐9 to
ICD‐10 codes. Many differences between the two coding systems
such as the level of detail and number of codes complicate analysis
of data across this transition period. The Biologics and Biosimilars Col-
lective Intelligence Consortium (BBCIC) uses a distributed research
network (DRN) to generate post‐marketing evidence for safety and
effectiveness of biologics and biosimilars. Active surveillance of prod-
ucts' safety and effectiveness in DRNs requires a robust approach for
converting ICD‐9 to ICD‐10 codes used in defining study populations,
covariates and outcomes.
Objectives: To examine three ICD‐9 to ICD‐10 mapping methods for
health conditions (HCs) of BBCIC's interest and compare their inci-
dence identified with ICD‐9 versus ICD‐10 codes in BBCIC's DRN.
Methods: We applied forward‐backward mapping (FBM), using direct
links of forward and backward General Equivalence Mappings devel-
oped by CMS, to all the 110 HCs. More complicated secondary map-
ping (SM) and tertiary mapping (TM), based on iterations of FBM, were
tested for 7 selected variables. A physician reviewed the relevance of
mapped ICD‐10 codes and compared the three methods to one
another. Incidence of the 110 HCs defined by ICD‐9 versus ICD‐10
codes was examined in the DRN of data from 5 large healthcare orga-
nization partners during the period from three years before the ICD‐
10 implementation in October 2015 to the latest available data (9/
1/2012–3/31/2018). We visually assessed incidence trends before
and after October 2015 and used a threshold of 20% level change
to examine the performance of ICD‐9‐to‐ICD‐10 conversion.
Results: Nearly 4 times more ICD‐10 codes were mapped by SM and
TM compared to FBM. However, the additional codes identified by
SM or TM were mostly irrelevant or too non‐specific to be used alone.
For distinct conditions such as myocardial infarction, SM or TM did
not add any ICD‐10 codes to FBM mapping. Through visual inspec-
tion, 22% HCs had inconsistent ICD‐9 versus ICD‐10 trends; in gen-
eral, ICD‐10 algorithms led to a higher incidence. 15% HCs had an
incidence level change greater than +/−20% between ICD‐9 and
ICD‐10 algorithms.
Conclusions: FBM is generally the most efficient way to convert ICD‐
9 to ICD‐10 codes, yet manual review of converted ICD‐10 codes is
recommended for all three methods. No existing guidance is available
to compare the performance of ICD‐9 versus ICD‐10 codes, leading to
challenges in empirically determining the quality of conversions.
428 | External validation of an algorithm to
identify patients with high data‐completeness
in electronic health Records for Comparative
Effectiveness Research
Joshua K. Lin1,2; Yinzhu Jin1; Robert J. Glynn1;
Sebastian Schneeweiss1
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
2Massachusetts General Hospital, Boston, MA
Background: Electronic health records (EHR) discontinuity, i.e. receiv-
ing care outside the reach of an EHR system, is associated with sub-
stantial information loss and bias when using EHR data for
comparative effectiveness research (CER). We had developed a pre-
diction algorithm to identify patients with high EHR‐continuity to
reduce such bias, but its performance across different EHR systems
is unknown.
Objectives: To describe EHR‐continuity pattern of two demographi-
cally distinct US systems and test the performance of the prediction
model for identifying patients with high EHR‐continuity developed in
one system, using the external data.
Methods: Study cohort comprised all patients aged ≥65 in EHR from
two EHR systems linked with Medicare claims data from 2007/1/1 to
2014/12/31, one each in Massachusetts (MA) and North Carolina
(NC). We quantified EHR‐continuity by the Mean Proportion of
Encounters Captured (MPEC) by the EHR system when compared to
records in the claims data. With predictors available in EHR, we built
a prediction model for MPEC by Lasso regression in the MA system
and performed external validation in the NC system. Within levels of
predicted EHR‐continuity, for 40 variables that are typical con-
founders in a range of CER studies, we quantified misclassification
by Mean Standardized Differences (MSD) between the proportions
of these variables based on EHR alone vs. the linked claims‐EHR data.
We compared the combined comorbidity scores in those with high
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(defined as top 20% based on literature) vs. low (the remaining popu-
lation) predicted EHR‐continuity.
Results: Based on 104,403 patients in the MA system and 33,205 in
the NC system, MPEC was 24% in the MA and 26% in the NC system.
Our prediction model yielded a score highly correlated with the mea-
sured EHR‐continuity (MPEC) in both systems (Spearman correla-
tion = 0.77, 0.72, C‐statistic = 0.86, 0.85, respectively). In the
validation set, patients in the best predicted EHR‐continuity decile
had 3.27 (95% confidence interval [CI] 3.25–3.29) fold smaller MSD
(i.e. less misclassification), when compared to those in the worst pre-
dicted EHR‐continuity decile for the 40 key confounding variables.
Patients with high EHR‐continuity had similar comorbidity profiles
when compared to the rest of population (MSD in the comorbidity
score categories = 0.02).
Conclusions: Restricting a CER analysis to patients with high predicted
EHR‐continuity may reduce misclassification of key variables without
losing representativeness in terms of their co‐morbidity profiles.
429 | Incidence rates of and risk factors for
opioid overdoses in new users of prescription
opioids among US Medicaid enrollees: A
cohort study
Young Hee Nam; Warren Bilker; Francesco DeMayo III;
Mark Neuman; Sean Hennessy
University of Pennsylvania, Philadelphia, PA
Background: The number of opioid overdoses has been escalating
exponentially in the US, particularly in the Medicaid population, yet
incidence rates of and risk factors for opioid overdoses among new
users of prescription opioids are unknown.
Objectives: To measure the rates of and risk factors for incident opi-
oid overdoses among new users of prescription opioids in the Medic-
aid population.
Methods: Design ‐ Cohort study. Setting ‐ Medicaid population cap-
tured by Medicaid claims, supplemented with Medicare claims for
dual‐enrollees, from California, Florida, New York, and Pennsylvania
from 1999 to 2012. Adults (at cohort entry) continuously enrolled in
Medicaid for at least 3 years and free of opioid prescriptions and opi-
oid overdoses before cohort entry date (dispensing date of the first
observed opioid prescription) were eligible. Exposure of interest ‐ Pre-
scription opioid use. Outcome measure ‐ Opioid overdoses, identified
by ICD‐9‐CM diagnosis codes appearing in inpatient or outpatient
claims. Statistical analysis ‐ Incidence rates during 2002–2012 and
adjusted hazard ratios (HRs) of opioid overdoses for potential risk
factors.
Results: Among new users of prescription opioids identified
(1,336,140 persons; 246,466 person‐years), the incidence rate of opi-
oid overdoses during 2002–2012 was 247.1 (95% confidence interval
(CI): 227.5–266.7) per 100,000 person‐years, with about a 3.0% (CI:
1.0%–5.1%) per year of cohort entry relative decrease. A lower hazard
for opioid overdose was seen for age 65–80 years (HR = 0.50; CI:
0.37–0.66) and 80–100 years (HR = 0.35; CI: 0.23–0.52) compared
to 18–35 years; females (HR = 0.79; CI: 0.67–0.93) compared to
males; and other/unknown race/ethnicity (HR = 0.71; CI: 0.54–0.93)
compared to whites. A higher hazard was seen for opioid daily dose
(in morphine milligram equivalents) 50–100 mg/day (HR = 1.52; CI:
1.24–1.86) and > 100 mg/day (HR = 1.98; CI: 1.55–2.53) compared
to <50 mg/day; prior (during 1 year before cohort entry) diagnosis of
substance use disorders (HR = 2.30; CI: 1.91–2.79) or mental health
disorders (HR = 1.75; CI: 1.47–2.08); and prior (during 30 days before
cohort entry) benzodiazepine prescriptions (HR = 1.43; CI: 1.13–1.81).
Conclusions: During 2002–2012 in sampled Medicaid enrollees, the
incidence rates of opioid overdoses among apparent new users of pre-
scription opioids declined by cohort entry year. Younger age, white
race/ethnicity, higher opioid daily doses, and prior substance use dis-
orders, mental health disorders, and benzodiazepine prescriptions
were associated with a higher risk of opioid overdose incidence.
430 | Risk of opioid overdose associated
with concomitant use of opioids and muscle
relaxants
Yan Li1; Yu‐Jung Wei1; Joshua Brown1; Gary M. Reisfield1;
Chris Delcher2; Almut G. Winterstein1
1University of Florida, Gainesville, FL; 2University of Kentucky, Lexington,
KY
Background: The CDC's opioid prescribing guideline cautions against
the concomitant prescribing of opioids and muscle relaxants based
on the pharmacological theory that muscle relaxants can potentiate
the central nervous system depression associated with opioids. How-
ever, the clinical importance of this potential drug–drug interaction is
not well understood.
Objectives: To compare the risk of opioid overdose hospitalizations or
emergency department visits associated with concomitant use of opi-
oids and muscle relaxants versus opioids use alone.
Methods: Using the IBM MarketScan Commercial Claims Database
from 2005 to 2015, we assembled two opioid user cohorts based on
whether individuals were incident (cohort 1) or prevalent (cohort 2)
users. In cohort 1, incident opioid users with concomitant muscle
relaxant use were directly compared with incident opioid‐only users.
In cohort 2, concomitant users were compared with randomly selected
(1:3) opioid‐only users who filled an opioid prescription on the same
calendar date as the concomitant users. We used a validated algorithm
to measure opioid overdoses during follow‐up. Cox proportional haz-
ards models with propensity score standardized mortality ratio
weighting were used to compare the risk between concomitant users
and opioid‐only users, accounting for 54 potential confounders.
Results were measured separately for each cohort and then combined
with random effect meta‐analysis.
Results: Our study included 1.3 million concomitant users and 13.9
million opioid‐only users in cohort 1, and 1.1 million concomitant users
and 3.3 million matched opioid‐only users in cohort 2. Crude incidence
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rates of opioid overdose were 1.2 and 1.0 per 1000 patient‐years,
respectively, for concomitant users and opioid‐only users in cohort
1, and 2.7 and 2.0, respectively, in cohort 2. Adjusted HRs were
1.09 (95% CI: 0.74–1.62) and 1.26 (1.00–1.58) in cohorts 1 and 2,
respectively, generating a combined estimate of 1.21 (1.00–1.48). This
risk increased with duration of use (<15 days: HR 0.91, 95% CI 0.67–
1.44; 15–60 days: 1.37, 0.81–2.37; >60 days: 1.80, 1.30–2.48) and
was greater for carisoprodol (1.82, 1.15–2.90) and baclofen (1.84,
1.33–2.56). Patients using daily morphine equivalent opioid dose
≥50 mg (1.50, 1.18–1.92) and patients who had a history of benzodi-
azepine use (1.39, 1.08–1.79) also had greater risk.
Conclusions: Concomitant use of muscle relaxants and opioids was
associated with a slightly increased risk of opioid overdose compared
to opioid use alone, which was largely driven by long‐term use, use of
baclofen or carisoprodol, and use among certain high‐risk patient
groups.
431 | The association between prescription
opioid use and bone fracture: A self‐
controlled case series study
Emily Peach1; Fiona Pearce1; Janice Fuller2; Andrew Cooper3;
Li‐Chia Chen4; Roger Knaggs1,5
1University of Nottingham, Nottingham, UK; 2Mundipharma Research
Ltd, Cambridge, UK; 3Mundipharma Research Ltd (former employee),
Cambridge, UK; 4University of Manchester, Manchester, UK; 5Primary
Integrated Community Solutions, Nottingham, UK
Background: Observational studies have reported positive associa-
tions between use of prescription opioids and bone fracture. Hypoth-
esized mechanisms include acute central effects, and long‐term effects
on bone density. Most studies have been limited by potential expo-
sure misclassification, residual confounding and confounding by indi-
cation. Alternative study designs are required to overcome these
limitations.
Objectives: To estimate the association between prescription opioids
and the incidence of bone fracture in adult opioid users.
Methods: Using a self‐controlled case series study, adult opioid users
registered in the UK Clinical Practice Research Datalink between 2009
and 2017, with a record of first fracture were identified. Opioid users
were defined as those prescribed an opioid during the study period,
with no record of an opioid prescription in the two years prior to first
prescription. First fracture occurrences were defined as the earliest
fracture code recorded one year before, or any time following, opioid
initiation. Exposed time was categorized into risk periods: the 1st
week, 2nd week, 3rd and 4th weeks, and any remaining time; for initial
and subsequent periods of exposure. The baseline period consisted of
unexposed time: 1‐year before first opioid prescription, gaps in expo-
sure, and remaining observation time following the final exposed
period. Pre‐exposure and post‐exposure periods were introduced to
eliminate bias arising from event‐dependent exposure and residual
drug effects. Conditional Poisson regression was used to estimate
the risk of fracture during the risk periods as an adjusted incidence
rate ratio (IRR), with 95% confidence intervals (CI).
Results: There were 43,639 opioid users with a record of first fracture.
Median follow‐up time was 4.6 years (IQR: 2.9, 6.3), 61% of the study
population were female and the median age was 62 years (IQR: 45,
77). The IRR of fracture during the first week following opioid initia-
tion compared with the baseline period was 6.63 (95% CI: 5.68,
7.73), after adjustment for age, season and opioid dose. The adjusted
IRR decreased with time following initiation, the IRR for remaining opi-
oid exposure, at least four weeks after initiation was 2.20 (95% CI
1.89, 2.56) compared to the baseline period.
Conclusions: The results are consistent with the hypothesis that acute
central effects of opioids can increase the likelihood of bone fracture
and that there may be longer‐term effects on bone health. Patients
and prescribers need to be aware of the potential increase in frac-
ture‐risk associated with opioids, particularly during the initial weeks
of use.
432 | The proportion of patients in the
United States receiving postsurgical opioids
exceeding recommended thresholds
increased between 2006 and 2015
Jessica C. Young1; Brooke A. Chidgey2; Til Stürmer1;
Michele Jonsson Funk1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2University of North Carolina School of
Medicine, Chapel Hill, NC
Background: Studies have found that patients routinely receive more
opioids than medically necessary for adequate postsurgical pain man-
agement. This excess prescribing contributes to unused supply,
increasing the risk of diversion and nonmedical use. In response to
the US opioid crisis, opioid prescription (Rx) limits have been imple-
mented on a state‐by‐state basis beginning in 2016, with 32 states
currently enforcing prescribing limits.
Objectives: Among a broad cohort of opioid‐naïve surgical patients in
the US, examine trends in 1) the proportion filling opioid Rxs for post-
surgical pain, and 2) the initial volume prescribed.
Methods: We identified patients undergoing surgery in MarketScan
(2006–2015) and Medicare (2007–2015) claims. We defined the index
opioid Rx for postsurgical pain as the first opioid filled in the week sur-
rounding surgery following 180 days with no prior use. To reflect
recent policy recommendations, we examined the proportion of
patients whose index opioid Rx exceeded 7 days supply, 40 quantity
dispensed (QTY), or 300 morphine milligram equivalents (MME).
Results: We identified 5,148,485 opioid‐naïve surgical patients in
MarketScan (mean age = 45), of whom 2,957,115 (55%) received an
index opioid (median: days supply = 5; QTY = 30; MME = 240). The
proportion of all patients with an index opioid Rx increased from
51% in 2006 to 62% in 2013, followed by a decline to 42% in 2015.
Among patients receiving an index opioid, the proportion receiving
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>7 days supply increased monotonically, nearly doubling between
2006 (11%) and 2015 (19%). Similarly, the proportion of patients
receiving >40 QTY more than doubled throughout the study period,
rising from 14% in 2006 to 29% in 2015, and the proportion receiving
>300 MME rose from 21% in 2006 to 34% in 2015. Parallel analyses
in Medicare found that the proportion receiving post‐op opioids con-
tinued to increase through 2015, with parallel trends of increasing
proportions of patients filling index opioid Rxs above defined thresh-
olds throughout the study period.
Conclusions: Between 2005 and 2013, there was an increase in both
the probability of opioid receipt for postsurgical pain, and the propor-
tion of Rxs exceeding recommended thresholds. While the proportion
of patients filling opioids began to decline in 2014 among the
MarketScan population, the proportion of high threshold Rxs contin-
ued to increase. Understanding trends in post‐surgical prescribing
are vital in informing and evaluating policies aimed at reducing unnec-
essary opioid exposure and curbing the opioid crisis in the US.
433 | Healthcare utilization associated with
chronic opioid use among hospitalized
patients
Siyana Kurteva; Daniala Weir; Todd Lee; Michal Abrahamowicz;
Robyn Tamblyn
McGill University, Montreal, QC, Canada
Background: Hospitalized patients are at high risk of chronic opioid
use as hospitalization itself may inadvertently be a risk factor to initi-
ating opioids. Inadequate communication of prescribed medications
and changes to patient medication history at the time of discharge
could lead to inappropriate continuation of opioids post discharge.
Objectives: This study identifies discrepancies in opioid prescribing at
transitions in care and quantifies the impact of long‐term opioid use
on the healthcare system.
Methods: Cohort study using patients admitted to an academic hospi-
tal in Montreal (2014–2016) as part of an electronic medication recon-
ciliation trial. Patients were included if they had filled at least one
opioid prescription in the community. Provincial health administrative
claims were used to measure opioid dispensations in the 1 year post‐
discharge period as well as hospital re‐admissions and ED visits. Time‐
varying use of opioids was modeled as cumulative and continuous
duration of use to differentiate between different opioid risk profiles.
Cox models were used for the association between use of opioids and
risk of ED visits and hospitalizations, while adjusting for a rich set of
clinically important covariates including patient comorbidities, medica-
tion history and healthcare system characteristics.
Results: A total of 1525 patients filled an opioid prescription in the
1 year post‐discharge, of which the majority (64%) were for oxyco-
done; 1166 patients received an opioid prescription at discharge, of
which 66% were newly written by in‐hospital physicians. The remain-
ing 23% of patients had an opioid dispensation post‐discharge despite
documented evidence of having the opioid stopped in the medical
chart. Among patients with previous opioid use, 9.0% had a discontin-
uation status of their opioid prescription at discharge but had, never-
theless, an opioid dispensation post‐discharge. For cumulative opioid
use, there was a 41% increase (HR 1.41, 95% CI: 1.11–1.79) in ED
visits and re‐admissions associated with every additional 30 days of
opioid use. When modeling exposure of opioids as continuous use,
there was a 21% risk increase, albeit non‐significant (HR 1.21, 95%
CI: 1.00–1.49).
Conclusions: Our findings reflect a difference in the risk of adverse
events associated with distinct profiles of opioid users with increased
susceptibility to opioids side effects for patients accumulating opioid
use over longer periods of time. Communication of changes to opioid
medications may help reduce excess of opioid prescriptions in the
community and its associated risk of preventable ED visits and
hospitalizations.
434 | High‐risk opioid utilization and
mortality among hemodialysis patients
Matthew Daubresse; G. Caleb Alexander; Deidra C. Crews;
Dorry L. Segev; Mara A. McAdams‐DeMarco
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background: Patients undergoing hemodialysis (HD) frequently report
moderate to severe pain and receive three‐fold more opioid prescrip-
tions compared to the general United States population. Despite these
high rates of opioid utilization, the burden, risk factors, and sequelae
of high‐risk opioid utilization among HD patients remain unclear.
Objectives: To identify risk factors for high‐risk opioid utilization and
quantify its association with mortality among patients initiating HD.
Methods: Retrospective cohort study of adults initiating HD in the
United States between 2007 and 2014 using national registry data
linked to Medicare claims (United States Renal Data System). We used
Cox regression accounting for competing risks to identify risk factors
for high‐risk opioid utilization (≥120 morphine milligram equivalents
[MME] & ≥30 days) and adjusted Cox regression with a time‐varying
exposure to quantify the hazard of all‐cause mortality associated with
high‐risk opioid utilization.
Results: Among 327,344 patients initiating HD, the cumulative inci-
dence of high‐risk opioid utilization was 2.1% at six months, 2.9% at
one year, and 3.8% at two years. Between 2007 and 2014, high‐risk
opioid utilization within one year was most common among HD
patients with prior drug (7.6% vs. 2.5%; p < 0.0001) and tobacco use
(5.0% vs. 2.3%; p < 0.0001). Among patients with an episode of
high‐risk utilization, the proportion of days ≥120 MME increased
from 3.5% (95% CI: 3.4–3.6) in 2007 to 8.6% (95% CI: 8.5–8.7) in
2014. HD patients who were aged 18–35 years (HR = 2.50; 95% CI:
2.29–2.72), non‐Hispanic (HR = 2.31; 95% CI: 2.15–2.49), and in the
Far West region of the United States (HR = 3.57; 95% CI: 2.06–
6.18) were at increased risk of high‐risk opioid utilization. High‐risk
opioid utilization was associated with a 30% increased risk of death
(HR = 1.30; 95% CI: 1.24–1.35).
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Conclusions: Efforts designed to prevent high‐risk utilization and
deaths among HD patients should target HD patients who are youn-
ger and non‐Hispanic, especially during periods where opioid use
exceeds 120 MME for over thirty days.
435 | Opioid prescription use after vaginal
delivery and subsequent persistent opioid use
and misuse
Yanmin Zhu1; Krista F. Huybrechts1; Rishi J. Desai1; Alexis Krumme2;
Loreen Straub1; Raisa Levin1; Helen Mogun1; Sonia Hernandez‐Diaz3;
Brian T. Bateman1,3
1Brigham and Women's Hospital and Harvard Medical School, Boston,
MA; 2Vertex Pharmaceuticals, Boston, MA; 3Harvard T. H. Chan School
of Public Health, Boston, MA
Background: Prior studies show that approximately 30% of women in
the U.S. fill an opioid prescription after vaginal delivery, making this a
common source of exposure to opioids in young women. Limited evi-
dence is available regarding the impact of prescription opioid use after
vaginal delivery on the risk of subsequent persistent opioid use and
misuse.
Objectives: To evaluate the impact of prescription opioid use after
vaginal delivery on the risk of subsequent persistent opioid use and
misuse.
Methods: We assembled a nationwide cohort of Medicaid beneficia-
ries who delivered vaginally between 2009 and 2013 and who were
not chronic opioid users/diagnosed with an opioid use disorder
(OUD) during pregnancy. We required continuous Medicaid enroll-
ment from ≥90 days before to 365 days after vaginal delivery. We
identified prescription opioid dispensings within 7 days of the date
of delivery. Persistent opioid use (primary outcome) was defined as
≥10 opioid fills or > 120 days' supply dispensed from 30–365 days
after the date of delivery. Newly recorded diagnoses of OUD (second-
ary outcome) were ascertained during the same interval. We used
logistic regression after propensity‐score (PS) 1:1 matching to control
for potentially confounding. To control for potentially unmeasured
confounders, we performed an instrumental variable analysis (IVA)
using a 2‐stage least squares approach. To define the instrument, facil-
ities were ranked within region according to their opioid dispensing
rate after vaginal delivery and divided into deciles.
Results: Among 226,995 vaginal deliveries, 29.9% had an opioid dis-
pensing within 7 days of delivery. Overall, 3,113 of the 67,954
(4.6%) prescription opioid exposed vs. 1,445 of the 159,041 (0.9%)
unexposed had persistent opioid use during follow‐up, for an unad-
justed odds ratio (OR) of 5.2 (95% CI, 4.9–5.6) and a risk difference
(RD) of 3.7% (95% CI, 3.5% ‐ 3.8%). After PS matching, the risk
remained higher among the exposed, with an OR of 2.7 (2.5–3.0)
and a RD of 2.4% (2.3%‐ 2.6%). This was confirmed by the IVA
(pseudo R2 = 0.3) with an RD of 2.8% (2.5% ‐ 3.1%). For newly diag-
nosed OUD, the unadjusted OR associated with opioid exposure after
delivery was 2.4 (2.2–2.5), which attenuated to 1.5 (1.4–1.6) after PS
matching. The adjusted RD was 0.9% (0.7% ‐ 1.0%) after PS matching
and 2.1% (1.8% ‐ 2.4%) using IVA.
Conclusions: Opioid exposure following vaginal delivery appears to be
a trigger for future persistent opioid use and misuse, independent of
confounding factors. Given this risk, prescription opioid use after vag-
inal deliveries should generally be avoided.
436 | Postpartum opioid prescribing and the
risk of persistent opioid use
Sarah S. Osmundson1; Jae Young Min1,2; Andrew D. Wiese2;
Robert E. Hawley1; Stephen W. Patrick1; Marie R. Griffin1;
Carlos G. Grijalva1
1Vanderbilt University, Nashville, TN; 2Veterans Health Administration
Tennessee Valley Healthcare System, Nashville, TN; 3Nashville, TN
Background: Millions of US women are exposed annually to pre-
scribed opioid pain relievers (OPRs) as part of childbirth. The associa-
tion between postpartum OPR use and the risk of persistent OPR use
is unclear.
Objectives: To examine the association of postpartum OPR prescrib-
ing with persistent OPR use following childbirth.
Methods: We studied women age 15–44 years enrolled in Tennessee
Medicaid with deliveries between 1/1/2007 to 9/30/2015. Women
with >1 prescription for an OPR in the 180 days prior to delivery or
with diagnoses of opioid use disorder were excluded. We examined
OPR prescription fills during the postpartum period (up to 42 days
after delivery) and defined OPR exposure groups as 0, 1, 2, or > 2
postpartum fill(s). Follow‐up started on day 43 after delivery and con-
tinued through the earliest of loss of enrollment, death, identification
of opioid use disorder, 1 year post‐delivery or becoming a persistent
OPR user. We defined persistent OPR use as filling >90 days' supply
of OPRs within a 180‐day window with no gaps >32 days. We com-
pared the risk of persistent OPR use among postpartum OPR expo-
sure groups using Cox proportional hazards models while adjusting
for demographic and baseline clinical characteristics. All data were
stratified by cesarean versus vaginal delivery.
Results: Among 231,551 women who met eligibility criteria, 161,175
(69.6%) had vaginal and 70,376 (30.4%) had cesarean deliveries; 58%
of women with a vaginal delivery and 91% of women with a cesarean
filled ≥1 OPR prescription in the postpartum period. The rate of per-
sistent OPR use with 0, 1, 2, >2 prescriptions was 4.9, 6.4, 27.0, 87.0
per 1000 person‐years (py) respectively among women with cesarean
and 3.5, 8.2, 37.8, 106.2 per 1000 py respectively among women with
vaginal deliveries. After adjusting for additional delivery procedures
and postpartum complications, women with cesarean deliveries
receiving 1, 2, >2 prescriptions had higher risk of persistent OPR use
compared with no prescription (HRs: 1.5 [1.0–2.3], 4.8 [3.2–7.4],
12.5 [8.2–19.0]). Similar findings were observed among women with
vaginal deliveries (HRs: 1.9 [1.6–2.3], 6.2 [5.2–7.5], 13.4 [11.0–16.5]).
Conclusions: Postpartum prescription OPR use is strongly associated
with risk of persistent OPR use, regardless of delivery route. Reducing
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both OPR prescribing following vaginal delivery, and the number of
OPR prescriptions in the postpartum period are potential intervention
targets.
437 | Prevalence and predictors of ADHD
medication use in a cohort of pregnant
women
Maxim Lemelin1,2; Takoua Boukhris1,2; Odile Sheehy2; Anick Bérard1,2
1University of Montreal, Montreal, QC, Canada; 2Research Center CHU
Sainte‐Justine, Montreal, QC, Canada
Background: Attention deficit with or without hyperactivity disorder
(ADHD) is common. Increased prevalence of ADHD medication use
has been reported in adults and thus its utilization in pregnancy has
become a concern.
Objectives: We sought to determine the 1) prevalence and trends of
ADHD medication use before and during pregnancy, (2) ADHD medi-
cation mean dosages by classes, and prevalence of medication
switches, and (3) determinants of ADHD medication use during
pregnancy.
Methods: A longitudinal cohort study was performed, using data from
the Quebec Pregnancy Cohort (QPC), which includes data on all preg-
nancies of mothers covered by the provincial prescription drug insur-
ance in Quebec and their children fromJanuary 1998, to December
2015. The cohort entry date was the first day of gestation. Women
aged 15–45 years old at cohort entry, and covered by the RAMQ pre-
scription drug plan for at least 12 months before and during pregnancy
were eligible. ADHD medication users were defined as those having at
least one ADHD medication filling before or during pregnancy overall,
and stratified by trimester. Generalized estimating equation (GEE)
were used to estimate crude and adjusted odds ratios (OR) with 95%
confidence intervals (CIs) to identify determinants associated with
ADHD medication use during pregnancy.
Results: 428,479 pregnant women were included in the study. A sig-
nificant increase in the prevalence of ADHD medication use in preg-
nant women was observed from 0.08% 1998 to 1.2% in 2015
(p < 0.01). Methylphenidate, a stimulant, was the most used (70.1%
of ADHD medication users). ADHD medication fillings were at optimal
dosages 91.8% of the time; 28.1% of women switched to another
ADHD medication class or had concomitant multiple ADHD medica-
tions use during gestation. Determinants associated with ADHD med-
ication use during pregnancy were being on welfare (aOR 1.27; 95%CI
1.06–1.52), hypertension (aOR 1.85; 95%CI 1.31–2.62), asthma (aOR
1.39; 95%CI 1.13–1.71), psychiatric disorders (aOR 3.28; 95%CI
2.51–4.27), depression (aOR 3.18; 95%CI 2.58–3.93), or other medi-
cation use (aOR 3.26; 95%CI 2.36–4.49) in the year before pregnancy;
pregnant women were also at increased risk of using ADHD medica-
tions during gestation with increasing calendar year (aOR 1.33;
95%CI 1.26–1.41).
Conclusions: Our findings show an increasing trend in ADHD medica-
tion use during pregnancy over the past 20 years. Our results are
suggestive of a detection bias given the increase in use associated
with increasing calendar year.
438 | Interrupted time series analysis to
assess prescription filling around conception
and implications for misclassification of
medication use in pregnancy
Jacqueline M. Cohen; Randi Selmer; Kari Furu; Øystein Karlstad
Norwegian Institute of Public Health, Oslo, Norway
Background: In studies based on administrative data, medication
exposures are often defined by one or more prescription fills in preg-
nancy or first trimester. Harmful exposure effects could be
underestimated if there is rapid discontinuation of use after pregnancy
recognition. We hypothesized that prescription fills for some psycho-
tropic drugs may decrease rapidly after conception, due to a prefer-
ence for avoidance of use in pregnancy. Few studies have used a
critical biological period as an intervention for interrupted time series
analysis (ITSA).
Objectives: To assess the change in the weekly rate of prescription
fills before and after conception and the immediate effect of concep-
tion and compare with different individual‐level exposure definitions.
Methods: Using data from the Norwegian Prescription Database
linked the Medical Birth Registry (2005–2015), we linearly modeled
the number of prescription fills in each of the 12 weeks before and
after conception with ITSA. The “intervention” was the earliest possi-
ble date of pregnancy recognition, i.e. 2 weeks after conception. We
examined psychostimulants, antidepressants, antipsychotics and anti-
epileptics (AEDs; separated by use for epilepsy or for other indication).
We used relative measures (%) to compare the model coefficients to
the predicted values. We also compared the number of pregnancies
defined as exposed (yes/no) when the earliest fill was respectively
30 days before the last menstrual period (LMP‐30 days), LMP, or con-
ception (LMP + 14 days).
Results: We observed similar patterns for psychostimulants, antide-
pressants, and AEDs (other indication): a sudden decline in prescrip-
tion fills from 2 weeks after conception (−47%, −30%, and − 23%)
and decreasing fills thereafter (−10.0%, −6.9%, and − 4.2% per
week). We also saw similar patterns for antipsychotics and
AEDs (epilepsy): The intercept‐only model fit the data better with
a trend toward a slight increase in prescription fills during the first
trimester. Only 77% of pregnancies with fills for psychostimulants
from LMP and 58% with fills from LMP‐30 days had fills from con-
ception to birth. Similar figures for AEDs (epilepsy) were 99% and
96%.
Conclusions: ITSA can help researchers understand rapid changes in
patient behavior around conception that have consequences for expo-
sure misclassification in pregnancy studies. The results suggest that a
more conservative definition of exposure prioritizing specificity by
avoiding inclusion of prescription fills before conception may be war-
ranted in some cases, e.g. for psychostimulants.
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439 | Trajectories of antipsychotic use
before and during pregnancy and related
maternal and birth characteristics
Andrea L. Schaffer1; Helga Zoega1,2; Duong T. Tran1;
Nicholas A. Buckley3; Sallie Pearson1,3; Alys Havard1
1UNSW Sydney, Sydney, Australia; 2University of Iceland, Reykjavik,
Iceland; 3University of Sydney, Sydney, Australia
Background: Antipsychotics are increasingly being used for a wide
array of indications beyond psychotic illness, resulting in increased
heterogeneity in patterns of use and characteristics of treated per-
sons. There is no clear guidance antipsychotic use during pregnancy,
yet their use in pregnant women is increasing, with a lack of detailed
information about variations in treatment patterns.
Objectives: To identify trajectories of antipsychotic use prior to and
during pregnancy, and describe the maternal sociodemographic, men-
tal health, and obstetric characteristics, and birth outcomes associated
with different trajectories of antipsychotic use.
Methods: We conducted a retrospective cohort study of women who
were social security beneficiaries and gave birth in New South Wales,
Australia (2005–2012). We estimated the daily dose and duration of
antipsychotics in the 450 days prior to conception and during preg-
nancy using dispensing claims linked to birth records. We used
group‐based trajectory modeling to identify different patterns of anti-
psychotic use over time, and characterized women with different tra-
jectories according to maternal sociodemographic characteristics,
mental health diagnoses and hospitalisations, use of psychotropic
medicines, and birth outcomes.
Results: Of 135 252 women who gave birth, 2741 (2.0%) were
exposed to antipsychotics prior to or during pregnancy. We identi-
fied six distinct trajectories: in two trajectories, women used low
daily doses in the short‐term prior to pregnancy only (51.7%), while
three trajectories identified women with longer‐term use of low
(20.7%), moderate (11.0%), and high (2.0%) daily doses continuing
in pregnancy. Women in one trajectory (15.0%) had increased use
during pregnancy. Women with longer‐term use were more likely
to have a schizophrenia or bipolar disorder diagnosis, have used
mood stabilizers, and have a mental health hospitalization during
pregnancy. Compared with women with no antipsychotic exposure,
women using antipsychotics had a higher rate of preterm birth,
and a baby admitted to intensive care or diagnosed with neonatal
abstinence syndrome. Women with the greatest exposure to anti-
psychotics also had the highest rates of gestational diabetes and
hypertension.
Conclusions: Women using antipsychotics around pregnancy are het-
erogeneous, with varying patterns of use and associated birth out-
comes, most likely reflecting underlying differences in the treatment
indications and/or severity of illness. This heterogeneity should be
considered when developing clinical guidelines and designing safety
studies.
440 | Medication use patterns in pregnant
women with migraine
Rohini K. Hernandez1; Sonja Nakasian2; Lisa Bollinger1;
Brian Bradbury1; Susan Jick3,4; Paul Muntner5; Eric Ng1; Victoria Chia1
1Amgen, Inc., Thousand Oaks, CA; 2Ludwig‐Maximilians University of
Munich, Munich, Germany; 3Boston Collaborative Drug Surveillance
Program, Boston, MA; 4Boston University School of Public Health, Boston,
MA; 5University of Alabama at Birmingham, Birmingham, AL
Background: Potential risks from medications taken during pregnancy
are traditionally assessed through post‐approval prospective preg-
nancy registries, which often struggle to meet enrollment targets, pro-
viding limited power to evaluate outcomes. Large administrative
databases are a potential alternative data source to evaluate drug
safety during pregnancy. Migraine, with peak prevalence around
reproductive age, represents a population who may have increased
medication exposure during pregnancy.
Objectives: To describe the use of three classes of medications com-
monly used for migraine prevention (anti‐epileptic drugs [AED], anti-
depressants [AD], and beta blockers [BB]), before and during
pregnancy in a cohort of women with migraine in the MarketScan
commercial claims US database.
Methods: Women with migraine and a pregnancy resulting in a
livebirth between 1/1/2010 and 9/1/2015 were identified. Women
were required to have 180 days continuous enrollment prior to their
estimated date of conception (EDC) through childbirth. Multiple preg-
nancies per woman were included. We described medication use
180 days before EDC and by pregnancy trimester.
Results: Among the 88,084 women with evidence of migraine and a
livebirth during the study period, 98,155 unique pregnancy episodes
were evaluated. The average age at EDC was 31 years (14% were
18–24 years; 63% were 25–34 years; 21% were 35–40 years). AEDs
were filled by 2.3% of women within 180 days before EDC, dropping
to 1.1% during pregnancy. Of the pregnancies with AED exposure,
79%, 32%, and 27% had AED filled in the 1st, 2nd, and 3rd trimesters,
respectively. Similarly, 2.8% of women filled an AD within 180 days
before EDC, compared with 1.7% during pregnancy. Of the pregnan-
cies with AD exposure, 77%, 40%, and 34% had AD filled in the 1st,
2nd, and 3rd trimesters, respectively. Within 180 days before EDC,
1.4% of pregnant women filled a BB, increasing to 2.8% during preg-
nancy. Of 2,642 pregnancies with BB exposure, 50%, 54%, and 70%
had BB filled in the 1st, 2nd, and 3rd trimesters. Older women were
more likely to receive these 3 classes of medications during pregnancy
than younger women.
Conclusions: Use of migraine prevention medications was low in the
months leading up to and during pregnancy. However, due to the
large size of the underlying database, over 1,000 women filled each
class of medication during pregnancy. The low frequency of medica-
tion use may help explain some of the difficulties of identifying and
enrolling women in pregnancy registries and suggests that healthcare
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databases may offer a more practical approach to evaluating poten-
tial safety concerns during pregnancy, particularly for rare exposures.
441 | Baclofen decreases alcohol
consumption in real world clinical populations
Christopher T. Rentsch1,2; David A. Fiellin3,4; Kendall J. Bryant5;
Amy C. Justice2,3; Janet P. Tate2,3
1London School of Hygiene & Tropical Medicine, London, UK; 2VA
Connecticut Healthcare System, West Haven, CT; 3Yale School of
Medicine, New Haven, CT; 4Yale School of Public Health, New Haven, CT;
5National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
Background: Randomized trials demonstrate that baclofen, a GABA
beta‐receptor agonist used for spasticity, decreases alcohol use in sub-
stance use treatment‐seeking individuals with alcohol use disorder
(AUD).
Objectives: To determine if baclofen, prescribed for any indication,
was associated with changes in alcohol consumption among treat-
ment‐seeking and non‐treatment‐seeking patients, with and without
AUD, and by baseline levels of drinking and baclofen dose.
Methods:We used real‐world data from the US Veterans Birth Cohort
(n = 4.5 million). We included patients with Alcohol Use Disorder Iden-
tification Test ‐ Consumption (AUDIT‐C) scores >0 who received >1
pharmacy fill of baclofen (BACLO+) for ≥60 consecutive days for
any indication from 2009 to 2015, and compared them to 1:5 propen-
sity score (PS)‐matched, baclofen unexposed (BACLO‐) patients. Index
date was defined as prescription release date for BACLO+ patients
and a randomly selected outpatient visit date for BACLO‐. Change in
pre and post AUDIT‐C scores were compared using difference‐in‐dif-
ference analysis. Pre‐index AUDIT‐C scores were closest to index
date, and post‐index scores were closest to end of exposure
or < 90 days after. A 1‐point change in AUDIT‐C was considered clin-
ically meaningful. We defined three mutually exclusive groups: those
with AUD (defined by validated ICD codes) and baseline substance
use disorder treatment clinic visit (AUD‐SUD), those with AUD and
without a baseline SUD clinic visit (AUD‐OTH), and those without
AUD. We examined the association of baclofen with change in
AUDIT‐C in these groups overall, and by baseline AUDIT‐C and baclo-
fen dose.
Results: There were no demographic or clinical differences between
5,120 BACLO+ and 14,047 BACLO‐ PS‐matched patients (all stan-
dardized differences <0.1). Median age was 58 years (IQR: 53–63),
most were male (92%) and European‐American (69%), 27% were
AUD‐SUD, 10% were AUD‐OTH, and 63% did not have AUD. Among
AUD‐SUD prescribed ≥30 mg, the difference‐in‐difference (DiD) esti-
mate of the additional decrease in AUDIT‐C scores between BACLO
+/− was significant and potentially clinically meaningful (DiD 0.73,
95% CI 0.30, 1.16). Similar estimates were observed among AUD‐
OTH patients who reported heavy drinking (AUDIT‐C ≥ 6) (DiD
0.73, 95% CI 0.24, 1.22). Among patients without AUD, estimates
were not clinically meaningful (DiD 0.16, 95% CI 0.08, 0.24).
Conclusions: Provision of baclofen for any indication is associated
with significant decreases in AUDIT‐C scores in real‐world patient
populations, and clinically meaningful decreases among those with
AUD and heavy drinking.
442 | Long‐term effect of interferon and
Glatiramer acetate in real‐world settings use
on multiple sclerosis disability progression:
Input of time‐dependent propensity score
Mathilde Lefort1,2; Yohann Foucher3,4; Rémi Lenain3,5;
Sandra Vukusic6,7; Gilles Edan2,8; Emmanuelle Leray1,2,9
1Rennes University, EHESP, REPERES –, EA 7449 Rennes, France;
2 INSERM CIC‐P 1414, CHU Pontchaillou, Rennes, France; 3 INSERM
UMR 1246 – SPHERE, Nantes University, Tours University, Nantes,
France; 4Nantes Hospital, Nantes, France; 5Lille Hospital, Lille, France;
6Univ Lyon, Université Claude Bernard Lyon 1, Fondation EDMUS,
OFSEP, Lyon, France; 7Department of Neurology, Hospices Civils de Lyon,
Lyon, France; 8Department of Neurology, CHU Pontchaillou, Rennes,
France; 9EHESP, French school of public health, Rennes, France
Background: The long‐term effect of beta‐interferon (IFN) and
glatiramer acetate (GA) on multiple sclerosis (MS) disability progres-
sion showed controversial results, maybe due to lack of appropriate
control of confounding.
Objectives: To better assess the long‐term effect of IFN and GA on
disability progression in relapsing onset MS patients from the Rennes
expert MS centre, France using a time‐dependent propensity score
(PS).
Methods: This retrospective observational study is based on a series
of patients collected in the European Database for Multiple Sclerosis
(EDMUS). All patients with relapsing onset MS before 31/12/2005
and treatment‐naïve before 30/11/1995 (date of approval for IFN)
were included in the present study. Moreover, a minimal follow‐up
of 2 years from MS onset and a minimal of 3 visits were required.
We used a time‐dependent PS matching procedure. This procedure
consists of a Cox model to assess the time from MS onset to treat-
ment start to get the hazard of being treated at each time. The model
was adjusted for sex, age at onset and two time‐dependent covariates,
i.e. disability progression and relapse activity. The linear predictor of
this Cox model was used as time‐dependent PS; an IFN/GA‐treated
patient was matched to a not yet treated patient at the same time
and having the same hazard of being treated. A nearest neighbor
matching at random, with a caliper of 0.2 of the standard deviation
and without replacement has been used. The restricted mean times
to reach a moderate level of disability were compared between the
two groups in an intention‐to‐treat analysis. Bootstrap interval has
been estimated to handle the randomness of the matching procedure.
Results: Among the 1300 included patients, 627 were treated. Among
them, 409 were matched with a not yet treated patient. The median
follow‐up duration was 15 years (Interquartile range (IQR): 11–18)
for IFN/GA‐treated patients and 18 years (12–23) for IFN/GA‐not
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yet treated patients. Over 15 years, the mean time before reaching a
moderate level of disability was 12.8 years in the treated group and
11.2 years for in the not yet treated group. Thus, the time to reach
the outcome was significantly delayed by 1.6 year (95%CI: [0.40;
2.83]) in the IFN/GA‐treated group.
Conclusions: Our results tended to show that starting IFN and GA ear-
lier delayed disability progression. This time‐dependent PS seems rel-
evant to well balance the two groups over time while conventional PS
ignores the temporal features of the therapeutic decision. In the
future, we plan to explore the use of marginal structural models.
443 | Ethnic inequalities in prescribing
quality for patients with dementia: A cohort
study using electronic health records
Mary E. Jones1; Claudia Cooper1; Cini Bhanu1; Rosalind Raine1;
Gillian Manthorpe2; Kate Walters1; Irene Petersen1
1University College London, London, UK; 2King's College London, London,
UK
Background: The number of Black and Minority Ethnic People (BAME)
with dementia in Western countries is rising: in the UK it is projected
to increase seven‐fold in the next 40 years. Appropriate prescribing to
patients with dementia can be measured by high rates of anti‐demen-
tia drugs where indicated and low rates of antipsychotic, anticholiner-
gic, and hypnotic and anxiolytic drugs, which are associated with risk
of cognitive decline. It is unclear whether ethnicity is associated with
appropriate prescribing in patients with dementia.
Objectives: To determine whether differences exist by ethnicity in
prescribing of anti‐dementia drugs where indicated, and in prescribing
of antipsychotic, anticholinergic, and hypnotic and anxiolytic drugs.
Methods: Retrospective cohort using electronic longitudinal primary
care medical records from The Health Improvement Network (THIN),
a broadly representative database of UK general practices (GP).
Patients with dementia were identified by diagnosis or prescription
of an anti‐dementia drug, were aged between 50 and 105, and were
followed up for up to two years between 1 January 2014 and 31
December 2016. The primary outcome measures were a prescription
for: an anti‐dementia drug where indicated; an antipsychotic drug; a
hypnotic or anxiolytic drug; and two or more prescriptions in one year
for a drug with a definite anticholinergic burden. Multiple imputation
by chained equations was used to impute missing ethnicity. Poisson
regression was used to calculate prevalence rate ratios of each out-
come by ethnicity.
Results: We analyzed data from 53,715 people with dementia. Com-
pared to people from White ethnic groups, Asian people with demen-
tia were less likely to be prescribed anti‐dementia drugs when
indicated (adjusted prevalence rate ratio 0.86 (95% CI 0.75–0.98)),
and more likely to be prescribed anticholinergic drugs (1.22 (1.04–
1.44)), after controlling for gender, age and level of deprivation. People
from Black ethnic groups were less likely to be prescribed an anxiolytic
or hypnotic drug (0.58 (0.43–0.79)). Compared to people from White
ethnic groups, there was no difference in prescribing of antipsychotic
drugs between patients from Asian (0.94 (0.78–1.13)) or Black (0.99
(0.77–1.28)) ethnic groups.
Conclusions: Compared to people from White ethnic backgrounds,
people with dementia from Asian backgrounds appear to receive less
good quality prescribing. These results may identify a target for
improvement in primary care.
444 | Nested case–control study of
antidepressant drug use and subdural
hematoma risk
David Gaist1; Luis A. García Rodríguez2; Stine M. Hald1;
Maja Hellfritzsch3; Frantz R. Poulsen1; Bo Halle1; Jesper Hallas3;
Anton Pottegård3
1Odense University Hospital, Odense, Denmark; 22Centro Español
Investigatión Farmacoepidemiológica (CEIFE), Madrid, Spain; 3University
of Southern Denmark, Odense, Denmark
Background: Studies have raised concerns as to whether use of selec-
tive serotonin reuptake inhibitors (SSRIs) increases the risk of bleed-
ing. We investigated whether use of antidepressants is associated
with subdural hematoma (SDH), a specific type of intracranial
hemorrhage.
Objectives: To investigate the relationship between use of antidepres-
sant drugs and risk of SDH, and whether this risk is influenced by con-
comitant use of antithrombotic drugs or nonsteroidal anti‐
inflammatory drugs (NSAIDs).
Methods: We identified 10,885 patients (median 72 years; 65% men)
discharged from Danish hospitals with a first‐ever SDH diagnosis in
2000 to 2016. For each case, we selected 40 age‐, sex‐ and period‐
matched population controls. We used conditional logistic regression
to estimate odds ratios (OR), adjusted for comorbidity, co‐medication,
education level, and income (aOR).
Results: Current use of SSRI (aOR 1.60, 95%CI: 1.50–1.71) or ‘other’
antidepressants (aOR 1.35, 95%CI: 1.25–1.47) was linked to SDH risk.
For both groups of antidepressants, risk of SDH was inversely related
to duration of current use, e.g., <1 month of current use of antidepres-
sants yielded an OR of 2.55 (95% CI: 2.07–3.15) for SSRI and 1.88
(95% CI: 1.46–2.41) for ‘other’ antidepressants whereas >3 years of
current use returned ORs of 1.04 (95%: 0.93–1.17) and 1.12 (95%CI:
0.98–1.28), respectively. Combined use of antidepressants with either
antithrombotics or NSAIDs yielded similar ORs to those observed for
single use of antithrombotics or NSAIDs. For instance, SSRI combined
with DOAC returned a risk of SDH of OR 0.84, 95%CI: 0.42–1.68),
while SSRI combined with VKA yielded OR 3.79, 95%CI: 2.66–5.42),
results that were similar to single use of DOAC 1.20, 95%CI: 0.87–
1.65), or single use of VKA (OR 3.01, 95%CI: 2.62–3.46). The highest
risk of SDH was observed in patients receiving therapy of antidepres-
sants together with both VKA and NSAIDs (combined with SSRI: OR
5.51, 95%CI: 2.70–11.22; combined with ‘other’ antidepressants: OR
6.81, 95%CI: 2.37–19.60). Supplementary analyses of single use (i.e.,
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excluding concomitant users), new users, sex and age stratification,
and other groupings of antidepressants yielded similar results as in
the main analyses. In analyses of specific single use of antidepressant
drugs, estimates ranged from an OR of 1.04 (95%CI: 0.84–1.29) for
mianzerine to an OR of 1.95 (95%CI 1.52–2.50) for fluoxetine.
Conclusions: Compared with non‐use, antidepressant use was associ-
ated with higher risk of SDH, more so for SSRI than ‘Other’ antide-
pressants. In absolute terms, the observed excess risk of SDH was
small and declined after prolonged drug use.
445 | Co‐occurring neuropsychiatric
diagnoses and use of psychotropic drugs in
children with autism Spectrum disorder
Svetlana Skurtveit1; Yury Kiselev2; Marte Handal1; Vidar Hjellvik1;
Ted Reichborn‐Kjennerud1; Camilla Stoltenberg1; Pål Suren1;
Alexandra Havdahl1
1Norwegian Institute of Public Health, Oslo, Norway; 2Oslo Metropolitan
University, Oslo, Norway
Background: Autism spectrum disorder (ASD) is a complex
neurodevelopmental disorder. Co‐occurring psychiatric and neurolog-
ical comorbidities are common, and many children with ASD receive
psychotropic medications with uncertain efficacy and safety.
Objectives: In a nationwide Norwegian sample of children (2–17 years
old) in 2014 we aimed to calculate lifetime prevalence of ASD. For the
individuals with an initial diagnosis of ASD in the registry in 2014 we
aimed to estimate the proportion of co‐occurring psychiatric and neu-
rological diagnoses and to investigate use of psychotropic drugs
according to ASD subtype, age and gender. Further we aimed to
explore the relationship between co‐occurring diagnoses and CNS
active drug use.
Methods: Individual‐level registry data from the Norwegian Patient
Registry and Norwegian Prescription Database were linked using the
unique personal identity number assigned to all individuals living in
Norway. We calculated the proportion who were dispensed selected
groups of psychotropic drugs during the 365 day period after the date
of the first diagnosis.
Results: In 2–17 year old children, the ASD lifetime prevalence was
0.76%. Of the children who received an initial ASD diagnosis in
2014 (n = 1234), 64.8% had one or more co‐occurring neuropsychiat-
ric diagnosis. Children with autistic disorder were mainly prescribed
hypnotics: 16.3 and 17.3% of the girls and boys, respectively. Children
with Asperger's syndrome were mainly prescribed stimulants (25.2 and
23.3% of girls and boys) and hypnotics (25.2 and 18.2% of girls and
boys), while there was a disparity in the use of antidepressants: they
were prescribed to 16.5% of girls and only 7.2% of boys. Children with
atypical or unspecified autism were mainly prescribed stimulants (16.9
and 19.9% of girls and boys) and hypnotics (19.1 and 17.6% of boys
and girls). There was a relatively good match between prescription
of stimulants/ADHD drugs, antiepileptic drugs, and antidepressants,
and co‐occurring diagnoses for which these drugs are indicated. In
contrast, a small proportion of children who received treatment with
antipsychotic drugs had a diagnosis where such treatment is indicated.
The children who had ASD, but non of the studied neuropsychiatric
comorbidities, received very little psychotropic drugs in general.
Conclusions: Use of psychotropic drugs was common among children
with ASD and co‐occurring neuropsychiatric and neurological diagno-
ses, and most children who usied medications had a diagnosis for
which the drug was indicated. Drug use among children without co‐
occurring conditions was low.
446 | Concurrent use of Neurocognitively‐
active medications and alcohol increases risk
of community‐acquired pneumonia
Christopher T. Rentsch1,2; Janet P. Tate2,3; Kirsha S. Gordon2,3;
Kathleen M. Akgün2,3; Supriya Krishnan2,3; Alice Tseng4;
Julie A. Womack2,5; Maria C. Rodriguez‐Barradas6; Cynthia L. Gibert7;
Kendall J. Bryant8; E. Jennifer Edelman3,9; Amy C. Justice2,3,9
1London School of Hygiene & Tropical Medicine, London, UK; 2VA
Connecticut Healthcare System, West Haven, CT; 3Yale School of
Medicine, New Haven, CT; 4University Health Network, Toronto, ON,
Canada; 5Yale School of Nursing, West Haven, CT; 6Michael E. DeBakey
VA Medical Center and Baylor College of Medicine, Houston, TX;
7Washington DC VA Medical Center and George Washington University
School of Medicine, Washington, DC; 8National Institute on Alcohol
Abuse and Alcoholism, Bethesda, MD; 9Yale School of Public Health, New
Haven, CT
Background: Accumulating evidence suggests that some
neurocognitively‐active potentially inappropriate medications (NC‐
PIMs) have immunosuppressive properties and increase risk of infec-
tions, including community‐acquired pneumonia (CAP). Concurrent
alcohol use may exacerbate this effect.
Objectives: To evaluate the independent and interactive
effects of concurrent alcohol use and NC‐PIM exposure on the risk
of CAP.
Methods: From a base cohort using real‐world data from the Veterans
Birth Cohort (n = 4.5 million), we conducted a nested case–control
study from 2008 to 2015. Cases with CAP requiring hospitalization
(n = 52,122) were 1:5 matched to controls without CAP
(n = 260,610) at the time of event by age, sex, race/ethnicity, baseline
year, and duration of observation time. Index date was event date for
cases and match date for controls. Exposure to NC‐PIMs, including
anticonvulsants, antidepressants, antipsychotics, muscle relaxants,
prescription opioids, and sedatives, was assessed in the 45 days prior
to index date. Odds ratios (OR) and 95% confidence intervals (CI) for
the independent and interactive effects of NC‐PIMs (overall and by
class) and alcohol use were estimated with conditional logistic regres-
sion models. Alcohol use was measured using Alcohol Use Disorder
Identification Test ‐ Consumption (AUDIT‐C, 4–5 = moderate
and ≥ 6 = heavy drinking). Models were adjusted for VACS Index
(i.e., physiologic frailty), number of outpatient medications, smoking
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status, steroid receipt, influenza and pneumonia vaccination status,
previous CAP, and comorbidity.
Results: Among 312,732 patients, median age was 59 years (IQR: 55–
61), 96% were male, 71% were white, and median follow‐up time was
3 years (IQR: 1–5). Cases were more likely to be prescribed at least
one NC‐PIM (70% vs. 53%) and ≥ 5 NC‐PIMs (11% vs. 4%) than con-
trols (p < 0.0001). Exposure to ≥5 NC‐PIMs (OR 1.72, 95% CI 1.61–
1.84) and heavy alcohol use (OR 1.57, 95% CI 1.48–1.67) indepen-
dently increased the risk for CAP. Concurrent exposure increased risk
even further (OR 3.29, 95% CI 2.76–3.92). Exposure to anticonvul-
sants, antipsychotics, opioids, barbiturates, or benzodiazepines inde-
pendently increased risk for CAP and had significant interactions
with moderate and heavy alcohol use (all p < 0.001). Antidepressants,
muscle relaxants, and other sedatives were not associated with CAP.
Conclusions: NC‐PIMs, including anticonvulsants, antipsychotics, opi-
oids, barbiturates, and benzodiazepines, especially in the context of
heavy alcohol use, were associated with CAP in a national healthcare
system.
447 | Patient‐, disease‐ and treatment
related factors that impact values attached to
drug effects: A preferences study among
patients with type 2 diabetes
Sonia Roldan; Douwe Postmus; Sieta De Vries; Peter Mol;
Hans Hillege
University Medical Centre Groningen, Groningen, Netherlands
Background: About 50% of patients with type 2 diabetes do not reach
their glucose (HbA1c) treatment targets. Incorporating patient prefer-
ences at the time of prescribing may improve treatment satisfaction,
adherence, and subsequently outcome. Preferences may be influenced
by patient‐, disease‐ and treatment‐related characteristics.
Objectives: To evaluate to what extent patient‐, disease‐ and treat-
ment‐related factors affect the importance patients attach to certain
drug effects.
Methods: A cross‐sectional survey was administered to type 2 dia-
betic patients aged between 57 to 80 years who received≥1 prescrip-
tion of an oral anti‐diabetic drug in the last 4 months. The survey
comprised patient‐ (age, sex, BMI, education), disease‐ (diabetes dura-
tion) and treatment‐ (adverse drug events (ADEs), HbA1c levels)
related questions and a discrete choice experiment (DCE) to elicit
patients' preferences for hypothetical anti‐diabetic agents described
in terms of six attributes: HbA1c decrease, cardiovascular risk reduc-
tion, weight change, gastrointestinal (GI) ADEs, hypoglycemic events
and bladder cancer risk. A latent class logit model was used to model
preference heterogeneity and identify factors associated with class
membership probabilities.
Results: The 199 patients were on average 67 (SD 4.4) years old, 54%
were male, had a BMI of 29 (SD 4.8) and 20% were higher educated.
The mean diabetes duration was 9 (SD 8.8) years. ADEs were reported
by 23% of the patients. The analyses identified two classes. Class 1
attached more importance to decreasing HbA1c levels, reducing car-
diovascular risk, maintain body weight and no increasing risk of cancer.
Class 2 allocated more importance to decreasing GI ADEs and reduc-
ing hypoglycaemic events. Characteristics with the strongest influence
of belonging to class 2 were male gender (OR: 0.51; 95% CI: 0.34–
0.77), BMI (OR: 0.90; 95% CI: 0.87–0.94) and diabetes duration (OR
0.93; 95% CI: 0.91–0.94).
Conclusions: Males with high BMI and long diabetes duration pre-
ferred agents with larger effects on HbA1c reduction and cardiovascu-
lar risk reduction, that maintain body weight and do not increase the
risk of cancer despite an increase in GI ADEs and hypoglycaemic
events. The observed heterogeneity among patient preferences
should be acknowledged when prescribing new ‐ and or additional ‐
drugs.
448 | Impact of medicines regulatory risk
Communications in the United Kingdom on
prescribing and clinical outcomes: Systematic
review, re‐analysis and meta‐analysis
Daniel R. Morales1; Bruce Guthrie2; Tobias Dreischulte3;
Chris Weatherburn1
1University of Dundee, Dundee, UK; 2University of Edinburgh, Edinburgh,
UK; 3University of Munich, Munich, Germany
Background: Risk communications about medicines from regulatory
bodies are important to ensure medication safety, but their impact is
often uncertain.
Objectives: The aim of this study was to systematically review studies
measuring the impact of United Kingdom risk communications and
quantify their effect on medication use and other outcomes.
Methods: Systematic review and overview of published studies
reporting prescribing and/or health outcome data relevant to the reg-
ulatory risk communication. Data were extracted and re‐analyzed
using interrupted time‐series regression analysis to quantify the
impact on prescribing and health outcomes twelve months following
the date of the regulatory intervention. Effect estimates for mean
changes were pooled using a random effects generic inverse variance
method to examine the impact of the following risk communication
subgroups: drug withdrawals; restrictions/changes in indications; ‘be
aware’ messages without specific recommendations for action; com-
munication via Direct Healthcare Practitioner Communications
(DHPCs); communication via drug bulletins.
Results: After screening 11,466 articles, 40 studies were included
examining 25 separate UK regulatory risk communications using vari-
able methods of analysis. At 12 months post‐risk communication,
product withdrawals, restriction in indications and ‘be aware’ commu-
nications were associated with mean relative changes of −78% (95%CI
‐60% to −96%), −34% (95%CI ‐12 to −55%) and − 11% (95%CI ‐8% to
−15%) in targeted drug prescribing respectively. DHPCs were associ-
ated with a mean relative change of −47% (95%CI ‐27 to −68%) com-
pared to −13% (95%CI ‐6 to −20%) for drug bulletins. Regulatory risk
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communications were associated with a 8% (95%CI 4 to 11%) change
in clinical outcomes examined.
Conclusions: UK medicines regulatory risk communications were
associated with significant changes in targeted prescribing and poten-
tially significant changes in clinical outcomes. Communication using
direct letters was associated with greater change compared with via
drug bulletins. Further research is needed to more systematically
study the impact of regulatory interventions.
449 | Risk minimisation studies outcomes
and process indicators
Esther Artime; Nawab Qizilbash
Oxon Epidemiology, Madrid, Spain
Background: Good Pharmacovigilance Practice (GVP) Module XVI rec-
ommends the evaluation of additional risk minimisation measures
(aRMMs) with process indicators and outcomes. Outcomes are diffi-
cult to assess and most evaluations study only process indicators.
Objectives: To describe risk minimisation (RM) evaluation plans that
assess both process and outcome indicators.
Methods: The EU Register of Post‐Authorisation Studies (EU PAS
Register) was used to identify survey studies evaluating the effective-
ness of aRMMs in EU and any outcome studies linked to the surveys.
Results: From 1189 studies in the EU PAS Register as of October
2017, 106 were risk minimisation studies, of which 98 were con-
ducted in ≥1 EU country. The number of RM studies with survey
component was 52 of which 15 also assessed outcomes (28.9%;
46.7% included in the same protocol). One RM plan included a sur-
vey and two drug utilization studies. While all surveys were cross‐
sectional, the outcome studies included retrospective (75.0%),
cross‐sectional (18.8%) and prospective (6.3%) designs that assessed
aRMMs pre/post‐implementation (37.5%) or only after implementa-
tion (62.5%). Data sources for outcomes consisted of EMR databases
(43.8%), medical chart review (25.0%), drug safety databases (12.5%),
primary data collection (12.5%) and a prescription questionnaire
(6.3%). The most frequently assessed outcomes were: off‐label/on‐
label use (8), rate of spontaneous adverse events (2), proportion of
prescriptions (2) and rate of infections (2). A correlation between
survey results and outcomes was reported in five studies. Two stud-
ies attempted to correlate aggregate survey results with spontane-
ous reporting rates, two with outcomes recorded in the clinical
records at an individual patient level, and one with prospectively col-
lected events. Key limitations of the research methods included: for
EMR databases, no information on rationale for metabolic monitor-
ing and missing information on treatment duration and doses; for
spontaneous reporting databases, only ecological correlations were
possible which are affected by underreporting and the lack adjust-
ment for confounding; for chart reviews, bias in extrapolating cur-
rent survey results with past events, small sample size and missing
data; for prescription questionnaires, recall bias.
Conclusions: A minority of RM studies assessed both process indica-
tors and outcomes with varying degrees of success. Further innovative
hybrid studies to overcome these limitations are needed to meet
expectations from regulators.
450 | Ivabradine drug utilization study in five
European countries: A pass to assess
effectiveness of risk‐minimization measures
Linda Salem1; Alexandre Malouvier2; Jon Blathford2;
Elena Rivero‐Ferrer3; Nicolas Deltour1; Emmanuelle Jacquot1
1SERVIER, Suresnes, France; 2PRA Health Sciences, Levallois‐Perret,
France; 3RTI Health Solutions, Barcelona, Spain
Background: Ivabradine hydrochloride, a pure heart rate lowering
agent, was first granted marketing authorization in Europe in October
2005 for the treatment of symptomatic chronic stable angina pectoris.
Following the SIGNIFY study, which evaluated ivabradine at higher
starting and maintenance doses than the recommended and showed
an increase of cardiovascular events in a sub‐group of patients, the
benefit–risk ratio of ivabradine was re‐assessed in 2014 and new
risk‐minimization measures (RMM) were implemented.
Objectives: To evaluate prescribers' compliance with the RMMs.
Methods: This was a multinational (France, Germany, Italy, Spain, and
the United Kingdom), retrospective, chart review‐based, drug utiliza-
tion study with pre‐ and post‐RMM study periods. Patients were iden-
tified by general practitioners (GPs) and cardiologists sampled from
very large source lists. Data were collected at ivabradine initiation
and during ≤6 months of treatment start. The primary outcome was
the compliance with the following RMMs: use in patients with a heart
rate ≥ 70 bpm at initiation, no doses higher than those recommended
in the Summary of Product Characteristics (SmPC) (starting and main-
tenance doses should not exceed 2.5 and 5 mg twice daily, respec-
tively), and no concomitant use of verapamil or diltiazem. The
differences between proportions of the study outcomes in the pre‐
and post‐RMM periods were calculated as estimates of the changes
using the Newcombe score.
Results: Out of 60,675 contacted sites, 522 were interested in partic-
ipating and 68 were active. Overall, 711 and 506 eligible patients were
included in the pre‐RMM and post‐RMM periods, respectively. The
percentage of patients for whom ivabradine prescriptions were com-
pliant with all above mentioned RMMs increased in the post‐RMM
period (70.6% pre‐RMM and 78.4% post‐RMM; p‐value = 0.0035).
The compliance increased for each individual component: patients
with heart rate ≥ 70 bpm at initiation (79.4% pre‐ and 85.2% post‐
RMM; p‐value = 0.0141), no dose higher than the SmPC doses at ini-
tiation and during follow‐up (92.8% pre‐ and 94.1% post‐RMM; p‐
value = 0.3957), and no concomitance with verapamil or diltiazem
(96.1% pre‐ and 99.2% post‐RMM; p‐value = 0.0007). The increase
in RMMs compliance was observed in both GPs and specialists and
in all countries except Italy.
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Conclusions: The RMMs for ivabradine were well implemented across
the participating European countries ensuring a favorable benefit–risk
balance of ivabradine in chronic stable angina pectoris.
451 | Comparative effectiveness of risk
mitigation strategies to prevent fetal
exposure to mycophenolate
Amir Sarayani1; Yasser Albogami1; Mohannad Elkhider1;
Juan M. Hincapie‐Castillo1; Babette A. Brumback2;
Almut G. Winterstein1
1College of Pharmacy, University of Florida, Gainesville, FL; 2College of
Medicine, University of Florida, Gainesville, FL
Background: In 2012, the Food and Drug Administration approved a
Risk Evaluation and Mitigation Strategy (REMS) program to prevent
fetal exposure to mycophenolate products (MPA). Prior to the imple-
mentation of the REMS, which includes training for prescribers and a
pregnancy registry, the teratogenic risk was solely mitigated via a
black‐box warning in the label and a medication guide (2008–2012).
To date, there is no evidence on the effectiveness of the REMS for
MPA.
Objectives: To compare the proportion of women who were pregnant
on the day of MPA initiation (study 1) and the risk of pregnancy onset
during an MPA treatment episode (study2) before and after REMS
implementation.
Methods: We conducted a retrospective cohort study using the IBM
MarketScan® Research Databases for Commercial Claims (2007–
2015). Study enrollees were women aged 15 to 44 who filled &ge 1
MPA prescription and without medical encounters indicating infertil-
ity. For outcome 2, we further excluded patients who were pregnant
or who used medications with pregnancy contraindication on MPA ini-
tiation. We extracted demographics, clinical indications, and comor-
bidities within a 6‐months look‐back period. Pregnancy episodes and
conception were measured with an algorithm based on diagnosis and
procedure codes for pregnancy outcomes or screening services. We
used Poisson and Cox proportional hazard regression with inverse
probability of treatment weighting to estimate the rates, relative
risk/hazard ratio, and absolute risk differences.
Results: We identified 38,098 treatment episodes of which, 24,899
were eligible for the study. Tissue disorders and kidney transplant
were the most common indications for MPA (67.9%). For study 1,
we included all eligible treatment episodes from 12,501 unique
women and found 73 pregnancies at the point of MPA initiation.
The risk of pregnancy was reduced during the REMS period: adjusted
risk ratio 0.42 (95% confidence interval 0.23, 0.76) and adjusted risk
difference − 2.1 pregnancies (−3.4, −0.8) per 1000 treatment initia-
tions. For study 2, we examined 20,381 treatment episodes from
10,277 women. We found 106 pregnancies over 8,592 MPA treat-
ment‐years. The REMS period showed a non‐significant reduction in
pregnancy risk: hazard ratio 0.78 (0.52, 1.18) and adjusted risk differ-
ence − 3.0 (−.7.2, 2.1) per 1000 person‐years.
Conclusions: While the REMS program has been successful in
preventing MPA initiation during pregnancy compared to the use of
only the black‐box warning and a medication guide, its effectiveness
in preventing pregnancy during MPA treatment might not be superior.
452 | Post‐authorisation amendments to
additional risk minimisation measure
requirements of medicines authorized in the
EU: A cohort study
Reynold D.C. Francisca1,2; Emna Baba2; Christina E. Hoeve1,2;
Inge M. Zomerdijk1,2; Miriam C.J.M. Sturkenboom3;
Sabine M.J.M. Straus1,2
1Erasmus Medical Centre, Rotterdam, Netherlands; 2Medicines
Evaluation Board, Utrecht, Netherlands; 3University Medical Centre
Utrecht Julius Centre, Utrecht, Netherlands
Background: Additional risk minimisation measures (aRMMs) may be
required to strengthen the benefit–risk profile of medicines that are
associated with serious risks. ARMMs may be required at the time of
authorisation, but risks may also become evident during the life cycle.
Moreover, the recommended actions in the aRMMs may become part
of clinical practice and aRMMs may therefore no longer be required.
There is limited information about post‐authorisation amendments
(PAA) to aRMMs of medicines authorized in the European Union (EU).
Objectives: The aim of this study is to describe PAA to aRMMs for
medicines authorized in the EU.
Methods: We performed a retrospective cohort study that included all
new active substances authorized through the EU centralized proce-
dure between January 1st 2006 and December 31st 2017. Medicines
were followed up until July 1st 2018, when data extraction took place.
We extracted the following data from European Public Assessment
Reports (EPARs) available on the website of the European Medicines
Agency (EMA) on www.ema.europa.eu: active substance, Anatomical
Therapeutic Chemical (ATC) classification, date of Marketing Authori-
sation, presence (yes/no) of aRMMs at the time of MA, PAA to
aRMMs (yes/no) and type of PAA to aRMMs (introduction/discontin-
uation), and date of PAA. Descriptive statistics were used to analyze
frequency data.
Results: There were 476 medicines authorized during the study period
with a total of 32.514 months of follow‐up. Median follow‐up time
was 60 months (range 8–150). At the time of marketing authorisation,
aRMMs were required for 27.3% of the medicines. During the study
period, 19 (4%) medicines were identified with PAA to aRMM includ-
ing introduction of aRMM for 15 products (79%) and discontinuation
of existing aRMMs for four products (21%). The median time to PAA
to aRMM was 46 months for introduction, 90 months for discontinu-
ation. All products with PAA to aRMM were approved between 2006
and 2013. No PAA to aRMM occurred between 2006 and 2008; intro-
duction of aRMMs in the post‐authorisation phase occurred since
2009, while the discontinuation of aRMMs occurred since 2015. The
ATC groups with the highest proportion of PAA were “Blood and
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blood‐forming organs” (15.8%), “Musculoskeletal system” (15.4%) and
“Various” (8.0%).
Conclusions: The proportion of medicines with PAA to aRMM was
low (4%) and the majority of amendments to aRMM concerned intro-
ductions of new aRMMs. Notably, the proportion of discontinuation
of aRMMs post‐authorisation is very low.
453 | Effect of a novel pharmacist‐delivered
behavioral intervention for patients with
poorly‐controlled diabetes: The enhancing
outcomes through goal assessment and
generating engagement in diabetes mellitus
pragmatic, database‐randomized controlled
trial
Julie Lauffenburger1; Roya Ghazinouri1; Saira Jan2; Sagar Makanji3;
Christina Ferro3; Jennifer Lewey4; Eric Wittbrodt5; Jessica Lee1;
Nancy Haff1; Constance Fontanet1; Niteesh Choudhry1
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
2Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ; 3Magellan Rx
Management, Newport, RI; 4Hospital of the University of Pennsylvania,
Philadelphia, PA; 5AstraZeneca, Gaithersburg, MD
Background: Many factors contribute to suboptimal diabetes
control, including insufficiently‐intensive treatment and non‐adher-
ence to medication and lifestyle. Determining which of these is most
relevant for individual patients is challenging. Patient engagement
techniques may help identify contributors to poor control and
address barriers (using motivational interviewing) and help facilitate
choices among treatment augmentation options (using shared deci-
sion‐making). These methods have not been used in combination
to improve diabetes outcomes.
Objectives: The study objective was to evaluate the impact of a
telephone‐based patient‐centered intervention on glycated
hemoglobin (HbA1c) control and medication adherence.
Methods: ENGAGE‐DM was a two‐arm, pragmatic, database‐ran-
domized controlled trial of 1,400 US commercially‐insured partici-
pants (18–64 years old) with poorly‐controlled type 2 diabetes.
Eligible patients were identified via administrative claims and
linked laboratory data and randomized to usual care or a pharma-
cist‐delivered phone intervention that consisted of an integrated
brief negotiated interview and shared decision‐making to identify
patient goals and options for diabetes management. The primary
outcome was change in HbA1c from baseline. Secondary outcomes
were medication adherence measures. Outcomes were
evaluated using intention‐to‐treat principles with routinely‐collected
claims and lab data; multiple imputation was used for missing HbA1c
values in the 12‐month follow‐up. We also conducted as‐treated
analyses using propensity score matching to identify similar patients
in the usual‐care arm as those in the treatment arm who received
the intervention.
Results: Participants had a mean (SD) age of 54.7 (8.3) years and base-
line HbA1c of 9.4 (1.6). Change in HbA1c was −0.79 (2.01) in the
usual‐care arm and − 0.75 (1.76) in the intervention arm (difference:
+0.04, 95%CI: −0.22, 0.30). There were no significant differences in
adherence to medication. In as‐treated analyses, the intervention sig-
nificantly improved diabetes control (−0.48, 95%CI: −0.91, −0.05) in
the 30% of patients in the intervention arm who received it versus
usual care.
Conclusions: A novel telephone‐based patient‐centered intervention
did not improve HbA1c in patients with poorly‐controlled diabetes,
although as‐treated analyses suggest that the intervention was effec-
tive when balanced for potential confounders.
454 | Reduced healthcare utilization in
patients using Empagliflozin: An interim
analysis from the Empagliflozin comparative
effectiveness and safety (EMPRISE) study
Mehdi Najafzadeh1; Ajinkya Pawar1; Anouk Déruaz‐Luyet2;
Kimberly G. Brodovicz3; Anastasia Ustyugova2; Lily G. Bessette1;
Nileesa Gautam1; Sebastian Schneeweiss1; Elisabetta Patorno1
1Brigham & Women's Hospital, Boston, MA; 2Boehringer Ingelheim
International GmbH, Ingelheim am Rhein, Germany; 3Boehringer
Ingelheim International GmbH, Ridgefield, CT
Background: The efficacy of Empagliflozin (EMPA) for reducing the
risk of cardiovascular (CV) death (HR 0.62; 95% CI 0.49–0.77) and
hospitalization for heart failure (HHF) (HR 0.65; 95% CI 0.50–0.85)
was demonstrated in the EMPA‐REG OUTCOME trial in adults with
type 2 diabetes (T2D) and established CV disease. EMPRISE is a study
program on the comparative effectiveness, safety and health care
resource utilization (HCRU) of EMPA for T2D patients in routine care
across a spectrum of CV risk in two US commercial (Optum and
MarketScan) and Medicare claims datasets (2014–2019).
Objectives: To compare HCRU among EMPA versus dipeptidyl pepti-
dase‐4 inhibitor (DPP4i) users observed during the first two years of
EMPRISE (08/2014–09/2016).
Methods: In this interim analysis,we identified a 1:1 propensity‐score‐
matched cohort of T2D patients ≥18 years initiating either EMPA or a
DPP4i, and assessed balance on ≥140 covariates including clinical,
HCRU, and cost‐related covariates at baseline using absolute stan-
dardized differences (aSD). We compared risk of first hospitalization,
risk of first emergency department (ED) visit, hospital length of stay
(LOS), and number of hospital admissions, office visits and ED visits
in EMPA and DDP4i users.
Results: We identified 17,549 matched pairs in the three data sets
with mean follow‐up of 5.4 months. All baseline characteristics were
well balanced (with aSD < 0.1) after propensity matching. The mean
age was 59 and 47% were female. Approximately 24% of patients
had history of CV disease and mean HbA1c was 8.6%. Risk of first
hospitalization [hazard ratio (HR) = 0.84; 95%CI: 0.76–0.92] and ED
visit (HR = 0.83; 0.73–0.94) was lower in EMPA than DDP4i users
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as was the number of all hospital admissions (12% and 15% per mem-
ber per year [PMPY]; Incidence rate ratio (IRR) = 0.78; 0.72–0.86). LOS
was 0.52 days PMPY in EMPA compared to 0.75 days in DDP4i group
(Diff = −0.23, 95% CI = −0.38‐ ‐0.08). Number of ED visits (0.07 and
0.09 PMPY; IRR = 0.80; 0.71–0.89) and number of office visits (8.03
and 8.39; IRR = 0.96; 0.95–0.98) were also lower in EMPA than DPP4i
initiators. Our findings in the pooled data were consistent across indi-
vidual databases; however, rate ratios for risk of first hospitalization
and first ED visit only reached statistical significance in Medicare data-
bases in this first analysis.
Conclusions: We observed significantly lower HCRU in EMPA com-
pared to DDP4i initiators in the pooled dataset within the first two
years of EMPRISE. The findings in each individual database were con-
sistent with the overall results in the pooled analysis.
455 | The effectiveness of glucagon‐like
Peptide‐1 receptor agonists in preventing
hospitalizations for chronic lower respiratory
disease
Yasser Albogami1,2; Kenneth Cusi1; Michael Daniels1;
Yu‐Jung Jenny Wei1; Almut Winterstein1
1University of Florida, Gainesville, FL; 2King Saud University, Riyadh,
Saudi Arabia
Background: Limited evidence supports tailoring antidiabetic regimens
for patients with type II diabetes (T2DM) and chronic lower respira-
tory disease (CLRD). Animal and ex‐vivo human studies have demon-
strated positive effects of glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) in reducing pulmonary exacerbations, providing potential
benefits over other antidiabetic regimens for patients with comorbid
CLRD and T2DM.
Objectives: To evaluate the effectiveness of GLP‐1RAs in preventing
CLRD‐related hospitalizations in a population with T2DM and CLRD
using real‐world data.
Methods: About 6.5 million antidiabetic users were identified in the
IBM MarketScan Commercial Claims database between 2006–2017.
Patients who initiated second‐line therapy were categorized into
GLP‐1RAs or non‐GLP‐1RAs, which comprised sulfonylureas, DPP‐4
inhibitors, SGLT2 inhibitors and thiazolidinediones (TZDs). Non‐insulin
users with CLRD and T2DM and no T1DM diagnoses within one year
before drug initiation were included. We followed the patients up to
one year to compare incidence rates of CLRD hospitalizations
between GLP‐1RAs and non‐GLP‐1RAs users. We used stabilized
inverse probability treatment weighting (SIPTW) to adjust for con-
founders including age, prescriber specialty, insulin use, healthcare uti-
lization, comorbidities, CLRD regimens and the adapted diabetes
complications severity index. We used absolute standardized differ-
ences (ASD) with a threshold of 10% to evaluate SIPTW performance.
Sensitivity analyses were conducted to compare GLP‐1RAs against
each of the following: sulfonylureas, DPP‐4 inhibitors, SGLT2 inhibi-
tors and TZDs.
Results: The study sample comprised 8,600 and 88,709 users of GLP‐
1RAs (median age of 53) and non‐GLP‐1RAs (median age of 55),
respectively. The largest ASD after applying SIPTW was 7.8% showing
well‐balanced covariates. The CLRD‐hospitalizations incidence rate
was 13.3 and 20 per 1000 patient‐years for GLP‐1RAs and non‐
GLP‐1RAs users, respectively. The unadjusted rate ratio (RR) was
0.67 (95% CI: 0.55–0.81, p‐value <0.01). After applying SIPTW, the
RR was 0.74 (95% CI: 0.61–0.90, p‐value <0.01). Sensitivity analyses
were consistent with the main analysis except for SGLT‐2 showing
non‐significant difference.
Conclusions: GLP‐1RAs demonstrated potential benefits in preventing
CLRD‐related hospitalizations. Further studies including randomized
clinical trials are needed to provide evidence for the causality of
GLP‐1RAs.
456 | Risk factors for progression to vision
threatening diabetic retinopathy
Brian L. VanderBeek; Yafeng Li; J. Clay Bavinger; Yinxi Yu
Scheie Eye Institute/University of Pennsylvania, Philadelphia, PA
Background: While numerous studies have examined the risk factors
of diabetic retinopathy progression, none have taken an all‐
encompassing approach accounting for systemic medical conditions,
laboratory values and current prescription medications in the same
study.
Objectives: To assess all factors that are associated with the hazard of
progression from non‐proliferative diabetic retinopathy (NPDR) to
vision‐threatening diabetic retinopathy (VTDR), proliferative diabetic
retinopathy (PDR), or diabetic macular edema (DME).
Methods: This is a time updating retrospective cohort study using
medical claims data from a large U.S. insurer. Cohorts were created
from all NPDR patients who had lab values from 2002–2016. Exclu-
sion criteria consisted of any previous diagnosis of VTDR, proliferative
vitreoretinopathy or treatment used for VTDR. Patients were also
excluded if they had a diagnosis of VTDR within 2 years of insurance
plan entry, regardless of when NPDR was first noted in the plan. The
main outcome was a new diagnosis of VTDR (defined as either PDR or
DME), DME or PDR individually. Cox proportional hazard regression
was used to determine demographic, systemic medical conditions, lab-
oratory values and prescription drug usage (assessed in a time‐
updating manner based on date of prescription fill and days of medica-
tion supplied. Anemia (hemoglobin) levels and kidney function (eGFR
level) were based on laboratory values and were also time‐updated.
Results: 69,982 NPDR patients were included for analysis, of which
12270, 2162, 10322 progressed to VTDR, PDR and DME, respec-
tively. After controlling for all covariates, both mild and moderate/
severe (mod/sev) anemia were associated with an increased hazard
for progression to VTDR (mild HR:1.10,95%CI:1.04–1.16,p < 0.001;
mod/sev HR:1.20,95%CI:1.12–1.29,p < 0.001), to PDR (mild
HR:1.29,95%CI:1.13–1.46,p < 0.001; mod/sev HR:1.43,95%CI:1.21–
1.69,p < 0.001), and to DME (mild HR:1.06,95%CI:1.00–1.13,
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p < 0.001; mod/sev HR:1.14,95%CI:1.05–1.24,p < 0.001).
Fenofibrates were associated with a protective effect for VTDR
(HR:0.89,95%CI:0.82–0.98,p = 0.01) and PDR (HR:0.71,95%CI:0.56–
0.91,p = 0.006), but not DME (HR:0.96,95%CI:0.87–1.06,p = 0.39).
Statin use was not associated with VTDR (HR = 0.98, 95%CI:0.94–
1.02,p = 0.26) or DME (HR = 1.01,95%CI:0.97–1.06,p = 0.48), but
showed an increased hazard for PDR (HR = 1.12,95%CI:1.02–1.23,
p = 0.01).
Conclusions: Anemia, independent of kidney function was associated
with increased risk of VTDR progression. Use of fenofibrates was pro-
tective for PDR, but not DME. Statin use was not associated with
DME, but showed an increased risk for PDR.
457 | Dipeptidyl Peptidase‐4 inhibitors and
risk of inflammatory bowel disease: Real
world evidence in US adults
Tiansheng Wang1; Jeff Y. Yang1; John B. Buse3; Virginia Pate1;
Huilin Tang; Edward Barnes2; Robert S. Sandler2; Til Stürmer1
1University of North Carolina Gillings School of Global Public Health,
Chapel Hill, NC; 2University of North Carolina School of Medicine, Chapel
Hill, NC; 3 Institute for Drug Evaluation, Peking University Health Science
Center, Beijing, China
Background: A recent cohort study raises the concern that dipeptidyl
peptidase‐4 inhibitors (DPP4i) are associated with increased risk of
inflammatory bowel disease (IBD).
Objectives: Evaluate the association between new use of DPP4i vs
other antihyperglycemics and IBD risk.
Methods: We implemented an active comparator, new user cohort
study using two US administrative claims databases for commer-
cially‐insured (MarketScan) and elderly (Medicare fee‐for‐service,
20% random sample) patients from January 2007 to September
2015. We identified patients, aged 18+, who initiated DPP4i vs sul-
fonylureas (SU), or DPP4i vs thiazolidinediones (TZD), and without
prior diagnoses, treatments or procedures potentially related to
IBD. The primary outcome was incident IBD, defined by IBD diagno-
sis preceded by colonoscopy and biopsy within 30 days before diag-
nosis, and followed by IBD treatment within 30 days after diagnosis.
Secondary analyses assessed the risk of incident Crohn's disease
(CD) and ulcerative colitis (CD). Follow‐up started 180 days (latent
period) post the 2nd prescription to account for diagnostic delay of
IBD, continued 180 days (the carry‐over period) after treatment
changed or stopped. We used standardized mortality/morbidity
weighted Cox proportional hazards models to estimate propensity
score adjusted hazard ratios (aHRs [95% CI]) censoring treatment
change. We performed random‐effects meta‐analysis models with
inverse variance weighting to pool aHRs across cohorts. We strati-
fied analyses by age at cohort entry (MarketScan: <50/ ≥50 years;
Medicare: <75/ ≥75), sex, duration of use (<1/ ≥1 year) and pre‐
existing gastroenterological disease. Sensitivity analyses applied dif-
ferent latent and carry‐over periods (0, 90, 365 days, respectively),
no censoring for treatment change, relaxed outcome definitions,
relaxed exclusion criteria, and multivariable‐adjusted Cox regression.
Results:We identified 839,949 eligible initiators of DPP4i, SU or TZD;
IBD incidence rates ranged from 13.4–35.4 per 100,000 person‐years.
Over a median treatment duration of 1.04–1.45 years, DPP4i were
not associated with increased IBD risk across comparisons. Pooled
aHRs for IBD were 0.89 (95% CI: 0.56–1.41) comparing DPP4i
(n = 146,691) vs SU (n = 285,724), and 0.66 (0.40–1.08) comparing
DPP4i (n = 183,698) vs TZD (n = 83,264). Overall, results were robust
across secondary and sensitivity analyses.
Conclusions: Our population‐based cohort study of US adults with
diabetes suggests that DPP4i treatment for approximately one year
does not increase IBD risk.
458 | Dipeptidyl Peptidase‐4 inhibitors and
the risk of bullous pemphigoid among
patients with type 2 diabetes: A population‐
based cohort study
Antonios Douros1,2,3; Julie Rouette1; Hui Yin3; Oriana Hoi Yun Yu3;
Kristian B. Filion1,3; Laurent Azoulay1,3
1McGill University, Montreal, QC, Canada; 2Charité ‐ Universitätsmedizin
Berlin, Berlin, Germany; 3Lady Davis Institute, Montreal, QC, Canada
Background: There are concerns that dipeptidyl peptidase‐4 (DPP‐4)
inhibitors, a class of second‐ to third‐line antidiabetic drugs, may be
linked to the development of bullous pemphigoid, a rare but poten-
tially severe autoimmune blistering skin condition.
Objectives: To assess whether the use of DPP‐4 inhibitors, when
compared with the use of other second‐ to third‐line antidiabetic
drugs, is associated with an increased risk of bullous pemphigoid in
patients with type 2 diabetes.
Methods: Using the United Kingdom Clinical Practice Research
Datalink we conducted a population‐based cohort study, thereby
including all patients initiating antidiabetic drugs between January 1,
2007 and March 31, 2018. We used time‐dependent Cox proportional
hazards models to estimate adjusted hazard ratios with 95% confi-
dence intervals of incident bullous pemphigoid associated with current
use of DPP‐4 inhibitors, compared with current use of other second‐
to third‐line antidiabetic drugs. We also investigated whether there
was a duration‐response relation modeling duration of use as a contin-
uous variable using restricted cubic splines. Finally, we conducted a
propensity score‐matched analysis to further assess the impact of
residual confounding.
Results: Among 168,774 patients initiating antidiabetic drugs and
during 711,311 person‐years of follow‐up, 150 patients were newly
diagnosed with bullous pemphigoid (crude incidence rate, 21.1 per
100,000 person‐years). Current use of DPP‐4 inhibitors was associ-
ated with an increased risk of bullous pemphigoid (47.3 versus
20.0 per 100,000 person‐years; hazard ratio, 2.21; 95% confidence
interval, 1.45 to 3.38) when compared with current use of other sec-
ond‐ to third‐line antidiabetic drugs. Hazard ratios gradually
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increased with longer duration of use, reaching a peak after
20 months of use (hazard ratio, 3.60; 95% confidence interval,
2.11 to 6.16). Similar results were obtained in the propensity
score‐matched analysis (hazard ratio, 2.40; 95% confidence interval,
1.13 to 4.66).
Conclusions: In this large population‐based study, the use of DPP‐4
inhibitors was associated with an at least doubling of the risk of bul-
lous pemphigoid in patients with type 2 diabetes.
459 | Identifying drug classes whose
initiation may be a proxy for frailty
Henry T. Zhang1; Robert J. Glynn2; Til Stürmer1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2Brigham and Women's Hospital and
Harvard Medical School, Boston, MA
Background: Frailty is a potentially important confounder, not well
measured in insurance claims data. Attempts to find proxies for frailty
have largely omitted drug use variables or focused on prevalent drug
use. Since drug initiation is driven by the treatment indication and
expectation of benefit, it may serve as a better proxy for frailty than
prevalent drug use.
Objectives: To identify drug classes whose initiation is associated with
high or low short‐term mortality and may therefore be a proxy for
frailty.
Methods: Using U.S. Medicare data from 2009–2010, we identified
initiators of drug classes defined by the second level of the Anatomical
and Therapeutic Classification coding system (e.g. C03 Diuretics) and
randomly sampled outpatient visits from all beneficiaries to create a
general population comparator. For all groups, we required people to
be ≥65 years old, with ≥1 year of prior continuous Parts A, B and D
coverage. We assessed demographics, the components of a common
comorbidity score and the components of a frailty score for each per-
son. Since frailty was unavailable, we assessed 30‐day mortality as the
outcome, assuming that frailty would increase short‐term mortality.
We compared mortality between each group of initiators and the
comparator group using logistic regression, controlling for all baseline
covariates.
Results: The 62 initiator groups larger than 5,000 people were con-
sidered, resulting in a range from 5,033 (M02, Topical products for
joint and muscular pain) to 528,354 (J01 Systemic antibacterials)
people. Crude mortality was 0.41% for the comparator group and
ranged from 0.09% (J07 Vaccines) to 13.84% (B05 Blood substitutes
and perfusion solutions) for the initiator groups. J07 Vaccines, D10
Anti‐acne preparations and G03 Sex hormones and modulators of
the genital system were the drug classes with the most reduced
odds of death, with adjusted odds ratios of 0.41 (95% CI: 0.28,
0.60), 0.65 (0.42, 0.99) and 0.81 (0.63, 1.05) respectively. B05 Blood
substitutes and perfusion solutions, A04 Antiemetics and
antinauseants and A15 Appetite stimulants were the drug classes
with the most increased odds of death, with adjusted odds ratios
of 14.4 (12.6, 16.4), 12.1 (10.8, 13.5), and 10.0 (8.8, 11.3) respec-
tively. Most drug classes showed increased odds of death relative
to the comparator.
Conclusions: Several commonly used drug classes were associated
with high or low short‐term mortality. While these associations are
not causal and reflect both treatment indications and prescribing pat-
terns, initiation of these drug classes may serve as markers of poor or
good health to improve confounding control in
pharmacoepidemiologic studies.
460 | Validation of a five‐year mortality
prediction model among US Medicare
beneficiaries
Rachael K. Ross; Tzy‐Mey Kuo; Michele Jonsson Funk;
Jennifer L. Lund
University of North Carolina, Chapel Hill, NC
Background: A recent claims‐based five‐year mortality prediction
model was developed including comorbid conditions and indicators
of frailty, disability, and functional impairment. The model was devel-
oped and internally validated in a 2008 cohort of North Carolina
(NC) Medicare beneficiaries.
Objectives: We aimed to externally validate this new model in a
nationwide sample of US Medicare beneficiaries.
Methods: From a 20% random nationwide sample of US Medicare
beneficiaries, we created a cohort of beneficiaries 66 years and older
with an office visit in 2008, not receiving hospice care, and at least
one year of continuous pre‐visit Medicare A/B enrollment. Residents
of NC were excluded. The outcome was 5‐year all‐cause mortality
determined from enrollment files. We applied model estimates
derived in the original study cohort and computed the predicted
probability of 5‐year morality for each beneficiary. For comparison,
we also ran a model using a Charlson and Elixhauser combined
comorbidity score. To assess discriminatory performance, we calcu-
lated c‐statistics with 95% confidence intervals. To evaluate
improvement in reclassification between the new model and the
comorbidity score model, we computed the net reclassification
improvement (NRI) and integrated discrimination improvement (IDI)
for the change in the difference of the average predicted probabili-
ties between those who died and those who survived. For both met-
rics, a positive number indicates improved classification.
Results: The cohort included 1,116,745 beneficiaries of whom
284,154 (25%) died within 5‐years, similar to the original study
cohort. The mean age was 76.0 years (SD 7.3) and 65% of the
cohort was female. Based on the new model, 27% of the cohort
had a predicted probability of death of <10% and 8.6% had a pre-
dicted probability of death of >80%. Predictions from the new model
slightly overestimated the 5‐year mortality. The c‐statistic for the
new model was nearly identical to that obtained in the internal val-
idation (0.823 [95% CI 0.823, 0.824] and 0.825 [95% CI 0.823,
0.828], respectively) and higher than that from the comorbidity score
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(0.795 [95% CI 0.794, 0.796]). The new model improved reclassifica-
tion of death at five years compared to the comorbidity score: NRI
11.9% and IDI 9.2%.
Conclusions: Our results provide external validation for the new five‐
year mortality prediction model. Using US Medicare beneficiaries, the
model had strong discrimination and generally improved classification
compared to a combined comorbidity score model, although the new
model slightly overestimated 5‐year mortality.
461 | The impact of polypharmacy
definitions on the estimation of
polypharmacy prevalence in older individuals:
A population‐based evaluation
Marie‐Eve Gagnon1; Houssem Missaoui2; Bernard Candas2;
Guillaume Boucher2; Marc Simard3; Caroline Sirois1,4
1Université Laval, QC, QC, Canada; 2 Institut National d'Excellence en
Santé et Services Sociaux, QC, QC, Canada; 3 Institut National de Santé
Publique du Québec, QC, QC, Canada; 4Centre of Excellence on Aging of
Quebec City, QC, QC, Canada
Background: There are numerous definitions of polypharmacy. Yet,
there is little data on how these definitions influence estimates of
polypharmacy prevalence in a single population.
Objectives: To assess the impact of different definitions of exposure
to medications on the mean count of medications used and on the
proportion of individuals exposed to polypharmacy at a population‐
level.
Methods: We created a population‐based cohort of individuals
≥65 years insured by the universal public drug plan in Quebec, Can-
ada, between April 1, 2016 and March 31, 2017. We extracted all
medications used by a random sample of 10% of the population
(n = 120,652) and described their medication use according to five
definitions: 1) simultaneous polypharmacy: number of medications
used on a single day; 2) cumulative polypharmacy: number of distinct
medications over a 3‐month period; 3) weighted polypharmacy: num-
ber of distinct medications weighted according to the duration of
exposure; 4) persistent polypharmacy: number of distinct medications
used over the first 3 months that were still used in the last 3 months;
5) persistent polypharmacy without interruption: number of distinct
medications used persistently without gaps. We used descriptive sta-
tistics and performed sensitivity analyses by varying grace periods
between refills.
Results:With the simultaneous definition of polypharmacy, the mean
number of medications used was 4.44 (SD:3.45). Cumulative counts
resulted in a mean of 4.98 (3.65) medications, while weighted count
totaled 4.43 (3.44). Persistent polypharmacy definition yielded a
mean of 4.16 (3.43) medications, while it was 2.85 (3.09) for the
persistent polypharmacy without gaps. According to the definitions,
the proportions of individuals using at least 5 medications were
respectively 44.0% (1&3), 49.4% (2), 42.9% (4) and 36% (5), while
the proportion of those using at least 10 medications were 8.9%
(1&3), 12.3 (2), 8.0% (4) and 4.0% (5). Sensitivity analyses yielded
similar results.
Conclusions: Prevalence of polypharmacy varies according to defini-
tions, but graphic representations show similarity in medication use
patterns. There is a need to explore which definitions best predict out-
comes and what cut‐off should be used for polypharmacy. As one‐
third to one‐half of the population is exposed to at least five medica-
tions, this threshold would be of little use for a population
polypharmacy indicator whose purpose is to predict health outcomes.
462 | Measuring frailty in administrative
claims data: Comparative performance of four
claims‐based frailty measures in the United
States Medicare data
Dae Kim; Elisabetta Patorno; Ajinkya Pawar; Hemin Lee;
Sebastian Schneeweiss; Robert Glynn
Brigham and Women's Hospital, Boston, MA
Background: Administrative claims data are a valuable data source to
inform clinical and public health policy decisions for older adults.
Recently, 4 claims‐based models were developed to measure frailty
in the United States Medicare data. Comparative performance of
claims‐based frailty measures has not been examined.
Objectives: To evaluate the performance of the 4 claims‐based frailty
measures in identifying older adults with frailty and at high risk for
adverse health outcomes.
Methods: This retrospective cohort study included 2,326 community‐
dwelling Medicare beneficiaries who had at least 1 health care
encounter within 6 months of their 2008 assessment in the Health
and Retirement Study. The claims‐based frailty measures by Davidoff,
Faurot, Segal, and Kim were estimated from claims data and compared
against clinical measures of frailty (gait speed, grip strength) and
adverse health outcomes (e.g., mortality, hospitalization, activities‐of‐
daily‐living disabilities) over 2 years. The associations between
claims‐based frailty measures and outcomes were examined using cor-
relation coefficients and C‐statistics after adjusting for age and sex.
Results: The correlation coefficients with gait speed for Davidoff,
Faurot, Segal, and Kim indices were − 0.19, −0.33, −0.37, and − 0.37,
respectively. Age and sex adjustment attenuated the correlation to
−0.17, −0.22, −0.18, and − 0.33, respectively. The corresponding cor-
relation coefficients with grip strength were − 0.17, −0.27, −0.35,
and − 0.24, which attenuated to −0.09, −0.14, −0.05, and − 0.23 after
age and sex adjustment, respectively. The models that included age,
sex, and each of Davidoff, Faurot, Segal, and Kim indices showed C‐
statistics of 0.67, 0.71, 0.71, 0.75 for mortality (versus C‐statistic for
age and sex: 0.66); 0.59, 0.64, 0.63, 0.70 for hospitalization (versus
C‐statistic for age and sex: 0.58); and 0.64, 0.63, 0.63, 0.70 for activ-
ities‐of‐daily‐living disabilities (versus C‐statistic for age and sex: 0.61),
respectively.
Conclusions: The choice of a claims‐based frailty measure results in
meaningful variations in the identification of frail older adults at high
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risk for adverse health outcomes. Claims‐based frailty measures that
included demographic variables offer limited additional risk adjust-
ment beyond age and sex alone.
463 | Predictive modeling in patients with
heart failure: A comparison of machine
learning and traditional statistical approaches
Rishi J. Desai; Shirley Wang; Muthiah Vaduganathan;
Sebastian Schneeweiss
Harvard Medical School/Brigham & Women's Hospital, Boston, MA
Background: Accurate risk‐stratification in heart failure (HF) with
respect to clinically‐important outcomes is critical to effectively
deploy targeted interventions including palliative care and to guide
prognostic discussions with patients.
Objectives: To compare machine learning approaches including classi-
fication and regression trees (CART), random forests (RF), gradient
boosting modeling (GBM), least absolute square shrinkage operator
(LASSO) regression with traditional logistic regression in predicting
1‐year mortality in patients with HF.
Methods: We linked Medicare claims (2007–2014) to electronic
medical records (EMRs) from two academic medical centers in Bos-
ton, MA to construct a cohort of HF patients based on a recoded
diagnosis in claims and a recorded ejection fraction (EF) measure-
ment within 30 days from EMRs. Patients were followed for the
outcome of all‐cause mortality for 1 year. Predicted probabilities
were calculated from logistic regression, LASSO, CART (in condi-
tional inference framework), RF, and GBM. Predictors were sequen-
tially added to these models with claims‐based variables first
(demographics, HF related variables, co‐morbid conditions, frailty
score, and a socioeconomic status index) and subsequently EMR‐
derived variables (EF, natriuretic peptides, serum creatinine, blood
urea nitrogen). All models were constructed using data from Center
1 and validated using data from Center 2. The performance was
reported based on C‐statistics, calibration plots, and Brier score in
validation data.
Results: A total of 9502 HF patients were included; 6113 from Center
1 and 3389 from Center 2, with 1‐year mortality of 20.6% and 22.6%,
respectively. In claims‐only models, the performance of various
approaches was similar except for CART, which underperformed com-
pared to all other models (C‐statistics for logistic, LASSO, CART, RF,
GBM: 0.724, 0.725, 0.678, 0.723, and 0.725, respectively; Brier
scores: 0.158, 0.157, 0.165, 0.156, 0.157, respectively). Addition of
EMR variables markedly improved performance for all models, espe-
cially for GBM (C‐statistics for logistic, LASSO, CART, RF, GBM:
0.746, 0.747, 0.703, 0.748, and 0.756, respectively; Brier scores:
0.152, 0.152, 0.160, 0.152, 0.151, respectively). Visual inspection of
the calibration plots revealed generally better calibration with LASSO,
RF, and GBM.
Conclusions: Machine learning methods offered limited improvement
over traditional methods in predicting mortality in HF. Clinical
parameters from EMRs may offer enhanced risk prediction informa-
tion beyond claims‐based data.
464 | Performance of machine learning
algorithms for hysterectomy risk prediction
among women with endometriosis in the
United States
Bradley Saul1; Ryan D. Kilpatrick2; Leah J. McGrath1; Diane Reams1;
Lani Wegrzyn2; Stephanie E. Chiuve2; M. Alan Brookhart1
1NoviSci, Durham, NC; 2AbbVie, Inc., North Chicago, IL
Background: Machine learning algorithms are increasingly used in
healthcare delivery research, yet have not been used to identify
women at risk for surgical management of endometriosis.
Objectives: To compare the performance of machine learning algo-
rithms for estimating the 1‐year risk of hysterectomy among women
with endometriosis.
Methods: Women aged 18–49 years were identified in Optum®
data from January 1, 2006 through December 31, 2016. Patients
had a laparoscopic procedure plus an endometriosis code within
the 90 days before or 14 days after the procedure. The index date
was the latter of the two dates. Patients were censored for hormone
replacement therapy initiation, disenrollment, or reaching age 50,
and inverse probability of censoring weights were used in the model.
We identified 50 covariates to use in the prediction models, includ-
ing demographics, comorbidities and medications found in the rele-
vant lookback period (i.e. either all available data or 1 year before
index, depending on the variable). We used the H20 machine learn-
ing package in R to fit the following algorithms to predict 1‐year risk
of hysterectomy: generalized linear model (penalized elastic‐net
logistic), distributed random forest, gradient boosted classification
trees, deep learning, a stacked ensemble of these methods, and
H20’s automated algorithm. The data were randomly split 80/20
into training and testing sets, and 10‐fold cross‐validation was used
on the training set. Area under the receiver operator curves (AUC)
and log loss statistics were used to compare methods. A model‐
agnostic variable importance metric was used to measure each
covariate's influence on a model's predictive ability.
Results: We identified 23,358 eligible women, of whom 1,975 (8.5%)
had a hysterectomy within 1 year of index. The AUC for the different
models in the testing data ranged from the lowest performing model
at 0.65 (random forest) to the best fitting algorithm at 0.77 (stacked
ensemble). The automated machine learning had similarly high predic-
tive ability (AUC = 0.74). Log loss statistics suggested a similar pattern.
Within the auto machine learning method, the stacked ensemble
models had the highest AUC. Age was the most influential predictor
of hysterectomy risk.
Conclusions: Combining multiple machine learning algorithms (e.g.
stacked ensemble) resulted in substantially better prediction than
any of the individual methods in this data set. When using machine
learning methods in healthcare research, assessing the performance
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of different algorithms is an important step to maximize a model's pre-
dictive ability.
465 | Inferring mortality in claims data
Dana Y. Teltsch; Feng Zhang; Amanda M.B. Kelly; Dawn G. Albright
Aetion, New York, NY
Background: Mortality is an important outcome in many epidemiologi-
cal studies. However, deaths are not reported in many databases, and
are under‐reported in others. We hypothesize that machine learning
based approaches can be used to accurately identify likely mortalities
in claims data, thus enabling the use of death as an outcome in studies.
Objectives: To assess the feasibility of inferring deaths in claims data
when mortality is not reported.
Methods: We used data from the Optum Clinformatics® Data Mart,
a nationally representative de‐identified claims dataset that includes
near‐complete patient level mortality information prior to September
of 2011. We developed and assessed a classifier to identify which
disenrollment events are due to death on training and testing sets
prior to 11/2011. Classifiers based on diagnosis and procedure
codes (any and count), demographics, and utilization‐based variables
in the month prior to disenrollment were developed from logistic
regression and several probabilistic machine learning approaches
including random forest (RF), and gradient boosted trees (GBT).
Analyses were performed in Apache Spark MLLib. Each model's per-
formance was evaluated based on sensitivity, specificity, positive
predictive value, and negative predictive value, and the area under
receiver curve (AUC) and bootstrapped‐based standard deviations
(StD) were calculated. Models were developed for the general popu-
lation as well as for condition‐based cohorts: chronic obstructive
pulmonary disease (COPD), metastatic and non‐metastatic tumors,
congestive heart failure (CHF), and chronic kidney disease (CKD).
Results: The full cohort comprised over 36 million patients, and
nearly 600,000 reported deaths. Several methods led to models with
good properties, but GBT followed by RF performed the best. GBT
classified deaths with specificity of 0.99 when sensitivity was higher
than 0.8, and AUC of 0.97 with a StD of 0.0017. Age, place of ser-
vice, number of days in the hospital, total medical cost, as well as
diagnosis codes indicating cardiac arrest, respiratory failure, or the
count of diagnosis codes for hypertension, fatigue and shortness of
breath were strong predictors of death in the general population.
The models for the disease‐based cohorts performed well, with
specificity that ranged from 0.98 for COPD and non‐metastatic
tumors, to 0.90 for CKD and CHF (with sensitivity greater than
0.8). Strong predictors were similar, with place of service surpassing
age as the most important in the cancer, CKD, and CHF cohorts.
Conclusions: Our results suggest that mortality events can be
inferred in claims data using machine learning approaches, with very
high accuracy.
466 | Federated learning for predicting
clinical events with distributed patient data
sets
Yoonyoung Park; Issa Sylla; Amar K. Das; Olivia Choudhury
IBM Research, Cambridge, MA
Background: There is a growing research effort in using
machine learning to predict clinical events among hospitalized
patients. Sharing sensitive patient data across hospitals to create a
large central database is difficult due to privacy concerns, single
point of failure, and high latency, making large‐scale learning
difficult.
Objectives: To demonstrate a novel approach based on
federated learning, wherein a global predictive model is trained on
local data residing at hospitals, without ever sharing the raw data.
Methods: We used a public benchmark data generated from MIMIC‐
III (2001–2012), an electronic health data set from intensive
care units (ICUs) in a tertiary hospital. All adult subjects (age > =
18) were included, excluding those who transferred between
units or had insufficient data. The benchmark data had 714
features based on physiological variables from the first 48 hours
of data. Logistic regression (LR) and support vector machine (SVM)
predicting in‐hospital mortality were trained and evaluated for per-
formance, using both centralized and federated learning methods.
Centralized learning results were averaged over 10 iterations with
7:3 train and test data split. In federated learning, we either
randomly divided data into 5 sites or divided by 5 different ICU
types, using the second‐largest ICU type (n = 3,665) as the test
set, and updated model coefficients over 10 rounds of aggregation.
Results: The final data set had 21,139 ICU stays with a mortality
rate of 13.23%. In centralized learning, the accuracy and AUC
was 0.88 (standard deviation +/−0.01) and 0.62 (+/−0.03) for SVM
and 0.88 (+/−0.002) and 0.64 (+/−0.02) for LR, respectively. In ran-
dom‐split federated learning, the accuracy and AUC for SVM was
0.86 (+/−0.002) and 0.64 (+/−0.006) and those for LR was 0.84
(+/−0.003) and 0.64 (+/−0.02), respectively. When data was split
by ICU types, the accuracy and AUC from centralized learning for
SVM was 0.94 (+/−0.008) and 0.68 (+/−0.04) and those for LR
was 0.95 (+/−0.004) and 0.68 (+/−0.02), respectively.
Federated learning across 4 different ICU units generated accuracy
and AUC of 0.94 (+/−0.60) and 0.65 (+/−0.001) for SVM and 0.81
(+/−0.02) and 0.82 (+/−0.004) for LR. The low mortality at test
ICU site contribute to higher accuracy compared to random split
experiment.
Conclusions: We show that federated learning can achieve
comparable predictive performance to centralized learning,
while preserving data privacy. This approach is applicable for
predicting clinical events or predicting adverse drug reactions
without sharing patient data across hospitals.
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467 | Using machine learning to predict risk
of opioid overdose in Medicare
Weihsuan Jenny Lo‐Ciganic1; James L. Huang1; Hao H. Zhang2;
Jeremy C. Weiss3; Yonghui Wu1; Chian K. Kwoh2; Julie M. Donohue4;
Jerry Cochran5; Adam J. Gordon5,6; Daniel C. Malone2;
Courtney C. Kuza4; Walid F. Gellad4,7
1University of Florida, Gainesville, FL; 2University of Arizona, Tucson, AZ;
3Carnegie Mellon University, Pittsburgh, PA; 4University of Pittsburgh,
Pittsburgh, PA; 5University of Utah, Salt Lake City, UT; 6Salt Lake City
Health Care System, Salt Lake City, UT; 7VA Pittsburgh Healthcare
System, Pittsburgh, PA
Background: Current approaches to identify individuals at high risk for
opioid overdose have major limitations, leading to burdensome inter-
ventions that are targeting many patients who are not truly at high
risk.
Objectives: To apply machine learning approaches to claims data to
improve the accuracy of identifying individuals at varying risks for opi-
oid overdose.
Methods: A retrospective cohort study included 560,057 fee‐for‐ser-
vice Medicare beneficiaries without cancer, who filled ≥1 opioid pre-
scription from 2011–2015. We randomly and equally divided
beneficiaries into training, testing, and validation samples. Potential
predictors (n = 268) including socio‐demographics, health status, pat-
terns of opioid utilization, and provider‐ and regional‐level factors,
were measured in 3‐month windows starting from 3 months before
initiating opioids until loss of follow‐up or end of 2015. We identified
diagnosis‐based opioid overdose (fatal or nonfatal) episodes from
inpatient and emergency department claims. We applied multivariate
logistic regression (MLR), least absolute shrinkage and selection oper-
ator‐type regression (LASSO), random forests (RF), gradient boosting
machine (GBM), and deep neural network (DNN) to predict overdoses
in the subsequent 3 months. We assessed prediction performance
using the C‐statistic and other metrics (e.g., sensitivity, specificity,
number needed to evaluate to identify one overdose [NNE]). We used
the Youden index to identify the optimized threshold of predicted
score that balanced sensitivity and specificity.
Results: The training (n = 186,686), testing (n = 186,685), and valida-
tion (n = 186,686) samples had similar characteristics (mean
age = 68.0 ± 14.5; female = 63.1%; white = 82.2%; ≥1 over-
dose = 0.60%). In the validation sample, DNN (C‐statistic = 0.91,
95%CI = 0.88–0.93) and GBM (C‐statistic = 0.90, 95%CI = 0.87–
0.94) outperformed LASSO (C‐statistic = 0.84, 95%CI = 0.80–0.89),
RF (C‐statistic = 0.80, 95%CI = 0.75–0.84), and MLR (C‐statistic = 0.75,
95%CI = 0.68–0.81) for predicting overdose. When at the optimized
sensitivity and specificity, DNN had a 92.3% sensitivity, 75.7% speci-
ficity, and NNE of 542. The DNN classified patients into low, medium,
and high‐risk subgroups (76.2%, 18.6%, and 5.2% of the cohort,
respectively), with only 1 in 10,000 in the low‐risk subgroup having
an overdose. Over 90% of overdoses occurred in the high and
medium‐risk subgroups.
Conclusions: Machine learning algorithms achieved excellent perfor-
mance for risk prediction and stratification of opioid overdose, espe-
cially in identifying low‐risk subgroups that have minimal risk of
overdose.
468 | Dual‐trajectories of opioid and
Gabapentinoid use and risk of subsequent
drug overdose among United States Medicare
beneficiaries
Lili Zhou1; Sandipan Bhattacharjee1; C. Kent Kwoh1; Patrick J. Tighe2;
Gary M. Reisfield2; Daniel C. Malone1; Marion Slack1;
Wei‐Hsuan Jenny Lo‐Ciganic2
1University of Arizona, Tucson, AZ; 2University of Florida, Gainesville, FL
Background: Increasing opioid (OPI) overdose deaths involving
gabapentinoids (GABAs) in the US has raised concerns of misuse/
abuse of GABAs. Little is known about the patterns of concurrent opi-
oid and gabapentinoid use (hereafter OPI‐GABA) most associated with
drug overdose risk.
Objectives: We examined the association between OPI‐GABA dose
and duration trajectories and subsequent drug overdose risk among
Medicare beneficiaries.
Methods: This retrospective cohort study included Medicare benefi-
ciaries with fibromyalgia, low back pain, neuropathy, and/or osteoar-
thritis who newly initiated prescription OPIs and/or GABAs from
2011–2016. We used dual group‐based trajectory models to identify
distinct OPI‐GABA use patterns, based on average daily morphine mil-
ligram equivalent for OPI and standardized daily dose for GABA,
within the first year of OPI and/or GABA initiation (i.e., index‐year).
We used inverse probability of treatment weighted multivariable
Cox proportional model to estimate the risk of time to the first drug
overdose episode within 12 months following the index‐year,
adjusting for socio‐demographics and health factors.
Results: Among 71,005 beneficiaries (mean age ± SD = 65.5 ± 14.5,
female = 68.1%), 10 distinct trajectories were identified (3 OPI‐only tra-
jectories, 3 GABA‐only trajectories, and 4 OPI‐GABA trajectories).
Compared to OPI‐only early discontinuers (40.6% of the cohort), the
1‐year drug overdose risk varied by trajectory group: consistent low‐
doseOPI‐only users (16.6%; HR = 1.50, 95%CI = 1.21–1.84); consistent
high‐doseOPI‐only users (1.8%;HR=4.33, 95%CI = 2.99–6.27); GABA‐
only early discontinuers (12.5%;HR = 1.43, 95%CI = 1.13–1.81); consis-
tent low‐dose GABA‐only users (11.0%; HR = 1.46, 95%CI = 1.14–
1.87); consistent high‐dose GABA‐only users (3.1%; HR = 1.60,
95%CI = 1.07–2.38); early discontinuation of OPI and consistent low‐
dose GABA users (6.9%; HR = 1.25, 95%CI = 0.91–1.70), consistent
low‐dose OPI‐GABA users (3.4%; HR = 2.23, 95%CI = 1.61–3.11); con-
sistent low‐dose OPI and high‐dose GABA users (3.2%; HR = 2.18,
95%CI = 1.55–3.07); and consistent high‐dose OPI and moderate‐dose
GABA users (0.9%; HR = 4.56, 95%CI = 2.82–7.37).
Conclusions: Subsequent overdose risk varied substantially by differ-
ent OPI‐GABA trajectories among Medicare beneficiaries. High‐dose
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OPI‐only users and all consistent OPI‐GABA users, especially high‐
dose OPI and moderate‐dose GABA users, were associated with more
than doubled drug overdose risk.
469 | Estimates of prolonged opioid use
following surgery vary by orders of
magnitude across various definitions
Jessica C. Young1; Jennifer M. Wu2; Virginia Pate1;
Michele Jonsson Funk1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2University of North Carolina School of
Medicine, Chapel Hill, NC
Background: Chronic opioid use has been reported as the most com-
mon post‐surgical complication. Methods to accurately define
prolonged opioid use in claims data are needed to quantify the impact
of measures that target this outcome. As opioids are typically pre-
scribed on an as‐needed basis (PRN), values listed for ‘days supplied’
on prescription (Rx) claims may not represent actual consumption
patterns.
Objectives: Among a cohort of women undergoing hysterectomy, we
examined the impact of varying definitions of prolonged opioid use on
estimates of prolonged opioid use post‐surgery.
Methods: We identified women undergoing hysterectomy in
MarketScan insurance claims, 2005–2015. We defined the index opi-
oid Rx for postsurgical pain as the first opioid filled in a perioperative
window beginning 30 days prior and extending 7 days post‐surgery,
with no baseline opioid Rx in the 180‐day washout. We examined
two categories of prolonged opioid use definitions: 1) Continuous
Use definitions based on reported Rx date and days supplied, allowing
varying grace periods (GP) between Rx fills; 2) Time Window defini-
tions counted any Rx within specific target windows during follow‐
up. To compare with published estimates, we also report the propor-
tion with an opioid Rx 90–180 days post‐op. We report estimates of
prolonged use following surgery based on the array of definitions.
Results: A total of 414,544 women meeting our inclusion criteria
underwent a hysterectomy, of whom 348,590 (84.1%) filled a periop-
erative opioid Rx (median days supplied: 4, IQR: 3, 5; median qty dis-
pensed: 30, IQR: 25, 40). Among women with a perioperative opioid
Rx, the proportion with a continuous supply of opioids through
90 days post‐op ranged from 0.09% using a 7‐day GP to 0.69% using
a GP of two times the days supplied. In contrast, the proportion of
women with evidence of an opioid Rx occurring in the 4th month of
follow up (90–120 days) was 2.7%. Finally, defining prolonged use as
evidence of any opioid Rx 90–180 days post‐op identified 6.8% of
women.
Conclusions: When analyzing prolonged opioid use, continuous use
measures resulted in drastically different estimates compared to
methods based on fills within target windows during follow‐up. Over-
all, continuous use measures found a small proportion of hysterec-
tomy patients had prolonged opioid use following surgery.
Meanwhile, defining prolonged use as evidence of an Rx occurring
90–180 days after surgery resulted in estimates 10 to 80 times higher.
Irregular consumption patterns with PRN medications complicate our
ability to define periods of drug exposure and examine prolonged
use in claims data.
470 | Concurrent use of opioids and strong
metabolic inhibitors and the risk of serious
infections
Andrew D. Wiese; Marie R. Griffin; C. Michael Stein;
William Schaffner; Robert A. Greevy; Edward F. Mitchel; Jr;
Carlos G. Grijalva
Vanderbilt University Medical Center, Nashville, TN
Background:Opioid use, including the use of methadone, is associated
with an increased risk of serious infections. The concurrent use of
methadone and strong inhibitors of its main metabolic pathways
would increase methadone levels and increase its toxicity. Cyto-
chrome P4530A4 (CYP3A4) was previously postulated to play a role
in the metabolism of methadone, yet whether the concurrent use of
CYP3A4 inhibitors impacts the risk of serious infections associated
with methadone use remains unclear.
Objectives: To compare the risk of serious infection among patients
using methadone during periods with and without concurrent use of
CYP3A4 inhibitors.
Methods: We conducted a retrospective cohort study among adult
Tennessee Medicaid enrollees initiating use of methadone (1995–
2015). Hospitalizations for serious infection were identified using val-
idated coding algorithms for pneumonia, bacteremia/sepsis, pyelone-
phritis, meningitis/encephalitis, osteomyelitis/septic arthritis,
endocarditis, and cellulitis. We compared the risk of infection during
periods of methadone use with and without concurrent use of
CYP3A4 inhibitors not indicated for treatment of HIV and fungal
infections (i.e., diltiazem, verapamil, nefazodone). We used multivari-
able Poisson regression to calculate adjusted incidence rate ratios
(aIRR). Analyses accounted for demographics, opioid dose, calendar
year, prior medication use, comorbidities, frailty indicators and
healthcare utilization history measured in the prior 366‐day period
for each day of follow‐up using exposure propensity scores. We con-
ducted similar comparisons among long‐acting morphine users as a
negative control.
Results: We identified 691 serious infections among 10,210 person‐
years (py) of long‐acting methadone use, including 437 py (4.3%) of
concurrent CYP3A inhibitor use. The absolute rate of infections was
highest during periods of concurrent methadone and CYP3A inhibitor
use compared to no concurrent use (9.4 vs. 6.7 per 100 py). However,
after adjustment, the use of CYP3A inhibitors was not significantly
associated with an increased risk of infections among methadone
users [aIRR: 1.23 (95% CI: 0.88–1.71)]. No association was observed
for concurrent metabolic inhibitor use among morphine users [aIRR:
0.97 (95% CI: 0.90–1.12)].
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Conclusions: Preliminary evidence suggests certain medications previ-
ously thought to impact the metabolism of methadone do not increase
the risk of serious infections associated with its use, though larger
studies may increase the precision of our preliminary estimates.
471 | Methods to account for time‐varying
medication use when developing a model for
patient prognosis
Romin Pajouheshnia1; Noah Schuster2; Rolf Groenwold3;
Linda Peelen4
1Utrecht University, Utrecht, Netherlands; 2Amsterdam UMC,
Amsterdam, Netherlands; 3Leiden University Medical Centre, Leiden,
Netherlands; 4University Medical Center Utrecht, Utrecht, Netherlands
Background: Prognostic models can help clinicians make decisions
over whether to prescribe certain medications for individual patients.
For this purpose, models should estimate what a patient's outcome
risk would be if they were to remain unexposed to a certain treat-
ment. However, data used to develop prognostic models typically
include treated individuals and standard methods fail to account
for this.
Objectives: To compare methods for utilizing routinely collected infor-
mation on medication use in prognostic model development and
assess the benefits for risk prediction, using the prescription of selec-
tive β‐blockers (SBBs) in chronic obstructive pulmonary disease
(COPD) patients as a case study.
Methods: Clinical and prescription information on COPD patients were
identified from the Utrecht General Practitioners (UGP) database. We
compared 7 approaches to model time‐varying treatments: 1) ignoring
treatment, 2) excluding treated patients, 3) censoring treated patients,
4) inverse probability of treatment weighting after censoring (IPTW),
modeling treatment as a 5) binary or 6) time‐varying covariate and 7)
marginal structural modeling (MSM). First, directed acyclic graphs
(DAGS) were used to assess the theoretical properties of the different
approaches. Next, models to predict 5‐year mortality risk without SBB
use were developed in the UGP data using the 7 approaches. The abso-
lute risk predictions and overall performance (calibration slope, c‐statis-
tic, Brier score) of the models were compared.
Results: Based on DAGs, we found IPTW and MSMs have the best
theoretical properties, as they can account for the effects of treat-
ment and avoid selection bias. In our case study, 1906 patients were
included in the analysis and 325 received SBBs during follow‐up.
Compared to ignoring SBBs, approaches (2) and (5) provided predic-
tions that were 1% and 2% higher on average. Measures of model
performance varied minimally between approaches.
Conclusions: We found IPTW and MSMs are preferred in theory, but
found little difference between methods in our case study. Future
studies should consider using data on time‐varying medication use to
better model prognosis.
472 | Using the reverse waiting time
distribution with random index dates to
estimate prescription durations with seasonal
variation
Katrine Bødkergaard Nielsen1; Randi Marie Selmer2; Jesper Hallas3;
Lars Jøran Kjerpeseth2; Anton Pottegård3; Eva Skovlund2;
Henrik Støvring1
1Aarhus University, Aarhus, Denmark; 2Norwegian Institute of Public
Health, Oslo, Norway; 3University of Southern Denmark, Odense,
Denmark
Background: The reverse Waiting Time Distribution (rWTD) has been
shown to provide valid estimates of prescription durations expressed
as the time within which 80% of the current users have redeemed a
new prescription. The method considers each patient's time since last
prescription redemption before an index date. This index date must be
chosen independently of the individual redemption processes. This is,
however, violated if rates of prescription redemptions exhibit seasonal
variation and a fixed index date is used.
Objectives: To modify the rWTD to provide valid estimates of pre-
scription durations when redemption rates have seasonal variation.
Methods: We selected a one‐year sample window supplemented with
a preceding period of equal length. For each patient we uniformly
sampled a random index date within the sample window and identified
the last prescription, if any, within one year prior to the index date.
From this, we estimated prescription durations using the parametric
rWTD. We conducted a simulation study where we generated log‐
normal distributed prescription durations, but with a longer average
duration when filled within the last two months of the year. This mim-
icked a situation where patients stockpile medication at the end of the
year. We generated 2,500 datasets such that on average 15,000
patients had prescriptions each year, of whom 25% stopped treat-
ment. We analyzed the simulated datasets with the new method and
with the rWTD with fixed dates of Nov 1 and Jan 1 the subsequent
year. For each method, the data were analyzed using a single log‐nor-
mal distribution and we estimated the relative bias and coverage prob-
ability of nominal 95% confidence intervals. As a real‐world example,
we applied the methods to Norwegian data on prescription redemp-
tions of warfarin in 2014.
Results: In simulations, the method with random index dates had a
low relative bias (−0.1%) and retained nominal coverage (94.4%),
even though the model is misspecified due to prescription durations
originating from a mixture of two log‐normal distributions. Using
Nov 1 and Jan 1 the following year as index dates led to substantial
relative bias (<−5.1%) and coverage probabilities close to 0%. For
warfarin prescriptions in Norway 2014, the estimated duration was
130 (128; 131) days with random index dates and 122 (121; 123)
with index date Nov 1 2014 and 101 (100; 102) days with Jan 1
2015.
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Conclusions: In case of seasonal stockpiling the rWTD method with
fixed index dates yields biased estimates of prescription duration. This
bias can be mitigated using random index dates.
473 | Exploring longitudinal trajectories to
model paternal exposure in evaluating risk of
adverse outcomes in their offspring
Minna Vehkala1; Ruben Hermans2; Silvia Narduzzi2;
Deborah Layton2,3
1StatFINN, Espoo, Finland; 2 IQVIA, London, UK; 3University of Keele,
Keele, UK
Background: New analytical methods have been developed to enable
more precise descriptions of drug exposure during pregnancy and dis-
tinguish different profiles of exposure which may vary in their terato-
genic or long‐term health impact on the mother's offspring. Such
methods for evaluating drug exposure during the 3‐month spermato-
genic cycle of the father immediately prior to conception and corre-
sponding impact of exposure on the offspring has yet to be examined.
Objectives: To explore the feasibility of defining clusters of paternal
exposure to medicines prior to conception.
Methods: A dataset of 5000 males was simulated using posology of an
antiepileptic drug as the motivational example. Using this sample size a
hazard ratio of 2 should be detectable with 5% significance and 80%
power when the risk of the outcome in the reference group is 1%. Pre-
scription data were introduced using normal and uniform distributions
for each month for 3 months. Representing real‐world situations, 7
patterns of longitudinal drug exposure were created: constant use
(n = 440[0), start of use at month 2 (n = 100), start of use at month
3 (n = 100), end of use after month 1 (n = 100), end of use after month
2 (n = 100), increasing usage (n = 100) and decreasing usage (n = 100).
K‐means longitudinal clustering analysis (KmL) was then conducted to
determine homogeneuous exposure trajectories based on the monthly
cumulative dose and patterns of drug exposure. Calinski‐Harabasz cri-
terion values were used to evaluate the optimal number of clusters (1–
10). All analysis were conducted in R (kml package).
Results: Through conducting KmL, the optimal number of clusters in
which to partition men exposed during the 3 month pre‐conception
period was 7, each representing a unique trajectory of exposure: 3
levels of constant use (high n = 1130, intermediate n = 2070, low
n = 1350), start of use at month 2 (n = 96), start of use at month 3
(n = 104), end of use after month 1 (n = 127), and end of use after
month 2 (n = 121).
Conclusions: This simulation suggests that the application of KmL
cluster analysis can facilitate the description of paternal exposure
patterns over time. Specifically designed to deal with longitudinal
data, KmL shows its potential for investigating the relationship
between adverse outcomes in offspring of fathers exposed to med-
ications in the 3‐month period of highest risk pre‐conception. As
with most algorithmic clustering methods, KmL is mainly an explor-
atory technique and the determination of the optimal cluster number
still can be challenging. Sensibility assessment is therefore
recommended.
474 | Using machine learning algorithms to
predict medication initiations and
discontinuations
Hoa V. Le1; Chi Truong2
1PAREXEL International, Durham, NC; 2MedCodeWorld LLC, Chapel Hill,
NC
Background: Current treatments for chronic kidney disease (CKD)
focus on slowing disease progression but do not address the underly-
ing inflammation and cause of kidney disease. Mineralocorticoid
receptor antagonists (MRA) include spironolactone and eplerenone.
A new MRA may have some beneficial effect on CKD patients. There
was previously little information about treatment patterns, initiation
and discontinuation of MRA in CKD patients.
Objectives: To predict and determine factors associated with initiation
and discontinuation of MRA in CKD patients in the UK CPRD.
Methods: A retrospective cohort of CKD patients was created from
the CPRD GOLD dataset (Jan 2008‐Mar 2012) linked with Hospital
Episode Statistics and the Office of National Statistics for mortality.
Inclusions were age ≥ 18 years, CKD diagnosis, ≥1 year baseline his-
tory, and ≥ 2‐year follow‐up. The cohort was divided into a derivation
cohort (70%) and a validation cohort (30%). For all models, the set of
predictors included patient demographics, lifestyle factors, laboratory
tests, CKD stages, time from the first CKD diagnosis, co‐morbidities,
and co‐medications. Gradient Boosting Classifier (GBC), LASSO, and
Random Forest (RF) were used to predict and determine factors asso-
ciated with the risk of the initiation and discontinuation of MRA. Aver-
age (95% CI) AUC was used to evaluate the performance of the
methods.
Results: There were 11,053 CKD patients with diabetes with median
age of 72 (mean 70.4) years old. GBC and LASSO outperformed RF
in predicting MRA initiation, with an average AUC of 0.836 (95% CI:
0.835–0.838) and 0.843 (95% CI: 0.841–0.845) compared to 0.807
(95% CI: 0.805–0.809), respectively. Predictors that increase MRA ini-
tiation included longer CKD history, older age, A&E visits, and prior
use of ARB, CCB, BB, ACEI, and diuretics. Similarly, among 729 naïve
MRA users in CKD patients without diabetes, GBC and LASSO
outperformed RF in predicting MRA discontinuation, with an average
AUC of 0.743 (95% CI: 0.740–0.747) and, 0.741 (95% CI 0.738–
0.745) compared to 0.714 (95% CI: 0.710–0.718), respectively. Predic-
tors that increase the risk of MRA discontinuation included hyperlipid-
emia, hyperkalemia, dialysis, and A&E visits.
Conclusions: GBC and LASSO models performed better than the RF
model in term of AUC in predicting the risk of MRA initiation and dis-
continuation. Variables of importance for MRA initiation and discon-
tinuation were determined. These findings support the potential of
incorporating machine learning models into a study cohort to inform
treatment pattern, medication initiation and discontinuation.
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475 | Assessing differences in treatment
effects: Interactions with propensity score
splines
David J. Graham1; Jiemin Liao2; Elande Baro1; Rongmei Zhang1;
Michael Wernecke2; Yuqin Wei2; Mao Hu2; Sandia Akhtar2;
Thomas E. MaCurdy2; Jeffrey A. Kelman3; Frank E. Harrell4
1US Food and Drug Administration, Silver Spring, MD; 2Acumen LLC,
Burlingame, CA; 3Centers for Medicare & Medicaid Services, Washington,
DC; 4Vanderbilt University, Nashville, TN
Background: Assessing heterogeneity of treatment effects (TEs) is
important for regulatory decision‐making. A recent study compared
effectiveness and safety of three non‐vitamin K antagonist oral antico-
agulants (NOACs), and warfarin in Medicare patients with nonvalvular
atrial fibrillation. Subgroup analyses suggested that TEs may vary by
age, sex, and calendar year. Since 65% of warfarin users were
excluded via propensity score (PS) matching, the benefit–risk for those
patients similar to excluded warfarin users was unknown. We explored
using PS spline (nonlinear) regression models to adjust for con-
founders, while allowing valid estimation of TEs under limited PS over-
lap (in terms of relative frequencies), and assessed TE variation by
different values of PS.
Objectives: To investigate using PS splines to identify variation in TEs
in a study evaluating risk of major extracranial bleeding in beneficiaries
initiating a NOAC (apixaban, dabigatran, or rivaroxaban) vs. warfarin.
Methods: A multinomial regression model, including nearly 100
patient and provider characteristics, was used to estimate three PSs.
The logit of PSs was included in a Cox regression model as cubic
splines and interacted with treatment. We estimated hazard ratios
(HRs) and 95% confidence intervals (CIs) across values of the warfarin
propensity score (PSw). We added important covariate interactions
with treatment to the model to explore variation in TEs across
subpopulations.
Results: The PS spline model showed substantial variation in TEs
across PSw when comparing dabigatran vs. warfarin: HR = 0.78 (95%
CI 0.68–0.9) and HR = 1.77 (95% CI 1.47–2.13) when PSw was 0.5
and 0.9 respectively. This implies that dabigatran users had signifi-
cantly higher bleeding risk compared to warfarin if they had a higher
likelihood of receiving warfarin, and significantly lower bleeding risk
otherwise. When two‐way interactions of treatment with age spline
and sex were added to the model, the difference in TE across PS
values decreased: HR = 0.96 (95% CI 0.81–1.14) and HR = 1.39
(95% CI 1.10–1.74) when PSw was 0.5 and 0.9 respectively. A model
further interacting calendar year with treatment showed strong evi-
dence for TE variation by year.
Conclusions: Models with PS splines interacted with treatment offer
an alternative to other methods of confounding adjustment in sub-
group analyses for assessing variation in TE. This approach allows all
patients to be included in the model, including those with limited PS
overlap. Additionally, it allows one to easily assess whether any het-
erogeneity exists, by estimating TEs over different values of the PS.
476 | A challenge of real world data: How to
assign individuals to a treatment strategy
when their data are consistent with several
treatment strategies at baseline
Xabier Garcia de Albeniz1; John Hsu2; Miguel A. Hernan3
1RTI Health Solutions, Barcelona, Spain; 2Massachusetts General
Hospital, Boston, MA; 3Harvard T.H. Chan School of Public Health,
Boston, MA
Background: When using real world data to emulate a hypothetical
target trial, eligible individuals are assigned to a treatment strategy
at time zero (baseline). However, when the exposure strategy
involves timing, the information available at baseline may be insuffi-
cient to determine an individual's treatment strategy, that is, for
some individuals, the baseline data could be consistent with more
than one strategy. For example, in emulating a target trial of stop-
ping vs. continuing annual mammograms among elderly women,
many subjects have baseline data that could be consistent with
either strategy.
Objectives: To compare two approaches for the assignment of individ-
uals to treatment strategies at baseline: random assignment and
cloning.
Methods: The simplest way to allocate women to a screening strat-
egy when their data are consistent with both strategies is to ran-
domly choose at baseline one of the two strategies: “stop” or
“continue” screening. A second option is cloning the eligible women
and assigning one clone to each strategy. While both approaches are
unbiased, cloning is expected to be more efficient. However, the rel-
ative efficiency of the two approaches has not been studied in real
data. Under both approaches, we censored women when they
stopped following the assigned strategy (i.e., when receiving a
screening mammogram if assigned to “stop” and at month 14 after
the last mammogram if assigned to “continue”). We estimated the
breast cancer‐specific mortality hazard ratio for “continue” vs “stop”
screening using a pooled logistic regression that included the screen-
ing strategy, time and baseline covariates. To adjust for the potential
selection bias due to censoring, the model was inverse probability
weighted using weights that depended on baseline and time‐varying
variables.
Results: 1,235,459 eligible women aged 70–74 years received a
screening mammogram at baseline. Using the random assignment
approach, we randomly assigned half of the women to each strategy:
continue screening for 8 years vs. stop screening. The hazard ratio
(95% CI) of breast cancer mortality was 0.74 (0.57–0.96) for con-
tinuing vs. stopping screening. When we repeated the procedure
100 times, the hazard ratios varied from 0.62 (0.48–0.79) to 0.94
(0.72–1.22), with an average hazard ratio of 0.79. Using the cloning
approach, we created and assigned 1,235,459 clones to each strat-
egy and the corresponding hazard ratio was 0.78 (0.64–0.96).
Conclusions: Cloning individuals is more efficient than randomly
assigning them to strategies that have overlapping initial follow‐up.
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477 | Development and validation of
algorithms to estimate live birth gestational
age in Medicaid analytic extract data
Yanmin Zhu1; Thuy N. Thai1; Brian T. Bateman1,2;
Sonia Hernandez‐Diaz4; Jessica M. Franklin1; Loreen Straub1;
Almut G. Winterstein1; Kathryn J. Gray1; Yandong Qiang4; Wei Hua4;
Lockwood G. Taylor4; Krista F. Huybrechts1
1Brigham and Women's Hospital and Harvard Medical School, Boston,
MA; 2University of Florida, Gainesville, FL; 3Harvard T. H. Chan School of
Public Health, Boston, MA; 4United States Food and Drug Administration,
Silver Spring, MD
Background: While healthcare utilization data are a useful source for
post‐marketing surveillance of drug safety in pregnancy, the date of
last menstrual period is generally not recorded and has to be esti-
mated using diagnostic codes indicative of gestational age at birth
(GA). Well performing predictive algorithms (ALG) are available, but
none are specific to U.S. Medicaid Analytic eXtract (MAX).
Objectives: To develop and validate an ALG for estimating GA among
live births specific to the Medicaid insured population.
Methods: From the existing 1999–2010 MAX cohort linked to birth
certificates (BC) for Florida, Texas, and New Jersey, we identified
mothers with continuous Medicaid enrollment from ≥12 months prior
to delivery to 1 month post‐delivery and infants enrolled for
≥3 months after birth unless they died sooner. We used the clinical/
obstetric estimate of gestation on the BC as the gold standard. Four
different approaches to estimate GA were developed based on: ALG
1 ‐ preterm codes; ALG 2 ‐ pre−/post‐term codes; ALG 3 ‐ timing of
prenatal screening tests; ALG 4 ‐ prediction via multiple linear regres-
sion, LASSO regression and random forests, using pre‐specified pre-
dictors from ALG 1–3 plus additional predictors selected based on
clinical relevance or their prevalence and strength of association in
the dataset. ALG performance was assessed based on the mean
squared error (MSE) and the proportion of deliveries with estimated
GA within ±1 and 2 weeks of the BC GA in the full cohort and the sub-
set of preterm deliveries (10‐fold cross‐validated for ALG 4).
Results: We identified 114,117 eligible deliveries with a valid BC GA.
Among ALG 1–3, ALG 3 performed the worst (63.5% within 1 week,
80.7% within 2 weeks of BC GA), while ALG 2 had the highest agree-
ment (79.7% and 93.9% respectively). Estimated GA based on the mul-
tiple linear regression model of ALG 4 was within 1 week of the BC
GA for 84.0% of the deliveries and within 2 weeks for 96.1% (MSE:
1.5; R2: 0.6). LASSO regression performed similarly to the multiple lin-
ear regression model. Random forests including all 255 predictors per-
formed the best: 98.4% of estimated GA within 1 week and 99.6%
within 2 weeks of BC GA (MSE: 0.3, R2: 0.9). Of note, random forests
also performed the best for the subset of preterm deliveries (91.4%
within 1 week, 97.7% within 2 weeks, MSE: 1.0, R2: 0.9).
Conclusions: Using a random forests approach, we were able to
develop a highly accurate ALG for estimating GA among live births
in MAX, both for term and preterm infants. This algorithm performs
substantially better than existing validated algorithms based on GA
related diagnostic codes.
478 | Utility of prenatal tests to estimate
pregnancy start in sentinel
Lockwood G. Taylor1; Steven T. Bird1; Danijela Stojanovic1;
Sengwee Toh2; Elnara Fazio‐Eynullayeva2; Andrew Petrone2;
Jennifer G. Lyons2
1U.S. Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School, Boston, MA
Background: Pregnancy start among live births can be accurately esti-
mated using gestational age‐specific ICD‐CM codes. The general
absence of this information for non‐live birth outcomes in electronic
healthcare data often precludes evaluation of medications potentially
associated with these outcomes. Algorithms using prenatal tests rou-
tinely performed during specific gestational windows may provide a
proxy for pregnancy start in the absence of gestational age
information.
Objectives: To evaluate whether the performance of algorithms based
on combinations of prenatal tests can accurately estimate pregnancy
start in the Sentinel live birth pregnancy cohort.
Methods: Using ICD‐9‐CM and ICD‐10‐CM codes we selected 16
prenatal tests and procedures clinically recommended within specific
windows of gestation. A reference estimate of gestational age and
pregnancy start was assigned to each live birth pregnancy based on
a previously validated algorithm. We then assessed the prevalence
of each prenatal test and the distribution of the timing of gestational
age at each test. The proportion of tests that occurred within two
weeks of the most common gestational day for each test based on
the distribution (i.e., sensitivity within the two‐week window) was cal-
culated. Tests were added stepwise to 3 algorithms in order of perfor-
mance within the two‐week window. For each algorithm, we
calculated 1) the proportion of pregnancies with ≥1 test in the algo-
rithm and 2) the mean difference between the reference pregnancy
start estimate and the algorithm‐based pregnancy start estimate.
Results: In over 4.7 million live birth pregnancies, the sensitivity of
each test ranged from 20.9% (1st trimester ultrasound) to 90.6%
(nuchal translucency). Our final algorithms included 12 tests with
>50% sensitivity within the two‐week window. When adding these
tests stepwise in order of performance, algorithm 1 included 6 tests,
each of which had a sensitivity of ≥80%. Most (81.9%) of live birth
pregnancies had at least one of these tests. The mean (median) differ-
ence between the reference‐ and test‐based pregnancy start was
−5.5 days (0 days). Algorithms 2 and 3, based on sensitivity cut‐off
points of ≥70% and ≥ 60%, respectively, included 87.6% and 97.9%
of pregnancies with mean differences of −4.4 days (0 days)
and − 3.7 days (0 days), respectively.
Conclusions: In a population of primarily commercially‐insured preg-
nant women, certain prenatal tests implemented according to our
algorithms can accurately identify pregnancy start. These results may
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be particularly useful for non‐live birth outcomes, for which algorithm
validation is underway.
479 | Estimation of the beginning of
pregnancies ending in stillbirths
Tania Schink1; Ulrike Haug1,2
1Leibniz Institute for Prevention Research and Epidemiology ‐ BIPS,
Bremen, Germany; 2University of Bremen, Bremen, Germany
Background: In studies based on claims data, the beginning of
pregnancy is usually estimated by subtracting a median length
of pregnancy from the date of birth. Due to the variability in
pregnancy lengths, this results in non‐negligible errors, especially
in stillbirths where the individual pregnancy lengths typically have
a high variability. It has been shown that he expected delivery
date (EDD), which can be coded in German claims data, allows
to reliably estimate the beginning of pregnancy for live births.
Objectives: To assess the whether the EDD can be used to
reliably estimate the beginning of pregnancy in stillbirths by examin-
ing the availability, consistency and plausibility of the EDD informa-
tion in the German Pharmacoepidemiological Research Database
(GePaRD).
Methods: We included data of all pregnancies in GePaRD ending in
a stillbirth between 2006 and 2015 in women of childbearing age
(12–50 years). For each pregnancy, we searched for EDDs coded
in the three quarters before and in the quarter of the end of preg-
nancy. We determined the number of EDDs coded per
pregnancy and their concordance if more than two EDDs were
coded. For the assessment of consistency, we also examined the
differences between discordant EDDs. The beginning of pregnancy
was estimated by subtracting 280 days from the EDD or from the
most frequently coded EDD (if ≥2 discordant EDD). To assess
the plausibility of the EDD, we examined the resulting length of
pregnancy and assessed whether the gestational age at which prena-
tal examinations were coded was plausible.
Results: We identified 3,333 pregnancies ending in a stillbirth (about
0.3% of all pregnancies). In 82% of these pregnancies at least on
EDD was available. In most of these pregnancies (70%) two or
more EDDs which were all concordant were coded, in 14%
only one EDD was identified and in 16% ≥ 2 EDDs which were
not all concordant were identified. The maximal difference between
discordant EDDs was in median 6 days (25%–75%: 3–11 days). The
median length of pregnancy was 224 days (25%–75%: 179–264,
5%–95%: 154–282) and the timing of prenatal examinations was
plausible.
Conclusions: A key prerequisite for studies on the safety of drugs
during pregnancy is the correct assessment of drug exposure in
vulnerable gestational windows. By using the EDD, the beginning of
pregnancy and thus gestational age at exposure can plausibly be esti-
mated in more than 80% of stillbirths.
480 | Validation of ICD‐9‐CM coding
algorithms to identify non‐live birth outcomes
in an automated database
Yanmin Zhu1; Kathryn Gray1; Brian T. Bateman1;
Sonia Hernandez‐Diaz2; Loreen Straub1; Rebecca M. Reimers1;
Beryl Manning‐Geist1; Elizabeth Yoselevsky1; Yandong Qiang3;
Lockwood G. Taylor; Wei Hua3; Krista Huybrechts1
1Brigham and Women's Hospital and Harvard Medical School, Boston,
MA; 2Harvard T. H. Chan School of Public Health, Boston, MA; 3United
States Food and Drug Administration, Silver Spring, MD
Background: Observational studies using automated databases, such as
the Medicaid Analytic eXtract, play a major role in generating evidence
on drug safety in pregnancy. Such studies are often restricted to live
births, mainly due to lack of established algorithms to identify non‐live
births.
Objectives: To develop and validate ICD‐9‐CM coding algorithms for
the ascertainment of stillbirth, spontaneous abortion (SAB) and termina-
tion in healthcare utilization databases.
Methods: Weused the Partners Research Patient Data Registry (RPDR)
2000–2014, a registry of electronic medical record data for patients
receiving care at a Partners affiliated hospital in Boston, to assemble a
cohort of women enrolled in Medicaid with a non‐live birth outcome.
We identified 1) stillbirths based on ≥1 inpatient ICD‐9 diagnosis (Dx)
codes 656.4x, V27.1, V27.4 or V27.7; 2) SAB based on ≥1 inpatient/
≥ 2 outpatient Dx codes 632.xx, 634.xx, 637.xx or CPT4 procedure
(Px) codes 01965, 59812, 59820–1, or 59830; 3) terminations based
on ≥1 inpatient/ ≥ 2 outpatient Dx codes 635.xx, 636.xx, 779.6x or
CPT4 Px codes 01966, 59840–1, 59850–1, 59852, 59855–7, 59866
or ICD‐9 Px codes 69.01, 69.51, 74.91, 75.0x. We randomly sampled
100 cases each for validation. In sensitivity analyses, we 1) excluded
cases with codes for other live/non‐live birth outcomes within ±5 days
of the outcome of interest, and 2) relaxed the definitions for SAB and
termination by allowing cases with 1 outpatient diagnosis only. Cases
were adjudicated based onmedical chart review.Weestimated the pos-
itive predictive value (PPV) for each non‐livebirth outcome and for the
composite of any non‐livebirth outcome. Validated algorithms will be
converted to ICD‐10.
Results: The PPV was 71.0% (95% CI, 61.1–79.6) for stillbirths; 79.0%
(69.7–86.5) for SABs, and 93% (86.1–97.1) for terminations. When
excluding cases with adjacent codes for other birth outcomes, the
PPV increased to 80.6% (69.5–88.9) for stillbirth, 86.4% (75.0–94.0)
for SAB and 97.7% (91.8–99.7) for termination. Relaxing the definition
while removing cases with adjacent codes did not affect the PPV sub-
stantially: 86.6% (80.5–91.3) for SAB and 94.9% (91.1–97.4) for termi-
nation. For the composite outcome, the PPV was 94.4% (92.3–96.1).
Conclusions: Algorithms for all three non‐live birth outcomes using
ICD‐9 codes had high PPVs, suggesting these outcomes can be validly
identified and studied in healthcare utilization databases. The improve-
ment in performance after excluding cases with adjacent codes for
other birth outcomes highlights the need for hierarchical algorithms to
distinguish specific birth outcomes.
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481 | Immortal time bias in comparative drug
safety studies in pregnancy
Kristian B. Filion1,2; Colin Dormuth3; Pauline Reynier2;
J. Michael Paterson4; Robert W. Platt1; Samy Suissa1,2
1McGill University, Montreal, QC, Canada; 2Lady Davis Institute, Jewish
General Hospital, Montreal, QC, Canada; 3University of British Columbia,
Victoria, BC, Canada; 4 ICES, Toronto, ON, Canada
Background: The presence and consequences of immortal time bias in
drug safety studies of pregnant women remains poorly understood,
particularly in the presence of an active comparator.
Objectives: To describe the occurrence of immortal time bias
in studies examining the comparative safety of prescription
drugs during pregnancy and its impact on estimated treatment
effects.
Methods: We identified a retrospective cohort of pregnant women
using the Pregnancy Register of the Clinical Practice Research
Datalink (CPRD) as part of a Canadian Network for Observational
Drug Effect Studies (CNODES) distributed protocol study that
included seven databases. We examined the risk of fetal death,
defined as a composite of spontaneous abortion or stillbirth, for: 1)
ondansetron versus other antiemetics; and 2) fluconazole versus
other antifungals. Inclusion in the study cohorts was restricted to
pregnancies involving women who received the exposure or compar-
ator of interest during the pregnancy. Treatment effects were esti-
mated using time‐fixed and time‐dependent Cox proportional
hazards models, both adjusted using high‐dimensional propensity
scores.
Results: The ondansetron cohort (n = 10,460) included 862 fetal
deaths, and the fluconazole cohort (n = 42,165) included 2,153 fetal
deaths. The median gestational age at the time of first exposure was
85 days (interquartile range: 67, 108) for ondansetron and 70 days
(interquartile range: 54, 100) for other antiemetics. In contrast, the
median gestational age at the time of first exposure was 34 days
(interquartile range: 17, 82) for fluconazole and 160 days (interquar-
tile range: 96, 217) for other antifungals. Compared with the use of
other antiemetics, the hazard ratio (HR) of fetal death with
ondansetron was 0.68 (95% CI 0.47, 0.98) when using a time‐fixed
model and 0.99 (95% CI 0.68, 1.43) when using a time‐dependent
approach. Compared with other antifungals, the HR of fetal death
with fluconazole was 5.25 (95% CI 4.67, 5.89) when using a time‐
fixed model and 1.75 (95% CI 1.56, 1.97) when using a time‐depen-
dent approach. We observed similar differences between time‐fixed
and time‐dependent models in analyses conducted in the pregnancy
cohorts across other CNODES sites.
Conclusions: The use of time‐fixed exposure definitions can result in
substantial bias in comparative safety studies in pregnancy. Impor-
tantly, this bias can go in either direction in the presence of an
active comparator, depending on the relative timing of the study
drugs. The use of a time‐dependent approach is essential to ensure
validity.
482 | Comparing the use of propensity and
disease risk scores in signal detection for
prematurity on medico‐administrative
database
Romain Demailly1,2; Sylvie Escolano1; Françoise Haramburu3;
Pascale Tubert‐Bitter1; Ismaïl Ahmed1
1 INSERM, Villejuif, France; 2Lille Catholic University, Lille, France;
3Regional Pharmacovigilance Center, Bordeaux, France
Background: Pregnant women are often excluded from clinical tri-
als despite their need to use drugs. So, there is a lack of informa-
tion of drugs adverse effects during pregnancy. Administrative
databases are a promising tool for post‐market surveillance in this
population and confounder summary scores can improve signal
detection.
Objectives: To evaluate signal detection performance for drug
induced prematurity and compare strengths and limits of pro-
pensity and disease risk scores using several ways to build
them.
Methods: Using the French national health insurance database, we
included all pregnancies identified by ICD‐10 codes in the hospital-
ization database, lasting more than 24 weeks of amenorrhea and
whose delivery occurred between 01/01/2019 and 12/31/2016.
Scores were calculated on delivered drugs according to trimester
of pregnancy and on associated diseases occurring during the study
period by two methods: cross validated lasso logistic regression and
cross validated extreme gradient boosting. Effect of variable prese-
lection algorithm was studied. Scores were used through adjusting,
1:1 matching and weighting. Score computation times and predic-
tion AUCs were analyzed. Signal detection pertinence was evalu-
ated through Pubmed literature review and a pharmacovigilant
expertise.
Results: Computation times of the disease risk score were lower
than the propensity score whose computation times depended
heavily of the exposure prevalence. Disease risk score AUCs were
more homogeneous than propensity score AUCs but the latter
reached greater values for certain drugs. Boosting took 1.5 to 10
times longer computation time than lasso, especially when the num-
ber of initial variables increased. Regarding signal detection, adjust-
ment allowed the best detection performance especially when
coupled with boosting. False positive signals due to indication bias
were reduced and certain classes such as antivirals and antidepres-
sants appeared particularly at risk in our analysis.
Conclusions: High dimensional preselection algorithm is an effective
way to reduce computation time without loss of performance and
detection rate. Disease risk scores for the exploration of many drugs
with different levels of exposure allow a better stability than pro-
pensity scores. Adjusted analysis with boosting disease risk scores
leads us to think that some classes of drugs such as antivirals and
antidepressants should be further investigated for their risk of
prematurity.
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483 | Pneumococcal vaccine safety
surveillance using three statistical methods:
Disproportionality analysis, tree‐based scan
statistics, and empirical Bayes geometric
mean
Hyesung Lee; Ju Hwan Kim; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Republic of
Korea
Background: Concerns on the safety profile of pneumococcal vaccine
(PV) have been raised due to increased spontaneous adverse event
(AE) reports over the recent years in South Korea. Empirical Bayes
geometric mean (EBGM) and tree‐based scan statistics were intro-
duced newly in local AE database to generate safety signals compared
with disproportionality analysis.
Objectives: To identify safety signals after pneumococcal vaccination
using disproportionality analysis, tree‐based scan statistics, and
EBGM, and to compare detected signals across statistical methods
to confirm the consistency of results.
Methods: We conducted a vaccine safety surveillance study by
applying the three statistical methods in the Korea Institute of Drug
Safety & Risk Management‐Korea adverse event reporting system
database (KIDS‐KD) between 1989 and 2017. The following statisti-
cal methods were used for signal detection: disproportional analysis
using proportional reporting ratio, reporting odds ratio and informa-
tion component simultaneously; EBGM using the lower bound of
the 90% posterior probability interval; tree‐based scan statistics at
a significance level of 0.05. We repeated signal detection for pneu-
mococcal polysaccharide vaccine (PPSV) and pneumococcal conju-
gate vaccine (PCV) to identify the difference among the subtypes
of PV.
Results: A total of 20,156 spontaneous reports were related to any
vaccine, and 1,272 spontaneous reports were related to PV. We iden-
tified 111 AE‐pairs, and signals detected by disproportionality analysis,
tree‐based scan statistics, and EBGM were 21 (18.9%), 14 (12.6%),
and 11 (9.9%), respectively. Only six signals (5.4%) were simulta-
neously detected by three statistical methods: fever (369); injection
site discharge (218); cellulitis (52); oedema (19); injection site inflam-
mation (14); angioedema (12). We identified 79 and 77 AE‐pairs from
PPSV and PCV, and different number of signals were detected by the
three methods, respectively: PPSV (13 (16.5%), 14 (17.7%), 7 (8.9%));
PCV (14 (18.2%), 5 (6.5%), 3 (3.9%)). Cellulitis was the only AE
detected simultaneously from PPSV and PCV by all statistical
methods.
Conclusions: Discrepancy in the detected signals were observed
among the three statistical methods. Compared to disproportionality
analysis, EBGM generated the least signals, and tree‐based scan statis-
tics generated either less or equal number of signals; both seems to
calibrate noise. Nonetheless, the difference of results should be
interpreted with caution due to lack of gold standard of signal
detection.
484 | Early season self‐controlled risk
interval analyses of Guillain‐Barré syndrome
risk following influenza vaccination using
claims delay adjustment
Mao Hu1; Silvia Perez‐Vilar2; Michael Wernecke1; Deepa Arya2;
Jeffrey Kelman3; Steve Chu3; Tom MaCurdy4,1; Richard Forshee2
1Acumen, LLC, Burlingame, CA; 2Center for Biologics Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, MD; 3Centers
for Medicare & Medicaid Services, Washington, DC; 4Stanford University,
Stanford, CA
Background: The U.S. Food and Drug Administration monitors the risk
of Guillain‐Barré syndrome (GBS) following influenza vaccination using
a multilayered approach. This includes end‐of‐season self‐controlled
risk interval (SCRI) analyses to compare GBS rates in post‐vaccination
risk windows (days 8–21 and 1–42) with the rate in a control window
(days 43–84), using Medicare claims data. However, due to the delay
in the observation of GBS hospitalized cases, results from these end‐
of‐season analyses are often not available in time to inform decisions
regarding next season's vaccinations.
Objectives: Develop and assess the performance of a methodology to
conduct SCRI analyses to evaluate the GBS risk following influenza
vaccination earlier in the season, accounting for the differential delay
in claims between risk and control windows.
Methods: We conducted a simulation study using SCRI methods. We
used claims data of beneficiaries enrolled inMedicare Parts A andB dur-
ing the 2017–18 influenza season to identify influenza vaccinations and
reported GBS hospitalized cases. To account for claims delay, we esti-
mated the probability of observing a case using historical data and used
it to adjust the follow‐up time in the offset term of the conditional logis-
tic model. We simulated seven scenarios varying the surveillance
assessment between weeks 15 and 25. For each scenario we ran three
SCRI models, one with claims delay adjustment, one without adjust-
ment, and one with end‐of‐season data. We compared the difference
in the log odds‐ratio estimates from the models versus the true value
used in the simulation (bias), as well as the variance and coverage.
Results: By surveillance week 20 (by December 29, 2017), the average
bias of the log odds‐ratio for the adjusted SCRI model was 0.014,
~95% less than the bias for the unadjusted model (0.286). The vari-
ance of the log odds‐ratios were comparable (0.111 vs 0.108) and
the coverage of the 95% confidence interval with adjustment was
96% versus 87% without adjustment. The SCRI adjusted model had
comparable performance to the model using end‐of‐season data by
week 20.
Conclusions: Our results suggest that, in an SCRI analysis using claims
data, the delay in observation of GBS cases may be controlled for
without substantially increasing bias or variance. This adjustment, if
used during the past season, would have allowed us to obtain risk esti-
mates 20 weeks earlier than an end‐of‐season analysis. This approach
may provide reliable and timely interim analysis results to support reg-
ulatory decisions for future seasons.
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485 | Comparative effectiveness of high‐
dose versus standard‐dose influenza vaccine
among patients on chronic hemodialysis
Anne M. Butler1; J. Bradley Layton2; Vikas R. Dharnidharka1;
John M. Sahrmann1; David J. Weber3; Leah J. McGrath4
1Washington University School of Medicine, St. Louis, MO; 2RTI
International, Research Triangle Park, NC; 3University of North Carolina,
Chapel Hill, NC; 4Novisci, Durham, NC
Background: The standard‐dose influenza vaccine (SDV) may not pre-
vent influenza‐related outcomes in patients on chronic dialysis. Little
is known about the comparative effectiveness of high‐dose influenza
vaccine (HDV) versus SDV in this population.
Objectives: To compare the risk of all‐cause mortality, hospitaliza-
tion due to influenza or pneumonia, and influenza‐like illness dur-
ing the influenza season among adult recipients of HDV versus
SDV.
Methods: We performed a cohort study using Medicare data from
the United States Renal Data System (USRDS) for patients with
end‐stage renal disease (ESRD). We constructed yearly cohorts of
adults with ESRD undergoing in‐center hemodialysis during five indi-
vidual influenza seasons (2010/11 to 2014/15). We required vacci-
nation to occur prior to the start of each influenza season.
Baseline covariates were ascertained during the 6‐month period
prior to vaccination. Follow‐up began at the start of influenza sea-
son. Patients were eligible for inclusion in multiple yearly cohorts,
thus our unit of analysis was the influenza‐season. To examine the
relationship between vaccine dose and effectiveness outcomes, we
estimated risk differences (RD) using propensity score weighting of
Kaplan–Meier functions, accounting for a wide range of patient‐
and facility‐level characteristics. For non‐mortality outcomes, we
used competing risk methodology to account for high mortality in
the dialysis population. Patients were censored at the earliest of a
competing risk event (death for non‐mortality outcomes), loss of
Medicare Parts A or B, kidney transplant, peritoneal dialysis, subse-
quent influenza vaccine, or end of influenza season. The primary
analysis was conducted in adults aged ≥65 years, and a secondary
analysis was conducted in adults aged <65 years.
Results:We identified 255,281 eligible adult patients who contributed
507,552 unique patient‐seasons. Within 225,215 patient‐seasons
among adults aged ≥65 years, 97.4% received SDV and 2.6% received
HDV. We observed similar risk estimates for HDV and SDV recipients
for mortality (RD, −0.1%; 95% CI, −0.9% to 0.8%), hospitalization due
to influenza or pneumonia (RD, 0.2%; 95% CI, −0.7% to 0.9%), and
influenza‐like illness (RD, 0.0%; 95% CI, −1.5% to 1.1%). Our findings
were similar among adults aged <65, as well as within subgroups
defined by influenza season, age group, years on dialysis, month of
vaccination, and vaccine valence.
Conclusions: HDV does not appear to provide additional protection
beyond the SDV against all‐cause mortality or influenza‐related out-
comes in the adult dialysis population.
486 | Effect of age on relative effectiveness
of high‐dose versus standard‐dose influenza
vaccines among US Medicare beneficiaries
ages 65 years and older
Yun Lu1; Yoganand Chillarige2; Hector Izurieta1; Yuqin Wei2;
Wenjie Xu2; Michael Lu2; Heng‐Meng Sung2; Arnstein Lindaas2;
Michael Wernecke2; Thomas MaCurdy2,3; Jeffrey Kelman4;
Richard A. Forshee1
1Food and Drug Administration, Silver Spring, MD; 2Acumen LLC,
Burlingame, CA; 3Stanford University, Stanford, CA; 4Centers for
Medicare and Medicaid Services, Washington DC, DC
Background: Influenza causes substantial morbidity and mortality, and
influenza‐related hospitalization and death disproportionately affects
older adults. Several studies have found that the high‐dose (HD) influ-
enza vaccine has higher relative vaccine effectiveness (RVE) compared
to standard‐dose (SD) vaccines in some seasons.
Objectives: This multi‐season study investigates effect modification
by age on the RVE of HD versus SD influenza vaccines among Medi-
care beneficiaries ≥65 years.
Methods: This retrospective six‐season cohort study from August
2012 to August 2018 using Medicare claims and enrollment data
included beneficiaries ≥65 years of age who received inactivated
HD or a SD influenza vaccine in a community pharmacy setting prior
to January 31st of an influenza season. The primary outcome was
influenza hospital encounters, defined by inpatient hospitalizations
or emergency department visits listing an influenza code. Linear func-
tion and cubic splines of continuous age were used to explore linear
and non‐linear relationships. We used a series of Poisson regression
models interacting age with vaccine status to evaluate the effect of
age on the RVE of HD versus SD influenza vaccines.
Results: A total of 35,156,602 (42%) HD and 47,760,909 (58%) SD
influenza vaccinations were recorded in our study period (HD/SD
ratio increased over time). After applying inclusion criteria, there were
13,770,207 (69%) HD and 6,151,913 (31%) SD vaccinations from eli-
gible Medicare beneficiaries. The RVE estimates indicate that the HD
vaccine was at least as effective as SD vaccines in preventing influ-
enza hospital encounters across all seasons, and was more effective
in the 2012–13 (RVE 23.1%, 95% CI 17.7–28.3%), 2013–14 (RVE
15.3%, 95% CI 7.8–22.3%), 2014–15 (RVE 8.9%, 95% CI 5.6–12.1%),
and 2016–17 (RVE 12.6%, 95% CI 6.3–18.4%) seasons. We found a
slightly increasing trend in RVE for HD versus SD vaccines with age
in all seasons. The cubic spline model, which fit the data best, indi-
cated notable improvement in RVE among those ages ≥80 years.
For example, the predicted RVE increased from 4.8% (95% CI ‐10.9‐
18.2%) among 65‐year‐old beneficiaries to 15.0% (95% CI 8.3–
21.2%) among 85‐year‐old beneficiaries in the 2016–17 season. We
also found that the HD vaccine was consistently more effective than
SD vaccines for people ages ≥85 years across all seasons.
Conclusions: This six‐season study showed that RVE of the HD versus
SD influenza vaccines increased slightly with age across seasons, and
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that the HD vaccine was consistently more effective for people ages
≥85 years.
487 | Risk of pneumonia after varicella
vaccination
Chia‐Hung Liu1,2; Yi‐Chen Juan3; Yen‐Yum Yang3; Yi‐Chun Yeh4;
Wan‐Ting Huang5; K. Arnold Chan3
1Graduate Institute of Epidemiology and Preventive Medicine, College of
Public Health, National Taiwan University, Taipei, Taiwan; 2Department
of Family Medicine, Shuang Ho Hospital, Taipei Medical University, New
Taipei city, Taiwan; 3Health Data Research Center, National Taiwan
University, Taipei, Taiwan; 4Department of Medical Research, National
Taiwan University Hospital, Taipei, Taiwan; 5Taiwan Centers for Disease
Control, Ministry of Health and Welfare, Taipei, Taiwan
Background: Post‐marketing surveillance data suggested that live
attenuated varicella vaccine may be associated with post‐vaccination
pneumonia.
Objectives: To exam the risk of pneumonia after administration of var-
icella vaccine.
Methods: This nationwide study was based on linkage of the Taiwan
National Health Insurance data and National Immunization Informa-
tion System from January 2004 through September 2014. Since Janu-
ary 2004, varicella vaccination has been included in public vaccination
program for all children older than 12 months and born after 2003.
The study population was 12‐ to 35‐month old children who received
varicella vaccine, excluding those were coadministered with other vac-
cines on the same day. Exposure date was the day of varicella vaccine
administration. Incident pneumonia was defined as patients with rele-
vant ICD‐9‐CM diagnosis codes for hospitalization (052.1, 480.8,
480.9, 483.8, or 485) without the same diagnosis during the previous
14 days. The distribution of incident pneumonia was evaluated
through 84 days after vaccination. We conducted a self‐controlled risk
interval analysis with a risk period for pneumonia incidence in 1 to
42 days after vaccination, and a reference period in 43 to 84 days
for the same individual. Incidence rate ratio (IRR) of pneumonia was
evaluated by conditional Poisson regression with adjustment of age
(13–24, 25–36 month) and seasonal (1–3, 4–6, 7–9, 10–12 month)
effects. The risk for fractures (ICD 800–829), which were unlikely to
be associated with varicella vaccination, was also assessed as a nega-
tive control. Sensitivity analysis was performed with different condi-
tions: excluding patients having the same diagnosis 28 days before
outcome of interest, first‐ever diagnosis, and a risk period of 8–42 days
postvaccination.
Results: Of the 2,263,242 varicella vaccinees during study period,
1,194,189 (59.9%) were eligible for study cohort and 10,188 incident
pneumonia episodes were observed 1–84 days after vaccination. The
numbers of events were evenly distributed within 84 days, except in
the first week, when fewer cases occurred. The crude IRR of pneumo-
nia during 1–42 days was 0.94 (95% confidence interval (CI), 0.90 to
0.97), and the adjusted IRR was 0.97 (95% CI, 0.93 to 1.01). For the
negative control, fractures, no association was observed with varicella
vaccine (adjusted IRR: fracture 1.06 (95%CI, 0.79 to 1.41)), as
expected. Sensitivity analysis of different scenarios showed similar
results.
Conclusions: Our study showed no increased risk of pneumonia fol-
lowing varicella vaccination.
488 | No increased risk of Kawasaki disease
among young children in 28 days after PCV13
vaccination
Meghan A. Baker1; Bethany Baer2; Martin Kulldorff3;
Lauren Zichittella1; Rebecca Reindel2; Sandra DeLuccia1;
Hana Lipowicz1; Katherine Freitas1; Robert Jin1; W. Katherine Yih1
1Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA; 2Food and Drug Administration, Silver Spring, MD; 3Harvard
Medical School and Brigham and Women's Hospital, Boston, MA
Background: The US Vaccine Safety Datalink compared the risk of
Kawasaki disease within 28 days of 13‐valent pneumococcal conju-
gate (PCV13) vaccination with the historical risk after 7‐valent PCV
vaccination, using chart‐validation. A relative risk of 2.38 (95% CI:
0.92, 6.38) was found. Concurrently, a post‐licensure safety review
by the US Food and Drug Administration identified cases of Kawasaki
disease after PCV13 through adverse event reporting.
Objectives: To assess the existence and magnitude of any increased
risk of Kawasaki disease in the 28 days after PCV13 vaccination.
Methods: The study population was children 0–23.99 months old
from participating Sentinel data partners in 2010–2015. PCV13 vacci-
nations were identified in claims data by CPT, HCPCS, and NDC
codes. Potential cases of Kawasaki disease were identified by ICD‐9
code 446.1 or ICD‐10 code M30.3 in the inpatient setting. Medical
records were sought for potential cases and adjudicated by board‐cer-
tified pediatricians. The primary analysis used chart‐confirmed cases in
a self‐controlled risk interval (SCRI) design, which controls for time‐
invariant potential confounders. The pre‐specified risk interval was
Days 1–28 after vaccination; a 28‐day‐long control interval followed.
The varying background risk by age was adjusted for in logistic regres-
sion using offset terms obtained by modeling the risk of Kawasaki dis-
ease by age in 2009 hospitalization data from the Healthcare Cost and
Utilization Project. Sensitivity SCRI analyses without age adjustment,
with possible cases included, and with alternative control intervals
were conducted. A secondary analytic approach used a cohort design
and Poisson regression, with alternative risk intervals of Days 1–28
and 1–42 and age adjustment based on the study population. Tempo-
ral scan statistics were used to look for clustering of onsets during
Days 1–56.
Results: In the primary analysis, there were 43 confirmed cases of
Kawasaki disease in the risk interval and 44 in the control interval.
The age‐adjusted risk estimate was 1.07 (95% CI: 0.70, 1.63). The
results of all secondary and sensitivity analyses were also null. Tempo-
ral scan statistics found no statistically significant clustering of cases.
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Conclusions: With more than 6 million doses of PCV13 administered,
no evidence was found of an association between PCV13 vaccination
and Kawasaki disease onset in the 4 weeks after vaccination nor of an
elevated risk extending or concentrated beyond 4 weeks. These null
results were consistent across alternative designs, age‐adjustment
methods, control intervals, and categories of Kawasaki disease case
included.
489 | Reaplicating clinical trial data using
RWD
Kai‐Li Liaw1; David Martin2; Jessica Franklin3; Miriam Sturkenboom4;
Solomon Iyasu1
1Merck Research Laboratories, North, UK, PA; 2FDA, Potomac, MD;
3Harvard University, Boston, MA; 4University Medical Center Utrecht,
Utrecht, Netherlands
Background: As part of the FDA's efforts to lay the groundwork for
using RWE on product effectiveness and safety to support regula-
tory approval for new or expanded indications, several demonstra-
tion projects were initiated to assess the feasibility, utility and
methodological challenges of replicating clinical trial results using
real‐world data (RWD) stemming from claims and electronic health
records. The idea is to first demonstrate the validity of the use of
RWD analysis techniques by replicating clinical trial results that
were already known; then the evidence on the utility of these tech-
niques can be expanded for RWD usage to predict clinical trial
results or to serve as an external control arm for single arm trials.
In addition to the FDA project, several demonstration projects by
other sponsors also have been presented and showed promising
results. This symposium is intended to have focused presentations
and panel discussion with panel members who have been contribut-
ing in the various initiatives in this area to provide updates on their
projects and insights gained from the work so far. In addition, the
regulatory implications of these findings and insights will be
discussed.
Objectives: 1. To provide an overview of completed and ongo-
ing projects replicating clinical trial results using RWD a. To dis-
cuss the methodologies that were used in the various projects
b. To identify important considerations for control of bias and
confounding when conducting such analyses 2. To provide
insights on the potential applications of the methodologies
and learnings from the various projects for regulatory submis-
sions using RWE a. From regulator's perspective b. From
researcher's perspective.
Description: The symposium will start with a brief introduction of
the background and objectives of the symposium (Solomon Iyasu,
5 minutes). An overview of the landscape, updates of the demon-
stration projects and regulatory applications will be provided (David
Martin, 20 minutes). The findings of the demonstration projects will
be discussed (Jessica Franklin, 20 minutes). Methodologic and study
design considerations will be discussed (Miriam Sturkenboom,
20 minutes). Panel discussion (all, 20 minutes) and a brief conclu-
sion will then follow (Solomon Iyasu and Kai‐Li Liaw, 5 minutes).
490 | Data diversity in multi‐database
Pharmacoepidemiologic studies and its role in
outcome misclassification: A curse or a
blessing?
Rosa Gini1; Stephan Lanes2; Kaat Bollaerts3; Gianluca Trifirò4;
Ursula Kirchmayer5; Gillian C. Hall6
1Agenzia regionale di sanità della Toscana, Florence, Italy; 2HealthCore
Inc, Wilmington, DE; 3P95 epidemiology and pharmacovigilance, Leuven,
Belgium; 4Università di Messina, Messina, Italy; 5Dipartimento di
Epidemiologia del Servizio Sanitario Regionale del Lazio, Rome, Italy;
6Gillian Hall Epidemiology Ltd, London, UK
Background: Pharmacoepidemiologic studies can be conducted on
multiple data sources, which may be profoundly heterogeneous. This
may cause different levels of outcome misclassification. Misclassifi-
cation can be burdensome to quantify so is often neither measured
nor accounted for, as was shown by a review of outcome misclassi-
fication in published studies conducted by the ISPE Database SIG
(DB SIG).
Objectives: To highlight issues of resource diversity and outcome
misclassification and to describe and demonstrate how this diversity
can be leveraged to estimate misclassification in the absence of a
gold standard and to correct the point estimate.
Description: The session will be chaired by two coauthors and fea-
ture the following topics and presenters, followed by discussion. (a)
Highlight diversity between databases used in
Pharmacoepidemiology research including those generated in North
America, Europe, Australia and Asia, with a focus on diversity in out-
come recording and ascertainment (b) Review the literature on bias
from outcome misclassification, and on methodologies to address
this bias using estimates of positive predictive value (PPV) and sen-
sitivity (SE), with a focus on the meaning and consequences of dif-
ferential misclassification(c) Describe a novel methodology to
quantify outcome misclassification bringing together a) and b). By
simultaneously using multiple data sources, and leveraging on their
diversity, the method incorporates existing validation studies to
allow estimation of PPV and SE of outcomes in the absence of a
gold standard, and to support or challenge the assumption of non‐
differentiality between exposed and non‐exposed. Some examples
will be used to illustrate the methodology: an acute disease (acute
myocardial infarction), a chronic disease (type 2 diabetes), and an
infectious disease (pertussis) (d) Demonstrate how point estimates
can be adjusted using PPV and SE from exposed and unexposed
strata, using a publicly available online tool developed by the DB
SIG. Examples will include cumulative incidence adjusted using indi-
ces generated from the work in point c), as well adjustment of rela-
tive risk.
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491 | Characterizing patient experience data
in medical product development: What is it,
what is expected, and how can you
contribute based on anticipated regulatory
guidance?
Rachael DiSantostefano1; Brett Hauber2; Laura Lee Johnson3;
Peter Mol4,5; Cindy Girman6
1 Janssen R&D, LLC, Titusville, NJ; 2RTI‐Health Solutions, Research
Triangle Park, NC; 3FDA, Silver Spring, MD; 4University Medical Center,
Groningen, Netherlands; 5Dutch Medicines Evaluation Board, Utrecht,
Netherlands; 6CERObs, Chapel Hill, NC
Background: In response to mandates of the 21st Century Cures Act
and other initiatives, regulators areworking to ensure that patient expe-
riences are meaningfully captured in medical product development and
evaluation via the use of patient experience data (PED). This includes
engaging patients on trial design, endpoint development, clinical out-
come assessment (COA) [e.g., patient reported outcomes], preference
data, as well as other data collected from patients using qualitative,
quantitative, or mixed method approaches; however, not all PED are
equal. The FDA is issuing a series of PED guidances to outline expecta-
tions for scientifically sound methods to collect robust, meaningful, and
sufficiently representative patient input to consider in regulatory deci-
sion making. The ISPE community needs to increase awareness of
FDA and EMA expectations regarding the inclusion of PED inmedicines
development so that epidemiologists can contribute to and incorporate
expected practices into any trial or observational studies being planned.
Objectives:
1. To understand regulators' intent and expectations related to PED
data, including how anticipated guidances may change our approach
to patient reported outcomes and benefit–risk.
2. To review examples of PED, including those that raise unanswered
questions or potential gaps in our understanding on how and when to
engage regulators.
3. To discuss opportunities to contribute to the science and guidances
on PED.
Intended audience: Epidemiologists who would like to better under-
stand and contribute to PED methods and its use in medical product
development for regulatory decision making.
Description: This session will be organized as follows:
• The introduction will introduce issues related to current regulatory
policy development that motivates incorporation of patient input to
inform medical product development, regulatory decision‐making,
and post‐marketing surveillance. (10 min: RD).
• Regulators will present intent and maturing expectations about the
use of PED in decision making including anticipated guidance series.
(~30 min: LLJ, PM).
• Examples of patient input in trial design, endpoints, COAs, and
patient preference information will be reviewed in the context of
engaging regulators and understanding evolving expectations.
(~30 min: CG, BH).
• An interactive discussion with audience participation including ques-
tions, discussion about potential barriers to inclusion of PED, and
opportunities to contribute to best practices (20 min: CG, LLJ).
492 | Existing databases for drug utilization
research in LatinAmerican andAfrican countries
Maribel Salas1,2; Björn Wettermark3; Luciane Cruz Lopes4;
Raquel Herrera Comoglio5; Joseph O. Fadare6;
Olayinka O. Ogunleye7; Macarius M. Donneyong8; Dan Kajungu9;
Anahi C. Dreser Mansilla10
1Daiichi Sankyo Inc, Basking Ridge, NJ; 2Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA; 3Karolinska Institutet and
Public Healthcare Services Committee, Stockholm, Sweden; 4Universidade
de Sorocaba UNISO, Sao Paulo, Brazil; 5Facultad de Ciencias Médicas,
Univ. Nacional de Córdoba, Cordoba, Argentina; 6Ekiti State University
College of Medicine, Ado‐Ekiti, Nigeria; 7Lagos State University College of
Medicine and Teaching Hospital, Lagos, Nigeria; 8The Ohio State
University, Columbus, OH; 9Makerere University, Kampala, Uganda;
10National Institute of Public Health, Mexico, Mexico
Background: Knowledge of the quantitative and qualitative patterns of
drug use is a key element for a health care system either from the eco-
nomic perspective and/or public health perspective. Drug utilization
research (DUR) can provide such information including the estimation
of exposed population, indication and duration of treatment derived
from different sources. Data sources to be used in DUR include primary
(e.g. data collected prospectively) and/or secondary sources. The mea-
sures of drug exposure will differ in each of the healthcare settings.
DUR has been recognized as an important area for cross‐national
(CNC) comparisons of drug use and also to describe and measure the
patterns, extent, and determinants of drug exposure between/within
countries. Therefore, we understand that valid CNC studies can only
be performed if the available data sources can deliver valid data. There
is the urgent need to identify databases for DUR in Latin American
and African countries that at the end can be used for decision making.
Objectives: To provide an overview of key information of databases for
DUR and describe the current status of existing databases for DUR of
some Latin American and African Countries. Researchers, payers and
regulators involved in the development, interpretation and use of data-
bases on drug utilization would be benefit from the symposium.
Description: The Symposiumwill be moderated by Maribel Salas. Björn
Wettermark will present the key information in databases in DU
research followed by presentations on the current status of databases
forDUR in Latin American andAfrican countries. Each speakerwill pres-
ent the challenges and potential solutions of current databases in their
countries. For Latin America, Luciane Cruz Lopes will present the situa-
tion in Brazil, Anahi Cristina Castro in Mexico, and Raquel Herrera
Comoglio in Argentina. For Africa, JosephO. Fadare will present the sit-
uation in Nigeria, Macarius Donneyong in Ghana and Dan Kajungu in
Uganda. All presenters and Olayinka O. Ogunleye from Nigeria will par-
ticipate in the discussion.
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493 | Introducing lactation real world data to
ISPE
Leyla Sahin1; Christina Chambers2; Laura Shaughnessy3;
Philip Anderson2
1FDA, Silver Spring, MD; 2University of California, San Diego, San Diego,
CA; 3UCB Pharma, Raleigh, NC
Background:
At last year's ICPE in Prague, ISPE's Medications in Pregnancy Special
Interest Group (SIG) was renamed the Medications in Pregnancy and
Lactation SIG, because real world data (RWD) should be used to better
understand the safety of medications in infants who are exposed
through breastfeeding. Pregnant women who require treatment for a
chronic condition will generally need to continue treatment in the
post‐partum period and can face the dilemma of deciding whether to
breastfeed. In addition, breastfeeding women may need to initiate
treatment for acute or chronic conditions. The safety of medications
in breastfeeding infants have not been well studied. There are short
and long‐term benefits of breastfeeding both to the mother and the
infant, and these factors are important in the overall risk–benefit deci-
sion making process. Therefore, it is important that ICPE has a sympo-
sium (for the first time) to address this important issue.
Objectives: The objective of this symposium is to understand how real
world data can be used in the assessment of the safety of medications
in breastfeeding infants.
Description:This symposiumwill provideanoverviewof theuseofmed-
ications by breastfeeding mothers and identify the gaps in knowledge.
The sessionwill also discuss the use of strategies (e.g.,modeling and sim-
ulation) to evaluate the utility of RWD in assessment of the safety of
medications used during breastfeeding. The experience of harmonizing
safety data collection in breastfeeding infants with ongoing pregnancy
registry studies, and the experience of developing a human milk reposi-
tory will be presented. A case example will provide the industry experi-
ence of real world data collection and submission to the FDA to inform
labeling. Additionally, the FDA perspective about the assessment and
integrationofavailabledata intodrug labeling to informrisk–benefit con-
siderations in breastfeeding women will be discussed. The symposium
will provide a platform for discussion for researchers and industry to
develop methods to assess the safety of medications and biologics in
breastfeeding infants. Audience participationwill be encouraged.
494 | Structured benefit–risk assessment of
prophylactic subcutaneous C1‐esterase
inhibitor for hereditary angioedema
management
Ami S. Patel1; Henrike Feuersenger2; Sarah Mycroft1; Ingo Pragst2;
Daniel Wood1; Thomas Machnig2; Douglas Watson1
1CSL Behring, King of Prussia, PA; 2CSL Behring, Marburg, Germany
Background: The first subcutaneous C1‐esterase inhibitor (C1‐INH
[SC], 60 IU/kg) for routine prophylaxis to prevent hereditary angio-
edema (HAE) was approved in the United States and Canada in
2017. To improve transparency and consistency of the benefit–risk
decision‐making process, a structured framework was employed.
Objectives: Utilize a structured framework to quantitatively assess the
benefits and risks of C1‐INH [SC] plus possible on‐demand treatment
as compared to on‐demand treatment alone in patients with an aver-
age of 2 or more attacks per month.
Methods: A cross‐functional team employed the Centre for Innova-
tion in Regulatory Science Benefit–Risk Action Team (CIRS‐BRAT)
framework to establish the decision frame and identify key benefit
and risk outcomes relating to prevention of HAE attacks, control of
HAE symptoms, global assessment of response to therapy (GART)
and treatment emergent adverse events (TEAEs). Risk differences
(RD) for each outcome were calculated per 100 patients as proportion
of C1‐INH [SC] plus possible on‐demand treated patients minus pro-
portion of on‐demand treatment alone patients using data from the
pivotal, double‐blind cross‐over study COMPACT (NCT01912456)
and displayed in a forest plot.
Results: The value tree was refined iteratively to allow for dichoto-
mous expression of outcomes and to eliminate redundant outcomes.
Using the intent‐to‐treat population (N = 45), RDs for reduction of
HAE attacks to less than 1 per month and free of any attack was 76
(95% Confidence Interval (CI) = 62–89) and 40 (95% CI = 26–54)
respectively and favored C1‐INH [SC]. Investigator graded “none/
mild” attacks (RD = 56, 95% CI = 41–71), no days with HAE symptoms
(RD = 40, 95% CI = 26–54), or good/excellent subject (RD = 53, 95%
CI = 36–71) and investigator (RD = 78, 95% CI = 65–91) GART were
higher for C1‐INH [SC] than for on‐demand alone treatment. In the
safety population (N = 43), no significant differences were detected
for other TEAEs, no thromboembolic and anaphylaxis events were
confirmed, and a favorable safety profile was observed.
Conclusions:Benefits of options to treat HAE attacks favors prophylac-
tic C1‐INH [SC] treatment while risks are low and comparable to on‐
demand treatment alone. A structured framework for assessing the ben-
efit–risk profile and resulting visual outputs can facilitate balanced and
improved communication of benefits and risks to clinicians and patients.
495 | Impact of complex drug approval
decision‐making processes on safety‐related
regulatory actions for drugs approved by the
European medicines agency
Lourens T. Bloem1,2; Mariana Karomi1; Jarno Hoekman3;
Svetlana V. Belitser1; Hubert G.M. Leufkens1; Olaf H. Klungel1,4;
Aukje K. Mantel‐Teeuwisse1
1Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University,
Utrecht, Netherlands; 2Medicines Evaluation Board (CBG‐MEB), Utrecht,
Netherlands; 3Copernicus Institute of Sustainable Development, Utrecht
University, Utrecht, Netherlands; 4 Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
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Background: Although regulators make a binary decision at initial drug
approval, decision‐making processes vary widely in complexity.
Whether greater complexity as a proxy for greater uncertainty leads
to more safety‐related regulatory actions post‐approval is unknown.
Objectives: To assess associations between complexity of drug
approval decision‐making processes and regulatory actions concerning
new safety issues.
Methods:We performed a retrospective cohort study of 40 innovative
drugs approved by the European Medicines Agency (EMA) in 2009–
2010, excluding influenza vaccines. For these, we identified revocation,
suspension, non‐commercial withdrawal, non‐renewal, Direct
Healthcare Professional Communications (DHPCs) and new restrictions
of indications, contraindications and warnings in the product informa-
tion until 31 Oct 2017. Complexity was assessed as ‘low’, ‘medium’, or
‘high’, based on presence of significant concerns regarding clinical trial
data, procedure duration, whether consensus was reached, and nega-
tive initial opinion. Data were extracted from regulatory sources. A
recurrent time‐to‐event model was applied to estimate adjusted hazard
ratios (aHRs) and 95% confidence intervals (CIs), comparing levels of
complexity, and adjusted for pre‐approval patient exposure.
Results: We identified no revocations, suspensions, non‐commercial
withdrawals and non‐renewals, 14 DHPCs, and 222 product informa-
tion changes, of which 72 concerned new restrictions of indications,
contraindications and warnings. Complexity was ‘low’ for 11, ‘medium’
for 16, and ‘high’ for 13 drugs. When considering complete follow‐up
(median 7.9 years), we did not identify a significant association
(medium/high vs. low aHR 1.23 [0.63–2.42]; medium vs. low aHR
1.42 [0.71–2.82]; high vs. low aHR 1.00 [0.34–2.92]). However,
post‐hoc analyses restricted to the first 2.5 years suggest an increased
hazard (medium/high vs. low aHR 4.31 [0.96–19.33]; similar for
medium and high vs. low), in contrast to a slightly reduced hazard dur-
ing later follow‐up (medium/high vs. low aHR 0.80 [0.42–1.54], which
was even more pronounced for high vs. low).
Conclusions: Complexity of drug approval decision‐making processes
does not lead to more safety‐related regulatory actions post‐approval.
This may indicate that risk minimisation processes have been ade-
quately implemented, as also suggested by the differential timing of
regulatory actions between levels of complexity.
496 | The occupational hazards of measuring
risk tolerance: Convergent validity in
preference elicitation
Sumitra Sri Bhashyam1; Kevin Marsh1; Adrian Quartel2; Ari Gershman2
1Evidera, London, UK; 2BioMarin Pharmaceutical Inc., Novato, CA
Background: Phenylketonuria (PKU) leads to an accumulation of phe-
nylalanine (Phe) in the blood and subsequent neurologic, cognitive,
psychiatric, and behavioral dysfunction. Many patients report social
isolation and decreased quality of life. Pegvaliase is an enzyme substi-
tution therapy that reduces blood Phe levels in patients with PKU and
is associated with a risk of hypersensitivity reactions.
Objectives: Given there is no consensus about the best way to elicit
patients' preferences, this study empirically test the consistency of
responses to two different preference elicitation methods. Such
research has been encouraged by the FDA and is one of the key moti-
vators of the Innovative Medicine Initiative funded Patient Prefer-
ences in Benefit–Risk Assessments during the Drug Life Cycle
project (PREFER).
Methods: Two methods, thresholding and adapted swing weighting
(ASW), were adopted to elicit patients' minimum acceptable benefit
(MAB) for pegvaliase, a treatment for phenylketonuria (PKU). Both
elicitation methods used the same attributes and associated levels:
the ability to lower phenylalanine (Phe) levels, and the likelihood of
experiencing allergic reactions. To enable the reasons for differences
in MAB obtained from these two exercises the participants were
asked to outline their rational for their choices.
Results: Patients would require a minimum likelihood of 22.67%
(ASW) to 34.4% (thresholding) of achieving a Phe level less
360 μmol/L before they would tolerate the risks. This is less than
the benefit generated by pegvaliase. There was no relationship
between MAB and patient's current Phe level, perception of PKU con-
trol, or satisfaction with treatment. Seven participants had their MAB
increase significantly between the ASW and the thresholding exercise.
In four cases, this was explained by their refusal to take an injectable,
which was an aspect highlighted in the introduction to the
thresholding but not in the ASW exercise.
Conclusions: The insight generated by both methods supported
patients would be willing to take pegvaliase despite its risks, and both
methods drew the same conclusions with regards to treatment prefer-
ence. However, this study highlights the impact of the elicitation for-
mat and framing of questions on the elicited trade‐offs. The
introduction of the treatment characteristic could explain most of
the discrepancies between the MABs in the two exercises.
497 | Determinants for safety issue coverage
by lay and social media
Esther de Vries1,2; Petra Denig1; Sieta T. de Vries1;
Taco B.M. Monster1,2; Jacqueline G. Hugtenburg3; Peter G.M. Mol1,2
1University Medical Center Groningen, Groningen, Netherlands;
2Medicines Evaluation Board, Utrecht, Netherlands; 3Amsterdam
University Medical Center, Amsterdam, Netherlands
Background: Drug safety issues communicated by Direct Healthcare
Professional Communications (DHPCs) may receive substantial media
coverage, e.g. thrombosis risk of oral contraceptives. However, what
triggers media coverage in general is unknown.
Objectives: What are determinants for media coverage of DHPCs in
the Netherlands?
Methods: Newspaper articles covering issues mentioned in 387
DHPCs issued from 2001 till 2015 were retrieved from Lexis Nexis
Academic™, a repository of newspaper and magazine articles. Articles
published two months before to two months after the DHPC was
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issued were retrieved. Web postings were retrieved from Coosto™, a
repository of social media, for 220 DHPCs issued from 2010 till
2015. We retrieved postings mentioning the drug/brand name from
14 days before to 14 days after the DHPC was issued. Media cover-
age in newspapers and in social media were defined as binary out-
comes. As potential determinants ATC code (first level), date of
DHPC (years), month of DHPC, type DHPC message (i.e. safety issue,
shortage/delivery, defect/recall), withdrawal yes/no, drug age
(≤2 years, 3–5 years, 6–11 years, and > 11 years (ref)), amount of
users (low/unknown use (<1000), moderate use (1000–10000), wide
use (>10000) (ref)), specialist drug (yes/no) were collected. We used
Multivariate logistic regression analyses to evaluate which determi-
nants were associated with media coverage, showing adjusted odds
ratio (ORadj) and 95% confidence interval (95% CI).
Results: Of the issues mentioned in 387 DHPCs, 55 (14.2%) were cov-
ered in newspaper articles in the four months around the DHPC was
issued. Shortages or delivery problems (ORadj 4.90; 95% CI [1.36–
17.65]), drug age (3–5 years ORadj 0.24; 95% CI [0.06–0.91], 6–
11 years ORadj 0.20; 95% CI [0.06–0.65]) and amount of users
(low/unknown ORadj 0.16; 95% CI [0.06–0.43], moderate ORadj
0.28; 95% CI [0.09–0.83]) were all associated with newspaper cover-
age. DHPCs issued more recently were less likely to be covered by
newspapers (ORadj 0.86; 95% CI [0.78–0.95]). 143 (65%) drugs men-
tioned in 220 DHPCs were covered by the social media in the month
the DHPC was issued. Drugs with a safety message (ORadj 4.04; 95%
CI [1.51–10.83]) and non‐specialist drugs (ORadj 2.57; 95% CI [1.05–
6.26]) were associated with social media coverage.
Conclusions: Determinants associated with media coverage differed
for newspapers and social media. Newspapers focused more on old
drugs, those that are widely used, or shortages or delivery problems,
whereas social media coverage was more related to non‐specialist
drugs and safety messages.
498 | Monitoring benefits and risks of
medicines for overactive bladder in primary
care; building a bridge between daily practice
and research
Karin Hek1; Leàn Rolfes2; Linda E. Flinterman1; Saskia Vorstenbosch2;
Eugène van Puijenbroek2; Liset van Dijk1; Robert A. Verheij1
1Nivel, Utrecht, Netherlands; 2Lareb, Den Bosch, Netherlands
Background: Monitoring benefits and risks of medicines in the post‐
marketing phase is important for a safe and effective treatment of
patients. Aim of this project is to develop a flexible infrastructure with
general practitioner's (GP) routine electronic health records triggering
the collection of patient reported outcomes (PROs) regarding the
effect and adverse reactions (ADRs) of pharmaceutical treatment.
Objectives: To evaluate the feasibility of acquiring real world data to
monitor the effects and ADRs of medicines.
Methods: For this pilot study, two general practices in the Nether-
lands were included. Overactive bladder (OAB) was used as a use case.
OAB patients were flagged in electronic health records data that are
collected by Nivel on a weekly basis. The GPs checked whether the
patient was eligible for the study. PROs were obtained by an elec-
tronic survey, using the Lareb Intensive Monitoring system. Questions
involved bladder complaints, treatment (physiotherapeutic interven-
tions and medicines), ADRs, therapy compliance, and quality of life.
Results: 109 OAB patients were flagged in the electronic health
records data. After revision by the GPs, an invitation to participate
was sent to 82 (75%) patients. Reasons for excluding patients were:
patient cannot work with a computer or questionnaire (10x), cogni-
tive/mentally not fit to fill in questionnaire (10x), patient in hospital
(3x), patient died/moved (2x). GPs were enthusiastic about the study
procedure. Nineteen patients (23%) filled in the questionnaire. Aver-
age age was 63 years (38–79 years) and 14 of them were women.
Patients reported an average score of 4.0 for urogenital complaints,
on a scale from 1 (none) to 10 (very much). Eleven patients received
physiotherapeutic interventions and 5 received medicines to treat
the OAB. Of these, 3 patients experienced ADRs.
Conclusions: The developed infrastructure is successful in providing
clear information about patients' perspective of the benefit and ADRs
of their treatment at relatively low effort. The pilot shows that infor-
mation about effectiveness and ADRs of medicines can be acquired
using this system. The system is designed to be applied to any new
medication on the market and has several advantages above more tra-
ditional monitoring instruments like longer follow‐up, and a real life
setting.
499 | Effectiveness of risk evaluation and
mitigation strategies to prevent maternal
exposure to aTopiramate weight loss product
Amir Sarayani; Yasser Albogami; Almut G. Winterstein
Department of Pharmaceutical Outcomes and Policy, University of
Florida, Gainesville, FL
Background: In 2012, the Food and Drug Administration (FDA)
approved a combination product for weight loss (phentermine/
topiramate (PT)) with a Risk Evaluation and Mitigation Strategy
(REMS) to prevent maternal exposure and mitigate topiramate terato-
genicity. However, the evidence on the effectiveness of such REMS
programs is scarce.
Objectives: To evaluate the effectiveness of the REMS program for PT
to prevent maternal exposure to topiramate compared to other anti‐
obesity medications (AOMs).
Methods: We conducted a retrospective cohort study using IBM
MarketScan® Commercial Claims Databases (2011–2017) to compare
the risk of pregnancy during exposure to PT versus other AOMs
approved for long‐term use (naltrexone/bupropion, lorcaserin,
liraglutide, orlistat). Females of child‐bearing age 14–50 with &ge
12 months continuous enrollment before the first prescription fill
and not having diagnoses or procedures indicating infertility were
included. Multiple treatment episodes were allowed if the gap
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between fills was >14 days. The outcome was defined as conception
identified by an algorithm based on diagnosis and procedure codes
indicating &ge 2 medical encounters for pregnancy or screening tests.
Other teratogenic drug use, hormonal contraception, and comorbidi-
ties were measured as potential confounders. Patients were followed
up to two years and were censored due to infertility, drug discontinu-
ation, conception, or end of the study. We used Cox proportional haz-
ard regression with inverse probability of treatment weighting to
compare the study groups, accounting for multiple treatment
episodes.
Results: We included 14,517 treatment episodes for PT and 47,173
episodes for other AOMs. Mean age was 39.7 (7.5) vs. 39.9 (7.5) in
the PT and other AOMs groups, respectively. The median follow‐up
time was comparable (30.0 (43.0) vs. 30.0 (34.0), respectively). Hyper-
tension (26.0%) and hyperlipidemia (21.3%) were the most common
comorbidities. Use of hormonal contraception within two months
before and one month after the index date was 16.9% in the PT and
16.0% in other AOMs groups. The adjusted conception rate was 7.1
per 1000 person‐years in the PT group and 11.0 in other AOMs group.
The unadjusted and adjusted hazard ratios were 0.70 (0.43, 1.14) and
0.66 (0.40, 1.08), respectively. Sensitivity analyses including varying
assumptions to estimate conception and assuming discontinuation of
drug exposure before the last fill showed minimal changes in the risk
estimates.
Conclusions: The REMS program for PT appears to have limited effec-
tiveness in preventing maternal exposure.
500 | Agomelatine post‐authorization safety
studies program: Comprehensive results
Emmanuelle Jacquot1; Valérie Olivier1; Christèle Percheron1;
Fanny Mazens1; Nicolas Deltour1; Susana Perez‐Gutthann2
1Servier, Suresnes, France; 2RTI Health Solutions, Barcelona, Spain
Background: Agomelatine, indicated from 2009 in Europe to treat
major depressive episode, is covered by a risk management plan
including hepatotoxic reaction as an important identified risk. Risk‐
minimisation measures (RMMs) were implemented from marketing
authorization, and consist of contraindications in patients with hepatic
impairment and precautions of use in patients at risk of liver injury;
liver testing at several time points, as well as a prescriber's guide and
a patient booklet. Two information letters were distributed to pre-
scribers in 2012 and 2013.
Objectives: Five post‐authorization safety studies were conducted in
9 countries overall allowing a diverse geographic representation of
Europe, to further characterize agomelatine hepatic risk or measure
effectiveness of these RMMs.
Methods: A prospective observational cohort assessed the safety of
agomelatine in current medical practice as the drug was launched,
with focus on hepatic reactions. A pharmacogenomics study aimed
at identifying genomic biomarkers associated with agomelatine‐
induced liver injury. A prescription survey assessed prescribers'
knowledge on the risk of hepatotoxicity. A chart review evaluated
the adherence to the liver test requirements and compliance with con-
traindications and precautions of use, and a patient survey assessed
reasons for non‐compliance with the liver testing. A case–control
study nested in an antidepressant new users cohort quantified the risk
of acute liver injury (ALI) comparing agomelatine to citalopram.
Results: The incidence rate and type of hepatic events observed in the
prospective cohort were comparable to what was observed in clinical
trials. No genomic biomarkers were identified to be associated with
agomelatine‐induced liver injury. The prescription survey suggested
that physicians, with up to 80% of the psychiatrists and up to 51%
of GPs, have a good knowledge of the safety concerns associated with
agomelatine. The chart review showed that after the last RMMs were
implemented 16% of patients treated with agomelatine had one test
at initiation and during treatment (25% had a test at initiation and
61.5% during treatment) and 99% of patients were treated with
respect to the contraindications. The nested case control study
showed that, in the context of the current RMMs, the risk of ALI
among agomelatine users is not higher than that for citalopram users.
Conclusions: These studies allowed to better characterize the
agomelatine hepatotoxic risk and to assess the effectiveness of the
RMMs, showing that altogether these RMMs with the current level
of adherence are effective in preventing ALI among agomelatine users.
501 | Area‐level linkages to enrich primary
care electronic health data for research
Susan Hodgson; Elizabeth Crellin; Kirsty Syder; Sonam Sadarangani;
Shivani Padmanabhan
Medicines and Healthcare Products Regulatory Agency, London, UK
Background: Clinical Practice Research Datalink (CPRD) collects de‐
identified patient data from a network of general practitioner (GP)
practices across the UK. These longitudinal data, encompassing >35
million patient lives, are available for research into drug safety, use
of medicines, health policy, health care delivery and disease risk fac-
tors. Linkage of these primary care data to a range of health and
health‐relevant contextual data further enriches their research value.
Objectives: To describe area‐level linkages recently made available in
CPRD and review their application in research studies of drug safety,
care utilization and public health.
Methods: Patient and GP practice postcodes were mapped to lower
layer super output area (LSOA, England/Wales, average 1,600 popula-
tion), super output area (SOA, Northern Ireland, average 2,100 popu-
lation) or datazone (DZ, Scotland, population 500–1,000). Linkage to
practice‐level Rural–Urban classification was made to support
research where access to services, employment and educational
opportunities might be an important confounder. Inclusion of the indi-
vidual domains of the Index of Multiple Deprivation (IMD) ‐ housing,
employment, income, access to services, education, crime, and living
environment ‐ was implemented to facilitate research requiring a more
nuanced adjustment for aspects of material deprivation; within
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England, correlations between practice‐level quintiles of IMD and the
IMD domains range from 0.36–0.89. Linkage to Carstairs Index pro-
vided an alternative index of material deprivation covering England,
Wales and Scotland.
Results: 1615 GP practices contributing to CPRD's primary care data-
base (January 2019) were linked to these area‐level measures,
representing 19.5, 18.2, 10.8, and 7.9% of GP practices in England,
Wales, Scotland and Northern Ireland, respectively. Since being made
available in June 2018, protocols requesting linkage to these area‐
level variables have included a study looking at the influence of
patient and practice‐level factors associated with vaccine uptake,
and a study assessing the social and demographic characteristics of
high cost patients in primary and secondary care. The next release of
linkage data will include linkage of these area‐level measures to
patient postcode.
Conclusions: The research value of electronic health datasets, like those
held by CPRD, can be enhanced via linkage to other health and health‐
relevant datasets. Area‐level data can provide a context within which
health care is delivered, act as a proxy for socioeconomic status, and
support the planning and targeting of health and social care services.
502 | Role of health plan administrative
claims data in participant recruitment for
pragmatic clinical trials ‐ an ADAPTABLE
(aspirin dosing: A patient‐centric trial
assessing benefits and long‐term
effectiveness) example
Qian Shi1; Sonali Shambu1; Amanda Marshall1; Elaine Rose‐Kennedy1;
Holly Robertson2; Mark Paullin1; William Schuyler Jones3;
Mark Cziraky1; Kevin Haynes1
1HealthCore Inc., Wilmington, DE; 2Duke University Medical Center,
Durhan, NC; 3Duke University School of Medicine, Durhan, NC
Background: The utility of longitudinal claims to identify eligible
patients across health systems provides an innovative and valuable
potential solution for large pragmatic clinical trial recruitment.
Objectives: This study sought to evaluate the HealthCore/Anthem
Research Network (HCARN) recruitment outreach, compare member
of visits to the ADAPTABLE study's recruitment portal, and assess
enrollment rates for different outreach strategies.
Methods: Setting/intervention: We conducted outreach to health plan
members identified by a previously validated PCORnet common data
model computable phenotype and their providers utilizing HCARN
administrative claims data, during 11/2017 — 08/2018. Provider out-
reach preceded member outreach, and allow the provider to opt out
their patients. We conducted two phases of member outreach, phase
1 consisted of 2 batches of email/mail and 1 phone call, phase 2 com-
pared two equal batches of either email/mail or brochure and 1 phone
call. Main outcome: The main outcomes were whether outreached
members visited the study portal or enrolled into ADAPTABLE study.
Additionally, we compared our different outreach strategies across the
two phases of outreach. Statistical analysis: Rates of portal visit and
enrollment were reported by phases and by outreach methods.
Descriptive statistics were used to examine outreached members, por-
tal visitors and enrollees' demographic and clinical characteristics.
Results: We outreached to 28,593 providers in phase 1 and an addi-
tional 5,077 providers in phase 2. In phase 1, 301,375 mixed e‐mail/
mail were delivered to 133,373 members, followed by 90,481 phone
calls. In phase 2, post randomization 51,777 members to email/mail
or brochure groups, 51,623 communications were sent to 25,914
members via mail/e‐mail, and 50,160 brochures to 25,863 in the bro-
chure group. Following 2 waves of mail/e‐mail or brochure outreach,
16,608 and 16,600 calls were made to the groups, respectively. Over-
all, 1,549 HCARN members visited the study portal; resulted in 355
enrollments. Brochures drove more portal visits in Phase 2, but less
conversion to enrollment. Recruitment was better in Phase 2 — 2.3
vs 1.8 enrollees per 1,000 outreach members in Phase 1.
Conclusions: This study showed that a health plan within PCORnet
has the ability to identify potential study participants with administra-
tive claims and facilitate recruitment and enrollment for pragmatic
clinical trials facilitating pragmatic pharmacoepidemiology research.
503 | Impact of length of pre‐index
enrollment criterion on patient characteristics
in a cohort of heart failure patients using a
large U.S. Medicare advantage claims
database
Shannon L. Reynolds1; Vinay Mehta2; Stephen Stemkowski3;
Huifang Liang4; Efe Eworuke5; Dimitri Bennett6; Karine Marinier7;
Matthew W. Reynolds8
1Aetion, Inc., New York, NY; 2Merck & Co., Inc, Kenilworth, NJ; 3Humana
Healthcare Research, Inc ‐ A Humana Company, Louisville, KY; 4AbbVie
Inc, North Chicago, IL; 5US Food and Drug Administration, Silver Spring,
MD; 6Takeda Pharmaceutical Company Limited, Cambridge, MA;
7Servier, Suresnes, France; 8 IQVIA, Rockville, MD
Background: When designing retrospective claims database studies,
researchers must define the pre‐index enrollment criterion for the
cohort. This decision is often driven by optimizing availability of data
and limiting patient attrition.
Objectives: This study aimed to examine the impact of the selected
lengths of pre‐index period on the characteristics of a heart failure
patient cohort.
Methods: A cohort of patients diagnosed with heart failure was iden-
tified in a large Medicare Advantage database. The index date was
defined as the first heart failure diagnosis. Key demographic and clin-
ical characteristics were examined using data from varying pre‐index
periods (including ≥3 months, ≥ 6 months, ≥ 12 months, ≥
18 months, and ≥ 24 months). Comorbidities and comorbidity burden
were assessed based on diagnosis codes and prescription records/pro-




≥3 months of pre‐index enrollment, 170,697 (63.3%) had≥12 months,
and 129,001 (47.9%) had ≥24 months. Demographic characteristics,
including gender and average age, were similar (mean age 76 or 77, male
rangingfrom50.4%to49.7%)acrossthevaryingpre‐indexstudyperiods.
As expected, the longer the pre‐index period, the higher the observed
prevalenceof comorbidities.However, the increase in comorbidityprev-
alence was most pronounced between patients with ≥3 months vs. ≥
6 months pre‐index enrollment (e.g., hypertension 83.4% vs 89.7%),
and likewise for≥6 months vs.≥ 12 months (89.7% vs 93.9%), but was
marginal for the comparisons of longer time periods after ≥12 months
(93.9% vs 94.0% vs 94.1%). Comorbidity burden showed similar esti-
mates across the varying pre‐index periods.
Conclusions: Choice of pre‐index time can affect the prevalence esti-
mates of pre‐index comorbidities and clinical variables. These results
suggest that periods longer than 12 months may only provide marginal
additional detail on patient medical history while reducing available
sample size.
504 | Predicting the likelihood of 30‐day
hospital readmissions among stroke patients:
An application of machine‐learning
techniques
Jordan Menzin; Mark Friedman; Anna Watzker; Joseph Menzin
BHE, Boston, MA
Background: Understanding the patients most at risk for hospital
readmission is of great interest to clinicians and policymakers. Stroke
patients are known to have a substantial risk for early hospital read-
mission, but prior studies show fairly low predictive accuracy.
Objectives: The objective of this study was to assess the accuracy of
standard techniques along with machine‐learning (ML) approaches in
predicting 30‐day readmissions among ischemic stroke patients.
Methods: This single cohort retrospective analysis used the
HealthCore Integrated Research Database (HIRD), an administrative
claims database with over 50 million members. The study cohort
consisted of patients with a first‐listed diagnosis of ischemic stroke
between 1/1/08 and 3/31/15, one year of eligibility prior to the
stroke hospitalization (“Index”), and at least 30 days of eligibility fol-
lowing discharge from the index stay. Predictors (e.g., demographics,
comorbidities, characteristics of the index stay) of all‐cause hospital
readmission were pre‐specified based on the results of a literature
review and in consultation with the study physician. Additional fea-
tures were generated automatically based on the frequency of medi-
cations, diagnoses, and procedures summarized to a CCS or Multum
level for the one year prior to index and during the index stay. Five
models were generated, including logistic using the LACE score
(“LACE”), logistic based on pre‐specified measures (“standard L"), and
3 ML models with all features (“ALL”). The models used a 15% holdout
with a 75%/25% train/validation split. All analyses were undertaken
using the Instant Health Data (IHD) platform (BHE, Boston, MA, USA).
Results: A total of 79,642 ischemic stroke patients were identified
(median age: 67 yrs; 49.9% female), of whom 17.9% were readmitted
within 30 days. AUC values were 58.8% (LACE), 70.6% (standard L),
73.1% (Lasso regression, ALL), 73.2% (feed‐forward neural net, ALL),
73.3% (logistic, ALL), and 73.7% XGBoost (ALL). We picked XGBoost
for the final holdout test, which had: Accuracy: 77.3%, AUC: 73.4%,
Recall: 67.3%, Precision: 42.4% and F1: 0.52.
Conclusions: In this cohort of almost 80,000 ischemic stroke patients,
ML techniques provided a modest benefit in terms of AUC. Further
testing and evaluation would be useful in a database that includes
additional structured clinical measures and unstructured clinical notes.
505 | New automated signal detection
methods in pharmacovigilance combining
medico‐administrative database controls and
spontaneous reporting cases
Émeline Courtois Mrs; Pascale Tubert‐Bitter; Ismaïl Ahmed
INSERM, Paris, France
Background: Pharmacovigilance aims to detect early adverse reactions
of marketed drugs. Classically, it relies on large spontaneous reporting
databases (SRD), which is a collection of case reports of suspected
adverse drug reactions. Statistical methods have been proposed to
mine these large databases and highlight suspicious drug‐adverse
event (AE) associations, called signals. With these approaches, controls
for a given AE are cases of other AEs.
Objectives: We aim to develop new signal detection methods by
building a control group from the general population using hospital
and healthcare claims databases. An empirical assessment with a real
application on “acute liver injury” (ALI) is conducted.
Methods: We constructed an hybrid database (HB) with the ALI cases
from the French national SRD and a large set of controls from the
Echantillon Généraliste des Bénéficiaires, a representative sample of the
French population's healthcare claims data. In HB and SRD, we imple-
mented i) a classical univariate signal detection method: the reporting
fisher's exact test (RFET) and ii) a logistic lasso. We also investigated
detection rules based on various outcome combinations from HB and
SRD. Finally, we evaluated approaches derived from the adaptive lasso
in which statistics (e.g. log (OR) or p‐values) from the HB detection are
included as prior weights in a lasso performed on SRD. Performances
were mainly measured in terms of sensitivity and false discovery pro-
portion on the basis of a published reference set for ALI. Methods were
compared at identical number of generated signals.
Results: For the same number of generated signals, RFET showed
comparable performances. The lasso in HB showed a better sensitivity
for large number of signals. We observed that a decision rule based on
the union of the signals lasso‐generated in each database slightly
improved performance compared to the same procedure in the SRD.
Finally, our “adaptive lasso” had a better sensitivity compared to the
classical lasso in the SRD and shows a lower false discovery
proportion.
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We also observed that a significant proportion of HB and SRD signals
were different.
Conclusions: From this empirical evaluation, we conclude that signal
detection using controls from medico‐administrative databases is a
complementary approach to signal detection on SRD only.
506 | Total hip or knee replacement surgery
and risk of thromboembolic outcomes: A
retrospective cohort study
Xiaofeng Zhou; Kui Huang; Liu Qing; Patrick Arena; Shen Rongjun;
Charles Wentworth; Richard Gong; Sundaresan Murugesan;
Andrew Bate; Jingping Mo
Pfizer Inc, New York, NY
Background: Patients undergoing total knee or hip replacement (TKR/
THR) surgeries are at high risk of deep vein thrombosis (DVT) and pul-
monary embolism (PE). Detailed risk characterizations in this popula-
tion are limited.
Objectives: To estimate incidence rates (IRs) of DVT/PE across multi-
ple risk windows (RWs) among adults undergoing TKR/THR in United
States (US), stratified by potential risk factors.
Methods: A retrospective cohort study using 2007‐ mid 2018 Optum
EHR data was conducted. Patients aged 18–85 years with ≥183 days
of enrollment prior to TKR/THR and met study inclusion/exclusion
criteria were included. Two cohorts (TKR and THR), 2 outcomes
(DVT and PE), and selected clinical characteristics for stratifications
were defined based on ICD‐9/10 codes. IRs and 95% confidence
intervals (CIs) were estimated in the following 6 RWs: during surgical
hospitalization and ≤ 10, 30, 90 180, or 365 days post‐operation.
Results: 168,785 TKR and 88,284 THR patients were eligible for the
study. The IRs and 95% CIs for DVT following TKR and THR per
1000 person‐years ranged from 828.99 [787.46, 872.72] and 554.77
[507.58, 606.35] during surgical hospitalization to 43.23 [42.14,
44.35] and 33.92 [32.58, 35.31] ≤ 365 days post‐operation; and for
PE, they were 529.20 [496.26, 564.33] and 281.52 [248.51, 318.91]
during surgical hospitalization to 17.23 [16.55, 17.94] and 13.02
[12.21, 13.89] ≤ 365 days post‐operation. These IRs decreased con-
sistently across all RWs (mean surgical hospitalization = 3 days) in both
cohorts. Stratified analyses revealed that older patients (≥66 years),
males, or those with longer hospital stays (LHS), diabetes, allogenic
blood transfusion, or prior medical history of DVT/PE had a higher
IRs of DVT and PE in both cohorts. The LHS could be a consequence
of these events. Higher IRs of DVT in bothTKR and THR patients with
implanted material during surgery, prior permanently implanted
device, or history of ankylosing spondylitis were observed. Higher
IRs of PE in black patients with TKR, and THR patients with prior per-
manently implanted device were also observed. Revisional surgery sta-
tus revealed no substantial differences in DVT/PE in either cohort.
Conclusions: Using a large US EHR database, we show that IRs of DVT
and PE inTKR/THR patients are highest during surgical hospitalization
and attenuated with prolonged risk periods. Sub‐populations with
higher IRs of DVT and PE in TKR/THR patients were also identified.
Future analyses may benefit from further confounder adjustment,
effect modifier identification, medical chart review to confirm out-
comes, and estimation with other databases.
507 | Validation of cancer diagnoses in
electronic health Records in Catalonia:
Preliminary results from the information
system for research in primary care (SIDIAP)
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Diana Puente1,2; Maria del Mar Garcia‐Gil1; Daniel Prieto‐Alhambra3,4;
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(FUNCA). Institut d'Investigació Sanitària Pere Virgili, Reus, Spain;
8Cancer Prevention Unit and Cancer Registry, Department of
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Background: The Information System for Research in Primary Care
(SIDIAP) includes electronic health records of >6 million people living
in Catalonia assigned to a primary healthcare centre of the Catalan
Institute of Health. SIDIAP may be a useful tool for cancer research,
but the recorded diagnoses need to be validated.
Objectives: To validate 25 types of incident cancer cases in SIDIAP
using the population‐based cancer registries of Girona (CRG) and Tar-
ragona (CRT) as gold‐standard and to assess the time‐difference in the
date of diagnosis between SIDIAP and the registries.
Methods: We performed a cross‐sectional study during 2009–2015
including the SIDIAP adult population (≥18 years) of Girona and Tar-
ragona. We identified 25 types of incident cancer cases in SIDIAP
(using the registered ICD‐10 codes and date of diagnosis) and com-
pared them to those from the CRG (2009–15) and the CRT (2009–
13). We used cases registered during 2005–08 to exclude prevalent
cases. For each cancer type, we calculated the sensitivity, positive pre-
dictive values (PPV) and the time‐difference in the date of diagnosis in
SIDIAP vs. the registries.
Results: In SIDIAP, we identified 497,331 persons living in Girona and
289,187 in Tarragona in 2016. Out of 22,785 registered incident can-
cer cases in SIDIAP, we confirmed 9,296 (57%) cases in Girona and
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4,389 (67%) in Tarragona. The sensitivity for all cancer types was 74%
in Girona and 70% in Tarragona. Breast (90%), colorectal (82%), and
prostate (81%) had the highest sensitivity in Girona and breast (86%)
prostate (81%), and malignant skin melanoma (76%) in Tarragona.
Bone (54%) and gallbladder and biliary tract (32%) had the lowest sen-
sitivity in Girona, and head and neck (37%) and gallbladder and biliary
tract (20%) in Tarragona. In both regions, trachea, bronchus, and lung
(72% in Girona and 81% in Tarragona) and stomach (71% and 78%,
respectively) had the highest PPVs. Most cancer diagnoses were first
reported in the registries than in SIDIAP with less than two months
of difference.
Conclusions: Out of 25 cancer types validated in SIDIAP using the
population‐based cancer registries as gold‐standard, 22 had a sensitiv-
ity >60% in Girona, and 18 in Tarragona. Overall, SIDIAP reports can-
cer cases with less than two months of difference than the registries.
Our results support the use of SIDIAP cancer diagnoses for research
on most common cancer types in Catalonia. Low PPVs could be due
to cases treated in centres outside the study reference area, but more
research is needed to understand the potential false positive cancer
diagnoses recorded in SIDIAP.
508 | Quality and completeness of diagnoses
recorded in the new CPRD aurum database:
Evaluation of pulmonary embolism
Susan Jick1; Rebecca Persson1; Puja Myles2; Elizabeth Crellin2;
Katrina Wilcox Hagberg1; Catherine Vasilakis‐Scaramozza1
1Boston Collaborative Drug Surveillance Program, Lexington, MA;
2Medicines and Healthcare products Regulatory Agency, London, UK
Background: The first studies using what is now Clinical Practice
Research Datalink (CPRD) GOLD were published around 1990. Since
that time the database has been repeatedly validated, has grown and
evolved to contain electronic patient records on millions of UK resi-
dents, and has been the basis for thousands of important epidemiol-
ogy studies reporting on many health outcomes. CPRD is now
providing data from a new medical record database, CPRD Aurum.
Like CPRD GOLD, CPRD Aurum contains electronic medical record
data recorded by GPs, but the data is captured using a different GP
patient management software, EMIS. Evaluating the quality and com-
pleteness of this new database is important for future studies.
Objectives: To assess the quality and completeness of data present in
CPRD Aurum for research purposes by evaluating presence of pulmo-
nary embolism (PE) diagnoses recorded in CPRD Aurum compared to a
gold standard data source, Hospital Episode Statistics (HES).
Methods: We identified a sample of patients in CPRD Aurum with
linkage to HES data (1997–2017), a database that contains informa-
tion on hospitalizations in England. We confirmed PE diagnoses
recorded in CPRD Aurum using HES and report positive predictive
values (PPV). We further evaluated completeness of CPRD Aurum
data by identifying primary or secondary PE diagnoses in HES and
report the proportion of these diagnoses also present in CPRD Aurum.
Results: Among the 50,000 patients evaluated, there were 593
patients with a PE diagnosis in CPRD Aurum, of whom 431 also had
a PE diagnosis in HES (PPV = 72.7%). The proportion confirmed was
higher when we restricted the analysis to patients with a PE diagnosis
and concomitant anticoagulation therapy in CPRD Aurum
(PPV = 76.8%). Of the 378 patients with a primary PE diagnosis in
HES, 299 (79.1%) also had a PE diagnosis in CPRD Aurum, whereas
of the 254 patients with a secondary PE diagnosis in HES only 132
(52.0%) had a PE diagnosis in CPRD Aurum. In patients with compli-
cated medical conditions (e.g. cancer) or who were close to death,
PE diagnoses were less likely to be recorded in both data sources.
Because CPRD Aurum data are newly available, these results are
preliminary.
Conclusions: This preliminary evaluation of PE recording in CPRD
Aurum is reassuring and suggests that the quality and completeness
of these data are promising. However, detailed assessment is under-
way and further discussion will be provided at ICPE. PE is a serious
outcome that requires medical attention, but there are reasons that
could explain differential recording between the two data resources.
509 | Use of Joinpoint regression in drug
utilization research: Post‐tonsillectomy
codeine use in pediatrics, United States
(2005–2016)
Juan M. Hincapie‐Castillo; Patrick J. Antonelli; Almut G. Winterstein
University of Florida, Gainesville, FL
Background: Drug utilization researchers often evaluate effects of
policy or other interventions on secular trends via before and after
comparisons. The change point is determined a priori based on
assumptions regarding immediate change or predefined lag time.
Joinpoint regression methods offer an opportunity to identify devia-
tions in secular trends without a preconceived notion on specific break
points in the data. Use of codeine in pediatric patients in absence of
pharmacogenomic testing emerged as unsafe practice in the literature
and was subsequently addressed in guidelines and via labeling
changes. Evaluating prescribing trends using real‐world data in this
patient population can help explore the utility of the methodology in
future drug utilization research.
Objectives: To evaluate trends of codeine prescribing in pediatric
patients undergoing tonsillectomy procedures by applying joinpoint
regression.
Methods: We conducted an ecological study using data from the IBM
MarketScan Commercial Database 2005–2016. The study population
included patients aged 2–17 undergoing tonsillectomy with and with-
out adenoidectomy identified by ICD‐9, ICD‐10, and CPT procedure
codes. We calculated the monthly proportion of tonsillectomy patients
with a dispensing claim for codeine within 7 days of surgery. We used
the NCI Joinpoint regression software v4.6 to find significant months
associated with a rise or fall of codeine utilization. The joinpoints were
obtained by permutation tests using Monte Carlo samples, and we
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specified a maximum of 4 points for computing efficiency. We com-
pared the obtained joinpoints and their respective 95% CI with the
dates of regulatory action by the FDA on codeine products.
Results: There were 666,824 pediatric tonsillectomies in our study
period. The monthly proportion of patients undergoing tonsillectomy
that had a claim for codeine decreased from 41% at the start of
2005 to 4% at the end of 2016. We found four months associated
with significant shifts in the trend: Aug 2008 (95% CI 03/2006, 01/
2017), Feb 2009 (95% CI 05–07/2009), May 2012 (95% CI 02–09/
2012), and Jul 2013 (95% CI 03–10/2013). The latter two joinpoints,
which bordered the period with the largest decline, appeared soon
after an FDA issued safety communication on the use of codeine in
Aug 2012 and introduction of a black box warning for these products
in Feb 2013.
Conclusions: We detected significant time points of shifting trends in
codeine use using joinpoint regression. This method captured early
reaction to emerging evidence and highlighted regulatory action as
the greatest influence of shifts.
510 | Clinical evaluation of benzodiazepine
and Z‐drug use duration among adults with
anxiety and sleep disorders in primary care
Jaden Brandt; Silvia Alessi‐Severini; Dan Chateau; Christine Leong
University of Manitoba, Winnipeg, MB, Canada
Background: Long‐term use of benzodiazepines and Z‐Drugs remains
an ongoing concern in the treatment of anxiety and sleep disorder.
Understanding factors related to potentially inappropriate use is
important for reducing adverse events.
Objectives: i) To measure the incidence of ‘long‐term’ benzodiaze-
pines/Z‐Drug (BZD) use among a cohort of Canadian adults with anx-
iety and/or sleep disorders.
ii) To determine factors associated with progression to long‐term BZD
use.
Methods: Linked administrative data from 1996–2016 was used to
conduct an incident user cohort study. Individuals were deemed eligi-
ble for the cohort if they were adults at the time of their first prescrip-
tion, had an ICD‐9/10 diagnosed anxiety, mood or sleep disorder and
did not have co‐existing seizure disorder, cancer or palliative condi-
tion. Prescription records were used at the individual level to longitu-
dinally track duration of use and enumerate ‘use’ episodes. Co‐
variates, measured at baseline, comprising demographic, socio‐eco-
nomic, provider and prescription level variables were analyzed in a
multiple variable logistic regression model. Sensitivity analysis was
used to measure variance in the estimate of ‘long‐term’ use given
the range of definitions available.
Results: i) Of 206.933 individual patients meeting the cohort criteria,
only 4.5–9.6% progressed to ‘long‐term’ use within their first treat-
ment episode. The proportion of ‘long‐term use’ increased to
15.6%–35.1% after all subsequent episodes for each user were
accounted for in an individualized ‘duration of use’ average.
ii) Factors statistically associated with ‘long‐term’ use in the first treat-
ment episode include; being male (OR = 1.33), age ≥ 65 (OR = 5.15),
receipt of income assistance (OR = 1.68), previous psychotropic
(OR = 1.93) or opioid prescription use (OR = 1.16), high comorbidity
score (OR = 1.43), high healthcare resource use score (OR = 1.46), first
prescription from psychiatrist (OR = 2.11) and having the first pre-
scription later in the study period (OR = 2.99).
Conclusions: Less than one in ten patients become ‘long‐term’ BZD
users in their first treatment episode. However, with repeated BZD
treatment, between one in every 3 to 6 patients go on to become
‘long‐term’ users in primary care. Clinicians should carefully consider
baseline factors associated with progression to ‘long‐term’ BZD use
in individual patients' benefit–risk equation.
511 | Use of non‐insulin diabetes medicines
after insulin initiation: A retrospective cohort
study
Yunwen Xu1,2; Scott J. Pilla3; Caleb G. Alexander1,2,3;
Irene B. Murimi1,2
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Center for Drug Safety and Effectiveness, Johns Hopkins University,
Baltimore, MD; 3Johns Hopkins Medicine, Baltimore, MD
Background: Clinical guidelines recommend that metformin be contin-
ued after insulin is initiated among patients with type 2 diabetes, yet
little is known regarding how often metformin or other non‐insulin
diabetes medications are continued in this setting.
Objectives: Among patients with type 2 diabetes initiating insulin, to
characterize rates and use patterns of six classes of non‐insulin diabe-
tes medications: biguanides (metformin), sulfonylureas,
thiazolidinediones (TZDs), glucagon‐like peptide 1 receptor agonists
(GLP1 receptor agonists), dipeptidyl peptidase 4 inhibitors (DPP4
inhibitors), and sodium‐glucose co‐transporter inhibitors (SGLT2
inhibitors).
Methods: We conducted a retrospective cohort study using the
2010–2015 MarketScan Commercial Claims and Encounters data to
examine 72,971 patients with type 2 diabetes aged 18–65 years old
who initiated insulin and had filled a prescription for a non‐insulin dia-
betes medication in the 90 days prior to insulin initiation. Our primary
outcome was the proportion of patients refilling the various non‐insu-
lin diabetes medications during the first 90 days after insulin initiation.
We also used time‐to‐event analysis to characterize the time to dis-
continuation of specific medication classes.
Results: Metformin was the most common non‐insulin medication
used prior to insulin initiation (N = 53,017, 72.7%), followed by sulfo-
nylureas (N = 25,439, 34.9%) and DPP4 inhibitors (N = 8,540, 11.7%).
More than four out of five patients (N = 65,902, 84.7%) refilled pre-
scriptions for any non‐insulin diabetes medications within 90 days
after insulin initiation. Within that period, metformin remained the
most common medication with the highest continuation rate of
84.6%, followed by SGLT2 inhibitors (81.9%) and TZDs (79.3%).
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Sulfonylureas were the least likely medications to be continued (73.6%
continuation) though they remained the second most common medi-
cation class used after insulin initiation. The median time to discontin-
uation varied by therapeutic class from the longest time to
discontinuation of 26.4 months among metformin users to the
shortest (3.0 months) among SGLT2 inhibitor users.
Conclusions: While metformin was commonly continued among com-
mercially insured adults starting insulin, rates of continuation of other
non‐insulin diabetes medications were also high. Further studies are
needed to determine the comparative effectiveness and safety of con-
tinuing insulin secretagogues and newer diabetes medications after
insulin initiation.
512 | Feedback to general practitioners on
inadequate statin prescriptions results in a
lower prevalence of statin use and no change
in the incidence of Ischaemic heart disease or
stroke: An interrupted time series analysis
Albert Prats‐Uribe1; Ermengol Coma2; Francesc Fina‐Aviles2,3;
Mireia Fàbregas4,3; Samuel Hawley1; Manuel Medina2,5;
Daniel Prieto‐Alhambra1,5
1University of Oxford, Oxford, UK; 2Sistema d'Informació dels Serveis
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Background: There is controversial evidence on the risk–benefit of
statin therapy in primary prevention. The Catalan Health Institute
launched a feedback programme for affiliated general practitioners
to discourage statin primary prevention therapy in patients with low
estimated risk.
Objectives: we aimed to test the impact of the feedback programme
on the use of statins in low (<5%) vs high (>10%) cardiovascular risk
patients, and on their incidence of vascular events.
Methods: patients registered in the SIDIAP database in the study
period and with a 10‐year REGICOR cardiovascular risk, a re‐cali-
brated equation based on the Framingham score, recorded were
included. SIDIAP includes primary care records for >6 million people
(>80% of the population) from Catalonia, linked to pharmacy dispensa-
tions. Previously validated ICD10 codes were used to identify ische-
mic heart (IHD) and cerebro‐vascular (CVD) events separately; ATC
codes were used to identify statin dispensations. Monthly prevalence
of statins use and monthly incidence rates (IR) of IHD and CVD were
estimated for the period 1/1/2013 to 31/12/2018 for people aged 35
to 74 years old. ARIMA models were used to estimate the impact of
the feedback programme (established in May 2014, with a 12‐month
lag) on the secular trends of statin use, IHD, and CVD.
Results: A median of 755,518 low risk subjects and 36,674 with a high
risk were included. A median of 1,800,095 and 220,695 were
excluded due to lack of data on estimated risk or a previous cardiovas-
cular history. The prevalence of statins in low risk patients was already
in decline before the intervention but declined further immediately
after the feedback programme (p < 0.001), and continued to decline
in the following years (p < 0.001) shifting from a pre‐intervention
mean prevalence of 23% to 17% post‐intervention; pre‐existing slow
increases in IHD and CVD rates did not change after the intervention.
The prevalence of statins use in high risk patients was stable at 45%
before the feedback programme, followed by a continued decline in
use in the following 4 years (p < 0.001) to a 43% mean prevalence
after; no change in the secular trends of either IHD or CVD were
observed.
Conclusions: Electronic feedback to general practitioners resulted in a
progressive reduction in the prevalence of use in low risk patients
(inappropriate prescription), and a progressive decrease in use in high
risk subjects. No change in the secular trends of IHD or CVD were
observed in neither of low or high‐risk patients.
513 | Pregabalin use outside subsidy
restrictions in Australia
Tricia Roujia Chiu1; Sallie Pearson1,2; Andrea L. Schaffer1
1UNSW Sydney, Sydney, Australia; 2University of Sydney, Sydney,
Australia
Background: In March 2013, pregabalin was subsidized on Australia's
Pharmaceutical Benefits Scheme (PBS) for neuropathic pain after
treatment failure with other medicines. Since its public subsidy,
pregabalin use skyrocketed, raising questions about the appropriate-
ness of its use.
Objectives: We detail patterns of pregabalin initiation, discontinua-
tion, and consistency with PBS subsidy restrictions.
Methods: We performed a retrospective cohort study of people initi-
ating pregabalin using dispensing claims for a 10% sample of Austra-
lians (2013–2018). We examined patterns of initiation including
dispensing of other prescribed analgesics prior to initiation, and treat-
ment discontinuation in the first year. We used logistic regression and
Cox regression to identify predictors of initiation without prior use of
analgesics, and time to discontinuation, respectively.
Results: During our study period 142,910 people initiated pregabalin
(median age 61 years, 56.8% female). Initiation was constant over
time, from 25,604 in 2013/14 to 24,632 in 2017/18. In the 180 days
prior to pregabalin initiation, dispensing of other first‐line medicines
for neuropathic pain was low: tricyclic antidepressants (12.2%), SNRIs
(8.5%), and gabapentin (0.4%). However, dispensing of other pre-
scribed analgesics was common: weak opioids (30.6%), strong opioids
(28.3%), and NSAIDs (30.4%). Overall, 81.5% (n = 107,147) had not
been dispensed a first‐line treatment, and 35.8% (n = 47,002) had
not been dispensed any analgesic, which increased from 29.2% in
2013/14 to 40.3% in 2017/18. Predictors of initiation without prior
dispensing of analgesics included: male sex (adjusted OR (aOR) = 1.17,
95% CI 1.14–1.19), and both age < 45 years (vs 65–84 years)
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(aOR = 1.12, 95% CI 1.09–1.16) and ≥ 85 years (aOR = 1.11, 95% CI
1.06–1.17). In the year after initiation, 83.1% discontinued, with
46.3% discontinuing after the first dispensing. Predictors of discontin-
uation were younger age, initiating in 2016/17 (vs 2013/14)
(aHR = 1.23, 95% CI 1.21–1.26), no prior dispensing of neuropathic
pain medicines (aHR = 1.32, 95% CI 1.30–1.34) or other prescribed
analgesics (aHR = 1.19, 95% CI 1.18–1.21), and initiating on 75 mg
(vs 300 mg) (aHR = 1.42, 95% CI 1.33–1.53).
Conclusions: Few people initiating pregabalin had used recommended
first‐line neuropathic pain medicines, and more than one third had not
been dispensed any PBS‐subsidized analgesics. This suggests that pre-
scribers are not adhering to subsidy restrictions, which is increasing
over time. Further, high rates of discontinuation may indicate poor tol-
erability or use in patients where the medication is not effective or
appropriate.
514 | Impact of tramadol classification on
the prescribing of other pain medicines
commonly related to drug‐misuse deaths in
UK
Teng‐Chou Chen1; Roger D. Knaggs2,3; Li‐Chia Chen1
1Division of Pharmacy and Optometry, School of Health Sciences, Faculty
of Biology, Medicine and Health, University of Manchester, Manchester,
UK; 2Division of Pharmacy Practice and Policy, School of Pharmacy,
University of Nottingham, Nottingham, UK; 3Primary Integrated
Community Solutions, Nottingham, UK
Background: Tramadol was classified as a Controlled Substance in the
United Kingdom (UK) in June 2014 due to increased mortality related
to tramadol. Since then, there has been a decrease in tramadol pre-
scribing, but a concern was raised about a potential substitution effect
between tramadol and other pain medicines which are also associated
with drug‐misuse deaths (DMDs).
Objectives: This study aimed to evaluate the impact of tramadol clas-
sification on the utilization of other pain medicines commonly related
to DMDs in the UK.
Methods: A cross‐sectional study was conducted by using practice‐
level dispensing data from the UK National Health Service Digital
and the estimated population size from the Office for National Statis-
tics between August 2010 and July 2017. Primary care practices pre-
scribing pain medicines commonly related to DMDs during the study
period were included. Pain medicines were categorized into opioids
(excluding tramadol), benzodiazepines (BZDs), z‐drugs, antipsychotics,
selective serotonin reuptake inhibitors (SSRIs), serotonin‐norepineph-
rine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and
gabapentinoids (GABAs). Monthly utilization was measured as the
number of Defined Daily Doses/1000 registrants/month for each cat-
egory of medicines. Interrupted time‐series analysis was used to eval-
uate the impact of the intervention (tramadol classification) on the
utilization of each category of medicines after adjusting autocorrela-
tion by an auto‐regressive integrated moving average model.
Results: After the intervention, the trend of increasing (β1: 2.4,
p < 0.001) monthly opioids utilization did not change, but the trend
of increasing monthly utilization significantly elevated for SSRIs (β3:
3.2, p = 0.004) and SNRIs (β3: 0.18, p = 0.025). Furthermore, the
decreasing trend of monthly BZDs utilization (β1: −1.6, p < 0.001) sig-
nificantly raised (β3: 0.49, p < 0.001) after the intervention, while
increasing trend of monthly GABAs utilization (β1: 2.9, p < 0.001)
did not change and utilization consistently escalated.
Conclusions: After tramadol classification, the increasing trend of uti-
lization of SSRIs, SNRIs and BZDs implies a potential substitution but
the increasing prescribing of GABAs in England is not related to tram-
adol classification. Further studies should apply individual patient data
to clarify the switching between tramadol and these medicines and
evaluate the impacts of this substitution on DMDs in the UK.
515 | Mortality and hospitalization following
initiation of Sacubitril/valsartan in the
Medicare population
Nicholas S. Roetker; Yi Peng; William Eggert; David T. Gilbertso
Hennepin Healthcare Research Institute, Minneapolis, MN
Background: In 2015, sacubitril/valsartan received approval as a treat-
ment for chronic heart failure with reduced ejection fraction (HFrEF).
Few population‐based studies have characterized early users of the
drug.
Objectives: To describe a population‐based cohort of patients initiat-
ing sacubitril/valsartan in terms of their baseline characteristics and
subsequent clinical outcomes.
Methods: This study used claims data from a 20% general Medicare
sample for patients with Medicare Parts A/B (fee‐for‐service) and Part
D (prescription drug) coverage. We included all patients initiating
sacubitril/valsartan in 2015–2016, with the first prescription fill date
defined as the index date. We used claims from 2007–2016 to iden-
tify baseline covariates and required patients to have at least one year
of fee‐for‐service coverage prior to the index date. We estimated the
rates of hospitalization with HF as the primary discharge diagnosis (HF
hospitalization), cardiovascular death, and all‐cause death through the
end of follow‐up. The underlying cause of death was determined via
linkage with the National Death Index.
Results: 4,111 patients initiating sacubitril/valsartan were included in
the study, with mean age 72.6 (range: 28–97) years, 33% female,
and 80% white. Patients had a high burden of comorbidities, including
histories of hypertension (98%), diabetes (61%), atrial fibrillation (60%),
myocardial infarction (54%), and cerebrovascular disease (43%).
Patients were first diagnosed with HF an average of 5 years before
the index date, and 22% had a prior HF hospitalization. The most com-
mon starting dose of sacubitril/valsartan was 24/26 mg (63%),
followed by 49/51 mg (29%) and 97/103 mg (8%). Over a mean fol-
low‐up of 5.7 months, patients had an average of 4 fills of sacubitril/
valsartan (including the index fill), constituting an average drug supply
of 5 months. Treatment interruption (discontinuation or a gap
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between prescriptions of more than 45 days) occurred in 25% of
patients. The rates per 100 person‐years of clinical outcomes were
16.8 (95% confidence interval [CI] 15.0, 18.8) for the composite of
cardiovascular death and HF hospitalization, 7.9 (95% CI 6.8, 9.3) for
cardiovascular death, 10.2 (95% CI 8.9, 11.8) for HF hospitalization,
and 11.9 (95% CI 10.5, 13.5) for all‐cause death.
Conclusions: In this study, sacubitril/valsartan users had a high base-
line comorbidity burden and experienced a high rate of mortality and
hospitalization, as would be expected for patients with chronic HF.
Future work should assess the effectiveness and safety of sacubitril/
valsartan in population‐based studies.
516 | Negative control outcomes to control
for unmeasured confounding in device safety
research: A clinical example
Daniel Prieto‐Alhambra1; James Weaver2; Henry Morgan‐ Stewart3;
Anthony Sena2; Edward Burn4; Patrick Ryan2,5
1University of Oxford, Oxford, UK; 2 Janssen Research & Development,
Titusville, NJ; 3 IQVIA, London, UK; 4University of Oxford, Oxford, UK;
5Columbia University, New York, NY
Background: Negative control outcomes have been proposed to
adjust for uncontrolled confounding in drug safety research. There is
seldom experience on their use in medical device epidemiology.
Objectives:We aimed to demonstrate the use of negative control out-
come calibration after propensity score matching. We tested this in
the study of post‐operative infections following partial (PKR) com-
pared to total knee replacement (TKR).
Methods: ‐Design: Propensity score matched multi‐database parallel
cohorts. ‐Setting and participants: Data was obtained from 4 US
claims (IBM MarketScan® Commercial Database (CCAE), IBM
MarketScan® Medicare Supplemental Database (MDCR), Optum ®
de‐identified Clinformatics ® Datamart, Extended ‐ Date of Death
(Optum) and PharMetrics) databases. All these were mapped to the
OMOP common data model. Subjects undergoing PKR or TKR in any
of these databases from 2005 onwards at age 40 or older were
included. ‐Exposures: PKR and TKR were compared. ‐Outcomes:
post‐operative infections of the surgical area or the prosthesis within
60 days post‐surgery were considered. ‐Statistical analysis: Propensity
score matching with a 0.02 SD caliper width was used to minimize
confounding. Cox regression models were fitted to calculate Hazard
Ratio (HR) and 95% Confidence Intervals [95CI] for infection accord-
ing to device type, using TKR as the reference group. A list of 39 neg-
ative control outcomes was pre‐specified and results used to calibrate
the obtained HRs. All analyses were run separately for each of the
databases [Schuemie MJ et al. Stats Med 2014] using a common R
package.
Results: Propensity score matching worked to reduce confounding
for all observed variables below the pre‐specified threshold of a
standardized difference of <0.1. In CCAE, 96/7,779 (1.23%) PKR
and 845/58,290 (1.45%) TKR subjects had the outcome of interest;
compared to 58/4,093 (1.42%) PKR and 613/34,836 (1.76%) TKR
in MDCR; 71/5,750 (1.23%) PKR and 795/43,612 (1.82%) TKR in
Optum; and 141/12,777 (1.10%) PKR and 1,638/98,516 (1.66%) in
PharMetrics. Cox models in the propensity‐matched cohorts sug-
gested a consistent reduction in risk of infection with PKR, with
HR [95CI] ranging from 0.66 [0.55–0.78] in PharMetrics to 0.85
[0.68–1.05] in CCAE. Calibration after negative control outcomes
attenuated this and resulted in non‐significant associations in any
of the 4 databases, with HR ranging from 0.73 [0.45–1.24] in
PharMetrics to 1.04 [0.77–1.43] in CCAE.
Conclusions: Calibration for negative control outcomes was useful to
adjust for residual confounding (for unobserved variables) after pro-
pensity score matching.
517 | Tramadol analgesic use as a screening
tool for Total hip arthroplasty implant
survival: A population‐based cohort study
Tamer T. Malak1; Andrew Judge2; Daniel Prieto‐Alhambra1
1University of Oxford, Oxford, UK; 2University of Bristol, Bristol, UK
Background: The need for effective screening tools to monitor
implant performance and identify poorly performing implants early
has been highlighted by recent failings of metal‐on‐metal devices.
Objectives: To investigate whether tramadol utilization in the first
year following total hip arthroplasty (THA) surgery is associated with
long‐term implant survival.
Methods: A retrospective observational cohort study was conducted.
Data was used from the Catalan Joint Registry (RACAT) linked to pri-
mary care records and pharmacy invoice data in the SIDIAP Database
(www.sidiap.org). All participants registered in both SIDIAP and RACat
undergoing primary THA between 2005 and July 2012 were eligible
(n = 17,034). Patients under the age of 40 and revisions in the first‐
year post‐operation were not included. Fine & Gray models were used
to investigate the association between tramadol use and implant sur-
vival adjusting for age, gender, Charlson comorbidity index, socio‐eco-
nomic status, cardiovascular disease, atrial fibrillation, hypertension,
diabetes, depression, cancer, indication, previous fixation, fracture,
BMI, alcohol, smoking. Multiple imputation by chained equations
was used to adjust for missing values for the BMI, alcohol and smoking
variables.
Results: 16,433/17,034 (96.5%) patients were eligible. Of these 158/
16,433 (1.0%) revisions were observed after a median of 2.25 (1.22–
3.74) years follow‐up. Tramadol use following THA surgery was signif-
icantly associated with revision rate. Adjusted sub‐hazard ratio (SHR)
was 2·42 [95%CI 1.74–3.35, p < 0.001].
Conclusions: This study demonstrates an association between tram-
adol use within the first post‐operative year following THA surgery
and subsequent revision rates. Tramadol prescriptions can, through
linkage to arthroplasty registries, potentially be used as an early
surrogate to identify patients and implants at high risk of device
failure.
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518 | Long‐term outcomes following mid‐
urethral mesh sling surgery for stress urinary
incontinence
Sara Z. Dejene1; Jennifer M. Wu2; Virginia Pate1;
Michele Jonsson‐Funk1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2University of North Carolina School of
Medicine, Chapel Hill, NC
Background:Midurethral mesh slings are the gold standard surgery for
stress urinary incontinence (SUI). However, following FDA safety noti-
fications regarding risks of vaginal mesh surgery for other indications,
concerns have been raised about midurethral slings, with regulatory
agencies banning or restricting this surgery in some countries. Women
who undergo mesh sling procedures may need another procedure to
remove the sling due to complications, such as visible mesh exposure
or urinary retention, or a repeat SUI surgery for recurrent symptoms.
Objectives: To determine the long‐term risk of sling removal for either
mesh exposure or urinary retention and the risk of repeat SUI surgery
after initial sling surgery in a U.S. based population and to identify
potential predictors of these outcomes.
Methods: Using a population‐based cohort of commercially insured
individuals, we identified women aged 18 and older who underwent
a sling procedure between January 1, 2001 and September 30,
2015. We estimated the cumulative risk (95% confidence interval
[CI]) of sling removal and repeat SUI surgery annually using Kaplan–
Meier survival curves and evaluated predictors of sling removal and
repeat surgery using Cox proportional hazards models. Predictors
included age, year of initial sling surgery, region, and other concurrent
procedures for SUI.
Results: We identified 305,970 mesh sling surgeries. Median age was
53 (IQR: 45–61). The 10‐year cumulative risk of sling removal was
5.5% (95%CI, 5.3–5.7). The proportion of sling removals due to mesh
exposure was 59.1%, with a 10‐year risk of 3.6% (95%CI, 3.5–3.8),
and the proportion due to urinary retention was 37.4%, with a 10‐year
risk of 1.7% (95%CI, 1.6–1.8). For repeat SUI surgery, the 10‐year risk
was 12.9% (95%CI, 12.6–13.2). The 10‐year risk of any subsequent
surgery (removal or repeat SUI surgery) was 16.4% (95%CI, 16.1–
16.7). Women aged 18–29 had an elevated risk for both sling revision
and repeat SUI surgery compared to women over 70, with hazard
ratios of 1.55 (95%CI, 1.48–1.63) and 1.66 (95%CI, 1.58–1.74),
respectively.
Conclusions: In this population‐based analysis, the 10‐year risks of
sling removal and repeat surgery were 5.5% and 12.9%, respectively.
These findings are consistent with the results of previous studies
reporting relatively low risk of complications following these widely
used procedures, including a lower 10‐year odds of repeat surgery
compared to women who underwent Burch colposuspension. These
and other recent findings may provide critical data for women and
providers considering mesh sling surgery for SUI to support informed
decisions.
519 | Machine learning for probabilistic
phenotypes and exploration of complex
coding patterns in large real‐world healthcare
databases: An applied example in conversion
from minimally‐invasive to open
Sigmoidectomy
Stephen Johnston1; Stephen Fortin1; Jenna Reps2
1 Johnson & Johnson, New Brunswick, NJ; 2 Janssen, Johnson & Johnson,
Titusville, NJ
Background: Conversion from minimally‐invasive to open surgery
is a marker of adverse clinical circumstances and an important
outcome in surgical research; however, conversion codes may
be unavailable or under‐coded in real‐world healthcare
databases.
Objectives: We applied machine learning techniques to a high‐dimen-
sional US EHR dataset to develop an exploratory phenotypic predic-
tive model of conversions in patients undergoing sigmoidectomy.
We sought to identify factors that co‐occur with conversion codes
as candidates for inclusion in improved conversion identification algo-
rithms for use in future research.
Methods: We extracted electronic health records from the Optum
Pan‐therapeutic database for patients aged≥18y undergoing inpa-
tient sigmoidectomy between 10‐01‐2016—12‐31‐2017 (first admis-
sion = index). The outcome was defined as a documented code for
conversion (ICD‐10‐CM = Z53.3x) during index. We constructed a
high‐dimensional dataset comprising demographics, individual binary
indicators for every observed diagnosis, procedure, and ingredient‐
level medications recorded at index. We utilized regularized lasso
regression to develop and internally‐validate a prediction model
(75%/25% split model training/testing) based on the high‐dimen-
sional dataset.
Results: The analysis included 3,386 patients, of whom 501
(14.8%) experienced conversion. In testing, the final model pos-
sessed good discriminative accuracy (area under the curve
[AUC] = 0.902, 95% CI = 0.869–0.936) with poor sensitivity, but
otherwise good diagnostic accuracy (at predicted probability = 0.5:
specificity = 0.987, sensitivity = 0.559, ppv = 0.880, npv = 0.927).
Of 12,067 covariate candidates considered for inclusion in the
model, 245 were selected by lasso logistic regression. The three
covariates most strongly associated with increased risk of conver-
sion were “Inspection of Lower Intestinal Tract, Percutaneous
Approach,” “Accidental puncture and laceration of a genitourinary
system organ or structure during a genitourinary system proce-
dure,” and “Inspection of Peritoneum, Percutaneous Endoscopic
Approach”; these covariates appear to represent factors that co‐
occur (inspection procedures) or necessitate (accidental puncture/
laceration) conversions.
Conclusions: Our findings suggest that machine learning techniques
may be valuable for hypothesis‐generating exploration of complex
coding patterns in large healthcare databases.
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520 | Application of propensity scores odds
to visualize clinical equipoise for robotic
assisted surgery from 2003 to 2015
Gary Chung1; Art Sedrakyan2; Piet Hinoul1; Paul Coplan1;
Andrew Yoo1
1 Johnson & Johnson, New Brunswick, NJ; 2Weill Cornell Medical Center,
New York, NY
Background: Robotic assisted surgery (RAS) revolutionized surgical
practice since the early 2000s. Urology and gynecology appear to
be at a RAS adoption steady state in the USA. We define channeling
bias as the preference for a certain surgical approach and clinical
equipoise as the point of parity for RAS versus more traditional
approaches for a given patient‐hospital‐procedure (PHP) profile.
Given the diversity of possible PHP profiles, characterizing the evo-
lution of channeling bias and clinical equipoise over time remains a
challenge.
Objectives: To evaluate a method for visualizing channeling bias of
PHP profiles receiving robotic versus standard surgery.
Methods: This was a retrospective population‐based cohort study
utilizing the Premier Healthcare Database. Individuals >18 years old
who underwent prostate (n = 199,704) or uterus (n = 1,476,595)
surgery between July 2001 and July 2015 were included. RAS utili-
zation was identified by either ICD9 codes 17.4x or charge file text‐
search. 5 discrete adoption periods were identified using diffusion of
innovations theory. Clinical equipoise occurs when the odds of a
PHP profile receiving RAS compared to other approaches is 1:1.
We use propensity scores (PS) due to its unidimensional simplicity
and population comparability. Kernel densities of the PS distributions
were log‐scaled to number of persons to better visualize and inter-
pret population shifts. The ratio of these two distributions is termed
PS‐odds.
Results: The 5 discrete adoption periods for prostate and uterus
respectively were 2002‐‘03, ‘03‐‘05, ‘05‐‘07, ‘07‐‘11, ‘11‐‘15 and
2001‐’06,’06‐’08,’08‐’10,’10‐’12, and’12‐’15. For the first 3 periods,
the PS‐odds favored the non‐RAS groups by a mean of 59.6, 4.21,
3.00 and 64.1, 26.7, 4.32 odds for prostate and uterus, respectively.
Only in the last 2 periods did clinical equipoise begin to occur for
select PHP profiles. Mean PS‐odds still favored non‐RAS in these last
2 periods (1.98, 2.48 prostate and 2.67, 2.19 uterus). Splitting by PS‐
odds favoring RAS versus non‐RAS, the mean PS‐odds for prostate
were: .433 RAS vs 3.71 non‐RAS in period 4 and .498 vs 5.14 in
period 5; for uterus: .555 RAS vs 3.58 non‐RAS in period 4 and.451
vs 4.82 in period 5.
Conclusions: Patient propensity‐score odds is a useful tool for mea-
suring channeling bias and its evolution in the adoption of new surgi-
cal technologies. In the example of robotic assisted surgery, clinical
equipoise first occurred from 2007‐’11 in prostate and 2010‐’12 in
uterus. Compared to uterus, prostate RAS procedures appear to have
more channeling towards specific patient hospital profiles.
521 | Does operating room time affect the
rate of superficial, deep and organ system
post‐surgical infections in Total knee
replacement?
Zhenna Huang1; Abhishek S. Chitnis1; Chantal E. Holy1;
Deepak Krishnan2; John Wright1
1 Johnson and Johnson Inc., New Brunswick, NJ; 2Mu‐sigma, Bangalore,
India
Background: Post‐surgical infections are significantly associated with
postoperative morbidity and mortality. Prolonged operating room
time may increase the risk of infections due to increased surgical
wound exposure and contamination, increased damage to tissue
and bleeding. However, there is very limited data on relationship
between operating room time and type of post‐surgical infections
(superficial, deep and organ system) after total knee replacement
(TKR).
Objectives: To evaluate the association between operating room time
and types of post‐surgical infections (superficial, deep and organ sys-
tem) after unilateral TKR.
Methods: This was a retrospective observational cohort study.
Through data partnership with Mercy‐Technology‐Services,
patients who underwent unilateral TKR surgery were extracted
from 2011–2018 Mercy electronic health records, which is one
of the most comprehensive real‐world databases including preop-
erative and intraoperative information. The main independent var-
iable was operating room time for TKR. The dependent variable
was absence or presence of post‐surgical infection by types,
superficial, deep or organ system within 3 months of TKR. A
Multinomial logistic regression was constructed controlling for
patient demographic and clinical characteristics. Odds ratios (OR)
along with 95% confidence intervals (95% CI) and p‐values were
reported.
Results: A total of 21,584 patients with mean (SD) age 66.8 (9.9)
years, 61.8% females and mean (SD) Elixhauser score 2.8 (1.9) were
included in the analysis. Of these, 1.2% patients developed superficial
infections, 0.60% patients developed deep infections and 5.19%
patients developed any organ system infections within 3 months after
TKR. The adjusted multinomial logistic regression showed that with a
10‐minute increase in operating room time the odds for superficial
infection increased by 9% (OR, 1.09, 95% CI, 1.06–1.12), the odds
for deep infections increased by 10% (OR, 1.10, 95% CI, 1.06–1.12)
and the odds for any organ system infections increased by 5% (OR,
1.05, 95%CI, 1.03–1.07) (all P < 0.0001) as compared to patients with-
out infections.
Conclusions: This study found that increase in operating room time
was associated with an increased risk of superficial, deep and any
organ system infections after TKR. The study suggests that efforts
to lower the operating room time, thereby reducing the length of time
the surgical wound is open would reduce the rates of post‐surgical
infections.
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522 | Utilization of intrauterine device in
Europe ‐ prescription patterns in routine
medical practice
Tanja Boehnke; Anja Bauerfeind; Klaas Heinemann
ZEG ‐ Berlin, Center for Epidemiology and Health Research, Berlin,
Germany
Background: A variety of intrauterine devices are available on the
European market, including devices of different shapes, sizes, compo-
sition and mechanism. Guidelines identifying the appropriate intra-
uterine device (IUD) for an individual, only exists for mechanism of
action (i.e. hormonal vs. copper).
Objectives: To describe prescription patterns of IUDs in routine med-
ical practice in Europe and to identify women's characteristics that
may influence the choice of IUD.
Methods: Analyses were based on the multinational, prospective, non‐
interventional “European Active Surveillance Study on LCS12”
(EURAS‐LCS12). Participants were recruited from eight European
countries ‐ Germany, Austria, United Kingdom, France, Poland, Finland
and Sweden via health care providers. The association between
women's baseline characteristics and IUD characteristics were ana-
lyzed by multiple linear and logistic regression models.
Results: Approximately 48,000 women were included in the analysis.
Prescription patterns differed by country. Across all countries
observed, parity was consistently identified as having an influencing
effect on the choice of IUD characteristics. Parous women used larger
copper IUDs with a longer ‘duration of use‘and larger copper surface
area, compared to nulliparous women. Omega‐ and Y‐shaped devices
and additional coatings of gold and silver, respectively were also more
likely to be used in this subgroup. Nulliparous women more frequently
used copper sleeves or ‐beads. Other influencing factors for some IUD
characteristics were age, education, monthly household income, previ-
ous use of hormonal contraceptives and intrauterine devices.
Although trends in prescription pattern could be observed, there are
only a few hormonal intrauterine systems (IUSs) currently marketed
having similar characteristics. Therefore, trends could not be clearly
differentiated.
Conclusions: Parity of women is consistently an influencing factor for
the choice of copper IUD and hormonal IUS characteristics in all
observed European countries.
523 | Administrative burden of the Brazilian
rule that contributes to Price transparency in
the medical device market
Daniel Marques Mota; Júlia de Souza Ferreira;
Daniela Martins Ferreira; Gabrielle CunhaBarbosaCavalcanti e;
Cysne Troncoso; Gustavo Cunha Garcia
Brazilian Health Regulatory Agency (Anvisa), Brasília, Brazil
Background: The lack of transparency in the market is one of the main
factors for the great variation in prices of medical devices. In Brazil,
the Brazilian Health Regulatory Agency (Anvisa) published a rule
(RDC No. 185/2006) with the purpose of reducing the asymmetry of
information on prices of strategic medical devices for the public health
system. The prices are declared by the companies and are published in
a dashboard on the Anvisa website.
Objectives: The aim of this study was to estimate the administrative
burden of the RDC No. 185/2006 imposed on companies of informa-
tion and reporting obligations.
Methods: It was used the Standard Cost Model to measure the admin-
istrative burden of information and reporting obligations requested by
RDC No. 185/2006 and sent to Anvisa in the period from 2014 to
2017. Nine companies were contacted to respond to the instrument
of data collection. The basic parameters used in this measurement
were: i) price; ii) time; and iii) quantity. We used the Shapiro–Wilk test
to evaluate if the sample data presented a normal distribution and the
Grubbs test was performed to verify the presence of outlier. The final
estimate of the administrative burden is presented in annual monetary
value in dollars.
Results: Seven companies participated in the study, representing
10.4% of 67 who submitted 651 reports of economic information on
medical devices to Anvisa in the period from 2014 to 2017. The data
presented a normal distribution (W = 0.9655; p‐value = 0.8643) and
according to the Grubbs test the extreme observations of the sample
were not considered discrepant values. Thirteen information obliga-
tions were identified in the rule, resulting in an estimated average
annual administrative burden of $ 315,202.17. Companies spend more
resources to comply with the following information obligations: (i)
Familiarization with the rule; (ii) Price of the medical device practiced
in other countries; and (iii) List of substitute medical devices accompa-
nied by their respective prices.
Conclusions: This is a pioneer study assessing administrative burden
of the Brazilian rule that contributes to price transparency in the med-
ical device market. The results should be considered in a future revi-
sion of the RDC No.185/2006, with the purpose of reducing the
administrative burden for companies, if the information obligations
are not essential to minimize the problem of asymmetry of information
in the Brazilian market.
524 | Validation of algorithms for identifying
pulmonary hypertension patients using
diagnostic predictive modeling in large claims
databases
Eva‐Maria Didden1; Daniel Fife2; Deborah A. Quinn1; Lu Wang2;
Joel N. Swerdel2
1Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; 2 Janssen Research
& Development, LLC, Titusville, NJ
Background: Pulmonary hypertension (PH) is a progressive fatal dis-
ease with multiple etiologies. There is no consensus on its incidence
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and prevalence. Claims databases provide potential for real‐world
study of PH, but identifying PH patients based on administrative
codes (ICD‐9/10 and others) is challenging.
Objectives: To test a series of algorithms for identifying PH patients in
claims databases, using the PheValuator, a diagnostic predictive
modeling tool.
Methods: We used 4 US administrative claims databases: Optum©
De‐Identified Clinformatics® Data Mart Database, IBM®
MarketScan® Multi‐State Medicaid, Medicare Supplemental Benefi-
ciaries, and Commercial Claims and Encounters (data from 2010–17).
Using PheValuator in each database, we developed a diagnostic pre-
dictive model for PH, which was applied to 2 million random subjects
to estimate the probability of each subject being a PH case or non‐
case. These probabilities were then used to validate several PH algo-
rithms for patient identification. The tested algorithms included 1)
≥1 occurrence of a PH diagnosis code in the subject's record
[≥1DX], 2) ≥1 occurrence of a PH diagnosis in a hospital inpatient set-
ting [≥1DX‐IP], 3) a procedure code for right heart catheterization or
echocardiography (RHC/Echo) followed by a PH diagnosis [RHC/Echo
+DX], and 4) a PH diagnosis followed by a RHC or Echo and another
PH diagnosis [DX + RHC/Echo+DX].
Results: The proportion of patients identified as having PH was higher
in retired subjects, with variations by PH algorithm. The algorithm
[≥1DX] yielded an average proportion of 1.64% across the databases
(range: 0.25%–3.80%), showed the lowest positive predictive value
(PPV) (average: 83.4%, range: 74.3–92.5%) but highest sensitivity
(average: 99.8%, range: 99.7–99.9%). The most complex algorithm
that requires PH diagnoses before and after diagnostic test,
[DX + RHC/Echo+DX], yielded an average proportion of 0.14% (range:
0.02%–0.35%), showed highest PPVs (average: 91.4%, range: 83.6–
96.4%) but lowest sensitivities (average: 9.2%, range: 8.6–10.3%).
The performance characteristics of other algorithms fall between
these extremes. Specificities were high for all algorithms (>99%).
Conclusions: All the tested algorithms identified PH patients with high
specificity, but sensitivity and PPV varied widely. While sensitivity
substantially decreased with algorithm complexity, PPV tended to
increase. Model‐based tools like the PheValuator can help evaluate
and prioritize algorithms for PH patient identification in claims data-
bases to meet different research purposes.
525 | Incidence of systemic sclerosis. An
epidemiological study in a large insured
population in the US
Alexander Michel1; Marcela Rivera2; Tatsiana Vaitsiakhovich2
1Bayer, Basel, Switzerland; 2Bayer, Berlin, Germany
Background: Systemic Sclerosis (SSc), also called scleroderma, is a very
rare, chronic autoimmune disease, which can affect the skin, as well as
internal organs. Incidence estimates vary widely, which could be due
to the rarity of the disease, the wide range of possible symptoms, dif-
ferent disease definitions used as well as geographical variation.
Objectives: To estimate the contemporary incidence of SSc, using a
large US‐based claims database.
Methods: We conducted a retrospective cohort study in the IBM
Watson Health MarketScan Commercial Claims and Encounters Data-
base, containing data from over 50 million patients from over 150
large employers geographically distributed throughout the US. Study
period was 01. Jan 2010 until 31. Dec 2015. Following manual review
of electronic patient profiles from a sample of patients with SSc in
MarketScan, cases of SSc were defined using the following inclusion
criteria based on the ICD codes:
‐Raynauds Syndrome and two SSc outpatient diagnosis (at least
30 days apart) or ‐Three SSc outpatient diagnoses (two of these diag-
noses should be at least 30 days apart) or‐One SSc inpatient diagnosis
plus one SSc outpatient diagnosis (on different dates).
Yearly incidence estimates and 95% confidence intervals were calcu-
lated for each calendar year from 2010 until 2015. Incident cases were
required to have no recorded claim of SSc any time before the entry
date.
Results: Overall 4782 incident cases of SSc were identified over the
study period. Incidence rates per 100,000 person‐years (95% C.I.)
decreased from 4.49 (4.19–4.80) in 2010 to 2.73 (2.48–2.97) in
2015. In the adult population (>18 years) incidence rates in females
decreased from 9.13 (8.46–9.80) to 5.52 (4.99–6.06) and in males
from 1.38 (1.10–1.65) to 0.83 (0.61–1.04) over the same time‐period.
Results for the pediatric population have been published previously
(Michel A et al, Arthritis & Rheumatology, 2018, 70(S9):1576–1577).
Conclusions: Incidence estimates of SSc in the MarketScan database
are higher than previously reported from field studies in the USA,
but in the same range as reported from another claims database in
the USA (Furst et al. J Rheumatol 2012;39:784–6). A conservative
case definition has been used in our study, since SSc is a complex dis-
ease often requiring considerable time to be diagnosed. However, this
case definition may have led to the decrease in incidence seen over
the study time period, since patients diagnosed at the end of the time
window had less opportunity to fulfill the definition compared to
those diagnosed during the first years. Such artifacts need to be con-
sidered in database studies of similar conditions.
526 | Incidence of Vaso‐occlusive crisis and
setting of Care in Patients with sickle cell
disease from 2013 through 2017 in the
United States
Stephen E. Schachterle; Emily Rubinstein; Jingping Mo; Andrew Bate;
Richard Gong; Krupa M. Sivamurthy; Frank Shafer
Pfizer, New York, NY
Background: Despite an evolution in the care of patients with Sickle
Cell Disease (SCD), the incidence rate of vaso‐occlusive crisis (VOC)
in patients with SCD has not been estimated with recent data. The
availability of large insurance claims and Electronic Health Records
(EHRs) data allows for a rapid reassessment of VOC in these patients.
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Objectives: 1. Estimate the recent incidence rate of VOCs in patients
with SCD in large US insurance claims and EHR databases. 2. Examine
distribution of incident VOC events according to the setting of care.
Methods:
Design: Patients were followed longitudinally from their diagnosis of
SCD to the end of the study period, loss of enrollment, or a VOC
event.
Setting: SCD patients were identified in 3 US databases: the (1) Truven
Health Market Scan® Multistate Medicaid database, the (2) Optum
EHR, and (3) the Optum claims‐based Clinformatics® Data Mart from
2013 through 2017. These databases were selected because of the
high completeness of their health records and the inclusion of the
Medicaid data in the Truven database.
Exposures: Follow up began at the first of 2 diagnoses of SCD, which
were defined by diagnostic code, and a 30 day enrollment period
where patients were free of a VOC diagnosis.
Outcome: VOC events were were defined as a first diagnostic code for
a SCD crisis following the first qualifying SCD diagnosis. Treatment
setting included any hospital inpatient admission, emergency depart-
ment visit, or outpatient clinic visit that started within the 7 days fol-
lowing the incident VOC event.
Statistical Analysis: The incident rate of VOC events and proportions of
patients in each setting of care was estimated. Analyses were con-
ducted with Safety Works® V.6.5.0 and R V.3.5.0.
Results: VOC incidence rates were 0.64 per person*year (95% Confi-
dence Interval [CI]: 0.63, 0.66) in the Truven‐Medicaid data, 0.49 per
person*year (95% CI: 0.47, 0.51) in Optum Claims, and 0.32
person*year (95% CI: 0.31, 0.33) in the Optum EHR data. The propor-
tion of patients receiving any care in the outpatient setting following
the VOC ranged from 48.5% to 68.2%.
Conclusions: In these recent data, the incidence of VOC ranged from
0.32 to 0.64 per person*year which was lower than the last compara-
ble estimate of 0.8 pain episodes per person*year in data from 1979
to 1988. Treatment in outpatient clinics shortly after the VOC was
common and warrants further examination. These results provide a
much needed contemporary perspective on VOC incidence and treat-
ment, as well as, highlighting the need for further assessments of the
generalizability of these estimated across multiple data sources.
527 | The use of real‐world data in health
technology assessment of medications for
rare diseases
Christina J. Qian; Alexis T. Mickle; Alison M. Deighton;
Meagan M. Harwood; Shelagh M. Szabo
Broadstreet HEOR, Vancouver, BC, Canada
Background: Challenges exist when assessing the risk and benefit of
new therapy for rare diseases: small populations make assessing safety
and efficacy in controlled trials difficult, idiosyncratic presentations are
frequent, and collecting rigorous comparative data is costly. Both
health services researchers and decision makers are advocating the
consideration of real‐world data (RWD) ‐ data derived from sources
such as electronic health records, disease registries, and claims data-
bases ‐ in the health technology assessment (HTA) of medications.
However, how such data are being presently used for is unclear, as
is whether their inclusion impacts decision‐making.
Objectives: To characterize the use of RWD in HTA decision‐making
for medications for rare diseases in the United Kingdom (UK), and
explore whether its inclusion was associated with favorable HTA
recommendations.
Methods: All rare diseases with a prevalence of 10 to 50 per 100,000
were identified from Orphanet. Those with published National Insti-
tute for Health and Care Excellent (NICE) technical appraisals for med-
ications within the last 10 years were selected for review, data
extraction, and analysis. From the published appraisals, the proportion
including RWD was assessed, types of RWD submitted were classi-
fied, and whether submissions with RWD received favorable recom-
mendations was tabulated. RWD were also classified according to
whether they provided support for clinical effectiveness, cost effec-
tiveness, safety and tolerability.
Results: Twenty‐one of 205 rare diseases (10%) had ≥1 published
appraisal in NICE over 10 years, corresponding to 62 individual tech-
nology appraisals (Jan 2019). Overall, 23 (40%) submissions included
RWD; they were included in submissions for 40% of recommended
products and 7% of those not recommended. Types of RWD were
most frequently (75%) observational studies (for non‐comparative evi-
dence of clinical effectiveness), with a few preference or quality‐of‐life
studies (contributing to cost‐effectiveness evidence). Among the pub-
lished appraisals using RWD, almost all (96%) had a favorable
recommendation.
Conclusions: Among HTA submissions for medications for rare dis-
eases, RWD remain relatively infrequent; most often providing non‐
comparative evidence of the effectiveness of existing therapies. How-
ever, among published appraisals where RWD were included, almost
all submissions had a favorable recommendation. While these results
suggest that RWD are becoming more frequent in NICE submissions,
their incorporation in other HTA submissions, and how the use of
these data will change over time, remains unclear.
528 | Identification of inherited metabolic
disorders using temporal data and recurrent
neural network models
Sharon Hensley Alford1; Piyush Madan2; Italo Buleje3; Yanyan Han4;
Shilpa Mahatma5
1 IBM Watson Health, Cambridge, MA; 2 IBM Research, Cambridge, MA;
3 IBM Research, Miami, FL; 4 IBM Research, San Jose, CA; 5 IBM Research,
Yorktown, NY
Background: Inherited metabolic disorders are often left undiagnosed
due to either a lack of or ineffective newborn screening. Applying
deep learning techniques to electronic health records (EHR) can help
identify patients with these rare genetic disorders. Patients may not
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show symptoms for years to decades after birth and clinicians often
do not have experience with the rare disease to recognize or even
consider the disorder.
Objectives: We present different classification approaches, including a
novel approach that we developed for identification of a rare inherited
metabolic disorder ‐ Hereditary Hemochromatosis.
Methods: For this analysis, we used the IBM MarketScan® Commer-
cial Claims database that included patients enrolled from 2006 to
2016. The IBM MarketScan® database contains administrative claims
in the United States for commercially insured working‐age adults and
their dependents. The database encompasses the full continuum of
care across settings with longitudinal tracking at the patient level.
We applied three approaches to classify patients: one hot‐encoded
data, sequential diagnosis data, sequential diagnosis data along time
difference between the diagnosis. Finally, we built a novel model to
predict the presence of Hereditary Hemochromatosis a year before
the clinical diagnosis.
Results: We identified 9,926 patients diagnosed with Hereditary
Hemochromatosis. Patients had to have an outpatient encounter with
an ICD9/10 primary diagnosis code for Hereditary Hemochromatosis.
We randomly selected an equal number of patients from the general
population to include in the dataset as controls. Data were used from
the beginning of enrollment to one year prior to diagnosis or index
data. The final feature set included over 28,000 diagnosis and proce-
dure codes. The model AUCs ranged from 0.817 for the k‐nearest
neighbor model to 0.90 for our novel model approach which included
features for event sequence and timing.
Conclusions: In our model, we mimic the clinician's differential diagno-
sis approach by implementing a RNN framework that incorporates the
timing and sequence of events. This approach provided the best AUC
and we believe could be generalized to other rare disease.
529 | Prevalence of Friedreich ataxia in the
United States: Analysis of two large US
insurance claims databases
Chao Chen; Yizhou Ye; Shreya Davé
Takeda Pharmaceuticals International Co., Cambridge, MA
Background: Friedreich ataxia (FRDA) is a rare autosomal recessive
inherited disorder that progressively causes damage to the nervous
system, and in many cases, is associated with scoliosis, heart disease,
and diabetes. Although several epidemiological studies have been con-
ducted in European countries suggesting the prevalence ranged from
0.1 to 5 per 100,000, no such study has been conducted in the United
States (US).
Objectives: To estimate the prevalence of FRDA and describe patient
characteristics in the US using two large nationwide administrative
claims databases.
Methods: A retrospective cross‐sectional study was conducted using
two US administrative claims databases separately: 1) Truven Health
MarketScan® Research Database and 2) Optum Clinformatics® Data
Mart Database. 334.0, a specific ICD‐9‐CM code, was used to identify
FRDA cases. Considering FRDA is a life‐long disease with no cure, the
disease prevalence was calculated by dividing the numbers of patients
who had at least two diagnoses of FRDA on separate dates before or
on December 31, 2014, by the total numbers of patients in the data-
base on December 31, 2014. Only patients who had continuous
health plan enrollment throughout 2014 were included. Descriptive
analyses were used to summarize the demographics for the patients
with FRDA.
Results: In the Truven MarketScan analysis, 444 patients diagnosed
with FRDA were identified from the 27,632,078 enrollees. The crude
prevalence of FRDA in 2014 was estimated as 1.6 per 100,000 per-
sons (95% confidence interval [CI]: 1.46–1.76). Of the FRDA patients,
52.7% were female (n = 234) and the mean age was 49.0 years in
2014 (standard deviation [SD]: 23.2). In the Optum analysis, 317
patients diagnosed with FRDA were identified from the 9,768,738
enrollees. The crude prevalence in 2014 was 3.3 per 100,000 persons
(95% CI: 2.9–3.6). The FRDA patients identified from the Optum data-
base included 183 female patients (57.7%), and the average age was
60.3 years (SD: 21.0) in 2014.
Conclusions: The prevalence of FRDA among privately insured
patients ranged from 1.6 to 3.3 per 100,000 in the US in 2014. The
prevalence of FRDA calculated using the large US claims databases
was relatively higher than most estimates previously reported in
Europe. FRDA patients included in this study also included more
elderly patients. These differences may result from geographic differ-
ences in disease prevalence, measurement errors in the claims data-
base, or improved disease diagnosis and management in the US.
530 | Clinical manifestation of adult onset
Still's disease using administrative claims
database
Sujin Kim; Aleksander Lenert; G. Yeon Oh
University of Kentucky, Lexington, KY
Background: Adult Onset Still's Disease (AOSD) is a rare inflammatory
disorder of unclear clinical manifestation. The U.S. Centers for Medi-
care & Medicaid Services (CMS), requires the use of an ICD‐10‐CM
code such as M06.1 to file reimbursement claims with a date of ser-
vice on or after October 1, 2015.
Objectives: This exploratory study is to describe a cohort of AOSD
patients by utilizing large retrospective insurance claims' data based
on the adapted Yamaguchi criteria.
Methods: We used data from theTruven Claims and Encounters data-
base, from January 1, 2009 to December 31, 2017. This study ana-
lyzed complete longitudinal records of inpatient and outpatient
services and prescription drug claims with associated billing codes
from ICD9/ICD10, Current Procedural Terminology (CPT) codes, and
National Drug Codes (NDC). The cohort is defined as patients aged
18 or older with one or more diagnostic codes for AOSD (M06.1).
For the adapted Yamaguchi criteria, this study diagnoses, if 4 or more
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criteria are met with 2 or more being major criteria. Baseline data
includes patient demographics (age, gender), duration of follow‐up,
and Charlson Comorbidity Index (CCI) scores. In addition, cumulative
data was captured based on major AOSD treatment categories includ-
ing glucocorticoids, non‐steroidal anti‐inflammatory drugs (NSAIDs),
non‐biological disease‐modifying antirheumatic drugs (nbDMARDs),
immunosuppressants, IL‐1/IL‐1R blockers, anti‐TNFs, and non‐TNF
bDMARDs In addition, we included ferritin, C‐reactive protein, eryth-
rocyte sedimentation rate, and bone biopsy. Major complications such
as severe infection, macrophage activation syndrome (MAS), acute
respiratory distress syndrome (ARDS), interstitial lung disease (ILD)
were also measured. Descriptive statistics are calculated with means
and standard deviations or medians as appropriate.
Results: After we applied a 6 month washout period and more than
30 days of follow‐up criteria, we identified 517 AOSD patients who
had M06.1. The mean age was 46.31 (std = 14.72) with female pre-
dominance (60.4%) and a mean CCI of 1.27. At baseline, the major
clinical manifestations include fever (16.6%), arthritis (24%), rash
(13.5%), sore throat (10.1%), lymphadenopathy (3.1%), and hepato-
megaly (1.6%). During the study period, we found that therapeutic
markers had increased by 2% in comparison to the baseline data.
Interestingly, we found that only 7.4% of the AOSD cohort met the
adapted Yamaguchi criteria.
Conclusions: Existing diagnostic criteria is not comprehensive so
adding procedural and drug codes could improve the accuracy of
AOSD cohorts in claims research.
531 | Prediction model for identifying
patients with lipodystrophy in electronic
health records
Eline Houben1; Marina Bakker1; Rich Colbaugh2; Kristin Glass2;
Christopher Rudolf2; Mike Tremblay2,3
1PHARMO Institute, Utrecht, Netherlands; 2Volv Global SA, Lausanne,
Switzerland; 3University of Kent, Canterbury, UK
Background: Lipodystrophy is a rare disorder that is often difficult to
diagnose or undetected.
Objectives: The objective of this study was to develop a prediction
model to assist general practitioners (GP) to identify patients with
lipodystrophy based on electronic health records (EHR).
Methods: EHR from the GP Database of the PHARMO Database Net-
work were obtained for unsupervised feature learning and to evaluate
predictive performance of the model; 91 patients with a GP note that
included the word ‘lipodystrophy’, 200 randomly selected patients and
100 patients with a clinical presentation similar to lipodystrophy
patients (anorexia nervosa, thyrotoxicosis or Cushing's syndrome)
were included. The model was deployed in two steps. First, a simple
filter (predefined database queries) was applied to the complete GP
Database to identify patients whose records exhibit two attributes
(‘filtered EHR’): conditions common in obese patients presenting in a
patient with healthy/moderate BMI; diagnosis codes suggesting
possible confusion on the part of examining clinicians. In the second
step the prediction model was applied to all filtered EHR, yielding
the predicted probability that each of these patients has
lipodystrophy. A threshold of 65% predicted probability for the cut‐
off was used, based on confidence of the model and natural
breakpoint in the probabilities. Model performance was evaluated
using prediction accuracy and area under the receiver operator char-
acteristic curve (AUC).
Results: The model achieved an accuracy of 90.8% and AUC of 93.0%.
The model identified 36 patients with a predicted probability of
lipodystrophy above the threshold of 65% and of these, 20 patients
were identified as especially promising through outlier analysis. Of
these 20 patients, four patients were identified as ‘likely
lipodystrophy’, ten as ‘possible lipodystrophy’ and six as ‘(highly)
unlikely lipodystrophy’.
Conclusions: The results show that the prediction model, learned
through lipodystrophy‐related GP records, was able to identify high
potential lipodystrophy candidates using EHR.
532 | Gender differences in the
Management of Chronic Obstructive
Pulmonary Disease: Effect of a clinical audit
in a Sicilian general practice setting
Valentina Isgrò1,2; Janet Sultana1; Valentina Ientile2; Andrea Fontana3;
Umberto Alecci4; Riccardo Scoglio4; Francesco Magliozzo4;
Gianluca Trifirò2,5
1Department of Clinical and Experimental Medicine, University of
Messina, Messina, Italy; 2Unit of Clinical Pharmacology, Academic
Hospital G. Martino, Messina, Italy; 3Unit of Biostatistics, IRCCS Casa
Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy; 4 Italian
Society of General Practice (SIMG), Catania, Italy; 5Department of
Biomedical Sciences, Dentistry and Functional and Morphologic Imaging,
University of Messina, Messina, Italy
Background: COPD is considered a predominantly male disease, but
recent studies reported increasing diagnoses in women. Gender differ-
ences in quality of care (QOC) of chronic obstructive pulmonary dis-
ease (COPD) have not yet been described.
Objectives:TomeasuregenderdifferencesamongCOPDpatients'QOC
before and after educational interventions in a general practice setting.
Methods: In this prospective cohort study COPD patients were iden-
tified from electronic medical records of 33 Sicilian general practi-
tioners (GPs) using validated algorithms. Twelve process indicators
concerning diagnosis, preventative measures and therapeutic process
were developed by GPs, pneumologists and clinical pharmacologists.
Educational interventions consisted of clinical audits on COPD QOC
indicators at baseline, and after 12 and 24 months, plus continuous
remote education, i.e. disseminating important COPD‐related informa-
tion through a dedicated app. Patient characteristics and QOC indica-
tors were stratified by gender. Gender‐specific baseline QOC
indicators values were compared at 12 and 24 months.
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Results: Of 46,326 people registered with GPs, 1,465 COPD patients
(3.2%) were identified; of these, 536 (36.6%) were women. The median
age (interquartile range) was 74 (66–81) and 74 (64–82) in males and in
females, respectively. Hypertensionwas themost common comorbidity
in both sexes (59.4% males; 61.4% females; p‐value: <0.001); osteopo-
rosis was more frequent in females (38.6% vs. 6.7%; p‐value: <0.001).
Baseline QOC indicators were more positive for men. Interesting cases
include having a spirometry test anytime (64.3% males; 51.9% females;
p‐value: <0.001) and a recorded medical history of smoking (80.0%
males; 70.0% females; p‐value: <0.001). Baseline QOCs concerning
low adherence to long‐acting COPD therapy also favored men: 56.6%
vs. 71.4% (p‐value: <0.001). The gender disparity in QOC at baseline
largely remained unchanged at 12 and 24 months.
Conclusions: QOC gender disparity among COPD patients was
observed in a Sicilian general practice setting, with better disease
management in men, even following an educational program,
highlighting the need to improve recognition of gender‐specific signs
and symptoms and therapeutic response.
533 | Changes in persistent asthma care and
outcomes from 2006 to 2016 in France
Manon Belhassen; Maeva Nolin; Marine Ginoux; Eric Van Ganse
Pharmacoepidémiologie Lyon (PELyon), Lyon, France
Background: Changes in asthma care need to be documented at
arrival of biotherapies.
Objectives: To characterize changes in asthma care and outcomes in
patients with persistent asthma.
Methods:Repeated transversal analyses were conducted on a historical
cohort using theFrenchnational claimsdataover10years. Patients aged
18–40 years with either≥1 (any use [AU] population) or≥ 4 yearly dis-
pensings (high use [HU] population) of controller therapywere selected.
Clinical and demographic featureswere characterized, and comparisons
were made between 2006 and 2016 to assess temporal changes in
asthma therapy, healthcare resource utilization, and outcomes.
Results: In 2016, prevalent use of controller therapy was 5.2% (AUP)
and 0.8% (HUP) of the population aged 18–40 years. In the AU popu-
lation, the use of long‐acting β‐agonists (LABA) in monotherapy, and
inhaled corticosteroids (ICS) decreased (1.7 and 40.3% in 2016,
respectively), whereas the use of fixed‐dose combinations (FDCs)
increased (56.4%). In both populations, visits to respiratory or hospital
physicians and pulmonary function testing increased with time, in par-
allel to a decreasing number of general practitioner visits; in addition,
oral corticosteroids (OCS) use, and incidence of emergency room
(ER) visits increased. However, asthma hospitalizations and mortality
remained low and stable in both populations.
Conclusions: Changes in persistent asthma care included replacement
of ICS by FDCs, decreased use of LABAs as a monotherapy, and
increased involvement of secondary care physicians. In parallel, despite
stable figures for hospital admissions and mortality, overall use of OCS
and incidence of ER visits have increased over the last decade.
534 | Comorbid conditions in chronic
obstructive pulmonary disease patients: A
retrospective analysis of a large United States
electronic health record database
Georgios Varsos; Fred W. Peyerl; Meng Shen; Halit Yapici;
Laxmi Gannu; Apeksha Shenoy; David K. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Chronic Obstructive Pulmonary Disease (COPD) refers
to a group of progressive lung diseases that cause airflow blockage
and breathing‐related problems. COPD often co‐exists with multiple
comorbidities which impact the quality of life, and furthermore, com-
plicates management of the disease.
Objectives: The main objective of the present study was to evaluate
COPD patients, their demographics, and presence of comorbid
conditions.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All visits involv-
ing adult patients (≥ 18 years) with an ICD‐9/10 diagnosis for COPD
between 2014 and 2017 were analyzed. Comorbid conditions were
characterized by corresponding ICD9/10 diagnosis codes following a
medical review of the EHR data.
Results: The study included 998,912 patients with COPD with a total
of 2.7MM (45% male vs. 55% female) patient visits. It was observed
that the highest percentage of COPD patients were in the age group
of ‘>65 years’ (53.1%), compared to 44.3% in the ‘36–65 years’ age
group and 2.6% in the ‘18–35 years’ age group. Within visits where
race was specified, majority were Caucasian (81.3%), followed by Afri-
can‐American (12.2%), Asian/Pacific Islander (0.9%), and Hispanic
(0.1%). Given the major phenotypes of COPD, 17.2% of the visits
had a diagnosis of chronic bronchitis, 9% had emphysema, while the
majority had other forms of COPD (77.8%). The most prevalent
comorbid conditions among COPD patients were depression (9.8%),
pneumonia (7.8%), respiratory infections (4.3%), lung cancer (2.7%),
and pulmonary hypertension (2.1%).
Conclusions: This retrospective analysis examined EHR data from a
largeCOPDpatient cohort to better understand real‐worldpatient char-
acteristics as well as comorbidities. Identification of these characteris-
tics can potentially help develop new strategies to treat COPD patients.
535 | Assessment of asthma severity and
patient comorbidities: A retrospective
analysis of a large United States electronic
health record database
Georgios Varsos; Fred W. Peyerl; Meng Shen; Halit Yapici;
Laxmi Gannu; Apeksha Shenoy; David K. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
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Background: Asthma is a chronic disease that affects the airways in
the lungs which makes breathing difficult. Asthma attacks can range
from mild intermittent to severe. Severe asthma attacks can be life‐
threatening, significantly impairing quality of life. Several comorbidi-
ties are associated with asthma, making it harder to control, and may
influence disease management.
Objectives: The main objectives of the present study were to evaluate
asthma patients by their demographics, asthma severity, and their
comorbid conditions.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All inpatient
visits (age ≥ 18 years) between 2014 and 2017 with a principal
ICD9/10 diagnosis of asthma were evaluated in this study. Comorbid
conditions were characterized by corresponding ICD9/10 codes.
Results: A total of 293,744 patients with asthma were identified in the
database corresponding to 434,096 inpatient visits. It was observed
that 70.9% of asthma patient visits were female. Half of the visits
were in the ‘36–65 years’ age group (50.4%), 29.7% in the ‘>65 years’
age group, and 19.9% in the ‘18–35 years’ age group. Majority of
patient visits were Caucasian (63.8%), followed by African‐American
(25.8%). Number of patient visits with a diagnosis of mild intermittent
asthma was higher as compared to those with mild persistent asthma
(43.6% vs. 13.3%). Moderate persistent asthma was present in 25.2%
of patient visits, while 17.9% of visits had severe persistent asthma.
The most prevalent comorbid conditions among asthma patient visits
were obesity (49%), followed by depression (20.2%), respiratory failure
(12.2%), and pneumonia (10.8%).
Conclusions: The large database analysis provides insights into real‐
world evidence on the demographics, severity levels, and comorbid
conditions in asthma patients. Identification of these patient charac-
teristics can potentially help guide decision‐making for new asthma
treatment initiatives.
536 | Anemia and clinical outcomes in
patients with severe chronic kidney disease:
A Danish population‐based study
Gunnar Toft1; Uffe Heide‐Jorgensen1; Heleen van Haalen2;
Glen James3; Katarina Hedman2; Henrik Birn1; Henrik T. Sorensen1;
Christian F. Christiansen1; Reimar W. Thomsen1
1Aarhus University Hospital, Aarhus, Denmark; 2AstraZeneca,
Gothenburg, Sweden; 3AstraZeneca, Cambridge, UK
Background: Routine clinical care evidence is limited on clinical out-
comes associated with anemia in patients with chronic kidney disease
(CKD).
Objectives: To examine the association of anemia with risk of dialysis,
adverse cardiovascular events (CVEs), hospitalization, and death in
patients with severe CKD.
Methods: We linked population‐based medical databases to identify
all individuals with severe (stage 4 or 5) CKD (eGFR <30 mL/min/
1.73m2) in Northern Denmark from 2000 to 2016. We classified
patients as non‐anemic or anemic (categorized into anemia grade 1,
2, or 3+), using the lowest hemoglobin (Hgb) value in the year before
study inclusion. Patients were stratified by dialysis status and followed
for incident dialysis; first adverse CVE (hospitalization with myocardial
infarction, unstable angina pectoris, stroke, or heart failure); all‐cause
acute hospitalization; and all‐cause death. We derived risk curves
through cumulative incidence functions and computed incidence rates
and adjusted hazard ratios (HRs) using Cox proportional hazards
regression.
Results: Among 28,510 patients whose profiles showed severe CKD,
14% had no anemia, 35% had grade 1 anemia, 44% had grade 2 ane-
mia, and 17% had grade 3+ anemia. Rates of incident dialysis, CVE,
acute hospitalization, and death increased markedly with increasing
anemia grade. Adjusted HRs for non‐dialysis‐dependent patients with
grade 3+ anemia, compared to patients with no anemia, were substan-
tially elevated for dialysis (1.91, 95% CI 1.61–2.26), any acute hospi-
talization (1.74, 95% CI 1.57–1.93), all‐cause death (1.82, 95% CI
1.70–1.94), and CVE (1.14, 95% CI 1.02–1.26). For CVE the strongest
associations were observed for hospitalization with heart failure (1.24,
95% CI 1.09–1.41) and any fatal CVE (1.42, 95% CI 1.19–1.68). Similar
HRs were observed among dialysis‐dependent patients.
Conclusions: Among patients with severe CKD receiving routine clin-
ical care, presence and severity of anemia were associated with
increased risks of incident dialysis, CVE, acute hospitalization, and
death. The findings emphasize the need for attention to anemia in
CKD and the underlying disease.
537 | Duration of follow‐up of chronic
condition cohorts in the sentinel system
Emily C. Welch1; Ting‐Ying Huang1; Mayura Shinde1;
Michael D. Nguyen2; Sarah K. Dutcher2
1Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA; 2Food and Drug Administration, Silver Spring, MD
Background: The US FDA's Sentinel Initiative uses a distributed data
network to conduct active surveillance on medical product safety
using administrative and claims data. Observable person‐time in the
indicated population is instrumental to drug safety analyses. While
median length of observation time for members in commercial insur-
ance claims databases is <2 years, variation by chronic conditions is
unknown.
Objectives: To assess duration of follow‐up of chronic condition
cohorts in the Sentinel System.
Methods: We identified prevalent and incident cohorts of 24 chronic
conditions in the Sentinel System from 2008–2018. We operational-
ized the Centers for Medicare and Medicaid Services Chronic Condi-
tions Data Warehouse condition algorithms by including members
with evidence of at least 1 inpatient or 2 ambulatory claims with qual-
ifying diagnosis codes (exceptions of claim count and care setting
apply). We followed cohorts from the first qualifying diagnosis date
to the earliest occurrence of disenrollment, death, or end of data.
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We report follow‐up time for each condition cohort overall and strat-
ified by sex, age, and data partner (DP) type.
Results: Sample size ranged from 412,572 (endometrial cancer) to
50,788,725 (hypertension) members in the prevalent cohorts. Hyper-
tension and hyperlipidemia had the highest prevalence (26.3% and
23.9%), while all 5 cancers assessed had low prevalence (0.2–1.5%).
Median follow‐up ranged from 0.8 (lung cancer) to 2.7 years (hyperlip-
idemia). Conditions with shorter follow‐up time had a higher propor-
tion of members censored due to death (55% vs 11% for lung cancer
vs hyperlipidemia). The proportion of members with 3+ years follow‐
up time ranged from 17% (lung cancer) to 45% (glaucoma, hyperlipid-
emia, and osteoporosis). Follow‐up was consistent across sex but lon-
ger for members 65+ vs 19–64 years old (50% vs 35% of members
with hypertension had 3+ years follow‐up). Integrated delivery sys-
tems had longer follow‐up time than claims‐based DPs (59% vs 43%
of members with prostate cancer had 3+ years follow‐up). Incident
cohorts had similar follow‐up, with a few exceptions (e.g., median fol-
low‐up 2.4 vs 1.7 years in prevalent vs incident ischemic heart disease
cohorts).
Conclusions: We found that conditions with higher mortality had
shorter follow‐up, suggesting that disease prognosis impacts available
observation time in claims data. The Sentinel System may provide suf-
ficient person‐time to observe many outcomes of interest in claims‐
based drug safety evaluations in chronic condition patient cohorts,
although this ability will vary by chronic condition, patient age, and
data source.
538 | Incidence and prevalence of alopecia
Areata in the US and UK
Michiyo Yamazaki; XIaofeng Zhou; Lynne Napatalung; Rachel E. Sobel
Pfizer, Inc., New York, NY
Background: Global incidence and prevalence data for alopecia areata
(AA), an uncommon autoimmune disease that causes hair loss ranging
in severity from limited patches to the entire body, have relied on out-
dated US population‐based studies or convenience samples from sin-
gle hospitals or dermatology practices; severity of AA, if available, is
inconsistently defined.
Objectives: To estimate the incidence rates (IRs) and prevalence of AA
among adult and pediatric patients, using electronic healthcare records
(EHR) and claims data in the United States (US) and United Kingdom
(UK), stratified by severity.
Methods: A retrospective cohort study was conducted using 2 EHR
databases (DBs; The Health Improvement Network [THIN] from the
UK, and US Optum EHR) and 2 US commercial health insurance claims
DBs (Truven Health MarketScan® and Optum) via SÆfetyWorks™, an
analytic tool. ICD‐9/10 codes for the US data (704.01, L63*) and anal-
ogous Read Codes for UK THIN were used to identify AA patients.
Patients were eligible with ≥6 mo of enrollment in the DB before
the Index date (Jan 2016 or date of eligibility thereafter); observation
ended mid‐2017 depending on data availability for each DB. Patients
were required to have ≥2 AA diagnoses ≥6 wk apart. Two sub‐
cohorts were created: AT/AU [alopecia totalis (AT) and/or alopecia
universalis (AU)], and Non‐AT/AU. Additional stratification by age
(including pediatric groups), and sex was performed. IRs of AA were
calculated for the cohort overall and sub‐cohorts. Prevalence (%) was
calculated using any AA diagnosis within 2 yrs prior to the index date
and any time in the study period after index date.
Results: The IR of AA per 1000 person years (PYs) was 0.01–0.25
(0.22–0.25 in US claims data; 0.01–0.08 in UK and US EHR). The IR
for the AT/AU cohort was 0–0.015 (0.014–0.015; 0–0.006), and
Non AT/AU cohort was 0.01–0.24 (0.20–0.24; 0.01–0.08). In general,
IRs of AA and AT/AU were lowest among children aged ≤5 and higher
among females across age groups. The period prevalence (%) of AA
was 0.01–0.10 (0.08–0.10 in US claims data; 0.01–0.04 in UK and
US EHR), and in the AT/AU cohort was 0–0.003 (0.003; 0–0.002).
Conclusions: Using large US and UK healthcare data, we found that
the IRs and prevalence estimates were generally comparable with
those in the literature (i.e. IRs = 0.20–0.21 per 1000 PYs in 1975–89
and 1990–2009, respectively, and prevalence = 0.1–0.2%). The
observed variation in the estimates may be due to the differences in
data type (claims vs. EHR) and region (US vs. UK) as well as other
underlying population characteristics, which highlights the importance
of multiple database analyses. Future studies are warranted to confirm
these findings.
539 | Do alopecia Areata patients differ by
severity?
Rachel E. Sobel1; Michiyo Yamazaki1; Lynne Napatalung1;
Kelsey Gangemi2; Daina Esposito3
1Pfizer, Inc, New York, NY; 2HealthCore, Inc, Wilmington, DE; 3Boston
University School of Public Health, Westford, MA
Background: Alopecia areata (AA) is an uncommon autoimmune hair
loss disorder that generally starts as patchy hair loss on the scalp. It
can progress to total loss of scalp hair, (alopecia totalis [AT]) or to total
loss of body hair (alopecia universalis [AU]). Little is known about the
epidemiology of AA, including whether there are differences by sub-
type, because the literature is old, not population‐based, or
nonexistent.
Objectives: To describe the prevalence and characteristics of patients
with AA, both overall and stratified by sex, age, and severity (AT/AU
vs. non‐AT/AU).
Methods: A retrospective cohort study was designed using the
HealthCore Integrated Research Database (HIRD), which contains
healthcare and prescription data from US commercial insurance plans.
Cohort eligibility required at least 1 day of health plan coverage in the
most recent 5‐year (yr) period and was defined as patients with ICD9
(1/06–9/15, 704.01, AA only) or ICD10 (Oct 2015+) that had relevant
codes for AA, AT, or AU (L63*). We separately evaluated patients with
≥1, ≥2, or ≥ 2 diagnoses including ≥1 by a dermatologist. We further
stratified the groups as any AA, AT/AU, and non‐AT/AU, and by sex
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and age (0–5, 6–11, 12–17, 18–64, 65+ yr). The top 10 most common
dermatologic procedures by Current Procedural Terminology (CPT)
and top 20 medications by Generic Product Identifier (GPI) class in
patients with ≥2 diagnoses were described for each population. Sta-
tistical analyses were descriptive only; prevalence calculations were
generated with 95% CI. Primary analysis focused on the most recent
5‐yr period (7/13–6/18).
Results: Between 7/13 and 6/18, there were 31 M individuals with
≥1 day of health plan coverage in HIRD; the overall prevalence of
≥2 diagnoses of AA, AT/AU and non‐AT/AU was 89.0, 4.2, and 77.0
per 100,000 respectively, with narrow 95% CI; AT/AU accounted for
5.2% of the total AA burden. AA (overall and by severity) had a female
predominance (60.3–68.2%) and skewed younger (92.6–94.0%
were < 65 yrs; 12.3–15.2% were < 18 yrs). Thyroid medications and
premalignant lesion removal were observed among the 20 most com-
mon medications and 10 most common dermatologic procedures for
the AT/AU subgroup but not the non‐AT/AU subgroup. Other differ-
ences in the proportion and rank order of other medications and pro-
cedures were also identified.
Conclusions: Estimates of AA are generally consistent with the
existing literature; however we observed a clear female predominance
and detected differences in GPI medication classes and dermatologic
procedure patterns that may indicate important variation in the auto-
immune profile of AT/AU vs. non‐AT/AU patients. These differences
merit further research.
540 | Defining heat exposure in a climate‐
drug interaction study: A Pharmacoepi
approach
Soko Setoguchi1; Thomas A. Nahass1; Isao Iwata1; John Read2;
Edward Nommennacher3; Brian Strom4; Tobias Gerhard3;
Cecilia Huang3; David Robinson2
1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ;
2Rutgers University, New Brunswick, NJ; 3Rutgers Institute for Health,
Health Care Policy and Aging Research, New Brunswick, NJ; 4Rutgers
Biomedical Health Sciences, New Brunswick, NJ
Background: Heatwaves kill people. Many medications may interact
with the effect of extreme heat, exacerbating health outcomes in vul-
nerable older adults with multimorbidities and polypharmacy. To pre-
cisely assess the interaction between heat and medications applying
high‐resolution cohort design in pharmacoepidemiology, the initial
step is to better understand the effect of extreme heat in the vulner-
able population, as no standard definition of heatwave currently
exists.
Objectives: To understand the health effect of heatwaves defined by
various durations of maximum temperature (Tmax) at selected cut
offs.
Methods: We identified adults aged > = 65 linking Medicare Current
Beneficiary Survey (MCBS) from 2007 to 2013 via zip codes of resi-
dence with the Parameter‐elevation Relationships on Independent
Slopes Model (PRISM) daily temperature grid data. We assessed the
health effect of extreme heat with different lengths, i.e., one day,
two days and > = 3 days, and various cut offs, i.e., Tmax > = 95th,
97th, and 99th percentile (Tmax95, Tmax97, Tmax99) based on 30‐
year climatologies. Outcomes of interest included all‐cause mortality
and all‐cause hospitalization. We used multivariate Cox regression to
adjust for demographics, socioeconomic factors, comorbidities, and
physical/cognitive function.
Results: Among 26,325 older adults (mean age 71; 45% male; 85%
White) accrued 80,151 person‐years (PYs) of follow‐up, 39% (7,356)
were exposed to > = 1 day of Tmax95 (1,887 exposed PYs). We
observed 2,697 deaths and 18,577 hospitalizations. The mortality/
hospitalization rate using Tmax95 was 58/523, 42/433, and 40/349
per 1,000 PYs for 1 day, 2 days, and > = 3 days. The overall mortality
for any extreme heat exposure was 45, 27, and 61 per 1,000 PYs for
Tmax95, Tmax97, and Tmax99. The adjusted hazard ratios (HR) for
exposure to Tmax95 > = 1 day on mortality and hospitalization were
1.5 (95% confidence limit [CI] 1.2–1.8) and 1.4 (95%CI 1.3–1.5),
respectively. Defined as Tmax95 > =3 consecutive days, effects of
extreme heat were diminished: HR = 1.3 for mortality and 1.2 for
hospitalization.
Conclusions: Older adults had the highest risk for mortality and hospi-
talization at 1‐day exposure to extreme heat with this risk diminishing
with longer duration definitions. We observed a dose response to a
higher Tmax cutoffs in the mortality risk. While no standard definition
of heatwave exists, most previous studies defined heat waves as > = 2
consecutive days. Our findings suggest using > = 2 days to define heat
waves may underestimate the effects of extreme heat among vulner-
able adults in the climate‐medication interaction study.
541 | Identification of risk factors in chronic
kidney disease: A retrospective analysis of a
large United States electronic health record
database
Georgios Varsos; Fred W. Peyerl; Apeksha Shenoy; Kunal Lodaya;
Xuan Zhang; Laxmi Gannu; David K. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Chronic Kidney Disease (CKD) is a condition character-
ized by a gradual loss of kidney function over time which can lead to
kidney failure. Adults with chronic comorbidities like diabetes and/or
hypertension are at a high risk of developing CKD. In addition, patients
suffering from acute conditions like Acute Kidney Injury (AKI) are also
at risk for CKD.
Objectives: The main objective of the present study was to identify
patients in different CKD stages, assess risk factors, and explore the
relationship between AKI and CKD.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All inpatients
(≥ 18 years) between 2009 and 2016, with an ICD9/10 diagnosis of
CKD, were evaluated in this study. Hypertension and diabetes were
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identified using ICD9/10 diagnosis codes within Elixhauser Comorbid-
ities. AKI stages were based on KDIGO guidelines and were evaluated
using time‐stamped laboratory results.
Results: The study included 878,048 patients (51.1% male) with CKD,
61% of patients over 65 years of age. By race, 72.4% of patients were
Caucasian, followed by African‐American (17.0%). In patients where
CKD stages were available (N = 447,744), most were in stage 3
(65.5%), followed by 14.6% in stage 4. CKD was diagnosed in 13.6%,
18.1%, and 24.8% of patients with hypertension (N = 5,751,488), dia-
betes (N = 2,528,992), and a combination of hypertension and diabe-
tes (N = 1,760,992), respectively. Thirty‐four percent of all AKI
patients had some form of CKD. Patients with AKI stage 3 were more
likely to be in stage 5 CKD (5.6%) as compared to AKI stage 2 (0.3%)
and AKI stage 1 (0.9%) patients.
Conclusions: This real‐world analysis confirms that patients with
chronic comorbidities, such as hypertension and/or diabetes, are at
higher risk for CKD. This analysis also demonstrates the intercon-
nected relationship CKD has with AKI.
542 | Association of Diagnosis Code‐Based
and Laboratory Results‐Based Kidney Disease
with development of vision threatening
diabetic retinopathy
Yinxi Yu; Brian L. VanderBeek; Gui‐Shuang Ying; Maureen G. Maguire
University of Pennsylvania, Philadelphia, PA
Background: Studies have shown in diabetics that decreased renal func-
tion is stronglyassociatedwith retinopathy. In someadministrativemed-
ical claims databases, both diagnosis code and laboratory results are
available to identifydecreased renal function,butnostudyhasevaluated
whether there are differences in their associations with retinopathy.
Objectives: In this study, we compared the association of kidney dis-
ease (KD) identified through diagnosis code to lab value‐based identi-
fication of KD with development of vision threatening diabetic
retinopathy (VTDR).
Methods: A national administrative medical claims database was
used for this retrospective observational study. All individuals
age ≥ 18 years with diagnosed nonproliferative diabetic retinopathy
(NPDR) were followed longitudinally. ICD9/10 CKD diagnoses from
outpatient claims were used to classify KD without or with end
stage renal disease (ESRD). Serum creatinine results were used to
calculate estimated glomerular filtration rates (eGFR) which were
categorized based on the National Kidney Foundation's levels of dis-
ease. VTDR was defined as any new diagnosis of diabetic macular
edema or proliferative diabetic retinopathy. Multivariate Cox models
were used to assess the associations of KD diagnosis and eGFR
(modeled as time‐dependent variables) with progression to VTDR,
controlling for demographics and time‐updating covariates (systemic
health, laboratory values, insulin use). Hazard ratio (HR), C‐statistic(a
measure of model discrimination) and their 95% confidence intervals
(CI) were calculated.
Results: Among 69,982 enrollees with NPDR, 12,770(18.2%) devel-
oped VTDR during a median of 1.5 years follow‐up. In multivariate
analysis, lower eGFR was associated with higher risk of VTDR (eGFR
15–29:HR = 1.14;95%CI:1.02–1.27,p = 0.02; eGFR<15:
HR:1.37;95%CI:1.25–1.50,p < 0.001) compared to patients with eGFR
≥90. Whereas a diagnosis of ESRD was associated with higher risk of
VTDR (HR = 1.07,95%CI:1.01–1.13,p = 0.02), but a diagnosis of KD
without ESRD was not (HR = 0.97,95%:0.92–1.03,p = 0.35) when
compared to normals. C‐statistic was 0.60(95%CI:0.59–0.60) for the
model with eGFR and for the model with KD diagnosis.
Conclusions: Both diagnosis‐based and lab value‐based KD were asso-
ciated with development of VTDR. There was no difference in their
ability to predict development of VTDR.
543 | A Clinico ‐ epidemiological study of
acute poisoning cases in emergency
Department of Tertiary Care Hospital,
Warangal, India
Sreeja Vydhyam; Shiva Rama Krishna Marka; Vasavi Katkuri
Talla Padmavathi College of Pharmacy, Warangal, India
Background: “Poisoning is a critical condition. In developing countries
adverse outcomes from poisoning are more frequent than in devel-
oped countries because of weak regulation and limited healthcare
services”.
Objectives: To evaluate the rate of deviations from WHO guidelines
and adverse drug reactions occurring due to lack of specific antidotes
in poisoning cases and outcomes with alternative treatment in MGM
HOSPITAL, India.
Methods: A prospective and observational study of organophospho-
rus poisoning, snake bite, scorpion sting, multiple tablet intake, house
hold poisoning, unknown insect sting has been conducted in tertiary
care hospital, India. In the period of April 2018–October 2018. A suit-
able data collection form was prepared and data was collected accord-
ingly, all the poison intake cases were included in the study. Extent of
deviation in treatment plan were compared from the standard (WHO)
treatment guidelines. ADRs were assessed using Naranjo scale and
drug–drug interactions were checked through Micromedex.com.
Results: 365 Patient's data were collected, of these 195(53.42%)
patients were females and 170(46.57%) were male.22% cases are
deviated in (82) OP poisoning, 23% cases are deviated in (52)snake
bite, 53% cases are deviated in (56)scorpion sting, 22% cases are devi-
ated in (45) Multiple tablet intake, 6% cases are deviated in (119)
house hold poisoning, there is no deviation(0%) found in (11) unknown
insect sting poisonings. Out of 365 patients 235(64.3%) were inten-
tional poisoning and 133(36.4%) were accidental poisoning. Occupa-
tion wise farmer(32.32%) remain predominant followed by daily
wage workers(20%) and house wife(17.26%).Out of 365 patients
155(42.4%) have undergone first aid and 210(57.5%) have not taken
first aid before admission. 148 (30 types) Adverse events occurred:
18 headache, 14giddiness, 10 atropine psychosis were prominent;
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assessed on the basis of Naranjo scale. 13 types of drug–drug interac-
tions were found by using Micromedex.com, most prominent include
(55) Tetanus toxoid+ Hydrocortisone, (13) Ringer lactate+ Ceftriaxone,
(11) Atropine +5%Dextrose.
Conclusions: This study findings suggests extent of deviation in
treatment is high based on antidote administration.Awareness on
first aid to educate the people is required and availability of anti-
dotes in developing countries is needed & there is a need to
improve patient stability by administering specific antidote, thereby
reducing, morbidity mortality and pharmacoeconomic burden by
identifying, assessing, monitoring and reporting ADRs and drug
interactions.
544 | Chronic kidney disease in the real‐
world: Rationale and Design of the Global
Discover CKD program
Glen James1; Eric Wittbrodt2; Carol Moreno Quinn1; Alaster Allum1;
Esther Pascual1; Jenny Wei3; Katarina Hedman4;
Mary Beth DeYoung2; Jennie Medin4; Juan‐Jesus Carrero5;
Gary Curhan6; Steven Fishbane7; Hiddo Heerspink8; Eiichiro Kanda9;
Naoki Kashihara9; Mikhail Kosiborod10; Mitja Lainscak11;
Carolyn S.P. Lam12; Roberto Pecoits‐Filho13; Carol Pollock14;
Peter Stenvinkel15; David Wheeler16
1AstraZeneca, Cambridge, UK; 2AstraZeneca, Gaithersburg, MD;
3AstraZeneca, Zhangjiang Park, China; 4AstraZeneca, Gothenburg,
Sweden; 5Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden; 6Renal Division, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA; 7Division of
Nephrology, Zucker School of Medicine at Hofstra/Northwell, New York,
NY; 8Department of Clinical Pharmacy and Pharmacology, University of
Groningen, Groningen, Netherlands; 9Kawasaki Medical School, Kurashiki,
Japan; 10Saint Luke's Mid America Heart Institute, University of Missouri‐
Kansas City, US, The George Institute for Global Health, Sydney,
Australia; 11Faculty of Medicine, University of Ljubljana, Ljubljana,
Slovenia; 12National Heart Centre, Singapore & Duke‐NUS, Singapore,
Singapore; 13School of Medicine, Pontifícia Universidade Católica do
Paraná, Curitiba, Paraná, Maringá, Brazil; 14Kolling Institute, Royal North
Shore Hospital, University of Sydney, NSW, Sydney, Australia; 15Division
of Renal Medicine, Karolinska University Hospital, Karolinska Institutet,
Stockholm, Sweden; 16Department of Renal Medicine, University College
London, London, UK
Background: Chronic kidney disease (CKD) is a global health problem
associated with adverse clinical consequences and impaired quality of
life (QoL). Real‐world data on the journey of patients with CKD, spe-
cifically pertaining to clinical management, metabolic control, treat-
ment patterns, disease progression, QoL and diet are limited.
Objectives: This study aims to create a global cohort of patients with
CKD to provide robust data to address epidemiological knowledge
gaps and to understand determinants of clinical progression of CKD
across multiple geographic regions over time.
Methods: DISCOVER CKD will have an enriched hybrid study design
approach, utilizing a novel cloud‐based IT platform to integrate pri-
mary and secondary data from nephrology‐referred patients with
CKD stage 3 (estimated glomerular filtration rate < 60 ml/min/
1.73 m2) through to end stage kidney disease (ESKD, eGFR <15 ml/
min/1.73m2) from the UK, US, Sweden, Denmark, China and Japan.
Primary data will be prospectively captured over a 3‐year period from
>1,000 CKD patients followed for at least 1‐year via electronic case
report form (CRF) entry during routine clinical visits and via patient
questionnaires, mobile apps and interviews for patient reported out-
comes (PROs). Secondary data will be retrospectively captured from
>100,000 CKD patients from existing datasets and registries (via elec-
tronic health record (EHR) database linkage and data extraction).
Results: The DISCOVER CKD program will capture patient demo-
graphics, biomarker and laboratory measurements, medical history,
clinical outcomes, healthcare resource utilization, medications, diet,
physical activity, and other PROs, including QoL. Initial results are
anticipated in late 2019.
Conclusions: The DISCOVER CKD program will establish a global
cohort of patients with CKD with high quality retrospective and pro-
spective data to provide real‐world insights into the current manage-
ment and disease progression of patients with CKD.
545 | Treatment patterns of targeted
therapies among patients diagnosed with
rheumatoid arthritis in the United States
Jolyon Fairburn‐Beech1; Ayush V. Patel2; Rachel E. Williams2
1GlaxoSmithKline, Stockley Park, Uxbridge, UK; 2GlaxoSmithKline, Upper
Providence, PA
Background: Rheumatoid Arthritis (RA) is a chronic disease and the
most common autoimmune inflammatory arthritis in adults with a sig-
nificant negative impact on the ability to perform daily activities and
health‐related quality of life. Treatment often involves long term
targeted therapy (T‐Rx). This study evaluates current T‐Rx patterns
in the real world setting and provides information for future drug
development.
Objectives: The main objective of this study was to assess patterns of
T‐Rx among RA patients.
Methods: This retrospective cohort study was conducted among all
US adults (≥18 years) using IBM® MarketScan® Research database
(2012–2017). All eligible patients with continuous enrolment for at
least 2 years and minimum of 2 RA diagnoses at least 30 days apart
were included in the study. Patients were followed for 2 years after
the index date (date of first T‐Rx claim post RA diagnosis) to assess
patterns of T‐Rx treatment. T‐Rx was defined as claim of etanercept,
adalimumab, infliximab, tofacitinib, rituximab, golimumab,
certolizumab, tocilizumab or anakinra. After excluding all patients with
a history of T‐Rx prior to the index date the final cohort consisted of
9,630 RA patients. This study generated treatment sequence, identi-
fied treatment switches and discontinuation. Sankey charts and
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sunburst plots were developed to describe lines and order of T‐Rx
claims filled in the cohort. This study was funded by GSK.
Results: The cohort was mainly females (80%) with mean age of 53
(±12) years. The most common T‐Rx within 2 years of follow‐up were
etanercept (29%) and adalimumab (28%). Over 2 years of follow up
32% of all RA patients reported switching T‐Rx. 19% had 1, 8% had
2 and 5% had over 3 or more switches. While assessing lines of T‐
Rx therapy, the most commonly prescribed T‐Rx were etanercept
(34%), adalimumab (33%) and abatacept (7%) among first line;
adalimumab (21%), etanercept (18%) and abatacept (15%) among the
second line; and abatacept (20%), tofacitinib (18%) and tocilizumab
(13%) among the third line. Only 6% of the cohort report tofacitinib
claims as first line, but they increase to 11% and 18% in second and
third line use respectively.
Conclusions: This study estimates assesses lines of T‐Rx among RA
patients. Over half of all RA patients fill a prescription claim for
etanercept and/or adalimumab which are the choice of drugs for initi-
ation of RA treatment. Over 32% patients switch treatment within the
first 2 years of targeted therapy initiation, with some patients
switching 3+ times indicating the difficulty in obtaining optimal treat-
ment for RA patients.
546 | A descriptive analysis of Florida
medical marijuana registry patients from
2016–2017
Brianna Costales; Sascha van Boemmel‐Wegmann; Richard Segal
University of Florida, Gainesville, FL
Background: The Compassionate Medical Cannabis Act of 2014 (CCA)
legalized medical marijuana (MM) in the state of Florida. This legisla-
tion mandated providers to submit treatment plan forms to the Uni-
versity of Florida's College of Pharmacy (UF COP) for safety and
efficacy review.
Objectives: To describe the characteristics of Florida MM registry
patients including demographics, medical conditions for seeking treat-
ment with MM, and prescription medication usage among this
population.
Methods: An Initial Treatment (IT) Plan form and a Follow‐up Treat-
ment (FUT) Plan form were created to meet the CCA's requirements.
Providers submitted forms electronically via a secured portal main-
tained by the UF COP. Data elements collected on the forms cover
information on patients, providers, and the cannabis order. We retro-
spectively analyzed IT and FUT plan forms submitted between August
2016 to July 2017 (N = 12,798). Records were excluded if data were
invalid or incomplete.
Results: 7,963 IT and 2,075 FUT plans were available for the analysis.
At the initial visit for MM evaluation, patients were mostly white
(83.7%), on average 52.3 years (SD 16.4) of age, and were assessed
as at least moderately ill (42.9%) by the prescribing physician. At the
time of MM initiation, about one in four patients (26.3%) reported
concurrent use of prescription opioids. Antidepressants (24.2%) and
anxiolytics including benzodiazepines (23.7%) were the second and
third most frequently used medications, respectively. The top three
identified medical complaints for seeking MM were musculoskeletal
disorders including spasms (54.7%), chronic nonmalignant pain
(42.7%), and multiple sclerosis (33.3%) with at least one condition
per patient possible. Chronic nonmalignant pain and multiple sclerosis
are explicitly allowed by current law. Musculoskeletal disorders were
interpreted by the provider as meeting other qualifications allowed.
At a follow‐up encounter after MM initiation, providers' assessments
of patients' conditions showed that 31.7% were much improved and
30.1% were minimally improved while 25% were unchanged and less
than 3% were worse. MM discontinuation was reported by 5.0% of
patients and 1.7% reported indicators of adverse reactions to
cannabis.
Conclusions: Results suggest that patients with serious medical condi-
tions sought treatment with MM despite pharmacological options and
out‐of‐pocket expenses. Furthermore, the data suggests that a signif-
icant number of patients may benefit from MM therapy. This study
adds to the limited information available on the individuals and their
conditions who seek MM treatment.
547 | Hydroxychloroquine in systemic lupus:
Drug tapering/discontinuation and clinical
outcomes
Celline C. Almeida‐Brasil1; Cristiano S. Moura1; Evelyne Vinet2,1;
Christian A. Pineau2; Luck Lukusa1; Sasha Bernatsky2,1
1Research Institute of the McGill University Health Centre, Montreal, QC,
Canada; 2McGill University Health Centre, Montreal, QC, Canada
Background: Hydroxychloroquine (HCQ) is a cornerstone drug to con-
trol disease activity in Systemic Lupus (SLE). Since concern exists
regarding the safety of long‐term HCQ use, it may be tapered or
stopped to potentially lengthen the period over which patients may
benefit.
Objectives: We evaluated associations between tapering/
discontinuing HCQ and SLE outcomes.
Methods: We used data from a clinical cohort of adult SLE patients
exposed to HCQ at least once between January 2006 and October
2018 in Montreal, Canada. Baseline was defined as the first visit with
HCQ exposure. At the first follow‐up visit (one year after baseline), we
examined the percent of patients who tapered HCQ dose,
discontinued HCQ therapy, or did not change therapy. Logistic regres-
sions were conducted to examine whether HCQ taper/discontinuation
was associated with poor outcomes at the second follow‐up visit
(defined as an increase of ≥4 points in the SLE Disease Activity Index,
SLEDAI‐2 K, and/or hospitalization for SLE, and/or augmented SLE
therapy). Analyses were controlled for age, sex, and race/ethnicity,
and stratified by education, SLE duration, and baseline SLEDAI‐2 K.
Results: Of 469 potentially eligible patients, 412 completed at least 2
annual visits and were therefore included. In the first year of follow‐
up, 15.3% of patients tapered HCQ, 8.7% discontinued HCQ, and
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the remainder did not change therapy. Among the 367 patients with
outcome information, 48.5% had at least one poor outcome at the
second follow‐up visit. The proportion of patients having a poor out-
come was slightly higher for those tapering/stopping HCQ, versus
those maintaining therapy (difference of 11.9%, 95%CI 0.0%, 23.4%).
Having tapered or discontinued HCQ within the first year of follow‐
up was associated with experiencing a poor outcome at the subse-
quent follow‐up visit (one year later) independently of potential con-
founders (OR = 1.69; 95%CI 1.02, 2.80). Stratified analyses showed
that reducing/discontinuing HCQ was associated with poor outcomes
particularly for those with low educational level (OR = 3.06; 95%CI
1.29, 7.30), those within two years of SLE diagnosis (OR = 2.02;
95%CI 1.03, 3.96), and those with high SLEDAI‐2 K (≥4 points) at
baseline (OR = 2.28; 95%CI 1.09, 4.77).
Conclusions: Though some SLE patients do well after tapering or
discontinuing therapy, others have poor outcomes including lupus‐
related hospitalization. Tapering/discontinuing HCQ may be particu-
larly problematic in patients with low educational level, recent SLE
diagnosis or unstable disease. These issues are likely important in per-
sonalizing decisions for tapering/discontinuing HCQ in SLE.
548 | TNF‐alpha inhibitor treatment patterns
in patients with rheumatic diseases and those
with inflammatory bowel disease
Rosanne W. Meijboom1,2; Helga Gardarsdottir1,3; Matthijs L. Becker2;
Toine C.G. Egberts1,3; Hubert G.M. Leufkens1; Thijs J. Giezen2,1
1Utrecht Institute of Pharmaceutical Sciences, Utrecht, Netherlands;
2Pharmacy Foundation of Haarlem Hospitals, Haarlem, Netherlands;
3University Medical Centre Utrecht, Utrecht, Netherlands
Background: TNFα inhibitors are the first line biological treatment for
patients suffering from rheumatic diseases (RD) and inflammatory
bowel disease (IBD). Limited information is available about long‐term
treatment patterns of patients starting a TNFα inhibitor and whether
these differ between patients suffering from RD and IBD.
Objectives: To compare treatment patterns of patients with RD and
IBD starting a TNFα inhibitor.
Methods: Included were all patients starting (i.e. no prior use of a bio-
logical) with aTNFα inhibitor (ATC code: L04AB) between 1 July 2012
and 1 July 2017 at a Dutch general teaching hospital (the Spaarne
Gasthuis, Haarlem/Hoofddorp) and with a RD or IBD diagnosis. All
patients were followed for at least one year. Outcomes at one year
of follow‐up were: continuous use of the first TNFα inhibitor, switch
to a different TNFα inhibitor or to a biological with another mode of
action, or discontinuation. In addition, median duration of first TNFα
inhibitor treatment were compared for patients with RD and IBD
using the Kaplan Meier method. Data were analyzed by Pearson's
chi square and Kruskal Wallis test.
Results: 646 patients were included (median age 46 years, 84%
female), of which 63.9% (n = 413) received a TNFα inhibitor for RD
and 36.1% (n = 233) for IBD. After 1 year, 60.1% of patients
continuously used their first TNFα inhibitor, 13.4% switched to
another biological and 26.5% discontinued treatment. Significantly
less RD patients continued their TNFα inhibitor compared to IBD
patients (54.4% versus 70.0%, RR 0.78, 95% CI 0.69–0.88) and RD
patients discontinued treatment more frequently than IBD patients
(33.0% versus 15.0%, RR 2.19, 95% CI 1.57–3.06). 12.6% of RD
patients and 15.0% of IBD patients had switched, most patients
(71.1% of RD switchers and 91.4% of IBD switchers) to a second
TNFα inhibitor.
The median treatment duration of the first TNFα inhibitor was signif-
icantly (p < 0.01) lower for RD patients (437 days, IQR 686 days) when
compared with IBD patients (728 days, IQR 988 days).
Conclusions: RD patients discontinue their first TNFα inhibitor signif-
icantly more often than IBD patients and have a shorter duration of
treatment, patterns of switching are equal in both indications. These
findings show the importance of underlying disease in classification
of exposure to TNFα inhibitors and this should be taken into account
in future pharmacoepidemiologic studies.
549 | Comorbidities, infections and
treatment patterns in psoriasis patients: A
retrospective analysis of a large United States
electronic health record database
Georgios Varsos; Fred W. Peyerl; Meng Shen; Kunal Lodaya;
Laxmi Gannu; Apeksha Shenoy; David K. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Psoriasis is an immune mediated, chronic skin disease
marked by red patches covered with white scales. Several comorbid
conditions may exist with psoriasis, some of which may worsen psori-
asis, significantly impacting quality of life. Psoriatic patients are prone
to infections, a leading cause of death. Multiple therapeutic options
are available for treatment of psoriasis.
Objectives: The objective of the present study was to examine comor-
bid conditions, infections, and treatment techniques in psoriatic
patients.
Methods: This retrospective study examined data from a US elec-
tronic health record database (Cerner Health Facts®). All visits, includ-
ing inpatient (age ≥ 18 years), between 2012–2016 with a principal
ICD9/10 diagnosis of psoriasis were included in the analysis. ICD9/
10 diagnosis codes were used to identify comorbid health conditions
and prevalence of infections. Type of treatment provided was identi-
fied via medication names as well as procedure codes.
Results: The study included a total of 244,512 psoriasis‐related visits
(51.8% female), majority in the ‘36–65 years’ age group (64.7%). Pso-
riatic arthritis (21.7%), type 2 diabetes (12.2%), kidney disease
(4.5%), and cardiovascular disease (3.9%) were the most commonly
seen concomitant diseases. The most prevalent infections among pso-
riatic‐patient visits were skin infections (2.7%), fungal infections
(2.1%), urinary tract infections (2%), hepatitis C (1.4%), upper respira-
tory infections (1.4%), pneumonia (1.13%), herpes zoster (0.16%),
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hepatitis B (0.12%), and tuberculosis (0.03%). More than half of psori-
asis patient visits were prescribed topical treatments (56.5%) as com-
pared to light therapy (25.3%), and systemic medications (18.2%). The
most commonly prescribed systemic medication was methotrexate
(67.2%), followed by biologics (15.6%), cyclosporine (12.5%), and reti-
noids (4.7%).
Conclusions: This large database analysis examined various comorbid-
ities and types of infections associated with psoriasis and provides
insights into current pharmacological and other treatment strategies.
550 | Characterization of rheumatoid
arthritis (RA) in Puerto Rico: Prevalence,
demographics, and prescribing trends among
beneficiaries of the government sponsored
health care plan (GSHCP)
Wenfei Wei; Jose Hernandez
Texas A&M University, College Station, TX
Background: Rheumatoid arthritis (RA) is a debilitating disease charac-
terized by irreversible joint destruction. RA generally affects more
women than men, and incidence increases with age. The latest Amer-
ican College of Rheumatology Guidelines recommend nonbiologic dis-
ease modifying antirheumatic drug (DMARD) monotherapy for the
initial treatment of RA. Biologic agents include IFN inhibitors and are
generally reserved for refractory RA due to their high cost. Unfortu-
nately, there are no studies describing the prevalence,
sociodemographic distribution, and pharmacotherapeutic treatment
patterns of RA in Puerto Rico.
Objectives: This study aims to describe the prevalence,
sociodemographic features, and pharmacotherapeutic patterns of RA
patients in Puerto Rico.
Methods: A longitudinal retrospective review of RA medical and phar-
macy claims from Puerto Rico's GSHCP was performed. Demographic
features of age and gender were determined for each region in Puerto
Rico and prevalence was calculated following a previously validated
algorithm. Pharmacy claims were used to determine the frequency
that patients were prescribed nonbiologic DMARDs and biologic
agents.
Results: A cohort of 40,473 RA beneficiaries was generated from
October 1, 2015 to December 31, 2016. The average age of beneficia-
ries was 59 years. Females were 3 times as prevalent as males and
regions West and East had the highest prevalence of RA. The calcu-
lated prevalence of RA in Puerto Rico's GSHCP was 0.4%. 41% of ben-
eficiaries filed a claim for a biologic agent while 77% filed a claim for a
nonbiologic DMARD.
Conclusions: Demographic characteristics of RA in Puerto Rico fol-
low expected trends for RA; however, prevalence is higher in Puerto
Rico than other areas of the world. As suggested by guidelines,
majority of patients are taking nonbiologic DMARD therapy. Medica-
tion data should be further analyzed to determine prescribers' adher-
ence to guidelines.
551 | The importance of reliable data
collection: Using electronic medical records
to study lower extremity injuries in elite
football
Christina Mack1; Mackenzie Herzog1; Robert Anderson2;
Edward Wojtys3; Kristin Shiue1; Richard Kent4; Michael Coughlin5
1 IQVIA, Durham, NC; 2Green Bay Packers, Bellin Health Titletown Sports
Medicine and Orthopedics, Green Bay, WI; 3University of Michigan, Ann
Arbor, WI; 4University of Virginia; Biocore, Charlottesville, VA; 5Coughlin
Foot and Ankle Clinic, Boise, ID
Background: Lower extremity injuries impact the majority of elite
American football players over the course of their careers, and some
of these injuries can be career‐ending. Previously published studies
describing lower extremity injuries among National Football League
(NFL) players often rely on convenience samples from publicly‐
reported injury information, often from the lay press, which may be
inaccurate, incomplete, and biased towards more severe injuries.
Objectives: Accurately characterize incidence and impact of lower
extremity injuries in NFL athletes through use of a high quality, closed
electronic medical record (EMR) data collection system, and to com-
pare findings to previously published studies that utilized publicly‐
reported injury information.
Methods: All 32 NFL teams report injuries into the league‐wide EMR
under mandated, consistent data collection guidelines. Lower extrem-
ity injuries reported during 2015–2017 regular season games were
included, with. Injury data were linked with game statistics and player
participation, including the number of plays each player participated in
for each game. Rates per 1,000 game‐plays and 10,000 player‐plays
were calculated along with 95% CI for injuries overall, by specific
lower body injury, and stratified by characteristics such as roster posi-
tion and play type. Descriptive statistics were generated for number of
days missed from football participation for each injury. Findings were
compared to previously published results in the same population.
Results: Lower extremity injuries that resulted in missed time occurred
at a rate of 21.5 (21.0,22.0) injuries per 1,000 plays (n = 3538 over 3
seasons). Incidence of the most severe injuries was similar to that
reported from publicly available data; for example, occurrence of 34
game‐related Achilles ruptures across 5 years was captured in both
the EMR and a publication based on public reports (Krill et al, 2017).
However, injuries such as Jones fractures, which range in severity
and impact, were more likely to be underestimated; one published
study (Parekh et al, 2017) reported only 53.8% of the Jones fractures
that were reported in the EMR.
Conclusions: Use of a closed EMR, in this case within the NFL, linked
with game statistics and player participation, provides the ability to
capture reliable injury occurrence and player exposure, which are nec-
essary for incidence and impact assessment of these important inju-
ries. This system can be extended more broadly to health systems
interested in characterizing adverse event rates or for performing sur-
veillance and risk management.
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552 | Prescribing pattern of Janus kinase
inhibitors drugs in rheumatoid arthritis
patients in Taiwan
Hsing‐Yu Hsu; Yi‐Hui Lee; Ching‐Ya Huang; Yow‐Wen Hsieh
China Medical University Hospital, Taichung, Taiwan
Background: Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease. When patients are untreated, RA causes pain, joints damage
and disability. It also increases disease mortality in infection or osteo-
porosis. RA cannot be cured; therefore, the goal of treatment is to
achieve a state of clinical remission or low disease activity. Tofacitinib
is an oral Janus kinase inhibitor and a higher average cost per month
than other drugs in our hospital. In addition, little research has focused
on JAKIs treatment strategies for routine care in Taiwan.
Objectives:Our aim was to evaluate trends in use of prescription JAKIs
among RA patients and the changes in patterns of JAKIs as monother-
apy or combination conventional DMARDs utilization.
Methods:Weusedtheelectronicmedicalrecordsof2018JantoDecinhos-
pitalclaimsdatabasestoestablishresearchcohorts.Weincludedpatients
who are diagnosed RAby ICD10 and prescribed JAKIs at the same time.
We defined the date of first‐prescribe JAKIs as index date and observed
cDMARDsprescribingpatternsateverymonthaftertheindexdate.
Results:Drug consumption data presents that 62 patients were RA. The
mean age was 57 years and the average proportion of woman patients
was 80.6%. The percentage of patients initiated on JAKIs in combina-
tion with any cDMARDs was 79%, while combination with
hydroxychloroquine (HCQ) was about 45.1%, with methotrexate
(MTX) was about 32.2%. About 75.8% of RA patients were co‐prescrib-
ing oral steroids. A continuous decrease in combination cDMARDs ther-
apy was observed by months in 14.3% patients after prescribed JAKIs.
HCQ and MTX were the two most prescribed cDMARDs.
Conclusions: This study indicated that trend towards more aggressive
management of RA in our hospital. The utilization of JAKIs in combina-
tion with cDMARD major is HCQ. It is a difference from combination
with MTX in an international guideline. The consideration of treatment
strategies is not only patient tolerance of drug property individually
but also cost of average per course of therapy.
553 | Effect of reimbursement restriction
policy on the use of benzodiazepines in the
Netherlands: An interrupted time series
analysis
Eibert Heerdink1,2; Lennart J. Stoker1,3; Richard T.J.M. Janssen4,5;
Antoine C.G. Egberts1,6
1Utrecht University, Utrecht, Netherlands; 2Utrecht University of Applied
Sciences, Utrecht, Netherlands; 3Haaglanden Medical Centre, The Hague,
Netherlands; 4Erasmus University, Rotterdam, Netherlands; 5Tilburg
University, Tilnurg, Netherlands; 6University Medical Centre, Utrecht,
Netherlands
Background: Use of benzodiazepines has serious health risks. Reim-
bursement was restricted in the Netherlands from 1 January 2009
onwards with the goal to reduce chronic use and healthcare
expenditures.
Objectives: The aim of this study is to assess the initial and long‐term
effects of this policy on benzodiazepine use.
Methods: Setting: Benzodiazepine dispensings by out‐patient pharma-
cies between January 2002 and August 2015 were obtained from the
PHARMO Database. This database comprises GP and specialist pre-
scribed medication and covered a catchment area representing about
3.6 million residents in 2015. Participants: 2,500,800 benzodiazepine
prescriptions from 128,603 (66.6% female) patients were included.
Intervention: Reimbursement restriction policy from 1 January 2009
onwards. Design: A 10% random sample of PHARMO database was
obtained and analyzed. Interrupted times series design, segmented
regression models, Kaplan–Meier survival analysis and Cox‐propor-
tional hazard analysis were used to compare the use of benzodiazepines
before and after the reimbursement restriction policy. Main outcome
measures: Changes in the volume of dispensed prescriptions and doses,
as well as in the incidence and prevalence of incidental, regular and
chronic use and changes in discontinuation rates of benzodiazepines.
Results: The calculated volume of dispensed prescriptions and doses
decreased by 12.5% respectively 15.1% in January 2009 compared
to December 2018. A clear initial effect on the overall incidence (−
14.7%) and the prevalence of incidental (−17.8%), regular (−20.0%)
and chronic (−16.0%) use was observed. A statistical long‐term effect
was observed for the overall incidence (−0.017) and the prevalence of
incidental use (−3.624) but not for regular (−0.304) and chronic (0.136)
use. Patients who started treatment post‐policy had a slightly higher
probability of discontinuation (HR = 1.013; 95%CI, 1.004–1.022).
Conclusions: The reimbursement policy had a significant initial effect
on the volume, incidence and prevalence of BZD use. In addition,
there is a long‐term effect on overall incidence and on the prevalence
of incidental use. No long‐term effect on chronic use of BZD, the main
purpose of the reimbursement restriction, could be proven.
554 | Differences in patterns of prescribing
medications for depression in obese and
Normal weight patients
Svetlana Puzhko1; Tibor Schuster1; Tracie A. Barnett2; David Barber3;
Gillian Bartlett1
1McGill University, Montreal, QC, Canada; 2Université du Québec à
Montreal (UQAM), Montreal, QC, Canada; 3Queen's University, Kingston,
ON, Canada
Background: Patients with obesity often have more severe depression
than normal weight patients and may respond poorly to pharmacolog-
ical treatment. Certain depression medications can increase weight
(are obesogenic) contributing to the high prevalence of obesity in
patients with depression. Presently, it is unknown whether healthcare
providers account for body weight when they prescribe obesogenic
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medications for depression. It is, therefore, important to evaluate pre-
scribing patterns of obesogenic depression medications for patients
with depression and excess weight.
Objectives: Using a national primary care practice database, to exam-
ine the association between obesity and prescribing medications for
depression, focusing on obesogenic medications.
Methods: Study sample was extracted from the national Canadian Pri-
mary Care Sentinel Surveillance Network (CPCSSN) Electronic Medi-
cal Records database for 2011–2016. Adult patients (18 years of age
and older) diagnosed with depression were included. Measures were
prescribing of depression medications (outcome) and body mass index
(BMI) to categorize patients into weight groups (exposure). Data were
analyzed cross‐sectionally using multivariable binary logistic regres-
sion adjusting for age, sex, and the comorbidities.
Results: Among 61699 patients with depression, 41389 (67.1%) had a
prescription for at least one medication for depression. Compared
with normal weight patients, obese patients were more likely to
receive a prescription for at least one depression medication (adjusted
Odds Ratio [aOR] = 1.21; 95% Confidence Interval [CI]: 1.16–1.26).
Obese patients were less likely to receive obesogenic antidepressant
mirtazapine, belonging to the norepinephrine‐ and specific serotoner-
gic group (aOR = 0.64; 95% CI: 0.58–0.70); however, compared with
normal weight patients, obese patients were more likely to receive
other obesogenic depression medications: tricyclic antidepressant
amitriptyline (aOR = 1.26; 95% CI: 1.15–1.38), selective serotonin
reuptake inhibitor paroxetine (aOR = 1.19; 95% CI: 1.06–1.34) and
atypical antipsychotic quetiapine (aOR = 1.09; 95% CI: 1.00–1.18).
Conclusions: Compared with normal weight patients, obese patients
with depression appear to be more likely to be prescribed at least
one medication for depression and to receive obesogenic depression
medications amitriptyline, paroxetine and quetiapine. While causality
cannot be inferred, these prescribing patterns may contribute to the
issue of obese patients who are at higher risk for severe depression
and poor response to treatment.
555 | Trends in prescribing and dispensing of
common insomnia drugs as compared to
National Guideline Recommendations
Jenna Wong; Darren Toh
Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA
Background: Insomnia is often treated with medication, including on‐
label (eg, Z‐drugs) and off‐label (eg, trazodone) drugs. In 2017, theAmer-
ican Academy of Sleep Medicine (AASM) released its first‐ever clinical
guideline for the pharmacologic treatment of insomnia, recommending
thatphysicians considerusingZ‐drugsandconsidernotusing trazodone.
Objectives: To measure trends in the prescribing and dispensing of
four medications commonly used for insomnia (trazodone + three Z‐
drugs: zolpidem, eszopiclone, zaleplon) and to compare the findings
to the 2017 AASM recommendations.
Methods: Cross‐sectional analysis of two nationally representative US
data sources: 1) the National Ambulatory Medical Care Survey
(NAMCS), and 2) a 1% sample of the MarketScan® Research Data-
bases. NAMCS data were used to measure prescribing trends among
office‐based visits for insomnia from 2009 to 2015, while the
MarketScan data were used to measure dispensing trends among pri-
vately‐insured patients with insomnia from 2011 to 2016. The unit of
analysis in the NAMCS and MarketScan data was the insomnia visit
and patient, respectively. We calculated the annual percent of visits/
patients where each drug was prescribed/dispensed. In the
MarketScan data, we used dose information to restrict to trazodone
claims for <50 mg/day. We used multivariable logistic regression to
estimate adjusted yearly odds ratios (ORs) for the likelihood of each
drug being prescribed/dispensed. For the NAMCS data, we used
SAS survey analysis procedures to calculate weighted national esti-
mates and account for the complex survey design.
Results: Among a national weighted average of 10.4 million insomnia‐
related visits/year from 2009 to 2015 in NAMCS, the annual percent
of visits where trazodone was prescribed rose from 7.0% (95% CI
3.4%–10.5%) to 21.2% (11.0%–31.3%), while the annual percent of
visits where zolpidem was prescribed fluctuated widely around an
average of 21%. In the MarketScan data, among an average of 8,000
insomnia patients/year from 2011 to 2016, the annual percent of
patients with low‐dose trazodone dispensed increased from 4.5%
(4.0%–5.0%) to 7.3% (6.7%–7.8%) and fell from 32.9% (31.8%–
34.0%) to 26.3% (25.4%–27.2%) for zolpidem and from 4.8% (4.3%–
5.3%) to 3.6% (3.2%–4.0%) for eszopiclone. Zaleplon was dispensed/
prescribed infrequently. In both data sources, the adjusted ORs sup-
ported a statistically significant increase in trazodone prescribing/dis-
pensing over time among insomnia patients.
Conclusions: Contrary to the AASM guidelines, the off‐label use of
trazodone for insomnia appears to be increasing over time.
556 | Long‐term outcomes of early use of
long‐acting injectable antipsychotics in
schizophrenia
Yu‐Hsuan Joni Shao1; Su‐Chen Fang1; Cheng‐Yi Huang
1Taipei Medical University, Taipei, Taiwan; 2Bali Psychiatric Center,
MOHW, New Taipei, Taiwan
Background: Patients in the early stage of schizophrenia may be the
ideal candidates for long‐acting injectable (LAIs) antipsychotics. How-
ever, no studies examined the long‐term comparative effectiveness
between patients who added or switched to LAIs during the treatment
and those remaining on oral antipsychotics (OAPs).
Objectives: To assess whether patients adding or switching to LAIs in
early schizophrenia are associated with decreased risk of psychiatric
inpatient and emergency room (ER) visits and improved mortality.
Methods: Using Taiwan National Health Insurance Research Data
from 2008–2016, we formed a cohort by identifying all participants
from the base population of OAPs initiators who subsequently added
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or switched to a LAIs during hospitalization and further prescribed
LAIs at least 6 times in 1‐year post discharge. For each patient adding
or switching to LAIs, we identified a matched reference patient who
also was a OAPs initiator but remained on OAPs, using a prevalent
new‐user design. The potential reference patients were selected from
the corresponding exposure sets namely from the OAPs initiators in
the base cohort who spent the same duration of time in base cohort
as the exposed patients (defined as the period from the first prescrip-
tion of OAPs to first prescription of LAIs) and remained on OAPs
when exposed patients added or switched to LAIs. Survival and condi-
tional negative binomial regressions were adapted to estimate the risk
of mortality, psychiatric inpatient and ER visits associated with LAIs
and OAPs.
Results: In patients adding or switching to LAIs within 3 year of OAP
initiated, their all‐ and natural‐ cause mortalities were significant lower
than those remaining on OAPs. The hazard ratio (HR) was 0.45 (95%
Confidence Interval [CI]: 0.27–0.87) and 0.30 (95% CI: 0.15–0.60)
for all‐ and natural‐ cause, respectively. The unnatural cause mortality
was lower in the LAIs groups comparing with those remaining on
OAPs, but the HR did not reach a statistical significance. Patients
who added or switched to LAIs had a lower risk to have an inpatient
visit (IRR = 0.56, CI = 0.45–0.69), to have a psychotic inpatient visit
(IRR = 0.63, CI = 0.50–0.81) and to have a psychotics ER visit
(IRR = 0.58, CI = 0.45–0.75) than patients remaining on OAPs. The
improvement in survival and disease control is not observed in
patients who added or switched to LAIs in late phase of their diseases.
Conclusions: Using LAIs in early schizophrenia has a profound impact
on mortality. Our results provide an important piece of evidence to
support the idea that early phase schizophrenia patients may benefit
the most from LAIs.
557 | Concurrent use of gabapentin,
benzodiazepines and opioids: Prevalence and
risk factors among commercially insured
United States adults
Abisola Olopoenia; Wendy Camelo‐Castillo; Sean Fleming;
Linda Simoni‐Wastila
University of Maryland, Baltimore, MD
Background: Off‐label use of gabapentin within the United States is
rapidly increasing, ranging between 83 to 95%. Gabapentin, opioids
and benzodiazepines are commonly co‐prescribed, raising concerns
about an increased risk of central nervous system depression and
abuse. Little is known about factors potentially associated with co‐
prescription of these medications.
Objectives: To estimate the prevalence of co‐prescription of opioids,
gabapentin, and benzodiazepines (OGB) among adults ages 18
through 64, and evaluate associated risk factors.
Methods: We conducted a retrospective cohort study derived from a
1% random sample of enrollees within the IQVIA™ PharMetrics Plus
adjudicated claims database during January 1, 2007 to December 31,
2015. The index date was defined as the first opioid prescription
within the study period. We constructed a 3‐level categorical measure
of concurrent use based on medication receipt in the 12‐month post‐
index period: OGB, opioids and gabapentin only (OG), and opioids
only. Concurrent OGB exposure was defined as having at least one
day overlap of days supplied for gabapentin and benzodiazepine with
an opioid prescription. Clinical and demographic characteristics includ-
ing age, chronic pain, sedatives, muscle relaxants, mental health and
substance use disorders were assessed in the 6‐month pre‐index
period. We estimated the prevalence of concurrent OGB use, and
used a multinomial logistic regression (AOR; 95 CI) to estimate the
association of clinical and socio‐demographic factors with concurrent
use.
Results: Among 125,904 adult opioid users, 1588 (1.3%) and
451(0.3%) had concurrent use of gabapentin (OG) and gabapentin
and benzodiazepines (OGB), respectively. The prevalence of concur-
rent OGB use was higher among middle‐aged adults (46–55) with
diagnosis of chronic pain, mental health (MH), and substance use dis-
order (SUD) when compared to OG and opioid‐only users (p < 0.01.)
After adjusting for other demographic and clinical factors, back pain
(2.53;2.06–3.10), depression (2.33;1.86–2.76), anxiety (2.63;2.08–
3.36), mood disorders (1.95;1.43–2.65), and opioid‐related substance
use disorders (10.90;5.9–13.8) were the strongest predictors of con-
current OGB use.
Conclusions: Although prevalence of gabapentin is low among opioid
users, close to one third of OG users also use benzodiazepines.
Despite their increased vulnerability to opioid related adverse out-
comes, adults with MH and SUD are more likely to be OGB users.
558 | Real‐world evidence of disease
progression and treatment pattern of patients
diagnosed with Parkinson's disease
Chao Chen; Sudhakar Manne; Shreya Davé
Takeda Pharmaceuticals International Co., Cambridge, MA
Background: Parkinson's disease (PD) is one of the most common
neurodegenerative disorders, affecting 1–2 per 1000 of the popula-
tion at any time. As treatment algorithms and therapeutic options
have been continuously updated by the neurology community, it is
important to understand current PD diagnosis and treatment patterns
using real‐world data. Although large claims databases can be a valu-
able data source for epidemiological studies, they are limited by the
lack of information on disease stage.
Objectives: To explore potential proxies for PD stage and disease pro-
gression by delineating longitudinal treatment patterns and comorbid-
ity profiles of a PD patient cohort in a US administrative claims
database.
Methods: A retrospective cohort study was conducted using the
Truven Health MarketScan® Research Database, a US administrative
claims database from 2001–2017. PD patients were included if they
had health plan coverage for at least one year before and one year
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after the initial diagnosis of PD. Patient demographics, comorbidities
and PD therapies at baseline were summarized by descriptive analy-
ses. The median time to pharmacological therapy and deep brain stim-
ulation were also calculated. The incidence of comorbidities and
different PD therapies were estimated for each year after the initial
diagnosis of PD for up to 6 years.
Results: The cohort included n = 100,239 patients diagnosed with PD
from 2001–2017. Mean age was 72.4 years and about half of the
patients were over 60 years old. The cohort featured relatively more
male patients (55.2%), Medicare enrollees (41.3%) and more patients
from north central (33.7%) and southern (31.2%) US regions. The
median time to pharmacological therapy and deep brain stimulation
were 8.4 and 41.2 months respectively. The incidence rates of dual
and triple therapy increased over time, and the greatest increase was
seen in year 3. In the last year of follow‐up, incidence rates of dual
and triple therapy were 45.2 and 14.7 per 100 person‐years respec-
tively. Over time, patients experienced an increased diagnosis rate of
constipation, heart failure, diabetes, atrial fibrillation and peripheral
vascular disease, but a decreased diagnosis rate of depression, cere-
bral vascular disease and dyslipidemia during follow‐up.
Conclusions: Trends in treatment patterns and changes in incidence
rates of PD related comorbidities were described in this study. As dis-
ease progressed more complicated treatment regimens and different
comorbidity profiles were observed, which may be used as potential
disease severity indicators.
559 | Concomitant drug use among frequent
users of insomnia medications: A US claims
database study
Cathy Anne Pinto1; Praful Kumar2; Johanna Hyacinthe1;
Ankita Kumar2; Zhiwen Liu1
1Merck & Co., Inc., Kenilworth, NJ; 2Complete HEOR Solutions Pvt Ltd.,
North, UK, PA
Background: Prior studies have reported polypharmacy with sleep
hypnotics but there is limited evidence from database studies
supporting concomitant drug use. The ability to detect evidence of
concomitant drugs using an administrative database is challenging
given the high PRN use of insomnia medications.
Objectives: To describe concomitant drug use for frequent new users
of suvorexant (suvo), zolpidem (zol), temazepam (tem), and ramelteon
(ram).
Methods: A new user cohort study was conducted using the Optum
Research Database with patients having ≥2 prescriptions for the
index drug identified between January 01, 2015 to September 30,
2017, with ≥12‐months of follow‐up and baseline data. Given chal-
lenges with detecting concomitant medication use for drugs fre-
quently used on a PRN basis, the cohort was further restricted to
more chronic drug users defined as those with a refill ratio (RR) ≥0.8
with RR defined as cumulative days' supply/time between the first
and last prescription. Concomitant drug use was defined as having
≥1 overlapping prescriptions of the index drug and a second (non‐
index) insomnia drug, with a sensitivity analysis defining it with ≥2
overlapping prescriptions. Non‐index drugs also included low dose
doxepin and trazodone which is commonly used for insomnia. Given
the potential for channeling with newer medications, a subgroup anal-
ysis was performed for those with no prior insomnia medication use.
Descriptive statistics were used.
Results: The sample included 4,182 suvo, 46,400 zol, 15,217 tem, and
1,144 ram new users with ≥2 prescriptions. Among the cohort, 62%,
31%, 54%, and 69% of suvo, zolp, tem, and ram new users, respec-
tively, had an overall RR ≥0.8, with 12%, 20%, 25%, and 19% also hav-
ing no evidence of prior insomnia drug use. Concomitant drug use,
overall and for the subgroup with no prior insomnia drug use, respec-
tively, was 33.6% and 12.7% for suvo, 17.5% and 11.3% for zol, 28.8%
and 16.9% for tem, and 37.7% and 19.4% for ram. When requiring evi-
dence of ≥2 overlapping prescriptions, the proportions were further
reduced to 4.5% and 0.4% for suvo, 0.9% and 0.4% for zol, 2.5%
and 0.8% for tem, and 5.6% and 2.3% for ram.
Conclusions: Although evidence of overlapping insomnia medications
exists, the analysis demonstrates that database analyses are very sensi-
tive to the algorithm used to define concomitant drug use. When
attempting to control for baseline imbalances in important prognostic
factors by excluding prior insomnia drug users, there is still evidence of
concomitant drug use. However, the rates of concomitant use are lower
with greater numerical balance amongusers of different insomnia drugs.
560 | Antidepressant use in Denmark,
Germany, Spain, and Sweden from 2009 to
2014: Incidence and comorbidities of
antidepressant initiators
Joan Forns1; Anton Pottegård2; Tammo Reinders3;
Beatriz Poblador‐Plou4; Rosa Morros5,6; Lena Brandt7;
Miguel Cainzos‐Achirica1; Maja Hellfritzsch2; Tania Schink3;
Alexandra Prados‐Torres4; Maria Giner‐Soriano5,6; David Hägg7;
Jesper Hallas2; Jordi Cortés5,6,8; Emmanuelle Jacquot9;
Nicolas Deltour9; Susana Perez‐Gutthann1; Manel Pladevall1;
Johan Reutfors7
1RTI Health Solutions, Barcelona, Spain; 2University of Southern
Denmark (Institute of Public Health), Odense, Denmark; 3 Leibniz Institute
for Prevention Research and Epidemiology–BIPS, Bremen, Germany;
4EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS
Aragón, Miguel Servet University Hospital, Zaragoza, Spain; 5 Institut
Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAPJGol),
Barcelona, Spain; 6Universitat Autònoma de Barcelona, Bellaterra, Spain;
7Centre for Pharmacoepidemiology, Department of Medicine, Solna,
Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden;
8Universitat Politècnica de Catalunya, Barcelona, Spain; 9Les
Laboratoires Servier, Paris, France
Background: Antidepressants are among the most prescribed drugs in
Europe. Antidepressant choice is influenced by factors related to the
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specific antidepressant as well as patient‐related factors. No studies
have described the use of antidepressants and characteristics of adult
users in Europe since 2012.
Objectives: To describe patterns of use and characteristics of adult
users of 10 antidepressants from 2009–2014 in four European
countries.
Methods: The antidepressants were citalopram, escitalopram, fluoxe-
tine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline,
mirtazapine, and agomelatine. This included different classes of com-
monly used antidepressants in the participating countries.
Agomelatine was selected for regulatory reasons. Adult initiators of
each study antidepressant from 2009–2014 were identified in the
Danish and the Swedish National Registers, GePaRD (Germany),
EpiChron (Aragon, Spain), and SIDIAP (Catalonia, Spain). Cumulative
incidence of antidepressant initiation was calculated. Initiators were
characterized at the start of treatment episode according to age, sex,
and presence of comorbidities. Patterns of use, including use of anti-
depressants prior and during the current episode, were also assessed.
Results: The study included 4.8 million initiators of antidepressants.
Citalopram had the highest cumulative incidence (users per 1,000) in
all populations except in Aragon, ranging from 65 in Denmark to 38
in Catalonia. Agomelatine (fewer than 10), and paroxetine had the
lowest cumulative incidence. Women (> 60%) comprised the majority
of antidepressants initiators. Mirtazapine was used among older initia-
tors (median age range 54 years in Denmark ‐ 67 years in Aragon) with
higher prevalence of comorbidities, and fluoxetine was used among
younger and healthier initiators (median age range 38 years in Sweden
‐ 50 years in Aragon). The most prevalent comorbidities among initia-
tors were hypertension, diabetes, hyperlipidaemia, and obesity. The
results indicated that citalopram and amitriptyline were the most com-
mon first‐line treatments, whereas agomelatine and duloxetine were
mostly used in the second line. Agomelatine, venlafaxine, and
duloxetine were mostly used in combination therapy.
Conclusions: This study suggests that citalopram and mirtazapine
were the most commonly prescribed antidepressants in the popula-
tions studied during 2009–2014. Age, presence of comorbidities,
and patterns of use in adult initiators differed between
antidepressants.
561 | Comparability of antipsychotic‐treated
and non‐treated patients with schizophrenia
and the assessment of mortality in Taiwan
Darmendra Ramcharran1; Chao‐Hsiun Tang2; Po‐Ya Chuang2;
Hong Qiu1; Ching‐Wen Wendy Yang2; Kuo‐Hsuan Chung3
1 Janssen R&D, Titusville, NJ; 2Taipei Medical University, Taipei, Taiwan;
3Taipei Medical University Hospital, Taipei, Taiwan
Background: Treatment versus non‐treatment comparisons are often
performed to evaluate drug safety or effectiveness.
Objectives: To assess comparability of antipsychotic (AP)‐treated and
non‐treated patients with schizophrenia when evaluating mortality.
Methods: A retrospective cohort study estimated the risk of all‐cause,
sudden death, and cardiovascular (CV) mortality among AP‐treated
and non‐AP‐treated patients with schizophrenia. The study population
covering a period of 2001–2015 was identified using the linkage of
theTaiwan National Health Insurance (NHI) claims and National Regis-
ter of Death databases. In as‐treated and intention‐to‐treat (ITT) analy-
ses, incidence density estimates were calculated in AP‐treated and non‐
AP‐treated patients with schizophrenia. The study population included
patients with at least one inpatient or at least two outpatient diagnosis
codes of schizophrenia, and the subset of AP‐treated patients were
those with 2 or more AP prescriptions within a 90 day period.
Results: A total of 68,348 and 8,959 AP‐treated and non‐AP‐treated
patients with schizophrenia, respectively, were included in the study.
Demographic and clinical characteristics for non‐AP‐treated patients
with schizophrenia were inconsistent with the medically accepted pro-
file of patients with schizophrenia. Non‐AP‐treated patients compared
to AP‐treated patients, respectively, were substantially older (mean
ages 47.4 and 39.1 years old), were more likely to be male (55.5% and
49.3%), and had more comorbidity (mean Charlson comorbidity scores
0.49 and 0.15). In AP‐treated as‐treated analyses, AP‐treated ITT anal-
yses, and non‐AP‐treated patients, respectively, mortality outcome
estimates per 1,000 patient‐years were: all‐cause mortality (16.4,
14.5, and 27.4); sudden death (2.7, 2.4, and 2.8); CV death (0.7, 0.6,
and 2.1); all estimates were highest among non‐AP‐treated patients.
Conclusions: This analysis of a key outcome in a schizophrenia popu-
lation demonstrates how lack of comparability between populations
may be misleading. The results also suggest the need to closely scruti-
nize criteria for schizophrenia diagnoses, and potentially validate these
diagnoses in NHI by linkage to the Catastrophic Illness Registry. For
comparative effectiveness pharmacoepidemiology studies of patients
with a diagnosis of schizophrenia, AP treatment versus non‐treatment
comparisons without validation, matching, and other adjustment strat-
egies should be conducted with caution due to fundamental differ-
ences in these patient groups, which may bias effect estimates.
562 | Real‐world treatment patterns among
attention‐deficit/hyperactivity disorder
patients who initiated extended‐release
treatment
Jennifer Erensen1; Xuezhe Wang2; Yingjie Ding2; Frank A. Corvino2;
Jaromir Mikl1
1Purdue Pharma LP, Stamford, CT; 2Genesis Research, Hoboken, NJ
Background: Attention‐deficit/hyperactivity disorder (ADHD) affects
7.8%–11.0% of children and 4.4% of adults in the U.S. Extended‐
release (ER) and immediate‐release (IR) medications are commonly
prescribed for ADHD, with ER formulations gaining popularity in
recent years.
Objectives: To assess the real‐world treatment patterns of ER ADHD
medications among commercially‐insured adolescents and adults in
the U.S.
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Methods: Patients aged ≥12 years with ≥1 ADHD diagnosis and ≥ 2
ER or IR prescriptions (covering ≥60 days within the first 90 days of
treatment) were identified in a large US claims database from 2011
to 2017. Patients had ≥6 months of continuous enrollment pre‐
and ≥ 12 months post‐treatment initiation and were followed until
discontinuation (60‐day treatment‐free interval), enrollment end or
24 months post treatment initiation. Patients were untreated within
the 6‐month baseline period and grouped based on the first recorded
treatment as ER monotherapy, IR monotherapy or ER/IR combination.
Results: A total of 209,342 ADHD patients (49.7% female, median age
24 years) met the study inclusion criteria. Of these, 127,362 (60.8%)
initiated with ER, 80,600 (38.5%) with IR and 1,380 (0.7%) with ER/
IR combination. Of patients that initiated ER, 15,599 (12.2%) switched
to or added another ER, 12,333 (9.7%) switched to IR or multiple IR,
and 5,898 (4.6%) added an IR to an ER regimen. The median time on
ER therapy prior to any modification was 165 days. The most frequent
therapy modifications were generic ER amphetamine salts to Adderall
XR (16.5%) and from Vyvanse to generic ER amphetamine salts
(11.3%). The proportion of ER patients who switched or modified an
existing regimen increased with age among adults <40. The median
age for modifiers was 25 while those that remained on therapy was
22 (p < .001). The five most prevalent comorbidities of these patients
are depression (23.5%), anxiety (6.6%), insomnia (3.7%), bipolar disor-
der (3.1%), and substance use disorder (2.9%). Depression (28.0% vs
21.9%, p < .001), anxiety (8.2% vs 6.0%, p < .001) and insomnia
(4.6% vs 3.4%, p < .001) were significantly higher in patients who
modified their regimen.
Conclusions: In this population, a higher number of patients were ini-
tially treated with ER compared to IR therapy and more likely to
remain on the same treatment they initiated for the duration of the
study. Most ER patients who modified their regimen switched to
another ER. Age and the presence of psychological comorbidities
may play a role in the treatment management of certain ADHD
patients.
Purdue Pharma LP funded this research.
563 | Use of antidepressants and anxiolytics
among patients with chronic diseases in the
Netherlands
Jan Maurik van den Heuvel1; Charlotte E. Pelgrim2;
Aletta D. Kraneveld2; Anke‐Hilse Maitland van der Zee1
1Academic Medical Center, Amsterdam, Netherlands; 2Utrecht Institute
for Pharmaceutical Sciences, Utrecht, Netherlands
Background: In the Netherlands, around 8,8 million people suffer from
some form of chronic disease. Comorbid depression and axiety are
often found in patients suffering from chronic immune disease.
Untreated and undetected anxiety and depressive symptoms may
increase physical disability and morbidity and may affect health‐care
utilization. The risk of comorbid depression in patients with other
chronic diseases has not been fully explored. Understanding the use
of antidepressants among patients suffering from different chronic
diseases may lead to new methods of (mental) treatment for patients
suffering from chronic diseases.
Objectives: To understand the relation between chronic use of medi-
cation for different diseases and the use of antidepressants and
anxiolytics.
Methods: The NControl database containing prescription data of 800
pharmacies and over 7 million patients in The Netherlands was used.
Patients that received frequent dispensings of COPD medication,
statins (cardiovascular disease), oral glucose lowering medications
(type II diabetes mellitus), dermatology medications (anti‐psoriatics
and eczema treatments) and patients that received DMARDS (rheu-
matic arthritis) were analyzed for concomitant chronic dispensings of
antidepressants and anxiolytics. The WHO Anatomical Therapeutic
Chemical (ATC) codes were used to identify these medications.
Patients of age 55+ that received 2 or more of these drugs per year
between 2014 and 2018 were included. We also included two control
groups of patients aged 55+: the first with patients that received med-
ication in at least 2 out of these 5 years and that were not included in
the groups of chronic patients, and one control group of patients with
dispensed medications in less than 2 years and that were not included
in any of the previous groups.
Results: We found that patients that suffer from the studied chronic
diseases have a higher risk of using anti‐depressants or anxiolytics
than patients in the control groups. 49.9% of all patients that are
treated for dermal problems, 48% of patients that receive COPD
treatment, 44.9% of patients that receive DMARDS, 40.1% of patients
that received oral blood glucose lowering medication, and 39.5% of all
patients that receive statins are also treated for depression or anxiety,
compared to 31.2% of our first control group, and 15.6% of our sec-
ond control group.
Conclusions: Patients that suffer from chronic diseases have a higher
risk of also being treated for depression and anxiety.
564 | Factors associated with deep brain
stimulation surgery for Parkinson's disease:
Examining medication use and patient
characteristics
James A.G. Crispo1,2; Melody Lam3; Britney Allen3; Lucie Richard3;
Salimah Z. Shariff3; Dominique R. Ansell4,5; Melanie Squarzolo4,5;
Connie Marras6; Allison W. Willis1; Dallas Seitz7
1University of Pennsylvania Perelman School of Medicine, Philadelphia,
PA; 2 ICES North, Sudbury, ON, Canada; 3 ICES Western, London, ON,
Canada; 4Health Sciences North, Sudbury, ON, Canada; 5Northern
Ontario School of Medicine, Sudbury, ON, Canada; 6Toronto Western
Hospital, University of Toronto, Toronto, ON, Canada; 7Queen's
University, ICES‐Queen's, Kingston, ON, Canada
Background: Prior studies have shown that deep brain stimulation
(DBS) is superior to medical management alone for severe motor com-
plications of Parkinson's disease (PD), and may enhance activities of
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daily living and quality of life. Currently, there are limited data on PD
medication use prior to DBS surgery.
Objectives: The objectives of our study were (1) to describe the use of
PD medications in the 2‐year period prior to surgery for DBS cases
and matched controls and (2) to examine whether patient factors,
including use of multiple PD medication classes, were associated with
undergoing DBS surgery.
Methods: We used several health administrative datasets (Ontario,
Canada) to examine DBS surgery within a cohort of individuals diag-
nosed with incident PD between 1995–2009 at age 40 years or older.
Patients undergoing DBS surgery were matched with up to 4 non‐DBS
controls by age, sex, and time with PD. Analyses of prior use of PD
medications were restricted to a subset of the matched cohort who
were 67 years of age or older at their surgery/index date. Associations
between patient characteristics and receipt of DBS surgery for PD
were estimated using conditional logistic regression models.
Results: There were 46,237 individuals with PD in our cohort, with
747 patients (155 DBS cases, 592 controls) included our analyses of
PD medications. Compared to controls, patients receiving DBS surgery
were more likely to have used individual PD medication classes in the
previous 2‐year period, including levodopa (92.3% vs. 70.4%), non‐
ergot dopamine agonists (56.1% vs. 26.2%), ergot dopamine agonists
(11.6% vs. 6.1%), monoamine oxidase B inhibitors (12.9% vs. 10.5%),
catechol‐o‐methyltransferase inhibitors (38.1% vs. 16.0%), anticholin-
ergics (7.7% vs. 5.7%), and amantadine (45.2% vs. 17.2%). Relative to
patients treated with fewer medications, those treated with a greater
number of unique PD medication classes in the previous 2 years were
more likely to undergo DBS surgery (5+ vs. 0–2 PD medication clas-
ses: adjusted odds ratio = 4.95, 95% CI = 1.85–13.25). Other factors,
such as neighborhood ethnic concentration, were also found to be
associated with DBS surgery.
Conclusions: Patterns of PD medication use may serve to identify eli-
gible candidates for DBS surgery. Future studies should examine
whether identified disparities in DBS surgery are attributed to patient
preference, established care and referral pathways, or differences in
the biological need for DBS.
565 | The utilization of first and second‐
generation antipsychotic drugs in Denmark
from 1999 to 2017: A study using population‐
based data
Reeha Sharon; Morten Andersen
University of Copenhagen, Copenhagen, Denmark
Background: Both first generation antipsychotics (FGA) and second‐
generation antipsychotics (SGA) may cause serious adverse events
ranging from metabolic disorders to possible changes in brain struc-
ture and volume or desensitization of dopamine receptors, that may
eventually cause relapses of the psychotic disorders. Despite the wide
usage of antipsychotic drugs and the approval and marketing of sev-
eral new substances during the last two decades, little information is
available on longitudinal utilization patterns and the use in specific
age groups.
Objectives: To analyze the consumption of antipsychotic drugs in
Denmark with a focus on the transition from FGA to SGA and the uti-
lization pattern of SGA.
Methods: Nationwide data on outpatients' purchase of antipsychotic
drugs was obtained from national statistics on the total drug sales in
Denmark (Medstat.dk) during the period 1999 to 2017. The annual
use in million DDDs (MDDD) and the number of users was retrieved
for FGA, SGA, and single substances (ATC codes), stratified on 5‐year
age groups and sex. The one‐year prevalence of use and average con-
sumption in DDD/user/year was calculated for all strata.
Results: The total consumption of FGA decreased from 9.180 MDDD
in 1999 to 2.743 MDDD in 2017. Conversely, SGAs consumption sig-
nificantly increased from 3.481 to 18.209 MDDD. During the study
period, among the five most highly used SGA clozapine, olanzapine,
quetiapine, aripiprazole and risperidone, there was a distinct increase
in preference towards quetiapine and aripiprazole when compared to
the other SGA. Clozapine use was slightly decreasing throughout the
period. Age‐specific prevalences and annual average use revealed a
middle‐aged population treated with higher doses/longer duration
and an elderly population treated with lower doses/shorter duration.
Considerable variation in use was observed among the drugs.
Conclusions: Our study explored the longitudinal use of antipsy-
chotics showing a transition from FGA to SGA and an increasing pref-
erence for quetiapine and aripiprazole during later years. Furthermore,
populations with distinct utilization patterns were identified: younger
and middle‐aged patients (likely with chronic psychosis, e.g. schizo-
phrenia) and elderly (probably with acute psychosis or symptoms
related to dementia).
566 | Real‐world evidence for treatment
patterns of patients diagnosed with
depression in the United States
David Kern; M. Soledad Cepeda; Frank Defalco; Mila Etropolski
Janssen R&D, Titusville, NJ
Background: Understanding treatment patterns is vital to understand
how patients are treated in the real world, and to identify potential
non‐responders who might require alternative or new treatment
options.
Objectives: To describe the current patterns and duration of medica-
tion use for the treatment of depression and its symptoms in patients
diagnosed with depression.
Methods: We identified patients diagnosed with depression from a
large national claims database of commercially insured individuals.
The index date was the first observed medical claim in the database
with a diagnosis of depression. Patients were required to have contin-
uous enrollment in the database at least one year prior to and three
years following the index date. Patients were excluded if they had evi-
dence of treatment for depression more than 30 days prior to index.
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Treatment patterns were captured at the class level and included
selective serotonin reuptake inhibitors (SSRIs), serotonin and norepi-
nephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),
monoamine oxidase inhibitors (MAOIs), anxiolytics, hypnotics/seda-
tives, and antipsychotics. Treatment patterns were captured during
all available follow‐up, a minimum of 3 years.
Results: We identified 102,738 patients diagnosed with depression.
The median patient age was 58 years [interquartile range = 35 to
70 years] and 66% were female. One quarter (26%) of patients did
not receive any pharmacological treatment during follow‐up. Of the
treated, 56% received ≥2 different classes of therapy, while 25%
received ≥3 classes and 8% received 4 or more. Sixty‐four percent
of patients first received an SSRI or SNRI, however 34% received an
anxiolytic, hypnotic/sedative, or antipsychotic as the first treatment
prior to any antidepressive treatment. Anxiolytics and SNRIs were
the most common 2nd and 3rd treatments received, while antipsy-
chotics were the most common 4th treatment, received by 24% of
patients with at least 4 different treatments. Patients remained on
their first treatment for an average of nine months.
Conclusions: More than a third of patients received a non‐antidepres-
sant as their first treatment. More than half of patients received more
than one type of antidepressant or a completely different treatment
class ‐ anxiolytics, hypnotics, or antipsychotics ‐ during the study fol-
low up, suggesting that the first treatment received may not be opti-
mal for most patients.
567 | Levodopa misuse/abuse among
patients with Parkinson's disease
Richard S. Swain; Patty Greene; Sara Karami; Travis Ready;
Tamra Meyer
Food and Drug Administration, Silver Spring, MD
Background: Levodopa, often combined with carbidopa or with
carbidopa/entacapone to improve its bioavailability, is indicated to
treat symptoms of Parkinson's disease (PD). A small portion of PD
patients are thought to misuse/abuse levodopa, developing a pattern
of compulsive self‐medication called Dopamine Dysregulation Syn-
drome (DDS), in which patients increase their dosage despite
experiencing harmful consequences of high levodopa dosage.
Objectives: To describe prevalence, risk factors, and trends of levo-
dopa misuse/abuse among PD patients.
Methods: We extracted published epidemiologic studies on DDS or
misuse/abuse of levodopa using PubMedon June18, 2018using search
terms related to [Parkinson's disease] and [levodopa] and [(dopamine
dysregulation syndrome) or (misuse) or (abuse)]. We analyzed patterns
of US poison center exposure calls (2008–2017) related to levodopa
from theNational PoisonData System (NPDS) andU.S. outpatient retail
utilization patterns for levodopa‐containing products from IQVIA™
(2013–2017) to provide context for misuse/abuse calls over time.
Results: Twenty‐eight studies reported incidence, prevalence, or risk
factors for misuse/abuse of levodopa among PD patients. Among
the general PD population, reports of levodopa misuse/abuse preva-
lence ranged from 0–7.4%. High‐risk sub‐populations, including
patients with compulsive behavior disorders (4–58.8%) and candidates
for surgical sub‐thalamic stimulation (0–20.6%), reported higher prev-
alence of misuse/abuse. Patient characteristics associated with levo-
dopa misuse/abuse included: male gender, early onset PD, history of
drug abuse or compulsive behaviors, mood disorders, and high daily
dose of levodopa. U.S. retail drug utilization data showed the number
of patients taking levodopa in the outpatient setting ranged from an
estimated 541,000 patients in 2013 to 580,000 in 2017; including
long‐term care pharmacies, the number of tablets dispensed increased
from 570 to 721 million tablets during the same span. We identified
11,985 NPDS exposure calls related to levodopa from 2008–2017,
including 230 (1.9%) misuse/abuse calls. From 2013 to 2017, the
years with available drug utilization data, the rate of levodopa mis-
use/abuse calls increased from 3.5 to 5.7 calls per 100,000 patients
with a prescription for levodopa.
Conclusions: The epidemiologic literature and epidemiologic data sug-
gest misuse/abuse of levodopa occurs among some PD patients. How-
ever, one summary estimate for PD patients may not be appropriate,
as prevalence varies substantially based on patient characteristics.
568 | Regional variation and increasing
Gabapentinoids prescribing in England
G.U. Xinchun; Teng‐Chou Chen; Douglas Steinke; Li‐Chia Chen
Division of Pharmacy and Optometry, School of Health Sciences, Faculty
of Biology, Medicine and Health, University of Manchester, Manchester,
UK
Background: Gabapentinoids (GPNs; i.e. gabapentin and pregabalin)
will be classified as controlled substabces in the United Kingdom
(UK) from April 2019, due to increasing concerns of probable drug‐
misuse deaths. Medication use is often linked with geographical varia-
tion and health inequality, but variations of GPN utilization is still not
fully understood in the UK.
Objectives: This study aimed to quantify the amount and trend of pre-
scriptionGPNs in England and identify the geographical variation in use.
Methods: This cross‐sectional study applied practice‐level dispensing
data from the UK National Health Service Digital and the estimated
population sizes from the Office for National Statistics between Janu-
ary 2011 and December 2017. GPNs prescribed by general practi-
tioners in England were identified from the dispensing data. The
annual utilization of GPNs dispensed in England was calculated in
the number of defined daily doses (DDD)/1000 registrants. In 2017,
the 7467 general practices were grouped into 207 clinical commis-
sioning groups (CCGs) and ranked by the GPN utilization. Descriptive
statistics were used to report annual utilization and its trend from
2011 to 2017. The CCG regions with top GPN utilization in 2017
were identified.
Results: The annual DDD/1000 registrants of prescribed GPNs signif-
icantly increased 140% from 1847 in 2011 to 4450 in 2017, with an
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increasing annual rate of 442 DDD/1000 registrants per year. The
increasing trend is consistent when stratified into gabapentin and
pregabalin. In 2017, the median DDD/1000 registrants across the
207 CCGs was 4247 (interquartile range: 2857, 5302). The majority
of CCGs with the highest GPNs utilization was in the North of
England. Five of the top 10 ranking CCGs of GPN utilization were sit-
uated in the North West.
Conclusions: The prescribing of GPNs markedly and steadily increased
in England. There is a North–South divide in prescribing GPNs with
the North having a larger use than the South, which is potentially
related to socioeconomic status. Further study is needed to identify
the determinants of increasing GPNs prescribing and the associated
harms.
569 | Characterization of gabapentin use in
Kentucky
GYeon Oh1,2; Svelta Slavova2,3; Patricia R. Freeman4,5
1Department of Epidemiology, University of Kentucky, Lexington, KY;
2Kentucky Injury Prevention and Research Center, University of Kentucky,
Lexington, KY; 3Department of Biostatistics, University of Kentucky,
Lexington, KY; 4Department of Pharmacy Practice and Science,
University of Kentucky, Lexington, KY; 5 Institute for Pharmaceutical
Outcomes and Policy, University of Kentucky, Lexington, KY
Background: Due to high prevalence of gabapentin among Kentucky
(KY) drug overdose decedents and concerns for possible misuse in
communities, gabapentin was reclassified as a Schedule V controlled
substance (CS) in KY, effective July 2017.
Objectives: The purpose of this study was to characterize gabapentin
use in KY.
Methods: We used Kentucky All Schedule Prescription Electronic
Reporting (KASPER) data (Oct 2017‐Sep 2018). Gabapentin use was
defined as having received at least one gabapentin prescription during
the study period. Gabapentin use rates, including by age, sex, and
region, were calculated based on 2017 annual estimates of the resi-
dent population. Choropleth maps were created to examine regional
variations in county‐level gabapentin rate. Concurrent use of
gabapentin with opioids, pregabalin, and benzodiazepines (BDZ) with
7+ continuous overlapping days was assessed.
Results: The overall state rate of gabapentin use was 66.3 per 1,000
residents, with highest rates among residents 55–64 years of age
(133.4/1,000). Rates of gabapentin use were significantly higher in
females vs. males [rate ratio (RR): 1.47; 95% confidence interval (CI):
1.46–1.48]. The prevalence of gabapentin use was significantly higher
in eastern Kentucky counties, Appalachian region vs. Central region
[RR: 1.73; 95% CI: 1.72–1.75] and Appalachian region vs. Delta region
[RR: 1.36; 95% CI: 1.34–1.37]. The median days' supply of gabapentin
during study period was 179 days and the median daily dose was
911.0 mg. The median days' supply of gabapentin and the median
daily dose was significantly higher in Appalachian region [227 days;
1200 mg] than Central region [153 days (p‐value: <0.001); 900 mg
(p‐value: <0.001)] and Delta region [170 days (p‐value: <0.001);
900 mg (p‐value: <0.001)]. Among gabapentin users, 44.6%, 19.5%,
and 1.8% had 7+ continuous overlapping days with opioids, BDZ,
and pregabalin, respectively.
Conclusions: Given that gabapentin use is more frequent in vulnerable
populations (older age, female, and eastern Kentucky counties), further
studies should examine the factors related to gabapentin prescribing
and risk of having overlapping days with other CS.
570 | New treatments for comorbidities
after diagnosis with multiple sclerosis (MS): A
study in the UK clinical practice research
datalink (CPRD) GOLD
Rebecca Persson1; Sally Lee2; Neil Minton2; Steve Niemcryk2;
Anders Lindholm2; Susan Jick1,3
1Boston Collaborative Drug Surveillance Program, Lexington, MA;
2Celgene Corporation, Summit, NJ; 3Boston University School of Public
Health, Boston, MA
Background: Patients with MS have an elevated risk of many comor-
bid conditions. Few studies have examined patterns of new treatment
use for these conditions after MS diagnosis.
Objectives: To describe the patterns of new treatments for comorbid
conditions in MS patients compared with matched non‐MS patients.
Methods: We conducted a cohort study in the UK CPRD GOLD. Each
MS patient diagnosed from 2001–2015 with ≥1 year of pre‐diagnosis
history was matched with up to 10 non‐MS patients on age, sex, gen-
eral practice and record history length before cohort entry (MS diag-
nosis/matched date). We compared new use of treatments for
comorbid conditions in years 0 to <2 and 2 to <4 after cohort entry
using a chi‐square test. Prevalent users (patients with at least one
prior prescription in the year before cohort entry) were excluded sep-
arately from each treatment category.
Results: 6932 MS patients were identified and compared with 68,526
non‐MS patients (female, 70%; median age at cohort entry, 43 years).
In both time periods, MS patients had higher use of antihypertensives
(years 0–2: 7.9% vs. 5.3% [p < 0.0001] and years 2–4: 5.9% vs. 5.1%
[p = 0.03]), immunosuppressants for non‐MS autoimmune disorders
(years 0–2: 1.2% vs. 0.5% [p < 0.0001] and years 2–4: 0.6% vs. 0.4%
[p = 0.01]), proton pump inhibitors (PPIs) (years 0–2: 14.9 vs. 7.6%
[p < 0.0001] and years 2–4: 10.8 vs. 7.7% [p < 0.0001]), antibiotics
(years 0–2: 39.1 vs. 31.7% [p < 0.0001] and years 2–4: 30.2 vs.
24.9% [p < 0.0001] and sexual dysfunction treatments (males) (years
0–2: 11.0 vs. 1.6% [p < 0.0001] and years 2–4: 6.2 vs. 1.8%
[p < 0.0001]). Anticoagulant use was higher in years 0–2 (0.5% vs.
0.3% [p = 0.013]) but not years 2–4 (0.4% vs. 0.4%). MS and non‐
MS patients had similar new use of asthma/COPD treatments, but
the percentage of new users changed over time (years 0–2: 5.2 vs.
5.0% [p = 0.66] and years 2–4: 3.2 vs. 3.6% [p = 0.10]). Use of the fol-
lowing drug categories were similar for MS and non‐MS patients and
percentage of new users was consistent over time: statins (~2.5%),
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other CVD treatments (~0.7%), insulin (~0.2%), and other hypoglyce-
mics (~0.8%) [all p > 0.05].
Conclusions: In the UK CPRD GOLD, MS patients had a higher inci-
dent use of antihypertensives, autoimmune treatments, PPIs, antibi-
otics and sexual dysfunction treatments than matched non‐MS
patients. Use of anticoagulants was higher in the first 2 years after
MS diagnosis.
571 | Comorbid conditions and medications
in post traumatic stress disorder patients: A
retrospective analysis of a large United States
electronic health record database
Georgios Varsos; Fred W. Peyerl; Kunal Lodaya; Meng Shen;
Laxmi Gannu; Xuan Zhang; Apeksha Shenoy; David k. Hayashida;
Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Post Traumatic Stress Disorder (PTSD) is a mental health
condition which develops after experiencing a traumatic event. Epide-
miologic studies have demonstrated that over 90% of people with
PTSD have at least one lifetime comorbid mental disorder which
may influence the treatment choice for PTSD.
Objectives: The main objective of the present study was to evaluate
mental health conditions and treatments of PTSD patients.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All outpatient
visits (age ≥ 18 years) between 2012 and 2016 with a principal
ICD9/10 diagnosis of PTSD were evaluated in this study. Chronic
and acute PTSD were defined as a duration of symptoms of
>3 months, and 1–3 months respectively. Complications were identi-
fied by the corresponding ICD9/10 diagnosis codes. Medications were
classified into categories (antidepressants and anti‐anxiety) for further
examination.
Results: A total of 46,560 patients with PTSD were identified in
the database, corresponding to 197,856 outpatient visits, likely indi-
cating multiple visits per patient. Chronic PTSD was diagnosed in
43.2% of visits, while 1.9% of visits were associated with acute
PTSD. The majority of visits (74.1%) comprised female patients. It
was also observed that the highest percentage of PTSD patients
were in the age group of ‘36–65 years’ (67.2%). Other mental
health conditions prevalent in PTSD patients were depression and
anxiety (49.0%), followed by issues with drugs, substance, and alco-
hol use (18.3%), eating disorders (2.6%), and suicidal thoughts and
actions (0.1%). Prescriptions combining anti‐anxiety medications
and antidepressants (41.3%) were the most common, followed by
anti‐anxiety medications only (39.1%) and antidepressants only
(19.6%).
Conclusions: This large database analysis provides insight into the
real‐world evidence of mental health conditions that pose as both risk
factors and/or complications of PTSD, and their impact on medication
prescribing to treat PTSD patients.
572 | Predictors for methylphenidate
initiation in young individuals in the
Netherlands
Chii Chyi Cheung; Bram Dierckx; Hanan El Marroun;
Vincent W.V. Jaddoe; Loes E. Visser; Bruno HCh Stricker
Erasmus University Medical Center, Rotterdam, Netherlands
Background: Methylphenidate is widely used to treat children
with attention deficit hyperactivity disorder (ADHD), but the rea-
son to initiate pharmacological treatment remains unclear. Multiple
factors may contribute to the decision to start treatment, includ-
ing parents. However, relatively little is known about their char-
acteristics as predictive factors for treatment initiation.
Objectives: To examine the parental characteristics as predictors for
initiating pharmacological treatment with methylphenidate among
children.
Methods: A follow‐up study in a cohort of children within a large
prospective population‐based cohort investigating children's health
from fetal life onwards in Rotterdam, the Netherlands. Children were
included if their mother gave full consent for postnatal follow‐up.
Children were excluded if no pharmacy records could be obtained.
The outcome was defined as having a dispensing pharmacy record
of methylphenidate for the first time since birth. We evaluated
parental characteristics as potential determinants of methylphenidate
initiation through univariable and multivariable logistic regression
analysis. A Cox proportional hazard model was used to evaluate
these potential determinants among children whose mother have
completed the Child Behavior Check List at the age of 18 months,
1.5, 5 and 9 years.
Results: Overall, we found that these 4,243 children were less
likely to receive methylphenidate when mothers have a Turkish/
Moroccan (ORadj: 0.43, 95%CI: 0.21–0.86) or Surinamese/Antillean
background (ORadj: 0.35, 95%CI: 0.17–0.74) compared to Dutch
mothers, or if they had received a lower education (ORadj: 1.57,
95%CI: 1.12–2.21) or if they were smoking during pregnancy
(ORadj: 1.52, 95%CI: 1.01–2.28). Similar results were observed for
fathers. Of children where the questionnaire was completed, we
found that children with elevated ADHD symptoms born to a
Turkish/Moroccan (ORadj: 0.19, 95%CI: 0.06–0.62) or other non‐
western (ORadj: 0.17, 95%CI: 0.05–0.55) mother, were less likely
to receive methylphenidate treatment than children of Dutch
mothers. ADHD symptoms were more present in these groups
(Turkish/Moroccan OR: 1.60, 95%CI: 1.56–1.64; Surinamese/Antil-
lean OR: 2.22, 95%CI: 2.16–2.27; other non‐western OR: 1.90,
95%CI: 1.85–1.94).
Conclusions: Our study indicates that children were less likely to
receive methylphenidate prescriptions when their mothers have an
ethnic minority background, were lower educated or were smoking
during pregnancy. ADHD symptoms were more frequently reported
in ethnic minority groups, but they were less likely to receive
methylphenidate.
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573 | Use of atypical antipsychotics in the
Brazilian health system: Profile of users and
their self‐perception of health
Isabella Figueiredo Zuppo; Cristina Mariano Ruas;
Helian Nunes Oliveira; Edna Afonso Reis
Federal University of Minas Gerais, Belo Horizonte, Brazil
Background: Psychotic disorders are relatively common mental dis-
orders and are usually treated with antipsychotics, which mainly
aim to minimize the loss of functionality of individuals. In Brazil, in
the scope of the national health system, there are policies that direct
the health care of people with mental disorders, promoting the guar-
antee of integral care and access to medicines, among which are
atypical antipsychotics.
Objectives: To describe the profile of atypical antipsychotic users
and their self‐perception of health in a public pharmacy in
Brazil.
Methods: A cross‐sectional study was conducted with users of
atypical antipsychotics in a public pharmacy in Brazil. The patients
were invited to the interview and answered the questionnaire, after
free and informed consent. Sociodemographic, economic and clinical
data were collected. Self‐reported health status was measured by a
visual analog scale, where “zero” was the worst and “100” the best
possible state of health. The survey was conducted between Sep-
tember‐2017 to March‐2018 and data processed in November‐
2018.
Results: This study included 388 individuals who met the eligibility
criteria. For the sociodemographic characteristics, a majority of male
(55.2%; n = 214) and mean age of 46.1 years (SD 11.8) were identi-
fied. Most of the individuals had no spouse (77.3%; n = 300) and
studied until high school (68.0%; n = 264). It was observed that only
16.2% of the individuals were working at the time of the interview
and that 81.7% had a monthly family income of up to US$
1,002.74. For the clinical characteristics, 49.0% of the interviewees
reported having no disease other than psychotic disorder, most
(50.3%) performed their psychiatric consultations in the public health
sector, 35.5% had undergone an abortion and 34.8% % of respon-
dents have already made at least one suicide attempt. The majority
of the patients reported using olanzapine (35.6%, n = 138), followed
by quetiapine (18.6%, n = 72), ziprasidone (18.3%, n = 71), clozapine
(16.8%, n = 65) and risperidone (10.8%, n = 42). For the state of
health, a better self‐perception was associated with the use of cloza-
pine, with a mean VAS of 75.0 (SD 20.3), while for the other atypical
antipsychotics a mean VAS of 65.2 was reported (SD 24.7
p = 0.008).
Conclusions: The importance of knowing the profile of the popula-
tion with psychotic disorders and identifying the factors that inter-
fere in the health of these individuals is to enable the prioritization
of more efficient policies to guarantee the improvement of health
care and quality of life of this population, often in a situation of
vulnerability.
574 | Benzodiazepine drugs utilization
studies at few Indian hospitals
Venkateshwar Rao Jupally; Varun Talla; Satyanarayan Pattnaik
Talla Padmavathi College of Pharmacy, Warangal, India
Background: Benzodiazepine group of drugs are frequently pre-
scribed for treatment of patients with anxiety and insomnia as anxi-
olytics, hypnotics, tranquilizers, anticonvulsants, etc. Owing to their
diverse usages in different clinical specialities, there is a need to
assess utilization studies of benzodiazepines.
Objectives: To assess utilization pattern of benzodiazepine class of
drugs at few selected hospitals of an Indian city.
Methods: A prospective observational study design was adopted
including patients of either sex, aged more than 18 years and
who received benzodiazepine in their prescription during the
study period visiting the study site. The required informed con-
sent was obtained prior to the enrollment in the study. A stan-
dard data collection form was used to record the required
patient information which included demographic details, diagnosis,
medication, etc.
Results: Out of 473 patients receiving benzodiazepine in their pre-
scription, majority of the patients were diagnosed with schizophrenia
(36.45%) followed by anxiety disorder (21.23%). Among the various
benzodiazepines used, clonazepam (52.43%) was the most prescribed
drug followed by lorazepam (46.28%) apart from few fixed dose com-
bination drug products.
Conclusions: The study revealed that the usages of benzodiazepine
was in accordance to the treatment guidelines. Mostly, the drugs are
utilized in psychiatric specialties and the most commonly prescribed
drug in the class is Clonazepam.
575 | One‐year persistence of potentially
inappropriate medications use in older adults:
A population‐based study in Quebec, Canada
Barbara Roux1,2; Marie‐Laure Laroche1,2; Marc Simard3;
Marie‐Ève Gagnon3; Caroline Sirois3,4
1Centre of Pharmacovigilance and Pharmacoepidemiology, University
Hospital of Limoges, Limoges, France; 2 INSERM UMR 1248, University of
Limoges, Limoges, France; 3 INSPQ, QC, QC, Canada; 4Department of
Preventive and Social Medicine, Laval University, Québec, QC, Canada
Background: The use of potentially inappropriate medications (PIMs)
is associated with negative health outcomes. Although previous stud-
ies have assessed the trend of PIM use over time, none has deter-
mined whether PIMs are used continuously in the same individuals.
Objectives: To assess one‐year persistence of PIM use and to identify
factors associated with such persistence in community‐dwelling older
adults.
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Methods: We conducted a retrospective population‐based cohort
study of community‐dwelling older adults aged ≥66 years in Quebec,
Canada, using the Quebec Integrated Chronic Disease Surveillance
System. To be included, individuals had to be continuously insured
with the public drug plan between April 1st, 2013 and March 31st,
2015. We defined PIMs according to the 2015 Beers Criteria's list of
drugs that should be avoided. Individuals who initiated a PIM between
April 1st, 2014 and March 31st, 2015 (no PIMs prescription in the pre-
vious year) and who had at least one‐year follow‐up after the first PIM
dispensing were retained in the study. Persistence of PIM use at one
year was defined as a continuous treatment with any PIM, with no
interruption longer than 60 days between prescriptions refills. Simi-
larly, we measured one‐year persistence of specific PIM use in
subcohorts of individuals who had initiated those specific PIMs. Mul-
tivariate robust Poisson regressions were performed to identify fac-
tors associated with one‐year persistence. Results were reported as
rate ratios (RR) with their 95% confidence intervals.
Results: Among the 75 844 older individuals who initiated a PIM,
25.1% (95% CI: 24.8%–25.4%) had a persistent use of at least one
PIM over a one‐year period. The median time to first PIM discontinu-
ation was 31 days (IQR: 21–92) in non‐persistent individuals. The
probability of persisting at one‐year was higher for those who initiated
peripheral alpha‐blockers (50.5%), antipsychotics (43.9%), long‐dura-
tion sulfonylureas (40.2%) and proton pump inhibitors (36.0%). Factors
significantly associated with persistence of PIM use included being
older (≥86y, RR: 1.82; 1.76–1,89), being a man (1.13; 1.11–1.15),
and having a higher number of medications and chronic diseases
(ranges 1.06–1.34/1.18–1.62), specifically the presence of Alzheimer
disease and related disorders (1.81; 1.74–1.89).
Conclusions: A quarter of older adults initiating a PIM is persistently
exposed to at least one PIM the whole following year. There is a need
to further explore if persistent use of PIM leads to a higher risk of
adverse events than sporadic use.
576 | Changes in schizophrenia
documentation in nursing home residents
varies by antipsychotic exposure, dementia,
and race
Shekinah A. Fashaw; Theresa Shireman; Ellen McCreedy; Kali Thomas
Brown University, Providence, RI
Background: Since the CMS National Partnership to improve demen-
tia care, the inappropriate use of antipsychotics in nursing home (NH)
residents has been reportedly decreasing. However, the National Part-
nership may have contributed to an increase in schizophrenia
reporting, perhaps as a means to reclassify inappropriate antipsychotic
use as appropriate.
Objectives: The purposes of this work were to examine the effects of
the CMS National Partnership on the rate of schizophrenia diagnoses
among NH residents given antipsychotics with and without dementia
and identify variation in the reporting of schizophrenia between
Blacks and non‐Blacks. We hypothesized that following the partner-
ship initiative, assessments from NH residents with ADRD would
show higher rates of schizophrenia. Furthermore, we hypothesized
that Blacks would also experience lower increases in schizophrenia
reporting.
Methods: This study used a quasi‐experimental difference‐in‐differ-
ence (diff‐in‐diff) design to test the effect of National Partnership that
took effect in March 2012. Using 2011–2015 Minimum Data Set 3.0
resident assessment data, we analyzed the admission assessment for
newly admitted NH residents. There were 6 quarters of data prior to
and 14 quarters post partnership initiative. Trends in schizophrenia
diagnoses for residents with and without Alzheimer's disease and
related dementias (ADRD) and according to Black versus non‐Black
race were compared.
Results: There were over 8.5 million new admission assessments.
The overall rate of schizophrenia reported on assessments declined
for both ADRD and non‐ADRD residents after 2012, though the
decline was less for those with ADRD (Δ = 0.056%) compared to
those without ADRD (Δ = 0.260%) (Diff‐in‐diff = 0.00204;
p < 0.001). Schizophrenia rates also dropped for ADRD and non‐
ADRD residents after 2012, except for those on an antipsychotic
at the time of assessment (Diff‐in‐diff = 0.01603; p < 0.001). They
saw a 3.3% increase in reported schizophrenia. Among assessments
which reported antipsychotic drug use, the rates of schizophrenia
increased slightly after 2012 (Diff‐in‐diff = 0.024; p < 0.001), but
the increase was greater for Black residents (6.25%) as compared
to non‐Blacks.
Conclusions: These findings show that there have been statistically
significant changes in the documentation of schizophrenia on MDS
assessments. However, changes, direction, and magnitude depend
upon the subpopulation under consideration. Those who use antipsy-
chotics and Blacks have seen small but significant increases in diag-
nostic coding, which call for further investigation.
577 | Treatment patterns among elderly
patients diagnosed with diffuse large B‐cell
lymphoma in the United States
Leonardo M. Simonella1; Per‐Olof Thuresson1; Andy Surinach2;
Pavel Napalkov3; Frank A. Corvino2
1F.Hoffmann‐La Roche, Basel, Switzerland; 2Genesis Research, Hoboken,
NJ; 3Genentech, South San Francisco, CA
Background: Diffuse large B‐cell lymphoma (DLBCL) is the most com-
mon aggressive Non‐Hodgkin Lymphoma (NHL), accounting for a third
of all new NHL diagnoses in the United States (US) and generally
occurs in elderly with a median age at diagnosis of 70 years. For pre-
viously untreated patients, CHOP‐like chemotherapy (R‐CHOP) is the
standard of care. For patients not cured by front‐line therapy there is a
need for effective subsequent treatment.
Objectives: To describe the treatment patterns of elderly DLBCL
patients in the US enrolled in Medicare.
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Methods: Patients diagnosed with DLBCL between 2004–2011 were
identified from the SEER‐Medicare linked database. Patients aged
65 years or older at diagnosis, with no evidence of hospice care prior
to diagnosis, and 12 months of continuous enrollment in Medicare
Part A and Part B prior to diagnosis were included in the analysis. Che-
motherapy, stem cell transplant (SCT), and immunotherapy claims
were used to construct lines of therapy after initial diagnosis. The pro-
portion of patients treated in first line (1 L), second line (2 L), and third
line (3 L) were reported. The most common regimens for each line of
therapy were described.
Results: Of 22,004 DLBCL patients (50% male, median age: 78y)
meeting the selection criteria, 52.7% (N = 11,603) were treated on
or after initial diagnosis. 7,943 patients (76.3% of untreated patients)
died without receiving treatment. 3,615 patients were treated in the
2 L setting and 1,121 were treated in 3 L. The most common regimens
in the 1 L setting were R‐CHOP (58.7%), rituximab (RTX) monotherapy
(9.9%), and R‐CVP (6.5%). The three most common 2 L regimens were
RTX monotherapy (14.1%), R‐CHOP (11.3%), and rituximab and
bendamustine (R‐Benda) (5.9%). In the 3 L setting, the most common
regimens were RTX monotherapy (12.4%), R‐Benda (7.8%), and SCT
(6.4%). There were 219 (1.9%) treated patients that received SCT, with
most occurring in a 2 L+ setting (85.4%, n = 187).
Conclusions: Among treated elderly DLBCL patients, most are receiv-
ing guideline recommended therapies in the 1 L setting. Treatment in
the 2 L and 3 L setting is more heterogeneous indicating the difficulty
of treating relapsed or refractory (R/R) disease. Recent approvals of
chimeric antigen receptor T‐cell (CAR‐T) therapies will offer new
options for R/R disease. Further studies are necessary to understand
the most effective regimens in the R/R setting.
578 | Attitudes towards Deprescribing in
older adults with limited life expectancy: Two
systematic reviews
Alaa Burghle1,2; Carina Lundby1,2; Jesper Ryg1,2; Jens Søndergaard2;
Anton Pottegård1,2; Trine Graabæk1,2; Dorthe Nielsen1,2,3
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark; 3University College Lillebælt, Odense,
Denmark
Background: Deprescribing of unnecessary medications is particularly
relevant in older adults with limited life expectancy, as they have a
considerable use of prescription drugs and are generally more suscep-
tible to the potential harms of multiple medications.
Objectives: To explore the attitudes of health care professionals
(HCPs), as well as patients and their relatives towards deprescribing
in older adults with limited life expectancy by performing two system-
atic reviews.
Methods: We conducted a systematic literature search from inception
to December 2017 using MEDLINE, EMBASE, and CINAHL. Both
quantitative and qualitative studies were included if they concerned
older people with limited life expectancy, including older people
residing in any kind of aged care facility, or were based on representa-
tive patient profiles. The studies included in the review of HCPs' atti-
tudes towards deprescribing were analyzed with inspiration from
Joanna Briggs Institute's method for synthesis of qualitative data in
systematic reviews. Results from the studies concerning the attitudes
of older adults and their relatives were obtained by narrative
synthesis.
Results: Eight studies were included in the review of HCPs' attitudes
towards deprescribing in older adults with limited life expectancy.
The studies mainly concerned the views of general practitioners and
other physicians. Factors that influenced HCPs' decisions to initiate
or suggest deprescribing in this population were related to four overall
themes: 1) Patient and relative involvement, 2) The importance of
teamwork, 3) HCPs' self‐efficacy and skills, and 4) The impact of orga-
nizational factors. Six studies were included in the review of the atti-
tudes of older adults and their relatives. A number of facilitators and
barriers to the process of deprescribing in older people with limited
life expectancy were identified. Facilitators included discussing the
deprescribing process with HCPs, experiencing adverse events and
weaning off the medications, while barriers included fear of deteriora-
tion, acceptance of condition, and lack of current harm.
Conclusions: We have identified multiple and interdependent barriers
and facilitators for deprescribing among older adults with limited life
expectancy. Initiatives to facilitate deprescribing practices within this
population should target several of the possible issues identified.
579 | Potentially inappropriate medications
and risk of autonomy loss for activities of
daily living in the elderly
Emilie Hucteau1; Pernelle Noize2; Antoine Pariente2;
Catherine Helmer1; Karine Pérès3
1Bordeaux Population Health Research Center, Team LEHA, UMR1219,
University of Bordeaux, Inserm, Bordeaux, France; 2Bordeaux Population
Health Research Center, Team Pharmacoepidemiology, UMR1219,
University of Bordeaux, Inserm/Clinical Pharmacology, Bordeaux
University Hospital, Bordeaux, France; 3Bordeaux Population Health
Research Center, Team SEPIA, UMR1219, University of Bordeaux, Inserm,
Bordeaux, France
Background: Elderly persons are subject to polypharmacy that may be
partly justified but can lead to adverse effects. In this population,
explicit criteria were proposed to identify potentially inappropriate
medications (PIM) that must be avoided. The prevalence of PIM use
was found to be high (40–50%) and the loss of autonomy could be a
significant adverse effect associated with PIM.
Objectives: The objectives were i) to estimate the prevalence of PIM
use and its evolution over time and ii) to study the relationships
between PIM and autonomy loss for Activities of Daily Living (ADL).
Methods: The study was conducted on the Echantillon Généraliste des
Bénéficiaires (EGB) among people aged 65 and over. ADL‐dependency
was defined using an algorithm previously developed and validated,
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which includes data on reimbursed drugs, medical acts, products and
deliveries, chronic diseases, age and sex. PIM were defined based on
the Beers 2015 criteria that were considered into two groups: i) PIM
+ including criteria directly measurable or measurable under condi-
tions that can be identified using EGB data and ii) PIM‐ including
criteria with conditions that are not entirely measurable. The associa-
tion between PIM and ADL‐dependency was analyzed using a delayed
entry Cox model with adjustment on the number of drugs used and
Charlson's comorbidity index. PIM criteria that were associated with
ADL‐dependency were determined.
Results: In 2010, 50.5% of elderly subjects had used at least one PIM+
or PIM‐ and 35.5% at least one PIM+. In 2015, prevalence had
decreased by 7%. Most users consumed 1 PIM criterion, 8.5% 2
criteria and 3.5% ≥3 criteria. PIM related to CNS were the most com-
monly used, especially BZD and BZD‐related hypnotics. Proton pump
inhibitors (PPI) were also frequently used (21.2%). There was an
increased risk of ADL‐dependency as soon as a PIM criteria was used.
Of the 22 PIM+ criteria, first‐generation antihistamines, barbiturates,
BZD, BZD‐related hypnotics, meprobamate and antipsychotics were
significantly associated with ADL‐dependency. By adding PIM‐
criteria, 3 additional criteria were significantly associated with ADL‐
dependency: digoxin, amiodarone and PPI.
Conclusions: This study showed that PIM are still frequently used in
the elderly population and were associated with an increased risk of
becoming dependent. It is therefore essential to take into account pre-
scribing recommendations in order to better adapt the treatment in
the elderly.
580 | Patterns of antipsychotic use among
older adults with late‐life psychotic disorders
Dallas Seitz1; Soham Rej2; Simone Vigod3; Colleen Maxwell4;
Tarek Rajji5; Simon Davies5; Nathan Herrmann5; Paul Kurdyak5;
Paul Nguyen1
1Queen's University, Kingston, ON, Canada; 2McGill University, Montreal,
QC, Canada; 3Women's College Hospital, Toronto, ON, Canada;
4University of Waterloo, Waterloo, ON, Canada; 5University of Toronto,
Toronto, ON, Canada
Background: There are growing numbers of older adults who are diag-
nosed with schizophrenia and related forms of late‐life psychosis
(LLP). Antipsychotics are necessary medications for the majority of
individuals with LLP although there are few randomized controlled tri-
als of antipsychotics (APs) for individuals with LLP and this population
may be susceptible to AP related side‐effects. There is limited infor-
mation available about the current patterns of AP use among individ-
uals with LLP. Our study examined the patterns of antipsychotic use
among older adults with LLP in Ontario, Canada.
Objectives: 1.) To describe AP use among older adults with LLP in
Ontario, Canada including types of antipsychotics (typical or atypical
antipsychotics), patterns of use (monotherapy, polypharmacy), routes
of administration, and dose equivalencies.
Methods: We undertook a cross‐sectional study to describe the pat-
terns of AP use among older adults LLP using linked administrative
databases at ICES at Queen's University. We identified all adults in
the province of Ontario, Canada who met case criteria for LLP using
an algorithm for psychotic disorders. Individuals age 66 years or older
who met cohort inclusion criteria were included in the study sample.
Exposure to AP medications was determined using outpatient pre-
scription medication claims in the 120 days preceding index. AP use
was characterized as typical AP or atypical AP as well as whether AP
use was monotherapy or polypharmacy. Dosage of AP were recorded
for each AP and converted to Olanzapine equivalents. Descriptive sta-
tistics were used to summarize AP use within the study sample.
Results: There were 48,354 individuals in the LLP cohort using the
sensitive case definition. In the study sample 52% received no AP,
33% received atypical AP monotherapy 6% received typical AP mono-
therapy and 8% received AP polypharmacy. The respective AP catego-
ries in the sensitive cohort definitions were: no AP 28%, atypical AP
monotherapy 44%, typical AP monotherapy 44%, and AP
polypharmacy 21%. In the sensitive cohort, individuals receiving AP
polypharmacy had the highest mean daily (SD) Olanzapine dose equiv-
alents 24.5 mg (22.9 mg), followed by typical AP monotherapy
9.49 mg (15.7 mg), and atypical AP monotherapy 8.1 mg (8.3 mg).
Conclusions: Our large population‐based study found variation in the
patterns of AP use among older adults with LLP. Some prescribing
practices such as high‐doses of AP medications and polypharmacy
may be associated with adverse events in this population and the out-
comes associated with different patterns of AP prescribing require fur-
ther study.
581 | Risk of major bleeding in elderly users
of non‐vitamin K antagonist Oral
anticoagulants according to advanced age
Min Taek Lee; Hyunji Koo; Sun‐Young Jung
Chung‐Ang University, Seoul, Republic of Korea
Background: Recently, use of non‐vitamin K antagonist oral anticoag-
ulants (NOAC) are increasing worldwide. However, evidence on the
bleeding risk associated with increasing age among elderly NOAC
users have been lacking.
Objectives: We aimed to investigate risk of major bleeding in elderly
NOAC users in different age groups.
Methods: We performed a case‐crossover study using Korea Insur-
ance Review and Assessment Service‐Aged Patient Sample database
during January 1, 2016 to December 31, 2016. Aged patients with
hemorrhagic events using NOAC were included. Major bleeding
events were defined as gastrointestinal, cerebrovascular, or other
bleedings. We defined the case period as 1 to 30 days and the control
period as 60 to 90 days, respectively, before the date of hemorrhagic
event. We categorized aged patients into 3 groups (65–74, 75–84,
and 85 or older). Odds Ratios (ORs) with 95% confidence intervals
(CIs) were calculated by conditional logistic regression.
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Results: A total of 8,042 patient with bleeding were studied, with
means age of 75.5 (±6.2) years, of whom 4,601 (57.21%) were female.
The number of patients using dabigatran, rivaroxaban, apixaban, and
edoxaban was 1,570 (19.5%), 4,758 (59.2%) 1,773 (22.0%), and 685
(8.5%). The OR of bleeding associated with NOAC use was 2.85
(95%, CI 2.50–3.20). The OR of major bleeding in each age groups
was 2.86 (95% CI, 2.38–3.42) for 65–74 years, 2.79 (95% CI, 2.32–
3.34) for 75–84 years, and 3.19 (95% CI, 2.02–4.96) for 85 years or
older.
Conclusions:Major bleeding events needs to be carefully monitored in
elderly patients using NOAC, especially in patients aged 85 years or
older. Additional factors including diseases and NOAC dose need to
be further investigated.
582 | Real‐world evidence of statin
effectiveness in older adults
Michele Jonsson Funk; Mitchell M. Conover; Virginia Pate
Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC
Background: Uncertainty regarding the benefit, if any, of statin use in
the elderly persists. This population is poorly represented in trials, and
those that are included rarely have the complex constellation of
comorbid conditions typically present in patients age 75 and older.
Objectives: Among older patients at elevated cardiovascular risk, esti-
mate the effect of statin initiation on 2‐year all‐cause mortality.
Methods: Using Medicare fee‐for‐service data (2007–2013), we iden-
tified patients ≥66 years of age at the time of an outpatient visit with
12‐months of continuous enrollment, at elevated cardiovascular risk,
with no major contraindications to statin initiation and no statin pre-
scription fills in the preceding year. We classified patients with a statin
claim in the 14 days after the index visit as exposed (otherwise unex-
posed) and assessed all‐cause mortality over 2‐years of follow‐up.
Level II CPT codes were used to control for differences in low‐density
lipoprotein (LDL), HbA1C, systolic and diastolic blood pressure at
baseline. (We used multiple imputation [N = 20] to impute values for
patients without a baseline level coded.) Propensity score models
were fit within strata of sex and age (≤75, >75 years) to allow covar-
iate effects to vary between these patient subgroups. We estimated
relative and absolute effects of statin initiation within these subgroups
using standardized mortality ratio weighting (SMRW) with 1% asym-
metric trimming.
Results: We identified 646,394 eligible patients, 13% of whom initi-
ated a statin within 14 days of an index visit. Median 2‐yr mortality
was 8%. Crude estimates indicated implausibly strong effects in some
groups and substantial heterogeneity (e.g. RR = 0.55 among women
>75; RR = 0.75 in men ≤75). After adjusting for age and sex specific
propensity scores, estimates moved towards the null but statin initia-
tion remained protective in all subgroups. Among those ≤75, effec-
tiveness did not differ by sex (RRwomen = 0.82, 95%CI: 0.76, 0.89;
RRmen = 0.85, 95%CI: 0.78, 0.93). Among those >75, statin initiation
was more beneficial in women (RRwomen = 0.79, 95%CI: 0.75, 0.83)
than men (RRmen = 0.87, 95%CI: 0.81, 0.93). Heterogeneity by age
was more pronounced on the absolute scale, while the difference by
sex among those >75 was more modest (RDwomen = −1.7% vs
RDmen = −1.3%).
Conclusions: Among older adults at elevated cardiovascular risk, we
found reductions in all‐cause mortality consistent with estimates from
prior meta‐analyses for patients age 66–75. Among those >75 years of
age, the estimated treatment effect in the treated also indicates a ben-
efit in a diverse, real‐world patient population.
583 | The association between potentially
serious alcohol medication interactions and
falls in community dwelling older adults: A
longitudinal Irish study
Alice Holton1; Fiona Boland2; Paul Gallagher3; Tom Fahey2;
Frank Moriarty2; Rose Anne Kenny4; Grainne Cousins1
1School of Pharmacy, Royal College of Surgeons in Ireland, Dublin,
Ireland; 2HRB Centre for Primary Care Research, Royal College of
Surgeons in Ireland, Dublin, Ireland; 3School of Pharmacy, National
University, Singapore, Singapore; 4The Irish Longitudinal Study on Ageing
(TILDA), Trinity College Dublin, Dublin, Ireland
Background:Assessment andmanagement strategies to prevent falls in
community‐dwelling older adults stress the importance of taking into
account patient's medications. However, observational studies have
not considered alcohol‐medication interactions as a risk factor for falls
in community dwelling older adults, despite the high propensity for con-
current use of alcohol with medications among older adults.
Objectives: The aim of this study was to investigate the association
between potentially serious alcohol‐medication interactions
(POSAMINO criteria), hypothesized to increase the risk of falls in older
adults, and falls in community dwelling older adults at two and four
years follow‐up.
Methods: This prospective cohort study included 1457 community
dwelling older adults aged ≥65 years who participated in the nation-
ally representative Irish Longitudinal Study on Aging (TILDA), with
complete alcohol and regular medication data to allow for the applica-
tion of the 23 falls‐related POSAMINO criteria. Self‐reported falls at
two and four years follow‐up were assessed including any falls (yes/
no); injurious falls (yes/no) and the number of falls (count variable).
Results: In total, 357 (24%) and 608 (41.8%) participants reported fall-
ing since their baseline interview at 2‐ and 4‐years respectively; 145
(10%) reported an injurious fall at 2‐years and 268 (18%) at 4‐years.
Median (IQR) number of falls was 1 (1–2) at 2‐years and 2 (1–3) at
4‐years. Exposure to CNS POSAMINO criteria, hypothesized to
increase the risk of falls due primarily to increased sedation, was asso-
ciated with an increased risk of falls (aRR 1.50, 95% CI 1.21 to 1.88)
and injurious falls (aRR 1.62, 95% CI: 1.03 to 2.55) at 4‐years, after
adjusting for established risk factors for falls in community dwelling
older adults.
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Conclusions: Exposure to potentially serious alcohol‐medication inter-
actions involving CNS agents are positively associated with the risk of
falls and injurious falls among community‐dwelling older adults at four
years follow‐up. Assessment and management strategies to prevent
falls in community‐dwelling older adults should consider patients' alco-
hol consumption alongside their assessment of patient medications,
particularly among those receiving CNS agents.
584 | Potentially inappropriate medications
among Chinese older adults in community
healthcare institutions in Beijing
Mengyuan Fu1,2; Luwen Shi1,2; Xiaodong Guan1,2,3
1School of Pharmaceutical Sciences, Peking University Health Science
Center, Beijing, China; 2 International Research Center for Medicinal
Administration, Peking University, Beijing, China; 3Department of
Population Medicine, Harvard Medical School and Harvard Pilgrim Health
Care Institute, Boston, MA
Background: Potentially inappropriate medications (PIMs) are promi-
nent prescribing issues in elderly patients worldwide, enhancing the
risk of adverse reactions and negative health outcomes. However, lit-
tle research has focused on the PIMs of Chinese older adults in com-
munity healthcare institutions (CHIs).
Objectives: To evaluate the PIMs prevalence and influence factors
associated with PIMs in CHIs for the elderly.
Methods: We conducted a retrospective study, deriving data on diag-
noses, prescriptions and demographic characteristics of patients aged
≥60 from the electronic health records of 65 CHIs in Beijing, 2014–
2017. Criteria of PIM for Older Adults in China, including 28 high‐risk
medications to be avoided, 44 low‐risk medications to be used with
caution and 28 medications that could cause drug‐disease interac-
tions, were applied to evaluate PIMs. Multivariate logistic regression
was used to analyze the influence factors of PIMs. Ethics approval
was obtained from Peking University Institution Review Board.
Results: 3,283,254 prescriptions were included in total. The percent-
age of prescriptions with at least one PIM was 27.0% (30.1%, 24.6%,
25.6% and 27.6% from 2014 to 2017, respectively). 991,141 medica-
tions were detected resulting in 0.3 PIMs per prescription on average
and the distribution of PIMs in our sample was as follows: 17,955
high‐risk medications were identified and the most commonly pre-
scribed PIMs were diazepam (47.2%), lorazepam (21.6%) and alprazo-
lam (20.8%); 354,608 low‐risk medications were identified and the
most commonly prescribed PIMs were clopidogrel (36.1%), estazolam
(31.9%) and ibuprofen (17.3%); 618,578 medications that could cause
drug‐disease interactions were identified and the nonsteroidal anti‐
inflammatory drugs use for hypertension patients was the most prev-
alent (94.1%). Age ≥ 90 (OR: 2.027, 95% CI: 1.992–2.062), with com-
mercial medical insurance (OR: 1.189, 95% CI: 1.093–1.293), having
≥5 prescribed medications (OR 10.244, 95% CI 10.136–10.353) and
having 4–6 comorbidities (OR: 3.810, 95% CI: 3.787–3.832) were sig-
nificant predictors for PIMs.
Conclusions: Prescribing of PIMs for older adults is common in CHIs in
China, especially for patients who are aged, having more comorbidities
and medications, and insured by commercial medical insurance. PIM
Criteria can be used as tools to guide clinicians and pharmacists to
identify PIMs. More strategies aiming at promoting prescribing prac-
tices and quality use of medicines are needed.
585 | Trends in skeletal‐related event
hospitalization and use of bone targeting
agents in older patients with bone metastases
from solid tumors in the United States: 1994–
2015
Shuling Li1; Haifeng Guo1; Suying Li1; Rohini K. Hernandez2;
Jiannong Liu1; Yi Peng1; Alan Fu2
1Chronic Disease Research Group/Hennepin Healthcare Research
Institute, Minneapolis, MN; 2Amgen Inc., Thousand Oaks, CA
Background: Skeletal‐related events (SREs) are associated with bone
metastases (BMs) from solid tumors leading to decreased quality of
life and increased healthcare resource utilization, particularly hospital-
izations. Clinical trials have shown efficacy of bone targeting agents
(BTAs) in reducing SRE incidence, but few population‐based studies
have examined trends in BTA use and SRE‐related hospitalization in
older pts with BMs.
Objectives: To describe BTA use and assess rates of first SRE‐related
hospitalization over time (1994–2015) in a population‐based cohort of
elderly pts with BMs from solid tumors in the US.
Methods: We assembled period prevalent cohorts of pts with BMs in
each year 1994–2015 using Medicare 5% (1993–2007) and 20%
(2007–2015) sample data. For each yearly cohort, we required
age ≥ 66 years at BM index date and continuous Medicare fee‐for‐
service enrollment for 12 months prior. Pts were followed from BM
index date to the earliest of death, disenrollment, or 12/31 of the
cohort year. During follow‐up, we identified pts with first SRE‐related
hospitalization (spinal cord compression, pathologic fracture, surgery
to bone, radiation to bone) and pts treated with BTAs (pamidronate;
zoledronic acid [ZA]; denosumab). We described trends in proportions
of pts receiving BTAs and rates of first SRE‐related hospitalization
over years. We evaluated trends in first SRE‐related hospitalization
rates using a Poisson regression model with splined curve of calendar
year after adjusting for baseline characteristics.
Results: Yearly cohorts included 3599–4559 eligible pts in 1994–
2007 and 17,774–19,423 in 2008–2015. Proportions receiving BTAs
were < 1% in 1994–1995, steadily increased to 18% in 2001, and dra-
matically increased to 34%–44% in 2003–2015, mainly due to intro-
duction of ZA in 2002 and denosumab in 2010. Overall, crude rates
of first SRE‐related hospitalization decreased from 19.5 per 100
patient‐years in 1994 to 9.2 in 2015. Rates of first SRE‐related hospi-
talization decreased, on average, 3% each year before 2008 and 4.3%
per year from 2008 after adjustment for changing patient
characteristics.
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Conclusions: From 1994–2015, BTA use increased substantially after
2002 among older pts with BMs from solid tumors, although most pts
did not receive a BTA within any given calendar year. Rates of first
SRE‐related hospitalization decreased over the same time period, with
a more rapid decrease from 2008 onwards. Further studies are needed
to better understand SRE management among pts with BMs in the
real‐world setting.
586 | Benzodiazepines and risk of autonomy
loss for activities of daily living in the elderly
Emilie Hucteau1; Antoine Pariente2; Clément Mathieu3;
Pernelle Noize2; Karine Pérès4; Catherine Helmer1
1Bordeaux Population Health Research Center, Team LEHA, UMR1219,
University of Bordeaux, Inserm, Bordeaux, France; 2Bordeaux Population
Health Research Center, Team Pharmacoepidemiology, UMR1219,
University of Bordeaux, Inserm/Clinical Pharmacology, Bordeaux
University Hospital, Bordeaux, France; 3Bordeaux Population Health
Research Center, Team Pharmacoepidemiology, UMR1219, University of
Bordeaux, Inserm, Bordeaux, France; 4Bordeaux Population Health
Research Center, Team SEPIA, UMR1219, University of Bordeaux, Inserm,
Bordeaux, France
Background: Benzodiazepines (BZD) are widely used drugs that can
lead to important adverse effects such as falls and fractures, behav-
ioral disorders, and a faster cognitive decline. These effects are mainly
observed among the elderly in whom BZD can accumulate. In addition
to these effects, BZDs could also increase the risk of autonomy loss
among the elderly.
Objectives: The objective of this project was to study relationships
between BZD and autonomy loss for Activities of Daily Living (ADL)
among the elderly.
Methods: The study was conducted on the Echantillon Généraliste de
Bénéficiaires de l'Assurance Maladie from 2010 to 2015 among people
aged 65 and over affiliated to the general scheme of health insurance.
ADL‐dependency was defined using an algorithm previously devel-
oped and validated, which includes information on reimbursed drugs,
medical acts, products and deliveries, chronic diseases, age and sex.
BZD use profiles were defined as follows: no use, current use‐not
chronic (<6 months over 12), chronic use‐currently discontinued,
chronic and current use. BZD were also categorized into anxiolytics/
hypnotics and short/long half‐life. After a descriptive analysis of
BZD use, the analysis of the association between BZD and ADL‐
dependency was performed among men and women separately, using
a delayed entry Cox model and time‐dependent variables. Adjustment
considered the use of other drugs (anti‐dementia drugs, opioid analge-
sics, other psychotropic medications), the number of drugs used each
month, and the Charlson comorbidity index.
Results: Women represented two third of BZD users; anxiolytics were
more used than hypnotics and short half‐life BZD were twice more
used than long half‐life BZD. Moreover, most users presented with
chronic use. Risk of autonomy loss was increased in BZD users,
slightly more in men; this was found for both anxiolytics and hyp-
notics. Regarding short versus long half‐life BZD, the association was
found mainly for short half‐life BZD. For long half‐life BZD, it was sig-
nificant only in women. Current use‐not chronic was associated with
the highest increase (men: RR = 1.9, 1.6–2.2; women: RR = 1.6, 1.4–
1.8).
Conclusions: This study highlighted the association between BZD use
and the occurrence of ADL‐dependency, for both anxiolytics and hyp-
notics, whatever the use profile. Risk was especially increased for
short‐term ongoing use, consistently with what has been shown for
trauma or accidents.
587 | Drug use among older people admitted
to nursing homes
Mette Reilev1; Carina Lundby1; Helene Hoffmann2; Søren P. Larsen2;
John Jensen2; Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Type2Dialog,
Copenhagen, Denmark
Background: Nursing home residents represent a particularly vulnera-
ble population with a high burden of morbidities and an extensive drug
use. Drug use patterns should be investigated to promote safe and
appropriate treatment.
Objectives: To describe drug use patterns in nursing home residents in
relation to time of admission to nursing home.
Methods: In collaboration with 11 Danish municipalities, we con-
structed a database on all older people admitted to nursing homes
from January 1, 2015 to December 31, 2017. Individual level data
on time of admission was linked to the Danish health registries to
obtain information on morbidity and drug use. We described use of
drugs from 24 months before and up to 36 months after admission
to nursing homes.
Results:We identified 5279 residents admitted to nursing homes from
January 1, 2015 to December 31, 2017. The majority was female
(67%) and the median age was 84 (interquartile range [IQR] 77–89).
Thirty‐eight percent were still alive after three years. At time of admis-
sion, cancer (25%), stroke (24%), and dementia (22%) were the domi-
nant diagnoses. The median number of unique drug classes filled
within the last six months increased from 6 ([IQR] 3–9) two years
before admission to 8 ([IQR] 5–11) by the time of admission. Hereaf-
ter, it remained constant throughout the two‐year follow‐up period.
At time of admission, paracetamol was the most frequently used drug
(56%), followed by diuretics (37%), agents working on the renin‐angio-
tensin system (31%), opioids (30%), and statins (30%). Prevalent use of
preventive medications, e.g. statins and antihypertensive agents,
remained fairly unchanged from two years before to two years after
admission to nursing home, whereas a pronounced increase was
observed for paracetamol, laxatives, anti‐infectives, and anti‐depres-
sants during the same period. Incident use of new drug classes simi-
larly increased markedly from 20/100 residents per month to 65/
100 residents per month during the last 9 months before admission.
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This was mainly driven by an increasing proportion of new users of
laxatives, analgesics (paracetamol and opioids), and anti‐infectives.
Additionally, incident use of benzodiazepine derivatives increased
more than a 3‐fold during this period. After admission, the overall inci-
dent rate rapidly declined and leveled off at around 30/100 residents
per month.
Conclusions: Incident and prevalent use of drugs increased in relation
to time of admission to nursing home. Both use of preventive medica-
tion and drugs at high risk of causing adverse side effects are
widespread.
588 | Receipt of psychotropic treatment
among working‐age, long‐stay nursing home
residents with serious mental illness
Christine M. Ulbricht; Yiyang Yuan; Kate L. Lapane
University of Massachusetts Medical School, Worcester, MA
Background: Nursing home care may be inappropriately replacing
community‐based care and specialty psychiatric long‐term care, partic-
ularly for working‐age adults with serious mental illness (SMI). Con-
temporary information is scarce about these residents with SMI,
including how long they say in the nursing home and what mental
health care they receive.
Objectives: To describe clinical characteristics and receipt of psycho-
tropic treatment among working‐age, long‐stay nursing home resi-
dents with SMI within the first 90 days of the nursing home stay.
Methods: We used the national Minimum Data Set (MDS) 3.0 to first
identify 62,079 working‐age adults (aged 18–64 years) with SMI who
were newly admitted to U.S. nursing homes in 2014 and then exam-
ined who remained in the nursing home for at least 90 days. MDS
3.0 is a comprehensive assessment of active clinical diagnoses, func-
tioning, medication, and non‐pharmacological treatments. It is com-
pleted for all residents of all Medicare−/Medicaid‐certified nursing
facilities throughout the nursing home stay. SMI was broadly defined
as an active diagnosis of schizophrenia, other psychotic disorder, bipo-
lar disorder, depression, and/or anxiety disorder. Receipt of psycho-
tropic medication included antidepressants, antianxiety medication,
antipsychotics, and hypnotics received at any time in the seven days
before the admission assessment and the first 90‐day assessment.
Results: Of the newly admitted working‐age residents with SMI,
25.9% (n = 16,088) remained in the nursing home for at least 90 days.
Nearly one‐fifth of these long‐stay residents were less than 50 years
old. Depression was the most common active psychiatric diagnosis
at admission (68.6% of long‐stay residents), followed by an anxiety
disorder (41.2%) and schizophrenia or other psychotic disorder
(33.5%). Comorbid psychiatric diagnoses were documented for
47.7%. Almost all received at least one psychotropic medication at
admission (92.9%) and the first 90‐day MDS (93.2%), with antidepres-
sants most commonly received (admission: 70.3%; 90 days: 72.7%).
Antipsychotics were received by almost half of residents (admission:
45.6%; 90 days: 46.5%). Multiple psychotropic medications were
received by slightly more than half of residents (admission: 51.1%;
90 days: 54.1%).
Conclusions:Working‐age adults with SMI are long‐stay nursing home
residents and likely have complex care needs. Additional research on
potential unmet need and predictors of functioning is necessary for
understanding the quality of life for these adults and their likelihood
of returning to the community.
589 | Adverse drug reactions as cause of
hospital admissions in older adults in a
teaching Hospital in Chile
Marcela Jiron; Tamara Sandoval; Carolina Gutierrez
University of Chile, Santiago, Chile
Background: The safety of drug prescribing has become a very impor-
tant topic in geriatric medicine. Adverse drug reactions (ADRs) are
common problems causing hospital admissions and higher health care
costs. Limited information is available of ADRs as cause of hospital
admissions in older adults in Chile.
Objectives: To estimate incidence and determinants of hospital admis-
sions for ADRs in older adults in a medicine unit of a teaching hospital
in Chile.
Methods: A prospective cohort study was conducted in a sample
of older adults 60 years and older admitted in the medicine unit
of a teaching hospital in Chile. Sociodemographic characteristics,
clinical and pharmacotherapy profile of was collected by patient
interview and medical records. Suspected hospital admission for
ADRs were subsequently evaluated by an internal medicine physi-
cian and two clinical pharmacists, and causality assessment of
each ADR was undertaken to determine whether each suspected
reaction was possible, probable or established. The assessment of
ADRs causality was performed using the Naranjo algorithm. Drugs
were classified according to Anatomical Therapeutic Chemical
classification. Determinants of hospital admission for ADRs were
identified by using multivariate logistic regressions.
Results: During the study period a total of 350 older adults were
admitted at medicine unit. The mean ± SD age was 73.0 ± 8.7 years,
51.1% were women, and 63.1% of patients were using 5 or more
medications (mean 6.5 ± 3.6 drugs/patient). The most common
comorbidities were hypertension (68.9%) and Type 2 Diabetes
Mellitus (36.3%). Twenty eight (8.0%) patients suffered a hospital
admission for ADR at medicine unit. Cardiovascular drugs
accounted for 28.9% of the cases, followed by alimentary tract
and metabolism drugs (23.7%), and nervous system drugs
(13.2%). The most common system organ class affected for ADRs
was metabolism (8 cases). The drugs most frequently involved
were glyburide (6 cases) and hydrochlorothiazide (4 cases). The
causality of ADRs detected were established (5.3%), probable
(57.9%), and possible (36.8%). Polypharmacy (5+ drugs) was a pre-
dictor of hospital admissions for ADR in the sample studied (OR:
3.3; 95%CI 1.3–8.9).
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Conclusions: Approximately one in ten hospital admissions of older
adults at medicine unit were due to ADRs in the sample studied.
Future interventions to prevent ADRs could be focused mainly on car-
diovascular and metabolism drugs, and patients with polypharmacy.
Better understanding of ADRs could improve safety of care and to tar-
get potential interventions to prevent or reduce severity of ADRs
among older adults.
590 | The goldilocks of diabetes care: A
retrospective evaluation of prescribing
practices related to the intensity of glycemic
control among the elderly population with
type 2 diabetes across Canada
Sai Krishna Gudi1; Shawn Bugden2; Kevin Friesen1; Jamie Falk1
1University of Manitoba, Winnipeg, MB, Canada; 2Memorial University of
Newfoundland, St. John's, NL, Canada
Background: Diabetes is highly prevalent among older adults. Overall
evidence suggests a less intensive approach with heightened atten-
tion to safety is recommended in this population. Significant con-
cerns have been raised about the potential over‐treatment in older
adults.
Objectives: To assess potential over‐treatment related to intensity of
glycemic control in an elderly primary care population with diabetes
across Canada.
Methods: A retrospective population‐based cohort study was con-
ducted from 2010–2017, utilizing prescriptions generated within
the Canadian Primary Care Sentinel Surveillance Network (CPCSSN)
database. Patients aged ≥65 years with diabetes defined by the
CPCSSN validated case definition with at least one HbA1c measure-
ment were included. The intensity of glycemic control was assessed
in two cross‐sectional years (2012, 2016). Over‐treatment was
defined as an index HbA1c (the first recorded HbA1c of the year)
of <7% and prescription of any anti‐diabetic medication other than
metformin within 9 months before and 3 months after the index
HbA1c. Secondary outcomes included the proportion of patients
with HbA1c <7% and prescription of high‐risk hypoglycemic agents
(sulfonylureas, insulins, or meglitinides), and the number of medica-
tions per patient within HbA1c subcategories (<7%, 7% ‐ <8%, 8%
‐ <9%, and ≥ 9%).
Results: A cohort of 33,864 patients (51.6% male) with a mean
age of 76.3 years was identified. The rate of over‐treatment
was 7.0% in 2012 and 6.9% in 2016 with a p‐value of 0.64
(CI ‐0.32 to 0.52). High‐risk hypoglycemic agents accounted for
84.4% and 68.6% of over‐treatment medications in 2012 and
2016, respectively. The majority of patients (53.4% (2012) and
56.4% (2016)) were not receiving any anti‐diabetic medications.
Approximately one‐third of the patients with HbA1c ≥ 9% were
prescribed no medications (33.6% (2012) and 35.8% (2016)). Met-
formin‐only users made up 19.1% (2012) and 21.5% (2016) of
the cohorts.
Conclusions: Although potential over‐treatment (too hot) exists in
this broad Canadian primary care population, the rate was low with
no evidence that it was increasing over time. Of concern, however,
is that over 1/3 of patients with poorly controlled diabetes receiving
no medications (too cold). Clearly, there is a need for much more
individually tailored (just right) personalized diabetes management
in Canada.
591 | Use of benzodiazepines and other
sedative medications among older patients in
Quebec: A population‐based study between
2000–2015
Gosselin Emmanuelle1,2; Marc Simard2; Caroline Sirois1,3,2
1Laval University, QC, QC, Canada; 2 Institut National de Santé Publique
du Québec, QC, QC, Canada; 3Centre of Excellence on Aging of Quebec,
QC, QC, Canada
Background: Benzodiazepines and other sedative medications have
been associated with an increased risk of falls, cognitive problems
and hospitalizations in older individuals. Yet it is difficult to develop
interventions to ensure optimal use, since there is little information
on the actual use of these medications among older patients in the
province of Quebec, Canada.
Objectives: To describe the annual prevalence of use of benzodiaz-
epines and other potentially inappropriate medications prescribed
to treat insomnia among older patients in Quebec from 2000 to
2015.
Methods: We conducted a population‐based cohort study using data
from the Quebec Integrated Chronic Disease Surveillance System.
We included all individuals aged 66 years and over who were cov-
ered by the public drug insurance plan in each financial year (April
1stto March 31st) from 2000 to 2015. For each year, we evaluated
the age‐standardized proportion of individuals using benzodiaze-
pines, defined as the presence of at least one claim for one drug
of the class in the given year. Similarly, we calculated age‐standard-
ized proportions of users for antidepressants (trazodone and tricy-
clic), quetiapine (up to 25 mg), cyclobenzaprine and hydroxyzine in
the same period.
Results: The proportion of individuals with at least one claim of
benzodiazepines decreased from 33.43% in 2000 to 25.78% in
2015. An overall decline in the proportion of users was observed
for all benzodiazepines with the exception of clonazepam whose
proportion increased from 3.22% to 4.24%. Conversely, the propor-
tion of users increased for some potentially inappropriate sedatives,
in particular for trazodone (1.15% to 3.12%) and quetiapine (0.07%
to 1.88%).
Conclusions: From 2000 to 2015, older adults in Quebec were less
likely to be prescribed benzodiazepines but used more trazodone
and quetiapine. However, the proportion of individuals using seda-
tive medications remains high. Given the risks associated with these
drugs, there is a need to develop interventions to reduce their use.
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592 | Polypharmacy among older individuals
with chronic obstructive pulmonary disease:
Trends between 2000–2015 in Quebec,
Canada
Caroline Sirois1,2,3; Amina Ouali1; Marc Simard3
1Laval University, QC, QC, Canada; 2Centre of Excellence on Aging of
Quebec, QC, QC, Canada; 3 Institut National de Santé Publique du
Québec, QC, QC, Canada
Background: The treatment of chronic obstructive pulmonary disease
(COPD) and concomitant diseases requires several medications. Yet
there is little data on how the pharmacological burden progressed over
time among older individuals with COPD.
Objectives: 1) To describe the proportion of older adults with COPD in
Quebec,Canada, thatwereexposed topolypharmacy (≥10,≥15or≥20
medications/year) between 2000 and 2015; 2) To calculate the propor-
tion of individuals receiving specific prescriptions for COPD (short‐act-
ing bronchodilators, long‐acting bronchodilators, inhaled or oral
corticosteroids, antibiotics, anti‐smoking agents, phosphodiesterase 4
inhibitors and methylxanthines) during this period.
Methods:Weconductedapopulation‐basedcohortstudywithdatafrom
theQuebec IntegratedChronicDisease Surveillance System. Individuals
aged ≥66 years with COPD, covered by the universal public drug plan
andaliveforthedurationoftheyearstudied(2000to2015)wereincluded.
Wecalculatedthetotalnumberofdrugsusedatleastoncebyeachindivid-
ual during each of the studied years.We used age‐standardized propor-
tions to compareproportions ofusersbetween theyears studied.
Results:The average number of drugs used increased from 12.0 in 2000
to 14.8 in 2015. The proportion of individuals using ≥10 drugs
increased from 62.0% to 74.6%; while it increased from 31.2% to
45.4% for≥15 drugs; and from 12.3% to 22.4% for≥20 drugs. The pro-
portion of individuals receiving long‐acting bronchodilators increased
from 18.7% in 2000 to 69.6% in 2015. For the same period, the use of
short‐acting bronchodilators decreased from 81.5% to 67.9%, and that
of inhaled corticosteroids from60.6% to 26.0%. The proportion of users
of methylxanthines inhibitors decreased from 15.0% to 1.9%.
Conclusions: Older individuals with COPD are increasingly exposed to
polypharmacy. Identifyingwhich polypharmacy is beneficial is a priority.
593 | SSRI & SNRI use in adults & elderly
Mikkel Z. Ankarfeldt1; Espen Jimenez‐Solem2; Cecilie D. Sperling3;
Janne Petersen1
1Frederiksberg and Bispebjerg Hospital, Frederiksberg, Denmark;
2Bispebjerg and Frederiksberg University Hospital, Copenhagen,
Denmark; 3Danish Research Cancer Center, Copenhagen, Denmark
Background: Antidepressants, and specifically selective serotonin
reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake
inhibitors (SNRIs), are widely used. Their efficacy in the elderly is
however debated, and it is believed that this population is over‐
treated.
Objectives: To determine the development in users of SSRI and SNRI in
Sweden (SE), Denmark (DK) and Norway (NO) over time, with focus on
elderly users.
Methods: A registers study from 2006–17 in SE, DK and NO identify-
ing adults each calendar year with a least one redeemed prescription.
Adults were defined as age of 18+ in DK and age of 20+ in SE and NO.
Elderly were defined age of 80+. We collected information for the fol-
lowing drugs: SSRIs (ATC code: N06AB): citalopram (N06AB04),
escitalopram (N06AB10), fluoxetine (N06AB03), fluvoxamine
(N06AB08), paroxetine (N06AB05) and sertraline (N06AB06); and
for SNRIs: duloxetine (N06AX21) and venlafaxine (N06AX16). All
numbers are given as users per 1000 inhabitants.
Results:For SSRIs the proportion of elderly userswere 2–3 times higher
than among adults both in SE and DK, though the proportion of elderly
users have decreased since 2010. In NO, the proportion of adult and
elderly users were lower and more stable over time. [2017 adults: SE
78, DK 52, NO 44 per 1000. Elderly: SE 169, DK 115, NO 64.2 per
1000]. The most prevalent candidates of SSRIs among elderly users
were citalopram and sertraline; They had the same trend as for SSRIs
combined, with most users in SE and DK and a high proportion among
the elderly users. However, whereas the users of citalopram have been
decrease since 2010, the users of sertraline have been increasing SE and
DK. [citalopram 2017 adults: SE 24, DK 21, NO 5 per 1000. Elderly: SE
98, DK 67, NO 10 per 1000; Sertraline 2017 adults: SE 32, DK 22, NO 8
per 1000. Elderly: SE 48, DK 34, NO 9 per 1000]. For the third most
common candidate, escitalopram there has been an increase in users
in NO and SE and higher proportion of elderly users. [2017 adults: SE
15, DK 5, NO 27 per 1000. Elderly: SE 22, DK 11, NO 42 per 1000].
Decreasing proportions of adult and elderly users were observed for
paroxetine, fluvoxamine and fluoxetine, being the least prevalent SSRIs
[2017 all countries <6 per 1000]. The proportion of SNRIs users of
duloxetine and venlafaxine increased in the study period. NO had the
lowest proportion of users of duloxetine [2017 adults: SE 7, DK 7, NO
2 per 1000] and venlaflaxine [2017 SE 12, DK 11, NO 8 per 1000].
The proportions of elderly users were lower than among adults.
Conclusions: In general, NO had fewer users of SSRIs and SNRIs than
SE and DK. For citalopram and sertralin the proportion of elderly aged
80+ were much higher than in the adult population.
594 | Potentially inappropriate medication
users with pre‐clinical Alzheimer's disease
more susceptible to anticholinergic challenge
Ashley I. Martinez1; Brooke F. Beech2; Erin A. Abner3,2;
Gregory A. Jicha4,2; Frederick A. Smith2,4; Lynne Eckmann5;
Mark Huffmyer5; Daniela C. Moga1,3,2
1University of Kentucky College of Pharmacy, Lexington, KY; 2Sanders‐
Brown Center on Aging, Lexington, KY; 3University of Kentucky College of
Public Health, Lexington, KY; 4University of Kentucky College of Medicine,
Lexington, KY; 5PRO2RX LLC Pharmacy Consulting Services, Lexington, KY
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Background: Potentially inappropriate medication (PIM) use may
lower cognitive reserve (CR), decreasing the threshold for Alzheimer's
disease (AD) symptom expression. Given the high burden of both PIM
use and AD in the older adult population, optimizing medication use
may delay progression from pre‐symptomatic AD (pAD) to AD by aug-
menting CR.
Objectives: We investigated the association between baseline PIM
use and CR among participants with and without pAD in a randomized
medication therapy management (MTM) trial.
Methods: We are conducting a randomized trial targeting PIM use
through an MTM intervention. The Medication Appropriateness Index
for medications in 2015 Beers' criteria (MAI‐PIM) quantified PIM use.
Cognitive outcomes were quantified using change scores of executive
function and immediate recall neuropsychological tests (Trail Making
Test B [TMTB] and California Verbal Learning Test [CVLT]), standard-
ized to the population mean. Tests were administered with and with-
out anticholinergic challenge, such that larger change scores between
two paradigms corresponded to lower CR (i.e. the participant compen-
sated less for anticholinergic challenge). Participants were stratified by
pAD status derived from PET scans. Spearman correlation coefficients
(r) were used to assess the relationship between medication appropri-
ateness and CR at enrollment. P‐values of <0.05 were considered sta-
tistically significant.
Results: Based on 41 participants (mean age 73.1 years [SD 5.7]; 66%
female), the median (IQR) MAI‐PIM at baseline was 4 (0.5–6.5), and
34.3% met criteria for pAD. 21.5% of reported medications (n = 120)
were present in the Beers' criteria. The most common PIMs were anti-
cholinergics, non‐steroidal anti‐inflammatory drugs, and proton pump
inhibitors (31.7%, 25.8%, and 18.3% respectively). Those with pAD
had larger change scores for executive function and immediate recall
(mean [SD] TMTB ‐0.34 [1.2]; 0.08 [1.1] and CVLT 9.0 [6.8]; 3.3
[7.4] for pAD and non‐pAD respectively). Higher MAI‐PIM scores
were correlated with larger change scores (r = 0.27 [p = 0.087] and
r = 0.33 [p = 0.036] for TMTB and CVLT).
Conclusions: Among community‐dwelling non‐demented older adults,
anticholinergic challenge resulted in larger observed differences in
cognitive test scores both among participants with evidence of pAD
and among participants taking more PIMs. These results support the
hypothesized relationship between CR and medication appropriate-
ness, highlighting the potential significance of medication manage-
ment therapy as a tool to delay progression to symptomatic AD.
595 | Computer support and collaboration in
the older Person's medication use
Kerstin B. Jorsater Blomgren
Malardalen University, Academy of Health, Care and Welfare, Sweden
Background: Interprofessional collaboration has become a concept to
improve patients care and safety. An increased focus on collaboration
between different professions and the patient itself is important for
optimizing safe medication use.
Objectives: To study if the use of a web‐based computer support sys-
tem for patients and healthcare professionals can facilitate the discov-
ery and identifying of potential adverse drug reactions in an early
phase and thereby contribute to a safer drug treatment.
Methods: A prospective crossover design was conducted including
50 patients, aged 75–95 year, living in their own homes. Information
was obtained from patients monitoring of potential symptoms by a
web‐based computer support system for one year. The first half part
of the study period, the patients register freely, while during the sec-
ond half, they were suggested symptoms. The symptoms were based
on prodromal symptoms to conditions most frequently causing
hospitalisations. The VM signaled when registration of symptoms
was made on three occasions under 21 days. The patient received
a “call” to contact their nurse for assessment of the symptoms. After
screening the nurse determined whether these symptoms warranted
a doctor's visit, a medical examination or a consultation with the
nurse.
Results: Preliminary results based on to date, 27 completely moni-
tored patients, totally 367 (39%) registrations for men and 583 (61%)
for women. The average of symptoms recorded by men was 9,5, range
(1–34) and 17,0 range (2–93) for women. Under the period of sponta-
neous registration, the mean value for men and women was 9,5 (1–34)
and 11 (1–44) respectively and under the period of predefined symp-
toms 1,3 (1–5) and 5,1 (0–49). Average number of symptoms at each
registration for men was 1,9 range (1,0‐3,7) and 2,1 range (1,0‐3,8)
for women. Symptoms mostly reported by patients was; tiredness,
pain, symptoms from the GI‐tract, breathlessness and instability. A
total of 72 signals were provided, from these, about ten medication
reviews were generated. Fifteen ordinary physician visits were per-
formed and about 25 nurse contacts were conducted under the mon-
itoring period.
Conclusions: We have evaluated a method of a patient‐based moni-
toring process, by uptake of the patient's directly described symptoms
by a vigilance module adapted in a web‐based computer support sys-
tem. A first source signal from the patients for further evaluation and
thereby facilitate the discovery and identifying of potential adverse
drug reactions in an early phase and thereby contributing to a safer
drug treatment.
596 | Translation, cultural adaptation, and
psychometric properties of the Danish
version of the revised Patients' attitudes
towards Deprescribing questionnaire
Carina Lundby1; Trine Simonsen1; Jesper Ryg1; Jens Søndergaard2;
Anton Pottegård1; Henrik Hein Lauridsen2
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark
Background: The revised Patients' Attitudes Towards Deprescribing
(rPATD) questionnaire is a 22‐item instrument capturing older
patients' beliefs and attitudes towards deprescribing.
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Objectives: To translate and culturally adapt the English version of the
rPATD questionnaire into Danish and subsequently validate the Dan-
ish version in a cohort of nursing home residents.
Methods: The rPATD questionnaire was translated and culturally
adapted according to recognized guidelines. Following this, the pre‐
final questionnaire was pilot tested through semi‐structured inter-
views with 11 nursing home residents and ultimately adjusted into a
final version. The validation of this final version was carried out among
nursing home residents recruited from nursing homes within the
Region of Southern Denmark.
Results:The rPATDquestionnairewas successfully translated intoDan-
ish, and the subsequent pilot test showed that the Danish version was
acceptable by the nursing home residents. A total of 159 participants
were included in the validation (median age of 82 years; 39% males).
More than half of the participants believed that they took a large num-
ber of medications (63%; n = 100), and 27% (n = 43) felt that they took
one or more medications which they no longer needed. Overall, 44%
(n = 70) of the participants would like to try stopping one of their med-
ications to see how they would feel without it, and 37% (n = 59) would
like their physician to reduce the dose of one or more of their medica-
tions. Further, the majority of the participants were willing to stop tak-
ing one or more of their regular medications if their physician said it
was possible (86%; n = 137). Despite this, 93% (n = 148) of the partici-
pants reported not having troubles taking their daily medications, and
73% (n = 116) did not consider their medications a burden to them.
The psychometric testing will be conducted during the spring.
Conclusions: We have successfully translated and culturally adapted
the rPATD questionnaire into Danish. The current results from the
field test suggest that Danish nursing home residents believe their
use of medication is extensive and that they are open towards
deprescribing. Pending psychometric testing, the Danish version of
the rPATD questionnaire can be used in future studies.
597 | Potentially inappropriate medication
use in older adults in Quebec, Canada: A
population‐based cohort study
Barbara Roux1,2; Caroline Sirois3,4; Marc Simard3; Marie‐Ève Gagnon3;
Marie‐Laure Laroche1,2
1Centre of Pharmacovigilance and Pharmacoepidemiology, University
Hospital of Limoges, Limoges, France; 2 INSERM UMR 1248, University of
Limoges, Limoges, France; 3 INSPQ, QC, QC, Canada; 4Department of
Preventive and Social Medicine, Laval University, QC, QC, Canada
Background: The use of potentially inappropriate medication (PIMs) in
the older population remains common. Yet their use is associated with
negative health outcomes and significant cost for health care organiza-
tions. Few population‐based data exist on PIM use and associated fac-
tors according to the 2015 Beers Criteria in community‐dwelling older
people.
Objectives: To assess the prevalence of potentially inappropriate
medication (PIM) use and identify associated factors in a large cohort
of community‐dwelling older adults aged ≥66 years insured with a
universal health care system in Quebec, Canada.
Methods: A population‐based cohort study was conducted using the
Quebec IntegratedChronicDiseaseSurveillanceSystem (QICDSS) data-
base. TheQICDSS includes data on drug claims for community‐dwelling
olderadultsaged≥65yearswithchronicdiseasesorat riskofdeveloping
themwhoare insuredby the public drug plan (90%of older people). Indi-
viduals aged ≥66 years continuously insured by the public drug plan
betweenApril 1st, 2014 andMarch 31st, 2016were included. PIMswere
defined using theAmericanGeriatrics Society 2015 version of theBeers
Criteria. The proportion of individuals who had at least one claim for a
PIM between April 1st, 2015 and March 31st, 2016 was calculated.
Descriptive statisticswere performed to describepatient characteristics
andPIMuse.Weconductedmultivariate robustPoisson regressionanal-
yses toexplore factors associatedwithPIMuseandcalculated rate ratios
(RR) and 95% confidence intervals.
Results: A total of 1,105,295 individuals were included (mean age:
74.9 [SD 7.0] years, women: 56.4%). Of these, 48.3% (95% CI: 48.2–
48.4%) were prescribed at least one PIM. The most prevalent PIMs
were benzodiazepines (25.7%), proton‐pump inhibitors (21.3%), anti-
psychotics (5.6%), antidepressants (5.0%) and long‐duration sulfonyl-
ureas (3.3%). Factors associated with PIM exposure included being a
woman (RR: 1.20; 95% CI: 1.20–1.21), increased number of medica-
tions and having a high number of chronic diseases, especially mental
disorders (1.50; 1.49–1.51).
Conclusions: Almost one out of two community‐dwelling older adults
in Quebec use a least one PIM. From a public health perspective, it is
imperative to reduce the use of PIMs, by limiting their prescription and
by promoting their deprescribing, which necessitates not only the
active involvement of prescribers, but also patients.
598 | Identification of potential drug‐related
problems and drug‐related risk factors in
home‐dwelling older adults
Ana I. Plácido1; Maria Teresa Herdeiro2; Fátima Roque1,3
1Research Unit for Inland Development, Polytechnic of Guarda (UDI‐IPG),
Guarda, Portugal; 2Department ofMedical Sciences, Institute of Biomedicine
– iBiMED, University of Aveiro, Aveiro, Portugal; 3Health Sciences Research
Centre, University of Beira Interior (CICS‐UBI), Covilhã, Portugal
Background: Complex combination of medicines, associated to the
decline of physic and cognitive functions entails older adults an
increased risk of adverse drug events. In home‐dwelling adults, 4%–
53% of the prescriptions are inappropriate and are associated with an
increased risk of hospital admission and emergency department visits.
Taking in account that medications errors remain a leading public health
issue among the elderly, identifying Drug‐related problems (DRPs) and
DRPs‐ risk factors in home‐dwelling older patients would help to find
assertive strategies to decreased DRPs in these population.
Objectives: Systematically review the most frequent DRPs and DRPs‐
risk factors in home‐dwelling older adults.
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Methods: A MEDLINE‐PubMED scientific database search with the
combination of terms drug‐related problems, elderly, older and medi-
cation‐related problems was performed. Studies that analyses DRPs
in people living in the community without residing in assisted living
facilities or long‐term care facilities, publish in January 2001 through
December 2018 were included.
Results: After a critical selection, 15 studies were systematically
reviewed, 6 in community pharmacies, 6 in primary care, 2 home medi-
cation review notes and 1 outpatients departments of a hospital.
Despite diverged in design all studies report and classified DRPs. The
number of DRPs identified per article range from [131; 11419] per-
formed 24392 DRPs.Major DRPs observed are related with drug selec-
tion (20. 2%) followed by compliance (12.2%) and dose selection (9.4%).
Drug use process problems were also observed in 7.4% of the patients.
8.6%DRPs results in problems of treatment safety. The main DRPs‐risk
factors pointed out in the included articles were related with the num-
ber of drugs and the number of health care providers visited. According
with the included studies both risk factors are associated with compli-
ance, drug selection and drug interaction problems.
Conclusions: The high prevalence of DRPs in home‐dwelling older
adults clearly demonstrated the need of interventions to improve med-
icines use in this population. Funding: Project MedElderly [SAICT‐POL/
23585/2016], supported by FCT/MCTES, Portugal 2020 and Centro
2020; Project APIMedOlder [PTDC/MED‐FAR/31598/2017], sup-
ported by POCI, in its FEDER/FNR component POCI‐01‐0145‐
FEDER‐031598, and the FCT, in its state budget component (OE).
Thanks are due for the financial support to Institute for Biomedicine ‐
iBiMED (UID/BIM/04501/2013 and POCI‐01‐0145‐FEDER‐007628).
599 | Drug burden of polypharmacy and
anticholinergic/sedative drugs and physical/
cognitive/mental related outcomes of the
community‐dwelling elderly people: The
Kawasaki well‐being project
Ringo Asano1; Asahi Tanaka2; Yasumichi Arai2; Takumi Hirata2,3;
Yukiko Abe2; Yuko Oguma4; Hisashi Urushihara Professor2
1Nada Senior High School, Kobe, Japan; 2Keio University, Tokyo, Japan;
3Tohoku University, Sendai, Japan; 4Keio University, Fujisawa, Japan
Background: Drug burden due to polypharmacy and anticholinergic
drugs is associated with reduction in physical and cognitive functions,
posing significant problems in elderly population.
Objectives: To assess drug burden and its association with patient out-
comes in the community‐dwelling independent elderly.
Methods: The cross‐sectional survey was conducted from March to
December 2017 on the community‐dwelling elderly in an urban area of
Kawasaki City, as a part of The Kawasaki Well‐being Project. Inclusion
criteria were independent, aged 85 to 89 years, participating in The
Kawasaki Well‐being Project. Data on drugs and physical/cognitive/
mental outcomeswere collectedwith self‐administrated questionnaires
and interview, as well as physical exams. We investigated the
associations between drug burden and physical/cognitive/mental out-
comes. Drug burden was measured using the number of medications
(polypharmacy) and Drug Burden Index (DBI) based on the use of anti-
cholinergic and sedative drugs.Multivariate regression analysiswas per-
formedontheoutcomemeasures includingActivityofDailyLiving (ADL),
Instrumental Activity of Daily Living (IADL), Mini Mental State Exam
(MMSE), Japanese‐version CHS (J‐CHS), and EQ 5D5L.
Results: A total of 389 subjects were analyzed, the mean age of the
study population was 86 years, 48% were male and most had 5 dis-
eases or more. Polypharmacy of five concomitant drugs or more was
found in 243 people (62%) and exposure to the drugs accounting for
DBI in 142 people (36.5%). We found that this population was physi-
cally healthy, and had high quality of life. After adjustment with sex,
age, education levels, the number of diseases, smoking status, and
alcohol drinking, the number of the drugs was significantly associated
with J‐CHS (p = 0.003) and EQ 5D5L (p = 0.001). The DBI score was
significantly associated with EQ 5D5L (p = 0.01).
Conclusions: The study participants were healthier than general elderly
population. It was suggested that polypharmacy and anticholinergic
burden may affect frailty and QOL in the elderly. Because of cross‐sec-
tional nature of the study, causal relationship cannot be established.
Further research is warranted to investigate the long‐term effects of
polypharmacy and anticholinergic/sedative drugs on elderly people.
600 | Prescription pattern for geriatrics a case
study of JosUniversity teaching hospital Nigeria
Rachel U. Odesanya; Juliet Igbanugo
Jos University Teaching Hospital, Jos, Nigeria
Background: There is a high rate of polypharmacy and prevalence of
potentially inappropriate medication (PIM) use among the elderly,
affecting over 30% of this group of patients.
Objectives: To describe the prescription pattern and inappropriate
medication use in elderly Nigerian out‐patients.
Methods: This was a descriptive retrospective study of 350 elderly
patients aged 65 years and above who attended the general, medical,
eye and surgical out‐patient clinics of a Nigerian tertiary teaching hos-
pital for a period of one year. The WHO prescribing indicators were
used for the drug utilization while the Beers Criteria 2015 was used
to screen for potentially inappropriate medications.
Results:Drugs prescribed were 1378, giving an average of 3.94 ± 1.97/
patientoutofwhichantihypertensivesaccounted for26.06%, analgesics
13.58%, multivitamins/food supplements were 8.24%. Study identified
131 patients with at least one potentially inappropriatemedication, rate
being37.43%, classesofdrugs inappropriatelyused includenonsteroidal
anti‐inflammatory, cardiovascular andmuscle relaxant drugs.
Conclusions: The drug utilization pattern among elderly outpatients of
this tertiary hospital were not optimal and 37.43% inappropriate pre-
scribing occurred which constitute a major problem in management of
the elderly. Healthcare providers therefore need to be trained/retrained
for proper handling of geriatrics.
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601 | Use of cardiovascular drugs among
older people in Greece consuming more than
five drugs daily
Paraskevi Papaioannidou; Maria Michailidou
1st Laboratory of Pharmacology, Medical School, Faculty of Health
Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Background: Polypharmacy is common among older people in Greece,
with cardiovascular drugs being the most frequently used category of
medications in this group of patients.
Objectives: The aim of this study was to explore the use of cardiovas-
cular drugs in older patients (> 65 years) receiving five or more than
five drugs daily in the community of Thessaloniki, Greece.
Methods: The sample was collected using the new Electronic Health
Records that have been applied in pharmacy stores during the last
years in Greece. All prescriptions dispensed during one month in a
pharmacy store of western Thessaloniki were used. Prescriptions
concerning patients older than 65 years were collected for the study.
Medications were coded by the Anatomic Therapeutic Chemical clas-
sification. The statistical package SPSS was used for statistical analysis.
Results: Polypharmacy (≥5 medications daily) was observed in 55% of
patients older than 65 years (mean age 77 years, range 65–99), ofwhom
42% were male and 58% female. Cardiovascular drugs were used by
86% of these patients. The most commonly used categories of cardio-
vascular drugs were: diuretics (75%), AT1 inhibitors (66%), calcium cha-
nel blockers (53%), beta blockers (46%), ACE inhibitors (18%),
vasodilators (11%). 74% of patients used a combination of cardiovascu-
lar drugs.
Conclusions: One out of two people older than 65 years used five or
more medications daily. The majority of older patients using ≥5 med-
ications daily (almost 9 out of 10) used cardiovascular drugs, with 74%
of them using a combination of cardiovascular drugs.
602 | Effect of adverse drug reactions on
length of stay in older adults in a teaching
Hospital in Chile
Carolina Gutierrez; Tamara Sandoval; Marcela Jiron
University of Chile, Santiago, Chile
Background: Aging is associated with a variety of physiological
changes affecting the pharmacokinetics and pharmacodynamics,
which may increase the potential for drug toxicity and Adverse Drug
Reactions (ADRs). The effect of ADRs on length of stay (LOS) in older
adults has been insufficient described.
Objectives: To determine the incidence of ADRs and its effect on the
LOS among hospitalized older adults in an Internal Medicine
Department.
Methods: A prospective cohort study was conducted in a sample of
hospitalized older adults 60 years and older admitted in the internal
medicine department of a teaching hospital in Chile. Sociodemographic
characteristics, clinical and pharmacotherapy profile were collected by
patient interviews and medical records. A clinical pharmacist joined in
clinical rounds and each suspected ADR detected was analyzed by an
internal medicine physician and two clinical pharmacists. Causality
assessment of each ADR was undertaken to determine whether each
suspected reaction was possible, probable or established. The assess-
ment of ADRs causality was performed using the Naranjo algorithm.
The effect of ADRs on LOS was determined using multivariate Cox
regression model.
Results: A total of 229 patients were included, the mean age was
72.9 ± 8.7 years, and 57.6% (132) were women. The 33.2% of older
adults suffered at least one ADR. A total of 112 ADR were detected
in 76 patients. The causality of ADRs detected were established
(4.5%), probable (55.4%), and possible (39.3%). Inpatient older adults
with ADRs spent a mean of 2 more days hospitalized in the internal
medicine department than those without ADRs (8.2 ± 5.0 vs
6.2 ± 4.2; p < 0.005). LOS was statistically higher in older adults with
ADRs versus those without ADRs (HR 1.47; 95%CI 1.10–1.96) con-
trolling by Charlson comorbidity index, sex, age, number of drug taken
and previous ADR.
Conclusions: One on three older adult patients suffer at least one
ADR in the Internal Medicine Department, increasing significantly
the mean LOS in 2 days. There is a potential to optimize the use of
hospital beds and patient safety preventing ADR in older adults.
603 | Usefulness of a new clinical
pharmacology service in a Single Center to
optimize drug therapy in the elderly in
Colombia
Jefferson Antonio Buendia; Carlos Rodriguez; Andres Felipe Zuluaga
University of Antioquia, Medellin, Colombia
Background: In the elderly, the polypharmacy and inappropriate use of
drugs is worsedue to the co‐morbidities that lead to more prescrip-
tions, frequently exceeding >10 drugs per patient. This excessive for-
mulation of drugsincreases at least twice the risk of adverse events
and is a marker ofincreased mortality.
Objectives: To implement a clinical pharmacology service in a devel-
oping country wecharacterized the pharmacological risk of a popula-
tion of 3734 individualsin order to promote the rational use of drugs
and the reduction of excessivemedicine consumption in the patients
with highest pharmacological risk.
Methods: A scale of pharmacological risk with 4 categories was built.
The highest risk (Group 4) commonly includes women older than
65 years, with acreatinine clearance <50 ml/min and receiving at least
10 drugs. Pharmacologist reviewed the medical records of group 4
patients. Additionally, Beers and STOPP criteriawere assessed and
major and moderate drug interactions werechecked. With the
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previous analysis an optimization plan was set to remove inappropri-
ate drugs. The program began in mid‐November 2017 and is currently
ongoingat the IPS Universitaria in Medellín, Colombia.
Results: The target population comprised 3734 patients. After stratifi-
cation,770 subjects were allocated to Group 4 (baseline). Group
3(moderate risk) included 2141 patients, Group 2 (low risk) 389sub-
jects and Group 1 (minimal risk) 434 patients. The most frequently
deprescribed drugs (reason) were: protonpump inhibitors (no indica-
tion), aspirin (no indication), trazodone (ineffective), albuterol (no indi-
cation), furosemide (noindication as first line for hypertension),
sertraline (no indication). The baseline features of G4: median of age
(range min to max) 79 (21–104), women (69%),median of drugs per
patient (range min to max) 12 (11–24),number of patients with risk
reduction (G4 to G3) 93 (13%),number of drugs deprescribed by clini-
cal pharmacologist 895, estimated savings related to deprescribed
drugs (U$) 113.502 per year, median of drug interactions found (range
min to max) 7 (0–45).
Conclusions: A drug optimization program was succesfully imple-
mented in an ambulatory healthcare setting in Colombia. After
10 months of intervention, 13% ofthe patients from Group 4 were
reclassified to Group 3, mainly by the deprescription of drugs without
indication. The impact of the program onquality of life, hospital admis-
sions and incidence of adverse drug reaction will be assessed after
1 year.
604 | Physicians' knowledge of appropriate
prescribing for the elderly ‐ a survey among
family and internal medicine physicians in
Nigeria
Joseph O. Fadare1,2; Abimbola M. Obimakinde3,4; Okezie O. Enwere5;
Olufemi O. Desalu6; Raphael O. Ibidapo2
1Ekiti State University College of Medicine, Ado‐Ekiti, Nigeria; 2Ekiti State
University Teaching Hospital, Ado‐Ekiti, Nigeria; 3College of Medicine,
University of Ibadan, Ibadan, Nigeria; 4University College Hospital,
Ibadan, Nigeria; 5 Imo State University, Orlu, Nigeria; 6University of Ilorin,
Ilorin, Nigeria
Background: Drug treatment of elderly patients is associated with
potential adverse drug reactions (ADRs). Prescription and use of inap-
propriate medications have been identified as being responsible for
the ADRs in many cases. Several tools/criteria such as the Beers
criteria have been developed to screen for inappropriate prescribing
in elderly patients. There is dearth of information about the knowl-
edge of Nigerian physicians regarding appropriate prescribing for the
elderly.
Objectives: The primary objective of this study was to assess the
knowledge of Nigerian physicians working in Family Medicine and
Internal Medicine about appropriate prescribing of medications for
the elderly.
Methods: The study was a cross‐sectional questionnaire‐based study
conducted among physicians working in four tertiary healthcare
facilities located in two contiguous regions in Nigeria. The question-
naire apart from the bio‐demographic details included ten clinical
vignettes which assessed the knowledge of respondents about medi-
cine use in the elderly with a total score of 10 marks. A score of less
than 5 was taken as poor knowledge. Descriptive analysis and Chi
square were used to obtain the general characteristics of the study
participants and determine the level of significance of groups of cate-
gorical variables respectively.
Results: One hundred and five (105)physicians working in Family and
Internal Medicine departments of four Nigerian tertiary healthcare
facilities returned completed questionnaires. Twenty percent of
respondents knew about Beers criteria while 15.6% were familiar with
the STOPP criteria. Majority (83; 84.7%) of the respondents were con-
fident of their ability to prescribe rationally for elderly patients. The
mean knowledge score was 5.3 ± 2.0 with 32 (30.5%), 41 (39%) and
32 (30.5%) having low, average and good scores respectively. The
association between the knowledge score, duration of practice and
seniority was statistically significant (p = .004 and.012 respectively.
The strength of this association is further confirmed by the Odds
Ratios (OR) of 3.6 and 3 respectively.
Conclusions: The knowledge of Nigerian doctors on appropriate pre-
scribing for the elderly was good. This is despite their poor familiarity
with the screening tools for inappropriate medications.
605 | Cost‐effectiveness of adjuvant whole
breast irradiation
Kyrian Ezendu1; Askal Ali1; Vakaramoko Diaby2
1Florida Agricultural and Mechanical University, Tallahassee, FL;
2University of Florida, Gainesville, FL
Background: Combining External Beam Whole Breast Irradiation
(EBWBI) with endocrine therapy remains a recommended alternative
to endocrine therapy alone for elderly women with Estrogen Positive
(ER+) Early Stage Breast Cancer (ESBC), post‐breast conserving sur-
gery (BCS). Although EBWBI in adjunct with endocrine therapy results
in superior loco‐regional tumor recurrence outcomes, metastatic and
survival outcomes for both strategies have been shown to be similar.
EBWBI is expensive and physically inconvenient for the elderly.
EBWBI is associated with increased toxicities among which
cardiotoxity is the most concerning. An earlier cost‐effectiveness
study found the combination of EBWBI with endocrine therapy more
cost‐effective than endocrine therapy alone, however the study failed
to consider cardiotoxicity of EBWBI and the life expectancy of elderly
patients.
Objectives: To estimate the lifetime cost‐effectiveness of including
EBWBI in the adjuvant regimen for elderly ER+ ESBC women, post‐
BCS, considering radiation‐induced cardiotoxicity.
Methods: Using Markov model, Incremental Cost‐Effectiveness Ratio
(ICER) due to EWBI was estimated from payers' perspective. In the
model, the cohort became tumor‐free post‐BCS, and could either
remain tumor‐free, or experience ipsilateral tumor recurrence,
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metastasis or both before death, over their remaining lifetime. Some
patients in the cohort may develop coronary heart disease at any living
stage. The progression of each patient in the model depends on the
adjuvant strategy received. Cost data, transitional probabilities and
health state utilities data were all derived from the literature. The
Net Monetary Benefits (NMB) were also estimated. Costs in Dollars
were adjusted by cumulative inflation rate and future costs were
discounted. Quality Adjusted Life Years (QALYs) were used as unit of
effectiveness. Future QALYs were discounted. Deterministic and
probabilistic sensitivity analyses were conducted.
Results: Endocrine therapy alone resulted in average lifetime cost and
effectiveness of $28478.94 and 15.50 QALYs respectively. EBWBI
plus endocrine therapy resulted in average lifetime cost and effective-
ness of $40061.72 and 33.76 QALYs respectively. The NMB from
endocrine therapy alone was $746585.55 while EBWBI plus endo-
crine therapy had a NMB of $1648104.65. With the Willingness to
Pay (WTP) of being $50,000, EBWBI plus endocrine therapy had
higher probability of being cost‐effective (0.926).
Conclusions: Including EBWBI in the adjuvant regimen for elderly ER+
ESBC women post‐BCS appeared to be more cost‐effective than
omitting it even when cardiotoxicity of radiation is considered.
606 | Impact of drug insurance type (private/
public) on the cost of drugs of Quebecers
Michel Chamoun
University of Montreal, Montreal, QC, Canada
Background: In the province of Quebec, residents are either insured
by the public drug insurance (RPAM) or a private drug insurance. Drug
cost in Quebec has three components: molecule's price, wholesaler
margin of profit and pharmacist's fee. The first two components are
regulated by the RPAM and are the same for publicly and privately
insured patients. The third component is fixed (between CAD$8.40
and CAD$9.00) and regulated by the RPAM for publicly insured
patients while it is determined freely by the pharmacy owner for pri-
vately insured patients. Although with methodological limitations, four
studies reported higher drug cost for privately than publicly insured
patients.
Objectives: This study aimed to compare the drug cost of Quebec res-
idents covered with private drug insurance to those covered by the
RPAM.
Methods: We used a sample of patients selected from reMed, a drug
claims database of Quebecers insured by the RPAM and private drug
insurances. We matched 3766 pairs of prescriptions bought by 1386
patients between January 1st 2015 and September 14th 2017. Each
pair of filled prescriptions had the same drug, dose and formulation
(i.e. DIN), same quantity dispensed, were dispensed in the same phar-
macy and had to be bought twice within three months by the same
patient: once while the patient was insured by the RPAM and once
while he/she was insured by a private drug insurance. The difference
in drug cost for each prescription before and after the drug insurance
change was analyzed with Student's t‐test for paired samples.
Results: 65.2% of the patients in our sample were between 40 and
65 years old and 59.2% were covered by a private drug insurance
before changing to the RPAM and 59.1% contributed to 2 prescrip-
tions or more to the analysis. We observed that privately insured
patients had to pay more for their medications (CAD$46.50) than pub-
licly insured patients (CAD$38.96): mean difference = CAD$7.54;
(95% CI 7.03–8.05) representing a difference of 25.7%. At the provin-
cial level, we estimated that this difference in cost could represent an
annual excess cost of about CAD$971 million (based on an estimated
128 800 00 prescriptions bought annually by Quebecers covered by
private drug insurances).
Conclusions: This study showed that, on average, drug cost is substan-
tially higher for privately insured Quebecers. Knowing that adherence
is affected by drug cost, these results will be useful to help public
health authorities to make informed decisions about drug insurance
policies.
607 | Mind the gap: A comparison of
encounter location and medical costs during
the one‐month periods immediately before
and after a short gap in United States
Medicaid healthcare coverage
Harriet Dickinson1; John Logie2; George Mu3
1GSK, Stevenage, UK; 2GSK, Uxbridge, UK; 3GSK, Collegeville, PA
Background: Patients may experience short (7–60 days) gaps in Med-
icaid coverage due to a variety of societal, lifestyle, and employment
reasons. During these gaps it is difficult for these individuals to easily
find alternate sources of coverage or access health services.
Objectives: This study aimed to understand if the types of admission
and healthcare costs of patients differed between the one‐month
periods immediately before and after a short gap in Medicaid enrol-
ment. A GSK funded study.
Methods: IBM Watson Health Medicaid data was used. Gaps in enrol-
ment were evaluated for each patient enrolled during 2010–2017, and
the first gap between 7–60 days was used. The one‐month periods of
continuous enrolment immediately before and after the gap were
evaluated. Age and gender were determined one month before the
gap. The location of encounters during these periods were deter-
mined. Costs analyses were determined for patients with Fee‐for‐Ser-
vice plans only, and costs were inflation‐adjusted to 2017 US dollars.
Results: 30.8% of Medicaid patients (7,292,231) had a gap of at least
one day, and of these 2,208,752 (30.3%) had an eligible gap. The mean
gap length was 27.8 (SD 10.6) days. The mean age was 17.2 (14.6)
years, and 58.6% were female. Patients were more likely to have an
ER visit (7.8% vs 7.1%, p = < 0.0001), an inpatient encounter (3.6%
vs 2.9%, p = < 0.0001), and/or require home help (2.3% vs 2.1%,
p = < 0.0001) after the gap than before. Overall, more diagnosis codes
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were recorded after the gap (mean 7.4 (SD 32.3) vs 7.1 (SD 30.3),
p = <0.0001).
1,489,021 (67.4%) of gap patients had eligible cost data. The mean
(SD) total medical costs were higher after return to coverage
($368.31 (6,002.4) versus $196.13 (2,841.3), p = < 0.0001). Procedure
costs were also significantly increased after their return to coverage,
($362.31 (5,965.7) versus $193.52 (2,829.6), p = < 0.0001). There
was no difference in medication cost.
Conclusions: Healthcare costs and resource utilization were found to
increase once patients were able to return to coverage. This may
reflect the patients' inability to seek care during the gap, and so they
require more care once they return to coverage.
This has implications for pharmacoepidemiology studies as, if a study
period starts immediately after a gap, then the observation will start
with an unrepresentative high cost (and potentially high ‘risk’) period.
This work highlights a unique patient subset enrolled in Medicaid cov-
erage that may require careful consideration when designing
pharmacoepidemiology studies.
608 | Utilization patterns, expenditures, and
estimated savings associated with analog or
human insulin products in the Medicare part
D program
Jing Luo; Aaron Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and
Women's Hospital, Boston, MA
Background: High cost insulin analogs (e.g. glargine) are frequently
used to treat patients with type 2 diabetes in the US. Recent evidence
shows that switching older adults with type 2 diabetes from analog to
lower cost human insulin (e.g. NPH or human premixed 70/30) is not
associated with worsened glycemic control or increased risk of hypo-
glycemia and may result in cost savings for payors and patients.
Objectives: To describe utilization patterns and expenditures for ana-
log and human insulins separately in the Medicare Part D program and
to estimate potential savings under 3 counterfactual scenarios
between 2012 and 2016.
Methods: We used the Medicare Part D Spending Dashboard, which
summarizes data available the Part D Prescription Drug Event (PDE)
data to tabulate volume (where 1 dosage unit = 1 ml = 100 IU insulin)
and expenditures for human or analog insulin products from 2012 to
2016. We included all standard strength insulin formulations except
inhaled insulin. To estimate potential savings and informed by litera-
ture, we considered 3 counterfactual scenarios: 1) optimistic, where
utilization in Part D was 70% human and 30% analog, 2) moderate,
where utilization was 50% human and 50% analog and 3) pessimistic,
where the overall proportion represented by analogs was 10% less
than observed each calendar year. We report gross and net expendi-
tures for the observed and counterfactual scenarios, after accounting
for a class‐specific 25% rebate. We inflated all dollars to 2016 using
the CPI‐U.
Results: Our sample included 8 human and 19 analog insulin products.
The number of beneficiaries increased from 4.1 million in 2012 to 5.2
million in 2016. Similarly, the volume of insulin dispensed increased
from 389 million units to 486 million units. The mean units dis-
pensed/beneficiary was 94.8 (range 92.8 to 96.1). The proportion of
insulin dispensed as analogs increased from 78% in 2012 to 83.6%
in 2016. Gross expenditures for all insulin products increased from
$4.9 billion in 2012 to $11.9 billion in 2016, a cumulative total of
$43.7 billion. The estimated 5‐year savings under optimistic, moder-
ate, and pessimistic counterfactual scenarios, inclusive of rebates,
would have been $11.6 billion, $7.2 billion and $2.2 billion,
respectively.
Conclusions: Most insulins dispensed in the US Medicare drug benefit
program were for analog products. Where it may be clinically appro-
priate, increased utilization of comparable human insulin products
may result in substantial savings for Medicare.
609 | Depression treatment, healthcare
expenditures, and depression severity in
patients with depression using patient health
questionnaire‐9 scores to assess depression
severity
Elizabeth R. Packnett; Debra E. Irwin
IBM Watson Health, Bethesda, MD
Background: Depression is a prevalent mental health condition associ-
ated with significant economic burden and morbidity. Severity of
depressive symptoms is an important factor when determining appro-
priate treatment for depression. Though the Patient Health Question-
naire‐9 (PHQ‐9) is a validated tool used to assist clinicians in assessing
depression severity, these scores are often unavailable in administra-
tive claims databases.
Objectives: To characterize treatment for depression and healthcare
expenditures by depression severity among patients administered
the PHQ‐9.
Methods: Adult patients with PHQ‐9 score between 1/1/2011 and 9/
30/2016 were identified using MarketScan Claims and Electronic
Medical Records Database (CED). The first PHQ‐9 was the index date;
12 months continuous enrollment before and after the index date was
required. Depression severity, assessed via PHQ‐9 scores, was catego-
rized as minimal (<5), mild (5–9), moderate (10–14), or severe (>14).
Depression treatment and all‐cause healthcare expenditures during
follow‐up were assessed and stratified by pre‐existing mental health
(MH) diagnoses.
Results: 11,066 patients met inclusion criteria; mean patient age was
66 years and 56% of patients were female. 11% of patients had PHQ‐
9 scores indicating depression (4% mild, 4% moderate, and 3% severe).
Patients with a pre‐existing MH diagnosis (19%) reported more severe
depression compared to those without a pre‐existing MH diagnosis
(MH: 6%mild, 7% moderate, 6% severe; no MH: 3%mild, 3% moderate
3% severe; p < 0.001 for all). Antidepressant treatment was more
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common in patients with severe depression during follow‐up; those
with a pre‐existing MH diagnosis had the highest rates of treatment
(MH: 56% minimal, 76% mild, 83% moderate, 82% severe; no MH:
14% minimal, 48% mild, 62% moderate, 76% severe; p < 0.001 for all).
Mean all‐cause expenditures were similar in patients with mild
($14,983), moderate ($15,403), and severe depression ($15,046);
expenditures for each groupwere significantly higher than expenditures
in patients with minimal depression ($11,161; p < 0.001 for all).
Conclusions: Though 7% patients had severe or moderate depression,
a significant proportion received no antidepressant therapy which may
represent unmet need. Further research is needed to understand bar-
riers for depression treatment and the impact on healthcare costs.
610 | Cost effectiveness analysis of
rivaroxaban compared to warfarin and aspirin
for stroke prevention atrial fibrillation in the
Indonesian healthcare setting
Erna Kristin Dr.1; Iwan Dwiprahasto Prof1; Dwi Endarti Dr.2;
Rizaldy Taslim Pinzon dr3; Alfi Yasmina Dr.4; Jarir At Thobari Dr.1;
Woro Rukmi Pratiwi Dr.1; Yolanda Dyah Kartika Dr.1;
Christiana Trijayanti Dr.5
1Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia;
2Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia;
3Faculty of Medicine, Yogyakarta, Indonesia; 4Faculty of Medicine,
Universitas Lambung Mangkurat, Banjarmasin, Indonesia; 5Respira Lung
Hospital, Yogyakarta, Indonesia
Background: Main drugs used in the prevention of stroke among atrial
fibrillation (AF) patients are antiplatelets (aspirin) and oral anticoagu-
lants (OAC). OAC therapy can be difficult to administer due to drug
and food interactions, adds the burden of required blood monitoring,
narrow therapeutic window, and requirements for dose titration.
Rivaroxaban is a single‐dose oral anticoagulant which does not require
blood monitoring, dose titration or has dietary interactions. Phase III
clinical data from the ROCKET trial have recently been reported the
non‐inferiority of rivaroxaban over warfarin for the prevention of
strokes in AF patients.
Objectives: To develop an economic model evaluating the clinical and
cost‐effectiveness of rivaroxaban for the prevention of stroke in non‐
valvular AF patients in the Indonesian health care settings.
Methods: This economic evaluation study with cost‐effectiveness
analysis included patients diagnosed with non‐valvular atrial fibrilla-
tion in several hospitals in Indonesia during the period of 2012–
2013. The perspective of the study was the health care perspective.
The intervention was rivaroxaban, compared to warfarin. Markov
model was used, comprised of health and treatment states describing
the management and consequences of AF. The main analysis was
based on data from the phase III trials. Three months was used as
cycle length. The time horizon was set at patients' lifetime (20 years).
Costs and outcomes were discounted at a 3% annual rate. Subgroup
analysis and extensive sensitivity analysis was conducted.
Results: Willingness to pay (WTP) threshold in Indonesia was set as
IDR 133,375,000 per quality‐adjusted life year (QALY). Base case
rivaroxaban vs warfarin has ICER of IDR 141,835,063 per QALY at
the current cost of rivaroxaban IDR 23,500 and ICER of
130,214,687 per QALY at the proposed cost of rivaroxaban IDR
22,000. One‐way sensitivity analysis showed that the key drivers of
cost‐effectiveness were the utility decrement applied to stable warfa-
rin patients, discontinuation/subsequent discontinuation rates for
rivaroxaban, and discontinuation/subsequent discontinuation rates
for warfarin. The probabilistic sensitivity analysis suggested that
rivaroxaban was cost‐effective compared to warfarin in about 45%
of cases at the WTP per QALY.
Conclusions: Rivaroxaban with the proposed price of IDR 22,000 was
more cost‐effective when compared to warfarin.
611 | Accuracy of budget impact estimations
of new oncology drugs in the Netherlands
Joost W. Geenen1; Mark Jut1; Cornelis Boersma2,3; Olaf H. Klungel1;
Anke M. Hövels1
1Utrecht University, Utrecht, Netherlands; 2Health‐Ecore, Zeist,
Netherlands; 3University Medical Center Groningen, Groningen,
Netherlands
Background: Innovations in oncology has resulted in an increased
number of treatment options for cancer patients. The growing expen-
ditures for expensive medicines is considered as a major challenge to
healthcare systems. For governments or other payers, high prices,
off‐label potential and increasing number of oncology approvals and
label extensions cause a substantial financial risk. When deciding on
reimbursement of an expensive drug, the pharmaceutical company
and/or payer usually quantify the expected costs known as Budget
Impact (BI). Accurate BI estimates are important as they are used in
reimbursement decisions. BI estimates can thus directly affect patient
access to new potentially life‐saving oncology drugs.
Objectives: To assess the accuracy of BI estimates of new oncology
drugs in the Netherlands.
Methods: We selected products for which Marketing Authorization
was granted by the European Medicines Agency between 1‐1‐2000
and 1–10‐2015. Of these, products belonging to the L01 (antineoplas-
tic agents) ATC‐category for which a reimbursement dossier was pub-
lished by the National Health Care Institute (ZIN), were included. From
the dossiers, we extracted the estimated (est) annual BI per product.
These estimates are the annual BI for the 3‐year period after the pub-
lication of a dossier. Data on observed (obs) BI were provided by
FarmInform. This population‐level data comprises of monthly volumes
of all prescription drugs that was multiplied by the official list price at
the time of prescription in the Netherlands. We used the final year of
the 3‐year period to compare to the observed BI. Prediction accuracy
was calculated as net difference (est ‐ obs), absolute difference (|est ‐
obs|), relative difference (obs / est; range = [0, ∞]) and symmetric rel-
ative difference (e ^|Ln (obs/est)|, range = [1, ∞]).
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Results: We included 22 products that had a total estimated and
observed BI of € 572 million (M) and € 380 M, respectively. The abso-
lute‐ and net difference was € 404 M and € ‐191 M, respectively. The
mean and median net difference in BI was € ‐8.7 M and € ‐2.9 M,
respectively. For the absolute difference, these figures were €
18.4 M (mean) and € 6.0 M (median). The relative difference was
1.07 (mean) and 0.64 (median). The mean and median symmetric rela-
tive difference was 8.62 and 2.15, respectively.
Conclusions: The median symmetric relative difference of 2.15 implies
that >50% of estimations were off by more than a factor 2. On the 22
novel oncology products, € 191 million less than estimated was actu-
ally spent. We think that these large deviations warrant further devel-
opment of independent BI prediction models based on sound methods
and tools.
612 | The impact of cost‐related medication
nonadherence on out‐of ‐pocket costs and
productivity among cancer survivors
Xiaomo Xiong1; Minghui Li2; Kevin Lu3
1China Pharmaceutical University, Nanjing, China; 2University of
Tennessee, MEMPHIS, TN; 3University of South Carolina, Columbia, SC
Background: A large body of evidence shows that nonadherence to
medication may lead to worse health outcomes, and further reduces
patients' productivity and increase total medical costs. Despite the
heavy economic burden among patients with cancer, the impact of
cost‐related medication nonadherence on patients' productivity and
personal financial burden remains unclear.
Objectives: To estimate the impact of cost‐related medication
nonadherence on productivity and out‐of‐pocket costs among
patients with cancer.
Methods: A retrospective, pooled cross‐sectional study was con-
ducted using data from the National Health Interview Survey (NHIS),
2011–2017. Cost‐related medication nonadherence was identified if
the respondent answered a “yes” to any of the following NHIS sur-
vey prompts: “skipped medication doses to save money in past
12 months”, “took less medication to save money in past 12 months”
or “delayed refilling prescription to save money in past 12 months”.
An ordered logistic regression was used to determine the impact
of cost‐related medication nonadherence on patients' out‐of‐pocket
costs (less than $2,000, $2,000‐4,999, $5,000 or more). A negative
binomial regression was implemented to estimate the impact on pro-
ductivity, which was measured as productivity loss by using the lost
workdays per year. In addition, demographics, income, health status
and insurance related information were controlled in these two
regressions.
Results: A total of 6,734 and 18,027 patients were identified out of
705,669 respondents for nonadherence on productivity and out‐of‐
pocket‐costs, respectively. The results showed that the cost‐related
medication nonadherence could increase out‐of‐pocket costs by
84% [OR = 1.84, (95% CI: 1.65 to 2.05, P = 0.000)] and productivity
loss by 24% [IRR = 1.24, (95% CI: 1.03 to 1.49, P = 0.023)] among
patients with cancer.
Conclusions: Cost‐related medication nonadherence may lead to a
decrease in productivity and a higher financial burden for
patients with cancer, suggesting strategies and interventions are
needed to further enhance cancer patients' affordability and
adherence.
613 | Opportunity costs of receiving
palliative chemotherapy for metastatic
pancreatic ductal adenocarcinoma (mPDAC)
Erin Bange; Abigail Doucette; Peter Gabriel; Robin Wang;
Andrzej P. Wojcieszynski; Bethany Mooney; Ben Boursi;
Kim Anna Reiss; Ronac Mamtani
Hospital of the University of PA, Philadelphia, PA
Background: The median overall survival (OS) of mPDAC is less than
1 year. Factors that contribute to quality of life during treatment are
critical to study. One key measure, time spent obtaining clinical ser-
vices, is understudied.
Objectives: We compared cumulative outpatient time with OS
among patients (pts) with mPDAC receiving palliative chemotherapy.
Methods: We conducted a retrospective analysis using 4 patient‐
level time measures calculated from the medical records of pts with
mPDAC receiving FOLFIRINOX, gemcitabine, or gemcitabine + nab‐
paclitaxel within the University of Pennsylvania Health System
between 1/1/2011 and 1/15/2019. These measures included total
number of days with at least one visit (encounter days), total visit
time (time between leaving and returning home on each visit day,
using geocoded coordinates of each pt's home address), care time
(time spent with providers, receiving cancer treatment, or undergo-
ing imaging studies), and non‐care time (difference between total
visit time and care time). We provided descriptive statistics on
cumulative time measures and compared each measure to overall
survival time.
Results: 365 pts were identified (median age 65 years, 52% male,
78% white, 62% received gemcitabine + nab‐paclitaxel, 79%
deceased, and median OS 231 days (IQR, 110–438)). On average,
pts had 22 (IQR, 10–41) calendar days with at least one outpatient
visit, accounting for nearly 10% of their total days survived. Per visit,
median visit time was 4.6 hours, of which greater than 50% of time
was accounted for by non‐care time including wait and commute
time.
Conclusions: Pts receiving palliative chemotherapy for mPDAC spend
10% of their OS time on outpatient healthcare. More than half of this
time is spent commuting and waiting for care, with a median of
2.5 hours of non‐care time per encounter. These data highlight the
need to optimize outpatient healthcare efficiency.
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614 | Healthcare resource use and economic
burden of respiratory illness among extremely
preterm infants in the Netherlands
Eline Houben1; Csaba Siffel2; Jetty Overbeek1;
Fernie Penning‐van Beest1; Sujata P. Sarda2
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands;
2Takeda, Lexington, MA
Background: Improvements in neonatal care have led to increased
survival of extremely preterm infants along with associated increases
in healthcare resource utilization (HRU). Respiratory illness is a key
driver of hospitalization and costs for this population. Characterizing
clinical burden is critical to develop strategies to improve outcomes
and reduce HRU.
Objectives: This study assessed HRU in terms of bronchopulmonary
dysplasia (BPD) and chronic lung disease (CLD) of preterm infants
born in the Netherlands.
Methods: A retrospective analysis of the PHARMO Database Net-
work was conducted on infants with a birth record in the Netherlands
Perinatal Registry and data in the Out‐patient Pharmacy and Hospital-
ization Database. Infants born at 24–37 weeks gestational age (wGA)
from 1999–2015 without congenital malformations were selected.
Prevalence of BPD and CLD was determined by diagnostic codes, hos-
pital admissions and a medication‐based algorithm; HRU and costs
were stratified by those complications. This abstract focuses on
extremely preterm (<28 wGA) infants.
Results: Of 101,329 infants born, 7,328 were preterm, and168
extremely preterm infants (52% female) were included. Of those,
40% and 29% had BPD and/or CLD, respectively. Mean (SD) costs
of the birth hospitalization for extremely preterm infants were
€126,350 (€101,900). In the period up to 1‐ and 2‐year corrected
age (CA), total costs for HRU, including hospitalisations and medica-
tion, were €10,500/PY and €6,700/PY, respectively. Costs and HRU
were higher for infants with BPD or CLD than for those without
either. Mean (SD) costs for birth hospitalization were: €163,850
(127,000) and €101,150 (71,350) for infants with or without BPD,
respectively; €166,700 (125,750) and €101,800 (75,050) for infants
with or without CLD. Readmission rates at 1 year CA were also
higher for infants with respiratory illnesses: 1.30 and 1.05 per per-
son‐year for infants with or without BPD, respectively; 1.34 and
0.86 per person‐year for those with or without CLD. At 1 year
CA, 50% of extremely preterm infants received pulmonary medica-
tions: inhaled bronchodilators (36%), diuretics (20%), inhaled steroids
(18%), and systemic corticosteroids (5%).
Conclusions: Among preterm infants born in the Netherlands, extreme
prematurity was associated with high rates of BPD and CLD and
accompanying increased costs and HRU. These findings underscore
the need for new interventions to reduce the burden of respiratory ill-
ness in this vulnerable population.
615 | Healthcare costs and resource
utilization associated with select severe
adverse events in patients with metastatic
urothelial cancer treated with first‐line
systemic therapies
Rahul Shenolikar1; François Laliberté2; Yunes Doleh1;
Cristi Cavanaugh3; Maral DerSarkissian4; Petros Grivas5
1AstraZeneca US, Gaithersburg, MD; 2Groupe d'analyse, Ltée, Montréal,
QC, Canada; 3Analysis Group, Inc., Boston, MA; 4Analysis Group, Inc., Los
Angeles, CA; 5University of Washington; Fred Hutchinson Cancer
Research Center, Seattle, WA
Background: Prior studies reported substantial economic burden due
to metastatic urothelial cancer (mUC), but limited information on
costs and healthcare resource utilization (HRU) related to severe
adverse events (SAEs) is available for this population.
Objectives: To estimate incremental healthcare costs and HRU associ-
ated with select SAEs among patients (pts) with mUC treated with
first‐line (1 L) systemic therapy.
Methods: Adults treated with 1 L chemotherapy or immuno‐oncology
therapy (IO) (first therapy administration defined index) between 1/
2012–9/2017, ≥1 UC diagnosis code, and continuous enrollment for
≥6 months pre‐ and ≥ 3 months post‐index date were identified using
IQVIA™ Real‐World Data Adjudicated Claims ‐ US database. Pts with
incident SAEs (febrile neutropenia [FN], dehydration, acute kidney
injury [AKI], sepsis, colitis, hepatitis, adrenal insufficiency, and pneumo-
nitis) during the 1 L treatment period (up to earliest of treatment switch,
discontinuation, end of continuous enrollment, or end of data availabil-
ity) were identified using inpatient claims. Per pt per month (PPPM)
incremental cost differences (CDs) and HRU rate ratios (RR) comparing
pts with and without the select SAEs were calculated using multivariate
linear regression and Poisson regression, respectively, to adjust for
baseline differences.
Results: Of 2,031 pts, 94% were treated with chemotherapy and 6%
with IO. The median age of pts was 62 years and 34% were female.
The adjusted mean PPPM CD between pts with and without SAEs
was $6,130 (p < 0.01). The greatest CDswere observed for pneumonitis
($20,242; p < 0.01), sepsis ($9,490; p < 0.01), and AKI ($8,843; p < 0.01).
Significant CDs were also observed for colitis ($7,202; p < 0.01), dehy-
dration ($7,125; p < 0.01), and FN ($4,231; p < 0.01). HRU burden
was greater in pts with SAEs than in pts without SAEs (hospitalization
RR = 7.82 [p < 0.01], emergency room RR = 1.64 [p < 0.01], outpatient
visits RR = 1.05 [p < 0.01]). Pts with the following SAEs had a higher rate
of hospitalization compared to pts without the SAE: AKI (RR = 4.83;
p < 0.01), dehydration (RR = 4.72; p < 0.01), sepsis (RR = 4.49;
p < 0.01), pneumonitis (RR = 4.43; p < 0.01), colitis (RR = 3.45;
p < 0.01), FN (RR = 3.17; p < 0.01), and hepatitis (RR = 2.21; p < 0.01).
Conclusions: SAEs occurring during 1 L therapy for mUC can result
in significant burden to pts, families, and healthcare systems. Appro-
priate selection of therapies based on future validated biomarkers,
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patient education, and early AE diagnosis may reduce the impact of
SAEs on healthcare costs and HRU.
616 | An analysis of the effectiveness
outcomes of economic studies evaluating
ophthalmic drugs: A systematic review
Inês Ribeiro1,2; Francisco Batel Marques1,2; Carlos Alves1,2
1AIBILI ‐ Association for Innovation and Biomedical Research on Light
and Image, Coimbra, Portugal; 2School of Pharmacy, University of
Coimbra, Coimbra, Portugal
Background: Poor consistency has been observed between the clinical
outcomes assessed in trials to support the marketing approval of new
drugs and the clinical outcomes subsequently used in cost‐effective-
ness studies to support decision‐making processes.
Objectives: To characterize the type of clinical outcomes (primary or
secondary) considered as effectiveness measures of economic studies
of ophthalmic drugs.
Methods: Cost‐effectiveness studies evaluating ophthalmic drugs were
identified through a systematic search conducted in Pubmed and
Embase from its inception until November 2018. Cost‐utility, cost–ben-
efit and cost minimization analysis were excluded. Therapeutic area
(according to “Preferred Term (PT) of MedDRA dictionary, type of eco-
nomic study (trial‐ ormodel‐based), effectivenessmeasures and sources
of effectiveness were extracted. Study design, primary and secondary
outcomes were extracted from the sources of effectiveness.
Results: Twenty‐eight cost‐effectiveness studies were included. Most
cost‐effectiveness studies (n = 18; 64.2%) retrieved their effectiveness
measures from experimental sources, while five (17.9%) retrieved from
observational sources and five (17.9%) from other type of data
sources. Seven (25%) cost‐effectiveness studies used data from a pri-
mary outcome of a clinical study as an effectiveness measure, six
(21.4%) used data from both primary and secondary outcomes and
five (17.9%) used data from secondary outcomes. It was not possible
to identify the outcomes used as effectiveness measures in ten
(35.7%) cost‐effectiveness studies.
Conclusions: A considerable number of cost‐effectiveness studies in
ophthalmology used effectiveness measures not defined as primary
outcomes in clinical studies. Cost‐effectiveness studies should include
data from relevant clinical outcomes in order to properly assess the
economic value of drugs.
617 | Economic evaluation of bevacizumab
added to chemotherapy for metastatic
colorectal cancer (mCRC) in Indonesia
Erna Kristin Dr.1; Dwi Endarti Dr.2; Rizaldy Taslim Pinzon Dr.1;
Woro Rukmi Pratiwi Dr.1; Dwi ArisAgung Nugrahaningsih Dr.1;
Alfi Yasmina Dr.3; Didik Setiawan Dr.4; Ratih Puspita Febrinasari Dr.5;
Tri Murti Andayani Dr.2
1Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia;
2Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia;
3Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin,
Indonesia; 4Faculty of Pharmacy, Universitas Muhammadiyah
Purwokerto, Purwokerto, Indonesia; 5Faculty of Medicine, Universitas
Sebelas Maret, Surakarta, Indonesia
Background: Studies of metastatic colorectal cancer (mCRC) should be
performed to evaluate the use of bevacizumab in mCRC patients and
provide scientific evidence for policy maker. Currently, bevacizumab is
available in the National Formulary and is included in the national
health insurance benefit package.
Objectives: The aim of this study is to review the cost‐effectiveness
of adding bevacizumab to the chemotherapy regimen for mCRC
patients in Indonesia.
Methods: The Economic evaluation used methods of cost‐effective-
ness analysis (CEA), cost‐utility analysis (CUA), and budget impact
analysis (BIA) analysis included patients diagnosed with mCRC in
several hospitals in Indonesia during the period of 2009–2017. The
perspective of the study was the societal perspective. The interven-
tion was bevacizumab added to chemotherapy, compared to chemo-
therapy alone. CEA applied real‐world data approach measuring the
clinical outcome of progression‐free survival and overall survival.
CUA used modeling‐based economic evaluation was used in this
study to calculate the lifetime cost, lifetime outcome, and ICER
(incremental cost‐effectiveness ratio) values of both interventions.
The pharmacoeconomic analysis uses a cost‐utility analysis method
which compares the cost with QALY (quality‐adjusted life‐year) out-
come. BIA estimated additional budget to provide therapy for all
mCRC patients in Indonesia.
Results: The addition of bevacizumab to the chemotherapy regimen
for the treatment of mCRC patients resulted in a longer 1‐month
PFS clinical outcome and a 2 month longer OS. Adding bevacizumab
to chemotherapy in mCRC patients resulted in better clinical out-
come (longer PFS and OS), with the ICER of IDR 531.527.028 per
year PFS and IDR 1.012.060.452 per year OS. Adding Bevacizumab
to chemotherapy in mCRC patients was not cost‐effective, with the
ICERs from healthcare perspective were IDR 653.336.010 per QALY
and IDR 354.719.903 per QALY if using secondary data approach
and real‐world data approach, respectively. Meanwhile, the ICERs
from a societal perspective were IDR 668.091.070 per QALY and
IDR 385.393.873 per QALY using secondary data approach and
real‐world data approach, respectively. Adding bevacizumab to che-
motherapy in mCRC patients would require an additional budget of
IDR 514.855.919.662 for 6,110 mCRC patients for duration therapy
of 1,5 years.
Conclusions: The addition of bevacizumab on the current standard of
care for metastatic colorectal cancer patients was not a cost‐effective
treatment.
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618 | How different regulatory systems
recognize and reward pharmaceutical
innovation ‐ a comparative analysis of
intelectual property (IP) protection, marketing
authorization and pricing/reimbursement
systems with a focus on oncology
Nahila Justo1; Linus Jönsson1,2; Nils Wilking2
1Karolinska Institute, Stockholm, Sweden; 2Lundbeck A/S, Copenhagen,
Denmark
Background: Innovation is recognized in different ways among the
various organizations regulating the development and commercializa-
tion of medicines; leading to differences in requirements and incentive
structures.
Objectives: We aim at reviewing and comparing definitions, incentives
and rewards to innovation among decision‐making bodies in the US
and Europe (EU, Belgium, France, Germany, Netherlands, Sweden
and UK).
Methods: Methods: Review of the published literature through
Medline and gray sources (guidelines, legislation and official communi-
cations, and decisions) illustrated with a case study in oncology.
Results: The definition of innovation varies significantly across stake-
holders. The establishment of a New Chemical Entity by patenting
an invention is followed by the registration of a pharmaceutical
product that may or may not be assigned a new ATC class, depend-
ing on novelty of chemical class and pharmacological properties.
Then, regulators assess the degree of innovation more comprehen-
sively to consider early access (FDA, EMA). Finally, HTA bodies con-
sider the value of that innovation in terms of patient, caregiver and/
or societal benefit in order to determine premium pricing and cover-
age. Criteria for differentiation varies across countries (formulation,
mechanism of action, mode of administration, etc.). Premium pricing
for a patent‐protected innovative product requires therapeutic
advantage in terms of safety, efficacy (HAS/France), quality
(IQWIG‐GBA/Germany), morbidity and quality of life (CRM/Belgium),
or cost (TLV/Sweden and NICE/England and Wales) and demon-
strated additional clinical benefit over existing therapies. Other
criteria such as unmet need or disease severity have been consid-
ered though rarely and the value of incremental innovation or
patients/carers' convenience have been insufficient to justify pre-
mium pricing by themselves.
Conclusions: Patent protection, marketing authorization and pricing/
reimbursement systems serve different purposes so the thresholds
to define “innovativeness” escalate with each step and so do geo-
graphical disparities. IP protection follows international conventions.
Incentives for innovation are rather consistent across regulators;
entailing mainly expedited procedures and less burdensome evidence
requirements. Conversely, priorities for pricing/reimbursement to
recognize and reward innovation do not align.
619 | Opioid use, healthcare expenditures,
and pain severity in osteoarthritis patients
using patient reported pain scores to assess
pain severity
Elizabeth R. Packnett; Debra E. Irwin
IBM Watson Health, Bethesda, MD
Background: Over 30 million adults in the U.S. have osteoarthritis
(OA) and the economic burden of OA‐related pain is substantial. Opi-
oid use is prevalent OA patients to manage OA‐related pain. Though
treatment guidelines for management of chronic pain recommend
against using opioids to manage mild pain or as a first line therapy to
manage chronic pain, opioids may still be used to manage mild pain
or as a first line therapy in OA patients.
Objectives: To describe the prevalence of opioid use and healthcare
expenditures in OA patients by patient reported pain severity.
Methods: Adult OA patients with valid pain scores at OA diagnosis
were identified between 1/1/2002 and 9/30/2016 in the MarketScan
Claims and Electronic Medical Records Database (CED). Date of pain
score was the index date; 12 months continuous enrollment before
and after the index date was required. Patients with baseline opioid
use or joint replacement during the observation period were excluded.
Four pain severity cohorts, based on score at diagnosis, were used:
none (0), mild (1–3), moderate (4–6), severe (> 6). Opioid use and
healthcare expenditures were measured during follow‐up and com-
pared by pain severity.
Results: 3,984 OA patients met the patient selection criteria; mean
patient age was 66 years and 58% were women. 65% of patients
had pain at diagnosis (15% mild, 26% moderate, 24% severe). Strong
opioid use was more prevalent in patients with mild (27%), moderate
(28%), and severe pain (36%) relative to patients without pain (18%,
p < 0.001 for all); prevalence of strong opioid use was similar in
patients with mild and moderate pain (p = 0.59). Mean healthcare
expenditures in patients with moderate ($14,106) or mild ($12,235)
were not significantly higher than patients with no reported pain
($14,342). Patients with severe pain had significantly higher mean
expenditures ($16,796) than patients with no pain; p = 0.04) and
patients with mild pain (p < 0.01).
Conclusions: Though highest rates of strong opioid use were observed
in patients with severe pain, strong opioid use was also prevalent in
patients with mild pain. Further research is necessary to assess
whether use of strong opioids is consistent with treatment guidelines
for patients with mild OA‐related pain.
620 | Analysis of the price difference rate
between essential and non‐essential
medicines in China
Xinzhao Cai; Zhi Cui; Zhiting Liu; Ying Bian
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institute of Chinese Medical Sciences, University of Macau, Macau,
Macao
Background: China launched the current health care reform in 2009 to
address the issue of access to appropriate medicines for 1.3 billion
people. The new editions of the National Essential Medicines List
(NEML) have been launched since June 1, 2015, with the aim of pro-
viding essential medicines to all.
Objectives: The purpose of this study was to analyze the price of
essential and non‐essential medicines in the market, to review the
impact of essential drug policies on drug pricing, and to provide rec-
ommendations for policy makers.
Methods: In this study, 21 dynamic monitoring and data collections
were conducted for drug retail distributors (n = 62) and hospital phar-
macies (n = 61) in China's provinces (n = 27) between 2014 and 2017,
and drugs (n = 5379) From different manufacturers (n = 2806) to
assess the impact of the essential drug policy on drug pricing. Define
the “Price Difference Rate (PDR)” as “(retail price‐ex‐factory price) /
ex‐factory price x 100%”. Descriptive analysis, chi‐square test, case
analysis are used in this study.
Results: 1. The medicines with PDR of less than or equal to 0.25
accounts for 59.1% of the total, 18.2% is PDR of greater than 0.25
and less than or equal to 0.5, 11.7% is PDR of greater than 0.5 and less
than or equal to 1, and 9.3% is PDR of greater than 1 and less than or
equal to 3, PDR of more than 3 accounted for 1.7%; 2. Among the drugs
with PDR of more than 5, 82.12%were domestically produced, 75.93%
belonged to the NEML, Rx accounted for 99.74%, and only 19.91%
were sold in hospital pharmacy; 3. The top three PDR medicines are
Ganmao Granule (PDR = 1685.52%, Chinese patent drug, cold medi-
cine), Ofloxacin Glucose Injection (PDR= 1667.66%, antibiotic), Yuanhu
Anodyne((PDR = 1221.86%, OTC, Chinese patent drug). 4. Drugs with
PDR of less than 1 are classified into three categories. Rename the drug
with PDR of 0.25 or less for A, PDR is greater than 0.25 and less than or
equal to 0.5 for B, and the others for C:①Drugs in NEML of A(68.07%),
is lower than B(66.73%) and C(63.79%) significantly (chi‐
square = 66.279,p = 0.000); ②Western drugs of A(73.17%) is over
B(55.20%) and C(61.57%) with statistically significant difference (chi‐
square = 1014.425,p = 0.000); ③Injection in A was 28.41%, which
was significantly higher than 13.60% in B and 19.63% in C (chi‐
square = 1163.150, p = 0.000); ④2.9% of A was OTC, is lower than
B(5.06%) and C(5.52%) significantly (chi‐square = 131.148, p = 0.000).
Conclusions: The coverage of the types of essential drugs is still not
broad enough, the price of drugs is floating and unstable during circu-
lation, and the price of national essential drugs needs to be strictly
controlled.
621 | The cost of hospitalization and length
of stay due to hypoglycemia in patients with
diabetes mellitus: A cross‐sectional study
Abdallah Y. Naser1; Sinaa Alaqeel2; Hassan Alwafi3
1Al‐Isra University, Amman, Jordan; 2King Saud University, Riyadh, Saudi
Arabia; 3University College London, London, UK
Background: hypoglycemia in patients with diabetes mellitus is a fre-
quent and costly adverse drug event. There have been no studies in
the Middle East countries that estimate the hospitalization cost and
length of stay due to hypoglycemia in patients with DM.
Objectives: to estimate hospitalization cost and length of stay due to
hypoglycemia, and to identify determinants of variation in hospitaliza-
tion cost and length of stay among patients with diabetes mellitus.
Methods: a cross‐sectional study was conducted in Jordan using inpa-
tients records of two private hospitals for patients with diabetes
mellitus, who have been hospitalized due to hypoglycaemia between
January 2009 and May 2017. All hospitalization costs were inflated
to costs in 2017. Hospitalization cost was estimated from patients
perspective in Jordanian dinars (JOD). Multiple linear regression anal-
ysis was used to identify predictors of hypoglycemia hospitalization
cost and length of stay.
Results: a total of 126 patients with diabetes mellitus were hospital-
ized due to hypoglycemia. The mean patients age was 64.2 (SD = 19.6)
years old, of which half were male. The median length of hospital stay
was two days (IQR = 2 days). The median cost of hospitalization for
hypoglycemia was 163.2 JOD ($230.1) (IQR = 216.3 JOD, $305.0).
Patients who had a family history of diabetes mellitus had higher hos-
pitalization cost and longer length of stay (0.306 and 0.275, p < 0.05).
Male patients and patients who were without smoking history had
longer length of stay (0.394 and 0.456, p < 0.01).
Conclusions: hospitalization due to hypoglycaemia among patients
with diabetes mellitus represents a substantial economic burden
within hospital settings. Healthcare professionals should give more
attention to this adverse drug event to decrease the burden of its
associated cost.
622 | The devil you should know:
Adjustment for confounding bias is rare in
observational economic evaluations in
cardiology
Jason R. Guertin1; Blanchard Conombo1; Raphaël Langevin1;
Frédéric Bergeron1; Anne Holbrook2; Brittany Humphries2;
Alexis Matteau3; Brian J. Potter3; Christel Renoux4; Jean‐Eric Tarride5;
Madeleine Durand3
1Université Laval, Quebec City, QC, Canada; 2McMaster University,
Hamilton, ON, Canada; 3Université de Montréal, Montréal, QC, Canada;
4Lady Devis Institute for Medical Research, Jewish General Hospital,
Montreal, QC, Canada; 5McMaster University, Hamilton, QC, Canada
Background: Similar to comparative effectiveness studies, observa-
tional economic evaluations (i.e., economic evaluations based solely
on observational data) are prone to confounding bias. However, prior
studies have shown that adjusting for confounding is poorly done if
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done at all in observational economic evaluations. In 2013, Kreif et al.
published a checklist aimed at improving the quality of confounding
bias adjustment in these studies. In the same year, Husereau et al.
published the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) Statement that identified what items should be
reported in all economic evaluations. We hypothesized that these
publications improved the methodological quality of observational
economic evaluations.
Objectives: Our primary objective was to investigate whether and
how confounding is accounted for in observational economic evalua-
tions in Cardiology. Our secondary objective was to assess adherence
to the CHEERS Statement in selected publications.
Methods: We performed a systematic review of PubMed, Embase,
Cochrane Library, Web of Science and PsycInfo databases using a
set of Medical Subject Headings (MeSH) and keywords covering
topics in “Observational Economic Evaluations in Health” and “Car-
diovascular Diseases”. Any study published between January 1st
2013 and December 31st 2017 answering our search criteria was eli-
gible for inclusion; no other exclusion criterion was imposed. We
screened all eligible reports to identify which confounding adjust-
ment method, if any, was used. We also assessed which items of
the CHEERS Statement were reported.
Results: A total of 8,771 unique citations were screened, with 43 man-
uscripts selected for full text extraction. Out of the first 10 studies
fully reviewed, only 3 (30%) adjusted for confounding bias; 1 study
used covariate matching, 1 study used propensity score matching
and 1 study used multivariate regressions. Secondary results indicate
that, on average, studies reported 16 (range 13–19) out of the 21 rel-
evant items identified in the CHEERS Statement.
Conclusions: Despite previous efforts, our interim results indicate that
confounding bias is poorly controlled for in observational economic
evaluations. Such results support continued educational efforts aimed
at improving researchers' knowledge and skills regarding confounding
bias and methods aimed at addressing this issue. Revising the CHEERS
Statement to better account for observational economic evaluations
(e.g., adding items specific to confounding bias) may improve the
methodological quality of future publications.
623 | Incidence and treatment‐related
economic burden of HPV‐related cervical,
vulvar, vaginal, and anal cancers in the US
Vimalanand S. Prabhu; Jinghua He; Christine Velicer; Teesta Banerjee;
Smita Kothari
Merck & Co., Inc., Kenilworth, NJ
Background: Human papillomavirus (HPV) infection is the most com-
mon sexually transmitted infection in the US. Persistent infection with
high‐risk types can progress to cancer.
Objectives: To estimate the incidence and direct medical costs of cer-
vical, vaginal, vulvar, and anal cancers attributable to high‐risk types
targeted by the 9‐valent (9v) HPV vaccine in US.
Methods: Cervical, vaginal, vulvar, and anal cancer cases were identi-
fied from the SEER (Surveillance, Epidemiology, End Results) cancer
registry. Included patients were newly diagnosed at age 9 and above
in the year of 2015. Cancer histology was limited to squamous cell
carcinomas. Incident cases were estimated by using age/gender/site‐
specific SEER incidence rates and published US population data. Since
only a proportion of these cancers are attributable to HPV, Published
estimates of the proportion of each cancer site attributable to the
9vHPV vaccine‐types were further applied to estimate incident cases
attributable to these types.
Results: The 2015 annualized incidence rate per 100,000 person‐
years of cervical, vaginal, vulvar, anal (female), and anal (male) cases
was 5.85, 0.29, 1.42, 1.78, and 0.95, respectively. The economic bur-
den of cervical, vaginal, vulvar, anal (female), and anal (male) cancer
was $671 million, $50 million, $88 million, $129 million, and $71 mil-
lion, respectively. Cervical cancer treatment costs accounted for 63%
of the overall treatment costs of the 4 types of cancers. The economic
burden of these cancers attributed to the 9vHPV vaccine types was
over $1.0 billion.
Conclusions: Cancers attributable to 9vHPV vaccine types inflict sub-
stantial health and economic burden on society. The estimate of eco-
nomic burden is conservative, as it does not include costs of prevalent
infection (other than newly diagnosed cases), costs associated with
screening and treatment of pre‐cancers, indirect costs such as produc-
tivity losses due to cancer morbidity and mortality, and the burden of
other HPV‐related cancers (e.g., penile, oropharyngeal). Screening/
HPV vaccination can help reduce the burden of these HPV‐related
cancers.
624 | Cost analysis of hepatitis C treatments
in Saudi Arabia
Sondus Issam Ata1; Mohammed Al‐Owairdhi2; Taif Khalid Albassri1;
Fatimah Al‐Hussain2; Sara Al‐Hassan2; Abdulaziz Al‐Shehri2;
Fahad Al‐Nutaify2; Tariq Mohammed Alhawassi1
1King Saud University, Riyadh, Saudi Arabia; 2Saudi Food and Drug
Authority, Riyadh, Saudi Arabia
Background: Hepatitis C is a costly disease that requires economic
allocation of resources towards medication selection and purchases
to avoid huge budget impacts. The Ministry of Health in Saudi Arabia
stated that 1,327 new cases of Hepatitis C were identified in 2015
with an incidence rate of 4.21 per 100,000 populations. A blood test-
ing and screening suggest a prevalence rate of 0.4%–1.1% of the total
population.
Objectives: To analyze the cost of anti‐hepatitis C medications pre-
scribed at a tertiary hospital in Saudi Arabia by achieving the follow-
ing objectives: estimating the total cost of hepatitis C treatment for
each patient and determining the incident rate based on the hospital
data.
Methods: A retrospective data retrieved from Electronic medical
records (EHR) for all adult patients attended the Hepatology
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outpatient clinic at a tertiary hospital during the period of (Jun 2015‐
Dec 2017) with positive hepatitis C test and treated with the following
medication: Harvoni (ledipasvir‐sofosbuvir), Viekira Pak (ombitasvir,
paritaprevir, ritonavir, dasabruvir), Daklinza (daclatasvir) with Sovaldi
(sofosbuvir) or Zepatier (grazoprevir‐elbasvir). Micro‐costing bottom
up approach used to determine the direct medical costs of the disease
from the perspective of the hospital. An excel worksheet was created
for data entry. Study was approved by the institutional review board
(IRB) with reference no (17/0045).
Results: A total of 89 patients with a positive serology of hepatitis C
were identified. The mean age of the patients were 61 years. The
genotype 4 is most dominant (60%) followed by genotype 1 (17%).
Patient presented with other comorbidities include hypertension and
other cardiovascular disease 49%, Diabetes Miletus (23%) and thyroid
disorder (9%). A 12 weeks course of antiviral agents used to treat hep-
atitis C was: Harvoni 57%, Viekira Pak 21%, Daklinza with Sovaldi 15%
or Zepatier 7%. Most common reported side effect were fatigue,
heartburn and shortness of breath mostly seen with Harvoni treated
patients. Complication of the disease includes cirrhosis 47%, fibrosis
27% and cancer 6%. 67% of patient treated with Harvoni has end
up with cirrhosis while 69% of patient treated with Daklinza has fibro-
sis. Viekira Pak was associated with less disease complication cases.
The estimated cost associated with treating one patient was around
179,380 Saudi Riyals ($ 47,835).
Conclusions: Hepatitis C has a huge impact on the health budget spe-
cifically when associated with the disease complications. Although the
treatment is expensive, but rational use of this medication together
with early intervention will result in cost reduction.
625 | Assessment of incidence and severity
of drug related problems in patients with
chronic diseases and pharmacist intervention
in net cost savings
Adepu Ramesh; Manohar Gopal
Vikas College of Pharmaceutical Sciences, Suryapet, India
Background: Patients suffering from hypertension and diabetes with
comorbidities receive poly pharmacy and likely experience drug
related problems, that may negatively affect therapeutic outcomes
and treatment costs. Many global studies have suggested the positive
influence of pharmacist intervention in improved health outcomes and
net cost savings.
Objectives: To assess the prevalence and severity of drug related
problems (DRP) in patients with chronic disorders and influence of
pharmacist intervention in minimizing the DRP and net cost savings.
Methods: Cross sectional intervention study design.
Results: During the study period, a total of 1210 houses were visited
and health status of 4327 people were assessed in urban Suryapet,
Telengana State, India. Among them, 304 (7.02%) individuals (Male:
63%, Females: 37%) were found suffering from chronic diseases.
Among them, 223 (75%) patients were suffering from cardiovascular
and 81 (25%) patients were suffering from endocrine disorders. As
per Cipole's classification, a total of 141 Drug Related Problems were
identified among the prescriptions received by the patients. Drug
interactions were 93 (66%), adverse drug reactions 26 (18.4%), Failure
to receive drugs 11(7.8%), sub‐therapeutic dosage 5(3.5%), over dos-
age 4 (2.8%) and Drug use without indication 2(1.4%). The net cost
of DRP was calculated using direct and indirect medical costs. it was
found that, a sum of Indian Rupees 26,200/− (USD 400) can be saved
if timely interventions are made in the above 141 DRPs.
Conclusions: Pharmacist intervention through pharmaceutical care
can minimize drug related problems and improve health outcomes
and reduce health care expenditures. <!‐‐EndFragment‐‐ > .
626 | Possible channeling bias in the
evaluation of cardiovascular risk of triptans:
The importance of comparator selection in
observational research
Hu Li; Xiang Zhang; Robert Goodloe; Maurice Vincent
Eli Lilly and Company, Indianapolis, IN
Background: In observational research, comparator choice can directly
affect the validity of study results, clinical interpretation, and implica-
tions. Triptans, widely prescribed acute migraine medications, have
vasoconstriction properties and, therefore, triptan labels contain a
contraindication for ischemic heart conditions.
Objectives: To explore the potential of channeling bias in the evalua-
tion of adverse cardiovascular (CV) outcomes among migraine patients
initiating triptans and alternative active comparators.
Methods: We conducted a retrospective, new‐user cohort study
using the MarketScan Database (2004–2016) to evaluate the risk
of myocardial infarction (MI) and stroke among treated and
untreated patients with acute migraine and nonmigraine controls.
To assess the impact of comparator choice, migraine patients initiat-
ing triptan treatment were compared to those initiating opiates or
prescription nonsteroidal anti‐inflammatory drugs (NSAIDs). We used
propensity score methods and Cox‐proportional hazard regression to
estimate adjusted hazard ratios (aHRs) with 2‐sided 95% confidence
intervals.
Results: 455,776 patients (mean age ± SD: 37.62 ± 12.31 years) ini-
tiated triptan treatment. These patients were younger, had fewer
comorbidities, concomitant medications, CV risk factors, and hospital
visits compared to untreated migraine patients (n = 1,240,116) or
those initiating prescription NSAIDs (n = 325,419) or opiates
(n = 52,793). Consistent with current knowledge, patients with
migraine were found to be at an increased risk for stroke compared
to nonmigraine patients (aHR = 2.16, 2.08–2.23), but not for MI
(aHR = 0.96, 0.91–1.02). Inconsistent with existing evidence, the
aHRs for MI and stroke of patients initiating triptans were 0.52
(0.29–0.92) and 0.47 (0.35–0.63), respectively, compared to patients
initiating opiates, and 0.92 (0.44–1.90) and 0.39 (0.27–0.55), respec-
tively, compared to patients initiating NSAIDs.
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Conclusions: Given the CV warnings included in current triptan label-
ing, the finding of ‘protective’ effects of triptans for MI and stroke
compared to alternative treatments suggest channeling of migraine
patients at high CV risk away from triptans and towards alternative
treatments. Such channeling may pose substantial challenges in using
triptans as comparators for novel migraine treatments in future obser-
vational post‐marketing CV risk studies.
627 | Cohort study of the relative incidence
of major cardiovascular events among
patients initiating prucalopride versus a
matched comparator cohort in a multinational
study: Study design and comparability of
cohorts
Joan Fortuny1; Alicia Gilsenan2; Miguel Cainzos‐Achirica1;
Oscar F. Cantero3; Robert W.V. Flynn4; Luis Garcia‐Rodriguez3;
Bianca Kollhorst5; Pär Karlsson6; Love Linnér6;
Thomas M. MacDonald4; Estel Plana1; Ana Ruigómez3; Tania Schink5;
Ryan Ziemiecki2; Elizabeth B. Andrews2
1RTI Health Solutions, Barcelona, Spain; 2RTI Health Solutions, Research
Triangle Park, NC; 3Centro Español de Investigación
Farmacoepidemiológica, Madrid, Spain; 4University of Dundee, Dundee,
UK; 5Leibniz Institute for Prevention Research and Epidemiology—BIPS,
Bremen, Germany; 6Karolinska Institutet, Stockholm, Sweden
Background: Given prior safety experience with other 5‐HT4 agonists,
an observational cohort study was conducted to evaluate the cardio-
vascular (CV) safety of prucalopride in support of approval of
prucalopride for chronic constipation (CC) in the United States.
Objectives: To describe methods and resulting comparability of
cohorts in a multi‐database, multinational study of prucalopride and
polyethylene glycol 3350 (PEG) initiators treated for CC, following a
harmonized protocol; assess the performance of propensity score
(PS) stratification and trimming to obtain comparable study cohorts;
and report study design decisions undertaken when comparability
could not be achieved.
Methods: In this observational, population‐based cohort study
(EUPAS9200) conducted in 5 data sources from 3 European member
states, prucalopride initiators were matched on age, sex, and index
date to PEG initiators (1:5 ratio). Data sources included the Clinical
Practice Research Datalink (CPRD), The Health Improvement Network
(THIN), and the Information Services Division (ISD) of Scotland in the
United Kingdom; the Swedish National Registers (SNR) in Sweden;
and the German Pharmacoepidemiological Research Database
(GePaRD) in Germany. Study exposures, CV risk factors, and other
covariates were identified from health care utilization codes harmo-
nized across databases. CV outcomes were identified using data-
base‐specific algorithms based on diagnosis codes. PS in each
database was estimated using logistic regression, with prucalopride
versus PEG as the outcome and including clinically relevant variables
associated with major adverse CV events, which were the primary
Post‐authorisation Safety Study (PASS) endpoint.
Results: 12,030 prucalopride initiators and 59,985 PEG initiators were
identified. After matching and trimming, cohorts from the UK and
Sweden were well balanced for CV risk factors and cancer. Matching
on 2 additional variables (recent hospitalization, prescriber type) was
needed in Sweden. However, in Germany, PEG initiators remained
older and sicker than prucalopride initiators. Prevalence of these char-
acteristics also differed from those in the UK and Sweden.
Conclusions: Matching, trimming, and PS stratification yielded compa-
rable cohorts in 4 of 5 data sources. Use of these methods could not
achieve balance for key covariates within the German cohort, likely
due to reimbursement differences in Germany. Consequently, the
pooled PASS analyses included only data from the UK and Sweden.
628 | Confounding effect of smoking on the
association between fluoroquinolone and risk
of aortic aneurysm
Mingfeng Zhang; Monique Falconer; Lockwood Taylor
US Food and Drug Administration, Silver Spring, MD
Background: Several epidemiologic studies have reported an approxi-
mately 2‐fold increased risk of aortic aneurysm associated with fluoro-
quinolone use. However, none of these studies collected information
on smoking status, which is an important confounder and could poten-
tially explain away the observed increased risk in these studies.
Objectives: To conduct a series of quantitative bias analyses to evalu-
ate the impact of unmeasured smoking on the association between
fluoroquinolone use and aortic aneurysm risk.
Methods: We applied three common approaches previously pub-
lished ‐ the E‐value approach, the rule‐out approach and the array
approach, to evaluate the potential confounding effect of smoking.
The E‐value represents the minimum strength of association on
the risk ratio scale that an unmeasured confounder would need
to have with both the exposure (RREC) and disease outcome
(RRCD) to fully explain away an apparent exposure‐disease associa-
tion (APR). The rule‐out approach is similar to the E‐value
approach but provides a more precise estimation of RREC and
RRCD based on a prior assumption on the marginal prevalence of
confounder (PC) and exposure (PE). The array approach is mathe-
matically similar to the rule‐out approach but estimates the “true”
exposure‐disease association based on APR, RRCD and the preva-
lence of confounder in the exposure group (PC0) and non‐exposure
group (PC1).
Results: For an APR of 2, the E‐value is 3.41, suggesting that smoking
needs to be associated with both aortic aneurysm and fluoroquinolone
with a minimal magnitude of 3.41 (when RREC equals RRCD) to fully
explain a 2‐fold increase of the observed risk. The array approach
found that if smoking increases the risk of aortic aneurysm by at least
7‐fold (high estimate in literature), the smoking prevalence in fluoro-
quinolone users needs to be at least 45%, assuming a smoking rate
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of 15% in the reference group to drive an APR from 2 to null. An in‐
house simulation based on a wide range of PC ‐ PE combinations using
the rule‐out approach found that the required RREC and RRCD by rule‐
out approach were always larger than the E‐value (3.41, when RREC
equals RRCD).
Conclusions: It would require strong associations between smoking
and both aortic aneurysm and fluoroquinolone use to explain away
the observed association between fluoroquinolone and aortic aneu-
rysm. Therefore, it is unlikely that smoking alone would explain the
observed association.
629 | Antidepressant medication, suicidal
behavior and violent crime in a cohort of
Danish patients with affective disorders
Merete Osler1; Marie Wium‐Andersen1; Ida Wium‐Andersen2;
Frederikke Gronemann1; Martin Jørgensen2; Maarten Rozing2
1Center for Clinical Research and Prevention, Frederiksberg, Denmark;
2Psychiatric Center Copenhagen, Copenhagen, Denmark
Background: Initiation of antidepressant medication may increase the
risk of self‐harm and aggressive behavior the weeks after start due to
alleviated psychomotor inhibition preceding the improvement of
mood.
Objectives: To examine the association between initiation of antide-
pressant medication and subsequent suicidal behavior and violent
crime in relation to time since initiation.
Methods: A cohort of 95 794 patients with a first‐time hospital con-
tact for an affective disorder in the Danish National Patient Registry
(DNPR) were followed for purchase of antidepressant medication, sui-
cide, suicide attempts and conviction for violent crime in the Danish
Prescription Registry, Cause of Death Registry, DNPR and the
National Crime Register between 1997 through 2015. Associations
between antidepressant medication and outcomes were analyzed
using Cox proportional hazard regression for the first 28 days, 28 to
365 days and more than 365 days after initiation. Hazard ratios were
adjusted for sociodemographic and clinical variables.
Results: During follow‐up, 73.7% (n = 70 577) of patients initiated
antidepressant medication, 0.8%(n = 798) committed suicide and
6.2%(n = 6101) attempted, while 3.4%(n = 3226) were convicted a vio-
lent crime. Patients, who initiated antidepressant medication had the
same rates of suicide (adjusted hazard ratio 0.86 (0.58 to 1.20), as
patients with no use of antidepressant medication the first 28 days
and the following 28–365 days, while there was a slightly higher risk
after 365 days. Patients who started antidepressant medication had
higher rates of attempted suicide but not the first 28 days of treat-
ment. Antidepressant medication was not associated with violent
crime.
Conclusions: Initiation of antidepressants was not associated with sui-
cidal behaviour or violent crime, when confounding by indication was
reduced by restricting analyses to patients with affective disorders
assumed to be more homogenous with regard to psychatric
comorbidity.
630 | Use of external comparators for health
technology assessment submissions ‐ an
analysis of HTA accelerator
Dony Patel; Fiona Grimson; Elena Mihaylova; Yulia Chan;
Deborah Layton
IQVIA, London, UK
Background: For rare diseases and cancers a high demand exists for
faster access to novel therapies. Patient populations are often limited
in size, making randomized control trials impractical. The number of
approvals through facilitated regulatory pathways supported by sin-
gle‐arm trial (SAT) data is increasing. Absence of direct comparators
poses HTA assessment challenges. External comparators may provide
supporting contextual evidence, however for HTA assessment no for-
mal guidance exists. The aim of this study was to characterize HTA
submissions regarding use of external comparators and submission
success.
Objectives: Quantify and characterize HTA submissions, with a focus
on SATs and external comparators.
Methods: A retrospective descriptive study using a database of pub-
licly available information on HTA submissions (HTA Accelerator)
which covers submissions globally across all therapies 1996–2018
from 100+ agencies in 32 countries. Submissions were selected based
on inclusion of external comparator data. Descriptive statistics sum-
marized submission characteristics and outcomes, qualitative analyses
explored feedback on acceptability of evidence and methodology.
Results: In 16 countries, 165 SAT submissions were identified;
61%(n = 100) for oncology indications. Submissions originated most
frequently from France 25%(n = 41) and UK 18%(n = 30). The fre-
quency increased annually (n = 1 in 2011; n = 49 in 2017). External
comparators were used in 47%(n = 78) of submissions, most often
from prior RCT(45%, n = 35) and observational studies(32%, n = 25).
A positive or positive with restrictions outcome was received for
68%(n = 53) submissions with external comparators vs 55%(n = 35)
without. For submissions with positive outcomes the increased uncer-
tainty of evidence compared to a direct comparator was acceptable if
the evidence was sufficiently strong and aligned with patient values.
For submissions with negative outcomes the low quality of external
comparator evidence and/or use of inappropriate methodology was
highlighted.
Conclusions: This study showed use of external comparator data in
HTA submissions based on SAT has increased over time. Use of such
data is associated with higher submission success. The qualitative
analysis of HTA feedback suggested that it is important to consider
external comparator data in a strategic way and to consider why and
how the comparator is selected and incorporated into the analysis. A
limitation of this study was that not all the data within submission
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packages were publicly available, so the frequency of use of external
comparators may be underestimated.
631 | Assessment of channeling among
initiators of suvorexant compared to other
insomnia drugs
Cathy Anne Pinto1; Praful Kumar2; W. Joseph Herring1;
Johanna Hyacinthe1; Ankita Kumar2; Mani Lakshminarayanan2;
Zhiwen Liu1
1Merck & Co., Inc., Kenilworth, NJ; 2Complete HEOR Solutions Pvt. Ltd.,
North UK, NJ
Background: Channeling bias is a selection bias which may occur
when a newly marketed drug and an established drug, with similar
indications, are prescribed to patients with different prognostic
characteristics.
Objectives: To assess potential channeling of newly marketed
suvorexant compared to other FDA approved insomnia medications
(zolpidem, temazepam, ramelteon, and low dose doxepin) on impor-
tant baseline prognostic factors.
Methods: A new user cohort study was conducted using the Optum
Research Database with patients initiating the insomnia drugs
between January 01, 2015 to September 30, 2017. A look‐
back period of 12 months prior to the index date was used to
describe baseline characteristics using ICD and NCD codes. Baseline
characteristics were summarized using descriptive statistics.
Between‐group differences in baseline characteristics were com-
pared using absolute standardized differences (ASD) with an
ASD ≥ 10% representing a meaningful difference. The ability to bal-
ance important prognostic factors was examined using propensity
score (PS) matching and inverse probability of treatment weighting
(IPTW).
Results: The analysis included a total of 24,450 suvorexant, 438,756
zolpidem, 116,549 temazepam, 9,104 ramelteon, and 1,322 doxepin
new users. Compared with zolpidem, suvorexant users were gener-
ally older (mean [SD] =65.0 [14.7] vs 56.3 [15.5] years, 59% vs
32% ≥65 years, ASD = 57.8%); included a greater proportion of
females (65% vs. 48%, ASD = 15%); with a higher percentage of
comorbidities, most notably ASD ≥ 25% for depression, diabetes,
musculoskeletal pain, arthritis, anxiety, hypothyroidism, hyperlipid-
emia, urinary problems, and prior insomnia drug use (57% vs 6%,
ASD = 134%). Baseline characteristics for new users of suvorexant
were more similar to ramelteon and low dose doxepin. PS matching
and IPTW allowed us to achieve reasonable balance (ASD <10%) in
important prognostic variables.
Conclusions: Channeling of suvorexant to patients with different
prognostic characteristics was observed, most notably in comparison
with zolpidem. In this analysis, PS matching and IPTW allowed us to
achieve reasonable balance in important measured covariates. The
observed channeling and ability to achieve balance in measured
covariates is an important consideration for future comparative
effectiveness and safety studies of suvorexant and other sleep
hypnotics.
632 | Lurking Berkson's bias in
pharmacoepidemiology: Tales of colliders
Nicole M. Bailey; Andy R. Wilson; Aaron W.C. Kamauu
PAREXEL, LLC, Salt Lake City, UT
Background: Pharmacoepidemiology has made enormous strides in
the last decade due to adoption of causal modeling and new methods
in biostatistics, allowing for novel discoveries and associations among
exposures and outcomes of life‐threatening diseases. However, when
exploring new avenues of association context is often lost, which can
introduce spurious associations between pairs of variables when one
is conditioned (by design or analysis) on a common effect of a pair
of variables. This is due to selection bias, and is often referred to as
collider bias, or Berkson's bias.
Objectives: The objective of this study was to explore possible collider
biases in data from a survey used to identify self‐reported HPV vac-
cine uptake, as well as attitudes about the vaccine among 18–26 year
old women.
Methods: A survey including questions about health, vaccine atti-
tudes, demographics and HPV vaccine series initiation and completion
was distributed to women age 18–26 in Utah. 327 surveys were
included in the analysis.
Directed acyclic graphs (DAGs) were used to identify potential sets of
variables that can become correlated (d‐connected) after adjusting on
a potential collider. Generalized linear models were used to test rela-
tionships between variables. The structural model considered was
whether attitudes about vaccines (e.g., vaccines are a good way to
protect public health) and age commonly cause vaccine initiation and
would become d‐connected after conditioning on initiation.
Results: There was a significant relationship between belief that vac-
cines are a good way to protect the public health and vaccine initi-
ation (p = 0.00367) as well as age and initiation (p = 0.00237).
Furthermore, there was no relationship between age and belief vac-
cines are good for public health in the overall cohort (p = 0.281).
However, after restricting analysis to the subset of participants
who had initiated the vaccine series, age and belief about vaccines
for public health became significantly associated (p = 0.0402). This
would imply vaccine initiation is a potential collider or introduces
collider‐stratification bias, i.e., age is not independent of vaccine
belief given vaccine initiation.
Conclusions: Recognizing the significance of context in
pharmacoepidemiology is vital. Conditioning on a collider can lead to
seemingly paradoxical findings that can have an enormous impact on
how we view and design research in the healthcare setting. Without
recognizing this, precious resources can be allocated in the wrong
direction due to spurious associations among otherwise independent
variables, creating delays in true discoveries, treatment and cures
where time is of the essence.
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633 | Analytic and design approaches to
unmeasured confounding by body mass index
Tracy L. Kinsey; Til Stürmer; Michele Jonsson Funk; Charles Poole;
Ross J. Simpson; Jr; Robert J. Glynn
University of North Carolina, Chapel Hill, NC
Background: Body mass index (BMI), often an important confounder,
is unavailable in insurance claims data and its accurate prediction is
difficult. There is increasing interest in internal validation via
linkage to electronic health records (EHR) systems to augment claims
data.
Objectives: To describe confounding of the association of NSAIDs ini-
tiation and venous thromboembolism (VTE) by BMI in a cohort study
of U.S. women, and explore approaches to control confounding by
mimicking a claims data analyses with BMI data available from an
internal EHR validation study.
Methods: We identified new use of NSAIDs (exclusive of aspirin and
coxibs) and incident VTE (deep vein thrombosis or pulmonary embo-
lism) among 39,876 participants of the Women's Health Study
(WHS) followed from 1993–2011 with annual questionnaires. We
defined NSAID initiation as the first reported use for ≥4 days of the
past month and counted only VTE events confirmed by an endpoint
committee. We designed as‐treated analyses comparing NSAIDs ini-
tiation with non‐initiation (NIC) and acetaminophen initation (AIC)
comparators. The unit of analysis was the questionnaire. At‐risk fol-
low‐up periods began on the questionnaire date. Follow‐up was cen-
sored on the earliest of the first reported treatment change or
5 years after each eligible index date. Propensity scores incorporat-
ing age, BMI, comorbidities, concurrent medication use, and interac-
tion with calendar time were estimated and implemented by
standardized morbidity ratio weighting. We estimated hazard ratios
(HR) with 95% confidence intervals (CI) using Cox proportional haz-
ard models with a robust variance. We describe confounding by BMI
in the NIC and AIC analyses and examine the performance of multi-
ple imputation (MI) of BMI using 10% and 50% internal validation
samples under scenarios of missing completely at random (MCAR)
and 1.5 and 3.0‐fold increased probabilities of missingness for nor-
mal BMI values (18.5‐ < 25 kg/m2).
Results: HRs (95% CI) for NIC and AIC analyses were, crude:
HRNIC = 1.33 (1.06, 1.66) and HRAIC = 1.03 (0.65, 1.65), and fully
adjusted: HRNIC = 1.29 (1.03, 1.62) and HRAIC = 0.87 (0.53, 1.44).
Adjusted HRs changed +5% (HRNIC = 1.36) and + 2% (HRAIC = 0.89)
with omission of BMI. Prediction models for BMI yielded R2 = 0.15.
Fully adjusted HRs from MI ranged 1.28–1.31.
Conclusions: MI approaches show potential for confounding control
with internal validation data despite suboptimal prediction, but resam-
pling is needed to describe the sampling distributions. Availability of
BMI, an important confounder, had less impact on the treatment esti-
mate than use of an active comparator.
634 | Multiple risk factor control and risk of
cardiovascular events and mortality in people
with type 2 diabetes in the UK
Alison K. Wright1; Fabian Suarez Ortegon2; Jeremy Walker2;
Evangelos Kontopantelis1; Iain Buchan3; Richard Emsley4;
Naveed Sattar5; Darren M. Ashcroft1; Sarah Wild2; Martin K. Rutter1,6
1University of Manchester, Manchester, UK; 2University of Edinburgh,
Edinburgh, UK; 3University of Liverpool, Liverpool, UK; 4King's College
London, London, UK; 5University of Glasgow, Glasgow, UK; 6Manchester
University NHS Foundation Trust, Manchester, UK
Background: Control of multiple cardiovascular risk factors among
people with type 2 diabetes (T2DM) improves outcomes in trial set-
tings but whether this relationship between simultaneous achieve-
ment of risk factor targets and cardiovascular (CVD) risk exists in
routine clinical practice is not well established.
Objectives: Our aim was to describe the association between control
of five key modifiable risk factors and risk of CVD in people with type
2 diabetes in contemporary clinical practice.
Methods: We used electronic health records from the Clinical Prac-
tice Research Datalink (CPRD) in England and SCI‐Diabetes in Scot-
land, to identify people with T2DM during years 2006–2015. Patient
profiles for HbA1c (≥7.0% /53 mmol/mol), systolic blood pressure
(>140 mmHg), total cholesterol (>4 mmol/L), triglyceride
(>1.7 mmol/L), and current smoking status were determined at the
index date for study entry. Missing data on risk factors were multi-
ply imputed. Cox models estimated adjusted hazard ratios (HRs) for
incident or recurrent major CVD events (fatal or non‐fatal coronary
heart disease or stroke) associated with the number of risk factors
above thresholds. Risk estimates were meta‐analyzed across the 2
databases.
Results: During the study period, 27,900 (27.4%) of 101,749 T2DM
patients in CPRD and 101,362 (30.6%) of 330,892 T2DM patients in
SCI‐Diabetes experienced one or more CVD events. CVD risk
increased for each additional risk factor above recommended targets.
Compared to all risk factors at target, those with 5 risk factors above
target had pooled adjusted HRs of 1.40 (95% CI 1.33–1.47) for
overall CVD events, 1.25 (1.18–1.32) for non‐fatal CHD, 2.30
(2.02–2.63) for non‐fatal stroke, 1.46 (1.31–1.63) for heart failure
hospitalization, 1.43 (1.35–1.52) for CVD morality, 1.84 (1.60–2.11)
for CHD mortality and 1.80 (1.33–2.43) for stroke mortality. In
patients defined as at low risk for CVD (no history of CVD or
CKD‐stages 4/5), the association with risk factor control was
greater, with a two‐fold increase in risk for total CVD events (HR
1.96; 95% CI 1.82–2.12) and CVD mortality (HR 2.27; 95% CI
1.85–2.79) with 5 risk factors above targets compared to all risk fac-
tors at target. In those defined as at high risk of CVD, overall there
was a weak association with the number of risk factors above target
and risk of CVD events.
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Conclusions: Every additional risk factor above recommended targets
increased cardiovascular event risk. There is considerable scope to
improve CVD risk factor control in people withT2DM, especially those
at low risk of CVD.
635 | Evaluation of confounding by smoking
and obesity in a study of pancreatic and
thyroid cancer incidences in patients treated
with exenatide, an administrative healthcare
database investigation supplemented with
medical records
Caihua Liang1; Monica L. Bertoia1; C. Robin Clifford1; Yan Ding1;
Qing Qiao2; Joshua J. Gagne1,3,4; David D. Dore1,5
1Optum Epidemiology, Boston, MA; 2Medical Evidence and
Observational Research, AstraZeneca, Gothenburg, Sweden; 3Division of
Pharmacoepidemiology and Pharmacoeconomics, Department of
Medicine, Brigham and Women's Hospital and Harvard Medical School,
Boston, MA; 4Department of Epidemiology, Harvard T.H. Chan School of
Public Health, Boston, MA; 5Department of Health Services, Policy &
Practice, Brown University School of Public Health, Providence, RI
Background: Residual confounding by unmeasured or poorly captured
factors, such as smoking and obesity, is an important concern in stud-
ies using administrative healthcare databases. Sensitivity analyses to
estimate the extent of confounding required to fully explain the
observed findings are necessary.
Objectives: To estimate the impact of confounding by smoking and
obesity on the observed findings of exenatide use and pancreatic
and thyroid cancers using information abstracted from medical
records.
Methods: We applied the rule‐out approach presented by
Schneeweiss to explore the extent to which residual confounding
could explain the observed findings relating to exenatide use and pan-
creatic and thyroid cancers in a propensity‐score matched cohort
study of patients with diabetes. We abstracted information on
smoking and obesity from medical records within a subset of patients
included in a nested case–control study. We projected a wide range of
magnitudes of association between smoking or obesity and each can-
cer (RR confounder‐disease (CD)) and between exenatide and smoking or
obesity (OR exposure‐confounder (EC)) based on the information abstracted
from medical records and the literature. The impact of confounding by
smoking and obesity were quantified to demonstrate how strong the
OREC and RRCD must be to fully explain the observed findings (the
apparent relative risk [ARR]).
Results: The originally observed findings of ARR from the claims‐
based cohort study were 0.76 (95% confidence interval [CI]: 0.47–
1.21) for exenatide use and pancreatic cancer and 1.46 (95% CI:
0.98–2.19) for exenatide use and thyroid cancer. From the medical
records, the observed prevalence of smoking was 21% and obesity
75%; the observed OREC was 0.26 for exenatide and smoking and
2.65 for exenatide and obesity. In the literature the observed RRCD
was 1.7 for smoking and pancreatic cancer and 2.08 for obesity and
pancreatic cancer; RRCD was 0.75 for smoking and thyroid cancer
and 1.50 for obesity and thyroid cancer. The analyses show that the
OREC and RRCD for smoking or obesity would have to be much stron-
ger than the observed OREC and RRCD in order to fully explain the
observed ARR between exenatide use and pancreatic and thyroid
cancers.
Conclusions: It is unlikely that residual confounding by smoking or
obesity alone explains the original findings between exenatide use
and pancreatic and thyroid cancers.
636 | Using different look back periods to
calculate the Charlson comorbidity index
(CCI) in NVAF patients treated with oral
anticoagulants (OACs)
Sophie Graham1; Anna Schultze1; Beth Nordstrom2; Faisal Mehmud3;
Sreeram Ramagopalan3
1Evidera, London, UK; 2Evidera, Waltham, MA; 3Bristol Myers‐Squibb,
London, UK
Background: The definition of look back windows can influence the
estimated prevalence of chronic conditions.
Objectives: We investigated how different look back periods influ-
enced estimates of the prevalence of comorbidities included in and
estimates of the Charlson Comorbidity Index (CCI) in non‐valvular
atrial fibrillation (NVAF) patients receiving oral anticoagulants (OACs).
Methods: Adults with NVAF in the UK newly initiating warfarin,
apixaban or rivaroxaban (index date) between 2012 and 2017 were
identified from linked primary (Clinical Practice Research Datalink)
and secondary care (Hospital Episode Statistics) data. The look back
period used for identifying comorbidities was defined as ever (all avail-
able data), 3 years and 1 year prior to index date. CCI scores were esti-
mated using previously published methods and described using
number and proportions.
Results: A total of 15,860 patients were identified, which included
56.6% warfarin, 17.1% apixaban and 26.3% rivaroxaban users. The
prevalence of all comorbidities was higher when using the ever look
back period compared to 1 and 3‐year periods. The largest differences
were observed for renal disease, where the prevalence increased from
12.1% to 18.5% and 28.8% for a 1‐year, 3‐year and ever look back
period for all treatment groups. The second largest difference was
for malignancies, which increased from 4.8% to 7.7% and 17.0%,
respectively. Using a 1‐year look back period, 44.1% of users had a
CCI score greater than 0; the equivalent estimates were 53.5% using
a 3‐year lookback and 65.9% using an ever look back period.
Conclusions: These data emphasize the importance of considering all
available data when constructing look back windows to estimate the
prevalence of chronic conditions, and highlights the high prevalence
of renal disease in NVAF patients initiating treatment. Further
research is needed to determine the impact of varying look backs on
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consequent ability to control for confounding in comparative studies
of treatment effectiveness and safety.
637 | Missing the trees for the forest plots:
Where subgroups fall short
Michael Webster‐Clark; Daniel Westreich; John A. Baron;
Michele Jonsson‐Funk
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Interest in precision medicine and application of random-
ized trials to external populations are topics of increasing interest.
Subgroup analyses, forest plots, and outcome models examining mar-
ginal interaction have been used to indicate if drugs perform better or
worse in some patients, but many are reluctant to draw conclusions
from them due to concerns regarding chance findings. Less attention
has been paid to causal relationships that render marginal estimates
of effect measure modification (EMM) from subgroup analyses
misleading.
Objectives: Evaluate potential for bias in estimates of treatment effect
modification by subgroups related to study eligibility.
Methods: We posited a source population described by two inde-
pendent binary variables: M and N. Individuals with at least one of
M or N = 1 were eligible for a randomized controlled trial of treat-
ment X on risk of outcome event Y (risk = 0.10 when X = 0). In
the base population, M caused EMM of X while N did not: in
patients with M = 0, X doubled risk of Y, while in patients with
M = 1, X tripled risk of Y. We varied prevalence of M and N in
the source population between 25%, 50%, and 75%. M and N were
used as stratification variables for crude subgroup analyses and cal-
culation of the ratio of risk ratios (RRR) between the strata. We also
conducted regression analyses including terms for X, M, N, and
interaction terms for both M and N.
Results: Distortion in M and N's modification of X's treatment effect
was consistent and calculable. Subgroup estimates of the M interac-
tion term were unbiased with a RRR of 1.5 comparing stratum
M = 1 to M = 0 regardless of M or N prevalence. While N did
not modify the effect of X in the source population, analyses of
EMM by N comparing stratum N = 1 to N = 0 indicated RRRs of
0.75, 0.83, and 0.92 when the prevalence of M in the source popu-
lation was 25%, 50%, and 75% respectively; the prevalence of N
was irrelevant. This problem persisted with risk differences, if M
and N both caused EMM, and if M and N were associated with
increased sampling probability rather than inclusion criteria. Multi-
variable regression, however, generally produced accurate estimates
of EMM by M and N.
Conclusions: If M is a modifier, requiring M or N for study eligibility
distorts estimates of EMM by N: stratum N = 0 all have M = 1 while
stratum N = 1 inherits the source population's distribution of M. Asso-
ciations between modifiers and trial selection can result in misleading
estimates of treatment effect heterogeneity. Investigators should be
wary of using simple forest plots and instead take into account
multiple variables when evaluating potential effect heterogeneity,
even when treatment has been randomized.
638 | Post‐surgery infection and subsequent
mortality among hip fracture surgery patients:
Different methods for dealing with time‐
varying confounding in a Danish population
based cohort study, 2004–2016
Nickolaj R. Kristensen1; George Luta2,1; Lars Pedersen1;
Vera Ehrenstein1; Alma B. Pedersen1
1Aarhus University Hospital, Aarhus N, Denmark; 2Georgetown
University Medical Center, Washington, DC
Background: Complications and comorbidities affecting mortality,
such as heart diseases and infections, are common after hip fracture
surgery. Thus, when estimating the causal effect of infection on subse-
quent mortality, adjustment for baseline confounders alone may be
insufficient.
Objectives: We compared different methods of handling time‐varying
exposure and confounding when estimating the effect of having a
post‐surgery hospital‐treated infection on 1‐year mortality in hip frac-
ture patients.
Methods: In this nationwide cohort study using data from Danish
registries, we included patients aged ≥65 years with a first‐time
hip fracture surgery in 2004–2016. Patients were classified as
exposed after they had a record of a hospital‐treated infection
within 1‐year after the surgery. With infection as a time‐varying
exposure, we calculated adjusted hazard ratios (aHR) for 1‐year mor-
tality with 95% confidence intervals (CI) using 1) Cox regression with
baseline confounders only, 2) Cox regression with time‐varying con-
founders, and 3) marginal structural models (MSM). Among the con-
founders were comorbidities and medications at baseline and during
follow‐up as time‐dependent covariates.
Results: We included 81,704 patients with hip fracture surgery of
whom 22,023 (27%) had a hospital‐treated infection within 1 year
after the surgery, including pneumonia (9,327 patients, 11%). The
crude mortality rates per 100 person years among patients with and
without infections were 69 and 29, respectively. The corresponding
estimates for patients with and without pneumonia were 111 and
31. The aHRs for mortality for any infection (yes vs. no) were 2.71
(CI 2.64–2.79) when adjusting for baseline variables only, 2.55 (CI
2.48–2.63) after additionally adjusting for time‐varying confounders,
and 2.44 (CI 2.36–2.52) when using MSM. For pneumonia (yes vs.
no), the aHRs corresponding to the three approaches were 3.51 (CI
3.39–3.63), 3.20 (CI 3.09–3.31), and 3.33 (CI 3.19–3.47), respectively.
Conclusions: Having a hospital‐treated infection, particularly pneumo-
nia, yielded an increased risk of 1‐year mortality after hip fracture sur-
gery. The aHRs were attenuated when accounting for time‐varying
confounding, supporting the notion that adjustment for baseline con-
founders alone may yield a biased estimate of the causal effect of
infection on mortality in this setting.
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639 | Indication bias in the study of
comparative effectiveness of direct oral
anticoagulants in the prevention of stroke
Lamiae Grimaldi‐Bensouda1,2; Jean Ferrières3,4; Didier Leys5,6;
Jean‐Marc Davy7,8; Mikel Martinez9; Nicolas Morisot10;
Pegdwende O. Dialla10; Didier Smadja11; Norbert Nighoghossian12,13;
Jacques Bénichou14,15; Clémentine Nordon10,16;
Emmanuel Touzé17,18; Lucien Abenhaim19,20
1University of Versailles Saint‐Quentin en Yvelines, Versailles, France;
2Ambroise Pare Hospital, Boulogne‐Billancourt, France; 3Rangueil
Hospital, Toulouse, France; 4Toulouse University School of Medicine and
INSERM UMR 1027, Toulouse, France; 5Lille University Hospital, Lille,
France; 6 INSERM U1171, Lille, France; 7Arnaud De Villeneuve Hospital,
Montpellier, France; 8U1046 INSERM/UMR9214 CNRS University of
Montpellier, Montpellier, France; 9Dax hospital, Dax, France; 10Laser
Core, Paris, France; 11Sud‐Francilien Hospital Centre, Corbeil‐Essonnes,
France; 12Pierre Wertheimer Hospital, Bron, France; 13 INSERM U1206/
CNRS UMR 5220, Lyon, France; 14University Hospital of Rouen, Rouen,
France; 15 INSERM U1219, Rouen, France; 16Maison Blanche Public
Hospital, Paris, France; 17Caen Normandie University Hospital, Caen,
France; 18 INSERM U1237, Caen, France; 19LA Risk Research, London,
UK; 20London School of Hygiene & Tropical Medicine, London, UK
Background: Oral anticoagulants are indicated for the prevention of
stroke in patients with atrial fibrillation. Observational studies compar-
ing the effectiveness of individual OACs have poorly documented and
controlled for sources of indication bias.
Objectives: To assess the preventive effect of individual DOACs on
stroke as compared to VKAs according to the type of atrial fibrillation.
Methods: From two national registries, patients with previous history
of atrial fibrillation and with or without a first‐ever incident stroke
were selected. Atrial fibrillation was confirmed with an EKG as non‐
valvular (NVAF) and stratified according to (i) type of NVAF ([paroxys-
mal and persistent] or permanent) and (ii) incident (<1 year) or preva-
lent NVAF (1–5 years; >5 years). Stroke and non‐stroke patients
were matched on index date, age and gender. VKAs and dabigatran,
rivaroxaban or apixaban use before index date and association with
stroke was studied in different NVAF strata using multivariable condi-
tional logistic models, controlled for clinically significant confounding
factors (liver or renal impairment, cardiovascular history, other risk
factors).
Results: 2586 stroke cases with NVAF history were matched to 4810
randomly selected non‐stroke patients with NVAF history. An inverted
U‐shape association for the duration of the NVAF and stroke was
observed (OR = 0.53 95%CI[0.45–0.62] for incident NVAF, OR = 1
for mid‐duration prevalent NVAF and OR = 0.58 95%CI[0.51–0.67]
for long‐term prevalent NVAF; the OR for permanent NVAF and stoke
as compared to paroxysmal and persistent NVAF was 2.35
95%CI[2.02–2.73]). Sources of indication bias occurred as VKAs and
each individual DOAC displayed very different patterns of use accord-
ing to the type and history of atrial fibrillation. In incident NVAF,
dabigatran, rivaroxaban and apixaban had an overall OR for stroke of
respectively 0.53 95%CI[0.24–1.13], 0.61 95%CI[0.36–1.02] and
0.32 95%CI[0.17–0.60] when compared to VKAs while they were
respectively 0.54 95%CI[0.33–0.89], 0.78 95%CI[0.54–1.13] and
1.13 95%CI[0.64–1.98] in mi‐duration prevalent NVAF (or similar
ORs in long‐term prevalent NVAF). No difference between these
NOACs compared to VKAs was observed in permanent vs paroxysmal
and persistent AF (all point OR in the vicinity of 0.6 in both strata).
Conclusions: Studies concluding on a relative beneficial effect of some
individual NVAF as compared to others without stratifying for indica-
tion should be interpreted with caution particularly in view of the
observed U‐shape risk relation/effect modification for history of AF.
640 | Challenges in conducting a
multinational European study of severe
hypersensitivity reactions among recipients
of intravenous iron
Lia Gutierrez1; Irene D. Bezemer2; Jochen Dress3; Vera Ehrenstein4;
Michael Forstner5; Carla Franzoni1; Regis Lassalle6; Marie Linder7;
Cecile Droz‐Perroteau6; Ingvild Odsbu7; Jetty A. Overbeek2;
Susana Perez‐Gutthann1; Federica Edith Pisa8; Katherine Rascher9;
Lawrence Rasouliyan1; Jonas Reinold8; Kenneth Rothman10;
Nuria Saigi‐Morgui1; Mathias Schaller9; Elisabeth Smits2;
Antje Timmer11; Gunnar Toft4; Gero von Gersdorff9; Joan Fortuny1
1RTI‐HS, Barcelona, Spain; 2PHARMO Institute for Drug Outcomes
Research, Utrecht, Netherlands; 3 Information system for health care data
(data transparency), DIMDI, Cologne, Germany; 4Aarhus University
Hospital, Aarhus, Denmark; 5PrimeVigilance, Guildford, UK; 6Bordeaux
PharmacoEpi, INSERM CIC1401, University of Bordeaux, Bordeaux,
France; 7Centre for Pharmacoepidemiology, Karolinska Institutet,
Stockholm, Sweden; 8Clinical Epidemiology, Leibniz Institute for
Prevention Research and Epidemiology ‐ BIPS, Bremen, Germany;
9Department II of Internal Medicine – QiN‐group, University of Cologne,
Faculty of Medicine and University Hospital Cologne, Cologne, Germany;
10RTI‐HS, Waltham, MA; 11Carl von Ossietzky Universität Oldenburg,
Oldenburg, Germany
Background: Severe hypersensitivity reactions (SHRs) in intravenous
(IV) iron treatment are a known but rare, and therefore poorly charac-
terized, safety concern. A regulatory‐mandated postauthorization
safety study (PASS) with multiple sponsors will assess the risk of SHRs
in IV iron users in Europe. A multidatabase study approach is required
to evaluate this rare safety outcome. Results will be available in 2020.
Objectives: To describe cohort attrition of IV iron users and challenges
encountered in conducting this PASS.
Methods: Cohorts of new and prevalent adult IV iron users with at least
12 months of available information were identified from seven data
sources in five countries: Denmark (national and regional registers),
France (SNDS), Germany (GePaRD, QiN, DIMDI‐DaTraV), the Nether-
lands (PHARMO), and Sweden (national registers). The algorithms used
to identify SHRs rely both on diagnostic codes and markers of SHRs
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(e.g., symptoms and treatments). A cohort of IV penicillin users was
identified, where feasible, to assess the performance of the algorithm.
Code lists for the algorithm and covariateswere harmonized across data
sources. Validation of cases through source record review is planned in
Denmark and the Netherlands. Indirect external validation of the SHR
algorithm will be conducted in the Oldenburg University Hospital in
Germany. Data source‐specific analyses and pooled analysis of aggre-
gate data will follow a common protocol.
Results: Heterogeneity in the data available across data sources was
addressed through collaborative work across all research centers.
Drug exposure is captured through prescription, dispensing, or admin-
istration records from hospital or outpatient settings, thus requiring
tailored definitions of “time at risk” windows. As of January 2019,
based on data from three data sources after cohort attrition, approxi-
mately 180,000 IV iron users with a first use, 102,000 IV iron users
with a second use, and 80,000 IV iron users with a third or subsequent
use were eligible for the study. The IV iron cohort sizes vary greatly
across data sources and countries. Data for all IV iron types are not
captured in any single data source.
Conclusions: Initial data suggest sizeable numbers of IV iron users.
However, the informativeness of results for individual drugs will
depend on the relative use of each IV iron subtype and the frequency
of SHRs. Understanding the commonalities and differences of the data
available in the collaborating centers and standardizing data defini-
tions are critical to conducting a multidatabase study.
641 | Bias reduction with multiple
imputation of lab results from a limited
internal sample
Tiansheng Wang1; Magdalene M. Assimon2; Virginia Pate1;
Emily W. Gower1; Jennifer L. Lund1; Michele L. Jonsson‐Funk1;
Michele L. Jonsson‐Funk1; John B. Buse2; Til Stürmer1
1University of North Carolina Gillings School of Global Public Health,
Chapel Hill, NC; 2University of North Carolina School of Medicine, Chapel
Hill, NC
Background: Trials suggest that GLP1 receptor analogues (GLP), a
class of injectable antidiabetics, may increase retinopathy risk.
Assessing drug safety in MarketScan data offers opportunities to
examine this signal but presents challenges due to the lack of clinical
detail. Lab results, e.g. Hemoglobin A1c (HbA1c), which may improve
confounding control, are only available for a fraction of enrollees.
Objectives: To evaluate if multiple imputation (MI) of lab results in an
internal validation study could further balance cohorts for diabetes
severity when assessing whether GLP increases diabetic retinopathy
(DR) risk compared with long acting insulin (LAI), a drug usually
reserved for more severe diabetes.
Methods:UsingMarketScandata2007–2015,weidentifiedGLPandLAI
new‐userswhowere < 65 years of age.We excluded patientswith a his-
tory of blindness, low vision, or retinopathy therapy. We defined DR as
having a claim for photocoagulation, intravitreal injection, or vitrectomy
plus ≥1 DR or diabetes diagnosis code on the same day. We identified
baseline lab values (HbA1c, GFR, HDL, LDL, triglycerides) in the 30 days
prior to the index date. GFR was based on serum creatinine andMDRD
formula (not including race) for those with GFR = 0 (14% of values). We
set implausible lab values tomissing.We then usedMI using fully condi-
tional specification regression in arbitrary missing pattern to impute lab
values. We used propensity scores (PS) to evaluate the balance of mea-
sured and imputed confounders. We estimated adjusted hazard ratios
(aHR) and95%CI using inverse probability treatmentweightedCoxpro-
portional hazardsmodels censoring for treatment changes.
Results:Labvalueswere available for ~6%ofGLP (1896/31599) andLAI
(3643/60723). BeforeMI,HbA1c levelwas 7.6% inGLPand8.4% in LAI.
The imputed mean HbA1c levels were virtually identical. After PS
weighting, HbA1c level was 7.6% for both GLP and LAI. The crude rates
of DR/1,000 person‐years were 10 in GLP and 29 in LAI over a median
duration of 0.64 and 0.58 years, respectively. Comparing GLP to LAI,
the crude HR was 0.34 (0.30–0.39), the aHR ignoring lab values was
0.46 (0.40–0.53). After adjustment for imputed lab measures, the aHR
was 0.55 (0.45–0.67).
Conclusions: Using MI to leverage lab data on a fraction of the cohort
movedtheaHRtowardsthenull.Residualconfounding is likelyasbalance
of imputed value does not achieve full confounding control, since the
imputed values do not capture the full risk associatedwithHbA1c. Iden-
tifying comparatordrug classesused for similar disease severity,may still
be themost robust approach to implicitly control for diabetes severity.
642 | Comparison of new user definitions in
multi‐specialty EMR data
Jeffrey Curtis1; Lang Chen1; James Oates2; Cassie Clinton1;
Fenglong Xie1; Shuo Yang1; Tim Beukelman1
1University of Alabama at Birmingham, Birmingham, AL; 2Medical
University of South Carolina, Charleston, SC
Background: New user designs are typically preferred in
pharmacoepidemiology to avoid bias.
Objectives: The optimal implementation of a new user design in elec-
tronic medical record (EMR) data, where the concept of ‘enrollment’
does not exist, has not been well studied.
Methods:We used data from PCORnet, a large U.S. comparative effec-
tiveness research network consisting of multiple EMR data sources, to
compare various new user definitions, with rheumatoid arthritis (RA)
as an exemplar use case. The first prescription appearing in the data
for RA medications of interest (methotrexate [MTX], a biologic, or
targeted therapy [i.e. tofacitinib]) was identified in the EMR prescribing
data and defined as the index date. Five new user definitions with vary-
ing requirements for the type of prior EMR data needed to construct a
‘baseline’ period were evaluated. New user definitions tested included
0) no requirement for any prior data; 1) >6m from first medical inpatient
or outpatient medical encounter of any type; 2) >6 months from first
prescription for any medication; 3) > 6 months from first medical
encounter for RA (ICD9:714.*; ICD10:M05.*, M06.*); 4) >6 months
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from first prescription for any RA therapy (biologics, targeted therapy,
or conventional DMARD includingHCQ, SSZ, LEF). The rate of hospital-
ized infection according to new user definition was examined.
Results: A total of 6621 RA patients initiated one of 9 unique
DMARDS, biologics or targeted medications. Mean (SD) age was
55(16) years, 78% women, 43% MTX, 38% TNFi biologics; 19% non‐
TNFi therapy, 38% oral glucocorticoids. The distribution of time from
the first medical encounter to the index date for the first RA medica-
tion was a median (IQR) of 1428 (590,2704) days for definition 1,
appreciably longer than for definition 4 (median 1178 days; IQR:
581–2068). The proportion of patients that would be classified as
new users across the five definitions was: 100% (base case, 1st Rx is
index date with no prior data required), 83% (>6 m from first visit),
57% (>6 m from first Rx of any type), 71% (>6 m from first RA visit),
and 29% (>6 m from first RA drug), respectively. The overall rate of
serious infections in the first 6 months after initiation was 2.8/100
patient years; ongoing work is evaluating how infection rates vary
across the 5 new user definitions.
Conclusions: A range of tradeoffs exist in how to best apply new user
definitions to multi‐specialty EMR data. These design features can
misclassify new medication use and result in high variability in sample
size, patient characteristics, and outcomes. More rigorous and specific
definitions are likely preferred for most pharmacoepidemiology stud-
ies to avoid bias.
643 | A simple method to find applicable
lengths of washout periods for identifying
new users in pharmacoepidemiologic study
Nai‐Yu Chen1,2; Chien‐Chou Su2; Edward Chia‐Cheng Lai2
1Department of Pharmacy, Kaohsiung Veterans General Hospital,
Kaohsiung, Taiwan; 2 Institute of Clinical Pharmacy and Pharmaceutical
Sciences, College of Medicine, National Cheng Kung University, Tainan,
Taiwan
Background:New‐user design can exempt from potential selection bias
and therefore serves as standard approach in pharmacoepidemiologic
study. However, appropriate lengths for washout period to identify
new users vary among studies.
Objectives: We proposed a method to test the rate of prevalent users
to find applicable lengths of washout period for identifying new users
of medications.
Methods: We used Longitudinal Health Insurance Database which
included a random sample of 1 million Taiwanese population from
2003 to 2013.We included four study cohorts with patients receiving
antidiabetic, antihypertensive, lipid lowering agents and antipsy-
chotics, respectively, during study period. We assumed those without
a record of specific cohort medications for 10 years washout period
were incident users. We adopted different lengths of washout period
from 0 to 10 years and examined corresponding rate of residual prev-
alent users we included. We defined 10% or less as acceptable rate for
residual prevalent users.
Results: We included 60343, 185067, 73715, and 55602 users of
antidiabetic, antihypertensive, lipid lowering agents and antipsy-
chotics, respectively. We identified 6009, 16573, 11288, 17545 inci-
dent users of antidiabetic, antihypertensive, lipid lowering agents
and antipsychotics, respectively, by 10 years washout period. While
1‐year washout period was implemented, we included 4.6%, 12%,
13.8%, and 44.2% residual prevalent users of antidiabetic, antihyper-
tensive, lipid lowering agents and antipsychotics. We found it required
0.94, 1.5, 1.8 and 5.7 years washout periods to include less than 10%
of prevalent users in the antidiabetic, antihypertensive, lipid lowering
agents and antipsychotic cohorts, respectively.
Conclusions: The findings indicated the applicable lengths of washout
period various in medications. We suggest investigators to use this
simple method and trade‐off between simple size and validity issues,
to find applicable lengths of washout period while designing a
pharmacoepidemiologic study.
644 | Impact of non‐adjustment for smoking
status during pregnancy and pre‐pregnancy
obesity on the association between
gestational antidepressant use and risk of low
birth weight infants
Jin‐Ping Zhao1; Odile Sheehy1; Anick Berard1,2
1CHU Sainte‐Justiona, Montreal, QC, Canada; 2Faculty of Pharmacy,
University of Montreal, Montreal, QC, Canada
Background: Use of antidepressants during pregnancy has been asso-
ciated with increased risk of low birth weight in claim database stud-
ies. However, such results may be confounded by maternal smoking
status during pregnancy and pre‐pregnancy obesity for which no
information is generally available in administrative databases.
Objectives: To estimate the degree of bias introduced by the non‐
adjustment for smoking status during pregnancy and pre‐pregnancy
obesity in the association between gestational antidepressant use
and the risk of low birth weight infants.
Methods: We identified a subgroup of women from the Quebec Preg-
nancy Cohort (QPC) who had delivered a singleton live birth, and
answered a self‐administered questionnaire on family history and life-
styles during pregnancy. We linked the questionnaire data to the QPC
data using the unique personal identifiers. We first estimated the asso-
ciation between antidepressant use during pregnancy and the risk of
low birth weight infant without adjusting for smoking and pre‐preg-
nancy obesity. We then calculated the association while adjusting for
smoking and maternal pre‐pregnancy weight. We finally calculated the
percent bias induced by the lack of information on smoking and pre‐
pregnancy obesity in the QPC estimates using Schneeweiss' method.
Results: Among 3,192 participants, 460 (14.4%) used antidepressants
during pregnancy. Antidepressant users were more likely to be
smokers (47.1% vs. 33.3%), and had higher prevalence of pre‐preg-
nancy obesity (14.2% vs. 10.8%) than non‐users. Overall, the crude
estimate for the association between antidepressant use during
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pregnancy and the risk of low birth weight was 1.74 (95%CI 1.5–2.0;
p < 0.01). Adjusting for smoking status resulted in an estimate of
1.18 (p > 0.05), and for maternal pre‐pregnancy weight, 1.00
(p > 0.05). The percent bias introduced by the non‐adjustment for
smoking and maternal pre‐pregnancy obesity using only the QPC data
was 6.24%, which did not change the direction of the effect.
Conclusions: Lack of adjustment for smoking and maternal pre‐preg-
nancy obesity led to a small overestimation (6.24%) of the association
between gestational antidepressant use and the risk of low birth
weight infants, but the direction of the association was unaffected.
Given that studies performed on cohorts such as the QPC usually
adjust for proxies of missing data, such as physician visits, hospitaliza-
tions, of maternal comorbidities, the percent bias is expected to be
even lower, which is reassuring.
645 | Case validation of cutaneous
lymphoma to minimize protopathic bias
Lia Gutierrez1; Helen Booth2; Daniel Dedman2; Elizabeth Crellin2;
James A. Kaye3; Carla Franzoni1; Alejandro Arana1;
Marcus Schmitt‐Egenolf4; Anders Sundström5; Camilla Byström5
1RTI‐HS, Barcelona, Spain; 2Medicines and Healthcare products
Regulatory Agency, London, UK; 3RTI‐HS, Waltham, MA; 4Umeå
University, Umeå, Sweden; 5CPE, Karolinska Institutet, Stockholm,
Sweden
Background: Protopathic bias (PB) occurs when a drug is prescribed
for initial signs/symptoms of an outcome not yet diagnosed, reflecting
a reversal of cause and effect. PB may be of particular concern when
studying outcomes with long latencies, such as cancer. It is commonly
controlled by including a time lag in sensitivity analyses. In a multi‐
country study on the association of topical tacrolimus and
pimecrolimus with cutaneous lymphoma (CL), PB was a concern
because CL may present symptoms resembling atopic dermatitis and
therefore may be treated with the study medication.
Objectives: To evaluate the potential for PB by acquiring further infor-
mation on the medical history of CL cases, specifically to assess
whether treatment with the study medications was initiated for symp-
toms that were compatible with early manifestations of CL.
Methods: In Sweden, researchers reviewed hospital medical records
of CL cases identified through the Swedish national cancer registry.
In the United Kingdom, researchers from the Clinical Practice
Research Datalink (CPRD) sent questionnaires to general practitioners
(GPs) with CL cases. Information extracted included date of CL diag-
nosis; date of start of symptoms; location and extent of CL; biopsy
results; and skin conditions such as psoriasis or atopic dermatitis,
including location, extent, and date of onset.
Results: In total, 29 (CPRD) and 73 (Sweden) potential CL cases were
identified. In CPRD, GP questionnaires were sent for all 29 potential
cases identified, and 19 have been returned to date. One did not pro-
vide additional information. Diagnosis was confirmed in 13 cases, and
date of CL diagnosis was identified earlier by GPs than by case
screening algorithm in four cases. Six cases had a prior history of skin
condition on the same location as CL, one did not, and six did not pro-
vide enough information. In Sweden, it was possible to request infor-
mation for 65 potential cases. To date, 48 medical records have been
received.
Conclusions: Based on reviewed cases, the additional clinical informa-
tion modified the outcome diagnoses or the date of symptoms initia-
tion in half of the patients. Nearly half of the confirmed cases were
previously diagnosed with benign skin conditions that share signs
and symptoms with CL. Reverse causation could then introduce bias
in the study results.
646 | Unmeasured confounders may cause
underestimation of anti‐osteoporotic drug
effects in postmenopausal women with
osteoporosis in Taiwan
Pin‐Tsen Yeh1; Yea‐Huei Kao Yang1; Edward Chia‐Cheng Lai1,2
1School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical
Sciences, College of Medicine, National Cheng Kung University, Tainan,
Taiwan; 2Department of Pharmacy, National Cheng Kung University
Hospital, Tainan, Taiwan
Background: Previous pharmacoepidemiologic studies showed con-
troversial results while evaluating effectiveness of anti‐osteoporotic
drugs, possibly because unmeasured confounders were not consid-
ered in some studies.
Objectives: The study aimed to evaluate confounders that were not
available in the claims data but measureable in a validation dataset
for the studies assessing anti‐osteoporotic drugs.
Methods: We analyzed Taiwan's National Health Interview Survey
(NHIS) 2005 and 2009 for the study, which included 30,680 and
30,528 random sample of Taiwanese population respectively. We iden-
tified a cohort of postmenopausal women over 55 years old diagnosed
with osteoporosis and a history of fracture. We classified patients into
treatment of anti‐osteoporotic drugs and non‐treatment group. We
included factors that may associate with healthier behaviors or recur-
rence of fracture, such as patients' age (65+ vs 55–65), bodymass index
(BMI), education level (junior high school and above or not), exercises
(within two weeks or not), smoking, alcohol, betel nut and job status.
Adjusted odds ratios and 95% confidence intervals (CI) derived from
multivariate modified Poisson regression were used to evaluate the dif-
ferences between treatment vs non‐treatment group.
Results: We identified a total of 1592 postmenopausal women over
55 years old with osteoporosis and fracture, and 52% of them were
treatment group. The mean age and BMI were 67.63 (SD 8.94) and
24.35 (SD 3.75) respectively. We found treatment group was older
(adjusted odds ratio 1.09; 95% CI 1.07–1.11), had higher BMI (1.04;
1.01–1.08), had lower education level (1.38; 1.01–1.89), without exer-
cises (1.21; 0.95–1.56) and more alcohol intakes (1.20; 0.86–1.69)
compared to non‐treatment group. We found the rates of smoking
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(3.0%) and betel nut (1.3%) were low in the study population, and
there was no difference between treatment and non‐treatment group.
Conclusions: The finding indicated the treatment group of anti‐osteo-
porotic drugs had higher baseline risk of recurrence of fracture com-
pared to non‐treatment group. We may underestimate the effects of
drugs if the unmeasured confounders were not considered or unmea-
surable while using claims databases for pharmacoepidemiologic
studies.
647 | Misclassification of case–control
studies in PubMed
Stephen Kim
University of Utah College of Pharmacy, Salt Lake City, UT
Background: Authors' accurate use of terminology about epidemiolog-
ical methods is important for clearly communicating about research to
readers. Users of the medical literature rely on such information to
guide them in their use of evidence to support patient care. However,
historical changes in the meanings of epidemiologic terms could
undermine these goals. For example, the term “retrospective” has his-
torically been used to refer to a case–control study design. More
recently, however, the term has come into wide usage as a description
of a study's data source.
Objectives: Using a corpus of human immunodeficiency virus (HIV)
studies, we evaluated the association between use of the term retro-
spective in a study's title/abstract and the likelihood that it would be
indexed as a case–control study in PubMed.
Methods: We conducted a cohort study of PubMed research articles
that were indexed with the MeSH term HIV between 1992 and
2017. We identified observational studies using a validated search fil-
ter for observational studies from the National Institute for Health and
Care Excellence (NICE). The exposure of interest was the presence of
the term retrospective in the title and/or abstract of an article, and the
outcome was the PubMed Medical Subject Heading (MeSH) term for
case–control studies. We estimated risk ratios (RRs) and 95% confi-
dence intervals for the association between the exposure and the out-
come overall and by year.
Results: A total of 88,771 studies met the eligibility criteria during the
study period. The number of studies per year ranged from 2667 (3.0%)
in 1992 and 3997 (4.5%) in 2010. The RR for the association between
the term retrospective and the MeSH term for case control studies was
29.2 (27.8, 30.7), and 26.4 (25.1, 27.8) when controlling for year. By
year, the association was strongest in the first year (RR 72.4, 95% CI
46.0, 113.9), but then declined substantially in each subsequent year,
stabilizing at a magnitude below 40% by 1998. The magnitude was
lowest in 2005 (RR 21.1, 95% CI 16.1, 27.7).
Conclusions: Use of the term retrospective is strongly associated with
the MeSH term for case–control studies. This association initially
decreased but has remained stable from 2005 onward. This suggests
potential bias in study classification if use of the term retrospective is
now more commonly associated with data source than with study
design. In ongoing research, we are examining the association
between true study design and classification as a case–control study,
as well as examining use of the term retrospective.
648 | Gender and authorship in
pharmacoepidemiology: Studying the
authorship patterns of Canadian network for
observational drug effect studies research
Melissa Helwig1; Keri McCaffrey1; Robyn Traynor1; Elaine Burland2;
Ingrid S. Sketris1; Samuel A. Stewart1
1Dalhousie University, Halifax, NS, Canada; 2University of Manitoba,
Winnipeg, MB, Canada
Background: The Canadian Network for Observational Drug Effect
Studies (CNODES) studies the benefits and risks of post‐market drugs
using de‐identified population‐based administrative healthcare data.
Its KnowledgeTranslation (KT) Team is evaluating the efforts to mobi-
lize this research for accountability, demonstrating value, and learning.
Acknowledging the gender gap in authorship across academia, the
CNODES KT Team looked at the relationship between gender and
authorship, both in their own articles and the broader
pharmacoepidemiology literature.
Objectives: To investigate gender patterns in authorship of both
CNODES articles and the body of literature that cites them.
Methods: CNODES articles published between 2012 and 2017 were
identified in SciVal; all articles that had cited the CNODES articles
were extracted using Scopus' citation tracking tools. Scopus author
IDs for each author were used to extract their full name from the
Scopus application programming interface (API). A web service
(www.genderapi.com) was used to estimate the gender of both the
CNODES authors and the citing authors. The service provides an esti-
mated gender and a probability of being correct; all probabilities <80%
were converted to “indeterminate”. Once the data were extracted,
cross tabulations and visualizations were created, and testing was per-
formed using chi‐square tests.
Results: The 28 CNODES articles (2012–2017) were written by 106
authors with many appearing multiple times (266 total authorships).
The web service estimated 46 female, 54 male, and 8 indeterminate
gender authors for the CNODES articles; total authorship credits were
estimated as 84 female, 161 male, and 21 indeterminate. These
authorship patterns roughly matched the gender balance in the citing
literature, with 774 female, 1817 male, and 73 indeterminate (32% vs.
29% female, p‐value = 0.399). Six of the 28 CNODES articles had no
female authors, but there was no noticeable pattern in authorship
position (e.g. first, second, last, etc.) for either the CNODES articles
or the citing literature.
Conclusions: The female authorship rate in the CNODES‐cited
pharmacoepidemiology literature was 29%; CNODES publications
had a similar rate. Further work is needed to determine barriers and
facilitators to women's inclusion in project teams and publications, as
well as work towards interventions to remove modifiable barriers.
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649 | Performance of genetic risk scores as
an instrumental variable in
pharmacoepidemiology
Md Jamal Uddin1,2; Claus Thorn Ekstrøm2; Merete Nordentoft3
1Shahjalal University of Science and Technology, Sylhet, Bangladesh;
2University of Copenhagen, Copenhagen, Denmark; 3Mental Health
Centre, Copenhagen, Denmark
Background: Genetic risk scores (GRS) has been used as an instrumen-
tal variable (IV) to control for unmeasured confounding in Mendelian
randomization studies. However, little is known if the genetic marker
(GM) acts as confounding and that marker simultaneously used for cal-
culating the GRS.
Objectives: We aimed to assess methodological issues of the GRS as
an IV in realistic pharmacoepidemiologic settings.
Methods: We simulated data in several scenarios with varying
strength of the IV (GRS), little violation of the basic IV assumptions
(e.g. GM directly affects the outcome), and GM acts as confounding.
In each scenario, the number of replications was 1000 times with
100000 observations. All variables were time‐invariant, exposure
effect was homogeneous, and in the standard situation, the GRS sat-
isfied its basic assumptions (e.g. independence from pleiotropy). The
GMs were simulated using the uniform distribution on the interval
from 0.05 to 0.95 and the effect of the markers was generated using
the lognormal distribution with mean zero and standard deviation
one. We constructed the GRS using a weighted sum of allelic count
where the weights being given by regression coefficients in the
same data. The true exposure effect for all scenarios was β = 1.
Two‐stage linear IV models were applied to estimate the exposures
effects on the outcome. Confidence intervals (CI) were estimated
in a non‐parametric way using 2.5 and 97.5 percentiles of the
1000 estimates.
Results: In standard situation (i.e. perfect IV), the exposure effects
were similar with the true value (β = 1), 1.00 [95% CI: 0.99–1.01].
However, when a marker acts as a measured confounder and that
marker also used for calculating the IV (GRS), the effect estimate
was shifted away from the true value, 1.18 [1.16–1.19] and the bias
was increased with the strength of the confounding. Furthermore,
when a GM violates its basic assumption (e.g. GM directly affects
the outcome), the effect estimate was highly biased 1.34 [1.32–
1.36]. When we removed those GM that acts as confounding or
has small association with confounders, the IV estimate was similar
to the true value.
Conclusions: Our study suggests that the exposure effects from the
IV analysis using GRS as an IV can be valid when the estimates are
reported from perfect IV models. We recommend not to use those
genetic markers that act as confounders or slightly violates the basic
IV (GRS) assumptions.
650 | Outcome classification methodology
and heterogeneity of association between
BMI and COPD in the UK biobank cohort
Jonathan M. Davitte1; Jessica L. Chao1; Oksana Kirichek2
1GlaxoSmithKline, Collegeville, PA; 2GlaxoSmithKline, Uxbridge, UK
Background: Phenome‐wide association studies (PheWAS) to assess
phenome‐wide correlates of specific exposures often use readily avail-
able outcome definitions (e.g. through ICD10 codes) in lieu of more
complex disease definitions that require additional methodological
and analytic considerations. However, these crude disease definitions
may be vulnerable to measurement bias.
Objectives: This GSK‐funded study evaluated how the association of a
well‐measured risk factor with disease phenotype varies by phenotyp-
ing methodology. To explore this question, we assessed the associa-
tion between body mass index (BMI) and chronic obstructive
pulmonary disease (COPD) using three definitions of COPD cases;
and, how this association is modified by smoking status. While
smoking status is a stronger risk factor for COPD, we selected BMI
as our primary exposure given its limited vulnerability to reporting bias
(compared to self‐reported smoking) and low BMI's well‐established
association with COPD.
Methods: We used data from 502,616 UK Biobank participants to
evaluate BMI and smoking measures from baseline data collection
against three COPD case definitions: 1) “raw” defined as forced expi-
ratory volume in one second (FEV1) over forced vital capacity
(FVC) < 0.7; 2) “best” defined as FEV1/FVC < 0.7 controlling for the
quality of the blow; 3) “ICD10” defined as having a record of a
COPD‐related ICD10 code (J440, J441, J449) in Health Episodes Sta-
tistics (HES) records. We used multiple logistic regression models to
calculate ORs and 95% CIs per 5 kg/m2 increase in BMI on the odds
of COPD for each COPD definition, stratified by smoking status,
adjusting for sex and age.
Results: Our results indicate heterogeneity in the strength and direc-
tion of association across all COPD definitions and smoking status
strata. Among never smokers, the odds of COPD per 5 kg/m2 increase
in BMI were 0.78 (0.77, 0.79) for “raw”, 0.75 (0.74, 0.76) for “best”, and
1.54 (1.47,1.61) for “ICD10”. Among previous smokers, ORs were 0.82
(0.81, 0.83) for “raw”, 0.83 (0.82,0.84) for “best”, and 1.42 (1.38, 1.46)
for “ICD10”. Finally, for current smokers, ORs were 0.66 (0.64, 0.67)
for “raw”, 0.64 (0.62, 0.66) for “best”, and 1.02 (0.99, 1.06) for “ICD10”.
Conclusions: This example shows that readily available homogenous
disease traits in lieu of more complex disease definitions can lead to
substantial heterogeneity in association estimates. Particularly, the
common practice of using disease‐related ICD10 codes from HES to
derive disease phenotypes in the UK Biobank could be biased towards
more severe cases given the hospital source population.
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651 | Outcome definition influences the
relationship between genetic polymorphisms
of ERCC1, ERCC2, SLC22A2 and cisplatin
nephrotoxicity in adult testicular cancer
patients
Zulfan Zazuli1,2; Leila S. Otten3; Britt I. Drogemoller4;
Galen E.B. Wright4; Susanne J.H. Vijverberg1; Rosalinde Masereeuw3;
Colin J.D. Ross4; Geoffrey Liu5; Bruce C. Carleton6;
Anke Hilse Maitland‐van der Zee1
1Amsterdam UMC, AMC, Amsterdam, Netherlands; 2School of Pharmacy,
Bandung Institute of Technology, Bandung, Indonesia; 3Utrecht Institute
for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands;
4British Columbia Children's Hospital Research Institute, Vancouver, BC,
Canada; 5Princess Margaret Cancer Centre ‐ University Health Network
and University of Toronto, Toronto, ON, Canada; 6BC Children's Hospital,
Vancouver, BC, Canada
Background: Although previous research identified putative genetic
polymorphisms associated with cisplatin nephrotoxicity, varying out-
come definitions potentially contributed to the variability in effect size
and direction of this relationship.
Objectives: To validate the use of already associated genetic variants
to predict cisplatin nephrotoxicity and to determine if different cis-
platin nephrotoxicity definitions contributed to the variability in effect
size and direction of already published associations between these
genetic polymorphisms and cisplatin nephrotoxicity.
Methods: We selected variants that have been significantly associ-
ated with cisplatin‐induced nephrotoxicity in more than one pub-
lished study (SLC22A2 rs316019; ERCC1 rs11615 and rs3212986;
ERCC2 rs1799793 and rs13181) and performed a replication study
to confirm associations between genetic polymorphisms and cisplatin
nephrotoxicity using various outcome definitions. We included 282
germ cell testicular cancer patients treated with cisplatin from
2009 to 2014, aged >17 years recruited by the Canadian
Pharmacogenomics Network for Drug Safety. Nephrotoxicity was
defined in four grading tools: (1) Common Terminology Criteria for
Adverse Events (CTCAE) v4.03 for acute kidney injury (AKI) or
CTCAE‐AKI; (2) adjusted cisplatin‐induced AKI; (3) elevation of
serum creatinine; and (4) reduction in the estimated glomerular filtra-
tion rate (eGFR). Logistic and multiple regression was used to calcu-
late the effect sizes.
Results: Significant relationships were only found when using the
CTCAE v4.03 definition: heterozygous carriers of the ERCC1
rs3212986 variant had a protective effect from cisplatin nephrotoxi-
city (ORadj 0.24; 95% CI:0.08–0.70; p = 0.009) while carrying the
SLC22A2 rs316019 polymorphism was associated with a higher risk
of cisplatin nephrotoxicity (ORadj 5.06; 95%CI:1.69–15.16;
p = 0.004). No significant associations were identified using the other
three nephrotoxicity definitions.
Conclusions: Our study showed that different case definitions lead to
variability in the genetic risk ascertainment of cisplatin nephrotoxicity.
Therefore, consensus on a set of clinically relevant outcome defini-
tions that all such studies should follow is needed.
652 | Uptake of the Ontario naloxone
program for pharmacies
MinaTadrous1; Diana Martins1; Beatrice Choremis2; Tonya Campbell3;
Tony Antoniou1; Tara Gomes1
1St. Michael's Hospital, Toronto, ON, Canada; 2Queens University,
Kingston, ON, Canada; 3 ICES, Toronto, ON, Canada
Background: Naloxone is a life‐saving antidote for opioid overdose.
Increased access to take‐home naloxone has been endorsed for
regions with an ongoing opioid crisis. In June 2016, the Ontario gov-
ernment implemented the Naloxone Program for Pharmacies (ONPP)
to enhance free access to naloxone.
Objectives:We examined the uptake of the ONPP and characterized
individuals receiving and pharmacies dispensing naloxone kits.
Methods: We conducted a population‐based study of all Ontario
residents who received a naloxone kit between July 1, 2016 and
March 31, 2018. This involved 1) a cross‐sectional analysis of
monthly rates of naloxone kits dispensed, individuals accessing nal-
oxone and pharmacies dispensing naloxone; 2) a descriptive analysis
of all individuals and pharmacies who accessed and dispensed nalox-
one, respectively. In each analysis, we stratified individuals according
to their opioid exposure as follows: current prescription opioid ago-
nist therapy (OAT) recipient, current prescription opioid recipients,
past opioid exposure, and no/unknown opioid exposure.
Results: Over the study period, the rate of naloxone kits dispensed
increased from 1.9 to 54.3 kits per 100,000 Ontario residents. By
March 2018, 2,729 community pharmacies dispensed 91,069 nalox-
one kits to 67,910 unique individuals. Naloxone uptake differed
between exposure groups, which were highest among OAT recipi-
ents (40.7%), and low among current prescription opioid recipients
(1.6%) and individuals with past opioid exposure (1.0%). Naloxone
dispensing was highly clustered within pharmacies, with one‐third
(33.7%) of kits being dispensed by 1.0% of naloxone‐dispensing
pharmacies.
Conclusions: The ONPP led to substantial uptake of naloxone in
Ontario; however, access is concentrated among a small proportion
of pharmacies and is low among high‐risk prescription opioid
recipients.
653 | Opioid prescription patterns among
patients diagnosed with rheumatoid arthritis
in United States
Jolyon Fairburn‐Beech1; Ayush V. Patel2; Rachel Williams2
1GlaxoSmithkline, Uxbridge, UK; 2GlaxoSmithkline, Collegeville, PA
318 ABSTRACTS
Background: Rheumatoid Arthritis (RA) is a chronic disease associ-
ated with chronic pain. Patients often seek medical consultation
not only to treat RA but also to manage pain. Literature shows that
about 40% of RA patients receive opioids.
Objectives:To assess opioid prescription patterns among RA patients.
Methods: This retrospective cohort study was conducted among all
US adults (≥18 years) using IBM® MarketScan® Research database
(2012–2017). The study includes eligible patients with continuous
enrolment for at least 2 years, minimum of 2 RA diagnoses ≥30 days
apart and at least one opioid prescription (cohort A). We cannot ver-
ify if opioids were filled for RA pain from the data, but we excluded
patients with history of malignancies and other inflammatory condi-
tions to narrow the scope of the population. Patients were followed
for 2 years after index date (date of 1st opioid prescription post RA
diagnosis) to assess opioid treatment patterns. We also analyzed a
subset of RA patients that had targeted therapy prior to index date
(cohort B). Opioids were grouped as: strong (fentanyl, hydrocodone,
hydromorphine, morphine, oxycodone, oxymorphone, propoxyphene)
and weak (codeine, tramadol, tapentadol). The study estimated
sequence and switches of opioids and developed sankey charts
and sunburst plots to describe patterns in both cohorts. This study
was funded by GSK.
Results: About 36% of all RA patients receive an opioid prescrip-
tion. The study identified 62,131 and 15,452 patients in cohort
A and B respectively. Demographic distribution and opioid patterns
were consistent in both cohorts. Both cohorts were mostly female
(78–79%) with mean ages of 57(±13) and 55(±12) years respec-
tively. Among those with any opioid prescribed, most received at
least one strong opioid (A: 83%, B: 84%) over the follow‐up
period. Mean (±SD) number of opioid prescription fills over 2 years
was 10(±12) [strong: 7(±11); weak: 3(±6)] in cohort A and 8(±10)
[strong: 6(±9); weak: 2(±4)] in cohort B. On assessing lines of opi-
oid prescriptions, the most commonly prescribed opioid was
hydrocodone followed by tramadol and oxycodone in both
cohorts. Among those who switch to a new opioid (42–44%);
hydrocodone, tramadol and oxycodone remain choice of opioid.
Analysis of treatment sequence show that 13–15% switch ≥3
times over 2 years.
Conclusions: Most RA patients that receive opioids get multiple pre-
scriptions within 2 years of follow up. Over 40% of patients switch
opioids. Additionally, over 80% receive a strong opioid prescription.
The study concludes that irrespective of the cause, there is high bur-
den of pain among RA patients.
654 | Opioid prescribing and health
outcomes in Indiana, USA before and after
release of Centers for Disease Control and
prevention opioid prescribing guidelines
Sariya Udayachalerm1; David R. Foster1; Michael D. Murray1,2
1Purdue University College of Pharmacy, Indianapolis, IN; 2Regenstrief
Institute, Indiana University School of Medicine, Indianapolis, IN
Background: From the opioid epidemic in the U.S., one of the
most significant strategies to mitigate misuse is the release of
CDC's guideline for prescribing opioids for chronic pain in March
2016. However, there has been debate regarding its impact on
patients.
Objectives: To compare opioid prescribing and health outcomes
before and after the release of the CDC guidelines.
Methods: This is a retrospective cohort study of patients whose
data are contained within the Indiana Network for Patient Care
(INPC) data. INPC is a health information exchange data from
Indiana's health systems covering approximately 70% of Indiana's
population. Inclusion criteria was opioid naive patients (age ≥ 18)
who received the first opioid prescription (index) within study
period with no history of opioid prescription in the previous year.
Exclusion criteria was cancer, hospice care, and terminally ill
patients. The outcomes include number of day supply, dose in mor-
phine milligram equivalent (MME), recipient of opioid and benzodi-
azepine within 1 month, use of short and long acting opioids
within 1 year, and diagnoses of opioid abuse, dependence, and
overdose. These outcomes were compared between before and
after the guideline was released using t‐test or Wilcoxon rank
sum for continuous variables and Chi‐square for categorical vari-
ables. Data for patients with index date in 2014 and 2017 was
used as the period before and after the guideline release, respec-
tively. The follow‐up was 1 year after the index. All statistical anal-
yses were performed using SAS 9.4 and p value<0.05 was
considered statistically significant.
Results: A total of 127,421 and 34,090 opioid prescriptions were
identified for 50,053 and 19,213 patients in 2014 and 2017 respec-
tively. After the guideline release, the median number of day supply
for each prescription decreased (7 [range 1, 120] vs 5 [range 1, 90],
p < 0.0001), but the median MME did not differ significantly (5 [range
0.19, 240] for both years). Patients receiving opioid and benzodiaze-
pine increased (4.0% vs 9.5%, p < 0.0001) and patients using both
short and long acting opioids decreased (4.5% vs 1.5%, p < 0.0001).
Patients with opioid abuse diagnoses decreased from 0.08% to
0.03% (p = 0.0366), dependence diagnoses decreased form 0.17% to
0.08% (p = 0.0087), and those with overdose decreased from 0.03%
to 0 (p = 0.0165).
Conclusions: Opioid prescribing and adverse health outcomes related
to opioids generally decreased after the release of the guideline but
further research should be conducted to include patients in other
years and account for temporal changes.
655 | Assessing the impact of opioid
prescribing guidelines for dentists in Ontario,
Canada
Qi Guan1; Tonya Campbell2; Diana Martins3; Mina Tadrous3;
David Juurlink4; Michael Paterson2; Muhammad Mamdani3;
David Mock1; Tara Gomes3
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1University of Toronto, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada; 3St. Michael's Hospital, Toronto, ON, Canada; 4Sunnybrook
Research Institute, Toronto, ON, Canada
Background:New dental opioid prescribing guidelines were introduced
in November 2015 in Ontario, Canada. The document suggested using
opioids as a third or fourth line of therapy for acute dental pain and rec-
ommended limits on prescription quantity when opioids are warranted.
Objectives: As dentists are the second largest group of opioid pre-
scribers in this province, we sought to examine the impact of these
guidelines on their prescribing patterns.
Methods: We conducted a population‐based, cross‐sectional study of
Ontarians who received a prescription opioid from a dentist between
July 1, 2012 and September 30, 2017. We calculated the rate of indi-
viduals dispensed prescription opioids per 100,000 population, and
the population exposure to opioids (volume) in total morphine milli-
gram equivalents (MME) per 100,000 population, monthly over the
study period. We used interventional autoregressive integrated mov-
ing average (ARIMA) models to examine the impact of the dental opi-
oid prescribing guidelines on prescribing patterns.
Results: The rate of individuals that were dispensed prescription opi-
oids from a dentist remained stable over the study period (range from
161 to 140 individuals per 100,000 population between July 2012 and
September 2017), and was not significantly impacted by the release of
the dental opioid prescribing guidelines (p = 0.10). Although, the
release of the guidelines were associated with a significant decrease
in the volume of opioids dispensed to dental patients (p = 0.01), which
reduced by 23.2% between November 2015 and September 2017
(from 20.7 MME to 15.9 MME per 100,000 population, respectively).
Conclusions: Changes in the volume of opioids prescribed by dentists,
even in the absence of reductions in the population‐adjusted rate of
opioid prescribing, suggest that dental opioid prescribing guidelines
can lead to important practice change. Future studies should examine
consistency of practice between dentists, and whether opioid expo-
sure among dental patients is leading to long‐term use.
656 | A comparison of opioid‐involved
fatalities captured in the National Poison
Data System and in death certificate literal
text data
Celeste Mallama; James Trinidad; Richard Swain; Yueqin Zhao;
Corinne Woods; Jana McAninch
FDA, Silver Spring, MD
Background: The ongoing epidemic of opioid‐related deaths necessi-
tates timely and detailed surveillance data. The National Poison Data
System (NPDS) collects near real‐time, drug‐specific information from
exposure calls to US poison control centers (PCCs). However, NPDS
captures only a fraction of opioid‐involved fatalities, and whether the
proportion of deaths captured varies across time, drug, and other
factors is unknown. Previous studies comparing PCC death data to
National Vital Statistics System‐Mortality (NVSS‐M) data were limited
by lack of drug specificity in International Classification of Diseases
codes. The recently‐developedDrug‐InvolvedMortality (DIM) database
now allows identification of specific opioid moieties involved in death.
Objectives: To describe and compare the number and characteristics
of opioid‐involved deaths captured in NPDS and US death certificates,
across commonly prescribed opioids and over time.
Methods: NPDS, which collects data on calls to US PCCs, and DIM,
which combines information from literal text of US death certificates
and NVSS‐M, were queried for opioid‐involved deaths from 2010–
2015. Characteristics of the two case‐series were compared.
Results: DIM contained 154,016 opioid‐involved deaths, and NPDS
contained 2,524 fatal opioid exposures, a ratio of 61:1. The number
of opioid‐involved deaths remained stable in NPDS but increased in
DIM. On average, deaths involving opioids with higher mean potency
per unit (as measured by morphine milligram equivalents) among dis-
pensed prescriptions were more likely to be captured in DIM relative
to NPDS, as compared to those with a lower mean potency per unit.
Notably, the increase in fentanyl‐related deaths seen in DIM since
2013 was not observed in NPDS. Proportion of female decedents
was higher in NPDS relative to DIM, as was proportion of suicide
cases. Mean and median ages were slightly higher in NPDS compared
to DIM. The majority of cases in DIM (65.4%) did not include route of
exposure, whereas >90% of cases in NPDS specified route.
Conclusions: NPDS and DIM are useful resources for examining
trends in opioid‐involved deaths, but there are important differences
between them. While NPDS captures more information on route of
exposures, it captures a small fraction of opioid‐involved deaths, and
caution is warranted in making inferences about mortality trends and
comparisons across opioids using this data source. Of particular note,
the sharp increase in fentanyl‐involved deaths observed in DIM was
not seen in NPDS, possibly due to illicit fentanyl's high potency and
rapidly fatal effects.
657 | Persistent opioid prescribing after
minor surgery in Trinetx
Brian Buysse1; Jayashri Desai2; Jessica Albano2
1Syneos Health, Farnborough, UK; 2Syneos Health, Raleigh, NC
Background: There is concern about persistent opioid prescribing
after surgery, with recent data indicating that ~6% of US patients
are affected.
Objectives: To assess persistent opioid prescribing after minor surgery
inTriNetX, a federated research network that provides statistical sum-
maries of de‐identified patient data. Differences by age, sex, and his-
tory of mental health disorders were explored.
Methods: Opioid‐naïve patients aged ≥18 years who underwent
minor surgery (i.e. varicose vein removal, laparoscopic cholecystec-
tomy, laparoscopic appendectomy, hemorrhoidectomy, thyroidec-
tomy, transurethral prostate surgery, parathyroidectomy or carpal
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tunnel release) were analyzed in TriNetX “Analytics” (TriNetX, Cam-
bridge, MA), which contains electronic medical record data of ~38 M
US patients (analysis 8‐Feb‐2019). Patients had to have their first opi-
oid prescription record (VA code CN101) in the perioperative period
between 1 month before and 2 weeks after surgery. Persistent opioid
prescribing was defined as at least one opioid prescription between 90
and 180 days after surgery, a time at which patients are expected to
have recovered from minor surgery. Patients with an anesthesia pro-
cedure code during 180 days after surgery were excluded as to mini-
mize inclusion of patients with potential postoperative opioid
prescribing because of other procedures or diagnoses.
Results: 122,793 patients met the eligibility criteria. The mean age
was 51 years (SD 18). About 61% were women, 74% were white
and 9% African‐American. Persistent opioid prescribing after minor
surgery occurred in 4.8% of the patients (range: 2.5% for parathy-
roidectomy to 9.2% for varicose vein removal). It was similar in
men and women (odds ratio [OR] 1.00, 95% confidence interval
[CI] 0.95 to 1.06) but increased with higher age (OR 40–64‐year‐
olds vs. 18–39‐year‐olds 1.48, 95% CI 1.38 to 1.58; OR 65‐year‐olds
and above vs. 18–39‐year‐olds 1.74, 95% CI 1.62 to 1.86). In a joint
analysis of sex and age, men aged 18–39 years had the lowest risk
(referent) and men aged 65+ years the highest risk (OR 2.79, 95%
CI 2.48 to 3.14). Higher risk was also seen in patients with a preop-
erative diagnosis of mood disorders (ICD‐10 codes F30‐F39; OR
2.08, 95% 1.93 to 2.25) and mental and behavioral disorders due
to psychoactive substance use (ICD‐10 codes F10‐F19; OR 1.74,
95% CI 1.61 to 1.89).
Conclusions: This analysis based on electronic medical record data
indicates that persistent opioid prescribing after minor surgery occurs
in ~5% of patients, and lays bare sex and age differences and higher
risk among patients with mental health disorders. These results are
in line with previous data.
658 | Differences in opioid prescriptions
among age categories of older adults
Yvette M. Weesie1; Liset van Dijk2; Tjard Schermer1;
François Schellevis1; Hubert G.M. Leufkens3; Elisabeth J. Rook4;
Karin Hek1
1Nivel, Utrecht, Netherlands; 2University of Groningen, Groningen,
Netherlands; 3Utrecht University, Utrecht, Netherlands; 4Medicines
Evaluation Board (MEB), Utrecht, Netherlands
Background: Pain is increasingly treated with opioids, especially in
older adults. This increase is seen not only in the United States, but
also in Europe. There is evidence that the potential harms of opioid
therapy disproportionality affect older adults and little is known about
differences in opioid use within the older adult population.
Objectives: The aim of this study is to provide information on trends
of frequency and nature of opioid prescriptions for older adults of dif-
ferent age categories, in a primary care setting.
Methods: Data (2005–2017) were derived from routine electronic
health records of general practices participating in Nivel Primary Care
Database. All opioid prescriptions with ATC‐code N02A were
selected, with the exception of codeine. Diagnoses were recorded
using ICPC‐classification. Older adults were categorized in three age
categories (65–74, 75–84 and 85 years and older). Descriptive analy-
ses were used to describe the trend of opioid prescriptions to older
adults in different age categories for specific opioids and the nature
of opioid prescriptions described with diagnoses registered with the
prescribed opioids and duration of the opioid prescriptions.
Results: There is an increase in the proportion of older adults who
received at least one opioid between 2005 and 2017 (170% increase
for 65–74 year olds, 167% for 75–84 year olds and 263%for patients
aged 85 years or older). Patients in the oldest age category are more
likely to be prescribed an opioid compared to the other age categories,
especially when it comes to strong opioids (128,9 patients per 1.000
registered patients compared to 52.5 (65–74 years) and 84.4 (75–
84 years) per 1.000 in 2017). Opioids, both strong and weak are
mostly prescribed for musculoskeletal diagnoses in all age categories.
Yet there are differences in other diagnoses patients in the three dif-
ferent age categories get a prescription for. Over half of the older
adults received two or more opioid prescriptions and more than 30%
of the older adults used strong opioids chronically.
Conclusions: Opioid use in older adults changes with increasing age in
frequency and nature. The high risks associated with opioid use in
older adults, stresses the importance to monitor patients individually
throughout the treatment.
659 | Risk factors for new and persistent
chronic opioid use after hip fracture surgery:
A Danish nationwide cohort study from 2005
to 2016
Nina M. Edwards1; Claus Varnum2; Søren Overgaard3;
Lone Nikolajsen1; Alma B. Pedersen1
1Aarhus University Hospital, Aarhus, Denmark; 2Vejle Hospital, Vejle,
Denmark; 3Odense University Hospital, Odense, Denmark
Background: Opioids are commonly prescribed for acute pain treat-
ment in hip fracture (HF) patients. However, 80% of patients taking
opioids will experience an adverse effect and some patients might
develop a chronic use of opioids after surgery.
Objectives: The aim was to examined several patient‐ and surgery
related risk factors for new and persistent chronic opioid use after
HF surgery.
Methods: Using Danish nationwide health registries, we identified all
HF surgery patients ≥65 years of age (n = 69,456). Among opioid
naïve patients before surgery, we defined new chronic opioid use as
at least two dispensing of opioid within 1 year after surgery. Persistent
chronic opioid use was defined as at least one dispensing of opioids
6 months before and two dispensing within 1 year after surgery. We
calculated adjusted odds ratios (aOR) with 95% confidence intervals
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to explore following risk factors: age, sex, surgical indications, preoper-
ative medications, and comorbidities defined through Charlson
Comorbidity Index (CCI low, medium and high) and a number of indi-
vidual comorbidities.
Results: A total of 9% patients were new users, whereas 13% were
persistent users. The aORs for being a new user were 1.39 (1.28–
1.50) and 1.23 (1.15–1.32) for age groups 65–74 and 75–84 years,
(ref = 85+) 1.09 (1.02–1.16) for female (ref = male), 1.02 (0.96–1.09)
and 0.93 (0.86–1.02) for medium and high CCI (ref = low, no known
comorbidity), 1.20 (1.12–1.29) and 1.53 (1.38–1.70) for overweight
and obese patients (ref = normal body mass index), and 1.26 (1.15–
1.37) for preoperative use of NSAID. The aORs for being a persistent
user were 1.45 (1.35–1.55) and 1.25 (1.18–1.33) for age groups 65–
74 and 75–84 years, 1.83 (1.72–1.95) for female, 1.59 (1.50–1.69)
and 2.07 (1.93–2.22) for medium and high CCI, 1.19 (1.10–1.1.29)
and 1.35 (1.23–1.48) for underweight and obese patients, and 1.75
(1.63–1.88) for preoperative use of NSAID. There was no association
between other potential risk factors and chronic opioid use.
Conclusions: We identified several risk factors associated with new
and persistent chronic opioid use, including high age, female sex,
comorbidity and preoperative NSAID use. This is clinically relevant in
order to identify and develop more effective and targeted preventive
intervention strategies to reduce opioid use and thereby the associ-
ated adverse events among elderly patients.
660 | Prescription opioid use and dose
trajectories before diagnosis of opioid use
disorder or overdose among US adults
Yu‐Jung Wei; Cheng Chen; Amir Sarayani; Roger Fillingim;
Siegfried Schmidt; Almut Winterstein
University of Florida, Gainesville, FL
Background: With increasing efforts to scrutinize opioid prescribing,
little is known about how prescription opioid patterns preceding opi-
oid use disorder (OUD) or overdose have been changed.
Objectives: To determine prescribed opioid fills and dose trajectories
in the year before an OUD or overdose diagnosis among US adults.
Methods: This retrospective cohort study used 2005–2016 Truven
MarketScan Commercial Claims data to construct a cohort of individ-
uals aged 18 to 64 years with incident OUD or overdose following
12 months of health plan enrollment preceding the diagnosis. We
measured prevalence of opioid prescription fills and trajectories of
opioid morphine equivalent dose (MED) prescribed in the year before
OUD or overdose.
Results: Of 218,690 adults with incident OUD or overdose, 34.0%
were aged 18 to 30 years, 46.9% were females, and 85.1% were met-
ropolitan residents. Over one‐third of 199,617 adults with incident
OUD and 20,417 with incident opioid‐related overdose filled no opi-
oid prescription in the year before the diagnosis. In both OUD and
overdose cohorts who filled opioid prescriptions, 5 distinct prescribed
daily dose trajectories preceding diagnosis emerged: consistent low
dose (less than 3 mg MED, 34.4% for OUD and 44.4% for overdose);
consistent moderate dose (20 mg MED, 27.5% and 8.8%); consistent
high dose (150 mg MED, 14.6% and 14.3%); escalating dose (from less
than 3 to 20 mg MED, 14.1% and 10.4%); and de‐escalting dose (from
20 to less than 3 mg MED, 9.4% and 22.1%). Overall, over two‐thirds
of patients with OUD or overdose with prescription opioids were pre-
scribed a mean daily dose below 90 mg MED before diagnosis.
Conclusions: In US commercially insured adults with incident OUD or
overdose, absence of opioid prescription fills in the year before diag-
nosis was prevalent, and the majority received prescription opioid
doses below the recommended risk threshold of 90 mg MED. Current
programs flagging high‐risk patients from their prescription opioid use
may be ineffective at identifying patients with OUD or overdose.
661 | Trends in opioid use among
commercially insured pregnant women with
severe maternal morbidity in the United
States, 2007–2015
Aakash Bipin Gandhi; Danya M. Qato
University of Maryland School of Pharmacy, Baltimore, Baltimore, MD
Background: Severe maternal morbidity (SMM), or life‐threatening
complications during delivery, affects more than 50,000 pregnant
women in the United States annually‐ its incidence more than dou-
bling over the past two decades. Little research has evaluated the
association between prenatal exposure to high risk medications, such
as opioids, and SMM.
Objectives: To compare and contrast the prevalence and patterns of
opioid use in a cohort of pregnant women with and without SMM.
Methods: This retrospective study used a 10% random sample of
commercially insured enrollees in the IQVIA™ PharMetrics Plus adjudi-
cated claims database. We identified all women (12–55 years of age)
with completed pregnancies from 2007–2015, having continuous
medical and prescription drug coverage for three months prior to the
date of conception through three months post‐delivery. We then
identified pregnancies with SMM using an algorithm developed by
the Centers for Disease Control and Prevention. Opioid exposure dur-
ing pregnancy was defined as having at least one claim for an opioid
product at any period during pregnancy; exposure during each prena-
tal and postnatal period was also estimated separately. Chi‐square
tests were employed to test for differences in opioid exposure.
Results: Among 154,200 pregnant women in our sample, 2,004 (1.3%)
had SMM. Prevalence of opioid exposure increased in pregnancies
with SMM from 8.2% in 2007 to 14.0% in 2015 (p < 0.01). The reverse
was seen for pregnancies without SMM, with prevalence of opioid use
decreasing from 10.7% in 2007 to 8.3% in 2015 (p < 0.01). The prev-
alence of opioid exposure at any time during pregnancy and in each
period was significantly higher (all p‐values <0.01) for pregnancies
with SMM as compared to those without: any time during pregnancy
(14.5% vs 9.8%); three months prior to conception (9.5% vs 7.3%); 1st
trimester (6.3% vs 4.2%); 2nd trimester (5.9% vs 3.7%); 3rd trimester
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(6.3% vs 4.3%) and three months post‐delivery (62.1% vs 45.7%).
Among pregnant women who were exposed to at least one opioid
during pregnancy, a significantly higher proportion were dispensed
≥3 opioids in the SMM group compared to those without SMM
(20.7% vs 16.2%, p < 0.01).
Conclusions: This study provides evidence that opioid exposure in
pregnancies with SMM has increased in the past decade and is more
common in pregnant women with SMM compared to pregnant
women without SMM. Further research should be undertaken to
establish the potentially causal relationship between high risk medica-
tion use, including of opioids, and increased trends in SMM nationally.
662 | Concomitant use of Z‐drugs with
prescribed opioid agents and the risk of
overdose: A cohort study
Alejandro Szmulewicz1; Brian Bateman2; Raisa Levin2;
Krista Huybrechts1,2
1Harvard TH Chan School Of Public Health, Boston, MA; 2Division of
Pharmacoepidemiology and Pharmacoeconomics, Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School,
Boston, MA
Background: Mortality from opioid‐related overdose continues to
increase in the US, with prescription opioids involved in at least 30%
of all overdoses in 2017. Z‐drugs are central nervous depressants
and, although generally perceived as safe, may increase the risk of
overdose when prescribed with opioids.
Objectives: To determine the rate of overdose among patients using
opioids and z‐drugs as compared to patients using opioids alone.
Methods: We conducted a cohort study using the MarketScan
research databases 2004–2015. Patient episodes with concomitant
exposure to z‐drugs (zolpidem, zopiclone, zaleplon) and prescription
opioids (‘exposed’) were 1:1 matched to patient episodes with expo-
sure to prescription opioids alone (‘reference’) based on type of opioid
(generic), morphine equivalents, calendar year, and hospitalization
within the last 30 days of the qualifying prescription. Patients with
cancer or palliative care were excluded. Primary outcome was defined
as opioid and/or psychotropic‐related overdose within 30 days of
index date, using an intention‐to‐treat approach. Hazard Ratios (HR)
and 95% CI were estimated from cox proportional hazard regression
models with fine stratification on the propensity score (including 65
variables) to control for confounding. Sensitivity analyses were per-
formed to test the robustness of the findings, including extending
the follow‐up time to 90 days, and employing a stricter outcome def-
inition (i.e., requiring respiratory failure code).
Results: The cohort comprised 750,819 exposed and 750,819 refer-
ence episodes. The mean age was 50 years and 41% were male.
Most characteristics were well balanced, except for number of
generics, clinical diagnoses, and depressive comorbidity, which were
more common among patients with concomitant z‐drugs. There
were 787 overdose events among the exposed (13 per 1,000
person‐years) versus 365 events among the reference group (6 per
1,000 person‐years), for an unadjusted HR of 2.13 (95% CI: 1.88–
2.41). With fine stratification on the PS, the HR attenuated to 1.74
(1.55–1.96). Results of sensitivity analyses were consistent: 90 days
follow‐up period (HR = 1.50, 1.39–1.62) and stricter outcome defini-
tion (HR = 1.43, 1.13–1.79).
Conclusions: Among patients receiving prescription opioids, after con-
trolling for characteristics of the opioid use and other confounders,
concomitant treatment with z‐drugs was associated with a substantial
increase in the risk of overdose. Caution is required when prescribing
these agents to patients on opioid therapy and interventions to
improve rational prescription are needed.
663 | Direct and indirect effects of
medication assisted therapy on nonfatal
opioid overdose among patients with opioid
use disorder within prescriber networks
Tianyu Sun1; Ashley Buchanan1; Hilary Aroke1; Jeffrey Bratberg1;
Jing Wu2; Josiah Rich3; Joseph Hogan4; Stephen Kogut1
1Department of Pharmacy Practice, College of Pharmacy, University of
Rhode Island, Kingston, RI; 2Department of Computer Science and
Statistics, College of Art and Science, University of Rhode Island, Kingston,
RI; 3The Warren Alpert Medical School of Brown University, Providence,
RI; 4Department of Biostatistics, Brown University School of Public
Health, Providence, RI
Background: Medication Assisted therapy (MAT) is approved for the
treatment of OUD (buprenorphine/naloxone, methadone, naltrexone).
Patients prescribed MAT may influence each other's health outcomes
due to shared prescribers and prescriptions. In the presence of dissem-
ination (or spillover), four effects are: direct (effect on patients pre-
scribed MAT themselves compared to those not prescribed, at a
fixed MAT coverage); indirect (effect on patients not prescribed
MAT, but sharing a network with patients prescribed MAT, comparing
two coverage levels); total (direct and indirect); overall (comparing two
coverage levels).
Objectives: To assess these causal effects of MAT on nonfatal opioid
overdose (OOD) among patients with diagnosed OUD within pre-
scriber networks in the U.S.
Methods: This was a retrospective cohort study using an administra-
tive database (Optum Clinformatics® Data Mart; Optum Insight, Eden
Prairie, MN). Patients (> = 18 years) with OUD diagnosis between
2010 and 2015 were identified and did not have OUD, OOD or
MAT during the previous year. Within 60 days of OUD diagnosis
(index period), patients were considered exposed to MAT if they had
> = 1 prescription. Patients were grouped into prescriber networks
by their main prescriber (determined by prescribing patterns), cover-
age of MAT for network was calculated, and networks >3 patients
were included. We used an inverse probability weighted approach to
quantify these effects of MAT during the index period on nonfatal
OOD.
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Results: A total of 18,353 patients in 2,278 networks were included,
11% had MAT prescriptions; 2% had nonfatal OOD during follow‐
up; 54% were female; mean age was 53 years; and mean Charlson
Comorbidity Index (CCI) was 1.37. Among networks with no MAT pre-
scribing, the unadjusted cumulative incidence of OOD was 2% (95%
confidence interval (CI): 0.016, 0.021). Adjusting for age, gender,
CCI, number of opioid dispensing and clustering by network with a
random intercept, the high coverage (87.5%) networks had 9% reduc-
tion in the total (CI: −0.17, −0.01) and an 8% reduction in the overall
effect estimates (CI: −0.14, −0.01) compared to medium coverage
(50%). The direct (8%) and indirect (1%) estimates were protective
but not significant (CI = −0.18,0.02; CI = −0.11, 0.09, respectively).
Conclusions: Among patients prescribed MAT in higher coverage net-
works, there were 9 per 100 patients fewer cases of nonfatal OOD
than among patients not prescribed MAT in medium coverage net-
works. Increasing MAT coverage within the prescriber practices could
offer additional benefit among OUD patients.
664 | Dual trajectories of opioid and
benzodiazepine use and risk of opioid
overdose among US Medicare beneficiaries
Ting Wang1; Yong Ge2; Walid F. Gellad3; James L. Huang4;
Weihsuan Lo‐Ciganic5
1Agricultural Information Institute, Beijing, China; 2University of Arizona,
Tucson, AZ; 3University of Pittsburgh, Pittsburgh, PA; 4University of
Florida, Gainesville, FL; 5University of Florida College of Pharmacy,
Gainesville, FL
Background: Despite clinical guidelines and US Food and Drug Admin-
istration black‐box warnings cautioning against concurrent opioid and
BZD use (hereafter OPI‐BZD use), the number of patients with OPI‐
BZD use increased by 41% between 2002 and 2014. OPI‐BZD use
increases the risk of overdose and other adverse outcomes, especially
among older adults. Little is known about the patterns of concurrent
OPI‐BZD use most associated with opioid overdose risk.
Objectives: To examine the association between OPI‐BZD dose and
duration trajectories and subsequent opioid overdose among Medi-
care beneficiaries.
Methods: This nested case–control study included 412,930 fee‐for‐
service Medicare beneficiaries who newly initiated prescription opi-
oids (OPIs) from 2011–2015. Cases (n = 346) were identified as having
a diagnosis of opioid overdose from inpatient or emergency depart-
ment claims within the year after initiating OPIs. We identified 1,524
controls (up to 1:10 ratio) matched by the propensity score including
age, gender, calendar year of OPI initiation, Elixhauser comorbidity
index, and the corresponding index date (i.e., matched case's overdose
date ±30 days) for each case. We used a machine learning approach,
specifically, bi‐kmeans clustering modeling, to identify distinct OPI‐
BZD dose and duration trajectories, based on average daily morphine
milligram equivalent (MME) for OPIs and standardized daily dose for
BZDs, within 90 days preceding the opioid overdose episode or the
corresponding index date. We used multivariable logistic regressions
to estimate odds ratios (OR) of opioid overdose risk across trajecto-
ries, adjusting for socio‐demographics and health status factors (e.g.,
mental health disorders) selected by the least absolute shrinkage and
selection operator (LASSO).
Results: Among 1,870 beneficiaries (mean age ± SD = 56.3 ± 15.4,
female = 41.4%, white = 78.3%), 4 distinct trajectories were identified
(1 trajectory with minimal or no OPI‐BZD use, and 3 OPI‐BZD trajec-
tories with different doses). Compared to beneficiaries with minimal or
no OPI‐BZD use (34.1% of the cohort), the overdose risk varied by tra-
jectory: consistent low‐dose OPI‐BZD use (58.7%; OR = 2.00,
95%CI = 1.38–2.90); consistent low‐dose OPI use and extremely
high‐dose BZD use (3.3%; OR = 5.76, 95%CI = 2.51–13.21); and consis-
tent high‐dose OPI‐BZD use (3.9%; OR = 11.45, 95%CI = 5.57–23.54).
Conclusions: Among Medicare fee‐for‐service beneficiaries, opioid
overdose odds varied substantially across OPI‐BZD use trajectories,
with individuals having consistent high‐dose OPI‐BZD use having
more than 10 times overdose odds.
665 | Concomitant use of opioids or
psychotropic medications among skeletal
muscle relaxant users in the United States: A
cross‐sectional study
Yan Li1; Gary M. Reisfield1; Chris Delcher2; Yu‐Jung Wei1;
Joshua Brown1; Almut G. Winterstein1
1University of Florida, Gainesville, FL; 2University of Kentucky, Lexington,
KY
Background: Skeletal muscle relaxants (SMR), a group of medications
indicated for acute and painful musculoskeletal conditions, are com-
monly co‐prescribed with opioids and psychotropic medications for
the treatment of pain and other comorbidities.
Objectives: To estimate the prevalence of SMR and concomitant opi-
oid or psychotropic medication use among commercially insured
adults in the US.
Methods: A cross‐sectional study was conducted using the IBM
MarketScan Commercial Claims Database. For each year from 2006
to 2015, we calculated proportions of SMR users with concomitant
use of opioids, antidepressants, anticonvulsants, benzodiazepines, or
other sedatives and hypnotics, where concomitant use was defined
as total overlap in days' supply of SMRs and the medication class of
interest for more than 14 days. The results were stratified by age
group and gender.
Results: We identified 6.7 million unique beneficiaries with SMR fills
during the study period. Overall, proportions of SMR users with con-
comitant medication use were 21.8% for opioids, 19.9% for antide-
pressants, 10.4% for anticonvulsants, 6.0% for benzodiazepines, and
5.5% for other sedatives and hypnotics. From 2006 to 2015, concom-
itant use of anticonvulsants increased by 59.5%. The increasing utiliza-
tion of opioids peaked around 2011 and declined slightly thereafter. In
comparison, changes in the use of other medication classes were
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small. Females had greater concomitant psychotropic medication use,
but similar concomitant opioid use compared to males. For all medica-
tion classes, concomitant use increased with age.
Conclusions: Concomitant use of opioids and psychotropic medica-
tions was common among SMR users. Given the overlapping adverse
event profiles, future studies should examine the risk of potential
harms associated with the use of these psychoactive medication
combinations.
666 | Predictors of long‐term opioid use in
HIV patients who initiated antiretroviral
therapy
GYeon Oh1,2; Emily S. Brouwer3,4; Erin L. Abner1,5,6;
David W. Fardo5,6; Patricia R. Freeman3,7; Daniela C. Moga1,3,5,7
1Department of Epidemiology, University of Kentucky, Lexington, KY;
2Kentucky Injury Prevention and Research Center, University of Kentucky,
Lexington, KY; 3Department of Pharmacy Practice and Science,
University of Kentucky, Lexington, KY; 4Takeda Pharmaceuticals,
Cambridge, MA; 5Sanders‐Brown Center on Aging, University of
Kentucky, Lexington, KY; 6Department of Biostatistics, University of
Kentucky, Lexington, KY; 7 Institute for Pharmaceutical Outcomes and
Policy, University of Kentucky, Lexington, KY
Background: Pain management is important for quality of life in
patients with HIV. However, pain management via opioids may have
an inappropriate risk/benefit ratio. Little is known about risk factors
associated with long‐term (LT) opioid use in this population.
Objectives: To identify the predictors of LT opioid use in HIV patients
who initiated standard combination anti‐retroviral therapy (cART).
Methods: Using Medicaid data (2002–2009) from Kentucky (KY),
Maryland (MD), North Carolina (NC), and Washington (WA), we con-
ducted a retrospective cohort study to examine LT opioid use in HIV
patients initiating cART. LT opioid use was defined as 90 days of con-
tinuous use, accepting <32 days gap over a six‐month period. We
excluded any patients who filled a prescription of ART or opioid during
the washout period defined as the six‐months prior to initiating cART.
Potential predictors of LT opioid use (demographic characteristics,
comorbidities, specific medications, and polypharmacy based on num-
ber of medications used, excluding cART) were measured during the
washout period and identified using logistic regression with backward
selection, and adjusted odds ratios (aOR) with 95% confidence inter-
vals (CI) were estimated.
Results: LT opioid use occurred among 1,192/13,003 (9.2%) eligible
patients. Strong predictors of LT opioid use were metastatic solid
tumors (aOR = 2.51; 95% CI = 1.15–5.47), substance use disorders
excluding alcohol and tobacco use (1.78; 1.53–2.07), hepatitis C infec-
tion (1.67; 1.41–1.98), pain‐related disorders [back pain (1.47; 1.14–
1.88), neuropathic pain (1.57; 1.27–1.94), and unclassified pain (1.50;
1.07–2.12)], chronic obstructive pulmonary disease (1.22; 1.01–
1.47), benzodiazepine use (1.48; 1.21–1.82), non‐opioid analgesics
(1.38; 1.19–1.59), antidepressant use (1.30; 1.14–1.49), and
polypharmacy (1.89; 1.55–2.32). Patient factors associated with lower
odds of LT opioid use were cardiovascular disease (0.69; 0.54–0.89),
younger age (0.98; 0.97–0.98), male sex (0.88; 0.77–0.99), and black
vs. white race (0.66; 0.56–0.78).
Conclusions: Comorbidities and polypharmacy were important predic-
tors of LT opioid use in HIV patients initiating cART. Further studies
should evaluate patient outcomes associated with prescribing LT opi-
oids in this population.
667 | Patterns of opioid use among patients
with cancer‐related pain diagnoses
ThamT. Le; Sean Fleming; Oluwadamilola Onasanya; Danya M. Qato;
Linda Simoni‐Wastila
University of Maryland, Baltimore, MD
Background: Efforts to curb the opioid overdose crisis are sweeping
and may impact the prescribing of controlled substances in unin-
tended ways. Anecdotal reports suggest patients with cancer‐related
pain bear a disportionate burden as scrutiny of opioid utilization inten-
sifies, but this population's patterns of opioid use remain
understudied.
Objectives: To examine patterns of opioid use among patients with
cancer pain diagnoses.
Methods: A retrospective cohort study of 18 to 64 years old cancer
patients identified in IQVIA™ PharMetrics Plus (1/1/2007–12/
312015). Patients with cancer pain diagnoses (ICD‐9 code 3383) were
compared to those without cancer pain diagnosis. Individuals were
required for continuous enrollment of insurance plans for 12 months
pre‐ and 24 months post‐index date of cancer diagnosis. Prevalent
opioid use was defined as any use post‐index. Incident opioid users
were individuals with opioid use post‐index but no use pre‐index.
Morphine equivalent daily dose (MEDD) was calculated as (Quantity
x Strength x Conversion Factor)/Total Days Supplied. Descriptive
analyses examined prevalence, incidence, duration of use, and MEDD.
As well, adjusted logistic regression compared opioid use in those with
and without cancer pain.
Results: Our sample included 34,979 individuals, 648 (1.9%) with
and 34,331 (98.1%) without cancer pain. Of these, 38.3% were
males, with mean and median age of 54 and 55 years. Overall,
8,856 (25.3%) patients used opioids during follow‐up, and 272
(3.1%) were new users. Prevalent opioid use in patients with and
without diagnoses of cancer pain were 42.0% and 25.0%, respec-
tively. In addition, 1.9% and 2.0% of patients with and without can-
cer pain were new users. Mean (median) duration of opioid use
24 months post‐index were 345 (230) days and 21 (120) days for
patients with and without cancer pain. Mean (median) MEDD among
individuals with and without cancer pain were 58.6 mg (30.1 mg),
and 25.7 mg (12.2 mg), respectively. Adjusting for other clinical,
demographic, and prescription factors, patients with diagnoses of
cancer pain had 2.3 times (95% CI = 1.7–3.1) the odds of using opi-
oids compared to patients without cancer pain.
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Conclusions: Despite higher likelihood of opioid use, over half of
patients with cancer pain diagnoses had no opioid use during follow‐
up. Overall, cancer patients with cancer‐related pain were more than
two times likely to receive an opioid and had double MEDD than
those without cancer pain. Optimal treatment of cancer pain are diffi-
cult to define. More research to examine the impact of increasingly
restrictive opioid policies on patients requiring pain management is
needed.
668 | Opioid overdose in patients treated
with extended‐release naltrexone:
Postmarketing data from 2006 to 2018
Gary Bloomgren; Made Wenten; Kimberly Marcopul;
Prashanthi Vunnava; Marie Liles‐Burden; Avani Desai; Sarah Akerman;
Maria A. Sullivan; James Fratantonio; Priya Jain
Alkermes, Inc., Waltham, MA
Background: Opioid overdose rates are rising in the United
States. Patients with opioid use disorder (OUD) treated with
monthly naltrexone extended‐release injectable suspension (XR‐
NTX), a μ‐opioid receptor antagonist, may be vulnerable to opioid
overdose if they attempt to override the blockade, miss a dose,
or discontinue XR‐NTX. Clinical trials of patients treated with
XR‐NTX have not demonstrated an increase in overdose suscepti-
bility compared with treatment‐as‐usual, placebo, or
buprenorphine‐naloxone.
Objectives: To assess postmarketing rates of reported fatal and non‐
fatal opioid overdose, and all‐cause overdose, during and after treat-
ment with XR‐NTX.
Methods: Case data from postmarketing adverse event reports
received from 2006 to 2018 for patients treated with XR‐NTX (for
any indication) were manually reviewed for reported opioid overdose
cases; identified cases were adjudicated by ≥2 reviewers. Assessable
cases were categorized by overdose type and timing of the event from
the last dose of XR‐NTX (latency): ≤28 days (on‐treatment), 29–
56 days, and > 56 days.
Results: An estimated 495,602 patients were treated with XR‐NTX
(for any indication) from 2006 to 2018. We identified 161 cases in
which opioids were specifically stated as the cause of overdose;
41% (66/161) of cases contained adequate information to assess
latency of event from last dose of XR‐NTX. For the 66 assessable
cases, opioid overdose rates were similar for each latency category.
For the assessable cases of opioid overdose, the reporting rates
(per 10,000 patients) were 0.54 (0.24, fatal), 0.34 (0.16, fatal), and
0.44 (0.40 fatal) for ≤28 days, 29–56 days, and > 56 days from last
dose of XR‐NTX, respectively. For 63 cases with sufficient informa-
tion, the median latency for events occurring ≤28 days from last
XR‐NTX dose was 18 days (range: 1 to 28 days); for 29–56 days
was 43 days (range: 29 to 56 days); and for >56 days was 76.5 days
(range: 60 to 145 days). For the 131 assessable cases of all‐cause
overdose, the reporting rates (per 10,000 patients) were 1.11
(0.46, fatal), 0.67 (0.38, fatal), and 0.87 (0.71, fatal) for ≤28 days,
29–56 days, and > 56 days from last does of XR‐NTX, respectively.
Conclusions: Based on assessment of 12 years of postmarketing
overdose data, the rates of fatal and non‐fatal opioid overdose and
all‐cause overdose during or after treatment with XR‐NTX were < 1/
1000. As the incidence of opioid overdose in the United States con-
tinues to rise, further research is needed to better understand the
risk of overdose in patients receiving or discontinuing medication
for opioid use disorder. Analysis was funded by Alkermes, Inc.
669 | Recent changes in the prevalence of
rapid tapering of opioid doses in Ontario,
Canada
Mina Tadrous1; Wayne Khuu2; Diana Martins1; David N. Juurlink2;
J. Michael Paterson2; Muhammad M. Mamdani1; Tara Gomes1
1St. Michael's Hospital, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada
Background: There is emerging concern that opioid doses are being
rapidly tapered to quickly conform with new opioid guidelines and
changing policies. This practice is concerning as it may lead to patients
to rapidly entering withdrawal, and potentially seeking opioids from
illicit sources.
Objectives: To investigate the prevalence of rapid opioid tapering in
Ontario, Canada.
Methods: We conducted a cross‐sectional study among patients
receiving high‐dose (≥ 200 MME for at least 30 days) opioids from
January 2014 to December 2017. We measured the proportion of
recipients who experienced a drop in their dose of ≥50% that was
sustained for at least 30 days. We also explored the proportion of
recipients who had their opioids abruptly discontinued.
Results: Overall, 38.3% of individuals who met our eligibility criteria
were rapidly tapered during the study period. The annual prevalence
of rapid tapering was stable between 2014 (16.2%) and 2016
(16.3%), before increasing to 20.2% in 2017. The monthly prevalence
of rapid tapering ranged between 1.8% and 2.3% prior to November
2016 at which point it increased, reaching a high of 3.4% in March
2017. A similar trend was observed in the annual prevalence of abrupt
opioid discontinuation (range 5.9 to 6.1% from 2014 to 2016; rising to
7.4% in 2017).
Conclusions: Recent policy changes and updated guidelines may
have led to a small increase in the rate of rapid dose tapering
and abrupt opioid discontinuation. The implications of this increase
should be studied for potentially serious adverse effects on
patients.
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670 | Association of new opioid continuation
with surgical specialty and type in the United
States
Omar Mansour1; Mark Bicket2; Irene Murimi1; Christopher Wu3;
G. Caleb Alexander1
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Johns Hopkins University School of Medicine, Baltimore, MD; 3Hospital
for Special Surgery, New York, NY
Background: The consequences of opioids—including post‐surgical
prescriptions—remain a critical public health issue.
Objectives: To determine how procedure type and subspecialty group
influence new opioid use after procedures.
Methods: Design and setting: Retrospective cohort study using IBM
MarketScan Commercial Claims and Encounters data from January
2011 to December 2015 of adult individuals who had only one proce-
dure on a given day and filled at least one opioid prescription in the peri-
operative period, from 30 days before to 2weeks after the procedure. A
multivariable logistic regression model was used to determine the dif-
ference in new opioid continuation among type of procedure and sub-
specialty. Exposure: The preassigned MarketScan service categories
were used to define two types of procedures: (1) “operating room
(OR) procedures” were those prespecified as “major” procedures or
occurring in the operating room, and (2) “non‐ORprocedures”were pro-
cedures prespecified as “minor”, “other”, or not occurring in the operat-
ing room. For each invasive procedure claim, the surgical subspecialty
was identified using the provider type associated with the claim. For a
comparison group of individuals not exposed to procedures, we identi-
fied a 10% sample of patients aged 18 to 64 who did not undergo a pro-
cedure in the study periodOutcome: New opioid continuation defined
priori as receipt of prescription opioids between 90–180 days after
the procedure.
Results: Among 912,882 individuals, new opioid continuation was
higher for non‐OR compared to OR procedures (13.1% versus 9.2%;
aOR 1.61; 95% CI 1.59–1.64) and higher for subspecialties including
colorectal surgery (aOR1.35; 95%CI 1.26–1.43) and cardiovascular sur-
gery (aOR 1.30; 95% CI 1.12–1.50) compared to urology as a referent.
Conclusions: Opioids prescriptions associated with non‐operating
room surgical exposures appear to confer higher risk regarding con-
version to new long‐term opioid use.
671 | Opioid and concomitant
benzodiazepine outpatient prescription
claims among women with pregnancies in
2014
Elizabeth C. Ailes; April D. Summers; Shin Y. Kim; Kayla N. Anderson;
Suzanne M. Gilboa
CDC, Atlanta, GA
Background: Opioid exposure during pregnancy has been associ-
ated with adverse neonatal and infant outcomes; some evidence
suggests that concomitant use of benzodiazepines may increase
these risks.
Objectives: To document the proportion of women who filled any opi-
oid prescription, as well as those who filled both an opioid and a ben-
zodiazepine prescription, during pregnancy.
Methods: We used data from the 2013–2015 IBM MarketScan
Commercial Database for this analysis. We included women aged
15–44 years with private health insurance and prescription drug
coverage. Pregnancies were identified using pregnancy‐related diag-
nosis or procedure codes indicating a live birth or pregnancy loss.
We included pregnancies with an estimated date of last menstrual
period (LMP) or date of delivery/end of pregnancy in 2014 (i.e., at
least one day of pregnancy in 2014). We then restricted to pregnan-
cies with continuous enrollment from 90 days before LMP to 90 days
after the end of pregnancy or that were missing only one month of
enrollment during that time period. To capture any prescriptions
filled during pregnancy (defined as LMP to seven days before date
of delivery/end of pregnancy to exclude delivery‐related dispensa-
tions), we searched outpatient pharmacy prescription claims for opi-
oid‐ and benzodiazepine‐containing medications using National Drug
Codes.
Results: Among the 482,917 pregnancies that met our inclusion
criteria, 9.7% of women filled at least one prescription for an opioid
from an outpatient pharmacy during pregnancy. The most common
types of opioids dispensed during pregnancy were hydrocodone
(5.0% of all pregnancies), codeine (3.3%) and oxycodone (1.8%). Opioid
claims varied by time period during pregnancy, with 5.1% filling in
their first trimester, 3.7% in second, and 4.1% in third (excluding the
week before delivery/end of pregnancy). Among women who filled a
prescription for an opioid during pregnancy, 7.8% also filled a prescrip-
tion for a benzodiazepine‐containing medication during pregnancy,
with the most frequent combination of medications being
hydrocodone and alprazolam (2.4%).
Conclusions: In this dataset, nearly 1 in 10 women filled a prescription
for an opioid from an outpatient pharmacy during pregnancy; among
these women, about 8% also filled a prescription for a benzodiazepine.
Because prenatal use of opioids poses recognized fetal and infant risks
with additional safety concerns around concomitant use of benzodiaz-
epines, more work is needed to understand opioid prescribing patterns
and outcomes to promote guideline‐concordant prescribing during
pregnancy.
672 | How many elderly in Norway are
persistent opioid users? ‐a comparison of two
approaches to define persistent opioid use
Kristian Svendsen1; Beate H. Garcia1,2; Kjell H. Halvorsen1;
Lars Småbrekke1
1UiT ‐ The Arctic University of Norway, Tromsø, Norway; 2Hospital
Pharmacy Northern Norway Trust, Tromsø, Norway
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Background: Traditional methods for identifying persistent opioid use
provide limited information on the longitudinal course of use. Group
based trajectory modeling (GBTM) may overcome some of these
limitations.
Objectives: Aim 1: Defining persistent opioid use and comparing the
results from two approaches; 1) two traditional definitions using
amount dispensed and distribution of dispensing; 2) GBTM Aim 2:
Use GBTM in a persistent opioid use population to look at the trajec-
tories of use.
Methods: We used data from the Norwegian Prescription Database
(NorPD) from 2013–2014 of dispensed opioid use among persons
65 years or older. We included only persons receiving at least two pre-
scriptions within 365 days. We defined persistent opioid use to cap-
ture continuous high‐dose users over one year (strict), or to capture
persistent use of lower doses allowing for at least one quarter of the
year without dispensing (wide). The results were compared to GBTM
with three groups. The model used oral morphine equivalents and
investigated changes in amount from the first 30 days of use in
2013 in the following 11 periods of 30 days. The overlap between
the clinical definitions and the GBTM was used to compare the
approaches. In addition, GBTM was applied on the strict definition
population to discover any additional useful information about the
usage patterns.
Results: There are 104,411 elderly with more than one prescription
of opioids. By the strict definition 4.7% of the opioid users were
persistent users and by the wide definition 28.3%. Using GBTM,
6.1% of patients had an increasing use of opioids and 40.2% had a
stabile use. The overlap between the strict definition and GBTM
was poor. Only 26% of the increased use GBTM group and 8% of
the steady use group was also part of the strict definition. The over-
lap for the wide definition was better, 87% of the increased use
GBTM group and 52% of the stabile use group was included in both.
These two GBTM groups covered almost all persons in the strict/
wide definitions. In the non‐overlapping part of the GBTM groups,
the average doses dispensed were too low to be captured by the
clinical definitions, indicating low doses or intermittent use. Finally
the GBTM grouping of patients in the strict definition showed that
14.2% had a strong increasing use, 18.3% had a mildly increasing
use and the rest had use throughout the 360 days without any
increases.
Conclusions: Using GBTM in NorPD does not identify persistent opi-
oid users well enough. Our GBTM model had high specificity but low
sensitivity. However GBTM can provide interesting results when used
in conjunction with other approaches.
673 | Regional examination of increased
buprenorphine in the US (2008–2017)
Amir Reza Pashmineh Azar; Warren Lam; Alyssa Muchisky;
Suhail Kaleem; Laura Lockard; Mark Mandel
Geisinger Commonwealth School of Medicine, Scranton, PA
Background: The opioid epidemic in the United States continues to be
a problem with no clear solution. Recent advances in the medical field
have offered prescription medications such as buprenorphine to treat
opioid dependence.
Objectives: The purpose of this study was to identify trends in
buprenorphine prescriptions across states and U.S. territories.
Methods: Data were extracted from the U.S. Drug Enforcement
Administration's Automation of Reports and Consolidated Orders Sys-
tem (ARCOS) for 2008–2017. Each state was analyzed for
buprenorphine prescription in milligrams per 100,000 persons.
Results: The average percent increase across all states and territories
from 2008–2017 was 304%. North Carolina and Arkansas saw the
greatest percentage increase in buprenorphine prescription per
100,000 at 785% and 701%, respectively. Maine and Utah had the
lowest percentage increase with 105% and 116%, respectively. In gen-
eral, the midwest had the greatest overall percentage increase in
buprenorphine prescription over the decade, however, the northeast
region has consistently shown the highest prescriptions per 100 K
throughout the ten‐year span.
Conclusions: All states and territories across the United States had
increased buprenorphine prescription over the last decade from
2008–2017. Further investigation into the causal factors underlying
these pronounced elevations are ongoing.
674 | Incidence and persistence of opioid
use after surgery among opioid‐Naïve adults
in a large commercial US health plan
Sandra Wu1; Xian Zhang1; Shawn Boykin2; Richard Scranton2;
Mary Helen Tran2
1Healthcore, Inc., Wilmington, DE; 2Pacira Pharmaceuticals, Inc.,
Parsippany, NJ
Background: Postsurgical opioid use has been well characterized in
the US, but less is understood about the incidence and persistence
of opioid Rx among insured opioid‐naïve pts across surgical specialties.
Objectives: To investigate the incidence/persistence of opioid use
after surgery among opioid‐naïve adults in a large US commercial
health plan and provide insights on postsurgical opioid overuse for
pts, payers, and providers.
Methods: Using the HealthCore Integrated Research Database, we
conducted a retrospective claims study of pts aged ≥18 y who
underwent primary surgical procedures between 4/1/2015 and 3/
31/2016. Eligible pts had 1 surgery during the index period, no opioid
Rx filled 1–6 mo before index surgery, inpatient stay ≤30 d, ≤2 cancer
diagnoses, and complete medical/Rx claims during 6 mo before and
after index surgery. Opioid use was tracked in 3 time periods:
perisurgical (opioid medical claim/Rx between 1 mo presurgery & 2
wk postsurgery), continued (perisurgical opioid & ≥1 opioid Rx filled
between 3 wk & 3 mo postsurgery), and persistent use (perisurgical
opioid & ≥1 opioid Rx filled 4–6 mo postsurgery).
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Results: Of 778,479 screened pts, 387,186 were eligible. Mean (SD)
age was 54 (16) y and 54% were women. Among surgeries with
>100 pts (n = 384,976), 198,257 (52%) pts had perisurgical opioid
use. Among these, 22,291 (11%) pts had continued and 14,355 (7%)
had persistent opioid use. Incidence of perisurgical opioid Rx initiation
was higher (82%) among pts undergoing musculoskeletal vs
nonmusculoskeletal (44%) surgery. Incidence varied by specialty
(range, 10–92%) but was ≥75% for high‐volume surgeries (eg, chole-
cystectomy, 89%; arthroscopic rotator cuff, 89%; inguinal hernia,
88%; cesarean, 79%). A gradated decrease was seen in opioid Rx from
perisurgical to continued to persistent use following high‐volume mus-
culoskeletal procedures, with the highest rates of persistent use for
knee replacement (16%), cervical fusion (14%), and lumbar decompres-
sion (10%). In contrast, a steep drop‐off in opioid Rx use from
perisurgical to continued use was observed for high‐volume
nonmusculoskeletal surgeries followed by similar levels of continued
vs persistent use (eg, cholecystectomy, 5–6%; inguinal hernia repair,
5%; cesarean delivery, 4–5%).
Conclusions: ~200,000 (52%) opioid‐naïve surgery pts initiated post-
surgical opioids in a large commercial US health plan, of whom 7%
had persistent use. Patterning of opioid Rx duration varied by spe-
cialty/procedure. These data highlight procedures that may benefit
most by adoption of opioid‐reducing multimodal pain‐management
protocols.
675 | Incidence of chronic opioid use in
seniors
Audrey Beliveau1; Anne‐Marie Castilloux1; Cara Tanenbaum1,2;
Philippe Vincent1,3; Cristiano Soares de Moura4; Sasha Bernatsky4;
Iris Pujade5; Yola Moride1
1Université de Montréal, Montreal, QC, Canada; 2 Institut de Gériatrie de
Montréal, Montreal, QC, Canada; 3 Institut universitaire en santé mentale
de Montréal (IUSMM), Montreal, QC, Canada; 4McGill University,
Montreal, QC, Canada; 5University Hospital of Bordeaux, Bordeaux,
France
Background: Chronic opioid use in non‐cancer patients is a well‐
known predictor of opioid‐related harms. Data on opioid use in vul-
nerable populations, such as seniors, are scarce.
Objectives: i) To estimate the incidence of chronic opioid use in
seniors (age ≥ 65); ii) To compare the characteristics of chronic and
non‐chronic opioid users.
Methods: A cohort study was conducted using the Quebec adminis-
trative claims (RAMQ) databases. We selected a random sample of
non‐cancer outpatients aged ≥65 initiating an opioid (index date)
between 01 January 2014 and 31 December 2016. Patients were
followed for 12 months after index date. The standard definition for
chronic opioid use adopted was 90 consecutive or 120 cumulative
days with an active opioid prescription during the 12‐month follow‐
up. Demographic characteristics, medical history, comorbidity, and
opioid treatments were compared in the chronic and non‐chronic opi-
oid users.
Results: The cohort included 34,779 elderly opioid‐initiators, of
whom 1601 (4.6%) transitioned to chronic use (mean [SD] duration
of use was 241.8 [87.4] days vs 13.2 [17.3] days in non‐chronic
users). The mean daily dose in morphine equivalent (MME/day)
[SD] was however lower in chronic than in non‐chronic users (29.2
[28.1] vs 32.9 [21.0]). Chronic users were more likely (71.2%) than
non‐chronic users (60%) to be female (11% diff. 95%CI: 9–14%).
Over a quarter (27.8%) of chronic users were ≥ 85 years of age
vs 12.0% in non‐chronic users (16% diff. [14–18%]). In the year prior
to index date almost half of chronic users (46.4%) had a diagnosis
associated with chronic pain (arthritis, spinal stenosis, fibromyalgia,
neuropathy, etc.) vs 32.0% in non‐chronic users (14% diff. [12–
17%]). One‐fifth (20%) of chronic users had a psychiatric comorbid-
ity (mood disorder, schizophrenia, anxiety, etc.) vs 10% in non‐
chronic users (10% diff. [8–12%]) and, 10.6% of chronic users had
dementia vs 4.1% in non‐chronic users (6% diff. [5–8%]). Of chronic
users, 22.5% started opioid therapy with a long‐acting opioid vs
1.4% of non‐chronic users (21% diff. [19–23%]) and transdermal fen-
tanyl at initial prescription was more frequent in chronic (7.3%) than
non‐chronic (0.3%) users (7% diff. [6–8%]). Almost a quarter of
chronic users (24.1%) had an initial opioid prescription ≥30 days vs
3.8% in non‐chronic users (20% diff. [18–23%]).
Conclusions: Female sex, age ≥ 85, chronic pain, mental health issues,
dementia, initial prescription of ≥1 month and long‐acting opioids
were more common in chronic opioid users. A better understanding
of these factors may inform targeted interventions and policies to
reduce opioid use in seniors.
676 | Trends in the acquisition and
distribution of opioid drugs among ten
contiguous states
Michael Belko; Elizabeth Stackhouse; Zoe Landau; Alex Mettler;
Christine Murphy; Kristin Feickert; Ceilia Severini; Stephanie Nichols;
Kenneth McCall; Brian Piper
Geisinger Commonwealth School of Medicine, Scranton, PA
Background: The opioid epidemic has garnered nationwide attention
in recent years as a public health crisis and national emergency, with
an estimated 130 Americans dying each day from an opioid overdose.
West Virginia, Ohio, New York, and Pennsylvania have been particu-
larly impacted.
Objectives: This study seeks to examine the pattern of acquisition/
distribution between 2007 and 2017 for 19 different opioid medica-
tions across 10 contiguous states (PA, NY, NJ, DE, MD, WV, OH,
MI, IN, KY) in the eastern and midwestern USA.
Methods: Drug weights were obtained from the US Automated
Reports of Consolidated Orders System (October, 2018), a compre-
hensive publicly available resource from the Drug Enforcement
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Administration. Total drug weight acquired/distributed is reported
each quarter year, and these values were converted to oral morphine
equivalents to facilitate comparison among drugs.
Results: Over the studied period, there has been a general downward
trend in legal acquisition/distribution of common opiates such as fen-
tanyl and oxycodone. For example, in Pennsylvania, oxycodone usage
declined by 22.7% between 2012 and 2017. Similarly, New York and
Ohio oxycodone usage between 2012 and 2017 declined by 31.8%
and 20.3% respectively. Oxycodone usage declined notably in West
Virginia, decreasing by 44.9% between 2012 and 2017.
Conclusions: With a better understanding of patterns of use and how
that may affect adjacent states, public policy may be shaped to best
mitigate the worst outcomes of the opioid epidemic locally and
nationwide.
677 | Oversight of extended release/long
acting (ER/LA) opioids by the U.S. Food and
Drug Administration: A narrative review
James Heyward1; Lily Olson1; Josh Sharfstein1; Peter Lurie2;
G. Caleb Alexander1,3
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Center for Science in the Public Interest, Washington, DC; 3 Johns
Hopkins Medicine, Baltimore, MD
Background: Extended release and long acting (ER/LA) opioids are
powerful pain relievers with a high potential for non‐medical use.
Since 2012, they have been subject to a U.S. Food and Drug Adminis-
tration (FDA)‐mandated Risk Evaluation and Mitigation Strategy
(REMS), including voluntary prescriber continuing education (CE), to
“reduce serious adverse outcomes resulting from inappropriate pre-
scribing, misuse, and abuse.”
Objectives: To evaluate FDA and sponsor assessments of the REMS,
including whether and how well such assessments allowed the effec-
tiveness of the REMS to be appraised.
Methods: We conducted a narrative review of 5,963 pages of FDA
documents obtained through a Freedom of Information Act (FOIA)
request, including annual, manufacturer‐submitted, REMS assess-
ments from 2012 through 2017 and FDA reviews of these
assessments.
Results: Based on a preliminary review of the documents obtained,
the REMS assessments included enrollment targets, compliance
audits, prescriber and pharmacist surveys, and safety and prescribing
surveillance. The REMS's primary goal was to train 60% of ER/LA pre-
scribers (192,000/320,000) within four years; 46% of this target num-
ber (88,316/192,000) were trained within four years from REMS
initiation. Audits of REMS programs indicated close adherence to
FDA guidelines for the design of CE, non‐representative surveys of
self‐selected populations suggested modestly greater ER/LA knowl-
edge among CE completers than non‐completers and most claims‐
based surveillance indicated declining ER/LA use. Despite this, the
effect of the REMS on prescribing or safety outcomes could not be
ascertained because claims‐based analyses lacked adequate controls
and were not linked, on a prescriber‐level, to CE completion. Although
the FDA requested studies tracking prescribing and safety as a func-
tion of CE training, as of the 60‐month report (2017), these had not
been performed. In its 2017 review, the FDA concluded it was impos-
sible to determine if the REMS was successfully impacting prescribing
or patient safety.
Conclusions: Five years after initiation, the FDA and ER/LA sponsors
could not determine whether the ER/LA REMS reduced inappropri-
ate prescribing or improved patient outcomes. Alternative observa-
tional study designs would have allowed for stronger causal
inference.
678 | Antidiabetic medication, level of
glycaemic control, and risk of fracture in
patients with type 2 diabetes mellitus: A
nested case–control study
Sarah H.R. Charlier1,2; Janina Vavanikunnel1; Claudia Becker1,2;
Susan S. Jick3,4; Christian Meier1; Christoph R. Meier1,2,3
1University Hospital Basel, Basel, Switzerland; 2University of Basel, Basel,
Switzerland; 3Boston Collaborative Drug Surveillance Program, Lexington,
MA; 4Boston University School of Medicine, Lexington, MA
Background: Patients with diabetes mellitus type 2 (DM2) have an
increased risk of fracture. However, the effect of antidiabetic medica-
tion in association with glycaemic control on the risk of fracture is not
well understood.
Objectives: To evaluate the association between use of antidiabetic
medication, level of glycaemic control, and risk of low‐trauma frac-
tures in patients with incident DM2.
Methods: We conducted a nested case–control analysis with
patients registered within the UK‐based Clinical Practice Research
Datalink who had an incident diagnosis of DM2 from 1995–2017.
Cases were patients with a low‐trauma fracture after the DM diag-
nosis. We excluded patients with diagnosed osteoporosis, cancer,
HIV, and alcoholism. We matched four controls to each case by
age, sex, general practice, fracture date, DM type and DM duration.
Exposure of interest was any prescription for an antidiabetic drug
(metformin, DPP4‐inhibitors, GLP‐1 receptor agonists, SGLT‐2 inhib-
itors, sulfonylureas). We assessed glycaemic control as the average
HbA1c level during the last three years before the fracture. We
conducted conditional logistic regression analyses, and adjusted for
covariates including body mass index, smoking, and previous
fractures.
Results: We identified 8122 cases (31.6% males) and 32470 matched
controls. Current use (last prescription ≤60 days before the fracture)
and past use (last prescription >60 days before the fracture) of
glitazones (pioglitazone and rosiglitazone) was significantly associated
with an increased risk of fracture compared to non‐use of glitazones.
Long‐term use of glitazones also led to an increased risk of fracture
(1–9 prescriptions aOR 1.22, CI 95% 1.10–1.34; 10–19 prescriptions
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aOR 1.39, CI 95% 1.22–1.59; ≥20 prescriptions aOR 1.41, CI 95%
1.27–1.55) compared to non‐use. Both associations were independent
of HbA1c levels. In contrast, we found a statistically significant
decreased risk of fracture in current users of metformin with good
to moderate HbA1c levels of 6.5–7.5% (aOR 0.88, CI 95% 0.80–
0.96) and 7.5–8.5% (aOR 0.79, CI 95% 0.68–0.91) compared to non‐
users of metformin. However, patients with HbA1c levels <6.5%
(aOR 0.90, CI 95% 0.80–1.01) or > 8.5% (aOR 0.86, CI 95% 0.71–
1.04) had no altered risk of fracture compared to non‐users. We
observed no statistically significant association between the use of
other antidiabetic medication, HbA1c level, and the risk of fracture.
Conclusions: The effect of glycaemic control on the risk of low‐trauma
fracture differs between metformin and glitazone users.
679 | Risk of hand osteoarthritis in new
users of hormone replacement therapy: A
nested case–control analysis
Theresa Burkard1,2; Marlene Rauch1,2; Julia Spoendlin1,2;
Daniel Prieto‐Alhambra3; Susan S. Jick4,5; Christoph R. Meier1,2,4
1University of Basel, Basel, Switzerland; 2University Hospital Basel, Basel,
Switzerland; 3University Oxford, Oxford, UK; 4Boston Collaborative Drug
Surveillance Program, Lexington, MA; 5Boston University School of Public
Health, Boston, MA
Background: The increase in hand osteoarthritis (OA) incidence in
postmenopausal women and the presence of estrogen receptors in
cartilage suggest that hormone replacement therapy (HRT) could help
to prevent the development of OA. Small cross‐sectional studies
investigating the association between HRT and hand OA yielded con-
flicting results.
Objectives: To estimate the risk of hand osteoarthritis (OA) in new
users of hormone replacement therapy (HRT).
Methods: We conducted a nested case–control study using data
from the UK based Clinical Practice Research Datalink (1998–
2017). In an inception cohort of women entering at age 45, we
matched patients with hand OA during follow‐up (cases) to OA‐free
controls (1:4, risk‐set sampling) on age and calendar date (index
date). We applied multivariable conditional logistic regression to cal-
culate odds ratios (OR) with 95% confidence intervals (CI) of hand
OA in association with new HRT use when compared to non‐use,
overall, stratified by timing of HRT use (current or past use) and
in patients with recorded menopause only. In women with recorded
menopause, we calculated separate ORs subdivided by time
between menopause and HT initiation (current users) and by time
between HT cessation and the index date (past users) when com-
pared to non‐users.
Results: Among 3440 cases and 13,760 controls (mean age 50.9 years),
we observed an overall adjusted OR (aOR) of hand OA of 1.32 (95% CI
1.17–1.48) in HRT users compared to non‐users which attenuated to
0.98 (95% CI 0.85–1.14) in patients with recorded menopause. In all
analyses, compared to non‐use, current HRT use was associated with
lower and past use with higher aORs of hand OA than overall HRT
use. Among women with recorded menopause, the proportion of hand
osteoarthritis diagnoses decreased with time after menopause. A max-
imum proportion of 18.4% of women (158 of 860 cases) had hand
osteoarthritis recorded within ≤1 year after recorded menopause.
Furthermore, in patients with recorded menopause, we observed a
non‐significantly decreased aOR of hand OA in current users if HRT
was initiated within 90 days before/after recorded menopause (0.72,
95% CI 0.55–0.96), aORs increasing with later HRT initiation. Further-
more, among past users, compared to non‐users, the aOR of hand OA
was non‐significantly increased (1.25, 95% CI 0.86–1.81) if HRT was
stopped ≤1 year before the index date, aORs approximated the null
with increasing duration between HT cessation and the index date.
Conclusions: HRT was associated with a decreased risk of hand OA if
initiated around menopause and the risk of hand OA increased shortly
after HRT cessation.
680 | Association between fluoroquinolone
use and Achilles tendon pathology: Active
comparator new user investigation
Mackenzie M. Herzog; Virginia Pate; Jennifer L. Lund;
Stephen W. Marshall
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Fluoroquinolones are broad‐spectrum antibiotics that
have an affinity for connective tissue, which may result in a nega-
tive impact to collagen fibrils. Previous case series have suggested
a potential association with increased risk of Achilles tendon
pathology.
Objectives: Further investigate the association between fluoroquin-
olone use and Achilles pathology using an active comparator new
user study design in a large population of commercially‐insured
individuals.
Methods: The MarketScan Commercial Claims and Encounters data-
base was used to assess Achilles pathology among fluoroquinolone
initiators from 2000–2014. Two comparator groups were used: sul-
fonamide and amoxicillin initiators, both antibiotics with similar indi-
cations for treatment. Oral fluoroquinolone, sulfonamide, and
amoxicillin initiators aged 13–64 years were identified using a 180‐
day washout period and followed until discontinuation (with a 60‐
day grace period), end of continuous enrollment, or switching treat-
ments. Achilles pathology included ruptures and tendinopathies,
which were identified by ICD‐9 or CPT code following a 180‐day
washout period. Cox proportional hazard models were used to esti-
mate adjusted hazard ratios (adjHR) and 95% confidence intervals
(CI) after standardizing the cohort by age, sex, baseline comorbidi-
ties, and indications using inverse probability of treatment weighting
(IPTW).
Results: There were 14,735,795 fluoroquinolone, 7,287,896 sulfon-
amide initiators, and 22,927,124 amoxicillin initiators. Fluoroquino-
lone initiators were slightly older, more likely to be female, and
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had more baseline comorbidities. There were 12,802 Achilles
pathologies among fluoroquinolone initiators (45.7 per 10,000 per-
son‐years), 4,170 Achilles pathologies among sulfonamide initiators
(35.0 per 10,000 person‐years), and 8,596 Achilles pathologies
among amoxicillin initiators (60.2 per 10,000 person‐years). After
IPTW, fluoroquinolone initiators were 12% more likely than sulfon-
amide initiators (adjHR = 1.12, 95% CI 1.08, 1.15) and 26% more
likely than amoxicillin initiators (adjHR = 1.26, 95% CI 1.23, 1.30)
to have an Achilles pathology during or immediately following anti-
biotic use.
Conclusions: An increased risk of Achilles pathology was observed
among fluoroquinolone initiators compared to sulfonamide and amox-
icillin initiators, but the increase in risk was attenuated when com-
pared to sulfonamide initiators. These findings highlight the
importance of selecting an appropriate comparator group and carefully
considering unmeasured confounders.
681 | Dose‐dependent effects of gabapentin
and pregabalin on the day of surgery in total
hip and knee arthroplasties
Tetsu Ohnuma1; Karthik Raghunathan1,2; Sean Moore1;
Soko Setoguchi3,4; Alan R. Ellis5; John Whittle1; Srinivas Pyati1,2;
William E. Bryan2; Marc J. Pepin2; Raquel R. Bartz1;
Vijay Krishnamoorthy1
1Duke University Medical Center, Durham, NC; 2Patient Safety Center of
Inquiry, Durham VA Medical Center, Durham, NC; 3Rutgers Robert Wood
Medical School, Piscataway, NJ; 4Rutgers School of Public Health,
Piscataway, NJ; 5North Carolina State University, Raleigh, NC
Background: Gabapentinoids (GBPs), gabapentin and pregabalin, are
commonly prescribed drugs within perioperative multimodal analgesia
protocols. Despite widespread use in a wide range of doses, little is
known regarding the optimal dose which reduces opioid consumption
with minimal risks.
Objectives: To assess dose‐dependent effects of GBPs on pulmonary
complications and opioid consumption following total hip or total knee
arthroplasty (THA/TKA).
Methods: Using the Premier Database of more than 500 US hospi-
tals, including information on patient demographics, hospital charac-
teristics, patient‐specific date‐stamped billing logs, and ICD‐9 codes,
we identified adults who underwent elective primary THA/TKA
between 2009 and 2014. The exposure was receipt of a GBP
(gabapentin or pregabalin) on the day of surgery. Gabapentin dose
was categorized into five groups: none, 1–350, 351–700, 701–
1050, and > 1050 mg per day. Pregabalin dose was categorized
into four groups: none, 1–110, 111–250, and > 251 mg per day.
The outcomes were measures of postoperative complications:
receipt of naloxone after the day of surgery, non‐invasive ventila-
tion (NIV), invasive mechanical ventilation (IMV), and opioid con-
sumption (measured using parenteral morphine equivalents) on the
day of surgery and the day before discharge. We used multilevel
regression models to examine associations between the categorized
exposures and the outcomes.
Results: Among 863,139 patients undergoing THA/TKA, overall,
11.5% received gabapentin and 10.7% received pregabalin. Preva-
lence of naloxone use, NIV, and IMV was 0.6%, 2.5%, and 0.5%
respectively. GBP receipt at any dose on the day of surgery was
associated with increased odds of each postoperative pulmonary
complication. Compared with lower doses, the highest dose of
gabapentin (>1050 mg) was associated with greater odds of nalox-
one use (OR, 2.90; 95% CI, 2.49–3.88), NIV (OR, 1.58; 95% CI,
1.44–1.72), and IMV (OR, 1.58; 95% CI, 1.29–1.93). Similarly, the
highest dose of pregabalin (>250 mg) was associated with greater
odds of naloxone use after surgery (OR, 2.17; 95% CI, 1.61–2.93),
NIV (OR, 1.52; 95% CI, 1.27–1.82), and IMV (OR, 1.68; 95% CI,
1.15–2.46). We found no clinically meaningful association between
exposure to either gabapentin or pregabalin and opioid
consumption.
Conclusions: Exposure to GBPs at any dose on the day of surgery was
associated with increased odds of postoperative naloxone use, NIV,
and IMV, and the effects were generally greater at higher doses. In
contrast, there were no clinically meaningful differences with respect
to opioid consumption.
682 | Sodium‐glucose cotransporter 2
inhibitors and risk of fractures: Analysis of the
FDA adverse event reporting system
database
Wenchao Lu1,2; Lulu Sun2; Luwen Shi1; Tiansheng Wang3
1School of Pharmaceutical Sciences, Peking University, Beijing, China;
2Peking University Ninth School of Clinical Medicine (Beijing Shijitan
Hospital, Capital Medical University), Beijing, China; 3Gillings School of
Global Public Health, University of North Carolina at Chapel Hill, Chapel
Hill, NC
Background: The CANVAS trial showed that canagliflozin, a sodium‐
glucose cotransporter 2 inhibitors (SGLT2i), may increase the risk of
bone fracture. However, a recent large cohort study suggested no
increased risk of fractures for canagliflozin, the recent EMPA‐REG
OUTCOME and DECLARE‐TIMI 58 trials showed no increased risk
for other SGLT2i. The effect of SGLT2i on fractures remained
uncertain.
Objectives: To assess the association between SGLT2i and fractures
using FDA Adverse Event Reporting System (FAERS) database.
Methods: By running a query on AERSMINE (an open access web data
mining tool of FAERS) from 2013 Q2 to 2018 Q1, we obtained the
fractures cases related to SGLT2i (dapagliflozin,canagliflozin,
empagliflozin) and comparator drugs. The fractures events were iden-
tified by MedDRA v21.0. We conducted two mutually exclusive com-
parisons: 1) compared SGLT2i to all other glucose lowering drugs
(GLDs) excluding insulins; 2) compared SGLT2i to
dipeptidylpeptidase‐4 inhibitors (DPP4i) as both classes are new
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second‐line treatment for diabetes with similar reporting rates and
DPP4i are not associated with increased risk for fracture. Additionally,
we stratified analyses on individual SGLT2i and age groups (25–
65 years,≥65 years). In each comparison, we calculated proportional
rate ratio (PRR) and 95% CI using 2 × 2 tables by SAS 9.4. A signal is
defined as PRR >2.
Results: A total of 295 SGLT2i associated fractures cases were identi-
fied, 153 cases for canagliflozin, 93 cases for dapagliflozin, 50 cases
for empagliflozin. Compared to all other antidiabetic drugs excluding
insulins, the PRR for SGLT2i, canagliflozin, dapagliflozin and
empagliflozin was 0.67(0.60–0.76), 0.60(0.51–0.71) 0.86(0.70–1.06)
and 0.62(0.47–0.81), respectively. In the analyses stratified by age
group, the PRR for 25–65 years, >65 years was 0.70(0.58–0.85) and
0.80(0.65–0.97) respectively. Compared to DPP4i, the PRR for
SGLT2i, canagliflozin, dapagliflozin and empagliflozin was 0.46(0.40–
0.54), 0.44(0.37–0.53), 0.54(0.42–0.69) and 0.43(0.31–0.60),
respectively.
Conclusions: Our analysis based on FAERS database indicated that
there was no significant association between SGLT2i and fractures.
However, this study is limited by reporting bias, lack of denominator
data, and FAERS cannot be used to assess the incidence. Thus, further
studies are warranted to assess the potential fractures risk associated
with SGLT2i.
683 | Assessing the incidence of
osteosarcoma among teriparatide users via
linkage of data from Medicare part D and
multiple state cancer registries in the USA
Alicia Gilsenan1; Kirk Midkiff1; David Harris1; Lisa McQuay1;
Shannon Hunter1; Nicole Kellier‐Steele2; Elizabeth Andrews1
1RTI Health Solutions, Research Triangle Park, NC; 2Eli Lilly & Company,
Indianapolis, IN
Background: Teriparatide, approved for treatment of osteoporosis in
adults, caused a dose‐dependent increase in the incidence of osteo-
sarcoma (OS) in rats during preclinical testing. This study is 1 of 5
OS surveillance studies initiated since initial drug approval in 2002
to evaluate a potential increased risk of OS with teriparatide
treatment.
Objectives: To estimate the incidence rate ratio (IRR) of OS among
patients aged 65 years or older treated with teriparatide versus a
cohort of matched comparators. The secondary objective was to
describe characteristics and similarities of each cohort.
Methods: All state cancer registries in the United States (US) were
invited to participate in this population‐based comparative cohort
study. Exposure details for each teriparatide user and up to 4 com-
parators matched on age, sex, 3‐digit zip code, date of prescription
fill and number of unique therapeutic classes of medications dis-
pensed were identified via Medicare Part D prescription claims.
Demographic and clinical characteristics were assessed on a subset
using Medicare Parts A, B, and D. Outcomes were identified via
linkage with participating state cancer registries through Medicare's
trusted third party. Patients were followed to date of OS diagnosis,
death, or end of study.
Results: Among patients, 153,316 in the teriparatide cohort and
613,247 in the comparator cohort were linked to 811 OS cases from
26 participating state cancer registries (covering 68% of US cases
aged 65+ diagnosed 2007–2014). Cohorts were predominantly
female (91%); 59% were aged 75+ on the index date. Corticosteroid
use was higher in the teriparatide versus comparator cohort in the
baseline (39% vs. 31%) and follow‐up periods (45% vs. 36%). History
of fracture was higher in the teriparatide cohort compared to the
comparator cohort (23% vs. 8%). The cohorts were well balanced
on known OS risk factors and the Charlson comorbidity index. Mean
duration of treatment with teriparatide was 10 months. No cases of
OS were observed in the teriparatide cohort and the rate in the
comparator cohort was consistent with the background rate among
adults aged 65+. (To protect patient privacy, non‐zero cell counts
<11 cannot be disclosed for Medicare). The IRR was 0.0 (95% CI,
0.0 to 3.2).
Conclusions: The incidence of OS among teriparatide‐treated
patients aged 65 years or older in the US ranges from 0 to 3.2 times
the incidence of OS in US patients aged 65 years or older
treated with other medications. Given the low incidence of OS, this
range of effect is inconsistent with a large absolute increase in risk
for OS.
684 | Risk of fall injuries with concomitant
use of beta‐blockers and CYP2D6 inhibitors
Max Vikström1; Karin Leander1; Marja‐Liisa Dahl2;
Karin Söderberg‐Löfdal2
1 Institute of Environmental Medicine, Karolinska Institutet, Stockholm,
Sweden; 2Department of Laboratory Medicine, Karolinska Institutet,
Stockholm, Sweden
Background: Fall injury is a common public health problem that
increases with an aging population and so does the use of beta‐
blockers with risk of adverse effects such as drop in blood pressure,
dizziness and syncope leading to an increased risk of fall injury. Several
beta‐blockers including the most frequently used beta‐blocker meto-
prolol are metabolized through CYP2D6; inhibited metabolism results
in increased concentrations in blood and may thus increase the risk of
adverse effects.
Objectives: To investigate if the initiation of beta‐blockers associates
with increased risk of fall injury. Further, to investigate if concomitant
use of a drug that inhibits CYP2D6 increases the risk of fall injury in
patients with newly initiated treatment of CYP2D6‐metabolized
beta‐blockers.
Methods: Design: This is a national, registry‐based case‐crossover
study covering all adults in Sweden. Setting: We have retrieved all
cases of hospital‐admitted first‐time occurring fall injuries in adults
2006–2013 from the National Patient Register with linked data
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about dispensed drugs from the Swedish Prescribed Drug Register.
Exposures: The exposure to newly initiated treatment with beta‐
blockers (7838 cases) in the case period, the 14 days preceding
the occurrence of fall injury, was compared to a previous control
period of equal length. CYP2D6‐inhibitor use was considered if dis-
pensations occurred within the 91 days preceding the index date (in
a similar way for the control period) as in Sweden, one prescription
covers the treatment up to a maximum length of three months. We
did separate analyses with the strongest CYP2D6‐inhibitors to
explore a potentially larger impact on risk of fall‐related injuries.
Main outcome measures: All hospitalized first fall‐related injuries
classified according to ICD‐10, codes W00‐W19. Statistical analysis:
The case‐crossover design can be thought of as a matched case–
control study where the case serves as its own control. Conditional
logistic regression was applied to calculate odds ratios (OR) with
95% confidence interval (CI).
Results: For beta‐blockers (all types), the OR of fall injury was
1.02 (95% CI 0.97–1.07) without concomitant use of CYP2D6‐
inhibitors while with concomitant use of CYP2D6‐inhibitors the
OR was 1.03 (95% CI 0.93–1.14). Restriction to use of strong
CYP2D6‐inhibitors resulted in an increased risk (OR 2.13; 95% CI
1.38–3.22).
Conclusions: The risk of fall‐related injuries related to beta‐blocker
use was not affected by overall CYP2D6‐inhibitor use. However, the
risk of fall injury was increased for beta‐blockers when strong
CYP2D6‐inhibiting drugs were used at the same time.
685 | Evaluation of myalgia related adverse
event reports attributed to proprotein
convertase subtilisin/kexin type 9 (PCSK9)
inhibitors within the FDA adverse events
reporting system (FAERS)
Yasmin Elsobky1,2; Mohamed A. Mekkawy1,2
1High Institute for Public Health, Alexandria University, Alexandria,
Egypt; 2NAPHS Consultancy, Alexandria, Egypt
Background: The proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors are a new class of cholesterol‐lowering medica-
tions that provide significant reductions in lipids but at a large cost
relative to statins. There has been concern about the effect of
PCSK9 inhibitors on the muscles as a side effect as seen in
most lipid‐lowering agents. However, no study has analyzed sponta-
neous reports of myalgia related adverse events with this drug
class.
Objectives: The objective of this study is to describe and evaluate the
myalgia related spontaneous adverse event reports attributed to
PCSK9 inhibitors.
Methods: The published FAERS database quarterly files starting
from the third quarter of 2015 till the third quarter of 2018 were
queried for reports listing myalgia related adverse events mainly
fibromyalgia and all types of muscle pain and stiffness attributed to
two drugs in PCSK9 inhibitors (Alirocumab; Evolocumab) as the pri-
mary suspected drug with event dates from 2015 to 2018. We cal-
culated the proportional reporting ratio (PRR) and the reporting odds
ratio (ROR) for each drug which is calculated like risk ratio and odds
ratio, respectively using a two‐by‐two contingency table as the
framework for analysis.
Results: Among 1,910,439 FAERS reports between July 2015 and
September 2018, there were 47,069 myalgia related adverse events
reports. Of which 3035 (6%) mentioned PCSK9 inhibitors as the pri-
mary suspected drugs: 827 (1.75%) mentioned alirocumab, while
2208 (4.69%) mentioned evolocumab. The PRR and ROR for the men-
tioned drugs was: alirocumab (PRR: 6.166, 95%CI: 5.78–6.57, ROR:
7.07, 95%CI: 6.56–7.62), evolocumab (PRR: 4.11, 95%CI: 3.95–4.28,
ROR: 4.45, 95%CI: 4.25–4.65).
Conclusions: The study showed a statistically significant result. Among
PCSK9 inhibitors, alirocumab exposure was associated with the
highest frequency of reported myalgia related adverse effects than
evolocumab. Although FAERS is subjected to significant limitations,
the results suggest that PCSK9 inhibitors are associated with a higher
risk of myalgia related adverse events as statin agents.
686 | Association between SGLT‐2 inhibitors
and lower extremity amputation among
patients with type 2 diabetes: A systematic
review
James Heyward1; Omar Mansour2; ClaireTwose3; Hsien‐Yen Chang1;
Sonal Singh4; G. Caleb Alexander1,3
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Monument Analytics, Baltimore, MD; 3Johns Hopkins Medicine,
Baltimore, MD; 4University of Massachusetts Medical School, Worcester,
MA
Background: SGLT2 inhibitors (SGLT2i) are a commonly prescribed
treatment for type 2 diabetes. Although they reduce the risk of major
cardiovascular events and all‐cause mortality compared with many
alternatives, some evidence suggests they are associated with an ele-
vated risk of lower limb amputation.
Objectives: To comprehensively synthesize evidence regarding
whether SGLT2i therapy is associated with increased risk of lower
limb amputation and other serious cardiovascular events as compared
with other antihyperglycemic agents (AHAs).
Methods: We conducted a systematic review based on searches of
PubMed, EMBASE, Scopus, and CENTRAL. We included randomized
controlled trials and cohort studies, case control, or self‐controlled
studies assessing the safety outcomes of interest in adults with type
2 diabetes taking SGLT2i. The primary outcome was risk of lower limb
amputation. Secondary outcomes included peripheral arterial disease,
peripheral vascular disease, venous ulcerations, and diabetic foot
infections.
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Results: Preliminary searches have yielded six retrospective cohort
studies including a total 451,801 SGLT2i patients and 2,856,950
users of other AHAs. Two studies examined the risk for canagliflozin
alone against other AHAs, while four examined the risk for the
entire SGLT2i class. One study comparing amputation risk for
SGLT2i against all non‐SGLT2i AHAs found a statistically significant
increased risk of amputation (adjusted hazard ratio (aHR) = 1.99,
95% confidence interval [CI] = 1.12–3.51), while two studies found
no difference. One study found a statistically significant decreased
risk of amputation (aHR = 0.74, CI 0.57, 0.96) for use of SGLT2i
vs. sulfonylureas. None of three studies comparing amputation risk
of SGLT2i against DPP‐4 inhibitors found a statistically significant
difference in amputation risk (aHR range 0.88–1.50), nor did the
study comparing risks in users of GLP‐1 receptor agonists
(aHR = 1.41). Four of the six studies examined prescribing data
among commercially insured adults only, and all studies used pro-
pensity score‐matched cohorts to compare risks across treatment
groups. The studies were of fair to good methodological quality.
Incorporation of randomized studies, and meta‐analysis, are
forthcoming.
Conclusions: This ongoing systematic review revealed considerable
heterogeneity in the results of six retrospective cohort studies exam-
ining the association between SGLT2i and lower extremity amputa-
tion. The magnitude and direction of risk difference varied by study
and by drug class comparator.
687 | Risk of tendinopahty associated with
fluoroquinolones: A systematic review and
meta‐analysis
Carlos Alves1,2; Diogo Mendes1; Francisco Batel Marques1,2
1AIBILI ‐ Association for Innovation and Biomedical Research on Light
and Image, Coimbra, Portugal; 2School of Pharmacy, University of
Coimbra, Coimbra, Portugal
Background: Tendinopathy is a known adverse reaction associated to
fluorquinolones, but a meta‐analysis was not yet published.
Objectives: This study aims to investigate the risk of tendinopathy
associated with fluoroquinolones.
Methods: A literature search was conducted to identify observa-
tional studies evaluating the risk of tendinopathy associated with
fluoroquinolones. The outcomes assessed were the risk of Achilles
tendon rupture (ATR), risk of Achilles tendinitis (AT) and risk of
any tendon disorders (ATD). A meta‐analysis was performed by
pooling odds ratios (ORs) with their 95% confidence intervals
(CIs). Results were stratified according to age, type of fluoroquino-
lone and corticosteroid use.
Results: Thirteen studies were included. Fluoroquinolones were
associated with an increased risk ATR [OR 2.24 (95% CI 1.70–
2.94); I2 = 82.9%], AT [OR 3.95 (95% CI 3.11–5.01); I2 = 0%]
and ATD [OR 1.99 (95% CI 1.35–2.93); I2 = 89.5%]. Patients
aged ≥60 years old presented an increased risk of ATR and AT.
Patients aged <60 years presented an increased risk of ATD.
Ofloxacin (OR 2.84; 95%CI 1.31–6.19) and norfloxacin (OR 3.02;
95%CI 1.32–6.93) are associated with an increased risk of ATR.
Risk of ATR is superior among patients simultaneously using
fluoroquinolones and corticosteroids (OR 16.04; 95%CI 6.28–
41.00) when compared those using only fluoroquinolones (OR
2.31; 95%CI 0.82–6.51).
Conclusions: The results of this meta‐analysis confirm the risk of
tendinopathy associated with fluoroquinolones. Older age and con-
comitant use of corticosteroids seems to be additional risk factors
for tendinopathy.
688 | Results of a long‐term postmarketing
case series of adult osteosarcoma and
teriparatide in the United States
Kirk Midkiff1; David Harris1; Alicia Gilsenan1; Nicole Kellier‐Steele2;
David McSorley1; Elizabeth Andrews1
1RTI Health Solutions, Research Triangle Park, NC; 2Eli Lilly & Company,
Indianapolis, IN
Background: The Osteosarcoma Surveillance Study was initiated at
the time of approval of Forteo in the United States (US) to monitor
for a potential association between teriparatide (an osteoporosis
treatment) and osteosarcoma (OS). OS occurs at a background inci-
dence rate of approximately 2.5 cases per million per year in US
adults aged 40 years or older.
Objectives: To provide final study results, including descriptive char-
acteristics of adult patients with OS.
Methods: Incident cases of OS diagnosed between January 1, 2003,
and December 31, 2016, were identified through participating can-
cer registries in the US. Information on prior exposure to medica-
tions and possible risk factors was obtained via self‐report (or
proxy‐report) telephone interview. Exposure information was verified
through medical record abstraction for a sample of patients. A stan-
dardized incidence ratio was estimated to compare the observed to
expected number of OS cases with a prior history of teriparatide
treatment. The expected number of exposed OS cases was the prod-
uct of the background incidence rate of OS standardized to the age
and sex distribution of teriparatide‐treated patients, the person‐years
at risk following first exposure to teriparatide, and the percentage of
cases that were interviewed.
Results: Interviews were completed for 24% (1,173) of patients
diagnosed with OS between 2003 and 2016; three reports of
teriparatide use prior to diagnosis were identified. Based on the
background incidence rate, the expected number of OS cases
among patients treated with teriparatide was 4.17. Given the three
observed cases, the standardized incidence ratio was 0.72 (90% CI,
0.20–1.86). Demographic characteristics were similar for
interviewed and noninterviewed patients, and agreement was 92%
or higher between self‐reported and chart‐recorded osteoporosis
medication exposure information. Mean age of interviewed patients
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was 61 years, 53% were male, and 84% were white. The preva-
lence of known risk factors for development of OS among the OS
cohort was 19% for history of radiation and 4% for history of
Paget's disease of bone.
Conclusions: This study found that the incidence of OS associated
with teriparatide use during the 15‐year surveillance period was no
different than that which would be expected based on the background
incidence rate of OS.
689 | Statin use and muscular problems: A
cross‐sectional analysis of the ELSA‐Brasil
musculoskeletal cohort
Aline F. Pedroso1; Bruce B. Duncan2; Maria de Fátima HS Diniz3;
Luciana A.C. Machado3; Rosa W. Telles3; Sandhi M. Barreto3;
Roberta C. Figueiredo1
1Universidade Federal de São João del‐Rei, Divinópolis, Brazil;
2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil;
3Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Background: The efficacy and relative safety of statins is well
stablished but they have been associated with muscular problems,
ranging from pain and weakness to rhabdomyolysis.
Objectives: To investigate the association of statin use and muscular
pain and weakness, according to type, intensity and duration of use
and the modification of this association by hypothyroidism, altered
liver function and use of drugs known to interact with statins in a het-
erogeneous sample of Brazilian adults.
Methods: We conducted a cross‐sectional study using baseline data
from ELSA‐Brasil Musculoskeletal cohort, an ancillary study of the
Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil). Those
providing data on statin use and pain and/or weakness, and without
rheumatoid arthritis and lupus, were included. Pain was defined as
pain, discomfort or stiffness in the last seven days in the lower back
or hips/thighs. Five‐times sit‐to‐stand (FTSTS) and handgrip tests
were used as proxy of muscle weakness (i.e. greater times in FTSTS
and lower grip strength). Statin users were identified by self‐
reported statin use in the last two weeks. Associations were tested
through logistic (pain) and linear (muscle weakness) regressions. Mul-
tivariate models were adjusted for age, sex, education, body mass
index (BMI), physical activity, pain in other sites and analgesic/anti‐
inflammatory use. Multinomial models (univariate and adjusted for
age, sex and BMI) tested the modification effects of hypothyroidism,
altered liver function and drugs that interact with statins. Muscle
weakness variables were dichotomized for multinomial analysis,
using the first and last quintiles of distributions of handgrip and
FTSTS tests, respectively, as cut‐offs.
Results: The sample comprised 2843 participants (55.9 +/− 8.9 years;
52.5% women; 21.0% current statin users). After adjustments, asso-
ciations were only observed for statin use and pain in the hips/
thighs among those using the drug for <1 year [OR 2.26; IC 95%
1.35–3.79] and between atorvastatin use and longer times in the
FTSTS test, 0.5 (0.44–1.33) seconds more compared to non‐users.
There were indication that hypothyroidism and altered liver function
modify the relationship between statin use and pain in the hips/
thighs.
Conclusions: Our study provides evidence for differential effects of
the type and duration of statin use in the occurrence of muscular
problems. Additionally, findings on the increased chance of adverse
events among individuals with certain comorbidities may indicate the
need for considering individualized risk–benefit evaluations to guide
clinical decision‐making.
690 | Concomitant opioid and
benzodiazepine or Z‐drug use: Analysis of the
Food and Drug Administration's adverse
event reporting system
Anh Thy H. Nguyen1; Darren Scheer1,2; Skai Schwartz1
1University of South Florida, College of Public Health, Tampa, FL;
2Biotech Research Group, Tampa, FL
Background: While adverse consequences of the opioid epidemic
has captured the public's attention there is less awareness of a
possible contributing role of hypnotics. The concomitant dispensing
of opioids and benzodiazepine along with evidence of increased
risks for difficult breathing and death led the FDA to issue their
strongest Boxed Warnings in 2016. Investigations of other adverse
events occurring with concomitant use of opioids and Z‐drugs
are scarce.
Objectives: To investigate the association of concomitant use of opi-
oids and benzodiazepines or Z‐drugs with five serious adverse events
using spontaneous adverse‐event reports.
Methods: Data from the United States Food and Drug Administra-
tion's Adverse Event Reporting System (FAERS) from 1969 through
third quarter 2018 were utilized. Preferred Terms according to
MedDRA were used to identify reports related to drug abuse,
death, completed suicide, cardiac arrest, and overdose. Benzodiaze-
pines included chlordiazepoxide, alprazolam, diazepam, clonazepam,
and lorazepam. Z‐drugs included zaleplon, zolpidem, zopliclone,
and eszopiclone. Opioids included oxycodone, hydrocodone, and
fentanyl. The selected drugs were included, regardless of route of
administration, if they were noted to be suspect in the case report.
Associations between drugs and events were measured by Empirical
Bayes Geometric Mean (EBGM) and the corresponding lower bound
of the 90% confidence interval (EB05). EB05 ≥ 2 were considered
significant signals.
Results: For opioid‐only, EBGMs ranged from 3.84 [EB05 = 3.81]
for death to 12.59 [12.44] for drug abuse. In contrast, concurrent
benzodiazepine or Z‐drugs and opioid EBGMs were 7.72 [7.56]
for death, 12.87 [12.37] for overdose, 22.04 [21.16] for cardiac
arrest, 22.05 [21.35] for drug abuse, and 37.42 [35.88] for com-
pleted suicide. With the exception of completed suicide, concomi-
tant benzodiazepine and opioid had stronger signals (EBGM
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ranged from 7.84 [7.68] for death to 36.01 [34.43] for completed
suicide) for each outcome relative to concomitant Z‐drugs and opi-
oid (EBGM ranged from 6.59 [6.21] for death to 52.32 [47.56] for
completed suicide).
Conclusions: Concomitant use of benzodiazepines or Z‐drugs
and opioids are more strongly associated with five serious adverse
events compared to opioid use alone. Health care professionals must
be judicious in co‐prescribing opioids with benzodiazepines or Z‐
drugs, especially in patients at risk of suicide.
691 | Benzodiazepines, opioids, & mortality
in hemodialysis patients
Mara McAdams DeMarco; Abimereki Muzaale; Sunjae Bae;
Matthew Daubresse; Nadia Chu; Dorry Segev
Johns Hopkins, Baltimore, MD
Background: In the general population, benzodiazepine‐related mor-
tality is a growing public health concern especially in light of the
opioid epidemic; mortality risk is elevated when benzodiazepines
are combined with medications that affect the central nervous sys-
tem. Patients initiating hemodialysis (HD) are 3‐times as likely to be
prescribed opioids and have an excess burden of conditions that are
indications for benzodiazepines. Yet, among HD patients, the bur-
den of benzodiazepine prescribing, and the mortality risk associated
with benzodiazepines among those with and without opioid co‐pre-
scribing are unclear.
Objectives: To describe benzodiazepine prescribing, opioid co‐pre-
scribing and subsequent mortality risk among HD patients.
Methods: A cohort study of adults initiating HD (1/2013–12/2014)
was assembled linking the national registry of HD patients to Medi-
care claims through the United States Renal Data System. We iden-
tified risk factors (registry‐ and claims‐based) for incident
benzodiazepine prescribing and quantified the association between
benzodiazepines (time‐varying) using adjusted Cox proportional haz-
ards models. We tested for effect modification by time‐varying
opioids.
Results: Of the 120,123 HD patients, 26.3% had at least one prescrip-
tion for a benzodiazepine between 2013 and 2014. However, within
6 months of HD initiation, 21% of white and only 12% of non‐white
patients had a prescription for benzodiazepine; after adjustment,
white patients were 1.66‐fold (95% CI: 1.62–1.71) more likely to have
a prescription for benzodiazepine. Furthermore, prior use of opioids
(HR = 2.06, 95% CI 2.00–2.13), sedatives (HR = 1.86, 95% CI 1.80–
1.92), and antipsychotics (HR = 2.21, 95% CI 2.13–2.30) were all inde-
pendently associated with initiation of benzodiazepines. HD patients
with a benzodiazepine prescription were at 1.49‐fold (95% CI 1.41–
1.57) greater risk of mortality. This mortality risk differed by opioid
prescriptions (p for interaction<0.001): among those with opioids,
benzodiazepines were associated with a 1.80‐fold (95% CI 1.62–
1.99) increased risk of mortality, while among those without opioids
it was associated with a 1.34‐fold (95% CI 1.26–1.43) increased risk.
Inferences were similar in a sensitivity analysis using an ITT approach
with propensity score adjustment.
Conclusions: Patients initiating HD, and particularly white
patients, are often prescribed benzodiazepines, which increased
risk of mortality by 1.5‐fold. This risk is elevated in patients who are
also prescribed opioids. This high‐risk co‐prescribing should be recog-
nized by physicians caring for this vulnerable population.
692 | Comparative safety of medications for
insomnia and risk of suicide attempt in the
Department of Veterans Affairs
Jill E. Lavigne1; Kwan Hur2; Cathleen M. Kane1; Anthony Au2;
Todd M. Bishop1,3; Wilfred R. Pigeon1,4
1US Department of Veterans Health Affairs, Canandaigua, NY; 2US
Department of Veterans Health Affairs, Hines, IL; 3University of
Rochester, Rochester, NY; 4University of Rochester School of Medicine
and Dentistry, Rochester, NY
Background: Guidelines for the treatment of adult insomnia recog-
nize that trazodone and other off‐label medications are commonly
prescribed despite poor evidence. The Department of Veterans
Health Affairs (VA) fills high volumes of inexpensive, over‐the‐coun-
ter sedating antihistamines and older antidepressants in addition to
benzodiazepines and zolpidem. Yet little is known about the com-
parative safety of these agents with regard to suicidal behavior.
Objectives: To assess the comparative effectiveness of the safety of
medications routinely used to treat insomnia in VA.
Methods: Design: Comparative safety using propensity score‐
matched samples. Data and Setting: Electronic medical records from
the US Department of Veterans Health Affairs (VA) Corporate Data
Warehouse. Subjects: VA patients without any history of suicidal
ideation or behavior 12 months prior to first exposure. Exposures:
VA formularies and data were used to identify prescriptions for
insomnia. Agents accounting for at least 1% of total insomnia fill
volume were < 200 mg trazodone, hydproxyzine, diphenhydramine,
zolpidem, lorazepam, diazepam and temazepam. Exposure was
defined as an incident monotherapy exposure preceded by 12‐
months without any insomnia medications. Subjects with insomnia
polypharmacy or cross‐overs in the 12 months following first expo-
sure were excluded. Outcomes: Suicide attempts within 12 months
of first exposure.
Results: 348,449 subjects met criteria and three well‐balanced cohorts
by drug class matched to zolpidem were created. After adjusting for
days' supply, mental health history and, pain and central nervous sys-
tem medication history, hazard ratios (compared to zolpidem) were as
follows: (<200 mg) trazodone (HR = 1.61, 95% CI: 1.07–2.43); sedating
antihistamines (HR = 1.37, 95% CI: 0.90–2.07) and benzodiazepines
(HR = 1.31, 95% CI: 0.85–2.08).
Conclusions: Compared to zolpidem, hazard of suicide attempt was
61% higher with trazodone (<200 mg). No significant differences in
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suicide attempt risk were identified between benzodiazepines or
sedating antihistamines and zolpidem, respectively. These findings
provide the first comparative effectiveness evidence against the use
of trazodone for insomnia.
693 | Assessing the risk of depression
associated with 5A‐reductase inhibitor use: A
population‐based retrospective cohort study
in Korea
Bora Yeon; Ah. Young Suh; Bonggi Kim; Soo Youn Chung;
Soonyoung Han
Korea Institute of Drug Safety and Risk Management, Seoul, Korea,
Republic of
Background: 5α‐reductase inhibitors (5ARI) are one of the most
prescribed treatments for benign prostatic hyperplasia (BPH).
Recently, several cases of depression after administration of 5ARI
have been reported from the Korea Adverse Event Reporting Sys-
tem (KAERS).
Objectives: To compare the association between use of 5ARI or α‐
blocker (AB) as a treatment for benign prostatic hyperplasia (BPH)
and the risk of depression.
Methods: We performed a retrospective cohort study using the
Health Insurance Review and Assessment Service (HIRA) claim data
from 2011 to 2017. New patients diagnosed with BPH and who
take treatments that contain either a 5ARI or an AB (i.e. alfuzosin,
tamsulosin, terazosin, silodosin, doxazosin; comparator group)
between July 1, 2013 and June 30, 2015 were included. Patients
with mental illness(i.e. depression, self‐harm) in the 2 years prior
to first exposure(5ARI or AB) were excluded. The primary outcome
was depression (defined by ICD‐10: F32–34, F38, F412, F432 and
related drugs), and the secondary outcome was an anxiety disorder
(ICD‐10: F40–41). To adjust for confounding we used logistic
regression to implement 1:1 propensity score (PS) matching of
patients initiating 5ARI to those initiating AB. To compare the risk
of depression associated with 5‐ARI use compared to AB use we
used cox proportional hazard models.
Results: We identified 1,461 5ARI and 18,650 AB patients. Balance
in baseline characteristics between the treatment groups was
achieved within PS matched pairs (1,461 pairs). Compared with
the AB medication group, the 5ARI group significantly had lower
depression (HR: 0.69, 95% CI: 0.51–0.92). However, we could not
statistically find clinically relevant differences after PS matching
(HR: 0.91, 95% CI: 0.61–1.36). Similar results were observed when
evaluating the risk of anxiety.
Conclusions: The risk of depression or anxiety associated with 5ARI
use was not meaningfully different from use of AB. We suggest
that medical officials perform appropriate medication treatment for
BPH patients by considering treatment benefit rather than depres-
sion risk.
694 | Switching from methadone syrup to
capsule and all‐cause mortality risk
Sandy Maumus‐Robert1; Joëlle Micallef2; Michel Mallaret3;
Yohann Mansiaux1; Nicolas Authier4; Maryse Lapeyre‐Mestre5;
Antoine Pariente6
1Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center,
Team Pharmacoepidemiology, UMR 1219, Bordeaux, France; 2AMU AIX‐
MARSEILLE, Institut Neurosciences des Systèmes, INSERM U 1106,
Centre d'Addictovigilance PACA Corse & Centre de Pharmacovigilance‐
Service de Pharmacologie Clinique et Pharmacovigilance, Assistance
Publique ‐ Hôpitaux de Marseille, Marseille, France; 3Centre Régional de
Pharmacovigilance, Centre d'Evaluation et d'Information sur la
Pharmacodépendance – Addictovigilance, Grenoble, France; 4Université
Clermont Auvergne, CHU Clermont‐Ferrand, Inserm 1107, Neuro‐Dol,
OFMA, Service de Pharmacologie médicale, Centres Addictovigilance et
Pharmacovigilance, Clermont‐Ferrand, France; 5Service de Pharmacologie
Clinique, CEIP‐Addictovigilance, UMR‐INSERM 1027 Université de
Toulouse, Toulouse, France; 6Univ. Bordeaux, Inserm, Bordeaux
Population Health Research Center, team Pharmacoepidemiology, UMR
1219; CHU de Bordeaux, Pole de sante publique, Service de
Pharmacologie médicale, Bordeaux, France
Background: In France, various interventions have targeted metha-
done to increase its accessibility and safety. They included
the possibility to switch to a capsule form after treatment stabiliza-
tion under syrup since 2008, and the extension of capsule maxi-
mum prescription from 14 to 28 days since October 2014.
This led to an increasing use of methadone. However, growth in
methadone misuse resulting in fatal cases have also been observed
over the last years, and the potential role of switching from
syrup to capsule in the occurrence of these events has been
questioned.
Objectives: To assess the risk of all‐cause mortality associated with
switching from methadone syrup to capsule.
Methods: This study was carried out over a total period extending
from January 1st, 2008 to December 31st, 2015, using the nation-
wide French Health Insurance database. A case‐time‐control
design was used to take into account time trends estimated from
a time‐control group. Cases and time‐controls had to meet
the following eligibility criteria: (i) age 16 years or over, (ii) affiliated
to the General Scheme of the French Health Insurance from 2008/
01/01 to 2015/12/31, (iii) at least one reimbursement
of methadone between 2009/01/01 and 2015/12/31. The expo-
sure of interest was the switch from methadone syrup to capsule.
All events of death that occurred between 2009/10/01 and
2015/12/31 were considered for the outcome of interest. Each
case was matched on sex, age +/− 1 year, and coverage by supple-
mentary state health insurance coverage (CMU‐c) at index date to
one randomly selected time‐control. A risk window of 60 days prior
to the event was retained for the main analysis. It was separated
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from the three 60‐days control windows considered by a 30‐days
wash‐out period. Patients were included only when date(s) of switch
could be ascertained for all time periods of interest. The association
between switch from methadone syrup to capsule and the risk of
death was analyzed using a conditional logistic regression model.
Results: 5,310 subjects (77.8% men; median age 44 years, IQR: 36–
51; 36.2% covered with CMU‐c) were included in the main analysis
(2,650 cases and 2,650 time‐controls). Of these, 204 cases and 126
time‐controls appeared discordant for exposure between the risk
and control windows. The analysis found no association between
death and switch from methadone syrup to capsule in the 60 pre-
ceding days (OR IC95%: 1.31; 0,80–2.16). Sensitivity
analyses provided consistent results.
Conclusions: Switching from methadone syrup to capsule was not
associated with an increased risk of death in methadone users,
although a short‐term risk increase cannot be fully eliminated.
695 | Impact of the extension of maximum
prescription duration of methadone capsule
on all‐cause mortality
Sandy Maumus‐Robert1; Maryse Lapeyre‐Mestre2; Nicolas Authier3;
Yohann Mansiaux1; Michel Mallaret4; Joëlle Micallef5;
Antoine Pariente6
1Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center,
team Pharmacoepidemiology, UMR 1219, Bordeaux, France; 2Service de
Pharmacologie Clinique, CEIP‐Addictovigilance, UMR‐INSERM 1027
Université de Toulouse, Toulouse, France; 3Université Clermont Auvergne,
CHU Clermont‐Ferrand, Inserm 1107, Neuro‐Dol, OFMA, Service de
Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance,
Clermont‐Ferrand, France; 4Centre Régional de Pharmacovigilance,
Centre d'Evaluation et d'Information sur la Pharmacodépendance –
Addictovigilance, Grenoble, France; 5AMU AIX‐MARSEILLE, Institut
Neurosciences des Systèmes, INSERM U 1106, Centre d'Addictovigilance
PACA Corse & Centre de Pharmacovigilance‐ Service de Pharmacologie
Clinique et Pharmacovigilance, Assistance Publique ‐ Hôpitaux de
Marseille, Marseille, France; 6Univ. Bordeaux, Inserm, Bordeaux
Population Health Research Center, team Pharmacoepidemiology, UMR
1219; CHU de Bordeaux, Pole de sante publique, Service de
Pharmacologie médicale, Bordeaux, France
Background: Case reports of misuse or death related to methadone
use have increased in France over the last years, while several inter-
ventions have been set up to improve methadone accessibility and
safety, including the possibility to switch to a capsule form after treat-
ment stabilization under syrup, and the extension of capsule maximum
prescription duration.
Objectives: To analyze the impact on mortality of the extension of
maximum prescription duration of methadone capsule form.
Methods: An Interrupted Time Series analysis was performed over a
total period extending from January 1st, 2009 to December 31st,
2016, using the nationwide French Health Insurance database. The
studied intervention was the extension of maximum duration of pre-
scription of methadone capsule from 14 to 28 days, which is permitted
since mid‐October 2014. The studied population consisted of all sub-
jects with at least one reimbursement of methadone capsule between
01/01/09 and 12/31/16, aged 16 or older and affiliated to the Gen-
eral Scheme of French Health Insurance. The time series was consti-
tuted of the measured number of deaths per 100,000 methadone
capsule users, estimated on a monthly basis. The intervention impact
was estimated considering i) the change in the monthly number of
deaths consecutive to the intervention; ii) the change in the slope of
the studied time series consecutive to the intervention. Firstly, the
series was decomposed using a moving‐average model and seasonal
adjustment was performed. The series was then analyzed using a seg-
mented linear regression model. The date of intervention was consid-
ered to be November 1st 2014 in the model. To observe a possible
anticipation or delay in the intervention effect, sensitivity analyses
considered different intervention dates (10/01/14, 11/01/14 and
01/01/15).
Results: The monthly number of users of methadone capsule increased
steadily over the study period, from 4,229 in January 2009 to 29,912 in
December 2016. Themonthly number of deaths per 100,000 users var-
ied from 0 (March 2009) to 95.6 (July 2009); most measures were com-
prised between 25 and 75/100,000. No significant impact of the
intervention was found neither on the monthly number of deaths (− 5/
100,000) nor in its trend (pre‐intervention slope: 0.04 (−0.15; 0.23);
post‐intervention: −0.4 (−1.2; 0.4). Sensitivity analyses provided consis-
tent results.
Conclusions: The extension of the maximum duration of prescription of
methadone capsule to 28 days, which was accompanied by a huge
increase in the number of methadone capsule users, did not appeared
associatedwithan increase inmortalityamongmethadonecapsuleusers.
696 | Trend analysis of amphetamine‐class
overdose deaths in Kentucky
Patrick J. Ward; Svetla Slavova; David Akers
University of Kentucky, Lexington, KY
Background: In 2016, for the first time, amphetamine was listed
among the top 15 most commonly detected substances among U.S.
drug overdose decedents, with methamphetamine listed as fourth.
From 2011 to 2016, the rate of methamphetamine‐involved overdose
deaths in the U.S. more than tripled.
Objectives: The purpose of this study was to analyze how increases in
amphetamine‐salt prescriptions dispensed is related to amphetamine‐
class involved drug overdose deaths in Kentucky, and to examine if
amphetamine‐class overdose deaths cluster geographically.
Methods: Data from the Kentucky Drug Overdose Fatality Surveil-
lance System, years 2016–2018, was analyzed to identify decedents
that tested positive for methamphetamine or amphetamine in their
post‐mortem toxicology testing. Prescription drug monitoring program
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data was analyzed to calculate the number of amphetamine‐salt pre-
scriptions dispensed to Kentucky residents. These measures were cal-
culated at the quarter level. A negative‐binomial regression was used
to estimate the effect the number of amphetamine‐salt prescriptions
dispensed in each quarter has on the count of amphetamine‐class
overdose deaths. Additionally, counts of amphetamine‐class over-
doses by county were aggregated for the entire study period and a
Moran's I analysis was performed to determine if amphetamine‐class
overdose deaths are clustered geographically.
Results: Preliminary data from 2018 overdose fatality surveillance
indicate sustained increases in amphetamine‐class overdose mortality,
as counts of overdose deaths per quarter increased 97% from Q1/
2016 to Q3/2018. The count of amphetamine‐salt prescriptions dis-
pensed to Kentucky residents was significantly associated with the
count of amphetamine‐class overdose deaths (p = 0.01), with every
1,000 additional prescriptions dispensed associated with a 3%
increase in amphetamine class‐involved overdose mortality. Geo-
graphically, the Moran's I test resulted in a z‐statistic of 0.28 with a
p‐value of 0.001, indicating that similar rates of amphetamine‐class
overdose deaths cluster spatially.
Conclusions: Amphetamine class‐involved overdose deaths have
increased substantially over time in Kentucky. This increase is posi-
tively associated with the number of amphetamine‐salt prescriptions
that were dispensed in the same quarter. Moreover, high rates of
amphetamine class‐involved overdose deaths are clustered geograph-
ically. This finding provides insight into areas that can be targeted for
public heath interventions to reduce amphetamine‐class overdose
morbidity and mortality.
697 | Predictors of justice system
involvement in antipsychotic users in
Manitoba, Canada
Donica Janzen; Ifan Kuo; Christine Leong; James Bolton;
Silvia Alessi‐Severini
University of Manitoba, Winnipeg, MB, Canada
Background: Mental illness increases the risk of criminality and victim-
ization. Antipsychotic medications reduce criminality, but less is
known about the effect of antipsychotic use on victimization.
Objectives: To describe characteristics of antipsychotic users who had
justice system involvement and to identify risk factors for justice sys-
tem involvement as accused or victim.
Methods:Weused administrative databases at theManitobaCentre for
Health Policy (MCHP) to create a cohort of incident antipsychotic users
in Manitoba, Canada from 2002–2015. We linked prescription records
to population registry, hospital abstracts andmedical services databases
to obtain descriptive statistics. We used justice databases to identify
antipsychotic users with justice system involvement after incident anti-
psychotic use, categorized as accused or victim. We used multivariable
logistic regression to identify predictors of justice system involvement,
adjusting for age, sex, socioeconomic status, incident antipsychotic
and baseline diagnoses. Analyses were conducted with SAS® software.
Results: There were 76 459 incident antipsychotic users from 2002 to
2015; 5.3% were subsequently accused of a crime and 3.5% were vic-
tims.Only 40.2%of accused and 33.7%of victims filled an antipsychotic
prescription in the 6 months prior to a justice incident. Common base-
line diagnoses were mood/anxiety disorder (65.0%), dementia (21.2%),
substance use disorder (16.9%), psychotic disorder (15.5%), ADHD
(12.0%) and personality disorder (5.6%). Females were 52.6% less likely
to be accusedof a crime (adjustedOR0.48, 95%CI 0.42, 0.53) but 78.3%
more likely to be the victim (aOR 1.78, 95%CI 1.54, 2.06) versus males.
Predictors of being accused included having a baseline diagnosis of
ADHD (aOR 1.2, 95%CI 1.0, 1.3) mood/anxiety disorder (aOR 1.5,
95%CI 1.3, 1.6), personality disorder (aOR 1.5, 95%CI 1.3, 1.8), sub-
stance use disorder (aOR 1.2, 95%CI 1.1, 1.4), or suicide attempt (1.4,
95%CI 1.1, 1.8). ADHD,mood/anxiety disorder and personality disorder
were associatedwith being a victim of a crime (aOR1.3 [95%CI 1.1, 1.5],
1.2 [95%CI 1.0, 1.4], and 1.5 [95%CI 1.2, 1.9], respectively).
Conclusions: Our preliminary results suggest individuals with mental
illness diagnoses remain at elevated risk of criminality and victimiza-
tion despite antipsychotic use. Efforts to improve antipsychotic persis-
tence may mitigate risk in this population, but further research is
warranted. Disclaimer Results and conclusions are those of the
authors; no official endorsement by Manitoba Health, Seniors and
Healthy Living or MCHP is intended or should be inferred.
698 | Does aspirin use increase the risk of
age‐related macular degeneration: A
population‐based comparative cohort study
Wan‐Ju Annabelle Lee1,2; Ching‐Lan Cheng2,3,4;
Yea‐Huei Kao Yang2,3,4
1Department of ophthalmology, National Cheng Kung University
Hospital, Tainan, Taiwan; 2 Institute of Clinical Pharmacy and
Pharmaceutical Sciences, College of Medicine, National Cheng Kung
University, Tainan, Taiwan; 3School of Pharmacy, National Cheng Kung
University, Tainan, Taiwan; 4Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan
Background: In elderly people with cardiovascular diseases, aspirin is
the medication prescribed for prevention of secondary events. Its
well‐known side effectwas bleeding,whether in gastrointestinal or ocu-
lar fields. However, its effect on AMD occurrence is inconclusive and
conflicting from previous studies. To compare those people taking aspi-
rin to those who do not is not fair because those two groups are not
comparable. Aspirin users are prone to have more underlying diseases,
especially cardiovascular diseases. Confounding by indication bias is a
major concern when aspirin users are compared to non‐aspirin users.
Clopidogrel is a drug often used in patients similar to aspirin users, espe-
cially when patients were intolerant to aspirin. It is an alternative medi-
cation for aspirin users and is indicated with acute coronary syndrome,
recent myocardial infarction, recent stroke, or coronary artery diseases.
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Therefore, to investigate the risk of AMD for aspirin use in this study,
we used clopidogrel to compare the estimated risk of AMD for these
two groups.
Objectives: To estimate the risk of age‐related macular degeneration
(AMD) among aspirin users compared with clopidogrel.
Methods: Method: We conducted a population‐based retrospective
comparative cohort study using Taiwan's Longitudinal Health Insur-
ance Database (LHID), which was randomly selected from the National
Health Insurance Research Database (NHIRD). We included patients
more than 45 years‐old who initiated aspirin during 2001–2010 and
they all tracked to 2013. The comparison groups are patients who
were prescribed clopidogrel.
Main Outcome:The outcome of interest was AMD defined by
ICD‐9‐CM code of 362.50–52 or 362.57. We used multivariate
Cox regression modeling and propensity score (PS) matching to
balance the characteristics of patients between groups to esti-
mate the hazard ratio.
Results: After applying the methods, we had 109,534 aspirin users and
3,619 clopidogrel users. Male gender (51.12%) was predominate over
females (48.88%) in the aspirin‐user group. Our results showed no sig-
nificant different risk of AMD between aspirin and clopidogrel users,
while the multivariate Cox model showed HR was 1.13 (95% CI,
0.97–1.32) and the PS model showed HR was 1.09 (95% CI, 0.54–
2.17). The incidence of aspirin users developing AMD was 8.18 per
person‐year, while the incidence of clopidogrel users was 10.07 per
person‐year.
Conclusions: Patients with long‐term use of aspirin did not have
higher risks in developing AMD compared to clopidogrel users.
699 | The association between treatment
with montelukast and migraine ‐ a symmetry
analysis
Daniel P. Henriksen1; Jesper Hallas2
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark
Background: Leukotriene receptor antagonists (LTRA) are used to
treat asthma and rhinitis. Headache has been reported as a very com-
mon adverse event, and a few pharmacovigilance reportings identified
migraine as suspected adverse event of LTRA. However, the associa-
tion has not been established in controlled designs. On the contrary,
LTRA have been tested as a potential migraine treatment but failed
in a single randomized controlled trial.
Objectives: To assess whether treatment with the only approved
LTRA in Denmark, montelukast, was associated with the initiation of
triptans.
Methods: A prescription sequence symmetry analysis was employed
on all Danish residents aged ≥18 years with at least one filled pre-
scription of the montelukast (ATC R03DC03) from 2000–2016, who
also filled their first ever prescription for triptans (ATC N02CC) within
an interval of 180 days before or after the montelukast initiation. We
calculated the crude sequence ratio (SR) and corresponding 95% con-
fidence intervals (95%CI). The SR is the ratio between subjects with
montelukast prescribed before sumatriptan and subjects with
montelukast prescribed after triptans, which is a valid estimate of
the incidence rate ratio.
Results:During the study period, 440 persons were identified initiating
triptans within 180 days before and after their initial montelukast pre-
scription. Of those, 352 (80.0%) were females, and 280 (63.6%) had a
Charlson Comorbidity Index of 0 corresponding to a low comorbidity
burden. Of the incident users of montelukast and triptans, 209 initiated
montelukast before and 231 initiated montelukast after triptan treat-
ment, yielding a crude SR of 0.90 (95%CI 0.75–1.10). The SR of females
and males were 0.92 (95%CI 0.75–1.14), and 0.83 (95%CI 0.56–1.29),
respectively. Neither therapeutic indications of asthma (short‐ and
long‐acting inhalation treatment without recorded prescriptions of sys-
temic antihistamines or nasal topical anti‐allergic treatment) SR 0.72
(95%CI 0.48–1.15) nor therapeutic indications allergic rhinitis (recorded
prescriptions of systemic antihistamines or nasal topical anti‐allergic
treatment or both without short‐ and long‐term inhalation treatment)
SR 0.79 (95%CI 0.53–1.21) were associated with a modified risk of trip-
tan initiation. Post‐hoc analyses with time‐windows of 30‐ and 90 days
showed similar SRs (1.22 [95%CI 0.76–2.11] and 0.96 [95%CI 0.74–
1.26] respectively).
Conclusions: We did not find any association between initiation of
montelukast and onset of migraine (initiation of triptans), neither in
patients with suspected asthma or patients with suspected allergic rhi-
nitis without asthma.
700 | Excess of all‐cause mortality
associated with benzodiazepine use: A cohort
study
Clément Mathieu; Pierre Joly; Hélène Jacqmin‐Gadda;
Mathilde Wanneveich; Bernard Bégaud; Antoine Pariente
Bordeaux Population Health Research Center, UMR 1219, Inserm,
University of Bordeaux, Bordeaux, France
Background:At the moment benzodiazepine are steered at for over-
use in the opioid‐epidemic context, better understanding how their
patterns of use could be associated to the risk of death appears
essential. Although previous studies included large populations and
yielded precise estimates, the key issue concerns the influence of
the definition used for assessing benzodiazepine use on the results
and conclusions.
Objectives: To investigate the association of chronic use of benzodi-
azepines with all‐cause mortality.
Methods: A cohort of non‐prevalent benzodiazepine users aged
≥65 years at beginning of follow‐up was identified using a French
national health care insurance system claims database (Echantillon
Généraliste de Bénéficiaires, EGB), between 2010 and 2015. Chronic
usewas defined as a cumulated use of at least six months over the previ-
ous 12months on the basis of a monthly assessment of benzodiazepine
use status during the whole follow‐up. Adjusted Hazard ratios (aHR) for
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all‐causemortalityovera six‐year follow‐up,estimatedusingCox regres-
sion model with patterns of benzodiazepine use and confounders as
time‐dependent covariates.
Results: 54,958 met the inclusion criteria: mean age at inclusion
76 years, 53% female. Exposure to benzodiazepines represented
7.7% of the cumulative time of follow‐up for the whole cohort.
6,314 benzodiazepine chronic users represented overall 6.1% of the
cohort follow‐up time. aHR decreased with age for all patterns of ben-
zodiazepine use. At age 65, aHR for all‐cause mortality were 2.26
(1.96–2.61) for benzodiazepine short‐term use, 3.86 (3.04–4.90) for
benzodiazepine chronic use ‐ discontinued, and 3.05 (2.17–4.29) for
benzodiazepine chronic use ‐ ongoing, respectively at age 80, 1.62
(1.48–1.79); 2.00 (1.82–2.19) and 1.13 (1.02–1.26).
Conclusions: These findings confirm the existence of an excess risk of
mortality associated with the use of benzodiazepines, and provide pat-
tern‐specific and age‐specific estimates for this association: age < 80,
short‐term use, or chronic use (≥6 months over one year) recently
interrupted. If the latter were likely to be driven by an indication bias,
the associations found for ongoing chronic use and, to a lesser extent,
for short‐term use conversely support a potential causal hypothesis.
Consequently, these findings provide further evidence to support the
recommendation that benzodiazepines should be used with caution in
theyoungelderly inwhomtheyareoftenconsideredwell tolerated,even
after the initiation period.
701 | Spontaneous parasomnia adverse
event reports associated with
benzodiazepines and Z‐drugs
Darren Scheer1,2; Anh Thy H. Nguyen1; Skai Schwartz1
1University of South Florida, College of Public Health, Tampa, FL;
2Biotech Research Group, Tampa, FL
Background: While prescriptions for benzodiazepines plateaued over
the past 20 years, new prescriptions for Z‐drugs skyrocketed. Through
consistent case reports and case‐series, it is known that Z‐drugs are
associated with parasomnias, but epidemiological investigations of
these adverse events are scarce. As benzodiazepines were the primary
drug class used for sleep prior to the introduction of Z‐drugs, a direct
comparison of Z‐drugs with benzodiazepines is warranted.
Objectives: To assess the association of parasomnia adverse event
reports with benzodiazepines and with Z‐drugs.
Methods: Data from the United States Food and Drug Administra-
tion's Adverse Event Reporting System (FAERS) from 1969 through
third quarter 2018 were utilized. Preferred Terms according to
MedDRA were used to identify reports of somnambulism (includes
sleep‐walking and sleep‐driving), sleep‐related eating disorders, sleep
terror (includes night terror), and nightmare. Benzodiazepine drugs
included chlordiazepoxide, alprazolam, diazepam, clonazepam, and lor-
azepam. Z‐drugs included zaleplon, zolpidem, zopliclone, and
eszopiclone. The selected drugs were included, regardless of route of
administration, if they were noted to be suspect in the case report.
Associations between drugs and events were measured by Empirical
Bayes Geometric Mean (EBGM) and the corresponding lower bound
of the 90% confidence interval (EB05). EB05 ≥ 2 were considered sig-
nificant signals.
Results: From 1969‐2018Q3, there were over 123,000 complaints
related to benzodiazepines and over 45,000 complaints related to
Z‐drugs. Of these, 746 benzodiazepine complaints and 2600 Z‐drug
complaints were parasomnias. EBGM's were substantially higher for
Z‐drugs than for benzodiazepines for all four adverse event catego-
ries. For benzodiazepines, EBGM's ranged from 1.68 for sleep‐
related eating disorder to 2.57 for somnambulism, with only som-
nambulism providing a statistically significant signal (EB05 = 2.2). In
contrast, for the Z‐drugs, EBGM and corresponding EB05 values
were elevated for sleep terrors (3.71, 2.59), nightmares (5.52, 5.06),
somnambulism (85.13, 81.22), and sleep related eating disorder
(95.72, 83.99).
Conclusions: Our analyses of the FAERS database revealed that Z‐
drugs are strongly associated with four types of parasomnias including
three for which there was no signal on benzodiazepines.
702 | Risk of death associated with the use
of antipsychotic drugs among Parkinson's
disease with psychosis
Hoa V. Le1; Phuong Le2; Chi Truong3
1PAREXEL International and UNC Charlotte, Durham, NC; 2University of
Toronto, Mississauga, ON, Canada; 3MedCodeWorld LLC, Chapel Hill, NC
Background: The use of antipsychotics is associated with increased
mortality in the general population and patients with certain diseases,
but whether this risk extends to patients with Parkinson's with Psy-
chosis (PDP), particularly for typical/conventional and atypical antipsy-
chotics (TAP and AAP), has not been well known.
Objectives: To estimate the association between new use of antipsy-
chotic medications and mortality.
Methods: PDP patients ≥65 years old were identified from the CMS
Medicare data (2012–2015) to create three cohorts: new users of
TAP, of AAP, and untreated. For treated patients, index date was
the date of the first TAP or AAP exposure after the first PDP diag-
nosis in the study period. For untreated PDP, index date was the
date of the first PDP diagnosis. Patients were censored at earliest
of loss to follow‐up, death, end of enrollment, end of study period,
end of treatment, or switch from AAP to TAP or vice versa, wher-
ever appropriate. Untreated patients should not have any exposure
to antipsychotics during the study period. Age‐standardized mortality
rates were estimated based on US Census 2000. Three separate
pairwise matched cohorts were generated by using propensity score
matching to adjust for confounding. All‐cause deaths were compared
for each matched pair using Cox proportional hazards models, if
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proportionality assumptions were held. Otherwise, Poisson regres-
sion was used. Sensitivity analyses including adjustment of residual
confounding for time since the first PDP were performed.
Results: Of 33,415 elderly people in the study cohort, 818 initiated
a TAP, 4,793 an AAP, and 27,804 were untreated of any AP. Age‐
standardized mortality rates per person‐year were 0.68 (95% CI:
0.47–0.90), 0.29 (95% CI: 0.28–0.30) and 0.21 (95% CI: 0.19–0.24)
among TAP, AAP and untreated, respectively. New use of TAP vs
AAP was associated with an increased risk of death (HR = 1.74,
95% CI: 1.31–2.31). New use of TAP vs untreated was associated
with an increased risk of death (IRR = 2.16, 95% CI: 1.70–2.72). In
contrast, new use of AAP compared to untreated, was associated
with a decreased risk of death (HR = 0.56, 95% CI: 0.51–0.62).
Results were confirmed in sensitivity analyses.
Conclusions: Our finding confirmed that among elderly PDP
patients, the risk of death associated with TAP is greater than the
risk of death associated with AAP. Interestingly, with the same study
design to minimize the immortal bias while comparing with
untreated PDP, the study found that new TAP use increased mortal-
ity risk, but not AAP. Further research may need to confirm our new
finding by using non‐active comparator.
703 | Association of macular disease with
use of pentosan polysulfate sodium
Brian L. VanderBeek1; Alexandra L. Li2; Yinxi Yu1; Neiraj Jain2
1Scheie Eye Institute/University of Pennsylvania, Philadelphia, PA;
2Emory University, Atlanta, GA
Background: Recently a unique pigmentary maculopathy in the setting
of chronic exposure to pentosan polysulfate sodium (PPS), a treatment
for interstitial cystitis (IC) was described. These patients all had macu-
lar pigmentary changes that were ascribed to dry macular degenera-
tion or pattern dystrophy. Herein, we assess the risk of macular
disease in PPS users.
Objectives: To determine if an association between PPS use and mac-
ular disease exists.
Methods:A retrospective, matched cohort study using data from a large
national US medical claims database was performed. The exposure
cohort consisted of all patients prescribed PPS from 2002–2016. The
index date was the date when the patient first filled a prescription for
PPS, and patients were required to have at least 2 years prior to and
5 years after the index date for inclusion. Controls were matched 5:1
for age, gender, race, insurance plan eligibility start/end date and were
assigned the same index date their exposed match. Another analysis
required 7 years of follow up. Exclusion occurred for being <18 years
old and any dry macular degeneration (dAMD) or drusen diagnosis prior
to the index date. Two primary outcomes were identified. The first was
defined as a new International Classification ofDisease (ICD‐9/10) diag-
nosis code for a hereditary or secondary pigmentary retinopathy
(maculopathy)with the secondary outcomealso including a newdiagno-
sis of dAMD or drusen (maculopathy+AMD). Multivariate logistic
regression analyses were performed controlling for demographic and
systemic health variables. Subanalysis was also performed comparing
only IC patients.
Results: 3012 and 1604 PPS users were compared to 15060 and
8017 at 5 and 7 years respectively. At 5‐ and 7‐year follow‐up,
9(0.3%) and 10 (0.6%) PPS patient had a maculopathy outcome,
compared to 32(0.2%) and 25(0.3%) control patients respectively.
There were 103(3.4%) and 87(5.4%) PPS patients with
maculopathy+AMD compared to 440(2.9%) and 328(4.1%) control
patients at 5 and 7 years, respectively. At 5‐years, multivariate
analysis showed no significant associations (p > 0.13). However,
at 7 years PPS users had a significantly increased odds of having
Maculoapthy+AMD (OR = 1.41, 95% CI: 1.09–1.83, P = 0.009),
but not maculopathy (OR = 1.87, 95% CI: 0.87–3.99, P = 0.11).
IC subanalysis showed increased odds at 5 years (OR = 2.91,
95% CI: 1.15–7.36, P = 0.02), but not at 7(OR = 1.46, 95% CI:
0.66–3.24, P = 0.35) for the maculopathy outcome.
Conclusions: PPS exposure was associated with a new diagnosis of
macular disease. These results corroborate findings of the initial case
series that suggest an association between PPS exposure and a novel
maculopathy.
704 | Stuttering and methylphenidate
Thierry Trenque; Brahim Azzouz; Gwladys Claustre;
Emmanuelle Herlem; Agathe Trenque; Aurore Morel
Pharmacovigilance Pharmacoepidemiology Department, CHU, Reims,
France
Background: Methylphenidate (MPH) is a piperidine derivative struc-
turally and pharmacologically similar to amphetamine. MPH is indi-
cated for Attention Deficit Hyperactivity Disorder (ADHD) over
6 years of age. Stuttering affects about 5% of all children, especially
boys. Several studies demonstrate a higher prevalence of stuttering
in ADHD. The studies concerning the combination stuttering with
methylphenidate are contradictory: MPH sometimes suitable for
treating stuttering, on the other hand stuttering associated with the
use of MPH.
Objectives: To investigate the association between methylphenidate
and stuttering.
Methods: Data from Vigibase, the WHO pharmacovigilance database
including more than 18 million reports of Individual Case Safety
Reports (ICSRs) sent by national pharmacovigilance systems were
used for this disproportionality analysis. We analyzed reports in the
database that were coded with the MedDRA Preferred Term
“dysphemia” and with the Lower Level Terms (LLT) “stutter” and
“stuttering”. Association between exposure to MPH and occurrence
of the adverse drug reaction was estimated by a disproportionality
analyze. For this analyze, the Proportional Reporting Ratio (PRR)
and the Reporting Odds Ratio (ROR) were calculated. The 95% Con-
fidence Intervals (CIs) were calculated using the Woolf Method. All
analyses were performed using SAS 9.4 Software.
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Results: Among the 18 446 691 ICSRs registered in Vigibase, 2 975
were dysphemia cases of which 46 reports were associated with
MPH treatment. Most of them were observed in males (n = 33), mean
age was 13.52 years +/− 13.12. For the PT “dysphemia”, the PRR and
ROR were as following: PRR = 7.3 (95% CI: 5.4–9.7) and ROR = 7.3
(95% CI: 5.4–9.8). With the LLT “stuttering”, 584 cases were registered
in the database. We identified 17 cases with MPH with the mean age
of 13.28 +/− 9.75 years and 67% male. The PRR and ROR were
respectively 13.9 (95% CI: 8.6–22.5) and 13.9 (95% CI: 8.6–22.5).
Conclusions: Our data have to be considered as a pharmacovigilance
signal. The mechanisms inducing stuttering are not completely known.
An increased dopamine activity has been associated with stuttering.
MPH increases dopamine release. So, further pharmacovigilance sur-
veys and clinical studies are needed to conclude about MPH and
stuttering.
705 | Use of B2‐adrenoreceptor agonist and
antagonist drugs and risk of Parkinson's
disease
Franziska Hopfner1; Mette Wod2; Günter U. Höglinger3;
Morten Blaabjerg4; Thomas W. Rösler3; Gregor Kuhlenbäumer1;
Kaare Christensen2; Günther Deuschl1; Anton Pottegård2
1Christian‐Albrechts‐University Kiel, Kiel, Germany; 2University of
Southern Denmark, Odense, Denmark; 3Technical University of Munich,
Munich, Germany; 4Odense University Hospital, Odense, Denmark
Background: A recent high‐impact study showed that use of the β2‐
adrenoreceptor (β2AR) agonist salbutamol was associated with a
dose‐dependent decreased risk of PD in both an epidemiological and
biochemical setting. Consistently, chronic use of β2‐adrenoreceptor
(β2AR) antagonists, e.g. propranolol, was reported to be associated
with an increased risk of PD in the epidemiological substudy.
Objectives: To further investigate the association between β2AR ago-
nist and antagonist use and risk of idiopathic Parkinson's disease (iPD).
Methods: We used the nationwide Danish healthcare registries to
conduct a case–control study of incident cases of iPD between
2000 and 2011. Comparing the use of β2AR agonists among iPD cases
to that among disease‐free population controls (matched 1:4), we
obtained odds ratios (ORs) associating use of β2AR agonists and
antagonists with iPD, using conditional logistic regression and
adjusting for potential confounders.
Results: We identified 2790 iPD cases matched to 11,160 population
controls. Long‐term β2AR agonist use was associated with reduced risk
of PD (adjusted OR 0.57; 95% CI 0.40–0.82). However, short‐term
β2AR agonist use showed a comparable association (OR 0.64; 95% CI
0.42–0.98) and a formal test for risk reduction per year of exposure
was negative (ptrend = 0.97). We additionally found protective associa-
tion with other markers of smoking, i.e. chronic obstructive pulmonary
disease diagnosis (OR 0.61), long‐term use of inhaled corticosteroids
(OR 0.46), and inhaled anticholinergics (OR 0.33). Finally, strengths of
associations were consistent regardless of timing of use relative to date
of diagnosis. Regarding β2AR antagonist use, increased risks were only
observed for propranolol and metoprolol and associations were mark-
edly stronger for short‐term than long‐term use.
Conclusions: We confirmed an association between β2AR agonist
and antagonist use with reduced and increased PD risk, respectively.
However, our data indicate the association of β2AR agonists to be
indirectly mediated by smoking, which is known to be associated
with reduced risk of PD. The association of β2AR antagonists indi-
cates reverse causation, with PD symptoms triggering their prescrip-
tion, rather than β2AR antagonists causing PD. Thus, current
epidemiological data does not support a causal link between β2AR
agonists and antagonists and PD risk.
706 | Association of the inhaled
corticosteroids and the risk of cataract
requiring surgery in adults with asthma: A
population‐based study in South Korea
Na‐Young Jeong1; Mi‐Sook Kim2; Chang‐Hoon Lee3;
Heung‐Woo Park4; Bo Ram Yang5; Joongyub Lee6; Nam‐Kyong Choi1
1Ewha Womans University, Seoul, Korea, Republic of; 2 Seoul National
University College of Medicine; Medical Research Collaborating Center,
Seoul National University Hospital, Seoul, Korea, Republic of; 3Seoul
National University Hospital, Seoul, Korea, Republic of; 4Seoul National
University College of Medicine, Seoul National University Hospital, Seoul,
Korea, Republic of; 5Medical Research Collaborating Center, Seoul
National University Hospital, Seoul, Korea, Republic of; 6 Inha University
Hospital, School of Medicine, Inha University, Incheon, Korea, Republic of
Background: In asthmatic patients, inhaled corticosteroids (ICS) are
usually recommended globally as well as in Korea, but the relationship
with cataracts is not clear yet. As the number of prescription for ICS
and cataract operations increases every year, studies on the relationship
between the use of ICS and the occurrence of cataract are needed.
Objectives: The study aimed to examine the association between the
use of ICS or ICS/Long‐acting beta‐adrenoceptor agonist (LABA) and
the incidence of cataract requiring surgery among the asthmatic
patients aged 40–99 in Korea.
Methods: We conducted a population‐based retrospective cohort
study using the Health Insurance Review & Assessment database from
Jan 2013 to Dec 2016. Newly diagnosed asthmatic patients between
Jan 2014 to Dec 2015 with no history of cataract diagnosis and surgery
were identified. The study outcome was the cataract surgery. It was
followed‐up until the time of the outcome of interest or the end of
the study, whichever comes first. After applying propensity‐score
matching, we compared the risk of cataracts by using Cox proportional
hazards model.
Results: Among 1,025,857 asthmatic patients who were initiated asth-
matic medication, 146,499 (14.28%) were on ICS or ICS/LABA and
most of patients were prescribed oral corticosteroids (1,025,192;
99.9%). The number of patients who had cataract operations were
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2,266 (1.55%) in ICS users and 11,280 (1.28%) in non‐users. We found
no statistically significant association between the use of ICS and the
cataract requiring surgery during the entire follow‐up period (Hazard
Ratio (HR): 0.957; 95% CI:0.897–1.021). Similarly, in the subgroup
analyses, there were no significant differences in the results by gen-
der, prescription of oral corticosteroids, and comorbidity.
Conclusions: The study did not support the relationship between ICS
or ICS/LABA medication to adult asthmatic patients and the occur-
rence of cataract that led to surgery comparatively within a short
period of time.
707 | A safety signal of somnambulism with
the use of antipsychotics: A
pharmacovigilance disproportionality analysis
Amandine Gouverneur1; Amandine Ferreira1; Cécile Pageot2;
Camille Morival1; Marie Tournier3; Antoine Pariente1
1CHU et Université de Bordeaux, Inserm, Bordeaux Population Health
Research Center, Pharmacoepidemiology Team, UMR 1219, Service de
Pharmacologie Médicale, Bordeaux, France; 2CHU de Bordeaux, Service
de Pharmacologie Médicale, Bordeaux, France; 3Centre Hospitalier
Charles Perrens et Université de Bordeaux, Inserm, Bordeaux Population
Health Research Center, Pharmacoepidemiology Team, UMR 1219,
Bordeaux, France
Background: Antipsychotics are widely used in psychiatry, particularly
in schizophrenia bipolar disorders.
Objectives: This study aimed at investigating the risk of somnambu-
lism adverse drug reaction (ADR) associated to their use.
Methods: Individual case safety reports (ICSRs) collected in
VigiBase®, and related to antipsychotics (Anatomical Therapeutic
Chemical (ATC) classification N05A) and Preferred terms (PT) “Som-
nambulism” of the MedDRA classification were analyzed. A descrip-
tive analysis was performed according to median age, gender,
seriousness, drug and indication. Disproportionality analyses were per-
formed using information component (IC) in comparison to full data-
base. A signal was considered if the lower limit of 95% credibility
interval (LL 95%CI) was positive.
Results: A total of 450 ICSRs of somnambulismwere identified for anti-
psychotics; median age of patients was 47 years (interquartile range:
36–58), and 39% were men. Only one antipsychotic was involved in
most cases (94%); 40%were serious and 14% resulted in hospitalization
or hospitalization prolongation. Quetiapine was involved in 51% of
ICSRs, olanzapine in 12%, and aripiprazole in 10%. The indication was
informed in 68% of ICSRs; the main represented were bipolar disorders
(26%), depression (11%), and schizophrenia (14%). ADR co‐reported
with somnambulism concerned mostly somnolence (10%), insomnia
(10%), and weight increased (9%). Signals of disproportionate reporting
were found for 10 antipsychotics including quetiapine (IC 3.39, LL
CI95% 3.20), asenapine (IC 3.17, LL CI95% 2.49), ziprasidone (IC 2.68,
LL CI95% 2.09), lurasidone (IC 2.43, LL CI95% 1.45), olanzapine (IC
1.57, LL CI95% 1.16), pimavanserin (IC 2.08, LL CI95% 1.15),
aripiprazole (IC 1.43, LL CI95% 0.98), lithium (IC 1.04, LL CI95% 0.22),
brexpiprazole (IC 1.63, LL CI95% 0.10), and tiotixene (IC 2.09, LL
CI95% 0.04), yet not for risperidone (n = 14, IC ‐0.98, LL CI95% ‐1.83),
clozapine (n = 13, IC ‐1.56 LL CI95% ‐2.45) or haloperidol (n = 6, IC ‐
1.85, LL CI95% ‐0.47).
Conclusions: This study found signals of disproportionate reporting of
somnambulism for major antipsychotics including quetiapine,
olanzapine and aripiprazole, yet not for risperidone, clozapine or halo-
peridol. All signals concerned atypical antipsychotics (expected lith-
ium) and none classical antipsychotics. The absence of signal with
classical antipsychotics will have to be further investigated through
ad‐hoc and more robust studies.
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709 | Spontaneous reporting of rare events
associated with atypical antipsychotics using
the FDA adverse event reporting system
Nnadozie Emechebe1; Fahad Mukhtar1,2; Darren Scheer1,3;
Arshiya Patel4; Abhishek Wadhawan2; Skai Schwartz1; Janice Zgibor1
1Department of Epidemiology and Biostatistics, College of Public Health,
University of South Florida, Tampa, FL; 2Saint Elizabeths Hospital,
Psychiatry Residency Training Program, Washington, DC; 3Biotech
Research Group, Corp, Tampa, FL; 4Department of Global Health, College
of Public Health, University of South Florida, Tampa, FL
Background: Atypical antipsychotic drugs (APD) have chiefly replaced
typical antipsychotics (TA) as first line drugs for the management of
schizophrenia and related disorders. Although APD cause less extra‐
pyramidal side‐effects than TA, further identification of their safety
profile is required. Few case reports and studies have reported an
association between APD and cardiomyopathy, hypothermia and pria-
pism. However, to the best of our knowledge, no study has collec-
tively examined the safety profile of all FDA approved APD with
very rare adverse events (AEs), particularly cardiomyopathy, priapism
and hypothermia.
Objectives: To assess the association of APD with spontaneous
reporting of cardiomyopathy, priapism and hypothermia in the FDA
Adverse Event Reporting System (FAERS).
Methods: Reports from 1989 to 2018 in FAERS of all single ingredient,
FDA approved APD, regardless of the route of administration were
included in the analysis. Identified APD were aripiprazole, asenapine,
clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine,
risperidone, ziprasidone, brexpiprazole and cariprazine. AEs of interest
included cardiomyopathy, hypothermia, and priapism. Reports were
restricted to instances where the drug was noted as suspect in the case
report. Associations between drugs and events were measured by
Empirical Bayes Geometric Mean and the lower bound of the 90%
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confidence interval (EB05). A signal was defined as drug‐AE pair having
an EB05 ≥ 2. All analyses were performed using DrugLogic‐QSCAN®.
Results: There were 386,029 reports included in the analysis. Risperi-
done (20.9%), clozapine (19.5%) and quetiapine (19%) were the most
reported APD, while brexpiprazole (1.8%), iloperidone (0.2%),
cariprazine (0.18%)were the least reported. Therewas disproportionate
reporting of cardiomyopathy with clozapine and olanzapine
(EB05 = 6.95 and 2.2, respectively). Similarly, olanzapine, risperidone,
quetiapine, aripiprazole and clozapine were associated with higher
reporting of hypothermia (EB05 = 7.4, 7.1, 2.8, 2.7, and 2.6 respec-
tively). Last, all APD were associated with disproportionate reporting
of priapism except for lurasidone, asenapine, brexpiprazole and
cariprazine.
Conclusions: APD are associated with disproportionate higher
reporting of cardiomyopathy, hypothermia and priapism. Although
the results do not indicate causality, they should raise awareness
among physicians to monitor for these potentially life‐threatening
AE, particularly with certain APD. Further studies are needed to vali-
date these findings.
710 | Disproportionality analysis of
emotional and mood disturbances with
statins using the Food and Drug
Administration adverse event reporting
system
Catherine Patterson1; Mikel Alberdi1; Darren Scheer1,2
1Biotech Research Group, Tampa, FL; 2Department of Epidemiology and
Biostatistics, College of Public Health, University of South Florida, Tampa,
FL
Background: Statindrugsareprescribedtotreatpatientswithhypercho-
lesterolemia. Their popularityhasbeen temperedby various side effects.
Caseandanecdotalreportsnotethepossibilityofanincreaseinemotional
and mood disturbances (i.e. anger and irritability) as more patients are
exposed to statins. Few studies have reported an association between
statinuseandthesetypesofadverseevents.Tothebestofourknowledge,





turbances NEC. This HLT includes the Preferred Terms (PTs) anger,
irritability, emotional distress, among others. The FDA Adverse Event
ReportingSystem(FAERS)wasusedforanalyses.
Methods: All FAERS data from 1969 to 2018 (3rd Q) was used. Oral
formulation, single active ingredient statins were included (atorva-
statin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin,
and simvastatin). The association of the HLT Emotional and Mood Dis-
turbances NEC to the individual statins was evaluated using the
Empirical Bayes Geometric Mean (EBGM) and the lower bound of
the 90% confidence interval (EB05). A signal was defined as drug‐
event pair having an EB05 ≥ 2. The secondary analysis signal thresh-
old was the combination of Proportional Reporting Ratio (PRR) ≥2,
N ≥ 3, and Chi2 ≥ 4. The DrugLogic‐QSCAN® platform was used
for all analyses.
Results: Atorvastatin was associated with the greatest number of
overall case reports for any adverse event (N = 291705), while
pitavastatin was the lowest (N = 4661). None of the statins
achieved an EB05 of ≥2: simvastatin (0.72), atorvastatin (0.65), prava-
statin (0.56), lovastatin (0.55), rosuvastatin (0.55), fluvastatin (0.39),
pitavastatin (0.33). Similarly, none of the statins reached the signal
threshold for the secondary analysis. All PRR values were below 1.0.
Conclusions: In our analyses, none of the FDA approved and U.S.
marketed statins were associated with disproportional reporting for
the HLT Emotional and Mood Disturbances NEC. In fact, all seven
statins were reported at a lower frequency than expected, compared
to the entire FAERS database. The values suggest a possible protec-
tive effect. However, due to well‐known underreporting associated
with spontaneous reporting databases, caution is warranted. Further
studies are required to confirm these findings.
711 | Impulse control disorders associated
with dopamine agonists in patients with
prolactinomas: A literature review
Anindit Chhibber1; William Barbeau2; Marco Bortolato3;
Nakyung Jeon1
1Department of Pharmacotherapy, College of Pharmacy, University of
Utah, Salt Lake City, UT; 2Department of Family and Preventative
Medicine, University of Utah, Salt Lake City, UT; 3Department of
Pharmacology, College of Pharmacy, University of Utah, Salt Lake City,
UT
Background: Dopamine agonists (DAs) have been associated with
impulse control disorders (ICDs). Previous studies evaluating the epi-
demiology of ICDs have generally been limited to patients with
Parkinson's disease (PD) and the prevalence and characteristics of
DA‐associated ICDs are relatively unknown in patients with
prolactinomas.
Objectives:We conducted a literature review of epidemiologic studies
evaluating the DA‐associated risk of ICDs among patients with
prolactinomas, with a focus on cabergoline and bromocriptine.
Methods: Keywords were searched on PubMed and EMBASE for
English‐language articles published through January 2019. We
included epidemiologic studies that are designed to investigate the
association between any types of ICD and either cabergoline or bro-
mocriptine. Following PRISMA guideline, two independent reviewers
screened, adjudicated, and extracted data. Any discrepancies were
resolved through discussion and a third reviewer if needed.
Results:Of the potential 621 articles, 1 randomized control trial (RCT), 2
observational studies and 12 case reports/series were eligible for inclu-
sion in this review. According to the RCT and observational studies, the
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incidence of ICDs ranged from 3% to 25% in prolactinoma patients
receiving cabergoline or bromocriptine. In the RCT of 38 patients and
an observational study of 25 patients who received cabergoline, hyper-
sexuality was the only type of ICDs reported. Furthermore, hypersexu-
ality, followed by pathological gambling and excessive shopping, was
the most predominant ICDs in the larger observational study among
77 patients received either cabergoline or bromocriptine. Twelve case
reports/series on a total of 22 prolactinoma patients with DA‐associ-
ated ICDs were identified. Manifestations include hypersexuality
(n = 13), pathological gambling (n = 10), excessive shopping (n = 1) and
compulsive eating (n = 1), indicating some patients experiencedmultiple
ICDs. These ICDs were usually reversible after a decrease or cessation
of dopamine agonists. Interestingly, all instances of hypersexuality
occurred in men with wide age (16–78 years) and drug dose range
(0.07–1 mg/day for cabergoline and 0.07–15 mg/day for
bromocriptine).
Conclusions: The results of our review indicate that prolactinoma
patients may develop ICDs, especially hypersexuality, as side effects
of bromocriptine or cabergoline treatment. However, the available evi-
dence remains largely anecdotal and insufficient to draw conclusions
about the causality and factors associated with the increased ICD risk.
712 | Risk of Stevens‐Johnson syndrome
and toxic epidermal necrolysis associated
with anticonvulsants in a Japanese population
Toshiki Fukasawa1; Hayato Takahashi2; Nanae Tanemura1;
Masayuki Amagai2; Hisashi Urushihara1
1Graduate School of Pharmaceutical Sciences, Keio University, Tokyo,
Japan; 2Keio University School of Medicine, Tokyo, Japan
Background: Previous overseas studies and case reports have sug-
gested that anticonvulsants be associated with Stevens‐Johnson syn-
drome (SJS) and toxic epidermal necrolysis (TEN). However, evidence
for the risks is scarce in Japan.
Objectives: To investigate the risk of SJS/TEN in patients newly‐
treated with anticonvulsants in Japan.
Methods: We conducted a 1:4 matched case–control study using
2005–2017 claims data from the JMDC Inc. SJS/TEN cases were
identified using a claims‐based algorithm developed from the elec-
tronic medical records in a Japanese university hospital in a previous
study (sensitivity 76.9%, specificity 99.0%). This algorithm consisted
of the following three domains: 1) clinical course for SJS/TEN; 2) med-
ical encounters for mucocutaneous lesions from SJS/TEN; and 3) item
to exclude differential diagnosis of paraneoplastic pemphigus. SJS/
TEN‐free controls were matched to cases on age, sex, and index date
(date of diagnosis) by risk‐set sampling. Conditional logistic regression
was used to estimate odds ratios (ORs) and 95% confidence intervals
(CIs) for SJS/TEN associated with each suspected anticonvulsant use
(90 days prior to the index date) versus anticonvulsant non‐use. We
calculated cumulative incidences of SJS/TEN for new users of 33 anti-
convulsants. Causality between anticonvulsants and SJS/TEN in each
exposed case was assessed using the algorithm of drug causality for
epidermal necrolysis (ALDEN) score.
Results: The case–control study included 49 SJS/TEN cases (20 male
and 29 female) and 196 controls. Mean age at index date for cases
and controls combined was 42.5 years. There were increased odds
of SJS/TEN in the new users of lamotrigine (OR 21.14, 95% CI
3.59‐∞) and carbamazepine (OR 21.14, 95% CI 3.59‐∞). The ALDEN
score was more than probable for 100% of cases exposed to
lamotrigine or carbamazepine. Cumulative incidences of SJS/TEN
were 87.0/100,000 new users for lamotrigine, and 48.4/100,000
new users for carbamazepine. We found no significant elevated odds
in the users of other anticonvulsants.
Conclusions: Exposure to lamotrigine and carbamazepine was associ-
ated with an increased risk of SJS/TEN.
713 | Risk of extrapyramidal syndromes
associated with antipsychotic polypharmacy:
A retrospective study based on spontaneous
reporting system databases
Kouichi Hosomi; Hiroki Kagoyama; Satoshi Yokoyama;
Mitsutaka Takada
Kindai University, Higashi‐osaka, Japan
Background: Extrapyramidal syndromes (EPS) are adverse events
associated with use of antipsychotics. Antipsychotic polypharmacy is
common in clinical practice although supporting evidence is limited.
Many reports suggest an association between each antipsychotic drug
and EPS; however, the risk of EPS associated with their polypharmacy
has not been fully evaluated.
Objectives: The purpose of this study is to examine the association of
antipsychotic polypharmacy on EPS using US and Japanese spontane-
ous reporting system databases.
Methods:We analyzed reports of EPS between 2004–2017 in the FDA
Adverse Event Reporting System (FAERS) and the Japanese Adverse
Drug Event Report database (JADER), and calculated the reporting odds
ratio (ROR)ofantipsychoticpolypharmacyassociatedwithEPS.Antipsy-
chotic polypharmacywasdefined as use ofmore thanone antipsychotic.
Results: For EPS, the RORs of antipsychotics were 6.33 (95% CI 6.20–
6.46) in FAERS, and 18.18 (16.90–19.55) in JADER, respectively. The
ROR of a multiple antipsychotic (FAERS: ROR 7.01, 95% CI 6.72–7.32,
JADER: 15.27, 13.86–16.82) was higher than that of a single antipsy-
chotic (FAERS: 5.88, 5.74–6.01, JADER: 12.08, 11.17–13.07).
Conclusions: Antipsychotics were significantly associated with EPS,
and the profile was stronger in antipsychotic polypharmacy. That sug-
gests the possibility of an increased risk of EPS with increasing num-
ber of antipsychotics. Further investigation is needed to confirm
these findings.
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714 | Risk of suicide attempt and the use of
antidepressants in Taiwan
Chih‐ying Tsai1; Yea‐Huei Kao Yang1; Edward Chia‐Cheng Lai1,2
1National Cheng Kung University, Tainan, Taiwan; 2National Cheng Kung
University Hospital, Tainan, Taiwan
Background: Use of antidepressants to reduce risk of suicide in
patients with major depression remained controversial. It warrants
cautions on possible confounding by indications in the comparisons
between antidepressant users and non‐users from previous studies.
Objectives: To compare the risk of suicidal attempts between patients
with depression persisted to antidepressants vs non‐persisted patients.
Methods: We analyzed Taiwan's National Health Insurance Research
Database (NHIRD) between Jan 1, 2003 andDec 31, 2010.We included
patients newly received antidepressants for 90+ days from two or more
antidepressant prescription and diagnosedwith depression.We consid-
ered persisted patients as those continuously used antidepressants
after index date, which was defined as 90 days after drug initiation, oth-
erwise non‐persisted patients were defined as those who discontinued
antidepressants after index date. We followed patients until discontin-
uation of the antidepressant or occurrence of suicide and suicidal
attempts. We performed Cox's proportional hazards models with
adjustment for patients' age, sex and psychiatric conditions andmedica-
tions to evaluate the risk of suicide attempts between antidepressants
persisted and non‐persisted patients.
Results: We identified a total of 5238 patients in the study; with amean
age of 50.9 (SD 16.8) and 35.1% were male. We found 4172 were
persisted patients and 1066 were non‐persisted. The incidence rates
of suicide attempts were 3.9 per 100,000 person‐years and 6.9 per
100,000 person‐years in persisted and non‐persisted patients, respec-
tively. We found the risk of suicide attempts were lower in persisted
patients (adjusted hazard ratio, 0.79; 95% CI, 0.35 to 1.8) compared to
non‐persisted patients; however no statistical significance.
Conclusions: This population based study indicated that the risk of
suicide attempts tended to be lower in antidepressant persisted
patients compared to non‐persisted patients. It warrants future inves-
tigations to include larger sample size to confirm the findings.
715 | Comparative risk of mortality among
individual antipsychotics in patients with
dementia
Shi‐Jie Lai1; Chien‐Chou Su1; Yea‐Huei Kao Yang1;
Edward Chia‐Cheng Lai1,2
1School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical
Sciences, College of Medicine, National Cheng Kung University, Tainan,
Taiwan; 2Department of Pharmacy, National Cheng Kung University
Hospital, Tainan, Taiwan
Background: Antipsychotic medications are commonly used for
behavioral and psychological symptoms of dementia (BPSD);
however the US FDA warned an increased mortality risk of antipsy-
chotics in elderly patients. Understanding different mortality risk
profiles among antipsychotics helps to avoid unintended outcomes.
Objectives: To compare the mortality risk between individual antipsy-
chotics in patients with BPSD.
Methods: We conducted a retrospective cohort study using the
Taiwan's National Health Insurance Research Database (NHIRD) from
2003–2013. Study population consisted of patients aged 65+ years
who diagnosed with BPSD newly receiving antipsychotic medications.
The outcome of interest was all cause of mortality. We performed
intent‐to‐treat analysis and followed patients until they died or
180 days after antipsychotics initiation. Quetiapine was selected as
reference group for comparison because it was most commonly used
antipsychotic. We performed Cox proportional hazards models with
adjustments of covariates such as age, sex to compare the mortality
risk between antipsychotic users.
Results: We identified a cohort of 41,932 patients with a mean age of
81.1 years (SD 7.04) and 47.49% female. Quetiapine (38.4%) was the
most frequently used antipsychotics, followed by haloperidol (16.5%)
and Risperidone (16.0%). The overall mortality rate was 0.84 cases per
person‐year among all antipsychotic groups. We found the mortality
risk were higher in haloperidol (adjusted hazard ratio, 1.78; 95% CI,
1.70–1.85) and risperidone (1.23; 1.17–1.29) comparedwith quetiapine
users. Olanzapine (1.07; 0.91–1.25) posed similar risk compared with
quetiapine. We found patients receiving amisulpride (0.86; CI 0.69–
1.08) and aripiprazole (0.64; 0.49–0.84) had lower risk of mortality com-
pared to quetiapine users.
Conclusions: The finding warrants caution on increased mortality risk
in patients receiving haloperidol and risperidone. Amisulpride and
aripiprazole may provide more favorable risk profiles in mortality that
could be considered for patients with BPSD.
716 | Oral antidiabetes drugs and risk of
stroke
Lamiae Grimaldi‐Bensouda1,2; Nicolas Morisot3;
Pegdwende O. Dialla3; Clémentine Nordon3,4; Lucien Abenhaim5,6
1University of Versailles Saint‐Quentin en Yvelines, Versailles, France;
2Ambroise Pare Hospital, Boulogne‐Billancourt, France; 3Laser Core,
Paris, France; 4Maison Blanche Public Hospital, Paris, France; 5 LA Risk
Research, London, UK; 6London School of Hygiene & Tropical Medicine,
London, UK
Background: Diabetes is a known risk factor for stroke. Publications
have reported increased risk of stroke in users of sulfonylureas, with
little consideration for indication comorbidities, coprescriptions or
type of stroke (ischemic or hemorrhagic).
Objectives: To explore the association between type of oral
antidiabetes treatment used and the risk of stroke in patients with
diabetes.
Methods: From two national registries, patients with diabetes were
identified, excluding patients treated with insulin or other injectable
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antidiabetes treatments. Incident stroke was defined as: (i) a first‐ever;
(ii) fatal or non‐fatal; (iii) ischemic stroke or haemorrhagic stroke; (iv)
documented by CT scan or MRI; (v) irrespective of symptom duration.
Stroke cases were matched to non‐stroke patients (referents) on age,
gender, index date (date of stroke diagnosis for cases and date of
recruitment for non‐cases) and history of atrial fibrillation (AF). All treat-
ments received in the previous 12 months before stroke or index date
were considered (most documented from medical records). The associ-
ations between each OAD used and the risk of stroke were assessed
with multivariable conditional logistic models. Potentially cofounding
risk factors considered in the model were: antiplatelet agents and anti-
coagulants use, history of cardiovascular diseases, hyperlipidemia, renal
impairment, liver disease.
Results: The prevalence of diabeteswas 22% in stroke registry and 19%
in AF registry (adjusted odds ratio (OR) for diabetes and incident stroke:
1.25 with a 95% confidence interval (CI) of [1.05–1.49], with similar OR
for ischemic and hemorrhagic stroke). Among them, 362 stroke cases
with diabeteswere identified in the registries,matched to 362 randomly
selected non‐stroke patients with diabetes. The adjustedOR for the use
of metformin only was OR = 0.90;95%CI [0.56–1.43], for of the
use of sulfonylurea only OR = 0.89;95%CI [0.49–1.64], for of the use
of glinide only OR = 1.65;95%CI = [0.71–3.80], for of the use of DPP‐
4 only OR = 0.78;95%CI [0.32–1.90]. Similar results were found when
each OAD was used in combination with any other OAD. Analyses
restricted to ischemic stroke provided similar results.
Conclusions: No significant difference in the risk of stroke was
observed for each individual OAD used in isolation or in combination
with other OAD in patients with diabetes.
717 | Trazodone use and risk of dementia: A
population‐based cohort study
Ruth Brauer; Wallis Lau; Joseph F. Hayes; Kenneth K.C. Man;
David P.J. Osborn; Robert Howard; Joseph Kim; Ian C.K. Wong
University College London, London, UK
Background: In vitro and animal studies have suggested that trazo-
done, a licensed antidepressant, may protect against dementia. How-
ever, no studies have been conducted to assess the effect of
trazodone on dementia in humans.
Objectives: We conducted an electronic health records study to
assess the association between trazodone use and the risk of develop-
ing dementia in clinical practice.
Methods: We used The Health Improvement Network (THIN) primary
health care data to identify patients aged ≥50 years who received at
least two consecutive prescriptions for an antidepressant between Jan-
uary 2000 and January 2017.We compared the risk of dementia among
patients who were prescribed trazodone to that of patients with similar
baseline characteristics prescribed other antidepressants, using a Cox
regression model with 1:5 propensity score matching. Patients pre-
scribed trazodone who met the inclusion criteria (n = 4,716; 59.2%
female) were older (mean age 70.9 ± 13.1 versus 65.6 ± 11.4 years)
and were more likely than those prescribed other antidepressants
(n = 420,280; 59.7% female) to have cerebrovascular disease and use
anxiolytic or antipsychotic drugs. After propensity score matching,
4,596 users of trazadone and 22,980 users of other antidepressants
were analyzed.
Results: The median time to dementia diagnosis for people prescribed
trazodonewas 1.8 years (interquartile range [IQR] = 0.5–5.0 years). Inci-
dence of dementia among patients taking trazodone was higher than in
matched users of other antidepressants (1.8 versus 1.1 per 100 person‐
years), with a hazard ratio (HR) of 1.80 (95% confidence interval [CI]
1.56–2.09; p < 0.001). When we restricted the control group to users
of mirtazapine only in a sensitivity analysis, the findings were very sim-
ilar to the results of the main analysis. Whilst the incidence of dementia
among patients taking trazodonewas higher than that in patients taking
other antidepressants, the risk differences were closer to zero with
increasing duration of treatment, suggesting that people in the prodro-
mal stage of dementia might be more likely to be prescribed trazodone.
Conclusions: We found no association between trazodone use and a
reduced risk of dementia compared with other antidepressants. These
results suggest that the clinical use of trazodone is not associated with
a reduced risk of dementia.
718 | Risk of bullous pemphigoid after
initiating dipeptidyl peptidase 4‐inhibitor
versus 2nd generation sulfonylurea: Multi‐
database cohort study
Hemin Lee1; Hye Jin Chung2; Ajinkya Pawar1; Elisabetta Patorno1;
Dae Hyun Kim1
1Brigham and Women's Hospital, Boston, MA; 2Boston University School
of Medicine, Boston, MA
Background: Dipeptidyl peptidase 4‐inhibitors (DPP4i) have been
linked to bullous pemphigoid. Yet this risk has not been well‐
established in population‐based studies.
Objectives: To compare the risk of bullous pemphigoid in diabetes
patients initiating DPP4i versus second generation sulfonylurea.
Methods:We conducted a 1:1 propensity‐score matched cohort study
of adults aged≥40 years with type 2 diabetes mellitus whowere newly
treated with DPP4i or second generation sulfonylurea using 2006–
2016 data from two large commercial insurers' databases (Optum
Clinformatics™ Datamart and Truven MarketScan) and Medicare. We
calculated the incidence rate of bullous pemphigoid identified using
diagnosis codes. Hazard ratios (HRs) and 95% confidence intervals
(CIs) associatedwithDPP4i versus sulfonylureawere estimated formid-
dle‐age (40–64 years) and older patients (≥65 years) in each database.
The inverse‐variance fixed‐effects meta‐analysis was used to pool the
results from the three databases.
Results: The analysis included 173,279 propensity‐score matched
pairs in Optum database (mean age, 61 years; median follow‐up,
120 days), 353,580 pairs in Truven database (58 years; 129 days),
and 308,170 pairs in Medicare (74 years; 149 days). Initiation of
DPP4i compared with sulfonylurea was not associated with bullous
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pemphigoid in middle‐age patients (incidence rates per 1000 person‐
years for DPP4i versus sulfonylurea: 0.09 versus 0.14; pooled HR,
0.62; 95% CI, 0.37–1.04). However, DPP4i initiation was associated
with an increased risk in older patients (incidence rates, 0.95 versus
0.62; pooled HR, 1.55; 95% CI, 1.30–1.84). The results were consis-
tent across the databases.
Conclusions: These results suggest an increased risk of bullous pem-
phigoid after initiating DPP4i compared with sulfonylurea in older
adults with type 2 diabetes mellitus.
719 | Risk of acute kidney injury and chronic
kidney disease following aciclovir and
valaciclovir therapy
Lars Christian Lund; Daniel P. Henriksen; Peter B. Jensen;
Kasper B. Kristensen
Clinical Pharmacology and Pharmacy, Odense, Denmark
Background: Aciclovir and valaciclovir are the most commonly pre-
scribed nucleoside analogues for the treatment of herpes simplex virus
infections in Denmark. Use of these drugs has been associated with
crystalluria and renal failure. Most studies investigated the association
between intravenous use of thesedrugs and acute kidney injury (AKI),
but data on oral use and chronic kidney disease (CKD) is sparse.
Objectives: To assess the potential association between use of val−/
aciclovir and AKI and CKD.
Methods: The study population consisted of all adults residing on the
island of Funen, Denmark (population size: 490,000) at some time dur-
ing 2000 to 2016, who had at least one creatinine measurement
recorded. We defined CKD and AKI according to Kidney Disease
Improving Global Outcome (KDIGO) definitions and usedDanish health
register data combined with data from the Funen Laboratory Cohort
(FLaC). To assess the association between val−/aciclovir and AKI a
self‐controlled case series (SCCS) analysis was undertaken to estimate
incidence rate ratios (IRR), these were estimated in 10‐day intervals
up to 180 days after start of exposure. IRRs were calculated using con-
ditional Poisson regression.We conducted a nested case–control study
to assess the association between val−/aciclovir and CKD. We used
risk‐set sampling and sampled up to 10 sex‐ and age‐matched controls
per case. Conditional logistic regression was used to estimate
odds ratios (OR).
Results: Assessing the risk of AKI, a total of 69,734 individuals
redeemed one or more prescriptions of val−/aciclovir in the study
period. Of these, 6635 had AKI and were included in the SCCS‐analysis.
The crude IRR of AKI during the risk period (prescription duration and
14‐days washout period) was 2.12 (95% CI: 1.67–2.70), and the age‐
adjusted IRRwas 2.02 (95%CI: 1.59–2.57).Maximum IRRwas observed
during ongoing exposure and fell to baseline after 40 days after initia-
tion. Assessing the risk of CKD, 1752 cases (10.4%) and 10,496 controls
(10.0%) were exposed to val−/aciclovir. Use of val−/aciclovir was not
associated with CKD (adjusted OR: 0.97 95% CI: 0.91–1.03), nor was
chronic use (>35 DDD: 0.81 95% CI: 0.54–1.20). We did not observe
dose–response patterns related to the cumulative dose.
Conclusions: An increased IRR of AKI was observed during
current exposure to val−/aciclovir. However, since one may expect a
diagnostic delay this could be due to protopathic bias. We found no
association between exposure to val−/aciclovir and CKD.
720 | Fluoroquinolone adverse drug events:
Results of an active surveillance project
Nathan Sylvain; Sherrie Aspinall; Fran Cunningham; Kelly Echevarria;
Rongping Zhang; Diane Dong; Peter Glassman; Matthew Goetz
Department of Veterans Affairs, Hines, IL
Background: Use of fluoroquinolones has been associated with
increased risk of rare but serious adverse drug events (ADEs). The Food
and Drug Administration has released several warnings recommending
use of alternative antibiotics when feasible.
Objectives: The purpose of this active surveillance project was to
evaluate risks of rare, serious ADEs in outpatient Veterans treated
with fluoroquinolones versus common alternatives (amoxicillin/
amoxicillin‐clavulanate and azithromycin).
Methods: This was a retrospective cohort analysis of Veterans with
new outpatient prescriptions for oral levofloxacin, ciprofloxacin or
moxifloxacin (Group 1), amoxicillin or amoxicillin/clavulanate (Group
2), or azithromycin (Group 3) between 6/1/2008 and 5/31/2018.
Patients could have multiple prescriptions≥30 days apart. Primary out-
comes were hospitalization or ED visit due to acute myocardial infarc-
tion (AMI), ventricular arrhythmia, aortic aneurysm/dissection, Achilles
tendon rupture/tendinitis, or peripheral neuropathy over the 30 days
following release of the prescription, and 30‐day all‐cause mortality.
Secondary outcomes were outpatient visits for these diagnoses. Pro-
pensity score matching adjusted for potential treatment selection bias.
Cox proportional hazards models assessed the association between
fluoroquinolones and ADEs versus the other antibiotics.
Results: After propensity score matching for baseline demographics,
comorbidities, antibiotic indication, and concomitantmedications, there
were 795,709well matched outpatients in Groups 1 and 2 and 551,269
in Groups 1 and 3. Based on preliminary results, patients in Group 1 had
a greater risk for aortic aneurysm/dissection compared with Group 2
(HR = 1.74; 95% CI 1.27–2.40) or Group 3 (HR = 2.17; 95% CI 1.41–
3.34). Patients in Group 1 also had a greater risk for AMI versus Group
2 (HR = 1.52; 95% CI 1.35–1.71) or Group 3 (HR = 1.41; 95% CI 1.22–
1.62) and a greater risk for 30‐day all‐cause mortality versus patients
in Group 2 (HR = 2.28; 95% CI 2.19–2.37) or Group 3 (HR = 2.02;
95% CI 1.93–2.12). There was no significant difference in the risk of
ventricular arrhythmia between Group 1 and Groups 2 (HR = 1.12;
95% CI 0.85–1.48) or 3 (HR = 1.33; 95% CI 0.92–1.90). Results were
similar in secondary analyses.
Conclusions:We identified a possible signal of an increased risk of aor-
tic aneurysm/dissection, AMI, and all‐cause mortality with fluoroquino-
lone use versus amoxicillin/amoxicillin‐clavulanate and azithromycin in
Veterans. Our findings warrant further investigation in a formal
research study with adjustment for additional confounders.
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721 | Under‐reporting of adverse drug
reaction: pharmacovigilance awareness and
challenges among resident doctors
Hala Shokr1; Didi Ahmed2; Yousra El‐adwy3
1Aston University, Birmingham, UK; 2McMaster University, Hamilton,
ON, Canada; 3Faculty of Medicine, Alexandria, Egypt
Background: Adverse drug reaction (ADR) reporting is the
keystone of pharmacovigilance (PV) and one of the fundamental
roles of any healthcare provider. However, under‐reporting is
recognized as the main cause of poor ADR detection worldwide.
Objectives: To evaluate resident doctors' knowledge and attitude
regarding pharmacovigilance and adverse drug reaction reporting sys-
tem in Alexandria, Egypt.
Methods: A Cross sectional, questionnaire based study conducted to
identify themain reasons behind the under‐reporting of ADR behaviour
among resident doctors. The study was conducted in Alexandria Uni-
versity Hospitals, Egypt. A total number of 304 resident were included.
Reporting responsibilities and mechanisms were evaluated and data
analysis was conducted usingTIBCO Statistica software.
Results: The Majority of the respondents 85.6% never reported any
adverse drug event and almost half of them (49%) never heard about
the PV reporting centers. Lack of time and poor knowledge about the
ADR reporting process were the main reason (75%) behind under‐
reporting. Other factors associated with under‐reporting were fear of
appearing unreasonable (35%), believing that only safe drugs allowed
in market (42%), indifference (26%) and uncertainty (I'm not sure which
drug responsible for this adverse reaction) (36%). General attitude of the
respondents about ADR reportingwas as follows: ADR reporting should
be compulsory (16.27%), doctors should be paidwhen reporting an ADE
(68.5%), prescriber and reporter identity should be concealed (61.42%).
Conclusions: While pharmacovigilance perception and attitude showed
a strong influence in ADR reporting, our study found that personal fac-
tors appear to play a huge role as well. Regular training sessions and
closer relationships with the PV centers could be useful to improve
ADR reporting rates. Making ADR reporting guidelines, booklets or
posters can also increase the awareness of PV among healthcare
professions.
722 | Calcium Channel blocker induced
lymphedema among breast cancer patients: A
nested case control study
Mrinmayee Lakkad; Amanda Stolarz; Jacob Painter
University of Arkansas for Medical Sciences, Little Rock, AR
Background: Lymphedema is a common complication subsequent to
breast cancer treatment. Research has shown varying effects of anti-
hypertensive agents, including calcium channel blockers, on lymph-
edema development.
Objectives: To assess the risk of lymphedema associated with use of
calcium channel blockers among breast cancer patients.
Methods: A nested case–control study of adult female breast cancer
patients receiving an antihypertensive agent was conducted. The
nest comprised patients of breast cancer female patients exposed
to antihypertensive agents using administrative claims data between
2007 and 2015. Cases were patients with 1 or more medical claims
with a primary or secondary diagnosis for lymphedema or procedure
claim for lymphedema treatment and 180 days of continuous enroll-
ment prior to event date. Up to 5 controls from the nest were
matched to cases based on nest entry date (180 days), age (5 years),
number of hypertensive drug classes, Charlson comorbidity score,
thiazide exposure, and insurance type in the 180 days prior to nest
entry. Exposure to calcium channel blockers and covariates were
identified in the 180 day exposure period prior to event date or
imputed event date for controls Conditional logistic regression was
used to assess exposure among cases and controls. All statistical
analysis was conducted using SAS version 9.3, Cary, N.C.
Results: A total of 717 cases and 1681 matched controls were iden-
tified. After matching on baseline characteristics mastectomy (7.8%
vs 4.8% p = 0.0039), exposure to radiation therapy (27.1% vs
21.7% p = 0.0046), taxane‐based chemotherapy (11.7%vs 7.4%
p = 0.0007), anthracycline‐based chemotherapy (6.0% vs 3.6%), cal-
cium‐channel blocker use (28.3% vs 23.3% p = 0.0087), and
Charlson Comorbidity Index (19.8% vs 12.7% p < 0.0001,score of
4 or above. Were all higher in cases during the 180 days prior to
the event date. After regression adjustment for cancer treatment,
antihypertensive use and Charlson Comorbidity Index during the
180 days prior to event, calcium channel blockers were significantly
associated with and increased risk of lymphedema (odds ratio: 1.320
95% confidence interval 1.003–1.737).
Conclusions: Calcium channel blocker use was significantly associ-
ated with lymphedema development in breast cancer patients com-
pared to no use of calcium channel blockers.
723 | Incidence of depression and anemia
among users of hormonal treatments for
endometriosis ‐ final results from the VIPOS
study
Klaas Heinemann; Sabine Moehner; Kerstin Becker; Jens Lange
ZEG ‐ Berlin Center for Epidemiology and Health Research, Berlin,
Germany
Background: Endometriosis is a chronic, gynecological condition
characterized by pain and impaired fertility. Dienogest (DNG) 2 mg
(Visanne) was approved for endometriosis treatment in 2010. The
VIPOS study was part of the post‐authorization safety and risk min-
imization commitment and was designed to assess the safety of
DNG 2 mg in comparison to other hormonal treatments for endome-
triosis with a special focus on clinically relevant depression and
anemia.
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Objectives: To investigate the incidence of first‐time occurrence or
worsening of clinically relevant depression and anemia associated with
endometriosis‐related bleeding.
Methods: Large, prospective, controlled, non‐interventional cohort
study with active surveillance in six European countries (Germany,
Poland, Hungary, Switzerland, Russia and Ukraine). Women with a
new hormonal therapy for endometriosis were enrolled by gynecolo-
gists and specialized centers between 2010 and mid‐2016. Informa-
tion was collected via self‐administered questionnaires at study
entry and during follow‐up until October 2018. Follow‐up questions
included information on current health status and further use of endo-
metriosis treatment. All self‐reported clinical outcomes of interest
were validated by health care professionals.
Results: A total of 27,840 were included into the study, 11.7% of
them users of DNG, 12.5% users of other approved endometriosis
drugs (OAED) and 75.8% users of hormonal treatments not approved
but frequently used for endometriosis treatment (NAED). The last
interim analysis in May 2018 was based on 73,512 women years of
observation. Overall, 103 depression cases occurred, thereof 12 in
DNG users, 2 in OAED users, 52 in NAED users and 37 in Ex‐users
(women who stopped their endometriosis treatment more than
3 months before). In total, there were 146 anemia cases: 15 in DNG
users, 11 in OAED users, 73 in NAED users and 47 in Ex‐users. For
both depression and anemia, we observed differences between the
participating countries.
Conclusions: The VIPOS study will be the largest non‐interventional
cohort study investigating the risk profile of hormonal endometriosis
treatment conducted to date. The final results will be presented at
ICPE.
724 | The role of dose escalation in new
users of lamotrigine inducing Stevens‐
Johnson syndrome/toxic epidermal
necrolysis: Results from the German registry
Sophie Diederich; Maren Paulmann; Maja Mockenhaupt
Dokumentationszentrum schwerer Hautreaktionen (dZh), Dept. of
Dermatology, Faculty of Medicine and Medical Center – University of
Freiburg, Freiburg, Germany
Background: Lamotrigine is known to have a high risk for Stevens‐
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). SJS/TEN
are severity variants of a rare but life‐threatening disease with com-
mon pathogenesis and etiology. It has been suggested that slow dose
escalation of lamotrigine, as recommended by the manufacturer, can
prevent SJS/TEN.
Objectives: To determine the impact of dose escalation in new users
of lamotrigine on development of SJS/TEN.
Methods: The population‐based German Registry on severe skin reac-
tions ascertains all hospitalized SJS/TEN‐cases in Germany since
1990. 103 SJS/TEN‐cases with exposure to lamotrigine were identi-
fied between 1992 and 2018 in the Registry. 88 cases were validated
as definite, 7 as probable and 8 as possible. We only considered prob-
able and definite cases with recent exposure to lamotrigine in patients
≥12 yrs (n = 86) for this analysis and thus excluded 5 cases with long‐
term use and 4 children <12 yrs. Causality assessment was performed
with a specific algorithm.
Results: 50/86 cases with SJS, 28 with SJS/TEN‐overlap and 8 with
TEN were analyzed. The median age was 43 yrs (12–91 yrs). Women
(67.4%) were more often affected than men. 73 patients (85%) were
diagnosed with epilepsy. 24 (27.9%) patients developed SJS/TEN
while hospitalized; 23 (26.7%) reported a recent infection. Lamotrigine
was considered to be the “very probable” cause in 67 (77.9%) cases,
“probable” in 17 (19.8%) and “possible” in 2 (2.3%) cases.
Comedication in the relevant time period with highly suspected and
suspected drugs to induce SJS/TEN was 5.8% (5/86) and 15.1% (13/
86) respectively. The mean number of concomitantly used drugs was
7 (0–59), for antiepileptic comedication 1 (0–7). The most common
treatment indication was epilepsy/seizure (87.2%), followed by psychi-
atric disorders (10.5%). Mean time latency from beginning of
lamotrigine use to reaction onset was 23.5 days. We evaluated the
dosing regimen for 75 patients with complete medication and dosing
history considering the initial dose and dose escalation. In 10 cases,
a lower initial dose compared to lege artis dosing led to a prolonged
time to onset of the reaction (29.9 vs 21.8 d). In particular, 2 patients
developed SJS/TEN despite a very low dose of 5 mg/d for 4 weeks.
Conclusions: No relevant differences in terms of reaction severity and
overall outcome could be observed with respect to the dosage regi-
men. However, time to onset was longer when the starting dose was
low. These results suggest that the applied dosage regimen is not
the decisive factor for triggering SJS/TEN.
725 | Cutaneous allergy as potential long‐
term effect of hormonal intrauterine systems
Jill Huppert1; Chunliu Zhan1; Yasameen Azarbaijani2;
Yelizaveta Torosyan2
1Agency for Healthcare Research and Quality, Rockville, MD; 2FDA, Silver
Spring, MD
Background: As part of the research aimed at real‐world performance,
we are exploring new sources of evidence as well as new approaches
to predictive device evaluation. Implantable/insertable devices (e.g.,
intrauterine system ‐ IUS) may result in foreign body responses involv-
ing allergic/immune mechanisms. Our previous analysis (ICPE 2018)
showed that the likelihood of allergic/inflammatory skin conditions
may be increased among inpatient women with IUS removals vs.
insertions.
Objectives: In this project, we used a claims database to explore the
risk of cutaneous allergic conditions among outpatient women.
Methods: We used the Truven Health Analytics MarketScan database
to review all outpatient claims from women (aged 15–44) with contin-
uous enrollment from 2008 to 2014. We constructed a cohort with
any claim for IUS in 2009, as the populations exposed to either
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levonorgestrel‐(LNG) IUS or copper‐IUS for contraception. As con-
trols, we used a random sample of age‐matched women with no IUS
use as well as a group with any oral contraceptive use (OC). Cutaneous
allergic conditions (Atopic Dermatitis, Eczema, Allergic Urticaria and
other Urticaria) were defined per ICD9 codes. After comparing condi-
tions in the baseline year (2008) to 5 years post insertion (2010–
2014), we estimated the odds ratios (OR) and confidence intervals
(CI) for having cutaneous allergic conditions, controlling for covariates
(age, geographic region, urban), other conditions (e.g., diabetes, obe-
sity, smoking, asthma), and presence of allergic conditions at baseline.
Results: Of 8,013,682 eligible women (per 2009), 2.3% had outpa-
tient claims for IUS use. The study cohort was comprised of
10,632 women with 5‐year enrollment and either copper‐IUS
(N = 1,454) or LNG‐IUS (N = 9,169) inserted in 2009. Women using
no IUS (N = 21,246) and women using OC (N = 20,758) formed two
comparison groups. Baseline characteristics of all study groups and
controls were similar. Logistic regressions showed that, after control-
ling for baseline characteristics and potential confounders, claims for
cutaneous allergic conditions were more frequent among LNG‐IUS
(but not copper‐IUS) users compared to non‐IUS users: OR = 1.111
[95% CI: 1.039; 1.187]. No significant difference for cutaneous
allergy was found for women using LNG‐IUS vs. OC.
Conclusions: Hormonal IUSs may slightly increase risk of cutaneous
allergy, as shown by the analysis of out‐patient women exposed to dif-
ferent contraceptives. Claims data can be suggested as a potential
source of pre‐existing data that can support evaluation of real‐world
performance of medical products.
726 | Population‐level impact of low‐dose
aspirin on the prevention of cardiovascular
disease, colorectal cancer and safety
outcomes in Europe: A micro‐simulation
model
Kaatje Bollaerts1; Pareen Vora2; Elodie Sole1; Jorne Biccler1;
Katsiaryna Holl2; Ruth Langley3; Angel Lanas4; Luis A.G. Rodríguez5;
Thomas Verstraeten1; Montse Soriano‐Gabarró2
1P95, Heverlee, Belgium; 2Bayer, Berlin, Germany; 3University College
London, London, UK; 4University of Zaragoza, Zaragoza, Spain; 5CEIFE,
Madrid, Spain
Background: Evidence indicates that low‐dose aspirin is effective in
preventing cardiovascular disease (CVD) and colorectal cancer (CRC),
but also increases the bleeding risk. Understanding the population‐
level impact of low‐dose aspirin use is important for informed deci-
sion‐making.
Objectives: The study aims at simulating the population‐level impact
of regular low‐dose (75–150 mg/day) aspirin use on CVD (myocardial
infarction and ischemic stroke), CRC and major bleeding among indi-
viduals eligible for primary or secondary CVD prevention in the UK.
This abstract summarizes the methodological approach followed.
Methods: Individual‐level state transition modeling based on a dis-
crete‐step multi‐state model (micro‐simulation) is used to model the
impact of regular low‐dose aspirin use on CRC, CVD, and safety
events: gastrointestinal bleeding (GI), intracranial hemorrhage (ICH),
and symptomatic peptic ulcers (sPU). Individual event histories are
simulated for a hypothetical cohort of 1 million adults aged 50–59
and 60–69 years each who are eligible for aspirin use for primary or
secondary CVD prevention. Each age cohort is simulated twice with
and without low‐dose aspirin regular usage. Model parameters are
informed based on published scientific literature. Monte Carlo simula-
tion is used to reflect the uncertainty in the input parameters. Multiple
scenarios are investigated. The model is developed mimicking the UK
epidemiology and prevention guidelines.
Results: The model allows for the simulation of the incidence of study
outcomes in cohorts of low‐dose aspirin users and non‐users, strati-
fied by age and type of CVD prevention. Baseline analysis of 50–
59 year old subjects not using low‐dose aspirin indicates 596x103
CVD events, 41x103 CRC events, 59x103 GI bleeding events,
11x103 ICH events, and 21x103 sPU events for 1 million subjects with
an average follow‐up time of 17.6 years.
Conclusions: Modeling through simulation is increasingly used to
inform public health and regulatory decision‐making. This micro‐simu-
lation model constitutes a novel approach to further elucidate the
expected benefits as well as risks of low‐dose aspirin at the population
level.
727 | Safety of dietary supplements use
among cancer patients: A systematic review
of clinical trials
Zhen Zeng1; Ahmed UIIah Mishuk2; Kadijah Edwards2;
Chiahung Chou2; Jingjing Qian2
1Fujian University of Traditional Chinese Medicine, Fuzhou, China;
2Auburn University Harrison School of Pharmacy, Auburn, AL
Background: Dietary supplements (DS) are commonly taken by cancer
patients, but safety of DS use among cancer patients remains unclear.
Objectives: To review the literature regarding safety of DS use among
cancer patients systematically.
Methods: A systematic literature search was conducted using
PubMed, Clinicaltrial.gov, International Pharmaceutical Abstracts and
Alt HealthWatch databases from their inception through October
2018. The included literature was limited to clinical trials published
in English, with interventions including DS products in the market,
and including outcome measures related to safety endpoints of DS
use. Evidence was reviewed by two researchers independently.
Results: Sixty‐five studies met inclusion criteria and were included in
the review. Use of DS was examined among patients with multiple
or unspecified (18), breast (10), colorectal (9), gastrointestinal (GI)
and esophageal (7), prostate (6), liver (3), pancreas (3), leukemia (3),
head and neck (3), lung (1), skin (1), and thyroid (1) cancer. Botanical
DS (12), vitamins (8) and probiotics and synbiotics (7) were the top 3
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types of DS evaluated in these trials. While most of studied DS were
found to be safe among breast cancer patients, magnesium oxide
and alpha lipoic acid products were associated with higher incidence
of diarrhea, nausea, and GI related adverse events (AEs). Among
patients with colorectal, pancreas, and thoracic esophageal cancer,
those using probiotics or synbiotics had significantly lower incidence
of infection compared to the control group (n = 6). While most of
the trials found vitamin D or vitamin E was safe and tolerable, two
studies showed that high doses of vitamin D3 (10000 IU/d) and vita-
min E (3200 mg/d) were associated with more AEs. Use of omega‐3
fatty acids supplements had mixed results among different types of
cancer patients, with 1 study showing its association with reduction
of AEs but other 5 studies showing insignificant results. Among 19
trials including different cancer patients undergoing chemotherapy,
most (n = 17) of studied DS (e.g., vitamins, botanical, omega‐3 fatty
acid) were found to be safe.
Conclusions: While most types of DS appeared safe, this systematic
review found limited evidence in the safety of DS use among cancer
patients. Cancer patients and their healthcare providers should moni-
tor potential sides effects associated with DS use and its marginal ben-
efits on patient's health conditions carefully. More research using
large‐scale, rigorous clinical trials is needed to examine the safety of
DS use among cancer patients.
728 | Population based estimates of
community based adverse drug reactions
(ADRs) in the Kingdom of Saudi Arabia
Rasha A. Almubark1; Thamir M. Alshammari1,2; Amani S. Alqahtani1;
Nasser F. BinDhim1
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 2Medication
Safety Research Chair, King Saud University, Riyadh, Saudi Arabia
Background: Adverse drug reactions (ADRs) represent important pre-
ventable causes of mortality, morbidity, hospitalization and increased
healthcare costs. Traditionally, ADRs are studied in a clinical setting,
but it is also important to estimate rates of ADRs in the community.
Objectives: The current study aimed to estimate population‐based
rates of ADRs in the community in the Kingdom of Saudi Arabia
(KSA).
Methods: Nationwide cross‐sectional survey was conducted via regis-
tered pharmacists at community pharmacies across the 13 regions of
KSA. This study used a weighted national sample of KSA community
members presenting to community pharmacies for advice or to make
a purchase. The data were collected on an electronic online platform
and included questions about participants' demographics, health char-
acteristics, experience with ADRs within the last 12 months and
assess their knowledge about Saudi Food and Drug Authority
reporting system. Descriptive analysis for ADR rates, sample demo-
graphics, clinical characteristics, and ADR patterns was conducted.
The survey package was used to develop weighted rates with 95%
confidence intervals (CI).
Results: Data collection was conducted between June and August
2018. Data from 5,228 surveys were analyzed. After weighting, the
national annual rate of ADRs was estimated to be 28.00% (95% CI
26.10% ‐30.00%). The following chronic diseases were statistically sig-
nificantly associated with ADR status: high blood pressure, high cho-
lesterol, diabetes, chronic lung disease‐asthma and emphysema,
kidney disease, and gastrointestinal diseases. The most common ADRs
symptoms reported were gastrointestinal disorders, and these were
experienced by over 60% of women experiencing ADRs and over
50% of men experiencing ADRs in the last year. General disorders
and administration site conditions were also relatively high, with over
18% of men and over 21% of women experiencing ADRs over the last
year reporting these symptoms. The largest group of medications
reported causing ADRs (38%) fell in many disparate classes. The larg-
est classes reported for causing ADRs were Nonsteroidal
antiinflammatory drugs (NSAIDS) (11%), anti‐bacterial medications
(10%), antihypertensive medications (9%), and oral hypoglycemics
(9%).
Conclusions: The results of this population‐based estimates of com-
munity‐based ADRs nationally in KSA showed that more than one‐
quarter of the population had experienced ADR in the last 12 months.
Future study is needed to better understand why these rates are
higher in some regions than others, and what is needed to prevent
high rates in the subgroup populations.
729 | Mortality due to adverse drug
reactions: An analysis of an international
pharmacovigilance database
Gwladys Claustre; Aurore Morel; Brahim Azzouz; Emmanuelle Herlem;
Thierry Trenque
Pharmacovigilance Pharmacoepidemiology Department, CHU, Reims,
France
Background: Adverse drug reactions (ADRs) are a leading cause of
death. ADRs are the fourth commonest cause of death after heart dis-
eases, cancers and stroke.
Objectives: The aim of this study was to evaluate the mortality related
to ADRs spontaneous reported, in an international pharmacovigilance
database and compare the data between areas.
Methods: An extraction of Vigibase, which contains World Health
Organization individual case safety reports (ICSRs), was performed.
We included, in our study, all reports registered until the December
31, 2018 with the preferred term (PT) “death”. Demographic charac-
teristics of reported cases were evaluated. Geographic variations were
also assessed.
Results: Of the 18,446,691 ICSRs reported to Vigibase, 378,025 were
death cases. Mean age was 62 +/− 20.2 years with a sex ratio male/
female of 1.07. The majority of patients was over 65 years old
(31%), across age groups 45–64 (17%), 18–44 (7.6%) and under
18 years (2.3%). Most reports came from America (84%) and from
Europe (11%). The most suspected drugs were: fentanyl
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(n = 16,574), oxycodone (n = 15,868), morphine (n = 13,976), oxyco-
done/paracetamol (n = 12,537), hydromorphone (n = 12,439). In
Europe, the first incriminated drugs were: darbepoietin alfa
(n = 2,329), clozapine (n = 1,609), warfarin (n = 1,462), leuprorelin
(n = 924) and zoledronic acid (n = 681). The results of Oceania were
similar to those of Europe, including clozapine in the first place. The
mortality of the pediatric population under two years old represented
1% of the worldwide data and, also, in Europe. In France, in this pop-
ulation, the data showed high prevalence (3%) corresponding to data
observed in Africa, particularity in South Africa (3.1%).
Conclusions: ADRs are an important cause of mortality. In our study,
the main drug class involved was opioids. This study showed hetero-
geneity between the different areas. Analysis by age group indicated
a relation between the PT “death” and increasing age. Comparing the
developing countries, France has the highest percentage of mortality
in children under two years old. Some drugs require a reassessment
of their benefit/risk ratio.
730 | Evaluation of ethnic differences in
incidence of severe cutaneous adverse
reactions in east Asians
Tsugumichi Sato1; Ching‐Lan Cheng2; Heung‐Woo Park3;
Yea‐Huei KaoYang2; Min‐Suk Yang4; Mizuki Fujita1; Takuya Imatoh5;
Yuji Kumagai6; Masahiro Tohkin7; Yoshiro Saito5; Kimie Sai5
1Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda,
Japan; 2School of Pharmacy, Institute of Clinical Pharmacy and
Pharmaceutical Sciences, Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan; 3Department of Internal
Medicine, Seoul National University College of Medicine, Seoul, Korea,
Republic of; 4Department of Internal Medicine, SMG‐SNU Boramae
Medical Center, Seoul, Korea, Republic of; 5Division of Medicinal Safety
Science, National Institute of Health Sciences, Kawasaki, Japan; 6Clinical
Research Center, School of Medicine, Kitasato University, Sagamihara,
Japan; 7Graduate School of Pharmaceutical Science, Nagoya City
University, Nagoya, Japan
Background: Functional genetic polymorphism which affects drug
responses is one of important intrinsic factors causing ethnic differ-
ences. For example, allopurinol‐related severe cutaneous adverse
reactions (SCARs) are known to be associated with HLA‐B*58:01, of
which allele frequency (AF) is largely different among East Asians.
However, evidence on ethnic differences in SCARs and relevance of
genetic factors among East Asians are still limited.
Objectives: To evaluate ethnic differences in incidence of SCARs and
relevance of genetic factors in East Asians.
Methods: We conducted retrospective cohort studies using claims
databases in Taiwan, Korea, and Japan; the Health and Welfare Data-
base (HWD) in Taiwan, the Health Insurance Review and Assessment
Service (HIRA) database in Korea, and the Japan Medical Data Center
(JMDC) claims database in Japan. We selected allopurinol as a target
drug, and phenytoin or carbamazepine as a control drug because the
differences in AFs of those functional genetic factors of phenytoin
or carbamazepine for SCARs are little or much smaller than allopurinol
among East Asians. The outcome was the first hospital admission for
SCARs including Stevens‐Johnson syndrome, toxic epidermal
necrolysis, and drug‐induced hypersensitivity syndrome/drug reaction
with eosinophilia and systemic symptoms during the follow‐up period.
Crude incidence rates (IRs) of SCARs in allopurinol new users were cal-
culated and compared with those in phenytoin or carbamazepine new
users. Crude incidence rate ratios (IRRs) of SCARs were used for eval-
uation of ethnic difference to cancel out the potential regional differ-
ences in diagnostic criteria, and compared with authentic values of
AFs.
Results: Crude IRs (95% confidence intervals: CIs) of SCARs in allopu-
rinol users were 2.57 (2.37–2.79), 2.31 (2.30–2.31), and 2.00 (1.24–
3.21) per 1000 person years inTaiwan, Korea, and Japan, respectively.
The crude IRRs (95%CIs) comparing to phenytoin were 0.63 (0.56–
0.72), 0.34 (0.29–0.40), and 0.037 (0.016–0.083), and the IRRs com-
paring to carbamazepine were 1.22 (1.01–1.47), 0.82 (0.59–0.61),
and 0.16 (0.087–0.29) in Taiwan, Korea, and Japan, respectively.
Conclusions: The order of crude IRRs of SCARs, Taiwan > Korea >
Japan, was in accordance with the order of the AFs of HLA‐B*58:01,
0.101, 0.061, and 0.004 in Taiwan, Korea, and Japan, respectively.
Our results suggest that ethnic differences in functional genetic fac-
tors might contribute to those for SCAR development among East
Asians. Further studies are also needed to evaluate contribution of
other non‐genetic factors to the ethnic differences.
731 | Medication related hospital admissions
to a tertiary care teaching hospital: A
prospective cross sectional study
Ramesh Madhan; Patil Aishwarya; Anjali James; Grishma G. John;
Melwala Mihir; Chalasani Sri Harsha
JSS College of Pharmacy, Mysuru, India
Background: Increasing availability and usage of medicines can cause
medication related problems (MRP) leading to hospitalization and
often affecting morbidity and mortality rates.
Objectives: To determine the incidence, nature, and risk factors asso-
ciated with medication related admissions and their severity and
preventability.
Methods: A prospective cross sectional study design was adapted. All
those patients admitted due to MRP to the departments of emer-
gency, medicine, pediatrics and dermatology were enrolled over a
period of six months. Hepler and Strand's classification of MRP was
adopted. All the required data were collected and analyzed using stan-
dard descriptive analysis and the risk factors were assessed by using
Chi Square test.
Results: of the 500 patients followed, 197 (39%) patients were admit-
ted to the study site due to medication related problems. Males pre-
dominance was observed [n = 105 (53%)]. Majority of patients' were
presented with diabetes [n = 97 (49%)] and hypertension [n = 77
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(39%)] as prevalent comorbid conditions. The most common type of
MRP was failure to receive the drugs [n = 119 (60%)] followed by
adverse drug reactions [n = 58 (29%)]. Metformin with glimepiride
[n = 24 (9%)] followed by insulin [n = 18 (7%)] were most commonly
implicated drugs. Majority [n = 102 (51%)] of these patients had a hos-
pital stay of 3–5 days. The severity of MRPs was observed to be mod-
erate [n = 189 (96%)] followed by severe [n = 8 (4%)]. Majority
[n = 167 (85%)] of MRPs were preventable. Polypharmacy, non‐adher-
ence, comorbidities were found to risk factors.
Conclusions: The incidence of Medication related hospital admission
was high due to polypharmacy, non‐adherence, and comorbidities.
While, majority of these problems were deemed to be preventable,
appropriate use of medications can reduce the medication related hos-
pital admissions.
732 | Frozen in time; contemporizing generic
labels
Lester Reich1; Barbara De Bernardi2; Douglas Ross1; Karilyn Halloran1;
Ma Fides Binasoy3; Nicholas Manuel Gonzales3; Philip Arena1;
Ravi Nair4; Tricia Racanelli1
1Pfizer Inc, New York, NY; 2Pfizer Inc, Milan, Italy; 3Pfizer Inc, Makati
City, Philippines; 4Freyr Solutions, Hyderabad, India
Background: In April 2018, the FDA commissioner noted that for
generic drugs specifically, safety information may not be necessarily
up to date. Generic drug labels may get “frozen in time” if the Innova-
tor withdraws from the market leaving only the generic applicants to
submit label updates. A key component of optimal product use is ade-
quate and up to date label content that provides the essential informa-
tion necessary for the safe and effective use of the drug as per
relevant available data. Pfizer acquired a number of generic sterile
injectables licensed in multiple markets worldwide following an acqui-
sition of a generic company in 2015.
Objectives: To develop a consistent approach and process to contem-
porize the safety sections of owned sterile injectable labels by use of a
core safety document.
Methods: A project team was assembled to create or update an
internal document containing Core Safety Information (CSI) and to
harmonize safety content of labels, which were dependent on a
CSI. Label comparisons to identify differences among the labels
and prepare a CSI and accompanying justification document based
on safety information in the different local labels were prepared.
The relevant information was then integrated into local labels if
missing. Redundant and/or repetitive information and concepts,
and descriptions of likely routine practice of medicine were not
included in the CSI. Standard agreed upon language across products
was utilized for concepts such as Driving & use of machines, Clos-
tridium difficile diarrhea (for anti‐infectives), and Hypersensitivity.
Justification data sources included published medical literature and
in some circumstances the Pfizer safety database. A Pfizer safety
database review was conducted for ADRs that met predefined
statistical criteria applied to World Health Organization's safety
database.
Results: A total of 29 CSIs were reviewed and 255 updates were
incorporated into Contraindications, Warnings and Precautions, Over-
dose, Drug interactions, Pregnancy and lactation or ADR sections.
Conclusions: A consistent process for the development and mainte-
nance of CSIs for generic products to ensure contemporary labeling
is possible.
733 | Prospective cohort study of adverse
drug reactions on all admissions to internal
medicine: Prevalence, incidence and risk
factors
Aduragbenro D.A. Adedapo1; Waheed Adedeji2;
IfetiOluwanimi A. Adedapo1; Kayode S. Adedapo1
1University College Hospital/University of Ibadan, Ibadan, Nigeria;
2University College Hospital, Ibadan, Nigeria
Background: Adverse drug reactions (ADRs) constitute major clinical
burden of public health concern. Intensive adverse drug reactions
monitoring in hospitals, though advocated are rare.
Objectives: This study aimed at the intensive monitoring of medical
patients for ADRs to assess prevalence, incidence, risk factors and
fatality of ADRs leading to hospital admission or occurring in the
hospital.
Methods: Prospective cohort observational study on adult patients
admitted to the six medical wards of a tertiary institution over a
12 month period. Each patient was assessed for ADRs throughout
admission. Patient's demographics, all drugs administered one month
prior to admission, on admission and prescribed on discharge were
recorded. Statistical analysis included independent T‐test, Chi‐square
test, 95% confidence interval, p = 0.05 was taken as significant.
Results: One thousand two hundred and eighty patients admitted to
the medical wards were enrolled in the study. Sixty‐six patients
(5.2%) had adverse drug reactions, which was the cause of admission
in 46 (3.6%) while 19 (1.6%) developed ADRs during admission. Sev-
enty ADRs occurred in these 66 patients and involved 43 drugs.
NSAIDs (23.3%), antibiotics (20.9%), antituberculosis drugs, glucose
lowering drugs and herbal remedies 6.9% each were the most com-
mon. Monthly income (p < 0.001), and alcohol use (p = 0.042) signifi-
cantly impacted on the occurrence of ADRs. Risk factors for ADR
were alcohol use (χ2 = 4.148, p = 0.042) in patients, polypharmacy,
self‐medication and cognitive impairment in the elderly. Patients with
ADRs stayed longer on admission, 15 days versus 12 days (p = 0.029)
and though not significantly were more likely to be older 49.3 versus
49.2 years (F = 0,003, p = 0.956), females 5.8% versus males 4.8%
(χ2 = 0.512, p = 0.474), ingested more medications prior to admission
and on admission (4.2 versus 3.8; F = 0.486, p = 0.486, 95% CI ‐1.296
to 0.516 and 7.2 versus 6.8; F = 0.327, p = 0.567, 95% CI ‐1.364 to
0.549) but were discharged with fewer medicines (3.9 versus 5.1;
F = 0.145, p = 0.703, 95% CI ‐0.012 to 2.481). Most ADRs were GIT
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complications 27/70 (38.6%), cutaneous 14/70 (20.0%), neurological
17/70 (24.3%). Most reactions (71.2%) were adduced to known phar-
macological properties of the drugs. Most, 79% patients with ADR
fully recovered, 13% died while 7% had prolonged hospital stay.
Conclusions: ADRs involved prescription drugs, and self‐medication in
this study. Alcohol use was a major risk. Efforts to curtail the menace
should include health education and prohibition of sales of prescrip-
tion drugs without proper prescription.
734 | Real world data
Pharmacoepidemiological study on the
prevalence of potential drug–drug
interactions in Thessaloniki, Greece
Panagiotis Nikolaos Lalagkas1; Georgios Poulentzas1; Labros Tsiolis1;
Eleftherios Berberoglou2; Christos Kontogiorgis2;
Theodoros Constantinides2; Dimitra Hadjipavlou‐Litina2
1Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Democritus
University of Thrace, Alexandroupolis, Greece
Background: Drug–drug interactions may lead to severe clinical out-
comes concerning patients' health, thus posing a serious threat to var-
ious fields of Public Health. The above phenomenon is worsened
when the number of interactions is risen.
Objectives: The goals of this study are to determine the prevalence of
potential drug–drug interactions (pDDIs) among patients of commu-
nity pharmacies, to shed light on the factors responsible for the
growth of this problem and to estimate the probability of major clinical
outcomes.
Methods: Data of 24.200 e‐prescriptions (2012–2017) were anony-
mously obtained from community pharmacies of Thessaloniki, the sec-
ond biggest city of Greece, including gender, age, number of doctors
visited, administered medicines and the purchase date. We chose by
chance 1.000 patients per year, who were taking 2 or more drugs
simultaneously for more than 3 months. For this purpose, the raw data
were processed and filtered with specific criteria using R programming
language, excluding drugs administered for less than 3 months and
nonprescription medicines and patients taking only 1 drug. The first
1.000 patients from each year were isolated and by listing their med-
icines on the online Drug Interaction Checker of the F.D.A., pDDIs
were categorized depending on their clinical significance as major
and moderate. The results were analyzed statistically with the IBM
SPSS Statistics v.15.0 program using descriptive statistics, chi‐square
and odds ratios (ORs).
Results: 1307 major pDDIs (185 unique) were found between 17.4%
of the patients. Analyses about the APIs, that are most frequently
causing major pDDIs, showed that statins are responsible for their
occurrence on 8.23% of the patients (6.98% due to simvastatin).
Studying pDDIs' clinical outcomes, 8.18% of the patients had
increased risk of suffering from major myopathy. Furthermore, while
a pDDI occurred in only 5.6% of the patients taking 2–3 drugs, this
percentage rose to 16.1% for 4–6 drugs and to 42.5% for more than
7 drugs (p = 0.000). Lastly, age over than 65 years old and number
of prescribing doctors greater than 4 proved to be risk factors for
the occurrence of pDDIs, both for men (OR 1.642, 95% CI: 1.3–2.1,
p = 0.000) and for women (OR 1.943, 95% CI: 1.1–3.6, p = 0.02).
Conclusions: The percentage of patients with at least one major pDDI,
compared to that of other developed Western countries like Switzer-
land (pDDIs between less than 2% of the population), is really high,
which needs to be under severe analysis from the Ministry of Health.
Additionally, polypharmacy proved to result in increased possibility of
emergence for major pDDIs.
735 | Patient exposure during pre‐market
trials and relationship with post‐market
safety outcomes
Sanae Cherkaoui1; Ellen Pinnow1; Ilynn Bulatao1; Brendan Day2;
Manish Kalaria1; Sonja Brajovic1; Gerald Dal Pan1
1Food and Drug Administration, Silver Spring, MD; 2University of
Maryland School of Medicine, Baltimore, MD
Background: Drug exposure substantially increases after approval
allowing for identification of new risks. The relationship between
patient exposure in pre‐market clinical trials and post‐approval safety
label changes is not well understood.
Objectives: To characterize pre‐market exposure for New Molecular
Entity (NME) and Original Therapeutic Biologic (OTB) and its relation-
ship to post‐market safety outcomes.
Methods: We evaluated pre‐market exposure and regulatory charac-
teristics for NMEs and OTBs approved by FDA between 10/1/02 and
12/31/14 using publicly available FDA documents. We recorded the
number of patients in the clinical development program included in
the FDA‐ defined safety population and the number exposed for
6 months (6 M) and 12 months (12 M). Descriptive statistics were used
to describe the safety population, and 6 M and 12 M for products
intended for long term use. Post‐market safety outcomes sere defined
as a safety‐related withdrawal or safety‐related update to the Boxed
Warning, Contraindications,Warnings and Precautions, Adverse Reactions
or Drug Interactions sections of the label. We evaluated the relationship
of defined quartiles of the safety population to regulatory pathways and
post‐market safety outcomes using chi square/Fisher's exact tests.
Continuous variables were analyzed using Wilcoxon test.
Results: 339 products (278NMEs, 61OTBs)were included in our study.
The median size of the safety population was 947 with no change over
time. NMEs had more pre‐market exposure than OTBs (median: 1057
vs 880, p = 0.04). 111 (33%) were orphan products. The median expo-
sure was lower in orphan compared to non‐orphan products (524 vs
1806, p < 0.001). The median size of the safety population was signifi-
cantly smaller for fast track designation (599 vs 1396, p< 0.001), priority
review (612 vs 1662, p < 0.001), and accelerated approval (505 vs 1148,
p < 0.001). Expedited programs were associated with a smaller safety
population size for non‐orphan, but not for orphan products. 236 prod-
ucts were intended for long term use; data was available for 6 M in 176
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and 12 M in 169 products. 127 (72%) met the ICH guidelines for 6 M
(≥300 participants) and 127 (75%) of the drugs met the ICH guidelines
for 12 M patient exposure (≥ 100 participants). The quartiles that had
larger safety population size were more likely to have post‐market
safety outcomes (p < 0.001).
Conclusions: Orphan drugs and expedited programs are associated
with varying pre‐market exposures. The median size of pre‐market
exposure has not changed over time. Larger safety population size
was associated with an increase in post‐market safety outcomes.
736 | Adverse drug reactions on female
fertility: A study in VigiBase
Daphné Toledano; Mélanie Araujo; Jean‐Louis Montastruc;
Christine Damase‐Michel; Justine Benevent; Isabelle Lacroix
CHU de Toulouse, Inserm, Université de Toulouse, 1027 Toulouse, France
Background: Few studies have investigated drug effects on female
fertility.
Objectives: We conducted a descriptive study investigating adverse
drug reactions (ADRs) on female fertility reported in VigiBase®.
Methods: Vigibase® is an international Pharmacovigilance database
created in 1960 and holding over 16 million of ADRs. All reports of
ADRs on female fertility registered on VigiBase® between 1967 and
December 2017 were analyzed. Female infertility reports were identi-
fied using the MedDRA specific terms: “infertility” and “female
infertility”.
Results: Among the 16,074,663 safety reports registered in VigiBase®,
1,806 ADRs (0.1‰) on female fertility were reported from 1967 to
December 2017 in VigiBase®. Notifications increased over time since
2008. Patients are mostly between 20 and 40 years old, a period corre-
sponding to a desire of maternity. ATC classes of drugs involved in
female infertility were “genitourinary system and sex hormones”
(n = 928 cases, 51.4%), “antineoplastic agents and immunomodulating
agents” (n = 359, 19.9%) and “nervous system” (n = 146, 8.1%). Themost
cited “suspected” drugs were levonorgestrel (25.9%),
medroxyprogestérone (8.5%), étonogestrel (5.8%), éthinylestradiol
(5.1%), diéthylstilbestrol (3.4%), etanercept (2.5%), vaccine HPV
(2.1%), adalimumab (2.0%) and drospirenone (1.6%).
Conclusions: This study found some drugs already known to impair
female fertility, like alkylating agents and diéthylstilbestrol. More inter-
esting, the present work described signals for drugs not known to
induce this ADR.
737 | The characteristics of drug information
inquiries in an Ethiopian University hospital: A
two year prospective observational study
Yonas Getaye Tefera; Begashaw Melaku Gebresillassie;
Asnakew Achaw Ayele; Yared Belete Belay; Yohannes Kelifa Emiru
University of Gondar, Gondar, Ethiopia
Background: The types of drug‐related information request from
patients and health professionals, the extent of inquiry and capability
of existing drug information centers are seldom studied in Ethiopia.
Objectives: This study aimed to identify the types and characteristics
of drug information inquiry at Gondar University specialized Hospital
(GUSH), Northwest Ethiopia.
Methods: A prospective observational study was employed from Jan-
uary, 2016 to December, 2017 at Drug Information Center (DIC) of
GUSH. The drug information query was collected by distributing the
drug information queries in different hospital units through 2 batches
of graduating undergraduate pharmacy students. Descriptive statistics
were used to describe, characterize and classify drug related queries.
Binary logistic regression was employed to identify predictor variables
to the type of drug related queries submitted to drug information
center.
Results: A total of 781 drug related queries were collected and 697
were included in the final analysis. Near to half (45.3%) of queries
comes from the pharmacists followed by general practitioner medical
doctors (11.3%) and nurses (10.2%). Slightly greater than half of the
queries (51.9%) were focused on therapeutic clinical information.
39.6% of drug related queries related to infectious disease case sce-
narios, followed by cardiovascular cases in 21.3% of queries. More
than half of (53.9%) and nearly one in five (19.4%) of the queries took
5 to 30 minutes and 30 minutes to 1 hour of literature searching to
answer, respectively. Pharmacists (with odds ratio of 2.474(95% CI
1.373, 4.458)) and patients (with odds ratio of 4.121(1.403–12.105))
ask patient‐specific questions in their drug related queries higher than
other group of health professionals.
Conclusions: In conclusion, pharmacists are the primary drug informa-
tion users and frequent drug related information inquirers at the DIC.
Most of the queries targeted therapeutic indications, adverse drug
events, infectious or cardiovascular disease related requests. Drug
information services can assist the growing pharmacist's role in patient
care and addressing patient specific drug related needs.
738 | Validation of maternal self‐reported
pregnancy complications using web‐based
questionnaires in a prospective cohort study
Pim Beekers; Hussein Jamaladin; Joris van Drongelen; Nel Roeleveld;
Marleen M.H.J. van Gelder
Radboud University Medical Center, Nijmegen, Netherlands
Background: Evidence for the validity of maternal self‐reports of com-
mon pregnancy complications is conflicting and these reports have not
been validated for web‐based questionnaires yet.
Objectives: To validate data on gestational diabetes, gestational
hypertension, and preeclampsia from web‐based questionnaires
administered during pregnancy and two months after delivery.
Methods: We included 1,809 women who participated in the PReg-
nancy and Infant DEvelopment (PRIDE) Study and gave birth in
2012–2017, for whom the relevant data were complete. Sensitivity,
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specificity, and positive and negative predictive values of self‐reported
diagnoses of gestational diabetes, gestational hypertension, and pre-
eclampsia were determined using obstetric records as reference stan-
dard. Furthermore, we determined whether maternal characteristics
affected the disagreement between the questionnaires and obstetric
record.
Results: For gestational diabetes and preeclampsia, we observed very
few false positive and false negative reports, yielding sensitivities of
93% (95% confidence interval [CI] 86–100) and 88% (95% CI 79–
98), respectively, and specificities of 100%. The positive predictive
values (PPV) were 91% (95% CI 90–92) and 88% (95% CI 87–90).
Depending on the definition of gestational hypertension, sensitivity
ranged from 62% to 89% with PVVs of 64% and 88%. The odds of dis-
agreement on gestational hypertension seemed to be lower for
women 25–29 years of age (odds ratio [OR] 0.6, 95% CI 0.3–1.0), with
low/intermediate education (OR 0.6, 95% CI 0.3–1.1), and/or having
had one or more previous births (OR 0.5, 95% CI 0.3–0.9).
Conclusions: We showed that maternal self‐reports of preeclampsia
and gestational hypertension in web‐based questionnaires are valid.
Gestational hypertension seemed to be of somewhat lower validity
due to relatively high numbers of false positive reports, but it is ques-
tionable whether an appropriate reference standard exists to validate
this pregnancy complication.
739 | Validation of a comorbidity index for
use in obstetric patients: A Nationwide
cohort study
Mette Bliddal1,2; Sören Möller1,2; Christina Vinter2; Katrine Rubin1,2;
Joshua Gagne3; Anton Pottegård1
1University of Southern Denmark, Odense, Denmark; 2Odense University
Hospital, Odense, Denmark; 3Brigham and Women's Hospital and
Harvard Medical School, Boston, MA
Background: A previously developed Obstetric Comorbidity Index has
been validated in highly selected cohorts. Validation of the index in an
unselected population as well as in other health care settings is, how-
ever, of high importance to determine external validity.
Objectives: To validate the Obstetric Comorbidity Index by examining
the tool's ability to predict the incidence of maternal morbidity (end‐
organ injury) or death.
Methods: Using the Danish National Birth Register, we formed a
nationwide cohort including completed pregnancies (both live and still-
born) in Denmark (2000–2014) linked to the National Patient Register.
Maternal age and 20 comorbid conditions were assessed and weighted.
Outcomes were maternal end‐organ injury or death within 30 days
postpartum. The predictive and discriminative ability of the index was
estimated by Brier score and the area under the receiver operating char-
acteristic curve, respectively. Logistic regression analysis was used to
estimate odds ratios (OR) with 95% confidence interval (CI).
Results: In 876,496 completed pregnancies by 527,079 women,
1.40% (n = 12,314) experienced an outcome. The majority of women
(64.1%) did not have any record of a condition included in the Obstet-
ric Comorbidity Index, 35.6% scored 1–6, and only 0.3% (n = 3,044)
had a score > 6. The incidence of an outcome increased with increas-
ing comorbidity score from 0.9% (95% CI 0.8–0.9) in women with a
score of 0 to 10.4% (95% CI 7.6–13.9) in women with a score 9–10.
The odds of the outcome increased by 41% (OR 1.41, 95% CI 1.39–
1.42) with each one‐point increase in the Obstetric Comorbidity
Index. Compared to women scoring 0, the OR for experiencing the
outcome increased with each increase in index category: Scoring 1–
2 yielded an OR of 2.34 (95% CI 2.25–2.44), 3–4 an OR of 5.16
(95% CI 4.81–5.54), 5–6 an OR of 4.84 (95% CI 4.31–5.44), and 8–9
an OR of 7.97 (95% CI 6.54–9.72). The index had a Brier score of
0.01 and an area under the receiver operating characteristic curve of
0.64.
Conclusions: The Obstetric Comorbidity Index showed a moderate
ability to discriminate and predict end‐organ injury and death in a
nationwide unselected cohort and performed in accordance with pre-
vious findings in other settings. These results suggest that the index
may be a useful tool to control for confounding in health research
and to identify women at high risk for adverse maternal outcomes.
740 | Social media monitoring on the safety
of medication use during pregnancy: A case
study from the Netherlands
Marleen M.H.J. van Gelder1; Annemarije Rog1; Sebastian J.H. Bredie1;
Wietske Kievit1; Hedvig Nordeng2,3; Tom H. van de Belt1
1Radboud University Medical Center, Nijmegen, Netherlands; 2University
of Oslo, Oslo, Norway; 3Norwegian Institute of Public Health, Oslo,
Norway
Background: An increasing number of women rely on the Internet for
information about medication safety during pregnancy. Online preg-
nancy‐related information is available through many sources, each
with different levels of credibility. However, a complete overview of
the quality and quantity of social media information available to preg-
nant women is lacking.
Objectives: To evaluate the availability and accuracy of social media
content on the safety of medication use in pregnancy.
Methods: We performed a systematic search of posts related to med-
ication safety during pregnancy in the Dutch language published on
social media, blogs, and forums between May 2012 and April 2016
using Coosto, a tool for social media monitoring. The perceived safety
in the posts was compared with the DutchTeratology Information Ser-
vice (TIS) safety classifications using descriptive statistics and logistic
regression analysis.
Results: We included 1,224 online posts, which described 1,441 sce-
narios about medication safety in pregnancy. A total of 820 (57%) sce-
narios described were in line with the TIS classification. Incorrect
perception was higher for prescription medication compared to medi-
cation available over‐the‐counter (odds ratio [OR] 4.6; 95% confi-
dence interval [CI] 3.7–5.8). Furthermore, the safety classification of
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medications with a TIS classification on strict indication or second line
drugs (OR 46.1, 95% CI 28.1–75.4) and medications with insufficient
knowledge on their safety during pregnancy (OR 10.1, 95% CI 6.8–
15.0) was more likely to be incorrectly perceived by the public com-
pared to medications considered safe during pregnancy according to
the TIS.
Conclusions: Social media monitoring may be useful for surveillance of
potentially unsafe use of medications in pregnancy. There is an abun-
dance of social media posts related to the safety of medication use
during pregnancy, but a large proportion of these posts provides inac-
curate information. As this information may influence women's per-
ceptions and decisions, accurate communication between healthcare
providers and pregnant women regarding the benefits and risks of
medications is vital.
741 | Implementation of ICD‐10‐CM Z3A%
codes in real‐world evidence studies of
pregnancy outcomes
Aziza Jamal‐allial1; Jade Dinh2; Shiva K. Vojjala3; Stephan Lanes3
1HealthCore Inc, Watertown, MA; 2HealthCore Inc, Alexandria, VA;
3HealthCore Inc, Wilmington, DE
Background: Healthcare claims databases are a source for real‐world
evidence and drug safety evaluation, but ICD‐9 codes often cannot
capture gestational age with sufficient accuracy. This limitation could
impact the validity of database studies of pregnancy outcomes. The
Z3A% code category is part of the ICD‐10‐CM codes that accurately
describes gestational age and is required reporting for service reim-
bursement. We used administrative claims data to assess how often
Z3A% codes are being used since the introduction of ICD‐10‐CM
codes in October 2015.
Objectives: To assess potential implementation of new ICD‐10‐CM
Z3A% code category as it pertains to better pregnancy clinical prac-
tices, by evaluating the occurrence of these codes in a large adminis-
trative claims database.
Methods: This study was conducted in the HealthCore Integrated
Research DatabaseSM (HIRD), which contains claims data from across
the US. The time period used in this study is between January 1, 2015,
and October 31, 2018.
Results: An algorithm for defining pregnancy episodes based on preg-
nancy outcomes identified 408,236 female members between the
ages of 15–49 years with at least one pregnancy outcome. Pregnancy
outcomes were defined as codes in medical claims indicating specific
pregnancy outcomes, i.e., live‐birth, and still‐birth; abortion which
includes, elective abortion, spontaneous abortion, and miscarriage;
and ectopic pregnancy. Among the identified live‐birth, and still‐birth
cases, at least five unique Z3A% codes were reported for 95.57%,
while for the identified abortion and ectopic, the percentage of
reporting was 85.63% and 80.86%, respectively.
Conclusions: The proper designation of the gestational age of any
pregnancy is integral to improving mother and child maternal health
outcomes. It is imperative for maternal research to accurately deter-
mine the start of any pregnancy for situations like assessing drug
exposure, as incorrect assessment may lead to inaccurate drug safety
profiles for use during pregnancy. Our results show the extensive
use of Z3A% codes even at the beginning of any pregnancy. These
findings prove to be fruitful for future maternal research, specifically
for drug safety surveillance during the time of pregnancy.
742 | Use of adverse events spontaneous
reporting for drug safety surveillance in
pregnancy
Wan‐Ting Hsu; Sonia Hernández‐Díaz
Harvard TH Chan School of Public Health, Boston, MA
Background: The U.S. FDA Adverse Events Reporting System (FAERS)
database is used postmarketing spontaneous reporting surveillance of
drug safety. However, the use of spontaneous reports for drug safety
in pregnancy has serious limitations and remains unclear.
Objectives: To detect drugs associated with specific adverse preg-
nancy outcomes as signals among reproductive‐age women who
reported pregnancy outcomes with or without anticonvulsants.
Methods: We conducted data mining in U.S. FAERS database from
2008 to 2017. To minimize heterogeneities and potential confounding
bias, the population was restricted to pregnant women aged 12 to
55 years old. Valproate was used as the exposure since it was one
of the most common anticonvulsants with a known risk of
malformations. To identify the reference groups, we first defined the
use of non‐valproate drugs in the entire pregnancy population as the
reference group, and then restricted only the use of non‐valproate
anticonvulsants. We included only reports for the pregnancy out-
comes to increase the comparability of the population in exposed
and reference groups. The data mining algorithms including propor-
tional reporting ratios (PRR) and reporting odds ratios (ROR) were
estimated.
Results: A total of 75817 pregnancy outcomes were identified. Among
them, spontaneous abortion was the most frequent outcome
(11.66%), followed by ectopic pregnancy (3.20%), stillbirth (1.95%),
and malformations (1.59%). Compared to non‐valproate use, valproate
use was associated with a malformation signal (PRR: 2.49; ROR: 2.56;
the number of co‐occurrences: 3.62). The association between
valproate use and malformation remained significant after restricting
the comparison to non‐valproate anticonvulsants (PRR: 3.06; ROR:
3.14; the number of co‐occurrences: 3.47). We did not find any signals
of spontaneous abortion and stillbirth among valproate users as com-
pared with non‐valproate users and non‐valproate anticonvulsant
users separately.
Conclusions: We confirmed utility of US FAERS to detect valproate
associated with malformations restricted the population to pregnant
women of reproductive age. FAERS database may be a robust
resource for surveillance of drug safety in pregnancy.
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743 | Every mother counts: Target sample
size estimates for pregnancy exposure
registries
Emily W. Bratton1; Katherine M. Lee2; William G. Hawkes3;
Suzanne N. Landi1; Kristen A. Hahn2
1 IQVIA, Durham, NC; 2 IQVIA, Cambridge, MA; 3 IQVIA, Rockville, MD
Background: Pregnancy exposure registries (PERs) are often required
as post‐marketing commitments to prospectively collect safety
information among women and their infants who may be exposed
to medicines during pregnancy. Meaningful analysis is often limited
by insufficient sample size. Enrollment challenges include lack of
registry awareness, few patient‐level benefits, limited medication
use during pregnancy, and the ability to capture women early in
pregnancy.
Objectives: With these known enrollment challenges, we demonstrate
how varying the parameters for powered sample size calculations
reach target enrollments beyond what is feasible for many of the
exposures under study in PERs.
Methods: For an internal comparator, sample size was calculated in
PASS v13.2 using Fisher's Exact test of two independent proportions.
Assumptions of a minimum detectable risk ratio (RR) for major con-
genital malformations (CMs) ranging from 2.0–3.0 and a 1:1 ratio of
exposed to unexposed patients were used with 80% power and
alpha = 0.05. An additional calculation for a single proportion com-
pared with the general population was performed using the same soft-
ware and parameters, with the baseline prevalence of major CMs
among live births in the general population set to 3%. A range of
projected live birth rates (LBRs), in addition to accounting for loss‐
to‐follow‐up (15%), were applied to increase enrollment targets to
achieve the number pregnancy outcomes needed.
Results: By varying the minimum detectable RR (2.0–3.0) and LBR
assumptions (62% ‐ 100%), PER enrollment targets ranged from
n = 148 to n = 676 for comparison of risk of major CMs relative to
the general population. PER enrollment targets to compare with an
internal comparator cohort ranged from n = 328 up to n = 1545 per
arm.
Conclusions: This exercise demonstrates that small variations in the
assumed parameters for sample size calculations can greatly impact
PER planning and commitments to regulatory agencies. PERs can be
used as supportive evidence, considered with the broader safety and
efficacy context reported across the clinical development portfolio.
However, high enrollment targets impact study cost, timelines, analy-
sis and interpretation of results, and come with ethical considerations.
PERs are long‐term obligations and in many PERs, sample sizes will not
be reached despite best efforts. Without sufficient numbers of
patients, the opportunity for adjusted analyses are limited. Sample size
calculations, although useful, should be adapted to the nature of the
underlying disease and anticipated exposure prevalence during
pregnancy.
744 | Calculating prevalence of spontaneous
abortion in pregnancy registries: Slippery
slope
Deborah Covington1; Kristin Veley2; Rebecca Buus2; Paige Churchill3
1Evidera, Wilmington, NC; 2Evidera, Raleigh, NC; 3PPD, Wilmington, NC
Background:When studying drug safety in pregnancy, it is important
to examine multiple outcomes, such as congenital anomalies, prema-
turity, small for gestational age, and spontaneous abortion (SAB).
Calculating the prevalence of SAB (defined as spontaneous fetal loss
before 20 weeks' gestation) is complicated due to varying times dur-
ing gestation at which women enroll in registries and the natural var-
iation of SAB by gestational age: SAB occurs at a higher prevalence
prior to gestational week 12 and a lower prevalence after gestational
week 14. To obtain an accurate estimate of SAB, it is critical to
examine SAB as a function of gestational age at enrollment. If SAB
is an outcome of interest, the prevalence should be calculated
among women enrolled prior to 20 weeks' gestation, and, if feasible,
using survival analysis to account for varying gestational age at
enrollment and censoring at 20 weeks' gestation.
Objectives: To examine the robustness of pregnancy registry methods
for the calculation of SAB prevalence.
Methods: Registries were identified from multiple sources: FDA
website, clinicaltrials.gov, and PubMed. Data were gathered on pri-
mary and secondary outcomes of interest and methods for calculating
SAB prevalence. Data were analyzed descriptively.
Results: The search identified 21 pregnancy registries with published
results. For those with multiple publications, the most recent was
included. Eight of 21 focused exclusively on congenital anomalies
and did not report SAB except 4 which descriptively reported SAB
in a frequency distribution of pregnancy outcomes. For 13 of the
21, SAB was listed as a primary or secondary outcome. These regis-
tries calculated SAB prevalence using a variety of methods. Nine of
the 13 calculated SAB prevalence as the number of SABs over the
total number of pregnancy outcomes; prevalence ranged from 2.2%
to 11.8%. Three registries calculated the SAB prevalence as the
number of SABs over the subset of pregnancies enrolled prior to
20 weeks' gestation; the prevalence was 3.4%, 8.6%, and 9.4%. Only
1 registry used a survival function accounting for gestational age at
enrollment and censoring at 20 weeks' gestation; the prevalence
was 3.9%.
Conclusions: This study found wide variability in reported SAB prev-
alence and the methods used for calculation. Most registries calcu-
lated SAB prevalence based on all women regardless of gestational
age at enrollment which leads to spurious SAB prevalence. Three
registries appropriately limited the calculation to pregnancies
enrolled prior to 20 weeks' gestation, and only 1 used survival anal-
ysis to account for varying gestational age at enrollment and
censoring.
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745 | Development of pregnancy
identification and trimester algorithm in US
claims data
Keele E. Wurst; Anna Ehlinger
GlaxoSmithKline, Collegeville, PA
Background: Using administrative claims databases to examine medi-
cation use during pregnancy is challenging due to limited information
available to estimate the timing of exposure. The pregnancy start date
is not routinely recorded in claims and gestational age is not always
available. Claims data algorithms are needed to accurately identify
women exposed to medications during pregnancy and time periods
of exposure.
Objectives: To create a standard method of identification of
pregnancies in US Marketscan using ICD‐9, ICD‐10 and procedure
codes.
Methods: Women 10 to 64 years of age from 2014 and 2016 were
identified in Marketscan Commercial and Medicaid. Algorithms were
developed; medical codes, including ICD‐9, ICD‐10 and CPT codes,
were identified and assigned (1) an estimated trimester (2) pregnancy
outcome (3) and pregnancy start and end date.
Results: Three challenges arose in development of the algorithm.
Conflicting trimester codes, conflicting outcome codes and/or con-
flicting gestational age occurred on the same day or within 30 days
of each other. Hierarchy algorithms were created to reassign these
codes. Estimated trimester codes were classified into four tiers rang-
ing from most to least specific trimester time period and assigned to
the code in the lowest tier. Second, if a record had a gestation
weeks code, the weeks were used to calculate the correct trimester
for those with conflicting codes either before and/or after. Then, the
frequency of trimester codes was assessed and those with the most
instances was used. To assign pregnancy outcomes, a set of rules
was created to address conflicting outcomes occurring within 30 days
of each other. For example, a record could not have an ectopic
pregnancy and a delivery on the same day. In this instance ectopic
pregnancy was assigned a priority in the hierarchy and thus classi-
fied as an ectopic pregnancy. A hierarchy was created for all types
of pregnancy losses and deliveries. Finally, to identify start and end
dates of the pregnancy, ICD‐10 and ICD‐9 codes that identified
gestation weeks were used, if multiple codes occurred, the latest
claim date was used as the maximum number of gestation weeks.
Outcome and trimester specific codes were then used to calculate
start and end dates. This algorithm identified 97.42% of pregnancy
claims with a start and end date.
Conclusions: Medical coding inconsistencies need to be addressed to
ensure an algorithm is valid. Using hierarchy algorithm to systemati-
cally resolve conflicting codes allowed for trimester, birth outcome
and start and end dates to be assigned. Study funded by GSK
208777.
746 | Timing of routine prenatal screening
tests relative to the last menstrual period
estimated from an ICD‐10 based algorithm
Kelesitse Phiri; Robin Clifford; Michael Doherty; Yuan Fan;
Florence Wang; John Seeger
Optum, Boston, MA
Background: Accurate estimation of the last menstrual period (LMP)
is essential in pregnancy studies. Several chart validated ICD‐9
based algorithms of varying complexity and accuracy are available
to estimate the LMP in administrative claims data. These
methods anchor estimates of LMP on the presence of pregnancy
outcomes, which may result in a potentially biased pool of pregnan-
cies used for a study. A new code category in ICD‐10 (Z3A)
specifically ties medical encounters to the pregnancy weeks of ges-
tation. The validity of these codes in estimating the LMP is not yet
fully described.
Objectives: To characterize the timing of routine prenatal screening
tests relative to the estimated LMP derived from an ICD‐10 based
algorithm.
Methods: Using the Optum Dynamic Assessment of Pregnancies and
Infants (DAPI) database, pregnancies of women who were enrolled
in their health plan from at least 6 months prior to the beginning of
pregnancy through the end of their pregnancy were identified from
January 2016 through December 2017. For each pregnancy, LMP
was estimated by subtracting the number of specific weeks from the
first observed Z3A code. Gestational weeks of pregnancy were calcu-
lated relative to the estimated LMP, and the proportion of pregnancies
with at least one claim for each of the prenatal screening tests was
estimated, per gestational week. Results were compared with clinical
guidelines for routine prenatal care of low‐risk pregnancies to assess
concordance. Non‐specific Z3A codes (Z3A.00, weeks of gestation
of pregnancy not specified and Z3A.01, less than 8 weeks gestation
of pregnancy) were not utilized.
Results: A total of 139,993 pregnancies were observed in the 2‐year
study period. From 22,724 pregnancies with at least 1 claim for
pregnancy‐associated plasma protein A (PAPP‐A), 77% occurred
between 11–14 weeks gestation. 49,564 pregnancies had a claim
for Alpha‐fetoprotein (AFP) test, 70% of which occurred between
15–20 weeks gestation. The glucose screening test was observed
in 104,195 pregnancies, 60% occurring between 24–28 weeks ges-
tation, and the Streptococcus B screening test was observed in
32,351 pregnancies, of which 75% occurred between 35–37 weeks
gestation.
Conclusions: A high proportion of pregnancies with at least 1 claim for
each of the prenatal screening tests had testing performed within the
recommended weeks of gestation based on clinical guidelines, show-
ing that utilization of the first observed Z3A code may allow for accu-
rate estimation of the LMP in administrative claims data.
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747 | Evaluation of a pregnancy and
trimester algorithm in US claims data
Keele E. Wurst; Anna Ehlinger
GlaxoSmithKline, Collegeville, PA
Background: Creation of algorithms to identify pregnancies and
trimesters in automated health care claims databases is important to
study medication use and pregnancy outcomes. Comparing new
algorithms to existing ones and external benchmarks assesses
how the algorithm performs.
Objectives: To compare percentages of select medications in
pregnancy, overall and by trimester, and selected pregnancy
outcomes obtained from a newly created algorithm to external
data and published literature.
Methods: A pregnancy and trimester algorithm, which utilized
gestational code and pregnancy outcome hierarchies, was used
to identify the number of pregnancies among women aged 10–64,
2014–2016 in Marketscan Commercial and Medicaid respectively.
Influenza, TDAP vaccine and anti‐epileptic use in pregnancy and
by trimester were calculated and compared to published
literature. The prevalence of selected pregnancy outcomes, live
births, C‐sections, preterm, twin and multiple births were compared
to US national rates and published literature.
Results: The percent of women with a code for TDAP vaccine during
pregnancy was lower in Medicaid than in the Commercial
population and differed by year. The distribution by trimester was
similar across years. The overall estimates in pregnancy were in line
with those from Sentinel Distributed network publication, though
there wer differences in the 2nd and 3rd trimester distributions.
The percent of pregnant women with a code for influenza vaccine
differed in Medicaid and Commercial populations. The distribution
of use was approximately equivalent across trimesters for both
databases and consistent with published literature. The percentage
of anti‐epileptic medications was similar in Commercial and Medicaid
as well as a Sentinel analysis, however distributions varied slightly by
trimesters. The rates of live births from the Commercial
population followed similar age trends to other privately insured
population published rates. Medicaid had a larger proportion of live
births in the younger age groups as would be expected given the
population. In both Commercial and Medicaid, the rates of C‐section,
preterm, twin and multiple births were similar to 2016 CDC rates
with the exception of a slightly lower preterm birth rate in
claims data.
Conclusions: The information obtained from the newly created
pregnancy algorithm was comparable to published estimates when
used on a Commercial database. The rates of vaccine use in the
Medicaid population and the population distribution make it difficult
to use this data source as a basis of comparison to national data
sources. Study funded by GSK 208777.
748 | Study of the Association of Uterine
Perforation and IUD expulsion with
breastfeeding and postpartum timing at IUD
insertion (APEX IUD)—Study size estimation
to actuality
Catherine W. Saltus1; Jennifer Gatz2; Mary E. Ritchey3;
Laura E. Ichikawa4; Mary Anne Armstrong5; Amy L. Alabaster5;
Maqdooda Merchant5; Richard Lynen6; Alex Asiimwe7;
Jiaxiao M. Shi8; Darios T. Getahun8; Fagen Xie8; Vicki Y. Chiu8;
Mary S. Anthony3
1RTI Health Solutions, Waltham, MA; 2Regenstrief Institute, Indianapolis,
IN; 3RTI Health Solutions, Research Triangle Park, NC; 4Kaiser
Permanente Washington, Seattle, WA; 5Kaiser Permanente Northern
California, Oakland, CA; 6Bayer HealthCare, Whippany, NJ; 7Bayer AG,
Berlin, Germany; 8Kaiser Permanente Southern California, Pasadena, CA
Background: The FDA required a study to determine the extent to
which breastfeeding and timing of postpartum intrauterine device
(IUD) insertion practices in the United States (US) are associated with
risk of uterine perforation and IUD expulsion. Uterine perforation is an
uncommon event: 1.3 cases per 1,000 IUD insertions, based on a pro-
spective European cohort of 61,448 women. Therefore, adequate
sample size to assess this outcome was critical for study feasibility.
A validation study was conducted to ensure adequate sample size,
availability of breastfeeding data, and validation of outcome variables
in four US health care systems (3 Kaiser Permanente sites—Northern
California, Southern California, and Washington state—and
Regenstrief Institute in Indiana) The validation study data accrual
ended September 30, 2015.
Objectives: We present the approach to projecting sample size and
the estimated and actual sample sizes in APEX IUD.
Methods: The APEX IUD start of patient inclusion varies by site
between January 1, 2001 and January 1, 2009; the end of patient
accrual for all sites is April 30, 2018. The cohort and postpartum esti-
mates for APEX IUD were based on the validation study's findings of
the total number of women aged ≤50 with IUD inserted after a min-
imum 12‐month look‐back, the number of women with IUD inserted
within 52 weeks postpartum, and the percentage of those who had
a postpartum insertion with breastfeeding status available. Projections
to estimate APEX IUD sample size involved including 31 additional
months of patient accrual beyond the validation study timeframe;
and, based on the validation study's results, estimating that 30%
would have an IUD inserted within 52 weeks postpartum, and that
90% of those with an IUD insertion within 52 weeks postpartum
would have breastfeeding data (exact percentages from validation
study projected by site). The estimated and actual numbers of women
in these categories are presented.
Results: Based on results from the validation study, the estimated
number of women in APEX IUD with an IUD insertion was 264,706,
those with insertion within 52 weeks postpartum was 79,412 and
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with breastfeeding status available was 71,471. The actual numbers
were 329,689, 98,576, and 95,529 respectively, about 25% higher
than estimated.
Conclusions: The numbers in the validation study used to estimate
sample sizes for the full‐scale study provided a basis for study feasibil-
ity, but accounting for a higher trajectory of IUD use over time could
have improved the projections.
749 | Prevalence of CYP2C19 genetic
polymorphisms in 26 population affecting
safety or efficacy of medications
Mohitosh Biswas
University of Rajshahi, Rajshahi, Bangladesh
Background: Individual genetic make up may regulate drug responses.
Genetic polymorphisms of CYP2C19 may affect safety or efficacy of
many clinically important medications.
Objectives: This study was aimed to determine the predictive pheno-
types based on genetic polymorphisms of CYP2C19*2,*3 and *17 var-
iants collectively in 26 population participated in 1000 Genomes
project. Subsequently, it was aimed to linking predicted phenotypes
with the safety or efficacy of clinically important medications.
Methods: The genotype data were obtained from 1000 Genomes pro-
ject Phase III in line with Fort Lauderdale principles. Based on the car-
rier of characteristics alleles, predictive phenotypes were assigned
using international standardized consensus terms. International
pharmacogenomics working groups such as clinical pharmacogenetics
implementation consortium (CPIC) etc. guidelines were used to deter-
mine the association of predicted phenotypes with the safety or effi-
cacy of clinically important medications.
Results: Out of the 2504 world population (26 population) partici-
pated in the 1000 Genomes projects (Phase III), 23.4% (95% CI
22%–25%) were predicted to be CYP2C19 Ultrarapid metabolizers
(CYP2C19*1/*17,*17/*17), 47.6% (95% CI 46%–50%) of extensive
metabolizers (CYP2C19*1/*1), 25.4% (95% CI 24%–27%) of intermedi-
ate metabolizers (CYP2C19*1/*2,*1/*3,*2/*17,*3/*17) and 3.6% (95%
CI 3%–4%) of poor metabolizers (CYP2C19*2/*2,*2/*3,*3/*3). The pre-
dicted phenotypes may affect safety or efficacy of 39 clinically impor-
tant drugs as outlined by different international pharmacogenomics
working group. Of these, at least eleven drugs have dosing guidelines
having strong evidence level based on the genetic variability of
CYP2C19*2, *3, or *17 that may need either alternative therapy or
dose adjustments. Overall, ~52% of world population had predicted
risk phenotypes in which at least 29% had high risk phenotypes poten-
tially leading to either therapeutic failure or increased toxicities of
standard therapy.
Conclusions: Genetic epidemiology of CYP2C19 variants may poten-
tially involved in drug safety or effectiveness. Translation of
pharmacogenomics in the form of precision medicine into routine clin-
ical practice is not too far away.
750 | Medication related problems among
post‐renal transplant patients at the renal unit
of a referral Hospital in Kenya: A cross
sectional study
Sylvia Opanga; Cyrus Kariuki
University of Nairobi, Nairobi, Kenya
Background: Medication related problems are unwanted events or
outcomes that may arise as a consequence of or lack of drug therapy.
Post‐renal transplant patients are at risk of medication related prob-
lems due to complex multiple medications they receive during therapy.
Objectives: To determine the prevalence, types and risk factors for
medication related problems in adult post ‐renal transplant patients
in a tertiary referral hospital in Kenya.
Methods: We conducted a cross sectional study of adult patients
18 years and older who underwent renal transplant and were on treat-
ment and follow up at Kenyatta National Hospital, between July and
September 2018. We excluded patients who were undergoing
haemodialysis before and after renal transplant and pregnant women.
Data were collected using a pretested questionnaire. Descriptive and
bi‐variable analysis was done. The Hepler and Strand Classification
was used to identify and classify medication related problems.
Results: Fifty post renal transplant patients were recruited into the
study. The prevalence of medication related problems was 100%.
The most common types of medication related problems were adverse
drug reactions (40%), failure to receive drugs (23%), and drug interac-
tions (16%). Risk factors for development of medication related prob-
lems were pill burden (41%), non‐adherence (25%), adverse reactions
(17%), inability to afford medication (14%), and medicine stock‐outs
(3%).
Conclusions: All the patients in the study had one or more medication
related problems. Comprehensive pharmaceutical care is required to
reduce this prevalence.
751 | 20 years of major and minor
malformations in Danish health registries: A
descriptive study
Per Damkier1,2; Mette Bliddal1; Anton Pottegård1; Jesper Hallas1,2;
Anne Broe1,2
1University of Southern Denmark, Odense, Denmark; 2Odense University
Hospital, Odense
Background: The prevalence of congenital malformation over time
may be an indicator for changes in environmental or lifestyle condi-
tions that effect health. The characteristics of malformations and
trends over time have not been systematically studied. Different over-
all prevalence rates of major malformations have been reported,
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indicating differences in the quality of the underlying data, the defini-
tions of malformations or different study periods.
Objectives: To describe the prevalence and changes in registration of
malformations among liveborn singletons in Denmark from 1997 to
2016.
Methods: Using nationwide Danish registries, we identified all deliver-
ies of liveborn singletons from January 1st, 1997 to May 31st, 2016
and followed these for 1 year. Within this population, we identified
the 10 most commonly registered major and minor malformations, as
well as the overall rate of malformations over time.
Results: We identified 1,179,956 liveborn singletons by 683,551
women during the study period. Of these, 59,466 newborns had a
record of any malformation within the first year of life when using
the Danish Medical Birth Registry alone (5.0%). Using EUROCATs def-
inition of malformations, 35,942 (3% of liveborn singletons) had major
malformations, and 29,877 (2.5%) minor malformations. Adding data
from the Danish National Patient Registry (DNPR) these numbers
increased to 39,322 (3.3%) and 31,895 (2.7%) respectively. The regis-
tration of major malformations ranged from 2.9% in 1998 to 4.1% in
2014, while minor malformations ranged from 1.6% in 1997 to 4.3%
in 2014. During the 1‐year follow‐up in the DNPR, only 0.9% of chil-
dren had a recording of a major malformation within 24 hours of deliv-
ery. By utilizing 1, 3, 6, and 12 months of follow‐up data, this number
increased to 1.5, 2.1, 2.4, and 2.8% respectively.
Conclusions: Within this nationwide cohort, 5.0% had a recorded
diagnosis of a malformation. The prevalence of major and particu-
larly minor malformations increased from 1998 through 2014. Com-
pleteness of malformation diagnoses increased when including data
from both the Medical Birth Register and the DNPR. These trends
in prevalence must be interpreted cautiously as they could reflect
changes in reporting practices, improvements in quality of diagnostic
tools, as well as represent true changes in the prevalence of
malformations.
752 | In utero exposure to antibiotics and
risk of congenital malformations: A
population‐based study
Per Damkier1; Louise M.S. Brønniche2; Johan F.B. Korch‐Frandsen1;
Anne Broe1
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark
Background: Antibiotics are commonly prescribed during pregnancy.
While the safety of many penicillins are well established, the preg-
nancy safety evaluation of other common antibiotics suffers from
inconsistent and inadequate data. Consequently, clinical decision sup-
port is largely insufficient and does not provide prescribing physicians
information based on a reassuring level of evidence.
Objectives: To determine the risk of overall‐, major‐, and cardiac con-
genital malformations following first trimester in utero exposure to the
10 most commonly prescribed antibiotics in Denmark.
Methods: This was a cohort study comprising all singleton liveborn
children in Denmark between 2000 and 2015. Merging validated
and comprehensive population‐wide Danish health‐care and civic reg-
istries, we merged data on pregnancy, prescription drugs purchases
during first trimester and congenital malformations. The exposed
cohorts were compared to a cohort exposed to either of four penicil-
lins (ampicillin, pivampicillin, benzylpenicillin, and
phenoxymethylpenicillin) considered safe during pregnancy (primary
analysis) and an unexposed cohort (sensitivity analysis). Using logistic
regression, we calculated odds ratios (OR) for congenital
malformations (any), major congenital malformations and cardiac con-
genital malformations for the 10 most commonly prescribed antibi-
otics (excluding the four penicillins that served as control). Covariate
adjustments were made for maternal age at conception, year of deliv-
ery, pre‐pregnancy BMI, parity, smoking, educational status, employ-
ment status and household income.
Results: We found no increased risk of congenital malformations
related to first trimester in utero exposure to the 10 most commonly
prescribed antibiotics in Denmark compared to a cohort of pregnant
women exposed to penicillins that are considered safe during preg-
nancy. Compared to unexposed pregnancies, small increased risks for
major malformations and cardiac malformations were apparent for
pivmecillinam (aOR 1.13; CI 1.06–1.19 and 1.19; CI 1.08–1.31,
respectively), sulfamethizol (aOR 1.15; CI 1.07–1.24 and 1.25; CI
1.10–1.41, respectively) and azithromycin (aOR 1.19; CI 1.02–1.38
and 1.29; CI 1.01–1.66, respectively).
Conclusions: In this large population‐wide cohort study, we found no
increased risk of congenital malformations following first trimester
exposure to 10 commonly prescribed antibiotics: doxycyclin, amoxicil-
lin, pivmecillinam, dicloxacillin, sulfamethizol, erythromycin,
roxithromycin, azithromycin, ciprofloxacin and nitrofurantoin.
753 | Asthma medication use and risk of
birth defects: National Birth Defects
Prevention Study 1997–2011
Meredith M. Howley1; Eleni A. Papadopoulos1; Carla Van Bennekom2;
Alissa R. Van Zutphen1; Suzan L. Carmichael3; JeanPierre W. Munsie1;
Michele L. Herdt1,4; Marilyn L. Browne1,4
1New York State Department of Health, Albany, NY; 2Slone Epidemiology
Center at Boston University, Boston, MA; 3Stanford University, Stanford,
CA; 4School of Public Health, University at Albany, Rensselaer, NY
Background: Asthma affects 4–8% of pregnant women. Evidence
regarding associations between asthma medication use during preg-
nancy and the risk of birth defects is mixed. Previous publications
from the National Birth Defects Prevention Study (NBDPS) found
associations between asthma medications and certain birth defects,
including gastroschisis (based on 1997–2002 births) and oral clefts
(based on 1997–2005 births).
Objectives: We estimated associations between early pregnancy
asthma medication use (one month before through the third month
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of pregnancy) and 52 specific birth defects using NBDPS data from
1997–2011.
Methods: The NBDPS was a population‐based, multicenter, case–con-
trol study in 10 US states. Cases were identified via birth defects sur-
veillance systems and controls were randomly sampled non‐
malformed, live‐born infants from the same areas. Exposure informa-
tion was collected from women via telephone interview. We analyzed
early pregnancy asthma medication use and further grouped by most
common types: bronchodilator use only, anti‐inflammatory use only,
or both. The reference group was women without asthma or asthma
medication use during pregnancy. We used logistic regression to cal-
culate odds ratios (OR) and 95% confidence intervals (CI), adjusting
for maternal age, race/ethnicity, body mass index, smoking, folic
acid‐containing supplement use, and parity.
Results: In our analysis of 27,270 birth defect cases and 10,894 con-
trols, 5% (n = 1,308) of case and 4% (n = 449) of control women
reported early pregnancy asthma medication use. Of the exposed,
57% (n = 742) of case and 57% (n = 255) of control women reported
using only a bronchodilator, 13% (n = 168) of case and 15% (n = 66)
of control women reported using only an anti‐inflammatory, and
24% (n = 317) of case and 24% (n = 109) of control women reported
both. Early pregnancy bronchodilator use was significantly associated
with choanal atresia (OR 2.19; CI 1.01–4.75), cleft palate (OR 1.52;
CI 1.13–2.05), cleft lip (OR 1.63; CI 1.15–2.30), longitudinal limb defi-
ciency (OR 2.28; CI 1.51–3.44), and truncus arteriosus (OR 2.43; CI
1.11–5.30). Early pregnancy anti‐inflammatory use was not associated
with any birth defect examined. Early pregnancy use of both types of
asthma medications was associated with biliary atresia (OR 3.54; CI
1.53–8.19) and pulmonary atresia (OR 2.42; CI 1.05–5.57).
Conclusions: Early pregnancy asthma medication use was not associ-
ated with most of the 52 birth defects examined. We observed mod-
estly elevated ORs for the association between bronchodilators and
several birth defects, but did not confirm all previous findings.
754 | Phthalate exposure from drugs during
pregnancy and risk of preterm birth and small
for gestational age
Anne Broe1; Anton Pottegård2; Jesper Hallas1; Thomas P. Ahern3;
Ronald F. Lamont1; Per Damkier1
1Odense University Hospital, Odense, Denmark; 2University of Southern
Denmark, Odense, Denmark; 3University of Vermont, Burlington, VT
Background: Phthalates are thought to be endocrine disruptors and
previous studies suggest that environmental phthalate exposure may
increase the risk of preterm birth, whereas studies of phthalate expo-
sure and birth weight have been contradictory and inconclusive.
Phthalates are used as plastic softeners in consumer products such
as cosmetics, food containers, toys, medication, and other soft plas-
tics. Users of medicinal drugs have been shown to have up to 50‐fold
higher urine phthalate metabolite concentrations than the general
population.
Objectives: To assess the effect of phthalate exposure from pharma-
ceutical drugs on preterm birth (PTB) and small for gestational age
(SGA).
Methods: Using Danish nationwide health registries, we performed a
case–control study nested within a cohort of 30,837 singleton deliver-
ies from 2004 to 2015 who were exposed to ≥1 of 23 selected drug
groups available in both phthalate‐containing and phthalate free for-
mulations. Using conditional logistic regression, we estimated associa-
tions between phthalate exposure and the risk of PTB and SGA. SGA
was defined by INTERGROWTH‐21st grow charts (SGA‐I) and by
Marsal's equation for expected birthweight (SGA‐M).
Results: We included 1,965 PTBs, 1,315 SGA‐Is, and 891 SGA‐M
cases, matched to 19,537, 12,008, and 7,573 controls, respectively.
Ortho‐phthalate exposure during the third trimester was positively
associated with PTB with a crude OR of 1.36 (95% CI: 1.06–1.76).
The association was mainly due to diethyl phthalate. No associations
were found between ortho‐phthalate exposure and SGA. Exposure
to polyvinyl acetate phthalate and hypromellose phthalate in late
pregnancy were associated with a risk of PTB with crude ORs of
5.13 (95% CI: 1.51–17.44) and 3.02 (95% CI: 1.21–7.50), respectively.
However, the number of exposed individuals was low. No strong asso-
ciations were found between cellulose acetate phthalate exposure and
either PTB or SGA.
Conclusions: We found an increased risk of PTB with exposure to
DEP and phthalate polymers used as drug excipients. As the use of
phthalates as drug excipients is easily avoided (all drugs are already
marketed in phthalate free versions), regulatory agencies should
reconsider the use of phthalates in pharmaceuticals until their safety
has been clarified.
755 | Estimating the causal effect of prenatal
Lead on Prepulse inhibition: A prospective
study in children and adolescents
Kale Kponee‐Shovein1; Marc G. Weisskopf1; Rachel Grashow1;
Ran S. Rotem1; Brent A. Coull1; Lourdes Schnaas2;
Carmen Hernández‐Chávez2; Brisa Sanchez3; Karen Peterson3;
Howard Hu4; Mauricio Hernandez‐Avila5; Martha M. Téllez‐Rojo5
1Harvard University, Boston, MA; 2 Instituto Nacional de Perinatología
Isidro Espinosa de los Reyes, Miguel Hidalgo, Mexico; 3University of
Michigan, Ann Arbor, MI; 4University of Washington, Seattle, WA;
5National Institute of Public Health, Mexico City, Mexico
Background: During pregnancy, maternal lead from earlier exposures
mobilizes and crosses placental barriers, placing the developing fetus
at risk for lead exposure and neurodevelopmental deficits. Some neu-
ronal circuits known to be affected in neurodevelopment disorders
can be probed with simple physiological behavioral paradigms. One
such neural biomarker is Pre‐Pulse Inhibition (PPI), an indicator of ade-
quate sensorimotor gating processing. In clinical studies, impairments
in PPI have been associated with neurodevelopmental deficits in
human subjects. To our knowledge, no studies have examined the
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use of PPI as a biomarker of toxicant effects on the brain in epidemi-
ological studies.
Objectives: We aimed to estimate the causal effect of prenatal lead
exposure, as assessed by maternal cortical bone lead concentrations,
on PPI in 279 children from Mexico City.
Methods: In vivo maternal cortical bone lead measurements were
taken at four weeks postpartum at the mid‐tibia shaft using a K‐Shell
X‐ray fluorescence instrument. PPI recording occurred in an isolated
clinical setting and eye blink responses were measured using electro-
myography. We assessed if the conditions for causal inference held
in our study population and used the results of our assessment to esti-
mate the effect of prenatal lead exposure on PPI using an ordinary
least squares regression model, a marginal structural model, and the
parametric g‐formula.
Results: Results were consistent across the three modeling
approaches. For the parametric g‐formula, a one standard deviation
(10.00 μg/g) increase in prenatal lead significantly reduced PPI by
approximately 13.32% (95% CI: 2.12%, 25.48%).
Conclusions: In a population of children from Mexico City, we esti-
mated the causal effect of prenatal lead exposure on PPI deficits.
Our results are consistent with findings from other studies establish-
ing an association between lead exposure and neurodevelopmental
disorders in children and suggest that PPI may be useful as an objec-
tive biomarker of toxicant effects on the brain.
756 | Oral corticosteroids during pregnancy
and offspring risk of congenital heart defects
‐ a Nationwide cohort study
Amalie B. Schmidt; Marie Lund; Giulia Corn; Nina Øyen;
Jan Wohlfahrt; Mads Melbye
Statens Serum Institut, Copenhagen, Denmark
Background: Pre‐pregnancy diabetes is a strong risk factor for con-
genital heart defects (CHDs), suggesting a role for glucose in the
causal pathway. Oral corticosteroids may cause hyperglycemia, and
maternal use could affect embryonic heart development.
Objectives: The objective was to determine the association between
maternal intake of oral corticosteroids 0–8 weeks after conception
and CHDs in offspring.
Methods: A register‐based nationwide prevalence study including all
live singleton births, Denmark, 1996–2016 was conducted. In total
1,194,687 individuals and their mothers were identified and linked
with information on CHDs and their mothers' use of oral corticoste-
roids in early pregnancy. Corticosteroid use was defined as a filled pre-
scription for maternal use of oral corticosteroid 0–8 weeks after
conception. CHDs were identified through International Classification
of Diseases codes. The association was estimated by prevalence
(odds) ratios using logistic regression and propensity score‐matched
analyses.
Results: Among 1,194,687 live births, 2,032 had a mother who had
used oral corticosteroids 0–8 weeks from conception. Of these, 32
had a heart defect. Among offspring of never‐users of oral corticoste-
roids, 10,534 had a heart defect. Adjusted prevalence ratio (PR) was
1.29, 95% confidence interval (CI) 0.90–1.84 comparing offspring
prevalence of heart defects in oral corticosteroid users with that in
oral corticosteroid never‐users. Propensity score‐matched analysis
yielded similar results, PR 1.38, 95% CI 0.95–2.02.
Conclusions: This study does not support an association between
maternal use of oral corticosteroids in the first 8 weeks after concep-
tion and CHDs.
757 | The safety of amoxicillin and
Clavuladoodles#123nic acid use during the
first trimester of pregnancy
Sharon Daniel; Maya Doron; Boris Fishman; Gideon Koren;
Eitan Lunenfeld; Amalia Levy
Ben‐GurioN University of the Negev, Beer‐Sheva, Israel
Background: Penicillins are widely used during pregnancy for various
infectious indications, but the safety of use during pregnancy was
not fully assessed.
Objectives: The goal of the current study was to assess the risk for
major congenital malformations following first‐trimester exposure to
and amoxicillin and clavulanic acid (ACA).
Methods: A population‐based retrospective cohort study was con-
ducted, by linking four computerized databases: maternal and infant
hospitalization records, drug dispensing database of Clalit Health Ser-
vices in Israel and data concerning pregnancy terminations. Multivari-
ate negative‐binomial regressions were used to assess the risk for
major malformations following first‐trimester exposure, adjusted for
mother's age, ethnicity (Bedouin vs. Jewish), parity, diabetes mellitus,
lack of perinatal care (LOPC) and the year of birth.
Results: The study included101,615 pregnancies, of which 6,919
(6.8%) were exposed to amoxicillin: 1,045 (1.0%) to amoxicillin only,
and 6,041 (5.9%) ‐ to ACA. No significant association was found, in
both univariate and multivariate analysis, between first‐trimester
exposure to amoxicillin or ACA and major malformation in general
(Crude OR = 1.05 95%CI 0.95 to 1.16, Adjusted OR = 1.09 95%CI
[0.98 to 1.20) or for major malformations according to organ systems.
No dose–response was found between exposure in terms of the
defined daily dose (DDD) and major malformations.
Conclusions: Exposure to amoxicillin and ACA during the first trimes-
ter of pregnancy was not associated with an increased risk of major
congenital malformations.
758 | Maternal early pregnancy use of
specific antidepressant medications and risk
for birth defects
Kayla N. Anderson1; Jennifer N. Lind1,2; Regina Simeone1;
William V. Bobo3; Tiffany Riehle‐Colarusso1; Kara N. Polen1;
Jennita Reefhuis1
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Background: Antidepressants are commonly used to treat depression
and anxiety. Data on individual antidepressant medication safety dur-
ing pregnancy are relatively limited.
Objectives: To examine associations between maternal use of com-
monly prescribed antidepressant medications during early pregnancy
(1 month before through the third month) and specific birth defects.
Methods: We used data from the NBDPS, a U.S. multicenter, popula-
tion‐based case–control study (1997–2011). Cases were from active
birth defects surveillance systems; controls included liveborn infants
without major defects. Medications were examined if used by >0.2%
of control mothers in early pregnancy, and included sertraline (1.1%),
fluoxetine (0.7%), paroxetine (0.4%), bupropion (0.4%), citalopram
(0.3%), escitalopram (0.3%), and venlafaxine (0.2%). We used multivar-
iable logistic regression to calculate adjusted odds ratios (aORs) and
95% confidence intervals (CIs) for the association between each med-
ication and birth defects with ≥4 exposed cases, controlling for mater-
nal education, race, smoking, and pre‐pregnancy body mass index. We
compared early pregnancy‐exposed women to those who were unex-
posed to an antidepressant in the three months before or during preg-
nancy, and to account for treated indication, women who reported
antidepressant use only outside of the early pregnancy period.
Results: Sertraline was associated with 6/38 defects (highest aOR:
some types of double‐outlet right ventricle (aOR: 3.3, 95% CI: 1.2–
9.3)). Fluoxetine was associated with 11/33 defects (highest aOR:
Dandy Walker malformation (aOR: 4.0, 95% CI: 1.4–11.2)). Paroxetine
was associated with 7/27 defects (highest aORs: total anomalous pul-
monary venous return (aOR: 4.0, 95% CI: 1.4–11.3); anencephaly
(aOR: 3.0, 95% CI: 1.3–7.1)). Of 25 defects examined, bupropion was
associated with spina bifida and diaphragmatic hernia. Of 24 defects
examined, citalopram was associated with one defect. Escitalopram
had no increased risk for the 21 defects examined. Venlafaxine was
associated with an increased risk for 16/20 defects, with aORs for
seven defects >3.0. Controlling for treated indication attenuated asso-
ciations for many defects, although new associations were seen for
some medication and defect combinations, and most associations
between venlafaxine and individual defects remained.
Conclusions: Except for escitalopram, each of the antidepressant med-
ications was associated with some birth defect risk. These results may
assist healthcare providers in counseling women about the safest anti-
depressant treatment options during pregnancy.
759 | Effect of N‐acetylcysteine
supplementation on women undergoing
assisted reproductive techniques: A
systematic review and meta‐analysis
Nagita Devi; Divya Bujimalla; Dipika Bansal
National Institute of Pharmaceutical Education and Research, Mohali,
India
Background: N‐acetylcysteine (NAC) possesses antioxidant, mucolytic
and insulin‐sensitizing properties, and has been proven to be a reason-
ably good candidate as a supporting therapy in women undergoing
assisted reproductive techniques (ART).
Objectives: To determine the effect of NAC supplementation on
women undergoing ART.
Methods: A systematic review and meta‐analysis study was con-
ducted on randomized controlled trials (RCTs) which compared the
effect of NAC supplementation with placebo or no treatment on
women undergoing ART. An electronic search was done on PubMed,
EMBASE, Cochrane and Ovid databases which included data till
December 2018. This search was limited to articles conducted on
humans and published in English. The estimation of ovulation rate
and pregnancy rate were the primary outcomes of this study. How-
ever, the miscarriage rate and multiple pregnancies were the second-
ary outcomes. The results were presented in an odd ratio (OR) with
heterogeneity and confidence intervals (95% CI).
Results: Nine RCTs, in accordance with the inclusion criteria, were
considered, which involved 1617 women for meta‐analysis. It was
observed that NAC supplementation was associated with an increased
ovulation rate (I2 = 60%; 3.62; 95% CI, 1.80 to 7.27) and pregnancy
rate (I2 = 69%; 1.94; 95% CI, 1.04 to 3.64) when compared to placebo
or no treatment. Although there was no significant association with
miscarriage (I2=0%; 0.94; 95% CI, 0.56–1.55) and multiple pregnancy
(I2 = 29%; 1.13; 95% CI, 0.33–3.81).
Conclusions: Evidence has suggested that NAC supplementation may
be beneficial to increase the ovulation rate and pregnancy rate in
women undergoing ART. However, high quality of evidence is
required to confirm these results.
760 | In utero opioid exposure and risk of
ADHD in childhood: A Scandinavian registry
study
Marte Handal1; Svetlana Skurtveit1; Ingvild Odsbu2; Helle Kieler2;
Mette Nørgaard; Buket Öztürk3; Angela Lupatelli4; Hedvig Nordeng4;
Ingunn Olea Lund1; Sonia Hernandez‐Diaz5; Mollie Wood5;
Milada Mahic1
1Norwegian Institute of Public Health, Oslo, Norway; 2Karolinska
Institutet, Stockholm, Sweden; 3Aarhus University Hospital, Aarhus,
Denmark; 4University of Oslo, Oslo, Norway; 5Harvard T. H. Chan School
of Public Health, Boston, MA
Background: Prescriptions for opioid analgesics increased sharply over
the past two decades. Knowledge about long‐term consequences of in
utero exposure to opioids is scarce.
Objectives: The aim of this study was to examine the association
between prenatal exposure to opioids and risk of ADHD in childhood
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a) in population of women with a history of chronic opioid prior to
pregnancy and b) among short‐ and long‐ term opioid users.
Methods: We used data from nationwide health registers in Norway
and Sweden, and linked data using personal identification numbers.
We identified exposure to opioids (ATC code N02A) from the Pre-
scription Databases. ADHD was identified as an ADHD diagnosis
(ICD‐10 F90) in specialist health care system or at least one ADHD
drug dispensed. a) Among women with chronic opioid analgesic expo-
sure one year prior to pregnancy start (n = 6 202), we compared those
who continued to use opioids during pregnancy (filled 30 Defined
Daily Doses (DDD) or more during pregnancy) (n = 3178) with
discontinuers (no opioid prescriptions during pregnancy) (n = 3024).
b) We studied dose–response by comparing long‐term (30 DDD or
more) (n = 8224) with short‐term (less than 30 DDD) (n = 38 578)
analgesic opioids in‐utero exposure. We followed the cohorts of live
born infants up the age of ten years. The association between expo-
sure and the cumulative risk of ADHD was analyzed using Cox propor-
tional hazard regression, with attained age as the time scale. Inverse
probability of treatment weights based on the propensity scores was
applied to adjust for measured confounders.
Results: a) The mean follow‐up time after age of three was 3.3 years in
the exposed group and 3.4 years in the discontinuers. There were 110
ADHD cases (3.5%) in the opioid exposed group and 61 (2.0%) in the
discontinuer group. The unadjusted HRs for the risk of ADHD was
1.77 (95% Confidence Interval 1.29 to 2.41). After adjustment the
HR decreased to 1.16 (0.72 to1.85). b) In the comparison between
short and long term use of opioids during pregnancy the unadjusted
HRs for the risk of ADHD was 1.77 (1.51 to 2.08). After adjustment
the HR decreased to 1.43 (1.18 to1.72).
Conclusions: We did not observe increased risk of ADHD among chil-
dren of women who used opioids long‐time during pregnancy when
compared with children of opioid discontinuers. Analysis of dose–
response indicated increased risk among long‐term exposed when
compared to short‐term exposed. Short‐time users may use small
amounts of opioids and be quite similar to the general pregnant pop-
ulation. Increased risk of ADHD in long term compared to short term
exposed children might thus be a result of residual confounding.
761 | Outcome measurement in pregnancy
exposure registries: A preliminary review of
publicly available resources
Suzanne N. Landi1; Jessica R. Probst1; Katherine M. Lee2; Elsa Garcia3;
Kristen Hahn2
1 IQVIA, Durham, NC; 2 IQVIA, Cambridge, MA; 3 IQVIA, Madrid, Spain
Background: Pregnancy exposure registries (PERs) can improve medi-
cation safety information formothers and their infant(s) and can be used
to update drug labeling. Accurate outcomemeasurement is critical. Cur-
rently there are no standardized recommendations to measure preg-
nancy and infant outcomes, leading to possible variation across PERs.
Objectives: To review and describe outcome measurement elements
for PERs conducted in North America and Europe.
Methods: We reviewed publicly available information from the U.S.
Food and Drug Administration List of Pregnancy Exposure Registries,
ClinicalTrials.gov, and European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance E‐Register of Studies.
Protocols or other posted materials were reviewed from ongoing,
completed or terminated registries through Jan. 2019; planned studies
were excluded. We extracted primary/secondary outcomes, infant fol-
low‐up time, and reporting sources (e.g. patients, healthcare providers
[HCPs]) as well as exposure details that influence outcome measure-
ment (e.g. medication class, lactation‐based exposure). Descriptive sta-
tistics were calculated using SAS 9.4.
Results: Our initial search yielded 357 entries. We then restricted to
prospective registries and after excluding planned registries, we exam-
ined 78 PERs in North America (n = 53), Europe (n = 7), or both regions
(n = 14) (missing n = 4). Among 69 PERs with available primary objec-
tives, 76.8% included congenital malformations (major and/or minor)
as the primary outcome; 29.0% included spontaneous abortion, and
23.2% included stillbirth. Few PERs (5.8%) included outcomes of lacta-
tion‐based exposure in the objectives. Median follow‐up time for
infant across registries was 1 year (range: 0–18 years). Over half
(56.4%) followed infants for ≥1 year after delivery. The most common
exposure medication class was monoclonal antibody (25%). Planned
sample size for ongoing registries (N = 56) varied from 1 to 10,200
patients (median 363). Among 44 PERs with posted information, 24
(54.5%) included HCPs as reporters for infant outcomes.
Conclusions: We observed variability in outcome ascertainment
across publicly available resources. A large proportion of PERs
included congenital malformations as a primary outcome; however,
just over half followed infants for ≥1 year after delivery. Sample size
and follow‐up length varied substantially. HCPs were not universally
included as reporters. As registering PERs is voluntary, our results
may not be generalizable to PERs that are not currently publicly listed.
762 | Risk of early neurodevelopmental
outcomes associated with prenatal exposure
to antiepileptic drugs: A Nationwide cohort
study based on the French National
Healthcare Databases
Pierre‐Olivier Blotière1,2; Sara Miranda3; Alain Weill1;
Mahmoud Zureik3; Rosemary Dray‐Spira3
1French National Health Insurance (CNAM), Paris, France; 2Université
Paris‐Descartes, Apemac, Université de Lorraine, EA 4360 Nancy, France;
3The French National Agency for Medicines and Health Products Safety
(ANSM), Saint‐Denis, France
Background: Valproate is known to be a cognitive and behavioral
teratogen. However, evidence for most of the ‘newer’ antiepileptic
drugs (AEDs) is still limited.
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Objectives: To assess the association between prenatal exposure to
monotherapy with the most commonly used AEDs other than
valproate during pregnancy and the risk of various
neurodevelopmental outcomes.
Methods: This cohort study was based on the French national
healthcare databases, which cover 99% of the 67 million inhabitants
in France. The cohort included children born alive between 2011
and 2014 and prenatally exposed to an AED in monotherapy. Women
were considered to be exposed to an AED during the 30 days follow-
ing each dispensing. Children prenatally exposed to lamotrigine were
used as the reference group. Outcomes included neurodevelopmental
disorders (NDDs), defined using long term diseases and hospital dis-
charge diagnoses with ICD‐10 codes F70 to F98 ‐ pervasive develop-
mental disorders (F84) and mental retardation (F70‐F79) were studied
separately ‐ and visits to a speech therapist. Children were followed
up until outcome, loss to follow‐up, death or 31 December 2016.
We performed inverse probability of treatment weighting analyses
using the propensity score, which included maternal (age, socioeco-
nomic status, psychiatric history, comedications...) and infant (gender,
gestational age and birth weight) characteristics. Hazard ratios (HRs)
were then calculated using Cox models.
Results: The cohort included 9,034 exposed children, with a median
follow‐up of 3.7 years. Of these, 2,916 were exposed to lamotrigine,
1,627 to pregabalin, 1,246 to clonazepam, 621 to levetiracetam, 502
to carbamazepine, 477 to topiramate, 378 to gabapentin and 143 to
oxcarbazepine. None of the studied AEDs were associated with
increased risks of neurodevelopmental outcomes compared with
lamotrigine (e.g. levetiracetam and NDDs: 8 cases, HR = 0.7 [0.3–
1.5]; pregabalin and NDDs: 28 cases, HR = 0.6 [0.4–1.0]). Similar
results were observed among children of women considered treated
for epilepsy. Furthermore, the expected positive association between
valproate and NDDs or visits to a speech therapist was confirmed in
this cohort.
Conclusions: This nationwide cohort study based on claims data pro-
vides reassuring results for all AEDs except valproate. Because of
the small numbers of cases, these results should be interpreted with
caution. In addition, due to the nature of the neurodevelopmental out-
comes investigated, a longer follow‐up is necessary to confirm the
findings.
763 | Fetal outcomes associated with
maternal asthma: Evidence from a large
healthcare database in the United States
Jennifer Yland1; Brian T. Bateman2,3; Krista F. Huybrechts2;
Michael Schatz4; Keele E. Wurst5; Sonia Hernandez‐Diaz1
1Department of Epidemiology, Harvard T.H. Chan School of Public
Health, Boston, MA; 2Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Brigham and Women's
Hospital and Harvard Medical School, Boston, MA; 3Department of
Anesthesiology, Brigham and Women's Hospital and Harvard Medical
School, Boston, MA; 4Department of Allergy, Kaiser Permanente Medical
Center, San Diego, CA; 5Department of Epidemiology and Real‐World
Evidence, GlaxoSmithKline, Collegeville, PA
Background: Asthma complicates between 3% and 10% of pregnan-
cies. Consequently, drugs used to treat asthma have become among
the most commonly prescribed medications in pregnancy. Poor mater-
nal asthma control has been associated with worse pregnancy out-
comes. However, results have been inconsistent and often from
small and selected samples.
Objectives: To quantify the risk of fetal and neonatal adverse events
associated with asthma during pregnancy in a large population, with
a focus on asthma severity and control.
Methods: This study was conducted within the Truven MarketScan
Commercial Claims and Encounters Database for 2011–2015. Asthma
was identified by diagnoses and treatments, severitywas based onmed-
ications dispensed, and control was based on hospitalizations, emer-
gency room admissions, and rescue oral corticosteroid dispensations.
We estimated the relative risks (RRs) of stillbirth, spontaneous abortion,
preterm birth (PTB), small for gestational age (SGA), neonatal intensive
care unit admission (NICUA), and congenital malformations, comparing
pregnancies with differing asthma status, severity, and control. Log‐
binomial generalized linear models were used to adjust for socio‐demo-
graphics, lifestyle factors, and comorbidities.
Results: Among 1,026,743 eligible pregnancies, we identified 29,882
pregnancies (2.9%) with asthma. Among these, 17% had severe asthma
and 24% had poorly‐controlled asthma. Neither asthma (vs. no‐asthma)
nor severity was associated with any of the outcomes considered; and
we observed no meaningful associations between asthma control and
pregnancy losses, SGA, or major congenital malformations. However,
compared to women with controlled asthma, pregnancies with poorly‐
controlled asthma were more likely to result in PTB (RR = 1.30; 95%
confidence interval 1.08–1.56) or NICUA (RR = 1.24; 1.02–1.51).When
we stratified by asthma severity, the RRs associated with poor control
were greatest among women not taking asthma control medications.
Conclusions: Maternal asthma during pregnancy was associated with
an elevated risk of PTB and NICUA only when it was poorly con-
trolled. We did not observe associations between asthma severity,
based on medications received, and adverse fetal outcomes. Funding:
GSK (206948).
764 | Risk of attention deficit hyperactivity
disorder in childhood after exposure to
serotonergic antidepressants in pregnancy
Angela Lupattelli1; Milada Mahic2; Marte Handal2; Eivind Ystrom2;
Ted Reichborn‐Kjennerud2; Hedvig Nordeng1,2
1University of Oslo, Oslo, Norway; 2Norwegian Institute of Public Health,
Oslo, Norway
Background: The time‐dependent effect of prenatal exposure to sero-
tonergic antidepressants on attention deficit hyperactivity disorder
(ADHD) risk remains unresolved.
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Objectives: To quantify the effect of time‐varying prenatal exposure
to serotonergic antidepressants on ADHD risk in childhood, as clinical
diagnosis and parent‐reported symptoms.
Methods: We used data from the Norwegian Mother and Child
Cohort Study, the Medical Birth Registry, the Prescription Database,
and the Patient Registry of Norway, limited to women with depres-
sive/anxiety disorders in pregnancy. The windows of self‐reported
antidepressant exposure were mid (week 16–28) and late pregnancy
(> week 28). Symptoms of ADHD at 5 years were parent‐reported
via the Conners' Parent Rating Scale‐Revised; ADHD diagnoses were
retrieved from the specialist health care system, the Patient Registry
(ICD‐10 F90). We fit general linear and Cox marginal structural models
(MSM) to account for time‐varying exposure and confounders
(depressive/anxiety symptoms as measured by SCL, co‐medication
with other psychotropics and analgesics), and time‐fixed maternal
and paternal factors.
Results: We included 3232 pregnancy‐child dyads within women with
self‐reported depressive/anxiety disorders in pregnancy. Overall, 481
(14.9%) children had been prenatally exposed to serotonergic antide-
pressants and 90 children (2.8%) had a clinical diagnosis for ADHD.
Relative to children born to women with non‐medicated depression/
anxiety (n = 2751), those exposed to serotonergic antidepressants in
mid (weighted HR: 1.74, 95% CI: 0.41–7.15) or late pregnancy
(weighted HR: 1.66, (0.41–6.82)) did not have an increased risk for
an ADHD diagnosis. Likewise, there were no differences on symptoms
of ADHD according to timing of exposure (midpregnancy: weighted β:
‐0.02, 95% CI: −0.30, 0.34; late pregnancy:weighted β: −0.04, (−0.32,
0.25)).
Conclusions: In a population of children born to women with depres-
sive/anxiety disorders in pregnancy, there was no evidence for a sub-
stantial association between prenatal exposure to serotonergic
antidepressants at different timings in pregnancy, and risk for ADHD
symptoms and diagnosis. However, we were unable to confirm or
refute whether a smaller increased risk exists.
765 | Prenatal antibiotics use and the risk of
attention deficit hyperactivity disorder
Amani Hamad; Silvia Alessi‐Severini; Salah Mahmud; Marni Brownell;
I. fan Kuo
University of Manitoba, Winnipeg, MB, Canada
Background: Prenatal antibiotic exposure induces changes in infants'
gut microbiota composition and is a possible contributor in the devel-
opment of Attention‐Deficit/Hyperactivity Disorder (ADHD).
Objectives: In this study, we examined the association between pre-
natal antibiotic exposure and the risk of ADHD.
Methods: This was a population‐based cohort study that included
187,605 children born in Manitoba, Canada between April 1, 1998
and March 31, 2017. Exposure was defined as having filled one or
more antibiotic prescription during pregnancy. The outcome was
ADHD diagnosis identified in hospital abstracts, physician visits or
drug dispensations. Risk of developing ADHD was estimated using
Cox proportional hazards regression models in a high dimensional pro-
pensity scores‐matched cohort and an exposure‐discordant sibling
cohort. Several sensitivity analyses were planned to test the robust-
ness of the risk estimates.
Results: A total of 102,974 children were included in the matched‐
cohort. During a follow‐up of 1,098,717 person‐years, 9717 (9.4%)
children received an ADHD diagnosis. Prenatal antibiotic exposure
was associated with increased ADHD risk (HR 1.14, 95% CI 1.09–
1.19). The highest risk was observed in those receiving 3 or more anti-
biotic courses or for a duration longer than 2 weeks (HR 1.37, 95% CI
1.19–1.58 and HR 1.28, 95% CI 1.16–1.42, respectively). In the sibling
cohort of 64,019 children, prenatal antibiotic exposure was associated
with a small increase in the risk of ADHD, though it was not statisti-
cally significant (HR 1.06, 95% CI 0.98–1.14).
Conclusions: Prenatal antibiotic use appears to increase the risk of
developing ADHD. However, much of this risk may have been
overestimated as a result of unmeasured confounding by genetic and
shared familial factors. Cautious interpretation of study finding is
warranted.
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Background: Past studies assessing whether exposure to interferon‐
beta during pregnancy can adversely affect foetal development have
been inconclusive, although evidence leans toward no association.
Adverse pregnancy outcomes such as spontaneous abortion have
been the focus of many studies, however foetal development can also
be assessed through birth measurements accounting for gestational
age, which will be used as outcomes in this study.
Objectives: To assess whether infants of women with multiple sclero-
sis (MS) exposed to interferon‐ beta show evidence of smaller size at
birth relative to infants of women with MS which were not exposed
to any MS disease modifying drugs (DMDs).
Methods: All pregnancies to women with MS between 2005 and 2014
in Sweden and Finland were identified using register data. For this
study, only births with a record of birth weight, height, and head
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circumference were included. Exposure was defined as having
occurred if an ATC code indicating a dispensation of interferon‐beta
was recorded in the 6 months prior to last menstrual period up until
the end of pregnancy. Generalized estimating equations, which used
mothers' ID number as a cluster, were used with continuous measures
of birth weight, height, and head circumference included as the out-
comes in separate models.
Results: Of pregnancies to women with MS in Sweden, 427 pregnan-
cies were exposed to interferon‐beta, and 974 unexposed to any MS
DMDs. The corresponding numbers for Finland were 233 and 331
respectively. Infants prenatally exposed to interferon‐beta were on
average 36 grams heavier (p = 0.16) in Sweden, and 50 grams lighter
(p = 0.26) in Finland than those unexposed. For birth height, those
exposed to interferon‐beta were 0.03 cm longer (p = 0.81) in Sweden,
and 0.03 cm shorter (p = 0.87) in Finland compared to those unex-
posed. For head circumference, those in Sweden had measurements
0.16 cm larger (p = 0.05) and in Finland 0.21 cm smaller (p = 0.17) rel-
ative to those unexposed.
Conclusions: This study provides evidence that exposure to inter-
feron‐beta during pregnancy does not adversely affect foetal growth
in infants of mothers with MS exposed to IFN beta.
Acknowledgement: We would like to acknowledge the European
Interferon Beta Pregnancy Study Group for their contribution to this
abstractFunding: Bayer AG, Biogen, Merck KGaA and Novartis
Pharma AG.
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Background: Prenatal screening can detect and attenuate pregnancy
complications, but limited evidence exists regarding determinants of
missing or delayed prenatal screening in the Medicaid population.
Objectives: To examine prevalence and determinants of missing or
delayed prenatal screening in Florida, Texas, and New Jersey Medicaid
populations during 1999–2010.
Methods: We conducted a retrospective cohort study using the 3‐
state Medicaid Analytic eXtract data linked to birth certificates.
Mothers had to be enrolled from ≥1 year before last menstrual period
(LMP) to delivery date. Evaluated outcomes were missing aneuploidy
screening (AS, defined as missing all of these tests: nuchal translu-
cency measurement, pregnancy associated plasma protein A, human
chorionic gonadotropin, alpha‐fetoprotein, estriol, and inhibin‐A tests),
missing or delayed (>20 gestational weeks) first anatomical ultrasound
(AU), missing group B streptococcus test among term and post‐term
deliveries (GBS), and missing or delayed (>28 weeks) first gestational
diabetes screen (GDS). To evaluate GDS, we excluded mothers with
diabetes diagnosed before LMP. Candidate determinants were mater-
nal sociodemographic and clinical conditions based on the Centers for
Medicare and Medicaid Services' hierarchical condition categories and
assessed during one year prior to LMP. Stepwise selection and gener-
alized estimating equation models were used to identify determinants
for each outcome.
Results: A total of 65,477 deliveries were included (64,186 deliveries
without diabetes diagnosis before LMP). We observed a high propor-
tion of missing AS (29%) and GBS (30%), and a high proportion of
missing or delayed AU (44%) and GDS (49%). Non‐Hispanic Black,
maternal age < 18 years (except for GBS), receiving cash subsidy, hav-
ing previous pregnancy with no or minor complication, newborn, or
having serious perinatal complications, and having drug or alcohol dis-
order within one year before LMP were associated with a larger pro-
portion of missing or delayed screening for IPS, AU, GBS, and GDS.
Mothers enrolled in Medicaid due to disability or poverty, with previ-
ous ectopic, molar, miscarriage, or terminated pregnancy, and a variety
of chronic and acute disease conditions were significantly likely to
have less missing or delayed screening.
Conclusions: Important determinants of having missing or delayed IPS,
AU, GBS, and GDS were identified and highlight significant disparities
in screening involving socio‐economic and clinical factors.
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Background: Ectopic pregnancy (EP) is a rare yet significant contribu-
tor to maternal morbidity and mortality in the United States (US). Due
to changes in management and a shift from inpatient to outpatient
care, traditional surveillance data cannot be used to validly quantify
EP rates. Electronic health record (EHR) data do not produce represen-
tative estimates of the disease rate at national levels as it does not
identify or capture all women at risk of EP including non‐users of
any contraceptive methods and uninsured women.
Objectives: To assess the prevalence of EP among subpopulations of
women at risk of pregnancy not represented in EHR systems including
women who are non‐users of any contraceptive methods and unin-
sured women between 2011 and 2015 in the US.
Methods: We utilized data from the 2011–2013 and 2013–2015
National Survey of Family Growth, conducted by the Centers for
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Disease Control, which captures a nationally representative sample of
women aged 15 to 44 years in the US. The study population included
women who were at risk of pregnancy. Information regarding preg-
nancy outcomes, method of contraceptive use, reproductive history,
and surrogates of socioeconomic status were used. Crude and age‐
standardized EP prevalence and corresponding 95% confidence inter-
vals (CIs) were estimated.
Results: A total of 6,029 women were enrolled to the study. 562
women were non‐users of any contraception. Sixteen percent
(1,115/6,029) of the study population did not have health insurance.
EP was reported in 29 women, six of which were among non‐users
of contraceptives. Age standardized EP prevalence was 0.5% (0.3%,
0.9%) for all and 0.5% (0.2%, 1.5%) for non‐contraceptive users. EP
prevalence among uninsured and insured women (private and Medic-
aid/government) was 0.7% (0.4%, 1.5%) and 0.5% (0.2%, 1.0%),
respectively.
Conclusions: Results of this study shows comparable EP risk among
populations under‐represented in EHR. The complexity of capturing
accurate information on disease and sexual habits further adds to
the need for innovative approaches that can accurately capture such
information and estimate disease burden at the national level.
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Background: Asthma is a chronic inflammatory disease of the lungs. It
has been associated with irregular menses and infertility in some stud-
ies, but there are limited data on the relation between asthma medica-
tion use and fecundability.
Objectives: We used data from Pregnancy Study Online (PRESTO), a
North American preconception cohort study, to examine the associa-
tion between asthma diagnosis and medication use with fecundability.
Methods: During 2013–2018, we enrolled 6,868 female pregnancy
planners who had been trying to conceive for ≤6 cycles at entry. Par-
ticipants completed a baseline questionnaire and bimonthly follow‐up
questionnaires for up to 12 months or until pregnant. At baseline, par-
ticipants reported if they had ever been diagnosed with asthma and
their asthma medication use in the past four weeks.
Results: We used proportional probabilities models adjusted for fac-
tors such as socio‐demographics and comorbidities to estimate
fecundability ratios (FR) and 95% CIs. The referent for all comparisons
was women without an asthma diagnosis. Overall, 1,149 women (17%)
reported an asthma diagnosis, of whom 395 (34%) reported use of
asthma medication in the past four weeks. Of those who used asthma
medication, 60% reported use when having symptoms, 22% reported
daily use, and 18% reported daily use plus more when having symp-
toms. Overall, an asthma diagnosis had little association with
fecundability (FR = 0.98, 95% CI: 0.90–1.06). For women with asthma
who reported medication use only when having symptoms, daily
asthma medication use, daily asthma medication use with additional
dosing for symptoms, or no medication use, FRs were 1.08 (95% CI:
0.91–1.28), 0.98 (95% CI 0.78–1.29), 0.79 (95% CI: 0.59–1.07), and
0.97 (95% CI 0.89–1.07), respectively.
Conclusions: Despite the near‐null findings overall, we found slightly
reduced fecundability for the heaviest users of asthma medication,
which might be a chance departure, confounding by asthma severity,
or an effect of greater asthma medication use.
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Background: Some studies have suggested that prenatal paracetamol
exposure might associate with the risk of child asthma. However,
some systematic reviews, indicate that despite knowing pathophysio-
logical mechanisms that could explain this association, the evidence
regarding the use of paracetamol and the development of asthma is
still inconclusive.
Objectives: the aim of this study was to analyze the prenatal and
infant exposure to paracetamol and ibuprofen and the risk of asthma
in children at 24 months of age.
Methods: this is a cohort study conducted in Pelotas, Brazil, in 2015.
This cohort recruited pregnant women during the prenatal period
n = 4,275, in order to collect variables related to pregnancy. The out-
come of the study was asthma in children at 24 months. The exposure
was the use of paracetamol, ibuprofen and both drugs during gesta-
tion and in childhood, 3 months, 12 months and 24 months. The inde-
pendent variables were: maternal age, maternal schooling, maternal
asthma, infection during pregnancy, child birth weight and
breastfeeding status. The analyzes were performed using poisson
regression.
Results: the cohort comprised 4,014 children at the 24 months follow‐
up. 71.9% of mothers reported white skin color, 47.1% were between
20 and 29 years old, 34.1% had 9 to 11 years of study. Tobacco use
was observed in 16.5% of the women. The prevalence of exposure
to paracetamol during gestation was 64.2%, ibuprofen was 2.5% and
of both drugs was 3.2%. Exposure to paracetamol and ibuprofen in
children up to 24 months was, respectively, 17.2% and 13.6%. The rel-
ative risk of having asthma among those exposed to paracetamol
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during pregnancy was 1.05 IC95% 0.96–1.15 in the crude analysis and
1.03 CI95% 0.93–1.16 in the adjusted analysis. The relative risk of tak-
ing ibuprofen was 1.17 CI95% 0.91–1.51 in the crude analysis and
1.16 IC95% 0.91–1.48 in the adjusted analysis. No association was
found when analyzing the simultaneous use of paracetamol and ibu-
profen during the pregnancy. When analyzing the children's exposures
to the medicines at 12 and 24 months, we observed a significant asso-
ciation with the use of paracetamol and ibuprofen: relative risk of 1.11
CI95% 1.01–1.23 and 1.16 CI95% 1.04–1.30 in the adjusted analysis,
respectively.
Conclusions: the findings suggest that there is no association between
prenatal exposure to paracetamol and ibuprofen and increased risk of
developing asthma at 24 months. However, the use of paracetamol
and ibuprofen from birth to 24 months of age increased the risk of
asthma in the children.
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Background: Prophylactic iron supplementation in pregnant women is
a universal practice of antenatal care. However, there is evidence that
high iron intake increase the risk of gestational diabetes mellitus
(GDM) for women with hemoglobin levels >11 g/dL in early
pregnancy.
Objectives: To evaluate the association between the use of iron salts
in pregnant, hemoglobin levels, and development of GDM.
Methods: Longitudinal study with women who participated in the
perinatal study (n = 4270) in 2015 Pelotas Birth Cohort, Brazil. Partic-
ipants were interviewed at the maternity about the antenatal period.
The analyzes were performed with all non‐anemic women before the
24th week of gestation (n = 2463). The GDM outcome was based
on maternal self report. All women with a previous history of diabetes
were excluded. The exposure “use of prophylactic iron in the first or
second trimester of gestation”, was defined as iron use in non‐anemic
pregnant women. In order to characterize this exposure, was used the
variable of use of vitamins and salts of iron in the gestation. It was
considered “yes” for the use of iron all the compounds with ferrous
sulfate and all the vitamins with iron. Descriptive analyses were per-
formed between exposed and unexposed and factors associated with
the development of GDM were evaluated using Poisson regression
with robust variance. Variables with p < 0.2 were included in adjusted
analysis. The regression followed a hierarchical backward selection
model. The distal level included socio‐demographic variables and
family history of diabetes; the second level includes pre‐gestational
body mass index (BMI), parity and smoking; and proximal level
included the use of iron salts. The significance level was set at 0.05.
Results: Younger non‐anemic women (19 years or younger) used more
iron salts (79.4%) than older women (71.0%, p = 0.02).
Sociodemographic characteristics, pre‐gestational BMI, parity,
smoking and family history of diabetes did not show statistically signif-
icant differences. The adjusted analysis did not find association
between the use of iron salts and the risk of GDM (Risk relative = 1.0,
95%CI 0.7–1.4).
Conclusions: Prophylactic supplementation of iron salts in non‐anemic
pregnant women is not a risk factor for GDM. To confirm our results,
future studies should include baseline hemoglobin levels and addi-
tional markers of iron status.
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Background: EXPECT is an observational study with the primary
objective of evaluating pregnancy outcomes in women exposed to
Xolair.
Objectives: Explore the potential risk to newborn infants exposed to
Xolair via breast milk within the EXPECT pregnancy registry.
Methods: This analysis report on safety outcomes for 230 infants born
to these women and for whom data were available on breastfeeding
status and long‐term outcomes. Data on infant outcomes were col-
lected from the mother and relevant healthcare providers at 6 and
12 months after delivery (follow‐up was extended to 18 months after
delivery if the mother continued Xolair treatment while breastfeeding).
Outcomes of interest were serious and non‐serious adverse events,
infections (used as a potential proxy for immune system development)
and thrombocytopenia. Analyses were descriptive and results summa-
rized as percentages.
Results: Among the 230 infants included in the analysis, 44 were not
breastfed, 154 were exposed to Xolair through breastfeeding, and
32 were breastfed without being exposed to Xolair. The overall fre-
quency of Serious Adverse Events (SAEs) reported was similar across
the 3 groups: 54.5%, 48.1% and 46.9% respectively. The most fre-
quently reported SAEs not related to infections were conditions iden-
tified in the immediate perinatal period (most common: prematurity,
jaundice, and fetal distress syndrome) and minor congenital anomalies
(most common: ankyloglossia, dacryostenosis, and hydrocele). The fre-
quency of reported SAEs categorized as “infections and infestations”
was 11.4%, 10.4% and 12.5% respectively. There was only one infant
diagnosed with thrombocytopenia, identified on her day of birth.
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Conclusions: The results of this analysis are not suggestive of a rela-
tionship between Xolair exposure via breastfeeding and an increased
risk of overall adverse events or deficiencies in immune system func-
tion in infants. Limitations of the data include the observational nature
of the registry, and the potential for under‐reporting of infections, par-
ticularly those that were clinically mild.
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Background: More and more studies suggest a potential impact of
prenatal drug exposure, in particular to psychotropic medicines, on
the occurrence of neuropsychiatric disorders in the offspring.
Objectives: This study aimed to describe prenatal drug exposure in
children receiving psychiatric care.
Methods: The study was conducted using the POMME cohort (Pre-
scriptiOn Médicaments Mères Enfants), which holds anonymous
medical information as well as drug and healthcare reimbursements
to more than 8,000 children, from the day of their conception. The
children recorded in POMME were born between July 2010 and
June 2011, thus they have reached 7 years of age. Data included
i) drugs and medical care reimbursements to children and their
mothers during pregnancy and ii) health certificates at birth, 9 and
24 months. Children were included if they i) consulted at least once
a psychiatrist, neurologist or psychiatrist, ii) presented at least two
signs of psychomotor development disorders mentioned in their
health certificates and/or iii) were prescribed at least one psychotro-
pic medicine (ATC classes N05 and/or N06).
Results: A total of 1,785 children were included (21.3% of the
POMME cohort). Among them, 442 (24.8%) consulted a neuropsychi-
atrist, neurologist or psychiatrist, 856 (48.0%) presented at least two
signs of psychomotor development disorders and 670 (37.5%) were
prescribed psychotropic medicines. Children were prescribed
10.4 ± 6.2 medicines during intrauterine life (versus 9.8 ± 6.1 in the
entire POMME cohort) and they were mostly exposed to medicines
for the digestive system during their intra‐uterine life. 68.6% were
prenatally exposed to nervous system drugs (67.1% in the POMME
cohort), the majority of whom was exposed to analgesic. Prenatal
exposure to psycholeptics and psychoanaleptics concerned 6.3% and
2.4% of the children respectively (4.8% and 1.9% in the POMME
cohort) and exposure was higher during the first trimester of
pregnancy.
Conclusions: More than two thirds of the children using psychiatric
care were prenatally exposed to nervous system drugs. A case–con-
trol study nested in the POMME cohort will assess the association
between neuropsychiatric disorders in the offspring and prenatal
exposure to psychotropic drugs.
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Background: Antibiotics alter the composition of intestinal microbiota,
even after discontinuation of use, influencing metabolic programming.
There are indications that intestinal microbiota may play a role in the
development of obesity. Some studies suggest that antibiotic use may
influence negatively weight gain in childhood. However, few studies
have examined this association during gestation and the first years of
life. Thus, the best knowledge can contribute to clarify this possible
association.
Objectives: To evaluate the association between antibiotic exposure
in pregnancy and infancy and overweight in the first childhood
through body mass index (BMI).
Methods: Longitudinal cohort study of children born in 2015 in
Pelotas (Brazil), whose mothers lived in the urban area of the city.
Data of this study are from the hospitalization to the delivery (peri-
natal study), and from the follow‐ups of three, 12 and 24 months of
the children. The use of antibiotics (ATC/DDD level 1 group J) was
self‐reported during pregnancy, at three, 12 and 24 months of the
children. Variables of cumulative exposure to antibiotics was con-
structed for each outcome period. The outcomes (at three, 12 and
24 months) were operationalized by the BMI in z‐score according
to WHO parameters (≤ −2dp to >2dp: low weight/eutrophic; ≥
2dp: overweight). The weight and height of the children were mea-
sured in all follow‐ups by standard interviewers.
Results: Our cohort comprised 4,014 children at the 24 months fol-
low‐up. 71.9% of mothers with skin color white, 47.1% with age
between 20 and 29 years old, 34.1% with 9 to 11 years of study,
about 20.0% with low income, and 44.5% were primiparous.
Tobacco use was observed in 16.5%. The prevalence of use of anti-
biotics by mothers during pregnancy was 43.4%. The prevalence of
use of antibiotics in children was 3.1%, 10.0%, 8.9% at 3 months,
12 months and 24 months, respectively. The prevalence ratio of
cumulative exposures to antibiotics at the 3 months was PR = 1.24
(95%CI 0.87; 1.77), at 12 months it was PR = 1.14 (95%CI 0.96;
1.34) and at 24 months PR = 1.04 (95%CI 0.83; 1.30). The use of
antibiotics at 3 months,12 months and 24 months, as well as during
pregnancy, were not statistically associated with an increase in BMI.
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Conclusions: Our findings suggest that the use of the antibiotics
increase the probability of higher BMI in the infancy, but these associ-
ations were not statistically significant.
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Background: Exposure to antiepileptic drugs (AED) such as valproate,
topiramate and carbamazepine has been associated with
increased risk of fetal malformations and is therefore contraindicated
during pregnancy. There is a current need for population‐based
data on trends in AED treatment during pregnancy in order to
facilitate contextualisation and decision making in this field.
Objectives: The objective of this study was to describe trends in the
use of AED during pregnancy in the Netherlands.
Methods: A cross‐sectional analysis was conducted using linked
pharmacy dispensing and pregnancy records from the Dutch Birth
Cohort (DUBC). Pharmacy dispensing records were obtained
from the PHARMO Database Network (PHARMO) ‐ a population‐
based network of electronic healthcare databases combining
data from different healthcare settings in the Netherlands. Preg-
nancy records were obtained from the Perinatal Registry of the
Netherlands (Perined) ‐ a nationwide registry containing maternal
and neonatal characteristics and data on perinatal care. Pregnancies
between 1999 and 2015 of women registered in Perined as well
as PHARMO were included in the study. Types of AED were
assessed per year among pregnant women dispensed at least one
AED (ATC N03A).
Results: The DUBC included 486,025 pregnancies of 355,448
women (mean ± SD age at delivery 31.0 ± 4.8 years) during which
2,038 women (mean ± SD age at delivery 31.6 ± 5.0 years) used
AED. In 1999, carbamezapine was the most commonly used AED
(42%), followed by valproate (27%) and in 2015 this was lamotrigine
(24%), followed by levetiracetam (19%). From 1999 to 2015,
decreasing trends in prevalence of exposure were observed for
carbamazepine (−28%) and valproate (−23%). Increasing trends
were observed for levetiracetam (+19%), lamotrigine (+17%),
pregabalin (+11%) and topiramate (+9%).
Conclusions: Although prevalence of exposure decreased over
time for most of the teratogenic AED, increasing trends were
observed for topiramate, as well as for new AED with ill‐defined
risks such as pregabalin. This highlights the need for an
expansion of medication‐risk knowledge and communication in the
Netherlands in terms of teratogenic effects of AED used during
pregnancy.
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Background: Many women with inflammatory bowel disease (IBD)
may require treatment with immunomodulatory agents during preg-
nancy to avoid disease activity, which in turn is associated with
adverse pregnancy outcomes. Population level data describing medi-
cation use in pregnant women with IBD are scarce.
Objectives: To study treatment patterns of systemic corticosteroids,
sulfasalazine/5‐ASA, thiopurines and anti‐TNF for IBD in pregnancy
in the US Medicaid program and in Sweden over time.
Methods: We identified a cohort of pregnant women who gave birth
in 2000–2013 who were enrolled in the US Medicaid and pregnant
women who gave birth in 2006–2015 in the national health registers
in Sweden with a diagnosis of either Crohn's disease or ulcerative
colitis, assessed in the 90‐day baseline period before pregnancy.
The proportion of women who filled prescriptions for drug classes
indicated for IBD during is presented by drug class and by calendar
year. We further assessed continuation patterns for each drug class
and presented the proportion of those on treatment at pre‐preg-
nancy baseline who were still on treatment in the third trimester.
Results: We identified 3,219 pregnant women with IBD from the
Medicaid cohort and 1,713 from the Swedish cohort. The proportion
with any treatment during pregnancy was 47.5% for Crohn's disease
and 49.3% for ulcerative colitis in Medicaid, and 60.9% for Crohn's
disease and 64.7% for ulcerative colitis in Sweden; proportions
which remained stable over time in both countries. In Medicaid,
26.7% were treated with systemic corticosteroids and 28.8% with
sulfasalazine/5‐ASA and the corresponding numbers were 20.0%
and 42.3% in Sweden. Thiopurines were more frequently used in
Sweden (22.6%), than in the Medicaid cohort (6.6%). Anti‐TNF treat-
ment increased over time from 3.6% in 2006 to 9.5% in 2013 in
Medicaid and from 2.7% to 9.8% in the same time period in Sweden.
Continuing anti‐TNF treatment throughout pregnancy was more
common in the Medicaid (43.0%) than in Sweden (22.6%).
Conclusions: In this large population‐based study from two coun-
tries, a higher proportion of women with IBD received treatment
during pregnancy in Sweden than in Medicaid, however, the pattern
of used drug classes differed. We further documented an increasing
trend in use of anti‐TNF in pregnant women with IBD over study
years in both countries, emphasizing the need for research on the
safety of these medications in pregnancy.
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777 | Switching patterns of antidiabetic
medications during pregnancy in women with
pre‐gestational diabetes in publicly or
privately insured US populations
Nicole Tsao1,2; Sonia Hernandez‐Diaz3; Brian Bateman1,2;
Seanna Vine1; Krista Huybrechts1,2
1Brigham and Women's Hospital, Boston, MA; 2Harvard Medical School,
Boston, MA; 3Harvard T. H. Chan School of Public Health, Boston, MA
Background: Pre‐gestational diabetes (pre‐GDM) affects around 1%
of pregnancies in the US, with pre‐existing type II diabetes being the
most common. The American Diabetes Association and American Col-
lege of Obstetrics and Gynecology have recommended insulin as the
preferred agent for management of diabetes in pregnancy due to a
lack of evidence on oral agents. However, it is unclear to which extent
treatment of pre‐GDM during pregnancy follows these guidelines.
Objectives: To characterize prescription patterns in women with pre‐
GDM treated with non‐insulin antidiabetic medications before the
start of pregnancy.
Methods: The source cohorts consisted of women aged 12 to 55 years
with pregnancies resulting in a delivery, and continuous eligibility in
their health insurance plan from 3 months prior to the date of their
last menstrual period (LMP) to 3 months after the date of delivery
(DoD) using nationwide Medicaid Analytical eXtract (MAX) data from
2001 to 2014, and OptumClinformatics data from 2004 to 2015.
Pre‐GDM was identified by 2 or more diabetes diagnostic codes
(250.xx, 648.0x) in out‐ or inpatient claims, and 1 or more prescrip-
tions for a non‐insulin antidiabetic medication during the 3 months
before LMP. Based on the prescription dispensing date, we describe
use of antidiabetic agents in 5 time windows (3 months before preg-
nancy, first, second, third trimester, and 3 months after DoD), and
medication switching patterns.
Results: The study cohorts consisted of 6933 pregnancies in MAX
and 942 in Optum treated with a non‐insulin antidiabetic medication
before pregnancy. The most common treatments before pregnancy
were metformin alone (53% in Optum; 35% in MAX), and metformin
in combination with other antidiabetics (35% in Optum; 47% in
MAX). The proportion of women that switched to insulin alone dur-
ing pregnancy was 42% in MAX and 27% in Optum by the second
trimester, and 47% and 35% respectively by the third trimester.
Switching to insulin has decreased in both cohorts over the study
period. During the first 3 months after delivery, the proportion on
insulin alone decreased to 15% in MAX and 10% in Optum, while
the proportion on metformin increased to 20% and 24%,
respectively.
Conclusions: Less than half of women using non‐insulin antidiabetic
medications before pregnancy had switched to insulin by the second
trimester. Switching to insulin was more common among publicly
compared to privately insured women but has decreased in both
groups over time. These findings highlight the need for additional
information on safety of oral medications during pregnancy.
778 | Use of sildenafil and other PDE‐5
inhibitors among pregnant women in
Scandinavia
Helle Kieler1; Anders Engeland2; Anne Broe3; Per Damkier3;
Kari Furu2; Pär Karlsson1
1Karolinska Institutet, Stockholm, Sweden; 2 Institute of Public Health,
Oslo, Norway; 3Odense University Hospital, Odense, Denmark
Background: Phosphodiesterase 5 inhibitors (PDE‐5‐I) may improve
the uteroplacental circulation and in 2014 a multinational random-
ized clinical trial was initiated to assess the effect of the PDE‐5‐I, sil-
denafil in growth restricted fetuses. The trial was halted prematurely
due to excess risk of neonatal lung problems and mortality.
Objectives: To describe women who filled prescriptions with PDE‐5‐I
before and during pregnancy and their singleton infants born in Den-
mark, Norway or Sweden 1995–2015.
Methods: From the Scandinavian national birth and drug registers,
we obtained information on maternal and infant characteristics
among women who had filled a prescription with any marketed
PDE‐5‐I product from 90 days before the last menstruation
period (LMP) until delivery. Small‐for‐Gestational‐Age (SGA) was
defined as a birthweight below two standard deviations from
the mean by gestational age and sex. Numbers and proportions are
presented. Due to restrictions for reporting small numbers from
the Danish national registers, numbers less than three are reported
as such.
Results: At least one prescription of a PDE‐5‐I drug was filled by 68
women and 52 had filled a prescription with sildenafil. Of the
68 women, 35 (51%) filled a prescription before LMP and
31 (46%) in the first trimester. Twelve women (18%) filled a pre-
scription only in the second or third trimester. The women were
generally of higher age and 31 (46%) were 35 years of age or older.
There were nine (13%) who reported smoking in early pregnancy
and four (6%) had a cardiovascular diagnosis. Twenty‐one (31%)
delivered by cesarean section and 48 (71%) had filled a prescription
with another drug during the exposure period of interest. Most
infants (52, 76%) were born 2006–2015, and 58 (85%) were born
at term. Five infants (7%) had an APGAR score below 8 and five
were born SGA. A total of 18 (26%) had been admitted to a neona-
tal intensive care unit (NICU) and seven (10%) had a respiratory or a
cardiovascular disease. There were less than three stillbirths, no neo-
natal deaths and less than three postneonatal deaths.
Conclusions: Prescriptions with PDE‐5‐I have been filled by Scandina-
vian women when pregnant. The prescribing indication is not known
and though only a handful had a cardiovascular diagnosis, the gener-
ally high age and the high rate of cesarean section and co‐medication
indicate a less healthy population. Some of the women may have filled
their prescriptions due to suspected intrauterine growth restriction as
the filling was only in the second or third trimester and the rate of
SGA was higher than expected.
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779 | Hypertensive disorders of pregnancy
and utilization of antihypertensive therapies
Elena Dudukina1; Uffe Heide‐Jørgensen1; Edith R. Bahmanyar2;
Henrik T. Sørensen1; Vera Ehrenstein1
1Aarhus University Hospital, Aarhus, Denmark; 2Ferring Pharmaceuticals
A/S, Copenhagen, Denmark
Background: Hypertensive disorders of pregnancy (HDP) affect 5–
10% of pregnancies and are associated with
mortality and morbidity in offspring and in mothers. Use of antihy-
pertensive therapies, including angiotensin‐converting enzyme inhib-
itors (ACEi) and angiotensin II receptor blockers (ARBs) is
contraindicated in pregnancy, and is therefore rare and not well
characterized.
Objectives: To describe utilization of antihypertensive therapies in
HDP, focusing on ACEi and ARBs overall and by pregnancy
trimester.
Methods: We conducted a nationwide cross‐sectional study using
routinely and prospectively collected data from the Danish Medical
Birth Registry, the Danish National Patient Registry, the Danish
National Prescription Registry, and the Danish Civil Registration
System. The study population consisted of all pregnancies ending
at ≥22 gestational weeks as a live or still birth in 1997–2016. We
reported prevalence of ACEi, ARBs and other HDP therapies utiliza-
tion as measured by dispensings during pregnancy. Whenever neces-
sary, reported frequencies were rounded (‘clouding’) to comply with
data protection regulations. Prevalences are reported based on
unrounded frequencies.
Results: Among the 1,218,633 included pregnancies, 73,960 (6.1%)
were complicated by a HDP. Of those, 19.3% (14,249/73,960) had
at least one dispensing of any antihypertensive therapy. Of women
with pregnancies complicated by a HDP, 1.0% had at least one
dispensing of ACEi or ARBs (735/73,960). The number of pregnan-
cies with dispensings of ACEi or ARBs was small and decreased with
trimester (N = 695 in first trimester vs. N = 50 in second trimester
vs. N = 25 in third trimester). The most frequently dispensed ACEi
and ARB were enalapril (255/73,960, 0.3%) and losartan (145/
73,960, 0.2%), respectively. Of pregnancies with a dispensing
of any antihypertensive therapy, the most prevalent condition
was chronic hypertension (7,745/14,250, 54.3%), followed by gesta-
tional hypertension (2,890/14,250, 20.3%), preeclampsia‐eclampsia
(1,890/14,250, 13.3%), and by preeclampsia superimposed
on chronic hypertension (1,720/14,250, 12.1%). ACEi or ARBs
were dispensed in pregnancies with chronic hypertension (720/
735, 98.0%), of whom (130/720, 17.7%) developed preeclampsia
superimposed on chronic hypertension, and in pregnancy with
gestational hypertension (15/735, 2.0%).
Conclusions: As expected, the utilization of ACEi or ARBs for ther-
apy of HDP was low, but not absent.
780 | Use of anti‐migraine medications
among commercially insured pregnant
women in the United States
Mollie Wood; Sonia Hernandez‐Diaz
Harvard TH Chan School of Public Health, Boston, MA
Background: Migraine headache is a debilitating pain condition
affecting 30% of reproductive‐age women, considered by the World
Health Organization to be one of the 20 most disabling conditions.
Management of migraine includes medications to prevent attacks
(beta blockers, tricyclic antidepressants (TCA), and anti‐seizure drugs)
and medications to treat symptoms (triptans, opioid and non‐opioid
analgesics). These medications have varying pregnancy safety
profiles.
Objectives: To study treatment patterns of medications used by preg-
nant women with migraine in a cohort of commercially‐insured US
women.
Methods:We used data from commercial insurers in the United States
gathered between 2011 and 2015. We identified pregnancies
resulting in a live or stillbirth, in which the insured women also
had klcomplete prescription drug coverage, and where there was at
least one diagnosis of migraine in the 90 days before last menstrual
period (LMP). We calculated proportions of women with at least one
prescription fill for medications of interest, for the 90 days prior to
LMP and each pregnancy trimester.
Results: We included 30,793 women with a diagnosis of migraine in
the 90‐day baseline period. Opioids were the most widely used
medications in women with migraine, with 20% filling at least one
prescription before pregnancy, and slight reductions during preg-
nancy (17, 16, and 15% in 1st, 2nd, and 3rd trimesters). 16% of the
sample used triptans prior to pregnancy, 8% in the 1st trimester
and 3% and 2% in the 2nd and 3rd trimesters, respectively. Non‐ste-
roidal anti‐inflammatory drugs were used by 11% before LMP, 4% in
1st trimester, 1% in 2nd trimester, and 2% in 3rd trimester. 20% of
the sample filled prescriptions for one class of preventive therapy,
6% filled for 2 classes, and < 1% filled for 3 classes. Antidepressants
were the most commonly‐used preventive medication, with 17% fill-
ing a prescription before pregnancy (10% SSRI and 4% TCA), 12% in
the 1st trimester (8% SSRI and 2% TCA), 7% in the 2nd (5% SSRI
and 1% TCA), and 7% in the 3rd (6% SSRI and 1% TCA). Antiepilep-
tic drugs were used by 9% pre‐pregnancy, 5% in the 1st trimester,
2% in the 2nd, and 2% in the 3rd; topiramate was most common,
with 6% using before pregnancy, 3% in the 1st trimester, and < 1%
in later trimesters. Antihypertensives were used by 7% of the sample
before pregnancy, 6% in the 1st trimester, 6% in the 2nd and 9% in
the 3rd; beta blockers were the most common with 5% filling a pre-
scription in each period.
Conclusions: In this population‐based study of pregnant women with
migraine, we noted highly prevalent use of multiple medications,
some of which had uncertain pregnancy safety profiles.
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781 | The association between annual
hospital delivery volume and discharge opioid
prescriptions after vaginal deliveries
Jea Young Min; Sarah Osmundson; Ed Mitchel Jr; Andrew Wiese;
Marie R. Griffin; Robert E. Hawley; Stephen Patrick; Carlos G. Grijalva
Vanderbilt University Medical Center, Nashville, TN
Background: Opioid use after vaginal delivery is highly variable,
although reasons for this variability are not well understood.
Delivery hospital characteristics, especially delivery volume, may
be associated with differences in discharge opioid prescribing.
Objectives: To examine whether annual hospital delivery volume is
associated with filling a discharge opioid prescription after vaginal
delivery.
Methods:We conducted a cross‐sectional study of women aged 15–
44 years enrolled in Tennessee Medicaid (TennCare) with a
vaginal delivery at a Tennessee hospital with ≥50 annual births (62
hospitals) from 2007–2015. Patients were continuously enrolled
in TennCare and had no evidence of opioid use disorder
in the 180‐day period prior to delivery. Hospital data were
obtained from the American Hospital Association Annual Survey
and Tennessee Hospital Joint Annual Reports. Delivery volume was
defined as the total number of births reported by the hospital in
the year of delivery and was categorized into quartile groups (1–4):
<400, 400–799, 800–1599, ≥1600. Deliveries and opioid prescrip-
tions were identified using TennCare claims data supplemented
with State hospital discharge and birth certificate information.
We used multilevel multivariable logistic regression to assess
whether delivery volume was associated with filling an opioid
prescription within 5 days of hospital discharge, controlling for
relevant risk factors and delivery year, and random effect of
hospital.
Results: Of 145,094 women with vaginal deliveries who met
study inclusion criteria, 49% filled an opioid prescription within
5 days of hospital discharge. The median (interquartile range) annual
proportion (%) of women who filled an opioid was 58 (32–72), 59
(24–78), 65 (47–75), 62 (35–72) for hospitals in quartiles 1–4,
respectively. Compared to patients who delivered at a hospital
with a delivery volume < 400, those who delivered at a hospital with
a delivery volume of 400–799 had lower odds of filling a
discharge opioid prescription (adjusted odds ratio [OR] 0.76, 95%
confidence interval 0.67–0.86). The odds of filling a discharge
opioid prescription was similar in hospitals with higher delivery
volumes (800–1599 and > =1600) compared to <400 (adjusted
OR 1.12 [0.98–1.27] and 0.92 [0.80–1.07], respectively).
Conclusions: Preliminary findings show that delivery at
hospitals with low‐intermediate delivery volume (2nd quartile)
was associated with the lowest odds of filling an opioid
prescription after vaginal delivery. We found no evidence that
high delivery volumes were associated with lower opioid use.
782 | Phosphodiesterase‐5 (PDE5) inhibitor
use among pregnant women and women of
child‐bearing age in the sentinel distributed
data network
Wei Liu1; Mayura Shinde2; Corinne Woods3; Nicole Haug2; JIe Li3;
Justin A. Mathew3; Christine P. Nguyen3; Grace P. Chai3;
David Moeny3; Talia Menzin2
1Division of Epidemiology, Office of Surveillance and Epidemiology, CDER,
FDA, Silver Spring, MD; 2Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Boston, MA;
3US Food and Drug Administration, Silver Spring, MD
Background: In July 2018, a Dutch clinical trial was terminated prema-
turely because of an unexpectedly high neonatal death rate associated
with use of sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, in
pregnancies complicated with early severe fetal growth restriction
(FGR). The prevalence of PDE5 inhibitor use in pregnant and repro-
ductive‐aged women in the US is unknown.
Objectives: To assess the prevalence and potential indications of
PDE5 inhibitor use among pregnant and reproductive‐aged women
in the US.
Methods: We examined PDE5 inhibitor use during pregnancy in the
Sentinel Distributed Database (SDD), a distributed administrative
claims database of mostly commercially‐insured patients. We identi-
fied women aged 15–50 years with a live‐birth between January
2001 and March 2018. We examined PDE5 inhibitor outpatient dis-
pensing data recorded within 90 days preconception through the
end of pregnancy, and identified potential indications, labeled and
off‐label, using pre‐defined ICD‐9/10 diagnosis codes. Separately,
we used IQVIA's Total Patient Tracker™ (TPT, a nationally‐estimated
dataset derived from retail pharmacy dispensed prescriptions) data
to estimate the number of female patients aged 15–50 with a dis-
pensed prescription for PDE5 inhibitors from outpatient retail pharma-
cies during 2013–2017.
Results: In SDD we identified over 3.3 million pregnancies during
2001–2018, 96 of which had PDE5 inhibitor use any time during preg-
nancy, yielding an overall prevalence of 2.85 per 100,000 live‐born
pregnancies (95% CI: 2.31–3.48). Sildenafil was the most commonly‐
used PDE5 inhibitor in pregnancy (89%). The prevalence of any
PDE5 inhibitor use was 2.61, 0.62, and 0.62 per 100,000 live‐born
pregnancies during the 1st, 2nd, and 3rd trimesters, respectively.
Among women exposed to a PDE5 inhibitor from 90 days preconcep-
tion to the end of the pregnancy, 25.0%, 31.1%, and 15.5% had a diag-
nosis code for FGR, preeclampsia, and pulmonary arterial
hypertension, respectively. The TPT analysis revealed that an esti-
mated 3.7 million US patients received prescriptions for PDE5 inhibi-
tors in 2017, of whom approximately 15,000 (0.4%) were female
patients aged 15–50 years.
Conclusions: Despite the limitations of data source (e.g., cannot assess
PDE5 inhibitor use in non‐live birth pregnancies in SDD; pregnancy
status and indication for use unavailable in TPT), we found a low
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prevalence of PDE5 inhibitor use in pregnant and reproductive‐aged
women. These drug utilization data help to inform the public health
impact of PDE5 inhibitor exposure in pregnancy in the U.S.
783 | Exposure to Fosfomycin trometamol
during pregnancy: A descriptive study using
the EFEMERIS database
Mélanie Araujo; Justine Bénévent; Diane Sicard;
Caroline Hurault‐Delarue; Jean Louis Montastruc; Isabelle Lacroix;
Christine Damase‐Michel
Laboratoire de Pharmacologie, Médicale et Clinique, UMR INSERM 1027,
CIC INSERM 1436, Faculté de Médecine de l'Université Paul‐Sabatier et
Centre Hospitalier Universitaire, Toulouse, France
Background: Fosfomycin trometamol has been recommended as first‐
line bactericidal antibiotic for urinary tract infections in pregnant
women since 2015 in France. However, too few studies have assessed
the risk of fosfomycin on pregnancy outcomes.
Objectives: The aim of this study was to compare pregnancy out-
comes between women exposed to fosfomycin during pregnancy
and the general population.
Methods: We performed a comparative study in EFEMERIS, the
French database including expecting mothers declaring their preg-
nancy to the French Health Insurance System of Haute‐Garonne
from July 1st, 2004 to December 31th, 2017. EFEMERIS contains
prescribed and dispensed reimbursed drugs during pregnancy and
pregnancy outcomes. Women receiving at least one prescription
and dispensation of fosfomycin during pregnancy were selected.
Results: A total of 5,887 women (4.3%) were included. Among them,
44.3% received at least one prescription of fosfomycin during the
first trimester, 38.9% during the second and 25.8% during the third
trimester. The mean maternal age was 30.6 ± 5.2 years (EFEMERIS:
30.6 ± 5.1 years; p = 0.99). A significantly higher percentage of
women suffering from a declared long‐term adverse health condition
(3.2% versus 2.6%; p = 0.003), number of ultrasound scans during
pregnancy (4.0 ± 1.8 versus 3.8 ± 1.8; p < 0.0001), number of mater-
nal pathologies during pregnancy (9.6% versus 8.6%; p = 0.01) and
number of drugs prescribed during pregnancy (excluding fosfomycin)
(11.7 ± 7.4 versus 9.1 ± 6.6; p = 0.0001) were observed in the
fosfomycin group compared to general population. The average
duration of pregnancy (36.2 ± 5.6 versus 36.4 ± 5.2; p = 0.004)
and the parity (1.7 ± 1.0 versus 1.7 ± 0.9; p = 0.004) were slightly
lower than in the general population. Pregnancy loss concerned
6.5% of the outcomes (n = 387) (EFEMERIS: 5.8%; p < 0.0001).
Among live births (n = 5,579 (93.5%)), preterm birth, newborn
weight, size, head circumference, neonatal pathology and psychomo-
tor development were similar between the two groups. The rate of
congenital anomalies (according to EUROCAT classification) was
comparable between pregnancies exposed to fosfomycin and the
EFEMERIS population (2.2% versus 2.4%; p = 0.39).
Conclusions: This study showed reassuring results about pregnancy
outcomes after prenatal exposure to fosfomycin. In order to minimize
confounding by unmeasured family‐level risk factors, further analysis
using a sibling approach will be carried out.
784 | Prescription patterns before, during
and after pregnancy among Dutch women: A
drug utilization study
Olivia N.C. Gussinklote; Alexis M.A. Blaauwhof; Jens H.J. Bos;
Catharina Schuiling‐Veninga
PharmacoTherapy, Epidemiology & Economics, University of Groningen,
Netherlands
Background: As knowledge about safety of drug use during preg-
nancy is still limited, monitoring of prescription patterns is important.
Objectives: Analyze prescribing patterns in Dutch women from 2 years
before until 3 months after pregnancy between 2004 and 2014.
Methods: A descriptive drug utilization study was performed by
using a large mother‐infant subset extracted from the IADB.nl data-
base. All mothers who were present in the database from 2 years
before the theoretical conception date (= 273 days before birth date
child) till 3 months after giving birth were selected. Only first known
pregnancies and singleton pregnancies were included in the analysis.
Drugs were classified into three categories: (1) drugs for chronic
conditions, (2) drugs for occasional and short‐time use, (3) drugs
for pregnancy‐related symptoms. The prescription rate was calcu-
lated as the number of women per 100 women who received one
or more prescriptions for a given drug within a specified time period.
Results: About 64,4% of the women received at least one prescrip-
tion (excluding contraceptives) during pregnancy. Although the pre-
scription rate for most drugs for chronic diseases decreased during
pregnancy, a sharp increase is noticed in the use of antihyperten-
sives (1,5%) and glucose lowering medication (1,33%) in the third tri-
mester. Antibacterials, especially penicillins, are the most prescribed
drugs for occasional and short term use (first trimester: 7,0%, third
trimester: 9,1%). Most prescribed drugs for pregnancy related symp-
toms were antiemetics (8,6%) during the first trimester and iron
preparations (10,1%) during the third trimester.
Conclusions: Although the use of drugs during pregnancy seems to
decrease compared to data describing drug utilization between
1994–2003, still almost two‐third of all pregnant women use one
or more drugs. Close monitoring of the safety for both the mother
and unborn child is still warranted.
785 | Spontaneous reporting systems as
proxy for drug utilization in pregnancy: The
example of insulin maternal exposure
Ayad K. Ali; Sirel Gurbuz
Eli Lilly and Company, Indianapolis, IN
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Background: There are challenges in characterizing insulin treatment
during pregnancy, and using adverse event reporting systems as a
proxy to characterize maternal exposure has not been employed
before.
Objectives: To describe the distribution of pregnancy exposure
reports submitted for insulin therapies in the US.
Methods: The FDA Adverse Event Reporting System (FAERS) was
used to identify maternal exposure reports spontaneously submitted
between Q2/2000 and Q2/2017 for insulin products that have
pregnancy exposure events. Insulin products identified by generic
names, and MedDRA preferred terms (PT) corresponding to fetal
and maternal exposures were used to create a maternal exposure
(ME) custom term. Reporting Rates (EBGM) and 95%CI were
used to assess insulin‐related ME during pregnancy, and compared
to those in other anti‐diabetes medications (ADM). Rates with
95%CI lower limit ≥2.0 are considered significant insulin‐ME
associations.
Results: During the analysis period, a total of 3,912 and 1,253 ME
reports were submitted for all insulins and other ADM, respectively.
Compared to other ADM, insulins showed significant reporting rates
of ME (EBGM = 0.38; 95%CI = 0.37–0.40 and EBGM = 2.23;
95%CI = 2.14–2.32, respectively). Number of ME reports and
reporting rates for individual insulin products were: aspart
(n = 522; EBGM = 5.06; 95%CI = 4.72–5.42), NPH (n = 29;
EBGM = 4.55; 95%CI = 3.32–6.11), detemir (n = 360; EBGM = 4.54;
95%CI = 4.16–4.95), human (n = 128; EBGM = 3.57; 95%CI = 3.08–
4.12), glulisine (n = 80; EBGM = 2.38; 95%CI = 1.97–2.84), degludec
(n = 37; 2.25; 95%CI = 1.71–2.93), lispro (n = 1153; EBGM = 2.05;
95%CI = 1.95–2.15), and glargine (n = 562; EBGM = 1.40;
95%CI = 1.30–1.50). Numbers and reporting rates of specific PT
for insulins were: ME timing unspecified (n = 21; EBGM = 1.91),
ME during pregnancy (n = 1769; EBGM = 2.60), ME before preg-
nancy (n = 30; EBGM = 1.23), maternal drugs affecting fetus
(n = 371; EBGM = 1.30), fetal exposure during pregnancy
(n = 835; EBGM = 2.07), and fetal exposure during breast feeding
(n = 217; EBGM = 2.72). Corresponding PT‐specific EBGM for other
ADM were: 0.23; 0.46; 0.17; 0.45; 0.30; and 0.14.
Conclusions: Reporting of ME for insulin therapy appears to reflect
the guidelines of diabetes management during pregnancy. These
events do not reflect safety outcomes, rather a proxy for insulin
treatment during pregnancy. Signal detection of congenital anomalies
or fetal exposures in diabetes therapies using FAERS should be
interpreted with caution due to confounding by indication.
786 | The French pregnancy cohort:
Prevalence and trend of medication use
during pregnancy in the French population
A. Berard1,2,3,4,5; F. Abbas‐Chorfa6; B. Kassai3,4,5; T. Vial3,4,7;
K.A. Nguyen3,4,5; O. Sheehy1; A.M. Schott8,9
1Research Center, CHU Sainte‐Justine, Montreal, QC, Canada; 2Faculty
of Pharmacy, University of Montreal, Montreal, QC, Canada; 3EPICIME‐
CIC 1407 Lyon, Inserm, Pharmacotoxicology Department, CHU‐Lyon,
Bron, France; 4University of Lyon 1, Lyon, France; 5 Laboratoire de
Biométrie et Biologie Evolutive, University of Lyon 1; CNRS, UMR, 5558
Villeurbanne, France; 6Hospices Civils de Lyon, Service de biostatistique‐
bioinformatique, Pôle Santé Publique, Lyon, France; 7Service Hospitalo‐
Universitaire de Pharmacotoxicologie, CHU‐Lyon, Lyon, France;
8Hospices Civils de Lyon, Pôle de Santé Publique, Lyon, France; 9HeSPeR,
Université Lyon Claude Bernard Lyon 1, EA 7425 Lyon, France
Background: The French Pregnancy Cohort (FPC) is a representative
cohort of pregnant women.
Objectives: We evaluated the potential usefulness and the validity of
FPC as a research tool in perinatal pharmacoepidemiology.
Methods: The FPC was built with the sampling of all pregnant
women included in the French Echantillon généraliste des
bénéficiaires (EGB), which is a 1/97th representative sample of the
population covered by the French health insurance. The EGB
includes anonymous information on the socio‐demographic and
medical characteristics of beneficiaries, and the health care services
they have received such as diagnoses and procedure codes, as well
as data on reimbursed filled medication; EGB also includes data on
hospital stays in all public and private French health facilities. Each
prescription record contains information on drug brand and generic
names, date of prescription and date of dispensing, quantity dis-
pensed, mode of administration, duration of prescription, dosage,
and prescribing physician specialty. The FPC includes data on all
pregnancies of women sampled in the EGB between 2010 and
2013 with long‐term follow‐up. Date of entry in FPC is the first
day of pregnancy regardless of pregnancy outcome (spontaneous
and planned abortion, livebirth, and stillbirth), and data on women
are collected retrospectively one year before pregnancy, and pro-
spectively during pregnancy, and after delivery. Prevalences of pre-
scribed medications before, during and after pregnancy were
compared; comparison was also done between trimesters.
Results: The FPC includes data on 36,065 pregnancies. Among them,
27,253 (75.6%) resulted in a delivery including 201 stillbirths (0.7%).
The total number of spontaneous abortions was 6,718 (18.6%), and
planned abortions was 2,094 (5.8%). The prevalence of prescribed
medication use was 91.1%, 89.9%, and 95.6% before, during and
after pregnancy, respectively. Although there was a statistically sig-
nificant decrease in the proportion of use once the pregnancy was
diagnosed (first trimester exposure, 76.4% vs. exposure in the year
prior to pregnancy 87.2% (p < .01)), post‐pregnancy medication use
was above the pre‐pregnancy level (95.6%). Maternal depression
was the most prevalent comorbidity during pregnancy (20%), and
post‐partum depression was higher in those who delivered a still-
born infant (38.8%) as well as in those with a spontaneous (19.5%)
or planned abortion (22.4%) compared to those with a liveborn
(12.0%).
Conclusions: The FPC has the advantage of including a representative
sample of French pregnant women, and study medications only avail-
able in France.
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787 | A systematic review on prescribing
patterns of Antidepresssants before, during,
and after pregnancy
Jet W.T. Scheffers1,2; Holly Dorning2; Irene Petersen2,3
1Utrecht University, Utrecht, Netherlands; 2University College London,
London, UK; 3Aarhus University, Aarhus, Denmark
Background: Although depression is common in pregnancy, many
women discontinue antidepressant (AD) treatment before or during
pregnancy due to a possible increased risk of adverse neonatal out-
comes. Limited information is available on how many of these
women restart AD therapy after pregnancy.
Objectives: To assess: (1) the prevalence of AD use in women before,
during, and after pregnancy, (2) associations between AD use in
women before, during, and after pregnancy, (3) the choice of AD pre-
scribed during pregnancy, and (4) time trends in gestational AD use.
Methods: We conducted a systematic review and narrative synthe-
sis. PubMed/Ovid MEDLINE and EMBASE databases were searched
from conception to September 2018 by using multiple keywords
relating to pregnancy and antidepressant drugs. Observational stud-
ies on AD drug use in pregnant women were included in the review.
A modified version of a Joanna Briggs Institute critical appraisal tool
was used to assess study quality.
Results: A total of 21 cohort studies from Europe, the US, and Can-
ada were included in the review: three studies examined only selec-
tive serotonin reuptake inhibitors (SSRIs), the rest considered various
types of ADs. Prevalence of AD use decreased in the months before
and during pregnancy and rose after delivery, and most women who
were using ADs before conception stopped using before or during
their first trimester. SSRIs were the most common class of ADs pre-
scribed during pregnancy. In the Netherlands, Canada, Italy, and
France, paroxetine was one of the most popular SSRIs for gesta-
tional use, while it declined in popularity during the early 2000s in
the US, the UK, and Nordic countries. From the mid‐1990s to the
mid‐2000s, the use of ADs during pregnancy increased. It has
remained relatively stable since then.
Conclusions: While many women stop the use of ADs when they
get pregnant, the prevalence of AD use during pregnancy has
increased since the 1990s to the mid‐2000s. Numerous studies
report on the prevalence of AD use before, during, and after preg-
nancy, but further research is needed to explore the associations
between AD treatment before conception and after delivery.
788 | Maternal early pregnancy
antidepressant use by medication class and
birth defect risk
Kayla N. Anderson1; Jennifer N. Lind2,3; Regina Simeone1;
William V. Bobo4; Tiffany Riehle‐Colarusso1; Kara N. Polen1;
Jennita Reefhuis1
1National Center on Birth Defects and Developmental Disabilities,
Centers for Disease Control and Prevention, Atlanta, GA; 2National
Center on Emerging Zoonotic and Infectious Diseases, Centers for Disease
Control and Prevention, Atlanta, GA; 3United States Public Health Service
Commissioned Corps, Atlanta, GA; 4Mayo Clinic, Jacksonville, FL
Background: Depression and anxiety, common conditions for women
during pregnancy, are often treated with antidepressants. Safety data
during pregnancy for each antidepressant class have yielded mixed
results.
Objectives: To examine associations between any maternal early preg-
nancy (1 month before through the third pregnancy month) antidepres-
sant use by medication class and specific birth defects.
Methods: We analyzed data from the NBDPS (1997–2011), a U.S. pop-
ulation‐based multicenter case–control study; cases were identified
from surveillance systems and controls were liveborn infants without
major defects. We used multivariable logistic regression to calculate
adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for asso-
ciations between maternal early pregnancy use of each antidepressant
class (selective serotonin reuptake inhibitors (SSRIs), serotonin‐norepi-
nephrine reuptake inhibitors (SNRIs), tricyclic (TCAs), other antidepres-
sants, multiple classes) and birth defects with ≥4 exposed cases,
controlling for maternal education, race, smoking, and pre‐pregnancy
body mass index. Comparisons were made to women who were unex-
posed to any antidepressant three months before or during pregnancy,
and, to control for treated indication, womenwhowere only exposed to
an antidepressant outside of early pregnancy.
Results: SSRIs were associated with an increased risk for 12/58 defects
(highest aORs: partial anomalous pulmonary venous return (aOR: 6.1,
95% CI: 3.2–11.7), cerebellar hypoplasia (aOR: 2.9, 95% CI: 1.1–7.4)).
SNRI use was associated with an increased risk for 15/22 defects
(highest aORs: anencephaly (aOR: 4.4, 95% CI: 1.7–11.6), gastroschisis
(aOR: 4.5, 95% CI: 1.9–10.5)). TCA use was not significantly associated
with an increased risk for the six defects examined; other antidepres-
sant medication use had an increased risk for 4/27 defects (highest
aOR: glaucoma/anterior chamber defects (aOR: 5.7, 95% CI: 2.0–
16.2)). Multiple class use in early pregnancy was associated with 8/23
defects, with the highest aOR for omphalocele (aOR: 4.7, 95% CI: 1.8–
12.1). Controlling for treated indication resulted in attenuated associa-
tions for most classes, with the exception of SNRI use, which retained
a significant association with more than half of the examined defects.
Conclusions: Each antidepressant class was associated with some birth
defect risk, which was attenuated when accounting for treated indica-
tion, except for SNRIs. Results support the need for evidence‐based
guidance for healthcare providers to select the safest options to treat
mental health conditions before and during pregnancy.
789 | Prevalence and trends in depression
and anxiety, antidepressant use and key
maternal conditions during pregnancy, 1998–
2015
Maëlle Dandjinou1,2; Odile Sheehy2; Simone Vigod3,4; Anick Bérard1,2
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1University of Montreal, Montreal, QC, Canada; 2Ste Justine Research
Center, Montreal, QC, Canada; 3Women's College Hospital and Women's
College Research Institute, Toronto, ON, Canada; 4University of Toronto,
Toronto, ON, Canada
Background: Depression, anxiety and use of antidepressants are
known to be common among women of reproductive age. However,
the prevalence of both during pregnancy and their potential associa-
tion with maternal obesity, and pregnancy related conditions (induced
hypertension and gestational diabetes) are unknown. Since these
adverse pregnancy outcomes could lead to substantial maternal and
child morbidity, an updated prevalence of these concomitant condi-
tions are needed.
Objectives: To estimate the prevalence and time trends of 1) maternal
depression and anxiety, 2) antidepressant use (overall and class‐spe-
cific), and 3) key maternal comorbidities including obesity, preg-
nancy‐induced hypertension, and gestational diabetes.
Methods: Using data from the Quebec Pregnancy Cohort, we defined
a cohort of pregnant women who delivered between 1998–2015.
Annual prevalence of antidepressant use identified in pharmacy
records, and annual prevalence of maternal comorbidities identified
using ICD‐9 and ICD‐10 codes were calculated. Time trend analyses
of prevalences, over the 17‐year span, were performed using
Cochran‐Armitage test.
Results: We included 249,234 deliveries with a mean gestational age
of 38.7 weeks (standard‐deviation (SD) 2.0). The prevalence of
depression and anxiety during pregnancy slightly increased from
5.2% in 1998 to 6.9% in 2015, corresponding to a 1.3‐fold increase
(Cochran‐Armitage Trend test: p < 0.01). From 1998 to 2015, antide-
pressant use in pregnant women with deliveries increased 3‐fold
from 2.2% to 6.2% (Cochran‐Armitage Trend test: p < 0.01), driven
by an increase in selective serotonin reuptake inhibitors (SSRI), and
serotonin‐norepinephrine reuptake inhibitors (SNRI) use. Between
1998–2015, we observed a 6.5‐ fold increase in maternal obesity;
2‐fold increase in gestational diabetes; and 1.3‐fold increase in preg-
nancy‐induced hypertension (Cochran‐Armitage Trend test: p < 0.01).
Conclusions: Our study found an overall and large increasing trend in
gestational antidepressant use, mainly due to the increase of SSRI and
SNRI use, despite a small increase in maternal depression and anxiety
prevalence. Concomitantly, increases have been observed for mater-
nal obesity, gestational diabetes, and pregnancy induced hypertension,
which could be partly related to antidepressant use or maternal
depression and anxiety. These results suggest that antidepressants
are used beyond known indications during pregnancy.
790 | Asthma medication use during
pregnancy: Does timing of asthma diagnosis
matter?
Simone Issa
University of Montreal, Montreal, QC, Canada
Background: Use of asthma medications during pregnancy is recom-
mended by international guidelines to achieve disease control. Newly
diagnosed asthma during pregnancy may put the fetus at a higher risk
of perinatal outcomes due to more severe asthma caused by hormonal
fluctuations or delay in the initiation of controller therapy during
pregnancy.
Objectives: To explore whether asthma medication use during preg-
nancy differs in women newly diagnosed with asthma during the
first 19 weeks of pregnancy compared to those newly diagnosed
with asthma in the 2 years prior to pregnancy.
Methods: We conducted a retrospective cohort study using the
Quebec asthma and pregnancy database, formed by the linkage of
Quebec healthcare administrative databases between January 1,
1998 and March 31, 2010. Pregnant women were included if they
were aged 15–45 years with new‐onset asthma at any point in time
2 years prior to pregnancy or in the first 19 weeks of pregnancy.
We compared the proportions of asthma medications use during
pregnancy between women newly diagnosed with asthma prior to
pregnancy and those diagnosed during the first 19 weeks of preg-
nancy. Use of asthma medications during pregnancy was defined
as filling at least 1 prescription from 20 weeks post‐pregnancy until
delivery or filling a prescription with a duration that covers week 20.
Results: The final cohort included 2007 pregnancies with 1749
women newly diagnosed with asthma 2 years prior to pregnancy
and 258 women newly diagnosed with asthma during the first
19 weeks of pregnancy. Mean age of enrolled women was 25 years.
Inhaled corticosteroids (ICS) use during pregnancy was slightly higher
among women with pregnancy‐onset asthma (10.9%; 95% CI: 7.1–
14.8) compared to those with new‐onset asthma prior to pregnancy
(9.1%; 95% CI: 7.8–10.5), but this difference was not statistically sig-
nificant. Proportions of use of short‐acting ß2‐agonists (15.0%; 95%
CI: 13.3–16.7 vs 13.3%; 95% CI: 9.1–17.4), ICS and long‐acting ß2‐
agonists fixed combination (0.9%; 95% CI: 0.4–1.3 vs 0.8%; 95% CI:
0.0–1.8), nasal corticosteroids (4.2%; 95% CI: 3.2–5.1 vs 2.7%; 95%
CI: 0.7–4.7) and oral corticosteroids (1.2%; 95% CI: 0.7–1.7 vs 0.8%;
95% CI: 0.0–1.9) during pregnancy did not significantly differ
between women newly diagnosed with asthma prior to pregnancy
and those diagnosed during the first 19 weeks of pregnancy.
Conclusions: Regression analyses will be done to adjust for potential
confounding variables and confirm or infirm the absence of signifi-
cant differences in the use of asthma medications during pregnancy
between women diagnosed with asthma prior to pregnancy and
those diagnosed during pregnancy.
791 | Antihypertensive drug use among
pregnancies in South Korea, 2003–2013
Yunha Noh; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, SungKyunKwan
University, Suwon, Korea, Republic of
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Background: Hypertensive disease is among the most common medi-
cal conditions of pregnancies, occurring in approximately 12–22%;
however, there is limited safety data to inform use of antihypertensive
drugs (AD) in pregnancies.
Objectives: To describe patterns of AD use before and during preg-
nancy and assess the AD use by maternal characteristics.
Methods: We used the Korean national claims database to identify
pregnancies with live births aged 15–44 years between 2003 and
2013. Pregnancy onset was estimated by subtracting 39 weeks from
the delivery date and all forms of AD examined by pregnancy stage
(pre‐conception [PC: 90 days before pregnancy onset], first trimester
[1 T], second trimester [2 T] and third trimester [3 T]), where the
time‐period of seven days before delivery was excluded. Labetalol,
hydralazine and nifedipine were considered as ‘recommended drugs’
and angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin
receptor blockers (ARB) as ‘contraindicated drugs’; all other AD except
thiazide diuretics were considered as ‘non‐recommended drugs.’ The
prevalence of AD use was calculated as the proportion of pregnancies
to women who received at least one AD. We also conducted multivar-
iable logistic regression to evaluate predictors of the AD use, such as
maternal age, urbanity, income, medical aid, history of obesity and dia-
betes, nulliparity and multiple gestation. Statistical significance was
determined by 95% confidence interval of adjusted odds ratio.
Results: Among total 88,248 pregnancies, 788 (0.89%) had exposure
to any AD during pregnancy. The AD use declined from 0.61% in PC
to 0.36% in 1 T and 0.25% in 2 T, but it was most common in 3 T
(0.64%). Nifedipine (0.27%), hydralazine (0.18%) and amlodipine
(0.16%) were most commonly used during pregnancy, while that of
in PC was propranolol (0.19%), hydrochlorothiazide (0.17%) and
amlodipine (0.07%). The use of recommended drugs increased with tri-
mesters (0.09%, 0.16% and 0.46% in 1 T, 2 T and 3 T, respectively)
compared with non‐recommended drugs (0.29%, 0.12% and 0.32%).
Despite the large decrease in the use of contraindicated drugs from
0.10% in PC to 0.01% in 3 T, 49 (0.06%) and 13 (0.01%) pregnancies
received ACEI and ARB, respectively, during pregnancy. The AD use
during pregnancy was significantly more prevalent in women 35–
44 years of age, those living in rural areas, with lower income, medical
aid, multiple gestation and history of obesity and diabetes.
Conclusions: The prevalence of AD use in Korea (0.89%) was lower
than that in the US (3.1%) and Italy (1.2%). AD use was dominated
by recommended drugs in 2 T and 3 T, although non‐recommended
drugs were more prevalent in PC and 1 T.
792 | Knowledge of the new Food and Drug
Administration pregnancy and lactation
labeling rule (PLLR) among physicians and
pharmacists
Ghada Alem1; Mary K. Maneno1; Monika Daftary1;
La'Marcus Wingate1; Earl Ettienne1; Adaobi Anyiwo2
1Howard University, Washington, DC; 2GlaxoSmithKline, Washington,
DC
Background: In December 2014, the U.S. Food and Drug Administra-
tion (FDA) issued a final Pregnancy and Lactation and Labeling Rule.
This new system eliminated the letter system (A, B, C, D and X) desig-
nations, and introduced several new sections to provide more compre-
hensive information on medication safety in pregnancy and lactation.
Assessment of the knowledge and level of awareness of the new Food
and Drug Administration (FDA) Pregnancy and Lactation Labeling Rule
(PLLR) among providers is important.
Objectives: To assess knowledge of the FDA PLLR among pharmacists
and physicians.
Methods: A cross‐sectional study was conducted among pharmacists
and physicians who were affiliated directly or engaged externally as
clinical preceptors, alumni or program participants with the Howard
University Health Sciences Enterprise and Howard University Hospi-
tal. The main outcome for this study was knowledge of the FDA PLLR.
Descriptive statistics of all study variables were estimated. Linear
regression analyses were conducted to assess predictive factors of
knowledge of the FDA PLLR. SPSS version 25 was utilized, and all
analyses were conducted at an alpha value of 0.05.
Results: A total of 167 participants were recruited in the study in
2018. Majority of them were pharmacists (78.4%) and provided direct
patient care to women who are pregnant or of reproductive age. The
mean age of the participants was 38.6 years and the mean number of
years in practice was 9.0 years. Findings on knowledge of the PLLR
showed that 40% of respondents were unsure about the new
“Females and Males of Reproductive Potential” and “Pregnancy” sub-
sections within the PLLR. Additionally, almost half were unsure about
the PLLR's effect on over‐the‐counter medications (47.3%). Findings
from multivariable linear regression analysis showed that gender
(P < 0.01) and knowledge score of the older pregnancy letter category
system (P < 0.05) were significant predictors of PLLR knowledge,
adjusting for the other factors. Type of provider was only a significant
predictor in the unadjusted analysis. Nearly all of the participants
(94.2%) acknowledged their need to learn more about the new PLLR.
Conclusions: Efforts are needed to increase pharmacists' and physi-
cians' knowledge of the new PLLR.
793 | Direct‐acting Oral anticoagulants
(DOACs) in pregnancy: New insight from
VigiBase®
Maurizio Sessa1; Annamaria Mascolo2; Torbjörn Callréus1;
Annalisa Capuano2; Francesco Rossi2; Morten Andersen1
1University of Copenhagen, Copenhagen, Denmark; 2University of
Campania "L. Vanvitelli", Naples, Italy
Background: To date, the largest case series that investigated preg-
nancy outcome data with Direct‐Acting Oral Anticoagulants (DOACs)
suggests that “there is no indication that DOACs exposure in pregnancy
carries a high risk of embryopathy”. However, the study lacked of a
disproportionality analysis and a case‐by‐case assessment to investi-
gate the role of comorbidities, concurrent teratogenic drugs (whenever
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reported), temporal and biological plausibility of drug‐event couples, i.e.
the presence of confounders that could potentially explain the outcome
and/or reduce the strength of the individual causality between the drug
and the adverse event.
Objectives: We aimed to perform an analysis of individual case safety
reports retrieved after the Standardized MedDRA Query “Pregnancy
and neonatal topics” for which DOACs were claimed as suspected/
interacting drugs. Additionally, to investigate if exists a disproportion
of cases reporting “Pregnancy and neonatal topics” adverse events
rather than other adverse events for DOACs in comparison with all
other drugs registered in VigiBase or warfarin.
Methods: VigiBase, the World Health Organization (WHO)’s global
database of individual case safety reports was used as data source.
Results: Forty‐two cases of abortion were detected of which 18
(42.8%) had alternative causes for its occurrence. Fourteen cases
reported congenital anomaly (8 cases) or low birth weight baby/fetal
growth restriction (6 cases) of which 62.5% and 33.3% had at least
one confounder, respectively. In the disproportionality analyses, a
potential safety signal for spontaneous abortion emerged for
rivaroxaban (Reporting Odds Ratio, ROR 2.70; 95%CI 1.79–4.07) and
apixaban (ROR 6.76; 95%CI 2.99–15.25). However, when the same
analyses were performed using only cases without alternative causes,
no statistically significant associations for rivaroxaban when compared
to all other drugs (ROR 1.05; 95%CI 0.54–2.02) or warfarin (ROR
0.79; 95%CI 0.47–1.32) were found. For apixaban, we found a statisti-
cally significant ROR for induced abortion when compared to all other
drugs or warfarin.
Conclusions: For the majority of cases claiming DOACs‐induced tera-
togenic effects, spontaneous or induced abortion there was at least
one alternative cause explaining the occurrence of the adverse events.
For rivaroxaban, when cases without confounders were considered,
no safety signals emerged. However, for apixaban, we found a poten-
tial safety signal suggesting an increased probability of reporting spon-
taneous/induced abortion rather than other events when compared to
all other drugs or warfarin.
794 | Complications and medication patterns
in preeclampsia patients: A retrospective
analysis of a large United States electronic
health record database
Georgios Varsos; Fred W. Peyerl; Meng Shen; Kunal Lodaya;
Laxmi Gannu; Apeksha Shenoy; David k. Hayashida; Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Preeclampsia is a pregnancy‐related complication char-
acterized by the onset of high blood pressure occurring after
20 weeks of gestation and up to six weeks postpartum. Risk factors
include age, race, and certain preexisting medical conditions. Medica-
tion prescribing is generally dependent on preeclampsia severity.
Objectives: The main objective of the present study was to examine
risk factors, complications, and medication prescribing in preeclampsia
patients.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All outpatients
(≥ 12 years) between 2012 and 2016, with an ICD9/10 diagnosis of
preeclampsia, were included in the analysis. Complications and comor-
bid conditions were characterized by corresponding ICD9/10 diagno-
sis codes. Medications were grouped into three major classes
(antihypertensives, corticosteroids, and anticonvulsants) for
evaluation.
Results: The study included 864,450 pregnant patients, with 18% of
patients having severe preeclampsia. Preeclampsia occurred in the
third trimester in majority of patients (81.1%) and was more prevalent
in the age group of ‘35+ years’ (1.4%) as compared to other age
groups. In addition, African‐American women had the highest pre-
eclampsia rates (1.0%) as compared to Asian/Pacific Islander (0.9%),
Caucasian (0.9%), and Hispanic (0.4%). Three percent of preeclampsia
patients had preexisting hypertension. Rates of eclampsia and HELLP
syndrome were 1.6% and 1.1%, respectively, in preeclampsia patients.
Corticosteroids and anticonvulsants were highly prescribed across
both preeclampsia severity types (73.1% and 80.7% of severe cases
vs. 53.7% and 48.6% of non‐severe cases). Among severe preeclamp-
sia patients, the most commonly prescribed anticonvulsant medication
was magnesium sulfate (80.7%).
Conclusions: This large database analysis examined risk factors of pre-
eclampsia and provides detailed description of several clinical charac-
teristics of preeclampsia patients including relevant complications
and medication usage.
795 | Use of medicines by mothers and
duration of breastfeeding in 2015 Pelotas
(Brazil) birth cohort study
Barbara H. Lutz1,2; Andrea D. Bertoldi1,3; Isabel C.M. Emmerick4;
Mariangela F. Silveira1; Diego G. Bassani2,5
1Federal University of Pelotas, Pelotas, Brazil; 2The Hospital for Sick
Children, Toronto, ON, Canada; 3Harvard Medical School and Harvard
Pilgrim Health Care Institute, Boston, MA; 4University of Massachusetts
Medical School, Worcester, MA; 5University of Toronto, Toronto, ON,
Canada
Background: Use of medicines by mothers may influence the success
of breastfeeding. These women may discontinue breastfeeding or not
consume medicines for fear of exposing the baby to drugs through
breast milk. In addition, many women are mistakenly advised to stop
breastfeeding or avoid treatment by health care providers.
Objectives: To evaluate the impact of the use of medicines on
breastfeeding duration.
Methods: Cohort, composed by all women who gave birth in Pelotas,
Southern Brazil, in the year of 2015. Data were collected at birth, at
three months and at 12 months of life of the children. Children of
HIV‐positive women were excluded, as well as the children who were
not breastfed for other reasons. Socioeconomic and demographic
data, information about use of medicines by mothers up to 3 months
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postpartum and information on breastfeeding were collected through
questionnaires. Medicines were classified according criteria of Brazil-
ian Ministry of Health. Duration of breastfeeding was analyzed
according to the exposure variables using Cox regression models and
Kaplan–Meier curves.
Results: Our final cohort comprised 4192 children. 71% of the
mothers were white, 47.4% with age between 20 and 29 years old,
34.3% with 9 to 11 years of schooling, 49.6% with middle income,
and 49.9% were primiparous. The prevalence of use of medicines by
mothers in the first three months postpartum was 89.4%, with a total
of 9,874 medicines used (195 distinct medication types). About 39.1%
(N = 3848) of the medicines were used up to 7 days and 18.4%
(N = 1810) were considered as chronic use (60 days or more). About
89.2% (N = 6872) of the medicines were considered compatible with
breastfeeding, 6.3% (N = 488) were considered of judicious use and
4.4% (N = 341) as contraindicated in breastfeeding. At 12 months of
life of the children, 1689 mothers (42.4%) still were breastfeeding.
45.3% of the mothers breastfed their children at least for 6 months.
For the survival analysis, we only considered children who were still
breastfeeding at 3 months (N = 2940). Women who used at least
one contraindicated drug had a 16% higher hazard ratio of not
breastfeeding at 12 months, compared to women who only used
breastfeeding‐compatible medications and adjusted for schooling, ges-
tational age, and maternal labor at 3 months. However, this associa-
tion was not statistically significant.
Conclusions: In the adjusted analysis, there was no difference in the
duration of breastfeeding regarding the use of medicines by the
mothers, according to the Brazilian Ministry of Health's classification
of adequacy for breastfeeding.
796 | Antimalarial prescription pattern
among pregnant women attending antenatal
Clinic in a Nigerian Tertiary Hospital
Rachel U. Odesanya1,2; Gdwin Atibili3
1 Jos University Teaching Hospital, Jos, Nigeria; 2University of Jos, Jos,
Nigeria; 3 Jos University Teaching Hospital, Jos, Nigeria
Background: Malaria in pregnancy is a serious public health problem.
World health organization recommend interventions including malaria
treatment with antimalarials.
Objectives: To assess the antimalarial prescription pattern among
pregnant women in Jos university teaching hospital.
Methods: This descriptive retrospective study was carried out at the
Antenatal Clinic of Jos University Teaching Hospital from March
2018 to July 2018, we assessed type of antimalarial prescribed/tri-
mester of use.
Results: A total of 41(25%) were prescribed sulfadoxine/
pyrimithamine of which 7 was in first trimester. Most women (92)
used the antimalarials in second trimester. Arthemether‐Lumefantrine
was the most frequently prescribed antimalarial (59%), with quinine
the least(2%) and was only in the first trimester.
Conclusions: Arthemeter‐lumefantrine (AL) was the most prescribed
antimalarial, prescription pattern was in line with WHO guidelines
for pregnancy except few uses of AL and SP in the first trimester.
797 | Monitoring of adverse events
following zoster vaccine (Shingrix) in
Department of Veterans Affairs
Kwan Hur1; Lucy Pandey1; Bharat Thakkar1; Rongping Zhang1;
Michelle Eskridge1; Cedric Salone1; Peter Glassman2; Chester Good3;
Francesca Cunningham1
1VA Center for Medication Safety (VAMedSAFE), Hines, IL; 2David Geffen
School of Medicine at UCLA, Los Angeles, CA; 3VA Pittsburgh Healthcare
System, Pittsburgh, PA
Background: In October 2017, a new zoster vaccine (Shingrix) was
approved for the prevention of shingles in adults aged ≥50 years by
the US Food and Drug Administration (FDA). Shingrix is a non‐live
vaccine to be administered intramuscularly in two doses separated
by 2 to 6 months. Shingrix like other vaccines has the potential to
cause adverse events (AE). The Department of Veterans Affairs imple-
mented a pilot project to track the utilization of Shingrix and potential
AEs in Veteran patients.
Objectives: The objective of this rapid cycle analysis of Shingrix is to
track utilization of both doses and monitor pre‐specified adverse
events (AEs) following Shingrix in a near‐real time setting.
Methods: Patients who received Shingrix were identified in Corporate
Data Warehouse (CDW) based on the name of vaccine and by proce-
dure codes (90750) from January 2018 to December 2018. Both ICD‐
9 and ICD‐10 codes only were used to identify AEs following the ini-
tiation of Shingrix and the calculation of historical rates based on
patients who received Zostavax from 2006 to September 31, 2017.
Pre‐specified AEs include anaphylaxis, polymyalgia rheumatica, rheu-
matoid arthritis, psoriasis, autoimmune thyroiditis, multiple sclerosis,
Guillain Barre Syndrome, idiopathic thrombocytopenia, optic neuritis,
inflammatory bowel diseases, Still's disease adult onset,
leukocytoclastic vasculitis, gout, temporal arteritis, and optic ischemic
neuropathy. The Poisson‐based maximized sequential probability ratio
test (MaxSPRT) was applied.
Results: Approximately, 293 K patients received one dose of Shingrix
in 2018. Of these, 133 K (45%) received a second dose, and 55 K
(19%) did not receive a second dose within 7 months. Approximately
70% were aged between 60 and 79 years old and 94% were male.
By December 31, 2018, the most commonly observed AE was gout
(270) followed by psoriasis (88). For each AE, the observed number
of AEs was compared with the expected number of AEs based on
the historical background rate. There were 10 observed cases of
leukocytoclastic vasculitis compared to 5.0 expected but test statistics
did not exceed a threshold. The observed rate of rheumatoid arthritis
in patients who did not receive a second dose was higher than those
who received second dose (4.8 vs 1.8 per 10000 patients, p < =
0.001).
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Conclusions: VA used weekly data to rapidly detect pre‐specified AEs
following administration of Shingrix. No signal was generated for any
of the pre‐specified AEs as of Dec. 2018. To date rheumatoid arthritis
appeared to occur more often in patients who did not receive a sec-
ond dose but further investigation and chart validation is needed.
798 | Tetanus, Diptheria, acellular pertussis
(Tdap) vaccination during pregnancy and risk
of pertussis in the newborn in publicly and
privately insured mother‐infant pairs in the
United States
Katrina Mott1; Krista Huybrechts2; Helen Mogun3;
Sonia Hernández‐Díaz1
1Harvard T.H. Chan School of Public Health, Boston, MA; 2Harvard T.H.
Chan School of Public Health, Brigham & Women's Hospital, Department
of Medicine, MA; 3Department of Medicine, Brigham & Women's
Hospital, Boston, MA
Background: Triggered by an increase in pertussis cases, the Advisory
Committee on Immunization Practices modified the guideline for Tdap
vaccination to provide more protection to vulnerable infants and,
since 2011, recommends Tdap vaccination to women during
pregnancy.
Objectives: The objective of this study is to describe the patterns of
prenatal Tdap in both publicly and privately insured women and to
determine the effectiveness of this maternal Tdap vaccination for
the prevention of pertussis in infants.
Methods: This study analyzed the insurance claims from 1,830,578
livebirth deliveries between 2000–2013 in women enrolled in Medic-
aid, and 457,980 livebirth deliveries between 2011–2015 in privately
insured women from the Truven Marketscan database. Women were
required to be enrolled from 90 days prior to pregnancy through
30 days postpartum, and infants were required to be enrolled at least
60 days after birth. Prenatal exposure was defined as any CPT or NDC
code for Tdap vaccination between the last menstrual period to 1 day
before delivery. Pertussis outcomes were defined using inpatient and
outpatient diagnosis codes, laboratory tests, and antibiotic treatments.
Results: In the Medicaid cohort, the proportion of women receiving
prenatal Tdap rose from 0% in 2000, to 1.33% in 2011 (when Tdap
was recommended), to 7.24% in 2013. Of 11,102 prenatally exposed
pregnancies, 12 (0.11%) infants developed pertussis by age 6 months.
In the 1,801,499 pregnancies without Tdap exposure, 2,875 (0.15%)
infants developed pertussis. In theTruven Marketscan cohort, the pro-
portion receiving Tdap during pregnancy rose from 5.93% in 2011 to
49.35% in 2015. Of 114,616 prenatally exposed pregnancies, 52
(0.045%) infants had pertussis. In the 326,189 pregnancies without a
Tdap exposure, 220 (0.06%) infants developed pertussis. In both
cohorts, the distribution of factors potentially associated with neona-
tal infections (e.g., maternal age, baseline comorbidities) were similar
for exposed and unexposed.
Conclusions: Adherence to the 2011 Tdap vaccination guidelines for
pregnancy remained low by 2013–2015. Preliminary findings suggest
a lower risk of pertussis following prenatal vaccination. Continued sur-
veillance of vaccination rates and pertussis cases can inform the need
for public health and clinician education programs.
799 | Influence of comorbidity status on
seasonal influenza vaccine effectiveness in
Canada: A systematic review and meta‐
analysis of test‐negative design studies
George N. Okoli; Florentin Racovitan; Christiaan H. Righolt;
Salaheddin M. Mahmud
University of Manitoba, Winnipeg, MB, Canada
Background: Comorbidity status influences seasonal influenza vaccine
effectiveness (VE) but not much is known on how the influence differs
across influenza types and subtypes.
Objectives: To summarize and compare seasonal influenza VE from
test‐negative design studies in Canada by comorbidity status.
Methods: We systematically searched appropriate bibliographic data-
bases and relevant websites from January 2011 to July 2018 for
full‐text articles from test‐negative design studies of seasonal influ-
enza VE against laboratory‐confirmed (PCR or culture) influenza con-
ducted in outpatient primary care settings during the 2010/11 to
2017/18 influenza seasons in Canada. Two reviewers independently
screened retrieved citations against the eligibility criteria using a
two‐stage sifting approach (screening of titles/abstracts and full‐text
articles) and extracted data from all included studies. Disagreements
were resolved by consensus or by involving a third reviewer. We
included only final seasonal influenza VE estimates. Pooled VE was
calculated using inverse variance, random‐effects model for all influ-
enza, H1N1, H3N2, influenza A, and influenza B.
Results: Five full‐text articles met our eligibility criteria and were
included in the meta‐analysis. Pooled VE against all influenza was
50% (CI: 23–68%; I2 = 89.3%; n = 5) for studies involving individuals
without comorbidity compared with 44% (CI: ‐26‐75%; I2 = 84.2%;
n = 2) for studies involving individuals with comorbidity. Pooled VE
for studies involving individuals without comorbidity was 75% (CI:
64–82%; I2 = 0%; n = 4) against H1N1, 36% (CI: ‐14‐64%;
I2 = 86.6%; n = 4) against H3N2, 44% (CI: ‐6‐71%; I2 = 90.6%; n = 4)
against influenza A, and 53% (CI: 26–61%; I2 = 36.4%; n = 4) against
influenza B. The observed high heterogeneity in some pooled VE esti-
mates was due to one study (2014/15 influenza season) during which
the available vaccine performed very poorly. There was only one study
each involving individuals with comorbidity and VE was 58% (CI: 24–
77%) for H1N1, 11% (CI: −42‐44%) for H3N2, 14% (CI: −36‐46%) for
influenza A, and 37% (CI: −37‐71%) for influenza B.
Conclusions: The available but limited evidence suggests that comor-
bidity status influences seasonal influenza vaccine effectiveness
against all influenza in Canada. More test‐negative design study
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comparisons of seasonal influenza VE by comorbidity status are
needed for influenza types and subtypes.
800 | Coverage rates, completeness, and
timeliness of recommended basic
immunizations in Swiss preschool children: A
descriptive analysis using claims data
Rahel Schneider1,2; Daphne Reinau1,2; Nadine Schur3; Eva Blozik4;
Mathias Früh4; Andri Signorell4; Matthias Schwenkglenks3;
Christoph R. Meier1,2,5
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and
Epidemiology, University of Basel, Basel, Switzerland; 2Hospital
Pharmacy, University Hospital Basel, Basel, Switzerland; 3 Institute of
Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland;
4Helsana Group, Zurich, Switzerland; 5Collaborative Drug Surveillance
Program, Lexington, MA
Background: Low vaccination coverage rates and incomplete vaccina-
tions are a risk for the individual and population protection from vac-
cine‐preventable diseases.
Objectives: To describe vaccination patterns for nationally recom-
mended basic vaccinations in a cohort of Swiss children aged up to
37 months.
Methods: We conducted a descriptive study based on administrative
claims data in cohorts of Swiss non‐preterm children born between
January 2010 and December 2016 insured with a single health insurer
(Helsana). We assessed coverage rates and completeness for the
nationally recommended basic vaccinations (i.e., diphtheria, tetanus,
acellular pertussis [DTaP], Haemophilus influenzae type b [Hib], polio-
myelitis [IPV], measles, mumps, and rubella [MMR]) for each birth
cohort at the age of 13, 25, and 37 months. Additionally, we analyzed
timeliness of the vaccinations using inverse Kaplan–Meier curves and
standardized the results to the Swiss population.
Results: The study population comprised 563,216 children. At
13 months of age, overall coverage rates for the first dose of DTaP,
Hib, IPV, and MMR amounted to 93.8%, 93.2%, 93.7%, and 67.2%,
respectively. At 25 months of age, we found a complete vaccination
status for DTaP, Hib, IPV (4 doses each), and MMR (2 doses) in
68.0%, 65.9%, 67.1%, and 62.9% of the children, respectively, with
slightly increased rates at 37 months of age. In contrast, 4.1% of
all analyzed children received none of the recommended basic vacci-
nations at 25 months of age. Overall, we observed continuously
increasing coverage rates across birth cohorts for all vaccinations,
leveling off after a peak in the 2015 birth cohort. Children were
mainly vaccinated within the recommended time window for each
vaccination.
Conclusions: National and international goals for vaccination coverage
were not reached in Swiss preschool children. However, vaccination
coverage rates increased over time, and the majority of vaccinated
children received the vaccines under study within the recommended
time windows.
801 | Signal detection of human
papillomavirus vaccines using the Korea
adverse events reporting system database,
2005–2016
Jung Ran; Ji‐Young Yang; Hye‐Jun Kim; Ju Hwan Kim; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Republic of
Korea
Background: Human papillomavirus (HPV) vaccine is known to prevent
about 70% of cervical cancer, and its safety and risk‐benefits ratio con-
firmed by many HPV vaccine safety studies. However, new adverse
events (AEs) have recently been reported in young girls following
immunization.
Objectives: To compare AEs of HPV vaccines with all other vaccines
using the Korea Adverse Event Reporting System (KAERS) database,
and to identify new AE‐signals not listed in the HPV vaccine labels
of South Korea and the United States.
Methods: We detected AE‐signals of HPV vaccines using information
on the spontaneously reported AEs from the Korea Institute of Drug
Safety and Risk Management KAERS Database (KIDS‐KD). We
extracted and compared all vaccine‐related AE pairs with AEs pairs
related to the following HPV vaccines between 1 January 2005 and
31 December 2016: 9‐valent human papillomavirus vaccine, 4‐valent
human papillomavirus vaccine, and 2‐valent human papillomavirus vac-
cine. AE‐signals were determined by meeting all three data mining
criteria: proportional reporting ratio (≥2, no of case≥3), reporting odds
ratio (≥2, no of case≥3), and information component (lower limit of
95% confidence interval ≥ 0). We then compared identified AE‐signals
with the HPV vaccine labeling information in Korea and the United
States.
Results: A total of 24,105 AE reports for all vaccines and 125,437 AE‐
pairs were selected from the KAERS database. Of those, the number
of HPV vaccine‐related AE reports and AE‐pairs were 2,566 (10.65%)
and 4,748 (3.79%), respectively. Among the 97 detected signals, 13
AE‐signals were not listed on the HPV vaccine labels of Korea and the
United States; the most frequent AEs were tremor (49), back pain (15),
hypotension (12), neuritis (12), anxiety (11), and circulatory failure (11).
Conclusions: We have identified new AE‐signals that were not listed
in the HPV vaccine labels. However, further studies are needed to
investigate the causal relationship between the AE‐signals identified
from the study and the HPV vaccines to update the safety information
of HPV vaccines in Korea.
802 | Monitoring the safety of high‐dose,
trivalent influenza vaccine in the vaccine
adverse event reporting system (VAERS),
2010–2018
Pedro Moro; Paige Lewis; Maria Cano
Centers for Disease Control and Prevention, Atlanta, GA
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Background: In December 2009, a high‐dose, trivalent inactivated
influenza vaccine (IIV3‐HD, Fluzone High‐Dose®) was licensed for
adults aged ≥65 years. Injection site (8.9%–35.6%) and systemic reac-
tions (16.8%–21.4%) were the most commonly observed adverse
events in pre‐licensure studies.
Objectives: To characterize reports to the Vaccine Adverse Event
Reporting System (VAERS), a US spontaneous reporting system among
older adults who received IIV3‐HD.
Methods: We searched VAERS for reports of persons aged ≥65 years
who received IIV3‐HD from July 1, 2010 through December 31, 2018.
We conducted an automated analysis of the characteristics of these
reports and the following pre‐specified conditions: Guillain‐Barré syn-
drome (GBS), and anaphylaxis. We compared the proportion of serious
events, pre‐specified conditions, and adverse events (AEs) with those
of Fluzone trivalent and Fluzone quadrivalent (IIV‐SD) vaccines.
Results: VAERS received 12,755 reports after IIV3‐HD; 754 (5.9%)
were serious which included 52 deaths. Females comprised 9,209
(72.2%) reports. Median age was 71 years (range 65–102 years). The
most common reported AEs were injection site erythema (15.9%),
fever (15.4%), pain in extremity. (15.3%), injection site pain (13.8%),
pain (13.8%) and chills (13.3%). There were 97 (0.8%) reports of GBS
and 43 (0.3%) of anaphylaxis after IIV3‐HD. Reports of serious events,
GBS, and anaphylaxis for IIV‐SD vaccines in adults ≥65 years
(n = 2,590) were 9.7%, 2.9%, and 0.3%, respectively. The most com-
mon AEs for IIV‐SD vaccines were injection site erythema (17.2%),
injection site pain (15.3%), pain in extremity (14.9%), fever (13.4%),
and pain (13.3%). Serious and GBS reports were reported less fre-
quently after IIV3‐HD when compared with IIV‐SD vaccines and the
proportion of the most common AEs were similar for both IIV3‐HD
and IIV‐SD.
Conclusions: AEs after IIV3‐HD were similar to those observed during
pre‐licensure studies and those reported after IIV‐SD in VAERS. No
new or unexpected safety concerns were identified for IIV3‐HD
reported to VAERS during 2010–2018. CDC will continue to monitor
the safety of IIV3‐HD and other influenza vaccines.
803 | Variation in vaccination for respiratory
infections and associated outcomes across
long‐term care facilities
Elliott Bosco1; Andrew R. Zullo1,2; Kevin W. McConeghy1,2;
Patience Moyo1; Robertus van Aalst3,4; Ayman Chit3,5;
Stefan Gravenstein1,2; Vincent Mor1,2
1Brown University School of Public Health, Providence, RI; 2Providence
Veterans Affairs Medical Center, Providence, RI; 3 Sanofi Pasteur,
Swiftwater, PA; 4University of Groningen, Groningen, Netherlands;
5University of Toronto, Toronto, ON, Canada
Background: Pneumonia and influenza (P&I) cause substantial harm to
frail older adults, especially those residing in long‐term care facilities
(LTCFs). Vaccination has proven to be an effective means of preventing
P&I, however little is known about LTCF‐level pneumococcal and influ-
enza vaccination rates and their association with resident outcomes.
Objectives: To examine the association between LTCF vaccination
rates and P&I hospitalizations while accounting for differences in res-
ident characteristics. We hypothesized that LTCFs with higher pneu-
mococcal and influenza vaccination rates would have fewer P&I
hospitalizations for both short‐stay and long‐stay residents.
Methods: We conducted a retrospective cohort study using 2013–
2015 Medicare claims linked to Minimum Data Set (MDS) assess-
ments and LTCF data. Short‐stay (<100 days) and long‐stay (100+
days) LTCF residents were followed from admission (short‐stay) or
day 100 (long‐stay) to hospitalization, discharge, Medicare
disenrollment, or death. Exposure was LTCF‐level pneumococcal and
influenza vaccination rates, calculated using MDS data through a pre-
viously defined algorithm. The outcome was risk‐standardized inci-
dence rates (RSIRs) for P&I hospitalization per 1,000 person‐years,
calculated by adjusting for over 30 LTCF resident covariates using
hierarchical logistic regression. LTCFs with vaccination rates above
the median were compared to those below.
Results: We included 1,767,241 short‐stay (13,683 LTCFs) and
922,863 long‐stay residents (14,495 LTCFs). The overall LTCF‐level
pneumococcal and influenza vaccination rates were a median of
66.67% (IQR: 47.84%–79.48%) and 53.85% (40.54%–66.46%) among
short‐stay residents, and 73.33% (59.41%–83.63%) and 66.67%
(55.74%–75.44%) among long‐stay residents, respectively. LTCFs with
higher pneumococcal vaccination rates had lower RSIRs (per 1,000
person‐years) for short‐stay residents [Mean (SD); Difference (95%
CI): 106.73 (24.40) vs. 108.58 (24.35); −1.85 (−2.66, −1.03)] and no
difference for long‐stay residents [94.60 (39.64) vs. 93.52 (35.96);
1.08 (−0.15, 2.31)]. LTCFs with higher influenza vaccination rates
had lower RSIRs for short‐stay residents [106.82 (24.67) vs. 108.49
(24.09); −1.67 (−2.48, −0.85)] and higher RSIRs for long‐stay residents
[95.43 (40.32) vs. 92.69 (35.14); 2.74 (1.50, 3.96)].
Conclusions: Higher LTCF‐level vaccination rates likely reduce P&I
hospitalizations among short‐stay residents. The absence of an associ-
ation between LTCF‐level vaccination rates and reduced P&I events
for long‐stay residents requires further study.
804 | Causality assessment of fatal
outcomes following vaccination errors
reported in EudraVigilance
Christina E. Hoeve1,2; Marcel S.G. Kwa2; Kartini Gadroen1;
Anja van Haren2; Miriam C.J.M. Sturkenboom3;
Sabine M.J.M. Straus1,2
1Erasmus University Medical Center, Rotterdam, Netherlands; 2Medicines
Evaluation Board, Utrecht, Netherlands; 3University Medical Center,
Utrecht, Netherlands
Background: Death following vaccination has occasionally been
described in the context of appropriate use, but also in the context of
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immunization errors. There is no thorough evaluation of spontaneously
reported fatal vaccination errors available in the literature.
Objectives: The aim of this study is to systematically review reported
Individual Case Safety Reports with a fatal outcome describing immu-
nization errors as captured by EudraVigilance.
Methods: A case‐series analysis of Individual Case Reports on cases
reporting vaccination errors and a fatal outcome. Causality was
assessed by two independent reviewers using the WHO tool for “Cau-
sality assessment of an Adverse Event Following Immunization”. Cau-
sality was classified as consistent, indeterminate, inconsistent/
coincidental, or unclassifiable. In addition, the impact of reported
errors on the fatal outcomes was estimated. Error impact was classi-
fied as large, moderate, small, none, or unclassifiable.
Results: Preliminary data (based on one reviewer) show that there were
151 evaluable cases. Vaccines reported most frequently were pneumo-
coccal (34), rabies (26) and influenza vaccines (24). Most frequently
reported errors were incorrect schedule of vaccination (62), vaccination
errors (23) and inappropriate age at vaccination (18). The most fre-
quently reported vaccine‐error combinations were rabies vaccines with
incorrect schedule of vaccination (22), pneumococcal vaccines with
incorrect schedule of vaccination (13), and influenza vaccineswith inap-
propriate age at vaccination (12). Ten caseswere classified as consistent
with large error impact. These cases concerned use of poor‐qualitymea-
sles vaccines (6), administration of live varicella or rotavirus vaccines to
immunocompromised patients (4). All but one of these cases was
described in the literature. A third of the cases (35%) was also described
in the literature, local newspapers or by regulatory authorities.
Conclusions: It is reassuring that very few cases were classified as
consistent with large error impact. Continued publication of vaccina-
tion errors in the medical literature aids in transparency and detection
of errors that need to be minimized. Delayed start of vaccination
remains an issue in rabies post‐exposure prophylaxis. More education
and availability of rabies vaccines is necessary to limit incorrect sched-
ule of vaccination and unnecessary deaths.
805 | Adverse events following adenovirus
type 4 and type 7 live Oral vaccine in the
vaccine adverse event reporting system
(VAERS), United States, October 2011–July
2018
Michael M. McNeil1; Iwona Paradowska‐Stankiewicz1;
Elaine R. Miller1; Paige Lewis1; Srihari Seshadri2; Limone C. Collins Jr2;
Maria V. Cano1
1Centers for Disease Control and Prevention, Atlanta, GA; 2Defense
Health Agency, Falls Church, VA
Background: In March 2011, the U.S. Food and Drug Administration
licensed adenovirus type 4 and type 7 live, oral vaccine (Teva Pharma-
ceuticals) (adenovirus vaccine) for use in military personnel 17 to
50 years of age. The vaccine was first universally administered to U.S.
military recruits in October 2011.
Objectives: We investigated adverse event (AE) reports following the
adenovirus vaccine submitted to the Vaccine Adverse Event Reporting
System (VAERS).
Methods: We searched the VAERS database for U.S. reports among
persons who received adenovirus vaccine during October 2011
through July 2018 including participants in a military observational
study. We reviewed all serious reports and accompanying medical
records. Since the VAERS form does not specifically identify recruits,
we compared the proportion of serious reports in a proxy recruit pop-
ulation i.e., reports to VAERS with a date of vaccination from July 1,
1999 through October 31, 2011 (when adenovirus vaccine was
unavailable) in service personnel aged 17–24 years old and from the
eight states having DoD initial entry recruit sites and 1 US Coast
Guard site. We also reviewed all reports of suspected allergic reac-
tions following adenovirus vaccination.
Results: During the analytic period, VAERS received 100 reports fol-
lowing adenovirus vaccination; 39 (39%) were classified as serious
and of these 17 (44%) were from the observational study. One death
was reported. Males accounted for 72% reports. Median age of
patients was 19 years (range 17–32 years). The most frequently
reported serious AEs were Guillain Barré syndrome (GBS) (n = 12)
and anaphylaxis (n = 8); of these two GBS and all the anaphylaxis
reports were reported from the observational study. 95% of reports
documented concurrent receipt of multiple other vaccines and intra-
muscular injection of penicillin G.
Conclusions: The percentage of serious AE reports in VAERS follow-
ing adenovirus vaccine was higher than with other vaccines adminis-
tered in the recruit military population (39% vs 18%); however, 17
(44%) serious adenovirus vaccine (including eight anaphylaxis) reports
were in the observational study. No serious anaphylaxis reports were
identified among persons who were not included in the military obser-
vational study suggesting the observational study stimulated serious
reports of anaphylaxis. Also, 95% of all reports documented co‐admin-
istration of other vaccines and intramuscular penicillin G in this mili-
tary population. These other exposures may have contributed to the
GBS and anaphylaxis outcomes observed with the vaccine.
806 | 3 years of post‐licensure safety data
on a live attenuated tetravalent dengue
vaccine (CYD‐TDV)
Andrey Rojas1; Owen Haney2; Lydie Marcelon3; Alena Khromava4
1Sanofi Pasteur, Bogota, Colombia; 2Sanofi Pasteur, Swiftwater, PA;
3Sanofi Pasteur, Lyon, France; 4Sanofi Pasteur, Toronto, ON, Canada
Background: The live attenuated tetravalent dengue vaccine (CYD‐
TDV) was first licensed in Dec 2015. Vaccine exposure through public
campaigns started in The Philippines and Brazil. Of the 2.9 million
doses distributed worldwide, ~2.3 million have been used in these
campaigns as of Dec 2018.
Objectives: To provide an update of the initial post‐licensure safety
data of CYD‐TDV over a 3‐year period.
390 ABSTRACTS
Methods: We have summarized the post‐marketing safety reports for
CYD‐TDV from worldwide sources at the marketing authorization
holder (MAH) pharmacovigilance department from 8 Dec 2015
through to 7 Dec 2018.
Results: As of 7 Dec 2018, 2,992 adverse event cases have been
reported, including 553 serious cases. The most frequently reported
adverse events (pyrexia, headache, dizziness, myalgia, and vomiting)
are consistent with those observed in the clinical development pro-
gram and in the product label. Treatment‐emergent allergic and ana-
phylactic reactions were reported at an estimated frequency of
<0.01%. There were 3 cases of anaphylactic reactions meeting the
Brighton Collaboration case definition, and 134 allergic reactions
within the first 7 days post vaccination, 69 of which occurred within
the first 24 hours. A total of 151 dengue cases, of which 101 hospital-
ized, were reported post vaccination either spontaneously from mar-
ket research studies, or from the Post‐authorization Safety study
(PASS) conducted by Sanofi Pasteur (DNG15; NCT02948933). Among
them, 51 cases were virologically‐confirmed dengue and 10 suspected
cases with a negative dengue NS1 antigen rapid diagnostic test. No
cases of yellow fever vaccine‐associated viscerotropic (YEL‐AVD) or
neurotropic (YEL‐AND) disease were reported. Of the 58 cases with
a fatal outcome, 16 had a dengue diagnosis, 5/16 were virologically
confirmed, and 15/16 occurred in the Philippines. In a report from July
2018, the WHO Global Advisory Committee on Vaccine Safety
(GACVS) concluded that, as it was not possible to differentiate cases
linked to vaccine failure from cases caused by vaccine‐related immune
enhancement in The Philippines, individual cases should not be attrib-
uted to one or the other but classified as indeterminate.
Conclusions: Safety surveillance in the initial post‐marketing stage has
been key to better assess the safety profile of CYD‐TDV vaccine. The
WHO GACVS considered indeterminate cause in fatal dengue cases.
Overall, the MAH considers that the safety profile of CYD‐TDV in per-
sons with previous dengue exposure is favorable.
807 | Vaccination and risk of atrial fibrillation
in the active component United States
military
Michael M. McNeil; Susan K. Duderstadt; Jennifer F. Sabatier;
Gina G. Ma; Jonathan Duffy
Centers for Disease Control and Prevention, Atlanta, GA
Background: Reports of atrial fibrillation following vaccination are
uncommon. Atrial fibrillation was a priority topic in the collaborative
Vaccine Analytic Unit's research agenda to investigate rare or longer
term adverse events potentially associated with anthrax vaccine
(AVA). Atrial fibrillation is the most common sustained cardiac arrhyth-
mia, with a lifetime risk of approximately one in four for men and
women aged 40 years and older. Substantial morbidity and mortality
is associated with atrial fibrillation primarily as result of ischemic
stroke, thromboembolism, heart failure, dementia and impaired quality
of life. Older age and several medical conditions predispose to atrial
fibrillation but this outcome may also occur in the absence of identifi-
able underlying risk factors or comorbidities (“lone atrial fibrillation”).
Objectives: To evaluate the hypothesis that receipt of anthrax vaccine
adsorbed (AVA) increases the risk of atrial fibrillation in the absence of
identifiable underlying risk factors or structural heart disease (lone
atrial fibrillation).
Methods: We conducted a retrospective population‐based cohort
study among U.S. military personnel who were on active duty during
the period from January 1, 1998 through December 31, 2006. Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification
(ICD‐9‐CM) codes were used to identify individuals diagnosed with
atrial fibrillation in the Defense Medical Surveillance System, and elec-
tronic records were screened to include only individuals without evi-
dence of predisposing medical conditions. We used multivariable
Poisson regression to estimate the risk of lone atrial fibrillation after
exposure to AVA. We also evaluated possible associations with influ-
enza and smallpox vaccines.
Results: Our study population consisted of 2,957,091individuals
followed for 11,329,746 person‐years of service. Of these, 2,435
met our case definition for lone atrial fibrillation, contributing approx-
imately 8,383 person‐years of service. 1,062,176 (36%) individuals
received at least one dose of AVA; the median person time observed
post‐exposure was 3.6 years. We found no elevated risk of diagnosed
lone atrial fibrillation associated with AVA (adjusted risk ratio = 0.99;
95% confidence interval = 0.90, 1.09; p = 0.84). No elevated risk
was observed for lone atrial fibrillation associated with influenza or
smallpox vaccines given during military service.
Conclusions: We did not find an increased risk of lone atrial fibrillation
after AVA, influenza or smallpox vaccine. These findings may be help-
ful in planning future vaccine safety research.
808 | Pandemrix exposure and the risk of
narcolepsy in children and adults: Validation
study comparing results from patient‐file‐
verified and register‐based data in Finland
Miia Artama1; Jukka Jokinen2; Hanna Nohynek2; Arto Palmu1
1National Institute for Health and Welfare, Tampere, Finland; 2National
Institute for Health and Welfare, Helsinki, Finland
Background: Register‐based health studies have been commonly
critized for poorly specific outcome definitions due to misclassification
bias resulting in biased false negative findings.
Objectives: To evaluate the validity of register‐based research with
previous research based on validated data from patient files on associ-
ation between Pandemrix vaccination and narcolepsy risk.
Methods: Methods: The child cohort included all children born during
the years 1991–2005 and living in Finland at any time during the years
2009–10. The adult cohort included persons born during 1945–1990.
Cases of narcolepsy (ICD‐10 G47.4) diagnosed in all Finnish hospitals
during 2009–10 were identified from the national hospital discharge
register including all ambulatory hospital visits and in‐patient
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hospitalizations. In the original study, all the relevant records of the
narcolepsy patients belonging to the cohort and diagnosed during
the follow‐up time were validated by reviewing the patient records.
Information on the vaccination was obtained from the National Vacci-
nation Register. The association of the Pandemrix exposure on the risk
of narcolepsy was analyzed using Poisson regression method. The vac-
cination exposure was used as a time‐dependent covariate in the anal-
yses. The results were expressed as incidence rate ratios (IRR) with
95% confidence intervals (CI).
Results: The number of narcolepsy cases and the follow‐up time, as
well as the IRR for narcolepsy was similar between the original study
(IRR 14.5, 95% CI 6.8–37.7) and the register study (IRR 13.1, 95% CI
6.4–31.3) in children. In adults, the number of narcolepsy cases was
higher and the follow‐up time was longer in the register study than
in the original study. For the adults, IRR for narcolepsy was lower in
the register study (IRR 1.7, 95% CI 1.2–2.3) than in the original study
(IRR 3.1, 95% CI 1.8–5.5).
Conclusions: Our study showed that the previously observed associa-
tions between Pandemrix and narcolepsy in the original study could be
identified also using the register data only. Further validation studies
on other vaccination exposures and outcomes are needed.
809 | Relative effectiveness of cell‐cultured
and egg‐based influenza vaccines among the
U.S. elderly, 2018–19
Hector S. Izurieta1; Yoganand Chillarige2; Jeffrey Kelman3;
Yuqin Wei2; Yun Lu1; Wenjie Xu2; Michael Lu2; Douglas Pratt1;
Michael Wernecke2; Thomas MaCurdy2; Richard Forshee1
1Food and Drug Administration (FDA), Silver Spring, MD; 2Acumen LLC,
Burlingame, CA; 3Centers for Medicare and Medicaid Services (CMS),
Washington, DC
Background: It has been speculated that the low influenza vaccine
effectiveness (VE) observed during the 2017–18 season may have
been due to vaccine virus adaptation to growth in eggs. During this
influenza A(H3N2)‐predominant season, for the first time, we evalu-
ated the relative VE (RVE) between cell‐cultured and egg‐based vac-
cines among 13 million Medicare beneficiaries and found that cell‐
cultured vaccines had a modestly higher VE than the comparable
quadrivalent egg‐based vaccines in preventing influenza hospital
encounters (RVE 10.0%, 95% CI: 7.0% to 13.0%). In an interim analysis
during weeks with a clearer A(H3N2) dominance, we found a slightly
larger RVE (RVE 16.5%, 95% CI: 10.3% to 22.2%). The High‐dose
(HD) vaccine was also more effective than the Standard‐dose egg‐
based vaccines.
Objectives: To analyze the RVE between the cell‐cultured and egg‐
based influenza vaccines during the 2018–19 influenza season among
Medicare beneficiaries ages ≥65 years.
Methods: Retrospective cohort study on beneficiaries ages ≥65 years
who receive an influenza vaccine (cell‐cultured, recombinant, egg‐
based quadrivalent; egg‐based HD, adjuvanted, or standard‐dose
trivalent) during the 2018–19 season. We will use inverse probability
of treatment weighting to adjust for potential confounders and
Poisson regression to evaluate RVE in preventing influenza hospital
encounters (inpatient hospitalizations and emergency room visits).
Results: Preliminary data as of January 31, 2019 indicate that, so far,
influenza A(H1N1) has predominated. Among 13,596,330 vaccinated
Medicare Fee‐for‐Service beneficiaries ages ≥65 years, 817,680
(6%), 270,992 (2%), 8,414,613(62%), 2,206,196 (16%), 1,551,096
(11%), and 335,753(3%) beneficiaries had received the quadrivalent
cel‐cultured, quadrivalent recombinant, egg‐based high dose,
adjuvanted, quadrivalent and trivalent standard‐dose influenza vac-
cines, respectively. The preliminary demographic breakdown of vacci-
nees showed that their median age was 74 years, 5,712,809 (42%)
were male, and 1,126,012 (8%) had low income (dual eligible) status.
Conclusions: Once the (ongoing) 2018–19 season study is completed,
the findings will provide new evidence for evaluating whether the cell‐
cultured vaccine is more effective than the comparable egg‐based vac-
cines during influenza A(H3N2) and A(H1N1)‐dominated seasons.
810 | Safety of trivalent Adjuvanted
influenza vaccine (aIIV3; Fluad), vaccine
adverse event reporting system (VAERS),
United States, July 2016–June 2018
Penina Haber1; Pedro Moro1; Carmen Ng1; Graça M. Dores2;
Lewis Page1; Maria Cano1
1Centers for Disease Control and Prevention, Atlanta, GA; 2U. S. Food
and Drug Administration, Rockville, MD
Background: Trivalent adjuvanted influenza vaccine (aIIV3; Fluad®)
was approved in the United States (U.S.) in 2015 for adults aged
≥65 years and has been in use since the 2016–17 influenza season.
Objectives: To assess the safety profile of Fluad vaccine.
Methods: We analyzed U.S. reports for aIIV3 submitted from July 1,
2016 through June 30, 2018 to the Vaccine Adverse Event Reporting
System (VAERS), a national spontaneous reporting system. Medical
records were reviewed for serious reports. Among individuals
≥65 years of age, the relative frequency of the most commonly
reported adverse events (AEs) after aIIV3 were compared with non‐
adjuvanted inactivated influenza vaccines given to adults aged
≥65 years, high‐dose trivalent influenza vaccine (IIV3‐HD) and triva-
lent or quadrivalent vaccines (IIV3/IIV4). Data mining analyses were
undertaken to identify whether AEs for aIIV3 occurred disproportion-
ately more than expected compared to all influenza vaccines.
Results: VAERS received 630 reports after aIIV3, of which 521 (83%)
were in adults aged ≥65 years; 79 (13%) in persons <65 years and in
30 (5%) reports age was missing; 19 (3%) reports were serious, includ-
ing two deaths (0.4%) related to cardiac condition and Sjogren's syn-
drome. The most common AEs reported in adults aged ≥65 years
were injection site pain (21%) and erythema (18%), with similar pro-
portions reported for IIV3‐HD (17% and 19%, respectively) and for
IIV3/IIV4 (15%, each). Except for reports related to vaccination of
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inappropriate age (n = 79) and syringe malfunction (n = 6), data mining
did not identify other disproportionately reported AEs.
Conclusions: Although our review of aIIV3 in VAERS did not identify
any unexpected health conditions of concern, we observed more than
twice the expected number of reports with administration of the vac-
cine to persons outside of the age range for which the vaccine is
approved in the U.S. Health care providers should be educated on
the age groups for whom aIIV3 is recommended.
811 | Opportunities and challenges for near
real time monitoring (NRTM) of vaccine
exposures and outcomes in the participating
databases of the ADVANCE consortium
Lina Titievsky1; Miriam Sturkenboom2,3,4; Kaatje Bollaerts5;
Tom de Smedt5; Giorgia Danieli6; Talita Duarte‐Salles7;
Hanne‐Dorthe Emborg8; Rosa Gini9; Johnny Kahlert10;
Simon de Lusignan11,12; Elisa Martin13; Chris McGee11,12;
Lara Tramontan6; Vincent Bauchau14
1Pfizer Inc, NYC, NY; 2P95 pharmacoepidemiology, Leuven, Netherlands;
3VACCINE.GRID Foundation, Basel, Switzerland; 4University Medical
Center, Utrecht, Netherlands; 5P95 pharmacoepidemiology, Leuven,
Belgium; 6PEDIANET, Padova, Italy; 7 Institut Universitari d'Investigació
en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; 8Statens
Serum Institut, Coppenhagen, Denmark; 9Agenzia regionale di sanità della
Toscana, Florence, Italy; 10Aarhus University Hospital, Aarhus, Denmark;
11Royal College of General Practitioners, London, UK; 12University of
Surrey, Guildford, UK; 13Spanish Agency for Medicines and Medical
Device, Madrid, Spain; 14GlaxoSmithKline Vaccines, Wavre, Belgium
Background: The Accelerated Development of VAccine beNefit–risk
Collaboration in Europe (ADVANCE) is a public‐private collaboration
aiming to develop and test a system for rapid Benefit–Risk (B/R) mon-
itoring of vaccines using electronic health record databases in Europe.
Rapid B/R monitoring or Near Real Time Monitoring (NRTM) is a peri-
odic collection and analysis of several key variables (e.g. coverage,
adverse events, and vaccine preventable diseases) where an alert is
triggered when these data suggest variations in the expected B/R pro-
file in the population. NRTM can serve as an important tool for various
stakeholders such as public health institutes, vaccine manufacturers
and regulatory authorities.
Objectives: To understand opportunities and challenges of conducting
NRTM (defined as a weekly refresh of data for analyses and visualiza-
tion) using databases of the ADVANCE consortium.
Methods: A survey was developed and administered to all databases
(DB) of ADVANCE Consortium (N = 10) that participated in the prior
DB characterization activities. Responses were further discussed dur-
ing an in‐person meeting. The survey assessed delays and barriers to
NRTM including data entry delay: an interval between the health
encounter and system dates (the date on which the record is actually
entered in the system that feeds the DB) and data release delay: an
interval between the system or last collection date (the date on which
data are last entered into a DB) and internal release date (the date on
which the data are ready for querying internally).
Results: Information was received from 9 out of 10 DBs. These
included 3 DBs from Italy: Val Padana, Tuscany, PEDIANET; 2 from
the UK: the Health Improvement Network, Royal College of General
Practitioners Research and Surveillance Centre (RCGP‐RSC); 2 from
Denmark: Statens Serum Institut (SSI), Aarhus Universitets Hospital;
and 2 from Spain:the Primary Care Research Informatics Network
(SIDIAP), Base de datos para la investigación Farmacoepidemiológica
en Atención Primaria (BIFAP). Five DBs (Val Padana, Tuscany, SIDIAP,
RCGP‐RSC and SSI) concluded that they would in principle be able to
implement NRTM of various types of outcomes during the ADVANCE
project. Estimated data entry delay varied from <24 hours to several
months depending on the DB and outcome of interest and data
release delays varied from being instantaneous to up to 12 months.
Conclusions: NRTM is deemed feasible in some databases within
ADVANCE, based on the qualitative assessment. Specific challenges
will become clear upon the implementation of the NRTM.
812 | Uptake of Papanicolaou testing by
HPV vaccination status
Gabriel Chodick1; Amy Leader2; Eduardo Schejter3; Sharon Larson4,5
1Maccabi Institute for Research & Innovation, Maccabi Healthcare
Services, Israel; 2Sidney Kimmel Cancer Center Thomas Jefferson
University, Philadelphia, PA; 3Maccabi Healthcare Services, Tel‐Aviv,
Israel; 4Main Line Health System, Wynnewood, PA; 5 Jefferson University
College of Population Health, Philadelphia, PA
Background: Although the annual incidence of cervical cancer in Israel
is relatively low (5.4 per 100,000), the Ministry of Health recommends
HPV vaccination among females and males at 8th grade as part of the
national childhood immunization program. It is unclear whether young
Israeli women who initiated HPV vaccination are more likely than
unvaccinated women to report having a Papanicolaou (Pap) test later
in life.
Objectives: To evaluate the impact of the HPV vaccine on cervical
cancer screening program and to examine if uptake of Pap testing dif-
fered across subgroups of age and income by vaccination status.
Methods: Design and settings: This retrospective cohort analysis was
carried out at Maccabi Healthcare Services (MHS), a 2.3‐million‐
enrollee integrated care provider in Israel. From all women immunized
with at least one dose of HPV vaccine from its introduction in Israel in
June 2007 to Dec. 2018, we excluded those who had a Pap test prior
vaccination as well as women who were no longer members of MHS
on Dec. 2018. Over 20 thousand eligible vaccinated women were indi-
vidually matched with non‐vaccinated MHS members on one to one
basis by exact birth year, socioeconomic level, and district of resi-
dence. Exposure: HPV immunization was collected from the women's
electronic medical records (EMR) as well as information on demo-
graphic factors (date of birth, district of residence, enumeration area),
body mass index, and ever smoked cigarettes. Socioeconomic status
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was categorized according to the poverty index of the member's enu-
meration area. Main outcome: Data on the uptake of Pap smears were
extracted from MHS central laboratory, and the number of Pap smears
for each woman during the study period was counted. Statistical anal-
ysis: We started follow‐up at the date of purchase of first vaccination
dose and then followed them forward until Pap test or Dec 2018,
whichever occurred first. We used Cox proportional hazards regres-
sion, with days of follow‐up as the time scale.
Results: Proportion of women having Pap was significantly higher
among HPV vaccinated women (27%) compared to 22% in non‐vacci-
nated (aHR = 1.34; 95%CI: 1.29–1.41). Higher adherence with Pap
smear tests among women vaccinated women was significantly higher
compared to non‐vaccinated across all relevant age groups.
Conclusions: We found no indication for lower adherence with Pap
tests among women who were immunized with HPV vaccine in the
past.
813 | BCG vaccination against
Mycobacterium tuberculosis infection in
pediatrics: A systematic literature review and
meta‐analysis
Md Azharuddin1; Mohammad Adil1; Pinaki Ghosh2; Prem Kapur3;
Manju Sharma2
1School of Pharmaceutical Education and Research, Jamia Hamdard,
New Delhi, India; 2Poona College of Pharmacy, Bharati Vidyapeeth, Pune,
India; 3Hamdard Institute of Medical Sciences and Research, Jamia
Hamdard, New Delhi, India
Background: Tuberculosis (TB) is contributing a major cause of mor-
bidity and mortality in pediatrics worldwide, and Mycobacterium tuber-
culosis infection are at increased risk of developing active TB.
Objectives: The objective of this study to determine the effect BCG
vaccination against Mycobacterium tuberculosis infection as assessed
by interferon γ release assays (IGRA) in pediatrics.
Methods: A systematic search on MEDLINE and Cochrane Central
Register of Controlled Trials, was performed with pairing relevant key-
words to identify English language articles published between January
2008 to December 2018. The eligible studies reporting vaccinated and
unvaccinated aged under 18 years old with known recent exposure
with pulmonary TB. A meta‐analysis was conducted to calculate the
risk ratio and 95% confidence intervals (CI) using random effect model.
Statistical analysis was performed using RevMan 5.3 software. Publi-
cation bias was assessed by using Begg funnel plots.
Results: A total 13 relevant studies met the inclusion criteria, ranging
in age from 1 month to 18 years. Included studies comprised of total
2230 patients in the vaccinated group and 840 patients in the unvac-
cinated group. The patients were screened for infection with Myco-
bacterium tuberculosis with the two types of interferon γ release
assays (ELISpot or QuantiFERON) across the studies. The estimated
overall risk ratio was 0.67 (95% CI 0.62, 0.73), indicating a significantly
protective efficacy of 33% against infection among vaccinated after
exposure compared with unvaccinated pediatric population. Sub
group analysis showed protection against infection was 37% (risk ratio
0.63, 0.57 to 0.69) compared with 25% (0.75, 0.64 to 0.87) against
active TB. No significant asymmetry was observed, suggested no evi-
dence of publication bias.
Conclusions: The current meta‐analysis found that, the BCG vaccina-
tion showed protective effect against Mycobacterium tuberculosis
infection. However, further RCTs and real world studies with long
term follow‐up warranted to make this finding more robust.
814 | Effect of expanding Pharmacist's
prescriptive authority on influenza and
pneumococcal vaccination rates in the United
States
Ahmed I. Fahmy1; Adel Abou‐Ali2
1Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 2Director
Pharmacovigilance, Sanofi, Toronto, ON, Canada
Background: Vaccines are essential tools in prevention of infectious
diseases including influenza and pneumococcal disease. However,
Vaccination rates remains below goals set by the United States gov-
ernment. Pharmacists can play a role in improving vaccination rates
by expanding their prescriptive authorities.
Objectives: The aim of this study is to evaluate the effect of recent
changes in vaccination laws on influenza and pneumococcal vaccina-
tion rates.
Methods: Data from the Behavioral Risk Factor Surveillance System
(BRFSS) were used to calculate weighted proportions for influenza
and pneumococcal vaccination rates from 2012 to 2016 along with
the 95% confidence interval for the states of Arizona, California,
Idaho, Louisiana, Maine, Montana, New Hampshire, West Virginia
and Wyoming. Chi‐square test was used to compare count data for
the year before and the year in which law changes took effect. Further
subgroup analysis was done on high risk groups including adults of age
65 or older, those who did not graduate high school and those with no
personal doctor.
Results: A statistically significant (P < 0.001) increase in influenza vac-
cination rates in the states of Arizona, Maine, Wyoming (Absolute dif-
ference (AD): 1%), Montana and New Hampshire (AD: 3%) was
observed. Meanwhile, there was no difference in vaccination rates in
the states of Idaho and West Virginia. Contrarily, there was a signifi-
cant decrease in vaccination rates in the states of California (AD:
3%) and Louisiana (AD: 2%). Furthermore, there was a significant
increase in Pneumococcal vaccination rates in Arizona, New Hamp-
shire and Wyoming (AD: 1%), Maine, Montana and West Virginia
(AD: 3%), Idaho (AD: 4%), Louisiana (AD: 5%). Dissimilarly, in the state
of California a statistically significant decrease was found (AD: 2%).
Conclusions: Changes in pharmacist's vaccine prescriptive authority
were associated with an increase in influenza and pneumococcal vac-
cination rates in most of the states understudy and a decrease in two
states. A number of demographic, socioeconomic and logistical factors
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could have contributed to the inconsistent effects found, which
emphasize the importance of post‐regulatory steps in adopting phar-
macist's role in vaccination.
815 | Trends in overall vaccine‐related
adverse event reports and vaccination during
pregnancy, 2000–2016
Dongwon Yoon; Ju Hwan Kim; Hyesung Lee; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, Suwon, Republic of
Korea
Background: Vaccine safety surveillance is critical to maintain confi-
dence in national immunization. Although the trends of overall adverse
events (AEs) following immunization are being established, information
on the vaccine utilization and safety during pregnancy are still in need.
Objectives: To present the overall trend of reported AEs following
immunization and describe the number and type of AEs reported from
immunization during pregnancy over the 17‐year period.
Methods: We described the trend of AEs following immunization and
detected signals using the Korea Institute of Drug Safety & Risk Man-
agement‐Korea Adverse Event Reporting System database (KIDS‐KD),
between January 2000 and December 2016. A total of 17 vaccines
were included. The number of reported AEs were calculated by year,
and AE reports were classified by vaccine and types of AEs. To identify
vaccine‐related AEs in pregnantwomen,WHO‐ARTCode 2221, “Expo-
sure during pregnancy”, was used to define pregnant women who were
vaccinated and experienced the AEs. The vaccine‐AE pairs were
detected as signals by meeting all three indices: proportional reporting
ratio (≥2, no of case≥3), reporting odds ratio (≥2, no of case≥3), and
information component (lower limit of 95% confidence interval ≥ 0).
Results: Vaccine‐related AE reports remained relatively consistent up
until 2011 and increased remarkably in 2013 (n = 2406), three‐fold
higher compared with 2011 (n = 774). Of total 11,042 reported AEs
for all vaccines, influenza vaccine accounted for more than half
(56.7%), followed by pneumococcal (11.6%), Bacillus Calmette‐Guérin
(BCG) (5.0%), Haemophilus influenzae type b (4.5%), human papilloma
virus (4.5%). Themajority of reportedAE pairs were non‐serious events:
injection site pain (23.6%), muscle pain (9.1%), fever (7.0%). In pregnant
women, human papilloma virus vaccine (n = 27), smallpox (n = 9) and
measles‐mumps‐rubella (n = 2) were the most reported vaccines. Abor-
tion (n = 5), fetal death (n = 1), and small for gestational age (n = 1) were
rarely reported during pregnancy. The most predominant signals
detected in influenza vaccines, pneumococcal and BCG were injection
site pain, cellulitis, and lymphadenopathy, respectively.
Conclusions: The findings on the overall trend of reported AEs follow-
ing immunization was mostly consistent with the previous reports from
the United States and Australia, except for BCG vaccine since routine
vaccination is not recommended in those countries. Lastly, HPV vaccine
safety during pregnancy needs to be investigated promptly as sug-
gested by our preliminary findings on the vaccine exposure during
pregnancy.
816 | Detection of adverse events after
pneumococcal vaccines immunization from
Korea adverse events reporting system
database, 2005–2016
Kwan Soo Kim1; Hyun Jeong Kim2; In‐Sun Oh2; Min Soo Park1;
Ju‐Young Shin2
1Yonsei University, Seoul, Korea, Republic of; 2 School of Pharmacy, SKKU
Pharmacoepidemiology, Suwon, Korea, Republic of
Background: As part of Korea's National Immunization Program,
Pneumococcal polysaccharide vaccines and Pneumococcal conjugate
vaccines are being used. However, safety concerns regarding these
vaccines persists as undetected adverse events (AEs) may exist.
Objectives: We aimed to compare adverse events of Pneumococcal
vaccines with all other vaccines using Korea Adverse Events Reporting
System (KAERS) database and to determine the signal of Pneumococ-
cal vaccines by comparing the information with the drug labels of
Korea.
Methods: We analyzed the cases of adverse events for Pneumococcal
vaccines and all other vaccines reported through KAERS Database
from 2005 to 2016. In this study, adverse events which were detected
by all three indices of data‐mining, PRR (Proportional Reporting Ratio),
ROR (Proportional Odds Ratio) and IC (Information Component) were
defined as a signal. After then, we determined the signals by compar-
ing the information on the drug labels of Korea.
Results: Of total 24,105 reports corresponding to 125,437 vaccines‐
AE pairs, 4,748 (26.4%) AE‐pairs were Pneumococcal Vaccines related.
The detected signals for Pneumococcal vaccines by met the criteria of
three data mining indices were 97 AEs. Among them, the total number
of 13 AEs were not listed on the drug label of Korea: the most fre-
quent AEs were tremor (49), back pain (15), hypotension (12), neuritis
(12), anxiety (11), and circulatory failure (11); all AEs were reported in
more than 10 cases.
Conclusions: Our signal detection found 13 new AEs associated with
Pneumococcal vaccines which may be causal, with respect to other
vaccines. Further research is needed to confirm causality associated
with Pneumococcal vaccines.
817 | Treatment patterns of checkpoint
inhibitors in metastatic melanoma
Marina A.A. Machado1; Cristiano S. Moura1; Jeffrey R. Curtis2;
Marie Hudson3; Sasha Bernatsky1
1Research Institute of the McGill University Health Centre, Montreal, QC,
Canada; 2University of Alabama at Birmingham, Birmingham, AL; 3 Jewish
General Hospital and Lady David Research Institute, Montreal, QC,
Canada
Background: Melanoma incidence is rising and the 5‐year survival for
melanoma with distant metastasis is 23%. Checkpoint inhibitors are
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indicated as first‐line therapy for metastatic melanoma, and discontin-
uation may be required due to disease progression or immune‐related
adverse events.
Objectives: To describe recent treatment patterns of ipilimumab (IPI),
pembrolizumab (PEM), and nivolumab (NIVO) for metastatic mela-
noma in the US.
Methods: We assembled a retrospective cohort study of adults with
metastatic melanoma using MarketScan® Databases. All patients were
assigned a time‐zero as the date of first exposure to IPI, PEM, NIVO, or
combination IPI/NIVO over Jan 2012‐Dec 2016. We required patients
to have health/drug plan coverage for 12months before and 12months
after time‐zero. We described baseline (year prior to time‐zero) charac-
teristics and treatment patterns during the first year of follow‐up.
Results: We studied 710 patients initiating IPI (n = 442), PEM (n = 121),
NIVO (n = 68), and IP/NIVO (n = 79). Median age was 59 (interquartile
range 52–65) years and 61% were male. IPI was the only drug available
from 2012–2014; use of other agents increased over time with PEM
being most common (39%) as of 2016. Overall, at baseline, 11% had
prior BRAF inhibitor use (vemurafenib, dabrafenib, and trametinib),
22% prior radiotherapy, 27% prior melanoma‐related surgery, and
34% prior conventional chemotherapy (mostly cisplatin, dacarbazine,
vinblastine) (non‐mutually exclusive proportions). Use of conventional
chemotherapy prior to checkpoint inhibitors declined from 50% in
2012 to 32% in 2016 (95% confidence interval, CI, for difference in pro-
portions 6–28%). Use of conventional chemotherapy during the first
year of follow‐up also declined (26% in 2012/2013 vs 14% in 2016/
2017, 95%CI for difference 3–21%) as did melanoma‐related surgery
(18% in 2012/2013 vs 9% in 2016/2017, 95%CI for difference 1–
17%). During the first year of follow‐up, additions of BRAF inhibitors
ranged from 8% in PEM to 19% in IPI/NIVO. Switching to another
checkpoint inhibitor ranged from17% in IPI/NIVO to 34% in IPI. Among
patients using IPI (alone or with NIVO), 64% completed the recom-
mended course (4 doses within 16 weeks from initial dose). At one year,
62% of NIVO users and 55% of PEM users remained on therapy (with-
out a gap of more than 6 weeks between doses).
Conclusions: The melanoma therapeutic landscape has changed con-
siderably throughout 2012–2017, with increasing checkpoint therapy
use. Over one‐third of IPI users did not complete 4 doses and a large
proportion discontinued NIVO and PEM at one year. Further analyses
will investigate reasons for discontinuation.
818 | Measuring treatment intensification in
patients with type 2 Diabete: An electronic
health records based study
Robert J. Romanelli1; Zachary A. Marcum2; Qiwen Huang1;
Jakob S. Knudsen3; Dominick L. Frosch1
1Sutter Health, Palo Alto, CA; 2University of Washington, Seattle, WA;
3Aarhus University, Aarhus, Denmark
Background: Delayed treatment intensification of glucose‐lowering
therapy (GLT) is a major contributor to suboptimal glycemic control
in patients with type 2 diabetes (T2D). Measuring treatment intensifi-
cation, however, is fraught with conceptual and methodological issues
when using secondary databases.
Objectives: We sought to quantify treatment intensification using an
existing electronic health records (EHR)‐based cohort and to identify
issues around operationalizing this clinical phenomenon.
Methods: This was a retrospective, observational study of adults,
≥21 years of age, with T2D and incident users of an oral GLT from a
community‐based healthcare delivery system in northern California
(2003–2017). We quantified the proportion of patients with treatment
intensification, defined as a daily‐dose increase of first‐line GLT or a
prescription for second‐line GLT (of a different class) in the 3 to
12 months following treatment initiation. We further classified delayed
treatment intensification as lack of intensification≤6months of uncon-
trolled hyperglycemia (HbA1c >7% for ages 21–75 of HbA1c >8% for
ages >75). Lastly, we highlighted potential issues in operationalizing
treatment intensification, and its timeliness, given the nature of retro-
spective databases.
Results: Among 58,586 patients with first‐line GLT, 77% initiated treat-
ment with metformin, 16% with a sulfonylurea, and 7% with a different
oral GLT. During follow‐up, 21% had treatment intensified between 3
and 12 months after treatment initiation: 9.5% with a daily‐dose
increase and 11% with a second‐line GLT. Most common second‐line
GLTs were sulfonylureas (30%) or metformin (28%) among patients
who did not initiate treatment on these agents, followed by insulin
(14.3%) and insulin sensitizing agents (14.1%). Mean time to intensifica-
tionwas 184.9 days (median = 168 days). Only 8% of patients had treat-
ment intensified within 6 months of first evidence of uncontrolled
hyperglycemia. Follow‐up HbA1c was missing among 23% of patients.
Conclusions: In a cohort of patients with T2D from a community‐
based healthcare system, approximately one‐fifth of patients initiating
GLT had treatment intensified within a year. Among patients with evi-
dence of uncontrolled hyperglycemia at follow‐up, the vast majority
had delayed or no treatment intensification. Determining when inten-
sification should occur is complicated by missing lab values, individual-
ized glycemic targets, and patient/physician preferences. Multiple
sensitivity analyses should be employed.
819 | Trends in blood pressure thresholds
for initiation of antihypertensive treatment in
patients with type 2 diabetes
Martina Ambroz1; Sieta T. deVries1; Grigory Sidorenkov1;
Klaas Hoogenberg2; Petra Denig1
1University Medical Center Groningen, Groningen, Netherlands; 2Martini
Hospital, Groningen, Netherlands
Background: There have been changes in the recommended systolic
blood pressure (SBP) threshold for initiating antihypertensive treat-
ment in patients with type 2 diabetes (T2D). Particularly, attention
for a more patient‐centered approach has increased over time, includ-
ing higher thresholds for the elderly population.
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Objectives: To assess trends in SBP thresholds at antihypertensive
treatment initiation in T2D patients, and the influence of patients'
age on these SBP thresholds.
Methods: We used the Groningen Initiative to Analyze Type‐2 diabe-
tes Treatment (GIANTT) database, which includes data about patients
with T2D treated in primary care in the north of the Netherlands. For
each calendar year between 2007 and 2013, patients were included if
they had initiated antihypertensive treatment, and had an SBP mea-
surement within 365 days before treatment initiation. The influence
of the year on SBP level at initiation was assessed using a linear
regression analysis. ANOVA was conducted per year to assess the
influence of age groups (<60 years; 60–69 years; 70–79 years;
≥80 years) on the SBP level at initiation.
Results: A total of 3,397 patients initiating treatment (296 in the year
2007; 366 in 2008; 486 in 2009; 490 in 2010; 623 in 2011; 587 in
2012 and 549 in 2013) were included (48% female, average age
65 years). The average SBP levels at treatment initiation significantly
decreased over time (β = −0.604, P = 0.002), from 157 mmHg to
154 mmHg. For patients aged <60 years a decrease from 155 mmHg
in 2007 to 152 mmHg in 2013 was seen, whereas in older patients
the thresholds seemed to peak in 2010 (around 160 mmHg) and
decreased to 156, 156, and 154 mmHg for the three higher age
groups in 2013, respectively. Statistically significant differences
between the age groups were observed in the years 2008, 2010,
2011 and 2012.
Conclusions: Over time, antihypertensive treatment was initiated at
lower SBP levels among patients with T2D treated in primary care.
In general, elderly patients initiated antihypertensive treatment at
higher SBP levels than younger patients, but the thresholds for the
older age groups also decreased in more recent years. This does not
appear in line with changes in treatment guidelines.
820 | Incidence of direct Oral
anticoagulation use for non Valvular atrial
fibrillation and characteristics of users in six
European countries (2008–2015): A cross‐
National Drug Utilization Study
Luisa Ibanez1; Mònica Sabaté1; Xavier Vidal2; Elena Ballarín1;
Marietta Rottenkolber3; Sven Schmiedl4; Andreas Heeke5;
Consuelo Huerta6; Elisa Martin Merino6; Dolores Montero6;
Luz M. Leon‐Muñoz6; Christiane Gasse7; Nicholas Moore8;
Cécile Droz8; Régis Lassalle8; Mia Aakjaer9; Morten Andersen9;
Marie Louise De Bruin10; Rolf Groenwold11; Rianne Van den Ham12;
Patrick Souverein12; Olaf Klungel12; Helga Gardarsdottir13
1Fundació Institut Català de Farmacologia, Hospital Universitari Vall
d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain;
2Fundació Institut Català de Farmacologia, Barcelona, Spain; 3Diabetes
Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der
Universität München, Munich, Germany; 4Witten/Herdecke University,
Philipp Klee‐Institute for Clinical Pharmacology and Helios University
Hospital Wuppertal, Witten, Wuppertal, Germany; 5AOK NORDWEST,
Dortmund, Germany; 6Pharmacoepidemiology and Pharmacovigilance
Division, Spanish Agency of Medicines and Medical Devices (AEMPS),
Madrid, Spain; 7Aarhus University, Aarhus, Denmark; 8Bordeaux
PharmacoEpi, INSERM CIC1401, Université de Bordeaux, CHU de
Bordeaux, Bordeaux, France; 9University of Copenhagen, Copenhagen,
Denmark; 10Copenhagen Centre for Regulatory Science (CORS),
University of Copenhagen, Copenhagen, Denmark; 11Leiden University
Medical Center, Leiden, Netherlands; 12Pharmacoepidemiology and
Clinical Pharmacology Division, UtrechtInstitute for Pharmaceutical
Sciences, Faculty of Science, Universiteit Utrecht, Utrecht, Netherlands;
13 Julius Center, University Medical Center Utrecht, University Medical
Center Utrecht and Faculty of Pharmaceutical Sciences, University of
Iceland, UtrechtReykjavik, Netherlands
Background: The newer direct oral anticoagulants (DOACs) have
been approved by the European Union since 2008. Utilization
of DOACs for stroke prevention in non‐valvular atrial fibrillation
(NVAF) and their effectiveness and safety in clinical practice have
been assessed in several European countries. However, little is still
known about their use beyond the clinical trial conditions, especially
in patients with hepatic or renal impairment.
Objectives: To estimate the incidence of Direct Oral Anticoagulant
Drugs use in non‐valvular atrial fibrillation (NVAF) and to
describe user and treatment characteristics in 8 European
health databases (Mondriaan, Bavarian CD, AOK Nordwest, BIFAP,
SIDIAP, CPRD, EGB and DNR) representing 6 European countries
(The Netherlands, Germany, Spain, United Kingdom, France and
Denmark).
Methods: Descriptive cohort study from January 2008 to December
2015. A common protocol approach was applied. Annual period inci-
dences and direct standardization by age and sex were performed.
An incidence percentage change in DOAC use, dose adjustment
related to change in age and by renal function as well as concomi-
tant use of potential interacting drugs during first DOAC episode
were assessed.
Results: A total of 186,405 new DOAC users (≥18 years) were iden-
tified. The standardized incidence increased for all DOACs over the
study period, with the highest increase for apixaban (554.5%)
followed by rivaroxaban (80.7%). The highest incidence for all
DOACs was found in Denmark and Germany, with lower values
and slight differences among the remaining databases. The incidence
of DOAC use increased for both genders in most databases and
especially in those older than 75. Concomitant use of contraindi-
cated drugs varied between 16.4% (SIDIAP), and 70.5% (EGB) and
dose adjustment ranged from 4.6% in the Spanish (BIFAP) to
15.6% in the French (EGB) population.
Conclusions: The overall incidence of new DOAC users increased,
with the highest increase for apixaban. Cross national drug utilization
studies with a standard protocol may help to compare drug use and
enable health care decisions. This study was funded by the European
Medicines Agency (EMA/2015/27/PH; EU PAS Register No: 16014).
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821 | Assessment of the Calcium Channel
blocker, lower extremity edema, loop diuretic
prescribing Cascade: A prescription sequence
symmetry analysis
Scott M. Vouri1; Xinji Jiang1; Carl Pepine1; Laurence Solberg1;
Daniel C. Malone2; Almut Winterstein1
1University of Florida College of Pharmacy, Gainesville, FL; 2University of
Arizona College of Pharmacy, Tucson, AZ
Background: Dihydropyridine calcium channel blockers (DH‐CCB) are
commonly used first‐line medications used to treat hypertension;
however, they are associated with lower extremity edema (LEE). A
previous case report and cross‐sectional study identified the potential
for a prescribing cascade (PC), in which DH‐CCB associated LEE was
treated with a loop diuretic instead of discontinuing the DH‐CCB.
Objectives: To assess temporality of the DH‐CCB associated LEE,
Loop PC and the estimated percentage of patients impacted by this
PC.
Methods: A prescription sequence symmetry analysis (PSSA) was used
to assess the initial prescribing of a loop diuretic relative to the initial
prescribing of a DH‐CCB among patients in outpatient clinics of a uni-
versity health system. Patients who initiated on a DH‐CCB and loop
diuretic on the same day were excluded. Patients with congestive heart
failure (CHF) were excluded, since the use of a loop diuretic in this pop-
ulation was likely due to volume overload. Crude (cSRs) and adjusted
sequence ratios (aSRs) with 95% confidence intervals (CI) were calcu-
lated within a 360‐day window of the DH‐CCB initiation. Stratified
analyses were performed on the basis of age (<65 and≥ 65), sex, initial
DH‐CCB dose (low/standard dose and high dose, and number of other
antihypertensive classes (0–1, 2–3, 4 or more) at the time of the DH‐
CCB initiation. The estimated percentage of patients impacted by the
DH‐CCB, LEE, Loop PC was calculated by the difference in the number
of initial loop diuretics after and before DH‐CCB initiation divided by
the number of DH‐CCB initiators.
Results: We identified 5,153 DH‐CCB initiators without a diagnosis of
CHF. A total of 106 patients were initiated on both a DH‐CCB and a
loop diuretic within the 360‐day window. Among DH‐CCB initiators
without CHF, the cSR was 2.21 and aSR was 2.10 (95% CI 1.39–3.17).
There appeared to be no differences in the aSR between age, sex, and
initial DH‐CCB dose.When stratified by number of other antihyperten-
sive classes, there were differences in aSR of 0–1 (2.35, 95% CI 1.29–
4.26), 2–3 (1.96, 95% CI 1.12–3.45), and 4 or more (0.80, 95% CI
0.34–1.90) classes.We estimated that 1%ofDH‐CCB initiatorswithout
CHF experienced the DH‐CCB, LEE, Loop PC.
Conclusions: Patients with CHF were two times more likely to be
prescribed a loop diuretic after a DH‐CCB relative to before,
confirming the temporality of the PC. Although a small percentage
of DH‐CCB initiators experienced a potential PC, the overall number
of patients impacted by this PC is likely substantial since DH‐CCB
are commonly used to treat hypertension.
822 | Appropriate prescribing in nursing
homes demonstration project: A pragmatic,
cluster‐randomized trial
Mina Tadrous1; Kinwah Fung2; Laura Desveaux3; Tara Gomes1;
Monica Taljaard4; Noah Ivers3
1St. Michael's Hospital, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada; 3Women's College Hospital, Toronto, ON, Canada; 4Ottawa
Hospital, Ottawa, ON, Canada
Background: Inappropriate medication use in the nursing home setting
is associated with preventable harms. Antipsychotics are a major cul-
prit of inappropriate medication use. Inappropriate antipsychotic use
has been the focus of significant clinical, research, and policy atten-
tion. The province of Ontario launched standard feedback tools to
nursing homes in the province which helped reduce antipsychotic
use. Additional proposed strategies to reduce inappropriate use of
antipsychotics centre on educational and interdisciplinary interven-
tions, such as academic detailing (AD). AD has been shown to have
considerable variation in effectiveness and unknown long‐term
sustainability.
Objectives: To assess the real‐world effectiveness of AD into nursing
homes targeting appropriate prescribing of antipsychotics.
Methods: We conducted a pragmatic, cluster‐randomized trial com-
paring AD (intervention) to audit and feedback (comparator) on pre-
scribing of antipsychotic medications in nursing homes in Ontario,
Canada. We used patient‐level administrative claims data to assess
changes in antipsychotic use. The primary outcome was the propor-
tion of antipsychotics dispensed to residents in the past 7 days. Sec-
ondary outcomes included prescribing of other psychotropic
medications and clinical outcomes such as falls and hospitalizations.
Descriptive statistics were reported for all home and patient charac-
teristics of interest at baseline. Outcomes were assessed at baseline
and 3,6, and 12 months after randomization. Data were analyzed using
home‐level repeated measures analysis with generalized linear mixed
effects regressions.
Results: A total of 40 nursing homes with 5,363 residents were ran-
domized (18 intervention homes and 22 control homes). At 12 months,
the proportion of residents with daily antipsychotic use in the past
7 days was similar between arms with 25.2% in the intervention group
and 25.6% in the control group (p = 0.49). Among a subgroup of
homes with higher baseline antipsychotic prescribing rates, there
was a higher rate of reduction in antipsychotic use. There was no sta-
tistically significant difference between arms in clinical outcomes (e.g.
falls) but the intervention group did experience a greater reduction in
pain (P < 0.001) and depression scores (P < 0.001).
Conclusions: AD may not reduce antipsychotic use in an environment
where standard quality improvement interventions are already achiev-
ing needed changes in prescribing. There may be a potential benefit of
a data‐driven approach to target homes with higher rates of antipsy-
chotic use.
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823 | Identifying signals of warfarin drug–
drug interactions: A translational biomedical
informatics approach using real world clinical
evidence
Meijia Zhou1; Lei Wang; Charles E. Leonard1; Colleen M. Brensinger1;
Warren B. Bilker1; Stephen E. Kimmel1; Todd E. Hecht1; Lang Li;
Sean Hennessy1
1Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA; 2Ohio State University, Columbus, OH
Background: Drug–drug interactions (DDIs) with warfarin are associ-
ated with increased risk of serious bleeding. Warfarin is susceptible
to numerous DDIs via various mechanisms.
Objectives: To systematically evaluate all potential interacting drugs
used concomitantly with warfarin (i.e. the object drug) in clinical prac-
tice to affect international normalized ratio (INR, a quantitative bio-
marker of warfarin‐induced anticoagulation) and to cause serious
bleeding.
Methods: We identified all oral medications frequently co‐prescribed
with warfarin in OptumInsight Clinformatics Data Mart (Optum),
2000–2016 as potential interacting precipitants. We conducted three
independent studies in parallel. First, we predicted potential DDIs to
affect the rate of serious bleeding using physiologically based pharma-
cokinetic (PBPK) modeling for each warfarin‐precipitant drug pair (R‐
and S‐warfarin examined separately). Second, we conducted a series
of cohort studies in Optum to identify which precipitants were associ-
ated with an increased or decreased INR in warfarin users. Change in
INR after vs. before precipitant initiation was estimated using condi-
tional mixed effect model adjusted for warfarin dose change. Third,
we conducted a series of self‐controlled case series studies using
Optum to identify which precipitants were associated with increased
rate of serious bleeding. Conditional Poisson regression was used to
estimate rate ratios (RR) comparing precipitant exposed vs. unexposed
time for each warfarin‐precipitant drug pair. Pravastatin was examined
as a quantitative negative control object drug. In the latter two stud-
ies, multiple estimation was adjusted via Semi‐Bayes shrinkage.
Results: We predicted 5 weak DDIs, 3 with S‐warfarin and 2 with R‐
warfarin based on PBPK modeling. We identified 63 precipitants asso-
ciated with statistically significantly elevated INR and 51 precipitants
associated with statistically significantly reduced INR following precipi-
tant initiation. There were 128 precipitants associated with increased
rate of serious bleeding. After adjusting for pravastatin, 20 (16%) precip-
itants were associated with increased rates of serious bleeding. There
was a positive association between pharmacokinetic prediction for S‐
warfarin and RR for serious bleeding (coefficient = 0.086, p = 0.006).
Conclusions: The translational approach of combining pharmacokinetic
prediction and pharmacoepidemiologic screening of biomarker and clin-
ical endpoint could be useful for systematic identification of DDIs.
824 | Drug safety signal detection in a
Chinese regional healthcare database using
the tree‐based scan statistic and comparison
to 3 other statistical methods
Hailong Li1,2; Lingli Zhang2; Siyan Zhan1
1Peking University Health Science Center, Beijing, China; 2Evidence‐
Based Pharmacy Center, West China Second Hospital, Sichuan University,
Chengdu, China
Background: The tree‐based scan statistic (TreeScan) is a statistical
data mining tool that has been used for drug safety signal detection.
Little is known, however, about its performance when compared to
other signal detection methods.
Objectives: To evaluate the relative performance of Tree‐based Scan
Statistic (TreeScan), crude cohort study, Bayesian confidence propa-
gation neural network (BCPNN) and Gamma Poisson Shrinker (GPS)
methods for detecting statins‐related Adverse Events (AEs) in elec-
tronic healthcare database.
Methods: Patients older than 18 years with a diagnosis of hyperten-
sion in Yinzhou healthcare database from 2010 to 2016
were included in our study. We identified statin users according
to the prescription information of out/in‐patients. The AEs
were defined by using the ICD‐10 codes of out/in‐patient diagnosis.
We established a set of reference signals to better evaluate the
performance of each method. Then the sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV),
accuracy, youden index and area under the curve (AUC) of
methods were calculated for evaluation. Moreover, our study
compared the evaluation indicators of 4 signal detection methods.
For AUC, we tested the statistical significance of the
difference between the areas under two curves with the
method of DeLong. In sensitivity studies, we compared these 4
methods in 2 different situations, including new‐user cohorts
and propensity score matched (PSM) cohorts.
Results: The sensitivities of TreeScan, BCPNN and GPS were the
same (69%) and larger than the crude cohort (46%). The specificity,
PPV, NPV, accuracy, youden index of TreeScan were the largest in
4 methods, 82%, 31%, 96%, 81%, 52%, respectively. And AUC of
TreeScan (0.75, 95%CI: 0.62–0.89) was significantly larger than
other 3 methods. In new‐user cohort and PSM cohort, the
results remained consistent in original cohort design. The AUC of
TreeScan were 0.79 (95%CI: 0.65–0.93) and 0.77(95%CI: 0.64–
0.92), which was significantly larger than the other 3 methods,
respectively.
Conclusions: In this example, TreeScan performs better
than crude cohort, BCPNN, and GPS. It is proposed as a comple-
ment for other signal detection methods in drug safety active
surveillance.
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825 | Contribution of natural language
processing in predicting risk of pleural and
pericardial effusions in small cell lung cancer
by line of therapy
Rui Jiang1; Ravi Potluri2
1AbbVie, Inc, North Chicago, IL; 2SmartAnalyst Inc., New York, NY
Background: The use of electronic health records (EHR) with natural
language processing (NLP) has been rising in pharmacoepidemiology
and pharmacovigilance.
Objectives: To evaluate the contribution of NLP use when
combined with diagnosis and procedure codes in predicting risk
of pleural (Pl) and pericardial (Pc) effusions in small cell lung cancer
(SCLC), by line of therapy (LOT), in Optum EHR.
Methods: Optum's EHR database consists of de‐identified EHR
data from a network of healthcare provider organizations in
the US. In addition to structured data tables, Optum Analytics
utilizes NLP computing technology to extract critical facts from phy-
sician notes into usable datasets. Of 8,291 patients with newly diag-
nosed SCLC between 01/01/2008 and 09/30/2016, 3,633, 1,211
and 428 patients received 1st, 2nd and 3rd LOT, respectively. Pl
and Pc effusions were each identified according to 3 criteria: crite-
rion 1 (ICD‐9/ICD‐10 codes), criterion 2 (ICD‐9/ICD‐10 or proce-
dures), and criterion 3 (ICD‐9/ICD‐10, procédures, or NLP SDS
term and sentiment). Incidence of Pl and Pc effusions in each LOT
was calculated by dividing number of patients with at least
one new occurrence from start of LOT to the earlier of (30 days after
end of current LOT or start of next LOT) by number of patients at
risk at start of LOT.
Results: At diagnosis, median age was 69, 46% were male, 84%
had extensive disease. The incidence of Pl and Pc effusions in SCLC
were similar according to criterion 1 and criterion 2; adding
procedures to criterion 1 did not generate additional Pl or Pc cases.
By further adding NLP SDS term and sentiment to criterion 2, the
incidence of Pl effusion increased from 8.4% (95% CI, 7.5–9.5%) to
19.0% (95% CI, 17.5–20.7%) in 1st LOT, 7.0% (95% CI, 5.5–8.8%)
to 11.8% (95% CI, 9.6–14.4%) in 2nd LOT, and 7.4% (4.9–10.7%)
to 15.0% (95% CI, 11.0–19.7%) in 3rd LOT. The incidence of Pc
effusion increased from 0.7% (95% CI, 0.4–1.0%) to 4.8% (95%
CI, 4.1–5.6%) in 1st LOT, 0.4% (0.1–1.0%) to 4.5% (95% CI, 3.3–
5.9%) in 2nd LOT, and 1.4% (95% CI, 0.5–3.1%) to 7.4% (95% CI,
4.9–10.6%) in 3rd LOT.
Conclusions: NLP use improves pleural and pericardial effusion
case identification in small cell lung cancer when combined
with diagnosis and procedure codes in Optum EHR. Future
studies on the validity of NLP‐based algorithm in adverse
event detection are warranted (such as positive predictive value).
826 | Text mining to identify drug–drug
interactions (DDIs) in elderly patients
admitted to emergency department
Iris Pujade1,2; Perrine Duthoit2; Grégoire Evrard2; Alicia Bel‐Létoile3;
Clément Goehrs3; Vianney Jouhet1,2; Sébastien Cossin1,2;
Antoine Pariente1,2; Frantz Thiessard1,2; Francesco Salvo1,2;
Louis Letinier1,2
1 Inserm, University of Bordeaux, Bordeaux, France; 2CHU de Bordeaux,
Bordeaux, France; 3Synapse Medicine startup, Bordeaux, France
Background: Clinically Significant drug–drug interactions (CS‐DDIs)
can have serious consequences, and lead to emergency department
(ED) visit, in particular in elderly. The Bordeaux ED has set up, for
patients over 75 years, a questionnaire to evaluate the usual treat-
ments at the entry of ED.
Objectives: To evaluate the performances of a text‐mining based‐
tool for the detection of CS‐DDIs in elderly admitted to ED,
and to estimate the prevalence of CS‐DDIs in this population.
Methods: Design: A retrospective study based on medical records of
ED of Bordeaux was performed. Patients ≥75 years old,
admitted between September, 2016 and August, 2017, with at least
one declared drug were included. Setting: Geriatricians
interviewed patients or caregivers through a standardized
questionnaire, filled‐in directly in the hospital information system in
free text. An automated program identified and coded drugs via Nat-
ural Language Processing techniques. Then, the text‐mining
and knowledge‐based algorithm developed within the Synapse
tool was used to identify automatically CS‐DDIs using the
French Drug Agency interaction thesaurus. Data analysis: A
subset of randomly selected 400 drug‐pairs was used to evaluate
the specificity of the tool in identifying CS‐DDIs compared to a Gold
Standard (GS) in which CS‐DDIs were selected by a pharmacologist
and an ED physician. A second analysis was performed using all
CS‐DDIs found by the tool among the completed questionnaires in
order to determine the positive predictive value (PPV) of the tool.
The prevalence of DDIs was calculated as the rate of CS‐DDIs on
the total number of questionnaires.
Results: Overall, 5860 questionnaires were completed (median of 5
treatments per questionnaire). Among these questionnaires, the tool
found 375 CS‐DDIs, for a prevalence of 6.4% (95% CI, 5.8%–7.0%).
The specificity of the tool was of 100%. Among the 400 analyzed
drug‐pairs, GS and tool found 398 non CS‐DDIs and two same CS‐
DDIs. The PPV was of 99.7 (95% CI, 99.2%–100%), as 374 of the
375 CS‐DDIs found by the tool were confirmed by the GS.
Conclusions: The automated identification of clinically significant
DDIs appeared reliable but needs to be confirmed on a larger data
set. The prevalence of CS‐DDIs found in the elderly admitted to
ED was higher than expected.
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827 | Nationwide adverse drug reaction
screening using high process computing
Te‐yuan Chyou1; Prasad S. Nishtala2
1University of Otago, Dunedin, New Zealand; 2University of Bath, Bath,
UK
Background: Detecting adverse drug reactions has a very important
role in minimizing drug‐related harms, particularly in older adults.
Previous studies have mainly focussed on ascertaining known
adverse drug reactions (ADRs). We present here a sequence‐symme-
try based approach aided by high process computing (HPC), to sys-
tematically detect all putative signals of abrupt ADRs and improve
efficiency of screening of administrative health databases.
Objectives: The aim of this study is to identify all signals of signifi-
cant drug‐event associations that can be abrupt ADRs, in the New
Zealand (NZ) 65 yr + population by parallelizing sequence‐symmetry
calculations.
Methods: We sourced hospital events and prescription data (2005–
2016) from the NZ Ministry of Health. We processed the data
using the HPC facility at Bath University and created a self‐matched
cohort. The day an individual started a drug of interest is the index‐
date, and this ascertains non‐exposure before the index‐date.
We defined a pre‐initiation window and a post‐initiation
window before and after the initiation respectively. We identified a
first‐time diagnosis of interest in both windows. Window
lengths of 7, 15 and 30 days were considered. Short window lengths
ascertain current or recent first‐time exposures at occurrences of
new events, and that the new events can be abrupt ADRs. We
calculated adjusted sequence ratios (ASR) to measure the
increased odds of first‐time event post‐initiation relative to the
background using the Hallas' method, with modifications that the
calculations are within the pre‐post window‐pairs. We stratified the
cohort by drug and diagnosis and used HPC to calculate all ASRs
in parallel. Starting with 7‐day windows, we detected signals with
100% odd increases (log (ASR) > 0.69), and then detected more sig-
nals with longer windows.
Results: Our dataset has 2,170,393 new events, covering 9009 ICD‐
10‐AM codes; and 37,359,480 drug initiations, covering 914 drugs.
We found a total of 183 strong drug‐event associations including
well‐known ADRs, for example ibuprofen and GI‐bleeding (K92.2,
log (ASR) = 0.79 [0.41–1.16]), as well as warfarin and subdural hem-
orrhage (I62.0, log (ASR) = 1.94 [0.52–3.36]). A number of less well‐
known associations that can be ADRs were also detected, for exam-
ple bendrofluazide and hyponatremia (E87.1, log (ASR) = 1.89 [1.22–
2.56]), codeine and enterocolitis (A04.7, log (ASR) = 0.76 [0.34–
1.17]).
Conclusions: With the aid of HPC, the symmetry‐based algorithm
has the potential for the development of an efficient, big‐data
ADR‐signal detection software to improve medication safety and
advance post‐marketing surveillance.
828 | Detecting rare diseases: A case study
using machine learning semi‐supervised
networks to identify under‐diagnosed
patients
Yunlong Wang1; Christina Mack2; Fan Zhang1; Yong Cai1; Emily Zhao1
1 IQVIA, Parsippany, NJ; 2 IQVIA, Durham, NC
Background: Patients affected by rare diseases may present with a
combination of symptoms that mimic more common conditions,
making it challenging for physicians without specific therapeutic area
experience to diagnose. These patients often spend years with a
misdiagnosis, or no diagnosis at all. With careful guidance, machine
learning within insurance claims can help identify likely rare disease
cases in as‐yet undiagnosed populations and provide key insights
for diagnoses and treatment. Precise predictive modeling is chal-
lenged, however, by the high dimensionality of medical features for
rare disease patients coupled with the small number of confirmed
diagnoses. Together, these issues limit the ability to “train” the
machine to detect undiagnosed patients.
Objectives: Develop and implement a novel machine learning
method to boost the ability to accurately predict undiagnosed rare
disease patients.
Methods: Deep learning models have achieved significant results in
recent years, but they require a large amount of “labeled data”‐ in
this case, diagnosed patients‐ to train. We created a Semi‐supervised
Generative Adversarial Network (SGAN) to support rare disease
detection. Model training techniques such as feature mapping and
pull away terms were applied to improve prediction accuracy. Syn-
thetic patients were then generated within the claims to boost weak
signals and inform machine algorithms. Due to the imbalanced
nature of rare disease data, Precision‐Recall and Area Under the
Curve (PR‐AUC) was used to measure model performance.
Results: These techniques were able to boost weak signals within
small samples to train a better predictor relative to the more com-
ment Logistic Regression and Random Forest techniques. The SGAN
had 0.34 PR‐AUC, meaning that it can identify 34 out of 100 undi-
agnosed rare disease patients. This is a 3‐fold improvement relative
to Random Forest techniques and 29% over standard Deep Neural
Networks.
Conclusions: Predicting symptomatic but undiagnosed rare disease
patients out of millions is a challenge to understanding these dis-
eases and providing the right treatment. Machine learning tech-
niques are needed to combat this issue, but they must work within
a complicated medical population and small available samples with
which to train the machine. The innovative network architecture of
the SGAN model provided the ability to leverage unlabeled patient
samples within claims data to improve precision and performance
of predictive models. This technique can be applied in similar “big
data” settings with only small populations of firmly diagnosed
patients.
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829 | Evaluation of bias in case‐crossover
analyses of persistent drug exposures
Katsiaryna Bykov; Shirley V. Wang; Joshua J. Gagne
Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background: Previous empirical investigations suggest that a case‐
crossover analysis may be biased when the population includes a
mix of transient and persistent medication users; however, these
results may have conflated other sources of bias.
Objectives: To evaluate the performance of the case‐crossover design
in the context of chronic therapy using simulated data.
Methods: We simulated cohorts, where either all patients were
exposed to (1) 180‐day therapy; (2) 30‐day therapy; or (3) some
patients were exposed for 30 days while the remaining portion
did not stop therapy following initiation (i.e., stayed on therapy
until the end of the study period). For scenario (3), we varied the
percentage of patients with persistent exposure (10%, 30%, 50%,
and 70%). We evaluated all scenarios under the null (true odds
ratio [OR] of 1.0), and scenario (3) with varying non‐null true ORs
(0.5, 0.8, 1.25 and 2.0). Cases were analyzed using conditional
logistic regression that compared odds of exposure on the outcome
date to the odds of exposure on a day 30 days prior to the out-
come. We generated 1,000 cohorts for each scenario and compared
mean estimates for the effect of exposure on the outcome and
mean bias.
Results: Case‐crossover estimates were unbiased in scenarios
where all patients were exposed for either 30 days or 180 days. In
scenarios where some patients had persistent exposure, the
estimates showed upward bias, which increased from 0.11 on the
log scale (OR, 1.12) when 10% of patients stayed on therapy to
1.21 (OR, 3.36) when 70% stayed on therapy. We did not observe
substantial changes in magnitude of bias when the true OR was
varied.
Conclusions: The case‐crossover design can provide unbiased esti-
mates when evaluating prolonged, but finite, exposures; however,
in situations where patients stay on therapy indefinitely, case‐cross-
over analyses will incur upward bias.
830 | Empirical assessment of case‐based
methods for the identification of drug‐related
health outcome of interest in the French
Nationwide Healthcare Database (SNDS)
Nicolas Thurin1,2,3; Régis Lassalle1; Patrick Blin1; Marine Pénichon1;
Martijn Schuemie4; Joshua J. Gagne5; Jeremy A. Rassen6;
Jacques Benichou7,8; Alain Weill9; Cécile Droz‐Perroteau1;
Nicholas Moore1,2,3
1Bordeaux PharmacoEpi, CIC1401, Université de Bordeaux, Bordeaux,
France; 2 INSERM U1219, Bordeaux, France; 3CHU de Bordeaux,
Bordeaux, France; 4Observational Health Data Sciences and Informatics
(OHDSI), New‐York, NY; 5Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Brigham and Women's
Hospital and Harvard Medical School, Boston, MA; 6Aetion, Inc., New‐
York, NY; 7 INSERM U1181, Université de Versailles, St‐Quentin‐en‐
Yvelines, France; 8CHU de Rouen, Rouen, France; 9Caisse Nationale de
l'Assurance Maladie, Paris, France
Background: With long‐term data for over 66.6 million patients, the
French Nationwide Healthcare Database (Système National des
Données de Santé ‐ SNDS) offers great potential for drug‐related risk
identification. However, it is not known how different study designs
compare for large‐scale screening in the database.
Objectives: To evaluate and compare the performance of 3 case‐
based methods ‐ self‐controlled case series (SCCS), case control
(CC), and case‐population (CP) ‐ as tools for risk identification in
the SNDS.
Methods: All hospitalized cases of acute liver injury (ALI), acute kidney
injury (AKI), myocardial infarction (MI), and upper gastrointestinal
bleeding (UGIB) in 2009–2014 were extracted from SNDS. The AKI,
UGIB and MI cases were sampled randomly at fractions of 1/3, 1/10
and 1/20, respectively, to reduce execution time. 139 positive and
negative drug controls corresponding to 273 drug‐outcome pairs were
screened; those with a minimum detectable relative risk (MDRR) <1.30
were analyzed. The pairs were used to compare 196 SCCS, CC, and CP
design variants (e.g., varying regarding risk windows, different adjust-
ment approaches). We evaluated each method based on its discrimina-
tive ability using area under the receiver operating curve (AUC). Mean
square error (MSE) was calculated for negative controls, assuming that
the true relative risk was 1.
Results: Over 6 years, there were before sampling, 5 152 cases of
ALI, 12 317 KI, 304 369 MI and 139 172 UGIB. The number of
drug‐outcome pairs with a MDRR<1.30 ranged from 61 for MI to
25 for ALI. SCCS variants achieved the best performance across all
outcome definitions with AUC ≥0.9 for ALI, ≥0.8 for KI and UGIB
and ≥ 0.7 for MI. MSE associated with the SCCS variants with
highest AUCs ranged from 0.07 to 0.47. The best predictive accu-
racy was observed for UGIB (0.07 ≤ MSE ≤ 0.10) and MI
(0.19 ≤ MSE ≤ 0.22). CC achieved higher AUC than CP for ALI
(≥0.89 vs. ≥0.85), KI (≥0.62 vs. ≥0.58) and MI (≥0.62 vs. ≥0.57).
CP performed better for UGIB (≥0.67 vs. ≥0.60). MSE was
lower for the most discriminating CC variants (0.23 ≤ MSE ≤ 1.34)
as compared to the most discriminating CP variants
(1.07 ≤ MSE ≤ 3).
Conclusions: This empirical assessment showed that SCCS designs
variants tended to achieve results with a higher discriminative ability
and predictive accuracy than CC and CP for screening of drug‐
related ALI, AKI, MI and UGIB. For each outcome of interest, a
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specific SCCS variant should be considered for drug‐related event
detection in the SNDS.
831 | Using active comparators in self‐
controlled studies
Jesper Hallas1; Suzanne Cadarette2; Nicole Pratt3;
Joseph A. Delaney4; Heather Whitaker5; Malcolm Maclure6
1University of Southern Denmark, Odense, Denmark; 2University of
Toronto, Toronto, ON, Canada; 3University of South Australia, Adelaide,
Australia; 4University of Washington, Seattle, WA; 5OPEN University,
London, UK; 6University of British Columbia, Vancouver, BC, Canada
Background: When self‐controlled designs are used to study the trig-
gering of medication‐related adverse effects, time‐varying confounding
by indication can occur if the indication or its severity varies over time.
Objectives: We aimed to describe how self‐controlled designs might
mitigate or eliminate such confounding by indication by incorporating
active comparators with similar indications, illustrated by an empirical
example.
Methods: Practical approaches to incorporating active comparators
will be described for case‐crossover, case‐time‐control, self‐con-
trolled case‐series and symmetry analyses.In the empirical example,
we used nation‐wide data from Denmark to study the association
between narrow‐spectrum penicillin and venous thromboembolism
(VTE), using a case‐crossover design. Macrolide antibiotics were
selected as active comparator. This example was chosen because
upper respiratory infection ‐ the main indication for narrow‐spec-
trum penicillin and macrolides ‐ is a transient risk factor for venous
thromboembolism, i.e., representing time‐dependent confounding
by indication.We identified Danish VTE patients, born 1950 or ear-
lier, during the period 1995–2012. If patients had more than one
VTE, we included only the first. The focal window was the 14‐d
period before VTE diagnosis. We compared the odds of exposure
in that window with one reference window 29–42 days before the
VTE. We counted a window as exposed if one of the two antibiotics
(penicillin or macrolide) was dispensed within it. We used a Wald‐
based method and an interaction term in a conditional logistic
regression model to estimate the exposure odds ratio (OR) with
95% confidence limits (CI) for the narrow‐spectrum penicillin users,
having the macrolide users as active comparators, i.e. adjusted for
transient confounding by indication.
Results: We identified 57486 patients, of whom 4898 (8.5%) were
dispensed penicillin during the focal window, and 2226 (3.9%) during
the reference window. Corresponding figures were 1192 (2.1%
and 572 (1.0%) for macrolide antibiotics. The case‐crossover esti-
mate for penicillin was 2.45 (CI: 2.32–2.59) and 2.22 (CI: 2.00–
2.47) for macrolide antibiotics. The Wald‐based estimate for penicil-
lin with macrolide antibiotics as active comparator was 1.10 (CI:
0.98–1.24), and the interaction‐term based estimate was 1.22 (CI:
1.07–1.39).
Conclusions: The strong association of penicillin and macrolides with
VTE suggests both are due mostly to time‐varying confounding by
indication. Such confounding can be mitigated by applying an active
comparator drug that has an similar indication.
832 | Development and application of a
hybrid matching algorithm to refine the
prevalent new‐user cohort Design for
Comparative Drug Effect Studies
Chenyi Yang1; Shihchen Kuo2; Chun‐Ting Yang1;
Edward Chia‐Cheng Lai1; Huang‐Tz Ou1
1College of Medicine, National Cheng Kung University, Tainan, Taiwan;
2Division of Metabolism, Endocrinology and Diabetes, University of
Michigan, Ann Arbor, MI
Background: The prevalent new‐user (PNU) cohort design was
recently introduced to accommodate the circumstance where incident
new users of a target drug are very scarce; most study drug users have
used the comparator old drug previously. The PNU cohort design used
either time‐ or prescription‐based exposure sets to compute time‐con-
ditional propensity scores (PS) of initiating the study drug and to iden-
tify matched individuals receiving the comparator drug to achieve the
comparability between two study groups.
Objectives: We adapted the PNU cohort design to propose a refined
matching algorithm which accounted for medication history before
the initiation of the study drug, and we illustrated this approach with
a comparative safety study of glucagon‐like peptide‐1 receptor ago-
nist (GLP‐1ra) vs. sulfonylurea (SU) on the risk of cardiovascular dis-
eases (CVDs) in patients with type 2 diabetes (T2DM).
Methods: To achieve the baseline comparability between the study
and comparator drug users, we defined stable users and developed
an enhanced hybrid algorithm with three‐step matching for (1) index
date at which the study drug was initiated (inspired by time‐based
exposure set), (2) medication possession ratios (MPRs) which quanti-
fied past exposures [e.g., exposure to all glucose‐lowering drugs
before the GLP‐1ra initiation in T2DM] (modified by prescription‐
based exposure set), and (3) PS estimated based on confounder
patient characteristics. We illustrated this refined approach with data
from Taiwan National Health Insurance Research Database 2009–
2015. Cox models were applied to compare the hazard of the com-
posite CVD and 3‐point major adverse cardiovascular event (MACE)
between the matched GLP‐1ra and SU groups.
Results: During 2011–2014, there were 3,195 and 773,026 stable
users of GLP‐1ra and SU, respectively. Most of 3,195 GLP‐1ra users
have been exposed to SU previously. After applying for our
matching algorithm, 1,573 stable users of GLP‐1ra were 1:1 matched
to 1,573 stable sets of SU. With a mean follow‐up of 2,520 and
2,591 person‐years, the use of GLP‐1ra compared to SU was associ-
ated with a significantly reduced risk of the composite CVD [hazard
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ratio (HR): 0.71, 95% CI: 0.54–0.95] but not MACE [HR: 0.71, 95%
CI: 0.44–1.15].
Conclusions: The refined PNU cohort design not only allows the use
of most subjects with prior medications but applies the enhanced
three‐step matching algorithm to comprehensively consider the past
exposure to all potential comparator drugs before initiating the study
drug, thus enhancing the study validity.
833 | Classes and prevalence of prevalent
new users: An example in Medicare
Michael Webster‐Clark; Til Stürmer; Jessie K. Edwards; Ross Simpson;
Charles Poole; Jennifer L. Lund
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: The prevalent new user (PNU) design has been proposed
to increase sample size and include a clinically relevant patient subset
in research. Few applied examples exist in large longitudinal claims
databases and whether all PNUs should be treated as one group has
yet to be examined.
Objectives: Determine sizes of potential classifications of PNUs and
sample size increase from implementing a PNU design in a compara-
tive effectiveness study of dabigatran versus warfarin among a sample
of Medicare beneficiaries.
Methods: We identified new users of dabigatran and warfarin in a
20% Medicare random nationwide sample from January 2010 to
October 2015 using 60‐day washout and 30‐ and 45‐day grace
periods, respectively. Next we found dabigatran initiators who did
not meet the washout criterion and divided them into three
mutually exclusive groups: true PNUs (TPNUs) whose initiation was
directly preceded by an eligible period of new use of warfarin in
the study period with no intervening gap; gap PNUs (GPNUs) whose
initiation was preceded by an eligible period of new use of warfarin
in the study period with a gap between 0 and 60 days; and other
PNUs (OPNUs) whose initiation was preceded by a period of warfa-
rin use in the study period that did not qualify as new use, regard-
less of gap. We included each individual once, taking first
chronological new use then first PNU period. We compared covari-
ates and hazard ratios (HR) for as‐treated all‐cause mortality across
these categories.
Results: We identified 11,240 dabigatran new users, 1,683 TPNUs,
263 GPNUs, and 1,332 OPNUs. The populations differed in many
covariates including cardioversion in the past year (9.3% in new
users, 16.9% in TPNUs, 19.8% in GPNUs, and 6.3% in OPNUs),
major bleeding event in the past year (8.5% vs 12.2% vs 17.5% vs
14.3%), and deep vein thrombosis in the past year (3.4% vs 6.6%
vs. 10.3% vs. 9.0%). Mortality comparisons showed similarity
between new users and TPNUs (new user vs TPNU HR: 0.93, 95%
CI 0.79–1.09) but improved survival for new users vs GPNUs and
OPNUs (new user vs GPNU HR: 0.72, 95% CI 0.51–1.01; new user
vs OPNU HR: 0.63, 95% CI 0.54, 0.73).
Conclusions: Adding all PNUs to the study would increase sample
size by 29%. However, these PNUs had different distributions of
potential confounders and GPNUs and OPNUs had poorer survival.
TPNUs had similar mortality to new users despite the presence of
more comorbid conditions. Matching the type of PNU to the appro-
priate type of warfarin user will be key for accurate estimates. Inves-
tigators conducting PNU analyses should articulate differences
between the PNU and new user populations as well as how they
change the causal questions being examined.
834 | Comparative performance of trend‐in‐
trend design and instrumental variable
methods in an active comparator new user
setting
Phyo T. Htoo1; Michele Jonsson‐Funk1; Gang Fang2; Virginia Pate1;
John Buse1; Jessie K. Edwards1; Nabarun Dasgupta3; Til Stürmer1
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2School of
Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;
3Eshelman School of Pharmacy, Chapel Hill, NC
Background: Trend‐in‐trend (TT) design has been proposed as an
extension of instrumental variable (IV) methods to compare preva-
lent vs. never users. Time varying confounding and time varying haz-
ards could however violate TT assumptions and bias estimates.
Relative performance of TT design and IV methods in the active
comparator, new user (ACNU) setting, where drug initiation patterns
change over time, has not been evaluated.
Objectives: To evaluate the TT design in ACNU setting, as compared
with calendar time IV methods and traditional new user cohort
design, using thiazolidinediones (TZDs) versus dipeptidyl peptidase‐
4 inhibitors (DPP4i) and TZDs known effect on congestive heart fail-
ure (CHF) hospitalizations as a positive control example.
Methods: Using Medicare fee‐for‐service claims data 2007–14, we
identified new users of TZD and DPP‐4i, aged over 65 years, after
a 6‐month drug‐free period, during which there was no TZD or
DPP‐4i prescription. We compared short‐term (3‐year) risks of inpa-
tient CHF with diagnosis in 1st or 2nd positions among TZD vs. DPP‐
4i initiators, starting from 2nd prescription dates until death or
administrative censoring. We estimated this intent‐to‐treat (ITT)
treatment effects 3 ways: (i) TT odds ratio (OR), and 95% confidence
intervals (CI) evaluating the trend in TZD vs. DPP4i initiation in 6‐
monthly calendar time intervals (crossover around 2011) (ii) binary
calendar time IV estimator (before and after 2011) using 2‐stage
generalized method of moments and (iii) cohort ORs based on
inverse probability of treatment weighting to control for measured
confounding.
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Results: TZD (n = 45,218) and DPP‐4i initiators (n = 87,338) had
similar baseline characteristics. With the overall inpatient CHF risk
of 5.3%, we identified 2,323 events among TZD and 4,786 among
DPP‐4i initiators. TZD has a higher risk of CHF than DPP‐4i with
TT OR (95% CI) of 1.16 (1.02, 1.33) and the weighted OR (95%
CI) of 1.31 (1.24, 1.37). IV estimate (risk difference) from 2‐stage
least square estimator is 0.08 (95% CI: 0.07, 0.09), while pseudo‐
OR calculated from the risk difference (and unscaled by treatment
compliance) is 1.62, revealing consistent direction of estimates.
Conclusions: We were able to extend the TT design to ACNU which
allows us to implement TT in settings with time varying confounding
or time varying hazards. In our positive control ACNU example, TT
results were consistent with other methods, likely due to limited
unmeasured confounding. We will further vary ITT risk periods and
implement IV estimator with 2‐stage probit regression to get compa-
rable OR estimates.
835 | Concomitant use of quinolones and
stimulants and the risk of cardiovascular
adverse events: A comparative safety study
Adel A. Alrwisan1; Yu‐Jung Wei2; Patrick Antonelli2;
Babette Brumback2; Almut Winterstein2
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 2University of
Florida, Gainesville, FL
Background: Stimulants can increase blood pressure and heart rate.
Cases of cardiac arrest and torsades de pointes have occurred with
the concomitant use of quinolones and other pro‐arrhythmic drugs.
Despite the plethora of evidence suggesting cardiac toxicities with
quinolones or stimulants, to date, no study has evaluated cardiac
outcomes related to their pro‐arrhythmic properties when used
concomitantly.
Objectives: To examine whether concomitant use of quinolones and
stimulants is associated with an increased risk of cardiac events in
adults.
Methods: Methods: A retrospective cohort study using IBM
MarketScan® commercial claims data from 2008 to 2015. Setting:
Adults between 18 and 64 years old with prescription fills of stimulants
(methylphenidate or mixed amphetamine salts) and continuous enroll-
ment in MarketScan® for the 6 months (baseline) prior to the date of
first dispensation (index date) of oral quinolones or comparators. Expo-
sure: Initiation of quinolones versus amoxicillin (amoxicillin/clavulanate)
during stimulant use. Main outcomes measures: Emergency room visits
or hospital admission related to palpitations or tachycardia. Analysis:
We adjusted for baseline covariates through inverse probability treat-
ment weighting. Adults were followed for up to 10 days after the index
date. The hazard of cardiac symptoms in stimulant/quinolones‐exposed
adults was compared to those who had stimulants/amoxicillin using a
weighted Cox proportional hazard model. We performed sensitivity
analyses to challenge the results' robustness.
Results: The study cohorts comprised 390,490 stimulants users who
initiated either quinolones or amoxicillin. The unadjusted incidence
rate for cardiac symptoms was 471 cases per 10,000 patient‐years
in stimulant/quinolones users and 244 cases per 10,000 patient‐years
in stimulant/amoxicillin users. The adjusted hazard ratio for cardiac
symptoms was 1.61 (95%CI, 1.30–1.98) with stimulant/quinolones
use. The sensitivity analyses findings including restriction to patients
without respiratory infections, censoring at stimulant discontinuation
during the 10‐day follow‐up, no censoring when antibiotics were
switched, and exclusion of patients who initiated stimulants within
30 days of index date were consistent with the primary analysis.
Conclusions: Concomitant use of stimulant and quinolones was asso-
ciated with an increased hazard of cardiac symptoms in comparison
to stimulant and amoxicillin concomitant use. Sample size constraints
limited our ability to examine severe arrhythmias.
836 | An unnecessary risk: Lack of benefit of
fluoroquinolone antibiotics in uncomplicated
exacerbations of chronic obstructive
pulmonary disease
Pierre Ernst1; Matthew Dahl2; Dan Chateau2; Nick Daneman3;
Jacqueline Quail4; Ingrid S. Sketris5; Anat Fisher6; Jianguo Zhang7;
Shawn Bugden8; for the CNODES Investigators9
1McGill University, Montreal, QC, Canada; 2University of Manitoba,
Winnipeg, MB, Canada; 3Sunnybrook Research Institute, Toronto, ON,
Canada; 4Health Quality Council, Saskatoon, SK, Canada; 5Dalhousie
University, Halifax, NS, Canada; 6University of British Columbia,
Vancouver, BC, Canada; 7University of Calgary, Calgary, AB, Canada;
8Memorial University of Newfoundland, St John's, NL, Canada;
9Canadian Network for Observational Drug Effect Studies (CNODES),
Montreal, QC, Canada
Background: Fluoroquinolone antibiotics are associated with rare,
but severe adverse events. Their effectiveness in treating severe
exacerbations of COPD (AECOPD) requiring hospitalization has been
well documented. However, they are frequently also used for
the treatment of mild and moderate acute exacerbations. The poten-
tial benefit of fluoroquinolone antibiotics in the ambulatory setting
is less clear, especially in uncomplicated patients with AECOPD.
Objectives: To compare health outcomes in patients treated with
fluoroquinolones compared to other antibiotics in uncomplicated
patients with AECOPD.
Methods:Wecarried out a retrospective cohort study inmultiple health
care databases from six Canadian provinces comparing 30‐day out-
comes in subjects with uncomplicated COPD visiting their physician
for an AECOPD and dispensed either a quinolone or other antibiotics.
Differences between the treatment groupswere adjusted for using high
dimensional propensity scores. Aggregate data from each province was
combined by random effects meta‐analysis.
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Results: We identified 286,866 AECOPD events among 203,642
unique individuals. The level of fluoroquinolones use, mostly
levofloxacin and moxifloxacin, varied by province and ranged from 8%
to 32% of AECOPD antibiotic prescriptions. The risk of a repeat ambu-
latory care visit was increased among patients dispensed a fluoroquino-
lone, OR 1.32, 95% CI 1.27–1.36. The risk of a hospitalization for
AECOPD for subjects dispensed a fluoroquinolone was higher than
for subjects prescribed other antibiotics; OR 1.52, 95% CI 1.33–1.74.
There was no difference in subsequent antibiotic prescriptions; OR
1.00, 95% CI 0.94–1.07.
Conclusions: There was no apparent benefit in short term outcomes
with fluroquinolones as compared to other antibiotics for the
ambulatory treatment of AECOPD in uncomplicated patients.
These findings support curent recommendations that fluoroquinolones
be reserved for AECOPD in patients with recurrent exacerbations, sig-
nificant co‐morbidity or requiring hospitalization.
837 | Excess risk of tendon rupture due to
fluoroquinolones with and without
concomitant corticosteroid use
Rebecca Persson1; Susan Jick1,2
1Boston Collaborative Drug Surveillance Program, Lexington, MA;
2Boston University School of Public Health, Boston, MA
Background: Fluoroquinolone antibiotics have been associated with an
increased risk of Achilles tendon rupture. However, the rate of Achilles
and other tendon rupture attributable to fluoroquinolones, with and
without concomitant corticosteroid use, has not been well described.
Objectives: To estimate the relative, absolute, and attributable risk of
non‐traumatic tendon rupture, at various sites, associated with use of
fluoroquinolones, with and without concomitant corticosteroids.
Methods: We conducted cohort and nested case–control studies
among fluoroquinolone users in the United Kingdom Clinical Practice
ResearchDatalinkGOLD. From the population of fluoroquinolone users
(ages 10–80), cases of tendon rupture were identified using Read codes
and matched 4:1 with controls on age, sex, calendar time and general
practice. Cases of traumatic tendon rupture, including cases within
90 days of a major trauma, were excluded, as were cases and controls
with a history of tendon rupture or strong risk factors for rupture (e.g.
organ transplant). We estimated the excess risk (incidence rate differ-
ences) using Byar's method (cohort analysis) and odds ratios (ORs) using
conditional logistic regression (case control) of tendon rupture by use of
fluoroquinolones (current, recent and past use verses unexposed) and
corticosteroids (current versus unexposed). Effect modification was
assessed for age, sex and corticosteroids.
Results: We identified 3957 cases of tendon rupture among 740,926
patients with a fluoroquinolone prescription. In the case–control analy-
sis, ORs with 95% confidence intervals (CI) among current fluoroquino-
lone users versus unexposed patients were elevated: any tendon
rupture 1.60 (1.22–2.09), Achilles tendon 2.71 (1.76–4.17) and bicep
tendon 1.53 (0.85–2.73). The risk of any tendon rupture was higher
among women (OR 2.27 (1.54–3.34)), patients aged 60+ (OR 2.42
(1.74–3.37)), and concomitant corticosteroid users (OR 6.64 (3.99–
11.1)). The excess risk due to current fluoroquinolone use was low:
any tendon rupture 3.73 cases (95% CI, 2.08–5.39) per 10,000 PY,
Achilles tendon rupture 2.91 (1.71–4.11) per 10,000 PY and bicep ten-
don rupture 0.59 (−0.14–1.32) per 10,000 PY. The excess risk of any
tendon rupture was much higher for current concomitant fluoroquino-
lone and corticosteroid use versus corticosteroids alone: 21.2 cases
(11.3–31.2) per 10,000 PY.
Conclusions: Fluoroquinolones increase the risk of Achilles tendon rup-
ture and, to a lesser extent, bicep tendon rupture, but the attributable
risk is low. The risk is materially increased with concomitant use of
corticosteroids.
838 | Early childhood antibiotics use and the
risk of attention‐deficit/hyperactivity
disorder: A population‐based cohort study
Amani Hamad; Silvia Alessi‐Severini; Salah Mahmud; Marni Brownell;
I. fan Kuo
University of Manitoba, Winnipeg, MB, Canada
Background: Early childhood antibiotic exposure induces changes in
infants' gut microbiota composition reportedly associated with the
development of Attention‐Deficit/Hyperactivity Disorder (ADHD).
Objectives: In this study, we examined the association between anti-
biotic use in the first year of life and the risk of ADHD.
Methods: This was a population‐based cohort study utilizing the
Manitoba Population Research Data Repository. The cohort included
187,605 children born in Manitoba, Canada between April 1,
1998 and March 31, 2017. Exposure was defined as having filled
one or more antibiotic prescriptions during the first year of life.
The outcome was ADHD diagnosis identified in hospital abstracts,
physician visits or drug dispensations. Risk of developing ADHD
was estimated using Cox proportional hazards regression models in
a high dimensional propensity scores‐matched cohort and a sibling
cohort.
Results: A total of 69,738 children were included in the matched‐
cohort. During follow‐up, 6087 (8.7%) children received an ADHD
diagnosis. ADHD risk was not found to be associated with antibiotic
exposure in early life (HR 1.02, 95% CI 0.97–1.08). In secondary
analyses, an association was observed in those receiving three or
more antibiotic courses or for a duration longer than three weeks
(HR 1.57, 95% CI 1.23–2.00 and HR 1.38, 95% CI 1.17–1.64,
respectively). In the sibling cohort of 67,671 children, antibiotic
exposure was not associated with the risk of ADHD (HR 0.96,
95% CI 0.89–1.03). No association was observed in any of the sec-
ondary analyses.
Conclusions: Antibiotic use in the first year of life does not appear
to pose an ADHD risk on a population level.
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839 | Comparative safety and cost
assessment of prescribing systemic steroids
for acute respiratory tract infections
Kueiyu Joshua J. Lin1; Sebastian Schneeweiss1; Evan Dvorin2;
Mehdi Najafzadeh1; Aaron S. Kesselheim1
1Brigham and Women's Hospital, Boston, MA; 2Ochsner Health System,
JeffersonParish, LA
Background: Evidence and guidelines do not support use of systemic
steroids for acute respiratory tract infections (ARTIs), but about one‐
in‐ten patients in the US receive this treatment.
Objectives: To assess how treating ARTIwith systemic steroids impacts
clinical outcomes and health care costs.
Methods: We used a large US national commercial claims
database, the IBM MarketScan, to identify patients aged 18–65 from
2007–2016, who entered the study cohort after an ambulatory visit
with an ARTI diagnosis (acute bronchitis, sinusitis, pharyngitis, otitis
media, allergic rhinitis, influenza, pneumonia, and unspecified
upper respiratory infections; ARTI diagnosis date was the cohort
entry date [CED]). Steroid user group consists of those receiving sys-
temic steroids within 7 days of the ARTI diagnosis and non‐user
group was selected by risk‐set sampling among the non‐use per-
son‐time within 7 days after CED. Those with systemic steroid use
and an extensive list of steroid‐indicated conditions in the prior year
before CED were excluded. We used Cox Regression to calculate
the hazard ratios (HR) of sepsis, gastrointestinal bleeding (GIB), and
fracture in 30, 31–90, 91–180 days after the index date (steroid dis-
pensing date for users and selection date for non‐users). We
also examined association with some negative control outcomes,
including pancreatitis, seizure, and acute kidney injury. We used
generalized linear models to calculate difference in mean health
care costs. Propensity‐score (PS) matching was used to adjust for
55 selected confounders.
Results: Our study cohort included 1,291,810 steroid users and
1,291,810 non‐users (855,535 of each group matched based on PS).
Most (84%) of the users were prescribed steroid for ≤7 days. Compar-
ing steroid users vs. non‐users, adjusted HR (aHR) was 1.26 (95% confi-
dence interval [CI] 1.07–1.48) for sepsis, 1.58 (1.01–2.48) for GIB, and
1.04 (0.98, 1.11) for fracture for the first 30 days. The corresponding
risks of sepsis and GIB attenuated to null before 90 days but the
increased risk of fracture from steroid use persisted in 90–180 days
(1.14 [95% CI, 1.09–1.19]). The adjusted mean total health care costs
were $346.34 (95% CI $324.08–368.60) more in steroid users than in
non‐users after the ARTI diagnosis, largely driven by outpatient costs
($260.33 [95% CI $247.45–273.21]). All the HRs for the negative con-
trol outcomes were null.
Conclusions: Prescribing systemic steroids for ARTI was
associated with elevated risks of GI bleeding and sepsis and increased
health care costs as early as the first 30 days after ARTI diagnosis.
840 | Antibiotic use and colorectal cancer
recurrence and mortality: A Danish
Nationwide prospective cohort
Veronika Fedirko1; Deirdre Cronin‐Fenton2; Anders Hammerich Riis2;
Henrik Toft Sørensen2; Timothy L. Lash1
1RSPH, Emory University, Atlanta, GA; 2Aarhus University Hospital,
Aarhus, Denmark
Background: Despite advances in screening and treatment, colorectal
cancer (CRC) remains the 4th most common cause of cancer related
deaths globally. Nearly 3.5 million CRC survivors worldwide are at risk
of adverse CRCoutcomes, including death fromCRC,which is preceded
by a recurrence. The human gut microbiome plays a vital role in the
host's gut physiology and potentially contributes to CRC progression
and response to treatment. Antibiotic (ABX) use has been associated
with reduced diversity and altered composition of the gut microbiota
in humans. Given the frequency of antibiotic use in the adult population
and their effects on the gut microbiome, the potential influence of anti-
biotics on the clinical course of CRC is of great public health interest.
Objectives: To assess the association of pre‐diagnostic and post‐diag-
nostic ABX use with the risk of CRC recurrence and mortality.
Methods: Using data from Danish registries, we followed
21,152 patients (5,036 recurrences, 7,084 deaths) diagnosedwith stage
I‐III CRC during 2001–2011 and registered in the Danish Colorectal
Cancer Database. We ascertained information on potential con-
founders from Danish population‐based and medical registries. We
examined the association between pre‐diagnostic and post‐diagnostic
antibiotic use and CRC recurrence and mortality, controlling for age,
sex, year of diagnosis, tumor stage, tumor location, treatment, comor-
bidities, history of inflammatory bowel disease, and the use of NSAIDs,
aspirin, and statins.
Results: After adjustment for potential confounders, any ABX prescrip-
tion 90 days prior to CRC diagnosis was not associated with recurrence
[adjusted hazard ratio (aHR) = 1.06, 95% confidence interval (CI): 0.98,
1.14]. ABX use after CRC diagnosis was also not associated with recur-
rence (aHR = 1.03, 95% CI: 0.97, 1.09). However, both pre‐diagnostic
and post‐diagnostic use of ABX was associated with overall and CRC‐
specific mortality (90 days prior to diagnosis: overall mortality
aHR = 1.13, 95% CI: 1.06, 1.20, CRC mortality aHR = 1.09, 95% CI:
1.01, 1.19; after diagnosis: overall mortality aHR = 1.38, 95% CI: 1.32,
1.45, CRC mortality aHR = 1.29, 95% CI: 1.21, 1.38). The association
of pre‐diagnostic ABX use and overall mortality was stronger for more
than one prescription of ABX compared to none (aHR = 1.16, 95% CI:
1.05, 1.27), and for broad spectrum ABX (aHR = 1.47, 95% CI: 1.39,
1.55).
Conclusions: Our results suggest ABX use not to be associated with
cancer recurrence in this group of CRC patients. A higher risk
observed for overall and CRC‐specific mortality is possibly due to
confounding by indication.
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841 | Staying on treatment matters:
estimating effects of dabigatran vs warfarin in
Medicare
Michael Webster‐Clark; Til Stürmer; Charles Poole; Ross Simpson;
Jessie K. Edwards; Jennifer L. Lund
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: There are many studies of the relative efficacy and
safety of dabigatran and warfarin in patients with atrial fibrillation
(AF), but little evidence exists on the risk differences (RD) necessary
for benefit‐harm assessment. In addition, few studies contrast as‐
treated (AT) and initial treatment (IT) designs or estimate treatment
effects in all new users.
Objectives: Estimate 2‐year RDs in ischemic stroke (IS), death, and
gastrointestinal bleeding (GIB) comparing new use of dabigatran ver-
sus new use of warfarin using AT and IT designs in dabigatran new
users or new users of either drug.
Methods: We identified new users (60‐day washout period) of war-
farin and 150 mg of dabigatran with AF in a Medicare 20% nation-
wide random sample from January 2010 through October 2015,
including first period of new use eligible for the RE‐LY trial. In the
AT design, we censored users after switching oral anticoagulants or
45‐ and 30‐day gaps in drug supply for warfarin and dabigatran
users respectively, with anticoagulation management procedure
codes refreshing warfarin supply. In the IT design, we followed users
until death or October 2015. We estimated 2‐year outcome risks
with a weighted Aalen‐Johansen estimator to allow for the compet-
ing risk of death and obtained RD variances via nonparametric boot-
strap. We used both inverse probability of treatment weights (IPTW)
and standardized morbidity ratio (SMR) weights targeting dabigatran
users, incorporating censoring weights in the AT.
Results: We identified 10,623 dabigatran users and 74,194 warfarin
users. Dabigatran users were younger (median age 75 vs 78 years)
with lower predicted probability of frailty (median 5.0% vs 7.3%) and
fewer comorbid conditions. IPTW 2‐year AT RDs showed decreased
IS risk with dabigatran versus warfarin (−0.7%, 95% CI ‐1.4%, −0.1%)
while IT RDs showed increased risk (RD 0.6%, 95% CI ‐0.1%, 1.4%).
AT RDs for death were more favorable than IT RDs, though both were
protective (AT RD: −3.2%, 95% CI: −5.3%, −1.2%; IT RD: −1.0%, 95%
CI ‐2.6%, 0.6%). GIB RDs increased in the AT design (AT RD: 1.8%,
95% CI ‐0.2%, 3.9%; IT RD: 1.1% 95% CI 0.1%, 2.1%). SMR showed
more benefit and less harm than IPTW, particularly for GIB (AT RD:
0.6%, 95% CI ‐0.3%, 1.4% IT RD: 0.4%, 95% C.I. ‐0.1%, 0.8%).
Conclusions: Our AT estimates suggest dabigatran is protective for
mortality and IS if patients stay on treatment; these effects diminish
or reverse in IT analyses. Dabigatran new users appear to be at lower
risk of experiencing harms than all new users. Future research on pos-
sible mortality benefits of oral anticoagulants in older adults and ways
to keep patients on anticoagulants are vital for AF patients.
842 | Comparative effectiveness and safety
of concomitant use of antiplatelets and
anticoagulants in acute coronary syndrome
patients with atrial fibrillation
Ghadeer K. Dawwas; Eric Dietrich; David Winchester;
Almut Winterstein; Richard Segal; Haesuk Park
University of Florida, Gainesville, FL
Background: Current treatment guidelines for patients with acute
coronary syndrome (ACS) and arterial fibrillation (AF) recommend
antiplatelets and anticoagulants. However, the optimal strategy to
balance the prevention of cardiovascular disease (CVD) and bleeding
risk remains unclear. There is limited evidence on the comparative
effectiveness and safety of concomitant antiplatelet‐anticoagulant
use in the era of direct‐acting anticoagulants (DOACs).
Objectives: We aimed to assess the comparative effectiveness and
safety of antiplatelet‐DOACs compared to antiplatelet‐warfarin in
patients with ACS and AF.
Methods: A retrospective cohort analysis of Truven Commercial and
Medicare supplemental database (2010–2016) was conducted for
treatment‐naive ACS patients with AF. Patients who were
(1) ≥ 18 years (2) had a diagnosis of ACS (ICD‐9, 410.xx; 411.xx;
ICD‐10: I21, I22) (3) a diagnosis of AF (ICD‐9, 427.31; ICD‐10, I48)
within the one year preceding the first ACS diagnosis and (4) used
concomitant antiplatelet‐anticoagulant within 30 days of their first
admission of ACS were included. The study outcomes including CVD
and major bleeding events were compared between users of antiplate-
let‐DOACs and antiplatelet‐warfarin. Cox‐proportional hazard models
after propensity score matching (PSM; 1:3) were used to obtain the
hazard ratio (HR) and 95% confidence interval (CI).
Results: It is worth noting that even prior to PSM, most baseline
characteristics were comparable between the two groups including
age (69 yrs vs. 69 yrs), presence of comorbidities including liver dis-
ease (0.6% vs. o.6%), cancer (7.0% vs. 8.0%) and use of medications
such as thiazide diuretics (2.0% vs. 2.0%). After PSM, a total of
1,783 were included (n = 506 patients for antiplatelet‐DOACs and
n = 1,277 for the antiplatelet‐warfarin). The incidence rate of
CVD was 10 and 23 per 100 person‐years in the antiplatelet‐
DOACs and antiplatelet‐warfarin groups, respectively. The incidence
of major bleeding was 4 and 11 per 100 person‐years in the anti-
platelet‐DOACs and antiplatelet‐warfarin groups, respectively. In
the Cox model, compared to antiplatelet‐warfarin the use of anti-
platelet‐DOACs was associated with a lower risk of CVD (HR,
0.47; 95% CI, 0.30, 0.73) and major bleeding (HR, 0.40; 95% CI,
0.20, 0.78).
Conclusions: Our findings suggest that when the combination ther-
apy is considered, DOACs with antiplatelets appears to be superior
to warfarin ‐antiplatelets in preventing the development of CVD
and bleeding events in treatment naïve ACS patients with AF.
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843 | Safety and effectiveness of direct oral
anticoagulants versus vitamin K antagonists,
results from three Italian regions
Ursula Kirchmayer1; Silvia Narduzzi1; Flavia Mayer2; Marco Tuccori3;
Olivia Leoni4; Valeria Belleudi1; Antonio Addis1; Marina Davoli1
1Lazio Regional Health Service, Rome, Italy; 2National Institute of Health,
Rome, Italy; 3University Hospital of Pisa, Pisa, Italy; 4Lombardy Region,
Milan, Italy
Background: In Italy, direct oral anti‐coagulant drugs (DOACs) were
authorized for stroke prevention in patients with non‐valvular atrial
fibrillation (NVAF) in 2013. There is conflicting evidence on their ben-
efit–risk profile under real world conditions.
Objectives: A population based study was funded by the Italian Med-
icines Agency with the aim to investigate effectiveness and safety of
DOACs compared to standard therapy with vitamin K antagonists
(VKAs) in three Italian regions (Lazio, Lombardy, Tuscany) accounting
for almost 20 million residents.
Methods: An observational study was conducted with a sequential
propensity‐score (PS)‐matched new user parallel‐cohort design in the
period July 2013–December 2015 using administrative health data.
DOAC (dabigatran, rivaroxaban, apixaban) users with NVAF diagnosis
were 1:1 matched to VKA (warfarin, acenocoumarol) users based on a
PS which accounted for over 90 potential confounders (socio‐demo-
graphic, comorbidity, drug consumption, CHA₂DS₂‐VASc and HAS‐
BLED scores) at baseline. Applying an as‐treated approach with a
90‐day renewal grace time, patients were followed from the day after
the first prescription of the study drug until occurrence of the out-
come, death, discontinuation, switch, end of health plan enrolment,
or study end. Outcomes were total mortality, cardiovascular mortality,
acute myocardial infarction, ischemic and haemorrhagic stroke, and
gastrointestinal bleeding. The 30 months were broken down into 9
time windows, and at the end of each interval, analyses were per-
formed, using Cox proportional hazard models. The results of the
regional analyses were combined through a random‐effects meta‐
analysis.
Results: During the first 30 months of authorisation for NVAF, DOACs
were increasingly prescribed and at the end outweighed VKAs. Over-
all, 72,429 new anticoagulant users were enrolled, 34% of whom
received a DOAC. After PS matching, 37,266 patients contributed to
the analysis. No differences between the two study groups were
found for total and cardiovascular mortality, myocardial infarction
and ischemic stroke. DOAC users were at higher risk of gastrointesti-
nal bleeding (HR:1.41, 95%CI:1.07–1.86), and at lower risk of
haemorrhagic stroke, which did not reach statistical significance due
to small numbers (HR:0.36, 95%CI:0.10–1.33).
Conclusions: The present study confirms findings from previous
research. Future investigations on head‐to‐head comparison
between single DOAC active agents and on population subgroups
who may particularly benefit from the new treatment options are
warranted.
844 | Comparative effectiveness and safety
of direct oral anticoagulants in non‐valvular
atrial fibrillation: a multi‐center observational
cohort study
Madeleine Durand1; Mireille E. Schnitzer2,3; Menglan Pang3;
Greg Carney4; Sherif Eltonsy5; Kristian B. Filion3,6; Anat Fisher4;
Min Jun7; I. fan Kuo8; Alexis Matteau9; J. Michael Paterson10,11;
Jacqueline Quail3,12; Christel Renoux3,6;
for the CNODES Investigators
1Centre Hospitalier de l'Université de Montréal (CHUM) and CHUM
Research Center, Montreal, QC, Canada; 2Université de Montréal,
Montreal, QC, Canada; 3McGill University, Montreal, QC, Canada;
4University of British Columbia, Vancouver, BC, Canada; 5Faculty of
Health Sciences, Manitoba, MB, Canada; 6 Jewish General Hospital,
Montreal, QC, Canada; 7University of New South Wales, Sydney,
Australia; 8University of Manitoba, Winnipeg, MB, Canada; 9Centre
Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada;
10 ICES, Toronto, ON, Canada; 11University of Toronto, Toronto, ON,
Canada; 12Health Quality Council, Saskatoon, SK, Canada; 13University
of Saskatchewan, Saskatoon, SK, Canada; 14Canadian Network for
Observational Drug Effect Studies (CNODES) Investigators, Montreal, QC,
Canada
Background: Atrial fibrillation is the most common cardiac arrhyth-
mia, with lifelong anticoagulation generally recommended to prevent
cardio‐embolic stroke. Direct oral anticoagulants (DOACs) are widely
replacing vitamin K antagonists for anticoagulation in non valvular
atrial fibrillation (NVAF). No randomized trials have compared
DOACs head to head, and large observational studies are needed,
especially to compare the newer apixaban to the other two available
DOACs.
Objectives: To compare safety and effectiveness among DOACs in
NVAF.
Methods: We conducted multi‐center observational cohort studies
with meta‐analyses using data from seven Canadian healthcare data-
bases, US MarketScan®, and the UK's Clinical Practice Research
Datalink. All adults with NVAF initiating anticoagulation therapy with
dabigatran, rivaroxaban, or apixaban between January 1st, 2009 and
March 31st, 2017 were included. Patients were matched on a propen-
sity score including sex, age, date of cohort entry, and clinically‐
defined potential confounders. The outcomes included ischemic
stroke, major bleeding and a composite of stroke, major bleeding, or
all‐cause mortality. For each of the matched cohorts and for each out-
come, we fit a Cox marginal structural proportional hazards model to
estimate the marginal hazards ratios contrasting the different types
of DOACs. Meta‐analysis techniques with random effects were used
to estimate pooled hazard ratios (pHR) across the databases.
Results: The cohorts included 73,414 new users of dabigatran, 92,881
of rivaroxaban, and 61,284 of apixaban. After matching, the pHRs (and
95% confidence intervals) comparing rivaroxaban initiation to
dabigatran were: 1.11 (0.93 to 1.32) for ischemic stroke, 1.26 (1.09
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to 1.46) for major bleeding, and 1.17 (1.05 to 1.30) for the composite
outcome. For apixaban vs dabigatran, they were: 0.91 (0.74 to 1.12)
for ischemic stroke, 0.89 (0.75 to 1.05) for major bleeding, and 0.94
(0.78 to 1.14) for the composite outcome. For apixaban vs
rivaroxaban, they were: 0.85 (0.74 to 0.99) for ischemic stroke, 0.61
(0.53 to 0.70) for major bleeding, and 0.82 (0.76 to 0.88) for the com-
posite outcome.
Conclusions: This large multi‐center observational study suggests that
apixaban is more effective at preventing stroke and safer with respect
to bleeding risks compared with rivaroxaban. Apixaban appears to
have similar effectiveness and safety compared with dabigatran. In
the absence of head‐to‐head trials, this large, multi‐database observa-
tional study adds important evidence to guide clinical use of DOACs.
845 | Comparative effectiveness and safety
of direct acting oral anticoagulants and
warfarin in cancer patients with venous
thromboembolism
Ghadeer K. Dawwas1; Eric Dietrich1; Kyle Davis2; Haesuk Park1
1University of Florida, Gainesville, FL; 2Wake Forest Baptist Medical
Center, Winston‐Salem, NC
Background: There is limited evidence to support the use of direct‐
acting oral anticoagulants (DOACs) in cancer patients with venous
thromboembolism (VTE).
Objectives: The study aimed to assess the comparative effectiveness
and safety of DOACs compared to warfarin in patients with VTE and
active cancer.
Methods: A retrospective cohort analysis using the Truven Commer-
cial and Medicare supplemental database (2013–2016) was con-
ducted. Patients who (1) were ≥ 18 years (2) had a diagnosis of VTE
(ICD‐9: 415.1, 451.1, 453.2, 453.4, 453.5, 453.8, or 453.9 and ICD‐
10: I80.2, I80.3, I80.1, I82.8, I80.9, I82.9, I80.8, O22.3, O22.9,
O87.1, I26.9, I26.0) (3) had a diagnosis of an active cancer within the
6 months period preceding their initial VTE and in treatment with
radiotherapy or chemotherapy and (4) initiated DOACs (apixaban,
rivaroxaban, dabigatran, edoxaban) or warfarin within 30 days of their
first VTE diagnosis were included. The risk of recurrent VTE and major
bleeding was compared between DOACs and warfarin using Cox‐pro-
portional hazard models after propensity score matching (PSM) (1:1).
In the subgroup analysis, we stratified the study outcomes into pulmo-
nary embolism vs. deep vein thrombosis (for the recurrent VTE out-
come), and gastrointestinal bleeding [GI] vs. intracranial bleeding (for
the major bleeding outcome).
Results: After PSM, a total of 10,006 patients were included in the
cohort (n = 5,003 DOACs users and n = 5,003 warfarin users). The
incidence of recurrent VTE was 5 and 9 per 100 person‐years in the
DOACs and warfarin groups, respectively. The incidence of major
bleeding was 3 and 6 per 100 person‐years in the DOACs and warfa-
rin groups, respectively. In Cox regression models, the use of DOACs
compared to warfarin was associated with a lower risk of recurrent
VTE (HR, 0.61; 95% CI, 0.48, 0.77) and major bleeding events (HR,
0.60; 95% CI, 0.45, 0.81). Study results remained consistent when
stratifying the study outcome into PE (HR, 0.65; 95% CI, 0.47, 0.90)
and DVT (HR, 0.51; 95% CI, 0.35, 0.73) (P interaction = 0.13), and GI
bleeding (HR, 0.63; 95% CI, 0.46. 0.87) and intracranial bleeding (HR,
0.45; 95% CI, 0.19, 1.03) (P interaction = 0.98).
Conclusions: Our findings suggest that among cancer patients with
VTE, DOACs offer superior effectiveness for the secondary prevention
of VTE as well as a lower risk of bleeding when compared to warfarin.
846 | Risk of major bleeding associated with
the use of individual direct oral anticoagulants
compared to vitamin K antagonists in patients
with non‐valvular atrial fibrillation: a meta‐
analysis of results from multiple population‐
based cohort studies using a common
protocol in Europe and Canada
Hendrika van den Ham1; Patrick Souverein1; Olaf Klungel1;
Robert Platt2; Pierre Ernst2; Sophie Dell'Aniello2; Sven Schmiedl3,4;
Birgit Grave5; Marietta Rottenkolber6; Consuelo Huerta7;
Elisa Martin Merino7; Luz León‐Muñoz7; Luz León‐Muñoz7;
Dolores Montero7; Morten Andersen8; Mia Aakjær8;
Marieke De Bruin9; Helga Gardarsdottir1,10,11
1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht
Institute for Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 2 Lady Davis Institute of the Jewish General Hospital and
Canadian Network for Observational Drug Effect Studies, Montreal, QC,
Canada; 3Department of Clinical Pharmacology, School of Medicine,
Faculty of Health, Witten/Herdecke University (UW/H), Witten,
Germany; 4Philipp Klee‐Institute for Clinical Pharmacology, Helios
University Hospital Wuppertal, Wuppertal, Germany; 5AOK NORDWEST,
Dortmund, Germany; 6Diabetes Research Group, Medizinische Klinik und
Poliklinik IV, Klinikum der Universität München, Munich, Germany;
7Division of Pharmacoepidemiology and Pharmacovigilance, Spanish
Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain;
8Pharmacovigilance Research Group, Department of Drug Design and
Pharmacology, Faculty of Health and Medical Sciences, University of
Copenhagen, Copenhagen, Denmark; 9Copenhagen Centre for Regulatory
Science, Department of Pharmacy, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark;
10Department of Clinical Pharmacy, Division Laboratory and Pharmacy,
University Medical Center Utrecht, Utrecht, Netherlands; 11Faculty of
Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland
Background: Several observational studies have been carried out
before to investigate the real world benefit–risk balance of direct oral
anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in
patients with non‐valvular atrial fibrillation (NVAF). However, informa-
tion on the differences in performance within the class of DOACs and
for different subgroups of patients is still inconclusive due to the lack
of statistical power.
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Objectives: The aim of this study was to establish the risk of major
bleeding in DOAC users (overall and by class) versus VKA users using
healthcare databases from four European countries and six provinces
in Canada.
Methods: All research groups used the same protocol to perform a
retrospective cohort study. First‐users of VKAs or DOACs with a diag-
nosis of NVAF were included. The main outcome of interest was major
bleeding and secondary outcomes included gastrointestinal (GI) bleed-
ing and intracranial hemorrhage (ICH). Incidence rates of events per
1,000 person years were calculated. Hazard ratios (HRs) and 95% con-
fidence intervals (95% CI) were estimated using a Cox proportional
hazard regression model. VKA or DOAC exposure and confounders
were measured and analyzed in a time dependent way. Risk estimates
were pooled using meta‐analysis techniques with a random effect
model.
Results: In total, 421,523 patients were included in the period of
2008–2015 of which 37.2% used a DOAC and 62.8% used a VKA.
The risk of major bleeding for the group of DOACs compared to
VKAs showed a pooled HR of 0.94 (95% CI: 0.87–1.02). Risk dif-
fered by age group; for those ≥75 years old, HR was 1.01, 95%
CI 0.94–1.09, while for those <75 HR was 0.83, 95% CI 0.73–
0.95. Rivaroxaban showed a modestly increased risk (HR 1.11, 95%
CI 1.06–1.16). Apixaban and dabigatran showed a decreased risk of
respectively HR 0.76 (95% CI 0.69–0.84) and HR 0.85 (95% CI
0.75–0.96) compared to VKAs. The observed risk on GI bleeding
was elevated around 20% for dabigatran and rivaroxaban and
lowered with around 30% for apixaban. The observed risk on ICH
was for all DOACs lower than for VKAs.
Conclusions: This study confirms that the risk of major bleeding of
DOACs compared to VKAs is not increased when combining all
DOACs. However, we observed a modest higher risk of major bleed-
ing for rivaroxaban, whereas for apixaban and dabigatran lower risks
of major bleeding were observed compared to VKAs.
847 | Impact of the publicly funded herpes
zoster immunization program on burden of
disease in Ontario, Canada
Mina Tadrous1; Daniel McCormack2; Diana Martins1; Tara Gomes1;
Jeff Kwong2; Sarah Buchan3; Tony Antoniou1
1St. Michael’s Hospital, Toronto, ON, Canada; 2 ICES, Toronto, ON,
Canada; 3Public Health Ontario, Toronto, ON, Canada
Background: Herpes zoster (shingles) infections are associated with
considerable morbidity and healthcare costs. In September 2009, a
live, attenuated herpes zoster (HZ) vaccine (Zostravax) became avail-
able in Canada. This was subsequently provided free of charge to all
Ontario residents aged 65 to 70 through a publicly‐funded immuniza-
tion program commencing in September 2016.
Objectives: To examine the impact of the HZ vaccine availability and
Ontario's immunization program on HZ incidence and associated
health service use in Ontario.
Methods: We conducted a population‐based time‐series analysis
among Ontarians aged 65 to 70, between January 2005 and June
2018. We report monthly rates of herpes zoster incidence, defined
as 1) physician visit for HZ with a HZ antiviral prescription dispensed
within +/− 5 days, or 2) emergency department (ED) visit or hospital-
ization for HZ. Secondary outcomes included monthly rates of HZ
related ED visits and hospitalizations. We stratified outcomes by sex,
income quintile and rural/urban residence. We used interventional
autoregressive integrated moving average (ARIMA) models to examine
the impact of the HZ vaccine availability and Ontario's immunization
program on our outcomes.
Results: The availability of a herpes zoster vaccine did not significantly
impact trends of incidence or related hospitalizations among Ontarians
aged 65 to 70 (p = 0.43 and p = 0.97, respectively). In contrast, the
subsequent implementation of Ontario's immunization program signif-
icantly reduced the rate of incidence among our population by 25.3%
between August 2016 and June 2018 (p < 0.01; from 4.8 to 3.6 indi-
viduals per 10,000 population). The rate of ED visits and hospitaliza-
tions for herpes zoster were relatively stable between January 2005
and August 2016, but significantly decreased following Ontario's
immunization program by 36.2% (p < 0.02; from 1.7 to 1.1 hospitaliza-
tions per 10,000 population between August 2016 and June 2018).
Findings were consistent when stratified by sex, income quintile and
rural/urban residence.
Conclusions: Ontario's publicly‐funded immunization program for her-
pes zoster led to significant reductions in the incidence of disease and
related hospitalizations among individuals aged 65 to 70 in the prov-
ince. Our future work will evaluate the cost savings associated with
the reduction in herpes zoster‐related health service use.
848 | Trends in human papillomavirus
vaccination uptake in girls and boys in the
United States: real‐world evidence from 2003
to 2016
Szu‐Ta Chen1; Krista F. Huybrechts2; Brian T. Bateman2;
Sonia Hernández‐Díaz1
1Harvard Chan School of Public Health, Boston, MA; 2Brigham and
Women's Hospital and Harvard Medical School, Boston, MA
Background: Human papillomavirus (HPV) vaccination is recommended
at age 11 and 12 to prevent HPV infection and subsequent occurrence
of HPV‐related cancers. The Healthy People 2020 goal for HPV vacci-
nation coverage is 80% by 15 years of age. In the U.S. there is a lack
of nationwide population‐based data on HPV vaccination.
Objectives: To describe the trends in HPV vaccination in children in
the U.S.
Methods: We identified a pediatric cohort within the Truven
MarketScan healthcare database between January 2003 and Decem-
ber 2016. Children were followed from the year they turned 9 until
the first dose of HPV vaccination, end of insurance coverage, the
end of the year when they turned 17, or death, whichever came first.
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HPV vaccination was defined using current procedure terminology
(CPT) codes. The monthly vaccination rate was calculated as the num-
ber of children that received the HPV vaccination in that month
divided by the sum of person‐months contributed by the eligible chil-
dren that month. The cumulative incidence of HPV vaccination was
estimated by using survival analyses to account for censoring. The
study population was stratified by birth year and gender. The cumula-
tive incidence of HPV vaccination at age 15 was mapped across 50
States. To test the robustness of our methods, we examined the use
of two vaccines: pneumococcal conjugate vaccine (PCV) and measles
vaccine, with an expected coverage over 88% in infants.
Results: The study included 7,500,397 children (49% females) and
18.8 million person‐years. The proportions of 15 years old girls and
boys who had received HPV vaccination increased from 38% and
5% (1996‐birth cohort) in 2011 to 54% and 45% (2001‐birth cohort)
in 2016. HPV vaccination tended to be higher in the Northeast than
in Southern states but varied substantially across states, from a 78%
coverage in girls in Rhode Island to 20% coverage for boys in Missis-
sippi. Restriction to children with continuous enrollment from ages 9
to 17 yielded almost identical estimates. For our positive controls, by
2016 the proportion of 3‐year‐old infants with at least one dose of
PCV and measles vaccination was 98% and 88%, respectively.
Conclusions: Despite the increasing trends in uptake, HPV vaccine
coverage in the U.S. remains behind target rates, with significant
regional disparities. Although HPV vaccination increased faster in
boys, since boys' recommendation lagged 5 years behind girls, it was
still lower in boys than in girls by 2016.
849 | Vaccination before first symptom of
central demyelination
Lamiae Grimaldi‐Bensouda1,2; Nicolas Morisot3;
Pegdwende O. Dialla3; Clémentine Nordon3,4; Lucien Abenhaim5,6
1University of Versailles Saint‐Quentin en Yvelines, Versailles, France;
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Research, London, UK; 6London School of Hygiene & Tropical Medicine,
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Background: Few studies have documented the role of vaccination
before first signs of central demyelination. HBV and HPV vaccines
have been the subject of distrust in some countries.
Objectives: To study the association between vaccines exposure and
central demyelination (CD), before CD's first symptom.
Methods: From a systematic national registry assembled in neurology,
patients with a first lifetime symptom of demyelination affecting the
brain, spinal cord or optic nerve were identified and documented for
their exposure to vaccines up to 24 months before the first symptom.
This exposure was compared to that of a representative sample of gen-
eral practice patients without a history of demyelination, randomly
selected in a national database (referents). Referents were matched to
CD cases on age, gender, index date (first symptom in cases) and region
of residence (northern or southern France). Vaccines against influenza,
hepatitis B (HBV), human papilloma virus (HPV), diphtheria‐tetanus‐
pertussis‐poliomyelitis haemophilus (DTPPHae) and others were stud-
ied. The associations between vaccination and the occurrence of CD
were assessed using multivariable conditional logistic models, con-
trolled for potential confounding factors including family history of
autoimmune diseases, geographic origin and co‐vaccinations.
Results: 564 cases of CD were matched to 1128 randomly selected
referents identified within the registries, with an age range of 2 yo
to 79 yo. 123 (22%) cases and 320 (28%) referents had received at
least one vaccine within the 24 months before the index date:
adjusted odds ratios (OR) were 0.69; 95%CI[0.54–0.88] for any CD
first sign (0.68 [0.51–0.90] for myelitis, 0.70 [0.42–1.17] for optic neu-
ritis). Similar results were observed for the 6‐month and 2‐month time
windows. Adjusted OR for any CD were 1.02 [0.71–1.47] for flu vac-
cines and 0.72 [0.53–0.99] for DTPPHae vaccines; vaccines against
HBV and HPV were used respectively by 1.1% and 1.3% of cases
and 2.9% and 3.2% of referents which statistically explained the odds
ratios below 1 observed for vaccination as a whole.
Conclusions: No increased association between vaccination and CD
was observed. Lower rates for vaccination against HBV and HPV in
patients with CD, may be due to an early withdrawal from exposure
in patients at risk of demyelination.
850 | Incidence of outcomes relevant to
vaccine safety monitoring in Europe using
two distinct data sources: National
Healthcare Registries (Sweden) and electronic
medical records (UK)
Lina Titievsky1; Nils Ekstrom2; James Stark1; Michael Törnblom3;
Dan Scott4; Rob Maroko4; Cassandra Hall‐Murray4; Peter McMahon5;
Leif Jörgensen6; Mats Rosenlund3,7
1Pfizer Inc, NYC, NY; 2Novo Nordisk Scandinavia AB, Stockholm, Sweden;
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Background: Readily available access to population‐based background
incidence rates (IRs) is critical for monitoring real world safety profiles
of vaccines in order to assess whether observed event rates exceed
expected rates that may be temporally but not causally associated
with vaccination. However, IRs may differ between regions due to dif-
ferences in population, outcome definition, disease reporting/record-
ing biases, and health care delivery system.
Objectives: To systematically estimate background IRs of 46 pre‐spec-
ified outcomes including autoimmune, allergic, and neurologic condi-
tions in Sweden (SE) and United Kingdom (UK) and evaluate the
extent to which these IRs differ given the potential underlying
variability.
Methods: The source populations were derived from national registers
in SE with hospital/speciality care and the Health Improvement
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Network (THIN) database, a UK primary‐care database. All patients
aged 0 to 100 years (yrs) from January 1, 2010 to December 31,
2016 were included. IRs were calculated as the number of events
divided by the total person‐time at risk (per 100,000 Person Years)
assuming a Poisson distribution with a 95% Confidence Interval (CI).
Results: 10,203,759 (SE) and 5,239,238 (UK) persons were included
with approximately 50% female in each cohort and mean age of
37.9 yrs (standard deviation (sd) = 25.1) in SE and 39.4 yrs (sd = 24.4)
in UK. Differences were seen in IRs between SE and UK, e.g. allergic
urticaria, SE: 40.3 (95% CI:39.8–40.7) vs. UK: 17.0 (95% CI:15.4–
16.5); anaphylactic shock, SE: 19.4 (95% CI 19.1–19.8) vs. UK: 5.9
(95% CI:5.6–6.2); arthritis, SE: 431.3 (95%CI: 429.7–433.0) vs UK:
783.1 (95% CI:779.3–786.9). Further divergence was seen in age
groups, e.g. in 0 to 5 yrs, IRs diverged for febrile seizures and myopa-
thies but not for Guillain‐Barre syndrome and angioedema; in 65+ yrs,
IRs diverged for acute disseminated encephalomyelitis and Raynaud's
disease but not for Idiopathic thrombocytopenic purpura and multiple
sclerosis.
Conclusions: This study systematically estimated IRs for a wide range
of pre‐specified outcomes in two large population‐based cohorts in
Europe. The differences in the magnitude of IRs between the two
were aligned with expectations of variability in population and health
care delivery systems and emphasize the importance of considering
these when conducting safety monitoring studies. This has the poten-
tial for significant impact in determining observed vs expected rates of
events in establishing or refuting the existence of a true safety issue.
851 | ADVANCE: towards near‐real time
monitoring of vaccination coverage, benefits
and risks using European electronic health
record databases
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Background: The Accelerated Development of VAccine beNefit–risk
Collaboration in Europe (ADVANCE) is a public‐private collaboration
aiming to develop and test a system for near real‐time (NRT) bene-
fit–risk (B/R) monitoring of vaccines using electronic health record
(eHR) databases in Europe.
Objectives: To test the feasibility of NRT monitoring (NRTM) of vacci-
nation coverage, benefits and risks based on multiple eHR databases
in Europe (EU), using acellular pertussis vaccination in children (<
6 years) as test case.
Methods: Among participating databases in the ADVANCE consortium,
which expressed interest in this NRTM study based on a preliminary
qualitative feasibility assessment, a dynamic cohort study was con-
ducted containing two distinct observation periods: a first period (Jan
2014 ‐ Feb 2018) to establish a baseline and a second period (March
2018–May 2018) to test the actual feasibility of NRTM of vaccination
coverage, benefits and risks. The events were dose‐specific vaccina-
tions (coverage), pertussis (benefit) and febrile convulsions, fever, hypo-
tonic‐hyporesponsive episodes, somnolence and persistent crying
(risks). Data latencies, differences in time between the date of diagnosis
and the data release date, were derived from consecutive data extracts
and an interactiveweb‐applicationwas developed for visualmonitoring.
Five databases from 4 European countries (Denmark: SSI; Italy: ARS,
ATSVP; Spain: SIDIAP and UK: RCGP RSCS) participated in this study.
Results: Five databases provided baseline data. Three databases (SSI,
ATSVP and RCGP RSC) successfully provided weekly data extractions
for a period of three months. The median data latency was 2 (SSI), 2
(ATSVP) and 1 week (RCGP RSC) for vaccinations and varied between
2 weeks and 3 month for the majority of benefit and risk events,
depending on type of event and database. ARS and SIDIAP did not
obtain approval in time to perform repeated data extractions.
Conclusions: This test case demonstrated that visual NRTM of vaccine
benefits and risks is possible with multiple EU eHR databases. Getting
the required approvals is a potential barrier.
852 | Variation in rotavirus vaccination
coding in US state Medicaid data
J. Bradley Layton1,2; Anne M. Butler3; M. Alan Brookhart2;
Catherine A. Panozzo4,5
1RTI Health Solutions, Research Triangle Park, NC; 2University of North
Carolina at Chapel Hill, Chapel Hill, NC; 3Washington University School of
Medicine in St. Louis, St. Louis, MO; 4Harvard Pilgrim Health Care
Institute, Boston, MA; 5Harvard Medical School, Boston, MA
Background: US state Medicaid claims databases may be an attractive
option for research into childhood vaccination use, safety, or effec-
tiveness. Variation in US state Medicaid reimbursement policies and
coding practices may present challenges for vaccination research that
seeks to use state Medicaid data. Rotavirus vaccines are the only oral
vaccine licensed for US infants, thus providing a useful test case for
exploring differences in the use of vaccine‐specific procedures codes
versus oral administration codes.
Objectives: We quantify state‐specific differences in procedure cod-
ing for rotavirus vaccination in Medicaid programs by identifying rota-
virus vaccine‐specific codes and oral vaccine administration codes.
Methods: We identified infants born between January 1 and June 30,
2010 in four US states' (California, Georgia, North Carolina, Texas)
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Medicaid programs. We identified all rotavirus vaccine‐related claims
in the cohort during the first 6 months of life and categorized each
claim as either vaccine‐specific or vaccine administration. As one vac-
cination could result in multiple codes of different types, we defined
unique vaccination events as discrete 7‐day periods during which at
least one rotavirus‐related vaccine code was present; all codes occur-
ring in the period were assumed to result from the same vaccination
event. We calculated the state‐specific proportions of eligible new-
borns with rotavirus vaccination claims and described the code types
used in each state.
Results: 59.4% of 273,312 eligible children had ≥1 rotavirus vaccine‐
related code in the first 6 months of life. We identified 259,857
unique vaccination events (~1.6 events/vaccinated child). The propor-
tion of vaccinated children with vaccine‐specific and oral vaccine
administration codes differed substantially across states: California
and Georgia used vaccine‐specific codes almost exclusively (96.7%
and 99.1%,); North Carolina had only oral vaccine administration
codes (>99.9%); Texas had a mixture (32.1% vaccine‐specific codes
alone, 40.0% oral vaccine administration codes alone, and 27.9% had
both).
Conclusions: Rotavirus vaccination coding varied substantially across
states. Vaccine‐specific codes were not used in all states, and Medic-
aid data in states without (or with incomplete) vaccine‐specific coding
may make ‐research on specific vaccine types infeasible. Investigators
should carefully evaluate state Medicaid policies and patterns of vac-
cination uptake, as vaccine reimbursement policies and availability of
vaccine claims may vary.
853 | Analysis of data from distributed
pharmacoepidemiologic networks
Romin Pajouheshnia1; Helga Gardarsdottir1; Robert Platt2;
Darren Toh3; Olaf Klungel1
1Utrecht University, Utrecht, Netherlands; 2McGill University, Montreal,
QC, Canada; 3Harvard Medical School, Boston, MA
Background: Distributed data networks allow us to address otherwise
inaccessible questions, such as the effects of uncommon treatments,
risks of rare adverse drug reactions and heterogeneity in the effects
of medicines across populations. Challenges in multi‐database studies
include both practical barriers, such as restrictions on data access, and
methodological issues, such as variation in the collection and coding of
information across centers.
Objectives: This symposium will address the challenges of using dis-
tributed data for pharmacoepidemiologic analyses. Specialists will
present current solutions, weigh the advantages and limitations and
highlight areas for further research. The practical recommendations
provided will benefit any researcher interested in conducting multi‐
center studies.
Description: The symposium will consist of a series of talks, summa-
rized by a moderator‐led discussion. 1. “Dealing with differences in
healthcare systems in multi‐database studies”. Examples of the impact
of differences, such as the capturing and registration of exposure and
outcomes, across healthcare systems will be presented. Different
approaches to deal with this, including common data models and stan-
dardized protocols, will be discussed (20 min). 2. “Methods for meta‐
analytic pooling of results from distributed networks: random effects,
fixed effects and Bayesian methods”. Distributed networks usually
work with site‐specific analyses pooled via meta‐analysis. The
strengths, weaknesses, and assumptions underlying different methods
as well as a proposal of best practices for the analysis of distributed
networks will be presented (20 min). 3. “Distributed analytic and
data‐sharing methods that enable robust statistical analysis without
the need to share individual‐level data”. Methods that ensure consis-
tent data processing and statistical analysis across data sources, and
methods that allow database‐specific analysis (e.g., covariate selection)
will be presented. Different analytic options based on different types
of outcomes and different adjustment methods will also be discussed
(20 min). 4. “Making the most of it: how to handle systematically miss-
ing information in multi‐database studies”. Several approaches exist to
handle missing data across a distributed network. A hierarchy of
approaches to leverage information across a network, along with a
hierarchy of their requirements will be presented for discussion
(20 min). 5. Panel discussion (10 min).
854 | Causal inference in
pharmacoepidemiology
Laura Pazzagli1; Elizabeth A. Stuart2; Miguel Hernán3;
Sebastian Schneeweiss4,5
1Karolinska Institutet, Stockholm, Sweden; 2 Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD; 3Harvard T.H. Chan School of
Public Health, Boston, MA; 4Brigham and Women's Hospital, Boston, MA;
5Harvard Medical School, Boston, MA
Background: When investigating associations between drugs and out-
comes of interest, researchers are generally interested in establishing
whether it is a causal link: whether the drug itself led to increased
(or decreased) risk of the outcome. The fact that two or more events
are associated does not imply a causal effect; confounding or other
challenges can lead to misleading results. Trying to draw inferences
regarding causal links between exposures (such as drugs) and out-
comes is obviously an important research field, however there are
multiple statistical difficulties.
Objectives: The aim of the symposium is to disseminate recent
advances in methods for estimating causal effects among researchers
within the pharmacoepidemiological community via the voices of
speakers with acknowledged expertise in the field. The symposium is
also devoted to opening a constructive dialog between speakers and
audiences interested in providing possible solutions to the challenges.
Description: The invited speakers will introduce important concepts
fundamental to the estimation of causal effects, as well as some
methods for estimation of those effects in non‐experimental studies
or when dealing with complications in randomized experiments. The
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symposium will end with a panel discussion with emphasis on speaker‐
audience interaction. The symposium will be moderated by Laura
Pazzagli, PhD, postdoctoral researcher at the Centre for
pharmacoepidemiology of Karolinska Instituted, and will include the
following speakers: Elizabeth A. Stuart, Professor at Johns Hopkins
Bloomberg School of Public Health, will discuss “Complications in ran-
domized trials: Dealing with non‐compliance and non‐representative sam-
ples”; Miguel Hernán, Kolokotrones Professor at Harvard T.H. Chan
School of Public Health, will discuss “Causal Inference from observa-
tional data as the emulation of a (hypothetical) target trial”; Sebastian
Schneeweiss, Professor at Harvard Medical School and Chief of the
Division of Pharmacoepidemiology and Pharmacoeconomics, Depart-
ment of Medicine, Brigham and Women's Hospital will talk about
“Causal inference principles augmented by machine learning: Can we
automate confounding adjustment in database studies?”
855 | Pharmacoepidemiology and rare
cancer research
Wei Zhou1; Leigh Marcus2; Anton Pottegård3; Bruce Carleton4;
Andrew Freedman5; Hans‐Georg Eichler6
1Merck Research Laboratories, North UK, PA; 2FDA, Silver Spring, MD;
3Odense University Hospital, Odense, Denmark; 4University of British
Columbia, Vancouver, BC, Canada; 5US National Cancer Institute,
Bethesda, MD; 6European Medicines Agency, Amsterdam, Netherlands
Background: Rare cancers are a heterogenous group, and there is no
internationally agreed definition of rare cancers. The estimated annual
incidence rate of all rare cancers in Europe was about 541,000 new
diagnoses. The overall public health burden of rare cancers has not
been adequately estimated.
Rare cancers are often inadequately diagnosed and treated due to lack
of knowledge and insufficient clinical expertise, including many pediat-
ric cancers. Recently, particular genomic markers or biomarkers have
been identified to subdivide common cancers into different subtypes
qualifying as “rare cancers”. The American Society of Clinical Oncology
names “Progress in Treating Rare Cancers” as the Advance of the Year
2018.
Rare cancers may develop as a consequence of common chronic dis-
eases and/or their therapies. More collaboration is needed across dif-
ferent regions and databases or registries, to understand the
epidemiology, treatment, and outcomes of rare cancers.
Objectives: 1). To provide an overview on the significant disease bur-
den and unmet medical need related to rare cancers in different
regions of the world.
2). To discuss the progress and gaps of research on rare cancers,
including regulator perspectives of rare cancer treatment and real‐
world data in supporting regulatory decisions, pediatric cancers, rare
cancer subtypes defined by specific genomic markers or biomarkers,
and drug‐cancer associations.
3). To foster future collaborations between diverse stakeholders in dif-
ferent geographic regions on rare cancer research.
Description: The workshop will start with a short introduction of the
panel members and topics, and continue with presentations from 3
speakers. The workshop will end with an 8 min summary and then
panel discussions, including response to questions from audiences.
The presentation topics of each panel member are as below:
a. Introduction and summary of the disease burden of rare cancers
(5 min, Wei Zhou).
b. Overview of rare cancer treatment development: Regulatory
approaches, methodological opportunities and challenges in the clini-
cal development of drugs (e.g., umbrella and pragmatic trials) (Leigh
Marcus, 20 min).
c. Rare cancers in pediatric population and in the precision medicine
era (Bruce Carleton, 20 min).
d. Progresses and challenges of understanding risk of rare cancers as
outcome of long‐term medical exposures or chronic diseases (Anton
Pottegård; 15 min).
e. Summary of the key messages and US NCI perspective (Andrew
Freedman, 8 min).
f. Panel discussion: How pharmacoepidemiology expertise will help
research and foster the collaboration between regulator, academic,
and industry (20 min, all panel members, moderated by Wei Zhou).
856 | Emerging solutions to addressing
challenges in measuring adherence to
multiple medications
Julie Lauffenburger1; Caroline Walsh2; Sarah‐Jo Sinnott3;
Jessica Franklin1; Petra Denig4
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
2Royal College of Surgeons in Ireland, Dublin, Ireland; 3LSHTM and BWH,
London, UK; 4University of Groningen, University Medical Center
Groningen, Groningen, Netherlands
Background: The Annals of Internal Medicine recently published
reporting guidelines for medication adherence research. While they
clarify aspects of reporting research, they fall short of providing guid-
ance on how to measure adherence in standardized ways, especially in
the setting of multiple medication use.
Many patients require several medications to manage chronic condi-
tions. Most efforts to measure adherence focus on single drug regi-
mens, which are increasingly less clinically relevant. While prior
research has improved methods for measuring adherence to one med-
ication, directly applying them in multiple medications presents chal-
lenges. For example, one common measure categorizes patients as
adherent based on being at least 80% adherent to at least one medi-
cation, but this and most other measures do not distinguish among
adherence to different medications and also compress long‐term
behaviors into a single measure.
Even though calculating adherence to multiple agents is an area of
increasing importance, consensus on optimal approaches has yet to
be achieved. These different approaches impact estimates of the ben-
efits or harms of interventions/policies on adherence or adherence on
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outcomes. As a research community, we need to better standardize
methods for measuring adherence to multiple medications.
Objectives: 1. To review the challenges of measuring adherence to
multiple medications in pharmacoepidemiologic studies, particularly
in claims databases, and potential health and economic implications
of the variety of measures being used.
2. To provide a balanced review of emerging solutions to address def-
icits in adherence measurement standardization to multiple medica-
tions and their strengths/limitations.
Description:
The symposium is organized by topic and each identified speaker:
1. Introduction/Background
1. Short overview of new EMERGE adherence guidelines
2. Most common measurements in claims data and their
strengths/limitations for multiple medications
2. Challenges of adherence measurement
1. Specific research examples showing how measurements of
adherence to multiple medications as both an outcome and
exposure differ depending on researcher choices
3. Implications of measurements on outcomes
1. Specific research examples about implications that different
measurements have on their association with health out-
comes, like utilization, mortality and quality of life
4. Emerging areas in measurement/possible solutions
1. Application of group‐based trajectory modeling to multiple
medications
2. New adherence software (AdhereR) for measurement in
claims databases
5. Moderated panel/audience discussion
857 | Mixing it up: implementing qualitative
& mixed methods in pharmacoepidemiology
research
M. Elle Saine1; Julia E. Szymczak1; Irene Petersen2; Rachel E. Sobel3
1Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA; 2University College London, London, UK; 3PFIZER, New
York, NY
Background: Qualitative methodologies allow researchers to better
understand the processes underlying health behaviors and outcomes.
Despite the ability of mixed‐methods research to minimize limitations
associated with quantitative and qualitative approaches independently,
these methods have largely been ignored in pharmacoepidemiology
research.
Objectives: This symposium will highlight how qualitative methods
can enrichen pharmacoepidemiologic research designs by adding
interpretation and context to quantitative findings. Four panelists will
discuss a range of study designs and populations, underscoring the
diversity of questions that these methods may answer.
Description: Timeline (90 Min): Introduction (10 min); Presentations
(15 min each); Discussion & Q&A (20 min).
Julia E. Szymczak The Social Determinants of Antimicrobial Prescribing:
Using Qualitative Methodology to Understand the Drivers of Antimicro-
bial Overuse The objectives of this talk are to review the
sociobehavioral factors that shape antimicrobial prescribing and evi-
dence for interventions that leverage social science theory to improve
prescribing. Best practices and practical approaches will be discussed.
Specific methodologies, including ethnography and semi‐structured
interviews, and techniques to establish rigor will be reviewed.
Irene Petersen Understanding theperspectivesofwomenwith severemen-
tal illness concerning the use of psychotropic medicines while pregnant The
researchpresented in this studyprovideswomen's accountsofdecisions
concerning the use of psychotropic medicines while pregnant. Through
interviewswithwomenwhohad to take the decisiononwhether to stop
or continue treatment in pregnancywe gain their perspectives.
Rachel E. Sobel How Industry Can Use Mixed Methods to Assess the
Effectiveness of Risk Minimization Activities The objectives of this talk
are to review the regulatory framework and to provide some examples
of how mixed methods can support the pharmaceutical industry and
others in performing effectiveness evaluations of risk minimization
activities such as required FDA Risk Evaluation and Mitigation Strate-
gies (REMS) and EU additional Risk Minimisation Measure (aRMM)
evaluations.
M. Elle Saine Using Mixed‐Methods Research to Identify Barriers to
Treatment of Hepatitis C Virus Infection in Philadelphia's Opioid Crisis
This talk explores how mixed‐methods research allows deeper insight
into social and patient‐level barriers to antiretroviral treatment and
adherence. The advantages and challenges of research among vulner-
able and marginalized populations will be presented.
858 | Improved real‐world outcomes for
type 2 diabetes patients on basal‐bolus
insulin therapy switching to insulin glargine
300 U/ml vs. insulin glargine 100 U/ml and
insulin Detemir
Jasmanda Wu1; Timothy S. Bailey2; Zsolt Bosnyak3;
Jukka Westerbacka3; Rishab A. Gupta4; Arjun A. Menon4;
Charlie Nicholls5; Lawrence Blonde6
1Sanofi, Bridgewater, NJ; 2AMCR Institute, Escondido, CA; 3Sanofi, Paris,
France; 4Accenture, Florham Park, NJ; 5Sanofi, Guildford, UK;
6Endocrinology Department, Frank Riddick Diabetes Institute, New
Orleans, LA
Background: Randomized controlled trials have indicated that insulin
glargine 300 units/mL (Gla‐300) is associated with less hypoglycemia
than insulin glargine 100 U/mL and insulin detemir (1st generation
basal insulins, 1G‐BI) in adults with type 2 diabetes (T2D).
Objectives: To comparatively evaluate real‐world clinical outcomes in
T2D patients on basal‐bolus insulin therapy (BBT) who switched their
BI to either Gla‐300 or 1G‐BI.
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Methods: This retrospective observational study used electronic med-
ical records from the Predictive Health Intelligence Environment data-
base (IBM Explorys). Adults (≥18 years) with T2D on BBT who
switched their BI were studied. Patients in the Gla‐300 and 1G‐BI
cohorts were propensity‐score matched (1:1). Endpoints were:
glycated hemoglobin (A1C) change from baseline and target attain-
ment (<7.0% and < 8.0%) at 6 months; hypoglycemia (ICD‐9/ICD‐10
and/or plasma glucose ≤70 mg/dL, or inpatient/emergency depart-
ment [ED]‐associated), with 6 months or variable (until discontinuation
or 6 months) follow‐up.
Results: Baseline demographics and clinical characteristics were simi-
lar: Gla‐300 (N = 1486) vs. 1G‐BI (N = 1486; insulin glargine 100 U/
mL, 29.4%; insulin detemir, 70.6%). Comparing matched groups at
6 months, mean A1C reduction was similar (0.52% vs. 0.45%;
p = 0.317), as was attainment of A1C goals <7.0% (16.0% vs. 19.0%;
p = 0.054) and < 8.0% (43.5% vs. 41.8%; p = 0.483). At 6 months (fixed
duration), adjusting for baseline hypoglycemia, Gla‐300 patients had
significantly fewer all hypoglycemia events (0.76 vs. 0.95 events per
patient per year [PPPY]; p = 0.036). With variable follow‐up, Gla‐300
patients had significantly fewer all hypoglycemia events (0.63 vs.
0.77 PPPY; p < 0.001) and inpatient/ED‐related events (0.15 vs.
0.25 PPPY; p < 0.001).
Conclusions: In patients with T2D on BBT, switching to Gla‐300 vs.
1G‐BIs was associated with similarly improved glycemic control, but
significantly lower risk of hypoglycemia and inpatient/ED‐related
hypoglycemia.
859 | Metformin use and risk of benign
prostatic hyperplasia
Mette Nørgaard; Bianka Darvalics; Reimar W. Thomsen
Aarhus University Hospital, Aarhus, Denmark
Background: Benign prostatic hyperplasia (BPH) is a common age‐
related condition. Metformin inhibits proliferation of prostate cells
and use of metformin seems to reduce the risk of prostate cancer
compared with use of other glucose lowering drugs (GLD). Yet, few
studies have examined the association between use of metformin
and risk of BPH.
Objectives: To compare the risk of BPH in men with type 2 diabetes
who initiated either metformin or sulfonylurea between 2000 and
2006 in Northern Denmark. In this period, Danish guidelines recom-
mended initiation of either a sulfonylurea or metformin as first line
oral GLD treatment.
Methods: We conducted a population‐based cohort study among men
with type 2 diabetes in Northern Denmark using Danish medical data-
bases. We identified 9,911 men who initiated treatment with either
metformin or sulfonylurea and filled at least 2 prescriptions for the
same GLD within 6 months (the index date). We used an intention
to treat (ITT) approach and computed rates and hazard ratios of BPH
(using Cox regression), comparing metformin users with sulfonylurea
users overall and stratified by HbA1C‐level achieved at the index date.
We adjusted for age, comorbidity, presence of micro‐ or macro‐vascu-
lar complications, obesity, marital status as a marker of social support,
and calendar year. We also used an as‐treated approach in which we
censored patients 30 days after change of type of monotherapy
regimen.
Results: In the ITT analysis, the overall rate of BPH (diagnosis or pre-
scription) in 3953 metformin users (Median follow‐up 10.1 years) was
33.4 (95% CI, 31.4–35.4) per 1000 person‐years. Compared with
5958 sulfonylurea users (median follow‐up 8.0 years), the crude haz-
ard ratio (HR) for BPH was 0.83 (95% CI, 0.77–0.89) but after adjust-
ment it was 0.97 (95% CI, 0.90–1.05). In the as treated analysis, BPH
risk was lower in metformin compared with sulfonylurea users,
adjusted HR = 0.91 (95% CI, 0.83–1.00). When stratified by baseline
HbA1c level we observed a slightly lower risk of BPH in metformin
compared with sulfonylurea use in those with HbA1c level below 7%
(adjusted HR 0.91 (95% CI, 0.80–1.03) but not among those with
HbA1c ≥ 7% in the ITT analysis. In the as‐treated analysis, adjusted
HRs associated with metformin were 0.88 (95% CI, 0.76–1.01) in
those with HbA1c below 7%, 0.92 (0.73–1.15) if HbA1C was ≥7%
and < 8%, and 1.10 (0.81–1.48) when HbA1c was ≥8%.
Conclusions: Compared with sulfonylurea, metformin did not seem to
substantially reduce the risk of BPH in men with diabetes overall.
However, in men achieving good glycemic control metformin treat-
ment may have a small benefit in relation to BPH risk.
860 | Comparative cardiovascular and
hypoglycemic safety of glimepiride in type 2
diabetes: a population‐based cohort study
Antonios Douros1,2,3; Sophie Dell'Aniello3; Oriana Yu3; Samy Suissa1,3
1McGill University, Montreal, QC, Canada; 2Charité ‐ Universitätsmedizin
Berlin, Berlin, Germany; 3Lady Davis Institute, Montreal, QC, Canada
Background: Ongoing cardiovascular outcome trials will report on the
efficacy and safety of newer antidiabetic drugs, including dipeptidyl
peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists,
compared with the sulfonylurea glimepiride. However, the pharmaco-
logic heterogeneity among sulfonylureas could limit the generalizabil-
ity of these trials regarding non‐glimepiride compounds.
Objectives: To assess the risk of cardiovascular and hypoglycemic
adverse events associated with use of glimepiride compared with
other second‐generation sulfonylureas among patients with type 2
diabetes in a real‐world clinical setting.
Methods: We used the United Kingdom Clinical Practice Research
Datalink and linked it to the Hospital Episode Statistics and Office
for National Statistics databases to identify all patients initiating a sul-
fonylurea between January 1998 and June 2017. Using a prevalent
new‐user cohort design, we matched 1:4 patients initiating glimepiride
with those initiating other second‐generation sulfonylureas on calen-
dar time, prior use of sulfonylureas, and time‐conditional high‐dimen-
sional propensity score. The two groups were compared using Cox
proportional hazards models to estimate adjusted hazard ratios (HRs)
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and 95% confidence intervals (CIs) of myocardial infarction, ischemic
stroke, severe hypoglycemia, cardiovascular death, and all‐cause
mortality.
Results: Among 66,032 initiators of sulfonylureas, 6,438 were initia-
tors of glimepiride matched to up to 20,582 initiators of other sec-
ond‐generation sulfonylureas. During a mean follow‐up of 1.3 years,
glimepiride was associated with a similar risk of myocardial infarction
(8.3 vs 8.7 per 1000/year; HR, 0.99; 95% CI, 0.75 to 1.30), ischemic
stroke (7.8 vs 8.1 per 1000/year; HR, 0.96; 95% CI, 0.72 to 1.27), or
severe hypoglycemia (7.2 vs 5.9 per 1000/year; HR, 1.24; 95% CI,
0.92 to 1.68) compared with other second‐generation sulfonylureas.
However, glimepiride was associated with a decreased risk of all‐cause
mortality (27.8 vs 37.0 per 1000/year; HR, 0.77; 95% CI, 0.67 to 0.89),
and a non‐significant but similar trend for cardiovascular death (10.7
vs 12.9 per 1000/year; HR, 0.83; 95% CI, 0.65 to 1.05).
Conclusions: In this population‐based study, glimepiride was associ-
ated with a decreased risk of all‐cause mortality and possibly of car-
diovascular death compared with other second‐generation
sulfonylureas. These findings will help in interpreting the upcoming
results of trials using glimepiride as an active comparator in the con-
text of other sulfonylureas.
861 | Major adverse cardiovascular events
associated with sodium glucose co‐
transporters versus other antidiabetes drugs:
population‐based cohort study
Colin Dormuth; Xiaoting Ding; Ellen Reynolds; Greg Carney
University of British Columbia, Vancouver, BC, Canada
Background: Randomized clinical trial data suggest sodium‐glucose
co‐transporter inhibitors (SGLT2i) reduce major adverse cardiovascu-
lar events (MACE), but their effectiveness in real‐world practice is
poorly understood.
Objectives: To study the association between SGLT2i and MACE
compared to patients treated with dipeptidyl peptidase‐4 inhibitors
(DPP4i), or sulfonylureas (SU).
Methods: We undertook a cohort study of adult patients with diabe-
tes in British Columbia, Canada. Patients were eligible for the study
if they initiated second‐line therapy with an SGLT2i, DPP4i or SU
between June 2014 and December 2017, having previously received
metformin as first‐line treatment. The metformin criterion was used
to reflect normal practice. Patients were ineligible if they were less
than 18 years of age, or had a record of gestational diabetes, malig-
nancy, renal disease, human immunodeficiency virus infection, or
organ transplant within a year prior to cohort entry. Our primary out-
come was risk of MACE (cardiovascular death, non‐fatal myocardial
infarction, non‐fatal stroke). A secondary outcome was emergency
admission to hospital for any reason. SGLT2i patients were matched
to DPP4i patients (cohort 1) and SU patients (cohort 2) on propensity
score using nearest neighbor matching. We estimated hazard ratios
(HR) using cox proportional hazards regression.
Results: There were 18,534 patients eligible for analysis after all inclu-
sion and exclusion criteria were applied. These comprised 6,360
SGLT2i users, 3,921 DPP4i users, and 8,253 SU users. After matching
into 3,172 SGLT2i‐DPP4i pairs, and 5,391 SGLT2i‐SU pairs, 0.3% of
patients on each drug experienced the primary outcome. SGLT2i
exposure was not significantly associated with risk of MACE com-
pared to DPP4i exposure (HR 0.70, 95% confidence interval [CI]
0.38–1.29), or SU exposure (HR 0.74, 95% CI 0.47–1.18). However,
a paucity of events prevented precise estimation of the primary out-
come. For the secondary outcome, SGLT2i exposure was not associ-
ated with reduced emergency admission to hospital compared to
DPP4i exposure (HR 1.03, 95% CI 0.78–1.36), but was associated with
reduced emergency admission to hospital when compared to SU
exposure (HR 0.71, 95% CI 0.57–0.87).
Conclusions: Although a paucity of events prevented precise estima-
tion of the primary outcome in second‐line treated patients in British
Columbia, observed hazard ratios for SGLT2i and MACE were compa-
rable to those reported in randomized trials. Larger studies are needed
to explore this association in a real‐world setting.
862 | Comparative risk evaluation for
cardiovascular events associated with
empagliflozin vs. dapagliflozin: a multi‐
institutional cohort study
Shih‐Chieh Shao1,2; Kai‐Cheng Chang3; Ming‐Jui Hung1;
Yuk‐Ying Chan4; Hui‐Yu Chen3; Yea‐Huei Kao Yang2;
Edward Chia‐Cheng Lai2
1Keelung Chang Gung Memorial Hospital, Keelung, Taiwan; 2National
Cheng Kung University, Tainan, Taiwan; 3Linkou Chang Gung Memorial
Hospital, Taoyuan, Taiwan; 4Chang Gung Medical Foundation, Taoyuan,
Taiwan
Background: Clinical trials have proved the cardiovascular benefits of
sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. However, the
comparative cardiovascular effects in real‐life patients with SGLT2
inhibitors (i.e., empagliflozin and dapagliflozin) remain unclear.
Objectives: To compare the risk of cardiovascular events in patients
without atherosclerotic cardiovascular disease receiving empagliflozin
versus dapagliflozin.
Methods: We analyzed a multi‐institutional electronic medical records
database (Chang Gung Research Database, CGRD) containing about
6% of the Taiwan population for this study. We used a retrospective
cohort design and included adult patients with type 2 diabetes who
were newly receiving SGLT2 inhibitors from 2016 to 2017. We
excluded patients with a history of cardiovascular events (e.g., ische-
mic stroke, myocardial infarction and heart failure). The primary out-
come was a composite of cardiovascular death, ischemic stroke,
myocardial infarction and heart failure. We performed intention‐to‐
treat analyses and followed up patients from initiation of SGLT2 inhib-
itors until the occurrence of cardiovascular events or the last clinical
visit date recorded in CGRD before December 31, 2018. We
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performed multi‐variate Cox proportional hazard modeling, taking into
consideration patients' age, sex, baseline blood glucose level indica-
tors, renal functions, lipid profiles, comorbidities, and co‐medications.
Results: We identified 12,868 new SGLT2 inhibitor users with a mean
age of 58.9 years, of whom 43.8% were male. A total of 12,089 per-
son‐years of empagliflozin and 10,426 person‐years of dapagliflozin
were included. There were similar risks of primary composite outcome
(adjusted HR: 0.94; 95% CI: 0.76–1.17), but higher risk of ischemic
stroke (adjusted HR: 1.19; 95% CI: 0.83–1.64) and lower risk of heart
failure (adjusted HR: 0.68; 95% CI: 0.48–0.96) were found for
dapagliflozin than empagliflozin users. Different sensitivity analyses
(e.g., propensity scores matching and per‐protocol approach) showed
trends consistent with the main analysis.
Conclusions: The findings indicated that dapagliflozin and
empagliflozin pose different risk profiles for cardiovascular events. Cli-
nicians should consider patients' baseline risk profiles for specific car-
diovascular events when selecting SGLT2 inhibitors.
863 | Empagliflozin selected cardiovascular
and safety outcomes in routine care: first
results from theempagliflozin comparative
effectiveness and safety (EMPRISE) study
Elisabetta Patorno1; Ajinkya Pawar1; Jessica M. Franklin1;
Mehdi Najafzadeh1; Anouk Déruaz‐Luyet2; Kimberly G. Brodovicz3;
Steven Sambevski2; Lily G. Bessette1; Martin Kulldorff1;
Sebastian Schneeweiss1
1Brigham & Women's Hospital, Boston, MA; 2Boehringer Ingelheim
International GmbH, Ingelheim am Rhein, Germany; 3Boehringer
Ingelheim International GmbH, Ridgefield, CT
Background: The EMPA‐REG OUTCOME trial showed that
empagliflozin (EMPA), a SGLT2 inhibitor (SGLT2i), reduces the risk of
cardiovascular (CV) death and hospitalization for heart failure (HHF)
in patients with type 2 diabetes (T2D) and established CV disease.
The implications of these findings, as well as the potential risks
observed for other SGLT2i agents or for the SGLT2i class, are yet to
be evaluated for EMPA in real‐world practice. EMPRISE studies the
comparative effectiveness, safety and healthcare utilization of EMPA
in routine care, using data from Medicare and 2 U.S. commercial claims
datasets from 08/2014 through 09/2019.
Objectives: To evaluate the risk of CV and safety outcomes associated
with the initiation of EMPA vs. DPP4 inhibitors (DPP4is) in an interim
analysis from EMPRISE based on data from 08/2014 through 09/
2016.
Methods:Within the three datasets (Medicare fee‐for‐service, Optum,
and MarketScan), we identified 17,551 pairs of 1:1 propensity score
(PS)‐matched patients ≥18 years with T2D initiating EMPA or a
DPP4i. We assessed a composite CV outcome (comprised of myocar-
dial infarction, stroke, or all‐cause mortality), an extended CV outcome
(plus HHF or coronary revascularization), and their individual compo-
nents. Safety outcomes of interest were lower‐limb amputations
(LLA), bone fractures, diabetic ketoacidosis (DKA), and acute kidney
injury (AKI). We estimated pooled hazard ratios (HR) and 95% confi-
dence intervals (CI) adjusting for >140 baseline covariates, including
several proxies of diabetes progression.
Results: After PS‐matching, covariates were well balanced with stan-
dardized differences <0.1, including laboratory test results available
in a subset of the cohort and thus not included in the PS model. Com-
pared to DPP4i, EMPA was associated with a trend to lower risk of the
CV outcome [HR (95% CI) = 0.82 (0.62–1.10)] and its individual com-
ponents, and a lower risk of the extended CV outcome [0.73 (0.60–
0.88)], and HHF [0.56 (0.43–0.73)]. Despite small numbers, no
increased risk of LLA [1.20 (0.57–2.53)], fractures [0.81 (0.41–1.57)],
or AKI [0.64 (0.43–0.95)] was observed among EMPA users, though
a numerical increase in DKA risk [1.74 (0.84–3.58)] was noted.
Conclusions: Early findings from EMPRISE showed that compared
with DPP4i, EMPA was associated with a lower risk of CV outcomes
with varying levels of precision, and a safety profile consistent with
currently documented information.
864 | Real‐world data on the use of biologics
in the treatment of colorectal cancer:
comparison between three European
databases
Katja Anita Oppelt1; Josephina G. Kuiper2; Ylenia Ingrasciotta3;
Valentina Ientile4; Ron M.C. Herings2; Gianluca Trifirò3; Ulrike Haug1
1Leibniz Institute for Prevention Research and Epidemiology ‐ BIPS,
Bremen, Germany; 2PHARMO Institute for Drug Outcomes Research,
Utrecht, Netherlands; 3University of Messina, Messina, Italy; 4A.O.U.
Policlinico "G. Martino", Messina, Italy
Background: An increasing number of biologics have been approved
for treating metastatic colorectal cancer (CRC), but only little is known
regarding their use in the real‐world setting.
Objectives: To explore the potential of databases from different Euro-
pean countries to provide real‐world data on the use of biologics in
the treatment of CRC patients.
Methods: Based on three different databases (PHARMO Database
Network from the Netherlands (NL), Caserta LHU from Italy (IT),
GePaRD from Germany (DE)) we identified ‐ for each database ‐ per-
sons treated with a biologic approved for metastatic CRC
(bevacizumab, cetuximab, panitumumab, or aflibercept) and a diagno-
sis of CRC in 2010 (cohort 2010) or 2014 (cohort 2014; IT: only
cohort 2014). The first dispensation date of one of these drugs in
the respective year was defined as cohort entry. The cohort was
followed for 12 months or until death, whichever occurred first. We
characterized the patients regarding age, sex, presence of metastases
and overall health (using the chronic disease score, CDS) at cohort
entry and survival patterns during follow‐up. We further described
the type and number of biologics used.
Results: Cohort 2010 included 112 patients from NL and 2,176 from
DE; cohort 2014 included 73 patients from NL, 49 from IT and
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2,454 from DE. The cohorts were comparable regarding age (mean:
65–67 years) and sex (>53% male). Mean CDS and proportion of
patients with metastatic disease were higher in DE and IT (~90%),
compared to NL (<75%). Most patients (78–82%) received only one
biologic. The proportion of dispensations of bevacizumab decreased
between 2010 and 2014 by ~10% (NL: 93% to 85%, DE: 72% to
61%) while it increased regarding panitumumab (NL: 16% to 29%,
DE: 5% to 13%). The second most frequently dispensed biologic was
panitumumab in NL and cetuximab in IT and DE. The trends between
2010 and 2014 regarding the proportion of patients receiving ≥2 dif-
ferent biologics differed between countries: increase from 11% to
18% in NL and from 20% to 22% in DE. In all cohorts, 33–38% of
patients died within one year; of these, ~20% died within 6 months.
Conclusions: The relatively high mean age and low 12‐month survival
indicate a less selective use of biologics among CRC patients in the
real‐world setting compared to clinical trials, including a potential
off‐label use given that no metastases were coded in ≥10% of
patients. Overall, the analyses showed plausible results that were
largely consistent across databases, underlining the potential of these
databases for real‐world monitoring regarding the use of novel onco-
logic drugs.
865 | Drug survival of targeted therapies for
plaque psoriasis: evidence from a large U.S.
claims database
Nathaniel Hendrix; David Veenstra
University of Washington, Seattle, WA
Background: Targeted therapies for plaque psoriasis (PsO) are associ-
ated with costly initiation regimens and may reduce the effectiveness
of subsequent targeted treatments. For these reasons, characterizing
drug survival (time to drug discontinuation) is essential for producing
valid cost‐effectiveness estimates for these drugs.
Objectives: To estimate drug survival for seven PsOdrugs: adalimumab,
apremilast, etanercept, infliximab, ixekizumab, secukinumab, and
ustekinumab.
Methods: Using the Truven Health MarketScan Commercial Database
from 2007 to 2017, we selected patients with at least one PsO diag-
nosis from a dermatologist. Patients enrolled for 12 months prior to
the first PsO diagnosis were considered biologic‐naïve at their first
targeted therapy. The first treatment sequences for patients not fitting
this definition were discarded, as we could not ascertain whether the
patient was biologic‐naïve. Two claims for the same drug were consid-
ered to be part of a single treatment sequence if the service date for
the second claim occurred within a time period equal to twice the indi-
cated days of supply for the first claim. Using Kaplan–Meier curves
and proportional hazards regressions adjusted for age at initiation,
year of initiation, sex, and region, we calculated median survival and
hazard ratio (HR).
Results: We identified 145,637 treatment sequences among 56,355
patients totaling 104,986 person‐years on targeted therapy. Of these
sequences, 18,576 (12.8%) were among biologic‐naïve patients. In bio-
logic‐naïve patients, secukinumab had the longest median drug sur-
vival with 477 days (95% confidence interval: 315 to 702);
ustekinumab had the shortest with 149 days (129 to 209). In bio-
logic‐experienced patients, ixekizumab and secukinumab had the
highest median survival with approximately 225 days, while
apremilast, etanercept and infliximab had the shortest with approxi-
mately 145 days. The proportional hazards regression corroborated
these results. We also found that female sex was associated with a
higher risk of discontinuation (HR: 1.09 [1.08 to 1.11]) and that dis-
continuation has become more likely in recent years (HR: 1.02 year
over year [1.01 to 1.02]).
Conclusions: We found that the interleukin‐17A inhibitors ixekizumab
and secukinumab provide superior drug survival in both biologic‐naïve
and ‐experienced patients relative to other targeted therapies. We
also found that discontinuation is more likely as more targeted thera-
pies have been released. With several new drugs for PsO recently
released or forthcoming, it will be important to frequently update
changes to drug survival.
866 | Risk of serious infections among new
users of Interleukin‐17, Interleukin‐12/23
inhibitors, compared to tumor necrosis factor
(TNF)‐alpha inhibitors, for the treatment of
psoriasis and psoriatic arthritis
Xintong Li1; Kathleen M. Andersen1; Hsien‐Yen Chang2;
Jeffrey R. Curtis3; G. Caleb Alexander1
1 Johns Hopkin University, Baltimore, MD; 2Johns Hopkin University,
Baltimore, MD; 3University of Alabama at Birmingham, Birmingham, AL
Background: Recently, interleukin‐17 (IL‐17) and interleukin‐12/23
(IL‐12/23) inhibitors have been approved by the U.S. Food and Drug
Administration for the treatment of psoriasis (PsO) and psoriatic
arthritis (PsA), yet existing evidence is mixed on the risk of serious
infections associated with these products.
Objectives: To determine whether initiation of IL‐17 or IL‐12/23
inhibitors, compared with tumor necrosis factor‐alpha (TNF‐α) inhibi-
tors, are associated with an increased risk of serious infection among
patients diagnosed with PsO or PsA.
Methods: A retrospective cohort study evaluated U.S. commercially
insured adults with PsO or PsA who received a first prescription of
an IL‐17 (ixekizumab and secukinumab), IL‐12/23 (ustekinumab), or
TNF‐α inhibitors (adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab) between January 2015 and May 2018. Serious
infection was defined as the first infection requiring hospitalization
after biologic initiation. Incidence rates were calculated by drug class.
Weighted Cox proportional hazards regression models were used to
estimate hazard ratios (HRs) with 95% confidence intervals (95% CI)
for the risk of a serious infection after biologic initiation. We used
inverse probability of treatment weighting (IPTW) propensity scores
to address the imbalance of baseline covariates.
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Results: Based on preliminary analysis, a total of 12,201 treatment
episodes in persons diagnosed with PsO or PsA who were previously
biologic‐naïve were included: 2,228 (18%) with IL‐17, 2,937 (24%) IL‐
12/23, and 7,036 (58%) TNF‐α inhibitors. Overall, 200 (1.64% of epi-
sodes serious infections were identified (incidence rate per 100 per-
son‐years: 2.09 (95% CI 1.46–2.89) for IL‐17 inhibitors, 1.32 (95% CI
0.92–1.83) for IL‐12/23 inhibitors, and 2.39 (95% CI 2.01–2.82) for
TNF‐ α. As compared to patients initiating a TNF‐ α, those initiating
with IL‐12/23 (adjusted HR 0.64, 95% CI 0.43–0.97), but not those
with IL‐17 inhibitors (adjusted HR 0.92, 95% CI 0.58–1.44) were less
likely to be hospitalized for serious infection. The risk of serious infec-
tion was not different between IL‐17 and IL‐12/23 inhibitors: HR 1.21
(95%CI 0.71–2.05).
Conclusions: In this cohort, IL‐12/23 inhibitors were associated with a
lower risk of serious infection than TNF‐ α inhibitors in adults with
PsO or PsA. No increased risk was observed in IL‐17 inhibitors com-
pared with TNF‐ α inhibitors.
867 | Risk of heart failure following
exposure to non‐TNFi compared to TNFi
biologics in US patients with rheumatoid
arthritis
Thomas Bo Jensen1; Nicole Tsao2; Ajinkya Pawar2; Rishi Desai2;
Seoyoung Kim2
1Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark;
2Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background: Biologic diseasemodifying drugs have become the corner-
stone of rheumatoid arthritis (RA) management. Case reports on new‐
onset heart failure (HF) following TNFi initiation led to an FDA black
box warning released in October 2001, but subsequent observational
studies have shown no association. There is a lack of knowledge regard-
ing the risk of HF following exposure to the newer non‐TNFi biologics.
Objectives: We aimed to assess the risk of incident HF following
exposure to non‐TNFi compared to TNFi biologics.
Methods: Using US claims data from Truven MarketScan (2004–
2016), we conducted a cohort study of RA patients who initiated a
‘TNFi’ (adalimumab, certolizumab pegol, etanercept, golimumab,
infliximab), or ‘non‐TNFi’ biologic or targeted synthetic DMARD
(abatacept, anakinra, tocilizumab, tofacitinib). Patients were excluded
if they were < 18 years old, had previous HF, an implantable cardio-
logic device, or a loop‐diuretics prescription. Patients were followed
from the day after treatment initiation until the earliest event of the
following: death, insurance disenrollment, treatment switching or dis-
continuation. The primary outcome of incident HF was defined based
on primary inpatient diagnosis. Cox proportional hazards regression
compared risk of HF among new users of non‐TNFi compared toTNFi.
To control for confounding, we used multivariable adjustment as well
as propensity score (PS) adjustment by decile with trimming. Covari-
ates in adjusted and PS models included year of cohort entry, age,
gender, region, comorbidities, prior drug‐use, and health utilization.
Results: A total of 13,290 non‐TNFi patients were included, primarily
consisting of abatacept (65%). For the TNFi group, we identified
67,892 patients, primarily consisting of etanercept (42%) or adalimumab
(37%). More patients treated with non‐TNFi were female, older, had
higher proportion of co‐morbidities and number of rheumatologist
visits; but lower proportion of NSAID/Coxib use. There were 16 events
of HF in the non‐TNFi exposed group (incidence rate [IR] 1.08 per 1,000
person‐years [py]), and 89 events in theTNFi group (IR 0.87/1,000py).
The crude hazard ratio (HR) of HF after initiating a non‐TNFi was 1.28
(95%CI 0.75–2.18) versusTNFi. After confounding adjustment in a mul-
tivariablemodel, theHRwas attenuated to 1.08 (95%CI 0.57–2.05). The
PS adjusted analysis showed consistent results.
Conclusions: In this large US‐based cohort of 81,182 RA patients, we
found no difference in the risk of incident HF after initiation of non‐
TNFi biologic or targeted synthetic DMARD versus TNFi.
868 | Risk of diabetes treatment
intensification associated with use of
abatacept versus other biologic drugs in
patients with rheumatoid arthritis and
diabetes mellitus
Sarah Chen; Hemin Lee; Yinzhu Jin; Jun Liu; Seoyoung Kim
Brigham and Women's Hospital, Boston, MA
Background: Rheumatoid arthritis (RA) patients have a high preva-
lence of cardiovascular comorbidities including diabetes mellitus
(DM). Past studies have suggested a potential beneficial effect of
abatacept on insulin sensitivity, but the effect of biologic therapy on
DM severity in patients with RA and DM is unknown.
Objectives: To compare the rates of DM treatment intensification
among patients with RA and DM (type 1 or 2), newly initiating
abatacept versus other biologic disease‐modifying antirheumatic drugs
(DMARD).
Methods:We identified RA patients aged ≥18 years with ≥2 RA diag-
noses separated by 7–365 days using insurance claims data from
Truven MarketScan database (2005–2016). We included new users
of abatacept, tumor necrosis factor inhibitors (TNFi) (adalimumab,
etanercept, certolizumab, golimumab, and infliximab), rituximab or
tocilizumab. The date of drug dispensing was defined as the index
date. We required ≥365 days of continuous enrollment prior to the
index date, defined as the baseline period. We excluded patients with
history of malignancy. Among these RA patients, we identified
patients with DM by using ≥1 diagnosis for either type 1 or type 2
DM and ≥ 1 anti‐diabetic drug prescription during baseline. The pri-
mary outcome was DM treatment intensification defined as adding
or switching to a different oral antidiabetic medication or insulin. We
calculated incidence rates (IR) and hazard ratio (HR) of DM treatment
intensification in patients initiating abatacept versus other biologics.
Results: We included 9,385 patients with RA and DM initiating
abatacept (mean age 58.5, female 78%), TNFi (56.7, 71%), rituximab
(58.1, 76%), or tocilizumab (57.6, 79%). Hypertension was present in
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up to 74% and hyperlipidemia was present in up to 67% of patients.
Baseline insulin use was highest in the rituximab group (44%) and low-
est in the TNFi group (36%). Over 7,012 person‐years of follow up,
1,565 DM treatment intensification events occurred. The IR per
1,000 person‐years ranged from IR 209.0 (tocilizumab) to 236.7
(abatacept). After adjustment, the risk of DM treatment intensification
was similar between abatacept and TNFi (HR 0.93, 95% confidence
interval [CI] 0.83–1.08), rituximab (HR 0.96, 95% CI 0.79–1.18), and
tocilizumab (HR 0.86, 95% CI 0.68–1.08).
Conclusions: In patients with both RA and DM, we found no differ-
ence in the risk of DM treatment intensification between patients ini-
tiating abatacept versus TNFi, rituximab, and tocilizumab.
869 | Intravitreal anti‐vascular endothelial
growth factor drugs and risk of serious non‐
ocular hemorrhage
Janet Sultana1; Francesco Giorgianni2; Giulia Scondotto2;
Valentina Ientile2; Pasquale Cananzi3; Olivia Leoni4;
Sebastiano Walter Pollina Addario5; Giovanbattista de Sarro6;
Adele de Francesco7; Maria Rosalia Puzo8; Christel Renoux9;
Gianluca Trifirὸ1
1University of Messina, Messina, Italy; 2Messina University Hospital G.
Martino, Messina, Italy; 3Regional Pharmacovigilance Centre, Palermo,
Italy; 4Regional Pharmacovigilance Centre, Lombardy, Italy; 5Sicilian
Regional Healthcare Centre, Palermo, Italy; 6University of Catanzaro,
Catanzaro, Italy; 7Mater Domini Hospital, Catanzaro, Italy; 8Regional
Pharmacovigilance Centre, Potenza, Italy; 9 Jewish General Hospital –
Lady Davis Institute, Montreal, QC, Canada
Background: Intravitreal (IVT) anti‐VEGF drugs aflibercept and
ranibizumab are used to treat neovascular retinal diseases. A meta‐
analysis reported inconsistent risk of hemorrhage but suggested that
this may differ among single IVT anti‐VEGF drugs. IVT dexametha-
sone, also used for various retinal diseases, can cause bleeding as well.
Objectives: To compare the non‐ocular hemorrhage risk of IVT
aflibercept vs. ranibizumab (primary aim) and for single IVT anti‐VEGFs
vs. IVT dexamethasone (secondary aim).
Methods: A cohort study was conducted using 4 Italian regional claims
databases, covering 18million inhabitants in a period ranging from2011
to 2016. Incident aflibercept users were propensity score (PS)‐matched
1:4 to incident ranibizumab users. The outcome was first non‐ocular
hemorrhage requiring hospitalization. Incidence of events per 1,000
person‐years (PYs) was estimated. An intention to treat approach based
on a Poisson distribution was used, whereby aflibercept and
ranibizumab users were followed for 180 or 365 days in separate anal-
yses. An as‐treated (AT) approachwas also employed as sensitivity anal-
yses, with censoring on date of switching to another drug or
discontinuation. All analyses were repeated for aflibercept vs. dexa-
methasone and ranibizumab vs. dexamethasone. Risk was expressed
in hazard ratios (HR) with 95% confidence intervals (CI) using a Cox pro-
portional hazards model.
Results: Overall 21,766, 3,150 and 3,900 incident users of
ranibizumab, aflibercept and dexamethasone were identified from
2009–2016 in 4 Italian regions. After matching, mean age was
76 ± 10 and female–male ratio was 1.4 for ranibizumab and
aflibercept users; slightly lower mean age and equal sex distribution
was seen when matching anti‐VEGFs to dexamethasone users. The
incidence of non‐ocular hemorrhage with low, at 4 events per 1,000
PYs for each drug. Aflibercept was not associated with increased risk
of hemorrhage vs. ranibizumab at 180 days (HR: 0.97 (95%CI: 0.37–
2.56)), which was confirmed at 365 days (HR: 1.01 (95%CI: 0.51–
1.99)). Results were consistent in the AT analysis: HR: 1.19 (95% CI:
0.52–2.75). No increased risk of hemorrhage was found for aflibercept
and ranibizumab at 180 days compared to dexamethasone (HR: 0.70
(95% CI 0.30–2.60) and 0.67 (95% CI: 0.33–1.38), respectively).
Conclusions: No association was identified between aflibercept and
non‐ocular hemorrhage compared to ranibizumab. A comparable risk
for these IVT anti‐VEGFs and IVT dexamethasone was observed.
Given the known benefits of IVT anti‐VEGF in retinal diseases, hemor-
rhage does not appear to be a significant risk.
870 | Heatwaves and heat‐sensitizing
medications in vulnerable older adults
J. Bradley Layton1; Wenhong Li2; Lily Wang3; Jiacan Yuan2;
Joshua P. Gilman4; Daniel B. Horton4; Soko Setoguchi4
1RTI Health Solutions, Research Triangle Park, NC; 2Duke University,
Durham, NC; 3Gillings School of Global Public Health, Chapel Hill, NC;
4Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background: Heatwaves kill people and have become more common
and severe in the past decades. Somemedicationsmay sensitize vulner-
able older patients with chronic conditions to the effects of heatwaves.
Objectives: To determine whether heat‐sensitizing medications, e.g.,
diuretics, antipsychotics, increase the risk of heat‐related hospitaliza-
tions during the warm summer months among older adults with debil-
itating conditions.
Methods: Linking 20% US Medicare Part A, B, and D data with daily
maximum surface air temperature (tasmax) using residence ZIP codes,
we identified patients with chronic kidney disease (CKD), diabetes on
chronic insulin use (DM), chronic obstructive pulmonary disease
(COPD), dementia, heart failure (HF), myocardial infarction (MI), and
stroke during June–August of years 2007–2012. We assessed expo-
sure to angiotensin blockers (ACE/ARB), loop diuretics (LD), antipsy-
chotics (AP), beta‐blockers (BB), and anticholinergic agents (AC). We
defined heatwaves as at least two consecutive days with tasmax
>95th percentile. We assessed heat‐related hospitalizations (heat
exhaustion, heat fatigue, heatstroke, dehydration, hyperosmolality, or
excessive exertion) during follow‐up. We conducted self‐controlled
case series analysis for censored or curtailed data to estimate risk
ratios (RR) and 95% confidence intervals (CI) for heatwave and medi-
cation effects. We evaluated each medication separately, both overall
in the full cohort and in each disease‐specific cohort.
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Results: Among 377,100 patients (73% female; 80% white; mean
age = 80, SD 8; 41% living in South region; 42% CKD, 29% dementia,
26% HF, 19% DM, 12% MI, 9% COPD, 7% stroke), 33% experienced a
heatwave. A heat‐related hospitalization occurred in 11,244 (3%).
Heatwaves were associated with modest increases in heat‐related
hospitalizations (RR 1.1 [1.0–1.2]). Medication exposure varied widely
ranging from 9% (AP) to 75% (AC). After accounting for heatwaves,
several drug classes moderately increased the risk for heat‐related
hospitalizations except for AC and AP: BB, 1.3 (1.1–1.6); LD, 1.4
(1.2, 1.7) and ACE/ARB RR = 1.6 (1.3–1.9). The effects of ACE/ARB
and LD were pronounced in subgroups with CKD, DM, and HF, with
RR >5 and lower CI bound >2.
Conclusions: Many of the heat‐sensitizing medications increased the
risk of heat‐related hospitalizations among older patients with chronic
disease. ACE/ARB posed greater risks in subgroups with CKD, DM,
and HF. Large high‐resolution cohort studies are needed to understand
the interactions between heatwaves and medications on heat‐related
hospitalizations and other health outcomes in vulnerable older adults.
871 | Opioid intensification versus adjuvant
gabapentin initiation and risk of
hospitalization for falls and fractures in
United States nursing home residents
Danni Zhao1; Anne Hume2; Shao‐Hsien Liu1; Christine Ulbricht1;
Matt Alcusky1; Giovanni Gambassi3; Kate L. Lapane1
1University of Massachusetts Medical School, Worcester, MA; 2University
of Rhode Island, Kingston, RI; 3Università Cattolica del Sacro Cuore,
Rome, Italy
Background: Opioids are commonly used in nursing homes and resi-
dents receiving opioids are at higher risk for falls and fractures. Adju-
vants (e.g., gabapentin) may be used with the pain medication regimen
when residents are intolerant for opioid side effects. Data on the com-
parative safety of different strategies for intensifying pharmacologic
pain management on fall and fracture risk are scant.
Objectives: To investigate the risk of hospitalization for falls or frac-
tures among residents for whom gabapentin was added to an opioid
regimen relative to residents whose oral morphine equivalent (OME)
was increased.
Methods: We conducted a retrospective cohort study among fee‐for‐
service Medicare beneficiaries aged ≥65 years living in 1790 nursing
homes from 2011 to 2016 linking Minimum Data Set 3.0, Medicare
Parts A and D. Using principles of a new user design, we identified res-
idents for whom gabapentin was added to an opioid drug regimen and
1:1 propensity matched them to residents with an increase in oral
morphine equivalent (OME). Residents contributed treatment epi-
sodes, and were followed up from the index date (date of gabapentin
initiation or OME increase) until fall/fracture hospitalizations, death, or
180 days. We estimated the intention‐to‐treat effect from competing
risks models from which we derived sub‐distribution hazard ratios
(aHRSD) and 95% confidence intervals (CI).
Results: Overall, 3,171 residents contributed 5,528 treatment epi-
sodes: 2,764 gabapentin initiators were 1:1 propensity matched to
residents whose opioid regimen was intensified. The incidence rate
of hospitalizations for falls and fractures per 100 person‐years was
2.98 (95% CI: 2.16–4.11) in residents with intensified opioid regimens
and 2.56 (95% CI: 1.79–3.66) in residents initiating gabapentin while
holding opioid dose constant. Gabapentin initiators had similar rates
of hospitalizations for falls and fractures rates as those with OME
increases (aHRSD = 0.85, 95% CI: 0.44–1.67).
Conclusions: Use of gabapentin as an adjuvant to opioids was uncom-
mon in US nursing homes. Given that nursing home residents typically
have limited mobility, the fracture rates were lower than observed in
community‐dwelling older adults. The risk of hospitalizations for falls
and fractures were similar regardless of pharmacologic pain manage-
ment approach. Whether gabapentin as an adjuvant to opioid therapy
is as effective as increased OME should be evaluated in older adults
living in nursing homes.
872 | Comparative safety and effectiveness
of apixaban and rivaroxaban versus warfarin
among US nursing home residents
Matthew Alcusky1; David D. McManus1; Marc Fisher2;
Anne L. Hume3; Jennifer Tjia1; Kate L. Lapane1
1University of Massachusetts Medical School, Worcester, MA; 2Beth
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;
3University of Rhode Island, Kingston, RI
Background: Research comparing direct‐acting oral anticoagulants
(DOACs) to warfarin has excluded nursing home residents, a vulnera-
ble population at high risk for vascular and bleeding events.
Objectives: To compare the safety and effectiveness of individual
DOACS (rivaroxaban, apixaban) versus warfarin in a contemporary
(2014–2016) cohort of nursing home residents.
Methods: Residents aged ≥65 years with non‐valvular atrial fibrilla-
tion newly initiating oral anticoagulation and enrolled in fee‐for‐ser-
vice Medicare for ≥6 months were studied. Nursing home residence
was determined using Minimum Data Set 3.0 assessments. Effective-
ness and safety outcomes were identified from Part A claims and
included 1) ischemic stroke or transient ischemic attack (IS/TIA); and
2) bleeding (extracranial or intracranial); 3) a composite of the IS/TIA,
bleeding, myocardial infarction, venous thromboembolism, systemic
embolism, and death; and 4) death. Follow‐up continued until an out-
come or 14‐day treatment gap (as‐treated). DOAC initiators were 1:1
propensity matched to residents initiating warfarin in the same year.
Cox proportional hazards models estimated cause‐specific hazard
ratios.
Results: Among 3,326 apixaban and 2,855 rivaroxaban initiators, 84%
and 99% were matched to warfarin initiators. Median age (84 years;
Q1 77, Q3 89), CHA2DS2‐Vasc (5; Q1: 4, Q3: 6) and ATRIA risk scores
(3; Q1: 3, Q3: 6) were similar across treatments and cohorts. Crude IS/
TIA incidence rates in the apixaban cohort were 0.93 events/100
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person‐years (PYs) for warfarin and 1.73 events/100 PYs for apixaban;
event rates in the rivaroxaban cohort were 1.29/100 PYs for warfarin
and 1.90/100 PYs for rivaroxaban. Bleeding rates were in the range of
6.58–6.84 events/100 PYs, with the exception of apixaban (4.24
events/100 PYs). Compared with warfarin, the IS/TIA rates were
higher among apixaban (HR: 1.93; 95% CI: 1.02–3.65) and rivaroxaban
users (HR: 1.48; 95% CI: 0.87–2.51). Bleeding rates were lower among
apixaban users (HR: 0.63; 0.47–0.85) and similar to warfarin for
rivaroxaban users (HR: 0.96, 95% CI: 0.74–1.23). Crude mortality rates
ranged from 29.34 to 36.96 deaths/100 PYs. Apixaban (HR: 0.79;
0.70–0.88) and rivaroxaban (HR: 0.80; 95% CI: 0.71–0.89) were asso-
ciated with lower mortality. Composite event rates were also lower
among apixaban (HR: 0.80; 95% CI: 0.72–0.89) and rivaroxaban users
(HR: 0.87; 95% CI: 0.79–0.96).
Conclusions: Nursing home residents initiating apixaban and
rivaroxaban had lower mortality compared with warfarin and higher
rates of IS/TIA hospitalizations. Bleeding was less common with
apixaban.
873 | Statin use in older Danes: an analysis
of discontinuation patterns
WadeThompson; Dorte E. Jarbøl; Peter Haastrup; Jesper Bo Nielsen;
Anton Pottegård
University of Southern Denmark, Odense, Denmark
Background: There is limited evidence on benefits and harms of
statins in the oldest old. Current guidance suggests individualized
decisions and discontinuation of statins may be considered in some.
Objectives: To investigate factors associated with statin discontinua-
tion in new statin users ≥70 years of age over the first four years of
use.
Methods: This was a register‐based descriptive drug utilization study.
The population was all Danish persons ≥70 years of age, starting
statins between 2008 and 2012. We evaluated statin discontinuation
at one year (early), two years, and four years. We also examined the
annual rate of early discontinuation from 2008 to 2015. As possible
factors associated with discontinuation, we considered age group,
sex, indication, co‐morbidities, concomitant medications, education,
marital status, and region of residence. Factors associated with
discontinuing were analyzed using logistic regression.
Results: We included 84,696 statin initiators. At one year, 13% had
discontinued their treatment. At two years, an additional 13%
discontinued, and at four years, another 17% discontinued. Increasing
age was associated with increased odds of discontinuation at all
timepoints (OR 1.95 [95% CI 1.28 to 3.00] at 1 year; OR 2.10 [95%
CI 1.29 to 3.41] at 2 years; OR 2.51 [95% CI 1.17 to 5.41] at 4 years,
for 95+ age group versus 70 to 74). Beyond one year, increasing co‐
morbidity scores (OR 1.85, 95% CI 1.60 to 2.15 for high versus zero
at 4 years) and increasing numbers of medications (OR 1.29, 95% CI
1.20 to 1.40 for 10+ medications versus 0 to 4 at 4 years) were asso-
ciated with increased odds of discontinuation. A secondary prevention
indication was associated with reduced odds of discontinuation at one
(OR 0.73, 95% CI 0.65 to 0.82) and four years (OR 0.85, 95% CI 0.76
to 0.96), but not at two years (OR 0.94, 95% CI 0.83 to 1.05). Use of
cardiovascular medications was associated with reduced odds of dis-
continuation. The annual proportion of early discontinuers ranged
from 14 to 17% for primary prevention and 10 to 12% for secondary
prevention between 2008 and 2015.
Conclusions: Statin discontinuation appeared to be influenced by age,
burden of co‐morbidities and medication use, indication, and concom-
itant cardiovascular therapies. Decisions surrounding statin may have
been made based on these person‐specific factors. Future research
should clarify reasons and discussions around statin discontinuation
the oldest old to provide additional insight on this topic.
874 | Does use of acetylcholinesterase
inhibitors prevent or delay the prescribing of
psychotropic medications in people with
dementia? Analyses of the Swedish dementia
registry (SveDem)
Edwin C.K. Tan1; Kristina Johnell2; J. Simon Bell3; Sara Garcia‐Ptacek2;
Johan Fastbom2; Peter Nordström4; Maria Eriksdotter2
1The University of Sydney, Sydney, Australia; 2Karolinska Institutet,
Stockholm, Sweden; 3Monash University, Parkville, Australia; 4Umeå
University, Umeå, Sweden
Background: Behavioral and psychological symptoms of dementia
(BPSD) are common. Psychotropics, such as antipsychotics, anxiolytics
and antidepressants, are often used to manage BPSD; however, they
are associated with significant adverse effects.
Objectives: To investigate whether prescribing of acetylcholinesterase
inhibitors (AChEIs) prevents or delays the subsequent initiation of psy-
chotropic medication in people with Alzheimer's disease (AD) and
Lewy body dementia (LBD).
Methods: This was a data linkage study of 17763 people with AD and
LBD, who did not use a psychotropic at the time of dementia diagno-
sis, registered in the Swedish Dementia Registry (SveDem) from 2007
to 2015. Data on AChEI use, psychotropic use and comorbidities were
linked using nationwide registers. Propensity‐score matched Cox pro-
portional hazards models were used to compute hazard ratios (HRs)
and 95% confidence intervals (CIs) for the association between time‐
dependent AChEI use and risk of psychotropic initiation.
Results: During a median follow‐up period of 2.6 [quartiles 1.3–4.2]
years, 9959 people initiated a psychotropic. In comparison with
matched controls, AChEI use was associated with a lower risk of anti-
psychotic (HR 0.80, 95%CI 0.73–0.88) and anxiolytic (HR 0.88, 95%CI
0.82–0.94) initiation, but no association with hypnotic or antidepres-
sant initiation. Low doses of AChEI (<0.67 defined daily dose) were
associated with a higher risk of anxiolytic, hypnotic and antidepressant
initiation compared with non‐use. In contrast, high AChEI doses
(≥1.33 defined daily dose) were associated with a lower risk of initia-
tion across all psychotropic drug classes.
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Conclusions: AChEI use may be associated with a lower risk of anti-
psychotic and anxiolytic initiation in people with AD and LBD, partic-
ularly at higher doses. Further investigation into the potential benefits
of AChEIs in BPSD management are warranted.
875 | Association rule analysis to evaluate
frequent drug combinations associated with
acute kidney injury in older adults
Prasad Nishtala1; Te‐yuan Chyou2
1University of Bath, Bath, UK; 2University of Otago, Dunedin, New
Zealand
Background: Older adults are at an increased risk of AKI because of
aging, multiple comorbidities, and polypharmacy.
Objectives: The aim of this case‐crossover study was to apply associ-
ation rule analysis to ascertain drug combinations contributing to the
risk of acute kidney injury (AKI) in adults aged 65 years and older.
Methods: We sourced a nationwide representative sample of New
Zealanders aged ≥65 years from the pharmaceutical collections and
hospital discharge information. Prescription records (2005–2015) of
drugs of interest were sourced from New Zealand pharmaceutical col-
lections (Pharms). We classified medication exposure, as a binary var-
iable, at individual drug level belonging to medication classes including
antimicrobials, antihistamines, diuretics, opioids, non‐steroidal anti‐
inflammatory medications. Several studies have associated the drugs
of interest from these medication classes with AKI in older adults.
The first‐time coded diagnosis of AKI was extracted from the National
Minimal Dataset (NMDS). A unique patient identifier linked the pre-
scription dataset to the event dataset, to set up a case‐crossover
cohort, indexed at the first AKI event. Association rules were then
applied to identify frequent drug combinations in the case and the
control periods (l‐day with a 35‐day washout period), and the associa-
tion of AKI with each frequent drug combination was tested by com-
puting a matched odds‐ratio (MOR) and its 95% confidence interval
(CI).
Results: We identified 55747 individuals (mean age 82.14) from 2005
to 2014 with incident AKI and exposed to at least one of the drugs of
interest. Association rules revealed that frequently used drug combi-
nations associated with AKI are trimethoprim (MOR = 1.68;
95%CI = [1.54–1.80]), ondansetron (MOR = 1.43; 95%CI = [1.25–
1.64]), codeine phosphate plus metoclopramide (MOR = 1.37;
95%CI = [1.11–1.63]), and norfloxacin (MOR = 1.24; 95%CI [1.05–
1.42]).
Conclusions: We applied association rules, a novel methodology, to
big data to ascertain drug combinations associated with adverse drug
events. Association rules identified several drug classes including anti-
microbials, nonsteroidal anti‐inflammatory medications and opioids
are associated with AKI. The finding that ondansetron and amoxicillin
plus clavulanic acid increases the risk of AKI requires further
investigation.
876 | Pharmacy‐based predictors of non‐
adherence, non‐persistence, and re‐initiation
of antihypertensive drugs among patients on
oral diabetes drugs in the Netherlands
Sofa Dewi Alfian1,2; Petra Denig3; André Coelho4; Eelko Hak5
1University of Groningen, Groningen, Netherlands; 2Universitas
Padjadjaran, Sumedang, Indonesia; 3University Medical Center
Groningen, University of Groningen, Groningen, Netherlands; 4 Instituto
Politécnico de Lisboa, Lisbon, Portugal; 5University of Groningen,
Groningen, Netherlands
Background: Adherence to antihypertensive drugs in patients with
diabetes is important. To support adherence, attention should be paid
to the dynamic process of initiation, implementation and persistence
on these drugs.
Objectives: To describe non‐adherence, non‐persistence, and re‐initi-
ation patterns of antihypertensive drugs in patients with type 2 diabe-
tes, and to identify pharmacy‐based risk factors of these processes.
Methods: We conducted a retrospective cohort study in patients on
oral diabetes drugs who initiated antihypertensive drugs registered
in the University of Groningen pharmacy database IADB.nl. Non‐
adherence was calculated in persistent patients and defined as a
medication possession ratio < 80% for any antihypertensive drug.
Non‐persistence was defined as a gap >180 days for all antihyper-
tensive drugs. We defined re‐initiation as the dispensing of an anti-
hypertensive drug within one year following a discontinuation.
Logistic regression and Cox regression analysis were applied to
assess independent associations with available sociodemographic
and drug‐related factors.
Results: Among 6,669 diabetes patients initiating an antihypertensive
drug, non‐adherence rates in persistent patients decreased from
11.0% in the first to 8.5% and 7.7% in the second and third year,
respectively. Non‐persistence rates decreased from 18.0% in the
first to 3.7% and 2.9% in the second and third year. Of the 1,201
patients who discontinued in the first year, 22.0% reinitiated treat-
ment within one year after discontinuation. Predictors of non‐adher-
ence were secondary prevention (OR: 1.45; 95% CI: 1.10–1.93) and
the use of diuretics as initial drug class (OR: 1.37; 95% CI: 1.08–
1.74). Predictors of non‐persistence were female gender (HR: 1.18;
95% CI: 1.05–1.32), older age (HR: 1.33; 95% CI: 1.08–1.63), and
the use of diuretics, beta‐blocking agents, or calcium channel
blockers as initial drug class. Longer duration of persistence (>
90 days) was a predictor of re‐initiation.
Conclusions: Filling prescriptions for antihypertensive drugs in
patients with diabetes is a dynamic process. The first year after initia-
tion is the most crucial with regard to non‐adherence and non‐persis-
tence, and risk groups are different for both processes. Since only a
fifth of all patients re‐initiated treatment within one year after discon-
tinuation, more attention should be paid to these patients during this
period.
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877 | The social determinants of non‐
adherence to antihypertensive medications
Macarius Donneyong1; Paul Juarez2; Teng‐Jen Chang1;
Shawnita Sealy‐Jefferson1; Pamela Salsberry1; Bo Lu1; Wansoo Im2;
John Jackson3; Michael Fischer4
1The Ohio State University, Columbus, OH; 2Meharry Medical College,
Nashville, TN; 3 Johns Hopkins University, Baltimore, MD; 4Brigham and
Women's Hospital, Boston, MA
Background: Non‐adherence to medications is a complex and multi-
dimensional health behavior rooted in the complex web of interac-
tions between patients and the social, physical, healthcare and
policy environments. However, the role of these factors ‐ collec-
tively known as the social determinants of health (SDH) ‐ as deter-
minants of medication non‐adherence has not been well
interrogated.
Objectives: Therefore, we examined the role of SDH constructs as
potential predictors of county‐level non‐adherence to antihyperten-
sive medications (AHM).
Methods: We linked the Centers of Disease Control and Prevention
(CDC) Atlas of Heart Disease and Stroke (2014–2016 cycle) and the
2016 County Health Rankings (CHR) datasets for this analysis. Both
datasets contain >100 individual county‐level variables in the fol-
lowing SDH domains per CHR definition: health behaviors, clinical
care, social and economic factors and physical environment.
County‐level non‐adherence to AHM is captured in the CDC Atlas
dataset as the proportion of days covered using Medicare Part D
claims data. Hierarchical linear models (HLM), weighted by the per-
cent of county populations aged ≥65 years old, were used to quan-
tify the variation and identify predictors of county‐level non‐
adherence to AHM. Two measures of county‐level SDH were
assessed: 1) predefined SDH in the CHR data; 2) constructs of
SDH created with principal component analysis (PCA). SDH con-
structs were modeled as level 1 predictors with states as a level 2
random intercept variable.
Results: PCA‐derived SDH models were a better fit compared to
those with CHR‐defined SDH domains. In multilevel models ‐ adjusted
for county‐level measures of race, sex and rural/urban status ‐ six out
of the 14 PCA‐derived SDH constructs that accounted for >80% of
variability in the data correlated strongly with non‐adherence. These
significant constructs are descriptors of the neighborhood (stress,
affluence, disadvantage), healthcare access and health seeking behav-
ior. Collectively, these SDH constructs accounted for 43% of county‐
level variation in non‐adherence to AHM after accounting for between
state variability.
Conclusions: This data confirms SDH as significant determinants of
non‐adherence to AHM. Future research will interrogate how these
contextual factors interact with patient‐level factors to influence
non‐adherence.
878 | Increased out‐of‐pocket costs lead to
decreased adherence and delayed treatment
reinitiation of branded diabetes drugs in
Medicare patients
Danielle S. Chun1; Mugdha Gokhale2; Stacie B. Dusetzina3;
Virginia Pate1; John B. Buse4; Emily Gower1; Til Stürmer1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2GlaxoSmithKline, Philidelphia, PA;
3Vanderbilt University School of Medicine, Nashville, TN; 4UNC School of
Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Studies have shown that high out‐of‐pocket costs for
medications may negatively affect patients' adherence to antidiabetic
treatment and clinical outcomes. For US Medicare beneficiaries who
reach the “coverage gap”, sudden increases in out‐of‐pocket costs
may disrupt treatment.
Objectives: To compare changes in adherence to dipeptidyl peptidase‐
4‐inhibitors (DPP‐4i), a branded expensive drug class, before and after
entering the coverage gap in 2015 between patients with and without
a low‐income subsidy (LIS). Analyses were repeated using sulfonyl-
ureas (SU), a cheaper alternative, to isolate cost‐related adherence
changes. We also explored seasonality of reinitiation, as patients are
more likely to reinitiate in January when out‐of‐pocket costs are
reduced.
Methods: Initiators of DPP‐4i or SU aged >65 years were identified
from a 20% random sample of 2014–2015 Medicare claims data.
Patients must have filled at least one antidiabetic prescription and
entered the coverage gap in 2015. We used difference‐in‐differences
(DiD) Poisson regression analyses to compare adherence (proportion
days covered ≥0.8) before and after entering the coverage gap
between patients with and without LIS. Among patients who
discontinued treatment during follow‐up, we used Cox proportional
hazard models to obtain monthly hazard ratios (HRs) for reinitiation
relative to January 2015.
Results: Among DPP‐4i initiators, 9,357 received LIS and 9,692 did
not. Among DPP‐4i users without LIS, adherence decreased from
65.5% to 46.8% when beneficiaries entered the coverage gap, differ-
ences were minimal in patients with LIS (71.6 vs. 68.8%). After
accounting for differences in patients with LIS, the effect of facing
higher costs reduced adherence by 16 percentage points (adjusted
DiD:‐15.9%; 95%CI:‐18.0%,‐13.8%). No such difference was observed
among our low‐cost control treatment (adjusted DiD:‐0.1%; 95%CI:‐
2.2%, 2.1%). HRs for reinitiation were lower in months prior to Janu-
ary (HR = 0.4–0.5), demonstrating a strong seasonal pattern for unsub-
sidized DPP‐4i group but not for those with subsidies. For SU, HRs of
reinitiation were similar across groups and time.
Conclusions: Our study showed that increased out‐of‐pocket costs
associated with entering the Medicare Part D coverage gap in 2015
were associated with poor adherence and delayed reinitiation of
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DDP‐4is. Despite the coverage gap steadily closing through 2019,
these findings remain relevant as enrollment in high‐deductible com-
mercial health plans requiring large out‐of‐pocket payments continues
to increase in the US.
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880 | Does nonadherence with
antidepressants differ by treatment
indication?
Jenna Wong1; Siyana Kurteva2; Robyn Tamblyn2
1Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA; 2McGill University, Montreal, QC, Canada
Background: Nonadherence with antidepressants for depression is a
known problem, but physicians commonly prescribe antidepressants
for other indications, many of which are off‐label. No studies have
measured antidepressant nonadherence for indications besides
depression.
Objectives: To determine if rates of antidepressant nonadherence for
depression differ from other treatment indications.
Methods: Cohort study using data from a Canadian primary care
electronic prescribing system where physician documentation of
treatment indications was mandatory. We identified all antidepres-
sant prescriptions from Jan 2003‐Dec 2012 for patients 18+ years
old with public drug insurance. Study variables were measured using
data from the prescribing system or patients' linked drug claims and
medical billing data. The outcome was antidepressant nonadherence,
defined as not filling a prescription for new or ongoing therapy
within 90 days. Covariates included the treatment indication for
the prescription (depression, anxiety, insomnia, pain, or miscella-
neous) and other adjusting factors (eg, patient demographics, co‐
pay, illness severity, past adherence patterns, and past experience
with drugs). We used multivariable alternating logistic regression to
estimate odds ratios (ORs) for the independent association between
90‐day nonadherence and treatment indication, using depression as
the reference and an interaction term to stratify the ORs by therapy
status.
Results: Among 37,801 antidepressant prescriptions (9,049 patients/
152 physicians), the 90‐day nonadherence rate for new and ongoing
antidepressant therapy was 34.4% and 4.1%, respectively. Compared
to depression, nonadherence rates for other indications differed. For
new therapy, patients were more likely to be nonadherent if antide-
pressants were prescribed for anxiety (OR 1.26, 95% CI 1.03–1.54)
but were less likely to be nonadherent if prescribed for insomnia
(OR 0.73, 95% CI 0.55–0.98). For ongoing therapy, patients were
more likely to be nonadherent if antidepressants were prescribed for
insomnia (OR 1.58, 95% CI 1.25–1.99) or miscellaneous indications
(OR 1.59, 95% CI 1.25–2.04).
Conclusions: Antidepressant nonadherence differed by treatment
indication, particularly for insomnia where nonadherence rates were
lower than depression for new therapy but conversely higher than
depression for ongoing therapy. Since insomnia is an off‐label indica-
tion for most antidepressants, further investigation is needed to deter-
mine whether the differing nonadherence rates between new and
ongoing antidepressant therapy for insomnia is due to treatment
ineffectiveness.
881 | A group based trajectory modeling to
study adherence patterns of atypical
antipsychotics in pediatrics and adolescents: a
retrospective cohort study using Texas
children health plan
Swarnava Sanyal; Tyler J. Varisco; Soham Yande; Hua Chen
University of Houston, Houston, TX
Background: The annual economic burden of pediatric mental health
disorders in US is $247 bn. Medication non‐adherence contributes
to high cost of care. Due to sparsity of available literature in pediat-
rics, it is necessary to explore patterns of adherence to atypical anti-
psychotics or second generation antipsychotics (SGAs) in this
population.
Objectives: To describe the adherence trajectory pattern of atypical
antipsychotics (SGAs) among children and adolescents enrolled in a
large pediatric Medicaid managed care plan in Texas.
Methods: Individuals enrolled during 2015 to 2016 were identified if
they were under the age of 21, had one inpatient or two outpatient
encounters with the primary diagnosis of bipolar disorder, autism
spectrum disorder schizophrenia, ADHD or disruptive behavioral,
and continuously enrolled for a period of three months prior and
six months post to a SGA initiation. The monthly SGA adherence
was measured using the proportion of days covered (PDC), and the
monthly PDC was further modeled using Group Based Trajectory
Model. After identifying the final number of latent trajectories, indi-
viduals were classified into a trajectory model according to their
highest probability of membership. Comparison of mean PDC
between groups was performed using ANOVA with Tukey's post
hoc test.
Results: 393 patients who met the inclusion criteria were identified.
Over half of the patients (55.43%) were prescribed aripiprazole
(n = 218), followed by risperidone (n = 101; 25.7%), quetiapine
(n = 44; 11.2%), olanzapine (n = 13; 3.31%), ziprasidone (n = 8;
2.04%), paliperidone (n = 6; 1.53%), asenapine (n = 3; 0.76%). The
mean PDC was 40.2 ± 28.3%. A 3‐group trajectory model was
selected on the basis of their Akaike Information Criteria (AIC) value
and clinical relevance. The patterns of the trajectories were identi-
fied as 1) Fully adherent (6.9%, mean PDC = 99.6 ± 2.5%), 2) Grad-
ual decline (31.4%, mean PDC = 64.8% ± 15.2%) and 3) Rapid
decline (61.7%, mean PDC = 21.5 ± 9.2%). The monthly PDC for
the fully adherent group was more than 90% throughout the
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6 month follow up period. The gradual decline group had above 80%
PDC for 2 months, gradually declining to 30% at the end of the fol-
low up period. Finally, the PDC of the rapid decline group quickly
dropped to 20% within 2 months since the SGA initiation.
Conclusions: This study demonstrated that patterns of SGA adher-
ence among pediatric patients may be described by three differing
clinical trajectories. The gradual and rapid decliners both represent tar-
gets for interventions aimed at sustaining use.
882 | Current practice in reporting exposure
in pharmacoepidemiological studies
Mirjam Hempenius1; Kim Luijken2; Anthonius de Boer1;
Olaf H. Klungel1,3; Rolf H.H. Groenwold2; Helga Gardarsdottir1,3,4
1Utrecht University, Utrecht, Netherlands; 2 Leiden University Medical
Center, Leiden, Netherlands; 3University Medical Center Utrecht, Utrecht,
Netherlands; 4University of Iceland, Reykjavík, Iceland
Background: Exposure definitions vary across
pharmacoepidemiological studies. As different definitions can lead to
different results, transparent reporting of the exposure definition is
of utmost importance.
Objectives: This study assessed the current status of reported expo-
sure definitions in pharmacoepidemiological research as baseline mea-
surement compared to the ISPE‐ISPOR taskforce reporting guideline
published in 2018.
Methods: We systematically reviewed all observational
pharmacoepidemiological studies that used routinely collected
health data. We included studies with > = 250 subjects published
in 2017 in six leading (pharmaco‐)epidemiological journals. Informa-
tion was extracted about all items regarding reporting of exposure
as presented in the ISPE‐ISPOR guideline. Primary outcome was
the percentage of studies reporting each ISPE‐ISPOR guideline
item.
Results: 91 studies were included. Almost all studies reported the
type of exposure (e.g. current use, cumulative dose) (n = 89,
97.8%), the exposure risk window in general terms (n = 77, 84.6%)
and the exposure assessment window (n = 89, 97.8%). The
operationalisation of the exposure window was poorly described:
only 14 (15.4%) studies explicitly reported the presence or absence
of an induction period, 5 (5.5%) respectively 21 (23.1%) studies
reported how they handled stockpiling and bridging of exposure epi-
sodes, and 28 (30.8%) studies mentioned how long the exposure
was extended. How switching between drugs was dealt with and
specific drug codes were reported in 52 (57.1%) and 24 (26.4%)
publications.
Conclusions: Reporting of exposure definitions in current
pharmacoepidemiologic studies is suboptimal when compared to the
ISPOR‐ISPE guideline. Publications of pharmacoepidemiological stud-
ies should include more details on exposure ascertainment to allow
both replication and quality assessment.
883 | Cause‐specific and all‐cause mortality
associated with proton pump inhibitors: a
cohort study
Jeremy P. Brown; John Tazare; Kathryn Mansfield; Kevin Wing;
Adrian Root; Laurie Tomlinson; Krishnan Bhaskaran;
Elizabeth Williamson; Liam Smeeth; Ian Douglas
London School of Hygiene and Tropical Medicine, London, UK
Background: Previous studies report associations between proton
pump inhibitor (PPI) use and a range of adverse outcomes, including
all‐cause mortality. It is unclear what is driving the association with
all‐cause mortality, and whether the association is causal or due to
residual confounding.
Objectives: To evaluate the association between PPI usage and both
all‐cause and cause‐specific mortality.
Methods: We conducted a cohort study comparing new users of PPIs
(defined by first receipt of PPI prescription) to new users of an alterna-
tive acid‐suppression therapy, H2 receptor antagonists (H2RA), and in
a secondary analysis to non‐users of acid‐suppression therapy
matched on age, sex, calendar year and general practice. We identified
eligible individuals registered with practices contributing to the UK
Clinical Practice Research Datalink (January 1998 to December
2015). Outcomes were defined based on International Classification
of Disease (ICD) codes recorded in linked death registry data; and
included all‐cause mortality, communicable and non‐communicable
disease mortality, and mortality due to outcomes previously associ-
ated with PPI use. We used Cox regression models, weighted using
average effect of treatment in the treated (ATT) weights, to estimate
the association with mortality.
Results: A total of 733,885 new users of PPIs and 124,410 new users
of H2Ras were identified. In secondary analysis, 689,602 PPI new
users were matched 1:2 to 1,361,245 non‐users. PPI users had a
higher prevalence of most comorbidities and concurrent medication
use in comparison to H2RA users and, particularly, compared to non‐
users. Weighted hazard ratios for all‐cause mortality for PPI usage
were 1.26 (95% CI 1.20–1.32) relative to H2RA use, and 1.98 (1.95–
2.00) compared to non‐use. Mortality from specific causes was fre-
quently higher shortly after initiation. For example, the hazard ratio
for PPI use over the first year of follow‐up was 1.50 (1.37–1.65) for
neoplasms, 4.08 (1.60–14.34) for C. difficile enterocolitis, and 1.70
(0.70–4.11) for liver cirrhosis, compared to H2RA use; and 5.52
(5.25–5.80), 4.11 (2.45–6.89), and 6.01 (3.99–9.05) respectively, rela-
tive to non‐use.
Conclusions: First prescription for a PPI was associated with increased
all‐cause mortality and mortality from several specific causes. How-
ever, consistently higher hazard ratios when comparing PPI users to
non‐users rather than H2RA users, and some unexpected short‐term
associations in the first year with cause‐specific mortality, suggest that
observed associations with mortality are, at least in part, due to resid-
ual unmeasured confounding.
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884 | Survival after Stevens‐Johnson
syndrome: a UK‐based cohort study
Carole Marxer1,2; Noel Frey1,2; Michael Bodmer3; Andreas Bircher4;
Susan S. Jick5; Christoph R. Meier1,2,5; Julia Spoendlin1,2
1University of Basel, Basel, Switzerland; 2University Hospital Basel, Basel,
Switzerland; 3Cantonal Hospital Zug, Zug, Switzerland; 4University
Hospital Basel, Basel, Switzerland; 5Boston Collaborative Drug
Surveillance Program, Lexington, MA
Background: Short‐term mortality after Stevens‐Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN) is estimated between
5–17% and 15–46%, but evidence on long‐term mortality is
scarce.
Objectives: We aimed to describe short‐ and long‐term mortality after
SJS/TEN and to evaluate risk factors for death.
Methods: We performed a retrospective cohort study using a vali-
dated cohort of SJS/TEN patients (PPV = 87%) extracted from the
UK‐based Clinical Practice Research Database (1995–2013). We
matched SJS/TEN patients 1:4 on a propensity score (PS) to patients
without SJS/TEN, and followed them until death (primary endpoint)
or censoring (max. Follow‐up = 5 years [y]). We performed Cox pro-
portional hazard (Cox PH) analyses to estimate hazard ratios (HR,
95% CI) for death during early (1–89 days [d]), intermediate (90–
364 d) and late (365 d ‐ 5 y) follow‐up overall, and within subgroups
of age. Using age‐adjusted Cox PH analyses, we compared short‐
term mortality (90 d) in patients with (a) a cancer diagnosis within
1 year before or (b) an antiepileptic drug (AED) within 64 d before
the SJS/TEN diagnosis to SJS/TEN patients without (a) or (b). To
evaluate differential outcome misclassification (DOM), we compared
short‐term mortality between GOLD‐standard confirmed (N = 80)
and non‐confirmed (N = 397) SJS/TEN patients.
Results:We included 477 SJS/TEN patients and 1908 matched com-
parator patients (mean age 38 y). In total, 12.4% of SJS/TEN
patients died (4.8% within 90 d, N = 23). In patients aged ≥65 years,
45.1% died (16.5% within 90 d, N = 15) and in patients aged
<65 years, 4.7% died (2.1% within 90 d, N = 8). After PS‐matching,
we observed an overall HR of 4.19 (95% CI 2.33–7.51) for death
during early follow‐up, HR of 0.99 (95% CI 0.54–1.83) during inter-
mediate, and HR of 0.76 (95% CI 0.48–1.21) during late follow‐up.
Compared to patients without SJS/TEN, SJS/TEN yielded a HR of
4.94 (95% CI 2.35–10.39) in patients aged ≥65 years, and a HR of
10.5 (95% CI 2.79–39.62) in patients aged <65 years during early
follow‐up (HR around 1 thereafter). A previously recorded a) cancer
diagnosis (vs. no diagnosis) and b) AED prescription (vs. no prescrip-
tion) yielded a HR for death of a) 1.90 (95% CI 0.56–6.44) and b)
1.76 (95% CI 0.52–5.97) among SJS/TEN patients during early fol-
low‐up. Comparing death during early follow‐up between confirmed
and non‐confirmed SJS/TEN patients resulted in a HR of 1.10 (95%
CI 0.52–2.34).
Conclusions: Our results suggest that long‐term survival after SJS/
TEN is comparable to non‐SJS/TEN patients after the first 90 days
after diagnosis, irrespective of age. Cancer and AEDs were risk factors
for early death (limited power), which was not explained by DOM.
885 | Real world effects of medications for
chronic obstructive pulmonary disease: a UK
population‐based non‐interventional cohort
study with validation against randomized trial
results
Kevin Wing1; Elizabeth Williamson1; James Carpenter1; Lesley Wise1;
Sebastian Schneeweiss2; Liam Smeeth1; Jenni Quint3; Ian Douglas1
1London School of Hygiene & Tropical Medicine, London, UK; 2Harvard
Medical School, Cambridge, MA; 3 Imperial College London, London, UK
Background: Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease affecting 3 million people in the UK, in which
patients exhibit irreversible airflow obstruction. Treatment is largely
informed by randomized controlled trial (RCT) results, but it is
unclear if these findings apply to patient populations not studied in
trials. Non‐interventional studies could be used to study patient
groups excluded from trials, but the use of these studies to estimate
treatment effectiveness is in its infancy.
Objectives: To use (1) individual trial data and (2) trial results to vali-
date non‐interventional methods for assessing COPD treatment
effectiveness.
Methods: First we obtained individual patient data from the land-
mark COPD TORCH trial. We matched these trial participants on a
range of characteristics to people with COPD in the UK Clinical
Practice Research Datalink (CPRD) between 1st January 2000 and
1st January 2017. We then determined whether analysis of this
trial‐analogous non‐interventional data generated comparable results
to the TORCH trial analysis of exacerbation rate for the following
comparisons: (1) Seretide vs no Seretide (analogous to placebo in
the TORCH trial) and (2) Seretide vs salmeterol. Cohort methodology
with propensity score techniques was used to adjust for potential
confounding.
Results: There were 2773 people from CPRD in each exposure
group for the Seretide vs no Seretide analysis and 939 people in
each exposure group for the Seretide vs salmeterol analysis. The
propensity score matched exacerbations rate ratio (Seretide vs no
seretide) was 1.25 (95% CI 1.14–1.37), compared to 0.75 (0.69–
0.81) for the TORCH Seretide vs placebo analysis. For the Seretide
vs salmeterol analysis, the rate ratio was 0.84 (0.73–0.97), compared
to 0.88 (0.81–0.95) in TORCH.
Conclusions: While we were unable to replicate COPD trial results
for analyses comparing treatment to no treatment using this meth-
odology, our results indicate that it is possible to obtain very similar
results for active comparator analyses in non‐interventional data
compared to trial data. The methodology applied here will now be
used for further (active comparator) studies of COPD treatment
effects for groups that were underrepresented or excluded from tri-
als, and to compare between a range of treatments.
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886 | Safety of Colobreathe: findings from
the UK cystic fibrosis registry
Sigal Kaplan1; Diana Bilton2; Susan C. Charman3; Andrew Lee3;
Noreen Caine3
1Teva, Netanya, Israel; 2Royal Brompton and Harefield NHS, London, UK;
3UK Cystic Fibrosis Trust, London, UK
Background: Colobreathe (colistimethate sodium) is indicated for the
management of chronic pulmonary infections due to Pseudomonas
aeruginosa (PA) in patients with cystic fibrosis (CF). Due to potential
safety concerns, a long‐term observational comparative study was
conducted as part of the risk management plan in Europe.
Objectives: The primary objective is to monitor the long‐term safety
of Colobreathe compared to other inhaled antibiotics. Secondary
objectives were to examine PA exacerbations (PEx) and rates of
discontinuation.
Methods: A matched cohort study using data from the UK CF Reg-
istry was designed to compare outcomes of patients on Colobreathe
to those on other inhaled antibiotics (comparator group) during
2014–17. Primary outcomes are defined as adverse safety events
(AEs) (e.g. cough fracture) and those considered new complications
(e.g. CF‐related diabetes). Incidence rates and incidence rate ratios
(IRR) were calculated for the primary outcomes and PEx. Rates of
discontinuations were compared between Colobreathe and
Tobramycin dry powder patients.
Results: A total of 1347 and 3469 patients were included in the
Colobreathe and comparator groups respectively. Mean age was
26 years (standard deviation [SD] = 10) and 23 (SD = 12), and the
proportion of males was 54% and 53%, respectively. Of the total
patients, 1033 (77%) and 2571(74%) had AEs in the Colobreathe
and comparator groups, respectively, including: cough fracture 7
(0.5%) and 13 (0.4%); pulmonary abscess 2 (0.1%) and 9 (0.3%);
septicaemia −12 (0.9%) and 55 (1.6%) and Haemoptysis ‐ 67 (5.0%)
and 160 (4.6%). Most common new complications included CF‐
related diabetes ‐ 197 (14.6%) and 461(13.3%); gastro‐oesophageal
reflux disease −160 (11.9%) and 518 (14.9%); and osteopenia ‐
228 (16.9%) and 453 (13.1%). The adjusted IRR for all types of pri-
mary event was 1.25, (95% confidence interval [CI]: 1.19, 1.31).
However,when new complications that are a part of natural CF dis-
ease progression, and are unlikely to be influenced by antibiotic
therapy,were excluded, there was no difference between the groups
(adjusted IRR 1.12 [95% CI 0.97–1.43]). PEx were common in both
groups (73.4% vs 77.1%, respectively), with annualized rates of
1.94 vs 1.85 per patient‐year and IRR of 1.08, 95%CI (1.06–1.12).
Rate of discontinuations of Colobreathe was similar to that of
Tobramycin dry powder: 32% and 33.0% respectively.
Conclusions: There was no evidence of a difference in the incidence
of safety events between the study groups. The observed excess risk
of any primary event, including those expected as part of natural CF
disease progression, is not considered to be related to antibiotic use.
887 | Where should I submit my manuscript?
Applying machine learning to enhance
communication of medical research
Jeremy Rassen
Aetion, Inc., New York, NY
Background: Neural networks have grown dramatically in sophistica-
tion over the last decade, with particular improvements in ability to
identify and utilize subtle predictive patterns in complex data. This
has created opportunities for predictions based on text and other
high‐dimensional input.
Objectives: Using 19 years of abstracts from PubMed, apply machine
learning (ML) to create a predictor of journals likeliest to have pub-
lished a particular abstract.
Methods: From PubMed data, we extracted 494,429 abstracts pub-
lished in 92 epidemiology and general medicine journals between
2000–2018, and created a multi‐layer neural network to predict
the journal in which the abstract was published. The first layer used
word embeddings of the 10,000 most frequent words to reduce
the dimensionality of the data and capture the contextual similarity
of the words. The embeddings were then passed to a convolutional
layer, which identified 128 filters that brought out distinguishing
features to best classify abstracts among the 92 journals. We then
employed two dense layers as the core of the predictive model,
followed by a dropout layer to reduce overfitting. The model
yielded predicted probabilities for each of the journals. We charac-
terized model accuracy using metrics of the correct journal
appearing as (a) the highest‐probability prediction (“exact match”),
and (b) one of the 3 top predictions (“top 3”). The model was
trained on 67% of the available data, with the remainder reserved
for testing.
Results: Within the test data, we were able to predict exact
matches for 64% of abstracts and top 3 matches for 82%. Journals
with the highest likelihood of correct prediction included PLoS One,
Circulation and Stroke (each ≥70% exact match and ≥ 90% top 3);
that pattern was observed for many of the topic‐specific publica-
tions. Pharmacoepidemiology and Drug Safety (PDS) was below
average and was identified in the top 3 46% of the time. NEJM
was identified in the top 3 76% of the time. Due to the non‐
explanatory nature of neural networks, no specific decision‐making
criteria could be observed.
Conclusions: ML methods are quickly improving, particularly as
applied to subtle predictive questions. In this study, those journals
with the clearest profiles had among the best predictive accuracy;
PDS was not strongly distinguished by the algorithm. To apply ML
more broadly, rich and publicly‐available training data sets
are beneficial; training sets to support causal analytics in
pharmacoepidemiology (eg, selection of covariates, screening for valid
study design, identification of instrumental variables) would be of
high value to the field.
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888 | Propensity score stratification and
inverse probability weighting compared to
surgical randomized clinical trial results in
device epidemiology
Victoria Y. Strauss1; Albert Prats‐Uribe1; Klara Berencsi1;
Andrew Carr1; Andrew Judge2; Alan Silman1; David W. Murray1;
Nigel K. Arden1; Irene Petersen3; Rafael Pinedo‐Villanueva1;
David J. Beard1; J. Mark Wilkinson4; Ian Douglas5; Jose M. Valderas6;
Sarah Lamb1; Daniel Prieto‐Alhambra1
1University of Oxford, Oxford, UK; 2Translational Health Sciences, Bristol
Medical School, University of Bristol, Bristol, UK; 3UCL, London, UK;
4University of Sheffield, Sheffield, UK; 5Faculty of Epidemiology and
Population Health, London School of Hygiene and Tropical Medicine,
London, UK; 6University of Exeter, Exeter, UK
Background: Propensity scores are popular in pharmacoepidemiology.
However, there is little data on their performance in the study of
devices, where confounding is related to more complex mechanisms
including not only patient but also surgeon characteristics.
Objectives: To test the performance of propensity score stratification
and inverse probability weighting (IPW) to emulate an ongoing surgical
RCT comparing partial to total knee replacement, the Total Or Partial
Knee Arthroplasty Trial (TOPKAT).
Methods: Patients who underwent either a partial or total knee
replacement were identified in the UK National Joint Registry
linked to hospital inpatients data (Hospital Episode Statistics
England) and patient reported outcome measures (PROMs).
TOPKAT eligibility criteria were applied. Logistic regression was
used to calculate PS for partial knee replacement using 28 covari-
ates including demographics, preoperative PROMs, comorbidity,
and procedures within 3 years before surgery. We compared differ-
ent methods to the trial results: 1) stratification based on the entire
cohort's PS (PSScohort); 2) stratification based on the PS of patients
with partial knee replacement (PSSexposure), and 3) IPW. Linear
regressions were used to derive average treatment effect (ATE)
estimates of difference in postoperative OKS between treatment
groups with adjustment for imbalanced covariates (absolute stan-
dardized mean differences (ASMD) >0.1). A chi2 test was applied
to test for significance differences between TOPKAT findings and
each of the proposed methods. Tau2 was used to quantify between
study variances.
Results: In total, 355 and 33,982 partial and total knee replace-
ment, respectively, were analyzed. PSSexposure resulted in excellent
covariate balance (all ASMD<0.1), while many covariates remained
imbalanced in IPW and PSScohort. Postoperative OKS average dif-
ferences were 1.2 (95%CI: 0.2, 2.1), 1.2(0.1, 2.2) and 1.2 (0.1,
2.2) in favor of partial knee replacement in IPW, PSScohort,
PSSexposure, respectively, compared to 1.8 (0.2, 3.4) in TOPKAT.
All methods obtained Chi2 P > 0.05 and small tau2 (<0.0001), sug-
gesting no significant difference in ATE estimates compared to the
TOPKAT RCT findings.
Conclusions: PSSexposure obtained better covariate balance than IPW
and PSScohort, though all methods resulted in similar treatment effect
estimates, all of them comparable to the TOPKAT RCT treatment
effect estimate.
889 | The performance of preference‐based
instrumental variables to emulate a
randomized clinical trial of comparative
medical device effectiveness
Albert Prats‐Uribe1; Klara Berencsi1; Andrew Carr1; Andrew Judge2;
Alan Silman1; David W. Murray1; Nigel K. Arden1; Irene Petersen3;
Rafael Pinedo‐Villanueva1; David J. Beard1; J. Mark Wilkinson4;
Ian Douglas5; Jose M. Valderas6; Sarah Lamb1; Victoria Y. Strauss1;
Daniel Prieto‐Alhambra1
1University of Oxford, Oxford, UK; 2Bristol Medical School, University of
Bristol, Bristol, UK; 3UCL, London, UK; 4University of Sheffield, Sheffield,
UK; 5Faculty of Epidemiology and Population Health, London School of
Hygiene and Tropical Medicine, London, UK; 6University of Exeter, Exeter,
UK
Background: Instrumental variables (IV) are used tominimize confound-
ing in pharmacoepidemiology. There is a scarcity of data on the perfor-
mance of preference‐based IVs in medical device epidemiology.
Objectives: We aimed to test the use of surgeon, centre and regional
preferences for partial knee replacement (PKR) as IVs to replicate an
ongoing RCT comparing PKR vs total knee replacement (TKR), the
TOPKAT trial.
Methods: Participants undergoing PKR or TKR according to the UK
National Joint Registry, andwith linked post‐operative patient reported
oxfordkneescores (OKS)datawere included.TOPKATexclusion criteria
wereappliedtomaximizecomparability.Wecalculatedpreferenceas the
%ofPKRinthe last20,30and50kneereplacementsurgeries for leadand
consultant surgeon, and the last 100, 300,500, and1000 for surgical unit
and regional area. We estimated IV strength using F‐statistic and odds
ratio (OR) on a regressionbetween IV andexposure (PKR).Weevaluated
balanceper groups (IV>median vs IV≤median)with standardizedmean
differences (SMD) for known confounders. IVs with confounding
(SMD > =0.1) and those considered weak (OR 95% confidence intervals
including 1 or F‐statistic<10) were not further evaluated. A 2‐stage IV
regression was fitted to calculate the effect of PKR on one‐year OKS
compared toTKR.Weused x2 to test differences in treatment estimates
betweenTOPKAT and IVs results; and τ2 to quantify between‐studies
variance.
Results: A total of 69,269 patients were included for preference calcu-
lations; 34,576 had OKS data and were included, with 358 undergoing
PKR. Lead surgeon preference based on 30 and 50 surgeries did not
balance for age; while consultant preference based on previous 50
surgeries, and all area (surgical unit and region‐based) IVs resulted in
imbalances in socio‐economic status. The results from lead surgeon
preference IV based on 20 previous surgeries were comparable to
TOPKAT: 9.1 (CI95: 0.1 to 18.1) vs 1.9 (0.2 to 3.6) respectively;
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p = 0.12; =15. Conversely, consultant preference IV based on 20 and
30 previous surgeries yielded significantly different results, with
p = 0.01 and p < 0.01 respectively.
Conclusions: Surgeon preference is a potentially valid IV, but treat-
ment estimates are sensitive to decisions made during the construc-
tion of IVs. More research is needed on best practices for the
estimation and diagnostics of surgeon preference IVs. Finally, caution
is advised in the interpretation of area‐based IVs, which fail to balance
regional confounders such as deprivation.
890 | Development and validation of
patient‐level prediction models for adverse
outcomes following total knee arthroplasty in
osteoarthritic patients
Ross Williams1; Jenna Reps2; H.E. Ying3; Peter Rijnbeek1;
Anthony G. Sena2; Daniel Prieto‐Alhambra3; Patrick Ryan2,4
1Erasmus MC, Rotterdam, Netherlands; 2 Janssen Research &
Development, Titusville, NJ; 3University of Oxford, Oxford, UK;
4Columbia University, New York, NY
Background: Elective total knee replacement (TKR) is safe and cost‐
effective in treating severe knee osteoarthritis (OA). Post‐operative
complications, although rare, have been reported.
Objectives: We aim to develop prediction tools and assess its perfor-
mance for predicting adverse outcomes after TKR in OA patients.
Methods: Through the Observational Health Data Sciences and Infor-
matics (OHDSI) network we conducted a multinational, multi‐database
cohort analysis using five US and UK healthcare databases mapped to
the Observational Medical Outcomes Partnership (OMOP) common
data model. Subjects undergoing a first TKR aged 40 years or older,
registered in any of the contributing databases for at least 1 year prior
to surgery were included. Lasso logistic regression models were fit to
predict post‐operative outcomes including 90‐day mortality, venous
thromboembolism (VTE), infection, readmission and long‐term (5‐year)
revision surgery. Models were evaluated for performance (discrimina-
tion and calibration), and those considered of value were then exter-
nally validated in other available datasets.
Results: A total of 504,103 participants were included, with size per
data source ranging from 15,292 to 158,549. We found 0.20%–
0.23% of post‐operative 90‐day mortality, 1.69%–2.99% of infection,
7.07%–8.98% of readmission, and 2.20%–4.79% of VTE after TKR.
The incidence of 5‐year revision surgery ranged from 1.99% to
3.13% among five databases. None of the models for VTE, infection
or 5‐year revision had good performance. Conversely, models for
90‐day mortality and readmission had acceptable discrimination
(AUC 0.78 and 0.69) and calibration internally. External validation for
90‐day mortality developed in OPTUM and THIN yielded an AUC
ranging 0.69–0.86 and 0.68–0.84, respectively.
Conclusions: We have developed models for the identification of sub-
jects at high risk of short‐term mortality and post‐operative
complications. We observed high predictability of short‐term mortality
and the unpredictability of the other outcomes. This suggests deci-
sion‐making should be stratified based on variated risk of short‐term
mortality, but may not for other complications.
891 | Medications, device use, and non‐
device associated urinary tract infections in
hospitalized patients
Paula D. Strassle1; Emily E. Sickbert‐Bennett2; Lauren M. DiBiase2;
Jennifer L. Lund1; Michael Klompas3; Paul Stewart1; David J. Weber1
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2University
of North Carolina School of Medicine, Chapel Hill, NC; 3Harvard School of
Medicine, Boston, MA
Background: Catheter‐associated urinary tract infection (CAUTI) rates
have declined over the past several years, but rates of non‐device
associated UTI (ND‐UTI) have remained stable. Because there is no
national surveillance of ND‐UTIs, there is a paucity of research on risk
factors for these infections.
Objectives: Assess the effect of inpatient medications (anticholiner-
gics, systemic antibiotics, sedatives, opioids, and neuroleptics) and
device use (urinary catheters, suprapubic catheters, and nephrostomy
tubes) on the incidence of ND‐UTIs.
Methods: All adults (≥18 years) admitted to UNC Hospitals for
>2 days between 2015–2017 were included. Electronic medical
records from these hospitalizations were linked to the UNC Hospital
Epidemiology database, which includes device and non‐device associ-
ated infections captured during comprehensive, hospital‐wide active
surveillance using CDC case definitions and methodology. Only the
first ND‐UTI within a hospitalization was included. Multivariable Cox
regression was used to assess the association between inpatient med-
ications and devices with ND‐UTIs, after adjusting for patient demo-
graphics, comorbidities, illness severity, urologic surgery, and trauma
admission. Medications, device use, and surgery were treated as a
time‐varying. Correlation between patients with multiple hospitaliza-
tions was accounted for using robust sandwich covariance matrix esti-
mates and death was treated as a competing risk.
Results: 87,718 hospitalizations (57,598 unique patients)were included
and there were 412 ND‐UTIs. 63% of patients received opioids, 58%
received anticholinergics, 42% received antibiotics, 39% received ben-
zodiazepines, and 10% received neuroleptics during risk period.
Nephrostomy tube and suprapubic catheters were used in 1% of hospi-
talizations, and 41% had a urinary catheter. After adjustment, patients
receiving opioids (HR 1.71, 95% CI 1.14, 2.56) or who had suprapubic
catheters (HR 2.30, 95% CI 1.58, 3.34) were more likely to develop an
ND‐UTI. Receiving antibiotics (HR 0.21, 95% CI 0.15, 0.28) and neuro-
leptics (HR 0.66, 95% CI 0.48, 0.92) reduced patient risk. Anticholiner-
gics (p = 0.49), benzodiazepines (p = 0.36), nephrostomy tubes
(p = 0.35), and prior urinary catheterization (p = 0.72) had no effect.
Conclusions: Opioids and suprapubic catheters increased the risk of
ND‐UTI. Opioids are known to cause drug‐induced urinary retention,
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which is a known risk factor for UTIs. Future research should explore
targeting opioid prescribing and non‐urinary catheter device use for
potential prevention strategies.
892 | Cardinality matching versus propensity
score matching for causal inference in
medical device research: an applied analysis
of minimally‐invasive versus open elective
thoracic segmentectomy
Stephen Johnston1; Iftekhar Kalsekar1; David Wei1; Annie Lied‐Lied2;
Jose Zubizarreta3
1 Johnson & Johnson, New Brunswick, NJ; 2Ethicon, Johnson & Johnson,
Somerville, NJ; 3 Jose Zubizarreta, Boston, MA
Background: Propensity score matching (PSM) is a mainstay of causal
inference in observational research. A recently developed method—
cardinality matching (CM)—uses integer programming to find the larg-
est matched sample for which pre‐specified balance criteria (e.g., stan-
dardized differences [SDiff]) are met for matching variables. In medical
device research, balance on clusters (e.g., hospitals) between groups
can be critical to internal validity.
Objectives: We describe the performance of PSM vs. CM when
requiring perfect balance on clusters between groups in a retrospec-
tive, observational study comparing economic and clinical outcomes
of minimally‐invasive surgery (MIS) vs. open surgery (OS) for thoracic
segmentectomy.
Methods: We extracted hospital discharge records from the Premier
Healthcare Database for patients undergoing elective thoracic
segmentectomy between 1‐1‐2010—6‐30‐2017 (first = index admis-
sion). Patients were classified as undergoing OS or MIS (video‐
assisted, robotic‐assisted, conversions). PSM was conducted through
nearest‐neighbor matching (1:1 w/caliper) and exact matching on
hospital. CM was conducted through 1:1 matching and exact distri-
butional balance for all matching variables, including hospital.
Matching variables included patient, procedure/admission, and pro-
vider/hospital characteristics. We evaluated PSM and CM on:
post‐match sample‐size N, post‐match SDiff for matching covari-
ates, and outcome comparison results (index admission's length of
stay [LOS], hospital discharge costs, respiratory failure, and inpa-
tient mortality) between MIS vs. OS.
Results: Total post‐match sample N's were: PSM = 852; CM = 1,702.
Across 37 matching variables, post‐match SDiffs were: PSM
mean = 0.03 (range = 0.0—0.16); CM mean = 0.0 (range = 0.0—0.0).
Outcome comparisons were similar between PSM and CM (expressed
as OS minus MIS): LOS—PSM = 1.3 days (P < 0.01), CM = 1.1 days
(P < 0.01); costs—PSM = $1,779 (P = 0.08), CM = $1678 (P = 0.09);
respiratory failure—PSM = 1% (P = 0.01), CM = 2% (P = 0.02); inpatient
morality—PSM = 0% (P = 0.451), CM = 0% (P = 0.81).
Conclusions: CM resulted in greater post‐matching sample N, perfect
distributional balance on all matching variables, and outcome esti-
mates with smaller standard errors as compared with PSM. CM is an
important advance in matching techniques for causal inference in
observational research; further applied evaluation of CM vs. PSM is
warranted.
893 | Self controlled case series in surgical
epidemiology: checking the underlying
assumptions in an empirical example
Danielle E. Robinson1; Ian Douglas2; Victoria Y. Strauss1;
Daniel Prieto‐Alhambra1
1University of Oxford, Oxford, UK; 2London School of Hygiene and
Tropical Medicine, London, UK
Background: The self controlled case series (SCCS) is a within person
study design which controls for all time fixed confounding. It has pre-
viously been shown to be useful for vaccine and drug safety studies,
however its use in surgical safety has not been investigated. One
key question is whether the assumptions underlying SCCS are likely
to hold in surgical epidemiology.
Objectives: Demonstrate the checking of assumptions of the SCCS in
a surgical safety setting.
Methods: Patients undergoing bariatric surgery who experienced an
osteoporotic fracture within 5 years prior or post‐surgery were identi-
fied in the clinical practice research datalink (CPRD) linked to hospital
episode statistics (HES). The outcome, osteoporotic fracture, included
all locations except skull and digits. An SCCS model, using a Poisson
model, compared the 5 year risk of fracture post surgery to the 5 year
risk pre‐surgery. Three assumptions of the SCCS were tested in sepa-
rate models: (I) The independence of the outcome and probability of
further exposure (surgery); (II) the independence of recurring events;
and (III) the lack of association between outcome and early departure
from study. These assumptions were tested by comparing the inci-
dence rate ratio (IRR) produced in the initial model to (I) a model with
an 8 week wash out period prior to surgery, and (II) a model of each
patient's first fracture. Assumption (III) was checked with a likelihood
ratio test comparing models with and without an interaction with early
departure. A histogram of the time between fracture and surgery was
also used to check assumption (I).
Results: Of 5,492 patients undergoing bariatric surgery, 252 patients
had 272 osteoporotic fractures within 5 years either side of surgery.
Risk of osteoporotic fracture was not increased after bariatric surgery
(IRR (95% confidence interval, CI) 1.17 (0.86, 1.60)). The histogram
was uniformly distributed, suggesting fractures did not affect the like-
lihood of surgery. 12 fractures occurred in the wash out period, and
20 were subsequent fractures within patient and 145 patients
departed early. The two adjustments to the dataset gave IRRs (95%
CIs) of 1.14 (0.78, 1.50), and 1.10 (0.76, 1.61) for assumptions (I) and
(II) respectively. The result of the LRT (assumption III) was 0.46. These
results suggest no assumption was invalid.
Conclusions: The SCCS appears to be suitable for use in surgical
safety settings in this specific example. The same assumption checks
used for vaccine/drug safety studies can be used for surgical safety
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studies using the SCCS. Different settings/surgical procedures would
require further testing.
894 | Use of ondansetron during pregnancy
and risks of spontaneous abortion, stillbirth
and major congenital malformation: an
international, multi‐Centre cohort study
Colin Dormuth1; Brandace Winquist2; Anat Fisher1; Fangyun Wu3;
Pauline Reynier4; Matthew Dahl5; Zhihai Ma6; Xinya Lu7;
Jianguo Zhang6; Colette Raymond5; Kristian B. Filion8;
Robert W. Platt8; Carolina Moriello4; J. Michael Paterson3;
CNODES Investigators9
1University of British Columbia, Victoria, BC, Canada; 2University of
Saskatchewan, Saskatoon, SK, Canada; 3 ICES, Toronto, ON, Canada;
4 Jewish General Hospital, Montreal, QC, Canada; 5University of
Manitoba, Winnipeg, MB, Canada; 6University of Calgary, Calgary, AB,
Canada; 7Saskatchewan Health Quality Council, Saskatoon, SK, Canada;
8McGill University, Montreal, QC, Canada; 9Canadian Network for
Observational Drug Effect Studies (CNODES), Montreal, QC, Canada
Background: Ondansetron is frequently used off‐label for treatment
of nausea and vomiting during pregnancy. While there have been
few important safety signals to date, few studies have been of suffi-
cient size to properly consider rarer outcomes such as stillbirth or
major birth defects.
Objectives: To study the association between ondansetron exposure
during pregnancy and the risks of spontaneous abortion, stillbirth,
and major congenital malformation.
Methods: We undertook an international, multi‐centre cohort study of
women aged 12–55 y who had a pregnancy event (spontaneous abor-
tion, induced abortion, stillbirth, or live birth) between April 2002 and
March 2016 recorded in administrative data from 4 Canadian provinces
(British Columbia, Alberta, Saskatchewan, and Manitoba), the US
MarketScan database, and the UK Clinical Practice Research Datalink.
Our primary outcomewas fetal death defined as a composite of sponta-
neous abortion or stillbirth. Secondary outcomes were the components
of the composite and major congenital malformation. To minimize con-
founding by indication, exposure to ondansetron was compared with
exposure to other antiemetics. We estimated hazard ratios (HR) and
odds ratios (OR) using high dimensional propensity score‐adjusted pro-
portional hazards regression and logistic regression, as appropriate, with
time‐dependent drug exposures. Sensitivity analyses excluded preg-
nancy losses during the first 6w, 20wgestation; considered second‐line
exposures and those during 4–10 w gestation; and studied the first
pregnancy per woman. Site‐level results were pooled using random‐
effects models.
Results: Among the 163,952 pregnancies exposed to ondansetron,
7.9% resulted in fetal death vs 5.6% of 309,565 exposed to other anti-
emetics. After adjustment, ondansetron exposure during pregnancy
was not associated with increased risks of fetal death (HR 0.92, 95%
confidence interval [CI] 0.67–1.26), spontaneous abortion (HR 0.81,
0.65–1.02), stillbirth (HR 0.97, 0.79–1.20), or major congenital malfor-
mation (OR 1.07, 0.91–1.26). Results of sensitivity analyses were gen-
erally consistent with those of the primary analyses, although risks of
stillbirth were increased in some settings.
Conclusions: In this large, multi‐centre cohort study, there was no
association between exposure to ondansetron during pregnancy and
increased risks of fetal death, spontaneous abortion, stillbirth or major
birth defects relative to exposure to other antiemetics. Larger studies
are needed to evaluate risks for specific malformations.
895 | Medically assisted reproduction and the
risk of being born small for gestational age
Jessica Gorgui1,2; Odile Sheehy1; Jacquetta Trasler3; William Fraser4;
Anick Bérard1,2
1University of Montreal, Montreal, QC, Canada; 2Research Center ‐ CHU
Sainte‐Justine, MontrealQC, Canada; 3McGill University, Montreal, QC,
Canada; 4Université Sherbrooke, Sherbrooke, QC, Canada
Background: Medically assisted reproduction (MAR) includes assisted
reproductive technology (ART) and ovarian stimulations (OS). These
methods are known to increase obstetrical complications and adverse
perinatal outcomes, including prematurity.
Objectives: We aimed to quantify the risk of being born small for ges-
tational age (SGA) associated with MAR use overall and by method
among those exposed.
Methods: Design: We conducted a cohort study in the Quebec Preg-
nancy Cohort (QPC), an ongoing population‐based cohort, which
includes all pregnancies of mothers covered by Quebec’ prescription
drug insurance and their children from 01/1998 and 12/2015. We
included singleton liveborns between 05/08/2010 and 15/11/2015,
whose mothers were covered by the RAMQ drug plan for at least
3monthsprior toandduringpregnancy. This time‐periodwasusedgiven
that theMARuniversal reimbursementprogramwasactiveat that time in
Quebec. Exposure:WeconsideredMAR use dichotomously, using spon-
taneous conception as the reference. We then categorized MAR into 3
exposure subgroups: ART (reference), OS, and OS/ART combined.Out-
come: We defined SGA as the lowest 10th percentile of gestational‐age
specific birth weight according to sex‐specific population‐based refer-
ences in Canada. Analyses: Crude and adjusted odds ratios (aOR) and
95% confidence intervals (CI) were obtained using generalized estima-
tion equationmodels. Covariates includedmaternal sociodemographics,
history of pregnancy complications, comorbidities, and concomitant
medicationuse,measured in theyearbeforethe1stdayofgestation.Sub-
group analyses were performedwithin theMAR‐exposed group.
Results: A total of 57,624 pregnancies met inclusion criteria and were
considered for analyses. During the study period, 2,055 women were
exposed to MARs, of which 419 (20.4%) to OS, 150 to ART (7.3%),
and 1486 (72.3%) to a combination of both. We found no association
between MAR use and being born SGA. Specifically, adjusting for
potential confounders, no association was found between overall
use of MAR and the risk of SGA (aOR, 1.08, 95%CI: 0.93–1.25, 202
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exposed cases). In our sub‐cohort of MAR users, we found no associ-
ation between OS alone when compared to ART and the risk of SGA
(OS: aOR, 1.20; 95%CI: 0.78–1.84, 46 exposed cases; and OS/ART
combined: aOR, 0.98 95%CI: 0.69–1.38, 102 exposed cases).
Conclusions: We found no association between MARs and the risk of
SGA, which is reassuring.
896 | Ondansetron use in early pregnancy
and late pregnancy outcomes
Elizabeth A. Suarez1; Kim Boggess2; Stephanie M. Engel1;
Jennifer L. Lund1; Til Stürmer1; Michele Jonsson Funk1
1Gillings School of Global Public Health, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2School of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC
Background: The effect of ondansetron use during pregnancy on com-
mon adverse pregnancy outcomes and complications other than birth
defects is understudied.
Objectives: Evaluate the risk of preterm birth and hypertensive disor-
ders among women with orders for ondansetron during early preg-
nancy compared to alternatives antiemetics while accounting for
competing risks.
Methods: A cohort of pregnancies was created using electronic health
record (EHR) data from the UNC Health Care system. Pregnancies
were identified at the date of first record of the pregnancy in the
EHR and followed until the outcome of interest, a competing event,
or loss to follow‐up (last record with evidence of pregnant status).
Pregnancies no longer at risk for the outcome of interest were classi-
fied as having competing events, e.g. miscarriage, or live birth without
hypertension diagnosis. Pregnancies were included if an order for
ondansetron or comparator antiemetics (metoclopramide or
promethazine) was made during the first 140 days of gestation. Pre-
term birth was defined as live birth at <37 weeks and very preterm
birth was defined at <32 weeks. Gestational hypertension was defined
using diagnosis codes among pregnancies without existing hyperten-
sion. Preeclampsia was defined by evidence of 2 inpatient encounters
with diagnosis codes. Cumulative incidence of all outcomes was esti-
mated on the gestational age timescale. We report adjusted risk differ-
ences (RD) and 95% confidence intervals (CI). Confounding by
antiemetic indication, maternal age, race, ethnicity, smoking status,
comorbidities, and medication use was controlled using stabilized
inverse probability of treatment weights.
Results: We identified 2730 eligible pregnancies with antiemetic
orders; 66% had first ondansetron order and 34% had first comparator
antiemetic order. Crude risk of preterm birth was slightly lower in the
ondansetron group than the comparator group (11.7% and 13.8%,
respectively); adjusted results suggested a small decrease in risk (RD
‐1.8%; 95% CI ‐5.0, 1.4). No difference was observed for very preterm
birth (crude risk 2.4% in ondansetron group and 2.6% in comparator
group; adjusted RD ‐0.2%; 95% CI ‐1.9, 1.5). Ondansetron exposed
pregnancies were also observed to have lower risk of gestational
hypertension (crude risk 5.4% and 7.0%, respectively; adjusted RD ‐
1.5%; 95% CI ‐4.0, 0.4), and slightly lower risk of preeclampsia (crude
risk 4.5% and 6.0%, respectively; adjusted RD ‐1.2%; 95% CI ‐3.3, 1.2).
Conclusions: We found no evidence of increased risk with
ondansetron exposure compared to alternative antiemetics for any
of these common adverse pregnancy outcomes.
897 | Misoprostol as an adjunct to oxytocin
can reduce postpartum hemorrhage among
pregnant women delivering in Bamenda
Cameroon, 2015–2016: a propensity score‐
matched retrospective chart review
Frederick Morfaw1; Mercy Fundoh2; Christopher Pisoh2; Bi Ayaba3;
Lawrence Mbuagbaw1; Laura N. Anderson1; Lehana Thabane1
1McMaster University, Hamilton, ON, Canada; 2University of Bamenda,
Bamenda, Cameroon; 3Regional Hospital Bamenda, Bamenda, Cameroon
Background: There is some evidence to suggest that misoprostol may
supplement the action of oxytocin in preventing post‐partum hemor-
rhage (PPH).
Objectives: Primary: To determine the effects of the administration of
600 μg misoprostol in addition to oxytocin versus oxytocin alone, on
the risk of PPH among pregnant women after delivery. Secondary:
To determine the effects of the above combination on maternal death
and blood transfusion among pregnant women after delivery. To
determine the prevalence of PPH, its case fatality, and the maternal
mortality ratio in our hospital.
Methods: Design and setting: Retrospective chart review of 1736
women delivering at the Regional Hospital Bamenda Cameroon,
between 2015–2016. This was a pre versus post study following a
policy change in the prevention of PPH. Exposure groups: One group
received oxytocin‐misoprostol (January–April 2016: period after pol-
icy change), and the second group received oxytocin‐only (January–
April 2015: period before policy change) after delivery. Outcomes:
The primary outcome was PPH, and the secondary outcomes were
maternal death and blood transfusion. Statistical analysis: A 1:1
matching was done with the propensity score (PS). Covariates
matched for included age, gravidity, parity, mode of delivery, birth
weight etc. We used standardized mean differences to assert the qual-
ity of the matching. The groups were compared using propensity score
matching with conditional logistic regression on the matched pairs as
the main analysis. A sensitivity analysis was done using other propen-
sity score adjustment methods and multiple regression.
Results: Of the 1736 patients included in this study, 1338 were
matched and compared. Women who received oxytocin‐misoprostol
were less likely to have PPH as compared to those receiving oxyto-
cin‐only (odds ratio [OR] 0.22, 95% confidence interval [CI] 0.08,
0.59, p = 0.003). This reduced odds of PPH was upheld in the different
sensitivity analyses. There were no significant differences in the odds
of maternal death and the use of blood transfusions between the two
groups: OR 0.26, 95% CI [0.03, 2.29], p = 0.22, and OR 0.89, 95% CI
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[0.14–5.63], p = 0.91, respectively. Sensitivity analyses showed similar
results. The prevalence of PPH was 2.9%, the case fatality rate was
1.96%, and the maternal mortality ratio was 293 maternal deaths/
100000 life births.
Conclusions: We found that using 600 μg misoprostol as an add‐on to
oxytocin in preventing PPH significantly reduces the odds of PPH
without affecting other maternal outcomes.
898 | Maternal opioid use and infant birth
defects in RI Medicaid enrolled population
Emily Murray; Nicholas Belviso; Xuerong Wen
The University of Rhode Island, Kingston, RI
Background: The rapid increase of opioid‐related overdoses and
deaths has become a public health threat in the United States.
The utilization of prescription opioids in pregnant women has
increased while the results from teratogenic studies remain
controversial.
Objectives: To evaluate the association between maternal opioid use
during pregnancy and the incidence of congenital malformations in
infants.
Methods: This retrospective cohort study evaluated Rhode Island
Birth Certificate data of live births from 2006 to 2016 for mothers
who were enrolled in the Rhode Island Medicaid program. The study
cohort included women who gave a live birth and had no opioid dis-
pensing or opioid use disorders during the study period. Mothers' pre-
scription opioid exposure was obtained through pharmacy claims and
defined as filled at least one prescription opioid for non‐cancer pain
during pregnancy. Study outcomes were assessed using ICD‐9 diagno-
sis codes and ascertained by medical records review. Conditional logis-
tic regression models with propensity score (PS) fine stratification and
weighting with 100 strata were applied to derive the effect estimates
of maternal opioid exposure on infant birth defects after adjusting for
other potential confounders.
Results: Of 25,205 pregnancies included in this study, 1,898 (7.5%)
mothers filled prescription opioids and 1,024 (4%) infants were diag-
nosed with birth defects, either major congenital malformations
(MCM) or minor anomalies (MA). Comparing opioid exposed vs unex-
posed, total birth defects were 9.5% vs 3.6% (P < 0.0001), MCMs
were 7.0% vs 2.7% (P < 0.0001), and MAs were 3.1% vs 1.2%
(P < 0.0001). Mother exposed to an opioid during pregnancy were
older (27.35 ± 5.36), more likely to have smoked (52.6%), and had a
higher number of prenatal care visits (13.04 ± 5.58). Infants with pre-
natal opioid exposure were more likely to be born preterm (gestational
age, mean ± SD: 38.3 ± 2.3 vs 38.6 ± 2.1, P = 0.07; preterm born, N(%):
194 (11%) vs 2108 (9%), P = 0.01). The conditional logistic regression
analysis with PS fine stratification and weighting with 100 strata also
showed significant increases of MCM and MA in infants with maternal
opioid exposure compared to those who were not exposed.
Conclusions: Our results suggest a significant association between
opioid use during pregnancy and an increased incidence of birth
defects. Further investigation is needed to examine the effects of
maternal opioid exposure on infants' long‐term health outcomes.
899 | Crowdsourcing as a novel method to
assess the impact of drug exposure on
Belimumab pregnancy registry enrollment
Kim Gemzoe1; Jeffery L. Painter2; Jeanne Pimenta1; Greg Powell3
1GSK, Stockley Park West, Uxbridge, Middlesex, UK; 2 Jivecast, Raleigh,
NC; 3GSK, Research Triangle Park, NC
Background: The belimumab (BEL) Pregnancy Registry (BPR; GSK
Study 114256), a prospective, voluntary study of BEL during preg-
nancy in women with systemic lupus erythematosus (SLE), has demon-
strated low enrollment (N = 60) despite awareness activities.
Crowdsourcing platforms collect feedback from online general popula-
tion or physician communities.
Objectives: UnderstandBELuse inpregnancy,ascertainBPRawareness,
and identify study enrollment barriers via two crowdsourcing platforms.
Methods: Patients (women with SLE; pregnant [P]/recently pregnant
[RP]/planning a pregnancy [PP]) completed an online Amazon
Mechanical Turk (mTurk) questionnaire about their SLE medication
use and BPR awareness. Rheumatologists (in 8 countries with active
BPR) with a history of prescribing BEL in pregnancy were surveyed
via SERMO on prescribing patterns and factors relating to BPR aware-
ness/enrollment. Surveys were active for 3 months.
Results: Overall, 151 patients (across 3 months) and 169 rheumatolo-
gists (within 48 hours) responded, primarily from the US. Most patients
were 26–35 years (58%), reportedmild (42) or moderate (56%) SLE, and
were P/RP (51%); 49% were PP. Exposure to BEL was reported by 42%
of patients (of these: P, 29%; RP, 33%; PP, 38%), of whom 54% were
exposed for ≤1 year (of these: P, 16%; RP, 14%; PP, 24%). Of patients
with prior exposure to BEL, 51% were BPR‐aware, versus 6% of those
without exposure. Overall, 60% of patients stopped BEL due to preg-
nancy (of these: P, 32%; RP, 37%; PP, 32%); BPR awareness did not
impact discontinuation. Among rheumatologists, 46%were BPR‐aware,
92% of whom were willing to refer patients to the BPR. Rheumatolo-
gists reported 23% of their patients had no concerns on BEL use during
pregnancy (multiple choices allowed); concerns included the unknown
BEL safety profile (75%) andwanting to reducemedication in pregnancy
(28%). Overall, 86% of physicians gave reasons for not prescribing BEL
during pregnancy (multiple answers allowed) including unknown preg-
nancy safety profile (78%), preference for other treatments (41%), and
mild disease or tolerable symptoms (33%). Rheumatologists (82%)
reported treating ≤5 (52%), 5–10 (26%), or > 10 (23%) patients who
were P/RP/PP with BEL.
Conclusions: Crowdsourcing platforms enable rapid, targeted, high‐
coverage, physician and patient feedback. Findings suggest women
are BEL‐exposed during pregnancy, but few take part in the BPR. Bar-
riers to BPR enrollment include moderate BPR awareness, BEL discon-
tinuation, and low knowledge of the BEL benefit/risk profile during
pregnancy. Study funded by GSK.
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900 | Discontinuation of anti psoriasis drug
treatments during pregnancy. The PSO
MOTHER cohort study
Valeria Belleudi1; Francesca Poggi1; Serena Perna2; Luigi Naldi3;
Renata Bortolus4; Alessandro Rosa1; Ursula Kirchmayer1;
Marina Davoli1; Antonio Addis1
1Lazio Regional Health Service; ASL Roma 1, Rome, Italy; 2 Italian
Medicines Agency, Rome, Italy; 3Azienda USL 8 Berica, Veneto Region,
Vicenza, Italy; 4Verona University Hospital, Verona, Italy
Background: Psoriasis is a chronic conditionwithworldwide prevalence
of about 2–3%. Fifty percent of patients are women, mostly diagnosed
during childbearing age. Studies evaluating the effectiveness of anti‐
psoriasis treatments on mother during pregnancy are limited with no
data regarding the impact of the pregnancy status on the compliance
to different available drug therapies, both topical and systemic. The
majority of the available treatments have important warnings on poten-
tial embryo‐fetotoxicity, which might play a role on the decision to con-
tinue treatment or not.
Objectives: Our aim is to investigate quality of care for women with
psoriasis in terms of use and discontinuation of different treatments
before and during pregnancy.
Methods: This is the first analytical report from a large cohort study
supported by the Italian Ministry of Health: Psoriasis in the Mother
with Treatments and Health Endpoints Risk (PSO‐MOTHER). All chil-
dren born between 2009 and 2016 in a central Italian region (Lazio)
by mothers with diagnosis of Psoriasis and with drug prescription
before the conception date (six months) were identified. Anti‐psoriasis
drug patterns (biological, systemic or topical prescriptions) before and
during pregnancy were analyzed according to women's socio‐demo-
graphic and clinical characteristics at delivery. Furthermore, use of
drugs specifically contraindicated in pregnancy (i.e methotrexate,
acitretinoin) was analyzed.
Results: Among 1,876 deliveries by women affected by Psoriasis 525
(28%) had at least one prescription of anti‐psoriasis drug treatments in
the six months before the conception date. Median age at delivery
was 33 years. For each class of drugs considered there was a general
decrease in their use during pregnancy. In particular, considering the
variations between the three months preceding the conception and
the third trimester of pregnancy, the following prescriptive percent-
ages were observed: from 8.4% to 0% for the biologicals, from 5.9%
to 2.5% for the conventional systemic drugs and from 52.0% to
9.4% for the topical treatments. Eight women had methotrexate pre-
scriptions in the three months before conception, only one had also
a prescription during pregnancy (third trimester). No prescriptions of
acitretinoin both before and during pregnancy were found.
Conclusions: Pregnancy appears to have a significant influence on the
prescriptive patterns of different pharmacological treatments for pso-
riasis. In the context of the PSO‐MOTHER project, we will aim to
understand the impact of this phenomenon on the health outcomes
of the mother with psoriasis and of their children.
901 | Long‐term neurodevelopmental
outcomes in children with prenatal opioid
exposure
Nicholas Belviso1; Kimford Meador2; Oluwadolapo Lawal1;
Debra Erickson‐Owens1; Brian Quilliam1; Shuang Wang1;
Kelly Matson1; Aisling Caffrey1; Xuerong Wen1
1University of Rhode Island, Kingston, RI; 2 Stanford University, Stanford,
CA
Background: Several studies suggested that maternal use of opioids is
associated with multiple maternal, fetal, and neonatal complications.
However, the research gap remains in long‐term effects of maternal
opioid exposure on children.
Objectives: To determine the risk of long‐term neurodevelopmental
outcomes in children with prenatal opioid exposure.
Methods: This study included pregnant women aged 12 to 55 years
and their liveborn infants enrolled in the Optum Clinformatics™ data
from January 1, 2010 to July 1, 2012. Mothers were required to have
continuous eligibility 3 months prior to the estimated last menstrual
period (LMP) and throughout pregnancy. LMP was determined by
counting back 2 weeks plus 35 weeks or 40 weeks for preterm and
term births. Women with cancer, opioid‐use disorder, opioid dispens-
ing during baseline, or exposure to teratogenic drugs during pregnancy
were excluded. Infants with diagnosis of chromosomal anomalies were
excluded. Infants were considered exposed if mother received at least
1 prescription opioid during pregnancy. The children outcomes
included the diagnosis of all mental disorders or specific development
delays. Conditional logistic regression with propensity score greedy
matching (PSGM) with 0.1 caliper width or propensity score fine strat-
ification and weighting (PSFSW) with 100 strata were used to obtain
adjusted risk ratios (RR). Maternal comorbidities and mental health
diagnoses, measures of illness burden, and concomitant drugs were
adjusted.
Results: Of the 83,332 mother‐infant pairs, 8,874 (11%) mothers used
opioids in pregnancies, 6,986 (0.8%) infants developed any types of
mental disorders and 4,994 (0.6%) were diagnosed with specific devel-
opment delays during the follow up period (median: 760 days). Unad-
justed comparisons showed a statistically significant differences
between exposed and unexposed in mental disorders (RR: 1.17,
95%CI: 1.10–1.26) and specific developmental delays (RR: 1.18,
95%CI: 1.09–1.29). After adjusting for confounding factors, the differ-
ences became insignificant for overall mental disorders (aRR from
PSGM: 1.04, 95%CI: 0.95–1.15; aRR from PSFSW: 1.04, 95%CI:
0.96–1.10), and specific developmental delays (aRR from PSGM:
1.05, 95%CI: 0.93–1.18; aRR from PSFSW: 1.04, 95%CI: 0.96–1.13).
Conclusions: In this study, the association between maternal opioid
exposure and risk for long‐term mental disorders in children was not
statistically significant. While future studies with larger cohort and
longer follow up are needed to confirm the findings, a careful evalua-
tion of the risk and benefits of opioids during pregnancy should be
encouraged.
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902 | Projected impact of pharmacogenetics
on veteran pain management
Catherine Chanfreau‐Coffinier1; Julie A. Lynch2; Leland E. Hull2;
David W. Oslin3; Scott L. DuVall1; Sony Tuteja4
1Department of Veterans Affairs, Salt Lake City, UT; 2Department of
Veterans Affairs, Bedford, MA; 3Department of Veterans Affairs,
Philadelphia, PA; 4Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA
Background: Veterans have a high burden of chronic pain. Safely
improving pain management is a priority for the Department of Vet-
erans Affairs (VA). Pharmacogenetic (PGx) tests detect individual
genetic variations associated with altered drug metabolism.
Objectives: To estimate the potential impact of PGx testing on pain
management for Veterans, focusing on CYP2D6 and opioid metabo-
lism, CYP2C19 and response to adjunct medications (antidepressants),
and CYP2C9 and celecoxib.
Methods: National retrospective study using data from VA Corporate
Data Warehouse, VA Pharmacy and VA GDx database for molecular
tests. We identified Veterans with ≥1 prescription for codeine, oxyco-
done, tramadol, or hydrocodone in 2012–2017. We built indicators for
chronic opioid use defined as lasting 90+ days with 10+ prescriptions
or 120+ day‐supply, and for coprescriptions of pain medications. We
summarized patient characteristics, healthcare utilization and PGx
testing. We projected the prevalence of actionable phenotypes for
CYP2D6, CYP2C9 and CYP2C19 using published frequencies and
race/ethnicity of the cohort.
Results: Among 2,687,831 patients with ≥1 opioid prescription in
2012–2017 (66% non‐Hispanic white, 20% Black, 7% Hispanic), 36%
experienced chronic use. Compared with non‐chronic opioid users,
chronic users were older (mean age 58 vs 55), more often white
(70% vs 64%), and had higher healthcare utilization during the year
of opioid prescription. The drugs most often coprescribed with opioids
were antidepressants (27% of cohort), and 15% (n = 407,602) received
a drug inhibiting CYP2D6 that may decrease opioid response. We esti-
mated that 3% of the cohort was at increased risk for codeine toxicity
(n = 91,600 CYP2D6 ultrarapid metabolizers) and 5% were at higher
risk for undertreatment and drug interaction (n = 142,400 CYP2D6
poor metabolizers). 33% of patients (n = 888,700) would have a
CYP2C19 phenotype relevant to antidepressant response, and 33%
(n = 881,700). a CYP2C9 phenotype influencing celecoxib treatment.
Overall, 70% of the patients were estimated to have a clinically action-
able phenotype. 2,768 patients (0.1%) had undergone PGx testing;
80% of the tests were CYP2C9 ordered to guide anticoagulant ther-
apy; 315 patients had been tested for CYP2D6 and 411 for CYP2C19.
Conclusions: Coprescriptions of opioids and interacting drugs is fre-
quent among Veterans. Although 70% of the patients would have an
actionable phenotype relevant to pain therapy, PGx testing is infre-
quently used in this population. Our findings can help VA leadership
develop a framework for comprehensive clinical implementation of
PGx testing to inform pharmacotherapy decisions.
903 | Mountin’ an expedition to find the
truth: Alps Bayesian pathway modeling of
tamoxifen pharmacogenetics
Thomas P. Ahern1; Lindsay Collin2; James Baurley3;
Anders Kjærsgaard4; Peer M. Christiansen5; Kristina B. Christensen6;
Per Damkier7; Bent Ejlertsen8; Maret L. Maliniak2;
Kristina L. Lauridsen6; Rebecca J. Nash2; Stephen Hamilton‐Dutoit6;
Deirdre P. Cronin‐Fenton4; Timothy L. Lash2
1University of Vermont, Burlington, VT; 2Emory University, Atlanta, GA;
3BioRealm, Culver City, CA; 4Aarhus University, Aarhus, Denmark;
5Randers Regional Hospital, Randers, Denmark; 6Aarhus University
Hospital, Aarhus, Denmark; 7Odense University Hospital, Odense,
Denmark; 8Danish Breast Cancer Group, Copenhagen, Denmark
Background: Tamoxifen and its metabolites compete with estrogens
for binding of the estrogen receptor (ER). Adjuvant tamoxifen therapy
is administered for 5—10 years at a dose considered to overwhelm the
ER, thereby reducing the hazard of recurrence by half. Previous stud-
ies have examined some functional polymorphisms in genes that may
alter tamoxifen effectiveness, but no study has evaluated the impor-
tance of the complete metabolic path in optimal tamoxifen response.
No earlier study of genotype‐guided tamoxifen therapy has included
a large stratum of premenopausal women, for whom tamoxifen is
guideline endocrine therapy.
Objectives: We evaluated the pharmacogenetics of tamoxifen metab-
olism and its impact on the hazard of breast cancer recurrence in a
cohort of premenopausal women.
Methods: We identified a cohort of 6000 Danish non‐metastatic pre-
menopausal breast cancer patients, of whom 4600 with ER+ tumors
received tamoxifen, and 1359 with ER− tumors did not receive tamox-
ifen. We also conducted a case–control study of 1082 predominately
postmenopausal women in Denmark. In both study populations,
women were followed for recurrence for up to ten years after initial
diagnosis. We identified and collected formalin‐fixed, paraffin‐embed-
ded primary tumor blocks from patients for whom samples were avail-
able (3959 ER+ and 1139 ER−). We genotyped 32 variants in 15 genes
involved in tamoxifen metabolism or transport. We used the Algorithm
for Learning Pathway Structure (ALPS), which incorporates well‐
established prior information about the tamoxifen metabolic pathway,
to evaluate the importance of the total metabolic capacity and to iden-
tify interactions between variants in the pathway.
Results: No individual variant was notably associated with the hazard
of breast cancer recurrence in either study population. For both the
premenopausal and post‐menopausal study populations, there was
weak evidence for the importance of phase 1 metabolism to the clin-
ical efficacy of adjuvant tamoxifen therapy [Bayes factor (BF) = 2.12
and 2.26, respectively].
Conclusions: Phase 1 metabolism is known to generate active tamox-
ifen metabolites, and consistent with this knowledge, our results sup-
port the importance of phase 1 metabolic capacity in optimal
tamoxifen response. Nonetheless, no individual variant substantially
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explained the overall phase 1 effect on metabolic capacity, and the
level of evidence for the overall effect was weak. These results are
consistent with existing guidelines recommending against genotype‐
guided tamoxifen prescribing, and provide the first large study in sup-
port in premenopausal women.
904 | Insurance coverage of
pharmacogenomic testing
Heather Anderson1; Kristy Crooks2; David Kao2; Christina Aquilante1
1University of Colorado School of Pharmacy, Aurora, CO; 2University of
Colorado School of Medicine, Aurora, CO
Background: Pharmacogenomics (PGx), a component of personalized
and precision medicine, focuses on how genetic variation contributes
to inter‐individual variability in drug disposition, response, and adverse
effects. Many potentially actionable PGx drug‐gene pairs exist, but
few are routinely implemented in clinical practice. While clinical use
of PGx testing is growing, little is known about how many patients
receive PGx testing through their insurance.
Objectives: To identify patients who received PGx testing through
their insurance; identify trends in PGx testing over time; and describe
characteristics of patients who received PGx testing.
Methods: We leveraged a random sample of 10 million patients from
an existing insurance claims dataset populated with medical and phar-
macy claims for 89 million patients from 75 commercial health plans in
the US. We identified a retrospective cohort of patients of all ages
who had at least one claim with a procedure code indicating receipt
of one of the following PGx tests: CYP2C19; CYP2D6; CYP2C9;
VKORC1; and HLA Class 1 typing. Patients who paid for 100% of
the costs of these PGx tests out‐of‐pocket are not represented in this
data source. We calculated counts and frequencies for categorical
characteristics, and means and medians for continuous characteristics.
Results: 5,695 patients received at least one of the PGx tests named
above from January 2012–September 2017. The median number of
tests received per patient was 3 (mean = 2.7, range 1–12; note
patients may have received certain tests more than once). Just over
half of the patients (55%) were female, and the average age was
43 years. For just over half (54%), the PGx test claim was processed
through government insurance (i.e., Medicaid or Medicare); for 43%,
the claim was processed through commercial insurance. Only a hand-
ful of patients (n = 12) received a PGx test in 2012. However, this
number increased to 1,948 in 2013, then 4,126 in 2015 and 3,889
in 2016. The most common PGx test was CYP2C19 (n = 4,581),
followed by CYP2D6 (n = 3,678) and CYP2C9 (n = 3,189). The most
commonly documented diagnosis for CYP2C19, CYP2D6, CYP2C9,
and VKORC1 was “long‐term (current) use of other medications.”
The most common diagnosis for HLA Class 1 typing was HIV.
Conclusions: The number of patients receiving PGx testing through
their insurance was low (less than 6,000 over nearly six years), but
nearly doubled from 2013 to 2016. While PGx test results were not
available from this data source, the most common diagnosis
documented on the PGx test claims was related to medication use.
This study emphasizes the need to better understand utilization pat-
terns and insurance coverage for common PGx tests.
905 | β2‐adrenergic receptor haplotypes and
risk of exacerbations in asthmatic children
and young adults treated with long‐acting β2‐
agonists: a meta‐analysis in the PiCA
consortium
Leila Karimi1; Susanne J. Vijverberg2; Marjolein Engelkes1;
Natalia Hernandez‐Pacheco3; Niloufar Farzan2; Patricia Soares4;
Ben R. Francis5; Maria Pino‐Yanes6; Celeste Eng7;
Somnath Mukhopadhyay8; Maximilian Schieck9; Michael Kabesch9;
Esteban G. Burchard7; Colin N.A. Palmer10; Steve Turner11;
Hettie M. Janssens12; Anke‐Hilse Maitland‐ Van Der Zee2;
Katia M. Verhamme1
1Erasmus University Medical Center, Rotterdam, Netherlands;
2Amsterdam University Medical Centers (Amsterdam UMC), Amsterdam,
Netherlands; 3Universidad de La Laguna, Santa Cruz de Tenerife, Spain;
4Brighton & Sussex Medical School, Brighton, UK; 5 Institute of
Translational Medicine, University of Liverpool, Liverpool, UK;
6Universidad de La Laguna, San Cristóbal de La Laguna, Santa Cruz de
Tenerife, Spain; 7University of California, San Francisco, San Francisco,
CA; 8Brighton & Sussex Medical School, Brighton, UK; 9University
Children's Hospital Regensburg (KUNO), Regensburg, Germany;
10Ninewells Hospital and Medical School, Dundee, UK; 11University of
Aberdeen, Aberdeen, UK; 12Erasmus MC/Sophia Children's Hospital –
University Medical Center, Rotterdam, Netherlands
Background: It is still unclear whether the haplotype combinations
of polymorphisms at positions 16 and 27 of the β2‐adrenergic
receptor (ADRB2) gene is associated with an increased risk of
asthma exacerbations in patients treated with long‐acting β2‐ago-
nists (LABA).
Objectives: We investigated the association between haplotype com-
binations of polymorphisms at positions 16 and 27 of the ADRB2 gene
and asthma exacerbations in asthmatic patients using LABA and
inhaled corticosteroids (ICS) from the multi‐ethnic Pharmacogenomics
in Childhood Asthma (PiCA) consortium.
Methods: We conducted a meta‐analysis of 880 children and young
adults aged (4–21) with asthma that were treated with LABA and
ICS. Polymorphisms at positions 16 (rs1042713;16Arg > Gly) and
27 (rs1042714; 27Gln > Glu) of the ADRB2 gene were extracted
and their haplotypes were determined. Asthma exacerbations were
defined as prescribed courses of oral corticosteroids and/or
asthma‐related hospitalizations/emergency room visits in the past
6 or 12 months prior to the study visit. The association between
haplotypes and exacerbations was analyzed by using the Haplo‐
Stats package adjusted for age and sex. A meta‐analysis was per-
formed using an inverse variance‐weighted method assuming a ran-
dom‐effect.
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Results: Three haplotypes were determined; Gly16Glu27, Arg16Gln27
and Gly16Gln27. Compared to the Gly16Glu27 haplotype, the
Arg16Gln27 haplotype was significantly associated with an increased
risk of asthma exacerbations (OR:1.37, 95% CI;1.03–1.81, P = 0.028,
I2 = 0.0%).
Conclusions: We found that the Arg haplotype (Arg16Gln27) in the
ADRB2 gene increased the risk of exacerbations among asthmatic
children using LABA and ICS. Whether or not this argues against
prescription of LABA in patients with this haplotype needs to be
considered.
906 | Prevalence of KRAS, NRAS, and BRAF
gene mutations in metastatic colorectal
cancer (mCRC) patients: a systematic
literature review and meta‐analysis
Lauren C. Bylsma1; Elizabeth D. Levin‐Sparenberg2; Kimberly Lowe3;
Laura Sangare4; Jon Fryzek5; Dominik D. Alexander2
1EpidStrategies, A Division of ToxStrategies, Inc., Ann Arbor, MI;
2EpidStat Institute, Ann Arbor, MI; 3Amgen, Seattle, WA; 4SimulStat,
Portland, OR; 5EpidStrategies, A Division of ToxStrategies, Inc., Rockville,
MD
Background: A systematic literature review and meta‐analysis was
conducted to summarize the prevalence of KRAS, NRAS, and BRAF
mutations in mCRC patients. These mutations have substantial impli-
cations for treatment decisions among mCRC patients.
Objectives: The objectives of this study were to provide a comprehen-
sive assessment of KRAS, NRAS, and BRAF mutation prevalence among
mCRC patients as reported in the scientific literature and to identify
potential sources of heterogeneity in mutation prevalence by
conducting pre‐specified subgroup analyses.
Methods: Multiple databases were searched to identify observa-
tional studies and clinical trials (standard of care arms only) that
reported mutation status among mCRC patients. Random effects
meta‐analysis models were used to estimate summary prevalence
estimates for each of the mutations. Subgroup and sensitivity anal-
yses were conducted to identify potential sources of heterogeneity
in mutation prevalence.
Results: The meta‐analyses included 275 studies comprising over
77,000 mCRC patients. The summary prevalence estimate was
35.9% for KRAS mutations, 7.1% for BRAF mutations, and 4.1% for
NRAS mutations. Female patients had significantly more KRAS and
BRAF mutations than males (KRAS: 42.2% vs. 37.3%, p = 0.011; BRAF:
11.0% vs. 7.9%, p = 0.018), and significant variation by study location
was observed for both KRAS (p = 0.025) and BRAF (p = 0.002) muta-
tion prevalence.
Conclusions: The prevalence of KRAS, BRAF, or NRAS mutations in
mCRC patients varies significantly by gender and study location. Com-
pared to patients with wild‐type tumors. The results of these analyses
are informative for clinicians, patients, and researchers.
907 | The role of ABCG1 gene DNA
methylations in lipid profiles and therapeutic
efficacy of simvastatin in Chinese patients
with hyperlipidemia
Shanqun Jiang1; Yi‐Hsiang Hsu2
1Anhui University, Hefei, China; 2Harvard University, Boston, MA
Background: ATP‐binding cassette transporter G1 (ABCG1) plays a
critical role in lipid homeostasis by controlling the efflux of cellular
cholesterol to HDL. DNA methylation is involved in lipid
metabolism.
Objectives: The aim of this study was to estimate associations
between DNA methylations in the ABCG1 gene and serum lipids as
well as their effect on the therapeutic efficacy of simvastatin in Chi-
nese patients with hyperlipidemia.
Methods: We selected 211 subjects with extreme high (n = 104) and
low response (n = 107) to simvastatin treatment from a total of 734
hyperlipidemic patients, who were treated orally with 20 mg/d simva-
statin for eight consecutive weeks. The definition of treatment
response was based on adjusted regression residuals for lipid‐lowering
response to simvastatin. Pretreatment DNA methylation levels at pro-
moter of the ABCG1 gene were measured by MethylTarget, a next
generation Bisulfite sequencing‐based multiple targeted CpG methyla-
tion analysis method.
Results: In the high response group, higher ABCG1_A and ABCG1_C
mean methylation levels were positively associated with higher TG
(r = 0.225, p = 0.0286; r = 0.337, p < 0.001, respectively). ABCG1_A
DNA mean methylation levels were inversely associated with base-
line HDL‐C level (r = −0.295, p = 0.00307) and inversely with mag-
nitude of change (r = −0.294, p = 0.00304) in HDL‐C response to
simvastatin (ΔHDL‐C) after adjustment for age, sex, BMI, and base-
line lipids. Similar patterns were also observed in the low response
group. There was significantly inverse association between ABCG1_A
methylation and the lipid‐lowering response (ΔTC: r = −0.295,
p = 0.00272; ΔHDL_C: r = −0.33, p < 0.001). Higher ABCG1_C
methylation was relevant to lower ΔTG and ΔHDL‐C (r = −0.25,
p = 0.0151; r = −0.394, p < 0.001, respectively). Multivariable linear
regression analysis of epigenetic predictors alone showed that
ABCG1_A_mean methylation can significantly contribute to the
inter‐individual ΔHDL‐C level variability (Adjusted R2 = 8.9%).
ABCG1_C_mean methylation can explain up to 17.5% of the inter‐
individual ΔHDL‐C level variability. Additionally, interaction on the
ratio scale of the ABCG1 gene DNA mean methylation and the
SNP rs4148114 was significant in association with the lipid‐lowering
effect of simvastatin therapy.
Conclusions: The DNA methylation levels at the ABCG1 gene are
importantly epigenetic determinants of lipid levels and the lipid‐lower-
ing effect of simvastatin therapy. Further functional studies will con-
tribute to a better strategy to stratify patients for a personalized
lipid‐lowering therapy.
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908 | Identifying two gene clusters that may
serve as a gene signature and biomarker of




Isra University, Amman, Jordan
Background: Calcineurin antagonists (pimecrolimus) treat atopic der-
matitis (AD) with different effectiveness and adverse events.
Objectives: The current report is to characterize and build a network
to serve as a gene signature for Atopic Dermatitis (AD) and to predict
pimecrolimus efficacy and pharmacoepidemiology.
Methods: Geneexpressiondata are taken fromGSE32473geneexpres-
sion profile of patients' skin suffering fromanAD from theGeneExpres-
sionOmnibus (GEO) publically availableweb tool. The sampleswere ten
baseline AD patients, and ten AD patients after topical treatment with
either pimecrolimus. A total of 73 geneswere foundwith unique expres-
sionspatterns incontrastbetweentheADpatient'sbaselineandpatients
receiving pimecrolimus. geneMANIA, online toolswere deployed to find
the relevant network and subnetwork clusters.
Results: geneMANIA database search yielded 49% in co‐expression
pattern. 27% overlaps in pathway networks between the submitted
genes. Four genes distinctly involved in regulation of receptor activity.
Another four were in regulation in IkappaB kinase signaling. Differen-
tially expressed after administration of pimecrolimus.
Conclusions: Analysis of differentially expressed genes after
pimecrolimus reveals two significant gene clusters that are involved
in receptor and Kappa kinase signaling pathways. These two important
networks and their genes might serve as biomarkers for AD and a pre-
dictor gene signature for pimecrolimus medicine activity and adverse
effects. Pathways related to gene clusters have been identified as a
genetic signature to comprehend the underlying biology causing the
AD clinical presentations. LRRC4, OPRM1, MFHAS1, OPTC, P2RY1,
and AVPR1A all clustered around GNB4 core gene. GNB4 core gene
was also found to be is among the under‐expressed inflammatory
genes after three weeks of treatment by pimecrolimus.
909 | Assessment of stakeholder
perspectives of the clinical utility of
pharmacogenomics in solid organ
transplantation
Kimberly M. Deininger1; Jacinda N. Tran2; Shirley M. Tsunoda2;
Gordon K. Young2; Yee Ming Lee1; Heather Anderson1;
Robert L. Page II1; Jan D. Hirsch3; Christina L. Aquilante1
1University of Colorado School of Pharmacy, Aurora, CO; 2University of
California San Diego, La Jolla, CA; 3University of California Irvine, Irvine, CA
Background: Pharmacogenomics (PGx) is a component of precision
medicine, with the goal of using an individual's genetic information
to guide drug selection and dosing. In solid organ transplantation
(SOT), several actionable PGx drug‐gene pairs exist (e.g., tacrolimus‐
CYP3A5, azathioprine‐TMPT, voriconazole‐CYP2C19); however, few
are routinely implemented in the clinical setting. A major obstacle
impeding the translation of PGx in the transplant clinic is the lack of
stakeholders' perspectives on its clinical utility.
Objectives: Assess patient and provider perspectives regarding the
clinical utility of PGx testing following kidney, liver, and heart
transplantation.
Methods: We conducted individual semi‐structured interviews and
focus groups with kidney, liver, and heart transplant patients and pro-
viders [i.e., physicians, pharmacists, and nurse practitioners (NPs)]
from the University of Colorado and University of California San
Diego. Audio‐recorded focus groups and interviews were transcribed
verbatim, coded using data management software, and thematically
analyzed to identify salient themes in transplant patient and provider
perspectives.
Results: The study enrolled 60 patients and providers. The patient
cohort consisted of 36 kidney, liver, and heart transplant recipients
who participated in 24 interviews or two patient focus groups
(72% white; 72% men; mean age 55 ± 13 years). The provider
cohort consisted of 24 kidney (33%), liver (33%), and heart (33%)
transplant clinician interviews (50% physicians, 25% pharmacists,
25% NPs; 79% white; 58% men; mean age 44 ± 10 years). Qual-
itative analysis revealed that patients lacked an understanding
about principles of PGx, but thought it sounded interesting and
useful, and maintained trust in their providers to deliver the best
possible care. Providers expressed willingness to use PGx testing
in their transplant clinic when appropriate, but reported barriers
to implementation of PGx, including lack of knowledge about
ordering a PGx test and applying the results, lack of evidence
demonstrating clinical utility in the transplant population, and
patient financial burden.
Conclusions: The gap between patients' expectations and providers'
level of knowledge about PGx indicates a need for provider education
and ongoing support for successful translation of PGx into the trans-
plant clinic. These results will be used to inform the development
and administration of a national survey of medical directors of SOT
programs to assess the perceived clinical utility of PGx in this
population.
910 | Hormone replacement therapy and the
risk of melanoma in post‐menopausal women
Blánaid Hicks1; Kasper Bruun Kristensen2; Sidsel Arnspang Pedersen3;
Lisbet Rosenkrantz Hölmich4; Anton Pottegård2
1Queen's University Belfast, Belfast, UK; 2University of Southern
Denmark, Odense, Denmark; 3Odense University Hospital, Odense,
Denmark; 4Herlev and Gentofte Hospital, Herlev, Denmark
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Background: There has been much speculation as to whether hor-
monal factors may affect malignant melanoma incidence; however,
studies to date investigating the risk of melanoma associated with hor-
mone replacement therapy (HRT) use have produced conflicting
results.
Objectives: This study aimed to investigate if HRT was i) associated
with an increased risk of melanoma ii) associated with an increased
rate of secondary melanoma or all‐cause mortality in patients diag-
nosed with malignant melanoma.
Methods: We conducted a nationwide case–control study (n = 8,279
incident melanoma cases; 2000–2015) using Danish healthcare regis-
tries. Conditional logistic regression was used to calculate odds ratios
(ORs) for melanoma according to HRT use, adjusting for potential con-
founders. To investigate survival and secondary melanoma a cohort of
all Danish women diagnosed with melanoma 2000–2013 (n = 6,575)
was identified and followed through 2015. Cox proportional hazards
models was used to estimate adjusted hazard ratios (HRs) with 95%
confidence intervals (CIs) for second melanoma and all‐cause mortality
associated with HRT use compared to non‐use.
Results: High use (≥1000 defined daily doses) of HRT was associated
with an OR of 1.21 (95%CI 1.13 to 1.29) for melanoma risk, with no
evidence of a dose–response pattern. Results were most pronounced
among recent high users (OR, 1.28 95%CI 1.17 to 1.41) and for local-
ized disease (OR, 1.25 95%CI 1.15 to 1.36). Similar estimates were
obtained for intravaginal estrogen therapy (OR, 1.38 95%CI 1.13 to
1.68). Regarding secondary melanoma, no association was observed
for post‐diagnostic new‐use of HRT (fully adjusted HR, 1.56 95%CI
0.64 to 3.80) nor continuous HRT use (fully adjusted HR, 1.26
95%CI 0.89 to 1.78). Similar associations were observed for all‐cause
mortality.
Conclusions: While we found evidence of an association between use
of HRT and risk of melanoma, the increase in relative risk was limited.
Further, the lack of dose–response, associations observed with recent
use, localized disease and similar associations for intravaginal estrogen
use suggests this is a non‐causal association.
911 | First‐line treatment of breast cancer
and the risk of hematologic malignant
neoplasms
Marie Joelle Jabagi
EPI‐PHARE (Scientific Cooperation Between the French National Agency
for Medicines and Health Products Safety (ANSM) and The French
National Health Insurance (CNAM‐TS), Saint Denis, France
Background: Survival after early stage Breast Cancer (BC) has
improved with the introduction of new therapeutic agents. At the
same time, secondary malignant neoplasms, including hematologic
malignant neoplasms (HMN), have become an increasing concern
among BC survivors. However, the role of the various BC treatment
modalities in explaining these secondary malignancies remains
uncertain.
Objectives: To identify the treatment modalities of BC that are asso-
ciated with the subsequent development of HMN.
Methods: A population‐based cohort study was conducted using
national data of the French National Health Data System. All women
aged 20–85 years, diagnosed with an incident primary breast cancer
between 2007 and 2015, who underwent surgery as first‐line treat-
ment for BC and who survived at least one year without developing
any HMN or other secondary cancer were included and followed until
December 2017. The risk of various types of HMN over time was
compared according to BC first‐line treatment modalities (surgery only
or along with chemotherapy/radiotherapy/hormonal therapy/G‐CSF
[supportive granulocyte colony‐stimulating factors]) using Cox models
adjusted for sociodemographic characteristics and risk factors.
Results: Among a total of 324 056 BC survivors, 80.2% received radio-
therapy, 37.8% received chemotherapy, 69.5% received hormone ther-
apy and 23.7% received G‐CSF. Overall, 2 291 cases of HMN occurred
during a median follow up time of 4.9 years. Chemotherapy was associ-
ated with an increased risk of acute myeloid leukemia (AML) (N = 436,
HR, 1.9, 95%CI, 1.5 to 2.6) and of Myelodysplastic syndrome (MDS)
(N = 552, HR, 1.4, 95%CI, 1.0 to 1.9). Radiotherapy was associated with
an increased risk of AML (HR, 1.5, 95%CI, 1.1 to 2.0). G‐CSFwas associ-
ated with an increased risk of acute lymphoblastic leukemia or lympho-
cytic lymphoma (ALL/LL) (N = 76, HR, 2.4, 95%CI, 1.1 to 5.3).
Conclusions: In our study, we found that certain types of HMN
increased after treatment by chemotherapy, radiotherapy and/or G‐
CSF. Those risks should be taken into account in the initial manage-
ment of BC.
912 | Corticosteroids and risk of
hospitalization for infection among cancer
patients treated with programmed cell death
receptor/ligand 1 (PD‐1/PD‐L1) inhibitors
Signe Sørup1; Bianka Darvalics1; Leo Russo2; Dina Oksen3;
Francois‐Xavier Lamy3; Patrice Verpillat3; Henrik T. Sørensen1;
Deirdre Cronin‐Fenton1
1Aarhus University, Aarhus, Denmark; 2Pfizer, Collegeville, PA; 3Merck
KGaA, Darmstadt, Germany
Background: Corticosteroids are often used to manage immune‐
related adverse events after administration of PD‐1/PD‐L1 immune
checkpoint inhibitors. Corticosteroid use has been previously associ-
ated with increased risk of serious infection in metastatic melanoma
patients treated with immune checkpoint inhibitors (mainly targeting
cytotoxic T‐lymphocyte antigen 4); there is no information on this risk
among other cancer types.
Objectives: To evaluate whether receipt of corticosteroids is associ-
ated with increased rate of hospitalization for infection in renal,
urothelial, and lung cancer patients treated with PD‐1/PD‐L1
inhibitors.
Methods: We included all patients in the Danish Cancer Registry with
a diagnosis of AJCC stage III or IV renal cell carcinoma (RCC), stage III
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or IV non‐small cell lung cancer (NSCLC), or stage II, III, or IV urothelial
transitional cell carcinoma between 2013 and 2016. We further
selected those who received treatment with PD‐1/PD‐L1 inhibitors
as recorded in the Danish National Patient Registry (DNPR) between
January 1, 2013 and March 1, 2018. We followed patients from the
first date of treatment with PD‐1/PD‐L1 inhibitors (index date) until
one year after the last treatment, death, emigration, or end of study
period (September 1, 2018), whichever came first. Patients were con-
sidered exposed to corticosteroids from the first date of redemption
of corticoid for systemic use (ATC codes H02AB or H02BX01) identi-
fied in the Danish National Prescription Registry after the index date.
We used Cox regression to estimate age‐ and sex‐adjusted hazard
ratios (HRs) and associated 95% confidence intervals (95%CI) of hospi-
talization for infections based on ICD‐10 codes in the DNPR.
Results: The cohort included 634 patients treated with PD‐1/PD‐L1
inhibitors (n = 55 RCC, n = 41 urothelial transitional cell carcinoma,
and n = 538 NSCLC). Median age at initiation of PD‐1/PD‐L1 inhibitor
treatment was 68.2 years (interquartile range (IQR), 61.4–73.4); 56%
were men. During follow‐up, 345 patients (54%) received corticoste-
roids at a median of 3.2 months after PD‐1/PD‐L1 inhibitor initiation
(IQR, 1.4–5.9). During 561 person‐years of follow‐up, 422 hospitaliza-
tions for infection occurred (incidence rate, 113.1 per 100 person‐
years if exposed to corticosteroids and 57.1 if unexposed). The
adjusted HR for hospitalization for infection was 2.38 (95%CI, 1.89–
2.99).
Conclusions: Risk of hospitalization for infection doubled after corti-
costeroid treatment initiation in cancer patients treated with PD‐1/
PD‐L1 inhibitors.
913 | Comparative safety and healthcare
expenditures associated with frontline
therapy for chronic myeloid leukemia
Ashley L. Cole1; Benyam Muluneh2; Jennifer Lund2; William Wood2;
Jennifer Elston Lafata2; Stacie Dusetzina2
1Cecil G Sheps Center for Health Services Research, Chapel Hill, NC;
2University of North Carolina, Chapel Hill, NC
Background: Tyrosine kinase inhibitors (TKIs) have dramatically
improved survival for patients with chronic myeloid leukemia (CML).
No overall survival differences have been observed between patients
initiating frontline imatinib, nilotinib, or dasatinib; however, real‐world
safety and cost outcomes have not been well‐studied.
Objectives: To evaluate the comparative safety and healthcare
expenditures among CML patients initiating frontline imatinib,
nilotinib, or dasatinib.
Methods: Eligible patients had 1+ fills for imatinib, nilotinib, or
dasatinib between 1/1/2011–12/31/2016 (earliest fill = index date),
6+ months pre‐index continuous enrollment, CML diagnosis, and no
TKI use in the pre‐index period. Safety events (defined as a hospitali-
zation or emergency department [ED] visit) were compared across
treatments using 1‐year propensity score weighted relative risks (RR)
and subdistribution hazard ratios (HR). Inflation‐adjusted 1‐year all‐
cause healthcare expenditures and out‐of‐pocket costs were com-
pared across treatment groups using median regression.
Results: Eligible patients included 1417 imatinib, 647 nilotinib, and
1067 dasatinib patients. The 1‐year risk of a safety event was high
across treatment groups (risk [95% CI]: imatinib 37% [35%, 40%];
nilotinib 40% [36%, 45%]; dasatinib 44% [41%, 47%]), with higher risks
among nilotinib (RR: 1.07 95% CI: 0.93, 1.23) or dasatinib (RR: 1.17
95% CI: 1.06, 1.30) patients, compared to imatinib. Over a median fol-
low‐up of 1.7 years (IQR: 0.8, 3.0), the cumulative incidence was
higher among nilotinib (HR: 1.08 95% CI: 0.95, 1.24) or dasatinib
(HR: 1.23 95% CI: 1.10, 1.38) patients, compared to imatinib. All‐cause
healthcare expenditures were high across treatment groups (median:
$125,987) and were significantly higher among nilotinib and dasatinib
patients, compared to imatinib (difference in medians [95% CI]:
dasatinib vs imatinib: $22,393 [$17,068, $27,718]; nilotinib vs ima-
tinib: $19,463 [$14,689, $24,236]). Median 1‐year out‐of‐pocket
costs were more similar across groups ($2,382), but higher among
nilotinib patients, compared to imatinib patients.
Conclusions: Patients who received frontline imatinib had the lowest
risk of hospitalization/ED visit and the lowest healthcare expenditures
in the year following treatment initiation. Given a lack of significant
differences in overall survival, imatinib may represent the preferred
frontline therapy for most patients.
914 | Safety and cost‐effectiveness analysis
of Ponatinib versus other tyrosine kinase
inhibitors in patients with chronic myeloid
leukemia in the United States
Xiaomeng Yue1; Ana Hincapie1; Bin Huang2; Jeff J. Guo1
1University of Cincinnati, Cincinnati, OH; 2Cincinnati Children Hospital
and Medical Center, Cincinnati, OH
Background: Chronic myeloid leukemia (CML) is a malignant disease
and the third most common type of leukemia. Tyrosine kinase inhibi-
tors (TKIs) with similar spectrum of adverse effects are approved for
CML therapy.
Objectives: To evaluate the cost‐effectiveness of ponatinib compared
to other second‐line TKIs, including dasatinib, nilotinib, and bosutinib,
in the treatment of patients with CML who failed or were intolerant
to first‐line TKIs in the United States.
Methods: A Markov state transition model was conducted to compare
cost‐effectiveness of second‐line TKI for treatment practice of target
patients using a US payer perspective over a life‐long time horizon.
Model transition, adverse‐effect probabilities, and utility data were
obtained from clinical trials and literature. Medical costs on CML treat-
ment was estimated using the Medical Expenditure Panel Survey data
between 2013 and 2016. Resource utilization included study drugs,
monitoring, follow‐up, adverse events and allogeneic stem cell trans-
plantation. Primary outcomes were patient quality‐adjusted life years
(QALYs), total costs and incremental cost‐effectiveness ratios (ICERs)
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per QALY gained with discount rate 3% per annum. Univariate sensi-
tivity analyses and Bayesian multivariable probabilistic sensitivity anal-
yses were conducted using Monte Carlo simulations.
Results: Total lifetime medical costs including follow‐up care after
allogeneic stem cell transplantation per CML patient were estimated
at $2,226,616, $2,272,596, $2,362,797, and $2,457,005 for nilotinib,
dasatinib, bosutinib and ponatinib, respectively. In the economic eval-
uation, dasatinib resulted in an ICER of $79,086/QALY compared to
nilotinib. Ponatinib yielded an ICER of $176,278/QALY compared to
dasatinib. Sensitivity analyses showed the model was robust to plausi-
ble changes in input parameters and had good face validity. Findings
were sensitive to price and response rate of TKIs, and cost of adverse
events management. The acceptability curve showed that dasatinib
was the optimal therapy at a willingness‐to‐pay (WTP) threshold of
$100,000/QALY. Between WTP thresholds of $160,000/QALY and
$180,000/QALY, the probability that ponatinib or dasatinib was the
optimal therapy was between 36% and 40%, indicating considerable
uncertainty in the choice of optimal therapy.
Conclusions: Based on current treatment guidelines, this analysis indi-
cates that dasatinib and ponatinib can be considered cost‐effective
options and provide clinical benefit compared to other TKIs for
treating patients with CML in US.
915 | Use of antibiotics against urinary tract
infections and risk of bladder cancer: a Danish
nationwide case–control study
Anton Pottegård1; Kasper B. Kristensen1; Søren Friis2; Jesper Hallas1;
Jørgen B. Jensen3,4; Mette Nørgaard3,4
1University of Southern Denmark, Odense, Denmark; 2Danish Cancer
Society, Copenhagen, Denmark; 3Aarhus University Hospital, Aarhus,
Denmark; 4Aarhus University, Aarhus, Denmark
Background: While bladder cancer mainly comprises urothelial carci-
nomas, squamous cell carcinomas are more prevalent in areas with
high rates of Schistosoma haematobicum infections. Furthermore,
some studies have demonstrated associations between frequent uri-
nary tract infections (UTIs) and risk of squamous cell carcinomas
specifically.
Objectives: To investigate the association between frequent UTIs,
reflected by use of specific antibiotics, and risk of bladder cancer by
histological subtype.
Methods: We conducted a nationwide case–control study using the
Danish health registries. From the Danish Cancer Registry, we iden-
tified patients with a first‐time diagnosis of histologically verified
bladder cancer (non‐invasive or invasive tumors) between 2000
and 2015. For each case, we age‐ and sex‐matched 50 population
controls free of bladder tumors. Use of antibiotics used against UTIs
in Denmark (sulfamethizole, trimethoprim, pivmecillinam, and
nitrofurantoin) was ascertained using the Danish Prescription Regis-
try and categorized as no use (0–1 prescriptions), low (≥2), interme-
diate (2–9) and high‐use (≥10), while applying a 2‐year lag‐period.
We estimated the odds ratio (OR) associating high use of antibiotics
against UTIs with squamous cell carcinoma bladder cancer, using
conditional logistic regression. For comparison, similar analyses were
performed for other bladder cancer histologies and for other
antibiotics.
Results: We identified 333 squamous cell carcinomas of the bladder
(2.7% of all cases). High‐use of antibiotics used against UTIs was asso-
ciated with squamous carcinomas with an overall OR of 11.4 (95%CI
7.6–17.0) and a clear dose–response pattern with ORs increasing from
2.5 (95%CI 1.7–3.6) with 2–4 prescriptions to 11.8 (95%CI, 6.2–22.4)
with 20+ prescriptions (ptrend < 0.001). Similar associations were seen
for the specific types of antibiotics used against UTIs (ORs ranging
from 5.9–16.8). A weak association was observed for
methoxyphenylpenicillin and squamous carcinomas (OR 2.4; 95%CI
1.3–4.7), but additional adjustment for antibiotics used against UTIs
removed this association (OR 0.5; 95%CI 0.1–2.2). Urothelial carcino-
mas (90%; n = 11,029) were not associated with antibiotics used
against UTIs (OR 1.1; 95%CI 0.97–1.3). Excluding patients with known
urogenital disease did not influence the estimates for squamous cell
carcinoma (overall OR 10.7; 95%CI 6.1–18.7).
Conclusions: UTIs, measured by use of specific antibiotics, are
strongly, dose‐dependently, and specifically associated with risk of
squamous carcinomas of the bladder.
916 | Association between concomitant
hydrochlorothiazide and cyclophosphamide
use, and chemotherapy regimen
discontinuation in breast cancer patients
Christine D. Hsu1; Sharon Peacock Hinton2; Til Stürmer1;
Michele Jonsson Funk1; Katherine E. Reeder‐Hayes3;
Hanna K. Sanoff3; Jennifer L. Lund1
1University of North Carolina, Chapel Hill, NC; 2University of North
Carolina (UNC) Lineberger Comprehensive Cancer Center, Chapel Hill, NC;
3University of North Carolina, Chapel Hill, NC
Background: Excluding some skin cancers, breast cancer is the most
common cancer of women in the United States, and cyclophospha-
mide is a preferred agent in breast cancer treatment regimens. Hyper-
tension is the most common chronic condition among older adults in
the United States, with 55% of Medicare beneficiaries in 2015 having
been diagnosed with hypertension. Hydrochlorothiazide, an antihyper-
tensive, is one of the top ten most commonly used medications in the
United States. Pharmacy reference databases (e.g. Micromedex) list
cyclophosphamide and hydrocholorothiazide as a major drug–drug‐
interaction (DDI) due to myelossuppresion risk. However, the only
study we found supporting this claim was an observational study con-
ducted in 1981 with 14 breast cancer patients. No studies to date
have evaluated clinical outcomes of this potential DDI in a large pop-
ulation of breast cancer patients.
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Objectives: Estimate the association between concomitant cyclophos-
phamide and hydrochlorothiazide use (potential DDI) and treatment
regimen discontinuation.
Methods: Using Surveillance, Epidemiology, and End Results (SEER)‐
Medicare data, we included women 65 years and older with a first pri-
mary stage I‐III breast cancer treated with cyclophosphamide. Poten-
tial confounders included colony stimulating factor (CSF) prior to
treatment (for myelosuppression prevention), age at diagnosis, stage
at diagnosis, race, treatment regimen, and Charlson comorbidity score.
The association between concomitant hydrochlorothiazide use and
treatment regimen discontinuation was assessed using modified
Poisson regression with robust variance. Treatment discontinuation
was defined as no treatment dose over 90 days after the expected
time for the regimen.
Results: Among 2,213 women receiving cyclophosphamide adjuvant
chemotherapy for first primary stage I‐III breast cancer, 602 (27%)
had concomitant hydrochlorothiazide and cyclophosphamide use and
1,740 (79%) completed their chemotherapy treatment regimen. The
adjusted risk of treatment regimen discontinuation was similar
between those receiving concomitant cyclophosphamide and hydro-
chlorothiazide vs. those unexposed to the potential DDI (risk ratio
(RR) = 0.96, 95% confidence interval (CI): 0.81, 1.14).
Conclusions: These results indicate lack of association between the
potential DDI and treatment regimen discontinuation. Results from
this study support re‐assessing and potentially lowering the severity
of the noted interaction in drug reference databases.
917 | Early‐life antibiotics use increases the
risk of asthma and eczema: a discordant twin
study
Elise M.A. Slob1; Chantal J.A.R. Kats1; Susanne J.H. Vijverberg1;
Mariëlle W. Pijnenburg2; Toos C.E.M. van Beijsterveldt3;
Gerard H. Koppelman4; Dorret I. Boomsma3;
Anke H. Maitland‐van der Zee1
1Academic Medical Center, Amsterdam Public health research institute,
Amsterdam, Netherlands; 2Erasmus Medical Center‐Sophia Children's
Hospital, Rotterdam, Netherlands; 3Nederlands Tweelingen Register, Vrije
Universiteit Amsterdam, Amsterdam, Netherlands; 4University Medical
Center Groningen, Groningen, Netherlands
Background: Epidemiological studies have shown that early‐life expo-
sure of antibiotics in children increases risk of asthma and eczema.
However, causal relationships were difficult to assess in these studies
(1,2).
Objectives: We aim to investigate evidence for causality in the rela-
tionship between early‐life antibiotic use and development of asthma
and eczema in a Dutch twin cohort.
Methods: We investigated 7,386 children (age: 3–10 years) from the
Netherlands Twin Register prospectively followed by questionnaires
(3). Outcome was defined as parental‐reported asthma at age 3, 5, 7
or 10 years. Early‐life antibiotic exposure was defined as parental‐
reported use of antibiotics between 0–2 years. Individuals derived
from twin pairs were included in unmatched case–control analyses,
using generalized estimating equation models. Conditional logistic
regressions were performed in twin pairs using a co‐twin control anal-
ysis. This design includes disease discordant twin pairs. Affected twins
were matched to their healthy co‐twin. It takes advantage of the fact
that MZ and DZ twin pairs share different degrees of genetic related-
ness and share their environment, while exposure to antibiotics can
differ within twin pairs (4).
Results: Early‐life antibiotic use was associated with an increased risk
of asthma (OR: 1.28, 95% CI: 1.18–1.45; n = 7,386) and eczema (OR:
1.17, 95% CI: 1.08–1.27; n = 7,038) in affected twins with unrelated
controls. After controlling for shared environmental factors by analyz-
ing disease discordant MZ and DZ twin pairs (healthy co‐twin as con-
trol), the risk of developing asthma was significantly increased (OR:
1.84, 95% CI: 1.05–3.22, n = 536), but non‐significant for eczema
(1.21, 95%CI: 0.81–1,80; n = 946). After controlling for both shared
environmental and genetic factors in disease discordant MZ pairs,
increased risk remained, but not statistically significant for developing
asthma (OR: 3.33, 95% CI: 0.92–12.11; n = 138) and eczema (OR:
2.00, 95% CI: 0.90–4.45; n = 306). Lack of statistical power may be
a reason for reaching this borderline significant finding. We could
not correct for prescription of antibiotics caused by viral infections,
which may be a confounder.
Conclusions: Our results suggest that the association between early‐
life antibiotic use and asthma or eczema is not confounded by envi-
ronmental or genetic factors, and might be causal. The risks and ben-
efits of using antibiotic therapy in young children should be
considered before the start of therapy.
918 | Patterns of prescription opioid use
among commercially insured United States
youth and young adults with co‐morbid
chronic pain and mental health conditions
Abisola Olopoenia; Julia Slejko; Linda Simoni‐Wastila;
Wendy Camelo‐Castillo
University of Maryland, Baltimore, MD
Background: Approximately 30% of youth and young adults experi-
ence chronic non‐cancer pain (CNCP) conditions. In adults, those with
CNCP and mental health conditions are more likely to use opioids and
to remain on opioid treatment. Among youth and young adults with
CNCP little is known about the patterns of prescription opioid use
and whether concurrent mental health conditions increase opioid use.
Objectives: Our goal was to examine the association between chronic
non‐cancer pain (CNCP), mental health disorders (MHD) and patterns
of opioid use among commercially insured youth and young adults
10–25 years.
Methods: We conducted a retrospective cohort study derived from a
10% random sample of enrollees within the IQVIA™ PharMetrics Plus
adjudicated claims database during January 1, 2006 to December 31,
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2015. CNCP was defined as the earliest diagnosis of back, head, neck,
arthritis or chronic pain (index date). MHD were assessed in the 6‐
months prior to the index pain diagnosis and included: mood disor-
ders, anxiety, depression, personality disorders, adjustment disorders,
and attention deficit hyperactivity disorders. Based on days supply
we developed a 3‐categorical level measure of opioid use (none, acute
[<90 days], chronic [>90 days]). Among youth with CNCP we esti-
mated the prevalence of opioid use among those with and without
MHD. Multinomial logistic regression (AOR; 95% CI) was used to esti-
mate the association of MHD with opioid receipt, controlling for
demographic and clinical factors.
Results: Among 151,587 youth and adults diagnosed with CNCP,
25,449 (16.8%) had a co‐morbid MHD. Both acute and chronic use
of opioids were more common among those with CNCP and MHD
(16.9% and 1.0%) compared to those with only CNCP (12.8% and
0.2%.) Youth with co‐morbid CNCP and MHD were more likely to
be prescribed opioids compared to those with only CNCP. The odds
were lower for acute (1.07; 1.02,1.12) versus chronic (1.81;
1.46,2.25) use after opioid initiation.
Conclusions: Although the overall prevalence of opioid use is low,
youth with CNCP and MHD are almost twice as likely than those
without MHD to be chronically treated with opioids. These findings
suggest potential adverse selection of youth with CNCP, where those
at highest risk for dependence or adverse outcomes, are more likely to
receive chronic opioid treatment.
919 | Outcomes associated with
antidepressant augmentation: a group‐based
trajectory modeling with propensity score
approach
O'Mareen Spence; Susan dosReis
University of Maryland Baltimore, Baltimore, MD
Background: Limited efficacy of antidepressant (ATD) in treating
Major Depressive Disorder (MDD) in youth often leads to psychotro-
pic augmentation soon after ATD initiation in community practice.
However, there is insufficient evidence to support this practice.
Objectives: To estimate the odds of hospitalization and emergency
department (ED) visits in youth with MDD who augment ATDs with
another psychotropic medication.
Methods: A new user design identified US youth≤18 (n = 3,055) diag-
nosed with MDD who initiated an ATD anytime from January 2007–
June 2014 using IQVIA™ PharMetrics Plus claims data. New users
had no ATD nor other psychotropic use 1‐year prior (baseline) to the
index ATD. Youth were followed for 1‐year post the index ATD. We
identified dose trajectories and augmentation (>15 days overlap of
ATD with another psychotropic) in the first 6 months post index
ATD. Outcomes (hospitalization and ED visits) were identified in
months 7–12 post index ATD. Latent class growth analysis defined
subgroups of youth with similar ATD dose trajectories. Within each
dose trajectory group, we estimated the predicted probability of
ATD augmentation, using baseline characteristics. Logistic regression
with inverse probability of treatment weighting, compared the odds
of hospitalization or ED visits among youth with ATD augmentation
versus those without, within each trajectory subgroup.
Results: The four dose trajectories were slow downward titration
(n = 287; 9%), sustained minimum (10 mg/d per FDA) dose
(n = 982; 33%), sustained maximum (20 mg/d per FDA) dose
(n = 1,361; 44%) and high dose titration (n = 425; 14%). ATD aug-
mentation was most prevalent in the slow downward titration
group (n = 90; 31%), followed by high dose titration (n = 112;
26%), sustained maximum dose (n = 292; 21%), and sustained min-
imum dose (n = 190; 19%). The proportion of youth who had a
hospitalization or ED visit ranged from 21% ‐ 26% across sub-
groups; the lowest in the sustained maximum dose and the highest
in the high dose titration. The odds of hospitalization or ED visits
among youth who augmented versus those who did not was 0.96
(95% CI: 0.48–1.92) for slow downward titration, 1.69 (95% CI:
0.84–3.39) for sustained minimum dose, 0.76 (95% CI: 0.42–1.37)
for sustained maximum dose and 2.2 (95% CI: 0.70–6.9) for high
dose titration.
Conclusions: ATD augmentation was not associated with a reduction
in hospitalization or ED visits among youth with MDD. Exposure to
concomitant psychotropic medications may carry safety risks that out-
weigh the potential benefits.
920 | A latent class growth analysis of
antidepressant dose trajectories and
treatment augmentation in youth
O'Mareen Spence1; Gloria Reeves2; Susan dosReis1
1University of Maryland Baltimore, Baltimore, MD; 2School of Medicine,
University of Maryland Baltimore, Baltimore, MD
Background: More than 40% of youth diagnosed with major depres-
sive disorder (MDD) will not achieve complete response to treatment
with an antidepressant (ATD). In community outpatient care, this is
translated to either psychotropic augmentation, switching, or discon-
tinuation of an ATD soon after starting treatment. Little is known
regarding the relationship between ATD dosing and these therapeutic
changes in community settings.
Objectives: This study aims are to a) determine if comorbid diagnoses
are associated with ATD dose trajectory and b) identify ATD dose tra-
jectories associated with augmentation, switch, or discontinuation
during the 6 months after ATD initiation.
Methods: A retrospective new user design identified 5,725 US youth
≤18 diagnosed with MDD who initiated an ATD anytime from Janu-
ary 2007–June 2015 using the IQVIA™ PharMetrics Plus claims data.
New users had no ATD nor other psychotropic use 1‐year prior to
the index ATD. Latent class growth analysis identified ATD fluoxetine
equivalent dose trajectories 6 months post‐index ATD and multino-
mial logistic regression identified factors associated with each dose
trajectory. A Cox proportional hazard model compared the adjusted
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hazard of the first event of augmentation (ATD overlap with another
psychotropic for >15 days), switch (change to another psychotropic
for >15 days), or discontinuation (no medication for ≥30 days) across
dose trajectories.
Results: The five ATD dose trajectories identified were rapid (926;
16%) and slow downward titration (1,049; 18%), sustained minimum
(10 mg/d per FDA) dose (1,406; 25%), sustained maximum (20 mg/d
per FDA) dose (1,794; 31%) and high dose titration (550; 10%). Anxi-
ety and/or PTSD was more likely in high dose titration (OR: 1.26;
95%CI: 1.01–1.39) and sustained maximum dose (OR: 1.18; 95%CI:
1.01–1.71), than the sustained minimum dose group. Severe mental ill-
ness (bipolar, schizophrenia) was more likely in the rapid (OR: 1.57;
95% CI: 1.23–1.99) and slow downward titration (OR: 1.71; 95% CI:
1.36–2.15) groups than the sustained minimum dose group. The
groups most likely to augment were sustained maximum dose (HR:
1.41; 95% CI: 1.15–1.71) and high dose titration (HR: 1.97; 95% CI:
1.56–1.71). Nearly all (97%) of the rapid downward titration group
discontinued or switched. A discontinuation or switch was also more
likely in the slow (HR: 2.99; 95% CI: 2.70–3.33) downward titration
group.
Conclusions: Comorbid psychiatric conditions may explain the thera-
peutic changes observed in each dose trajectory, however, further
research is needed to inform optimal therapeutic management of
MDD in youth.
921 | Selective serotonin reuptake inhibitors
and type 2 diabetes in adolescents and
youths
Jenny W. Sun1; Brian T. Bateman2; Sonia Hernandez‐Diaz1;
Sebastien Haneuse1; Florence T. Bourgeois3; Krista F. Huybrechts2
1Harvard T.H. Chan School of Public Health, Boston, MA; 2Brigham and
Women's Hospital and Harvard Medical School, Boston, MA; 3Boston
Children's Hospital and Harvard Medical School, Boston, MA
Background: There is recent evidence suggesting that antidepressant
use increases the risk of type 2 diabetes (T2DM) in adolescents and
youths. However, selective serotonin reuptake inhibitors (SSRIs), the
most widely used antidepressants in this age group, have minimal met-
abolic side effects questioning the biological plausibility of this finding.
Objectives: To examine the potential association between SSRIs and
the development of T2DM in adolescents and youths.
Methods: Using nationwide US claims data from the Medicaid Ana-
lytic eXtract (2000–2014), we identified a cohort of adolescents and
youths (age 10–24 years) with a medical diagnosis for an SSRI treat-
ment indication. Within this cohort, new users of SSRIs were com-
pared to new users of bupropion, an antidepressant that is known to
not result in metabolic side effects. To increase the likelihood that
the patient truly took the drug and to minimize exposure misclassifica-
tion, we required 1+ additional dispensing of the respective therapy
within 180 days after initiation. Additionally, to inform within‐class
treatment choices, we compared individual drugs within the SSRI
class, using fluoxetine as the reference. Cox proportional hazards
regression was used to estimate the association between SSRIs and
T2DM, using propensity score (PS) stratification (based on 160+ vari-
ables) to control for potential confounding. As a secondary analysis,
the high‐dimensional propensity score (hdPS) was used to account
for proxies of unmeasured confounding.
Results: Patients who initiated SSRIs (n = 366,225) were more likely to
be female and had fewer co‐occurring psychiatric conditions and pre-
scriptions compared to bupropion initiators (n = 39,468). After pro-
pensity score stratification, all patient characteristics were well
balanced between SSRI and bupropion initiators (absolute standard-
ized difference < 0.05). During follow up (mean: 2.8 years), the inci-
dence rate of T2DM was 2.4 and 2.3 cases per 1,000 person‐years,
respectively, among SSRI and bupropion initiators (crude HR = 1.04,
95% CI: 0.91–1.19). The association remained not substantial after
PS stratification and hdPS stratification (adjusted HR = 1.11, 95% CI:
0.96–1.27 in both analyses). In the within‐class comparison vs. fluox-
etine, paroxetine (adjusted HR = 0.83, 95% CI: 0.68–1.01) and sertra-
line (adjusted HR = 0.90, 95% CI: 0.79–1.01) were associated with a
decreased hazard of T2DM, and none of the hazard ratios were signif-
icantly increased.
Conclusions: In a large nationwide cohort of publicly‐insured adoles-
cents and youths, we found no substantial increase in the risk of
T2DM among new initiators of SSRIs.
922 | Trends in antidepressant use among
children and adolescents: a Scandinavian drug
utilization study
Rikke Wesselhoeft1; Peter Bjødstrup Jensen1; Ardesheer Talati2;
Johan Reutfors3; Kari Furu4; Katrine Strandberg‐Larsen5;
Per Damkier1; Anton Pottegård1; Mette Bliddal1
1University of Southern Denmark, Odense, Denmark; 2New York State
Psychiatric Institute, New York, NY; 3Karolinska Institutet, Stockholm,
Sweden; 4Norwegian Institute of Public Health, Oslo, Norway;
5University of Copenhagen, Copenhagen, Denmark
Background: The use of antidepressants in children and adolescents is
controversial and serious adverse effects have been reported. A black‐
box warning in 2004 led to changes in medication guidelines and for
now, selective serotonin reuptake inhibitors (SSRI) are the only antide-
pressants indicated for treatment in this age group.
Objectives: We aimed to describe and compare the use of antidepres-
sants in Scandinavian children and adolescents throughout the last
decade.
Methods: A population‐based study design including all individuals
aged 5–19 years in the study period of 2007–2017. Aggregate‐level
data on antidepressant use (ATC code N06A*) in Denmark, Norway
and Sweden was extracted from publicly available data sources.
Results: Throughout the study period, the number of young antide-
pressant users increased markedly in Sweden (from 9.3 to 18.0/
1000), whereas it increased slightly in Norway (5.1 to 7.6/1,000) and
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decreased in Denmark (9.3 to 7.5/1,000, after a 2010 peak of 12.9/
1,000). Hence, the percentage of Swedish children and adolescents
who filled at least one antidepressant prescription in 2017 (1.80%)
was more than twice as high compared to Denmark (0.75%) and Nor-
way (0.76%). Antidepressants were most frequently used in the age
group of 15–19 years and girls were more likely to receive treatment.
The ratio between girls and boys treated per 1,000 was similar in the
three countries (Sweden: 67.8/28.4 = 2.39, Denmark: 27.0/
11.1 = 2.44, Norway: 30.2/11.5 = 2.63).SSRI were the antidepressants
most commonly used in all three countries. The defined daily dose
(DDD) of SSRI in the year 2017 was 5,611 per 1,000 inhabitants in
Sweden, 2,709/1,000 in Denmark and 1,848/1,000 in Norway. The
use of ‘other antidepressants’ (ATC code N06AX) also increased in
Sweden, with a significantly higher use in 2017 (497/1,000) compared
to Denmark (225/1,000) and Norway (170/1,000). The use of tricyclic
antidepressants (TCA) in 2017 was generally low in all countries (Swe-
den: 30DDD/1,000, Denmark 38DDD/1,000, and Norway 42DDD/
1,000).
Conclusions: Although the Scandinavian countries are considered
comparable in regard to health care systems and medication guide-
lines, the trends of antidepressant use for children and adolescents
differ profoundly. Swedish children and adolescents are more likely
to receive treatment with antidepressants and the divergence to the
use in Denmark and Norway is expanding throughout the last decade.
The prevalence rates of childhood depression and anxiety disorders
are not believed to vary between the Scandinavian countries, and
obvious explanations for this finding are therefore lacking.
923 | Oral glucocorticoids and venous
thromboembolism in children
Daniel B. Horton1; Fenglong Xie2; Lang Chen2; Melissa L. Mannion2;
Jeffrey R. Curtis2; Brian L. Strom3; Timothy Beukelman2
1Rutgers University, New Brunswick, NJ; 2University of Alabama at
Birmingham, Birmingham, AL; 3Rutgers University, Newark, NJ
Background: Systemic glucocorticoid (GC) use is associated with many
toxicities. Nonetheless, risks of GC‐associated venous thromboembo-
lism (VTE) in children are poorly understood.
Objectives: To quantify rates of new‐onset VTE associated with GC
exposure in a large pediatric population.
Methods: Using Medicaid claims data (2000–2010), we studied chil-
dren age 1–18 with autoimmune disease (inflammatory bowel disease
[IBD], juvenile idiopathic arthritis [JIA], or psoriasis [PSO]) or a com-
parator condition (attention‐deficit/hyperactivity disorder [ADHD])
based on diagnoses ± pharmacy claims, excluding those with prior
VTE or anticoagulant use. We studied time‐varying oral GC use after
a ≥ 6‐month GC‐free baseline, classifying dose as low, medium, or
high based on prescribed prednisone‐equivalent dosage and age−/
sex‐imputed weights. Outcomes were the first use of oral or injectable
venous anticoagulants (primary) and VTE hospitalization plus anticoag-
ulant within 4 months (secondary). We used Cox regression and
weighted cumulative exposure (WCE) models to estimate adjusted
hazard ratios (aHRs) and number needed to harm (NNH).
Results: Among 924,786 children (21.3%GC‐exposed), 224 unexposed
children (0.18/1000 person‐years) and 58 currently exposed children
(5.68/1000 person‐years) were prescribed new VTE treatment. Among
the unexposed, VTE rates were higher in children with IBD and JIA than
in childrenwith ADHDor PSO. After adjusting for age, sex, race/ethnic-
ity, year, comorbidities, other medications, and healthcare usage, we
found strong dose‐ and time‐dependent relationships between GCs
and newly treated VTE (>180d ago: aHR 1.1 (95% CI 0.8, 1.5); 1–180d
ago: aHR 2.2 [95% CI 1.6, 3.0]; current low dose: aHR 6.1 [95% CI 3.4,
10.8]; current high dose: aHR 16.2 [95% CI 8.9, 29.2]). Associations
using the secondary outcome were similar. Effect sizes increased with
longer exposure duration and declined within 6 months after stopping
GCs. Based on WCE models, sustained low‐dose GCs (e.g., 0.1 mg/kg/
day) appeared relatively safe (aHR < 1.2), but risks increased even with
brief high‐dose exposures (2 mg/kg/day x7 days: aHR 1.7). Risk differ-
ences were ~10‐folder higher for children with IBD and JIA (NNH:
~55,000 for 2 mg/kg/day x7 days; ~2,000 for 2 mg/kg/day x30 days)
than for those with ADHD or PSO (NNH: ~500,000–600,000 for
2 mg/kg/day x7 days; ~20,000 for 2 mg/kg/day x30 days).
Conclusions: In children with chronic conditions, current oral GC use
is strongly associated with incident VTE in a dose‐ and duration‐
dependent fashion. VTE is a more common complication in pediatric
IBD and JIA, but in absolute terms, this toxicity is rare in children.
924 | Psychotropic drug prescribing to
children with attention deficit/hyperactivity
disorder in the United States, 2002–2016
Daniel B. Horton1; Brian L. Strom2; Matthew T. Taylor3;
Tobias Gerhard4
1Rutgers University, New Brunswick, NJ; 2Rutgers University, Newark,
NJ; 3Sidney Kimmel Medical College, Thomas Jefferson University,
Philadelphia, PA; 4Rutgers University, New Brunswick, NJ
Background: Use of ADHD drugs has been increasing in many coun-
tries, and prior studies of antidepressant and antipsychotic drugs have
identified ADHD as a common reason for off‐label usage. However,
few comprehensive studies of psychotropic drug use have been per-
formed for children with ADHD.
Objectives: To describe the extent and trends of prescribed non‐
ADHD psychotropic drugs for children with ADHD in the US and to
evaluate how conduct disorder (CD) affects prescribing.
Methods: We used the National Ambulatory Medical Care Surveys
(2002–2016) and outpatient National Hospital Ambulatory Medical
Care Surveys (2002–2011), which provide nationally representative
cross‐sectional, visit‐level data on demographics, diagnoses, and drugs
ordered in outpatient clinics in the US. The study included all survey
visits for children <18 excluding those for diagnoses or reported
symptoms of anxiety, autism, bipolar disorder, depression, epilepsy/
seizures, psychosis, or substance misuse/abuse. We identified visits
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for ADHD using ICD‐9‐CM codes and visits for CD based on ICD‐9‐
CM and reported symptoms. Antidepressants (AD), antiepileptics, anti-
psychotics (AP), and anxiolytics were grouped as non‐ADHD psycho-
tropic drugs. We compared rates of prescribing among groups with
and without ADHD and/or CD using chi‐square tests, accounting for
the complex survey design. Trends were evaluated through logistic
regression of elapsed time ([survey year‐2002]/15) on drug class,
adjusted for age, sex, race, ethnicity, insurance, setting of care, and
presence of CD.
Results: Physicians prescribed non‐ADHD psychotropic drugs at 9.8%
of visits for ADHD alone and 28.3% of visits for ADHD+ CD, compared
to 7.7% of visits for CD alone and 1.2% of visits without ADHD or CD.
Including ADHD drugs, ≥2 psychotropic drugs were prescribed at
19.1% of visits for ADHD and 32.8% of visits for ADHD + CD. Among
non‐ADHD psychotropic drugs, antidepressants were most commonly
prescribed at visits for ADHD alone (5.9%), while antipsychotics were
most commonly prescribed at visits for ADHD + CD (14.7%). Analyses
suggested trends of increasing AD use (OR 1.8, 95% CI 0.7, 4.9) and
decreasing AP use (OR 0.5, 95% CI 0.2, 1.5) over time.
Conclusions: US physicians frequently prescribe non‐ADHD psycho-
tropic drugs off‐label to children with ADHD even in the absence of
documented neuropsychiatric diagnoses or symptoms. Prescribing
rates of these drugs are substantially higher for children with docu-
mented comorbid CD. More research is needed to understand the rea-
sons for these prescribing patterns and their impact on outcomes.
925 | Variations in seasonal influenza
vaccine effectiveness: a systematic review
and meta‐analysis of test‐negative design
studies
George N. Okoli; Florentin Racovitan; Christiaan H. Righolt;
Salaheddin M. Mahmud
University of Manitoba, Winnipeg, MB, Canada
Background: Test‐negative design study using routine influenza sur-
veillance data can avoid or minimize bias associated with confounding
by health‐care‐seeking behaviour and misclassification of cases. In this
design, patients presenting with influenza‐like illness and testing pos-
itive for influenza virus are defined as cases and those testing negative
are defined as comparators.
Objectives: To summarize and compare seasonal influenza vaccine
effectiveness (VE) from test‐negative design studies according to
study region, influenza season characteristic, respiratory specimen
swab collection time, and target age group.
Methods: We systematically searched appropriate bibliographic data-
bases and relevant websites from January 2011 to July 2018 for
full‐text articles from test‐negative design studies of seasonal influ-
enza VE against laboratory‐confirmed (PCR or culture) influenza con-
ducted in outpatient primary care settings during the 2010/11 to
2017/18 influenza seasons. Two reviewers independently screened
retrieved citations against the eligibility criteria using a two‐stage
sifting approach (screening of titles/abstracts and full‐text articles)
and extracted data from all included studies. Disagreements were
resolved by consensus or by involving a third reviewer. We included
only final seasonal influenza VE estimates. Pooled VE was calculated
using inverse variance, random‐effects model for all influenza, H1N1,
H3N2, influenza A, and influenza B.
Results: Seventy full‐text articles met our eligibility criteria and are
included in the meta‐analysis. Pooled VE was higher in the Southern
hemisphere compared with the Northern hemisphere: 55% (CI: 49–
60%; I2 = 0%) compared with 40% (CI: 34–46%; I2 = 78.8%) for all
influenza, 66% (CI: 53–75%; I2 = 0%) compared with 51% (CI: 45–
56%; I2 = 55.1%) for H1N1, 40% (CI: 26–51%; I2 = 0%) compared
with 25% (CI: 18–31%; I2 = 61.7%) for H3N2, 53% (CI: 29–69%)
compared with 40% (CI: 28–50%; I2 = 71%) for influenza A, 58%
(CI: 48–66%; I2 = 0%) compared with 43% (CI: 36–50%;
I2 = 68.1%) for influenza B. Pooled VE across all influenza, influenza
types and subtypes differed by vaccine antigenic similarity with cir-
culating viruses (VE highest in antigenically similar), respiratory spec-
imen swab time (higher VE with swab time of <8 days compared
with swab time of ≤4 days), and age group (a reduction in VE with
increasing age).
Conclusions: The available evidence suggests that study region, sea-
sonal influenza vaccine antigenic similarity with circulating viruses,
specimen swab time, and age influence seasonal influenza vaccine
effectiveness.
926 | The risk of Arthus reaction following
Tdap vaccination: vaccine adverse event
reporting system and a review of literature
Vitali Pool1; Larissa Mege2; Adel Abou‐Ali3
1Sanofi Pasteur, Swiftwater, PA; 2Sanofi Pasteur, Lyon, France; 3Sanofi
Pasteur, Toronto, ON, Canada
Background: Repeated administration of tetanus toxoid‐containing
vaccines has been known in the past to result in an immune‐complex
reaction in hyper‐immunized individuals, also known as Arthus phe-
nomenon. Since 2013, the US Centers for Disease Control and Pre-
vention (CDC) has recommended administration of Tetanus Toxoid,
Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines Adsorbed
vaccine (Tdap) during each pregnancy and recently, one Tdap
(Adacel®, Sanofi Pasteur) was approved for repeat administration in
adults.
Objectives: The objectives of this review were 1) to describe trends in
spontaneously reported Arthus reactions following administration of
any vaccine or Tdap in the US, and 2) to assess the risk of this phe-
nomenon in persons receiving Tdap repeatedly.
Methods: We retrieved and reviewed “Type III immune complex
mediated reaction” reports submitted to the US Vaccine Adverse
Events Reporting System (VAERS) between 1990 and 2018.
Reporting rates were estimated using Tdap doses distributed in the
US from CDC and IQVIA's Drug Distribution Data. A systematic
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literature review was conducted in PubMed to identify and review
literature reports of Arthus reaction following any vaccination. Pub-
lished manuscripts of clinical trials and observational studies that
included safety outcomes after repeat Tdap vaccination were
reviewed for any mention of Arthus‐type reactions.
Results: A total of 192 suspected Arthus reaction reports were sub-
mitted to VAERS during the review period. Of these, 36 were
reported after Tdap administered alone or concomitantly with other
vaccines between 2008 and 2018. Vaccinee ages ranged between
11 and 64 years. There were more females (64%) among identified
cases. Between 2013 and 2017, 14 suspected Arthus‐type reaction
cases were reported after Tdap administration among approximately
104 million doses of Tdap vaccines distributed in the US; the esti-
mated conservative reporting rate was 0.1 cases per million doses
distributed. The PubMed search did not identify any case reports
of Arthus reaction published during the period of time when Tdap
vaccines were licensed in the US or other countries. Similarly, no
Arthus reaction cases were mentioned in published clinical trials
and observational studies of repeat Tdap administration.
Conclusions: Arthus‐type reactions following vaccination, including
Tdap, are extremely rare. Increasing frequency of repeat Tdap admin-
istration in adults in the past several years did not result in detectable
increases in the reporting rates of those events, confirming the favor-
able safety profile of the vaccine.
927 | Skin necrosis following 23‐valent
pneumococcal polysaccharide vaccination
Deborah L. Thompson; Graca M. Dores; Jaspal Ahluwalia;
Deepa P. Arya; Manette Niu
Food and Drug Administration, Silver Spring, MD
Background: Skin necrosis after vaccination is a rare local adverse
event (AE) that can result in serious complications.
Objectives: Describe the characteristics of skin necrosis cases after
administration of 23‐valent pneumococcal polysaccharide vaccine
(PPSV23).
Methods: A case series was conducted in the Vaccine Adverse Event
Reporting System (VAERS). PPSV23 reports submitted from 1990
(VAERS inception) through January 9, 2019 associated with AEs of
“injection site necrosis,” “necrosis,” “skin necrosis,” or “vaccination
site necrosis” were ascertained. A case of vaccination‐site skin
necrosis was defined as an individual whose report included a
description of skin necrosis at or near the PPSV23 injection site.
Empirical Bayesian data mining analyses were conducted to deter-
mine if skin necrosis was disproportionally associated with PPSV23
vaccine compared to other vaccine‐AE pairs reported to VAERS.
Results: A total of 71 reports were ascertained, of which 44 (62%) met
the case definition for vaccination‐site skin necrosis. The median age of
cases was 66 years (range = 51–96 years), and most were female (86%).
Themedian time to onset of symptomswas oneday (range=0–18days).
Thirty (68%) cases received PPSV23without concomitant vaccinations.
The route of vaccine administration was noted for 29 (66%) cases, of
which 21 (48%) received PPSV23 intramuscularly and 8 (18%) subcuta-
neously. Almost all cases (n = 42, 95%) were reported to have cellulitis
or were described as having a cellulitis‐like reaction in conjunction with
skin necrosis. Blood or wound cultures were obtained in 10 (23%) cases,
and in all but one case, culture resultswere negative. Fifteen cases (34%)
were hospitalized, 19 (43%) required wound debridement, and 2 (5%)
requiredaskingraft.Nopatternswere identifiedbyonsetdate, reporting
source,orproduct lotnumber.Dataminingdidnot revealdisproportional
reporting values for PPSV23 and skin necrosis.
Conclusions: Review of 28 years of US and international VAERS data
revealed skin necrosis as a rare AE following PPSV23 vaccination.
Most cases were associated with cellulitis or cellulitis‐like reactions,
not known to be of infectious origin, with some cases requiring hospi-
talization, wound debridement, and/or skin grafting. In addition to
ensuring proper injection technique (optimizing injection site location,
correct needle size), early recognition of skin necrosis and prompt
evaluation and management are warranted.
928 | Safety surveillance of the four‐
component meningococcal group B vaccine
(Bexsero®): vaccine adverse event reporting
system (VAERS), January 2015–June 2018
Silvia Perez‐Vilar1; Graça M. Dores1; Paige W. Lewis2; Carmen S. Ng2;
John R. Su2; Maria V. Cano2; Jonathan M. Duffy2
1U.S. Food and Drug Administration, Silver Spring, MD; 2Centers for
Disease Control and Prevention, Atlanta, GA
Background: Bexsero® (GlaxoSmithKline) is a four‐component
Neisseria meningitidis serogroup B vaccine (MenB‐4C). It was licensed
in the United States in 2015 under accelerated approval regulations
for use among individuals ages 10–25 years. The Advisory Committee
on Immunization Practices recommends MenB‐4C for persons ages
≥10 years at high risk for meningococcal B disease; adolescents and
young adults ages 16–23 years may also be vaccinated.
Objectives: To assess the post‐licensure safety profile of MenB‐4C by
analyzing reports to the Vaccine Adverse Event Reporting System
(VAERS).
Methods: VAERS is a national passive surveillance system for adverse
events (AE) following immunization that uses the Medical Dictionary
for Regulatory Activities (MedDRA) to code reported adverse events
(AEs) and the Code of Federal Regulations to classify reports by serious-
ness. We analyzed U.S. reports involving MenB‐4C received through
June 30, 2018. We used Empirical Bayesian data mining to identify
MenB‐4C/AEcombinations reported at least twice asoftenasexpected.
Results: VAERS received 1,470 reports following MenB‐4C vaccina-
tion (39% described concurrent administration of other vaccines).
Most reports were among females (59%), with a median age of
17 years (interquartile range: 16–18 years). The most commonly
reported AEs included injection site pain (23%), pyrexia (15%), and
headache (15%). Median time from vaccination to AE onset was 0 days
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(interquartile range: 0–1 days). There were 64 (4.4%) serious non‐fatal
and two (0.1%) death reports (none attributed to MenB‐4C). Data
mining identified disproportionate reporting for “injected limb mobility
decreased” (secondary to injection site reactions including extensive
swelling of the vaccinated limb and injection site pain).
Conclusions: The reported AEs for MenB‐4C are consistent with the
safety experience described in clinical studies and the product's pack-
age insert. We did not identify new safety concerns.
929 | Bacille Calmette Guerin vaccine safety
surveillance in the Korea adverse event
reporting system using tree‐based scan
statistics and traditional data mining methods
Ju Hwan Kim; Hyesung Lee; Ju‐Young Shin
School of Pharmacy, SKKU Pharmacoepidemiology, Suwon, Korea,
Republic of
Background: Comparable efficacy among Bacille Calmette‐Guérin
(BCG) vaccine with different strains or administration routes has been
thoroughly documented. However, Substantial variations in the safety
profile of different types of BCG vaccine have been reported.
Objectives: To conduct a data mining analyses using the tree‐based
scan statistic and traditional data mining methods to detect potential
adverse events (AEs) following BCG vaccine, and explore the differ-
ence in the AE reporting rates of BCG vaccine for intradermal injec-
tion (BCG‐ID) and BCG vaccine for percutaneous injection (BCG‐PC)
in the Korea Adverse Event Reporting System (KAERS) database.
Methods: We conducted vaccine safety surveillance study on the
reported AEs of BCG vaccine from the Korea Institute of Drug
Safety and Risk Management KAERS Database (KIDS‐KD). We
compared all vaccine‐related AE pairs with AE pairs reported from
the following BCG vaccines between 1 January 2005 and 31
December 2016: BCG‐ID Danish (strain 1331; Statens Serum Insti-
tute), BCG‐ID Tokyo (strain 172; Japan BCG Laboratory) and BCG‐
PC Tokyo (strain 172; Japan BCG Laboratory). Signal detection
using the following three different data mining methods were
compared: tree‐scan statistic, Gamma‐Possion shrinker Empirical
Bayes Geometric Mean (EBGM), and traditional data mining
method using reporting odd ratios, proportional reporting ratios
and Bayesian confidence propagation neural networks of informa-
tion components. Tree‐scan statistic was employed to identify sta-
tistical associations (signals) of AE following BCG vaccines at a
0.05 level of significance.
Results: Among 19,448 all vaccine‐related AE pairs, 620 AE pairs
and 32 types of AE related to BCG vaccines were identified. A total
of 4 signals were detected using traditional method, in which 3 sig-
nals were also detected by both tree‐scan statistic and EBGM. The
most predominant detected AE was lymphadenopathy (362/620;
58.4%), with higher reporting rate noted with intradermal injection
(79.3%).
Conclusions: Tree scan statistic data mining method was successfully
applied for signal detection of AEs following BCG vaccine in the
KAERS database. Although BCG‐ID was associated with higher AE
reporting rate, caution should be taken when interpreting the results
due to inherent limitations of data obtained from a spontaneous
adverse event reporting system.
930 | Signal detection for vaccine safety in
the vaccine adverse event reporting system
using change point models
Jing Huang1; Jingcheng Du2; Susan S. Ellenberg1; Sean Hennessy1;
Cui Tao2; Yong Chen1
1University of Pennsylvania, Philadelphia, PA; 2University of Texas Health
Science Center at Houston, Houston, TX
Background: The Vaccine Adverse Event Reporting System
(VAERS) have been a major data source for detecting signals of
potential adverse effects (AEs) and monitoring vaccine safety.
One of the main goals of VAERS is to monitor increases in
reporting rate of AEs, as such signals can suggest safety issues
caused by updates of vaccines or change in vaccine practices. Cur-
rent disproportionality methods were largely developed for FDA
Adverse Event Reporting System and ignore the temporal tends
of reported adverse events. Thus, they cannot detect such tempo-
ral trends. The change point model has proven to be a powerful
tool in detection of change over time in a sequence of observa-
tions in multiple research fields. In this study, we proposed a
change point method to detect changes in AE reporting rates after
flu vaccination.
Objectives: To examine temporal tends of reported AEs after flu vac-
cination using change point models.
Methods: We developed a change point model to detect the time
points at which the reporting rate of a given AE changes. To capture
the sparsity of events in VAERS data, we used zero‐inflated Poisson
model to characterize the number of reported events for a givenAE dur-
ing each year.We adapted the standard changemodel through compos-
ite likelihood‐based inference to address a unique challenge of VAERS
as a passive reporting system in which the study population varies
across years. We demonstrate the proposed method using seasonal tri-
valent influenza virus vaccine (FLU3) in VAERS data (1990–2013).
Results: We extracted 6813 VAERS reports with at least one of the
following serious outcomes: death, life‐threatening illness, hospitaliza-
tion, prolonged hospitalization, or permanent disability, which
contained 3784 unique preferred terms (PTs). We applied the pro-
posed method to the data and identified 2 PTs (“nuclear magnetic res-
onance imaging spinal abnormal” and “blood product transfusion”)
with increased reporting rates between 1990 and 2013, after
adjusting for multiple comparison. Currently, most studies focused
on general clinical AEs after vaccination. Imaging diagnosed AEs and
hemolytic transfusion reactions after flu vaccine are understudied,
although a few case reports were published. As VAERS is the front line
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for vaccine safety, the signals detected using change point models in
this study could provide early warning signals for further investigation.
Conclusions: As a complimentary tool to current signal detection
methods for monitoring vaccine safety using VAERS, the change point
model can be a useful method to detect potentially important changes
in reporting rate of adverse events over time.
931 | A simulation study of the statistical
power and signaling characteristics of an early
season sequential test for influenza vaccine
safety
Richard A. Forshee1; Mao Hu2; Deepa Arya1; Silvia Perez‐Vilar1;
Steven A. Anderson1; An‐Chi Lo2; Madeline Swarr2;
Michael Wernecke2; Tom MaCurdy3,2; Steve Chu4; Jeffrey Kelman4
1Center for Biologics Evaluation and Research, U.S. Food and Drug
Administration, Silver Spring, MD; 2Acumen, LLC, Burlingame, CA;
3Stanford University, Stanford, CA; 4Centers for Medicare & Medicaid
Services, Washington, DC
Background: The U.S. Food and Drug Administration (FDA) monitors
the risk of Guillain‐Barré syndrome (GBS) following influenza vaccina-
tion in a multilayered approach using Medicare and other data
sources. In the 2017–18 season, we modified our near real‐time sur-
veillance in Medicare to detect early increases in GBS risk while
avoiding false positives.
Objectives: To assess the ability of the Updating Sequential Probabil-
ity Ratio Test (USPRT) to detect elevated risk in the 8–21 days post‐
vaccination compared to a historical rate early in an influenza season
and the probability that signals accurately identify high GBS risk when
high‐risk seasons are uncommon.
Methods: We conducted a simulation study using a retrospective
cohort design. We used Medicare Parts A and B claims data from
the 2012–13 through 2016–17 influenza seasons to identify outpa-
tient influenza vaccinations and primary‐coded GBS hospitalized
cases in days 8–21 post‐vaccination. We simulated 20 different test-
ing schedules using these inputs by varying the USPRT parameters,
including the first testing week (between weeks 5–8) and the null
hypothesis (1x‐3x the historical rate). All testing schedules ended
at week 11 as majority of vaccinations are administered by this date,
after which regulatory action would have reduced impact. We then
assessed the USPRT's power to detect elevated risk of GBS versus
a fixed alternative rate (5x‐30x the historical rate) and estimated
the signal probability and the risk ratio (RR) after signaling when sim-
ulations were a mixture of low and high‐risk seasons.
Results: We found >80% power to detect a risk 30x the historical rate
in week 5 for the 1x null, and in week 6 for the 1.5x‐3x null. Nearly all
testing schedules had >80% power for a 5x risk by week 11. In simu-
lations with 1% high‐risk seasons, for the 1x null 10% of seasons sig-
naled by week 11, which decreased to ~1% with the ≥2.5x null. The
distribution of RRs after signaling was concentrated at high values
(RR ~16.0 under the 2.5x null versus ~1.4 under the 1x null).
Conclusions: In the 2017–18 season, we specified the USPRT to test
continuously from weeks 7–11 using the null hypothesis that the
observed GBS rate was 2.5x the historical rate. This testing schedule
allows the USPRT to detect a high GBS risk early in an influenza sea-
son or a pandemic. The selection of 2.5x the historical GBS rate as the
null hypothesis reduces the number of statistically significant results
when the risk is unlikely to be high, while maintaining adequate power
to detect risk increases that may warrant further investigation.
932 | Adherence to controller therapy in
chronic obstructive pulmonary disease: real
life setting
Leila Karimi1; Esmé J. Baan1; Tiana Geeraerd2; Johan Van Der Lei1;
Bruno H.C. Stricker3; Guy G. Brusselle4,3; Lies Lahousse2,3;
Katia M. Verhamme1,2
1Erasmus University Medical Center, Rotterdam, Netherlands; 2Faculty of
Pharmaceutical Sciences, Ghent University, Ghent, Belgium; 3Erasmus
University Medical Center, Rotterdam, Netherlands; 4Ghent University
Hospital, Ghent, Belgium
Background: Adherence to controller therapy in Chronic Obstructive
Pulmonary Disease (COPD) is low. Insight into the different adherence
trajectories and patient characteristics of each trajectory is important
to develop target tools to improve adherence to COPD controller
therapy.
Objectives: To investigate different patterns of adherence to COPD
controller therapy and compare patients characteristics of the identi-
fied trajectories.
Methods: A retrospective cohort study (2007–2016) was conducted
using electronic primary care data from IPCI (NL) and THIN (UK).
COPD was defined as ≥1 disease code and ≥ 2 prescriptions of respi-
ratory drugs in one year. Prescriptions of controller therapy were
retrieved by ATC code from patient records. COPD controller therapy
consisted of long‐acting beta2‐agonists (LABA), long‐acting muscarinic
receptor antagonists (LAMA), corticosteroids (ICS), LABA+ICS fixed
dose combination or LABA+LAMA fixed dose combination. Adherence
was assessed per month and good adherence was defined as ≥80% of
days covered by a prescription. A group‐based trajectory modeling
(GBTM) technique was applied to model 4 trajectories of adherence
to controller therapy in the 2 years following diagnosis of incident
COPD. Patient characteristics at baseline were compared between
trajectory groups.
Results: In total, 6,022 incident COPD patients (mean age of
66.15 years) in IPCI and 37,315 incident COPD patients in THIN
(mean age 67.12 years) were identified. In both databases, adherence
to COPD controller therapy were categorized into 4 trajectories
namely patients with; a good adherence (26.8% in IPCI; 29.8% in
THIN), a poor adherence (34.5% in IPCI; 31.2% inTHIN) and an adher-
ence which either decreased (23.9% in IPCI; 25.5% in THIN) or
increased (14.8% in IPCI; 13.5% in THIN) during follow‐up. Compared
to good adherent patients, poor adherent ones were younger, more
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frequently smokers, had less severe COPD and suffered more often
from depression and gastroesophageal reflux disease.
Conclusions: We identified distinctive adherence trajectories as well
as patient characteristics related to these trajectories. Whether knowl-
edge of risk factors of poor treatment adherence will result in
improved COPD control needs to be investigated in further research.
933 | Are patients adherent to
benzodiazepine treatment? Results of a
retrospective cohort study in primary care in
Spain
Mar Martín‐Pérez; Veronica Bryant; Elisa Martín‐Merino;
Dolores Montero‐Corominas; Consuelo Huerta
Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid,
Spain
Background: Data on primary non‐adherence to psychotropic medica-
tions is still sparse and, in Spain, where the prevalence of use of ben-
zodiazepines is among the highest within the Western countries, it is a
matter of particular relevance.
Objectives: To assess primary non‐adherence to benzodiazepines or
related drugs in a primary care database in Spain, the time elapsing
from prescription issue date until first dispensing and factors associ-
ated with primary non‐adherence.
Methods: A cohort of individuals 18 years or older between 2011 and
2015 were identified from The Spanish Primary Care Database For
Pharmacoepidemiological Research (BIFAP) and followed until a first
ever e‐prescription (written electronically by the primary care physi-
cian ‐PCP‐ and linked with dispensing data from the pharmacy) for a
benzodiazepine or related drug [ATC: N05BA, N05CD or N05CD],
death, end of available data or study period. We assessed the propor-
tion of primary non‐adherence, defined as failing to fill the new pre-
scription within one year of the issue date (index date), as well as
time until first‐fill using Kaplan–Meier analysis. We also estimated
the proportion of dispensations out of the total number of potential
refills calculated based to the PCP's instructions (i.e. duration, dosage
and pack size). Multiple logistic regression was used to estimate pre-
dictors of primary‐non adherence compared with primary adherent
patients.
Results: Out of 65,419 patients who received a fist ever benzodiaze-
pine e‐prescription, 10,910 (16.7%) were primary non‐adherent.
Among primary adherent patients (n = 54,509), 95.2% first filled their
prescription within 10 days from the issue date and almost 80% were
fully compliers (filled all the potential refills). Factors associated with
an increased likelihood of primary non‐adherence were: young age
(18–35 years), high use of healthcare services (within 6 months prior
to index date, ≥ 10 PCP visits: OR 1.64; 95%CI 1.51–1.79), benzodi-
azepine indicated for psychiatric conditions other than depression,
anxiety, or sleep disorders, having socio‐economic problems, duration
of treatment prescribed by the PCP (≥1 year: OR 3.06; 95%CI 2.89–
3.23) and not using any other drug concomitantly (OR 1.93; 95%CI
1.83–2.03).
Conclusions: The majority of benzodiazepines' new users in primary
care in Spain were early initiators and comply with the whole treat-
ment. Given special attention to individuals with the identified predic-
tors, particularly to the prescribed length of treatment, may help
improve primary adherence to benzodiazepines.
934 | Drug refill patterns of suvorexant and
other insomnia medications: a US
administrative claims database study
Cathy Anne1; Praful Kumar2; William J. Herring1; Johanna Hyacinthe1;
Ankita Kumar2; Mani Lakshminarayanan2; Zhiwen Liu1
1Merck & Co., Inc., Kenilworth, NJ; 2Complete HEOR Solutions Pvt Ltd.,
North Wales, PA
Background: Suvorexant is the first marketed drug in a new category
of insomnia medications known as orexin receptor antagonists. Lim-
ited data exist regarding refill patterns for suvorexant and other
hypnotics.
Objectives: To describe refill patterns and time to discontinuation for
new users of suvorexant and other insomnia drugs including zolpidem,
temazepam, ramelteon, and low dose doxepin.
Methods: A new user cohort study was conducted using the Optum
ResearchDatabasewith patients having≥2 prescriptions between Jan-
uary 2015 and September 2017, with ≥12 months continuous enroll-
ment before and after the index date. The primary utilization measure
wasadrugrefill ratio (RR)definedasdays' supply/timebetweenprescrip-
tions. Initial and overall RR were defined using time between the index
dateanddatesof firstand lastprescription, respectively.Baselinecharac-
teristics for suvorexant users with a high (≥0.8) RR and low (<0.8) RR
were summarized. For the entire sample and for consistent users (with
overall RR ≥ 0.8), time to discontinuation was described as the time
between the first and last refill date, plus days' supply of the last
prescription.
Results: The entire sample included 4,182 suvorexant, 46,400
zolpidem, 15,217 temazepam, 1,144 ramelteon and 183 doxepin
new users, with a mean age of 65 years, 59 years, 65 years, 68 years
and 58 years, respectively. Compared with zolpidem, suvorexant
new users had a higher median (IQR) initial and overall RR of 0.9
(1.1–0.6) vs 0.6 (1.0–0.3) and 0.6 (0.84–0.4) vs 0.3 (0.6–0.2), respec-
tively. The initial RR for suvorexant was comparable to other drugs
including temazepam (0.6 [0.8–0.3]), ramelteon (0.7 [0.9–0.4]), and
doxepin (0.6 [0.9–0.4]), with similar patterns also seen for the overall
RR. For suvorexant new users, those with a higher overall RR were
more likely female (70% vs 60%) and had more prevalent psychiatric
disorders (e.g. bipolar/mania 14% vs 9%) compared to those with a
lower RR. The median (IQR) time to discontinuation was 81.0
(153.3–36.1) days for the entire sample. For those with a high RR
(≥0.8), the median (IQR) time to discontinuation was 31.0 (60.9–
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25.7), 31.1 (57.7–24.8), 32.4 (65.3–26.1), 29.7 (63.9–23.0) and 28.5
(59.9–22.2) for suvorexant, zolpidem, temazepam, ramelteon, and
doxepin, respectively.
Conclusions: Among new users of insomnia medications, the data
trend towards more consistent use of suvorexant and other hypnotics
compared with zolpidem, with higher median refill patterns for all new
users during the initial refill and less frequent use over time. Time to
discontinuation was shorter for more consistent users.
935 | Comparative persistence of non‐
vitamin‐K Oral anticoagulants and
phenprocoumon in patients with non‐valvular
atrial fibrillation ‐ results from the reloaded
study
Niklas Schmedt1; Reinhold Kreutz2; Sebastian Kloss3; Dirk Enders1;
Dennis Häckl4; Hendrik Bonnemeier5
1 InGef – Institute for Applied Health Research Berlin, Berlin, Germany;
2Campus Charité Mitte, Berlin, Germany; 3Bayer AG, Berlin, Germany;
4WIG2 GmbH, Leipzig, Germany; 5University Medical Center of
Schleswig‐Holstein, Kiel, Germany
Background: Data on the persistence of factor‐Xa non‐vitamin‐K oral
anticoagulants (NOACs) for patients with non‐valvular atrial fibrillation
in the real‐world setting is limited.
Objectives: We aimed to compare the risk of treatment discontinua-
tion of individual NOACs vs. phenprocoumon in Germany.
Methods: We conducted a new user cohort study in patients with
non‐valvular atrial fibrillation (NAVF) based on German claims data
between January 1st, 2013 and June 30th, 2017. A multiple Cox‐
regression was performed to calculate confounder‐adjusted hazard
ratios (HRs) for the risk of treatment discontinuation in new users of
NOACs (rivaroxaban, apixaban and edoxaban) vs. new users of
phenprocoumon. Subgroup analyses were conducted in patients with
renal disease, frailty, by age group (<80 vs. 80+ years) and diabetes.
As a sensitivity analysis, we assessed the consistency of our results
following a stockpiling approach.
Results: The study population with NVAF comprised 22,339 initiators
of rivaroxaban, 16,201 of apixaban, 2,828 of edoxaban and 23,552 of
phenprocoumon. In the confounder‐adjusted analysis, a comparable
risk of treatment discontinuation was found for rivaroxaban (HR:
1.04; 95%‐confidence interval (CI): 1.02–1.07), and apixaban (HR:
1.00; 0.96–1.03) and a lower risk for edoxaban (HR: 0.81; 0.76–
0.86). In patients with renal disease, the risk was decreased for
rivaroxaban (HR: 0.82; 0.78–0.87), apixaban (HR: 0.77; 0.73–0.82)
and edoxaban (HR: 0.61; 0.53–0.70). Strong risk reductions for
NOACs were also observed in frail, older and diabetes patients ranging
from 57% to 20%. After allowing for stockpiling, a reduced risk of
treatment discontinuation compared to phenprocoumon was also
found in the overall population with similar risk estimates for
rivaroxaban (HR: 0.82; 0.80–0.85), apixaban (HR: 0.86; 0.83–0.90)
and edoxaban (HR: 0.77; 0.70–0.84).
Conclusions: Our study indicates a favorable treatment persistence
of NOACs compared to phenprocoumon in NAVF patients with sim-
ilar effects across individual NOACs. Beneficial effects were most
pronounced in patients with renal disease and diabetes, as well as
in older and frail patients. In addition, our results highlight the
importance of also considering stockpiling in comparative safety
and effectiveness studies assessing treatment persistence of NOACs
and phenprocoumon as different intake schemes might have an
influence on the prescribing patterns.
936 | Reality check: the mismatch of time to
bisphosphonate benefit and real world
persistence
Kevin J. Friesen1; Jamie Falk1; Shawn Bugden2
1University of Manitoba, Winnipeg, MB, Canada; 2Memorial University of
Newfoundland, St John's, NL, Canada
Background: Bisphosphonates are used to prevent osteoporosis‐
related fractures in older persons. Treatment persistence is essential
for clinical benefit, with a minimum of 1 year for any benefit to be
obtained. Clinical trials of bisphosphonate effectiveness have followed
fracture outcomes for up to 3 years. Canadian osteoporosis guidelines
suggest a course of at least 5 years of continuous therapy.
Objectives: 1) To characterize long‐term persistence with bisphospho-
nate treatment in the Province of Manitoba, Canada. 2) To examine
the relationship between risk factors for osteoporotic fractures and
persistence with treatment.
Methods: A longitudinal observational study was conducted using
population based administrative health care data from the Manitoba
Population Research Data Repository from April 1st, 1998 to March
31st, 2014 to examine persistence with bisphosphonate treatment.
Incident users over the age of 40 of alendronate, risedronate, or eti-
dronate were followed until treatment discontinuation. Persons with
Paget's disease, renal disease, or cancer were excluded. The primary
outcome of treatment persistence was measured using Kaplan–Meier
(KM) methods. Cox proportional hazard models were used to examine
the association between risk factors for osteoporotic fractures and
treatment persistence.
Results: There were 39,251 incident users of bisphosphonates identi-
fied. Median age at initiation was 71 years (IQR 62, 80), 89% were
female, and 10.7% of users had a history of osteoporotic fractures.
Despite treatment with bisphosphonates, only 53% of users had diag-
nostic codes for osteoporosis in their medical records prior to treat-
ment. KM estimates of persistence at 1, 3 and 5 years were 51%,
30% and 19%. Cox regression found that a diagnosis of osteoporosis
was associated with a lower likelihood to discontinue treatment (haz-
ard ratio (HR) = 0.81, p < 0.0001), as was being female (HR = 0.84
p < 0.0001), while a prior history of osteoporotic fracture was not sig-
nificant (HR = 1.00 P = 0.9).
Conclusions: In order for bisphosphonates to be effective in reduc-
ing rates of osteoporotic fracture, 1 year of treatment is necessary
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for a small, but statistically significant benefit to be seen. Approxi-
mately ½ of users discontinue bisphosphonates with less than a year
of therapy. Less than 20% of users meet the current guideline rec-
ommendation for 5 years of bisphosphonate treatment. Initial
assessments suggest that risk (previous fracture) was not related to
persistence. The results suggest greater support and patient‐driven
commitment may be required to ensure optimal drug duration with
bisphosphonates.
937 | The unintended consequences of cost‐
related medication nonadherence: cancer
survivors may substitute less expensive care
with more costly services
Kevin Lu1; Xiaomo Xiong2; Minghui Li3
1University of South Carolina, SC, SC; 2China Pharmaceutical University,
Nanjing, China; 3University of Tennessee, Memphis, TN
Background: Increasing evidence shows that good medication adher-
ence can improve patients' health and reduce health care utilization.
However, medication adherence among cancer survivors may
decrease for economic reasons, and its impact on health care utiliza-
tion remains unknown.
Objectives: This study aimed to evaluate the impact of cost‐related
medication nonadherence on primary care and inpatient/emergency
department (ED) services among cancer survivors.
Methods: A retrospective pooled cross‐sectional study was con-
ducted using data from the National Health Interview Survey
(NHIS) between 2011 and 2017. The measurement of cost‐related
medication nonadherence was based on a “yes” response of
respondents to any of the following survey prompts: “skipped
medication doses to save money in past 12 months”, “took less
medication to save money in past 12 months” or “delayed refilling
prescription to save money in past 12 months”. Multivariable logis-
tic regressions were used to assess the impact of a self‐reported
cost‐related medication nonadherence on primary care (home
health care visits, office visits) and inpatient care or emergency
department visits in past 12 months, controlling for demographics,
income, health status and insurance related information.
Results: A total of 18,305 cancer survivors were identified out of
705,669 respondents during 2011–2017. Cancer survivors who
responded “yes” to the survey prompt, indicating worse cost‐related
medication nonadherence, had a 6% decrease in home health care
visits (OR = 0.94, 95% CI: 0.78–1.13, P = 0.485), and 5% decrease
in physician office visits (OR = 0.95, 95% CI: 0.79–1.14,
P = 0.567). More importantly, the same patients increased emer-
gency department visits by 75% (OR = 1.75, 95% CI: 1.58–1.95,
P = 0.000), and hospitalizations by 20% (OR = 1.20, 95% CI: 1.07–
1.35, P = 0.003).
Conclusions: Cost‐related medication nonadherence may induce
cancer survivors to reduce use of primary care services such as
home care visits or physician office visits to save money. Unin-
tended consequences of this response may be poorer health out-
comes, and increased use of more costly services such as
hospitalizations or emergency department visits.
938 | Patient adherence and persistence to
oral targeted therapies for hematologic
malignancies: a retrospective cohort study
among managed care enrollees
Krish Patel1; Vinjamuri Sai Sudhir2; Shaum Kabadi3; Joanna C. Huang2;
Sanchita Porwal2; Kushan Thakkar2; John M. Pagel1
1Swedish Cancer Institute, Seattle, WA; 2ZS Associates, Evanston, IL;
3AstraZeneca LP, Gaithersburg, MD
Background: Existing studies evaluating patient adherence to oral
targeted therapies such as tyrosine kinase inhibitors focus on small
populations with single malignancies.
Objectives: To evaluate the patterns of use of oral agents in a large
population across multiple hematologic malignancies.
Methods: Adult patients diagnosed with a hematologic malignancy
and prescribed oral targeted therapy between 2011 and 2016
(N = 18,976) were identified from the MarketScan Commercial
Claims and Encounters, and Medicare Supplemental databases. Eli-
gible patients were enrolled in monthly prescription plans 6 months
before and 12 months after index date (date of first prescription
claim) (n = 2,442). Multivariable logistic regressions were used to
determine predictors of adherence using the medication possession
ratio (MPR), and persistence through prescription refill gaps.
Results: In total, 2,442 patients were included in the overall
cohort, 1,757 in the once‐daily (QD) group and 685 in the
twice‐daily (BID) group. The overall median adherence was 0.9
(MPR ≥ 80%) and was comparable between QD and BID groups.
In the overall cohort and the QD and BID groups, 59% of patients
were persistent at 12 months (gap = 60 days). Patients on QD
and BID products did not have significant differences in adherence
(fixed interval MPR, odds ratio [OR], 0.94; 95% CI, 0.75 to 1.18)
or persistence (OR, 0.93; 95% CI, 0.75 to 1.17) 12 months from
index. Significant predictors of adherence and persistence included
patient age (18–50 years vs 51–64 years: adherence OR 1.99,
95% CI 1.52 to 2.61; persistence OR 1.54, 95% CI 1.18 to
2.03), total inpatient admissions (0 vs 3+ admissions: adherence
OR 0.26, 95% CI 0.13 to 0.47; persistence OR 0.24, 95% CI
0.12 to 0.45), number of adverse events (continuous: adherence
OR 0.81, 95% CI 0.76 to 0.87; persistence OR 0.79, 95% CI
0.74 to 0.84) and total hospital visits (0–20 visits vs 41+ visits:
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adherence OR 0.49, 95% CI 0.37 to 0.67; persistence OR 0.50,
95% CI 0.37 to 0.67).
Conclusions: Patient‐specific clinical factors, rather than regimen‐
specific factors, were the main predictors of oral targeted therapy
adherence and persistence. Adherence to oral targeted therapies
appears to be similar for patients on QD and BID regimens in
the real‐world setting.
939 | Assessment of impact of knowledge
attitude & practice on patient medication
adherence in asthma patients
M.S. Srikanth1; Sonam Singh1; Shilpa Palakasha1; P.A. Mahesh2
1 JSS College of Pharmacy, JSS Academy of Higher Education & Research,
Mysuru, India; 2 JSS Medical college & Hospital, JSS Academy of Higher
Education & Research, Mysuru, India
Background: Asthma is a chronic inflammatory reversible disorder
which occurs at any age and requires special attention to the
management of drug therapy. Assessment of medication adherence
is crucial for understanding the patient need and also to assist
them with overcoming any non‐adherence for the better therapeu-
tic outcome. Hence this study was designed to assess the KAP of
asthmatic patients to understand its role in patient medication
adherence.
Objectives: Assessment of the impact of KAP on patient medication
adherence in asthma patients.
Methods: A randomized, interventional study was conducted in a ter-
tiary care teaching hospital among asthma patients during the period
of 10 months. Data were collected using data collection form. Patient's
KAP towards their disease was evaluated using a validated question-
naire. GINA scale and ACT questionnaire were used to assess severity
and symptoms control. Similarly, medication adherence was assessed
using the canister weight method, the pill count method. A checklist
was provided to measure the correct inhaler technique. A patient's
diary and the education was provided to ensure the adherence and
to correct the inhaler technique.
Results: A total of 80 patients out of 90 enrolled patients completed
the study. Among them 40% were using Rota‐haler in both groups
and inhaler with spacer were used by 40% and 37% in test and con-
trol group respectively. KAP questionnaire was validated as good by
all parameters. A statistically significant P‐value (<0.005) was
observed in KAP score from baseline to end visit in the test group.
Whereas in the control group KAP score was not statistically signif-
icant. The similar result was observed with ACT in Test (P‐value
<0.005) as well as in Control group (P‐value = 0.010). The question-
naire of GINA and ACT for assessing the level of asthma symptoms
were the same. There was an improvement in Test group in terms of
the level of asthma symptoms according to ACT and GINA (33%)
with the baseline of 4.4% and end visit of 37.7% of patients,
compared to the control group (11.42%). The difference in canister
weight was observed more in test group in each follow‐up as com-
pared to control group. Whereas in pill count method average num-
ber of capsule left was less in test group as compared to control in
each follow‐up. Average requirement of emergency medication was
more in Control as compared to test group.
Conclusions: the study findings concluded that KAP of asthmatics
patient has a greater impact on their medication adherence and better
treatment outcomes. So, there is a high need for providing the best
education to every asthmatic.
940 | Racioethnic and provider specialty
differences in adherence trajectories among
Medicaid insured children with attention
deficit hyperactivity disorder
Jagadeswara Rao Earla; Susan Abugosh; Hua Chen
University of Houston College of Pharmacy, Houston, TX
Background: Medication adherence among children with attention
deficit hyperactivity disorder (ADHD) is known to be strongly associ-
ated with patients' race/ethnicity.
Objectives: To examine the racioethnic disparities in adherence tra-
jectories among children with ADHD (6–12 years) and to assess
the role of providers' specialty in explaining the disparities.
Methods: A retrospective longitudinal observational study was con-
ducted using 2013–2016 data from a large pediatric Managed Care
Plan in Texas that covered more than 400,000 Medicaid enrolled
children and adolescents. Children aged 6–12 years with an ADHD
diagnosis (ICD‐9‐CM code 314.XX or ICD‐10‐CM code F90.9) and
a prescription for ADHD were first identified, and of which, those
who met the initiation follow‐up criteria of the Healthcare Effective-
ness Data Information Set (HEDIS) were included in the analysis.
The adherence pattern for 300 days after receiving the first ADHD
prescription, was examined using group‐based trajectory modeling.
A multivariable multinomial logistic regression was performed to
evaluate the association of race/ethnicity and provider specialty with
the adherence trajectory group.
Results: The 3,083 patients who met the inclusion criteria were
modeled into 3 different adherence trajectory groups (Complete
adherers‐4.12%, Rapid decliners/discontinuers‐76.35%, and Slow
decliners‐19.53%). Racial differences across the 3 trajectories were
noted. Compared to Caucasians, Hispanics were 3.51 times more
likely to be rapid decliners/discontinuers (Odds ratio [OR] 3.51,
95% Confidence Interval [CI] 2.28–5.40); whereas African Ameri-
cans were 6.41 times (OR 6.41, 95% CI 6.41–11.72) more likely
to be rapid decliners/discontinuers and 3.2 times (OR 3.2, 95%
CI 1.74–5.91) more likely to be slow decliners, respectively. Fur-
ther, children who consulted by psychiatrists were 41% (OR
0.58, 95% CI 0.39–0.87) less likely to be rapid decliners/
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discontinuers than those who consulted by primary care physicians
or others. Children who received combination therapy compared
to monotherapy were 94% (OR 0.06, 95% CI 0.04–0.09) less likely
to be rapid decliners/discontinuers and 36% (OR 0.64, 95% CI
0.41–0.99) less likely to be slow decliners. There was no interac-
tion effect between race/ethnicity with physician specialty.
Conclusions: There were significant racioethnic and provider spe-
cialty differences across patients in different ADHD medication
adherence trajectories. However, the racioethnic differences were
not associated with the access to mental health specialists.
941 | Adherence trajectories in asthmatic
patients
Esmé Baan1; Leila Karimi1; Astrid Heeremans2; Guy Brusselle3;
Miriam Sturkenboom4; Hettie M. Janssens5; Lies Lahousse2;
Johan C. de Jongste5; Katia Verhamme1
1Erasmus MC, Rotterdam, Netherlands; 2Ghent University, Ghent,
Belgium; 3Ghent University Hospital, Ghent, Belgium; 4University Medical
Center Utrecht, Utrecht, Netherlands; 5Erasmus University Medical
Center – Sophia Children’s Hospital, Rotterdam, Netherlands
Background: Adherence to asthma medication is often suboptimal,
leading to suboptimal control of the disease. Insight in adherence pat-
terns in real life is important to improve asthma management.
Objectives: To study adherence patterns of inhaled corticosteroids
(ICS) using group‐based trajectory models and investigate risk factors
for poor adherence in asthmatic patients.
Methods: A retrospective cohort study (2007–2016) in asthmatic
patients, ≥5 years old in 2 primary care databases: IPCI (NL)
and THIN (UK). Asthma was defined as ≥1 asthma disease code
in combination with ≥2 prescriptions of respiratory drugs in one
year. Prescriptions were retrieved by ATC code from patient
records. We used group‐based trajectory analysis to model 4
adherence trajectories of ICS within 2 years after asthma diagno-
sis, for children (5–17 years) and adults (≥18 years) separately.
Good adherence was defined as ≥80% of days covered by a pre-
scription. Patient characteristics at baseline were compared
between trajectory groups.
Results: In total, 12,524 adults and 3,152 children from the IPCI data-
base and 47,700 adults and 22,807 children from the THIN database
were included. In all databases a trajectory of ‘high adherent’, ‘decreas-
ing adherent’, ‘increasing adherent’ and ‘poor adherent’ patients were
observed. In children, ‘high adherent’ patients were significantly youn-
ger and had more often eczema and rhinitis or nasal polyposis than
‘poor adherent’ patients. In adults, ‘high adherent’ patients were signif-
icantly older, had more often diabetes and GERD, less often rhinitis
and were less often smokers than ‘poor adherent’ patients.
Conclusions: Conclusion: We observed different adherence trajecto-
ries with distinct patient characteristics. Targeting patients at risk for
poor adherence is important to improve asthma management.
942 | Factors associated with inhaled
corticosteroid non‐adherence in pregnant
women with asthma: a cross‐sectional
analysis
Annelies L. Robijn1; Megan E. Jensen1; Peter G. Gibson1,2;
Vanessa E. Murphy1
1Hunter Medical Research Institute, University of Newcastle, New
Lambton Heights, Australia; 2 John Hunter Hospital, New Lambton
Heights, Australia
Background: Among women prescribed inhaled corticosteroids (ICS)
for asthma during pregnancy, non‐adherence is common and may
have serious consequences for both mother and baby. However,
no previous studies have determined specific indicators of ICS
non‐adherence in this vulnerable group.
Objectives: To identify factors associated with ICS non‐adherence in
pregnant women with asthma.
Methods: Data utilized comes from three cohort studies (2004–2018,
Eastern Australia) involving pregnant women with asthma recruited
before 22 weeks of gestation (N = 1443). Demographics, asthma his-
tory and current symptoms were assessed and spirometry was per-
formed. Women reported current medication use and number of ICS
doses missed in the past week were recorded. Factors associated to
ICS non‐adherence (20% or more doses missed) were examined using
backward step wise logistic regression.
Results: Of the 582 women prescribed ICS, 219 women (38%) were
classified as non‐adherent. Both adherent and non‐adherent women
were prescribed a dose of 500 μg [400, 800] a day; yet the actual
daily dose in the past week was lower among non‐adherent women
(180 μg [0, 400] vs 500 μg [343, 800], p < 0.01). Non‐adherent
women were more likely to report season (p = 0.04) and work envi-
ronment (p = 0.02) as asthma triggers. Adherent women had better
lung function expressed in forced expiratory volume in one second,
(FEV1%) compared to non‐adherent women (92.3% [81.4, 99.6] vs
87.9% [77.7, 97.5] p = 0.04). In multivariate analysis, non‐Caucasian
(OR 2.14, 95%CI 1.12–4.12, p = 0.02) and Indigenous ethnicity (OR
2.53, 95%CI 1.10–5.83, p = 0.03) and currently smoking (OR 2.19,
95%CI 1.28–3.74, p < 0.01) were associated with higher odds of
being non‐adherent.
Conclusions: In order to target ICS non‐adherence during pregnancy,
strategies that are culturally appropriate and target current smokers
are needed.
943 | Patterns of adherence to prescribed
opioids: the differential between opioid naïve
and opioid existing patients of different age
groups
Che Suraya Zin1; Nor Hidayah Taufek1; Mazlila Meor Ahmad2
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Background: Opioid prescribing has increased tremendously in the last
two decades which concomitantly increased the unwanted conse-
quences such as opioid abuse, misuse and overdose death. Poor
adherence to opioid therapy is one of the factors contributing to these
problems which are associated with increased healthcare cost. Limited
data are available on opioid adherence and whether different age
groups play a role in adherence is unknown.
Objectives: This study examined the adherence to opioid therapy in
opioid naïve and opioid existing patients of different age groups.
Methods: This retrospective cohort study was conducted using phar-
macy databases of tertiary hospital settings in Malaysia from 2011
to 2016. Adult patients aged ≥18 years old receiving at least two opi-
oid prescriptions (buprenorphine, morphine, oxycodone, fentanyl,
dihydrocodeine and tramadol) during the study period were included
and stratified into opioid naïve and opioid existing pain patient groups.
They were followed either until end of study period, discontinuation
of therapy or death and were stratified into five age groups (18–40,
41–50, 51–60, 61–80 and ≥ 81 years old). Proportion of days covered
(PDC) was used to estimate the adherence to opioid therapy which
was calculated by dividing the total number of days covered with
any opioids by the number of days in the follow‐up period. Patients
were considered adherent to opioid therapy if PDC was ≥80%. Fac-
tors associated with PDC were examined using the generalized linear
modeling. The covariates used were age, sex, type of opioids and opi-
oid daily dose.
Results: A total of 10569 patients with prescribing episodes of 36650
were included in the study. Of these, 91.7% (n = 9696) were opioid
naïve patients and 8.3% (n = 873) were opioid existing patients.
Adherence to opioid therapy (PDC ≥ 80%) was achieved in 24.5% of
naive patients and 19.5% of existing patients. The median therapy of
PDC in naïve patients was 35.5% (IQR 10.3–78.7) and 26.8% (IQR
8.8–69.5) in opioid existing patients. Among different age groups,
patients in older age group of ≥81 years old (28.1%) were the highest
to achieve ≥80% PDC among naïve patients while patients of ages 41
to 50 years old (24.0%) were the highest in the opioid existing
patients.
Conclusions: Adherence to opioid therapy was shown in a small group
of pain patients. Opioid naïve patients were more likely to adhere to
opioid therapy compared to opioid existing patients. Close monitoring
is required in opioid existing patients who use opioids for long term as
poor adherence may contribute to adverse events of opioids.
944 | Statin adherence and risk of diabetes
among the United States Department of
Veterans Affairs Hospital Patient Population
Skai W. Schwartz1; Darren Scheer1,2; Pragati Ghimire‐Aryal1;
Kenneth Taylor1; Anh T.H. Nguyen1; Nnadozie Emechebe1;
Phillip Foulis3
1Department of Epidemiology and Biostatistics, College of Public Health,
University of South Florida, Tampa, FL; 2Biotech Research Group, Corp.,
Tampa, FL; 3Department of Pathology, James A Haley Veteran's Hospital,
Tampa, FL
Background: There have been several reports that statin use may
increase the risk of developing diabetes mellitus. Since statin therapy
is recommended based on cardiovascular risk, confounding by indica-
tion is suspected. However, few studies adjusted for pre‐statin lab
values, or considered objective adherence to statin therapy based on
post statin changes in low density lipoprotein.
Objectives: To investigate confounding by indication and non‐adher-
ence on the association between statin use and incident diabetes.
Methods: From a random sample of Veterans visiting James A Haley
VA hospital In Tampa, FL, between 2007 and 2011 with at least two
years of pharmacy records, we selected exposed patients (E) with an
incident statin record; or unexposed patients (U) with no statin
records. We then restricted patients to those with (1) no ICD code
for diabetes mellitus prior to their baseline prescription or with
180 days after; (2) low density lipoprotein (LDL) and glucose measure-
ments within 425 both before and after the baseline prescription. The
glucose had to be from a chemistry panel accompanying a lipid panel.
Since statins are known to reduce LDL by 30 to 50%, we estimated
“statin adherence” by the post minus pre change in LDL and defined
Group 1 (non‐adherent: decrease less than 10% or an increase); Group
2 (low adherence: LDL decrease 10 to 39.99%) and Group 3 (adherent:
LDL decrease by 40% or more) Follow‐up data for incident type 2 dia-
betes mellitus was available through 2014. Risk ratios were estimated
by Proc Genmod.
Results: Our final sample consisted of 1587 statin patients (E) and
2170 unexposed patients (U). Mean age was 61.2 and 59.0 and body
mass index kg/m2 was 28.9 and 28.5 in E and U respectively. Risk of
new type 2 DM after 180 days post baseline prescription was 13.9%
and 6.8% in E and U respectively (RR =2.03, p < 0.001). Adjustment
for age, BMI and baseline levels of LDL, triglycerides, glucose and cre-
atinine reduced the overall RR slightly (RR = 1.82 [95% CI = 1.44,
2.31]). However, when groups based on LDL change were each com-
pared to U, adjusted RR's were 2.07 (95% CI = 1.57, 2.72) for Group 1
(<10% LDL reduction or increase in LDL); 1.76 (95% CI = 1.32, 2.34)
for Group 2; and 0.98 (95% CI = 0.57, 1.69) for Group 3 (≥40%reduc-
tion in LDL).
Conclusions: Since statin users with the greatest reduction in LDL
have no increased risk of diabetes compared with non‐users, it seems
unlikely that statin use is responsible for the observed increase in dia-
betes risk. The increased risk is more likely to be due to unknown or
inadequately measured confounders.
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945 | Impacts of multi‐dimensional
interventions on medication adherence
among type 2 diabetes mellitus patients in a
Nigerian black population
Olayinka O. Ogunleye1; Modupe Oyawole2
1Lagos State University College of Medicine and Lagos State University
Teaching Hospital, Ikeja, Lagos, Nigeria; 2Lagos State University Teaching
Hospital, Ikeja, Lagos, Nigeria
Background: The mortality and morbidity associated with Type 2 Dia-
betes Mellitus remains high in Nigeria owing to poor glycemic control.
Non‐adherence to medication is identified as an important contribut-
ing factor. There is a need to explore means of improving medication
adherence among this population of patients.
Objectives: To determine the prevalence of medication non‐adher-
ence in a population of Type 2 Diabetes Mellitus patients seen in a
tertiary health institution in Nigeria.
Methods: A cross‐sectional survey over a 2‐months period (November
and December 2015) of Type 2 Diabetes Mellitus patients attending
diabetic outpatient clinic of Lagos State University Teaching Hospital,
Lagos, Nigeria who have been on medication for at least one year was
done to assess adherence to medication using Modified Morisky Scale
(MMAS‐8) and Glycosylated hemoglobin (HbA1c). Patients with
MMAS‐8 score of <80% and HbA1c > 6.5% were considered non‐
adherent and interventions namely: patient education, counseling
and regular medication reminder messages and phone calls were done
over a 6 months period. Post interventions adherence evaluation was
done. The results were summarized with descriptive statistics and the
mean HbA1c compared with Student's Paired T Test using SPSS 20.
Results: A total of 291 patients were studied, 73.2% were female and
77% of the population were above 60 years. 60% of the total respon-
dents were found to be non‐adherent. The six months interventions
brought about a significant reduction in the mean HbA1c of the
non‐adherent group (8.1 ± 1.6 vrs 7.1 ± 1.5, p < 0.01).
Conclusions: Non‐Adherence to medication was high among the stud-
ied population and interventions such as patient education, counseling
and regular medication reminder messages and phone calls improved
adherence and glycemic controls.
946 | Impact of intensity of statin therapy on
patients' persistence to treatment: a Scottish
population‐based study
Tanja Mueller1; Renata C.R. Macedo do Nascimento2;
Marion Bennie1,3; Brian Godman1,4; Simon Hurding5;
Sean MacBride Stewart6; Augusto Afonso Guerra Junior7;
Francisco de Assis Acurcio7; Alec Morton1; Amanj Kurdi1
1University of Strathclyde, Glasgow, UK; 2Federal University of Ouro
Preto, Ouro Preto, Brazil; 3NHS National Services Scotland, Edinburgh,
UK; 4Karolinska Institutet, Stockholm, Sweden; 5The Scottish
Government, Edinburgh, UK; 6NHS Greater Glasgow & Clyde, Glasgow,
UK; 7Federal University of Minas Gerais, Belo Horizonte, Brazil
Background: Current UK treatment guidelines recommend high‐inten-
sity statin therapy (atorvastatin 80 mg) for secondary prevention of
cardiovascular disease (CVD). However, information about treatment
persistence with this high statin dose is limited.
Objectives: To evaluate persistence with high intensity statin therapy
in comparison to moderate and low intensity in patients in Scotland.
Methods: Retrospective cohort study using the Scottish prescribing
dataset in linkage with hospitalization records, including patients (≥
18 years) who initiated statin treatment between January 2010 and
December 2015 (index date); statin intensity was defined as high, mod-
erate and low based on current National Institutes for Health and Care
Excellence classifications. Persistence was calculated using the anniver-
sary method; logistic regression models, adjusted for age, sex, comor-
bidity, type of prescribed statin and whether statins were indicated for
primary or secondary prevention, were used to determine differences
in persistence.
Results: A total of 73,716 patients (mean age 61.4 years, SD 12.6)
were identified; the majority of them (n = 65,125, 88.3%) received
moderate intensity statin therapy, while 7,163 (9.7%) received high
intensity statins. Overall crude 1, 2 and 3‐year persistence rates
were 69.9%, 63.7%, and 59.2%, respectively; rates differed signifi-
cantly between intensity levels, being consistently highest among
high intensity patients (1 year: 74.7%, 2 years: 68.0%, 3 years:
63.3%). Patients with a diagnosis of ischaemic heart disease, angina,
myocardial infarction or stroke during the one‐year period prior to
the index date (secondary prevention) had considerably higher rates
of persistence than patients without recent prior CVD (primary pre-
vention) (high intensity: 1 year 85.5% CVD vs 71.0% no CVD;
2 years: 78.0% vs 64.8%; 3 years: 73.5% vs 60.0%). Adjusted odds
ratios for 1 year persistence when comparing high to moderate
intensity were 2.94 (95% confidence interval (CI) 1.97–4.34) and
1.41 (95% CI 1.24–1.60) among patients with and without recent
CVD, respectively.
Conclusions: High intensity statin therapy was associated with better
persistence compared to moderate or low intensity, with almost two
thirds of patients in Scotland still on treatment three years after initi-
ation. However, whether this higher persistence translates into better
clinical outcomes needs further research.
947 | Post option B+ Programme in Nigeria:
schedule adherence among pregnant women
with HIV
Olumuyiwa Omonaiye1; Snezana Kusljic2; Pat Nicholson1;
Elizabeth Manias1
1Deakin University, Melbourne, Australia; 2The University of Melbourne,
Melbourne, Australia
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Background: Nigeria is responsible for one‐third of the global burden
of mother to child transmission of HIV (MTCT). Hence, Nigeria is a
crucial target in the global effort towards the elimination of MTCT.
Adherence to Antiretroviral Therapy (ART) is a primary determinant
of treatment success of HIV. In 2013, the World Health Organization
(WHO) endorsed Option B+ as the preferred approach for prevention
of MTCT in developing countries. Nigeria was the last country to
implement Option B+ in 2017.
Objectives: We assessed schedule adherence and the predictors of
schedule adherence in pregnant women with HIV under the Option
B+ programme in Nigeria.
Methods: A cross sectional approach was adopted that involved dis-
semination of a standardized survey to obtain information about
health behaviors and practices associated with the use of ART among
pregnant women in four high‐volume HIV treatment sites in Nigeria.
Participants were asked how often they had missed taking the medica-
tion at the prescribed time. A participant was considered adherent if
she had always taken her ART at the prescribed time over the four‐
day period. Not taking ART at least once at the prescribed time over
the four‐day period prior to the day of a survey was considered as
non‐adherent. The ART schedule adherence prevalence proportion
was calculated and the bootstrap technique was used to calculate
prevalence at 95% confidence intervals (CI). Multivariable logistic
regression was used to identify factors independently associated with
the primary outcome (ART schedule adherence), using a forward elim-
ination variable selection strategy with p < 0.10 inclusion and p < 0.05
retention criteria. Model adjusted odds ratios (adjusted OR) and 95%
CI were reported.
Results: The survey had a response rate of 92.6%.Of the 275 partic-
ipants, 29.5% (95% CI: 24.0 to 34.2) self‐reported taking ART at the
prescribed time in the past 96 hours all of the time. In the multivar-
iable logistic regression analyses, there were positive associations
between travel time to the treatment site (OR = 0.5, 95% CI: [0.3
to 1.0], p = 0.04) and WHO clinical staging (OR = 0.3, 95% CI:
[0.1 to 1.0], p = 0.05) with ART schedule adherence. The odds of
non‐adherence to ART schedule were 2.5 times lower in participants
who were diagnosed as a HIV positive before getting pregnant com-
pared with participants who were diagnosed as a HIV positive in
their current pregnancy (OR = 2.5, 95% CI: [0.3 to 0.7], p = 0.002).
Conclusions: The proportion of women who were adherent to ART
schedule was low. In order for Nigeria to be well positioned for elim-
ination of MTCT of HIV, it is crucial that medication adherence is
improved during pregnancy.
948 | Antiretroviral treatment non‐
adherence and virological failure in Côte
d'Ivoire: a cross‐sectional study
Mariam Mama Djima1,2; Jocelyne Moisan3; Jean‐Pierre Gregoire3;
Serge Paul Eholie4,2; Didier Koumavi Ekouevi5,2
1 Institut Pasteur de Côte d'Ivoire, Abidjan, Côte D'Ivoire; 2PACCI, CHU
Treichville, Abidjan, Côte d'Ivoire, Abidjan, Côte D'Ivoire; 3Axe Santé des
Populations et Pratiques Optimales en Santé, Centre de Recherche du
CHU de Québec – Université Laval, QC, QC, Canada; 4CHU de Treichville,
Abidjan, Côte D'Ivoire; 5Département de Santé Publique, Lomé, Togo,
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Background: For people living with HIV (PLHIV), antiretroviral treat-
ment (ART) adherence is essential for achieving an undetectable viral
load. However, in West Africa both ART adherence and access to
viral load measurement are ongoing challenges.
Objectives: The aims of this study were to describe ART non‐adher-
ence and virological failure and to identify factors associated with
them in adults living with HIV in Côte d'Ivoire.
Methods: Participants who were ≥ 18 years of age and had been on
ART for ≥1 year were enrolled from six HIV clinics. Trained social
workers interviewed participants using a standardized questionnaire.
Non‐adherence to ART in the preceding 30 days was assessed using
a visual analog scale. We defined virological failure as a viral load
≥1000 copies/ml. We identified associated factors using multivariate
Poisson regressions.
Results: Among the 1,458 participants, 445 (31%) were non‐adher-
ent to ART. Participants who were younger, had disease at an
advanced WHO stage, with ≥5 ARV pills, living with many people,
who consumed alcohol, or had received professional health advice
were more likely to be non‐adherent. Among participants with viral
load measurement available, 268 (18.5%) had virological failure. Par-
ticipants who were younger, attended a hinterland HIV clinic, not
working or working in informal sector, with ≥2 ARV pills, had a
monthly income ≥60,000 FCFA, were hospitalized in the year before
the interview, or were non‐adherent to ART had a higher risk to
have virological failure.
Conclusions: In our study, no ART adherence and virological failure
were optimal in PLHIV on ART at least one year and more. In the Afri-
can context of access limited to ART therapeutic options, innovative
strategies should be implemented to improve adherence to treatment
and regular monitoring of viral load.
949 | Associations between refill and
guideline adherence to lipid‐lowering
medications and risk of cardiovascular event
and mortality among patients with type 2
diabetes in Sweden
Sofia A. Karlsson1; Björn Eliasson1; Stefan Franzén2;
Mervete Miftaraj2; Ann‐Marie Svensson2;
Karolina Andersson Sundell1,3
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Background: High refill adherence to lipid‐lowering medications have
been shown associated with lower risk of cardiovascular (CV) event and
mortality among patients with type 2 diabetes (T2D). The impact of
guidelineadherenceonpatients' riskofCVeventandmortality isunclear.
Objectives: To analyze risk of CV events and mortality in patients with
T2D i relation to patients' refill adherence to lipid‐lowering medica-
tions and the treating healthcare centers' adherence to lipid‐lowering
prescription guidelines.
Methods: Design: Register‐based cohort study.
Setting: Swedish adults with T2D who initiated lipid‐lowering medica-
tion use in 2006–2012.
Exposures: Patients' refill adherence to lipid‐lowering medications and
the treating healthcare centers' adherence to lipid‐lowering prescrip-
tion guidelines were considered the exposures. Refill adherence was
measured using themedication possession ratio (MPR) and was catego-
rized as high or low based on an 80% cut‐off. Guideline adherence rep-
resented the annual prescription prevalence of lipid‐lowering
medications inT2D patients with LDL cholesterol above recommended
target levels, and was categorized as high or low based on the median,
48% for primary prevention and 78% for secondary prevention.
Main outcome measures: Risk of CV events and mortality was consid-
ered the main outcomes.
Statistical analysis: Risk of CV events and mortality was analyzed by
refill and guidelines adherence levels for primary and secondary pre-
vention patients separately using Cox proportional hazard regression
adjusted for age, sex, socioeconomic status and concurrent medication
use as well as clinical‐ and health‐related characteristics.
Results: Compared to high‐adherent patients (MPR > 80%), low‐
adherent patients (MPR ≤ 80%) showed higher risk of all outcomes.
Among primary prevention patient the increased risk was 44–51%
for CV events, 79–90% for CV mortality and doubled risk for all‐cause
mortality. Corresponding risk for secondary prevention patients were
17–19% for CV events, 66–79% for CV mortality and 88–97% for
all‐cause mortality. Furthermore, primary prevention patients treated
by low‐adherent healthcare centers (guideline adherence <48%)
showed higher risk of CV events and CV mortality. Otherwise, guide-
line adherence level showed no impact on risk of CV events or
mortality.
Conclusions: Our results demonstrate the importance of high refill
adherence to lipid‐lowering medications in patients with T2D.
950 | Early discontinuation of antidepressant
use by Dutch soldiers
Eibert R. Heerdink1,2; Debbie G.A. Janssen3,1; Antoine C.G. Egberts1;
Erik Vermetten3
1Utrecht University, Utrecht, Netherlands; 2Utrecht University of Applied
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Background: Soldiers have a higher risk for developing psychiatric
disorders that require treatment; often with antidepressants.
However, antidepressants as well as the psychiatric disorder, may
influence military readiness in several ways. In the general popula-
tion, early discontinuation of antidepressant treatment is often seen.
It is yet unknown whether this occurs to a similar extent in soldiers.
Objectives: to evaluate discontinuation of antidepressant use by
Dutch soldiers in the first 12 months after start and determinants
thereof.
Methods: Data was obtained from the military pharmacy. All Dutch
soldiers who started using an antidepressant between 2000 and
2014 were included. Kaplan Meier curves were constructed to esti-
mate the discontinuation rate over time and the influence of each
determinant on discontinuation rate was estimated using Cox
regression.
Results: 25.9% of the 2479 starters had discontinued their antide-
pressant use after one month; after three and six months this num-
ber increased to 52.7% and 70.3% respectively. Early discontinuation
was higher in soldiers who received their first prescription from a
neurologist or rehabilitation specialist (HR 1.85, 95% CI 1.55–2.21,
HR 2.66 95% CI 1.97–3.58). In addition, early discontinuation was
lower in soldiers who were prescribed serotonin reuptake inhibitors
and other antidepressants (HR 0.57, 95% CI 0.51–0.60, HR 0.63,
95% CI 0.55–0.73), in soldiers between 40 and 50 years of age
(HR 0.79, 95% CI 0.70–0.89) and when the antidepressants was pre-
scribed by a psychiatrist (HR 0.84, 95% CI 0.77–0.92).
Conclusions: More than half of the soldiers discontinued their pre-
scribed antidepressant within 6 months.
951 | Risk minimization effectiveness for
Mirabegron in the Netherlands, Spain, UK and
Finland
Edith Heintjes1; Daniel Prieto‐Alhambra2,3; Elisabeth Smits1;
Helen Booth4; Daniel Dedman4; Fabian Hoti5; Minna Vehkala5;
Fernie J.A. Penning‐van Beest1; Irene D. Bezemer1
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands;
2Universitat Autonoma de Barcelona and Instituto de Salud Carlos III,
Barcelona, Spain; 3Centre for Statistics in Medicine, NDORMS, University
of Oxford, Oxford, UK; 4Clinical Practice Research Datalink (CPRD),
London, UK; 5Statfinn & EPID Research, Espoo, Finland
Background: In September 2015, a Direct Healthcare Professional
Communication (DHPC) letter was disseminated as a risk
minimisation measure for mirabegron in the treatment of overac-
tive bladder with symptoms of urinary incontinence, urgency, and
urinary frequency. Mirabegron is contraindicated in patients with
“Severe uncontrolled hypertension defined as systolic blood pres-
sure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm
Hg”.
Objectives: To assess the effectiveness of the DHPC as a risk
minimization measure by quantifying the proportions of
mirabegron initiators with documented hypertension (severe or
non‐severe, uncontrolled or controlled hypertension) and the
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frequency of blood pressure recordings before and during
mirabegron treatment, relative to DHPC dissemination.
Methods: An observational cohort study using real‐world data from
the PHARMO Database Network (Netherlands), SIDIAP database
(Spain), CPRD (United Kingdom, UK) and the national healthcare regis-
ters and electronic medical records from Finland. Data sources were
selected based on uptake of mirabegron and availability of linked pre-
scription and blood pressure data. Mirabegron initiators were identi-
fied from December 2012 until December 2016. Hypertension
status was assessed at initiation based on hypertension diagnoses or
treatment and blood pressure records.
Results: The study population comprised 52,291 patients. Severe
uncontrolled hypertension was uncommon in all data sources: pre‐
DHPC overall proportion was 0.49% (145/29,799). Post‐DHPC pro-
portions were lower than pre‐DHPC in the Netherlands (0.61% pre‐
DHPC, 0.26% post‐DHPC, p = 0.053), similar in Spain and UK and
higher in Finland (1.05% pre‐DHPC, 1.60% post‐DHPC, p = 0.022).
For non‐severe uncontrolled hypertension, post‐DHPC proportions
were lower in the Netherlands (15.84% pre‐DHPC, 13.80% post‐
DHPC, p = 0.038), tended to be lower in Spain (12.54% pre‐DHPC,
11.38% post‐DHPC, (p = 0.071), and did not differ in the UK or Fin-
land. Blood pressure values at mirabegron initiation were available
for 29%–56% of patients across data sources. More frequent moni-
toring was observed in mirabegron users with hypertension than
with normal blood pressure, whereas no difference was observed
between post‐DHPC and pre‐DHPC.
Conclusions: Severe uncontrolled hypertension is uncommon among
mirabegron initiators, reflecting the low population prevalence and
suggesting that current labelling works well with respect to minimiz-
ing risks in this population. This study did not suggest further risk
reduction or evidence of improved blood pressure monitoring fol-
lowing DHPC dissemination.
952 | Considerations when applying a
structured benefit–risk assessment to drug
delivery combination products
Alicia W. Gilsenan; Mary E. Ritchey; Brett Hauber;
Elizabeth B. Andrews
RTI Health Solutions, Research Triangle Park, NC
Background: Structured benefit–risk assessments (BRA) using frame-
works such as the CIRS‐BRAT or PROACT‐URL have been evaluated
for use primarily with drugs. Applying the BRA to drug delivery combi-
nation products (DDCP) can lead to different challenges than when
used for a drug alone.
Objectives: To identify specific considerations when applying the
CIRS‐BRAT framework to a DDCP compared with a drug alone using
a triptan example.
Methods: The CIRS‐BRAT framework includes defining a decision
frame (including population, timeframe, and choice of comparator),
identifying key benefits and risks, gathering and assimilating relevant
data, and generating visualizations to communicate the results of the
assessment. Unique considerations for each step in the application
of the framework were identified to determine whether modification
would be needed when applied to DDCP.
Results: The published drug‐only triptan example used an active com-
parator and timeframe within 24 hours. Key benefits were reduced
pain, decreased sensitivity to light, reduction in functional disability,
and reduction in nausea and vomiting. Key risks included transient
triptan sensations, central nervous system adverse events, and
chest‐related adverse events. When considering BRA for iontophore-
sis as DDCP with a triptan, the decision frame remained the same,
although special consideration should be given in population and com-
parator selection. Improved quality of life due to the convenience of
DDCP was identified as a new benefit outcome, and skin burn was
identified as a new risk outcome. In this instance, where DDCP
impacts patient convenience, patient preference data could be impor-
tant to include in a BRA.
No differences in the framework were necessary for identification and
extraction of source data nor for customization of the framework,
though device‐specific regulatory documentation could be useful
when considering new benefits and/or risks associated with a device.
Additionally, weighting via patient preferences could be applied. Dis-
play and interpretation are no different.
Conclusions: The CIRS‐BRAT framework can be followed for DDCP,
as noted in this triptan example, although additional considerations
related to comparator, population, patient preferences, and timing
may be more challenging to resolve compared with conduct of a
BRA with a drug alone.
953 | Effectively communicating small
probability drug risks to patients, a systematic
review
Esther Yoon
Northwestern University Feinberg School of Medicine, Chicago, IL
Background: Adequate patient understanding of the benefits and risks
of drug treatments is vital for informed decision‐making. Many
patients, however, have a limited grasp of probabilistic concepts and
hence are unable to accurately make such an appraisal. This challenge
is especially acute in instances where the risks are severe but of low
probability (<5.0%).
Objectives: The aim of this study was to review the research literature
on different approaches to conveying small risk probabilities to
patients to determine which methods have been found empirically to
be most effective.
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Methods: This review was conducted according to PRISMA guidelines.
Pubmed, PsychINFO, Cinahl, and Embase databases were searched
systematically for drug risk communication studies that assessed
approaches to conveying drug risk probabilities to lay audiences. Stud-
ies which focused on small probabilities, or both small and large prob-
abilities, were eligible for inclusion. The systematic review covered
scientific research published between 1998 and 2018. The following
keywords (and its variations) were used in the search: risk perception,
risk communication, risk–benefit communication, benefit–risk commu-
nication, risk literacy, risk assessment, absolute risk, decision making,
decision model, numeracy, natural frequency, icon array. Two
reviewers independently reviewed the studies identified in the
resulting literature search and identified those which involved testing
of approaches to conveying small, or small and large, drug risk
probabilities.
Results: Forty‐four studies meeting inclusion criteria were identified
and reviewed. Of these, 5 (11%) involved small probability risks. A
combination of numerical information and visual aids was shown to
improve patient risk understanding as compared to numerical informa-
tion or visual aids alone. However, study findings were limited by the
fact that majority of studies reviewed had small sample sizes and
involved demographically homogeneous populations. Though there
were 39 studies that included both small and large probability risks,
these did not specifically evaluate small probabilities as different enti-
ties and did not specify how risk/benefit communication differed
between the two probability types.
Conclusions: A combination of both numeric and visual formats are
the most effective for conveying small probability risks to patients
and other lay audiences. However, further research is needed and
how best practices might differ from that of large risk drug
probabilities.
954 | Are the risk minimization measures for
diclofenac effective? A pre‐post comparison
based on German claims data
Oliver Scholle; Bianca Kollhorst; Ulrike Haug
Leibniz Institute for Prevention Research and Epidemiology – BIPS,
Bremen, Germany
Background: Since 2013—after a review of non‐steroidal anti‐inflam-
matory drugs by the European Medicines Agency—systemic diclofenac
has been contraindicated in persons with certain cardiovascular dis-
eases such as ischemic heart disease, peripheral arterial disease, and
cerebrovascular disease throughout Europe. To date, the impact of
these risk minimization measures has not been investigated.
Objectives: To compare diclofenac use before (2011) and after (2014)
implementation of risk minimization measures, focusing on diclofenac
initiators and the prevalence of ischemic heart disease, peripheral
arterial disease, and cerebrovascular disease (i.e., new absolute contra-
indications [new CIs]) in these patients.
Methods: Using the German Pharmacoepidemiological Research
Database (GePaRD) containing claims data of ~17% of the German
population, we included all individuals aged ≥18 years with health
insurance coverage on January 1, 2011 (cohort 2011) or January 1,
2014 (cohort 2014) and during a one‐year pre‐observation period
for each cohort. Within each cohort, we identified diclofenac initia-
tors, defined as persons with an outpatient prescription of systemic
diclofenac in 2011 (cohort 2011) or 2014 (cohort 2014) but without
any dispensation of diclofenac in the preceding year. We also identi-
fied persons with ≥1 new CI during the respective pre‐observation
periods. For each cohort, we calculated age‐standardized proportions
of persons initiating diclofenac in the entire cohort and among persons
with new CIs and we determined the proportion of diclofenac initia-
tors with ≥1 new CI.
Results: Each cohort comprised >10 million persons. Between 2011
and 2014, the proportion of persons initiating diclofenac decreased
by 29% (from 8.2% to 5.8%) among females and by 26% (from 8.5%
to 6.3%) among males. Among persons with ≥1 new CI, the decline
between 2011 and 2014 was higher compared to the entire respec-
tive cohorts, but the difference was less than 5 percentage points
(decline by 33% in women and by 30% in men). The proportion of
diclofenac initiators with ≥1 new CI did not change between 2011
(11.7%) and 2014 (11.5%).
Conclusions:While our study found an overall decline of about 30% in
diclofenac initiation between 2011 and 2014, this trend was largely
independent of the presence or absence of new CIs, suggesting that
physicians are unaware of new absolute CIs. The proportion of
diclofenac initiators with a new CI remained at a high level (at least
one in ten patients), demonstrating the need for research at the pre-
scriber level (e.g., interventional studies) and further measures to
improve patient safety.
955 | Differences among parents when
weighing benefits and risks of potential
treatments to delay insulin dependence in
Type‐1 diabetes in children
Rachael L. DiSantostefano1; Jessie Sutphin2; Kathleen Gallaher2;
Joseph Hedrick3; Carol Mansfield2
1 Janssen R&D, LLC, Titusville, NJ; 2RTI‐Health Solutions, Research
Triangle Park, NC; 3 Janssen R&D, LLC, Raritan, NJ
Background: Type‐1 Diabetes (T1D) onset can be predicted based on
the presence of autoimmune biomarkers identified via screening.
Treatments under development may offer a delay in T1D insulin
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dependence; however, little is understood about patient or parent per-
spectives about the acceptability of these treatments.
Objectives: To investigate parent preferences, and preference hetero-
geneity, for treatments that delay the onset of T1D insulin depen-
dence in children at risk of disease progression.
Methods: A discrete choice experiment survey using an online
research panel assessed the preferences of U.S. parents told to
assume one of their children (<18 years) would become insulin
dependent within 2 years. Respondents were offered a series of
8 choices between 2 hypothetical treatments that would delay
insulin dependence or no treatment (monitoring only). Treatments
were defined by 6 attributes with varying levels (years until insulin
dependence, reductions in the risks of long‐term health complica-
tions, diabetic ketoacidosis, serious infection, injection site reaction,
and nausea). Random parameters logit analysis provided the rela-
tive importance of benefits and risks. Latent class analysis was
used to assess preference heterogeneity.
Results: For parents of children without T1D (n = 901), delaying
insulin dependence, reducing risk of long‐term health complica-
tions, and serious infection were the most important treatment
attributes. These were also the 3 most important for parents of
children with T1D (n = 600), in addition to reducing the risk of
diabetic ketoacidosis. However, there was preference heterogene-
ity and 3 distinct classes of preferences. Class 1 (57% of sample)
valued the benefits most highly, traded off among all treatment
benefits and risks. Class members were more likely to have a col-
lege education, higher self‐reported numeracy, and a child without
T1D. Class 2 (23%) favored monitoring only and placed higher
importance on avoiding treatment risks. Class 3 (20%) had disor-
dered preferences, with membership predicted by Medicaid or no
insurance, male gender, having a child with T1D, and failing com-
prehension questions.
Conclusions: Parents' preferences for treatments to delay T1D
insulin dependence were heterogeneous, with some focusing on
benefits and others on risks, while a third group answered incon-
sistently. Heterogeneity of preferences expressed over the benefits
and harms in this survey provide guidance on what benefit–risk
tradeoffs may be acceptable, and to whom, in future treatments
to delay T1D insulin dependence.
956 | Assessment of colobreathe risk
minimisation measures in the European
Union: a cross‐sectional study
Sigal Kaplan1; Oliver Patino2; Carolyn Rainville3; Terri Madison4
1Teva, Netanya, Israel; 2Teva, Amsterdam, Netherlands; 3Teva, Malvern,
PA; 4Mapi, Lexington, KY
Background: Due to the potential safety concern of cough associ-
ated with the Colobreathe® (colistimethate sodium (CMS)) and
Turbospin inhaler and potential medication errors due to inappropri-
ate handling of the device, the product was approved with a require-
ment for additional risk minimisation measures (aRMM). Following
reports of throat irritation or coughing as a result of capsule break-
age in 2014, the instructions for inhaler use were revised and
enhanced.
Objectives: The objective of this study was to assess the effectiveness
of the aRMM, including the knowledge, receipt, and utilization of CMS
educational materials by HCPs and patients/caregivers, knowledge
regarding common side effects, and correct use of CMS and Turbospin
inhaler.
Methods: A cross‐sectional study was conducted using survey ques-
tionnaires for HCPs and patients/caregivers. The pre‐tested ques-
tionnaires were designed to assess the knowledge, receipt, and
utilization of CMS educational materials. Knowledge of common side
effects and correct use by HCPs and patients/caregivers was also
assessed.
Results: Of 124 HCPs surveyed, the majority of HCPs acknowledged
awareness (86%; 95% CI 78.6–91.9%), receipt (91%; 95% CI 83.6–
95.8%), and utilization (82%; 95% CI 71.9–89.1%) of the CMS edu-
cational materials and had knowledge of the 4 common side effects
associated with CMS (93%; 95% CI 87.0–97.0%). Most HCPs cor-
rectly answered questions regarding the proper use of CMS
(>90%),yet, awareness of the potential for capsule breakage was
moderate (68%; 95% CI 58.1–76.0%). Of the 29 patients surveyed,
almost half of patients/caregivers surveyed were aware of the edu-
cational materials (48%; 95% CI 28.7–68.1%); of those, 69.2%
received the materials and they all utilized them. Most patients/care-
givers had knowledge of common side effects associated with CMS
(82%; 95% CI 61.9–93.7%); however, awareness of the potential for
capsule breakage was low (48%; 95% CI 28.7–68.1%).
Conclusions: The majority of HCPs had a high level of awareness
regarding the minimization of the potentials risks of CMS by proper
use. While the sample size was small, patient/caregiver's knowledge
of potential risks associated with CMS use and proper use of the
Turbospin inhaler appeared high.
957 | Prevalence of antibiotic use,
knowledge and attitudes towards antibiotic‐
free meat, Pennsylvania — 2016
Nkuchia M. M'ikanatha1,2; Rachel A. Smith3; Lisa Dettinger4;
Heather Tate5
1Pennsylvania Department of Health, Harrisburg, PA; 2University of
Pennsylvania Perelman School of Medicine, Philadelphia, PA; 3The
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Pennsylvania State University, University Park, PA; 4Pennsylvania
Department of Health, Exton, PA; 5U.S. Food and Drug Administration,
Laurel, MD
Background: Antimicrobial resistance is a major threat to human
health worldwide. Inappropriate use of antibiotics in humans and agri-
culture fuels emergence of resistance. Understanding public's knowl-
edge and attitudes can inform interventions to promote judicious
use of antibiotics.
Objectives: Assess public knowledge about antibiotics, prevalence
of prescriptions and attitudes towards antibiotic‐free meat.
Methods: In 2016, a weighted probability sample (n = 6,810) of
Pennsylvania adults was asked questions about antibiotic prescrip-
tions and attitudes towards antibiotic‐free meat as part of state‐spe-
cific module in the national Behavioral Risk Factor Surveillance
System (BRFSS).
Results: Among Pennsylvania adults, 40.9% (95% confidence inter-
val [CI], 39.2%–42.6%) responded that they had been prescribed
antibiotics in the previous 12 months and 6.2% (95% CI, 5.0%–
7.7%) of these adults reported that they had persuaded their pro-
viders to prescribe these drugs. Asthmatic adults were significantly
more likely to report receiving antibiotics (59.0% (95% CI, 53.6% ‐
64.3%)) than non‐asthmatic adults (38.6% (95% CI, 36.8%–40.4%))
as were diabetic (55.1% (95% CI, 50.2%–60.0%)) versus non‐dia-
betic (39.1% (95% CI, 37.3%–40.9%)) adults. Females were more
like than males to have been prescribed antibiotics (45.1% of
females (95% CI, 42.7% ‐ 47.4%) vs. 36.3% of males (95% CI,
33.8% ‐38.8%)). Of respondents, 25.2% (95% CI, 23.6%–26.9%)
thought that antibiotics are always appropriate to treat non‐bacte-
rial illnesses (e.g., cough or cold). Although knowledge varied by
demographic characteristics, it increased with education and
income and was lowest among adults with chronic illnesses (e.g.,
asthma, diabetes). Additionally, among males, younger adults (18–
29), 32% (95% CI, 27.8%–37.1%) also thought that antibiotics
should be used to treat viral illnesses as did 27.7% (95% CI,
21.1%–35.5%) of uninsured Pennsylvanians. Overall 42% (95% CI,
40–44%) of the survey participants reported that that they try
to purchase antibiotic‐free meat. This preference was higher
among females (48.8% (95% CI, 46.0%–51.5%)) than males
(34.8% (95% CI, 32.1%–37.7%)).
Conclusions: Inappropriate prescriptions in ambulatory care settings
and deficiencies in the public's knowledge about ineffectiveness of
antibiotics to treat viral infections call for simultaneous interventions
among clinicians and patients. To promote judicious use of antibi-
otics in food animals, additional One Health measures are needed
to engage consumers and to address their expectations and
preferences.
958 | Assessment of the effectiveness of risk
evaluation and mitigation strategies for
Dulaglutide: 18‐ and 36‐month prescriber
surveys
Ayad K. Ali; John J. Kaiser; Ingrid E. Hensley
Eli Lilly and Company, Indianapolis, IN
Background: The anti‐diabetes medication dulaglutide (Trulicity®) had
a Risk Evaluation and Mitigation Strategy (REMS) in the U.S. to ensure
the benefits of the drug outweigh the risk of pancreatitis and the
potential risk of medullary thyroid carcinoma (MTC). The REMS
consisted of a communication plan whose elements included a
healthcare provider (HCP) letter, an HCP factsheet, and a website.
Objectives: To assess the effectiveness of dulaglutide REMS at 18‐
and 36‐months post‐launch.
Methods: Validated web‐based surveys were administered to 401
HCPs who have prescribed dulaglutide to at least one patient in the U.
S. Two waves of surveys were initiated at 18 months (n = 201) and
36 months (n = 200) after product launch to evaluate HCP awareness
of REMS key safety messages of informing HCPs about the risk of pan-
creatitis and the potential risk of MTC; appropriate patient counseling;
discontinuing dulaglutide and ordering confirmatory testswhen pancre-
atitis is suspected; and further evaluating dulaglutide users upon physi-
cal, imaging, or laboratory findings pertaining to the thyroid. Survey
instruments collected information regarding demographics, clinical
practice setting, and the safety messages above. Descriptive univariate
analyses were performed. The REMS program is considered effective if
the majority of HCPs demonstrated awareness of the key safety mes-
sages communicated.
Results: Participants were a reasonable representative sample of
dulaglutide prescribers in the U.S. (50% endocrinologists, 40% primary
care physicians; 7% nurse practitioners; and 3% physician assistants).
Overall, about 27% of HCPs were aware of dulaglutide REMS program
(30% in the 18‐month survey and 24% in the 36‐month survey), which
is consistent with most REMS programs. Awareness of dulaglutide
prescribing information and medication guide was higher than aware-
ness of REMS components (88% and 62%, respectively). Majority of
HCPs who received the REMS letter or REMS factsheet reported they
have read all or some of them. Approximately 97% of HCPs were
familiar with dulaglutide indications and limitations of use. Most of
HCPs were aware of the risk of pancreatitis and the potential risk of
MTC with dulaglutide (93% and 88%, respectively). HCP knowledge
scores of corresponding risks by survey wave were 95% and 86%
for the 18‐month survey, and 91% and 90% for the 36‐month survey.
Conclusions: The surveys showed that dulaglutide REMS program was
effective in communicating the key safety messages, and as a result,
the U.S. Food and Drug Administration has determined a REMS is
no longer required for dulaglutide.
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959 | Characteristics of risk evaluation and
mitigation strategies (REMS) assessment
plans: a review of REMS with ETASU (2014–
2018) using RE‐AIM
Gita A. Toyserkani1; Linda Huynh1; Elaine H. Morrato2
1FDA, Silver Spring, MD; 2University of Colorado, Aurora, CO
Background: The recently published FDA draft guidance for indus-
try on REMS assessments (2019) “encourages applicants and the
research community to develop novel methods for assessing REMS
⋯ [to] help advance the science of post‐market assessment of
effectiveness of risk mitigation strategies.” One such method is
RE‐AIM (Reach, Effectiveness, Adoption, Implementation, Mainte-
nance), an implementation science framework that has been widely
applied to evaluate health interventions (Glasgow, et al 2013) and
is a recognized standard used by the National Institutes of Health.
Objectives: To characterize REMS assessment plans using RE‐AIM
and identify areas for advancing methods for evaluating REMS
programs.
Methods: A review of REMS assessment plans was conducted for
REMS programs approved by the FDA between 1/1/2014–12/31/
2018. REMS assessment plans were eligible if they were: (1) for a new
drug application (NDA) or a biologic license application (BLA), (2)
included elements to assure safe use (ETASU), and (3) were not part of
a shared system. Publicly‐available approval letters through
REMS@FDA were the source of information. Three reviewers cali-
brated the application of RE‐AIMdimensions to each REMS assessment
item using three randomly‐selected assessment plans (Agree-
ment = 75%). Discrepancies were discussed and resolved. Each assess-
ment planwas adjudicated and assessed for gaps in RE‐AIMdimensions.
Results: The median number of assessment items per REMS was 31
(IQR: 21–36). The distribution of items per RE‐AIM criteria per
REMS was: Reach (median = 2 (IQR: 2–4); Effectiveness (median = 2.5
(IQR: 1–4); Adoption (median = 3.5 (IQR: 2–5); Implementation
(median = 18 (IQR: 14–24); Maintenance (median = 0 (IQR: 0–1).
Adoption (among prescriber, health system agents of implementa-
tion) was often more commonly assessed than Reach (population‐
attributable number of patients affected). Assessment of heteroge-
neity of Adoption and Reach was generally absent. Implementation
assessment items were most prevalent for drugs required to only
dispense or administer the drug with evidence of safe‐use conditions
(ETASU D). Effectiveness (patient‐level) and Maintenance assess-
ments were most common among drugs that required patient mon-
itoring (ETASU E).
Conclusions: Implementation science frameworks, such as RE‐AIM,
can be applied to characterize REMS assessment measures and iden-
tify opportunities for standardizing and strengthening their evaluation.
Methods to measure Maintenance are needed to provide real‐world
evidence of their integration into the healthcare system.
960 | Evaluation of the effectiveness of risk
minimisationmeasures targeting physicians on
prescribing practices of thiocolchicoside
containingmedicinal products for systemic use
Sophie Laurence Jouaville1; Carole Ehrhardt2; Marie‐Laure Kürzinger2;
Hanka de Voogd3; Massoud Toussi1
1 IQVIA, La Defense, France; 2Sanofi, Chilly‐Mazarin, France; 3Mylan,
DM, Amstelveen, Netherlands
Background: In 2014, risk minimisation measures (RMMs) concerning
thiocolchicoside (TCC) for systemic use were requested to be imple-
mented in all European countries marketing the product following an
Article 31 Referral procedure. A direct healthcare professional commu-
nication (DHPC) and educational materials (EMs), were distributed to
health care professionals to increase awareness related to genotoxicity
risk.
Objectives: This study aimed to measure the effectiveness of RMMs,
by ascertaining the proportion of targeted physicians who understood
and implemented the latest prescribing conditions and safety informa-
tion about systemic thiocolchicoside provided in the DHPC and EMs.
Methods: A cross‐sectional web‐based survey of prescribers of sys-
temic thiocolchicoside was conducted in France, Greece, Italy and Por-
tugal in 2017. Sampling targets for responding physicians were
determined based on country specific prescribing patterns. Frequency
of correct responses was calculated for six knowledge questions and
information related to recent patients' prescriptions of TCC was ana-
lyzed. Results were provided overall, by country and by physician type
(general practitioners, rheumatologists, orthopaedists‐orthopedic
surgeons).
Results: The recruitment rate (completers/eligible) was 71.4%. Among
651 responding physicians, 68.6% remembered having received either
the DHPC or the EM or both. Knowledge was the highest for contra-
indications to the use of systemic thiocolchicoside, related to patients'
age (85.0%), pregnancy (87.6%), and lactation (80.3%) and was lower
(49.1%) regarding restriction of use in women of childbearing potential
not using contraception. Overall, knowledge of the right indication for
use of systemic thiocolchicoside was 63.2%, while knowledge of dose
and duration of treatment was higher for the oral form (78.9%) than
for the injectable form (55.4%). These results were confirmed by the
analysis of recent patients' prescriptions. Knowledge varied by physi-
cian specialty and country and was higher for physicians who reported
receiving either the DHPC or the EM or both (p = 0.002).
Conclusions: This study revealed geographical as well as across pre-
scribers' specialty contrasts in the knowledge of TCC RMMs. In addi-
tion, the results showed that when risk minimisation materials
(DHPC and EM) receipt was acknowledged by physicians, it signifi-
cantly improved their knowledge and attitude towards appropriate
systemic TCC prescribing to patients.
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961 | Patient registries ‐ has the European
medicines agency patient registry initiative
had an impact on post‐authorisation
mandates?
Bettina K. Rillmann1; Juliane Mills2; Meg Richards3
1PRA Health Sciences, Mannheim, Germany; 2PRA Health Sciences, Blue
Bell, PA; 3PRA Health Sciences, South Kingstown, RI
Background: In 2015, the European Medicines Agency (EMA) put for-
ward an initiative on using data from patient registries to support the
benefit–risk evaluation of medicinal products pre‐ and post‐authorisa-
tion. One of the main aims of this initiative is to foster collaboration
between potential users of registry data such as between pharmaceu-
tical companies and registry holders within healthcare professional and
patient associations, academia and other institutions.
Objectives: This research will describe the current situation of indus-
try‐funded registry studies and to what extend industry is collaborat-
ing already with academia or other institutions. This research will
also explore trends in collaboration between the industry and registry
holders for EMA mandated post‐authorisation studies associated with
the roll‐out of the EMA patient registry initiative.
Methods: Clinicaltrials.gov was searched for registry studies funded
by pharmaceutical companies and conducted in collaboration with
regulators, academia, or other organizations. A study was considered
a company‐funded registry when it was classified as a patient registry
within the database, contained the term “registry” in the study records
or in the study title, had a prospective time perspective and was
labeled as industry‐funded. All registries first posted between 2014
and 2018 were included. The EU PAS register was searched for
EMA requested studies with the term “registry” in the title and
reviewed for collaborations.
Results: Clinicaltrials.gov lists 146 (36%) industry funded registries
which are conducted in collaboration with academia or other organiza-
tions. Most of the studies are single‐country studies of which 58% are
conducted in Europe. 95 (65%) were first posted after 2015. 53 indus-
try funded registries requested by the EMA are currently registered on
the EU PAS register. 13 of those studies are conducted in collabora-
tion with national or regional registries or registry networks of which
7 started after 2015.
Conclusions: There is a close collaboration between industry and aca-
demia on a country basis in conducting registries for a specific product
or disease. Collaboration of industry with registry holders in order to
reduce the initiation of new studies is only seen sporadically, and there
is only little impact on post‐authorisation mandates so far. As one of
the results of the patient registry initiative, specific collaborations
are being established for rare diseases and new therapies such as
cell‐based therapies.
962 | Medical benefit–risk assessment:
Creating the value‐tree an experience from
six case studies
Christine E. Hallgreen1; Shahrul Mt‐Isa2; Ed Waddingham3;
Kimberly Hockley2; Deborah Ashby2
1Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark; 2Faculty of Medicine, School of Public Health,
Imperial College, London, UK; 3Faculty of Medicine, School of Public
Health, Imperial College, L, UK
Background: In the past decade, there has been an increased focus
on structured benefit–risk (BR) assessment approaches and
methods to facilitate regulatory decision making on medicines.
The medical BR decision‐making problem typically involves multiple
conflicting objectives. A key consideration is establishing a sound
set of criteria to evaluate the decision problem. A useful tool when
identifying and visualizing the criteria for BR assessment is using a
value‐tree.
Objectives: To identify challenges related to creating the benefit–risk
value‐tree and to propose ways to address these challenges.
Methods: This study is based on six case studies from the IMI PRO-
TECT project work package 5 ‐ Benefit–risk integration and repre-
sentation (PROTECT BR group). Data on value‐tree creation in
relation to the BR methods BRAT, MCDA and/or SMAA, were
extracted from case study reports, associated supplemental material
and peer‐reviewed publications. A data extraction form was devel-
oped to retrieve information on the value‐tree creation in the source
material. The value‐trees iterations were compared in terms of;
changes in criteria, sub‐criteria and outcome definition, together
with the reasons for these changes. In addition, the final value‐trees
were assessed in relation to the basic properties; completeness,
operationality, non‐redundancy, and minimisation.
Results: Case study teams include medical specialists, statisticians
and decision scientists. All six case studies were retrospective. Five
case studies used a bottom‐up approach in creating the value tree.
For all case studies, value tree creation was an iterative process,
where definitions of objectives were strongly informed by available
data. Across all six case studies, three major challenges were iden-
tified: issues with double counting, completeness, and preference
inconsistency. The issues often arose due to problems with data
availability.
Conclusions: Regardless of the actual benefit–risk assessment meth-
odology that was used, the main challenges in the value tree creation,
in all six case studies, relates to data availability and accessibility.
These challenges should be addressed before implementation in daily
regulatory practice.
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963 | Direct healthcare professional
communications: Awareness, effectiveness
and distribution preferences in Saudi Arabia
Amal Alshatri Almotiry1; Zainab Alhassar2; Zainab Kazim2;
Wala'a Aldebasi2; Najla Alabdulkarim2; Adel Alharf1
1Saudi Food and Drug uthority (SFDA), Riyadh, Saudi Arabia; 2Princess
Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
Background: Direct Healthcare Professional Communication (DHPC)
is one of the risk minimization measures that is used to inform
healthcare professionals (HCPs) about the newly identified risks of
approved medicinal products. Measuring the effectiveness of DHPCs
is important to ensure that this tool is successful in mitigating certain
risks.
Objectives: To measure the awareness, effectiveness and distribution
preferences regarding DHPCs among HCPs in Saudi Arabia.
Methods: A descriptive cross‐sectional study was conducted in Saudi
Arabia in 2017. It employs a short online survey that is distributed ran-
domly to practicing HCPs.
Results: A total of 166 HCPs participated in the survey; 46% physi-
cians, 44% pharmacists and 10% Nurses. The majority of HCPs (86%
physicians, 71% pharmacists and 88% nurses) have never heard of
DHPC letters previously. Most physicians who read the letters agreed
that DHPCs' content has influenced their practice (75%). In assessing
preferences, 83% of respondents showed interest in receiving future
DHPC letters. Furthermore, the most preferred channel of communi-
cating DHPC letters among healthcare professionals was through e‐
mail (67%) and from the Saudi Food and Drug Authority (45%).
Conclusions: HCPs in Saudi Arabia have limited knowledge about
DHPCs. On the other hand, HCPs who had received DHPC letters
acknowledged the importance and impact of this risk minimization
tool on their knowledge and practice. Further research to elucidate
reasons for lack of access to DHPC letters is warranted.
964 | Applying CIRS‐BRAT framework in a
regulatory setting: Updated benefit risk
assessment for fibrinogen concentrate in the
setting of complex cardiac surgery
Alicia W. Gilsenan1; Andres Brainsky2; Susan Colilla2
1RTI Health Solutions, Research Triangle Park, NC; 2CSL Behring, King of
Prussia, PA
Background: Fibrinogen concentrate (FCH) has been successfully used
in perioperative bleeding in complex cardiac surgery (CCS), as reported
in several single center trials; a global, multicenter randomized clinical
trial did not show efficacy superiority over placebo, while the safety
endpoints were favorable to FCH. As part of the 2015 periodic safety
update report (PSUR) submitted to the European Medicines Agency
(EMA), the sponsor conducted a benefit–risk assessment (BRA) using
the CIRS‐BRAT framework, to evaluate the evidence for the use of
FCH in cardiac surgery. The EMA agreed that the benefit–risk profile
was favorable and requested an update of the BRA for the 2018 PSUR.
Objectives: To update the benefit–risk profile of FCH in the clinical
setting of CCS taking into account all published evidence and com-
pleted clinical trials as of April 2018.
Methods: The CIRS‐BRAT framework was followed to establish the
decision frame, identify key benefits and risks and gather and interpret
data. and produce visualizations to display the results. An updated sys-
tematic literature review was conducted to identify new studies pub-
lished since the original BRA. Forest plots were generated to show the
benefits and risks of FCH compared to placebo or standard of care in
randomized and observational studies by key benefits and risks, by
study, and by crude pooled analyses of identified placebo‐controlled
clinical trials.
Results: The original BRA included 6 studies and the updated litera-
ture search identified 1 new randomized clinical trial and 1 new obser-
vational study that met criteria included in the decision frame. The
updated BRA showed that the evaluated benefits (avoidance of alloge-
neic blood product transfusion within 24 hours, survival at 30 days
and avoidance of re‐operation due to bleeding) favored FCH in most
studies. For the risk outcomes, in all studies the point estimates for
TEEs and anaphylactic and hypersensitivity reactions were similar in
the FCH and comparator groups. The benefit–risk profile of FCH in
the setting of complex cardiac surgery was determined to still be
favorable.
Conclusions: The use of a structured approach (CIRS‐BRAT frame-
work) facilitated assessment of a large volume of information in a
complex setting, including both randomized trials and observational
studies. The favorable benefit–risk profile of FCH in the setting of
complex cardiac surgery was reconfirmed.
965 | Impact of European benefit–risk
reassessment procedures on drug prescribing
practices in Denmark
Christine E. Hallgreen; Morten Andersen; Marie L. De Bruin
University of Copenhagen, Copenhagen, Denmark
Background: Since the implementation of the new Pharmacovigilance
legislation (2012), the Pharmacovigilance Risk Assessment Committee
(PRAC) became responsible for the assessment of safety‐related refer-
rals (i.e. reassessments of the Benefit–Risk balance of a (class of) med-
icine(s) in the EU.
Objectives: To determine the public health impact of safety referral
assessments performed by PRAC in terms of intended and unintended
consequences on drug utilization.
Methods: We created a cohort of PRAC safety referrals (Jul 2012‐Sep
2017), and collected from information published on the EMA website:
type, urgent (y/n), start date, ATC, authorisation pathway. Procedures
were followed up until PRAC recommendation, which was categorized
as suspension/revocation, general warning, drug–drug interactions
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(DDI), restricted population, monitoring, safety confirmed (not mutu-
ally exclusive). Quarterly rates (Q1–2013 to Q3–2018) of drug utiliza-
tion per 10000 inhabitants in Denmark were calculated (DDDs from
the DK Health Statistics/population size from Statistics DK), and by
consensus it was determined whether prescribing decreased (y/n).
Multivariate logistic regression was used to determine the factors
associated with decreased use.
Results: 45 safety referrals were started, of which 4 had not received
PRAC recommendation by Sep 2017 and 1 concerned a broad class
referral of RAS‐acting agents, leaving 40 procedures for inclusion. Most
referrals concerned nervous system products (17.5%), followed by
products for blood and blood forming organs, musculoskeletal disease,
respiratory disease and genito‐urinary disease (all 12.5%). Average time
to PRAC recommendationwas 247 days. 20 productswere excluded for
impact analyses, as they were not marketed in DK, hospital use only,
OTC products, or use was too low (<1/10000). For the 2 referrals,
where all products were recommended to be withdrawn from the mar-
ket, drug use decreased just for one; in the other case, the recommenda-
tionwas not endorsed by CHMP.Of the remaining 18 referrals, drug use
decreased for 9 (50%). None of the studied indicators was significantly
associated with decrease in use. Recommendations to avoid DDI and
those to monitor patients showed a slight trend towards decreased
used after the referral.
Conclusions: For half of the referrals drug utilization of the products
under investigation decreased. However, for a subset of referrals this
was not in line with the PRAC recommendations and can be regarded
as an unintended consequence. For those where usage decreased it is
also uncertain whether it were the right patients that stopped using
the drug.
966 | Do conflicts of interest predict
interpretation of drug safety research? An
analysis of Authors' opinions on venous
thromboembolic risks of oral contraceptives
Barbara Mintzes
School of Pharmacy and Charles Perkins Centre, University of Sydney,
Sydney, Australia
Background: Oral contraceptives (OCs) are used by large populations
of mainly young, healthy women. Therefore, tolerance for rare, serious
harm is lower than for medicines used to treat or prevent serious dis-
ease. Epidemiological research has found higher risks of venous
thromboembolism (VTE) with specific progestins in OCs: desogestrel
and gestodene, from 1995, and drospirenone, from 2009. In both
cases older, less costly levonorgestrel or norethindrone containing
(‘second generation’) OCs had lower risks. European Medicines
Agency and the US Food and Drug Administration reviews supported
these risk differences; nevertheless, controversy persists.
Objectives: This study examines whether an association exists
between financial conflicts of interests of authors of secondary litera-
ture on VTE risks of OCs and interpretation of the research evidence.
Methods: Design: retrospective analysis of articles citing epidemiolog-
ical studies comparing drospirenone‐containing OCs with second gen-
eration OCs from Jan 1, 2010 to Dec 31 2016. Setting: Web of
Science search for articles citing at least 1 of 13 observational studies
on VTE risks of drospirenone‐containing OCs vs. second generation
OCs. Articles were included if OC VTE risks were mentioned in the
title or abstract or accounted for >50% of content. Outcome measure:
Authors' opinions on VTE risks of drospirenone‐ containing OCs and/
or desogestrel/gestodene‐ containing OCs vs. second generation OCs
(higher, equivalent, or neutral) vs. pharmaceutical industry funding
(present, absent, or no disclosure). Secondly, key stated rationales
are examined. Statistical analysis: Relative risks and 95% confidence
intervals calculated using SPSS 22.
Results: Of 481 citations, 148 met inclusion criteria, and 137/148
(93%) stated a position on VTE risks. In 60/137 (44%), authors
declared financial conflicts, 59/137 (43%) declared none, and 18
(13%) did not disclose. Among those with conflicts, 37/60 (62%)
judged drospirenone's VTE risks as equivalent to second generation
OCs vs. 5/59 (9%) with no conflicts, RR = 7.3 (95% CI 3.1 to 17.2).
In 109 both drospirenone and desogestrel/gestodene VTE risks were
discussed; opinions were similar in 104 (95%). The most commonly
cited reasons for judgments of equivalence were methodological limi-
tations of administrative data.
Conclusions: There was a strong association between financial con-
flicts of interest and authors' positions. These findings raise questions
about commercial influence on this ongoing scientific debate.
967 | Post market safety communications
for sodium glucose co‐transporter 2
inhibitors. An international case study of
regulatory decision‐making
Alice L. Bhasale1; Barbara Mintzes1; Ameet Sarpatwari2
1University of Sydney, Sydney, Australia; 2Harvard University, Boston,
MA
Background: Regulators use post‐market alerts to warn prescribers of
unexpected safety issues. However the US Food and Drug Adminis-
tration (FDA), Health Canada (HC), Australia's Therapeutic Goods
Administration (TGA), and the European Medicines Agency (EMA) dif-
fer considerably in these alerts. The reasons for this divergence are
unclear.
Objectives: To compare decision‐making about post‐market safety
communications for SGLT2 inhibitors (SGLT2s) by the FDA, HC,
TGA, and EMA.
Methods: We conducted an in‐depth process‐tracing case study of
post‐market safety communications for SGLT2s, for which marketing
approval occurred after major pharmacovigilance changes in all juris-
dictions except Canada. Information was taken from publicly available
regulatory documents in each jurisdiction from marketing approval to
July 2018. Analysis focused on regulatory interventions for five safety
issues: diabetic ketoacidosis (DKA), amputation, serious genitourinary
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infections, acute kidney injury (AKI) and bone effects. Data sources,
decision‐making processes, actions, and their timing were assessed.
Results: The FDA communicated all five safety concerns, HC four, and
the TGA and EMA two each. All regulators warned about DKA and
amputation and added warnings to labels. The three discordant safety
issues led to label changes for 16/21 (76%) drugs but only 10/21
(47%) were subject to advisories. Regulators warned less often or
more slowly if they had reviewed the risk at approval, even for more
serious events (amputation [HC], AKI (EMA) and fractures [EMA,
TGA]. Lags from first to last regulator on the same safety issue ranged
from 3 to 13 months. After the first advisory from another regulator,
the longest time to respond by HC was 402 days (bone effects),
FDA 242 days (AKI), TGA 90 days (DKA), EMA 42 days (DKA). EMA
label changes without advisories were prompted by routine periodic
safety reports or company‐submitted label changes, and were prod-
uct‐focused. Accordingly, FDA warned of serious genitourinary infec-
tions in all SGLT2s, whereas EMA did so in only one (canagliflozin).
The TGA provided the least information about decision‐making; EMA
the most.
Conclusions: The FDA communicated most but was not always the
fastest. A lack of EMA advisories reflected a more product‐focused
approach; this may relate to EMA policy regarding centralized commu-
nication for only certain label changes. Little information was provided
on the triggers for warnings; though TGA and HC tended to follow
larger regulators. The impact of communication practices on prescrib-
ing merits further study.
968 | Risk assessment (RA) in pulmonary
arterial hypertension (PAH) ‐ overview and
comparison
Rose Ong; Lilla Di Scala; Camille Du Roure; Rainer Zimmermann;
Daniel Rosenberg
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Background: PAH is a rare, life‐threatening disease. RA based on
patient and clinical characteristics is essential in treatment decisions,
but few publications have compared different RA strategies.
Objectives: To provide an overview and compare main RA strategies
in PAH.
Methods: A literature review was performed to identify RA strategies
in PAH. Key elements e.g. development, variables, assessment algo-
rithms and implementation were extracted and compared.
Results: We identified 4 main strategies: REVEAL risk score (RRS) and
strategies from French (FS), German (DS) and Swedish (SS) experts. All
strategies assessed 1 yr mortality risk. RRS was developed based on
Cox regression models using data from 2716 incident and prevalent
patients in the REVEAL registry. Variables independently associated
with survival were included in RRS. FS, DS and SS were developed
based on European PH guidelines and abbreviated by expert opinion.
RRS, DS and SS assigned patients into 5, 3 and 3 risk levels using up to
13, 6 and 8 variables, respectively. Each variable and risk level were
assigned a score. In RRS, the sum of all scores represented overall risk.
In DS and SS, average score of all variables was rounded to assess
overall risk. In FS, patients with ≥3 of 4 variables in the low risk cate-
gory were considered low risk. All strategies except FS allowed miss-
ing data, but impact of missing data on prediction accuracy has not
been thoroughly examined. All strategies included exercise perfor-
mance and right atrial pressure (RAP). Cardiac index (CI) was included
in all but RRS. RRS also included PAH etiology, age, gender, comorbid-
ity and vital signs. RA strategies were implemented in incident patients
from various registries started between 2006–2009 using data at
baseline (RRS N = 504; FS N = 1017; DS N = 1588; SS N = 530) and
1 yr follow‐up (FS N = 1017; DS N = 1094; SS N = 383; RRS: not stud-
ied). For all strategies, low risk patients had 1 yr survival of ≥95%
(Kaplan–Meier estimate). In an exploratory analysis (N = 603), replac-
ing invasive (RAP, CI) with non‐invasive variables (BNP/NT‐proBNP)
in FS had similar 1 yr survival in low risk patients. RRS had a c‐index
of 0.724. For FS, DS and SS, survival for all risk levels was significantly
different (log‐rank test p < 0.001).
Conclusions: Despite differences, all strategies identified patients who
achieved low risk status. Several new therapies were approved in
recent years; therefore, prediction accuracy of RA strategies in current
datasets should be evaluated. Replacing invasive clinical variables with
non‐invasive ones in RA reduces disease burden. Trade‐off between
invasiveness and model accuracy remains to be examined.
969 | What's the harm? Exploring evidence
of risk, seriousness of harm and prescriber
advice in medicine safety advisories
Lucy Perry1; Alice Bhasale1; Alice Fabbri1; Joel Lexchin2; Lorri Puil3;
Barbara Mintzes1
1University of Sydney, Sydney, Australia; 2York University, Toronto, ON,
Canada; 3University of British Columbia, Vancouver, BC, Canada
Background: Safety advisories are used by national medicines regula-
tors to communicate risks associated with the prescribing and use of
medicines. These advisories may also contain recommendations for
safer prescribing. It is currently unknown how the strength of the evi-
dence cited and the seriousness of the observed or theoretical harm
relate to the type of risk minimisation advice provided, or whether dif-
ferent regulators communicate different advice about the same safety
issue. These potential disparities could lead to national differences in
information available to prescribers to make informed choices.
Objectives: First, to determine the characteristics of and the relation-
ship between the strength of evidence cited, the seriousness of the
harm and regulators' recommendations to prescribers. Second, to
determine whether there are variations in the information provided
to prescribers and patients in medicine safety advisories about the
same harm released by regulators in the United States, Canada, the
United Kingdom and Australia.
Methods: This retrospective study analyses the content of safety
advisories issued by the US Food and Drug Administration (FDA),
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Health Canada (HC), the Australian Therapeutic Goods Administration
(TGA) and the UK Medicines and Healthcare products Regulatory
Agency (MHRA) from 01 January 2007 until 31 December 2016.
We will assess safety issues for which all included regulators had
issued an advisory about an approved medicine or medicine class.
Evidence cited, seriousness of the harm, and the actions recom-
mended to prescribers (e.g. monitoring patients or using alternative
medicines) will be extracted. Frequency counts and regression analy-
sis will be used to identify associations between regulators, the
strength of evidence, seriousness of the harms and the risk mitiga-
tion actions recommended.
Results: We identified 1441 advisories (FDA = 382 MHRA = 469
HC = 370 and TGA = 220), grouped into 680 drug safety concerns.
Of these, 70/680 (10.3%) were eligible for inclusion as all the regula-
tors that had approved the medicine or class had also issued an advi-
sory on the specific safety concern. Prescribing advice, of any kind,
was provided most often by the FDA: in 47/53 (88.7%) of included
advisories, followed by the MHRA in 55/66 (83.3%) advisories. The
TGA and HC included prescribing advice less often, in 42/53 (79.3%)
and 39/50 (78.0%) respectively.
Conclusions: We hypothesize that the individual regulatory authority
and the seriousness of the harm identified are the major explanatory
variables for action(s) recommended by the regulator.
970 | Risk communication in community
pharmacies ‐ impact on self‐medication
Hristina Lebanova1; Radiana Staynova2
1Medical University‐Pleven, Pleven, Bulgaria; 2Medical University‐
Plovdiv, Plovdiv, Bulgaria
Background: Self‐medication is defined as the selection and use of
medicines by individuals (or a member of the individuals' family) to
treat self‐recognized or self‐diagnosed conditions or symptoms.
Appropriate self‐medication has many benefits but it is also linked to
potential risks such as incorrect diagnosis, delays in seeking medical
advice when needed, infrequent but severe adverse reactions, danger-
ous drug interactions, incorrect manner of administration, incorrect
dosage, incorrect choice of therapy, masking of a severe disease and
risk of dependence and abuse.
Objectives: The aim of the study was to assess pharmacists' attitudes
and previous experience with risk communication on self‐medication
in community pharmacies in Bulgaria.
Methods: An anonymous, questionnaire‐based, descriptive study was
performed. A prevalidated close‐ended questionnaire was distributed
among random sample of community pharmacists in Bulgaria. Data
was analyzed using SPSS v.19.
Results: A total of 99 questionnaires were collected. 60.6% of the
responders claim that patients very often consult them about their
self‐medication practices but rarely about possible adverse drug reac-
tions and other drug‐related problems such as drug interactions.
51.5% of pharmacists consider presenting information about risks as
a mandatory part of the pharmaceutical consultation and the majority
of them (87.9%) believe that it could affect patients' decisions.
According to 18.2% of the responders up to 80% of self‐medicating
patients do not use their over‐the‐counter medicines as recommended
in the patient leaflet. 63.6% of the responders believe that over‐the‐
counter medical products have high potential for drug misuse and
abuse and 12.1% consider them with a substantial potential for drug
interactions.
Conclusions: Data suggests that patients consider over‐the‐counter
medicines safe and rarely seek information about possible risks. The
conducted pilot study showed that pharmacists should be the primary
and pro‐active source of information about risks of self‐medication
products.
971 | Efficacy and safety of tyrosine‐kinase
inhibitors as first‐line therapy in EGFR
mutant‐harboring advanced non‐small cell
lung cancer patients: A network meta‐
analysis
Abdullah Alanazi; Ismaeel Yunusa; Tewodros Eguale
MCPHS University, Boston, MA
Background: Epidermal growth factor (EGFR) mutation is presented in
about 10–15% of all Non‐Small cell lung cancer (NSCLC) cases in the
US. Five tyrosine kinases (TKIs) are approved as first‐line treatments
for NSCLC patients with positive EGFR mutation in the US; erlotinib,
gefitinib, afatinib, dacomitinib, and osimertinib. Most randomized clin-
ical trials (RCTs) compare one of these drugs with platinum‐based che-
motherapy (PBCT) and there is limited head‐to‐head trials that directly
compared EGFR‐TKI's. Clinicians needs to make a choice among mul-
tiple treatment options and a network meta‐analysis (NMA) enables
the comparison of EGFR‐TKI's simultaneously, even if some were
never compared directly.
Objectives: To compare the efficacy and safety of EGFR‐TKI's as first‐
line treatment in patients with locally advanced, metastatic NSCLC
with positive EGFR mutation.
Methods: We searched the following databases; PubMed, Embase,
Cochrane Library, and ClinicalTrials.gov for relevant articles up to
December 2018. We selected RCTs comparing at least 2 TKIs or a
TKI with PBCT. We performed a frequentist random‐effects NMA
using the multivariate meta‐analysis approach. The surface under the
cumulative ranking curve (SUCRA) was used to determine the proba-
bility that a given TKI would be the best for efficacy and safety. Using
SUCRA values, we created a cluster ranking plot to visualize both effi-
cacy and safety ranks as a guide for clinicians in decision making.
Results: Fifteen eligible trials (3750 patients) were included. There
were statistically significant differences between someTKIs and PBCT
for overall survival (OS), progression‐free survival (PFS) and grade 3 or
higher adverse events. PFS results suggests that dacomitinib had
highest probability of being the most effective (SUCRA, 75.9%),
followed by, osimertinib (SUCRA, 69.5%), erlotinib (SUCRA, 59.9%),
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afatinib (SUCRA, 55.9%), gefitinib (SUCRA, 36.1%), PBCT (SUCRA,
2.7%). We observed a similar ranking trend for OS except for the fact
that dacomitinib and osimertinib has no OS data. Adverse events
results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA,
78.9%) has the highest probability of being the safest. Upon simulta-
neously visualizing efficacy and safety in cluster plots, osimertinib,
gefitinib, and erlotinib formed a cluster for the most effective and safe
TKIs while dacomitinib and afatinib formed a cluster for lesser safety
and effective TKIs.
Conclusions: This NMA suggests that osimertinib, gefitinib, and erloti-
nib might be the most efficacious and safest TKIs.
972 | Use of postapproval safety studies in
the evaluation of safety concerns listed in the
European risk management plan of two
mature TNF inhibitors
Suzan Esslinger1; Marijo Otero‐Lobato1; Wim Noël2; Johnnie Lee3;
Michael Clark3; Anja Geldhof1
1 Janssen Biologics BV, Leiden, Netherlands; 2 Janssen Cilag NV, Zemst,
Belgium; 3 Janssen, LLC, Springhouse, PA
Background: In March 2017, revision 2 of Good pharmacovigilance
practice (GVP) Module V regulating the European risk management
plan (EU‐RMP) came into effect. Consequently, Janssen as the Mar-
keting Authorization holder (MAH) of two mature TNF inhibitors
(TNFi) was requested to re‐evaluate the safety concerns included in
the EU‐RMP and provide justification for keeping, removing or re‐clas-
sifying each of them.
Objectives: To develop a scientifically‐robust and consistent approach
that could be used for the evaluation of the EU‐RMP safety concerns
for the two TNFi (REMICADE [originator infliximab] and SIMPONI
[originator golimumab]), but also for other Janssen products.
Methods: Three independent algorithms informing the decision mak-
ing were developed for each risk category within the EU‐RMP. These
algorithms were composed of a set of questions to determine whether
the safety concerns were sufficiently characterized or needed further
analysis; whether risk minimization measures were in place and ade-
quate; and whether ongoing pharmacovigilance activities were likely
to support further characterization of the risk. A wide range of data
were analyzed: regulatory history, clinical data, post‐approval safety
study data, product information, trending analyses from the MAH's
global safety database and the availability/need for risk minimization
measures.
Results: A total of 13 and 7 post‐approval safety studies (ongoing and
completed) for originator infliximab and originator golimumab, respec-
tively, were included in the analysis. Studies were scrutinized in terms
of strength of evidence, length of follow‐up, incidence and indicators
of potential causality. Studies were also analyzed as to their potential
to further characterize these outcomes. Based on this comprehensive
evaluation, using the algorithms as a guidance, and taking all available
data sources and opportunities for risk minimization measures into
account, about 75% of the safety concerns were concluded to qualify
for removal without jeopardizing the effectiveness of the RMP.
Conclusions: Well‐designed post‐approval studies, along with other
data sources and risk minimization tools, are important to help charac-
terize a medicine's safety profile, thereby allowing to keep its EU‐RMP
contemporary while minimizing unnecessary burden to stakeholders.
973 | Use of immune checkpoint inhibitors
and risk of immune‐related adverse events
among patients with advanced melanoma: A
systematic review and network meta‐analysis
Ching‐Yuan Chang; Ching‐Yu Wang; Haesuk Park;
Wei‐Hsuan Lo‐Ciganic
University of Florida, College of Pharmacy, Gainesville, FL
Background: Immune checkpoint inhibitors (ICIs) have emerged as
effective treatment options with increasing overall survival for
advanced melanoma. Immune‐related adverse events (AEs) are an
increasing safety concern of ICIs, but little is known about the risk of
immune‐related AEs varies by ICI.
Objectives: We conducted a network meta‐analysis comparing the
risk of immune‐related AEs among different therapies for advanced
melanoma.
Methods: We systematically searched for phase II and III randomized
controlled trials (RCTs) of advanced melanoma from PubMed/
MEDLINE, EMBASE, Web of Science, and Scopus (01/01/2010–06/
30/2018). RCTs were included if they reported any immune‐related
AEs (e.g., pruritus, colitis, hypothyroidism, and hepatitis) comparing
ICIs (i.e., ipilimumab, nivolumab, pembrolizumab) with chemotherapies
(e.g., dacarbazine), different ICIs, or different doses of the same ICI.
Bayesian network meta‐analysis with Markov Chain Monte Carlo sim-
ulation was used to compare therapies simultaneously. We applied
non‐informative prior distribution, and random‐effect generalized lin-
ear models. Based on the pooled odds ratios (ORs) and 95% credible
intervals (95% CrI; Bayesian equivalent of confidence intervals), we
estimated the probability for immune‐related AEs for each treatment.
Results: Ten RCTs were included (n = 5,349 participants). Four RCTs
compared ICIs to chemotherapy. Six RCTs compared different ICIs
and/or different doses. Compared to chemotherapies, none of the ICIs
were associated with any increased immune‐related AE risk (point
estimates of the pooled ORs ranged from 0.41 to 3.20, all p‐values
>0.05). Within ICIs, compared to ipilimumab 10 mg/kg, a decreased
risk of immune‐related AEs was observed for ipilimumab 0.3 mg/kg
(OR = 0.13, 95% CrI = 0.02–0.77) and nivolumab 3 mg/kg (OR = 0.26,
95% CrI = 0.09–0.78). Except comparing to ipilimumab 0.3 mg/kg,
pembrolizumab 2 mg/kg was associated with a decreased risk com-
pared to other ICIs (point estimates of the pooled ORs ranged from
0.19 to 0.72, all p‐values <0.05). No association was found among
other ICI comparisons. The top three therapies with the lowest prob-
abilities for immune‐related AEs were ipilimumab 0.3 mg/kg,
pembrolizumab 2 mg/kg, and nivolumab 3 mg/kg.
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Conclusions: The risk of immune‐related AEs of ICIs was not different
from chemotherapies. Among ICIs, ipilimumab 0.3 mg/kg,
pembrolizumab 2 mg/kg, and nivolumab 3 mg/kg may be preferred
options for patients with advanced melanoma at high risk of
immune‐related AEs.
974 | Utilization of PCSK9 inhibitors in an
Italian region during the first year of access to
National Healthcare Service reimbursement
Carlo Piccinni1; Ippazio Cosimo Antonazzo2,3; Aldo Pietro Maggioni1;
Antonella Pedrini1; Silvia Calabria1; Giulia Ronconi1; Letizia Dondi1;
Nello Martini1; Giuseppe Roberto3; Tiziana Sampietro4;
Francesco Sbrana4; Beatrice Dal Pino4; Federico Bigazzi4;
Giuseppa Lo Surdo5; Elisabetta Volpi5; Stefania Biagini5; Rosa Gini3
1Fondazione ReS (Ricerca e Salute) – Research and Health Foundation,
Rome, Italy; 2University of Bologna, Bologna, Italy; 3Agenzia Regionale di
Sanità della Toscana, Florence, Italy; 4 Lipoapheresis Unit, Reference
Center for Diagnosis and Treatment of Inherited Dyslipidemias ‐
Fondazione Toscana Gabriele Monasterio, Pisa, Italy; 5Hospital Pharmacy,
Fondazione Toscana Gabriele Monasterio, Massa, Italy
Background: Italy has a single‐payer universal healthcare system.
Evolocumab and alirocumab (PCSK9i) were approved in Italy in 2017
for the treatment of hyperlipidemia. Due to their high cost, reimburse-
ment was restricted to very high‐risk patients in primary or secondary
cardiovascular prevention who had no benefit from, or were intolerant
to, oral lipid lowering therapies (LLT).
Objectives: To characterize patients treated with PCSK9i in Tuscany
(Italy) and describe the pattern of use during the first year of
reimbursement.
Methods: Patients claiming at least one PCSK9i inTuscany (3.7 million
inhabitants) from July 1st 2017 to June 30th 2018 were selected from
health administrative databases (HAD). Use of LLT and persistence (no
gap ≥60 days between subsequent prescriptions) in the previous six
months, as well as comorbidities since 1996, were described. In the
subpopulation starting PCSK9i in 2017, adherence (proportion of days
covered≥75%), persistence (no gap ≥30 days) and concomitant LLT
during the first six months of treatment were evaluated.
Results: Two hundred sixty‐nine PCSK9i new users (7.2 per 100,000
inhabitants) were included in the cohort: 176 used evolocumab and
93 alirocumab. Patients were mainly male (71.0%), ≥51 years old
(63.2%), in secondary prevention (70.2%) and affected by FH
(53.5%). In the cohort, 66 patients (24.5%) had diabetes and 12
(4.5%) chronic renal failure. Among secondary prevention patients,
the first PCSK9i prescription occurred on average 4.9 years after the
last cardiovascular event. During the six months before PCSK9i initia-
tion, 165 patients (61.3%) received high potency LLTs (HPLLT), and
78% of them were persistent; 24 additional patients (7.0%) were per-
sistent to non‐high potency LLT. During the first six months of treat-
ment (data available for 105 PCSK9i users), 83 patients (79.0%) were
adherent, 78 (74.3%) were persistent. 53 patients (50.5%) used
PCSK9i in monotherapy, whereas 36 (34.3%) received a concomitant
HPLLT.
Conclusions: Utilization of PCSK9i, in the first year of reimbursement,
was low. Patients were mainly in secondary prevention and persistent
to previous LLT, consistently with reimbursement access criteria.
Patients previously non‐persistent to LLT might have been involved
in clinical trials with no treatment records in HAD. During the first
six months, PCSK9i were mainly used in monotherapy and with high
adherence and persistence. This timely work sets the stage for future
longer‐term studies useful to improve appropriateness of use, drug
access and public healthcare assistance sustainability.
975 | Trends in biologic utilization for the
Management of Juvenile idiopathic arthritis in
the United States, 1997–2018
Kathleen M. Andersen1,2; Daniah Basodan3; Xintong Li1,2;
G. Caleb Alexander1,2,4
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
2Johns Hopkins University, Baltimore, MD; 3University of Alberta,
Edmonton, AB, Canada; 4 Johns Hopkins Medicine, Baltimore, MD
Background: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatological disease in pediatrics and associated with sig-
nificant morbidity and health care spending. Despite many new bio-
logic therapies, little is known regarding how JIA treatment has
changed over time.
Objectives: To describe annual volume of biologic prescriptions for
oligoarticular and polyarticular JIA in the United States (US) from
1997, the year the first biologic of interestwas approved, through2018.
Methods: We used the OptumLabs® Data Warehouse, a large data-
base with de‐identified administrative claims for the privately insured,
between November 1997 and October 2018. We focused on individ-
uals with a diagnosis of JIA (ICD‐9 714.3, ICD‐10 M08); we also
included persons with a rheumatoid arthritis code under age 20
(ICD‐9 714.X, ICD‐10 M06). We quantified use of tumor necrosis fac-
tor inhibitors (TNFi), abatacept, rituximab and tocilizumab, and
reviewed product approval dates and changes in major US clinical
treatment guidelines to provide qualitative context.
Results: Among the products of interest, a total of 29,537 unique pre-
scriptions were identified, with prescription volume increasingly
steadily over the years examined. Approximately three‐fifths (59%)
of prescriptions were for females, and the median age of biologic
recipients was 16 years (interquartile range 13–18 years). Etanercept
accounted for approximately 41% of total prescriptions and increased
relatively steadily between 1998 and 2018, whereas adalimumab
accounted for more than half (54%) of total prescriptions and
increased gradually between 2002 and 2007, moderate between
2007 and 2014 and sharply between 2014 and 2018. Certolizumab
pegol, while not approved for use in JIA in the US, comprised approx-
imately 3% of all biologic prescriptions, while other biologics
accounted for less than 1% of total volume observed.
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Conclusions: To our knowledge, this study is one of the first to exam-
ine long‐term trends in the biologic treatment of JIA in the US.
Despite the advent of novel inhibitors of interleukins, B‐cells and T‐
cells, the market remained dominated by two TNFi during the period
we examined. Further analyses will examine patient‐level factors asso-
ciated with biologic initiation, adherence and persistence in children
and adolescents with JIA, as well as the effect that utilization manage-
ment strategies, clinician and patient preferences may have on the
patterns observed.
976 | Rates of major adverse cardiovascular
events (MACE) and revascularization among
patients with psoriasis or psoriatic arthritis
treated with apremilast, biologics, DMARDs,
and corticosteroids in the US MarketScan
database
Rebecca Persson1; Katrina W. Hagberg1; Ellen Qian1;
Catherine Vasilakis‐Scaramozza1; Steve Niemcryk2; Michael Peng2;
Maria Paris2; Anders Lindholm2; Susan Jick1,3
1Boston Collaborative Drug Surveillance Program, Lexington, MA;
2Celgene Corporation, Summit, NJ; 3Boston University School of Public
Health, Boston, MA
Background: Patients with psoriasis or psoriatic arthritis (Psor/PsA)
are at increased risk of cardiovascular events.
Objectives: To compare rates of MACE and revascularization by treat-
ment type in patients with Psor/PsA.
Methods: We conducted a population‐based cohort study of treated
Psor/PsA patients in the MarketScan database in 2014–2016. The
cohort entry was the date of the first prescription for a study drug
(apremilast only or in combination, anti‐tumor necrosis factor‐α (anti‐
TNF‐α) biologics only, other biologics and disease‐modifying antirheu-
matic drugs (OBDs) only, corticosteroids only, OBDs + corticosteroids,
and anti‐TNF‐α biologics with OBDs and/or corticosteroids) after
March 21, 2014. Patients were followed from cohort entry through
censor date (first of date patient became a case, end of record, or
Dec 31, 2016). MACE was defined as inpatient myocardial infarction,
stroke or cardiac arrest; revascularization was a revascularization pro-
cedure without MACE; all ≥7 days after cohort entry. A patient was
considered currently exposed from prescription date through prescrip-
tion duration +30 days. We calculated incidence rates (IRs) and 95%
confidence intervals per 100 patient‐years. We compared IRs to OBDs
only using Poisson regression.
Results: The study population included 124,714 patients (median age:
51 years, 51% female, 3.9% serious cardiovascular disease (CVD) his-
tory). IRs were low for both outcomes, and few differences between
treatments reached statistical significance. Among the 569 MACE
cases, IRs were as follows: for apremilast only (0.22 [0.11, 0.39]),
anti‐TNF‐α biologics only (0.22 [0.18, 0.26], p < 0.001 vs. OBDs only),
OBDs only (0.36 [0.29, 0.43]), anti‐TNF‐α biologics with OBDs and/or
corticosteroids (0.39 [0.30, 0.51]), corticosteroids only (0.41 [0.32,
0.52]), apremilast in combination (0.56 [0.29, 0.98]), and OBDs + cor-
ticosteroids (0.64 [0.43, 0.91], p = 0.005 vs. OBDs only). Among the
580 revascularization cases, IRs were as follows: for apremilast only
(0.22 [0.11, 0.39], p = 0.047 vs. OBDs only), anti‐TNF‐α biologics only
(0.28 [0.23, 0.33], p = 0.005 vs. OBDs only), and OBDs only (0.40
[0.33, 0.49]). IRs for other exposures were between 0.36 and 0.43.
Among patients with no serious CVD history, IRs were generally lower
but relative effects between study drugs were consistent with the
main analyses.
Conclusions: Rates of MACE and revascularization were low for
treated Psor/PsA patients and generally were similar across
treatments.
977 | Biosimilar safety dashboard to assess
switching in veterans
Francesca Cunningham1; Ashir Shurmunov1; Diane Dong1;
Cedric Salone1; Jennifer Zacher1; Peter Glassman2
1Department of Veterans Affairs, Hines, IL; 2Department of Veterans
Affairs, Los Angeles, CA
Background: Biosimilar interchangeability has not been established for
biosimilars used in the US. Due to the rising cost of biologics,
healthcare systems will continue to use newly marketed biosimilars.
It is important to monitor the safety and effectiveness of switching
patients to biosimilars. The Department of Veterans Affairs (VA)
developed a prototype dashboard to allow for real‐time tracking and
safety monitoring of biosimilar switchers.
Objectives: To describe the real‐time biosimilar prototype dashboard
developed to assess biosimilar utilization, switching patterns, and out-
comes temporally associated with switching in Veteran patients.
Methods: This was a descriptive analysis of outpatients given
infliximab from 1/1/16–1/31/19 and switched to/from the originator
infliximab or a biosimilar (DYYB or ABDA). A real‐time infliximab
safety dashboard was developed using prescription, diagnosis and pro-
cedure data obtained from the corporate data warehouse. Patients
were identified as single switchers (only 1 switched product) or multi-
ple switchers (more than one product switch). Patient characteristics,
utilization, switching patterns, and outcomes such as adverse drug
events (ADE) were assessed. ADEs included anaphylaxis, angioedema,
angina, fatigue, headache, jaundice, myalgia, rash, and weight loss.
Results: A total of 4,814 infliximab patients (88% male) were identified
during the evaluation period. Of those, 1,690 (35%) patients had at
least one switch, and 1,024 (61%) were single switchers only. Of the
remaining 666 (39%) multiple switchers, 105 (16%) switched back to
the originator product after any biosimilar administration. Among all
switchers, 930 (55%) patients switched from originator to biosimilar,
607 (36%) had a biosimilar to biosimilar switch, and 153 (9%) switched
to an originator product from a biosimilar. Of single switchers, 335
(33%) and 69 (7%) patients had at least one ADE or hospitalization
respectively. For multiple switchers, 172 (26%) and 38 (6%) patients
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had at least one ADE or hospitalization respectively after the most
recent switch. Among recent biosimilar to biosimilar switchers, 138
(23%) had at least one ADE and 22 (4%) had at least one
hospitalization.
Conclusions: The biosimilar dashboard allows for real‐time assessment
of biosimilar utilization, switching patterns, and monitoring of safety
outcomes such as ADEs and hospitalization. This provides timely and
valuable information to providers and decision makers. In this early
assessment it appears that more switches do not correlate to
increased ADEs or hospitalizations. Future assessments will also
include outcomes for non‐switchers.
978 | Biosimilar use in the United States: An
analysis of filgrastim and infliximab
Sarah K. Dutcher1; Efe Eworuke1; Elnara Fazio‐Eynullayeva2;
Elizabeth Dee2; Michael D. Nguyen1; Catherine A. Panozzo2
1Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School and Harvard Pilgrim Health Care Institute, Boston, MA
Background: The Biologics Price Competition and Innovation Act of
2009 created an approval pathway for biosimilars in the U.S. As more
biosimilars are approved, accurate identification of biologics and
biosimilars in claims data and understanding use patterns and patient
characteristics are fundamental needs for conducting future post‐mar-
keting studies.
Objectives: To identify users of filgrastim and infliximab biologics and
biosimilars in 17 Data Partners in the Sentinel System, and describe
their use patterns and patient characteristics.
Methods: Filgrastim biologic and biosimilar products (Neupogen,
Zarxio, Granix) and infliximab biologic and biosimilar products
(Remicade, Inflectra, Renflexis) were included. Product use was
assessed monthly from 1/1/2015–1/31/2018 via administrations in
healthcare encounters (HCPCS codes) and dispensings from outpa-
tient pharmacies (NDCs). Among those with >1 administration, we cal-
culated the gap, in days, between the first and second administration.
Lastly, we described demographics and indication (gastrointestinal (GI)
vs. non‐GI) based on a diagnosis in the prior year for users of
infliximab.
Results: We identified 39,329 and 9,118 users of Neupogen and
Zarxio (filgrastim‐sndz), respectively, based on administrations, and
16,696 and 7,735 users, based on dispensings. The proportion of
filgrastim administrations for Neupogen declined from 85% in 1/
2015 to 30% in 10/2017, while Zarxio administrations increased to
53% in 10/2017 after market introduction in 9/2015. The proportion
of administrations for Granix (tbo‐filgrastim) remained stable over the
study period, ranging from 15%–23%. We identified 76,654 and 1,093
users of Remicade and a biosimilar to infliximab, respectively, based on
administrations. Dispensings identified 5,743 Remicade users com-
pared with 157 and 0 users of Inflectra and Renflexis, respectively.
Inflectra users tended to be older, more often female, and more likely
to have baseline diagnoses for non‐GI indications compared with
Remicade users. The median gap between administrations was 12,
11, and 11 days for Neupogen, Zarxio, and Granix, respectively, and
was 48 and 41 days for Remicade and biosimilars to infliximab,
respectively.
Conclusions: More users of filgrastim and infliximab biologic and
biosimilar products were identified from administrations in healthcare
encounters than dispensings. Data on observed gaps between admin-
istrations can be used when creating exposure definitions in future
studies on biosimilars. Additional analyses should assess whether ref-
erence biologics and biosimilars are given to different patient
populations.
979 | Post‐market safety outcomes for
original therapeutic biologics approved by the
Food and Drug Administration between 2002
and 2014
Ilynn Bulatao1; Ellen Pinnow1; Brendan Day2; Sanae Cherkaoui1;
Manish Kalaria1; Sonja Brajovic1; Gerald Dal Pan1
1Food and Drug Administration, Silver Spring, MD; 2University of
Maryland Baltimore, Baltimore, MD
Background: Biologics comprise a large and growing market in the
USA. Patterns of post‐market safety outcomes, and their association
with assignment to pre‐market expedited programs have not been
systematically described.
Objectives: This study was conducted to examine the association
between 3 expedited programs developed by the FDA to reduce
pre‐market review or development time (fast track designation, prior-
ity review designation, and accelerated approval with a surrogate end-
point) and post‐market safety outcomes for original therapeutic
biologics (OTBs) approved between October 1, 2002 and December
31, 2014.
Methods: Post‐market safety outcomes, defined as a safety‐related
withdrawal or a safety‐related update to the Boxed Warning (BW),
Contraindications (C),Warnings and Precautions (WP), Adverse Reactions
(AR) or Drug Interactions (DI) sections of the label from the OTB's
approval through December 31, 2015, were recorded following a
review of label updates posted on 2 public FDA websites: Drug
Safety‐related Labeling Changes database and Drugs@FDA. Wilcoxon
rank‐sum, chi‐squared, and Fisher's exact tests, and logistic regression
were utilized to examine bivariate associations. Kaplan–Meier analysis
with Wilcoxon tests were done to examine association with time to
first safety outcome.
Results: A total of 61 OTBs were approved during the study period.
Follow‐up was 1–13.2 years (median, 5.9 years). 30 (49.2%), 42
(68.9%) and 9 (14.8%) OTBs, respectively, were assigned fast track
designation, priority review designation, and accelerated approval with
a surrogate endpoint. Two OTBs were withdrawn from the market
due to safety reasons while 49 (80.3%) had at least one safety‐related
label update. There were 158 individual label updates addressing 935
safety‐related issues. There was a total of 26, 19, 101, 106 and 7
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individual label updates, respectively, for the BW, C, WP, AR, and DI
sections. 96, 31, 355, 537 and 13 safety issues were added to the
BW, C, WP, AR and DI sections, respectively. OTBs with a priority
review designation were less likely to have a safety outcome com-
pared to those without (100% vs 62%; P = 0.01). The other 2 expe-
dited review programs were not associated with the occurrence of a
safety outcome (fast track designation: OR = 1.3, 95% CI 0.3–4.8;
accelerated approval with a surrogate endpoint: OR = 0.5, 95% CI
0.1–4.7). None of the 3 expedited review programs were significantly
associated with time to the first safety outcome.
Conclusions: The 3 expedited programs examined were not associated
with an increase in post‐market safety outcomes.
980 | Social media data analysis with
population‐based methods: A pilot
investigation of mild hypersensitivity among
users of subcutaneously administered
monoclonal antibodies
Stephen E. Schachterle; Dina Tresnan; Manfred Hauben;
Sundaresan Murugesan; Rachel E. Sobel; Andrew Bate;
Robert Reynolds
Pfizer Inc., New York, NY
Background: Patients may turn to social media to express thoughts
about their use of medicines and the resulting data may comprise a use-
ful resource for pharmacovigilance (PV). Using the Brandwatch® Inc.
platform, we assessed social media datawith a pilot drug and event pair:
subcutaneously administered monoclonal antibodies (SA mAbs) and
symptoms indicative of mild hypersensitivity reactions (mild HRs).
Objectives: To identify and assess mentions of symptoms associated
with mild HRs among self‐reported users of SA mAbs and trends in
these mentions over time in Brandwatch data.
Methods: Design: Cross‐sectional monthly social media data was
searched for symptoms of mild HRs and self‐reported SA mAbs use.
Setting: Brandwatch has collected social media data from a variety of
Internet sources including social networks (eg. Facebook, Twitter),
news services, and industry websites; English language data from
2015 to 2019 were used.
Exposures: The exposure was patients' self‐reported use of a mAb
where SA is listed as the route of administration in the US Product
Insert.
Outcome: Outcomes included patients' mentions of symptoms associ-
ated with mild HS in the social media report that contained the refer-
ence to the use of a SA mAb. Mild HS was defined by symptoms
previously described in publications on hypersensitivity or social
media such as rash, fever, or hives.
Statistical Analysis: We conducted descriptive univariate analysis and
examination for temporal trends.
Results: Among all mentions of SA mAb use (n = 134263), 9622
(7.17%) included a mention of a symptom of a mild HR. Mentions of
mild HS increased over the study period among users of mAbs that
were introduced in the study period, but mentions of mild HR among
those who used mAbs introduced before the study period remained
stable. Mentions of all mild HRs regardless of drug use increased over
the observation period.
Conclusions: The observed large counts and proportions of mild HRs
mentioned among self‐reported users of SA mAbs over time suggest
the Brandwatch data may be useful for PV. Limitations of the analysis
included an inability to validate the social media mentions and the non
specificity of the reported events. Additionally, we focused on mild HS
because it is associated with SA drugs and potentially amenable to
self‐diagnosis and discussion on social media. In the future, we will
test new drug and event pairs, including severe events, in the context
of signal detection and compare those results to analyses from tradi-
tional PV data sources such as spontaneous reports and healthcare
databases.
981 | A survey among health care
professionals to assess their knowledge and
understanding on Darzalex® (daratumumab)
educational materials regarding the risk of
interference for blood typing in 12 European
countries
Mathieu Rosé1; Intissar Bourahla1; Alessandro Ghiddi2;
Assem Al‐Akabawi3; Edmond Chan; Massoud Toussi1
1 IQVIA, Paris, France; 2 Janssen, Milan, Italy; 3 Janssen, High Wycombe,
UK
Background: Darzalex® is a human IgG monoclonal antibody immuno-
therapy indicated for the treatment of adult patients with multiple
myeloma. Daratumumab in the serum binds to red blood cells (RBCs)
resulting in pan‐agglutination in indirect Coombs tests and induce
the risk of masking the presence of antibodies to minor antigens and
may persist for up to 6 months after the last daratumumab infusion.
As risk minimization measures (RMMs)Educational materials (EM)
were developed in 2016 and aimed to inform about the associated
blood compatibility risk and provide guidance for risk management
activities. The EM were distributed in 2016 and 2017 in European
countries where the drug was commercially available.
Objectives: This post‐authorization safety study (PASS) is designed to
evaluate whether the health care professionals (HCPs), and blood
transfusion management department personnel (BTMDP) received
and understood the EM.
Methods: This study was conducted in 12 European countries (Aus-
tria, Czech Republic, Denmark, Finland, France, Germany, Hungary,
Norway, Spain, Slovakia, Sweden, Switzerland) by using an anony-
mous, cross sectional and non‐interventional survey. The recruitment
target was 400 participants. Questionnaires were distributed via a
web‐based platform. The criteria for considering the EM as effective
were correct answers from ≥80% of respondents for key questions
of relevance to the RMMs. The questions assessed understanding of
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daratumumab and its mode of action to interfere with blood typing,
and knowledge of the potential for daratumumab to cause this inter-
ference and the relevant mitigation methods for this.
Results: A total of 408 participants completed the questionnaires with
254 HCPs (62.3%) and 154 BTMDP (37.7%). As preliminary results,
overall, between 95% and 100% of participants were aware of the
EM and between 80% and 100% have correctly answered key ques-
tions about the knowledge of the risk associated with the interference
of daratumumab and blood testing except the question relative to the
type of testing concerned (ABO typing, RhD typing or detection of
regular antibodies) with a result <65%. The responses were consistent
between HCPs and BTMDP.
Conclusions: The preliminary survey results suggest that the partici-
pants knew EM and were aware of the risk associated with the inter-
ference of daratumumab and blood testing which suggests an overall
satisfactory effectiveness of the risk minimization measures. The final
results will become available in July 2019.
982 | Effectiveness and safety of eculizumab
in the treatment of paroxysmal nocturnal
hemoglobinuria: Systematic review and meta‐
analysis
Carolina Zampirolli Dias1; Isabella de Figureiredo Zuppo1;
Mariana Michel Barbosa1; Pâmela Santos Azevedo1;
Marina Morgado Garcia1; Vânia Eloisa Araujo2;
Juliana Alvares‐Teodoro1; Francisco Assis Acurcio1;
Augusto Afonso Guerra‐Junior1
1Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil;
2Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Brazil
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare
chronic hemolytic anemia caused by a defect in the red blood cell
membrane mediated by the complement system. Eculizumab, is the
first drug indicated for this condition, with a high economic impact,
specially for countries that provide publicly‐funded drugs.
Objectives: To evaluate the effectiveness and safety of eculizumab in
PNH treatment.
Methods: A systematic review (SR) and meta‐analysis of cohort stud-
ies evaluating the effectiveness and safety of eculizumab in PNH
treatment was conducted in January 2019, through PUBMED,
EMBASE, LILACS and Cochrane Library databases, manual search
and gray literature. The selection of the studies was performed by
two independent reviewers and, in cases that were disagreements,
they were solved by a third reviewer. The meta‐analysis was con-
ducted in Review Manager® 5.3 software. The effectiveness out-
comes evaluated were: reduction of hemolysis, increase in
hemoglobin level, reduction of transfusions; and safety: thromboem-
bolic events and mortality. The methodological quality of the included
studies was assessed using the Newcastle‐Ottawa scale.
Results: A total of 1854 studies were found, of which eight were
included in SR. All the studies had low methodological quality, since
most of them have not presented comparator group (non‐exposed).
For the outcome reduction in hemolysis, a change in LDH levels (lac-
tate dehydrogenase) was observed, which showed a statistically signif-
icant decrease in patients using eculizumab. No statistically significant
difference was observed in the increase in hemoglobin level (median
1.53, 95% CI 0.55–4.39). Patients in the eculizumab group had a
greater chance of achieving transfusional independence (RR 2.77,
95%CI, 1.9–4.05), those who did not become independent required
fewer red cell bags. Regarding safety, eculizumab reduced the risk of
thromboembolic events (RR 0.13, 95% CI 0.07–0.25) and about the
mortality, it was observed that only after 36 months of treatment,
eculizumab had a protective effect with a statistically significant
difference.
Conclusions: Eculizumab is an innovative drug that has been shown to
be effective and safe for the treatment of patients with PNH. How-
ever, since it presents a high cost, it can compromise the population's
access to the treatment.
983 | Switching from infliximab‐originator to
infliximab‐biosimilar in rheumatologic
patients: The clinical impact inTuscan Region,
Italy
Irma Convertino1; Marco Tuccori2,3; Ersilia Lucenteforte1;
Marta Mosca2; Giuseppe Turchetti4; Valentina Lorenzoni4;
LeopoldoTrieste4; Sara Ferraro1; Luca Leonardi1; Giuseppe Roberto5;
Nicoletta Luciano2; Corrado Blandizzi1; Rosa Gini5
1University of Pisa, Pisa, Italy; 2University Hospital of Pisa, Pisa, Italy;
3Tuscan Pharmacovigilance Centre, Pisa, Italy; 4Scuola Superiore
Sant'Anna, Pisa, Italy; 5Tuscan Regional Healthcare Agency, Florence,
Italy
Background: In 2015, Tuscan Health Authority recommended to phy-
sicians the prescription of biosimilar infliximab (BI), thus promoting the
switching from originator infliximab (OI) to BI.
Objectives: To assess the clinical impact of the recommendation for
the use of BI in Tuscan rheumatoid arthritis (RA) patients.
Methods: We conducted two interrupted time series analyses on RA
patients in the Tuscan healthcare administrative databases. The analy-
sis 1 included naïve patients who started infliximab between January
1st, 2012 and December 31st, 2016. We followed patients up to 1 year.
The analysis 2 included prevalent infliximab users recorded from Jan-
uary 1st to December 31st, 2013 (group 1) and from January 1st to
December 31st, 2015 (group 2). Both groups were followed for 2 years.
In both analyses, we described the patterns of treatment as well as the
occurrence of rheumatologic visits, emergency department visits
(EDV) and hospitalizations for any causes.
Results: In the analysis 1, 214 patients were included (52 in 2012, 64
in 2013, 31 in 2014, 29 in 2015 and 38 in 2016). Patients starting with
BI were 18 (62.1%) in 2015 and 33 (86.8%) in 2016. Switching from OI
to BI occurred since 2014, and no switch from BI to OI was recorded.
We observed neither relevant differences in the pattern of treatment
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(frequency of treatment persistence, switching to another anti‐TNF or
swapping to another non‐anti TNF) nor in the frequency of the rheu-
matologic visits, EDV and hospitalizations over the observation years. In
the analysis 2, 354 patientswere included in group 1 and 334 in group 2.
All patients startedwithOI. In the group 2, we observed that: 96 (28.7%)
patients switched to BI; 66 patients (19.8%) switched to another anti‐
TNF drug, versus 55 patients (15.5%) of group 1; 7 patients (2.1%)
swapped to other non‐anti‐TNF drugs versus 6 patients (1.7%) in group
1. The mean number of rheumatologic visits per patient increased from
2.8 (group 1) to 3.9 (group 2). The proportion of patients with at least
one EDV increased from 35.9% (group 1) to 45.5% (group 2). The pro-
portion of hospitalized patients increased from 34.5% to 37.4%; the
mean number of hospitalizations per patient did not vary.
Conclusions: Over the study period, the recommendation of Tuscan
Health Authority was associated with an increased utilization of BI in
RA patients. In naïve users, no impact was observed on the patterns
of use and outcomes. Likewise, in prevalent users, no major changes
in the patterns of use were observed. The increase in EDV and rheu-
matologic visits could be explained with a cautious approach to BI
by both physicians and patients.
984 | The incidence of infusion reactions
associated with monoclonal antibody drugs
targeting the epidermal growth factor
receptor in metastatic colorectal cancer
patients: A systematic literature review and
meta‐analysis
Lauren C. Bylsma1; Rebecca Dean2; Kimberly Lowe3;
Christina Gillezeau4; Laura Sangare5; Dominik D. Alexander2;
Jon Fryzek6
1EpidStrategies, A Division of ToxStrategies, Inc., Ann Arbor, MI;
2EpidStat Institute, Ann Arbor, MI; 3Amgen, Seattle, WA; 4EpidStat
Institute, Rockville, MD; 5SimulStat, Portland, OR; 6EpidStrategies, A
Division of ToxStrategies, Inc., Rockville, MD
Background: Infusion reactions have been reported in studies of met-
astatic colorectal cancer (mCRC) patients treated with anti‐EGFR ther-
apies, including cetuximab and panitumumab, with incidences ranging
from 0–33%.
Objectives: A systematic literature review and meta‐analysis were
conducted to estimate the incidence of infusion reactions in this pop-
ulation and identify variations in this incidence by patient and study
characteristics.
Methods: Multiple scientific databases were searched to identify
observational studies or clinical trials of mCRC patients treated with
anti‐EGFR therapies that reported rates of infusion reactions, hyper-
sensitivity, or allergy/anaphylaxis. Random effects models were used
to meta‐analyze the incidence of infusion reactions overall and strati-
fied by therapy, study design, geographic location, KRAS mutation sta-
tus, and grade of reaction severity.
Results: Among 48 studies included in this meta‐analysis, the pooled
estimate for infusion reaction incidence was 0.049 (95% CI: 0.036–
0.065), or nearly 5%. Reactions of grades 1 or 2 were more common
than reactions of grades 3–5 (0.089 vs. 0.028) No significant varia-
tions in infusion reaction incidence were observed by study design,
KRAS status, or study location.
Conclusions: Infusion reactions occur in approximately 5% of mCRC
patients treated with anti‐EGFR therapies and the incidence varies sig-
nificantly by grade and severity. Future studies should consider inves-
tigating survival outcomes for only those patients with infusion
reactions to determine its prognostic relevance.
985 | Prescribing patterns from medical
chart abstraction of patients administered
lipegfilgrastim: A pilot study in Europe
Sigal Kaplan1; Nicole Lang2; Maja Gasparic3; Carolyn Rainville4;
George Haralabopoulos5; Emanuele Borroni5
1Teva, Netanya, Israel; 2Ratiopharm GmbH, Ulm, Germany; 3Teva,
Amsterdam, Netherlands; 4Teva, Malvern, PA; 5PRA, Mannheim,
Germany
Background: In the context of the regulatory approval for market
authorization of lipegfilgrastim in the European Union, the European
Medicines Agency requested a drug utilization study as part of the
pharmacovigilance plan to characterize the extent of off‐label use of
lipegfilgrastim. To address the challenges of implementing a study of
off‐label use in multiple countries with diverse healthcare systems
and clinical practices, a pilot study was designed.
Objectives: The objective of this pilot study was to explore the feasi-
bility of conducting a drug utilization study of lipegfilgrastim in Europe
using medical records and to examine the pattern of lipegfilgrastim on‐
label and off‐label use.
Methods: Data on lipegfilgrastim use between September 2014 and
April 2017 were abstracted from medical records by two independent
medical abstractors. Lipegfilgrastim indication was categorized either
as on‐label or as one of four types of off‐label (I‐IV) according to
pre‐defined criteria. An inter‐rater reliability analysis was conducted
to measure the degree of abstractor agreement for on‐label and off‐
label use.
Results: Information from 46 medical records was abstracted.
Lipegfilgrastim use during the first chemotherapy treatment cycle
was mostly indicated for prevention of neutropenia (82.6% of
patients). On‐label use was documented in 42 patients (91.3%),
while off‐label use was documented in two patients (4.3%); all
events of off‐label use were attributed to use with non‐cytotoxic
drugs. The remaining two patients (4.3%) had missing data. Overall
agreement between the abstractors was high (91.6%). For three
types (Types I‐III) of off‐label use, the kappa values suggested a per-
fect agreement (κ = 1). For Type IV off‐label use (use in patients
treated with non‐cytotoxic drugs), κ = 0, suggesting a poor
agreement.
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Conclusions: While recruitment was challenging, the results of this
pilot study confirm the feasibility and availability of medical records
and the use of pharmacists as abstractors to assess on‐ and off‐label
use of lipegfilgrastim. Lipegfilgrastim was mainly prescribed according
to the approved indications.
986 | Prescribing practices associated with
biologic therapies for psoriasis
Megan H. Noe; Daniel B. Shin; David J. Margolis; Joel M. Gelfand
University of Pennsylvania, Philadelphia, PA
Background: After a physician writes a prescription, several things can
happen: a patient can choose not to take the medication, it may not be
covered by insurance, or they may start it and discontinue because of
side effects or lack of efficacy. There is little information describing
physician prescribing practices associated with biologic therapies for
psoriasis.
Objectives: To investigate the physician prescribing practices associ-
ated with biologic therapies used to treat psoriasis in the United
States.
Methods: A cohort study was performed using data from
OptumInSight's electronic health records database, a de‐identified
dataset containing information from over 81 million individuals in
the United States with a diagnosis of psoriasis between 1/1/2007–
6/30/2017. Patients were classified as having psoriasis if they had 2
diagnosis codes for psoriasis, on 2 separate days or 1 diagnosis for
psoriasis and a prescription for a systemic psoriasis therapy/photo-
therapy on a separate day. Time began at the second qualifying event
and was continued until the patient left the database or died. Only
patients with at least 1 prescription for a biologic medication
(adalimumab, etanercept, infliximab, secukinumab and ustekinumab)
were included in the analysis. Time between first and last prescription
was used as a measure of drug survival in this dataset; at least 1 pre-
scription every 180 days was required for continuous therapy.
Results: There were 34,714 patients included in the analysis. Between
27.7% ‐ 53.1% of patients received a single prescription for the drug.
The median number of prescriptions written for each drug was 2 for
infliximab, secukinumab and ustekinumab and 3 for adalimumab and
etanercept. Patients prescribed infliximab had the longest median time
between first and last prescription (7.0 mos, IQR: 2.9–20.8 mos) and
patients prescribed secukinumab had the shortest time (3.4 mos,
IQR: 1.3–7.3 mos). A subset of patients (N = 12,857) on the same bio-
logic medication for at least 12 months was identified. Again patients
on infliximab had the longest median time between first and last pre-
scription (median: 34.7 mos, IQR: 21.5–54.2 mos) and those on
secukinumab had the shortest median time (15.4 mos, IQR: 13.3–
19.5 mos).
Conclusions: Up to 50% of patients who received a first prescription
for a biologic did not receive a second prescription for the same med-
ication. The median time between first and last prescriptions was less
than 12 months. Understanding prescribing patterns for biologic
medications, helps to understand some of the difficulty physicians
have selecting appropriate systemic treatments for psoriasis.
987 | Vemurafenib associated drug reaction
with eosinophilia and systemic symptoms:
Exploration of novel adverse effect using
disproportionality analysis
Neha Reddy; Subeesh Viswam; Beulah Elsa; Anusha Bellapu;
Vasista Sharma; Stephy Chacko
M S Ramaiah University of Applied Sciences, Bangalore, India
Background: Signal detection is one of the most advanced and emerg-
ing field in pharmacovigilance. It facilitates early adverse drug reaction
detection that may not have been identified in pre‐marketing clinical
trials. Vemurafenib is a BRAF inhibitor approved by the US Food and
Drug Administration (FDA) in 2011 for the treatment of metastatic
melanoma.
Objectives: This study aims in the identification of Drug Reaction with
Eosinophilia and Systemic Symptoms (DRESS) associated with
vemurafenib using disproportionality analysis of the FDA Adverse
Event Reporting System (FAERS).
Methods: Data were obtained from the public release of data in
FAERS. Case/non‐case method was adopted for the analysis of asso-
ciation between vemurafenib use and DRESS. The data mining algo-
rithm used for the analysis was Reporting Odds Ratio (ROR) and
Proportional Reporting Ratio (PRR). A value of ROR‐1.96SE > 1,
PRR ≥ 2 were considered as positive signal.
Results: A total of 7,869 reports for DRESS have been reported in the
FDA database as on December 2018. Among which 101 reports were
associated with vemurafenib. DRESS ranked 49th among 900
vemurafenib associated adverse drug events. A positive signal was
obtained with ROR: 13.10 and PRR: 13.12. Four deaths were reported
and the non‐death serious reports included hospitalization, life‐threat-
ening, disability, and other serious events with 61, 11, 2 and 39
reports respectively.
Conclusions: A positive signal was observed for vemurafenib associ-
ated DRESS, although a causal relation cannot be definitively proved.
Health care professionals should be cautious about the possibility of
encountering serious adverse events associated with vemurafenib
and should be reported to the regulatory authorities.
988 | Evaluation of thrombocytopenia and
hemorrhage associated with secukinumab
Mona Almaghrabi; Adel Alrwisan
Saudi Food and Drug Authority, Riyadh, Saudi Arabia
Background: Secukinumab is a human monoclonal antibody works by
inhibiting the action of interleukin (IL)‐17 involved in inflammatory and
immune responses. It is an immunosuppressant agent used in many
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autoimmune diseases: plaque psoriasis, psoriatic arthritis and ankylos-
ing spondylitis.
Objectives: The aim of this review is to evaluate the risk of blood
adverse events: thrombocytopenia and hemorrhage associated with
the administration of secukinumab.
Methods: A systematic search was conducted using PubMed, Ovid,
Cochrane and Google scholar of relevant studies for each adverse
event. The search terms include the following in different combina-
tions: Secukinumab, Cosentyx®, Interleukin‐17 inhibitor, thrombocy-
topenia, low platelet count, thrombopenia bleeding hemorrhage and
hemorrhage. Cases of thrombocytopenia and hemorrhage suspected
with secukinumab reported to World Health Organization (WHO) until
the 9th of Jan 2019, were reviewed. The association was assessed
using WHO‐Uppsala Monitoring Centre causality system.
Results: We Identified 27 serious cases of thrombocytopenia reported
to WHO database. Most of the cases were unassessable 14 (51.85%)
due to insufficient information. However, two cases of severe and
intense reduction in platelet counts during treatment with
secukinumab have been reported, and evaluated to be possibly related
to therapy with secukinumab. There were 41 serious cases of hemor-
rhage reported to the WHO database with secukinumab. Hemorrhage
was assessed unlikely to be related to secukinumab use.
Conclusions: There is a probable risk of thrombocytopenia associated
with secukinumab use. Platelet counts monitoring is recommended
before and during treatment. Skin monitoring is also recommended
for any discoloration that could indicate a reduction in platelet counts
in high‐risk patients. These risks need further close monitoring.
989 | Younger age is the main determinant
for first‐line biological treatment in
rheumatoid arthritis
Laura Angelici; Antonio Addis; Nera Agabiti; Marina Davoli;
Valeria Belleudi
Lazio Regional Health Service, Rome, Italy
Background: The EULAR guidelines for the treatment of rheumatoid
arthritis (RA) recommend the use of conventional synthetic anti‐rheu-
matic drugs (cs‐DMARDs) at the onset of the disease and only in the
case of therapeutic failure the addition of a biological drug (b‐
DMARD) is suggested. The use of biological treatment as first‐line
therapy is a critical issue.
Objectives: To evaluate in clinical practice determinants for first‐line
biological treatment in patients with RA.
Methods: A cohort of patients with RA, resident in a central Italian
Region (Lazio: about 6 million of inhabitants) and with at least one
DMARD prescription between 2010–2016 was selected using Health
Information Systems. Only new users (1 year wash‐out) were included
and the first‐line treatment was identified: cs‐DMARD or b‐DMARD.
Through multivariate logistic regression models (OR; IC95%) determi-
nants of therapy such as age, comorbidity and co‐medication were
investigated. The analysis was carried out for the whole population
and separately for sex. Moreover, among patients with cs‐DMARDs
as first‐line treatment, the switching versus a b‐DMARD in the first
year was analyzed.
Results: The DMARD‐new users with RA, between 2010–2016, were
5,391; 5.5% (N = 296) of them with b‐DMARD as first‐line treatment
(11.0% in combination with a cs‐DMARD). Considering the year of dis-
pensing, this percentage ranged from 3.6% (2015) to 7.4% (2011).
Among the cs‐DMARDs the most prescribed active ingredient was
metrotrexate (59.1%), while among the b‐DMARDs was etarnecept
(32.4%), followed by adalimumab (22%). The average age of the cohort
was 51 years with 77% of women; the prevalence of diseases such as
hypertension, diabetes, hypothyroidism and cardiovascular diseases
was 43.4%, 18.7%, 16.8% and 12.1% respectively. In the 6 months
preceding the start of therapy, 61.3% used NSAIDs and 62.1% corti-
costeroids. Determinants of first‐line b‐DMARD use were: age
(OR<30vs < 65 = 5.9; 3.9–8.9), cancer (OR = 2.8; 1.5–5.2), cardiovascular
diseases (OR = 1.8; 1.2–2.6), use of NSAIDs (OR = 0.6; 0.4–0.7) and
corticosteroids (OR = 0.6; 0.5–0.7). The association pattern was similar
between males and females. Finally, among the new users of cs‐
DMARDs, 7.5% of the patients started a b‐DMARD in the first year
of treatment.
Conclusions: In clinical practice, about 6% of patients with RA have a
b‐DMARD as first‐line treatment. This therapeutic option, even if not
supported by scientific evidence, is mostly link to younger age and
clinical profile of the patients. Further analyses on real world data
are necessary to investigate appropriateness and to promote a better
use of these drugs.
990 | Racial disparities associated with risks
of erythropoiesis‐stimulating agents in cancer
patients after Medicare reimbursement policy
change
Minghui Li1; Kevin Lu2
1University of Tennessee Health Science Center, Memphis, TN;
2University of South Carolina, Columbia, SC
Background: Due to risks of cardiovascular and thrombovascular
events, Centers for Medicare and Medicaid Services (CMS) issued a
Medicare reimbursement policy change for erythropoiesis‐stimulating
agents (ESAs) in cancer patients. Given different utilization patterns
in different racial groups, racial disparities are significant policy
concerns.
Objectives: To examine racial disparities associated with the risks of
myocardial infarction (MI), stroke, and venous thromboembolism
(VTE) events of ESAs after Medicare.
Methods: This study applied a retrospective incident user cohort
design using the Surveillance, Epidemiology, and End Results (SEER)‐
Medicare linked database. The index date was the date of the first
ESA prescription. Incident users of ESAs were followed up to one year
since the index date for a diagnosis of MI, stroke, or VTE. Individuals
who were aged 66 years or older, were eligible for Medicare because
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of age, had a primary diagnosis of breast cancer, colorectal cancer,
lung cancer, lymphomas, ovarian cancer, or prostate cancer, received
chemotherapy after cancer diagnosis, and initiated ESAs after chemo-
therapy were included in this study. We excluded individuals who had
a diagnosis of MI, stroke, or VTE one year before the index date. ESAs
use was measured based on Medicare Part B and D claims. The diag-
noses of MI, stroke, and VTE were measured from Medicare Part A
and B claims. Logistic regression models were used to examine racial
disparities associated with Medicare reimbursement policy change
on the risks of MI, stroke, and VTE among incident users of ESAs.
Racial disparities were measured based on odds ratios (OR) of adverse
events between Caucasians and African Americans.
Results: This study identified 17,236, 16,250, and 14,224 incident
users of ESAs free of MI, stroke, and VTE, respectively. In the adjusted
logistic regression analyses, Medicare reimbursement policy change
was not associated with the future development of MI (OR: 1.01;
95% CI: 0.74–1.39), stroke (OR: 0.99; 95% CI: 0.84–1.15), and VTE
(OR: 0.93; 95% CI: 0.84–1.03). Compared to Caucasians, African
Americans had similar risks of MI (OR: 1.20; 95% CI: 0.68–2.10) and
stroke (OR: 1.22; 95% CI: 0.94–1.59). African Americans, however,
had an increased risk of VTE (OR: 1.34; 95% CI: 1.12–1.61) than
Caucasians.
Conclusions: Medicare reimbursement policy change was associated
with racial disparities in the risk of VTE in cancer patients using ESAs.
Future Medicare policy changes should consider the potential unin-
tended consequences on racial minorities.
991 | Incidence rate of serious infections in
patients with ulcerative colitis with or
without systemic therapy in the United States
Huifang Liang; Raghava X. Danwada; Dongmu Zhang; Rachel W. Duan
AbbVie, Inc., North Chicago, IL
Background: Patients with ulcerative colitis (UC) are at a higher risk of
developing serious infections. Information on serious infections risk is
lacking in patients with UC on systemic therapies.
Objectives: To determine the incidence rate of serious infections in
patients with UC treated with and without systemic therapy.
Methods: A retrospective cohort study was conducted in the Optum™
Clinformatics™ Data Mart (CDM) in the US by including adults who
had at least two diagnoses of UC on medical claims ≥7 days apart in
2008–2018, and ≥ 1 year of continuous health plan enrollment before
the index date, defined as the first treatment after the first UC diagno-
sis. Patients were classified into those treated with biologics, non‐bio-
logic systemic therapy, and no systemic therapy based on UC
treatment. Descriptive statistics were generated for patient demo-
graphics and clinical characteristics. A standardized difference of
greater than 0.1 was used to indicate meaningful difference between
treatment groups. Crude and age and sex‐standardized incidence rate
and 95% confidence intervals (CIs) were estimated for serious infec-
tions by treatment.
Results: A total of 75,611 adults (45.3% male) with UC were eligible
for the study. Among them, 7,394 (9.8%), 39,618 (52.4%) and
28,599 (37.8%) received biologics, non‐biologic systemic therapy,
and no systemic therapy, with mean age 45.2, 55.2 and 57.5 years,
respectively. Patients who received no systemic therapy had higher
proportion of hypertension, hyperlipidemia, diabetes, COPD, and
chronic kidney disease than those on biologics and non‐biologic sys-
temic therapies, whereas those on biologics had the highest propor-
tion of extra‐intestinal manifestations and autoimmune diseases
compared with those on non‐biologic systemic therapy and not on
systemic therapy. A total of 6,609 serious infections occurred during
180,331.1 patient‐years, resulting in an overall incidence rate of 3.66
(95% CI 3.58–3.75) per 100 patient‐years. The incidence rate (per
100 patient‐years) was 4.86 (4.52–5.21), 1.87 (1.79–1.96) and 6.1
(5.91–6.29), with age‐ and sex‐standardized rate being 5.21 (4.81–
5.60), 1.65 (1.57–1.74) and 4.15 (3.99–4.30) among those who
received biologics, non‐biologic systemic, and no systemic therapy,
respectively.
Conclusions: Among patients with UC, the incidence rate was highest
in biologic users, followed by those not on a systemic therapy and
those on non‐biologic systemic therapy. These discrepancies may par-
tially be attributed to differences in the proportion of patients with
higher UC disease severity in the biologic users.
992 | Safety profile of two TNF‐a inhibitors
adalimumab and golimumab: An analysis of
FAERS database 2012–2018
Kelsey Byers; Xiaomeng Yue; Jeff Guo
University of Cincinnati, Cincinnati, OH
Background: Both adalimumab (Humira) and golimumab (Simponi) are
tumor necrosis alpha inhibitors that are indicated for the treatment of
rheumatoid arthritis. Adalimumab contains a black box warning for an
elevated risk of lymphoma and other fatal malignancies.
Objectives: The purpose of the study was to analyze the safety profile
and adverse events associated with adalimumab and golimumab.
Methods: A retrospective descriptive study was conducted for two
study drugs, adalimumab and golimumab, that were introduced into
the market in 2002 and 2009 respectively. The data source was the
FDA Adverse Events Reporting System (FAERS) from quarter 1 of
2012 to quarter 2 of 2018. Both brand names and bioequivalent
names were used to extract and analyze the adverse event (AE) data.
The frequently reported AEs were analyzed and categorized using the
MedDRA preferred terminology. Numbers of AE reports, case profiles
and malignancies were also compared between Humira and Simponi
and grouped by age, sex, and year. Trendlines, histograms, and pie
charts were used to present the descriptive data.
Results: There were approximately one million AEs reported for
brand‐name Humira, and 11,582 AEs reported for its bioequivalent
form adalimumab. There were 84,069 for brand‐name Simponi and
3,274 for golimumab. The most commonly reported AEs were nausea,
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headache, pneumonia, vomiting, diarrhea, pyrexia, tuberculosis, lower
respiratory tract infection, urinary tract infection, nasopharyngitis,
influenza, and malaise. For malignancies, there were 8,884 (0.87%)
cases reported for Humira and 1501 (2%) cases reported for Simponi.
The most commonly reported malignancies were Lymphoma with
1146 (12%) cases for Humira, and 198 (13%) cases of breast cancer
for Simponi. Average age was 51.2 for Humira and 58.3 for Simponi.
AE cases were more commonly reported in females for Humira
(46%) and Simponi (63%). The most commonly reported outcome
was a severe medical event for Humira (82,875; 8%) and Simponi
(13,934; 16.5%).
Conclusions: Both Simponi and Humira have serious safety profiles.
Simponi seems to have more cases of malignancies and severe medical
events than Humira. More post‐marketing surveillance study is war-
ranted for Simponi.
993 | Trends in the utilization of short‐acting
filgrastim following the United States market
launch of the first biosimilar
Shelley Jazowski1; Stacie Dusetzina2
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Vanderbilt
University Medical Center, Nashville, TN
Background: In September 2015, filgrastim‐sndz became the first
Food and Drug Administration approved biosimilar available in the
United States. Research suggests initial uptake of 32% in Medicare
Part B; however, the adoption of filgrastim‐sndz among Part D
patients remains unknown.
Objectives: To identify and compare trends in Medicare Part B and
Part D utilization of short‐acting filgrastim products following
biosimilar market entry.
Methods: We used 2015–2016 Part D Prescriber files and Physician
and Other Supplier files from the Centers for Medicare and Medicaid
Services Providers Utilization and Payment Data. We used the prod-
uct's brand‐name or Healthcare Common Procedure Coding System
codes to identify Medicare Part D prescriptions (≥11) or Medicare
Part B non‐institutional claims for filgrastim products indicated for
febrile neutropenia: filgrastim (originator biologic), tbo‐filgrastim (fol-
low‐on biologic approved prior to the implementation of the US
biosimilar licensure pathway) or filgrastim‐sndz (biosimilar).
Results: Prior to biosimilar entry, 146,559 Medicare claims were filed
for filgrastim products, of which Medicare Part B and D represented
91% and 9%, respectively. Originator filgrastim accounted for the
majority of all filgrastim product use (95% and 98% of Part B and Part
D claims, respectively). Following biosimilar entry of filgrastim‐sndz,
utilization of originator filgrastim declined to 60% of Part B and 74%
of Part D claims; the follow‐on biologic tbo‐filgrastim increased to
7% of Part B and 2% of Part D claims; and the biosimilar filgrastim‐
sndz made up the remaining 33% of Part B and 24% of Part D claims.
Conclusions: Our findings are consistent with prior research and sug-
gest that market entry of filgrastim‐sndz likely contributed to the
decreased use of originator filgrastim across Medicare beneficiaries;
and that increased market competition may have prompted providers
to switch to or increase the use of cheaper alternatives.
994 | Oral kinase inhibitors, biologics and
serious infection in rheumatoid arthritis
Benjamin A. Bates; Joshua P. Gilman; Poonam P. Gandhi;
Edward Nonnenmacher; Matthew Taylor; Haoqian Chen;
Soko Setoguchi
Rutgers University, New Brunswick, NJ
Background: Higher rates of serious infections have been reported in
rheumatoid arthritis (RA) patients using biologics. Tofacitinib is the
first of a unique class of oral kinase inhibitors that acts intrinsically
against the JAK_STAT pathway, thereby modulating lymphocyte
development and function. Studies have reported elevated risk of var-
icella zoster virus (VZV) infection in tofacitinib users but the risk of
other serious bacterial infections are not well examined.
Objectives: To estimate the risk of hospitalized infections in RA
patients started on tofacitinib (TOFA), abatacept (ABA), or tumor
necrosis factor inhibitors (TNFi).
Methods: We identified RA patients defined as ≥1 RA diagnosis
followed by biologic or tofacitinib use in the MarketScan® commercial
database (2008–2017). We identified TNFi, ABA and TOFA users and
followed them until the first occurrence of serious hospitalized infec-
tions (sepsis, pneumonia [PNA], meningitis, encephalitis, endocarditis,
pyelonephritis, septic arthritis, osteomyelitis and VZV, defined using
an inpatient primary diagnosis) or discontinuation of the drug. We
described patient's characteristics and calculated incidence rates (IRs)
of each infection endpoint and their 95% confidence intervals (CIs).
Results: Among 40,370 patients (mean age 50 years, 79% female),
6,117, 20,131, and 9,340 were TOF, TNFi, and ABA users, respec-
tively. TNFi users were slightly younger and more likely to be male
compared to ABA and TOFA users. TOFA users were more likely to
be on steroids in the last year and less likely to have a diagnosis of
hepatitis C. During a total follow‐up of 24,688 person‐years, we
observed 1,478 events. The crude IR (95% CIs) of hospitalized VZV
infection for TOFA, TNFi, ABA was 40 (32–48), 19 (17–21) and 22
(18–26), respectively. The RI for hospitalized PNA was 25 (19–31),
15 (13–17), and 12 (9–15) for TOFA, TNFi, and ABA, respectfully.
The crude IR of other infectious outcomes were much lower and sim-
ilar among the three groups.
Conclusions: The crude risk for VZV and PNA were significantly
higher inTOFA users compared toTNFi and ABA users. The VZV find-
ing was consistent with previous studies and the risk of other serious
bacterial infections were similar among three groups except for PNA.
Nonetheless, our current analyses are purely descriptive, as they do
not fully consider the differences in measured patient characteristics.
Also, we were not able to differentiate bacterial vs. viral PNA. Further
studies are needed to better understand the risk of serious bacterial
and viral infections among these novel DMARDs.
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995 | Premedication and the risk for infusion
related reactions among patients receiving
monoclonal antibody therapy: A systematic
review and meta‐analysis
Francis Mawanda; Joseph D. Orchowski; Emily F. Shafer;
Paul A. Ardayfio
Eli Lilly and Company, Indianapolis, IN
Background: Premedication before the infusion ofmonoclonal antibod-
ies have become standard of practice for many institutions; however,
limited research has examined the efficacy and safety of premedication.
Objectives: Thepurposeof this studywas todeterminewhether theuse
of premedication influences the risk of infusion related reactions (IRR)
among patients receiving intravenousmonoclonal antibody therapies.
Methods: Study design: Systematic review and meta‐analysis of ran-
domized controlled trials (RCT) and observational studies on
premedication and risk of IRR among adult patients receiving intrave-
nous monoclonal antibody therapy. Data sources: Ovid MEDLINE,
Embase and EBM Reviews databases were searched from 1980
through January 2018 using a combination of various MESH terms
and keywords. Statistical analysis: Random effects model was used
as the primary analysis.
Results: A total of 14 studies including 11 observational studies and 3
RCT met inclusion criteria and were included in the review. Overall,
meta‐analysis of the observational studies showed no significant associ-
ation between the use of any premedication regimen and the risk for IRR
(OR = 0.88; 95%CI = 0.48–1.64) with significant heterogeneity among
the studies (I2 = 90%). Similarly, meta‐analysis of the RCT also found no
significant association between the use of any premedication regimen
and the risk for IRR (RR = 0.93; 95%CI = 0.51–2.83) with significant het-
erogeneity among the studies (I2 = 71%). Regarding specific
premedication regimens, the use of antihistamines (OR = 1.86;
95%CI=1.53–2.26; I2=1%)oracombinationof corticosteroidsandanti-
histamines (OR = 2.85; 95%CI = 1.40–5.67); I2 = 39%) as premedication
were associated with an increased risk for IRR. There was no significant
associations between theuse corticosteroids (OR=1.06; 95%CI= 0.57–
2.14; I2 = 51%) as premedication and the risk for IRR.





996 | Medication persistence in the first line
of biological drugs in rheumatoid arthritis
Jéssica BarretoRibeiro dos Santos; Augusto Afonso Guerra Junior;
Michael RubersonRibeiro da Silva; Alessandra Maciel Almeida;
Francisco de Assis Acurcio; Juliana Alvares‐Teodoro
Federal University of Minas Gerais, Belo Horizonte, Brazil
Background: The majority of studies report that there are no differ-
ences between biological drugs for the efficacy in rheumatoid arthritis
(RA), but several factors may influence their persistence.
Objectives: To evaluate the persistence of biological drugs in the first
line of biological treatment in RA.
Methods: We evaluated a historical cohort composed of RA patients
of the Brazilian National Health System, who started the first line of
biological treatment in the period between 2013 June to 2014
December. A national database was developed, using three adminis-
trative databases of the Brazilian National Health System Computing
Department: The Outpatient Information System, the Mortality Infor-
mation System, and the Hospital Information System. The endpoint
was the medication persistence at 12 months. Kaplan–Meier survival
curves were traced to verify the time up to treatment discontinuation,
that is, the loss of biological drugs persistence at 12 months. Log‐rank
test was used to verify if differences between the groups have
occurred for the persistence endpoint.
Results: A population composed of 16,518 individuals started the first
line of biological drug. Out of such individuals, 8,622 (52.20%)
persisted in the treatment at 12 months. Abatacept was the drug that
presented higher persistence (300.32 days; Confidence Interval [CI]
95% 289.99–310.65), followed by golimumab (290.17 days; CI 95%
285.61–294.74), tocilizumab (286.61 days; CI 95% 274.75–298.48),
etanercept (278.63 days; CI 95% 275.35–281.92), and adalimumab
(274.20 days; CI 95% 271.37–271.37) and, with lower persistence
certolizumab (262.9 days; CI 95% 251.41–274.39) and infliximab
(245.18 days; CI 95% 238.64–251.71).
Conclusions: The medication persistence was different between bio-
logical drugs. The rigorous follow‐up of patients, by a multidisciplinary
team, is important to enable the development of strategies for the
adequate use of such drugs.
997 | Antimicrobial resistance in non‐
typhoidal salmonella from retail poultry meat
by antibiotic usage‐related production claims
‐ United States, 2005–2015
Xin Yin1,2; Nkuchia M. M'ikanatha2; Heather Tate3
1Penn State College of Medicine, Hershey, PA; 2Pennsylvania
Department of Health, Harrisburg, PA; 3U.S. Food and Drug
Administration, Laurel, MD
Background: Antimicrobial resistance (AMR) to non‐typhoidal Salmo-
nella from contaminated poultry is a public health concern. Antibi-
otic‐resistant Salmonella infections can be associated with severe
illness and prolonged hospitalization. Injudicious use of antibiotics in
humans and agriculture fuels emergence of resistance. The National
Antimicrobial Resistance Monitoring System (NARMS) tracks AMR in
Salmonella isolated from humans, animals and food sources.
Objectives: Characterize antimicrobial resistance in Salmonella recov-
ered from retail poultry sold in the United States by antibiotic usage‐
related production claims.
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Methods:We reviewed antimicrobial susceptibility and whole genome
sequencing data from 3,793 Salmonella isolates collected from 2005–
2015 through the NARMS retail meat program. These were recovered
from 32,911 poultry meat samples purchased from randomly selected
retail outlets across 14 states. Antibiotic usage claims on the poultry
packaging were used to categorize the sample as conventionally raised
or labeled as antibiotic‐free. Pearson's chi‐square tests and Student t‐
tests were used to compare drug resistance classes between isolates
from poultry meat with and without antibiotic‐related claims. Genetic
mechanisms for resistance to selected antibiotics were investigated in
a subset of isolates.
Results: The prevalence of Salmonella in conventional poultry meat
was 11.8% (3,494/29,522) versus 8.8% (299/3,389) in poultry meat
labeled as antibiotic‐free (p < 0.0001). Salmonella from conventional
poultry meat was more likely to be resistant to 3 or more drug classes
(27.3%, 954/3,494) as was poultry meat labeled as antibiotic‐free
(10.0%, 30/299) [p < 0.0001]. Salmonella from conventional poultry
exhibited significantly higher resistance in 5/9 drug classes including
tetracycline (p = 0.0379) and penicillin (p < 0.0001). Beta‐lactam resis-
tance genes including blaCMY‐2 were higher in isolates from conven-
tional meat compared with isolates from samples labeled as
antibiotic‐free, 16.1% (215/1328) versus 5.2% (11/209) [p < 0.0001].
Conclusions: Conventionally‐raised poultry meat was more likely to be
contaminated with multi‐drug resistant Salmonella. The presence of
genes that decrease the power of antibiotics to treat patients with
severe salmonellosis is concerning. These findings, from a decade‐long
collaborative national surveillance effort, highlight importance of judi-
cious use of antibiotics in food‐producing animals.
998 | Respiratory viral testing and
antimicrobial de‐escalation among
hospitalized patients at a tertiary care facility,
2015–2016: A matched cohort study series
Alan C. Kinlaw1; Emily J. Ciccone1; Melissa B. Miller1;
David J. Weber1; Jonathan J. Juliano1; Ravi Jhaveri1,2; Zachary Willis1
1University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Northwestern University, Chicago, IL
Background: The use of multiplex respiratory viral panel (RVP) tests is
increasing. Although costly, they enable identification of pathogens
that would otherwise be clinically undetectable. These tests have the
potential to limit unnecessary antibiotic use, but data are limited on
their clinical effectiveness.
Objectives: To estimate risk differences (RD) for the relation between
positive (+) and negative (−) inpatient respiratory viral tests (RVP vs
rapid polymerase chain reaction, PCR, tests for influenza with or with-
out respiratory syncytial virus) and subsequent antimicrobial de‐esca-
lation (discontinuation, intravenous to oral, or spectrum narrowing).
Methods: We reviewed electronic health record data on adults
(age ≥ 18 years) who were admitted to an inpatient floor or stepdown
unit at University of North Carolina Hospitals and had a respiratory viral
test collected within 48 hours of admission between September 2015–
April 2016 (n = 1342).We estimated3‐day RDs for the relation between
respiratory viral testing and antimicrobial de‐escalation. To control con-
founding and account for the 37‐hour mean lag between PCR (faster)
and RVP (slower) tests resulting, we leveraged the treatment decision
design over a series of 1:1 matched cohort studies. Each study targeted
a clinically relevant scenario: 1) orderingRVP test (vs noRVPorder) after
learning PCR‐ status; 2) learning RVP+ result (vs no RVP result) after
knowing PCR‐ status; 3) learning RVP+ result (vs RVP‐) after knowing
PCR‐ status; and 4) learning RVP+ result (vs RVP‐) given no prior PCR.
For each subcohort, referent patients were matched to index patients
by self‐reported race, self‐reported gender, respiratory viral test in prior
month (y/n), age (+/−10 years), and season (+/−1.7 months).
Results: The overall cohort was 61% White, 29% African‐American,
51% female, and median age was 56 years (IQR 39–69). Across all
matched subcohorts, the matching success rate ranged 79–88% and
referent 3‐day risk of antimicrobial de‐escalation ranged 0.6%–1.9%.
In scenario 1, ordering RVP results was associated with higher de‐
escalation (3‐day RD 7.6%; 95% confidence limits [CL] 3.2%, 12.1%).
In scenarios 2–4, learning RVP+ results was associated with even
higher de‐escalation (3‐day RDs 14.8%, 13.8%, and 15.4%, respec-
tively; largest 95% CL difference was 21.9%).
Conclusions: RVP testing and positive RVP results were associated
with increased antimicrobial de‐escalation. Future research should
evaluate potential effect modification across patient subgroups and
cost‐effectiveness of these tests.
999 | Comparing hospital and primary care
physicians' attitudes to antibiotic resistance
João C.F. Nunes1; António Teixeira Rodrigues2,3,1;
Adolfo Figueiras4,5,6; Fátima Roque7,8; Maria T. Herdeiro1
1Department of Medical Sciences, Institute of Biomedicine – iBiMED,
University of Aveiro, Aveiro, Portugal; 2Faculdade de Farmácia da
Universidade de Coimbra (FFUC), Coimbra, Portugal; 3Centro de Estudos
Farmacêuticos da (CEFAR) da Associação Nacional de Farmácias, Lisbon,
Portugal; 4Consortium for Biomedical Research in Epidemiology & Public
Health (CIBER en Epidemiología y Salud Pública ‐ CIBERESP), Santiago
Compostela, Spain; 5Department of Preventive Medicine and Public
Health, University of Santiago de Compostela, Santiago Compostela,
Spain; 6Health Research Institute of Santiago de Compostela (Instituto de
Investigación Sanitaria de Santiago de Compostela ‐ IDIS), Clinical
University Hospital of Santiago de Compostela, Santiago Compostela,
Spain; 7Research Unit for Inland Development, Polytechnic of Guarda
(UDI‐IPG), Guarda, Portugal; 8Health Sciences Research Centre,
University of Beira Interior (CICS‐UBI), Covilhã, Portugal
Background: Misuse of antibiotics either in primary care and hospital
setting has been identified as one of the main causes of bacterial
resistance.
Objectives: To identify attitudes of hospital and primary care physi-
cians about antibiotic resistances.
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Methods: The study was conducted in Portugal's Central Regional
Health Administration and included 480 physicians working in primary
care and 125 in working in hospitals setting, all in the National Health
Service (NHS). A self‐administered questionnaire with 17 statements
regarding knowledge and attitudes towards antibiotic prescribing,
antibiotic use and antimicrobial resistance was sent to the physicians.
The statements were followed by a continuous visual analog scale
(VAS) for respondents to mark with a cross, accordingly to their agree-
ment with the sentence (from 0 to 20).
Results: Both primary care and hospital physicians report high agree-
ment with the importance antibiotic resistances in their own setting,
and that the dispensing antibiotics without a prescription should be
more closely controlled. Primary care physicians are more convicted
that new antibiotics will be developed to solve the problem of resis-
tance [Percentile 75: 16, 11; p < 0,001], and that the prescription of
an antibiotic to a patient does not influence the possible appearance
of resistance [Percentile 75: 10, 3; p < 0,001]. They also have higher
accordance with the use of a broad‐spectrum antibiotic, in case of
doubt, to ensure that the patient is cured of an infection [Percentile
75: 16, 13; p = 0,013]. Physicians working in hospital setting have
higher accordance that in a primary‐care context, one should wait
for the microbiology results before treating an infectious disease [Per-
centile 75: 15, 11; p = 0,012].
Conclusions: This study revealed some differences between primary
care and physicians' attitudes and perceptions about antibiotics use
and bacterial resistances. A project to improve antibiotics use, the
eHealthResp Project [FCT (PTDC/SAU‐SER/31678/2017)] was
approved to evaluate the effectiveness of e‐Health tools in supporting
clinical decision‐making and empowerment of patients in the manage-
ment of upper respiratory tract infections. Acknowledgements: Project
PTDC/SAU‐SER/31678/2017, supported by the operational program
of competitiveness and internationalization (POCI), in its FEDER/
FNR component POCI‐01‐0145‐FEDER‐031678, and the Foundation
for Science and Technology, in its state budget component (OE) and
Institute for Biomedicine ‐ iBiMED (UID/BIM/04501/2013 and
POCI‐01‐0145‐FEDER‐007628).
1000 | The role of comorbidities, infections,
and treatments in sepsis: A retrospective
analysis of a large United States electronic
health record database
Georgios Varsos; Fred W. Peyerl; Meng Shen; Kunal Lodaya;
Halit Yapici; Laxmi Gannu; Apeksha Shenoy; David K. Hayashida;
Fabian D'Souza
Boston Strategic Partners, Inc., Boston, MA
Background: Sepsis is defined as life‐threatening organ dysfunction
caused by a dysregulated host response to infection, affecting more
than one million patients per year in the United States. Chronic
comorbid conditions that alter the immune system could also lead to
sepsis.
Objectives: The objective of the present study was to examine comor-
bidities, complications, common pathogens, infections, and treatments
of sepsis.
Methods: This retrospective study examined data from a U.S. elec-
tronic health record database (Cerner Health Facts®). All inpatient
visits (age ≥ 18 years) between 2012–2016 with a principal ICD9/
10 diagnosis of sepsis were included in the analysis. Chronic comorbid
medical conditions, complications, and infections were characterized
by corresponding ICD9/10 diagnosis codes. Laboratory test results
and medications were examined to analyze treatment patterns.
Results: The study included 510,720 sepsis‐related visits (50.2%
female), with 49.7% of the cohort over 65 years old. Septic shock
was present in 16.2% of visits, while 14.2% were in severe stage.
The most prevalent comorbid conditions were chronic obstructive pul-
monary disease (33.9%) and diabetes (33.5%). Organ failure was a
major complication seen in 59.5% of visits. Urinary tract infection
(31.4%) and pneumonia (31.2%) were observed to be the most com-
mon infections. The top pathogen identified was gram‐negative rod/
bacillus (13.7%), followed by E. coli (12.3%). During susceptibility test-
ing for gram‐negative rod/bacillus, aminoglycosides were the most
commonly tested (2,816 tests). Gram‐negative rod/bacillus was highly
susceptible to quinolones (96.6%; 1,792 of 1,856 tests) and was most
resistant to aminopenicillins (54.4%; 992 of 1,824 tests). IV hydration/
fluid challenges (79.5%) and antibiotics (73.2%) were most commonly
used for the treatment of sepsis. Within antibiotics, vancomycin
(28.1%), levofloxacin (21.6%), and ceftriaxone (20.9%) were prescribed
often.
Conclusions: This large database analysis provides insights on the
pathogenesis, comorbidities and most often employed diagnosis/
treatment strategies for sepsis.
1001 | Single nucleotide polymorphisms of
Pfdhfr and Pfdhps: Implications on
prophylactic malaria control measures in
Maiduguri, Northeast Nigeria
Sulayman Tunde Balogun1; Umar Kyari Sandabe1;
Olufunke Adebola Sodipo1; Kenneth O. Okon2;
Ayodele Oluwasoji Akanmu1; Fatai Adewale Fehintola3
1University of Maiduguri, Maiduguri, Nigeria; 2Federal Medical Centre,
Makurdi, Nigeria; 3University of Ibadan, Ibadan, Nigeria
Background: Prophylactic malaria control measures with Intermittent
Prophylactic Treatment in Pregnancy (IPTp), Intermittent Prophylactic
Treatment in Infancy (IPTi) and Seasonal Malaria Chemoprevention
(SMC) largely depend on efficacy of sulphadoxine‐pyrimethamine (SP).
Objectives: The present study assessed Single Nucleotide Polymor-
phisms (SNPs) of Pfdhfr and Pfdhps in Maiduguri, Northeast Nigeria
in other to ascertain the efficacy of SP in the region.
Methods: Dried blood‐spot (DBS), Giemsa‐stained thick and thin
blood smears were collected from 63 randomly selected subjects of
both sexes, aged <1–80 years with malaria parasitaemia at three study
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sites in Maiduguri between May and October, 2018 following an
informed consent. Plasmodium specie was determined and parasite
density (PD) was estimated using the smears. Genomic DNA (gDNA)
of P. falciparum was extracted from the DBS using QIAamp DNA Mini
Kit. The gDNA was subjected to Nested Polymerase Chain Reaction
(PCR) followed by Restriction Fragment Length Polymorphism (RFLP)
to determine SNPs at codons N51I, C59R and S108 N of Pfdhfr and
codons S436A/F, A437G and K540E of Pfdhps. The data were sub-
jected to statistical analysis using appropriate tools.
Results: The geometric mean PD of the 63 subjects was 8845 (2100–
13,400) asexual parasites/μl blood. The PD was neither influenced by
study sites (p > 0.05), age (p > 0.05) nor sex (p > 0.05) of the subjects.
The prevalence of triple Pfdhfrmutant alleles (51I, 59R and 108 N) was
60.3% (38/63) and was significantly higher (p < 0.05) than triple wild
alleles (N51, C59 and S108) with 17.5% (11/63). The prevalence of
the triple mutation was significantly higher (p < 0.05) among female
(68.4%; 26/38) than male (48.0%; 12/25) subjects. Mutant allele
108 N had significantly highest (p < 0.05) prevalence (82.5%; 52/63)
than 51I (60.3%; 38/63) and 59R (66.7%; 42/63). Double mutation
of Pfdhps at codons S436A and A437G was recorded in 4.8% (3/63)
of the samples with individual prevalence of 28.6% (18/63) and
27.0% (17/63) for 436A and 437G mutants, respectively (p > 0.05).
No mutation was recorded at codon K540E.
Conclusions: The detection of mutant alleles of Pfdhfr and Pfdhps in
the present study could be an indication of compromised efficacy of
SP in Maiduguri, hence, the need for caution in the implementation
of IPTp, IPTi and SMC in the region. These findings could contribute
to success of malaria prophylaxis. However, urgent clinical and robust
molecular studies may be required to ascertain the efficacy of the
drugs prior to introduction of other prophylactic measures.
1002 | Association between phosphate
disturbance and mortality among critically ill
patients with sepsis and septic shock
Albatoul Al Meshari1; Shmeylan Al Harbi2; Hassan Al Dorzi2;
Yassin Arabi2; Hani Tamim2; Sheryl Abdukahil2
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 2King Abdulaziz
Medical City, Riyadh, Saudi Arabia
Background: Phosphate disturbance is one of the most common elec-
trolyte disturbances encountered in the intensive care unit (ICU).
There are limited studies linked it with increased ICU mortality. How-
ever, results still controversial.
Objectives: The aim of this study is to examine the association
between hypophosphatemia, hyperphosphatemia on day one of the
ICU admission and the ICU and hospital mortality in critically ill
patients with septic and septic shock.
Methods: This is a retrospective cohort study that include adult
patient with age ≥ 18 years old, critically ill with septic or septic shock,
and admitted in either surgical, trauma or medical intensive care unit
between January 2014 to September 2017. The patients divided into
three groups based on their serum phosphate level during the first
24 hours of ICU admission. The hypophosphatemia less than
0.73 mmol/L, and hyperphosphatemia more than 1.52 mmol/L. The
primary endpoints were all‐cause ICU and hospital mortality. Second-
ary endpoints were ICU, hospital length of stay, and mechanical venti-
lation duration. Baseline characteristics and outcomes were reported
as numbers and percentages for categorical variables and were com-
pared among groups using Chi‐square test. While continuous variables
reported as means and standard deviations using ANOVA test. Multi-
variate logistic regression analysis was used to determine if phosphate
level was an independent predictor for ICU or hospital mortality.
Results were presented as adjusted odds ratio (OR) and 95% confi-
dence intervals.
Results: Of the 1422 patients enrolled in the study, 188 (13%) were
categorized as hypophosphatemia, 369 (26%) as hyperphosphatemia,
and 865 (61%) as normophosphatemia at day one of their ICU admis-
sion. There were significant association between hyperphosphatemia
and ICU mortality (adjusted OR 1.5, 95% CI 1.0–2.1, P = 0.04), and
hospital mortality (adjusted OR 1.7, 95% CI 1.2–2.3, P = 0.002). How-
ever, there was a reduction on mortality between hypophosphatemia
and ICU mortality (adjusted OR 0.5, 95% CI 0.27–0.9, P = 0.02), but
was not significant with hospital mortality (adjusted OR 0.8, 95% CI
0.54–1.32, P = 0.46). Furthermore, there were no significant differ-
ences in ICU and hospital length of stay or mechanical ventilation
duration between the groups.
Conclusions: Hyperphosphatemia is associated with increased ICU
and hospital mortality in critically ill septic and septic shock patients.
It serves as a strong independent risk factor for mortality. Future inter-
ventional studies are required to define the causal relationship
between phosphate level and mortality.
1003 | CD4+ count and antiretroviral
therapy contributing to patterns of prolonged
amenorrhea among women with or at‐risk of
the human immunodeficiency virus
Laura M. Bozzi; O'Mareen Spence; Susan dosReis
University of Maryland School of Pharmacy, Baltimore, MD
Background: Recent studies have shown that one‐third of HIV‐
infected women experience 12 months or more of prolonged amenor-
rhea (PA). This occurs more commonly in HIV‐infected women relative
to the general population. Research to date has not fully explored the
association between CD4+ and antiretroviral therapy (ART) and inter-
mittent PA.
Objectives: To assess the association between baseline
sociodemographic, clinical, and treatment characteristics and intermit-
tent PA.
Methods: Our study included 1,374 HIV+ and at‐risk HIV‐ women
age ≥ 18 years in the Women's Interagency HIV Study longitudinal
cohort with at least one episode of PA, defined as 12 months of
self‐reported amenorrhea. We excluded women with hysterectomy
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and double oophorectomy at any point, and women lost to follow‐up
after the first episode of PA. Patterns of amenorrhea were classified
as: 1) single PA episode without resumption of menses, 2) single PA
episode with resumption of menses, and 3) intermittent PA episodes.
Baseline characteristics include: age at first PA (<45 years; ≥45 years),
ART use, HIV status, race/ethnicity, BMI (underweight, normal, over-
weight/obese), current smoker, alcohol use (≥3 drinks/day), diabetes,
hepatitis, and CD4+ count. We conducted bivariate chi‐square analy-
sis, and multinomial logistic regression in a subset of HIV+ women
(n = 773) to examine the association between baseline ART and
CD4+ with PA group (reference = single PA episode without resump-
tion of menses), adjusting for all other baseline characteristics.
Results: Of our total sample, 66% (n = 910) had a single PA episode
without resumption of menses, 7% (n = 90) had a single PA episode
with resumption of menses, and 27% (n = 374) had intermittent PA
episodes. Age at first PA, current smoker, alcohol use, BMI, race/eth-
nicity, and Hepatitis C coinfection were significantly associated with
PA group. Baseline ART was not significantly different between
women with a single PA episode with resumption of menses (OR:
0.68; 95% CI: 0.24–1.91) or intermittent PA (OR:1.54; 95% CI: 0.84–
2.84) compared to women with a single PA episode who did not
resume menses. Relative to women with a single PA without resump-
tion of menses, women with a single PA episode and resumption of
menses were less likely to have low CD4+ between 200–500 cells/
mm3 (OR: 0.44; 95% CI: 0.20–0.98) and Hepatitis C coinfection (OR:
0.27; 95% CI: 0.09–0.82).
Conclusions: Low CD4+ count was associated with decreased likeli-
hood of resumed menses. Future research is warranted to see if
time‐varying CD4+ and ART, which alters CD4+, are associated with
PA group.
1004 | Bacteriological study and
antibacterial susceptibility of Ludwig's angina
Md. Mehedi Hasan1,2; Naima Ahmed Tamanna3; Md. Jamal Uddin4
1Square Hospitals Ltd., Dhaka, Bangladesh; 2Dhaka Medical College &
Hospital, Dhaka, Bangladesh; 3 Islamic University, Kushtia, Kushtia,
Bangladesh; 4University of Copenhagen, Copenhagen, Denmark
Background: The knowledge of the local pattern of infection and anti-
bacterial sensitivity in Ludwig's angina is essential to enable effica-
cious treatment for it. However, no previous studies in Bangladesh
have investigated the pattern of bacteria responsible for developing
Ludwig's angina and antibiotic sensitivity.
Objectives: We aimed to evaluate the association between microor-
ganisms responsible for Ludwig's angina and antibiotic sensitivity.
Methods: A prospective observational cohort study carried out from
April 2016 to September 2016 in the Department of Otolaryngology
& Head Neck Surgery (Dhaka Medical College Hospital, Bangladesh)
and Department of Clinical Microbiology (International Centre for
Diarrhoeal Disease Research, Bangladesh). A total of 100 patients with
Ludwig's angina were included in the study. The responsible micro‐
organisms and antibiotics sensitivity test were performed for all
patients. Data were analyzed using a logistic regression through SPSS.
Results: The most frequently isolated organism in Ludwig's angina was
Streptococcus (40%) followed bt Staphylococcus aureus (23%). The aer-
obic bacteria were found to be 60% resistant to doxycycline, 59% to
penicillin‐G and 59%% to ampicillin, whereas they were found to be
65% susceptible to ceftriaxone, 58% to ceftazidime and 56% to cipro-
floxacin. The vancomycin was sensitive to 70% patients for Strepto-
coccus, odds ratios (OR) = 2.19 [95% confidence interval (CI): 0.90–
5.42] and to 65% patients for staphylococcus aureas, (OR) = 1.63
[(CI): 0.65–5.44].
Conclusions: Early diagnosis and treatment is essential to prevent
complications. All patients must be treated initially with intravenous
antibiotics, with treatment subsequently updated based on a culture
and sensitivity report to reduce the mortality and morbidity.
1005 | Epidemiology of respiratory syncytial
virus‐associated illnesses in young children
AnnW. McMahon1; Noelle Cocoros2; Amol Purandare3; Nicole Haug2;
Michael Nguyen1; Prabha Viswanathan1
1Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School, Boston, MA; 3University of Missouri‐Kansas City School of
Medicine, Kansas City, MO
Background: RSV‐associated illness (RSV‐AI) is a primary cause of
morbidity and hospitalization of young children and infants, most
often presenting as bronchiolitis or other types of lower respiratory
tract infection.
Objectives: To determine clinical and demographic factors of RSV‐AI
cases and explore epidemiologic patterns of RSV‐AI in a cohort of
young children in the U. S to inform RSV product development.
Methods: This retrospective cohort analysis used claims data obtained
from 16 Data Partners contributing to the FDA's Sentinel System. We
identified RSV‐AI cases in children 1 month to 5 years from Jan. 2008
through June 2016. An RSV‐AI case was defined as an RSV diagnosis
code in the child's claims data during the study period. Baseline char-
acteristics examined included care setting of RSV‐AI diagnosis and
three RSV risk factors: prematurity, chronic lung disease (CLD), and
congenital heart disease (CHD). Risk factors were identified by occur-
rence of a relevant diagnosis code in the child's claims history from
birth through the RSV‐AI index date for prematurity, and through
2 months post RSV‐AI index date for CLD and CHD. RSV diagnoses
were classified by care setting: inpatient hospital stays or outpatient
encounters (emergency department and ambulatory care). We calcu-
lated the proportion of RSV‐AI cases with the risk factors of interest
and other demographic characteristics by care setting.
Results: Our analysis identified 138,669 cases of RSV‐AI among chil-
dren 1–6 months of age and 179,259 cases among children 7 to
60 months of age. Outpatient encounters predominated in both age
groups (1–6 months: N = 24,192 inpatient, N = 119,363 outpatient;
7–60 months: N = 20,002 inpatient, N = 156,019 outpatient). Children
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with documented risk factors for RSV‐AI comprised a small proportion
of total cases [CLD lt3%, CHD lt6%, extremely preterm (lt29 weeks)
lt5% for both groups].
Conclusions: It is well acknowledged that RSV‐AI is a significant con-
cern in children with CLD, CHD, or prematurity. However, using the
Sentinel System, we found that most children with RSV‐AI did not
have these risk factors. Future development of new RSV prophylactics
and therapeutics will need to consider these findings.
1006 | Identification of ordinal endpoints
indicating influenza complications: A
feasibility study relevant to the study of
medical countermeasures
Austin C. Cosgrove1; Nicole R. Haug1; Catherine A. Panozzo1;
Gregory T. Measer2; Robert P. Orr2; Alfred F. Sorbello2;
Henry Francis2; Crystal J. Garcia1; Sarah K. Dutcher2;
Noelle M. Cocoros1
1Harvard Pilgrim Health Care Institute and Harvard Medical School,
Boston, MA; 2US Food and Drug Administration, Silver Spring, MD
Background: Medical countermeasures (MCMs) are FDA‐regulated
products used in the event of a public health emergency. “Ordinal end-
points” (categorical outcomes evaluated on an ordered scale, e.g.
increasing severity) of influenza complications may be useful in evalu-
ating the utilization, safety, and/or effectiveness of influenza‐related
MCMs.
Objectives: To determine whether ordinal endpoints can be identified
for patients with influenza in the Sentinel System.
Methods: Using the Truven Health MarketScan® Databases in the
Sentinel Common Data Model, we identified health plan members
over 6 months of age with influenza‐like illness (ILI). ILI was identified
using ICD‐9‐CM and ICD‐10‐CM diagnosis codes (without lab confir-
mation) in the outpatient and emergency department settings in two
periods (July 2014–June 2015 and July 2015–June 2016). Starting
on the day of ILI diagnosis through 30 days after, we identified inpa-
tient admissions; using diagnosis and procedure codes, we identified
use of critical care, supplemental oxygen, mechanical ventilation, and
extracorporeal membrane oxygenation (ECMO). We calculated the
rate of these endpoints per 10,000 ILI diagnoses by period and age
group. We also calculated the proportion of the cohorts with influenza
vaccination (183‐day lookback) and influenza testing (days 0 through
30).
Results: We identified 551,777 ILI diagnoses in 2014–15. The end-
point rates ordered from least to most severe were: 111/10,000 ILI
diagnoses for inpatient care, 84/10,000 for critical care, 3/10,000
for supplemental oxygen, 6/10,000 for mechanical ventilation, and
0.14/10,000 for ECMO. Members over 65 years had the highest rate
of hospitalization following ILI diagnosis (836/10,000) as well as all
other endpoints, but they had the lowest rate of influenza testing
(3,747/10,000 compared to 6,999/10,000 among all other ages).
One‐quarter (25%) of patients with ILI had evidence of influenza
vaccination. We identified 267,314 diagnoses of ILI in the 2015–16
period and endpoints were captured at somewhat higher rates com-
pared to the prior period. Influenza vaccination was observed among
17% of those with ILI in the 2015–16 period; influenza testing
occurred among 66%.
Conclusions: We demonstrated the feasibility of identifying complica-
tions among individuals diagnosed with ILI, via ordinal endpoints, in a
large claims database. However, mechanical ventilation and supple-
mental oxygen may not be well captured due to the nature of billing
practices. Next steps include conducting this analysis in the Sentinel
System.
1007 | Hospitalizations due to Klebsiella
pneumoniae pneumonia in the United States
Naimisha Movva1; Paul Warrener2; Bret Sellman2; Jon Fryzek1
1EpidStrategies, A Division of ToxStrategies, Inc., Rockville, MD;
2AstraZeneca, Rockville, MD
Background: Klebsiella pneumoniae are an important source of commu-
nity‐acquired pneumonia. The prevalence of pneumonia infections
associated with K. pneumoniae has not been explored in the United
States (US) recently.
Objectives: To determine the rates of K. pneumoniae in the (US) using
National Inpatient Sample (NIS) Data and compare results with
existing literature.
Methods: Pneumonia associated with K. pneumoniae infections were
identified for 2012–2014 using the ICD‐9‐CM code 482.0 (K.
pneumoniae pneumonia) in the NIS, which provides data on inpatient
visits from a sample of US hospitals. Age‐ and gender‐specific hospi-
talization rates were calculated by dividing the number of hospitaliza-
tions for each gender & age group by the US population and then
averaging the rates. Two targeted literature searches were conducted
using PUBMED to estimate rates of K. pneumoniae pneumonia in the
US: the first to identify the proportion of pneumonia cases due to K.
pneumoniae, and the second to identify studies describing the total
prevalence of pneumonia. The proportion of pneumonia associated
with K. pneumoniae was then applied to the rate of pneumonia to
determine the literature‐based rate of K. pneumoniae pneumonia.
Rates calculated from the NIS data and the literature estimates were
applied to the US 2017 population to determine the prevalence of K.
pneumoniae.
Results: From 2012–2014, 66,065 hospitalizations were identified
with K. pneumoniae pneumonia in the NIS. There were 7.1 hospitaliza-
tions per 100,000 people per year on average. Higher rates of hospi-
talizations were consistently found among males (8.7 vs 5.5) and the
elderly (≥65: 28.7 vs <65: 3.6). Using the proportion of pneumonia
comprised by K. pneumoniae and the total prevalence of pneumonia
identified in the literature, the rate was estimated at 29.26 cases per
100,000 people per year; substantially more than the overall NIS esti-
mate, though similar to the NIS rate observed in the elderly. This may
be explained by the population included in the study used as the
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prevalence estimate for K. pneumoniae pneumonia, which had a
median age of 57.
Conclusions: NIS data is a conservative, population‐based estimate
and may be more robust than the literature‐based estimates, which lit-
erature are often determined from smaller subsets of specific popula-
tions and may not be an accurate representation of the true disease
burden. It is important to assess the representativeness of the patient
population before making national estimates of disease burden.
1009 | A conceptual model to evaluate
disease‐related stigma and access to
healthcare among patients with hepatitis C
virus infection
M. Elle Saine; Vincent Lo Re III; Julia E. Szymczak
Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA
Background: The number of individuals with hepatitis C virus (HCV)
infections has tripled since 2010, due to increasing injection opioid
use, and HCV now causes more deaths each year than any other infec-
tious disease. Despite curative medications, most patients remain
undiagnosed, are not linked into care, and do not receive antiviral
treatment. Disease‐related stigma, a social process linking individual
attributes to medical diagnoses, is associated with poor health out-
comes and decreased quality of life. Disease‐related stigma may be
intensifiedamong patients experiencing multiple forms of stigma, such
as due to racism or substance use. Several studies have called for con-
ceptual models to assess the impact of stigma on access to healthcare
and aid the development and testing of interventions.
Objectives: This paper proposes a conceptual model of the determi-
nants and consequences of HCV‐related stigma in access to
healthcare, treatment initiation, and antiretroviral adherence.
Methods: We conducted semi‐structured interviews among 20
patients with a history of HCV infection who presented to care at five
academic and community‐based outpatient clinics across Philadelphia.
We collected narrative data on patient experiences with HCV and sit-
uations within which perceptions of stigma arise and influence
engagement with healthcare.
Results: We identified multiple intersecting stigmatized attributes,
such as injection drug use, HIV coinfection, race, and poor HCV‐
related knowledge, which may amplify experiences of stigma among
patients with HCV. As a result of HCV‐related stigma, patients
described social distancing by family and friends, often choose not
to disclose their HCV status, and/or felt socially and emotionally
isolated.
Conclusions: Using an iterative approach, we developed a conceptual
model that links HCV‐stigma, stigmas of other attributes, and the
social effects on the patient's access to HCV testing, linkage to care,
and HCV treatment adherence. This model can be used to guide
research and interventions to improve patient engagement in care
and health‐related quality of life.
1010 | Geospatial analysis of gonorrhea
incidence, antibiotic resistance and internet
usage
Simon F. Semus; Fanny S. Mitrani‐Gold
GlaxoSmithKline, Collegeville, PA
Background: A geospatial analysis was performed to further under-
stand the relationship between gonorrhea incidence, antibiotic resis-
tance and internet usage has been performed.
Objectives: To investigate the purported relationship between the
increase in gonorrhea incidence and antibiotic resistance reported at
the country level in Europe and the use of hookup apps.
Methods: Gonorrhea incidence and resistance to the commonly pre-
scribed antibiotics, Ciprofloxacin, Azithromycin, Cefixime and Penicil-
lin G were obtained from the European Center for Disease Control
(ECDC) Surveillance Report 2014. Additional country level data that
represent general population characteristics and demographics were
obtained from the World Bank and Social Progress Index. Maps were
created in ArcGIS by combining the aforementioned data sources with
World boundary shapefiles, missing data were modeled using an
Inverse Distance Weighted (IDW) algorithm. Statistical analysis by
Principle Component Analysis (PCA) and Partial Least Squares (PLS)
as implemented in Simca 13.0 was combined with visual data explora-
tion performed in Spotfire.
Results: The PLS model obtained was moderately predictive of gonor-
rhea incidence across the full dataset, with ciprofloxacin resistance
and internet usage being among the most important variable descrip-
tors. Countries with the highest ciprofloxacin resistance were visually
selected from a box plot where the European region was divided geo-
graphically. The relationship between gonorrhea incidence and inter-
net usage was updated on a scatter plot to reflect the selected
countries, whereupon a strong correlation was observed. This was
not the case when all countries where included in the analysis.
Conclusions: A subset of European countries with high ciprofloxacin
resistance, predominantly situated through the center of the conti-
nent, demonstrated a strong relationship between gonorrhea inci-
dence and internet usage. This study may support the notion that an
increasing trend in gonorrhea incidence in certain countries could be
related to the use of internet‐based dating apps.
1011 | Describing the epidemiology of cold
and flu in hypertensive patients in the US by
analyzing with novel observational health
data sciences and informatics (OHDSI) tools
Beth K.L. Russell1; Pareen Vora1; Montse Soriano‐Gabarro1;
Charlene Ng2
1Bayer AG, Berlin, Germany; 2Bayer U.S. LLC, Whippany, NJ
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Background: With recent changes to guidelines published by the
American College of Cardiology/American Heart Association (ACC/
AHA), nearly half of all adult Americans are classified as having hyper-
tension (HBP). Oral decongestants, commonly taken by patients to
relieve nasal congestion due to cold or influenza (flu), may cause an
increase in blood pressure. The AHA therefore advises that hyperten-
sive patients be cautious in choosing cold/flu products.
Objectives: The aim of this study is to describe the characteristics and
incidence of patients in the United States (US) who are hypertensive
and have had at least one diagnosis of cold or flu.
Methods: The US Truven Market Scan Medicare Supplemental bene-
ficiaries (MDCR) and Commercial Claims and Encounters (CCAE) data-
bases converted to the Observational Medical Outcomes Partnership
(OMOP) Common Data Model (CDM) were used as data sources in
this study. MDCR includes elderly patients who are 65 or older. The
exposure of interest was a diagnosis of HBP whilst the primary out-
come was incidence rates of cold or flu annually from 2007–2016.
The secondary outcomes included identifying any seasonal trends in
incidence rates by looking at the monthly incidence rates as well as
describing patient characteristics such as comorbidities and co‐medi-
cations. ATLAS tool within OHDSI platform was used to create
cohorts and calculate the incidence rates.
Results: The majority of HBP patients with at least one diagnosis of
cold or flu were aged 40 and over. The most common comorbidities
in this patient population were inflammation, pain and hyperlipidaemia.
The average incidence rates of HBP patients with at least one diagno-
sis of cold or flu between 2007 and 2016 were 1.07 and 1.75 per 1000
person years in CCAE, respectively, and 0.70 and 0.85 in MDCR,
respectively. Incidence rates were lowest in 2007 for both cold and
flu. The incidence of flu peaked (4.05) in 2009, dropped in 2010,
before gently increasing until 2014 when the rate decreased again. In
contrast, the incidence rates of cold remained fairly stable over time.
Seasonally, the incidence rates were generally highest in December
and March each year for both cold and flu. The study results also
shows a peak for flu in 2009 when the pandemic flu occurred in US.
Conclusions: The results from this retrospective observational study
show that cold and flu are frequent events in patients diagnosed with
HBP. The incidence rates for HBP patients with at least one diagnosis
of cold or flu have been shown to fluctuate over time but typically
increase between the months of December and March.
1012 | Aerobic micro‐organisms and
antibiotic sensitivity: A study on head and
neck space infection
Md. Mehedi Hasan1,2; Naima Ahmed Tamanna3; Md. Jamal Uddin4
1Square Hospitals Ltd., Dhaka, Bangladesh; 2Dhaka Medical College &
Hospital, Dhaka, Bangladesh; 3 Islamic University, Kushtia, Kushtia,
Bangladesh; 4University of Copenhagen, Copenhagen, Denmark
Background: Antibiotics are extensively used in daily clinical practice
in many developing countries including Bangladesh. However, no
previous studies in Bangladesh have investigated in the association
between aerobic micro‐organisms and antibiotic sensitivity of head
and neck space infection.
Objectives: We aimed to evaluate the association between aerobic
microorganisms and antibiotic sensitivity for infections and antimicro-
bial susceptibility in head and neck (single and multiple) abscesses.
Methods: A prospective observational cohort study carried out from
January 2016 to July 2016 in the Department of Otolaryngology &
Head Neck Surgery (Dhaka Medical College Hospital, Bangladesh)
and Department of Clinical Microbiology (International Centre for
Diarrhoeal Disease Research, Bangladesh). After considering inclusion
and exclusion criteria, a total of 100 patients in both sex with deep
neck infections were included. The aerobic micro‐organisms and anti-
biotics sensitivity test were performed for all patients. Data were ana-
lyzed using a logistic regression through SPSS.
Results: The highly common bacteria were Staphylococcus aureus
(23%) and acinetobacter species (16%). The aerobic bacteria were
found to be 82% resistant to cefixim, 79% to azithromycin and 65%
to ampicillin. The antibiotic Ceftriaxone was most (89% patients) sen-
sitive for acinetobacter species, odds ratios (OR) = 2.67 [95% confi-
dence interval (CI): 0.75–9.42] and to 79% patients for
staphylococcus aureas, (OR) = 2.32 [(CI): 0.65–8.33].
Conclusions: Although there is a big signal for antibiotics sensitivity,
because of low power, we did not identify any significant associations
between aerobic microorganisms and antibiotic sensitivity. We recom-
mend to treated patients initially with intravenous antibiotics using
proper guidelines to reduce the antibiotic resistance.
1013 | Patient characteristics and current
management of systemic lupus
erythematosus patients in a large,
representative US‐based real world registry
cohort
Kathleen Mortimer; Kathryn Starzyk; Thomas Brecht; Shannon Cerf;
Phillip Ballentine; Richard Gliklich
OM1, Boston, MA
Background: Systemic lupus erythematosus (SLE) is a heterogeneous,
multifactorial disease with a debilitating and highly variable clinical
course. Real world data are critical to better understand these patients
and their unmet clinical needs, as clinical trials are by design highly
restrictive and typically not representative of the overall SLE
population.
Objectives: To assess clinical, laboratory, symptomatic and disease
activity information in SLE patients.
Methods: The OM1 SLE Registry (OM1, Boston), an ongoing, contin-
ually enrolling, representative sample of patients with SLE in the U.S.
who are followed prospectively by specialists was used to characterize
patient characteristics, disease manifestations, and treatments. SLE
Registry patient data and linked administrative claims data from Janu-
ary 2013–December 2018 were utilized.
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Results: The average age of the 35,484 SLE Registry patients was
49.9 years (standard deviation = 15.1), and consistent with the epide-
miology of lupus, 92% of patients were female. Nearly 20% had evi-
dence of lupus nephritis, while 2% had lupus endocarditis or
pericarditis. While 8.5% of patients were treated with the disease‐
modifying therapy (DMT) Benlysta (belimumab), 75% were treated
with anti‐malarials and many with other ‘off label’ therapies. Nearly
one‐third of patients had at least a one Multi‐Dimensional Health
Assessment Questionnaire score (MDHAQ). Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) scores were reported for
over 1,400 patients. and 20% showed high or very high disease
activity.
Conclusions: Use of a representative, real‐world cohort of SLE
patients followed by rheumatologists provides unique information on
treatment patterns and outcomes. Disease activity scores may be use-
ful to identify patients for trials, but are not routinely collected in clin-
ical practice. Treatment options are currently limited to a single DMT
and more typically a combination of off‐label immunosuppressants
and steroids, demonstrating an unmet clinical need for patients with
this debilitating condition.
1014 | Predictors for poor drug‐resistant
tuberculosis treatment outcomes in the
Netherlands: A retrospective cohort study
Ivan Surya Pradipta1; Natasha van't Boveneind‐Vrubleuskaya2;
Onno Akkerman3; Hans Wouters1; Jan‐Willem Alffenaar4; Eelko Hak1
1Unit of Pharmaco‐Therapy, Epidemiology and Economics, University of
Groningen, Netherlands; 2Metropolitan Public Health Services the Hague,
The Hague, Netherlands; 3University Medical Centre Groningen,
Groningen, Netherlands; 4University Medical Centrum Groningen,
Groningen, Netherlands
Background: Population migration and complex treatment of drug‐
resistant tuberculosis (DR‐TB) patients are major issues in low inci-
dence TB countries.
Objectives:We aimed to analyze patient risk factors for poor outcome
of TB treatment among DR‐TB patients in the Netherlands.
Methods: This retrospective cohort study included adult patients with
confirmed DR‐TB treated from 2005 to 2015. We obtained data from
a nationwide exhaustive registry of tuberculosis patients in the Neth-
erlands. Predictors for unsuccessful TB treatment (defaulted and failed
treatment) and TB‐associated mortality were analyzed using multivar-
iate logistic regression.
Results: Among 10,303 registered TB patients, 545 patients with DR‐
TB (5%) were included. The majority of patients were foreign‐born
(86%) and newly diagnosed TB (89%) patients. The cumulative inci-
dence for unsuccessful treatment and mortality were 5% and 1%,
respectively. Among all DR‐TB cases, having Multidrug‐resistant TB
(MDR‐TB) (OR 4.43; 95%CI 1.70–11.60), being homeless (OR 9.10;
95%CI 2.32–35.74), and drug addiction (OR 6.66; 95%CI 1.72–
25.82) were predictors for unsuccessful treatment, while miliary and
central nervous systemTB (OR 15.60; 95%CI 2.18–111.52) were pre-
dictors for TB mortality. Furthermore, males (OR 9.80; 95%CI 1.18–
81.68) and drug addicts (OR 7.50; 95%CI 1.07–52.37) were identified
as independent predictors for poor treatment outcomes (unsuccessful
treatment or TB‐associated mortality) in the subgroup of MDR‐TB
cases.
Conclusions: The majority of cases were primary drug‐resistant and
foreign‐born. To further improve treatment outcome, special attention
should be given to the high‐risk DR‐TB patients.
1015 | Risk of venous thromboembolic
events in adult patients with systemic lupus
erythematosus: Systematic review and meta‐
analysis
Nick Pooley1; Jinoos Yazdany2; Julia Langham1; Lindsay Nicholson1;
Sue Langham1; Nina Embleton1; Xia Wang3; Barnabas Desta3;
Volkan Barut4; Edward R. Hammond3
1Maverex Limited, Manchester, UK; 2University of California, San
Francisco, CA; 3AstraZeneca, Gaithersburg, MD; 4AstraZeneca,
Cambridge, UK
Background: Although observational studies suggest people with sys-
temic lupus erythematosus (SLE) have a heightened risk of venous
thromboembolic events (VTEs), meta‐analyses that integrate evidence
across studies to estimate the pooled risk have not been performed.
Objectives: To conduct a systematic review and meta‐analysis to esti-
mate risk of VTE, including pulmonary embolism (PE) and deep vein
thrombosis (DVT), in patients with SLE.
Methods: We conducted a systematic review using MEDLINE and
EMBASE from inception to March 2018 to identify observational
studies (cohort and cross‐sectional) that evaluated risk of several
major cardiovascular outcomes in patients with SLE compared with a
general population or healthy controls (protocol published in PROS-
PERO 2018 CRD42018098690). Here, we report the results for
venous thromboembolic outcomes. Studies were included that pro-
vided effect estimates (relative risks or hazard ratios) for the calcula-
tion of pooled effect estimates. Random effects models were used
to calculate pooled risk ratios (RRs) and 95% confidence intervals
(CIs) separately for VTE, PE, and DVT. Visualization of funnel plots
and the Egger's test were used to evaluate publication bias. Robust-
ness of the results was tested using the leave‐one‐out function. Sen-
sitivity analysis was used to assess the impact of removing studies
with high risk of bias (ie, cross‐sectional).
Results: A total of 9 studies were identified for inclusion in the meta‐
analysis: 7 for VTE (including 2 cross‐sectional studies), 3 for DVT, and
4 for PE. Meta‐analysis of the VTE studies showed a significantly
increased RR of 3.67 (95% CI: 2.10 to 6.42) for patients with SLE com-
pared with a general population. Removing the 2 cross‐sectional stud-
ies did not impact the results (RR 4.06 [95% CI: 3.12 to 5.28]). The
pooled RRs for PE and DVT were 4.47 (95% CI: 1.79 to 11.15) and
5.51 (95% CI: 2.27 to 13.39), respectively. The statistical
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heterogeneity was high, with an I2 ranging between 92% and 99%.
Visual examination of the funnel plots showed evidence of publication
bias; however, this was not supported by the Egger's test results. The
leave‐one‐out function confirmed the robustness of the results.
Conclusions: Overall, risk of VTE was found to be significantly higher,
>3–6‐fold higher, among patients with SLE compared with the general
population. Future research should focus on assessing the impact of
traditional and SLE‐specific modifiable risk factors on VTE to further
identify patients with SLE most at risk to support targeting prevention
and treatment strategies.
1016 | Bariatric surgery increases the risk of
major osteoporotic fracture: A self‐controlled
case series patients from the CPRD GOLD
database linked to HES
Danielle E. Robinson1; Ian Douglas2; Garry D. Tan3; Cyrus Cooper4;
Antonella Delmestri1; M. Kassim Javaid1; Andrew Judge5;
Victoria Y. Strauss1; Daniel Prieto‐Alhambra1
1University of Oxford, Oxford, UK; 2London School of Hygiene & Tropical
Medicine, London, UK; 3Oxford University Hospitals NHS Foundation
Trust, Oxford, UK; 4University of Southampton, Southampton General
Hospital, Southampton, UK; 5University of Bristol, Bristol, UK
Background: The number of people undergoing bariatric surgery is
likely to increase due to the obesity epidemic. Evidence suggests that
bariatric surgery may increase the risk of fracture, however it is
unclear whether this is due to the differences in characteristics
between patients with and without surgery.
Objectives: To assess the association between bariatric surgery and
fracture risk using a within person design.
Methods: A self‐controlled case series analysis was undertaken on
patients undergoing bariatric surgery and experiencing a fracture
within 5 years either side of surgery date in the clinical practice
research datalink (CPRD) GOLD dataset linked to hospital episode sta-
tistics (HES). The primary outcome was any fracture (except skull or
digits), secondary outcomes were major (hip, vertebrae, forearm and
humerus) and peripheral (forearm and lower leg) fractures. A Poisson
model, producing incidence rate ratios (IRR), compared the 5‐year
post‐operative fracture incidence to the 5‐year pre fracture window.
A post hoc analysis separated the two post‐operative time windows
into 0–2 years and 2.01–5 years. All models are adjusted for time
varying bisphosphonate use.
Results: Of 5,492 patients undergoing bariatric surgery, 252 patients
had 272 fractures at any site, 75 had 80 major osteoporotic fractures
and 126 had 135 peripheral fractures. Only major fracture risk was
found to be increased, with a near three fold excess risk (IRR (95%
CI), 2.70 (1.31, 5.57)). Other results were 1.17 (0.86, 1.60) and 0.92
(0.60, 1.42) for any and peripheral fractures respectively. The post
hoc analysis identified statistically significant increases to risk in the
3rd to 5th year post surgery for both any and major fractures 1.73
(1.08, 2.77) and 4.98 (1.94, 12.78) respectively. Major osteoporotic
fractures also showed an increase risk in the first two years IRR 2.49
(1.17, 5.30). No increase in risk of peripheral fractures was observed.
Conclusions: Although only 75 patients had major osteoporotic frac-
ture/s, risk post‐surgery increased 2.5 times for the first two years
before further increasing to 5‐fold for the next three years. Further
research is needed to understand the underlying mechanisms and
potential therapy.
1017 | Characteristics and symptom severity
of 21,101 patients reporting systemic lupus
erythematosus in the PatientsLikeMe online
health community
Elisabeth Nyman1; Edward Hammond2; Tim Vaughan3;
Barnabas Desta2; Xia Wang2; Volkan Barut4; Cathy Emmas5
1AstraZeneca, Gothenburg, Sweden; 2AstraZeneca, Gaithersburg, MD;
3PatientsLikeMe, Cambridge, MA; 4AstraZeneca, Cambridge, UK;
5AstraZeneca, Luton, UK
Background: Online health communities and research networks such
as PatientsLikeMe (PLM) may provide important insight into under-
standing chronic diseases, including systemic lupus erythematous
(SLE).
Objectives: To describe the characteristics of patients with SLE in
PLM.
Methods: Retrospective observational study in PLM online health net-
work database. Inclusion criteria were registration with PLM between
2011–2017, aged over 18 years at registration, and reported both SLE
and treatment with one or more SLE medications (anti‐malarials,
immunosuppressives, corticosteroids, calcineurin inhibitors and bio-
logics). Information reported within 30 days of registration was used
to assess eligibility and characterize demographics and clinical charac-
teristics, comorbidities, treatment, and severity of symptoms they
reported, both general (included in symptom panel for all PLM
patients) and additional SLE symptoms.
Results: 21,101 patients met the inclusion criteria. The median age at
registration was 46 years (IQR 38–53), the majority were female
(96.8%, N = 21 050), and 94.8% (18,491/19,502) patients who
reported country were US residents. The 17,994 patients who
recorded race were predominately Caucasian (67.8%) and African‐
American (22.4%). In the 6 489 patients who reported when they
had first experienced SLE symptoms the median age of onset was
30 years (IQR 21–39) and age at first diagnosis was 36 years (IQR
27–44) (N = 6 936). The most commonly reported comorbidities were
fibromyalgia 7.9%, discoid lupus 6.8%, lupus nephritis 6.3%, rheuma-
toid arthritis 4.8%, subacute cutaneous lupus 4.7%, Sjogren's Syn-
drome 3.9%, CNS lupus 3.9%, and lupus pneumonitis 3.1%. At
registration patients reported having tried an average of 2.2 SLE med-
ications, most commonly; anti‐malarials 83.8%, corticosteroids 78.8%,
immunosuppressive 32.3%, and biologic treatment 9.4%. Around 31%
of patients (N = 6,448) entered any symptom report at registration. Of
those who reported specific symptoms these were rated as moderate
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or severe by >80% for fatigue, pain, and joint pain and > 50% for
insomnia, brain fog, muscle pain, joint swelling, sun sensitivity and
muscle weakness.
Conclusions: The age, gender and race of SLE patients in the PLM
community are broadly consistent with the general US SLE population.
The PLM SLE population provides a unique source of real world infor-
mation on the patient experience of symptoms of SLE beyond the clin-
ical environment that can be utilized to improve understanding of SLE.
1018 | Systemic lupus erythematosus (SLE)
disease characteristics associated with the
type I interferon gene signature: Baseline
data of the SLE prospective observational
cohort study (SPOCS)
Edward R. Hammond1; Martin Aringer2; Laurent Arnaud3;
Christine Peschken4; Jacob Knagenhjelm5; Volkan Barut6; Xia Wang1;
Barnabas Desta1; Raj Tummala1; David Ginkel1; Richard Furie7;
Eric F. Morand8
1AstraZeneca, Gaithersburg, MD; 2University Medical Center and Faculty
of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany; 3Service
de Rhumatologie, Centre National de Référence des Maladies
Autoimmunes et Systémiques Rares (RESO), Université de Strasbourg,
INSERM UMR‐S 1109, Strasbourg, France; 4University of Manitoba,
Winnipeg, MB, Canada; 5AstraZeneca, Gothenburg, Sweden;
6AstraZeneca, Cambridge, UK; 7Hofstra Northwell School of Medicine,
New York, NY; 8Monash University, Clayton, VIC, Australia
Background: Despite accumulating data on the role of type I inter-
ferons (IFNs) in the pathogenesis of SLE, real‐world, longitudinal clini-
cal data on the type I IFN gene signature (IFNGS) collected from
patients with SLE are limited.
Objectives: This initial analysis of the SLE Prospective Observational
Cohort Study (SPOCS; NCT03189875) examined the prevalence of
the type I IFNGS (high vs low) and its association with baseline SLE
disease characteristics in patients with moderately to severely active
SLE receiving standard‐of‐care treatment.
Methods: SPOCS is an international, multicenter, prospective obser-
vational cohort study of patients enrolled with moderately to severely
active SLE (SLEDAI‐2 K ≥ 6 at entry) from Australia, Canada, France,
Germany, Italy, Spain, the United Kingdom, and the United States; a
completion date of 2022 is planned. Patients are evaluated biannually
during a 3‐year follow‐up period. At each visit, data are collected on
disease activity and damage, treatment received, type I IFNGS (strati-
fied high or low IFNGS based on a predefined cutoff), and several
patient‐reported outcomes.
Results: As of November 15, 2018, a total of 307 patients were
enrolled in SPOCS (North America, n = 184; Europe, n = 123), of
whom 96.1% (n = 295) were female, with a median age of 46 years
(range: 18–88). At study entry, the prevalence of high type I IFNGS
was 70.5% (n = 210) vs 27.9% (n = 83) for low type I IFNGS, with
1.7% (n = 5) unknown (9 missing data). IFNGS‐high patients were
younger than IFNGS‐low patients (median: 42.5 years [range: 18–82]
vs 50 years [19–88], P < 0.0001) and diagnosed with SLE at an earlier
age (P < 0.0001). SLEDAI‐2 K scores were greater for IFNGS‐high
patients vs IFNGS‐low patients (P = 0.0002), whereas SDI scores were
similar between the 2 groups. Fewer comorbidities were reported for
IFNGS‐high patients than for IFNGS‐low patients (79.5% [n = 167] vs
91.6% [n = 76], P = 0.0136). Lower complement C3 and C4 levels were
observed in IFNGS‐high vs ‐low patients. At study entry, antinuclear
antibodies and ribonucleoprotein antibodies were more frequent in
the IFNGS‐high vs IFNGS‐low subset of patients. A greater percent-
age of IFNGS‐high patients were dsDNA antibody positive vs
IFNGS‐low patients (P = 0.0411).
Conclusions: The profile of patients with a baseline high type I IFNGS
differed from those with low type I IFNGS, in that those with high
type I IFNGS comprised a group that on average was younger, had
greater SLEDAI‐2 K scores, was more serologically active, and seemed
to have fewer comorbidities.
1019 | Prevalence and incidence of venous
thromboembolism among patients with
rheumatoid arthritis in Japan
Tomoko Kobayashi1; Atsushi Nishikawa1; Krista M. Schroeder2;
Ayad K. Ali2
1Eli Lilly Japan K.K, Kobe, Japan; 2Eli Lilly and Company, Indianapolis, IN
Background: While there is an accumulating evidence on the relation-
ship between rheumatoid arthritis (RA) and thromboembolism, epide-
miological studies evaluating prevalence and incidence rates of
venous thrombotic events (VTE) among Japanese patients with RA
are sparse.
Objectives: To estimate prevalence and incidence rates of VTE among
patients with RA in Japan.
Methods: The Medical Data Vision (MDV) administrative claims data-
base was used to identify a cohort of adult (more than 18 years old)
Japanese patients with RA between September 2012 and August
2017. Patients had more than 2 times RA diagnosis codes plus use
of any disease‐modifying anti‐rheumatic drugs (DMARD) or Janus
kinase (JAK) inhibitors within 31 days, and had at least 365 days of
continuous enrollment prior to, and 365 days follow‐up period after
the index date (first prescription date of any conventional or biological
DMARD (cDMARD and bDMARD, respectively). Patients who had
prior history of VTE in the prior year and used another cDMARD or
bDMARD in the same class in 365 days prior to index date were
excluded. ICD‐10‐CM codes related to deep vein thrombosis or pul-
monary embolism were used to identify VTE, combined with inpatient
or outpatient drug claim for anticoagulant medications use within
31 days following the inpatient or outpatient VTE diagnosis. Addition-
ally, the procedure code of ultrasound was exploratory added to VTE
definition. Prevalence (%) and incidence rates per 100 person‐years
(PY) were estimated for the cohort, and reported overall and by
DMARD class.
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Results: A total of 15,095 patients with RA were identified (68.2%
females, mean age 65.2 years). The prevalence and incidence rate of
VTE were 1.1% and 0.44 per 100 PY, respectively. The corresponding
rate decreased when the procedure code of ultrasound was included
in VTE definition (prevalence, 0.3%; incidence, 0.11 per 100 PY). The
prevalence and incidence of VTE was slightly higher among patients
treated with bDMARD vs. cDMARD (1.3% vs. 1.1%; 0.47 vs. 0.43
per 100 PY).
Conclusions: The incidence of VTE among patients with RA in the
MDV database is consistent with previous studies. However, the addi-
tion of a requirement for an ultrasound procedure code to the defini-
tion of VTE leads to a lower rate. Further studies are suggested to
characterize VTE rates in Japanese patients with RA.
1020 | The effect of concomitant diabetes
on RA‐related outcomes: Results from the
ACR's RISE registry
Huifeng Yun1; Fenglong Xie1; Lang Chen1; Shuo Yang1; Leticia Ferri2;
Evo Alemao2; Jeffrey R. Curtis1
1University of Alabama at Birmingham, Birmingham, AL; 2Bristol‐Myers
Squibb, Princeton, NJ
Background: Some evidence has suggested that RA patients with dia-
betes might be more likely to have worse clinical outcomes and
adverse events compared to RA patients without diabetes.
Objectives: We evaluated the effects of diabetes on HAQ (Health
Assessment Questionnaire) change and infection in RA patients, com-
paring those with diabetes to those without diabetes.
Methods: Using the ACR's Rheumatology Informatics System for
Effectiveness (RISE) EHR‐based registry, we identified RA patients
who had ≥1 rheumatologist visit with a valid HAQ measured (index
visit) in 2016. Eligible patients were required to have ≥1 previous visit
and a subsequent outcome visit with any HAQmeasured at 12 months
(± 3 months) after the index visit. We identified diabetes based on ≥1
ICD‐9 or ICD‐10 diagnosis code, any medication for diabetes, or ele-
vated diabetes lab value (A1C, random glucose) using all available data
prior to the index visit. Mean HAQ change between the index and out-
come visit was calculated based on HAQ categories at the index visit
(0–0.5, 0.5–1, and 1–3). Generalized linear models was used to calcu-
late the adjusted mean HAQ change controlling for potential con-
founders, including demographics, conventional synthetic disease‐
modifying antirheumatic drugs (csDMARDs), and biologic use. First
infection during the follow up was defined by diagnosis codes or
anti‐infective medications. We calculated the incidence rate (IR) of
infections among patients with and without diabetes and compared
hazard ratios (HR) using Cox regression adjusting for potential
confounders.
Results: Among 457,950 patients included in the 2016 RISE registry,
we identified 3,853 RA patients with diabetes and 18,487 without dia-
betes. Overall, the mean HAQ change between index and outcome
visit among diabetes patients was 0.03 and among non‐diabetic was
0.002 (p < 0.01). After stratifying on baseline HAQ and compared to
patients without diabetes, diabetic RA patients worsened more and
improved less, depending on their baseline HAQ. Among those with
diabetes, we identified 761 infections, yielding an IR of 22.6 (95%
CI: 21.0–24.2) per 100 person years. For non‐diabetic patients, we
identified 3,239 infections with an IR of 19.8 (19.1–20.5). After
adjusting for potential confounders, the HR of infection among diabe-
tes (HR 1.17, 95% CI 1.08–1.27) was not significantly different from
non‐diabetes patients.
Conclusions: RA patients with concomitant diabetes had greater
worsening, or less improvement, in their functional status, suggesting
additional interventions may be needed for RA patients with diabetes
to optimize this and other comorbidities.
1021 | Temporal trends in the incidence of
non‐traumatic lower limb amputation in
patients with type 1 diabetes mellitus in the
United States from 2008 to 2016
Sampada K. Gandhi; Chuntao Wu; Zoran Doder; Xinyu Li;
Juhaeri Juhaeri
Sanofi, Bridgewater, NJ
Background: A few studies reported a declining trend in the incidence
of non‐traumatic lower limb amputation (LLA) in patients with type 1
diabetes mellitus (T1DM). However, limited data exist on the temporal
trends for the recent years, especially in the United States (US).
Objectives: To examine temporal trends in the incidence of non‐trau-
matic LLA in patients with T1DM using a US claims database during
the years 2008–2016.
Methods: Using a retrospective cohort study design, patients with
T1DM were identified using a modified approach based on a validated
algorithm published by Klompas et al during a study period from Jan-
uary 1, 2008 to June 30, 2017 from the Truven MarketScan database.
The first event of non‐traumatic LLA occurring from the date on which
a criterion of the algorithm was met until the end of the study period
was identified by the presence of ICD‐9/ICD‐10 procedure codes in
any setting. The patients were followed until the occurrence of LLA,
end of database enrollment, or study period. Temporal trends in inci-
dence rates (IR) were examined by calculating overall and sex‐specific
IR per 100,000 person‐years (PY) by calendar year, from 2008 to
2016, and mean annual percent change (±SD) in the IR.
Results: Mean age and length of follow‐up was 43.1 years and
3.6 years in the 93,813 T1DM patients identified during the study
period, respectively, and 500 non‐traumatic LLA events occurred dur-
ing the follow‐up. For all non‐traumatic LLA, IR per 100,000 PY
decreased by 57.8%, from 240.0 in 2008 to 101.1 in 2016. The annual
percent change in IR ranged from −15.6% to 30.2%, with a mean
annual percent reduction of 9.0% (±15.9%). When stratified by type
of LLA, the IR per 100,000 PY of minor LLA (below the ankle)
decreased from 151.5 in 2008, to 71.6 in 2016. The annual percent
change in IR ranged from −42.4% to 33.5%, with a mean annual
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percent reduction of 6.0% (±26.0%). The IR of major LLA (at or above
ankle) decreased from 88.5 in 2008 to 29.5 in 2016, per 100,000 PY.
The annual percent change in IR ranged from −45.2% to 36.1%, with a
mean annual percent reduction of 8.0% (±34.4%). Among males, IR per
100,000 PY of all LLA decreased from 317.8 in 2008 to 114.2 in 2016,
with a mean annual percent reduction of 9.7% (±21.1%). Among
females, the IR per 100,000 PY of all LLA decreased from 159.8 in
2008 to 87.2 in 2016, a mean annual percent reduction of 5.5%
(±20.1%).
Conclusions: In line with the findings from prior literature, the inci-
dence of non‐traumatic LLA declined by 9% per year, on average, dur-
ing the years 2008–2016 in the US, and the decline was comparable
between the two sexes and the types of LLA.
1022 | Availability of disease activity
measures from systemic lupus erythematosus
patients in a large, representative US‐based
real world registry cohort
Kathleen Mortimer; Kathryn Starzyk; Thomas Brecht; Shannon Cerf;
Phillip Ballentine; Richard Gliklich
OM1, Boston, MA
Background: Systemic lupus erythematosus (SLE) is a heterogenous,
multifactorial disease with a debilitating and highly variable clinical
course. Measurement of disease activity is resource intensive but
essential to monitoring of disease status. These scores can be used
for diagnosis, prognosis, and evaluation of changes over long periods
in routine clinical practice.
Objectives: To assess the availability of disease activity information in
SLE patients and assess changes over time.
Methods: This study used the OM1 SLE Registry (OM1, Boston), an
ongoing, continually enrolling, representative sample of patients with
SLE in the U.S. who are followed prospectively. Deep clinical data,
including patient‐reported outcomes, electronic medical records
(EMR) and administrative claims data were used to characterize
patient characteristics, disease manifestations, treatments, and out-
comes. Analyses included patients in the registry between January
2013 and December 2018.
Results: Within the SLE Registry (n = 35,484),the average age at
cohort entry was 50 years (SD 15.1) and consistent with the epidemi-
ology of SLE, 92% of patients were female. Systemic Lupus Erythema-
tosus Disease Activity Index (SLEDAI) scores, commonly used during
clinical development, were reported for over 1,400 patients (4%).
Based on the first observed score, 23% had no disease activity, 29%
were classified as mild, 28% were classified as moderate, 12% were
classified as high and 8% were classified as very high. With a mean
of 3 months between scores, 66% of the 790 patients with 2 or more
scores stayed in the same category while 23% showed improvement.
Among those with at least one SLEDAI score, 35% were treated with
Benlysta, and there was no discernable pattern of increasing propor-
tion of users based on SLEDAI severity. Additional analyses of the
timing of Benlysta and other medications relative to scoring will be
pursued. Proportion of patients with non‐specific to SLE health
related scores included: the Multi‐Dimensional Health Assessment
Questionnaire (MDHAQ, 31%), patient global assessment score
(30%), physician global assessment score (18%), and fatigue visual ana-
logue scale (10%).
Conclusions: Although a variety of non‐specific scores are recorded
for patients with SLE, capturing changes in diseases status over time
remains challenging in the absence of repeated measurements of dis-
ease‐specific scores in routine practice.
1023 | Characterizing differences in pain
score reporting among patients newly
diagnosed with rheumatoid arthritis in the U.
S. using Optum™ integrated claims‐EHR data
Jonathan M. Davitte; Ayush V. Patel; Rachel E. Williams
GlaxoSmithKline, Collegeville, PA
Background: Pain scores are a commonly used patient‐reported out-
come measure for rheumatoid arthritis (RA). However, there is limited
knowledge of pain measures in electronic health record (EHR) data
and systematic differences between those with and without pain
scores.
Objectives: Our GSK‐funded research measured differences in newly
diagnosed RA patients with and without recorded pain scores with
respect to demographic, insurance, and medication characteristics
over 2 years of follow‐up.
Methods: We used a retrospective cohort to evaluate our outcome
(≥1 pain score recorded vs. no pain score recorded) among US adults
with an initial RA diagnosis (index date) between 01 Jan 2013 and 30
Jun 2015 using EHR data from Optum's de‐identified Integrated Claims‐
EHR dataset (2007–2018)™. We limited pain scores to those recorded
the same day a patient received a RA diagnosis code. We assessed our
outcome at index date (ID), index date to 6 months (ID‐6mo), 6 months
to 1 year (6mo‐1 yr), and 1 year to 2 years of follow‐up (1 yr–2 yr).
Our sample included 40,543 RA patients after excluding patients with
history of RA prior to ID or under 18 years of age at ID. We also
required patients to be active in the database at least 12 months prior
to and 2 years following their ID. We calculated odds ratios and 95%
confidence intervals (OR [95% CI]) using logistic regression for each
characteristic with respect to our outcome.
Results: Pain scores were recorded for 20.5% of RA patients at ID,
20.6% for ID‐6mo, 17.3% for 6mo‐1 yr, and 26.7% for 1 yr–2 yr. At
ID, RA patients had a mean age of 58.6 years (SD = 14.4) and were:
female (77.6%); Caucasian (79.9%) or African American (11.4%); and,
not Hispanic (90.2%). Across all time intervals, the odds of having a
pain score recorded were greater among African Americans (1.21
[1.12,1.30] to 1.29 [1.20,1.39]) and lower among Asians (0.61
[0.49,0.77] to 0.72 [0.59,0.87]) compared to Caucasians; lower among
commercial insurance patients (Yes vs. No: 0.74 [0.71,0.78] to 0.83
[0.79,0.88]); higher among Medicaid patients (Yes vs. No: 1.41
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[1.31,1.53] to 1.77 [1.65,1.91]); and; higher among patients using
NSAIDS (Yes vs. No: 1.76 [1.64,1.90] to 2.07 [1.95,2.20]), corticoste-
roids (Yes vs. No: 1.81 [1.71,1.92] to 2.73 [2.58,2.87]), targeted ther-
apies (Yes vs. No: 1.13 [1.06,1.20] to 3.02 [2.87,3.19]), and opioids
(Yes vs. No: 3.28 [3.13,3.43] to 3.62 [3.40,3.85]).
Conclusions: There are several differences in newly diagnosed RA
patients with and without EHR pain score data. Research using EHR
pain score data should investigate potential bias due to missing data.
1024 | Pre‐operative predictors of post‐
operative pain relief: Pain score modeling
following spinal fusion surgery
Zhenna Huang1; Chantal E. Holy1; Jill Webster Ruppenkamp1;
Katherine Corso1; Deepak Krishnan2; John Pracyk1
1 Johnson and Johnson Inc., New Brunswick, NJ; 2Mu‐sigma, Bangalore,
India
Background: Pain relief is a strong predictor of patient satisfaction after
spinal fusion surgery. Despite the limitations in self‐reported measures,
specific pain performance assessments may provide health providers a
more distinct impression of pain among spinal fusion population.
Objectives: To establish the average pattern of self‐reported face‐rat-
ing pain score using linear mixed modeling and to explore pre‐opera-
tive predictors of post‐operative pain following spinal fusion surgery.
Methods: Through data partnership with Mercy Technology Services,
adult patients who underwent multilevel spinal fusion surgery were
extracted from 2011–2018 Mercy electronic health records, which is
one of the most comprehensive real‐world databases including preop-
erative and intraoperative information. Around 199, 108, 55, 37, and
25 out of 810 spinal fusion patients were with both baseline and fol-
low up pain score at 2‐week, 1‐month, 3‐months, 6‐months and 12‐
months after surgery, respectively. Average pain relief curve was char-
acterized using linear mixed regression modeling. Preoperative factors
associated with no‐pain‐relief (no change or increased pain score)
three months after surgery were investigated using multivariable logis-
tic regression. Both prior literature knowledge and p value (p < 0.05)
were used to obtain the final model.
Results: Although patients started with different levels of pain score,
similar pain relief patterns were observed (age: mean 62y (SD: 15);
56% female; 45% Commercial). The study population (N = 296) started
with an average pain score of 7.1 and changed by −0.2 per month one
year after surgery. Both intercept and slope of time were statistically
significant. Around 62.1% patients reported pain relief three months
after surgery. Main preoperative variables statistically significantly
associated with no‐pain‐relief were lower baseline pain level (aOR:
0.7, 95% CI:0.5–0.9), younger (10‐year increment: aOR: 0.4, 95% CI:
0.2,0.6), higher ASA score (aOR: 8.1, 95% CI:2.3–36.1) and lower sys-
tolic pressure (aOR: 0.97, 95% CI:0.93–0.996). We did not observe
statistically significant association between number of spine level
fused and pain relief three months after surgery (aOR:1.02, 95%
CI:0.86–1.21).
Conclusions: Over sixty percent of the study spinal fusion population
reported pain relief three months after surgery. Improving general
health status before surgery may increase the chance of pain relief
after spinal fusion surgery. Studies with larger simple size are
warranted.
1025 | Burden of illness in patients with
systemic sclerosis in the United Kingdom
Alicia V.A. Gayle1; Nils Schoof2; Margarida Alves2; Deborah Carke1;
Christina Raab1; Prithwiraj Das1; Toby Maher
1Boerhinger Inglehiem Ltd., Bracknell, UK; 2Boerhinger Inglehiem GmBh,
Ingelheim, Germany; 3University College London, London, UK
Background: Systemic Sclerosis (SSc) is a rare heterogeneous autoim-
mune disease of connective tissue characterized by immune dysfunc-
tion, widespread vasculopathy and fibrosis, which is clinically
manifested by multi‐organ involvement. Patients with SSc often
develop interstitial lung disease (ILD) which is currently the leading
cause of death. The burden of disease and effect of SSc on healthcare
costs in the UK is currently unknown.
Objectives: This study aimed to investigate patient characteristics and
the burden of illness related to first SSc diagnosis.
Methods: We carried out a population‐based cross‐sectional study
using data from the Clinical Practice Research Datalink (CPRD) linked
to Hospital Episode Statistics (HES). All adult patients with a diagnosis
of SSc were identified using International Classification of Diseases‐
10‐Clinical Modification diagnosis codes in hospital records and READ
codes in primary care electronic records combined with an adapted
version of the EULAR algorithm for defining SSc over 2005–2016.
Patients were classified into 3 groups: incident SSc, SSc with incident
ILD (SSc‐ILD), and SSc with other organ involvement (SSc‐OOI). All ‐
cause healthcare utilization costs (adjusted to 2016 GBP) were
reported overall and by disease group. Because of the overlap
between the 3 groups, statistical comparisons between the groups
were not conducted.
Results: The study included 675 individuals with incident diagnosis of
SSc, 19% of the cohort had SSc‐ILD and 71% had SSc‐OOI with an
SSc‐ILD&OOI overlap of 15%. 79% of the cohort were women and
the average age at diagnosis was 61 years (SD = 17). Median
healthcare costs were estimated at £2,601(IQR 962–6,885) per
patient per year among patients with SSc and were higher among
patients with SSc‐ILD (£5,899, IQR £2,986 ‐ £13,905) compared to
patients with SSc‐OOI (£3,449, IQR £1,271 ‐ £8,717). The majority
(42%) of the cost burden was attributed to inpatient hospital activity,
where 52% of appointments were planned (elective day and day cases
admission). The biggest driver of inpatient costs came from respiratory
and musculoskeletal‐related attendances.
Conclusions: Our results highlight the significant healthcare burden of
patients diagnosed with SSc through UK primary care or secondary/
tertiary care routes. These findings should inform the development
of initiatives to improve management of SSc.
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1026 | Evaluation of discriminative ability of
commonly used indices to predict outcomes
after spinal fusion surgery
Zhenna Huang1; Jill Webster Ruppenkamp1; Deepak Krishnan2;
Chantal E. Holy1
1 Johnson and Johnson Inc., New Brunswick, NJ; 2Mu‐sigma, Bangalore,
India
Background: American Society of Anesthesiologists (ASA) score,
Charlson (CCI), Elixhauser (ECI) and Functional Comorbidity Index
(FCI) have been used as risk‐adjustment tools in quality and safety
data. However, no study has compared the predictive performance
of these indices particularly in spinal fusion patients across varied
outcomes.
Objectives: To compare the discriminative ability of ASA, CCI, ECI,
FCI, as well as provider's spinal fusion surgery volume (PV) for postop-
erative outcomes following spinal fusion surgery.
Methods: Through data partnership with Mercy Technology Services,
adult patients who underwent spinal fusion surgery were extracted
from 2011–2018 Mercy electronic health records, which is one of
the most comprehensive real‐world databases including preoperative
and intraoperative information. Postoperative outcomes assessed
included: (1) infection within 3‐months after surgery, (2) all‐cause 3‐
months readmissions, (3) one‐year all‐cause mortality, and (4) self‐
reported pain relief 3‐months after surgery. For each outcome, six
multivariable logistic regression models were constructed. One base
model that included age, gender and BMI and five models with the
variables in the base model and an additional index, CCI, ECI, FCI,
ASA or PV. The predictive performance was assessed using area under
the curve analysis (AUC) derived from these models.
Results: A total of 810 spinal fusion patients were included in the
analysis (age mean: 60, SD: 15, 52% female, 52% commercial insured).
For infection, AUC (95% CI) of base and the two most predictive
models (ECI and ASA) were 0.52 (0.47–0.57), 0.68 (0.63–0.73) and
0.67 (0.62–0.72), respectively. For all cause 3‐months readmission,
AUC (95% CI) of base and the two most predictive models (CCI and
ECI) were 0.57 (0.507–0.63), 0.65 (0.60–0.71) and 0.65 (0.59–0.70),
respectively. For one‐year all‐cause mortality, AUC (95% CI) of base
and the two most predictive models (ASA and PV) were 0.70 (0.59–
0.81), 0.82 (0.71–0.93) and 0.77 (0.67–0.87), respectively. For 3‐
months self‐reported pain relief, AUC (95% CI) of base and the two
most predictive models (ASA and PV) were 0.72 (0.62–0.82), 0.76
(0.66–0.86) and 0.74 (0.64–0.84), respectively.
Conclusions: ASA score and provider's volume outperformed other
comorbidity indices in predicting mortality and pain relief. The discrim-
inative ability of all indices for infection and readmission was poor (all
AUC < 0.7). Future research developing comorbidity measures with
improved predictivity for infection and readmission after spinal fusion
surgery would be promising.
1027 | Evaluation of discriminative ability of
commonly used indices to predict outcomes
after fracture repair surgery
Zhenna Huang1; Jill Webster Ruppenkamp1; Chantal E. Holy1;
Deepak Krishnan2
1 Johnson and Johnson Inc., New Brunswick, NJ; 2Mu‐sigma, Bangalore,
India
Background: American Society of Anesthesiologists (ASA) score,
Charlson (CCI), Elixhauser (ECI) and Functional Comorbidity Index
(FCI) have been used as risk‐adjustment tools in quality and safety
data. However, no study has compared the predictive performance
of these indices particularly in fracture repair patients across varied
outcomes.
Objectives: To compare the discriminative ability of ASA, CCI, ECI,
FCI, as well as provider's spinal fusion surgery volume (PV) for postop-
erative outcomes following adult fracture repair surgery.
Methods: Through data partnership with Mercy Technology Services,
adult patients who underwent fracture repair surgery were extracted
from 2011–2018 Mercy electronic health records, which is one of
the most comprehensive real‐world databases including preoperative
and intraoperative information. Postoperative outcomes assessed
included: (1) infection within 3‐months after surgery, (2) all‐cause 3‐
months readmissions, (3) one‐year all‐cause mortality, and (4)
extended length of stay (LOS) (≥ 3 days). For each outcome, six mul-
tivariable logistic regression models were constructed. One base
model that included age, gender and BMI and five models with the
variables in the base model and an additional index, CCI, ECI, FCI,
ASA or PV. The predictive performance was assessed using area under
the curve analysis (AUC) derived from these models.
Results: A total of 14,044 fracture repair patients were included in the
analysis (age median: 65, IQR, 47–81, 59% female). For infection, AUC
(95%CI) of base and the two most predictive models (ECI and ASA)
were 0.66 (0.65–0.68), 0.703 (0.69–0.71) and 0.698 (0.69–0.71)
respectively. For all cause 3‐months readmission, AUC (95%CI) of base
and the two most predictive models (ECI and CCI) were 0.67 (0.66–
0.68), 0.69(0.68–0.70) and 0.68 (0.67–0.69), respectively. For one‐
year all‐cause mortality, AUC (95%CI) of base and the two most pre-
dictive models (CCI and ECI) were 0.79 (0.78–0.81), 0.84(0.83–0.85)
and 0.83 (0.82–0.84), respectively. For extend LOS, AUC (95%CI) of
base and the two most predictive models (ASA and ECI) were 0.72
(0.716–0.733), 0.76 (0.755–0.77) and 0.755 (0.747–0.763),
respectively.
Conclusions: Of the model evaluated, Elixhauser Comorbidity Index
had better discriminative ability across all outcomes assessed. The pre-
dictive ability of all indices for infection and readmission was poor (all
AUC ≤ 0.7). Future research developing comorbidity measures with
improved predictivity for infection and readmission after fracture
repair surgery would be promising.
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1028 | Ivabradine for the treatment of heart
failure: A systematic review and meta‐
analysis
Hadir Aljohani1; Hadeel Alkofide2; Hanin Aljohani1
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 2King Saud
University, Riyadh, Saudi Arabia
Background: Ivabradine has a pure heart rate reduction through its
selectivity to bind to If channels. However, the use of ivabradine
remains limited due to the conflicting evidence of its safety and
efficacy.
Objectives: To determine the efficacy and safety of ivabradine com-
pared to control in subjects with heart failure (HF) on clinical and
patient‐reported outcome measures used in HF management.
Methods: We performed a systematic search in the following data-
bases: Medline, Embase, Ovid and the Cochrane Central Register
of Controlled Trials from inception through June 2018. Peer‐
reviewed, randomized controlled trials of ivabradine versus control
group in patients with heart failure with or without low ejection
fraction, were included. We adhered PRISMA checklist and flow dia-
gram. Our primary outcomes were: all‐cause mortality, cardiovascular
mortality, or hospital readmission. Secondary outcomes include rest-
ing heart rate (HR)from baseline until the end of follow‐up, left ven-
tricular ejection fraction (LVEF), and adverse events. Two
investigators independently extracted data from each eligible study
and assessed risk of bias via Cochrane collaboration's risk of bias
tool. We assessed the treatment effect on binary outcomes by using
the risk ratio (RR) with the corresponding 95% confidence intervals
(CIs). For continuous outcomes, we calculated the difference in mean
changes from baseline between ivabradine and control group.
Results: Six trials with 17886 patients were included. There was no
significant difference among ivabradine treated group versus control
group in lowering all‐cause mortality, cardiovascular mortality, or hos-
pital readmission. There was no statistically significant difference
between ivabradine and control group in the mean difference in
change from baseline of heart rate. However, ivabradine had an
increase in mean difference in percentage of ejection fraction (EF) by
3% as compared with control group (summary RR, 3.27 [95% CI,
2.08 to 4.45]; I2 = 26%). The incidence of phosphenes, blurred vision
and bradycardia as adverse events were significantly higher with
ivabradine by 4 and 5 times as compared with control group (summary
RR,4.08 [95% CI, 2.80 to 5.95]; I2 = 0%) and (summary RR,5.04 [95%
CI, 2.49 to 10.18]; I2 = 85%) respectively.
Conclusions: Administration of ivabradine to adults with heart failure
with or without low ejection fraction significantly improved the ejec-
tion fraction. However, the incidence of bradycardia was higher with
ivabradine group.
1029 | Trends in ambulatory analgesic use
over an 8 year period in patients after
myocardial infarction using a Nationalwide
claims database
Eunyoung Kim; SuHeun Lee; Sunyoung Jung; MinGue Lee;
HaeGee Kim
ChungAng University, Seoul, Korea, Republic of
Background: Myocardial infarction (MI) is a leading cause of prema-
ture death; moreover, owing to global population growth and aging,
it represents a major disease burden. The current guidelines on MI rec-
ommend caution in the use of COX‐2 selective or non‐selective
NSAIDs.
Objectives: To explore the usage patterns of nonsteroidal anti‐inflam-
matory drugs (NSAIDs) and other analgesics in patients after myocar-
dial infarction (MI) over a period of 8 years, focusing on the indications
of analgesic use.
Methods: A nationwide cross‐sectional study using the Korea National
Health Insurance Service (NHIS) database was performed. We
assessed ambulatory analgesics used at least 30 days after discharge
from incident hospitalization with MI (ICD‐10, I21). We assessed the
prevalence of ambulatory analgesic medication, including NSAIDs,
acetaminophen, and opioids, used in three indication categories: mus-
culoskeletal (M00‐M99), respiratory (J00‐J99), and other diseases.
Annual trends in the prescriptions of individual analgesic medications
were also evaluated. For the prescriptions including analgesics as the
unit of analysis, we compared the proportion of prescriptions with
NSAIDs for each indication of the analgesic prescription, by using
Chi‐square test. we assessed the trends in individual analgesics
between 2008 and 2015. All analyses were computed by using SAS
version 9.4 (SAS Institute, Cary, NC).
Results: We identified 75,131 patients with a history of MI and an
ambulatory prescription for analgesics. Frequently used analgesics dif-
fered between musculoskeletal diseases (tramadol injection (19.4%),
aceclofenac (13.7%), and diclofenac injection (9.4%)) and respiratory
diseases (acetaminophen (35.5%), tramadol injection (15.6%), and
loxoprofen (15.3%)). During the study period, a significant increase in
the use of aceclofenac, loxoprofen, and tramadol/acetaminophen
fixed combination was observed, with a significant decrease in the
use of tramadol and diclofenac injections.
Conclusions: Patterns of analgesic use differed according to indica-
tion. The importance of drug‐disease interactions of NSAIDs used
after MI needs to be studied further, especially for patients with mus-
culoskeletal diseases. The high prevalence of aceclofenac and
loxoprofen use suggests the necessity of safety evaluations and mon-
itoring for medications for which a relatively small amount of evidence
on safety is available.
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1030 | The effects of initiation of secondary
prevention pharmacotherapy on 1‐year
mortality after stroke
Tiantian Ma1; Ian Wong1,2; Cate Whittlesea1; Li Wei1
1UCL School of Pharmacy, London, UK; 2The University of Hong Kong,
Hong Kong, China
Background: Combination pharmacotherapy is common in the initia-
tion of secondary prevention of stroke. However, evidence of optimal
combination therapy on mortality after stroke is limited.
Objectives: This study aimed to determine the effects of different
numbers of combined cardiovascular drug classes on 1‐year mortality
in stroke patients.
Methods: Patients aged 45+ with the first record of stroke or transient
ischemic attack were identified throughThe Health Improvement Net-
work database, UK from Jan 2007 to Dec 2016. Exposure to different
combined numbers of six cardiovascular drug classes (lipid‐regulating
drugs, antiplatelet drugs, angiotensin‐converting enzyme inhibitors
(ACEIs)/angiotensin receptor blockers (ARBs), calcium‐channel
blockers (CCBs), diuretics and β‐blockers) were defined according to
cardiovascular drugs prescribed during the first 90 days after the first
diagnosis of stroke. The study outcome was 1‐year all‐cause mortality.
A propensity score matched analysis was conducted using the Cox
proportional hazards models.
Results: Of the 38,151 patients, 6,255 were with 1 class (16.4%),
10,235 with 2 classes (26.8%), 8,238 with 3 classes (21.6%), 4,694
with 4 classes (12.3%), 1,473 with 5 classes and 174 with 6 classes
(0.5%). Compared with patients with 1 class, the hazard ratios of all‐
cause mortality were reduced with 2 classes (HR 0.80, 95% CI:0.67–
0.97), 3 classes (HR 0.72, 95% CI:0.61–0.86), 4 classes (HR 0.62,
95% CI:0.50–0.75), 5 classes (HR 0.60, 95% CI:0.43–0.85) and all 6
classes (HR 0.29, 95% CI:0.09–0.99).
Conclusions: The results suggest an additive effect of cardiovascular
drug classes on mortality in stroke patients. Increasing the number
of cardiovascular drug classes appears to be positively associated with
reduced risk of 1‐year mortality after stoke.
1031 | Relationship between daily versus
evening/bedtime statin dosing and changes in
low‐density lipoprotein cholesterol
Zachary Marcum1; Claire Huang2; Robert Romanelli2
1University of Washington, Seattle, WA; 2Sutter Health, Palo Alto, CA
Background: The Food and Drug Administration recommends certain
statins for evening/bedtime administration, whereas others are rec-
ommended for daily administration. However, little is known about
how these different dosing instructions may impactlow‐density lipo-
protein cholesterol (LDL‐c).
Objectives: To evaluate the association between daily versus evening/
bedtime statin dosing and changes in LDL‐camong new initiators.
Methods: This was a retrospective analysis of electronic health
records (EHR) and pharmacy claims data from a healthcare delivery
system in northern California between 2010 and 2016. The study
cohort was composed of new users of statin therapy ≥35 years of
age at the time of first electronic prescription, with EHR activity 12–
36 months before and after the index statin prescription, and at least
12 months of follow‐up. Statin administration was dichotomized as
daily vs. evening/bedtime based on the medication order field. We
excluded patients who had a change in instructions during follow‐up
and patients with all other dosing instructions (e.g., three times per
week). The outcomes were mean change in LDL‐c and likelihood of
attaining LDL‐c < 70 mg/dLbetween 12 and 24 months from baseline.
We used regression models to assess differences in mean change in
LDL‐c and the likelihood of attaining LDL‐c < 70 mg/dLfor patients
with daily vs. evening/bedtime dosing. Adjusted mean differences
and odds ratios (OR) with 95% confidence intervals (CI) were esti-
mated before and after statistical adjustment for patient, prescription,
and provider covariates, including statin adherence.
Results: Of 5099 eligible incident‐statin users (mean age, 63 years),
53% were prescribed evening and 47% daily dosing instructions. No
differences were observed in mean change in LDL‐c (adjusted mean
difference: 1.42 mg/dL; 95% CI: −1.02, 3.89) or likelihood of attaining
LDL‐c < 70 mg/dL (adjusted OR: 0.83; 95% CI: 0.67, 1.04) for evening
vs. daily dosing over a mean of 19‐months follow‐up.
Conclusions: Among incident statin users from a real‐world clinical
setting, those with daily and evening dosing instructions had similar
mean changes in LDL‐c and likelihood of attaining an LDL‐
c < 70 mg/dL. Given potential clinical equipoise for evening and daily
dosing, clinicians should consider patient‐tailored statin dosing
instructions to reduce potentially unnecessary regimen complexity.
1032 | Comparative effectiveness study of
combined antihypertensive medications for
Nigerians
Charles E. Okafor1; Chinwe V. Ukwe2; Maxwell O. Adibe2;
Benedict Anisiuba3; Samuel O. Ike3; Geoffery Nwuruku4
1Nnamdi Azikiwe University, Agulu, Awka, Nigeria; 2University of Nigeria
Nsukka, Nsukka, Nigeria; 3University of Nigeria, Enugu Campus, Enugu,
Nigeria; 4Federal Teaching Hospital, Abakaliki, Abakaliki, Nigeria
Background: In Nigeria, hypertension remains a preventable risk fac-
tor for cardiovascular (CV) diseases. Available data suggest that at
least 75% of patients will need a combination antihypertensive ther-
apy to achieve the therapeutic goal. In addition to risk reduction in
CV events and BP control, cost‐effectiveness has become an impor-
tant consideration in antihypertensive drugs selection.
Objectives: To compare and contrast the clinical and economic effec-
tiveness of antihypertensive drug combinations among Nigerian
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hypertensive patients with compelling indication to receive combina-
tion therapy.
Methods: A double‐blind randomized controlled trial of 4 groups of
antihypertensive drug combinations, Telmisartan/Amlodipine/
Chlorthalidone (TCA), TC, TA and CA was conducted among hyperten-
sive patients. The choice of medications for this study was based on
JNC‐7 recommendation, also based on recent cost‐utility analysis of
antihypertensive medications for Nigerians. The participants were
recruited from 3 private hospitals in Enugu Metropolis of Nigeria
and randomly assigned to the study groups. The primary outcome of
this study was BP control based on JNC‐8 guideline while the second-
ary outcomes were cost‐effectiveness per QALY, cost‐effectiveness
per control and patients' self‐reported health status. Descriptive and
inferential statistics were used for statistical analyses. P < 0.005 was
considered statistically significant.
Results: Of 110 patients enrolled in the study, more than half were
women (55.5%). The mean age of the patients was 54.93 ± 12.38.
On average, the enrolled patients have had hypertension for over
9 years (9.17 ± 8.4). At least 77% of the patients in all the groups com-
pleted the study except for TA group (66.7%). The probability of BP
control was highest in the TCA group (0.37 ± 0.00). The CA group
showed the best cost‐effectiveness per QALY. However, the group
with the most favorable cost‐effectiveness per control was TCA
(59.30 ± 0.00) followed by CA (79.09 ± 0.00). Patients reported health
status indices were highest for CA followed by TCA group.
Conclusions: The trial demonstrated no significant difference in BP
control across the 4 different combinations of anti hypertensives.
Although the highest probability of BP control was seen inTCA group.
The CA and TCA groups demonstrated the most cost‐effective per
QALY and per control respectively. Health care providers should con-
sider the use of TCA and CA in management of hypertension in
Nigerians with compelling indication to use dual or triple therapy.
Nonetheless, there is need to further validate the study findings using
larger population.
1033 | Anti‐hypertensive drugs and
endothelial function: Results from the
Brazilian longitudinal study of adult health
(ELSA‐Brasil)
Isabella Schettini1; Sandy Barreto2; Brant Luisa2; Antônio Ribeiro2;
Danyelle Rios1; Roberta Figueiredo1
1Universidade Federal de São João Del Rei, Divinópolis, Brazil;
2Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Background: The effects of different classes of antihypertensive drugs
on endothelialfunction and inflammatory markers are not yet well
established and may be relevant for therapeutic choices.
Objectives: To evaluate the association between the use of different
classes of antihypertensive drugs with serum CRP levels and endothe-
lial function (assessed by Peripheral Arterial Tonometry‐PAT) in a sam-
ple of Brazilian adults.
Methods: This cross‐sectional study was developed with a sample of
ELSA‐Brasilbaseline participants with medical diagnosis of hyperten-
sion, using at least one interest class of antihypertensive (ACEI, ARB,
calcium channel blocker, β‐blocker and diuretics) and without medical
diagnosis of CVD or coronary disease. The inflammatory and endothe-
lial function markers were, respectively, CRP levels and BPA and PAT
ratio. Thus, 3,522 participants who had PCR information and 397 with
BPA and PAT ratio information participated in this analysis. The asso-
ciations between use of different classes of antihypertensive drugs
(evaluated as binary variables; reference category was the use of other
classes of antihypertensive drugs) with response variables, PCR and
BPA and PAT ratio, were estimated using generalized linear models
and linear regression.
Results: Regarding CRP and PAT ratio, no statistically significant asso-
ciation wasfound with the use of none classe of antihypertensive drug,
even after adjusting for confounders. Participants using diuretics had
lower levels of BPA (better endothelial function) compared to those
not using diuretics [0.96 (0.93–0.99); p < 0.05] and participants using
beta‐blockers had a borderline association with higher levels of BPA
(worse endothelial function) compared to those not using this class
[1.03 (1.00–1.05); p = 0.05].
Conclusions: Our study contributes to the literature on effects of the
different classes ofantihypertensive on systemic inflammation and
endothelial function by providing evidence that endothelial function
seems to be better among diuretic users and worse among users of
beta‐blockers. Further studies are needed to assess if these effects
can, independently, provide a better prognosis for patients with arte-
rial hypertension and whether they may in fact add greater benefits
to clinical practice.
1034 | Does the comparative effectiveness
of first line anti‐hypertensive drugs differ
according to age?
Sarah‐Jo J. Sinnott; Ian J. Douglas; Elizabeth Williamson; Liam Smeeth;
Laurie Tomlinson
LSHTM, London, UK
Background: Current clinical guidelines recommend different first‐line
anti‐hypertensive drugs for hypertension based on whether the
patient is aged </≥55 yrs. The evidence underpinning these recom-
mendations is limited and not conclusive.
Objectives: To explore the comparative effectiveness of first‐line anti‐
hypertensive drugs stratified by age </≥55 yrs.
Methods: We used UK primary care data from the Clinical Practice
Research Datalink to establish a cohort study. We identified new initi-
ators of Angiotensin Converting Enzyme‐Inhibitor/Angiotensin Recep-
tor Blocker (ACE‐I/ARB), Calcium Channel Blocker (CCB) and thiazide
diuretics and followed to investigate change in systolic blood pressure
(BP) at 12 weeks post initiation. We also investigated changes in dia-
stolic BP, along with additional timepoints of 26 and 52 weeks. We
compared thiazides vs CCB, thiazides vs ACE‐I/ARB and CCB vs
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ACE‐I/ARB. We used mixed linear models with a random intercept for
each patient with interactions to model the effect of the exposure
drug across age ≥ 55 yrs (yes or no). Models were adjusted with pro-
pensity scores to adjust for confounding.
Results: We identified 154,257 initiators of ACE‐I/ARB, 115,931 initi-
ators of CCB and 39,632 initiators of thiazides. The mean age was
55.5 yrs (SD 12.7), 63.4 yrs (SD 12.2) and 66.4 yrs (12.7). At 12 weeks
after initiation, systolic BP was 2.46 mmHg (95% CI 0.56–1.31) higher
in patients aged ≥55 yrs prescribed thiazides than those prescribed
CCBs. This difference was larger than that seen for <55 yrs
(+1.46 mmHg, 95% CI 1.22–1.71). Systolic BP after 12 weeks was
higher in patients aged ≥55 yrs prescribed thiazides (+1.27 mmHg,
95% CI 1.07–1.46) than those prescribed ACE‐I/ARB. This difference
was larger than that seen for <55 yrs (+0.43 mmHg, 95% CI 0.09–
0.75). Patients prescribed CCB vs ACE‐I/ARB has lower systolic BPs
at 12 weeks and the difference trended towards being more pro-
nounced for those aged ≥55 yrs (−1.00, 95% CI ‐1.14 ‐ ‐0.86) than
those aged <55 yrs (−0.77, 95% CI ‐0.96 ‐ ‐0.58). Trends for diastolic
BP were similar.
Conclusions: In those aged ≥55 years CCB and ACE‐I/ARB appear
superior to thiazides. There was a trend towards CCB being superior
to ACE‐I/ARB in the older population, although the confidence limits
overlapped indicating similar effectiveness.
1035 | Does the comparative effectiveness
of first line anti‐hypertensive drugs vary by
gender?
Sarah‐Jo Sinnott; Ian J. Douglas; Elizabeth Williamson; Liam Smeeth;
Laurie A. Tomlinson
LSHTM, London, UK
Background: Previous drug utilization research indicates that thiazide
diuretics are used more often in women than men. Current research
on whether the effectiveness of anti‐hypertensive drugs differs by
gender is conflicting.
Objectives: To explore the comparative effectiveness of first‐line anti‐
hypertensive drugs stratified by gender.
Methods: We used UK primary care data from the Clinical Practice
Research Datalink to establish a cohort study. New initiators of Angio-
tensin Converting Enzyme‐Inhibitor/Angiotensin Receptor Blocker
(ACE‐I/ARB), Calcium Channel Blockers (CCB) and thiazide diuretics
with elevated blood pressure (BP) were identified and followed to
investigate change in systolic BP at 12 weeks post initiation. We also
investigated diastolic BP and additional timepoints 26 and 52 weeks.
We compared thiazides vs CCB, thiazides vs ACE‐I/ARB and CCB vs
ACE‐I/ARB. We used mixed linear models with a random intercept
for each patient with interactions to model the effect of the exposure
drug across gender (male or female). Models were adjusted with pro-
pensity scores to adjust for confounding.
Results: We identified 154,257 initiators of ACE‐I/ARB, 115,931 initi-
ators of CCB and 39,632 initiators of thiazides. The mean age was
55.5 yrs (SD 12.7), 63.4 yrs (SD 12.2) and 66.4 yrs (12.7) and the pro-
portion of females was 42.5%, 50.0% and 64.2% in ACE‐I/ARB, CCB,
thiazides respectively. At 12 weeks, systolic BP was +2.47 mmHg
higher (95% CI 2.25–2.68) in women prescribed thiazides than in
women prescribed CCB. This difference was larger than the same drug
comparison in men (+1.46 mmHg, 95% CI, 1.22–1.71). Similar results
were observed for thiazides in comparison to ACE‐I/ARB. Women
prescribed CCB had lower systolic BP at 12 weeks than women pre-
scribed ACE‐I/ARB (−1.30 mmHg, 95% CI ‐1.45 ‐ ‐1.14) and this dif-
ference was more substantial than the same drug comparison in men
(−0.73 mmHg, 95% CI, −0.88 ‐ ‐0.57).
Conclusions: Prior research suggests thiazides are used frequently in
women, however our analyses indicate that thiazide diuretics are less
effective at lowering systolic BP than CCB or ACE‐I/ARB in women.
CCB compared to ACE‐I/ARB reduced systolic BP to a greater extent
in women than men.
1036 | Risk factors of major bleeding in
patients prescribed rivaroxaban in primary
Care in England
Debabrata Roy1,2; Sandeep Dhanda1,2; Lesley Wise1; Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK
Background: The association between oral anticoagulant use and
bleeding risk has been widely reported. However, patients may have
underlying risk factors which predispose to bleeding. It is valuable to
understand the predictors for major bleeding in patients prescribed
rivaroxaban.
Objectives: Multivariable logistic regression analyses to explore
potential risk factors for major bleeding within gastrointestinal, uro-
genital and intracranial sites.
Methods: A case/non‐case design evaluated the association between
clinical risk factors and major bleeding in rivaroxaban patients
(N = 17546) enrolled to a 12‐month cohort study in England (2012–
2016). Clinical risk factors for bleeding and bleeding outcomes were
collected from general practitioners via questionnaires sent at ≥3,
and ≥ 12 months observation. Multivariable logistic regression analy-
ses examined the association for each site and models were based on
two approaches; clinical risk factors selection model and HAS‐BLED
model. The clinical risk factors selection model included all reported
clinical risk factors for bleeding. The HAS‐BLED model included
HAS‐BLED risk score categories (low, moderate, high) and gender. Sta-
tistically significant (p < 0.05) associations are presented in the results.
Results: Gastrointestinal major bleeds (n = 176) Clinical risk factors
selection model Age 65–74 vs. <65 years OR 2.4 [95% CI 1.3, 4.6];
Age ≥ 75 vs. <65 years OR 4.2 [95% CI 2.3, 7.5]; Predisposition to/
history of bleeding OR 4.8 [95% CI 3.1, 7.5] HAS‐BLED model Moder-
ate vs. low OR 4.0 [95% CI 2.1, 7.6]; High vs. low OR 8.9 [95% CI 4.0,
19.9] Urogenital major bleeds (n = 36) Clinical risk factors selection
model Age 65–74 vs. <65 years OR 0.2 [95% CI 0.1, 0.7]; Female vs.
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male OR 2.9 [95% CI 1.4, 6.1]; Malignancy OR 2.6 [95% CI 1.1, 6.3]
HAS‐BLED model Female vs. male OR 2.7 [95% CI 1.3, 5.6] Intracra-
nial major bleeds (n = 57) Clinical risk factors selection model Age ≥ 75
vs. <65 years OR 2.8 [95% CI 1.1, 6.9]; History of cerebrovascular
accident (including haemorrhagic)/transient ischaemic attack OR 2.2
[95% CI 1.3, 3.9]; Predisposition to/history of bleeding OR 2.6 [95%
CI 1.0, 6.7] HAS‐BLED model Moderate vs. low OR 3.3 [95% CI 1.2,
9.1]; High vs. low OR 9.0 [95% CI 2.5, 31.9].
Conclusions: Overall, findings from both models are in keeping with
known clinical risk factors for bleeding. For urogenital major bleeds
the higher risk in females and younger age group may be related to
menstrual bleeding. In clinical practice it is recommended that a bleed-
ing risk assessment, including individual patient characteristics, should
be performed prior to anticoagulation.
1037 | Comparative effectiveness of first
line anti‐hypertensive drugs: Variation by
ethnicity
Sarah‐Jo J. Sinnott; Ian J. Douglas; Elizabeth Williamson; Liam Smeeth;
Laurie A. Tomlinson
LSHTM, London, UK
Background: Current clinical guidelines recommend Calcium Channel
Blockers (CCB) and thiazides for black patients newly initiating drug
therapy for hypertension. The evidence underpinning these recom-
mendations is not conclusive.
Objectives: To explore the comparative effectiveness of first‐line anti‐
hypertensive drugs stratified by ethnicity; white, black and south Asian.
Methods: We used UK primary care data from the Clinical Practice
Research Datalink to establish a cohort study. New initiators of Angio-
tensin Converting Enzyme‐Inhibitor/Angiotensin Receptor Blocker
(ACE‐I/ARB), CCB and thiazide diuretics were identified and followed
to investigate change in systolic blood pressure (BP) at 12 weeks post
initiation. We also investigated diastolic BP and timepoints 26 and
52 weeks. We compared thiazides vs CCB, thiazides vs ACE‐I/ARB
and CCB vs ACE‐I/ARB. We used mixed linear models with a random
intercept for each patient with interactions to model the effect of the
exposure drug across 3 levels of ethnicity; white, black and south Asian.
Modelswere adjustedwith propensity scores to adjust for confounding.
Results: We identified 154,257 initiators of ACE‐I/ARB, 115,931 initi-
ators of CCB and 39,632 initiators of thiazides. More than 95% of the
population was white, 1.5% was black and 1.8% was south Asian. At
12 weeks, there was no evidence to suggest that black patients pre-
scribed thiazides had higher or lower systolic BP than those prescribed
CCB. In contrast, white patients and south Asian patients prescribed
thiazides had higher systolic BP when compared to patients on CCB
(+1.91 mmHg, 95% 1.72–2.10 and + 2.06 mmHg, 95% CI 0.82–3.30
respectively). Black patients prescribed thiazides had lower systolic
BP than those prescribed ACE‐I/ARB at 12 weeks (−2.57 mmHg,
95% CI ‐3.97 ‐ ‐1.18). In contrast, white patients prescribed thiazides
had slightly higher systolic BP (+0.52 mmHg, 95% CI 0.33–0.71)
compared to white patients prescribed ACE‐I/ARB. At 12 weeks post
initiation, both black and south Asian patients had lower systolic BP
on CCB compared to ACE‐I/ARB (−2.31 mmHg, 95% CI ‐3.29 ‐ ‐
1.55 and − 2.04 mmHg, 95% CI ‐2.71‐1.37 respectively). In white
patients prescribed CCB, systolic BP decreased by 1.15 mmHg (95%
CI ‐1.28 ‐ ‐1.02) vs white patients prescribed ACE‐I/ARB.
Conclusions: When compared to ACE‐I/ARB, CCB were more effec-
tive at lowering systolic BP in black patients than in white patients.
Similarly, when compared to ACE‐I/ARB, thiazides were more effec-
tive at lowering systolic BP in black patients than in white patients.
1038 | Improvements in disease activity
scores associated with bDMARD use by
rheumatoid arthritis patients in a large US‐
based real world cohort
Kathleen Mortimer; Anna Swenson; Thomas Brecht; Brian Strubel;
Shannon Cerf; Anna Lafontant; Richard Gliklich
OM1, Boston, MA
Background: Disease activity scores (DAS) are specific clinical mea-
sures used to quantify abnormalities in patients with rheumatoid
arthritis (RA). Changes in Routine Assessment of Patient Index Data
3 (RAPID3) scores, as well as swollen and tender joint counts and
remission status are useful metrics to assess treatment effects of
new and costly therapies such as biological disease modifying anti-
rheumatic drugs (bDMARDs).
Objectives: To characterize the changes in RAPID3 scores, joint
counts and remission status associated with bDMARD use.
Methods: The OM1 RA Registry (OM1, Boston, MA) follows more
than 100,000 adult patients longitudinally with deep clinical data,
including laboratory, symptom, patient‐reported and disease activity
information. The study period includes data from Jan 2013‐Jan 2019.
Differences in RAPID3 scores (range 0–10), joint counts (range 0–28)
and disease status (remission/low/moderate/high) before and 6‐
months after the start of 9 specific bDMARDS were assessed. Disease
remission is defined in accordance with the criteria described by Amer-
ican College of Rheumatology/European League Against Rheumatism.
Results: Overall, 88,424 patients had at least one DAS, 76.2% were
women and mean age was 65 years. Across a series of 9 bDMARDs,
baseline values of RAPID3 ranged from 4.14 to 4.69. After 6 months
following bDMARD treatment, scores ranged from 3.68 to 4.29, with
improvements seen for all bDMARD groups. Among the 16,467
patients with swollen joint measures, the range of improvement over
6 months was 1.23 to 2.03 joints. Among the 16,727 patients with
swollen joint measures, the range of improvement over 6 months
was 1.61 to 2.64 joints. The percent of patients transitioning from
moderate/high to remission/low status ranged from 16.5% to 24.2%.
Investigation of bDMARD‐specific improvements for all metrics,
adjusted for baseline factors is ongoing.
Conclusions: Withina realworld cohortofRApatients, bDMARDSwere
associatedwith a rangeof improvements in disease scores and remission
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status. Identificationof the impact thatbDMARDShaveonthesemetrics
provides insight into appropriate use of these costly medications.
1039 | Real‐world effectiveness of
methotrexate, ciclosporin, acitretin and
fumaric acid esters for psoriasis: Does
treatment history matter?
Kayleigh J. Mason1; On behalf of the BADBIR Study Group2
1The University of Manchester, Manchester, UK; 2British Association of
Dermatologists, London, UK
Background: Real‐world effectiveness of the systemic therapies meth-
otrexate (MTX), ciclosporin (CsA), acitretin (ACI) and fumaric acid
esters (FAE) prescribed to patients with moderate–severe psoriasis is
poorly characterized.
Objectives: To determine whether systemic treatment history predicts
the effectiveness of ACI, CsA, FAE and MTX.
Methods: The British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR) is a pharmacovigilance register
investigating the long‐term safety of systemic therapies prescribed to
psoriasis patients. Established in 2007, over 15,500 patients have been
recruited from 160 dermatology centres across the UK and Ireland.
Patients registering onMTX, CsA, ACI or FAEwith at least 6months fol-
low‐up were analyzed. Exposure time for the registration therapy was
calculated from initiation to censor at: discontinuation date; latest fol-
low‐up; or death. Effectiveness was defined as achieving Psoriasis Area
and Severity Index (PASI) ≤3 using the first longitudinal PASI reported
after initiating therapy. Treatment history was classified into incident
(first systemic), prevalent (prescribed registration therapy previously),
or previous systemic use (prescribed another systemic therapy previ-
ously). Multivariable logistic regression estimated the odds ratio (OR) of
achievingPASI≤3withaprioribaselinecovariates included.Missingdata
were accounted for using a multiple imputationmodel of 20 datasets.
Results: In total, of 4113 patients analyzed, 1991 (48%) were pre-
scribed MTX, 1022 (25%) CsA, 765 (19%) ACI and 335 (8%) FAE.
The proportions of incident, prevalent and previous systemic users,
respectively, were similar for MTX (41%; 18%; 41%), CsA (38%;
16%; 46%) and ACI (42%; 16%; 42%), but differed for FAE (19%;
15% 66%). The proportion of patients achieving PASI≤3 were 31%
MTX, 36% CsA, 22% ACI and 26% FAE. Prevalent users of ACI (OR
0.67, 95% confidence interval [CI] 0.45–0.99) and CsA (0.64, 0.47–
0.87) were less likely to achieve PASI≤3 compared with incident
users. Prevalent users of MTX (0.81, 0.64–1.02) and FAE (0.66,
0.33–1.31), and previous systemic users did not differ significantly to
incident users in achieving PASI≤3.
Conclusions: The effectiveness of MTX and FAE does not appear to
differ by treatment history categories and could be prescribed as first
or subsequent lines of therapy. Prevalent users of CsA and ACI regis-
tering on those therapies were less likely to achieve PASI≤3 compared
to incident users. The findings for CsA may reflect the intermittent
short‐term use in clinical practice.
1040 | Comparative effectiveness of long‐
term lifestyle and pharmacological
interventions for primary prevention of type
2 diabetes: A network meta‐analysis of
randomized controlled trials
Huilin Tang; Jin Xia; Keming Yang; Yiqing Song
Indian University, Indianapolis, IN
Background: Lifestyle modification and some pharmacological inter-
ventions have been proven effective in preventing or delaying type
2 diabetes (T2D); however, their comparative efficacy is unclear.
Objectives: We therefore undertook a network meta‐analysis to inte-
grate both direct and indirect evidence to estimate the relative effects
of all interventions against each other for preventing T2D.
Methods: We searched electronic databases through October 2018
and identified long‐term randomized trials (follow‐up ≥1 year) that
evaluated the interventions for T2D prevention in adults with predia-
betes (IFG or IGT). A network meta‐analysis was conducted to calcu-
late the summary odds ratio (OR) and 95% confidence interval (CI)
and rank the effectiveness of these interventions.
Results: We included thirty‐three trials involving 54,910 individuals
with prediabetes and 13,189 incident T2D cases during the median
trial duration of 3 years. Our network meta‐analysis showed that life-
style modification (OR, 0.53; 95% CI, 0.42 to 0.66), insulin sensitizers
(0.44; 0.31 to 0.62), alpha‐glucosidase inhibitors (0.60; 0.42 to 0.87),
and weight‐loss drugs (0.39; 0.23 to 0.66) were significantly associ-
ated with decreased risk of developingT2D as compared with the con-
trols. Lifestyle modification (0.57; 0.36 to 0.90), insulin sensitizers
(0.48; 0.28 to 0.81), and weight‐loss drugs (0.43; 0.22 to 0.82) were
associated with lower risk than renin‐angiotensin system blockage.
Weight‐loss drug was associated with lower risk of T2D than insulin
secretagogues (0.49; 0.25 to 0.98). Ranking of these interventions
suggested weight‐loss drugs being the optimal intervention for
preventing T2D (89.5%), followed by insulin sensitizers (84.1%), life-
style modification (66.7%), and alpha‐glucosidase inhibitors (54.4%).
Conclusions: Overall, four interventions (lifestyle modification, insulin
sensitizers, alpha‐glucosidase inhibitors, and weight‐loss drugs)
showed significant and comparable benefits on the primary prevention
of T2D, although weight‐loss drugs seemed to be the most effective.
1041 | Evaluation on therapeutic
equivalence of generic and brand‐name
controlled‐release doxazosin
Ju‐Ling Chen1; Ching‐Lan Cheng1,2; Yea‐Huei Kao Yang1
1 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan, Taiwan; 2Department
of Pharmacy, National Cheng Kung University Hospital, Tainan, Taiwan
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Background: It may not be feasible to assess the therapeutic equiva-
lence between brand and generic drugs by comparing efficacy, safety
and adherence as conducted in clinical trials. Instead, persistence, a
global measure of efficacy, safety, and tolerability, can be employed
as a surrogate outcome to examine therapeutic equivalence using a
retrospective claims database.
Objectives: To evaluate the prescription persistence of generic and
brand controlled‐release doxazosin.
Methods: A retrospective cohort study with new user design was con-
ducted by using two million random sampled database from Taiwan
National Health Insurance Database (NHID). BPH patients who aged
over 50 years and newly prescribed controlled‐release doxazosin dur-
ing 2009 to 2015 were enrolled. Patients were grouped to generic or
brand doxazosin users. The non‐persistence was defined as an event
of treatment change, which included discontinuation, switching study
drug or augmentation with another anti‐BPH medications. We
followed up patients who incurred treatment change, or up to one
year, whichever came first. We also conducted sensitivity analysis
based on patients' previous BPH medication history to eliminate con-
founding by BPH severity. Propensity score (PS) was performed and
Cox proportional hazards regression was used to calculate hazard
ratios and confidence interval.
Results: There were 8,596 brand and 1,472 generic users met study
criteria. The mean age was 68 years old and hypertension was the most
frequent comorbidity among two groups. Compared to brand users, the
adjusted hazard ratio for treatment change in generic users was 1.01
[95% CI: 0.9–1.14]. The result from sensitivity analysis was consistent
with primary result, implying no significant treatment change between
generic and brand users (HR 0.92 [0.77–1.11], HR 1.11 [0.88–1.41],
HR 0.95 [0.75–1.2] in mild, moderated and severe BPH, respectively.)
Conclusions: The findings indicate that generic and brand doxazosin
are therapeutic equivalent.
1042 | Real‐world safety and effectiveness
of onabotulinumtoxina treatment of Crow's
feet lines and glabellar lines: Results of a
Korean 4‐year postmarketing surveillance
study
Dong Jin Yi Dr.1; Seongjin Hwang Dr.2; JunHyuk Son Dr.3;
Irina Yushmanova Dr.4; Krystal Anson Spenta4; Suzanne St. Rose Dr.5
1BLS Clinic, Seoul, Korea, Republic of; 2Fulore Clinic, Seoul, Korea,
Republic of; 3Yeungnam University, Daegu, Korea, Republic of; 4Allergan
plc, Irvine, CA; 5Allergan plc, Marlow, UK
Background: Based on results from pivotal trials in North America,
Europe, and Asia, onabotulinumtoxinA was approved in the Republic
of Korea for treatment of moderate to severe lateral canthal lines (ie,
crow's feet lines [CFL]) and glabellar lines (GL), separately or in
combination.
Objectives: To fulfill Korean regulatory requirements, a postmarketing
surveillance (PMS) study was conducted to assess safety and
effectiveness of onabotulinumtoxinA in real‐world clinical practice
over a 4‐year period.
Methods: The study was conducted at 26 sites in the Republic of
Korea from February 2014 to February 2018. Adult Korean subjects
aged 18–75 years with moderate to severe CFL treated with
onabotulinumtoxinA from a 50 U vial at the labeled CFL dose (24 U
total) were enrolled; the target sample size was ≥600 subjects. Safety
and effectiveness data were collected at all in‐office visits within
3 months of the index treatment or before the subject received
another onabotulinumtoxinA treatment, if it occurred within the 3‐
month period. All adverse events (AEs), including serious AEs (SAEs),
were recorded, regardless of causal relationship or whether they were
considered unexpected (ie, AEs not mentioned in the
onabotulinumtoxinA Korean prescribing information). Investigators
assessed effectiveness by rating the overall change in CFL since last
treatment (improved, unchanged, or worsened). Data were summa-
rized by descriptive statistics.
Results: A total of 695 subjects were included in the full analysis set.
The safety population comprised 667 subjects (mean ± SD age,
40.9 ± 13.0 years; range, 20–75 years), 87.3% of whom were female.
Most subjects (69.9%) were treated for moderate to severe CFL, with
30.1% treated for moderate to severe CFL and GL simultaneously.
Fourteen AEs were reported in 11 subjects (1.7%). Most AEs were
mild (12; 85.7%), 1 was moderate, and 1 was severe (both eyelid pto-
sis). The majority (11; 78.6%) of AEs resolved without sequelae. Two
AEs (injection site pain) reported in 2 subjects were deemed possibly
related to onabotulinumtoxinA. One unexpected SAE (acute renal fail-
ure) occurred in 1 subject (0.3%). All unexpected AEs (n = 4 [0.5%])
were mild and considered unlikely to be related to treatment. Of the
376 subjects in the effectiveness analysis set, overall change from
baseline in CFL was rated as improved in 375 (99.7%) and as
unchanged in 1 (0.3%).
Conclusions: OnabotulinumtoxinA was well tolerated and effective for
treatment of CFL with or without GL in this Korean PMS study. No
new safety concerns were identified.
1043 | Treatment patterns of systemic
antifungal dispensation in hospitals in
England: An analysis of the health treatment
insights database
Orlagh U. Carroll1; Rachel L. Tham2; Benjamin D. Bray2,3;
Hassy Dattani2; Deborah Layton2,4
1London School of Hygiene and Tropical Medicine, London, UK; 2 IQVIA,
London, UK; 3King's College London, London, UK; 4Keele University,
Keele, UK
Background: Systemic fungal infections are a growing public health
challenge and are a major cause of morbidity and mortality in hospital-
ized or immunosuppressed patients. In the UK, the number of cases of
fungal bloodstream infection reported to national surveillance systems
increased 24% between 2013 and 2017 [1]. With antimicrobial
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resistance becoming a growing concern, it is important to understand
the reasons for antifungal use in hospital.
Objectives: To describe the indications for systemic antifungal therapy
in a large linked database of pharmacy and hospital discharge data in
England (The Hospital Treatment Insights (HTI) database) broken
down by primary and secondary diagnoses.
Methods: A retrospective cohort study of inpatients dispensed oral or
intravenous antifungal medications during a hospitalization occurring
between January 2010 and January 2017, as recorded within HTI.
Data on exposure were defined by molecule name and included:
Amphotericin B, Anidulafungin, Caspofungin, Fluconazole, Flucytosine,
Griseofulvin, Isavuconazole, Itraconazole, Ketoconazole, Micafungin,
Miconazole, Posaconazole, Voriconazole. Indications were inferred
using diagnostic codes (ICD‐10) recorded in Hospital Episode Statis-
tics and analyzed using descriptive statistics.
Results: The cohort comprised 101,151 patients with 155,194
hospitalisations from 2010 to 2017. The mean age was 58 years (SD
21.5). In 10‐year age bands, the most common band for children was
0–9 years (n = 4,142 (2.7% of hospitalisations)) and 60–69 years for
adults (n = 35,092 (22.6%)), closely followed by 70–79 years
(n = 34,360 (22.1%)). The top 5 primary diagnoses were: acute myelo-
blastic leukemia (n = 8,806 (5.7% of hospitalisations)), multiple mye-
loma (n = 8,758 (5.6%)), unspecified sepsis (n = 7,108 (4.6%)),
unspecified lobar pneumonia (n = 6,302 (4.1%)) and diffuse large B‐cell
lymphoma (n = 5,507 (3.6%)).
Conclusions: Our study shows that hematological malignancies are the
leading diagnoses associated with dispensation of systemic antifungals
in England. A limitation of this study includes the inferring of diagnos-
tic coding. However, results are consistent with clinical practice.
Linked pharmacy and hospital discharge data (HTI) can provide
insights into the likely indications of systemic antifungal use and mon-




1044 | Impact of fluoroquinolone pre‐
authorization on ceftriaxone use and
resistance in a large academic Hospital in
South East United States of America
Adeniyi J. Idigo1; Rachael A. Lee2; Allen Bryan Jr.2;
Matthew L. Brown3; Howard W. Wiener1; Russell L. Griffin1;
Sadeep Shrestha1
1University of Alabama at Birmingham, Birmingham, AL; 2University of
Alabama at Birmingham School of Medicine, Birmingham, AL; 3University
of Alabama at Birmingham Hospital, Birmingham, AL
Background: Antimicrobial pre‐authorization, a process that limits the
use of specific antimicrobials, is a useful antimicrobial stewardship (AS)
strategy that can improve antimicrobial prescribing and decrease bac-
terial resistance. The impact of pre‐authorization on the use of other
antibiotics and the subsequent emergence of bacterial resistance is
important in understanding the complex effects of AS interventions.
Objectives: To examine the relationship between fluoroquinolone pre‐
authorization (FP) and 1) ceftriaxone utilization and 2) the emergence
of bacteria resistant to ceftriaxone in a clinical setting.
Methods: In October 2005, the University of Alabama at Birmingham
hospital began implementing FP. Using a retrospective ecological
design, change in the days of ceftriaxone therapy per 1000 patient‐
days 5 years before (09/2000–08/2005) and 5 years after (12/
2005–11/2010) FP implementation was evaluated and compared
using a Poisson regression model. Logistic regression was used to esti-
mate and compare the emergence of ceftriaxone non‐susceptible
(CTR‐NS) isolates of E. coli, K. pneumoniae, E. cloacae and A. baumannii
3 years before (2003–2005) and 3 years after FP implementation
(2006–2008). Non‐susceptible isolates are either resistant or showed
intermediate resistance to ceftriaxone.
Results: After FP implementation, the average days of ceftriaxone
therapy per 1,000 patient‐days was 5 times more than before FP
implementation (RR: 5.03; 95% CI: 4.56, 5.53; p‐value: < 0.0001).
When compared to the period before FP implementation, there was
a decrease in the odds of CTR‐NS E. coli (OR: 0.58; 95% CI: 0.46,
0.72; p‐value: < 0.0001) and CTR‐NS E. cloacae (OR: 0.62; 95% CI:
0.53, 0.73; p‐value: < 0.0001) isolates by 42% and 38% respectively
after FP implementation. However, there was a statistically non‐signif-
icant increase in the odds of CTR‐NS A. baumannii (OR: 1.10; 95% CI:
0.88, 1.37; p = 0.39) and CTR‐NS K. pneumoniae (OR: 1.02; 95% CI:
0.81, 1.29; p = 0.89) isolates after the implementation, when com-
pared to the period before the implementation.
Conclusions: Antimicrobial pre‐authorization may increase the use of
another antibiotic, but the effect on emergence of bacterial resistance
is unclear. In this retrospective evaluation, fluoroquinolone pre‐autho-
rization resulted in increased ceftriaxone use; however, this did not
negatively affect ceftriaxone resistance among select gram‐negative
organisms. Large‐scale studies in other settings are needed to confirm
this finding.
1045 | National medication use evaluation of
combination antibiotic‐corticosteroid
ophthalmic products for acute conjunctivitis
Michelle Vu1; Nathan Sylvain1; Glenn Cockerham2; Muriel Burk1;
Chester B. Good1; Peter Glassman1; Xiang‐Ming Wei1; Diane Dong1;
Francesca Cunningham1
1Department of Veterans Affairs, Hines, IL; 2Department of Veterans
Affairs, Palo Alto, CA
Background: Antibiotic‐corticosteroid combination ophthalmic prod-
ucts (COPs) are not indicated for treatment of acute conjunctivitis
(AC), which is usually viral, and overuse increases the risk of adverse
reactions, including antimicrobial resistance and glaucoma.
Overprescribing of COPs among non‐specialists (non‐ophthalmolo-
gists/optometrists) is a potential medication safety concern, thus a
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medication use evaluation (MUE) was conducted within the Veterans
Health Administration (VA).
Objectives: This quality improvement initiative evaluated presence of
documented reasons, screening, and follow‐up care for COP use by
non‐specialist prescribers for Veterans with or without AC.
Methods: A retrospective, multi‐centered MUE was conducted utiliz-
ing database evaluations and chart reviews. Diagnosis codes, clinic
stop codes, and prescriptions were identified through corporate data
warehouse (CDW) and prescription databases. Veterans who received
outpatient prescriptions for COPs from April 1, 2017 to March 31,
2018 and visited a primary care (PCP), emergency department (ED)
provider, or other non‐specialists were identified. Two samples of Vet-
erans, with AC diagnosis codes and without AC codes, were included.
Veterans having chronic conjunctivitis over 4 weeks, COPs prescribed
by non‐VA providers, or ocular surgery were excluded. Chart reviews
were conducted to evaluate appropriate COP use, including verifying
documented reasons (AC and/or other diagnoses), screening of intra-
ocular pressure (IOP) at baseline, and screening IOP at follow‐up
within 30 days. Descriptive statistics were used to compare demo-
graphics and COP use.
Results: Overall, 300 Veterans were included, 216 (72%) with AC and
84 (28%) without AC. Baseline characteristics were similar between
groups. Most non‐specialists who prescribed COPs were ED providers
(41%), followed by PCPs (26%). Among non‐specialist prescribers, 92%
of patients with AC had that diagnosis alone documented as the rea-
son for COP use. For those without AC, 24% had no documented rea-
son for use. Screening rates of IOP were low at baseline (2.5% with
AC, 6.7% without AC). Follow‐up IOP screening rates was similarly
low (12% with AC, 8.9% without AC).
Conclusions: Inappropriate use and monitoring of COPs for AC among
non‐specialist prescribers is a concern. This finding prompted a medi-
cation safety newsletter alert and ophthalmology partnership to edu-
cate PCP and ED providers to avoid using COPs for AC and to
understand appropriate indications for use. Future evaluations will
assess the impact of these interventions on COP use.
1046 | Trends in pharmacotherapy for
uncomplicated urinary tract infections in the
United States, 2007–2016
Julia B. Ward1,2; Brian R. Matlaga3; Casey Pierce1; John Lim1;
Kevin C. Abbott4; Tamara Bavendam4; Ziya Kirkali4; Lydia Feinstein1,2
1Social & Scientific Systems, Durham, NC; 2University of North Carolina,
Chapel Hill, Chapel Hill, NC; 3 Johns Hopkins University School of
Medicine, Baltimore, MD; 4National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda, MD
Background: Concerns of multidrug resistance may be influencing
pharmacotherapy for urinary tract infections (UTI), but our knowledge
of recent trends is limited.
Objectives: To assess 10‐year trends in prescription practices for
uncomplicated UTI in a national adult population.
Methods: To assess trends among those aged 18–64 years
(N = 2,690,547), we utilized the Optum© Clinformatics® Data Mart
(CDM), a de‐identified administrative claims database that includes
15–18 million individuals covered annually by commercial insurance
in all 50 US states. For analyses among those aged 65+ years
(N = 371,227), we utilized the Medicare 5% Sample from the Centers
for Medicare and Medicaid Services. UTI was defined as an outpatient
claim with a UTI‐related diagnosis code followed by a pharmacy claim
within 72 hours for an anti‐infectious agent. We assessed temporal
trends in the prevalence of UTI‐related prescription fills from 2007
to 2016, overall and stratified by sociodemographic characteristics.
Results: Over the 10‐year study period, quinolones were the most
commonly used medications (CDM: 41.2%; Medicare: 41.5%),
followed by urinary anti‐infectives (CDM: 22.0%; Medicare: 17.2%),
and sulfonamides (CDM: 17.4%; Medicare: 15.8%). Over time, quino-
lone use decreased among both CDM enrollees (46.8% in 2007 to
32.9% in 2016) and Medicare enrollees (49.0% in 2007 to 34.0% in
2016). Conversely, urinary anti‐infective use increased from 18.8% in
2007 to 27.7% in 2016 among CDM enrollees, and from 15.4% in
2007 to 18.8% in 2016 among Medicare enrollees. Among CDM
enrollees, quinolone use increased with increasing age (34.5% among
those 18–24 vs. 46.4% among those 55–64), while urinary anti‐infec-
tive use decreased (24.7% among those 18–24 vs. 19.7% among those
55–64). Medication use was more similar across age groups among
Medicare enrollees. Quinolone use was more common among men
(CDM: 58.4%; Medicare: 47.7%) compared to women (CDM: 39.5%;
Medicare: 40.2%), while urinary anti‐infective use was more common
among women (CDM: 23.7%; Medicare: 18.8%) compared to men
(CDM: 5.2%; Medicare: 9.8%). We also found differences by race/eth-
nicity and socioeconomic status, with non‐Hispanic Black and low‐
income enrollees less likely to use a urinary anti‐infective and more
likely to use a sulfonamide.
Conclusions: Our study demonstrates shifting UTI treatment patterns
over time and differences by age, gender, race/ethnicity, and income.
1047 | Regional variation in the potentially
inappropriate first line use of
fluoroquinolones in Canada: A key to
antibiotic stewardship?
Audray St‐Jean1; Dan Chateau2; Matthew Dahl2; Pierre Ernst3;
Nick Daneman4; Ingrid S. Sketris5; Jianguo Zhang6; Fawziah Lalji7;
Jacqueline Quail8; Shawn Bugden9; for the CNODES Investigators10
1Lady Davis Research Institute, MontrealQC, Canada; 2University of
Manitoba, Winnipeg, MB, Canada; 3McGill University, MontrealQC,
Canada; 4Sunnybrook Research Institute, Toronto, ON, Canada;
5Dalhousie University, Halifax, NS, Canada; 6University of Calgary,
Calgary, AB, Canada; 7University of British Columbia, Vancouver, BC,
Canada; 8Health Quality Council, Saskatoon, SK, Canada; 9Memorial
University of Newfoundland, St John's, NL, Canada; 10Canadian Network
for Observational Drug Effect Studies (CNODES), Montreal, QC, Canada
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Background: Systemic oral fluoroquinolones are among the most
widely prescribed class of antibiotics and are associated with potential
harmful side effects. Their use has been expanded to milder infections,
such as urinary tract infections (UTI), acute bacterial sinusitis (ABS)
and acute exacerbation of chronic obstructive pulmonary disease
(AECOPD), with limited evidence of superiority to first line antibiotics.
Objectives: To determine the rates of initial antibiotic dispensations
for uncomplicated UTI, ABS and AECOPD in the outpatient setting
across Canada, and to describe the determinants of variation in the
use of fluoroquinolones.
Methods: We formed three retrospective population‐based cohorts,
one for each infection type, in each of six Canadian provinces (Alberta,
British Columbia, Manitoba, Nova Scotia, Ontario, and Saskatchewan).
We used administrative health data spanning January 1, 2005 to the
latest date of data availability for each site. We identified ambulatory
visits with a diagnosis for UTI in women, ABS or AECOPD, and deter-
mined antibiotic exposure by the first antibiotic dispensed within
5 days of the event. The proportions of fluoroquinolones among the
initial antibiotic dispensations for uncomplicated UTI, ABS or AECOPD
events were described by province and over the study period.
Results: Among 2,170,027 women, 4,303,144 uncomplicated UTI
events were identified. The proportion of events treated with
fluoroquinolones, mostly ciprofloxacin, varied by province and ranged
from 19% in Saskatchewan to 52% in Alberta. We identified
3,467,678 ABS events among 2,087,934 patients. Between 2% (Nova
Scotia) and 11% (Ontario) of events treated with an antibiotic were
dispensed a fluoroquinolone. Among 598,347 patients, 1,319,128
AECOPD events were identified. Fluoroquinolone use, mostly
levofloxacin and moxifloxacin, varied by province and ranged from
6% in Nova Scotia and 36% in Ontario. Differences in provincial for-
mulary criteria and enforcement, local practice and marketing patterns
may partly explain these large interprovincial variations in the use of
fluoroquinolones.
Conclusions: Systemic oral fluoroquinolones were commonly used as
first line therapies, particularly for uncomplicated UTI and AECOPD.
However, first line fluoroquinolone use varied widely across prov-
inces. Formulary criteria and enforcement may be a key to facilitating
better antibiotic stewardship and limiting potentially inappropriate
first line use of fluoroquinolones.
1048 | Dolutegravir exposure among women
of child‐bearing potential living with HIV and
during early pregnancy ‐ a drug utilization
study
James P. Trinidad1; Talia Menzin2; Elizabeth Dee2; Monique Falconer1;
Mayura Shinde2
1Food and Drug Administration, Silver Spring, MD; 2Harvard Medical
School and Harvard Pilgrim Health Care Institute, Boston, MA
Background: Dolutegravir (DTG) is an integrase strand transfer inhib-
itor indicated for the treatment of human immunodeficiency virus
(HIV) type‐1 infection. The U.S. Food and Drug Administration
approved Tivicay (DTG) for use in combination with other antiretrovi-
ral drugs in August 2013; a fixed dose combination (FDC) containing
abacavir/lamivudine/DTG was approved in August 2014; and a FDC
containing rilpivirine/DTG was approved in November 2017. This drug
utilization analysis was prompted by findings from theTsepamo Study
in Botswana, which identified a signal for neural tube defects (NTD) in
the offspring of mothers exposed to DTG at conception. Labeling for
DTG‐containing drugs was subsequently updated to warn of NTD risk
with DTG use at conception through the first trimester.
Objectives: To describe the prevalence of exposure to DTG‐contain-
ing regimens among pregnant women and women of child‐bearing
potential living with HIV in the Sentinel System.
Methods: Using the Sentinel Distributed Database (SDD), we exam-
ined the prevalence of DTG use (using National Drug Codes) among
women of childbearing age (15 to 49 years old) with an HIV diagnosis
and women aged 15 to 49 years old with live birth deliveries, August
2013 through March 2018. Prevalence of DTG use during the first
month of pregnancy and during the first trimester were specifically
examined.
Results: The prevalence of DTG use was high among women with
HIV, increasing from 304.1 users per 10,000 women (229 per 7,530)
in the first year of approval, to 2,133.5 users per 10,000 women
(719 per 3,370) in the nine‐month period starting August 2017. Over
1.1 million pregnancy episodes were identified, 21 of which had DTG
use during the first month of pregnancy and 25 during the first trimes-
ter of pregnancy. DTG use during the first trimester increased from 0
exposures out of 268,001 pregnancies in the year from August 2013–
July 2014, to 5 exposures out of 77,227 pregnancies in the nine‐
month period starting August 2017.
Conclusions: Although prevalence of DTG use in the SDD among HIV‐
infected women of childbearing age was substantial, the absolute
number of DTG‐exposed pregnancies was observed to be low.
Despite the inclusion of a diverse U.S. population in SDD, data used
in this analysis primarily include individuals who receive employer‐
based health care benefits plus a small proportion of Medicaid recipi-
ents. Therefore, the study's findings may not generalize to certain
populations such as Medicaid recipients.
1049 | Prevalence of isoniazid preventive
therapy use and factors predicting its use
among HIV‐infected patients in a Nigerian
teaching hospital
Abdulwasiu A. Busari1; Kaseem A. Oshikoya2;
Olamide A. Olanrewaju1; Ibrahim A. Oreagba1
1University of Lagos College of Medicine, Lagos, Nigeria; 2Lagos State
University College of Medicine, Lagos, Nigeria
Background: HIV/AIDS is a pandemic disease associated with oppor-
tunistic infection, especially tuberculosis, which may result in high
morbidity and mortality. The burden of the disease is high in Nigeria,
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which is ranked second among most prevalent HIV population in the
world. Despite the benefit of Isoniazid Preventive Therapy (IPT) in
reducing burden of HIV/TB co‐infection, the uptake is generally lim-
ited in developing countries.
Objectives: The aim of this study was to determine the prevalence of
IPT use and the limiting factors among HIV‐infected patients at Lagos
University Teaching Hospital (LUTH) in Nigeria.
Methods: This cross‐sectional study involved 300 HIV‐infected indi-
viduals attending APIN clinic at LUTH over a 3‐month period. A pro
forma was used to capture the socio‐demographic data, patients'
exposure to tuberculosis and IPT use. Clinical data of eligible patients
were also extracted and include the baseline laboratory parameters
such as CD4 count, Hemoglobin concentration and viral load. Main
outcome measure was prevalence of IPT use and IPT non‐use. We
also predicted the factors that affected the use of IPT. Data were ana-
lyzed using SPSS version 20.0. The demographic and clinical variables
among IPT users and IPT non‐users were compared. Binary logistic
regression was used to predict the demographic and clinical variables
determined IPT use among the patients. Any p value <0.05 was con-
sidered to be statistically significantly.
Results: Of the 300 cohort evaluated (218;72.7%) were females; their
mean age was 41.74 ± 10.46 years. Tuberculosis co‐infection was
most predominant (47;15.7%) among those with HIV‐infected and
majority (133; 44.3%) had a CD4 count in the range of 200–500
cells/ml. The uptake of IPT use was low (20;7.9%) among HIV‐infected
patients without TB co‐infection. Among the factors affecting the
uptake of IPT were: Lack of awareness of its benefit (23;7.7%), IPT
not prescribed (263;87.6%) and fear of adverse drug reaction
(5;1.6%) and affordability 2 (0.7%). Lack of awareness about IPT use
was found to be independently associated with poor IPT uptake (18;
2, p = 0.00).
Conclusions: IPT uptake was found to be very low in this study.
Increase awareness and policy implementation of IPT by healthcare
provider is necessary.
1050 | Utilization of direct acting antivirals
for the treatment of hepatitis C in he province
of Manitoba, Canada
Silvia Alessi‐Severini; Carole Taylor; Samantha Myers; I. fan Kuo
University of Manitoba, Winnipeg, MB, Canada
Background: Direct‐acting antivirals (DAAs) for the treatment of
chronic hepatitis C viral (HCV) infection have been approved by
Health Canada in recent years. These agents are significantly more
efficacious than previous interferon‐based therapies providing
sustained virologic responses (SVRs) as high as 100%. They also have
better safety and tolerability profiles and have become first line ther-
apy for HCV.
Objectives: To describe incident rates of HCV diagnosis, the charac-
teristics of the HCV patient population, and the utilization of the
DAAs in the province of Manitoba.
Methods: The administrative databases of the Manitoba Centre for
Health Policy (MCHP) Repository were used to determine all HCV
cases in the province between calendars years 1995 and 2017. Link-
age of the population registry with the provincial laboratory database
allowed for the construction of a cohort of HCV patients and the
description of their demographic characteristics. Dispensations of
the DAAs available on the Canadian market at the time of the study
were counted using the DPIN databases. Analyses were conducted
with SAS® statistical software.
Results: Incident rates of HCV diagnosis increased from 42 per
100,000 population in 1995 to 64 per 100,00 in 2001; subsequently,
rate of HCV diagnosis decreased to a 21 per 100,000 in 2011. In
2017, the annual rate was 38 per 100,000. Over the 22‐year period,
9,445 HCV cases were identified; mean age at diagnosis was
40.2 ± 13.7 years, 58% were males, 77% lived in urban areas and more
than 65% belonged to the lowest income quintiles. Between 1999 and
2011 fiscal years, 100% of the market share for HCV therapies
belonged to the peg‐interferon + ribavirin regimen, by 2017 fiscal year
99.7% of market share was for DAAs in Manitoba. The most pre-
scribed agent was the ledispavir/sofosbuvir combination product with
more than 60% of all prescriptions.
Conclusions: Our preliminary results demonstrate a rapid uptake of
the new DAAs which have taken the entire market of the medica-
tions for chronic HCV infection. The population treated was pre-
dominantly male and of low income. Further studies are warranted
to investigate the effectiveness of DAAs in patients who had not
responded to interferon‐based therapies or had relapsed after treat-
ment. Acknowledgements Results and conclusions are those of the
authors; no official endorsement by Manitoba Health, Seniors and
Healthy Living or MCHP is intended or should be inferred.
1051 | Ceftolozane‐Tazobactam utilization
in the national veterans affairs healthcare
system
Jaclyn A. Cusumano1,2; Emily Bodo1,2; Vrishali Lopes1;
Kevin W. McConeghy1,3; Laura A. Puzniak4; Eilish McCann4;
Kerry L. LaPlante2,1,5; Aisling R. Caffrey2,1,3
1Providence VA Medical Center, Providence, RI; 2University of Rhode
Island, Kingston, RI; 3Brown University, Providence, RI; 4Merck & Co., Inc.,
Kenilworth, NJ; 5Warren Alpert Medical School of Brown University,
Providence, RI
Background: Treatment of Gram‐negative infections is complex due
to underlying patient conditions, pathogen characteristics, and high
rates of resistance to antimicrobial treatments. Ceftolozane/tazobac-
tam is approved for the treatment of complicated urinary tract infec-
tions and complicated intra‐abdominal infections and has been
assessed in a trial of nosocomial ventilated pneumonia.
Objectives: We aim to understand how this newer antibiotic has been
used in clinical practice in the Veterans Affairs (VA) nationally.
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Methods: This retrospective study included VA patients receiving
ceftolozane/tazobactam between 1/1/15–4/30/18. The index date
was defined as the first date of ceftolozane/tazobactam receipt, deter-
mined from either barcode medication administration or pharmacy dis-
pensing records. Demographics and comorbidities were assessed at
the time of ceftolozane/tazobactam initiation. Organisms, source of
positive cultures, and antibiotic exposures were assessed before and
after the index date.
Results: A total of 231 unique patients received ceftolozane/tazobac-
tam. The mean age was 67.6 (±12.4), 98.7% were male, and 68.4%
were white. The most common infections were pneumonia (n = 79,
34.2%), urinary tract infections (n = 73, 31.6%), and osteomyelitis
(n = 46, 19%). Polymicrobial cultures were common (n = 107, 46.3%).
Most patients had cultures positive for P. aeruginosa (n = 174,
75.3%), with the most common source being the lung (n = 62,
35.6%, sputum and bronchoalveolar lavage), followed by urine
(n = 32, 18.4%), skin (n = 23, 13.2%), blood (n = 22, 12.6%), and
bone/joint cultures (n = 22, 12.6%). Additionally, 32.9% (n = 76) of
patients had a previous positive P. aeruginosa culture in the month
prior to the index date. Patients were commonly treated with other
antibiotics in the 30 days prior to initiating ceftolozane/tazobactam
(n = 215, 92.1%), including piperacillin/tazobactam (n = 92, 39.8%),
meropenem (n = 78, 33.8%), and cefepime (n = 71, 30.7%).
Ceftolozane/tazobactam was used as monotherapy in 39.4% (n = 91)
of patients from day 2 to day 7 after the start of ceftolozane/tazobac-
tam. The median time to ceftolozane/tazobactam initiation was 4 days
after culture, with a subsequent median 15‐day hospital stay.
Conclusions: In the national VA healthcare system, ceftolozane/tazo-
bactam is mostly being used for pneumonia, urinary tract infections,
and osteomyelitis, with the most common infecting organism being
P. aeruginosa. About one‐third of patients had previous positive cul-
tures for P. aeruginosa and the majority were treated with other antibi-
otics before ceftolozane/tazobactam was initiated.
1052 | Antibiotics utilization in Ghana using
real world claims data
Daniel Ankrah1; Ruby Mensah2; Francis Asenso‐Boadi2;
Lydia Dsane‐Selby2
1Korle‐Bu Teaching Hospital, Accra, Ghana; 2National Health Insurance
Authority, Accra, Ghana
Background: There is a global call to monitor the consumption pat-
terns of antimicrobials because of the looming threat of antimicrobial
resistance. In Ghana, most research on prescribing patterns of antimi-
crobials has been limited to just single centre studies and hence the
real national picture has never been clear enough.
Objectives: To study antibiotic utilization in Ghana using nationwide
claims data.
Methods: Using claims data from 1st January, 2015 to 31st December,
2015, we identified all antibiotics in the Medicines List of Ghana's
National Health Insurance Scheme (NHIS) using the Anatomical
Therapeutic Chemical (ATC) Classification System codes. We deter-
mined the prescription patterns according to in‐patient and out‐
patient clinic attendance, and by age and sex categories. We also cal-
culated the defined daily dose (DDD) of each prescribed antibiotic.
Concentrating on the ten most prescribed antibiotics, we determined
the types of morbidities they are used in treating. All diseases in the
claims data are classified using ICD‐10 codes.
Results: In all there were about 27 different types of antibiotics in the
operational NHIS Medicines List. The most prescribed antibiotic was
metronidazole with a DDD of 0.98 million, and was used predomi-
nantly for infectious gastroenteritis. This was followed by amoxicil-
lin‐clavulanic acid (DDD = 2.12 million) used most of the time to
manage pneumonia, Ciprofloxacin (DDD = 1.19 million), amoxicillin
(DDD = 1.70 million) and so on. Amoxicillin, cefaclor, azithromycin,
amoxicillin‐clavulanic acid, clarithromycin, cotrimoxazole, erythromy-
cin, flucloxacillin, were prescribed mainly among out‐patients, and
ampicillin, benzyl penicillin, ceftriaxone, and gentamycin were more
common among in‐patients.
Conclusions: This study shows that the NHIS claims data can be of
use in the study of treatment patterns for infectious diseases in
Ghana. The national dimension of the data gives a good picture of
antibiotics usage among out‐patient and in‐patients in the country.
1053 | Temporal trends in the dispensation
of systemic antifungal therapy in hospitals in
England: An analysis of the health treatment
insights database
Rachel L. Tham1; Orlagh U. Carroll2; Benjamin D. Bray1,3;
Hassy Dattani1; Deborah Layton1,4; Joseph Kim1,2
1 IQVIA, London, UK; 2London School of Hygiene and Tropical Medicine,
London, UK; 3King's College London, London, UK; 4Keele University,
Keele, Newcastle, UK
Background: Systemic fungal infections are a leading cause of mortal-
ity and morbidity in hospitalisations and are increasingly recognized as
an important cause of healthcare associated infection. As resistance is
a growing concern, it is of interest to understand trends of antifungal
use over time.
Objectives: The study aims to describe the trends of antifungal (Intra-
venous (IV) or oral) exposure in the Hospital Treatment Insights (HTI)
database from 2011 to 2016. HTI is a linked database of pharmacy
(Hospital Pharmacy Audit (HPA)) and hospital (Hospital Episode Statis-
tics (HES)) data which covers ≈ 28% of English trusts.
Methods: A retrospective cohort study of hospitalized patients dis-
pensed antifungal treatments in HTI between 2011 to 2016. Antifun-
gal drugs included: Amphotericin B, Anidulafungin, Caspofungin,
Fluconazole, Flucytosine, Griseofulvin, Isavuconazole, Itraconazole,
Ketoconazole, Micafungin, Miconazole, Posaconazole, Voriconazole.
Exposure was defined as the first antifungal dispensed during a hospi-
talization. Exposure over time was described and stratified by patient
demographics and analyzed with Chi‐Squared tests for trend.
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Results: A cohort of 139,203 antifungal dispenses during a hospitaliza-
tion were analyzed; the median duration of hospitalization was 11
(IQR: 3 to 28) days. IV's made up 16.6% (n = 22,647) of the cohort
while 83.7% (n = 116,556) of the cohort was dispensed oral medica-
tions. There was no difference in the number of dispensations by
sex: males (n = 69,466, 49.9%), females (n = 69,737, 50.1%); and the
mean age was 61.1 (SD: 20.1) years. Within 1 year of antifungal treat-
ment exposure from 2011 to 2015, 27,477 (23.9%) patients died in
hospital with the median time to death of 42 (IQR: 11 to 141) days.
In‐hospital antifungal dispensation increased year on year from
21,203 in 2011 to 24,139 in 2016. There was a larger (50.3%) increase
in IV antifungal dispenses from 2011 (n = 3,065) to 2016 (n = 4,607) (p
for trend <0.01). While death in hospital within one year of antifungal
exposure remained stable from 2011 to 2015 (23.9% to 24.7%,
p = 0.22).
Conclusions: Our study shows increasing annual antifungal use in
English hospitals from 2011 to 2016. Planned analyses will include
stratification by drug class and proportion of all hospitalisations
resulting in systemic antifungal dispensation. Overall, HTI can provide
insights into the trends of antifungal use over time and monitor treat-
ment patterns for this important cause of healthcare associated
infections.
1054 | Antibiotics utilization review in a
Nigerian tertiary hospital
Tarilate C. Temedie‐Asogwa
University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Background: Antibiotic resistance is a global problem and inappropri-
ate use is a major cause. This situation is worse in developing coun-
tries like Nigeria where infectious disease burden is higher.
Conducting antibiotics (AB) utilization reviews is key to identify prob-
lems with their use, evaluate causes and take remedial action. Most
studies undertaken in Nigeria assessed AB use in outpatient settings,
which could not address all factors/situations affecting AB use in hos-
pitals. This study, however, assessed AB utilization among inpatient in
a Nigerian University teaching hospital using 17 core inpatient AB use
indicators.
Objectives: To assess AB use among inpatients in a Nigerian tertiary
hospital.
Methods: A quantitative, cross‐sectional survey was conducted for all
patients admitted in medical, surgical, pediatrics, and obstetrics and
gynecology wards from October 2015 to March 2016 using 17 core
AB use indicators developed under the Rational‐Pharmaceutical Man-
agement (RPM‐Plus) program. It improved on the WHO outpatient
indicators and serve as a simple tool for evaluation of critical aspects
of AB use in health facilities. Also, 16 inpatient physicians were ran-
domly surveyed from the wards studied using semi‐structured inter-
views to understand the reason behind the prescribing practice
observed. Interviews were audio‐recorded, transcribed verbatim, and
thematically analyzed.
Results: Complete case‐notes of 2356 patients were surveyed. About
46.5% were females and 57.7% between ages 21–60 years
(SD = 41.40). AB was prescribed in 68.8% of hospitalized patients.
The overall AB prescription encounters were 4669, out of
which,60.4% were injections and 39.9% were prescribed in generics.
Each patient was prescribed an average of 2.8 antibiotics (SD = 0.89)
at an average cost of ₦13,632 ($40) (SD = 42.73) per hospitalization.
The proportion of prescribed AB actually administered was 87.4%,
while 88.5% were empirically prescribed. Only 62.2% of essential anti-
biotics were available. There were no systems regulating AB use. Phy-
sicians reported factors such as; poor laboratory services, pressure
from pharmaceutical companies, patients' AB abuse, among others to
have influenced the AB utilization.
Conclusions: The study identified poor AB utilization in the facility,
evidenced by over‐prescribing, high empiric and non‐generic AB pre-
scribing, etc. This calls for urgent intervention. Establishment of sys-
tems regulating AB use in this facility could promote rational use;
and curtail cost.
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1056 | Characteristics and timing of
treatment among patients with influenza‐like
illness
Crystal J. Garcia1; Nicole R. Haug1; Catherine A. Panozzo1;
Austin C. Cosgrove1; Henry Francis2; Alfred F. Sorbello2;
Robert P. Orr2; Gregory T. Measer2; Sarah K. Dutcher2;
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Boston, MA; 2US Food and Drug Administration, Silver Spring, MD
Background: Understanding the characteristics of those who do and
do not receive treatment for influenza can aid in the design of future
studies of medical countermeasure utilization, safety, and
effectiveness.
Objectives: To examine baseline characteristics of individuals with
outpatient influenza‐like illness (ILI) across two influenza seasons, by
treatment status and timing.
Methods: Using Truven Health MarketScan® Databases formatted to
the Sentinel Common Data Model, we identified individuals
≥6 months of age with incident ILI (30‐day washout) via influenza‐
specific diagnosis codes (without lab confirmation) in the outpatient
and emergency department settings, in July 2014–June 2015 and July
2015–June 2016, separately. We identified incident treatment with
influenza antivirals (oseltamivir, peramivir, zanamivir; 10‐day washout)
via dispensings and administrations. We assessed treatment on ILI
diagnosis date and separately on days 1–5 after diagnosis. We
assessed the presence of comorbidities in the 183 days preceding ILI
diagnosis for asthma, diabetes, chronic obstructive pulmonary disease
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(COPD), and obesity. Influenza vaccination in the 183 days prior to ILI
and influenza testing ±7 days from diagnosis were examined.
Results: In the 2014–2015 period, of the 26,923 ILI patient diagno-
ses identified, there were 15,827 ILI diagnoses with treatment on
the same day, 911 diagnoses with treatment in the 1–5 days after,
and 9,866 with no evidence of treatment within 5 days. The mean
age for each treatment group was 28.7, 33.1, and 29.8 respectively.
Asthma was observed among 7.5% of those treated the same day,
10.3% of those treated days 1–5, and 7.8% of the untreated. Diabe-
tes was observed in 5.0% of those treated the same day, 11.1% of
those treated days 1–5 days, and 5.8% of the untreated. History
of COPD and obesity also were higher among those treated days
1–5 compared to the those treated the same day as diagnosis as
well as the untreated group. Prior influenza vaccination was 23–
26% across groups; influenza testing was high in all groups but
highest among those treated same day (75%). There were 51%
fewer diagnoses of ILI in the 2015–2016 period, reflecting the mild
nature of that season, but the trends were similar for comorbidities
by treatment status.
Conclusions: For the 2014–2015 and 2015–2016 influenza seasons,
many patients who met our definition of ILI were treated with an
influenza antiviral. Individuals treated on days 1–5 were older and
had more comorbidities than those treated on the same day or not
treated at all. Future work will investigate additional stratifications of
treatment days in the Sentinel System.
1057 | Use of non HIV medication among
people receiving antiretroviral treatment in
Côte d'Ivoire, a cross sectional study
M.A.R.I.A.M.M.A.M.A. DJIMA1,2; Didier Koumavi EKOUEVI3,2;
Jean‐Pierre GREGOIRE4; Boris TCHOUNGA5; Boris TCHOUNGA5;
Patrick Ahuatchi COFFIE6; Viet‐Thi TRAN6; Franck Y. TOURE6;
Jocelyne MOISAN4
1 Institut Pasteur de Côte d'Ivoire, Abidjan, Côte D'Ivoire; 2PACCI, CHU
Treichville, Abidjan, Côte d'Ivoire, Abidjan, Côte D'Ivoire; 3Université de
Lomé, Département de Santé Publique, Lomé, Togo, Lomé, Togo; 4Axe
Santé des populations et pratiques optimales en santé, Centre de
recherche du CHU de Québec – Université Laval, Québec, Canada,
Quebec, QC, Canada; 5PACCI, CHU Treichville, Abidjan, Côte d'Ivoire,
PACCI, CHU Treichville, Abidjan, Côte d'Ivoire, Côte D'Ivoire; 6PACCI,
CHU Treichville, Abidjan, Côte d'Ivoire, ABIDJAN, Côte D'Ivoire
Background: In Côte d'Ivoire, people living with HIV (PLHIV) have free
access to antiretroviral therapy (ART) and cotrimoxazole. Yet, they
may use other medications to treat non‐HIV diseases. Scarce data
are available regarding the use of non‐HIV medications in Africa. This
study describes the use of non‐HIV medications and identifies the fac-
tors associated with their use by PLHIV on ART in Côte d'Ivoire.
Objectives: This study describes the use of non‐HIV medications and
identifies the factors associated with their use by PLHIV on ART in
Côte d'Ivoire.
Methods: A cross‐sectional study was conducted in six HIV clinics in
2016. HIV‐1‐infected adults receiving ART for at least one year
were eligible. A standardized questionnaire was used to collect
demographics, HIV characteristics and medication use data. Associ-
ated factors were identified using a multivariate adjusted Poisson
regression.
Results: A total of 1,458 participants (74% women) were enrolled. The
median age was 44 years, and the median duration of ART was
81 months. A total of 696 (48%) participants reported having used
at least one non‐HIV medication. Among the 1,519 non‐HIV medica-
tions used, 550 (36%) had not been prescribed and 397 (26%) were
from the nervous system class. Individuals who were more likely to
report the use of at least one non‐HIV medication included those
who had been treated in an Abidjan HIV clinic, had a high school edu-
cation level, had a monthly income between 100,000 and 200,000
FCFA, had a poor perceived health status, had WHO advanced clinical
stage, had used traditional medicine products and had not used
cotrimoxazole.
Conclusions: Half of PLHIV on ART reported using non‐HIV medica-
tion. Further research is needed to assess whether the use of non‐
HIV medication is appropriate iven the third of those medications
are not being prescribed.
1058 | Strategy to improve hepatitis C
treatment drug use in Colombia
Angela Viviana Perez Gomez1; Aurelio Mejia2; Antonio Trujillo1;
Johnny David Contreras2
1 Johns Hopkins University, Baltimore, MD; 2Ministry of Health and Social
Protection, Bogota, Colombia
Background: The high cost of treatment for H‐C can limit access and
adherence to treatment. The governments need to balance the incen-
tive to promote innovation and to provide access to treatment to the
population. In 2017 The Colombian Health System decided to design a
strategy to ensure the access and adequate drug utilization of Hepati-
tis C treatment. This strategy included centralized purchasing, design a
law, develop clinical practice guidelines and clinical and logistic path-
way, direct observe treatment, follow up to the cohort of patients,
assess the clinical outcomes and economic results.
Objectives: Multi‐criteria evaluation of the strategy to improve access
to Hepatitis C treatment and health outcomes in Colombia.
Methods: • Design: Descriptive study, follow up a cohort, the popula-
tion: patients with diagnostic of Hepatitis C in the contributory regime
in Colombian Health System. The follow up was from October 2017 to
October 31st, 2018. • The population was patients with a new diagno-
sis of Hepatitis C or Patients with a previous diagnosis of hepatitis C
without treatment but whit indication to start treatment. All patients
of the contributive regimen in Colombia with a confirmed diagnosis.
• Exposures: Treatment Daclatasvir, Ledipasvir/Sofosbuvir,
Sofosbuvir. • Outcomes: Cure of Hepatitis C defined how
undetectability of viral levels 12 weeks after finish treatment,
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treatment abandonment, serious adverse events, reduction in the cost
of drugs. • Descriptive statistics.
Results: 74% (n = 792) of the reported patients met the criteria to
take a treatment for hepatitis C. The number of patients that fin-
ished 12 weeks of treatment and the follow up to close the case
and determined the curation to October 2018 was 417 cases
(52%), of this 401 (73%) were cured, 2 patients suspended treatment
by physician decision, 12 patients died, 2 patients were disaffiliated
by the insurance. None of the patients abandoned treatment. Did
not report serious adverse events. Centralized purchasing has
reduced the drug prices in more than 60% in overall, before the mul-
tidimensional strategy the cost from 250, 250 and 720 treatment
(Dacla, Sofos, Sofo/ledi respectively, 84 tablets each one) US
$108.216.950, and after the strategy implementation the cost was
US $ 11.043.300, 90% saving.
Conclusions: The strategy implemented in Colombia health system
(contributory regime) improved the access to treatment through
reduced prices and was possible to achieve the clinical outcomes, cure
of the patients, improve the adherence of the patients and physicians.
This strategy will be replicated in a subsidized regime. Currently the
centralized purchasing it remains.
1059 | Indications for Otic quinolone use in
South Korea
Kiyon Rhew1,2; Phuong T. Tran1; Xi Wang1; Patrick J. Antonelli1;
Almut G. Winterstein1
1University of Florida, Gainesville, FL; 2Dongduk Women's University,
Seoul, Korea, Republic of
Background: Otic quinolones are widely used for the treatment of
acute otitis externa (OE) and otitis media (OM) with non‐intact tym-
panic membranes. Because they are considered to be safe, use for
unapproved indications may have become more common. Recent
studies have linked otic quinolones with tympanic membrane perfora-
tions, making off‐label use controversial.
Objectives: The aim of this study was to assess indications, which are
recorded on Korean prescriptions, for otic quinolones to elucidate the
prevalence and types of off‐label use.
Methods: Subjects receiving otic quinolones in 2016 were identified
from South Korean Health Insurance Review Agency data (HIRA‐
NPS). We considered only the first prescription fill within a given
30 day window designated as unique treatment episode, of otic quin-
olones including ofloxacin, ciprofloxacin plus hydrocortisone, cipro-
floxacin plus fluocinolone, and ciprofloxacin plus dexamethasone.
Indications for otic quinolones were reviewed and classified by a
senior otologist.
Results: Therewere 1,468,033 patients in the 2016HIRA‐NPS and otic
quinolones were prescribed for 18,568 patients (1.26%). We identified
22,888 unique quinolone treatment episodes, with 84.2% patients hav-
ing one episodes and 10.8% having two. Only 22.6% of prescriptions
were for patients less than 18 years old. 97.2% of indications were
deemed appropriate (eg, OMandOE). Questionable uses included ceru-
men impaction, post‐traumatic tympanic membrane perforation, and
temporal bone fractures. Proportions of questionableuses of otic quino-
lones were similar between pediatric and adult patients.
Conclusions: Otic quinolones are seldom prescribed for unapproved
indications in South Korea.
1060 | Trends of antibacterial‐effect
traditional Chinese medicine consumption in
secondary and tertiary hospitals in China: An
analysis of pharmaceutical sales data, 2011–
2015
Yue Zhou1; Haishaerjiang Wushouer2,3; Xiaodong Guan1; Luwen Shi1
1School of Pharmaceutical Sciences, Peking University, Beijing, China;
2Center for Strategic Studies, Chinese Academy of Engineering, Beijing,
China; 3School of Medicine, Tsinghua University, Beijing, China
Background: Antibiotic consumption is a major driver for antimicrobial
resistance. China, a large consumer of antibiotics, has implemented
substantial regulations towards antibiotic use in the past decade.
However, there is little evidence regarding the consumption of anti-
bacterial‐effect traditional Chinese medicines (AeTCM), which is com-
monly used in China and may have potential connection with
antibiotic usage.
Objectives: To describe the trends of AeTCM expenditure and con-
sumption in secondary and tertiary hospitals in China, using pharma-
ceutical sales data for the study period of 2011–2015.
Methods: We retrospectively analyzed aggregated monthly surveil-
lance data on AeTCM sales to 114 secondary hospitals and 468 ter-
tiary hospitals from 28 provinces in China from January 2011 to
December 2015. A total of 1294 drugs were identified in single or
compound preparation following Guideline for Clinical Application of
Chinese Patent Medicine ‐ Infectious Diseases. Expenditure and popu-
lation weighted consumption of AeTCM were analyzed. Compound
annual growth rate (CAGR) of expenditure and consumption
between 2011 and 2015 were calculated. Drug consumption was
expressed in DDD per 1000 per inhabitants per day (DID). We fur-
ther explored the consumption disparity between oral and injection
of AeTCM over the five years. Data were managed and analyzed in
Microsoft Excel 2016.
Results: Total AeTCM expenditure and consumption increased during
study period ($0.79 billion in 2011 to $1.31 billion in 2015; 4.07 DID
in 2011 to 6.82 DID in 2015). CAGR of expenditure and consumption
was 13.43% and 13.75% respectively. At provincial level, CAGR of
expenditure and consumption was the lowest in Fujian (−4.96%,
−5.60%) and the highest in Guansu (31.04%, 35.10%). Compared with
injective AeTCM, the expenditure and consumption of oral AeTCM
increased ($0.37 billion in 2011 to $0.68 billion in 2015; 3.41 DID in
2011 to 5.77 DID in 2015). CAGR of expenditure and consumption
of injective AeTCM were 9.49% and 5.35% and that of oral AeTCM
were 16.58% and 14.03%.
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Conclusions: Although major efforts had been made to reduce the
risks of excessive antibiotic use in China and certain progress had
been achieved, total AeTCM expenditure and consumption showed a
significant upward trend during the study period. It showed that there
was potential substitute effect between consumption of AeTCM and
antibiotics. Despite literatures showed that AeTCM had anti‐infection
effect, further research on rationality of AeTCM use is still in great
need to facilitate infection treatment.
1061 | Drug utilization evaluation of
antimicrobial agents at a tertiary care
hospital: Point prevalence survey
Zabiuddin Ahad Mohammed; Chiranjay Mukhopadhyay;
Muralidhar Varma; Vandana Kalwaje Eshwara
Kasturba Medical College, Udupi, India
Background: Antibiotics are considered as life‐saving drugs, but their
inappropriate and overuse is rendering them ineffective. The maxi-
mum use of antibiotics happen in hospitals, thus it is necessary to
identify the shortcomings and address the same. Point Prevalence Sur-
veys (PPS) have been found to be a feasible and efficient alternative to
prospective surveillance.
Objectives: To evaluate the appropriateness and compare antibiotic
utilization practices among medical and surgical departments.
Methods: At a tertiary care teaching hospital in south karnataka, pro-
spectively, in‐patients prescribed with one of the 10 selected antibi-
otics (amikacin, gentamicin, cefoperazone‐sulbactam, piperacilln‐
tazobactam, meropenem, vancomycin, teicoplanin, linezolid, poly-
myxin B and polmyxin E) were included (n = 188). Residents in clinical
microbiology were coordinated by clinical pharmacist for the training
and collection of data. Individual case records forms were then evalu-
ated by the Antimicrobial Stewardship team. Outcome measure was to
assess the appropriateness of therapy and to evaluate variation in the
practices of antibiotic use. Data was analyzed using IBM SPSS soft-
ware (16.0) and chi‐square test was used to identify the association.
Results: Median (IQR) age was 53.5(30.75) years with a male predom-
inance of 63%(119). No Microbiological Test (MT) was performed in
17%(32) of patients. Indication was empirical in 66% whereas defini-
tive in only 19%. Piperacillin‐tazobactam was prescribed in 23%(44),
followed by cefoperazone‐sulbactam 21%(40) and meropenem
16%(31), with only 2%, 13% and 16% of them having a definitive indi-
cation, respectively. Inappropriate dosing in 27%(51), with under‐dose
in 13%(25) and overdose in 14%(26). Under‐dosing was seen with
gentamicin 67%, polymyxin 33% and amikacin 29% whereas
overdosing with cefoperazone‐sulbactam 40%, amikacin 18% and
meropenem 13%. Statistically significant difference between medical
and surgical departments was observed in use of over dose
(p = 0.005) and the practice of requesting MT (p < 0.001).
Conclusions: The selected antibiotics are considered as reserved, but
most of those were used empirically and a varied utilization practice
was observed in medical versus surgical departments. The findings
underscore the need to perform more elaborate drug utilization stud-
ies, perform strict surveillance, promote evidence based medicine and
provide support for optimal antibiotic dosing.
1062 | Antimicrobial prescribing patterns
and compliance with treatment guidelines in
critical care unit at a National Referral
Hospital in Kenya
Emmah Obegi1; Margaret Oluka1; Faith Okalebo1; Sylvia Opanga1;
Dorothy Aywak2; Anastasia Guantai1; Loice Achieng1;
Amanj Ismael Baker Kurdi3; Brian Godman3; Marion Bennie3
1University of Nairobi, Nairobi, Kenya; 2Kenyatta National Hospital,
Nairobi, Kenya; 3Strathclyde Institute of Pharmacy and Biomedical
Science, University of Strathclyde, 161 Cathedral/University of
Strathclyde, Glasgow, UK
Background: Antimicrobial agents are among the commonly pre-
scribed medicines in hospitals, including the Critical Care Unit. The
inappropriate and unnecessary use of antimicrobial agents is a major
contributor to the development of antimicrobial resistance which has
substantial clinical and economic implications.
Objectives: To determine the patterns of antimicrobial prescribing and
the level of compliance to antimicrobial prescribing guidelines in Crit-
ical Care Units at Kenyatta National Hospital (KNH), the largest refer-
ral hospital in Kenya.
Methods: This was a descriptive retrospective longitudinal study
which involved extraction of data from medical records of patients
aged ≥13 years, who were admitted to the Critical Care Units in
2017. Data extracted included medication history, including the use
of antimicrobials agents, diagnosis, and any documented review of
the prescribed antimicrobials. Data was abstracted using a pre‐
designed standardized data collection tool, entered in Epi Info and
analyzed using STATA version 13.0.
Results: A total of 309 patients' records were included in this study.
The prevalence of antimicrobial prescribing was 98.4%. The antimicro-
bial agents commonly prescribed were Ceftriaxone (36.8%), Metroni-
dazole (16.9%) and Meropenem (12.4%). Only 40.9% of the
prescribed antimicrobials were compliant to the hospital's treatment
guidelines. Only 35% of the participants were on a single antimicrobial
agent while 36% (n = 111) were on two. Less than 2% (n = 5) of the
participants had more than five antimicrobial agents. The proportion
of patients who had a review or stopping of antimicrobial therapy doc-
umented in their medical records was 11.7% (n = 36).
Conclusions: There was a high prevalence of antimicrobial prescribing
in the Critical Care Unit with sub‐optimal compliance to the available
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guideline affecting patient clinical outcomes. The documentation of
antimicrobial indication, stoppage or review was sub‐optimal as well.
These findings highlight the need for antimicrobial stewardship pro-
gramme to improve the rationale use of antimicrobials at this referral
hospital.
1063 | Visualizing drug treatment pathways
in type 2 diabetes
Amanda R. Patrick; Sheila Nemeth; Sruthi Adimadhyam
Aetion, Inc, Boston, MA
Background: ADA/AACE treatment guidelines recommend metformin
as first line pharmacotherapy in T2DM for patients with A1C less than
9%. For patients requiring progression to dual therapy, recommended
2nd line treatments include SGLT2s, DPP4s, GLP1 receptor agonists,
sulfonylureas (SU), thiazolidinediones, and insulin, with treatment
choice based on drug‐specific effects, including cardiovascular benefit,
and patient factors, including presence of atherosclerotic cardiovascu-
lar disease (ASCVD).
Objectives: To explore real‐world drug treatment patterns among
commercially‐insured adults with type 2 diabetes initiating metformin
monotherapy during April 2014 to March 2016, including variation by
presence of ASCVD.
Methods: Patients were identified from the de‐identified Optum®
Clinformatics® Data Mart database. Patients entered the cohort on
metformin initiation and were required to have a diagnosis of type 2
diabetes in the preceding 180 days and no prior use of any oral or
injectable antidiabetic medications. Patients were followed for treat-
ment changes until disenrollment or the end of available data. Data
were analyzed using the Aetion Evidence Platform™.
Results: During the study period, 48,702 patients initiated metfor-
min monotherapy. Patients had a mean age of 60.5 (± 13.4) years
and 51.5% were male. Patients had prevalent co‐morbidities and
complications, including ASCVD (31.9%), neuropathy (12.7%), and
nephropathy (9.6%). Following metformin initiation, 38.2% remained
on metformin monotherapy to the end of follow‐up, 27.8% had a
90 + −day gap in treatment followed by re‐initiation or treatment
change, 17.6% discontinued treatment entirely, and 16.4%
progressed to another therapy with no gap. For the 7,996 patients
progressing, the most common pattern was dual therapy with met-
formin (98.0%), followed be triple therapy with metformin (1.0%),
and a switch to another agent (0.5%). There were 29 different
treatment patterns observed among patients progressing to dual or
triple therapy. The most frequent second‐line drug combination with
metformin were SU (48.9%), DPP4s (17.7%), insulin (12.3%), and
SGLT2s (10.0%).
Conclusions: We observed a range of treatment patterns following
metformin initiation in real‐world data. While patterns appeared
generally consistent with treatment guidelines, there were high
rates of non‐persistence. Given the complexity and variation in
real‐world treatment patterns, Sankey plots were a helpful visual-
ization tool.
1064 | Utilization of dulaglutide in primary
Care in England: Interim results from a post
authorisation safety study
Miranda Davies1,2; Lorna Hazell1,2; Sandeep Dhanda1,2;
Vicki Osborne1,2; Ayad K. Ali3; Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK; 3Eli Lilly and Company, Indianapolis, IN
Background: Dulaglutide is a once‐weekly injectable long acting gluca-
gon‐like peptide‐1 receptor agonist (GLP‐1 RA) authorized in England
for the treatment of type 2 diabetes mellitus (T2DM).
Objectives: To assess the utilization of dulaglutide in real‐world pri-
mary care practice in England.
Methods: A descriptive cohort study (Modified Prescription‐Event
Monitoring) identified dulaglutide users from dispensed primary care
prescriptions of dulaglutide between 2015–2017 in England. Patient
characteristics and drug utilization data were collected from prescribing
general practitioners (GPs) via questionnaires sent ≥12 months after
the 1st prescription issued for each patient. Summary descriptive statis-
tics were calculated.
Results: 1467 evaluable dulaglutide users with T2DM diagnosis con-
firmed.Medianage:58yrs (IQR51,66); 775males (52.8%).Baselineobe-
sity (Body Mass Index (BMI) ≥30 kg/m2) was present in 45.9% of the
cohort (89.9%whereBMIspecified),whilepoorT2DMcontrol, indicated
by Hemoglobin A1c ≥58 mmol/mol (7.5%) was observed in 60.1% of
patients (93.1% where specified). Median duration of T2DM was
10.0 yrs (IQR6.0, 14.1). The decision to initiatedulaglutidewasmost fre-
quently made by a specialist nurse (n = 766, 52.2%) followed by the GP
(n=352,24.0%), andhospitaldoctor (n=299,20.4%).Mostpatientswere
prescribed0.75mgonce‐weekly (n=233, 15.9%)or1.5mgonce‐weekly
(n = 762, 51.9%). There were a small number of reports (n = 14, 0.9%) of
>once‐weekly usage. In the majority of patients, dulaglutide was pre-
scribed as either add‐on dual therapy (n = 469, 32.0%) or add‐on triple
therapy (n = 908, 61.9%); the most frequently reported concomitant
anti‐diabetes medication (ADM) was metformin (n = 624, 42.5%). In
sub‐populations not previously studied in clinical trials, the most fre-
quently reported usage was in patients≥75 yrs (n = 80, 5.5%).
Conclusions: This interim analysis suggests that dulaglutide is largely
being prescribed in accordance with prescribing recommendations and
national T2DMmanagement guidelines. Results suggest most frequent
use in patients with poor diabetic control where existing treatmentwith
alternative ADMmay not have achieved optimum control. This prelim-
inary analysis of baseline data will be updated in the final report.
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1065 | European multi‐country drug
utilization study of dulaglutide
Ayad K. Ali1; Karen E. Wells2; Mathieu Rosé3; Massoud Toussi3
1Eli Lilly and Company, Indianapolis, IN; 2 IQVIA, Oakland, MI; 3 IQVIA,
Courbevoie, France
Background: Dulaglutide is a long‐acting glucagon‐like peptide‐1
receptor agonist approved in Europe for the treatment of type 2 dia-
betes mellitus.
Objectives: This study aimed to characterize dulaglutide utilization
patterns in real‐world conditions in subpopulations of patients for
which little data exist.
Methods: Electronic medical record databases in France, Germany,
and Spain were used to evaluate dulaglutide use in the following sub-
populations of interest: patients with severe renal failure, heart failure,
liver disease, and severe gastrointestinal disease; children and adoles-
cents (<18 years); elderly (≥75 years); and pregnant and breastfeeding
women. Eligible patients were those who initiated dulaglutide in 2017
with ≥6 months of continuous history before dulaglutide initiation.
Subpopulations of interest were defined by ICD‐10‐CM diagnosis
and procedure codes for respective conditions. Patients with a
recorded diagnosis of severe renal failure or an estimated glomerular
filtration rate of <30 ml/min/1.73 m2 recorded closer to dulaglutide
initiation date were considered having pre‐existing severe renal failure.
Results: A total of 4,420 dulaglutide initiators were identified, corre-
sponding to 1,309 in France; 1,891 in Germany; and 1,220 in Spain.
Mean age was 60 years and 53% males across the 3 countries. All
dulaglutide initiators in Germany, and vast majority of those in France
(96%) and Spain (98%) were diagnosed with type 2 diabetes, with pre-
ponderance of patients using dulaglutide as add‐on type 2 diabetes
therapy (France 79%; Germany 80%; and Spain 88%). No children or
adolescents were identified among initiators of dulaglutide during
the analysis year. Slightly over one‐third of dulaglutide initiators were
elderly patients (≥65 years old); those aged ≥75 years comprised
about 11% in France and Germany, and 8.3% in Spain. Among women
treated with dulaglutide, only 3 (one in Germany and two in Spain)
were pregnant or breast‐feeding at the time of starting treatment with
dulaglutide. Few to no patients had pre‐existing severe renal failure
(none in France; Germany 0.5%; and Spain 1.9%). The frequencies of
other pre‐existing conditions were: liver disease (France 0.6%; Ger-
many 3.0%; and Spain 16.9%), heart failure (France 1.9%; Germany
10.5%; and Spain 5.7%), and severe gastrointestinal disease (France
5.8%; Germany 9.9%; and Spain 9.0%).
Conclusions: This study showed that in 2017, dulaglutide is not widely
used by patient groups of interest and is used by the intended popu-
lation as an add‐on therapy rather than first‐line type 2 diabetes
mellitus therapy according to the labeled indication in these three
European countries.
1066 | Utilization of exenatide once‐weekly
(Bydureon®) in primary Care in England:
Results from a PASS
Sandeep Dhanda1,2; Vicki Osborne1,2; Debabrata Roy1,2;
Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK
Background: Exenatide extended‐release (Bydureon®) is a glucagon‐
like peptide‐1 receptor agonist administered once‐weekly by subcuta-
neous injection. Approved in 2011, Bydureon® is licensed to improve
glycaemic control in combination with other antidiabetes medications
(ADMs) in patients (pts) with type 2 diabetes mellitus (T2DM) when
current therapy, with diet and exercise, is inadequate. A Post Authori-
sation Safety Study (PASS) was conducted to monitor the use and
safety of Bydureon® in primary (1o) care in England.
Objectives: To describe the utilization of Bydureon® in 1o care.
Methods: A cohort study identified pts from dispensed Bydureon®
prescriptions in England (2012–2016). Pt characteristics and drug uti-
lization data was collected from prescribing general practitioners (GPs)
via questionnaires sent ≥12 months after the 1st Bydureon® prescrip-
tion issued for each pt. Summary descriptive statistics were calculated.
Results: Questionnaire response rate = 37.2% (7752/20860). Evaluable
cohort=6294ptsprescribedBydureon®forT2DM(medianage57years
[IQR 50, 65]; 55.2%male). 2 pts were < 18 years. 16 pts had an off‐label
indication of type 1 diabetes andwere excluded from analyses. At base-
line, where specified, 91.7% of pts (n = 2390) were obese (BMI≥30 kg/
m2) and/or had an HbA1c≥7.5% (n = 1986, 90.0%); of those pts with a
raised HbA1c, 66.0% (n = 1311) hadmeasurements of≥9.0% indicating
very poor diabetic control. Bydureon®wasmostly prescribed in 1o care
(n = 3269, 51.9%); ‘specialist decision’was the overwhelming reason for
prescribing (n = 3113, 49.5%). The majority of pts were exenatide naïve
(n = 4556, 72.4%), whilst 25.9% (n = 1629) were previous Byetta®
(exenatide twice‐daily) users. For 109 pts (1.7%), prior exposure to
Byetta® was unknown. Nearly all pts (n = 5948, 94.5%) were taking
Bydureon® 2 mg once/week, in accordance with the product label. Pts
predominantly started Bydureon® as triple therapy (n = 3876, 61.6%)
or dual therapy (n = 1936, 30.8%); monotherapy use was lower
(n = 161, 2.6%). Metformin (n = 5753, 81.5%) and sulphonylureas
(n = 2382, 45.0%) were themost frequent concomitant ADMs at index.
Conclusions: Bydureon® was largely used in accordance with pre-
scribing recommendations in 1o care in England, with most frequent
use in pts with poor diabetic control where treatment with alternative
ADMs may have been unsuccessful. In addition, characteristics of pts
prescribed Bydureon® are in keeping with the T2DM pt profile. This
study design allowed for the timely collection of drug utilization data
directly from GPs and suggests shared Bydureon® T2DM treatment
arrangements between 1o and 2o care.
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1067 | Determinants for initial treatment
choice in diabetic macular edema
Brian VanderBeek; Kurt Scavelli; Yinxi Yu
Scheie Eye Institute/University of Pennsylvania, Philadelphia, PA
Background: While attention is often paid to the physician role in ini-
tiating therapy, less consideration is given to the role patient choices
(out‐of‐pocket costs, insurance plan, geography) make in determining
initiation of treatment.
Objectives: To assess the patient‐related factors that may impact the
choice for initial therapy for diabetic macular edema (DME), focusing
on factors patient chose prior to diagnosis.
Methods: Setting:This is a retrospective cohort study using adminis-
trative medical claims data from a large, national insurer. Partici-
pants:All patients newly diagnosed with DME from 2013–2016 were
observed for 90 days after diagnosis or until first treatment was
received. Exposures:The different baseline demographic and patient‐
related factors when DME was diagnosed. Outcome measures: The
primary outcome was the odds of receiving the different possible ini-
tial treatments for DME (anti‐vascular endothelial growth factors (anti‐
VEGF), focal laser, steroids or observation), no treatment and not fol-
lowing up.
Results: Of 6220 new DME patients, 3010 did and 3210 did not have
a follow up (fu) exam within 90 days of diagnosis. 1557(51.7% of
patients who had fu) were seen, but had no treatment during the
observation window. Of those treated, 617(20.5% of those who had
follow up) received bevacizumab, 191(6.3%) ranibizumab or
aflibercept (rani/aflib), 560(18.6%) focal laser, 38(1.3%) steroid injec-
tion and 50(1.7%) had an injection with no drug noted. Having any
copay (vs. $0) lowered the odds of receiving any treatment
(OR:0.60,95%CI:0.51–0.71, p < 0.001) and treatments individually
(anti‐VEGF treatment OR:0.72,95%CI:0.59–0.88; bevacizumab
OR:0.73,95%CI:0.59–0.91; rani/aflib OR: 0.70; 95%CI:0.49–0.99,
focal laser OR:0.44,95%CI:0.35–0.55, p < 0.001). Contrary to copays,
having a high deductible and type of insurance plan were not associ-
ated with initiating treatment(p > 0.41 for all comparisons). Patients
in the Northeast had lower odds of initiating anti‐VEGF treatment
(OR:0.60, 95%CI: 0.44–0.82, p < 0.001) and were specifically
bevacizumab (OR:0.47, 95%CI:0.33–0.67, p < 0.001). Furthermore,
Northeast patients who were treated with anti‐VEGF had a higher
odds of receiving rani/aflib compared to bevacizumab (OR:2.39,
95%C:1.31–4.37, p < 0.001). Southern Midwest patients had a higher
odds of treatment (anti‐VEGF OR:1.35,95%:1.02–1.77,p < 0.001;
bevacizumab (OR:1.40,95%:1.04–1.87; focal laser OR:1.39,
95%:1.01–1.89,p < 0.001).
Conclusions: Patient choices such as copays and where they live are
important factors in determining the initial choice in the treatment
of DME.
1068 | Gender differences in reported
adverse drug reactions at different time
periods after drug initiation
Sieta T. de Vries1; Petra Denig1; Peter G.M. Mol2;
Eugène P. van Puijenbroek3
1UMCG, Groningen, Netherlands; 2Dutch Medicines Evaluation Board,
Utrecht, Netherlands; 3Netherlands Pharmacovigilance Centre Lareb, ‘s‐
Hertogenbosch, Netherlands
Background: Females may have a higher risk for reporting adverse
drug reactions (ADRs) than males. This has also been shown for drugs
commonly prescribed among patients with type 2 diabetes, such as
biguanides and sulfonylureas. It is unknown whether gender differ-
ences in ADRs are consistent at different time periods of exposure.
Objectives: To assess whether gender differences in reported ADRs
for biguanides and sulfonylureas are consistent at different time
periods of drug exposure after treatment initiation.
Methods: This study had a longitudinal design in which data of
patients with type 2 diabetes participating in Lareb Intensive Monitor-
ing (LIM) were used. LIM is a non‐interventional prospective observa-
tional cohort study of the Netherlands Pharmacovigilance Centre
Lareb in which patients initiating specific drugs were followed for a
period of 12 months. During this period, patients were asked to com-
plete a web‐based survey about experienced ADRs at 2 weeks,
6 weeks, 3 months, 6 months, 9 months, and 12 months after drug ini-
tiation. We included patients initiating a biguanide (i.e metformin) or
sulfonylurea (i.e tolbutamide, gliclazide, glimepiride). The outcome
was the proportion of patients reporting any ADR versus no ADR.
We assessed this proportion at each time point and per drug class.
Differences in proportions between males and females were tested
using Pearson Chi‐Squared tests. P‐values <0.05 were considered sta-
tistically significant.
Results: For the biguanides, 1,712 patientswere included (41% females,
average age 58 years), and 474 completed all surveys (37% females).
Over time, the proportion of females and males reporting an ADR
decreased from respectively 34% and 25% at 2 weeks after initiation to
17%forbothfemalesandmalesat12monthsafter initiation.Differences
betweenfemalesandmaleswerestatisticallysignificant for themeasure-
ment at 2 weeks, 6 weeks, and 3 months. For the sulfonylureas, 651
patients were included (41% females, average age 59 years), and 171
completed all surveys (36% females). The proportion of females and
males reporting an ADR decreased from respectively 27% and 17% at
2weeks after initiation to respectively 5%and9%at 12months after ini-
tiation. Statistically significant differences between females and males
were observed for the measurement at 2 weeks and at 6 weeks.
Conclusions: Differences between females and males in the reporting
of ADRs were only observed in the early phases after treatment initi-
ation. Further studies are needed to assess explanations for this
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pattern over time for instance by focusing on the somewhat larger
dropout rate of females.
1069 | Drug‐utilization study examining
characteristics of patients prescribed add‐on
treatment to metformin
Juan Carlos Bazo‐Alvarez1,2; Irene Petersen1; Irwin Nazareth1;
Manuj Sharma1
1University College London, London, UK; 2Universidad Católica Los
Angeles de Chimbote, Chimbote, Peru
Background: Despite availability of clinical guidelines, choosing which
treatment to add‐on for patients inadequately controlled on metfor-
min for type 2 diabetes mellitus (T2DM) can be challenging for
clinicians.
Objectives: To compare characteristics of patients prescribed differ-
ent anti‐diabetics as add‐on to metformin including: sulphonylureas,
gliptins, thiazols, sglt‐2 inhibitors, GLP‐1 analogues and insulins.
Methods: We compared characteristics of patients with T2DM at the
time they were prescribed different add‐on therapies to metformin
using The Health Improvement Network, a UK primary care database,
between 2007–2016. We examined demographics, risk factors and
the history of comorbidities across the different groups. We fitted
regression models to estimate prevalence ratios (PR) and identify
those factors most strongly associated with prescribing of particular
add‐on treatments.
Results: From a cohort of T2DMpatients, we identified 32,793 patients
who commenced add‐on therapy to metformin. Of this total, 20,905
were commenced on sulphonylureas, 7,488 on gliptins, 2,336 on
thiazols, 984 on insulins, 605 on GLP‐1 and 475 on SGLT‐2 s. Patients
prescribed sulphonylureas were on average older (59.8 ± 12.1 years).
More women were prescribed insulin (57%) and more men thiazols
(62%). Body weight was highest among GLP‐1 users (120.2 ± 24.7 kg)
and lowest for insulin users (89.9 ± 22.4 kg) at time of prescribing, while
HbA1c was lowest for GLP‐1 (69.9 ± 19 mmol/mol) and highest for
sulphonylureas (75.5 ± 20 mmol/mol). Those with history of CVD (car-
diovascular disease) at add‐on initiation were 4% more likely to receive
sulphonylureas (PR = 1.04, 95%CI: 1.02–1.07) and 22% less likely to
receive insulin (PR = 0.78, 95%CI: 0.65–0.94). Patients with history of
severe mental illness were 85% more likely to be prescribed insulins
(PR= 1.85, 95%CI: 1.35–2.52), whereas patientswith history of retinop-
athy were 20% more likely to be prescribed thiazols (PR = 1.20, 95%CI:
1.10–1.30). For each 1% increase in HbA1c, the probability of receiving
sulphonylureas increased by 4% (PR = 1.04, 95%CI: 1.03–1.04). Con-
versely, for each unit increase in BMI, the probability of receiving
sulphonylureas decreased by 2% (PR = 0.98, 95%CI: 0.98–0.98).
Conclusions: Characteristics of patients prescribed different add‐on
therapies after metformin for T2DM differed for several variables.
Patients with a history of CVD or higher HbA1c at baseline were more
likely to be prescribed sulphonylureas. A useful next step would be to
compare prescribing patterns to national guidelines and identify devi-
ations from recommended practice.
1070 | Utilization of prescription anti‐
obesity drugs in the U.S. Food and Drug
Administration's (FDA) sentinel system,
2008–2017
Sara Azimi‐Bolourian1; Emily C. Welch2; Candace C. Fuller2;
Rajani Rajbhandari2; Christian Hampp1; Michael D. Nguyen1
1Food and Drug Administration, Silver Spring, MD; 2Harvard Pilgrim
Health Care Institute, Boston, MA
Background: Obesity is major public health concern affecting 40% of
adults and is associated with $147 billion in medical costs in the
United States. Despite the availability of pharmacotherapy options
to augment diet and exercise lifestyle interventions, evidence of low
adoption of anti‐obesity medications (AOM) exists.
Objectives: To characterize the utilization patterns and treatment
duration of AOM approved for use in adults included in the U.S. FDA's
Sentinel System.
Methods: We conducted a descriptive drug utilization analysis in adults
>18 years initiating AOMs in 17 Sentinel Data Partners from 2008–
2017 (generally commercial insurers, but Medicare contributed fee for
service enrollee data). We characterized new users (first dispensing in
183 days) of any AOM (lorcaserin, bupropion/naltrexone, liraglutide,
phentermine/topiramate, orlistat, phentermine, benzphetamine,
diethylpropion, phendimetrazine), and individual AOMs. Baseline
patient characteristics, including BodyMass Index (BMI) and cardiovas-
cular history were described in the 183 days prior to first dispensing.
Treatment duration was depicted with Kaplan Meier survivor curves;
persistence was assessed primarily with a 60 day gap between dispens-
ings to account for inconsistent medication use.
Results: We identified 267,836 AOM new users, predominately
female (82%) and less than 65 years of age (92%). Only 50% of
AOM users had a diagnostic codes for obesity and only 14% had
one for BMI; among AOM users with a BMI diagnosis code, 87%
had a BMI ≥30 (obese). Hypertension (30%) and hyperlipidemia
(28%) were common comorbidities among AOM users. Phentermine
(n = 198,203) was the most common AOM, followed by bupropion/
naltrexone (n = 29,106). Approximately 37% of phentermine users
continued use beyond 90 days, despite labels recommending use for
a “few weeks”. Across AOM, duration of use was generally short
(median, 62 days); at 1 month, 59% of AOM users remained in treat-
ment andpersistence declined substantially thereafter (2months= 51%,
3 months = 37%). After 6 months, 17% of AOM users were still on
treatment.
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Conclusions: The most commonly used AOM was phentermine,
followed by bupropion/naltrexone. Most AOM users were female
and < 65 years of age. In the majority of AOM users, treatment dura-
tion was short.
1071 | Utilization pattern and adherence to
novel anti‐obesity medications: A
retrospective study in a privately insured
population
Amir Sarayani; Phuong Pham; Sascha van Boemmel‐Wegmann;
Almut G. Winterstein
Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL
Background: Obesity is an endemic medical condition in the United
States while access to anti‐obesity medications (AOM) has been lim-
ited due to safety and/or effectiveness issues. Sympathomimetic
agents are approved as short‐term AOM (SAOM) while five AOMs
are available for long‐term use (LAOM). The literature on utilization
pattern and adherence to AOMs is limited.
Objectives: To evaluate the utilization pattern of AOMs and adher-
ence to LAOMs (phentermine/topiramate, naltrexone/bupropion,
lorcaserin, liraglutide, orlistat).
Methods: We used the IBM MarketScan Database for Commercial
Claims data (2012–2017) to estimateAOMutilization among diagnosed
obese/overweight patients. Patients with continuous enrollment in
health plans were identified in each year and obesity/overweight was
measured with appropriate diagnosis codes (ICD‐9 and ICD‐10) on
medical encounters. AOM use was defined as having &ge 1 pharmacy
claim during the year. To evaluate adherence to LAOMs, patients with
6months of health plan enrollment before and after drug initiationwere
included. Patients with <2 LAOM claims and < 30 cumulative days' sup-
ply were excluded (early discontinuation).We calculated the proportion
of days covered (PDC) during the 6‐months period following initiation
and used a threshold of 80% to define high adherence. Demographic
and clinical characteristics including the Charlson Comorbidity index
were measured during the 6‐months baseline period. We also calcu-
lated the average out of pocket cost of LAOM for 30 days' supply. A
multivariable generalized estimating equation model was used to com-
pare adherence among the LAOMs.
Results: We identified 7.4 million prevalent obese/overweight
patients. SAOM utilization was 2.1% in 2012 and decreased to 1.6%
in 2017. In contrast, LAOM utilization increased from 0.1% in 2012
to 1.9% in 2017. We identified 63,337 eligible treatment episodes
with LAOMs (79.9% among females, mean age 46.3). Adherence to
LAOM was moderate (mean PDC: phentermine/topiramate (59.3%),
naltrexone/bupropion (54.3%), lorcaserin (51.4%), liraglutide (62.3%),
orlistat (51.9%)). In the adjusted model, liraglutide was weakly associ-
ated with high adherence compared to phentermine/topiramate (odds
ratio: 1.14; 1.08, 1.20) and both drugs were significantly associated
with high adherence compared to other LAOBs.
Conclusions: Utilization of AOMs appears to be low among insured
patients, but lack of formulary coverage resulting in self‐pay might
produce underestimates. Adherence to LAOMs is moderate which
require real‐world safety and effectiveness evaluations.
1072 | Antidiabetic therapy De‐
intensification from a physician perspective
and factors affecting their prescribing: A
cross‐sectional study
Abdallah Y. Naser1; Badi Alenazi2
1Al‐Isra University, Amman, Jordan; 2Alyamamah hospital, Riyadh, Saudi
Arabia
Background: There are limited guidelines that address antidiabetic
therapy de‐intensification in order to decrease the burden of its
associated hypoglycaemic events. The high prevalence of inappro-
priate intensive antidiabetic therapy has increased the importance
of investigating physicians' perspectives towards this approach,
including their decision to individualize their treatment goal, de‐
intensify antidiabetic therapy, and factors which affect their
prescribing.
Objectives: This study aims to understand the physicians' perspective
regarding antidiabetic therapy de‐intensification and factors that
affect their prescribing for patients with type 2 diabetes mellitus (DM).
Methods: A cross‐sectional survey study was conducted using a self‐
administrated questionnaire from January 2018 to January 2019 in
Saudi Arabia. Two previously validated questionnaires, one developed
by Genere and the other by Grant, were adopted and used in this
study. Univariate/multivariate logistic regression was used to assess
the relationship between physicians' demographic and practice char-
acteristics and their awareness of, agreement with and practice of
HbA1c individualisation and their practice of antidiabetic therapy de‐
intensification.
Results: A total of 205 physicians have participated in the study.
The findings of this study showed that the majority of the physi-
cians reported that they were familiar with the principle of antidi-
abetic therapy de‐intensification (89.3%, n = 183), and agreed with
it (68.2%, n = 118). However, only 78.6% of them reported that
they were applying it frequently. In addition, this study highlighted
factors considered while prescribing antidiabetic medications and
showed that physicians reported giving more importance to
patients' medical profiles such as comorbidity, last measured
HbA1c level, and physician's assessment of patient's health status
rather than other variables like patients adherence, preference to
delay or avoid therapy, or specific requests with regards to their
therapy.
518 ABSTRACTS
Conclusions: It is suggested that healthcare professionals should pay
more attention to other non‐clinical factors as they are associated
with better adherence and disease control.
1073 | Are medication adherence and Total
healthcare cost associated with generic and
brand levothyroxine initiation
Nan Huo; Jingjing Qian
Auburn University Harrison School of Pharmacy, Auburn, AL
Background: Although generic levothyroxine has been approved in
the U.S. since 2004, its use and substitution remains suboptimal.
Objectives: To examine the difference in medication adherence and
total healthcare cost between generic and brand levothyroxine new
users.
Methods: This was a retrospective cohort study of new users of brand
and generic levothyroxine identified in the fee‐for‐service 5% sample of
2013–2015Medicare (n = 13,606) and 11 states' 2011–2012Medicaid
(n = 7,871) administrative claims data. Brand and generic levothyroxine
use was identified with NDC codes in pharmacy claims files. Primary
outcomes included: 1) medication adherence (defined by proportion
of days covered (PDC) ≥ 80%) to levothyroxine treatment, and 2) total
healthcare cost (including outpatient, inpatients, prescription) during
12 months after levothyroxine initiation (index date). Patient demo-
graphics (sex, age, race, region, urban/rural, comorbidity) and health ser-
vice utilization factors were assessed at the 6‐month washout period in
bothMedicare andMedicaid cohorts. Provider (sex, credential) and pre-
scription (initial dosage) factors were also controlled in the Medicare
cohort. Multivariable logistic regression and generalized linear models
were used to assess the associations between generic vs. brand
levothyroxine initiationwithmedication adherence and total healthcare
cost, controlling for covariates, respectively.
Results: Among all levothyroxine new users, more Medicare benefi-
ciaries were adhering to treatment than Medicaid beneficiaries
(71.20% vs. 64.88%, respectively). However, there was no associa-
tion between generic vs. brand product initiation and adherence
to levothyroxine in either Medicare or Medicaid cohort (P > 0.05).
Medicare new users also had higher total healthcare cost than
Medicaid beneficiaries ($15,249 (standard deviation (SD) = 159.55)
vs. $10,249 (SD = 104.45), respectively). After controlling for
adherence and covariates, generic levothyroxine new users had
lower total healthcare cost than brand new users in both cohorts
(coefficient estimate (CE) with standard error (SE) = −0.59 (0.11)
in Medicare; CE (SE) = −0.28 (0.03) in Medicaid).
Conclusions: This large, real‐world analysis found no association
between medication adherence and brand/generic levothyroxine ini-
tiation. However, generic levothyroxine new users had significant
lower total healthcare cost than brand new users. Using generic
levothyroxine did not reduce medication adherence, and it may help
reduce total healthcare cost.
1074 | Proton pump inhibitor (PPI) use in
Australia: Evaluating national quality use of
medicines initiatives
Claudia Bruno1; Sallie‐Anne Pearson1; Benjamin Daniels1;
Nicholas Buckley2; Helga Zoega1
1Centre for Big Data Research in Health, UNSW, Sydney, Australia;
2School of Medical Sciences, USYD, Sydney, Australia
Background: Proton pump inhibitor (PPI) use has grown substantially,
prompting widespread concerns about overuse, in particular the use of
high dose PPIs for durations longer than clinically necessary. In
response to these concerns, initiatives encouraging quality use of PPIs
have been launched in many countries.
Objectives: To characterize recent trends of PPI use in Australia (2012–
2017) and evaluate the impact of the two nationwide campaigns
launched in 2015 targeting quality use of PPIs; one led by NPS
MedicineWise (NPS), the other by Choosing Wisely Australia (CWA).
Methods: Weused dispensing records from a nationally‐representative
10% sample of Australians eligible for subsidizedmedicines through the
Pharmaceutical Benefits Scheme (PBS). We estimated the annual prev-
alence, incidence and duration of PPI use among people 18 years and
over. To assess the impact of both initiatives, we used interrupted time
series (ITS) analysis of monthly PPI dispensings (stratified by tablet
strength; high, standard, low), monthly rates of switching from higher
to lower strength PPIs, and monthly rates of PPI discontinuation. We
used statins as a comparator medicine for the ITS analyses.
Results: 523 092 people were dispensed at least one PPI between
July 2012 and July 2017; their average age was 61 years (SD; 17 years)
and 56% were female. Annual prevalence of PPI use increased from
14.6 to 15.7 per 100 persons. Annual incidence and prevalence
increased with age, as did duration of use. Following the year‐long
NPS and CWA campaigns, we observed significant decreases in
monthly PPI dispensings, particularly for standard tablet strengths
(1.9% and 2.3% respectively). We found no significant changes in
monthly rates of switching to lower strength PPIs or discontinuing
PPI treatment. We did not observe changes in monthly dispensings
or rates of discontinuation for our comparator medicine, statins.
Conclusions: Our findings demonstrate the decline in monthly PPI dis-
pensing rates coincided with the roll out of national quality use of PPI
campaigns. However, this may be due, at least in part, to the increased
availability of over‐the‐counter PPIs from February 2016 onwards.
Rates of discontinuation and switching to lower PPI strengths did
not change, despite being the main target of these campaigns. Future
interventions should attempt to better educate older users, where use
is most common.
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1075 | National Trends in proton pump
inhibitors (PPIs) use and patient factors
associated with PPIs use in the United States:
2002–2015
Ahmed Ullah Mishuk1; Richard Hansen1; Li Chen1; Philippe Gaillard2;
Jingjing Qian1
1Department of Health Outcomes Research and Policy, Auburn
University, Auburn, AL; 2Department of Mathematics and Statistics,
Auburn University, Auburn, AL
Background: In the United States (U.S.), PPIs are among the highest‐
selling classes of drugs, but evidence in its utilization patterns among
patient subgroups is limited.
Objectives: To examine the trends in PPIs use, overall and by patient
subgroups, and identify patient factors associated with PPIs use
among nationally representative, noninstitutionalized U.S. population.
Methods: A retrospective, serial cross‐sectional analysis using the
2002–2015 Medical Expenditure Panel Survey (MEPS) data was
conducted. PPIs use was identified by matching generic PPI names
in the MEPS household prescribed medicines event files in each
calendar year. Trends in annual proportion of participants with
any PPI use, overall and by patient's self‐reported age (<25, 25–
39, 40–64, 65+), race/ethnicity (non‐Hispanic white, black, Asian,
other), sex (male, female), geographic region (Northeast, Midwest,
West, South), income (poor, low, middle, high), health insurance sta-
tus (public, private, uninsured), body mass index (BMI: underweight,
normal, overweight, obese), marital status (married, widowed, never
married, other), and esophageal disorder (presence, absence) were
examined using simple linear regression models. Merging all data
from 2002–2015, a multivariable model with generalized estimating
equation was used to identify patient factors associated with PPIs
use, controlling for year and self‐reported health status. All the
results were weighted to represent national estimates and
P < 0.05 was set for statistical significance.
Results: Overall proportion of PPIs use in U.S. increased from 5.5%
(standard error (SE) = 0.2) in 2002 to 8.8% (SE = 0.3) in 2015
(Ptrend < 0.001). PPIs use trend increased significantly in different
patient age (except 40–64), race/ethnicity, sex, region, income, and
marital status subgroups (Ptrend < 0.05). Trends also increased in partic-
ipants with public health insurance and those who were obese. Among
patients with esophageal disorders, PPIs use was 73.8% in 2002 and
78.8% in 2015 (Ptrend > 0.05). Multivariable results found that partici-
pants who were older than age 25, female, non‐Hispanic white, living
in Northeast, with higher income, having public or private health insur-
ance, obese, and married had higher likelihoods of using PPI.
Conclusions: PPIs use increased by 60% in 2002–2015 among the U.
S. population. PPI use trends were similar across most patient factors
but varied by the patient's health insurance and BMI. Understanding
utilization patterns of PPI could inform practitioners to identify poten-
tial treatment disparities and suboptimal uptake.
1076 | Use of proton pump inhibitors and
mortality among Icelandic prostate cancer
patients
Óskar Hálfdánarson1; Anton Pottegård2; Sigrún H. Lund3;
Margret H. Ogmundsdottir1; Helga M. Ogmundsdottir1;
Helga Zoëga1,4
1University of Iceland, Reykjavik, Iceland; 2University of Southern
Denmark, Odense, Denmark; 3deCODE genetics, Reykjavik, Iceland;
4University of New South Wales, Sydney, Australia
Background: Proton pump inhibitors (PPIs) are commonly used drugs
among cancer patients. While pre‐treatment with PPIs has been
reported to enhance the efficacy of chemotherapeutic agents, post‐
diagnosis PPI use has been associated with increased prostate can-
cer‐specific and overall cancer mortality.
Objectives: To determine whether post‐diagnosis PPI use is associ-
ated with mortality among prostate cancer patients.
Methods: In this population‐based cohort study, we identified patients
between 40–85 years of age with an incident diagnosis of prostate can-
cer in Iceland between 2007 and 2012 (n = 1058). Follow‐up was from
12months after diagnosis until death, emigration, or the end of Decem-
ber 31, 2015. We defined post‐diagnosis use as ≥2 filled prescriptions
following diagnosis and lagged the exposed person‐time by 12 months.
Pre‐diagnosis use was defined as≥2 filled prescriptions in 3 years prior
to diagnosis. Post‐diagnosis users where then further categorized as
continuous (post‐ and pre‐diagnosis use) and new users (post‐diagnosis
use only).We used time‐dependent Cox proportional hazard regression
models to compute hazard ratios (HRs) and 95% confidence intervals
(CIs) for prostate cancer‐specific and all‐causemortality associatedwith
post‐diagnosis use of PPIs. In secondary analyses we stratified PPI use
by timing of use (continuous use, new use), clinical stage (localized,
non‐localized) and cumulative dose (1–365 DDDs, >365 DDDs).
Results: We identified 347 (32.8%) post‐diagnosis PPI users and 711
(67.2%) non‐users. Out of the 347 patients using PPIs after diagnosis,
59 patients (17.0%) died due to any cause and 22 patients (6.3%) due
to prostate cancer, compared with 144 (20.3%) and 76 (10.7%) among
non‐users, respectively. Post‐diagnosis PPI use was not statistically
significantly associated with prostate cancer‐specific mortality (HR
0.88; 95% CI: 0.52–1.48) or all‐cause mortality (HR 1.02; 95% CI:
0.73–1.43). Stratification by timing of use and clinical stage did not
reveal any statistically significant associations to the mortality out-
comes of interest. Furthermore, we did not find any evidence of a sig-
nificant dose–response association.
Conclusions: Our findings did not indicate an association between
post‐diagnosis PPI use and mortality among prostate cancer patients.
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1077 | Utilization of linaclotide in United
Kingdom
Nafeesa Dhalwani1; Anna Schultze1; Robert Donaldson1;
Ahunna Ukah2; Darren Weissman3; Jim Wang3; Javier Cid Ruzafa4
1Evidera, London, UK; 2Allergan, Irvine, CA; 3Allergan, Madison, NJ;
4Evidera, Barcelona, Spain
Background: Linaclotide is used to treat moderate‐to‐severe irritable
bowel syndrome (IBS) predominantly with constipation (IBS‐C) in
adults. Data on its use in routine clinical settings and specific sub‐
groups are lacking.
Objectives: To describe the characteristics of patients prescribed
linaclotide and the linaclotide treatment patterns.
Methods: Patients with a prescription of linaclotide between 05/
2013–12/2017 in the Clinical Practice Research Datalink (CPRD),
a population‐based primary care database from the UK, were
included. We defined sub‐types of patients with IBS using an algo-
rithm based on diagnostic codes, prescriptions and symptomatology.
We describe patient characteristics, comorbidities, comedications
and certain sub‐groups. These included ≤17 years, patients with
chronic constipation and no IBS, patients with gastrointestinal (GI)
obstruction or inflammatory bowel disease (IBD) and abusive/exces-
sive use (patients with medical record of obesity, eating disorder,
anorexia, bulimia or most recent BMI ≥30 or < 20 during one year
up to index date, and no IBS). We also describe treatment patterns
i.e. persistence, switching and discontinuation in patients prescribed
linaclotide.
Results: 1319 patients were prescribed linaclotide, of whom 0.9%
were ≤ 17 years, 0.4% were patients with chronic constipation
and no IBS, 3.5% had GI obstruction or IBD and 17.0% had potential
for abusive/excessive use. 41% of patients had a missing IBS diagno-
sis in their records. Of the remaining 778 patients, 68.8% had IBS‐C,
6.7% had IBS predominantly with diarrhea, 6.4% had mixed IBS and
IBS sub‐type could not be determined in 18.1% of patients. The
mean age at linaclotide prescription was 46.7 years (SD: 16.7) and
86.3% were female. Around one‐third of all linaclotide patients were
overweight (30.6%), 22.9% were obese and 4.8% underweight.
Hypertension (25.2%) and cardiovascular disease (19.2%) were the
most common comorbidities in linaclotide users. Laxatives (71.9%),
antibiotics (61.3%), proton‐pump inhibitors (51.6%) and antispas-
modics (47.1%) were the most common comedications. A total of
48.6% of patients switched from linaclotide; of these 41% switched
to laxatives, while 36% discontinued without switching to another
drug. The median duration of linaclotide treatment was 28 days
(IQR 28–119 days). 15.3% of patients had a persistent use of
linaclotide.
Conclusions: Linaclotide in the UK was largely prescribed in accor-
dance with the EU label. Most patients with a linaclotide prescrip-
tion had IBS‐C. The median duration of treatment was around a
month, and among the patients who switched, the largest group
started on laxatives.
1078 | Bone mineral density testing after
initiation of androgen deprivation therapy for
prostate cancer
Jason Hu; Alice Dragomir
McGill University, MontrealQC, Canada
Background: Androgen deprivation therapy (ADT) is a staple of
advanced prostate cancer (PCa) treatment, however several side‐
effects are associated with its long‐term use. Notably, loss of bone
mineral density (BMD) is accelerated which increases fracture risk.
Clinical guidelines recommend BMD testing when initiating ADT to
properly assess baseline fracture risk.
Objectives: The objective was to examine the proportion of baseline
BMD testing in men initiating long‐term ADT in the province of Que-
bec, Canada.
Methods: The cohort consists of men extracted from a random
sample from Quebec public healthcare insurance administrative
databases who were diagnosed with PCa from 2004–2012 and
treated by ADT. Only patients who received at least one year of
continuous ADT treatment were included. The primary study out-
come was the receipt of baseline BMD testing (defined as a
BMD test identified from medical claims in the period from
6 months prior to or up to 12 months after ADT initiation). Multi-
variable logistic regression analysis was performed to identify vari-
ables associated with baseline BMD testing.
Results: We identified 3713 patients who initiated ADT at a mean
age of 75 years old during the study period, of which 700
(18.9%) underwent baseline BMD testing. Rates of baseline BMD
testing increased by year of ADT initiation, from 11.9% in 2004
to 19.7% in 2007 and to 24.1% in 2012. Following multivariable
analyses, year of ADT initiation remained associated with higher
odds of baseline BMD testing (odds ratio [OR] 1.09 for each
increasing year, 95% confidence interval [CI] 1.05–1.13,
p < 0.001), as did prior local radical treatment (OR 1.62, 95% CI
1.33–1.98, p < 0.001). Conversely, older patient age (OR 0.98,
95% CI, 0.97–0.99, p = 0.001) and rural residence (OR 0.60,
95%CI 0.48–0.75, p < 0.001) were associated with lower odds of
baseline BMD testing.
Conclusions: In our study population, the rate of baseline BMD
testing in men initiating ADT was low, although the rates were
increasing over time. Lower rates in rural areas suggest potential
healthcare access issues. Additional efforts emphasizing the impor-
tance of BMD testing in prostate cancer clinical guidelines may
be needed.
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1079 | Prestop: Patients perspective on
discontinuation of CML TKI‐treatment
Vashti N.M.F. Tromp1; Lonneke Timmers1; Leanne Koningen1;
Jeroen J.W.M. Janssen1; Peter E. Westerweel2; Inge G.P. Geelen2;
Jan de Jong3; Christel C.L.M. Boons1; Jacqueline G. Hugtenburg1
1Amsterdam UMC location VUMC, Amsterdam, Netherlands; 2Albert
schweitzer Medical Centre, Dordrecht, Netherlands; 3Hematon
Netherlands, Amsterdam, Netherlands
Background: Chronic myeloid leukemia (CML) is a malignant hemato-
logic disease with recommended life‐long treatment with tyrosine
kinase inhibitors (TKIs). The results of several trials show that approx-
imately half of CML patients with stable disease can discontinue TKI‐
treatment without loss of efficacy. However, little is known about
patients' perspective and attitude on, and willingness to discontinue
TKI treatment and influencing factors.
Objectives: To gain insight into patients' willingness and preferences
regarding discontinuation of CML TKI‐treatment and to identify fac-
tors that may influence this.
Methods: An observational, cross‐sectional, multicenter study by
means of an (electronic) questionnaire was conducted in the Nether-
lands. Adult CML patients were recruited through outpatient pharma-
cies and or hematology department of several Dutch hospitals, and
through the national patient association for patients with hematologi-
cal malignancies: Hematon. Patients were asked about their willing-
ness and preferences regarding discontinuation of TKI‐treatment.
Logistic regression analysis was used to determine factors associated
with patients' willingness to discontinue TKI‐treatment.
Results: A total of 185 patients participated in this study: 59% aged
≥55 years, 54% female and most patients using imatinib (36%). Most
Dutch CML patients on TKI‐treatment (79.5%) were willing to discon-
tinue treatment. Patients most frequently reported: no more side
effects, being afraid of an aggressive relapse, and being frequently
monitored as the most important advantage, disadvantage, and condi-
tion for discontinuing treatment respectively. Univariate logistic
regression showed that young age (0.41 (0.18–0.92) P = 0.03), paid
work (3.04 (1.44–6.41), P = 0.00), being informed about discontinua-
tion studies (6.25 (2.36–16,52) P = 0.00), and severe adverse advents
(2.64 (1.21–5.76), P = 0.01) were associated with patients' willingness
to discontinue TKI‐treatment.
Conclusions: Most patients were willing to discontinue TKI‐treatment
and reported advantages. However, patients also reported disadvan-
tages and conditions to discontinue treatment. Moreover, several fac-
tors were associated with TKI‐ treatment discontinuation. These
findings can be used to tailor the information provided to the patient
during patient counseling. However, additional research is needed to
get deeper information on patients who reported no willingness to
discontinue TKI‐treatment.
1080 | Design of a centrally aggregated
medication use evaluation: Anticholinergics in
dementia
Madeline McCarren1; Muriel Burk1; Ronald L. Carico Jr2;
Peter A. Glassman1; Chester B. Good1; Francesca E. Cunningham1
1Department of Veterans Affairs, Hines, IL; 2Marshall Health,
Huntington, WV
Background: Conducting medication use evaluations (MUEs) across a
large integrated health care system (HCS) such as the Veterans Affairs
(VA) HCS can be resource consuming and challenging to coordinate on
a timeline. VA Center for Medication Safety (VAMedSAFE) designed a
novel distributive approach termed centrally aggregated MUE
(CAMUE) whereby a facility‐provided toolkit allows for standardized
chart review, analysis, and submission of results to VAMedSAFE for
aggregation. We illustrate our CAMUE evaluating anticholinergic med-
ication (AChM) use in dementia patients.
Objectives: A CAMUE was used to assess, among Veterans with
dementia: (a) prescribing patterns of incident outpatient AChM; (b) if
non‐AChM alternatives were tried first; (c) whether risk–benefit anal-
yses were documented; (d) harms associated with AChM.
Methods: ACAMUE toolkit, consisting of a list of target patients, proto-
col, operations manual, and Microsoft Access database (data collection
form, table, pre‐programmed report)was electronically provided to each
site.TheVAPharmacyBenefitsManagement (PBM)outpatientprescrip-
tion database and Corporate Data Warehouse were used to identify
dementia patients with incident outpatient AChM prescriptions
(> = 7 days) in CY2016. Hospice/palliative care patients were excluded.
Reviewers verified eligibility, reviewed charts (6‐month look‐back and
30‐day follow‐up) per instructions, and transcribed de‐identified sum-
marymeasuresgeneratedbytheAccessReport intoaMicrosoft InfoPath
form. VAMedSAFE combined site counts into grand totals, with descrip-
tive statistics andmeasures of variability as appropriate.
Results: Nineteen sites submitted data on 1094 eligible patients for
aggregation. Antihistamines were the most common class (31%, 28.6–
34.1). Non‐pharmacological alternatives to the indication for the index
AChM were trialed in 18% (15.9–20.5); non‐AChMs were trialed in
36% (32.9–38.5). A risk–benefit assessment of AChMs in dementia was
documented in 13% (11.2–15.2) of cases. An untoward event (fall, delir-
ium, worsening dementia) was reported in 15% (12.6–16.7). In these,
32% (25.3–39.7) had the AChMdiscontinued or dose reduced.
Conclusions: CAMUE is a novel approach offering a standardized,
autonomous tool for efficiently conducting multi‐site MUEs. The
results suggest that the risk of AChM use in Veterans with dementia
is underappreciated by prescribers, although under‐documentation of
risk/benefit assessment is also likely. VAMedSAFE recommended a
prescribing tool or decisional support system to alert prescribers to
the potential risk.
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1081 | Retrospective interrupted time series
examining hypertension and diabetes
treatment affordability and government
expenditures following changes in patient
cost sharing in the “Farmácia Popular”
Program in Brazil
Isabel C.M. Emmerick1; Monica R. Campos2; Rondineli M. da Silva3;
Luisa A. Chaves4; Andréa D. Bertoldi5; Dennis Ross‐Degnan6;
Vera L. Luiza3
1University of Massachusetts, Worcester, MA; 2Oswaldo Cruz
Foundation., Rio de janeiro, Brazil; 3Oswaldo Cruz Foundation, Rio de
janeiro, Brazil; 4Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;
5Federal University of Pelotas, Pelotas, Brazil; 6Harvard Medical School,
Boston, MA
Background: Increasing medicines availability and affordability is a
key goal of Brazilian health policy. “Farmácia Popular” (FP) Program
is one of the government's key strategies to achieve this goal. Under
FP, antihypertension (HTN) and antidiabetics (DM) medicines have
been provided at subsidized prices in private retail settings under
FP since 2006, with increase in patient copay in 2009 and free of
charge since 2011.
Objectives: To analyze the affordability and government expenditures
of HTN and DM treatment under FP, focusing in public financing
mechanisms and sustainability.
Methods: Quasi‐experimental, longitudinal, retrospective study using
interrupted time series to analyze: HTN and DM treatment coverage;
total and per capita expenditure; percentage paid by Ministry of
Health (MoH); and patient cost sharing. Analyzes were conducted in
the dispensing database of the FP program (from 2006 to 2012).
Results: FP has increased its coverage over time; by December 2012
FP covered on average 13% of DM and 11.5% of HTN utilization in
Brazil, a growth of over 600% and 1500%, respectively. The overall
cost per treatment to the MoH ranged from R$19.0 to R$ 25.0 for
HTN and from R$16.8 to R$21.6 for diabetes over the period ana-
lyzed, representing a reduction in per capita cost of around 22%.
The amount paid by patients for the medicines covered increased over
time until 2011, especially following an increase in copayment in April
2009. Overall, considering all types of medicine, the average percent-
age of the sale price paid by patients ranged from 14% to 34% for
HTN and 18% to 44% for DM.
Conclusions: FP rapidly increased its coverage during the period ana-
lyzed. Costs of HTN and DM treatment in FP were reduced after 2011
for both patients (free) and government (better negotiated prices).
However, the overall FP expenditures by MoH increased due to mark-
edly increased utilization, raising questions about the financial sustain-
ability of the program over time.
1082 | Real‐world impact on pharmacological
management of Type 2 diabetes following a
drug subsidy decision: A joinpoint regression
on utilization data in Singapore, 2014–2017
Jiandong Sun; Kwong Ng
Ministry of Health, Singapore, Singapore
Background: Dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT‐
2) inhibitor was recommended by Singapore's Drug Advisory Com-
mittee (DAC) for listing on the Medical Assistance Fund (MAF) in
May 2017 as an add‐on therapy for managing type 2 diabetes
mellitus (T2DM) based on clinical and cost effectiveness.
Objectives: To examine the impact of MAF listing of dapagliflozin on
the utilization pattern of available SGLT‐2 inhibitors in both the public
and private healthcare sectors.
Methods: A pre‐post quasi‐experimental study was conducted using
commercially available sales data in Singapore between 2014q2 (when
SGLT‐2 drugs became available) and 2017q4. The public sector
includes public hospitals and government‐funded primary healthcare
clinics (polyclinics). Private sector includes private hospitals, private
clinics and retail pharmacies. The access to MAF is limited within the
public sector to patients who qualify based on means testing. Tempo-
ral changes by channel (hospitals, polyclinics, retail pharmacies and pri-
vate clinics) adjusted for background growth rate (1.4% per quarter) in
the national expenditure of all oral T2DM drugs were examined using
Joinpoint Regression analysis. The changes between slopes were
examined using t‐test at a significance level of 0.05.
Results: The total volume in defined daily doses (DDDs) of all SGLT‐2
drugs amounted to 1 million in 2017q1 prior to MAF listing of
dapagliflozin, with an average increase of 77,904 (95%CI: 72,429‐
83,379) per quarter since 2014q2. Following the MAF listing, the
quarterly growth increased significantly (p < 0.001) to 354,250
(95%CI: 261,658‐446,842). The total sales reached 1.8 million by
2017q4, of which 55% occurred in the public sector (32% pre‐listing);
and 46% was for dapagliflozin (29% pre‐listing). The post‐listing
(2017q2‐2017q4) sales of SGLT‐2 drugs reached 792,163 (18% of
all‐channel sales) in polyclinics, where none of the SGLT‐2 inhibitors
were used previously. The sales in the private sector and hospitals
continued to grow at similar rates to pre‐listing.
Conclusions: The real‐world impact of listing dapagliflozin on MAF has
shown to be the largest in the primary care sector (polyclinics). This
demonstrates the intended outcome of subsidy as a policy lever in
improving access and shifting management of T2DM from acute to
primary care, where care management is most appropriate. Further
analysis is required to identify the underlying factors that contribute
to differing utilization patterns of dapagliflozin across healthcare set-
tings after MAF listing.
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1083 | A rapid monitoring tool to provide
near real‐time evaluation after a new drug
policy implementation
Anat Fisher; Greg Carney; Colin R. Dormuth
University of British Columbia, Vancouver, BC, Canada
Background: Rigorous outcome evaluations of drug policy changes are
time consuming yet policymakers sometimes desire rapid feedback on
policy impacts.
Objectives: To describe a method to rapidly monitor changes in health
care utilization following the implementation of a change in drug
coverage.
Methods: The rapid monitoring tool (RMT) was first designed and
implemented in the Canadian province of British Columbia in 2014.
The RMT analyzes historical patterns of health care utilization (drugs,
physician services, and hospitalizations), and compares those historical
patterns against post‐policy data repeatedly and within weeks of policy
implementation. Historical data are drawn from 3 to 5 pre‐policy years
and consist of several cohorts of patients who used the policy‐related
medications on the historical anniversaries of the policy implementation
date. The historical cohorts are then followed for one year during which
the incidence of several health care outcomes are measured. When the
historical utilization patterns are stable they are used as a basis for
predicting expected utilization after the policy change, assuming the
policy had no effect. Departures from a historical pattern are then
recorded as possible policy‐related impacts, and post‐policy reports
are generated.
Results: For the drugs policies so far examined, historical utilization
patterns typically provided reasonably precise and stable utilization
patterns against which post‐policy data could be compared. In one
scenario, comparisons of post‐policy data with historical patterns in
the first year of a policy implementation showed no effect of the
policy on health care utilization, with post‐policy trends that over-
lapped or averaged the historical trends. RTM was easy to imple-
ment and provided rapid ongoing monitoring of the effects of the
policy.
Conclusions: Implementation of a data‐driven pattern detection algo-
rithm successfully provided rapid detection of unexpected changes in
health care utilization after new policy implementation.
1084 | To study the impact of educational
intervention on drug utilization of reserve
antibiotics
Zabiuddin Ahad Mohammed; Muralidhar Varma;
Chiranjay Mukhopadhyay; Vandana Kalwaje Eshwara
Kasturba Medical College, Udupi, India
Background: Emergence of antimicrobial resistance is shrinking the
pool of antibiotics and healthcare practitioners across the globe are
facing challenges even for the treatment of minor infections. Various
strategies have been suggested to promote rational use of antibi-
otics, of which, interventional approach is found to be the most effi-
cient one.
Objectives: To perform drug utilization evaluation and assess the
impact of educational intervention on the use of reserve antibiotics.
Methods: Retrospectively, at a 2000 bedded tertiary care teaching
hospital, data pertaining to use of antibiotics was obtained from
the pharmacy sales department. An educational intervention in the
form of a full‐day workshop was conducted for about 100 in‐house
health care practitioners. This was followed by post intervention col-
lection of antibiotics usage data. Data was collected for a span of
7 months in pre and post intervention groups during the same
months. IBM's SPSS Software (16.0) was used for statistical analysis
and comparison was done using paired sample t‐test.
Results: Over a period of 7 months pre and post intervention, about
45,664 and 48,886 patients where admitted with total hospital days
of 3,35,713 and 3,58,411 respectively. The mean DDD of colistin,
meropenem, vancomycin and linezolid before intervention was
0.00199, 19.66, 4.14 and 8.02 respectively whereas after interven-
tion was 0.00103, 18.16, 4.54 and 4.12 respectively. There was a
statistically significant (p < 0.05) decrease in the observed usage of
colistin and linezolid.
Conclusions: Educational intervention was helpful in reducing the
use of antibiotics, but had shown a statistical difference only in
the usage of colistin and linezolid. In depth evaluation needs to be
performed in order to evaluate the rationality of high volume use
of reserve antibiotics.
1085 | Development of the AbbVie
automated commercial exposure system
Chris Schneiderman; Robert Gregg; Seema Atre; Raghava Danwada;
Nancy Liu; John A. Saunders III; Brian Stavlo
AbbVie, North Chicago, IL
Background: Marketing authorization holders are required to produce
estimates of exposure to commercially distributed products for regula-
tory submissions and internal use. At AbbVie, producing exposure esti-
mates was a time‐consuming, manual task utilizing three internal
commercial databases with differing data orientation.
Objectives: Development of an Automated Commercial Exposure Sys-
tem (ACES).
Methods: Data acquisition and reorientation: Three large AbbVie
datasets (exUS: 01 Jan 1985–31 Dec 2013, US: 01 Jan 1995–31
Dec 2013, and Global Product Sales Cost and Reporting (PSCR),
01 Jan 2014 ‐ present) were acquired. These datasets include com-
mercial distribution information and other relevant AbbVie data. His-
torical data were reoriented to the PSCR data model, variables
renamed and crosswalks developed. All data reorientation was
checked for consistency with source data. Data filtering: Based on
list number and description, all observations were identified as an
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AbbVie commercially marketed product (ACMP = 1) or not
(ACMP = 0). All observations with ACMP = 1 are assigned a mole-
cule name, and each observations array of associated variables eval-
uated for filtering (was this observation; a finished good, commercial
sale, financial adjustment, device, or unique product specific filter).
Observations passing the filter test are given a value of 1, not pass-
ing, 0. Data conversion: Observations passing all filter tests are
assigned a conversion factor (Conv_Fact) and outcome unit of mea-
sure. Conv_Fact is based on list‐number, a unique identifier of for-
mulation and packaging. Conv_Fact is a composite calculation
including all functions to bridge distribution volume (EQU) to out-
come. The calculation for outcome is EQU/Conv_Fact. All outcomes
are compared to historical estimates for accuracy Additional vari-
ables: Other variables such as country, region, formulation labels,
etc, are recoded to normalize data. Data updates: PSCR data is
updated monthly as described above.
Results: More than 45 products across 33 years are represented in
ACES. ACES estimates are generally within 1% from historical estimates
based on the algorithms executed. Estimates with >1% deviation are
attributed to differing data sources or manual historical calculation
errors. Time to produce estimates within ACES, using all available vari-
ables is ~15 minutes, while manually, on average ~6 person‐hours for
summary level calculations.
Conclusions: ACES provides a reliable, comprehensive and efficient
patient exposure data system of the entirety of available AbbVie com-
mercial history. This solution may be generalized to other organizations
requiring exposure assessment.
1086 | Association between adherence to
guideline‐recommended preventive
medications and in‐hospital mortality among
non‐reperfused ST‐elevation myocardial
infarction patients admitted to a tertiary care
academic center in a developing country
Sylvi Irawati1; Surya Dharma2; Katja Taxis1; Nguyen Thang3;
Nunung Nursyarofah4; Bob Wilffert1; Eelko Hak1
1University of Groningen, Groningen, Netherlands; 2Department of
Cardiology and Vascular Medicine, Faculty of Medicine, University of
Indonesia, Indonesian Cardiovascular Research Center, National
Cardiovascular Center Harapan Kita, Jakarta, Indonesia; 3Department of
Pharmacology and Clinical Pharmacy, CanTho University of Medicine and
Pharmacy, Can Tho, Viet Nam; 4 Indonesian Cardiovascular Research
Center, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
Background: Although recommended by international guidelines, evi-
dence on the impact of pharmacological interventions in non‐reper-
fused ST‐segment elevation myocardial infarction (STEMI) patients is
limited.
Objectives: To assess the association between adherence to guide-
line‐recommended preventive medications and in‐hospital mortality
among non‐reperfused STEMI patients.
Methods: We conducted a cohort study using data obtained from
the Jakarta Acute Coronary Syndrome (JAC) Registry database from
a tertiary care academic hospital in Indonesia. We included 1132 of
2694 patients with STEMI recorded between 1 January 2014 and 31
December 2016 who did not undergo acute reperfusion therapy.
Adherence to guideline‐recommended preventive medications was
defined as the combined administration of aspirin, clopidogrel, anti-
coagulants, and statins within 24‐h of hospital admission. The main
outcome measure was in‐hospital mortality.
Results: Overall, 778 of 1132 patients (69%) received the combina-
tion of preventive medications. Clinical characteristics that were sig-
nificantly associated with in‐hospital mortality included symptom
onset of STEMI, Killip class >1, and thrombolysis in myocardial
infarction (TIMI) score ≥ 4. After adjustments for measured charac-
teristics using logistic regression modeling, exposure to the combina-
tion of preventive therapies was associated with a statistically
significantly lower risk for in‐hospital mortality (adjusted odds ratio:
0.46, 95% confidence interval: 0.30–0.70).
Conclusions: Although unmeasured indication bias may have played
a role, adherence to preventive medications was associated with
lower in‐hospital mortality. These findings reinforce the importance
of the use of evidence‐based medications in reducing the mortality
of patients with STEMI, particularly, when local challenges hamper
the provision of acute reperfusion therapy.
1087 | Abstract Withdrawn
1088 | Pre‐ and post‐intervention study to
assess the impact of the use of consensus
validated criteria explicit criteria on
prescribing of potentially inappropriate
medication and subsequent adverse drug
events‐related hospitalization in Pakistani
elderly
Faizan Mazhar1,2; Shahzad Akram3
1Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco”
University Hospital, Università di Milano, 20157, Milan, Italy; 2Dow
University of Health Sciences, Karachi, Pakistan; 3King Abdulaziz Medical
City, National Guard Health Affairs,, Riyadh, Saudi Arabia
Background: Mazhar criteria, an explicit consensus validated criteria
of potentially inappropriate medications (PIMs) for Pakistani seniors,
was proved to be a sensitive tool for screening PIMs. However, its
impact on routine practice and adverse drug events (ADE)‐related hos-
pitalization has not been studied.
Objectives: To compare the impact of the use of Mazhar criteria on
potentially inappropriate drug prescription (PIP) rate and ADE‐related
hospitalization pre‐ and post‐intervention.
Methods: We performed a two‐phase prospective observational con-
trol study. Patients ≥65 years who were admitted with acute illness to
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a university teaching hospital from January to April 2017 and from
May to August 2017, served as pre‐intervention and post‐intervention
group, respectively. The intervention consisted of the use of PIMs
criteria made available to all the departments of the hospital and phar-
macist recommendations to the physician on each individual prescrip-
tion. Adverse drug events were defined by the World Health
Organization‐Uppsala Monitoring Centre criteria and verified by a
local expert consensus panel, which also assessed whether ADEs were
causal or contributory to current hospitalization.
Results: A total of 10,453 prescriptions for 943 (n = 424 pre; n = 519
post) patients were analyzed during the study period. Compared with
pre‐intervention, the proportion of PIP (64% pre vs. 33.5% post;
p < 0.001), was significantly lower post‐intervention. In pre‐interven-
tion group, a total of 443 ADEs were detected in 140 patients of
424 patients; 208 of 443 ADEs (57%) were considered causal or con-
tributory to admission of 38 patients. The rate of ADEs were signifi-
cantly lower by 28% post‐intervention (57% pre vs. 29% post;
p < 0.01).
Conclusions: The use of our consensus validated criteria explicit
criteria of PIMs significantly associated with decreased ADEs in older
people that cause or contribute to hospitalization.
1089 | Intervention to improve penicillin
prescribing in primary care: A controlled
interrupted time‐series study
António Teixeira Rodrigues1,2,3; Fátima Roque4,5;
Maria Piñeiro‐Lamas6; Amílcar Falcão7; Adolfo Figueiras8,9,10;
Maria Teresa Herdeiro1
1Department of Medical Sciences, Institute of Biomedicine – iBiMED,
University of Aveiro, Aveiro, Portugal; 2Faculty of Pharmacy, University of
Coimbra (FFUC), Coimbra, Portugal; 3Centre for Health Evaluation and
Research (CEFAR), National Association of Pharmacies, Lisbon, Portugal;
4Research Unit for Inland Development, Polytechnic of Guarda (UDI‐IPG),
Guarda, Portugal; 5Health Sciences Research Centre, University of Beiara
Interior (CICS‐UBI), Covilhã, Portugal; 6Consortium for Biomedical
Research in Epidemiology and Public Health (Epidemiología y Salud
Pública‐ CIBERESP), Santiago de Compostela, Spain; 7Faculty of
Pharmacy, University of Coimbra (FFUC), Coimbra, Portugal;
8Department of Preventive Medicine and Public Health, University of
Santiago de Compostela, Santiago de Compostela, Spain; 9Consortium for
Biomedical Research in Epidemiology and Public Health (CIBER en
Epidemiología y Salud Pública‐ CIBERESP), Santiago de Compostela,
Spain; 10Health Research Institute of Santiago de Compostela (IDIS),
Santiago de Compostela, Spain
Background: Tackle antibiotic misprescription and overuse is of fully
importance to combat drug resistances. One of the important aspects
regarding the quality indicators of antibiotic prescribing is the overuse
of broad‐ against narrow‐spectrum antibiotics.
Objectives: to assess the impact of an educational intervention on
quality indicator of penicillin's prescribing.
Methods: A cluster‐randomized trial was designed in the Centre Health
Region of Portugal, with a sample size of ~1100 primary care physicians.
The multidisciplinary and multifaceted educational intervention
targeted physicians' attitudes and knowledge about antibiotic prescrib-
ing and resistances, throughout outreach visits and the distribution of
educational materials. The impact of the intervention of penicillin's pre-
scribing was assessed through relative ratios of prescription of penicil-
lin's sensitive to β‐lactamase (J01 CE) and penicillin combinations
including β‐lactamase inhibitors (J01CR). Interrupted time‐series analy-
sis with control group comparison was made.
Results: The physicians' participation was 64% (197/309) in a total of
25 counties. Simultaneously, significant improvements were obtained
in the prescription of penicillin's sensitive to β‐lactamase (overall rela-
tive increase of +896%) and penicillin combinations including β‐
lactamase inhibitors (overall relative decrease of −161%).
Conclusions: Simultaneous increase of narrow‐spectrum penicillin‐pre-
scribing and decrease of broad‐spectrum ones is of fully importance to
improve the quality indicators of antibiotic prescribing. The results
emphasize the potential impact of interventions acting on physicians'
attitudes and knowledge regarding antibiotic prescribing and resis-
tances. In order to further promote the appropriate use of antibiotics,
it was approved by the FCT (PTDC/SAU‐SER/31678/2017) a new pro-
ject to evaluate the effectiveness of e‐Health tools in supporting clinical
decision‐making and empowerment of patients in the management of
upper respiratory tract infections that will be performed in the same
region as a reinforced educative intervention. This work was supported
by Portuguese Foundation for Science and Technology (FCT/MCTES),
grant (PTDC/SAUESA/105530/2008). Project PTDC/SAU‐SER/
31678/2017, supported by the operational programof competitiveness
and internationalization (POCI), in its FEDER/FNR component POCI‐
01‐0145‐FEDER‐031678, and the FCT, in its state budget component
(OE) and Institute for Biomedicine ‐ iBiMED (UID/BIM/04501/2013
and POCI‐01‐0145‐FEDER‐007628).
1090 | Patterns of utilization of specific
insulin formulations and non‐insulin
antidiabetic therapies before, during, and
after implementation of a health plan insulin
switching intervention
Jing Luo; Nazleen Khan; Joshua Gagne; Aaron Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and
Women's Hospital, Boston, MA
Background: We previously showed that an intervention switching
older adults with type 2 diabetes from analog to human insulin
(broadly categorized) was associated with no significant differences
in hypoglycemic events, a modest, but clinically insignificant increase
in mean HbA1c, and large reductions in plan expenditures and
patient out‐of‐pocket costs. It is important to know what impact
the intervention had on utilization patterns of specific insulins and
other antidiabetic therapies.
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Objectives: To describe utilization patterns of specific analog and
human insulins formulations and of background antidiabetic therapies
before, during and after an insulin switching intervention.
Methods: We obtained enrollment and prescription claims from
14,635 members of a Medicare Advantage Plan who filled at least
1 insulin prescription between 2014 and 2016. We tabulated the
total number of insulin prescriptions dispensed across 6 categories
(long‐acting analog, rapid‐acting analog, pre‐mixed analog, intermedi-
ate‐acting human, premixed human and short‐acting human). We
report overall utilization of each category as a proportion of unique
insulin users during each calendar month as well as the proportion of
patients using non‐insulin glucose lowering medications.
Results: The proportion represented by long‐acting analogs
decreased from 0.73 (Jan 2014) to 0.23 (Dec 2016). The proportion
of rapid‐acting analogs decreased from 0.35 to 0.08, while premixed
human insulins increased from 0.06 to 0.43. Intermediate acting
human insulins increased from 0.04 to 0.26. The proportion of
short‐acting human insulin increased from 0.04 to 0.12. For non‐
insulin glucose‐lowering medications, proportions represented by
metformin decreased from 0.43 to 0.41; SUs decreased from 0.29
to 0.21. DPP‐4 s increased from 0.02 to 0.06; TZDs from 0.02 to
0.03. GLP1RAs were stable at 0.02 while SGLT‐2 s, meglitinides
and alpha‐glucosidase inhibitors were all unchanged at <0.01.
Conclusions: A health plan intervention substantially reduced the
proportion of insulin filled as long‐acting and rapid‐acting analogs
and increased the use of premixed and intermediate‐acting human
insulins. Among non‐insulin medications, utilization of SUs and met-
formin slightly decreased, while use of newer agents including
GLP1RAs and SGLTs remained largely unchanged. These results sug-
gest that the clinical results from the main insulin switching study
were more likely driven by insulin‐specific changes rather than by
dramatic changes to background therapy.
1091 | The impact of Interprofessional
Education (IPE) on the outcomes of pharmacy
practice experiences
Emily Murray1; Xuerong Wen1; Celia MacDonnell1; Matthew Lacroix1;
Yang Li2; Erica Estus1; Michelle Caetano1; Barbara Sweeney3;
Dara LoBuono3; Phillip Clark3
1The University of Rhode Island, Kingston, RI; 2The University of Florida,
Gainesville, FL; 3The University of Rhode Island, Kingston, RI
Background: Incorporating IPE experiences has shown a significant
positive impact on student attitudes towards other health professions
and improvement in overall knowledge. However, studies are rare in
this field.
Objectives: To examine the impact of exposure to multiple IPE prac-
tices on the attitudes of pharmacy students towards their pharmacy
program and profession.
Methods: This retrospective cohort study evaluated data from the Uni-
versity of Rhode Island (URI) from2013–2018.Datawas collected using
Graduating Student Surveys that were distributed to graduates of the
Doctorate of Pharmacy program. The two exposures were defined as
the number of required curricular activities and the total number of pro-
fession types that students interactedwith. Exposurewas dichotomized
into ≥6 or < 6 to define the high and low intensity of activities. The six
outcomes, including: enhanced understanding of a multi‐professional
team, engagement as amember of an interprofessional healthcare team,
collaboration with other healthcare professions, preparedness to enter
pharmacy practice, and satisfaction with the study of pharmacy and
the URI pharmacy program, were dichotomized into “strongly agree”
and “other.”Amultivariate logistical regression model was used to iden-
tify the association between the intensity of the exposure and the six
outcomes, while adjusting for demographic variables.
Results: Of the 493 students included, 38%weremales, 89%worked in
a pharmacy during the academic year, 39% sought continued education
post‐graduation, 74% of students participated in≥6 required curricular
activities, and 25% of students had≥6 interactions with students from
different professions. The multivariate analysis showed that the high
intensity of IPEwas significantly associated with enhanced understand-
ing of a multi‐professional team (OR 1.8, 95%CI 1.0–3.2) and satisfac-
tion with the URI pharmacy program (OR 3.1, 95%CI 1.7–5.5).
Statistically significant associations were also found between a high
number of professions that students interacted with and enhanced
understanding of a multi‐professional team (OR 1.8, 95%CI 1.0–3.4),
engagement as a member of an interprofessional healthcare team (OR
2.4, 95%CI 1.3–4.7), and preparedness to enter pharmacy practice
(OR 2.1. 95%CI 1.2–3.9).
Conclusions: The results of this study suggest that a higher intensity of
curricular activities and exposure to other professions positively
enhanced engagement and understanding of interprofessional teams,
preparedness to enter pharmacy practice, and overall satisfaction with
the pharmacy program.
1092 | Perceptions of Saudis towards
generic drugs use
Malak S. Almofada1; Lamya S. Alnaim2; Edward B. Devol3;
Asma A. AlHussaini4; Aljawhara A. AlShahrani4; Hessah I. AlSuwaidan4
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 2King Saud
University, Riyadh, Saudi Arabia; 3King Faisal Specialist Hospital &
Resear, Riyadh, Saudi Arabia; 4King Faisal Specialist Hospital & Research
Center, Riyadh, Saudi Arabia
Background: Generic drugs are a substitute to brand drugs to treat
illnesses. The use of generic drugs contributes to reducing costs of
patients and health care budgets.
Objectives: The study aims to test the hypothesis on whether Saudis
prefer taking brand over generic drugs as well as assessing the difficul-
ties that prevent Saudis from shifting to generic drugs.
Methods: This is a descriptive, cross‐sectional study. The study sam-
ple included 919 adults who were asked to complete a self‐adminis-
tered questionnaire. The first page in the questionnaire was added
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to provide general information about generic and brand drugs. The
questionnaire was adopted from the Shrank et al. study and edited
to fit the Saudi community. An expert in Arabic language and an
expert in the medical field audited the questionnaire.
Results: This study revealed that most of the significant items were
Saudi preferred brand over generic (e.g. overall value, Saudis should
use brand, insurance should cover, etc.). The main challenging obsta-
cles against shifting to generic was that nearly 40% of the respon-
dents were not able to confront their doctors on the given drug
and asking for generic availability. In addition, approximately 35%
of respondents felt that doctors should be talking more about
generic drugs. Regarding the age and preferences, increase age was
correlated to brand drugs preferences, as the older participants,
mainly age group of 40–49 agreed with the statement that generic
is less effective. Moreover, according to the overall perceptions of
Saudis pattern in drug use, there tended to be the belief that Saudis
spend too much on prescribed drugs. Although majority of the
respondents were indifferent, when asked if Saudis should use more
generic. But less than one third of the total respondents agreed with
the statement “government/insurance companies should force the
patients on using generic as a first option and only use brand if
the generic is not effective” and more than one third of the partici-
pants agreed on prescribing brand instead of generic. The results are
alerting for insurance companies and policymakers to do more edu-
cation and rebranding of generic drugs to get more acceptance.
Conclusions: To conclude, Saudis preferred taking brand over
generic drugs. Quite high percentages indicated that Saudis could
not switch to generic drugs. Hence, healthcare providers and institu-
tions should take the responsibility in providing more information
about generic and brand. Also, there is a need to communicate more
with the patients in order to increase the level of awareness and
clarify the differences between the given drugs.
1093 | Impact of the October 2016 policy
change on the delivery of MedsCheck annual
and MedsCheck diabetes services in Ontario
community pharmacies
Ahmad Shakeri1; Lisa Dolovich1; Lori MacCallum1;
John‐Michael Gamble2; Limei Zhou3; Suzanne M. Cadarette1
1University of Toronto, Toronto, ON, Canada; 2University of Waterloo,
Kitchener, ON, Canada; 3 ICES, Toronto, ON, Canada
Background: MedsCheck (MCA) is a community pharmacy led annual
medication review service funded since April 2007 for residents with
a valid Ontario healthcard taking three or more medications for chronic
conditions. MCA aims to improve patient outcomes by improving med-
ication adherence and identifying potential medication errors; thereby
lowering the risk of adverse drug events. In September 2010, MCA
was expanded to include follow‐up services and include all patientswith
diabetes (MCD) with added documentation specific to patients with
diabetes. In October 2016, documentation requirements changed
adding several components to MCA and MCD services.
Objectives: To estimate the impact of the 2016 policy change on the
number ofMCA andMCD services delivered in community pharmacies.
Methods: We identified all MCA and MCD services claimed from pro-
gram launch to November 2018 using pharmacy claims data housed at
ICES. Interrupted time series analysis (segmented linear regression with
autoregressive error models) was used to examine the impact of the
October 2016 (intervention date) policy change on themonthly number
of services delivered (24 months pre‐ and post‐policy change included
in the analyses), accounting for seasonality, non‐stationarity, and
autocorrelation.
Results: Since program launch, 2,684,142 patients received an MCA
and 672,006 received an MCD. The monthly number of services were
stable over the two years before the policy change with an average of
78,072 (SD = 6,182) MCA and 26,268 (SD = 2,471) MCD. Immediate
decreases in delivery of both services (−50.2% [95%CI:‐55.8,‐44.6]
MCA, −74.5% [95%CI:‐80.2,‐68.8] MCD) were identified in the first
month of the policy change with regional differences identified (range
from −55.7% South East to −44.5% North West for MCA; and from
−78.1% Central to −65.4% North West for MCD). Gradual increases in
the number of services deliveredwere seen over 24months after policy
change (slope of 1.54%MCAand 1.05%MCD), yet remained lower than
before the policy change (monthlymean betweenApril 2017 toNovem-
ber 2018 = 46,534 [SD = 4,414] MCA, 9,606 [SD = 1,149] MCD).
Conclusions: Substantial decreases in delivery of MCA and MCD were
seen after the 2016 policy change. Better understanding of how major
policy changes can impact the delivery of medication management ser-
vices by pharmacists is needed.
1094 | Global overview of the relative
consumption of access antibiotics within
WHO AWaRe categories
Verica Ivanovska; Wenjing Tao; Arno Muller
World Health Organization, Geneva, Switzerland
Background: In 2017, World Health Organization (WHO) grouped
antibiotics into three AWaRe categories ‐ Access, Watch, and Reserve,
based on their treatment profile and the potential for development of
resistance. This categorization is designed to ensure that antibiotics
are available when needed, the right antibiotics are prescribed for
the right infections, and the effectiveness of ‘last‐resort’ antibiotics
are preserved when all others fail. The Access category of antibiotics
represents the first‐ and second‐line therapy for common infections.
WHO GWP 13 target is that Access group antibiotics present at
≥60% of overall antibiotic consumption. Earlier, WHO launched its
global initiative to monitor antimicrobial consumption (AMC) through
aggregated sales data and was able to collate 2015 country AMC data
from 65 countries to establish baseline consumption rates.
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Objectives: We aimed to calculate the relative consumption of antibi-
otics by AWaRe categories to assess Access group rates per country.
countries met the cut‐off point of 60% for Access category.
Methods: Total antibiotic consumption is presented by the quantity of
antibiotics for systemic use (J01, A07AA, P01AB) as DDD per 1000
inhabitants per day. Relative consumption is a percentage of total con-
sumption by AWaRe categories. We counted how many countries met
the cut‐off point of 60% for Access category.
Results: In 2015, overall consumption of antibiotics in the 65 coun-
tries ranged from 4.4 DID to 64.4 DID. The relative consumption of
the Access category within AWaRe ranged from 11–89.5% (average
58.3%). In total, 29 countries met the cut‐off point of 60% for Access
category in 2015.
Conclusions: This study finds the consumption of Access antibiotics
made up on average 58.3% of the AWaRE consumption. In total, 29
out of 65 countries met the cut‐off point of 60% for Access category.
WHO will continue promoting the importance of incorporating the
AWaRE categories into national essential medicines lists and treat-
ment guidelines to ensure that first‐ and second‐line therapy is used
for common infections, and it is widely available. WHO will repeat
the analysis of the AWaRe relative consumption with post‐2017 data
to check whether more countries meet the GPW13 target.
1095 | Reduction in use of Cyproterone/
Ethinylestradiol (Diane‐35 and generics) after
risk minimisation measures in the
Netherlands, UK and Italy
Irene D. Bezemer1; Elisabeth Smits1; Fernie J.A. Penning‐van Beest1;
Luis A. García Rodríguez2; Lucía Cea Soriano2,3; Francesco Lapi4;
Monica Simonetti4; Alex Asiimwe5; Dalia Shash5; Ron M.C. Herings1,6
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands;
2Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain;
3Department of Public Health and Maternal Child Health, Faculty of
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Background: Cyproterone acetate combined with ethinylestradiol
(CPA/EE) is indicated for moderate to severe acne and/or hirsutism
in women of reproductive age. In 2013 the European Medicines
Agency concluded that the benefits of CPA/EE outweigh the risk of
thromboembolism. Among the recommendations for risk minimisation
was to emphasize the approved indications of use and to limit use in
combination with other hormonal contraceptives (HC).
Objectives: To assess CPA/EE user characteristics and concomitant
use of other HC before and after the risk minimisation measures.
Methods: This retrospective drug utilization study included data from
the PHARMO Database Network (the Netherlands), the Health Search
Database (HSD, Italy) and The Health Improvement Network (THIN,
United Kingdom. New CPA/EE users from 2011 until 2017 were
followed from their first CPA/EE prescription until 31 December of
each respective year. Recordings of acne, other hyperandrogenic con-
ditions, menstrual problems or GP consultations for contraceptive
management were assessed during the year preceding CPA/EE initia-
tion and up to 2014. Use of CPA/EE and concomitant use of other HC
was assessed during follow‐up and up to 2017.
Results: The number of new CPA/EE users per year decreased in all
databases between 2011 and 2017; from 2.8 to 0.2 per 1,000 women
in PHARMO, from 1.6 to 0.9 per 1,000 women in THIN and from 0.8
to 0.4 per 1,000 women in HSD. A recent record of acne diagnosis or
treatment was identified for 47–55% of users in PHARMO, 76–79% in
THIN and 18–21% in HSD. A diagnosis of hyperandrogenic conditions
other than acne was observed for 3% in PHARMO, 8–9% inTHIN and
7–10% in HSD. No evidence of increasing proportions with approved
indications over the years was observed. Concomitant use of other
HC was observed for 2–3% of users in PHARMO, up to 1% in THIN
and 1–2% in HSD. Another 22–28% in PHARMO had overlapping pre-
scriptions, likely indicating a switch from CPA/EE or vice versa. In
THIN and HSD, corresponding figures were 4–6% and 2–4%; overall
proportions of HC users were lower as well in these data sources.
Conclusions: Apart from a strong overall reduction in CPA/EE use, no
major difference was observed between the study periods before and
after the referral procedure in any of the databases between propor-
tions with acne or other hyperandrogenic conditions, or with concom-
itant use of other HC.
1096 | Influence of change in treatment
policy and ART regimen in HIV positive
patients on treatment out comes; a
observation from South Indian state funded
hospital
Varun Talla1; Satyanarayana Pattnaik1; Jupally Venkateshwar Rao1;
Vamshi Krishna1; V. Chandrasekar2; Hari Krishna1; D. Sandeep1
1Talla Padmavathi College of Pharmacy, Warangal, India; 2Kakatiya
Medical College, Warangal, India
Background: National AIDS Control Organization (NACO), India has
changed the treatment approach for HIV positive patients to test
and treat policy (P2), where patients were prescribed antiretroviral
therapy (ART) immediately after being confirmed as HIV + ve, in con-
trary to previous practices where ART was initiated in patients only if
CD4 cell count was less than 350cells/mm3(P1). Barriers (including
unavailability of medicines, ADRs & treatment failure) to change in
ART regimen are common in Indian practices. Its need to ascertain
aforementioned changes impact on CD4 cell count which is one of
the prominent treatment outcomes measured.
Objectives: To assess variation in CD4 cell count influenced by change
in treatment policy and ART regimen.
Methods: An observational study was carried out by recruiting HIV
positive patients (n = 847) who were on ART, visiting government
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tertiary care hospital (study site) at Warangal, India. Data were col-
lected from patient case notes, patient interviews and laboratory data.
The recruited patients were categorized into 2 groups: Catogery 1(C1):
patients in whom there is a change in treatment regimen due to vari-
ous reasons. (n = 228) Catogery 2(C2): patients in whom there is no
change in treatment regimen. (n = 619) Further, the patients were
again sub‐categorized into baseline CD4 cell count below 350cells/
mm3(P1) and above 350cells/mm
3(P2). Comparison of variation in
CD4 cell count was recorded in these patients following treatment
for a period of 12 months.
Results: In the C1P1 patients, a significant improvement in mean CD4
cell count was observed from 187 to 276 cells/mm3 (p < 0.05). There
were no patients in the C1 with CD4 count above 350 cells/mm
3. In
the C2 patients, the improvement in the CD4 cell count was found
to be from 171 to 236 cells/mm3 (C2P1) and from 493 to 533 cells/
mm3 (C2P2). The study has clearly indicated a better improvement in
CD4 cell count following initiation of ART at a higher baseline CD4
cell count complementing with the decision of NACO for change in
policy related to initiation of ART in HIV positive patients as soon as
they are detected positive irrespective of their baseline CD4 cell
count. Change in the treatment regimen also contributed towards
improvement in CD4 cell count.
Conclusions: The study indicated that quick initiation of ART may pro-
vide better immunological management in HIV positive patients. A
steeper improvement in CD4 cell count was observed in the patients
when ART was initiated at a higher baseline CD4 cell count. Moreover,
changed ART regimen also affected the CD4 cell count in the patients.
1097 | Impact of drug safety warnings and
cost‐sharing policies on osteoporosis drug
utilization in Spain: A major reduction but
with the persistence of over and underuse.
Data from the ESOSVAL cohort 2009–2015
Isabel Hurtado‐Navarro; Aníbal García‐Sempere;
Clara Rodríguez‐Bernal; José Sanfélix‐Genovés; Salvador Peiró;
Gabriel Sanfelix‐Gimeno
FISABIO, Valencia, Spain
Background: Recent studies in several countries show a significant
decrease in the consumption of osteoporosis drugs from a peak in
around 2009, including those for secondary prevention after hip frac-
ture (where treatment is widely recommended). Spain has being tradi-
tionally one of the countries with the highest utilization rates
worldwide, but whether it is following the global trends, for both,
low and high risk patients is unknown.
Objectives: The aim of this work is to assess changes in the utilization
of osteoporosis drugs in the Valencia Region (Spain) after safety warn-
ings from regulatory agencies and cost‐sharing changes, according to
patient socio‐demographic and risk of fracture characteristics.
Methods: We constructed a monthly series of osteoporosis drug con-
sumption for 2009–2015 from the ESOSVAL cohort (n = 11,035;
women: 48%; mean age: 65 years old) and used interrupted time
series and segmented linear regression models to assess changes in
osteoporosis drug utilization while controlling for previous levels and
trends after three natural intervention dates: the issue of the Spanish
Agency for Drugs and Medical Products (AEMPS) Osteonecrosis Jaw
Warning (Sept 2009), the AEMPS Atypical femur Fracture Warning
(Apr 2011) and the modification of the cost‐sharing scheme (Jul 2012).
Results: The AEMPS Osteonecrosis Jaw Warning was not associated
with a decline in the consumption of osteoporosis drugs, while the
warning on Atypical Fracture (a downward trend of 0.11% fewer peo-
ple treated each month) and the increase in the cost‐sharing scheme
(immediate change level of −1.07% in the proportion of people
treated) were associated with a strong decline in the proportion of
patients treated, so that by the end of 2015 osteoporosis drug con-
sumption was around half that of 2009. The relative decline was sim-
ilar in people with both a high and low risk of fracture.
Conclusions: The AEMPS Atypical Fracture Warning of Apr 2010 was
associated with a significant decrease in the number of people treated,
reinforced by the increase in the pharmaceutical cost‐sharing in 2012.
Decreases in treatment affected patients both at a low and higher risk
of fracture.
1098 | Impact of European label changes for
systematic diclofenac products: Post‐referral
prescribing trends for initiation of systemic
diclofenac products and time series
regression
Daniel R. Morales1; Tom MacDonald1; Steve Morant1; Martin Ernst2;
Jesper Hallas2; Lisa Smits3; Ron Herings3; Lizzie Nicholson4;
Marion Bennie5; Li Wei6; Rob Flynn1
1University of Dundee, Dundee, UK; 2University of Southern Denmark,
Odense, Denmark; 3PHARMO Institute, Utrecht, Netherlands; 4National
Services Scotland, Edinburgh, UK; 5University of Strathclyde, Glasgow,
UK; 6University College London, London, UK
Background: Non‐steroidal anti‐inflammatory drugs, such as
diclofenac, are widely prescribed agents across Europe for the man-
agement of pain, fever and inflammatory conditions. In June 2013, a
European Medicines Agency (EMA) referral procedure concluded that
diclofenac containing products were associated with an elevated risk
of acute cardiovascular events and that contraindications, warnings,
and changes to the product information, including direct healthcare
professional communication were required to be implemented across
the EU.
Objectives: The aim of the study was to evaluate the impact of the
EMA risk minimisation measures implemented in 2013 to manage
the cardiovascular risks of systemic diclofenac containing medicinal
products in Denmark, Netherlands, England and Scotland.
Methods: Drug utilization studies assessing diclofenac‐containing
medical products covering the regulatory intervention in June 2013.
Quarterly time series analysis measuring the prevalence of diclofenac
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initiation and discontinuation with statistical significance testing using
interrupted time series regression.
Results: The cohorts consisted of 5.6 million in Denmark, 5.3 million in
Scotland, 4.2 million in England and 1 million people from the Nether-
lands. The most common indication for diclofenac in all countries
among those assessed was osteoarthritis. In all countries the preva-
lence of diclofenac prescribing fell during the overall observation
period. The 2013 EMA regulatory intervention was associated with
a: significant immediate fall in diclofenac initiation in the Netherlands
(−0.42%, 95%CI ‐0.66% to −0.18%), England (−0.09%, 95%CI ‐0.11%
to −0.08%) and Scotland (−0.67%, 95%CI ‐0.79% to −0.55%) but not
Denmark; a significant falling trend in diclofenac initiation in the Neth-
erlands (−0.03%, 95%CI ‐0.06% to −0.01%) and Scotland (−0.04%,
95%CI ‐0.05 to −0.02%). There was no significant immediate impact
on diclofenac discontinuation or increasing trend in diclofenac
discontinuation.
Conclusions: The 2013 EMA referral was associated with reductions
in overall diclofenac prescribing the extent of which varied by country
and type of exposure.
1099 | Are NHIS clients served inferior and
sub‐standard medicines? Using standard
WHO RUM indicators to determine quality of
care under the NHIS in Ghana
Daniel K. Arhinful1; Daniel N.A. Ankrah2
1University of Ghana NMIMR, Accra, Ghana; 2Korle Bu Teaching
Hospital, Accra, Ghana
Background: The National Health Insurance Scheme (NHIS) has since
its establishment in 2003 become an integral part of Ghana's strategy
towards the attainment of Universal Health Coverage (UHC).
Increased enrolment and utilization over the years has however been
accompanied by client perceptions of quality of care and medicine
access that lower confidence in the scheme.
Objectives: To investigate lay perceptions that NHIS clients are being
served inferior and sub‐standard medicines compared to non NHIS
clients.
Methods: The design involved a case study of medicines access under
the Ghana NHIS involving a prescription survey in 20 health facilities
in four (4) purposively selected regions in all three ecological zones
of Ghana. A total of 569 retrospective cases on upper respiratory tract
infection for children up to 13 years, malaria cases for any age group
and five adult hypertensive cases were obtained for assessment. Main
outcome measures were the key WHO rational use of medicines
(RUM) indicators.
Results: Descriptive analysis using WHO rational use of medicines
(RUM) indicators showed that from a medically rational perspective,
the insured are actually receiving slightly more appropriate care. Per-
cent injection use was relatively high in non‐insured (29.9%) compared
to insured (21.3%). Percentage medicines on Essential Medicines List
(EML) was 98% and 96% while % medicines prescribed with generic
name was 93% and 95% for insured and non‐insured respectively.
Quite identical patterns were seen in % prescribed antibiotics for
insured (41.5%) and non‐insured (41.4%) as well as average number
of medicines per prescription for the insured (3.7) and non‐insured
(3.8).
Conclusions: From a technical biomedical perspective, our data sug-
gested that insured members in the Ghana NHIS are receiving more
appropriate care than the non‐insured because the scheme has
become an important enforcer of rational prescribing through claims
auditing, forcing providers to adhere to RUM prescribing rather than
lay perceptions. Lay perspective of clients however regard rational
medicine use indicators such as less injections, more generic and
EML medicines as inferior medicines access. Rational use of medicines
values need to be transmitted to clients as well as providers to better
harmonize technical and socially driven perspectives of quality of care.
1100 | Impact of European label changes for
systematic diclofenac products: Post‐referral
prescribing trends in switching to alternative
products following diclofenac discontinuation
Daniel R. Morales1; Tom MacDonald1; Steve Morant1; Martin Ernst2;
Jesper Hallas2; Lisa Smits3; Ron Herings3; Lizzie Nicholson4;
Marion Bennie5; Marion Bennie5; Li Wei6; Rob Flynn1
1University of Dundee, Dundee, UK; 2University of Southern Denmark,
Odense, Denmark; 3PHARMO Institute, Utrecht, Netherlands; 4National
Services Scotland, Edinburgh, UK; 5University of Strathclyde, Glasgow,
UK; 6University College London, London, UK
Background: Non‐steroidal anti‐inflammatory drugs (NSAIDs), such
as diclofenac, are widely prescribed agents across Europe for the
management of pain, fever and inflammatory conditions. In June
2013, a European Medicines Agency (EMA) referral procedure con-
cluded that diclofenac containing products were associated with an
elevated risk of acute cardiovascular events and that contraindica-
tions, warnings, and changes to the product information, including
direct healthcare professional communication were required to be
implemented across Europe.
Objectives: The aim of the study was to evaluate the impact of the
EMA risk minimisation measures implemented in 2013 on unintended
switching to alternative products in Denmark, Netherlands, England
and Scotland.
Methods: Drug utilization studies measuring trends in the prevalence
of initiation of other systemic NSAIDs, topical NSAIDs, paracetamol,
opioids and other chronic pain medication in people who discontinued
diclofenac‐containing medical products covering the regulatory inter-
vention in June 2013. Quarterly time series analysis with statistical
significance testing using interrupted time series regression.
Results: Among cohorts consisting of 5.6 million in Denmark, 5.3 mil-
lion in Scotland, 4.2 million in England and 1 million people in the
Netherlands, the regulatory intervention was associated with statisti-
cally significant immediate increases in switching to: other systemic
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NSAIDs in England (1.51%, 95%CI 0.22% to 2.80%) and Scotland
(5.21%, 95%CI 3.70% to 6.72%); topical NSAIDs in Scotland (0.35%,
95%CI 0.12% to 0.58%); paracetamol in Denmark (5.92%, 95%CI
4.07% to 7.77%) and Scotland (0.50%, 95%CI 0.28% to 0.73%); opi-
oids in Scotland (0.12%, 95%CI 0.04% to 0.21%); and other chronic
pain medication in England (0.39%, 95%CI 0.05% to 0.72%) and Scot-
land (1.31%, 95%CI 0.72% to 1.89%). The regulatory intervention was
associated with statistically significant rising trends in switching to:
topical NSAIDs in Denmark; paracetamol in Denmark and the Nether-
lands; and opioids in Scotland, whilst other countries were associated
with no or falling trends in switching.
Conclusions: The 2013 EMA referral was associated with significant
changes in switching to alternative pain medications following
diclofenac discontinuation the extent of which varied by country and
type of product.
1101 | Policies influencing access to new
targeted oncologic drugs in Ecuadorian
hospitals: An interrupted time series analysis
Carlos E. Durán1; Monique Elseviers1; Robert Vander Stichele1;
Sylvie Rottey1,2; Patricia Granja3,4
1Ghent University, Ghent, Belgium; 2Ghent University Hospital, Ghent,
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Background: Emerging countries continuously try to influence the
growing expenses of new oncologic drugs by applying a wide range
of policies.
Objectives: An Interrupted Time Series Analysis was performed to
measure the impact of two policy interventions over the accessibility
to new targeted oncologic drugs in Ecuador.
Methods: The first intervention decentralized the evaluation process
allowing Hospital Drug & Therapeutic Committees (DTCs) directly
select new drugs. The second brought back the final decision to a cen-
tral body but kept the first decision level in hospitals. Dispensing data
from the six largest Ecuadorian cancer hospitals (3 public, 3 private)
were analyzed over a period of five years (2010–2014). Targeted
drugs were defined as monoclonal antibodies, proteinkinase inhibitors,
vismodegib and vorinostat. Monthly incidence rate of targeted drug
users (out of 1000 cancer patients) was obtained. Level and trend
changes after interventions were studied.
Results: In public hospitals, incidence level dropped after the first pol-
icy (−18.04, p < 0.05). The slope increased by 1.05 until the second
policy (not significant). After the second intervention, incidence level
dropped by −12.67 and the slope was negative by −0.66 (both not sig-
nificant). In private hospitals, incidence level dropped after the first
policy (−4.46, p < 0.001). A statistically significant trend increase (+
1.39) was observed until the second intervention. After the second
intervention, significant changes in the level and trend were observed:
the level dropped by −4.09 (p < 0.05), with a negative slope of −1.35
(p < 0.001).
Conclusions: Transferring the responsibility to select new drugs to
DTCs produced an important increase in prescription intensity of
targeted oncologic drugs, mainly in the private sector. It was rapidly
corrected by the second intervention. Without the implementation
of either the first or second policy, depending on the sector, the con-
sumption of new targeted oncologic drugs would be difficult to con-
trol, framing a potential financial risk for the health system.
Combination of different levels of decision, meaning a DTC analysis
plus a reanalysis by a central body, proved to limit new prescriptions
of targeted oncologic drugs. Countries must be aware of the needed
capacities to respond to the challenges and pressures to include
expensive targeted drugs into benefit packages.
1102 | The part D enhanced medication
therapy management model: Monitoring
findings as the model enters Year Two
Karin Johnson1; Corey Triebwasser1; Ilene Harris1; Paul Dowell1;
Tracy Haidar1; Zippora Kiptanui1; Olivia Bundschuh1;
Catherine Cooke2; Nicole Brandt2
1 IMPAQ International, Columbia, MD; 2University of Maryland School of
Pharmacy, Baltimore, MD
Background: The Centers for Medicare & Medicaid Services (CMS)
Center for Medicare and Medicaid Innovation (CMMI) Part D
Enhanced Medication Therapy Management (MTM) model tests
whether providing Part D sponsors with additional payment incentives
and regulatory flexibilities promotes enhancements in the MTM pro-
gram, leading to improved therapeutic outcomes, while reducing net
Medicare expenditures.
Objectives: Gauge the implementation of the Enhanced MTM model
from January 2017–June 2018, including the number of patients
selected for and receiving MTM services.
Methods: Six Part D sponsors participate in the Enhanced MTM
model, representing approximately 1.7 million Medicare beneficiaries.
We independently assessed program implementation and intermedi-
ate outcomes for measure domains including Model‐Wide Quality
Indicators, Beneficiary Targeting, Beneficiary Engagement and Partici-
pation, and Unintended Consequences. We analyzed variation across
time and sponsors. This analysis reflects our role as the implementa-
tion contractor and should be considered independent from CMS'
own internal evaluation efforts.
Results: Enhanced MTM enrollment and targeting criteria, engage-
ment strategies, and intervention strategies varied across sponsors.
Thus, relative performance across monitoring measure domains was
not interpreted as success or failure. Nearly 2/3 of beneficiaries were
targeted overall (ranging by sponsor in Q2 2018: 20.56–78.76%).
Almost 1/3 of targeted beneficiaries had at least one encounter record
indicating participation in Q2 2018 (ranging by sponsor 13.91–
98.38%). Performance on Model‐Wide Quality Indicators in Q1 ‐ Q2
2018 was similar to 2017. Approximately 1/4 of hospital‐to‐home dis-
charges were followed by an MTM service. Roughly 7% of targeted
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beneficiaries had a medication therapy issue recorded. Review of
supporting documentation submitted by sponsors for data validation
purposes has indicated that there may be differences in how sponsors
record similar activities in their encounter data.
Conclusions: When Part D was developed, CMS estimated one‐
fourth of enrollees could benefit from MTM, but participation has
historically been low. The implementation of the Enhanced MTM
model appears to be achieving its goal of increasing enrollment
−assessed cumulatively, nearly two‐thirds of targeted beneficiaries
participated in 2017 and nearly half participated through Q2 in
2018. Model activities may be encouraging medication adherence
and other interventions relevant to pharmacoepidemiology studies
involving the Medicare population.
1103 | China pharmacovigilance under
reformed drug regulations
Li Zhang1; Haibo Song2; Ying He3; Jialin Cong1; Jukai Huang1
1Dongfang Hospital, Beijing University of Chinese Medicine, Beijing,
China; 2Center for Drug Reevaluation, National Medical Product
Administration, Beijing, China; 3Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences (NDORMS), University of
Oxford, Oxford, UK
Background: The National Medical Products Administration (NMPA) is
the Chinese agency for regulating drugs and medical devices (formerly
the China Food and Drug Administration, CFDA). NMPA joined the
International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH) in
2017, and became one of the management committee members in
2018.
Objectives: We aim to perform an overview of the current use, chal-
lenges and prospects of applying pharmacoepidemiological methods
in the Pharmacovigilance in China after reforming the drug regulatory
system, and promote the collaboration with Asian
Pharmacoepidemiology Network (AsPEN) and international
institutions.
Methods: The reform of China's drug regulatory system and its impact
on guiding pharmacovigilance were reviewed.
Results: SinceOpinions on the Reform of Review and Approval Process for
Drugs andMedical Devices issued in August 2015, NMPA has developed
series supporting guidelines to encourage new drug development,
including reforming clinical trial management, accelerating review and
approval process, prioritized review procedures, and expansion of the
Marketing Authorization Holder (MAH) Program. Since NMPA has
applied five ICH secondary guidelines including M4, E2A, E2D, M1,
E2B(R3) and MAHs are required to report adverse reactions directly,
the transmission of individual safety reports has become efficient.
Moreover, based on the hospital‐based electrical health records (EHR),
China National Center for ADR Monitoring (NCADRM) has started to
establish the active monitoring and evaluation system.
Conclusions: In the past three years, the development and reforming
of pharmacovigilance system by NMPA provided solid basis for the
drug life‐cycle surveillance in China. The following approaches for
international communication and cooperation, including, the improve-
ment of the industrial post‐marketing research ability, the integration
of pharmacoepidemiological methods using multiple databases, the
development of drug withdrawal technical system, the development
of coding system and the methodology for clinical evaluation of the
traditional and herbal medicines, are helpful to further improve
pharmacovigilance system in China and eventually achieve global reg-
ulatory integration.
1104 | Trends in polypharmacy and
dispensed drugs among adults in the
Netherlands as compared to the United
States
Monika P. Oktora1; Petra Denig1; Jens H.J. Bos2;
Catharina C.M. Schuiling‐Veninga2; Eelko Hak2
1University of Groningen, University Medical Center Groningen,
Groningen, Netherlands; 2University of Groningen, Groningen,
Netherlands
Background: Polypharmacy is becoming increasingly common in the
elderly, but there is limited information about the trends in other age
groups.
Objectives: We investigated the trends in polypharmacy and underly-
ing drug groups among adults in the Netherlands from 1999 to 2014
stratified by age, and compared these with findings from the United
States (US).
Methods: This was a repeated cross‐sectional study using the Dutch
IADB.nl prescription database. All patients aged 20 years and older
in the period 1999 to 2014 were included. Polypharmacy prevalence
was the primary outcome, which was defined as the dispensing of five
or more chronic drugs at the pharmacological subgroup level during
the last quarter of each year. Secondary outcomes included the prev-
alence ratios (i.e. relative changes over time), and the prevalence of
the top 20 dispensed drug groups at therapeutic level. Chi‐square
tests were applied to calculate the p‐value for trends. Changes in
prevalences were compared between the Netherlands and the US.
Results: The overall prevalence of polypharmacy increased from 3.1%
to 8.0% (p‐value for trend <0.001) over 15 years, and increased in all
age groups. The highest prevalences were observed in patients aged
65 years and older, but the relative increase over time was higher in
the younger age groups (prevalence ratio 2.5 versus 2.1 in the elderly).
At drug group level, large increases were observed for angiotensin‐II
inhibitors (from 2.25% to 5.41%), statins (from 1.52% to 4.74%) and
proton‐pump inhibitors (2.55% to 6.01%). The relative increase in
polypharmacy was larger in the Netherlands than in the US (preva-
lence ratio 2.4 versus 1.8). The Netherlands showed larger relative
increases for angiotensin‐II inhibitors, statins, proton‐pump inhibitors,
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biguanides, and smaller relative increases for antidepressants, benzo-
diazepines and insulins.
Conclusions: Polypharmacy more than doubled from 1999 to 2014,
and this increase was not limited to the elderly. The relative increase
was larger in the Netherlands compared to the US, which was partly
due to larger increases in several guideline‐recommended preventive
drugs.
1105 | Polypharmacy risk among five‐year
cancer survivors
Christine D. Hsu; Jennifer L. Lund; Hazel Nichols
University of North Carolina, Chapel Hill, NC
Background: Cancer survivors are increasing in the United States.
Survivors often face cancer sequelae and side effects from treat-
ment, which can arise during treatment or even months or years
later. Survivors may therefore experience greater medication burden
than the general population, increasing concerns for polypharmacy
and risk of drug interactions and non‐adherence.
Objectives: To characterize prevalence of polypharmacy by cancer
history in a nationally‐representative sample of U.S. adults.
Methods: Using National Health and Nutrition Examination Survey
(NHANES) data from 2003–2014, we identified 32,330 individuals
20 years or older, 1,672 of whom had been diagnosed with cancer
(excluding non‐melanoma skin) at least five years before the survey.
The association between cancer history and polypharmacy (5+ med-
ications) was examined using Poisson regression models to calculate
multivariable risk ratio (RRs) and 95% confidence intervals (CIs),
adjusted for education, ethnicity, marital status, and age at survey.
Results: Among five‐year cancer survivors, 35% had a diagnosis
within 5–9 years of the survey year, 26% within 10–14 years, 13%
within 15–19 years, and 26% had a diagnosis 20 or more years
before the survey year. Breast cancer was the most common type
of cancer (23%), followed by cervical cancer (18%), prostate cancer
(12%), and colon cancer (7%). Prevalence of polypharmacy was
higher in cancer survivors (33.6%; 95% CI: 30.7–36.6%) than in
those with no cancer history (13.0%, 95% CI: 12.4–13.7%) (RR:
1.32, 95% CI: 1.20, 1.45). Polypharmacy prevalence differed by age
group (4.83% in 20–39 year olds; 40.37% in 40–64 year olds;
54.8% in 65 years and older), and within each age group, risk of
polypharmacy was higher in cancer survivors than in those with no
cancer history, with the most pronounced difference in cancer survi-
vors 20–39 years old (RR: 2.93, 95% CI: 1.69–5.09), followed by 40–
64 year olds (RR: 1.52, 95% CI 1.27–1.83) and those 65 years and
older (RR: 1.17, 95% CI: 1.07–1.29).
Conclusions: Cancer survivors are more likely to experience
polypharmacy burden than those with no cancer history. Findings
from this study can increase awareness about the unique challenges
cancer survivors face and encourage medication reconciliation
services.
1106 | Variation in Belgian polypharmacy:
Trends 2013–2016
Victoria A. Fuchs1; Gabriela Boyle2; Nina Kouevi‐Gath1;
Carine De Vriese3; Fati Kirakoya‐Samadoulougou1
1Ecole de Santé Publique, Université Libre de Bruxelles, Bruxelles,
Belgium; 2King County Public Health Department, Seattle, WA; 3Faculté
de Pharmacie, Université Libre de Bruxelles, Bruxelles, Belgium
Background: Increased drug consumption has implications for both
individual health as well as for public health. No comprehensive study
of drug consumption has been conducted for the entire Belgian
population.
Objectives: This study assesses the prevalence of polypharmacy in the
Belgian population by age, sex and district for four consecutive years
between 2013 and 2016.
Methods: The data concerned the entire Belgian population and
were obtained from the Belgian national institute of health insur-
ance. Polypharmacy was defined as the dispensation of at least 5
prescribed and reimbursed drugs over a 3‐month period. Excessive
polypharmacy is at the same for at least 10 drugs dispensed. For
comparison between districts, prevalence for both polypharmacy
and excessive polypharmacy were standardized by age and sex, for
each year. For yearly comparisons, prevalence was standardized tak-
ing the population structure of 2013 as a reference.
Results: The crude national prevalence of polypharmacy in 2013 was
11.0% (95% confidence interval (CI): 10.9–11.0): 12.7% (95%CI:
12,6‐12,7) for women and 9.2% (95%CI: 9.1–9.2) for men. The prev-
alence of excessive polypharmacy was 1.33% (95%CI: 1.32–1.34):
1.57% (95%CI: 1.55–1.59) for women and 1.08% (95%CI: 1.06–
1.10) for men. In 2016, the crude prevalence of polypharmacy was
11.1% (95%CI: 11.1–11.2): 12.8% (95%CI: 12.7–12.8) for women
and 9.45% (95%CI: 9.40–9.50) for men. The prevalence of excessive
polymedication was 1.36% (95%CI: 1.35–1.38): 1.63% (95%CI: 1.61–
1.65) for women and 1.09% (95%CI: 1.07–1.11) for men. In terms of
relative variation in the prevalence of polypharmacy, Nivelles
recorded the largest decline between 2013 and 2016 with −3.84%,
going from 10.8% (95%CI: 10.7–10.9) to 10.4% (95%CI: 10.3–
10.4). Arlon had the largest increase with +4.44% from 10.6%
(95%CI: 10.3–10.9) to 11.1% (95%CI: 10.8–11.4). For excessive
polypharmacy, the greatest relative variation between 2013 and
2016 was also found in Arlon with +9.89% going from 1.19%
(95%CI: 1.09–1.30) to 1.31% (95%%CI: 1.20–1.42). The largest
decline was recorded in Turnhout with −7.84% going from 1.37%
(95%CI: 1.33–1.40) to 1.26% (95%CI: 1.23–1.29). In general, the
lowest prevalence of polypharmacy was observed in Flanders and
the highest in Wallonia. In 4 years, 28 of 43 districts registered a
decline in prevalence, the majority of which are in Flanders.
Conclusions: Overall polypharmacy is on the decline across study
years, although some districts in Belgium experienced a rise in preva-
lence. Wallonia and Flanders differ in polypharmacy prevalence;
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however, more studies are needed to understand the variables associ-
ated with this difference.
1107 | Comparing prescribing practices of
primary care providers using formulary
selectivity index, as one measure of
conservative prescribing
Tewodros Eguale1,2; Ismaeel Yunusa1,2; Ihtisham Sultan1,2; Lynn Volk2;
Diana Norwich2; Maria Mirica2; William Galanter3; Bruce Lambert4;
Gordon Schiff2,5
1MCPHS University, Boston, MA; 2Brigham Women's Hospital, Boston,
MA; 3University of Illinois at Chicago, Chicago, IL; 4Northwestern
University Feinberg School of Medicine, Chicago, IL; 5Harvard Medical
School, Boston, MA
Background: Rational prescribing, as advocated by the WHO, limits
the use of drugs within a therapeutic class. The use of only a few
drugs and learning how to use them judiciously is an essential principle
of conservative prescribing. Formulary Selectivity Index (FSI) is a mea-
sure of the dispersion and skewness of drug choices that can be used
to determine the extent of compliance with this practice.
Objectives: To determine the extent to which primary care providers
(PCPs) restrict the number of agents they prescribe within a drug class
comparing two academic medical centers descriptively.
Methods: We retrieved new prescription data from the electronic
health records of a pilot sample of 23 PCPs at Brigham and Women's
Hospital (BWH, Boston, MA) and 83 at the University of Illinois Hos-
pital and Health Sciences System (UIC, Chicago, IL). Using the FSI,
we assessed prescribing patterns from 1/1/2016 to12/31/2017 for
12 classes of drugs (statins, antihypertensives, opioids, antidiabetics,
antidepressants, gastrointestinal agents, antibiotics, anticoagulants,
hormones, nonsteroidal anti‐inflammatory drugs [NSAIDs], corticoste-
roids, and antivirals). We calculated the FSI as the Gini‐coefficient,
which is a number between 0 and 1, where 0 is equal prescribing of
each analog (no selectivity) and 1 is the prescribing of only one analog
(perfect selectivity). The Gini‐coefficient is the area between the
actual Lorenz curve for a drug class and the diagonal line for a drug
with complete equality.
Results: PCPs at BWH were more selective than those at UIC in pre-
scribing statins (FSI: BWH 0.61 vs. UIC 0.58), GI drugs (0.54 vs. 0.30)
and anticoagulants (0.26 vs. 0.25). PCPs at UIC were more selective
than those at BWH in prescribing opioids (FSI: UIC 0.62 vs. BWH
0.44), antidepressants (0.39 vs. 0.30), antibiotics (0.35 vs. 0.27), antivi-
rals (0.44 vs. 0.40), antihypertensives (0.22 vs. 0.15), and corticoste-
roids (0.73 vs. 0.62), NSAIDs (0.53 vs. 0.47), antidiabetics (0.52 vs.
0.47), and hormones (0.46 vs. 0.34). Of the opioid prescriptions, oxy-
codone and hydrocodone accounted for 29.7% and 3.5% in BWH,
and 2.1% and 32.2% in UIC, respectively. In addition, rosuvastatin
accounted for 11.3% and 3.6% of statin prescriptions in BWH and
UIC, respectively.
Conclusions: The findings show differences in prescribing among
PCPs at both sites, with more selective use within classes of opioids,
GI drugs, and corticosteroids than other commonly prescribed drugs.
There is a need to expand the analyses to larger sample of PCP to
make statistical inference.
1108 | Trends in inappropriate outpatient
antibiotic use in the United States
Mahek Garg; Haesuk Park
University of Florida, Gainesville, FL
Background: In the United States (U.S.), the National Action Plan for
Combating Antibiotic‐Resistant Bacteria has set a goal for reducing
inappropriate outpatient antibiotic use to 15% by 2020.
Objectives: To investigate recent trends in the appropriateness of
oral outpatient antibiotic prescriptions from 2010 to 2017 among a
privately insured U.S. population.
Methods: A cross‐sectional analysis using Truven Health MarketScan
database (January 2010–December 2017) was conducted for
patients who received at least one oral antibiotic prescription for
each calendar year. We included patients who had pharmacy benefit
coverage and were continuously insured for all 12 months each year.
For each antibiotic prescription fill, all diagnosis codes in medical
claims during a 7‐day lookback period were used to classify the
appropriateness of antibiotic prescribing based on a previously pub-
lished scheme. The outcomes included mean antibiotic prescriptions
per patient and proportion of fills in one of three mutually exclusive
categories: ‘appropriate’, ‘potentially appropriate’, or ‘inappropriate’
during the study periods. In addition, three most commonly used
antibiotics were assessed among the inappropriate fills for the year
2017.
Results: Approximately 11 and 7 million unique patients filled at
least one oral antibiotic prescription in 2010 and 2017, respectively.
The mean age of the patients ranged from 33.1 (±19.3) to 34.2
(±19.3) years with 40% to 41% males, and 43.1% to 50.7% from
the south. The mean number of new antibiotic prescriptions
remained at 2 new fills per patient between 2010 and 2017. During
the study periods, the proportion of appropriate (from 9.4% in 2010
to 12.5% in 2017) and potentially appropriate prescriptions
increased (from 37.6% in 2010 to 41.3% in 2017), respectively.
The proportion of inappropriate prescriptions decreased from
24.3% in 2010 to 20.8% in 2017. However, 37% of individuals
who filled antibiotics had at least one inappropriate antibiotic pre-
scription in 2017. Of these inappropriate fills, azithromycin (25.3%),
amoxicillin (12.6%), and cephalexin (7.1%) were the three most com-
monly prescribed antibiotics.
Conclusions: The rate of oral antibiotic utilization and proportion of
inappropriate prescriptions decreased from 2010 to 2017 in the U.S.
However, one in three privately insured individuals still filled at least
one inappropriate antibiotic prescription in 2017.
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1109 | A new tool to evaluate and promote
rational use of pharmacotherapy available to
all Danish general practitioners
Ulrik Hesse; Katrine Agergaard; Ghousia Javid;
Pernille Juul Kristensen; Maja Laursen
The Danish Health Data Authority, Copenhagen, Denmark
Background: Since 2003, the Danish Medicines Agency has provided
general practitioners (GP) with a tool to assist the GP in monitoring
own prescription pattern. The agreement between the GP organization
and the Danish health authorities has since 2016 included accreditation
of the GP. Knowledge of own prescription pattern is a part of the
accreditation. The focus has been to promote prescription of cost‐
effective drugs and reducing adverse drug reactions.
Objectives: By giving the GP an applicable overview of their prescrip-
tion pattern, the new tool makes it possible to identify and define qual-
ity indicators and track development in prescription pattern over time.
Thereby, the tool can assists theGPwith quality improvement and deci-
sion. The purpose of the tool was to give the GP a possibility to enhance
rational use of pharmacotherapy.
Methods: In Denmark, we have the opportunity to combine registries
for a whole population. In the new tool developed by the Danish Health
Data Authority in collaboration with the Danish GP's organization, we
have combined data from the Danish heath care databases (The
National Health Insurance Service Registry) with information on drug
use (Register of Medicinal Product Statistics). We have combined the
registries using the social security number and the GP number. Drug
groupings are developed according to disease specific treatment (e.g.
analgesics), treatment recommendation lists (e.g. narrow‐ vs. broad‐
spectrum antibiotics) and health care indicators (e.g. abusable drugs).
GPwill have access to the tool as an online databasewith a digital signa-
ture obligatory to all Danish companies. Data are presented with the
visualization software, Qlik®.
Results: Themes for the prescription of the following drug groupings
have been developed: psychotropic and analgesics, and antibiotics.
The GPs can compare themselves with clusters of GPs as well as
national levels. We are expecting to go live May 2019.
Conclusions: The new tool will make recommendation lists easier to
apply for the GPs. The GP will have easy access to prescription pattern
and thereby have an increased interest in reducing medicinal costs,
reducing use of certain drugs and promoting rational use of
pharmacotherapy.
1110 | Which part of unplanned hospital
readmissions within 30 days of discharge is
medication related and potentially
preventable?
Elien Uitvlugt1; Marjo Janssen1; Eva Kneepkens1; Bart van den Bemt2;
Patricia van den Bemt3; Fatma Karapinar1
1OLVG, Amsterdam, Netherlands; 2Sint Maartenskliniek, Nijmegen,
Netherlands; 3Erasmus University Medical Centre, Rotterdam,
Netherlands
Background: Hospital readmissions pose a major burden on
patients and healthcare systems but little is known about medica-
tion related hospital readmissions.
Objectives: Primary aim: to identify the percentage and prevent-
ability of unplanned readmissions ≤30 days of discharge due to
medication related problems. Secondary aims: to assess which
types of medication were responsible for potentially preventable
readmissions and potential causes of these readmissions.
Methods: A cross‐sectional observational study was performed in
the OLVG hospital, Amsterdam, the Netherlands, at the depart-
ments of internal medicine, pulmonology, cardiology, gastroenterol-
ogy, surgery, neurology and psychiatry. Inclusion criteria were:
patients (≥18 years) with a 30‐day unplanned hospital readmission
after discharge from one of the participating departments (i.e.
index admission). Exclusion criteria were: self‐discharge, transfer
to another hospital, (re)admitted due to intentional overdose or
drugs of abuse, multiple readmissions (≥2), index and readmission
are unrelated (e.g. index admission with pneumonia followed by
a readmission due to a car accident). Residents of all participating
departments and a pharmacist reviewed files of readmitted
patients. During multidisciplinary meetings potentially preventable
cases were discussed and consensus was reached. Percentage of
readmissions that were medication related, and potential prevent-
ability were assessed. For potentially preventable readmissions
types of medication responsible for the readmission and potential
causes were assessed. Potential causes were categorized into three
categories: problems due to transitions in care, prescribing and
adherence.
Results: 426 readmissions were included. Nineteen percent was
medication related and of these, 38% was potentially preventable.
Most common types of medication responsible for potentially pre-
ventable readmissions were: diuretics (20%), drugs used in diabetes
(17%) and cardiac therapy/beta blocking agents (13%). Potential
causes of these readmissions were problems due to prescribing
(43%), transitions in care (23%), and adherence (33%).
Conclusions: Thirty‐eight percent of medication related
readmissions is potentially preventable. Problems with prescribing,
transitions in care and adherence might be good starting points
for implementing interventions to reduce medication related
readmissions.
1111 | Appropriateness of otic quinolone
use among privately insured patients in the
United States
Phuong T. Tran1; Kiyon Rhew1; Xi Wang1; Almut G. Winterstein1;
Patrick J. Antonelli2
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1University of Florida College of Pharmacy, Gainesville, FL; 2University of
Florida College of Medicine, Gainesville, FL
Background: Otic quinolones have been linked to the development of
permanent tympanic membrane perforations, raising concern about
their use for conditions in which they have no proven benefit.
Objectives: To assess the extent of otic quinolone use for questionable
indications.
Methods: This cross‐sectional analysis included children and adults
with outpatient pharmacy claims for new prescriptions of otic or oph-
thalmic (OP) quinolones in Truven MarketScan 2017. Quinolones
included ofloxacin and ciprofloxacin, alone or in combination with dexa-
methasone, hydrocortisone, or fluocinolone. Indicationwas classified as
appropriate, questionable or undetermined by a senior otologist. We
considered each dispensing ≥30 days apart as a unique episode and
ascertained diagnoses from outpatient encounters within +/− 3 days
of dispensing. We excluded OP claims with eye‐related diagnoses
within +/− 30 days or within +/− 30 days from otic quinolone claims.
Results: We found 214,897 quinolone claims in 200,270 patients.
Questionable ear indications were found in 4.5%, appropriate ear indi-
cations in 72.5%, and undetermined in 23.0% in the 3‐day window.
OP quinolones were used in 16% of appropriate and questionable otic
episodes. Adults were twice as likely to have otic treatment with ques-
tionable indications (6.2% vs 3.0%). Sensitivity analyses with broader
time windows to ascertain diagnoses decreased the proportion of epi-
sodes with no ear indication but had similar distributions of appropriate
vs questionable otic use. Otalgia and cerumen impaction constituted
85% of claims with questionable indications.
Conclusions: Considering demonstrated risk for permanent tympanic
membrane perforations, opportunities exist to decrease otic quinolone
use, especially in adults.
1112 | Self‐medication practices in rural
communities, Alexandria, Egypt: Prevalence,
perception and attitude
Hala Shokr1; Mohamed Mekkawy2; Ola Fahmy2
1Aston University, Birmingham, UK; 2High Institute for Public Health,
Alexandria, Egypt
Background: Self‐medication is the use of a medicinal product to man-
age undiagnosed illness, it is one of the most serious public health
problems nowadays specially in developing countries. It involves
obtaining medications without having a prescription, using old pre-
scriptions to obtain drugs, sharing medicines with one's social circle.
Objectives: To assess the prevalence of self‐ medication practices
among rural population of Alexandria, Egypt and the reasons contrib-
uting to this practice.
Methods: A cross‐sectional study was conducted to determine the
prevalence and extent of self‐medication knowledge, attitudes, and
practices in pharmacy purchasers from January 2018 to September
2018. Data analysis was done using the Statistical Package for Social
Sciences (SPSS). Results obtained were expressed in counts and pro-
portions. Chi‐square (χ2) and Monte Carlo tests were used to com-
pare between groups. Qualitative data were described as numbers
and percentages. A p value of less than 0.05 was considered to be
statistically significant. Predictors of self‐medications was deter-
mined by Logistic regression analysis. The total percentage of some
questions is not always 100% as some of the questions had multiple
options to choose from.
Results: The prevalence of self‐medication among the study partici-
pants was 77.4% with highest prevalence among the middle age
group (15–45 years). A larger number of females were self‐medicat-
ing (78.3%) than males (65.5%). Level of education did not affect the
prevalence of self‐medication (p = 0.087) but medical education was
independently associated with increase the likelihood of self‐medica-
tion (p < 0.001). Analgesics and antipyretics are the most commonly
used groups of drugs in self‐medication and considering their illness
minor for consultation is the main reason behind this practice in 85%
of the study population. Almost 42% of the participants see self‐
medication as a self‐care practice that should be encouraged.
Conclusions: The very high prevalence of self‐medication in this
study is a cause of concern. General population should be enlight-
ened about the consequences of self‐medication, and the risks asso-
ciated with it. Strict rules should be introduced to forbid the supply
of drugs without prescription. The role of socioeconomics and stan-
dard of living and its effect on self‐medication practice need to be
explored in future studies.
1113 | Disparities in all‐cause mortality with
potentially inappropriate medication use:
Analysis of the REasons for Geographic And
Racial Differences in Stroke Study
Md Motiur Rahman1; George Howard2; Jingjing Qian1;
Kimberly Garza1; Ash Abebe3; Richard Hansen1
1Auburn University Harrison School of Pharmacy, Auburn, AL; 2Ryals
School of Public Health, University of Alabama at Birmingham,
Birmingham, AL; 3Auburn University, Auburn, AL
Background: Prior work has identified disparities in the quality and
outcomes of healthcare across socioeconomic subgroups. Mortality
with inappropriate medication use may be subject to similar
disparities.
Objectives: To assess the association between inappropriate medica-
tion use and all‐cause mortality and the effect of disparity parameters
(gender, age, race, income, education, and rural or urban areas) on this
relationship.
Methods: The analyses included 26,399 black and white US adults
aged ≥45 years from the REasons for Geographic And Racial Differ-
ences in Stroke (REGARDS) study, of which 13,475 participants were
of age ≥ 65 years (recruited 2003–2007). The appropriateness of
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medication use was measured at baseline by the presence of drug–
drug interactions (DDIs) and the use of potentially inappropriate med-
ications (PIMs) in older adults. Cox proportional hazards time‐to‐event
analysis followed the participants until their death (all‐cause) on or
before March 31, 2016, iteratively adjusting for disparity parameters
and other covariates. Sensitivity analysis by stratifying censored fol-
low‐up time intervals intended to seek the predictive capability of
baseline PIM use to assess mortality. The full models included interac-
tion terms between PIM/DDI use and other covariates.
Results: Approximately 87% of the participants aged ≥65 years used
at least one drug listed in the Beers criteria, and 3.8% of all partici-
pants used two or more drugs with DDIs. The fully adjusted model,
censored at all years, found that among whites, PIM use increased
the risk of all‐cause mortality (hazard ratio [HR] = 1.27, 95% CI
1.10–1.47). DDIs were found to increase the risk of mortality only
among females in the fully adjusted model censored at 2 years
(HR = 1.77, 95% CI 1.11–2.80). Higher medication use was a signifi-
cant predictor of mortality across all the fully adjusted models
(P < 0.01).
Conclusions: In the fully adjusted models, PIM use was associated
with a higher risk of mortal events. No significant disparities were
observed across the relationship between PIM use and mortality.
1114 | Antidepressants use and persistence
in Tuscany: A large regional drug‐utilization
study
Ippazio Cosimo Antonazzo1,2; Giuseppe Roberto2; Elisabetta Poluzzi1;
Rosa Gini2
1University of Bologna, Bologna, Italy; 2Agenzia Regionale di Sanità della
Toscana, Florence, Italy
Background: Among all the Italian regions, Tuscany consistently
showed the highest prevalence of AD utilization. Possible inappropri-
ateness of use is therefore a concern. A treatment shorter than
6 months is not effective for depression (DEP), the principal indication
for AD.
Objectives: To analyze the utilization of antidepressants in Tuscany
both in terms of baseline characteristics and in terms of pattern of
utilization.
Methods: We used the healthcare administrative databases of Tus-
cany. We selected new users of ADs during 2014 with no previous
use reported since 2011 and with at least 3 years of follow‐up into
the database. Demographic characteristics were collected at the index
date (ID), and comorbidities were evaluated in the previous period up
to 2 months after ID. During the follow‐up, presence and persistence
(i.e., no gap ≥60 days between dispensations) of ADs were assessed in
time windows of 6 months.
Results: In Tuscany, 89,509 individuals claimed at least 1 dispensation
of AD in 2014. The majority were females (65%), aged ≥45 years old
(76%), with cancer (17%) and diabetes (9%). The index AD was most
commonly a SSRI (69%). During the first 6 months, 39,504 individuals
(36%) had only 1 dispensation. However, in latter subpopulation new
dispensations were registered during the second semester (13%) and
the second year of follow‐up (25%). Moreover, 22,688 individuals
(25% of new users) had at least a treatment gap during the first
6 months. Finally, 27,313 patients (31%) were persistent in the first
6 months. Notably, 14,126 (51%) of them were persistent also in the
first year and 7,064 (26%) during the second year. The occurrence of
AD dispensations during the third year paralleled the persistence in
the previous years: from 16% among those who had only one dispen-
sation in the first 6 months, up to 92% of those who were persistent
during the entire period.
Conclusions: Only a minority of new AD users were persistent to the
treatment in the first semester. This could indicate a suboptimal use of
the drug in patients with DEP, or an over‐prescription for other indica-
tions (e.g., neuropathic pain). Future studies will address possible inap-
propriateness of ADs use inTuscany by comparing detailed patterns of
utilization with other Italian regions.
1115 | Prevalence of polypharmacy in Japan
Hiraku Kumamaru1; Nobutomo Matsui2; Kohta Sakuma2;
William Y.H. Kuan2; Hiroaki Miyata3
1University of Tokyo, Tokyo, Japan; 2 IQVIA Solutions Japan K.K, Tokyo,
Japan; 3Keio University Medical School, Tokyo, Japan
Background: Polypharmacy in elderly population has been associated
with adverse health outcomes including mortality, falls, adverse drug
reactions, as well as increased healthcare costs. Japanese government
is developing guidelines and policy interventions in the aim of reduc-
ing polypharmacy in the elderly.
Objectives: To assess the prevalence of polypharmacy in Japan across
different age groups.
Methods: We utilized IQVIA National Prescription Audit database
which is a dispensing claims database obtained form approximately
7500 out‐of‐hospital pharmacies throughout Japan, capturing approx-
imately 15% of all prescriptions. We included all patients with at lease
one record of drug prescription in the database between January and
March 2018. For each patient, we sampled 1 prescription that was dis-
pensed at a most recent date on record. We counted the number of
medications prescribed simultaneously in that prescription, and sum-
marized the number across the patients, by age groups of 0–14, 15–
64, 65–74 and 75 and above. We also assessed the therapeutic areas
of the medications that were most frequently prescribed for prescrip-
tions with 5 or more simultaneous medications.
Results: We identified 19,428,735 patients in the database; 16.1%
aged 0–14, 50.6% aged 15–64, 15.0% aged 65–74 and 18.2% aged
75 and above. In total, the median number of simultaneous drug pre-
scription was 3, with 25 and 75 percentiles as 2 and 4, respectively.
The percentage of patients with simultaneous prescription of 5 or
more drugs increased with age (20.7% for 0–14 y.o., 22.9% for 15–
64 y.o., 24.6% for 65–74 y.o, and 33.2% for 75 y.o. and above). The
age difference was more enhanced for prescriptions with 10 or more
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drugs: (0.6% for 0–14 y.o., 2.3% for 15–64 y.o., 4.1% for 65–74 y.o,
and 8.7% for 75 y.o. and above). While the most frequently prescribed
drug areas for prescriptions with 5 or more drugs were alimentary
tract and metabolism, cardiovascular system, and masculo‐skeletal
system drugs for those 65 and above, they were respiratory system,
systemic anti‐infectives, and cardiovascular system drugs for 0–14 y.
o. and 15–64 y.o.
Conclusions: Polypharmacy increased with age in the studied Japa-
nese population, especially evident for prescriptions for 10 or more
simultaneous medications. Prescriptions of 5 or more medications
were fairly common in younger patients below 65 y.o. Evaluation of
therapeutic area and its duration are important factors for assessing
potential adverse effects of polypharmacy.
1116 | Medication errors associated with the
use of antibiotics in critical care units
Ramesh Madhan; Awhamefule Urechi; Chalasani Sri Harsha
JSS College of Pharmacy, Mysuru, India
Background: Iatrogenesis is an inevitable reality under the current
complex healthcare framework. Medication errors (ME) jeopardizes
patient safety. It is important to understand how often and why these
errors are occurring and contributing factors. It is essential to reduce
their occurrence in the limited resources scenario. Further, safer use
of antibiotics will not only reduce the burden of antibiotic resistance,
but also limits the patient from unnecessary exposures to the adverse
effects.
Objectives: To determine the incidence, and nature of medication
errors associated with the use of antibiotics in the critical care units.
Methods: A descriptive cross‐sectional study was conducted in inpa-
tients of either gender, aged more 18 years who were admitted to crit-
ical care unit for more than 24 hours. All the required data were
collected and documented. All the diagnoses and antibiotics were
coded according to the International Classification of Disease 10
(ICD 10) and Anatomical Therapeutic Classification (ATC) codes
respectively. Each prescription was subjected for review to identify
the Medication errors associated with use of antibiotics.
Results: Of the 1162 antibiotic doses prescribed for 500 patients, 36
(7.2%) patients were presented with medication errors. A total of 47
medication errors were detected. The average number of medication
error was 1.31 errors/patient. Administration errors accounted for
21 (44%) MEs. Distractions [23 (48%)] and interruptions [16 (34%)]
were the major contributing factors for these errors. A total of 14
individual antibiotics, under 4 different classes were implicated in
the errors and Ceftriaxone (28%) was widely implicated. Most [27
(57%)] of the errors belonged to the category C as per the NCC
MERP index.
Conclusions: The use of antibiotics was found to be high in the Inten-
sive Care Unit. Of the total reported medication errors, Ceftriaxone
was most commonly implicated. Clinical pharmacist plays an important
role in the detection and management of MEs.
1117 | Distribution and storage of
medications in households from Mexico City
Ramiro Sánchez‐Huesca1,2; Vanessa S. Mejía‐Esquivel3
1Universidad Panamericana, Mexico City, Mexico; 2CEBECI Farmacología
Clínica, S.C, Mexico City, Mexico; 3CEBECI Farmacología Clínica, S.C,
Mexico City, Mexico
Background: Household storage of medications represent a latent
risk for irrational use that may lead to the presence of adverse drug
reactions and incorrect dosage to patients. The potential negative
effects increase when expired medications are stored.
Objectives: (1) To describe the distribution of medications in house-
holds from Mexico City and (2) to determine the prevalence of
expired medications in household storage.
Methods: A community based descriptive, cross‐sectional, retrospec-
tive and observational study was conducted during 2018 in Mexico
City. A sample of 229 households were randomly selected and a
standardized questionnaire was applied by face‐to‐face interview to
an adult family member. Name of medications and expire date were
recorded. Medications were classified according to their ATC class
and expiration date was dichotomized as expired or not expired at
the moment of data retrieval. Qualitative variables were described
using absolute and relative frequencies or median and range accord-
ingly. Categorical variables were compared using Chi‐square tests
using as statistical significance of p = 0.05.
Results: A total of 2,384 medications of 34 pharmacological groups
were stored in Mexican households, the median of medications per
household was 10 with a wide range of 04–42 medications within
the whole sample. There was statistical difference (p < 0.001) among
the most prevalent therapeutic classes including NSAIDs/analgesics
643(27%), cardiovascular 548(23%), respiratory 452(19%), antibiotics
286(12%) and metabolics 190(8%). The most frequent drug was
paracetamol 211(8.8%), this drug was either alone or in combination.
Regarding the characteristics of the stored medications in Mexican
households, the most prevalent were: oral administration route
2014(84.4%), tablets 1247(52.3%) and generic medications
1786(74.9%). The prevalence of expired medications was 34.8%.
Conclusions: Pain relievers and antihypertensives were the most fre-
quent medications in household storage in Mexico City. Mexican
households storage include in average one third of expiredmedications.
1118 | Insights of the health care work force
on establishing a medication error reporting
system in a tertiary care teaching hospital: A
survey questionnaire
Chalasani Sri Harsha1; Madhan Ramesh2
1 JSS College of Pharmacy, Mysuru, India; 2 JSS College of Pharmacy,
Mysuru, India
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Background: Iatrogenesis is an inevitable reality under the current
complex healthcare framework. Medication errors (ME) jeopardizes
patient safety. It is essential to reduce their occurrence and thereby
over all associated health care costs in the limited resources
scenario.
Objectives: To determine the perceptions of Health care profes-
sionals towards establishing a medication error reporting programme.
Methods: A questionnaire was designed, validated and circulated
among the health care professionals of a tertiary care teaching hos-
pital by clinical pharmacists to understand their perception on Med-
ication Error Reporting System.
Results: A total of 622 HCPs were approached with this question-
naire. Of which 535 HCPs, i.e., 376 (70.2%) Nursing staff, 32
(5.9%) Interns, 78 (14.5%) Post‐graduation students in various disci-
plines of Hospital, 49 (9.1%) Doctors had responded to the survey
with an overall response rate of 86%. General awareness of exis-
tence of Medication Error/ Error Reporting Centre was observed in
51.5% of doctors and 61.9% of nurses among whom 18.2% of doc-
tors and 44.4% of nurses only were aware of existence of Medica-
tion Error/Error Reporting Centre in India. During their practice,
72.3% of doctors and 5.5% of nurses have reported at least one
medication error and 81.7% of doctors and 83.5% of nurses wel-
comed Medication Error Reporting and Monitoring system at their
practice site. Further, the importance of clinical Pharmacist for inde-
pendent assessment of medication error was appreciated by 22.8%
of doctors and 64% of nurses. Medication Error Reporting and Mon-
itoring Centres' role for Health Care Professionals in medication
safety was accepted by 18.5% of doctors and 57.3% of nurses. Pref-
erence towards electronic reporting of medication error was shown
by 26.5% of doctors and 16.2% of nurses. The willingness to report
the medication errors to the Medication Error Reporting and Moni-
toring system if made available at their practice site is observed in
62.2% of doctors and 81.6% of nurses.
Conclusions: The senior workforce entourages the concept of man-
datory reporting with the identity of personnel involved in the error
while the newer staff wishes to opt the anonymous reporting of
medication errors. This has led to the initiation of several dialogs
between clinical pharmacists and other health care professionals to
understand further about their perceptions of reporting medication
errors and thereof to enhance the acceptance of medication error
reporting system.
1119 | Polypharmacy and associated factors
in primary healthcare users of the unified
health system in Minas Gerais state, Brazil
Thais A. Moreira1; Juliana A. Teodoro2; Mariana M. Barbosa1;
Renata C.R.M. Nascimento3; Augusto A. Guerra‐Júnior2;
Francisco A. Acurcio2
1Federal University of Minas Gerais, Belo Horizonte, Brazil; 2Federal
University of Minas Gerais, Belo Horizonte, Brazil; 3Federal University of
Ouro Preto, Ouro Preto, Brazil
Background: Despite representing a growing challenge in primary
healthcare and health services, few studies have analyzed
polypharmacy among the general population, in public health
services.
Objectives: This study aimed to characterize polypharmacy and its
associated factors in medicine users of primary healthcare of the
Unified Health System (SUS) in the state of Minas Gerais, Brazil,
2014–2015.
Methods: A cross‐sectional study with a representative sample of
users aged 18 years and older. These medicine users were stratified
according to the number of medicines used, the difference between
the groups being evaluated by the Pearson chi‐square test. Logistic
regression model (p < 0.05) was used to investigate factors associated
with polypharmacy (use of five or more medicines). The Hosmer‐
Lemeshow test was used to evaluate the fit quality of the model.
Results: The prevalence of polypharmacy among medicines users was
13.7% in the general population and 33.3% in the elderly population (≥
65 years). There was a positive association between polypharmacy and
the 45–64 years group (OR = 2.02, 95% CI: 1.03–3.94) and ≥ 65 years
group(OR=4.17,95%CI:1.92–9,17), inadditiontothefollowingchronic
diseases: stroke (OR = 4.20, 95% CI: 1.53–11.55); diabetes mellitus
(OR = 4.03; 95% CI: 2.43–6.68); heart diseases (OR = 3.18; 95% CI:
1.92–5.29); depression (OR = 2.85; 95% CI: 1.80–4.53); hypertension
(OR = 2.13; 95%CI: 1.17–3.86); dyslipidemia (OR = 1.73, 95%CI: 1.07–
2.80). Marital status (married/common‐law marriage) was inversely
associated with polypharmacy (OR = 0.34, 95%CI: 0.19–0.62).
Conclusions: A significant number of adults and elderly, using medi-
cines, primary care users of SUS, in Brazil, were exposed to
polypharmacy and some associated factors are relevant, such as spe-
cific morbidities and age. The multiple drug combination should be
judicious and evidence‐based, as it increases the risk of harm that
may outweigh the therapeutic benefit.
1120 | Reasons for self‐medication with
antibiotics among people with secondary
education or higher in Hyderabad, India: A
cross‐sectional study
Mansour Mahmoud1; Wajid Syed2; Mohammed Al‐Arifi2;
Fawiziah Al‐mana2; Atta Naqvi2
1Taibah University, Medinah, Saudi Arabia; 2King Saud University,
Riyadh, Saudi Arabia
Background: The use of prescription and non‐prescription medications
to treat self‐diagnosed illnesses without consulting a medical practi-
tioner refers to self‐medication. Antibiotics are commonly purchased
without prescription inmany developing countries and some developed
countries. Self‐medication with antibiotics is associated with an
increased risk of adverse drug reactions and antibiotics resistance.
Objectives: The study aim was to investigate self‐medication with
antibiotics among people with secondary education or higher in
Hyderabad city, India.
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Methods: Design: A cross sectional community based online survey
was conducted in the capital of Telangana state Hyderabad, from
March 2018 to June 2018. Setting: The survey was prepared in a Goo-
gle form and the link was distributed to the public through social
media (WhatsApp© and Facebook©). Study instrument: A structured
self‐administered questionnaire was developed based on extensive
review of similar studies worldwide. Validity of the study instrument
was determined by experts in the field and a pilot study was con-
ducted on randomly selected persons to ensure the easiness and read-
ability of the questionnaire. Based on the results of the pilot study, the
final version of the survey was modified. Main outcome measure: The
main study outcome was the underline reasons for self‐medication
with antibiotics. Statistical Analysis: Descriptive statistics were uti-
lized to analyze the study result. The data were presented as number
and percentages. The data were analyzed using the Statistical Package
of Social Science (SPSS) version 24.
Results: The majority of the respondents were male 62.3%. More than
half 53.75% were in the age group of 18–24 years. Most common rea-
son for self‐medication with antibiotics was disease considered not
serious for physician consultation (66.3%). The most commonly used
antibiotics were azithromycin (67.9%) and amoxicillin (64.8%). Fever
(76.8%), Common flue and cough (70.8%) and dental pain (42.3%)
were the most common conditions for which self‐medication were
thought. The most common sources of information about self‐medica-
tion were previous physicians' prescription (72.6%) and pharmacist
advice (72%).
Conclusions: Self‐medication with antibiotics is a common practice
among educated people. Regulatory bodies and healthcare profes-
sionals need to strengthen and advocate the roles and regulations
that mandate the restriction of antibiotics sales without
prescriptions.
1121 | Non‐prescription paracetamol:
Patients' knowledge and habits
Michael Petrides1,2; Christos Kontogiorgis1; Christos Petrou2;
Evangelia Nena1; Maria Papavasili2; Aliki Peletidi2;
Theodoros Konstantinidis1
1Democritus University of Thrace, Alexandroupolis, Greece; 2University of
Nicosia, Nicosia, Cyprus
Background: Over the counter (OTC) medicines can be bought with-
out a prescription and they are safe and effective, when patients fol-
low the directions written in the patient's information leaflet or
health care professionals' directions (HCPs). Paracetamol is one of
the most popular OTC medicines, which is considered to be rela-
tively safe due to its wide use. However, paracetamol is often used
in overdose in the developed world ‐ either by accident or on pur-
pose for intentional self‐poisoning ‐ which can potentially lead even
to acute liver failure. Under this perspective, further investigation is
needed with regards to the proper use of paracetamol by patients,
potential mistakes and proposals on how to avoid them.
Objectives: The aim of the present study was to investigate the
knowledge and habits of patients in the Republic of Cyprus,
concerning the use of paracetamol, a well‐known and frequently
used OTC medicine worldwide.
Methods: Questionnaires were distributed anonymously inside com-
munity pharmacies to those people who had just been supplied with
an OTC medicine. The statistical analysis was conducted using the
SPSS statistic program. There were no exclusion criteria, except for
people's unwillingness to answer the questionnaire. Matching and
selection was under Chi‐Square Tests evaluation. The main questions
were whether patients asked for the pharmacist's advice before buy-
ing the medication or not and if this medicine had any side‐effects.
Results: The original compound was shown to be more well‐known
compared to the generics. A notable percentage of patients, ranging
between 13.0% and 29.8%, answered incorrectly that some Non‐
Steroidal Anti‐Inflammatory Drugs (NSAIDs) contained paracetamol,
which increases risk for Public Health. Another notable percentage
of patients (6.7%) answered that the maximum allowed daily dose
of paracetamol was higher than the correct one, whereas a signifi-
cant percentage of patients (27.6%) answered that paracetamol is
not toxic. Finally, an outstanding percentage of patients (40.2%) con-
sumes alcohol in parallel or slightly after paracetamol consumption,
while the same group of patients also uses paracetamol after alcohol
consumption (OR 0.379, 95% CI (0.044–0.225), p = 0.000).
Conclusions: Paracetamol is frequently consumed by patients, both
in its generic and original forms. Nevertheless, a notable percentage
of patients is shown to confuse paracetamol medicines with NSAIDs.
Paracetamol usage is related to demographic characteristics such as
age, level of education and gender. It seems that patients need to
be educated and counseled more by HCPs on the safe and effective
use of paracetamol.
1122 | Drug overload in HIV management;
an Indian countryside clinical picture
Vamshi Krishna Sirigadhi1; Sandeep Digijarala1;
Hari Krishna Aanathoju1; Varun Talla1; Venkateswar Rao Jupally1;
Satyanarayana Pattnaik1; Chandrashekhar Valupadas2
1Talla Padmavathi College of Pharmacy, Warangal, India; 2Kakatiya
Medical College, Warangal, India
Background: Polypharmacy & unreported usage of medication are fre-
quent in Indian HIV patients. This is due to ease in access to medica-
tion in general and socio economic stigmas specific to self reporting of
Anti Retroviral Therapy (ART). With a scenario of unaccountable open
usage of medication without prescription and unavailability of proper
patient records, so this is high time to quantify pill burden on HIV
patients.
Objectives: To quantify the number of concomitant medications in
patients receiving ART and to assess the associated factors.
Methods: An observational study carried out by recruiting HIV posi-
tive patients who are on ART, visiting government tertiary care
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hospital (study site) at Warangal, India. Data were collected from
patient case notes, patient interviews and laboratory data. Drug usage
was considered unreported, when such usage is not on any patient
health records & declared by the patient himself following face to face
interviews.
Results: Out of 320 patients (n = 320) included in the study, 134 were
males (41.87%), 183 females (57.18%) and 3 transgender (0.93%).
Unreported drug usage was found to be 2395 times in 320 patients
from august 2017 ‐ October 2018. The mean of unreported concom-
itant medication usage was found to be 7.5. 86.56% patients were
prophylactically treated with atleast 1 antibiotic with a mean of 1.38.
Diabetes (DM) and hypertension (HT) were present in 10.93% and
14.06% subjects, respectively. Tuberculosis (TB) was found in 71 sub-
jects in which 26 subjects were infected with TB in past 15 months
and among 26 subjects, 12 subjects approached hospital with TB as
presenting illness and were subsequently diagnosed ass HIV + ve
and hence started ART & Anti TB therapy simultaneously. The ART pill
burden was single pill a day in 229 subjects & 2 pills in 91 patients.
Aforementioned co‐morbid conditions with ART usage revealed signif-
icantly daily pill burden of 4 pills a day in 45 subjects (DM or HT), 3
pills in 18 subjects (TB), 5 pills in 17 subjects (DM & HT) and 6 pills
in 3 subjects (DM, HTN & TB), not including drug use for prophylaxis
and unreported usage.
Conclusions: It is observed that the high pill burden in study subjects
is due to polypharmacy & unreported drug usage. Inspite of consider-
ing patients who are having only one opportunistic infection and two
co‐morbid conditions, it was observed that there was huge rise in pill
burden in HIV patients, we can apprehend more pill burden if patients
with multi opportunistic infections and co‐morbid conditions are con-
sidered. The substantial under‐reporting of drug use highlights the
need accurately record patient data.
1123 | Prevalence of long‐term oral
corticosteroid use in asthma evaluated from
different angles
Trung N. Tran1; Sharon MacLachlan2; Michael Ganz3; Wesley Hicks4
1AstraZeneca, Gaithersburg, MD; 2Evidera, London, UK; 3Evidera,
Waltham, MA; 4PPD, Cambridge, UK
Background: Systemic corticosteroids are a mainstay of treatment for
asthma exacerbations and are often prescribed orally as part of daily
maintenance therapy for patients with severe asthma. Exposure to
oral corticosteroids (OCS) is known to be associated with adverse
effects that can occur early in a treatment course or at a relatively
low dosage. The frequency of long‐term (LT) OCS use is not well stud-
ied in asthma, given that it has no universal definition.
Objectives: To examine the prevalence of LT OCS use in patients with
asthma using different LT OCS use definitions.
Methods: We used data from the Truven MarketScan® Commercial
Claims and Encounters, Medicare Supplemental, and Medicaid
Multistate Claims databases from January 2012–December 2017.
Patients who were at least 12 years old, met the 2‐year Healthcare
Effectiveness Data and Information Set criteria for persistent asthma,
and had 30 months of continuous clinical and pharmacy data coverage
(6 months before as baseline and 24 months after the persistent
asthma index date) were included. Patients with non‐asthma condi-
tions typically treated with OCS were excluded. Patients with LT
OCS use were primarily defined as those with filled OCS prescriptions
with cumulative doses ≥450 mg in a maximum period of 90 days, cor-
responding to an average daily dosage of ≥5 mg. Three other defini-
tions were used in sensitivity analyses: (A) continuous OCS use for
≥90 days with no gaps between refills, (B) ≥183 days of OCS use
within a 365‐day period, and (C) ≥4 OCS prescriptions within a 365‐
day period. Annual prevalence is presented for 2013–2017 to allow
for full follow‐up years.
Results: We identified 435,675 patients for this analysis. A quarter of
them had severe asthma (Global Initiative for Asthma Steps 4 or 5),
and 14.3% had ≥1 exacerbation during the 6‐month baseline period.
Using the primary definition, 19.3% were LT OCS users at some point
during follow up, and 10% were during the first post‐baseline year.
Annual prevalence of LT OCS from 2013–2017 ranged from 5.3–
7.6%, 0.8–1.6%, 1.0–1.4%, and 4.3–4.9% for primary and sensitivity
definitions A, B, and C, respectively.
Conclusions: The prevalence of LT OCS use varies depending on how
LT OCS use is defined. Prevalence was relatively high when we used
the primary definition that accounts for total OCS exposure. LT OCS
use was less frequent when we used definitions that considered only
prescription duration or number of prescriptions but not dosage. The
variety of LT OCS use definitions allows for a comprehensive and
objective assessment of actual OCS use in the population.
1124 | A longitudinal observational study
describing the prescribing of, and persistence
with, multiple‐inhaler triple therapy for
chronic obstructive pulmonary disease in the
United States
Leah B. Sansbury1; Lisa Wittenhagen2; Yi Ba2; Priyanka Joseph2;
Robyn Mueller2; Suren Samarasinghe3; Grace Lomax3
1GlaxoSmithKline, Collegeville, NC; 2Adheris Health, a Syneos Health
company, Burlington, MA; 3Patient Connect, Guildford, London, UK
Background: Point‐of‐care dispensing data from retail pharmacies
provides a comprehensive source of prescribing data, including per-
sistence with medication use. Multiple‐inhaler triple therapy (MITT),
comprised of a long‐acting β2‐agonist (LABA), a long‐acting musca-
rinic antagonist (LAMA), and an inhaled corticosteroid (ICS) in two
or three separate devices, is currently recommended for patients
with chronic obstructive pulmonary disease (COPD) who are symp-
tomatic and at risk of exacerbations. Previous studies have evaluated
treatment patterns for patients with COPD, but there is a
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knowledge gap about treatment patterns after MITT initiation,
including patient persistence with this therapy.
Objectives: This study describes MITT use for COPD, and persistence
with these therapeutic regimens, in the United States (U.S.) using a pre-
scription dispensing database. We also describe the most commonly
dispensed MITT regimen, as well as the median time to treatment dis-
continuation among each MITT regimen.
Methods: We conducted a retrospective, longitudinal, observational
study of dispensing of MITT via two or three separate devices (overlap-
ping≥1 day) from retail pharmacy dispensing databases in the U.S. We
collected dispensing data between November 1, 2013 and October 31,
2016. Eligible patients were aged 40 years or older, were new users of
MITT, and had 12 months of follow‐up data.
Results: Among the 50,099 patients who initiated MITT and were
followed for 24 months (43.4% male, mean age 66.3 years), approxi-
mately 25.9% had an exacerbation in the 90 days prior to MITT initia-
tion. Most patients initiated a regimen comprised of two separate
devices (99.5%) and on an ICS/LABA+LAMA regimen (84.7%). The
median duration of ICS/LABA+LAMA use among patients who initiated
MITT in our study was 150 days (interquartile range: 120–275 days),
and 7.7% of these patients were persisting with MITT at 24 months.
Among the patients that discontinued the ICS/LABA+LAMAMITT reg-
imen, 38.8% discontinued the ICS/LABA component, 34.4% the LAMA
component, and 19.1% stopped MITT altogether.
Conclusions: These results provide additional data on real‐world use of
MITT in the U.S., and the persistence with MITT among patients using
this treatment. We observed that most patients persist with MITT for
approximately 4–5months, which is consistent with findings from other
studies. Research through direct observation of COPD patients, with a
known diagnosis, receiving MITT is needed to further investigate per-
sistence with MITT in the real‐world setting.
1125 | Discontinuation of therapy among
COPD patients who experience an
improvement in exacerbation status
Mette Reilev; Kasper B. Kristensen; Jens Søndergaard;
Daniel P. Henriksen; Wade Thompson; Anton Pottegård
University of Southern Denmark, Odense, Denmark
Background: A subset of patients with chronic obstructive pulmonary
disease (COPD) experience a decrease in exacerbation frequency, lead-
ing to adiminishedneed for treatmentwith inhaled corticosteroids (ICS).
Objectives: We investigated prescribing and discontinuation patterns
of long‐acting bronchodilators and ICS in COPD patients according
to exacerbation frequency.
Methods: Using the nationwide Danish health registries, we con-
ducted a drug utilization study among patients who had at least two
exacerbations or one hospitalization due to an exacerbation during
2011–2012. This study population was stratified according to consis-
tency of exacerbation occurrence after 12‐, 24‐, 36‐, and 48‐months
of follow‐up and the groups were described according to use of ICS,
long‐acting β2‐agonists (LABA), long‐acting anticholinergics (LAMA),
and combinations thereof.
Results:We identified 29,010 COPD exacerbators during 2011–2012.
Upon inclusion, 70% received ICS‐containing regimens, in combination
with LABA (23%) or both LABA and LAMA (41%). The proportion of
prevalent users of ICS‐containing regimens decreased to 56% during
follow up among exacerbation‐free individuals, while it increased to
86% in individuals who experienced at least one exacerbation annu-
ally. Persistence to ICS‐containing regimens was 58% after 4 years in
individuals without exacerbations compared to 74% among those with
annual exacerbations. Similar patterns were observed for triple ther-
apy which was the most extensively used drug combination regardless
of consistency of exacerbation occurrence.
Conclusions: The extensive use of ICS and the relatively high persis-
tence to ICS‐containing regimens in individuals who had a decrease
in exacerbation occurrence highlight a need for the development and
implementation of de‐escalation strategies in clinical practice.
1126 | Utilization pattern of chronic lung
disease treatment prior to the start of
respiratory syncytial virus season
Yoonyoung Choi1; H. Cody Meissner2; Christian Hampp3;
Haesuk Park1; Babett Brumback1; Almut G. Winterstein1
1University of Florida, Gainesville, FL; 2Tufts Medical Center, Boston, MA;
3U.S. Food and Drug Administration, Silver Spring, MD
Background: Guidelines recommend palivizumab immunoprophylaxis
for preterm children with CLD in their first year of life but in the
second year of life only if they continue to receive treatment for
CLD within 6 months before the RSV season. Although the use of
chronic corticosteroid therapy, diuretic therapy, or supplemental
oxygen serve as a proxy for CLD severity to determine the use of
palivizumab, treatment utilization patterns of these therapies are
not well understood.
Objectives: This study aimed to describe utilization patterns of CLD
treatment 200 days before the start of the RSV season.
Methods: This was a retrospective cohort study using Florida and
Texas Medicaid claims data linked to birth certificates for children
aged 0–24 months and their mothers between 1999–2010. We
included preterm children with CLD (gestational age < 32 weeks; hav-
ing a CLD diagnosis [ICD‐9‐CM 770.7 or 769]; and oxygen supply or a
diagnosis of respiratory distress syndrome within 90 days of birth)
who were continuously enrolled during the 200 days before the start
of the RSV season. CLD treatment was ascertained from medical and
pharmacy claims related to diuretics, steroids, oxygen supplementa-
tion; and ventilation requirement on birth certificates. To capture
time‐varying utilization patterns, we calculated prevalences for each
of ten discrete 20‐day segments before the RSV season. We also
reported the prevalence of respiratory infections to provide back-
ground seasonal virulence, which can trigger the intermittent use of
steroids in addition to CLD severity.
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Results: Among 19,026 preterm children with CLD, 64.8% did not
receive treatment for CLD whereas 29.7%, 8.6%, and 3.2% received
steroids, oxygen, and diuretics, respectively, within 200 days before
the RSV season. Prevalences of oxygen and diuretics use decreased
as Infant age increased. The use of corticosteroid therapy was strongly
associated with seasonal virulence trends. Higher thresholds for
cumulative days' supply of steroids showed the least seasonal trends
in utilization patterns, indicating chronic treatment likely due to CLD
severity rather than acute infections.
Conclusions: Our findings on utilization prevalences of CLD treatment
could help to optimize eligibility thresholds for immunoprophylaxis.
1127 | Assessment of inhalation techniques
employed by asthma and COPD patients in
Warangal region, India
Rajashekar Bollu; Sai Phani Maddipatla; Ashok Eggiri; Shakeer Shaik;
Baikunta Prusty Korada
Talla Padmavathi College of Pharmacy, Warangal, India
Background: Inhalation mode of drug delivery is the mainstay treat-
ment for asthma and COPD, however, incorrect technique prevents
patients from receiving maximal therapeutic benefits.
Objectives: The aim was to evaluate the inhalation technique of
COPD and bronchial asthma patients using metered dose inhaler and
rotahaler to investigate the determinants of incorrect inhalation
technique.
Methods: It was a prospective observational study in Warangal region.
A consecutive nonrandom sampling method was used to enroll study
subjects. Basic sociodemographic information of the study subjects
was collected. The inhalation technique was visually observed and
scored on checklist, which was carried out in chest hospital in Waran-
gal city. Questionnaires were used for assessment of rotahaler inhala-
tion technique and MDI inhalation technique.
Results: Among the 350 patients observed, 300(86%) subjects are
using rotahalers and 50(14%) subjects are using MDI's. In case of
rotahaler Common steps missed by 210 (70%) ofrespondents was
not breathing out fully prior to inhalation which was followed by 82
(27.3%) ofthe respondents are failed to hold their breathe for 10 sec-
onds after inhalation and 30(10%) ofrespondents are failed to seal the
lips around the mouth piece. In case of MDI's commen stepsmissed by
31(62%) of respondents are to shake the inhaler prior to its use
followed by half of therespondents 25(50%) are missed to exhale the
breath before inhaling medication and 14(28%) of the respondents
are failed to hold their breath for 10 seconds after inhalation. No
significantcorrelation was found between accuracy of the age, sex,
education status, or area of residence ofthe patients.
Conclusions:Most patients used their rotahalers and MDI's incorrectly
with most common errors being failure to hold the breath after inha-
lation, missed to exhale breath prior to inhalation and inability to take
deep inspiration after inhalation. Source of information and re‐demon-
stration of technique was found to be significantly associated with
proper use. Regular assessment and reinforcement of correct inhala-
tion technique by health professionals and caregivers are essential to
improve compliance. Further studies are recommended to assess the
role of health professionals' and clinical pharmacists in the proper
use of inhalers. Pharmacists are currently less involved in patient edu-
cation about inhalers use; thus their active involvement in instruction
session may aid in correct usage of inhaler by patients.
1128 | Utilization of Olodaterol and
Indacaterol in Europe
Cristina Rebordosa1; Eline Houben2; Kristina Laugesen3;
Joelle Asmar4; JukkaT. Montonen5; Jaume Aguado1; Jetty Overbeek2;
Vera Ehrenstein3; Laura Wallace6; Alicia Gilsenan7
1RTI‐Health Solutions, Barcelona, Spain; 2PHARMO Institute for Drug
Outcomes, Utrecht, Netherlands; 3Aarhus University Hospital, Aarhus,
Denmark; 4 IQVIA, Paris, France; 5Boehringer Ingelheim International
GmbH, Ingelheim am Rhein, Germany; 6Boehringer Ingelheim
International GmbH, Bethel, CT; 7RTI‐Health Solutions, Research Triangle
Park, NC
Background: Olodaterol and indacaterol are authorized only for the
treatment of adults with chronic obstructive pulmonary disease
(COPD). Use of these drugs in patients with asthma, irrespective of
COPD, has been associated with increased morbidity and mortality,
and is considered off‐label.
Objectives: To quantify the potential off‐label use of olodaterol and
indacaterol and characterize use in clinical practice.
Methods: This descriptive drug utilization study used routinely col-
lected health data in the PHARMO Database Network in the Nether-
lands (PHARMO overall and PHARMO‐GP for the subset of patients
with general practitioner [GP] data), the population registers in Den-
mark, and the IMS Real‐World Evidence Longitudinal Patient Data-
base (RWE LPD) (GP panel and pulmonologist panel) in France. All
new users (treatment naïve) of olodaterol or indacaterol between
2014 and 2017 were included in the study. On‐label use was defined
as use among adults with a recorded diagnosis of COPD. Off‐label use
was use among adults with a recorded diagnosis of asthma without a
recorded diagnosis of COPD or as use among patients ≤18 years.
Potential off‐label use was defined as no recorded diagnosis of either
COPD or asthma.
Results: The study included 4,158 new users of olodaterol (1,386 in
PHARMO, 1,712 in Danish National Registers, and 1,060 in the
RWE LDP panels) and 9,966 new users of indacaterol (1,841 in
PHARMO, 6,406 in Danish population registers, and 1,719 in the
RWE LDP panels). For both drugs, median patient age at treatment
start ranged from 63 to 71 years, and approximately 50% were female
across the data sources. Initiators of both drugs were similar regarding
comorbidity burden and comedications. Prevalence of off‐label use
ranged from 3.5% for both drugs (PHARMO overall) to 11.9% for
olodaterol and 12.4% for indacaterol (RWE LPD GP panel). Prevalence
of on‐label use ranged from 47.8% (PHARMO overall) to 77.7% (RWE
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LPD pulmonologist panel) for olodaterol and from 28.7% (Danish pop-
ulation registers) to 70.1% (RWE LPD pulmonologist panel) for
indacaterol. The remaining new users of olodaterol and indacaterol
were classified as potential off‐label users, with prevalence ranging
from 17.3% (RWE LPD pulmonologist panel) to 48.6% (PHARMO
overall) for olodaterol, and from 20.5% (RWE LPD pulmonologist
panel) to 66.6% (Danish population registers) for indacaterol.
Conclusions: The prevalence of off‐label use of both drugs was lower
than reported in other studies evaluating off‐label use of medications
across Europe, and there was no pediatric use. Lack of direct evidence
on indication (potential off‐label) for a high proportion of patients is a
limitation for some data sources.
1129 | A day in the life: Prescription
medicine use in Australia
Benjamin Daniels1; Claire Wylie2; Sallie‐Anne Pearson1;
Jonathan Brett1; Nicholas Buckley2
1Medicines Policy Research Group, Centre for Big Data Research in
Health, University of New South Wales, Sydney, Australia; 2Clinical
Pharmacology and Toxicology Research Group, Discipline of
Pharmacology, Sydney Medical School, University of Sydney, Sydney,
Australia, Sydney, Australia
Background: Australia spends more than $11 billion, annually, on pub-
licly‐subsidized prescription medicines via the Pharmaceutocal Bene-
fits Scheme (PBS), but there are few data on how individual
Australians are using these medicines on a daily basis.
Objectives: To describe Australians' prescription medicine use on typ-
ical day.
Methods: We used dispensing records for a nationally‐representa-
tive, 10% sample of PBS‐eligible Australians to identify people
exposed to any prescription medicine on 25 September 2017 (World
Pharmacists' Day). We estimated exposure by calculating days
between dispensings for each PBS medicine using records from
2013–2017. We considered the time by which 75% of people
received a subsequent dispensing as the estimated period of expo-
sure (EPE). For each person, we added each medicine's EPE to the
date of the last dispensing prior to the 25th and if that EPE ended
on or after the 25th we considered that person exposed to and using
that medicine on that day. We grouped medicines by ATC code and
examined use by sex and age groups. We defined persons
experiencing polypharmacy as those with 5 or more unique medicine
exposures on the day. We used the Australian Bureau of Statistics
mid‐year population estimate for 2017 to extrapolate our findings
to the Australian population.
Results: 885,288 people used at least one prescription medicine on
September 25, 2017; their median age was 56 years (IQR: 36–69)
and 58% were female. In total, 2,327,530 prescripton medicines were
in use on the day. Cardiovascular, nervous system, and alimentary
tract and metabolism medicines accounted for the majority of use,
with 16%, 12%, and 10% of the population using each, respectively.
Persons ≥70 years of age accounted for 39% of all use on the day,
and 80% of Australians ≥70 were using at least one prescription med-
icine. 16% of medicine users were using 5 or more medicines
(polypharmacy) and 2% were using 10 or more medicines
(hyperpolypharmacy). Polypharmacy accounted for 42% of all medi-
cine use on the day and 58% of people experiencing polypharmacy
were ≥ 70 years of age. Broadly, the nature of medicine use was sim-
ilar between sexes, however females were using more genitourinary
and sex hormone medicines.
Conclusions: Over one third of the Australian population uses a pre-
scription medicine on a typical day and use increases with age. Nearly
half of all medicine use is in the setting of polypharmacy, and this is
particularly an issue for older Australians. These population‐based
estimates highlight potential quality use of medicines issues, particu-
larly in older people, and provide useful baseline data facilitating com-
parisons of disease epidemiology and medicine use over time.
1130 | Use of ovarian suppression with
endocrine therapy among premenopausal
women with breast cancer in the United
States, 2001–2016
Sophie E. Mayer; Jennifer L. Lund; Virginia Pate;
Katherine E. Reeder‐Hayes
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Clinical trials indicate that adding ovarian suppression
(OS) therapy to endocrine therapy (ET) in premenopausal women with
non‐metastatic breast cancer improves disease‐free and overall sur-
vival. However, injectable OS may add cost, potential side effect bur-
den, and additional clinic visits to adjuvant therapy. It is not known to
what extent OS is being used in contemporary community oncology
settings.
Objectives: We describe uptake of OS within a commercially‐insured
population of US women aged 18–50 diagnosed with incident breast
cancer (2001–2016) and using ET. We also describe predictors of
OS use in this population.
Methods: We identified women with incident breast cancer based on
diagnosis codes from 2001–2016 in the IBM® MarketScan® data-
base. Eligible patients were continuously enrolled for 12+ months
prior to cancer diagnosis and filled at least 1 prescription for oral ET
(i.e., tamoxifen, toremifene, anastrozole, letrozole, and/or exemestane)
in the year after diagnosis. We classified use of OS as any prescription
for a gonadotropin‐releasing hormone (GnRH) agonist in outpatient
pharmacy claims or procedure code for OS implant or injection 1) in
the week prior to ET initiation or 2) following ET initiation and for
up to 18 months after diagnosis. We estimated the proportion of
women that were OS users in each diagnosis year using linear binomial
regression, and examined associations between OS use, age at diagno-
sis, and geographic region.
Results: A total of 26,114 women meeting all inclusion criteria were
identified from the MarketScan® database, of whom 1,452 (5.6%)
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were OS users. The most common type of OS was leuprolide or
leuprorelin (55.2%), followed by goserelin (46.7%), and triptorelin
(1.1%); these were most often identified by procedure code. Annual
risk of OS use varied from 3.2% in 2001 to 9.3% in 2016, peaking at
11.4% in 2015. OS use varied by region (χ2 p = 0.0003), with the
highest risk of OS use observed in the Northeast (6.5%) and the low-
est in the South (5.0%). Younger patients were significantly more likely
to use OS than older patients, with each additional year of age at diag-
nosis associated with a 0.57 percentage point decrease in risk of OS
use (95% confidence interval [CI]: −0.63, −0.51). After controlling for
age group (≤40, 41–44, 45–46, 47–48, 49–50) and region, each addi-
tional calendar year was associated with 0.25 percentage point greater
risk of OS use (95% CI: 0.19, 0.31).
Conclusions: OS use with ET appears to be increasing in US breast
oncology practice among women under 50.
1131 | Type and characteristics of drug
information inquiries in Ethiopia University
Hospital: 2 year prospective observational
study
Yonas Getaye Tefera1; Begashaw Gebresillassie1;
Asnakew Achaw Ayele1; Yared Belay2; Yohannes Kelifa Emiru1
1University of Gondar, Gondar, Ethiopia; 2Mekelle University, Mekelle,
Ethiopia
Background: The drug related information demand, extent of inquiry
and functionality of existing drug information centers are seldom stud-
ied in Ethiopia.
Objectives: This study aimed to identify the types and potential areas
of drug information inquiry at Gondar University specialized Hospital
(GUSH), Northwest Ethiopia.
Methods: A prospective observational study was employed from Jan-
uary, 2016 to December, 2017 at Drug Information Center (DIC) of
GUSH. The study query was collected through 2 batches of graduating
class of undergraduate pharmacy students. Descriptive statistics used
to describe, characterize and classify drug related queries with various
perspectives. Binary logistic regression test was employed to identify
predictor variables to the type of drug related queries.
Results: A total of 781 drug related queries collected in the 2 years
period and 697 included in the final analysis. Near to half (45.3%) of
queries comes from the pharmacists followed by general practitioners
(11.3%) and nurses (10.2%). Slightly greater than half of the queries
(51.9%) are focused on therapeutic clinical information. 39.6% of drug
related queries comes with infectious disease case scenarios followed
by cardiovascular cases in 21.3% of queries. More than half of (53.9%)
and nearly one in five (19.4%) of the queries take 5 to 30 minutes and
30 minutes to 1 hour of literature searching, respectively. Pharmacists
and patients ask patient specific questions in their drug related queries
higher than others, with Crude odds ratio of 95% CI, 2.474(1.373,
4.458) and 4.121(1.403–12.105), respectively.
Conclusions: In conclusion, pharmacists are the primary drug informa-
tion users and frequent drug related information inquirers. Most of the
queries targeted therapeutic indications, adverse drug events, infec-
tious and cardiovascular disease related requests. Drug information
services are imperative for growing pharmacist's role in patient care
and addressing patient specific drug related needs.
1132 | Over‐the‐counter drugs: A
Pharmacoepidemiological study in Greece
during the financial crisis
Theodora Tatsiou1; Georgios Poulentzas1;
Panagiotis Nikolaos Lalagkas1; Eleftherios Berberoglou2;
Christos Kontogiorgis2; Theodoros Constantinides2;
Dimitra Hadjipavlou‐Litina1
1Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Democritus
University of Thrace, Alexandroupolis, Greece
Background: O.T.C. medicines' purveyance in Greece needs no pre-
scription from physicians. However, we still have no knowledge of
how people are informed about their use and whether this might be
a public health issue.
Objectives: The goal of this study is to determine the knowledge level,
habits, sources of information and selection criteria of Greek popula-
tion regarding O.T.C. medicines, as well as their opinion about the dis-
posal of these drugs in non‐pharmacy settings.
Methods: During 5 months, 920 adults, who have been approached in
community pharmacies and gathering points, have been interviewed
anonymously. Individuals participated (782, 85.0% response rate)
answering a predesigned, cross‐sectional questionnaire consisting of
12 multiple‐choice questions. The data collection followed and statis-
tical analysis was performed with the IBM SPSS Statistics v.15.0 pro-
gram using descriptive statistics, chi‐square and odds ratios (ORs).
Results: Τhe greatest proportion of respondents (79.8%) exhibited
mediocre to good knowledge about which drugs are categorized as
O.T.C. and which are not. Healthcare professionals (such as pharma-
cists and physicians) seem to be the main sources of information about
O.T.C. medications for the 84% of the respondents. When asked
about the selection criteria for the purchase of O.T.C. medication,
physicians seem to play the most critical role (66.1% of the patients),
with pharmacists (60%) and friends and family (22.4%) following. Prod-
uct price also seems to be a critical factor for 30.9% of people over
70+ years, in contrast with 13.8% of people aged 18–29 (p = 0.030).
Furthermore, it was found that most of the participants (79%) choose
self‐medication in case of common cold treatment. Additionally, 61.2%
of respondents stated that they are reluctant to buy O.T.C. from a
non‐pharmacy setting. Older people seem to be more negative about
purchasing them elsewhere than pharmacies than younger people:
more specifically 72.8% of respondents over 70 years old in contrast
to 55.9% of respondents aged 18–29 (p = 0.024). Those high rates
of reluctance could be supported by the fact that 69.6% of the
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respondents believe that retail of O.T.C. medicines in super‐markets
will increase their abuse and misuse.
Conclusions: Health professionals such as physicians and pharmacists
seem to play a crucial role in people's information about O.T.C. use.
On the other hand, self‐medication seems to be overspread in Greek
society due to financial crisis. Finally, Greek society presents reluc-
tance in accepting O.T.C. disposal elsewhere than community
pharmacies.
1133 | Glucocorticosteroids for the
treatment of anaphylaxis: A systematic
review
Xiaotong Li1,2; Yajuan Xiong2; Suodi Zhai1
1Peking University Third Hospital, Beijing, China; 2Peking University
Health Science Center, Beijing, China
Background: Glucocorticosteroids are widely used in the emergency
treatment of anaphylaxis. However, its practical effects in treating
anaphylaxis is suspectable.
Objectives: To evaluate the curative effects of glucocorticosteroids
for anaphylaxis.
Methods: Highly sensitive search strategies have been developed to
retrieve PuMed, Embase, the Cochrane Library, Web of Science,
ClinicalTrial.gov and three Chinese databases. These databases were
last searched on 7th December 2018. Ramdomised control trials and
observational studies reporting comparison of glucocorticosteroids
group versus non‐ glucocorticosteroids group were included. Litera-
ture screening and data extraction were performed independently by
two reviewers. Studies were pooled using random effects models
and presented as risk ratio, or odds ratio, with 95% confidence
interval.
Results: 15 studies were included‐3 cohort studies and 12 case con-
trol studies. For the outcome as length of hospital stay, one cohort
study showed non‐glucocorticosteroids group had longer length while
another cohort study demonstrated an opposite result. Regarding the
outcome as allergy‐related revisit to the emergency department, two
cohort studies showed there was no significant difference between
two groups. For subsequent use of epinephrine, one cohort study sup-
ported that glucocorticosteroids group was superior. As to the episode
of biphasic anaphylaxis, meta‐analysis of 12 case control studies
showed that the use of corticosteroids was similar between biphasic
group and non‐biphasic group (odds ratio 0.89, 95% confidence inter-
val 0.47 to 1.68, I2 = 61%).
Conclusions: Current evidence could not prove the effect of
glucocorticosteroids in treating anaphylaxis yet, thought its pharmaco-
logical effects suggest it is potentially useful. It is better to regard
glucocorticosteroids as second‐line therapy or third‐line therapy, and
not to delay the use of epinephrine, the first‐line agent, because of
glucocorticosteroids.
1134 | Pharmacoepidemiology capacity
building in the Latin American and African
regions
Maribel Salas1,2; Wendy Camelo Castillo3; Lucia D. Juarez4;
Chengchen Zhang3; Ariel Arias5; Kwame Appenteng6;
Macarius M. Donneyong7; Nicolas Thurin8; Luciane C. Lopes9;
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Ilse Truter21
1Daiichi Sankyo Inc, Basking Ridge, NJ; 2University of Pennsylvania
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Baltimore, MD; 4University of Alabama at Birmingham, Birmingham, AL;
5Health Canada, Ottawa, ON, Canada; 6Astellas Pharma US,
Northbrook, IL; 7The Ohio State University, Columbus, OH; 8Universite
de Bordeaux, Bordeaux, France; 9Universidade de Sorocaba UNISO, Sao
Paulo, Brazil; 10Universidad Autonoma del Estado de Morelos,
Cuernavaca, Mexico; 11North‐West University, Potchefstroom, South
Africa; 12DaKorle‐Bu Teaching Hospital, Accra, Ghana; 13Lagos State
University College of Medicine, Lagos, Nigeria; 14Ekiti State University,
Ado‐Ekiti, Nigeria; 15Univeristy of Maryland, Baltimore, MD; 16Lagos
University Teaching Hospital, Lagos, Nigeria; 17Universidad de San Carlos
de Guatemala, Guatemala, Guatemala; 18Cordoba National University,
Cordoba, Argentina; 19UTS, Sydney, NSW, Australia; 20National
University of Mexico, Mexico, Mexico; 21Nelson Mandela University, Port
Elizabeth, South Africa
Background: An electronic screening survey of pharmacoepidemiology
(PE) capacity building was developed for the Latin America (LatAm) and
African regions. The objective of the screening survey was to identify a
target population, to inform a second in‐depth questionnaire to iden-
tify current status, needs, gaps and priorities in pharmacoepidemiology
in these regions.
Objectives: To describe the results of the pharmacoepidemiology
capacity building electronic screening survey for the LatAm and Afri-
can Regions.
Methods: Following the Potter systemic capacity building model, a
screening survey was developed in collaboration with PE interna-
tional experts including those from the LatAm and African regions.
The screening questionnaire was translated from English to Spanish,
French and Portuguese by native speakers who were also PE
researchers, and validated by a second set of translators. An online
survey builder was used to develop the electronic survey.
Results: There were 110 participants, 91 (83%) from the LatAm and
19 (17%) from the African regions. From LatAm, 24% were from Brazil
followed by Colombia (23%), Mexico (11%), Argentina (10%), Chile
(9%), Ecuador (7%) and others (16%). From Africa, 26% were from
Nigeria followed by South Africa (21%), Ghana (21%), Cameroon
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(11%) and others (21%). More than half of all respondents (58%) were
pharmacists, followed by medical doctors (23%). In terms of primary
work, 35% were from academic institutions, 29% from government,
11% from industry, 10% from hospitals and the rest from other sec-
tors. Eighteen percent were currently working in PE, 34% in
pharmacovigilance (PV), 33% in both and the rest in neither. Of the
total, 53% had formal training in PE, 66% were involved in teaching
and 63% in research. Of those involved in teaching (N = 72), 51% have
worked in both, PE and PV and only 14% in PE only. Of those involved
in research (N = 68), 47% were in public health, 34% in clinical, 13% in
applied research, 3% in basic science and 3% in qualitative research.
Regarding main specific activity, 34% were working on policies, 30%
in pharmacovigilance, 13% in development, 9% in benefit/risk, 3% in
risk management plans and 11% in other areas.
Conclusions: There was a high response rate of the screening survey
particularly from the LatAm region. The overall eligibility rate set a
positive stage for the in‐depth questionnaire. The high proportion of
respondents involved in teaching and research will contribute to lever-
age the topics by region according to specific needs.
1135 | Association between self‐assessed
NYHA functional class and quality of life in a
cohort of Portuguese heart failure patients:
The PRIMe study
Maria Cary1; José Pedro Guerreiro1; Mariana Romão1;
António Teixeira Rodrigues1; Marta Afonso‐Silva2; Pedro Laires2
1Centre for Health Evaluation and Research (CEFAR), Lisbon, Portugal;
2HE&OR, Novartis Farma, Produtos Farmacêuticos SA, Porto Salvo,
Portugal
Background: Symptoms and quality of life measures are widely used
to classify heart failure disease state. It is of major interest to assess
the extent in which the self‐assessed New York Heart Association
(NYHA) classification associates with other quality of life scales.
Objectives: To assess the association between self‐assessed NYHA
class and quality of life, measured by EQ‐5D‐3 L and Minnesota Living
with Heart Failure Questionnaire (MLHFQ).
Methods: The PRiMe study is a cross‐sectional and multicentre study
to characterize clinical, sociodemographic and therapeutic characteris-
tics of sacubitril/valsartan (sac/val) users. Adult patients (≥18 years) or
caregivers with a prescription (initial or refill) of sac/val are being
recruited through Portuguese community pharmacies. Patient‐
reported outcomes (MLHFQ, EQ‐5D‐3 L and self‐assessed NYHA)
are being collected through a paper‐based self‐administered question-
naire. Higher values of NYHA and MLHFQ and lower values of EQ‐5D
address worse health status conditions. The association between self‐
assessed NYHA and quality of life was measured using Spearman Cor-
relation Coefficient. This study was approved by the competent Ethics
Committee and is compliant with the General Data Protection
Regulation.
Results: As of Jan 2019, a total of 193 eligible patients (51 new users)
were recruited in 125 community pharmacies, 26% through their care-
giver. Mean age was 70.7 years (SD = 12.7; range: 35–94) and 60.6%
were male. Among the 141 patients that self‐assessed their NYHA
class, 15% were NYHA class I, 43% NYHA II, 25% NYHA III and 17%
NYHA IV. Self‐assessed NYHA was positively correlated with MLHFQ
total score (r = 0.456; p < 0.0001) and was more correlated with
MLHFQ physical‐score (r = 0.496; p < 0.0001) than with MLHFQ
emotional score (r = 0.375; p < 0.0001). Regarding the association
with EQ‐5D‐3 L, self‐assessed NYHA was negatively correlated with
the index (r = −0.527; p < 0.0001) as well as with the VAS score
(r = −0.470; p < 0.0001).
Conclusions: The relationship between self‐assessed NYHA class and
quality of life measures is of importance to understand the clinical use-
fulness of patient reported outcomes.
1136 | Assessment of health related quality
of life of HIV positive patients in Warangal
region (India)
Navya Sri Gurram; Navya Poka; Nagalaxmi Valluri;
Venkateshwar Rao Jupally; Swethanjali K.
Talla Padmavathi College of Pharmacy, Warangal, India
Background: Access to affordable highly active anti‐retro viral therapy
(ART) has dramatically improved the life expectancy of HIV positive
patients, resulting in increased number of people living with HIV.
Many of these patients live with a substantial burden of psycho‐social
trauma and HIV related morbidity. Hence, the health related quality of
life of these people is critically important and need a careful assess-
ment by the healthy communication of a clinical pharmacist.
Objectives: The study objective was to assess the health related qual-
ity of life (HRQOL) in patients suffering from HIV by using WHOQOL‐
BREF scale which includes four major domains (Physical, Psychologi-
cal, Environmental, Social), to find the influential factors affecting
HRQOL in HIV patients. The patients were provided with counseling
in‐order to reduce the stigma (As in India stigma is the major barrier
for miscommunication in HIV patients) they were followed up to
assess the impact of the intervention.
Methods: We conducted a prospective interventional study in a gov-
ernment ART center in Warangal region from April 2018 to September
2018. The study included 668 outpatients who were assessed with
WHOQOL‐BREF questionnaire. The questionnaire included physical,
psychological, social and environmental domains. The QOL scores
were assessed pre‐ and post‐counseling. One‐way ANOVA (Tukeys
multiple analysis) and unpaired t‐tests were used to examine changes
in HRQOL scores for individual domains following counseling.
Results: The study revealed that in pre‐counseling session with
patients the mean score (0–100) of domains was highest for the envi-
ronmental domain (32.0), followed by psychological domain (22.7)
then physical (17.4) and lowest for social (16.8). There was a
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significant improvement (based on p values of pre and post counseling
scores) (p < 0.001) in psychological domain (22.7 to 51.3), environmen-
tal domain (32.0 to 47.4), physical domain (17.4 to 51.3) and social
domain (16.8 to 60.1) after the counseling intervention was done that
is the psychological status of the patient was improved with a con-
cerned communication.
Conclusions: The study revealed that after counseling HIV+ patients
showed a significant increase in their HRQOL. The study strongly sug-
gests that there is a need for establishing the counseling centers in
hospitals for the patients suffering with HIV. Finally the role clinical
pharmacist (who actually involved in the counseling of HIV patients)
was revealed which lead to the improvement in patient's psychological
behavior (which was assessed based on the psychological domain
scores taken from WHOQOL‐BREF scale).
1137 | Validated instruments of Quality of
Life (QoL) in Acute Myeloid Leukemia (AML)
patients
Maribel Salas1,2; Maggie Elsharkawy1;
Angelika Wientzek‐Fleischmann3; Zahidul Islam1; Nora Tu1;
Aikaterini Bilitou3; Ulf Stellmacher3
1Daiichi Sankyo Inc, Basking Ridge, NJ; 2University of Pennsylvania
Perelman School of Medicine, Philadelphia, PA; 3Daiichi Sankyo Europe,
Munich, Germany
Background: Acute myeloid leukemia is an aggressive and devastating
disease for patients, which often requires intensive chemotherapies
that negatively impact patients' quality of life (QOL). Multiple QoL
instruments have been developed and validated but only few are spe-
cific for AML patients.
Objectives: To identify from the published literature validated instru-
ments of QoL specific for AML patients and generic instruments used
in AML patients.
Methods: A systematic and cumulative literature review was per-
formed using Pubmed and OVID (Biosis, Embase and MEDLINE) data-
bases through January 1, 2019. The search terms included: QoL,
health‐related QoL, patient‐reported outcomes and validity, reliability,
validated, tools, instruments, test–retest, and leukemia myeloid acute,
leukemia, myeloid, acute, acute myeloid leukemia. References of rele-
vant articles were reviewed. Two investigators independently
reviewed the abstracts. Only papers with information of validity
and/or reliability in AML patients were included. Any discrepancy
was resolved by consensus.
Results: Eighty abstracts were reviewed and 10 full papers were
selected. Validated instruments included: the Functional Assessment
of Cancer Therapy with leukemia (FACT‐Leu), the Life Ingredient Pro-
file (LIP), the general European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC) and versions
EORTC‐Leu, and EORTC 8 Dimension EORTC‐8D); the 5‐level
EuroQoL five‐dimensional questionnaire (EQ‐5D‐5 L), the
Hematological Malignancy Patient‐Reported Outcome (HM‐PRO)
used for various hematological malignancies, and the health‐related
QoL questionnaire for patients with hematologic diseases (QOL‐E),
QLQ‐C30. The FACT‐Leu scale showed adequate internal consistency
(α = 0.75–0.96) and reliability (ICC =0.765–0.89). The LIP and EORTC
have shown good validity and reliability. The HM‐PRO showed ade-
quate agreement (0.84–0.98) in various categories of QoL and also
disease‐related symptoms. The QLQ‐C30 has an internal consistency
of 0.64–0.94. The EORTC‐8D, and EQ‐5D‐5 L included not only
QoL domains (physical functioning, role functioning, social functioning,
emotional function and cognitive functioning) but also burden of dis-
ease. The EORTC QLQ‐C30 and QLQ‐E have been used in elderly
AML patients.
Conclusions: Although there are QoL validated instruments (generic
and specific) for AML reported in the literature, more research is
required to determine the most responsive and clinically useful instru-
ment in AML especially in patients who relapse, are refractory or
respond to treatment.
1138 | Patient participation in PCORnet
Patient‐Powered Research Networks through
payer‐initiated member outreach
Xiaoxue Chen1; Abiy Agiro1; W. Benjamin Nowell2; Sara Loud3;
Robert McBurney3; Kalen Young4; Rebecca Sutphen5;
Elizabeth Bourquardez Clark5; Cristina Burroughs5; Jeffrey R. Curtis6;
Antoine Sreih7; Peter A. Merkel7; Kevin Haynes1
1Healthcore, Wilmington, DE; 2Global Healthy Living Foundation, Upper
Nyack, NY; 3Accelerated Cure Project, Waltham, MA; 4Vasculitis
Foundation, Kansas City, MO; 5University of South Florida, Tampa, FL;
6University of Alabama at Birmingham, Birmingham, AL; 7University of
Pennsylvania, Philadelphia, PA
Background: Patient‐Powered Research Networks (PPRNs) seek to
empower patient‐centered research by engaging patients and other
stakeholders directly to collect patient‐reported data and integrate it
with electronic health information, such as administrative claims. The
ability of payer‐initiated member outreach to engage patients in PPRN
research is novel and has not been evaluated.
Objectives: To quantify health plan members' registration rates in any
of four PPRNs, comparing two common payer‐initiated methods for
inviting member participation: mail and email.
Methods: This prospective randomized study linked enrollees from a
nationally‐representative private insurance network of 14 health plans
to 4 disease‐specific PPRNs patient registries. Members meeting diag-
nostic criteria who were not registered in any of the four PPRNs were
identified and randomly assigned to either mail or email group. The
intervention involved two outreach attempts with first contact on
04/23/2018 and one follow‐up communication on 05/23/2018. The
outcome of new registration with the PPRN was defined through pri-
vacy preserving record linkage with the PPRNs. Rates of new
ABSTRACTS 549
registrants by outreach approach at the time of 8/31/2018 were
reported as well as comparison of registrants and non‐registrants
using bivariate analysis.
Results: A total of 14,571 patients were assigned to the mail group
and 14,574 to the email group. Invitations were successfully delivered
to 13,834 (94.9%) mail group and 10,205 (70.0%) email group mem-
bers. A small but significantly larger proportion of the mail group mem-
bers (n = 78; 0.54%, 95% Confidence Interval [CI] {0.42% ‐ 0.67%})
registered in PPRNs relative to the email group (n = 24; 0.16%, 95%
CI {0.11% ‐ 0.25%}), p < 0.001. Members who registered had more
comorbidities (83.4% vs. 69.9%, p = 0.01), were more likely to be
female (87.3% vs. 78.4%, p = 0.03), and had marginally greater medical
utilization, especially emergency room visits, relative to non‐regis-
trants (52.0% vs. 42.5%, p = 0.05).
Conclusions: A health plan outreach to invite members to participate
in PPRNs was modestly effective, offering another means to engage
patients in the research opportunities afforded by membership to a
PCORnet PPRN. Regular mail outperformed less costly email. Addi-
tional studies using mixed modes or more direct ways of engaging
patients are needed to guide future outreach decisions.
1139 | Concordance of pharmacist vs patient
responses regarding counseling in community
pharmacy ‐ a quantitative assessment
Camelia Bucsa1; Mihaela Udrea2; Daniel Leucuta3; Marius Bojita1
1Drug Information Research Center, “Iuliu Hatieganu” University of
Medicine and Pharmacy, Cluj‐Napoca, Romania; 2Ced Pharma,
Bucharest, Romania; 3Department of Medical Informatics and
Biostatistics, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj‐
Napoca, Romania
Background: Patient counseling is one of the medication adherence
pylons. This activity can be successfully performed in community
pharmacy, given that effective communication between both parts
involved, pharmacist and patient, takes place.
Objectives: to assess the degree of concordance between the
responses of patient and pharmacist to the same questions regarding
the counseling provided in the same session.
Methods: Based on the good pharmaceutical practice rules from
Romania we developed 2 questionnaires (tailored in terms of language
for pharmacists or patients), where we inquired about the counseling
provided during the pharmacy visit that just ended. The two question-
naires contained a common block of 14 questions regarding the
counseling provided on the medications' way of use (4 questions),
the safety concerns (5 questions), the storage, validity term, disposal,
lifestyle change, and disease monitoring (1 question each). We paired
the questionnaires based on a code and we calculated the Kappa
Cohen coefficient1 (KCc) to quantitatively evaluate the degree of con-
cordance between pharmacist versus patient responses to the 14
questions. We interpreted the values of the KCc as per Altman (very
good concordance, KCc = 0.8–1.00; good, KCc = 0.61–0.8; moderate
KCc = 0.41–0.60 acceptable KCc = 0.21–0.40; and week,
KCc ≤ 0.20)2.
Results: For the 14 questions, we analyzed data from 2047–2378
questionnaires collected from 520 community pharmacies in 10 of
Romania's counties. The highest level of concordance was”very good”,
and was achieved on the items regarding the counseling on the med-
icines' route of administration (adjusted KCc = 0.88), time of adminis-
tration (KCc = 0.80) and doses (KCc = 0.82). The highest disagreement
(week concordance) was found on the question regarding the counsel-
ing on the medicines' adverse effects (KCc = 0.006), where 44.9% of
patients responded that they received counseling as compared to
93.1% of the pharmacists who responded that they offered counsel-
ing. The rest of the questions had a moderate concordance, except
the one on counseling the patients to return the expired medicines
to the pharmacy (KCc = 0.31).
Conclusions: We found a moderate level of concordance between the
pharmacist and patient responses to the majority of the questions. The
highest discrepancy was found for counseling on the medicines' possi-
ble adverse effects. Further studies are needed to investigate the fac-
tors that could generate this disagreement.
1140 | What is the availability of follow up
pain score in real world databases and who
are these patients?
Zhenna Huang; Jill Webster Ruppenkamp; Chantal E. Holy
Johnson and Johnson Inc., New Brunswick, NJ
Background: Pain relief is a strong predictor of patient satisfaction
after total knee arthroplasty. Longitudinal pain performance assess-
ments may provide health providers and researchers with a more dis-
tinct impression of pain change among the TKA population. However,
little is known about its availability and who the patients are that
report follow up pain score in real world setting.
Objectives: To evaluate the availability of longitudinal self‐reported
face‐rating pain score (scale 0–10) after TKA surgery in real world data
and investigate factors associated with available follow up pain score
report.
Methods: Through data partnership with Mercy Technology Services,
patients who underwent TKA surgery were extracted from 2011–
2018Mercy electronic health records, which is one of themost compre-
hensive real‐world databases including preoperative and intraoperative
information. In this study, we defined patients with follow up pain score
as those who had at least one available follow‐up pain score 2‐week to
one‐year after index surgery. A descriptive analysis was performed to
compare patients who had both baseline and follow up pain score and
thosewho only had baseline score. Preoperative and intraoperative var-
iables associated with follow up pain score availability (p < 0.2) in crude
analysis were included in the multivariable logistic regression develop-
ment. Manual backward selection was used to obtain the final model.
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Results: Overall, 23,389 (94%) out of 24,830 TKA patients had one‐
year baseline pain score and were included in this analysis. Of which,
7,750 (33%) patients were with reported follow‐up measurement 2‐
week to one‐year after index surgery. Higher baseline pain level
(aOR: 1.04, 95% CI: 1.02, 1.05), higher ASA score (aOR: 1.18, 95%
CI: 1.11, 1.26), higher number of opiate prescription before surgery
(10‐increment: aOR: 1.13, 95% CI: 1.02, 1.25), higher number of
anticoagulation prescription before surgery (10‐increment: aOR:
1.64, 95% CI: 1.25, 2.16), longer TKA operation room time (10‐minute
increment: aOR: 1.01, 95% CI: 1.002, 1.02), and longer length of stay
(aOR: 1.16, 95% CI: 1.13, 1.19) were statistically significantly associ-
ated with increased odds of follow up pain score report.
Conclusions: Although baseline self‐reported pain report was good
(94%), longitudinal follow up pain score report in real world database
was poor (33%). Those with reported follow up pain score suffered
more pain before surgery and were with inferior general health status
compared to their counterparts without reported follow up pain.
Future studies using other real‐world data sources are warranted.
1141 | Health related quality of life and its
determinants in asthmatic patients at a
tertiary teaching and Refferal Hospital in
Kenya
Mary Consepta Alubisia; Sylvia Opanga; George Arthur Mugendi
University of Nairobi, Nairobi, Kenya
Background: Majority of patients seek help from health care providers
because they perceive their health and well‐being to be impaired. Clin-
ical indices such as spirometry though being objective in measuring
asthma control do correlate weakly with asthma symptoms and dis-
ease targeted health related quality of life (HRQoL). Since the impact
asthma has on a patient's quality of life cannot be directly inferred
from clinical indices, it must therefore be directly measured.
Objectives: To assess the Health Related Quality of Life (HRQoL) and
its predictors in asthma patients who attend Kenyatta National Hospi-
tal (KNH) chest clinic for their routine management.
Methods: Following ethical approval, a cross‐sectional study was con-
ducted among 140 consecutively sampled teenage and adult asthmatic
patients on treatment for ≥3 months. Data was collected using the
Asthma Quality of Life Questionnaire with Standardized activities
(AQLQ(S)) and Determinants of asthma control and HRQoL Question-
naire tools in a patient guided interview. Descriptive, bi‐variable analy-
sis and logistic regression was done using STATA version 13.
Results: Asthma was found to be controled in 112 (80%) of the partic-
ipants of whom slightly over half (53%) reported high HRQoL scores.
All the 28 (20%) participants in whom asthma was uncontrolled had
low HRQoL scores (p < 0.001). The independent predictors of asthma
control and HRQoL included occupational risk exposure (p = 0.008),
GERD (0.006), type 2 diabetes mellitus (0.006) and cigarette smoking
(0.029). Of the four HRQoL domains studied, the symptoms
(p = 0.004) and activity limitation (p = 0.007) domains of were signifi-
cantly impacted by poorly controlled asthma.
Conclusions: Asthma‐HRQoL outcome among patients was largely
dependent upon the degree to which asthma was controlled.
1142 | Generalizability of patient‐reported
survey data linked with electronic health
records
Stephanie Huynh1; Carey Strader2; Jennifer L. Nguyen1; Tom Haskell3
1Kantar Health, New York, NY; 2Kantar Health, St Louis, MO; 3Kantar
Health, Horsham, PA
Background: Electronic health records (EHR) are increasingly being
used in population health research and can be linked with other data
sources to draw valuable patient insights. Although some studies have
evaluated EHR data quality and comparability, currently there is a lack
of research on the generalizability of EHR data that has been linked to
other data sources.
Objectives: This study aims to assess whether a database comprised
of patient‐reported survey data linked with clinical data from EHR is
representative of the adult US population actively seeking health care.
The study uses linked data to estimate and compare the prevalence of
patient characteristics with estimates from nationally‐representative
surveys.
Methods: Patient‐Centered‐Research (PaCeR) US data (2016;
N = 39,610) consisting of nationally‐representative self‐reported data
were linked with a large US ambulatory EHR database (2012–2018;
N = 50 million+) using a HIPAA‐compliant methodology. Data from
two cross‐sectional, nationally‐representative surveys were compared
with the linked data: National Hospital Ambulatory Medical Care Sur-
vey (NAMCS) (2016; N = 13,165) and National Health Interview Sur-
vey (NHIS) (2016; N = 33,028). NAMCS and NHIS estimates were
weighted to the general US population, with NHIS analysis limited to
respondents reporting a healthcare visit in the past year. Descriptive
statistics were used to compare PaCeR‐EHR respondent characteris-
tics (e.g., age, gender, BMI) and health behaviors (e.g., smoking, alcohol
use) with estimates from NAMCS and NHIS.
Results: Across all three data sources, similar distributions were
observed for demographic characteristics including race (PaCeR‐EHR:
80.1% White, NAMCS: 68.5% White, NHIS: 79.6% White) and geo-
graphic region (PaCeR‐EHR: 20.8% Northeast, NAMCS: 20.8% North-
east, NHIS: 19.5% Northeast). The percentage of males was slightly
lower in PaCeR‐EHR (PaCeR‐EHR: 34.3%, NAMCS: 42.0%, NHIS:
45.6%), and patients aged 65+ appeared to be underrepresented in
both PaCeR‐EHR (25.4%) and NHIS (23.9%) compared with NAMCS
(33.8%). Additionally, the prevalence of current smoking (PaCeR‐
EHR: 13.2%, NHIS: 14.1%), alcohol use (PaCeR‐EHR: 65.5%, NHIS:
66.4%), and obesity (BMI ≥ 30 kg/m2; PaCeR‐EHR: 33.5%, NHIS:
33.4%) were similar in PaCeR‐EHR and NHIS; NAMCS was not com-
pared as data were not available.
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Conclusions: Overall, prevalence estimates derived from linked
PaCeR‐EHR data demonstrated agreement with two nationally‐repre-
sentative surveys. These results suggest that linked data may be gen-
eralizable to the US adult population, particularly to those actively
seeking health care.
1143 | Attitudes and perceptions towards
hypoglycaemia in patients with diabetes
mellitus: A multinational cross‐sectional study
Abdallah Y. Naser1; Ian C.K. Wong2,3; Cate Whittlesea2;
Hassan Alwafi2; Amjad Abuirmeileh1; Fawaz Turkistani4;
Nedaa S. Bokhari4; Maedeh Y. Beykloo2; Dalal Al‐Taweel5;
Zahra K. Alsairafi5; Mai B. Almane6; Li Wei2
1Al‐Isra University, Amman, Jordan; 2University College London, London,
UK; 3The University of Hong Kong, Hong Kong, Hong Kong; 4Ministry of
Health, Mecca, Saudi Arabia; 5Kuwait University, Kuwait, Kuwait; 6Al
Amiri Hospital, Kuwait, Kuwait
Background: patients' knowledge and attitude towards their disease
plays an important role in the success of diabetes management and
prevention of disease development and complications.
Objectives: to explore hypoglycaemia problem‐solving ability of
patients who have diabetes mellitus and factors which determine their
attitudes and perceptions towards their previous events.
Methods: a cross‐sectional study was conducted in three Arab coun-
tries (Jordan, Saudi Arabia, and Kuwait) in patients with diabetes
mellitus, who were prescribed antidiabetic therapy and had experi-
enced hypoglycaemic events in the past six months, for the duration
between October 2017 and May 2018. The Hypoglycaemia Prob-
lem‐Solving questionnaire was used in this study. This questionnaire
contains two subscales; problem orientation (6‐questions) and prob-
lem‐solving skills (18‐questions), using 5‐point Likert scale (range 0–
4). Multiple linear regression analysis was used to identify predictors
of hypoglycaemia problem‐solving abilities.
Results: a total of 895 patients have participated in this study from the
three countries (300 from Jordan, 302 from Saudi Arabia, and 293
from Kuwait). The mean patient age was 53.5 (SD = 13.7) years, of
which 52.4% (n = 469) were males. Around 10.4% (n = 93) of the
patients had a previous history of severe hypoglycaemia that lead to
admission during the past 6 months. Patients had moderate overall
problem‐solving ability with a median score of 63.00 (IQR = 13.00).
Patients had better problem‐solving skills score, 68.1% compared to
problem‐orientation skills score, 58.3%. The highest sub‐scale scores
were for detection control, setting problem‐solving goals, and evaluat-
ing strategies, 75.0%. The lowest sub‐scale score was for problem‐
solving perception and immediate management, 50.0%. Older age,
being educated, married, having T2DM, prescribed insulin therapy,
and not admitted to hospital for hypoglycaemia were important pre-
dictors of patients problem‐solving ability (p < 0.05).
Conclusions: Healthcare professionals advised to educate patients
more on how to self‐manage their hypoglycaemic events; specifically,
they should focus on the overall problem‐solving perception of
hypoglycaemia, and its immediate management.
1144 | Anti‐diabetic drug utilization
knowledge and glycemic index control in
patients with uncontrolled diabetes mellitus
Naima Ahmed Tamanna1,2; Md. Mehedi Hasan3; Md. Jamal Uddin4
1 Islamic University, Kushtia, Kushtia, Bangladesh; 2 Jagannath University,
Dhaka, Bangladesh; 3Square Hospitals Ltd., Dhaka, Bangladesh;
4University of Copenhagen, Copenhagen, Denmark
Background: Diabetes has become the seventh leading burden of dis-
eases in South Asia. Roughly 1 in 13 achieves treatment targets to keep
control of the glycaemic index, one of the reasons may be lack of dia-
betic drug utilization knowledge. However, there is not much research
done on the impact of drug utilization knowledge to achieve glycaemic
control in Bangladesh.
Objectives: We aimed to investigate the proper anti‐diabetic drug use
and glycemic control among uncontrolled diabetic patients.
Methods: A prospective intervention study carried out from Septem-
ber 2017 to August 2018 in BIRDEM General Hospital, Bangladesh.
A structured diabetic education regarding the disease, medication
adjustment (e.g. Metformin) and glucose monitoring including exercise
management was provided to each patient separately and patients
were followed in 3 months. Data were analyzed using a logistic regres-
sion through SPSS.
Results: Metformin was used for 47% patients and 59% of patients took
Metformin plus Insulin. For the intervention group, the averageHbA1c sig-
nificantly (p<0.001) changed frombaseline (11.59 ±2.48) to endof the fol-
low‐up (7.55 ± 0.58). Similarly, Systolic Blood Pressure and Diastolic Blood
Pressure changed from (138.31 ± 15.73) to (126.90 ± 11.15) and from
(83.33 ± 6.50) to (80.24 ± 4.12), respectively (p < 0.001). Higher educated
patients weremore likely to have improved on glycemic control than lower
educated patients [OR = 1.5, CI = 0.24–9.30].
Conclusions: Proper knowledge on anti‐diabetic drug utilization can
help in glycemic control to include prevention of diabetes, improved
quality of life and delaying of complications.
1145 | Educational intervention to improve
knowledge and skills of drug addiction
prevention among health professionals and
opinion leaders in Lagos
Ibrahim A. Oreagba1; Tajudeen Abiola2; Azuka C. Opara3
1College of Medicine University of Lagos, Lagos, Nigeria; 2Federal Neuro‐
Psychiatric Hospital Barnawa, Kaduna, Nigeria; 3Faculty of Pharmacy
University of Benin, Benin City, Nigeria
Background: Drug Addiction is a problem that is causing serious con-
cern to both individuals and government all over the world. It contrib-
utes significantly to morbidity and mortality in our population and to
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the cost of health care. However, with effective intervention pro-
gramme, the problem can be tackled.
Objectives: To evaluate the impact of an educational intervention to
improve knowledge, attitude and skills of addiction prevention among
health professionals and representative stakeholders in Lagos East
Senatorial District.
Methods: A pre‐post educational intervention study designed to eval-
uate knowledge and skills of participants immediately and one month
after the workshop using a 36‐item structured questionnaire. The par-
ticipants were a representative group of stakeholders in the health
sector with a great potential to influence drug addiction in their
respective communities. Descriptive analysis was performed on the
data and the overall statistical test among the groups was done using
Analysis of variance (ANOVA). The primary outcome was the change
in overall score from pre‐test to post‐test and one month post test.
Results: The mean (SD) pre‐test score for the entire cohort was 30.59
(SD 5.85), and the post‐test score was 32.81 (5.27). Scores were sig-
nificantly improved from pre‐test to post‐test; mean difference (95%
CI) = 2.227 (0.1932, 4,260). 26 participants (37%) completed the on‐
line follow‐up survey. There was no significant difference between
mean pre‐test scores and mean one month post test scores (30.59
SD5.85 Versus 29.54 SD2.44).
Conclusions: This study shows that although participants had a good
addiction related baseline knowledge and skills, this was significantly
increased through an educational intervention workshop on Addiction
Prevention. This increased knowledge and skills was however not
sustained after one month of the workshop. Majority of respondents
coped well with the stress that accompany addiction prevention
campaign.
1146 | Risk of major bleeding associated
with the use of direct oral anticoagulants
compared to vitamin K antagonists in patients
with atrial fibrillation: A European multi‐
country population‐based cohort study
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Copenhagen, Copenhagen, Denmark; 7Copenhagen Centre for Regulatory
Science, Department of Pharmacy, University of Copenhagen,
Copenhagen, Denmark
Background: Non‐Valvular Atrial fibrillation (NVAF) is one of the most
common cardiac rhythm disorders. The introduction of direct oral anti-
coagulants (DOACs) has broadened the treatment arsenal for NVAF
compared to the traditional vitamin K antagonists (VKAs), but observa-
tional studies on the benefit–risk balance of DOACs vs VKAs are
needed.
Objectives: To characterize the risk of major bleeding in DOAC users in
a real‐world setting using longitudinal data collected in four electronic
health care databases from different EU countries.
Methods: A cohort study was conducted among new users (≥18 years)
of DOACs or VKAs with NVAF using electronic health care data from
the United Kingdom (UK; CPRD), Spain (BIFAP), Germany (AOK) and
Denmark (Danish National Registers). The incidence of major bleeding
events (both overall and by site) and any stroke was compared between
periods of current use of DOACs andVKAs. Cox regression analysiswas
used to estimate hazard ratios (HR) with 95% confidence intervals (CI)
and adjust for confounders. Several sensitivity analyseswere performed
(changing permissible gap length between prescriptions, using hospital
admissions only, excluding certain bleeding sites).
Results: In total 251,719 patients were included in the four study
cohorts (mean age ~75 years, % females between 41.3 and 54.3%), with
overall HRs of major bleeding risk for DOACs vs VKAs ranging between
0.84 (95% CI: 0.79–0.90) in Denmark and 1.13 (95% CI 1.02–1.25) in
the UK.When stratifying according to bleeding site, the risk of gastroin-
testinal (GI) bleeding (the majority of events) was statistically significant
increased by 48–67% in dabigatran (DBG) users and 30–50% for
rivaroxaban (RIV) users compared to VKA users in all data sources
except Denmark. The risk of any stroke was increased for RIV (HR
1.78, 95% CI 1.29–2.44) and apixaban (APX, HR 2.20, 95% CI: 1.45–
3.30) vs VKAs in the UK. Sensitivity analyses did not yield substantially
different results.
Conclusions: Compared to VKAs, APX was not associated with an
increased risk of GI bleeding in all data sources and seemed to be have
with the lowest risk of any major bleeding events vs VKAs when com-
pared to DBG and RIV. An increased risk of stroke was seen in the UK.
Differences in risk estimates obtained in randomized controlled trials
and other observational studies with this study could be partially due
to design (e.g. patient selection, dealing with drug discontinuation) and
definition choices (e.g. outcome coding) and ask for more transparency
in methods used.
1147 | Adverse drug event reporting among
patients who discontinued Empagliflozin or
Apixaban in the veterans health
administration
Paul M. Fina1; Francesca E. Cunningham2; Xinhua Zhao3;
Peter A. Glassman2; Von R. Moore2; Anthony Au2; Sherrie L. Aspinall2
1Chicago State University, Chicago, IL; 2VA Center for Medication Safety,
Hines, IL; 3VA Pittsburgh Healthcare System, Pittsburgh, PA
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Background: Passive and active surveillance of adverse drug events
(ADEs) are used to help inform safe and appropriate medication use.
However, providers are often expected to use multiple passive surveil-
lance systems when a patient experiences an ADE, and despite
advancements, it is unclear how often ADEs get into these spontaneous
reporting databases.
Objectives: To examine reporting rates at increasingly “higher” levels
of spontaneous reporting systems (i.e., point of care, then national
VA healthcare system, and then the FDA) of apixaban and
empagliflozin ADEs that led to discontinuation of the medication.
Methods: This was a retrospective cohort study of outpatients who
discontinued apixaban or empagliflozin within three years of FDA
approval. To increase the probability of finding patients who experi-
enced an ADE, we used an active surveillance strategy and identified
a subset of patients with ICD‐9/10 codes associated with a possible
ADE (e.g., GI bleed‐apixaban, ketoacidosis‐empagliflozin). Stratified
random samples of charts were reviewed to determine if patients
discontinued the medication due to an ADE. Then, we ascertained if
ADEs noted in the charts were entered into the VA electronic health
record/point of care reporting system (Adverse ReactionTracking Sys-
tem [ARTS]), VA national web‐based system (VA Adverse Drug Event
Reporting System [VA ADERS]), and FDA MedWatch, three spontane-
ous reporting databases.
Results: From the cohort of 2,973 patients who discontinued
apixaban, 321 (10.8%) were randomly sampled for chart review (61
patients with ICD codes for GI bleed and/or intracranial hemorrhage).
During chart review, 88 ADEs were identified; 40/61 (65.6%) from the
subset with ICD codes. Of the 88 total ADEs, 23.3%, 10.2%, and 6.8%
were reported in ARTS, VA ADERS, and FDA MedWatch, respectively.
Of the 1,555 patients who discontinued empagliflozin, 179 (11.5%)
were randomly sampled for chart review (40 patients with ICD codes
for ketoacidosis and/or amputation). During chart review, 78 ADEs
were identified; 19/40 (47.5%) from the subset with ICD codes. Of
the 78 total ADEs, 28.2%, 19.2%, and 7.7% were reported in ARTS,
VA ADERS, and FDA MedWatch, respectively.
Conclusions: We found substantial underreporting of apixaban and
empagliflozin ADEs that became worse at each “higher” level of spon-
taneous reporting. Improvements are needed at all levels, but one pos-
sibility is the use of ICD codes to identify potential ADEs; then, ensure
actual ADEs are included in the electronic health record reporting sys-
tem so the information is available for patient care decision making.
1148 | Complementary use of US FDA
adverse event reporting system and sentinel
distributed database to characterize Non‐
Vitamin K Oral Anticoagulants associated
Cutaneous Small Vessel Vasculitis
Mohamed Mohamoud1; Casie Horgan2; Veronica Sansing‐Foster1;
Elizabeth Dee2; Justin Bohn2; Oren Shapira2; Mihaela Jason1;
Efe Eworuke1; Monica Munoz1; Danijela Stojanovic1;
Lois La Grenade1
1United States Food and Drug Administration, Silver Spring, MD;
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Boston, MA
Background: Cutaneous Small Vessel Vasculitis (CSVV) has been
reported with Non‐Vitamin K Oral Anticoagulants (NOACs).
Objectives: To describe the temporal association between NOACs
and CSVV and inform subsequent inferential analysis using the FDA
Adverse Event Reporting System (FAERS) database and the Sentinel
Distributed Database (SDD).
Methods: We queried FAERS for all reports of CSVV associated with
NOACs from US approval date of each NOAC to March 16, 2018. We
used SDD from January 1, 2010 to June 30, 2018 to identify the inci-
dent CSVV cases among adults aged≥30 who received a NOAC in the
prior 90 days with no evidence of select autoimmune diseases in the
183 days prior to their CSVV diagnosis. We used NDCs and ICD‐9‐
CM/ICD‐10‐CM codes to define inclusion and exclusion criteria. We
also identified the recorded history of skin biopsy and corticosteroid
treatment within 14 and 90 days of CSVV diagnosis, respectively.
Results:Weidentified47probablecasesofCSVVwithrivaroxaban(n=25),
apixaban(n=14),dabigatran(n=7),andedoxaban(n=1)inFAERS.Themean
age for all caseswas74 years (range28–90years). Atrial fibrillation (Afib)
wasthemostcommonindicationforallNOACs(n=29).Themediantime‐
to‐onset was 10 days. When specified, the predominant type of CSVV
reported was leukocytoclastic vasculitis (n = 24), followed by Henoch‐
Schonlein purpura (n = 4). Hospitalization occurred in most of the cases
(n=34). Switchingof theoffendingagentafter thedevelopmentofCSVV
wasreported[(n=23)anotherNOAC(n=8),VKAs(n=7),LMWH(n=8)].Cor-
ticosteroids was the most frequently reported treatment (n = 26). Two
rivaroxaban(n=2)casesandonedabigatrancase(n=1)reportedapositive
rechallenge. In SDD, we identified 3,659 CSVV cases with prior NOAC
exposure,with 85%of events occurringwithin 10 days. Themean ageof




(30.7%). Similar to theFAERScases, themostcommonCSVVdiagnosis in
SDDwasvascular disorders of the skin (1,040patients; 28.4%), followed
byHenoch‐Schonleinpurpura(752patients;20.6%).
Conclusions: In both FAERS and SDD, the majority of CSVV cases
occurred within 10 days after exposure to NOACS, suggesting a pos-
sible cutaneous reaction. Future efforts will characterize the risk of
CSVV among the various NOAC users.
1149 | Fluoroquinolone use and serious
arrhythmias: A Nationwide case‐crossover
study
Lorenzo Porta1; Meng‐tse Gabriel Lee2; Wan‐Ting Hsu3;
Tzu‐Chun Hsu2; Chien‐Chang Lee2
1Università degli studi di Milano Bicocca, Milan, Italy; 2National Taiwan
University Hospital, Taipei, Taiwan; 3Harvard TH Chan School of Public
Health, Boston, MA
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Background: Fluoroquinolones have been associated with life‐threat-
ening ventricular arrhythmias and even sudden cardiac death.
Objectives: We aimed to assess the temporal relationship of fluoro-
quinolone use and serious arrhythmias via a case‐crossover analysis
of a large cohort of serious arrhythmias patients.
Methods: In a national administrative database, we compare the distri-
butions of fluoroquinolone exposure for the same patient across a 30‐
day period before the serious arrhythmia event and 5 randomly
selected 30‐day periods before the serious arrhythmia event. Odds
ratios (ORs) and 95% Confidence Intervals (CIs) were estimated using
conditional logistic regression analysis.
Results: From a total of 2 million participants, 7657 patients with seri-
ous arrhythmias were identified. Use of fluoroquinolones within the
30‐day period before the event was significantly associated with
increased risk for serious arrhythmia (OR: 3.03, 95% CI: 2.48, 3.71).
The risk association was attenuated, but remains significant after
adjustment for time‐varying confounders (OR: 1.48, 95% CI: 1.18,
1.86). A consistent increase in risk of serious arrhythmia was observed
for all time windows investigated (7 days, 14 days, 30 days, 60 days
and 90 days).
Conclusions: Exposure to fluoroquinolones was substantially associ-
ated with serious arrhythmic events, independent of the temporal
proximity of fluoroquinolone prescription.
1150 | A self controlled case series of
fluoroquinolone exposure and the risk of
aortic aneurysm or dissection
Ajit A. Londhe1; Chantal Holy2; James Weaver1; Sergio Fonseca1;
Angelina Villasis1; Daniel Fife1
1 Janssen Research and Development, Titusville, NJ; 2 Johnson and
Johnson, New Brunswick, NJ
Background: Four recent epidemiologic studies suggest increased risk
of Aortic Aneurysm or Dissection (AAD) after exposure to
Fluoroquinolones (FQ). Each acknowledged potential biases including
those from unobserved patient characteristics. This study evaluated
the risk of AAD following exposure to systemic FQs and other com-
mon antibiotics as well as untreated febrile illness using a study design
that minimizes such biases by controlling for within‐patient, unob-
served characteristics.
Objectives: Evaluate the risk of AAD following 1) exposure to FQs, 2)
exposure to other common antibiotics, and 3) untreated febrile illness.
Methods: We used a SCCS analysis in 3 US claims databases to assess
the association of 3 collagen‐related outcomes with exposure to FQs,
amoxicillin, azithromycin, trimethoprim with and without sulfamethox-
azole, and febrile illness not treated with antibiotics. Here we reported
the association with AAD. Risk windows were defined as drug expo-
sure period plus 30 days or observed febrile illness duration plus
30 days. Patients of all ages with outcomes and exposures between
2012 and 2017 were included. P values were calibrated using 38 neg-
ative control exposures (i.e., exposures known not to affect AAD) to
adjust for residual bias and pre‐exposure windows were used to eval-
uate timing of outcomes relative to exposures.
Results: Across all databases, negative control exposures produced
effect estimates for AAD that were on average greater than the hypo-
thetical null (i.e., incidence rate ratio [IRR] = 1) and indicative of resid-
ual bias, supporting the use of calibrated p values. In all databases, a
peak in AAD events was observed during the 60 days before first
exposure to FQ and trimethoprim with sulfamethoxazole, with IRRs
increasing from the 60‐ to 30‐day pre‐exposure window to the 29‐
to 1‐day pre‐exposure window. The IRR for AAD in the 29 days pre-
ceding FQ exposure ranged from 2.38 (95%CI: 2.22–2.55) to 3.45
(95%CI: 3.09–3.85) across databases. The IRR following FQ exposure
decreased to values ranging from 1.20 (95%CI: 1.12–1.30, calibrated
p 0.82) to 1.85 (95%CI: 1.64–2.08, calibrated p 0.24).
Conclusions: This study does not confirm results from prior studies
suggesting an association between FQs and AAD. Using calibrated p
values, the IRRs for AAD following FQ exposure were not significant.
In addition, a peak in AAD events was observed in the 60 days before
the first FQ exposure, casting doubt on the temporality of the effect
of FQ on AAD.
1151 | Acetylcholinesterase inhibitors,
cardiosuppresive drugs, and adverse cardiac
events in patients with dementia
Izumi Sato1,2; Isao Iwata3; Edward Chia‐Cheng Lai4; Soko Setoguchi1
1 Institute for Health, Health Care Policy and Aging Research‐ Rutgers,
The State University of New Jersey, New Brunswick, NJ; 2Graduate
School of Medicine, Kyoto University, Kyoto, Japan; 3Rutgers Robert
Wood Johnson Medical School, New Brunswick, NJ; 4National Cheng
Kung University, Tainan, Taiwan
Background: Acetylcholinesterase inhibitors (AChEI), widely used to
treat dementia, have a theoretical chronotropic effect. Thus, patients
using both AChEI and cardio‐suppressive drugs (CS) can have exces-
sive risks for bradycardia and atrioventricular (A‐V) block resulting in
syncope and/or pacemaker implantation.
Objectives: To assess the effect of a single and/or combined use of
AChEI and CS on syncope and permanent pacemaker implantation in
patients with dementia.
Methods: We conducted a cohort study of older adults with dementia
(age ≥ 65) residing in skilled nursing facility (SNF) enrolled in Medicare
Part D (7/2007–12/2013) in the US Medicare and the Minimum Data
Set (MDS). We identified four groups within a cohort of dementia
patients identified by validated definition; users of 1) concomitant
AChEI and CS (dual), 2) AChEI only, 3) CS only (CS), and 4) none of
either. The primary and secondary outcomes were syncope identified
as emergency department or inpatient diagnosis and new pacemaker
implantation. We calculated adjusted hazard ratios (HRs) in multivari-
able Cox proportional hazard regression models. We estimated rela-
tive excess risk due to interaction (RERI) for additive interaction in
the primary outcome.
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Results: We identified 159,038 subjects (mean age 83 years old, 71.%
female). Dual users (n = 15,311, 10%) had similar characteristics as CS
(n = 38,395, 24%) and none users (n = 80,548, 51%), had more heart
failure, cerebrovascular disease, pulmonary disease, and renal disease
compared to AChEI users (n = 24,784, 16%). The incidence rates for
dual, AChEI, CS and none users were 92, 75, 71 and 29 per 1,000 per-
son‐years (PY) for syncope and 4, 4, 3 and 2 per 10,000 PYs, respec-
tively. Adjusted HRs (95% CI,) for syncope comparing single were
2.1 (2.0–2.3) for dual use, 1.8 (1.6–1.9) for AChEI use, and 1.6 (1.5–
1.8) for CS use compared to none users. Adjusted HRs for new pace-
maker implantation for dual, AChEI, CS use were 2.2 (0.7–6.7), 2.1
(0.7–6.0), and 1.6 (0.6–4.19). The RERI for syncope was −0.1
(95%CI,‐0.6–0.4).
Conclusions: A single user of CS or AChEI was associated with a 1.6 or
1.8 fold increase in the risk of syncope among older SNF residents
even after adjusting for potential confounders including functional sta-
tus. The risk was significantly higher in dual users (2.1 fold), but no evi-
dence of additive interaction was found. While the risk patterns were
similar for pacemaker outcome, the effect estimates were not statisti-
cally significant due to small numbers. Clinicians should be aware of
the observed syncope risks from a single or dual use of CS and/or
AChEI in older patients with dementia.
1152 | Concomitant use of dronedarone and
dabigatran is not associated with increased
risk of major bleeding
Chuntao Wu1; Rania Boiron2; Juhaeri Juhaeri1
1Sanofi, Bridgewater, NJ; 2Sanofi, Chilly‐Mazarin, France
Background: Pharmacokinetic and pharmacodynamic studies have
shown that concomitant use of dronedarone can increase the expo-
sure to dabigatran 150 mg bid by two‐fold compared to using
dabigatran alone.
Objectives: To evaluate the risk of major bleeding in patients who
concomitantly used dronedarone and dabigatran in comparison to
those who used dabigatran alone.
Methods: Patients aged 18 years or older with a diagnosis of atrial
fibrillation or flutter who concomitantly used dabigatran and
dronedarone or used dabigatran alone between July 20, 2009 and
September 30, 2011 were identified in the Clinformatics database. A
patient's index date was defined as the date of the first concomitant
exposure to dabigatran and dronedarone or the date of the first dis-
pensing of dabigatran in the dabigatran alone users after July 20,
2009. Patients were excluded from analysis if there was less than six
months of enrolment in the database prior to the index date or there
was a diagnosis of major bleeding, defined using ICD diagnosis and
procedure codes, within the last six months prior to the index date.
The first major bleeding event while on treatment of interest was
identified from the index date to the end of study (September 30,
2011). Adjusted hazard ratio was calculated using Cox proportional
hazards model to evaluate the potential association between
concomitant use of dronedarone and dabigatran and the risk of major
bleeding, controlling for age, sex, year of index date, and use of antico-
agulants, antiplatelet agents, heparin, and other antithrombotic agents.
Results: A total of 638 patients who used dabigatran in combination
with dronedarone and 5,201 patients who used dabigatran alone were
identified. A total of 7 events of major bleeding were identified in the
concomitant users (incidence rate = 4.0 per 100 person‐years), and 94
events were identified in the dabigatran alone group (incidence
rate = 4.4 per 100 person‐years). The adjusted hazard ratio of major
bleeding was 0.82 (95% confidence interval: 0.32, 2.13) for concomi-
tant use of dronedarone and dabigatran compared to dabigatran alone.
Conclusions: The results of this study suggest that the risk of major
bleeding in concomitant dronedarone and dabigatran users was not
different from dabigatran alone users.
1153 | Hospitalization for heart failure
among patients using aclidinium bromide and
other COPD medications: A post‐
authorisation safety study in the CPRD
Estel Plana1; Elena Rivero‐Ferrer1; Jaume Aguado1;
Nuria Saigi‐Morgui1; Javier Nuevo2; Sami Z. Daoud3; Alejhandra Lei4;
Susana Perez‐Gutthann1; Cristina Rebordosa1
1RTI Health Solutions, Barcelona, Spain; 2Global Medical Affairs,
AstraZeneca, Madrid, Spain; 3Global Clinical Lead, AstraZeneca,
Gaithersburg, MD; 4Patient Safety RIA, AstraZeneca, Barcelona, Spain
Background: Aclidinium is an inhaled, long‐acting anticholinergic
(LAMA) approved in Europe in 2012 as a maintenance bronchodilator
to relieve symptoms in adults with chronic obstructive pulmonary dis-
ease (COPD). There have been safety concerns related to a potential
increase in heart failure (HF) events with the use of LAMA
medications.
Objectives: To estimate the adjusted incidence rate ratio (IRR) for HF
in patients with COPD initiators of aclidinium, tiotropium, other
LAMA, long‐acting beta‐agonists/inhaled corticosteroids (LABA/ICS),
and LAMA/LABA compared with initiators of LABA.
Methods: This population‐based cohort study included patients with
COPD aged 40 years or older initiating COPD medications in the Clin-
ical Practice Research Datalink (CPRD) in the United Kingdom from
2012 to 2017. First‐ever hospitalizations for HF events were identi-
fied in the Hospital Episode Statistics, the Office for National Statis-
tics, and general practitioner (GP) records from the CPRD and
validated by a review of patient profiles and questionnaires sent to
GPs. Poisson regression models were used to estimate the IRR of
HF for current use of COPD medications versus current use of LABA
adjusting for age, sex, COPD severity (GOLD 2016 definition), asthma,
diuretics, inhaled corticosteroids, and prior outpatient diagnosis of
chronic heart failure.
Results: The study included 4,350 new users of aclidinium, 23,405 of
tiotropium, 6,977 of other LAMA, 3,122 of LAMA/LABA, 26,093 of
LABA/ICS, and 5,678 of LABA (patients could enter more than one
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cohort). The mean age ranged from 69 to 70 years, and 48% to 52%
were females across study cohorts. Aclidinium users had the highest
proportion of severe COPD (category D), and LABA users had the low-
est (35% vs. 19%). The number of HF events/person‐years during cur-
rent use was 36/3,783 for aclidinium, 136/24,490 for tiotropium, 40/
5,036 for other LAMA, 13/1,571 for LAMA/LABA, 213/29,036 for
LABA/ICS, and 30/4,339 for LABA. Incidence rates ranged from 6.9
in LABA to 9.5 per 1,000 person‐years in aclidinium. Using LABA as
reference, for current use, the adjusted IRRs (95% confidence interval)
of HF were 0.90 (0.53, 1.53) for aclidinium, 1.02 (0.69, 1.51) for
tiotropium, 0.86 (0.50, 1.47) for other LAMA, 1.09 (0.41, 2.92) for
LAMA/LABA, and 1.01 (0.69, 1.48) for LABA/ICS.
Conclusions: Compared with LABA users, the study did not find an
increased risk of HF in new users of aclidinium, despite increased
COPD severity, nor in users of other COPD medications.
1154 | Major bleeding risk associated with
Oral anticoagulant in real clinical practice. A
multicentre population‐based prospective
cohort study over a period years
Jacques Bouget1; Frédéric Balusson1; Maxime Maignan2;
Laure Pavageau3; Pierre‐Marie Roy4; Karine Lacut5;
Lucie‐Marie Scailteux1; Emmanuel Nowak6; Emmanuel Oger1
1Univ Rennes, CHU Rennes, EA 7449 [Pharmacoepidemiology and Health
Services Research] REPERESF 35043 Rennes, Rennes, France; 2Grenoble
University Hospital, Grenoble, France; 3Nantes University Hospital,
Nantes, France; 4Angers University Hospital, Angers, France; 5Brest
University Hospital, Brest, France; 6Université de Bretagne Loire,
Université de Brest, INSERM CIC 1412, Brest, France
Background: Vitamin K antagonists (VKAs) and direct oral anticoagu-
lants (DOACs) are widely used in nonvalvular atrial fibrillation (AF),
but also in other indications. Real world data assessing safety has
mostly made use of administrative data for AF patients. The outcome
validity is therefore questionable.
Objectives: Main objective was to compare major bleeding risk per
type and dose of DOACs with VKAs, whatever the indication.
Methods: A population‐based prospective cohort study, using the
French national health data system (SNIIRAM), identified 47,469
adults living within five well‐defined geographical areas, who were
new users of oral anticoagulants in the period 2013–2015. From all
emergency departments within these areas, clinical data for all
referred for bleeding was collected and medically validated. Databases
were linked for common key variables. The main outcome measure
was time to major bleeding: intracranial hemorrhage, major gastroin-
testinal bleeding and other major bleeding events. Hazard ratios were
derived from adjusted Cox proportional hazard models. Used propen-
sity score weighting as a sensitivity analysis with separate analyses
according to indications (AF or venous thromboembolism).
Results: Compared to VKAs, full and reduced‐dose DOACs were asso-
ciated with a reduced risk of intracranial hemorrhage (adjusted hazard
ratio 0·55, 95% confidence interval 0·37 to 0·82 and 0·36, 0·18 to
0·79, respectively), and a reduced risk of other major bleeding events
(0·41, 0·29 to 0·58 and 0·27, 0·14 to 0·51 respectively), irrespective of
duration and indication. Neither DOAC dose was significantly differ-
ent from VKAs in terms of risk of major gastrointestinal bleeding.
Among patients with AF, full‐dose apixaban was associated with bet-
ter event‐free survival than VKAs or rivaroxaban.
Conclusions: There is a clear benefit in using DOACs with regard to
intracranial hemorrhage. The study provides new insight into major
gastrointestinal and other bleeding events.
1155 | Heart failure and AKI after hospital
admission with AKI among patients taking
ACE inhibitors and ARBs
Patrick Bidulka1; Fotini Kalogirou2; Edward Kingdon3;
Krishnan Bhaskaran1; Liam Smeeth1; Laurie Tomlinson1;
Dorothea Nitsch1
1London School of Hygiene & Tropical Medicine, London, UK; 2Cambridge
University Hospitals NHS Foundation Trust, Cambridge, UK; 3Brighton
and Sussex University Hospitals NHS Trust, Brighton, UK, Brighton, UK
Background: Angiotensin‐converting enzyme inhibitors (ACEI) and
angiotensin receptor blockers (ARBs) are believed to be associated
with a higher risk of acute kidney injury (AKI). The drugs are often
withheld following AKI. However, the effects of discontinuing these
drugs on outcomes like subsequent AKI and heart failure (HF) are
uncertain.
Objectives: To compare the rate of admission with HF or AKI among
patients who stopped ACEI/ARBs following discharge after AKI to
the rate in patients who were re‐prescribed the drugs.
Methods: We conducted a cohort study in the United Kingdom using
linked primary and secondary care data from the Clinical Practice
Research Datalink (CPRD) and the Hospital Episodes Statistics (HES).
We included patients with AKI recorded as a primary cause of hospital
admission between 2010–2016, and were prescribed an ACEI/ARB
within 60 days prior to the AKI admission. The primary outcomes were
re‐admission to hospital with HF, or (separately) AKI. We compared
rates of re‐admission for each outcome among patients prescribed
or not prescribed ACEI/ARBs post‐discharge (excluding the first
60 days post‐discharge to capture prescriptions) using multivariable
Cox regression. We stratified hazard ratios for HF admission by
spironolactone prescription prior to baseline AKI admission.
Results: The study population included 18,816 patients with a mean
age of 78 years (SD 11). Crude rates (per 1000 person‐years) for re‐
admission with HF in people with prior spironolactone prescription
was 244 (95% CI 222–267), and without a spironolactone prescription
was 70.8 (95% CI 67.3–74.5). The crude rate for re‐admission with
AKI was 105 (95% CI 100–109). Comparing patients who stopped
ACEI/ARBs post‐discharge with those re‐prescribed the drugs, the
adjusted hazard ratio (HR) for admission with HF was 0.98 (95% CI
0.88–1.11) among patients not prescribed spironolactone and 1.11
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(95% CI 0.90–1.36) for those prescribed spironolactone (p‐value for
interaction 0.34). For subsequent AKI, the adjusted HR was 0.88
(95% CI 0.81–0.97).
Conclusions: Rates of admission with HF and AKI are high following
an initial AKI hospitalization, reflecting a substantial burden on
health services. After an initial AKI we did not find an increase in
risk of re‐admission with HF among patients not re‐prescribed
ACEI/ARBs after AKI hospitalization including among those previ-
ously prescribed spironolactone. There is a potential protective
effect of ACEI/ARB cessation on subsequent re‐admission with
AKI. Ongoing work is exploring the impact of potential limitations
including survivor bias and confounding by indication and frailty.
1156 | The cardiovascular safety of anti‐
obesity drugs
Einat Gorelik1; Ilan Matok1; Boris Gorelik2; Reem Masarwa1;
Amichai Perlman1; Bruria Hirsh‐Raccah1
1The Hebrew University of Jerusalem, Jerusalem, Israel; 2N/A, N/A, Israel
Background: Over the past several decades, many anti‐obesity drugs
have been withdrawn from the market due to unanticipated adverse
events, often involving cardiotoxicity.
Objectives: This study aimed to evaluate the presence of cardiovascu-
lar safety signals with currently marketed anti‐obesity drugs.
Methods: We used the US Food and Drug Administration Adverse
Event Reporting System (FAERS) database and retrieved data from
January 2013 through September 2017. We performed
disproportionality analyses to detect cardiovascular safety signals
with three anti‐obesity drugs recently approved for marketing:
lorcaserin, naltrexone‐bupropion, and phentermine‐topiramate. Three
main cardiovascular outcomes were evaluated: cardiovascular
events (myocardial infarction, stroke, cardiovascular death, cardiac
failure, and arrhythmia), valvular disorders, and pulmonary
hypertension.
Results: During the evaluated period, a total of 5,385,720 adverse
event reports were submitted to FAERS. Of these, 2,559 involved
lorcaserin, 2,503 involved phentermine‐topiramate, and 2,609
involved naltrexone‐bupropion. None of the anti‐obesity drugs were
associated with a safety signal for cardiovascular events. However,
lorcaserin was associated with a significantly greater proportion of
reports of valvular disorders (ROR = 7.32; 95%CI 4.81–11.15) and
a small but significant increase in the proportion of reporting of pul-
monary hypertension (ROR = 1.91; 95%CI 1.05–3.45).
Conclusions: Our analyses did not detect a safety signal for most car-
diovascular events with recently approved anti‐obesity drugs. How-
ever, a signal was present for valvular disorders and pulmonary
hypertension with lorcaserin. Further research is needed to explore
and validate this signal.
1157 | Can enzyme‐inducing AEDs and
DOACs be co‐prescribed? Assessing
concordance between drug compendia for
proposed interactions
Emily K. Acton1,2; Allison W. Willis1,2; Michael Gelfand1;
Scott E. Kasner1
1University of Pennsylvania, Philadelphia, PA; 2University of Pennsylvania
School of Medicine, Philadelphia, PA
Background: Enzyme‐inducing antiepileptic drugs (EI‐AEDs) and direct
oral anticoagulants (DOACs) are commonly co‐prescribed, with an
estimated 100,000 concomitant prescriptions from just one large U.
S. commercial health insurer. This high prevalence of co‐prescriptions
is concerning given the mechanistically‐probable, yet scarcely
researched, pharmacokinetic interactions between these drug classes.
A crucial step to understanding current prescribing practices is to
assess consistency of classifications for these interactions by major
drug compendia.
Objectives: To compare the concordance of proposed interactions
between EI‐AEDs and DOACs as reported in leading, international
drug compendia.
Methods:We assessed consistency of interaction reporting and sever-
ity rankings for each DOAC with a group of EI‐AEDs among 8 provider
and consumer‐focused drug compendia: Cerner Multum, Clinical Phar-
macology, Drug Facts & Comparisons, Epocrates, Lexicomp,
Medscape, Micromedex, and RxList. Discrepant severity ranking sys-
tems between compendia were consolidated on a 0–4 scale. Concor-
dance was quantified using quadratically‐weighted Scott/Fleiss'
Kappa (wк).
Results: In ascending order, by DOAC, concordance among drug
compendia for presence and severity of interactions with EI‐AEDs
were: edoxaban (wк 0.08, 95% CI ‐0.32, 0.47), rivaroxaban (wк 0.34,
95% CI ‐0.37, 1.00), dabigatran (wк 0.48, 95% CI ‐0.23, 1.00), and
apixaban (wк 0.48, 95% CI ‐0.27, 1.00). The newest DOAC,
betrixaban, was consistently listed as not interacting with EI‐AEDs in
almost all assessed compendia (wк unreportable due to high concor-
dance), despite overlap in P‐glycoprotein induction‐based interaction
mechanism with other DOACs. Extreme inconsistences in interaction
reporting (i.e., some compendia assigning the highest possible severity
ranking, while others reported no interactions) were observed for 10
of the 25 individually examined interactions (40%).
Conclusions: We found inconsistent inclusion and severity rankings
for EI‐AED/DOAC interactions among the current standard drug
compendia used to guide prescription. Future studies are needed to:
(1) understand underlying reasons for inconsistent evidence reporting
within drug compendia; and, (2) generate high‐quality evidence
regarding EI‐AED/DOAC interactions to yield widespread and consis-
tent impacts on drug compendia and clinical practice.
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1158 | Celecoxib and cardiovascular safety:
Replicating clinical trial evidence from real
world data
Ayad K. Ali; Stephen P. Motsko
Eli Lilly and Company, Indianapolis, IN
Background: The PRECISION cardiovascular outcomes trial compared
celecoxib with other non‐steroidal anti‐inflammatory drugs (NSAIDs)
and did not show a link between celecoxib use and cardiovascular
safety. However, there are uncertainties about this risk in real‐world
settings.
Objectives: Using real‐world data to replicate findings from the PRECI-
SION trial.
Methods: Longitudinal patient data fromUSTruvenHealthMarketScan
(Truven) and UK Clinical Practice Research Datalink (CPRD) databases
were used to compare the incidence of major adverse cardiovascular
events (MACE) among adults with rheumatoid arthritis (RA) or osteoar-
thritis (OA) who initiated celecoxib vs. ibuprofen or naproxen. A com-
posite outcome of MACE comprised of non‐fatal myocardial
infarction, stroke, or unstable angina was defined by a combination of
diagnosis and procedure codes in the corresponding databases. Expo-
sure propensity scores were used to 1:1 match celecoxib initiators with
either of other NSAIDs initiators with 36‐months follow‐up. Patients
were followed until the occurrence of MACE, death, end of follow‐up,
end of data, or disenrollment, whichever occurred first. Risk ratios (RR)
and 95%CI were reported to estimate the risk of non‐fatal MACE for
both cohorts (celecoxib vs. ibuprofen; celecoxib vs. naproxen).
Results: InTruven, a total of 534,368 celecoxib and ibuprofen initiators,
and 545,530 celecoxib and naproxen initiators were matched. In CPRD,
a corresponding 20,206 and 35,186werematched. Patients in UKwere
older than those in US (mean age 67 vs. 60). On average patients in UK
had longer duration of RA/OA (3.8 vs. 1.4 years), in part, reflecting the
differences between database types.MACE risk in Celecoxib vs. ibupro-
fen (Truven, RR = 0.96, 95%CI = 0.94–0.98; CPRD, RR = 0.92,
95%CI = 0.75–1.14); celecoxib vs. naproxen (Truven, RR = 0.95,
95%CI = 0.93–0.97; CPRD, RR = 1.04, 95% CI = 0.89–1.22). the main
analysis results from both data sources were comparable to those from
the PRECISION trial: Celecoxib vs. ibuprofen (RR = 0.87, 95%CI = 0.75–
1.01); celecoxib vs. naproxen (RR = 0.97, 95%CI = 0.83–1.12).
Conclusions: Celecoxib initiators are not associated with an increased
risk for non‐fatal MACE compared to other conventional NSAIDs.
Real‐world data and analytics replicated the clinical trial evidence with
a fraction of the time and cost.
1159 | Oral fluoroquinolones use and risk of
aortic aneurysm and dissection: A meta‐
analysis of epidemiological studies
Md Salman Hussain; Abul Kalam Najmi
Jamia Hamdard, New Delhi, India
Background: Fluoroquinolones are the most commonly prescribed
antibiotics globally. In the last few years, several published epidemio-
logical studies raised alarm over its safety profile on its association
with aortic aneurysm (AA) or aortic dissection (AD).
Objectives: This meta‐analysis is aimed to assess the pooled risk of AA
or AD associated with the use of fluoroquinolones.
Methods: Electronic databases (PubMed, Embase, and Cochrane)
were searched for published studies assessing the association
between fluoroquinolones use and risk of AA or AD. Search was per-
formed by two independent reviewers using a combination of suitable
keywords from inception to January 2019. Risk of AA or AD associ-
ated with fluoroquinolones use was considered as the primary out-
comes. Two reviewers selected the articles, extracted data, and
carried out a critical appraisal using the Newcastle‐Ottawa Scale. Sta-
tistical analysis was performed using Review Manager software v5.3.
Results: Only four studies were eligible for inclusion in the meta‐anal-
ysis. Two studies were cohort in nature while remaining studies
followed case–control and case‐crossover design. All of the included
studies were of high quality. AA or AD cases were diagnosed based
on the international classification of diseases‐9 or 10 codes. Due to
the absence of significant heterogeneity analysis was performed using
the fixed effects model. Fluoroquinolones use was found to be signif-
icantly associated with the increased risk of AA or AD with a relative
risk (RR) of 2.33 (95% CI: 1.99–2.73), p < 0.00001 in an adjusted anal-
ysis (adjusted for various confounding factors). In subgroup analysis,
the RR for the association with fluoroquinolone use was 2.25 (95%
CI: 2.03–2.49), p < 0.00001 for AA and 2.79 (95% CI: 2.31–2.79),
p < 0.00001 for AD.
Conclusions: Fluoroquinolones use was found to be associated with
an increased risk of AA or AD. Therefore, physicians should judge crit-
ically (benefit–risk assessment) before prescribing fluoroquinolones to
patients at risk of AA or AD.
1160 | Use of drugs from the
Crediblemeds® list and risk of sudden cardiac
death: A population‐based cohort study
Marten E. Van den Berg; Katia M.C. Verhamme; Bruno H. Stricker
Erasmus MC, Rotterdam, Netherlands
Background: Several drugs can lead to torsade de pointes (TdP), a fatal
ventricular arrhythmia. Crediblemeds is an authoritative list of drugs
with TdP risk.
This list has not been studied systematically for risk of sudden cardiac
death (SCD) in a population‐based cohort.
Objectives: We investigated in a real‐life setting if use of these drugs
was associated with SCD. We also tested several genetic variants
modifying pharmacokinetics and pharmacodynamics of antiarrhythmic
drugs.
Methods: We used data from the Rotterdam study, a population‐based
cohort of middle‐aged and elderly. Drug use was set as a time‐varying
covariable in a Cox’modelwith the endpoint SCD.Drug usewas defined
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as use of any drug from the CredibleMeds list or use of a pharmacolog-
ical subgroup defined by the 3rd level of the ATC code containing a drug
from the CredibleMeds list. Furthermore, we studied the association
between use of the antiarrhythmic drugs Amiodarone, Digoxin, Sotalol,
Propafenone and Flecainide, and SCD. We selected genetic variants
known in the literature to modify the pharmacodynamic or pharmacoki-
netic characteristics: for Digoxin, three variants of ABCB1 (rs1128503,
rs2032582, and rs1045642) and for Amiodarone rs35599367
(CYP3A4), rs3892097 (CYP2D6), rs1799853 (CYP2C9), and
rs12143842 (hERG). These genetic variants were set as interaction var-
iables between use of the drug and SCD risk.
Results: The population consistedof 14,603 participants after exclusion
of those who died before July 1, 1991, the starting date prescriptions
were recorded. 41% were men and the mean age was 66 years. 609
cases of SCD occurred. Use of drugs known to be associatedwith a high
risk of TdP was associated with an increased risk of SCD: HR 1.66 (95%
CI 1.28–2.18). Nine of the 45 drug groups were significantly associated
with SCD: A03F (propulsives), C01A (cardiac glycosides), C01B
(antiarrhtymics class I and III), C07A (beta‐blockers), C09A (ACE inhibi-
tors), N01A (general anesthetics), N05A (antipsychotics), N05C (hyp-
notics), and N06A (antidepressants). We found a significant
association with SCD for use of Amiodarone and Digoxin. Of the
11,382 participants with genetic data, there was no significant interac-
tion between the selected genetic variants in combination with use of
amiodarone or digoxin, and risk of SCD.
Conclusions: In our population‐based cohort, use of drugs from nine
drug groups was associated with SCD. For the groups with cardiac
drugs this may be confounded by indication, but this is less likely for
the non‐cardiac groups. Other drugs from the studied drug groups
could be studied for risk of TdP and SCD.
1161 | Gender differences in the adverse
events induced by cardiovascular drugs:
Using National Adverse Event Reporting and
health insurance database
Han‐Heui Park; Dongwon Yoon; Ju Hwan Kim; Ju‐Young Shin
SKKU Pharmacoepidemiology, School of Pharmacy, SKKU
Pharmacoepidemiology, School of Pharmacy, Korea, Republic of
Background: Cardiovascular disease (CVD) is one of the three major
causes of death and cardiovascular drugs have been shown to be
one of the most frequently reported adverse events (AEs) in both gen-
ders. But female patients reported more AEs than male patients in
general practice. Given that gender differences are important, to date
most studies for gender differences have only focused on disease
related pharmacokinetics and pharmacodynamics.
Objectives: Gender differences in the occurrence of drug‐induced AEs
have not been systematically described, and so far, there have been
few studies dealing with that. We aimed to explore the gender differ-
ences with regard to AEs associated with cardiovascular drugs
between male and female patients.
Methods: This study used data from the National Health Insurance
Service‐National Sample Cohort Database on the patients and preva-
lence of CVD in 2015 and Korea Institute of Drug Safety & Risk Man-
agement‐Korea Adverse Event Reporting System Database (KIDS‐KD)
on the number of AEs caused by cardiovascular drugs. Study drugs
were included corresponding to C01‐C10 of the Anatomical Thera-
peutic Chemical Classification System. The number of AEs reported
to KIDS‐KD was divided by the number of patients with CVD as the
denominator, using the international classification of disease (ICD‐
10, I05‐I70). We estimated the AEs rate reported per 100,000 people
and the ratio of female to male reporting rate. To understand charac-
teristics of reports, the AE report of study drugs were analyzed and to
compare by gender each variable chi‐square test was performed.
Results: A total of 23,141 drug‐AEs pairs (KAERS) were identified
from 14,780,300 CVD patients (NHIS). Overall, female patients expe-
rienced much higher AEs (162.7 per 100,000 CVD patients in female,
150.2 in male, ratio = 1.1), although they experienced less serious AEs
than male patients (9.0 in female, 10.9 in male, ratio = 0.8). There were
seven cardiovascular drugs that showed higher female‐to‐male ratio of
AEs rate; digoxins (ratio = 1.4), calcium channel blockers (1.2), diuretics
(1.1), statins (1.2), angiotensin II receptor blockers (1.0), antiplatelets
(1.1), beta blockers (1.1). In particular, the use of digoxins, calcium
channel blockers, and diuretics were associated with more serious
AEs in female patients than in male patients.
Conclusions: The reporting rate of AEs was higher in female patients
than in male patients with CVD. Gender difference was also observed
for specific drug classes. Clinicians should be aware of and monitor
gender difference of AEs induced by cardiovascular drugs.
1162 | Risk of Bradyarrhythmia related to
Ticagrelor: A systematic review and meta‐
analysis
Iris Pujade; Justine Perino; Clément Mathieu; Mickael Arnaud;
Francesco Salvo
Bordeaux University Hospital, Bordeaux, France
Background: Ticagrelor was related to bradycardia in DISPERSE‐II
trial. This risk has been integrated into the European risk‐management
plan and a precaution of use is listed for patients at risk of
bradyarrhythmia. Nevertheless this risk was not already systematically
assessed nor measured.
Objectives: To estimate the risk of bradyarrhythmia associated with
ticagrelor.
Methods: A systematic review of literature and meta‐analysis was per-
formed. MEDLINE, Scopus, CENTRAL and ISI databases were
searched from 2005 to 2017 to select randomized controlled trials
(RCTs) or observational studies on patients with antiplatelet or antico-
agulant indication, treated by ticagrelor or comparator(s) and reporting
bradyarrhythmia events. ClinicalTrial.gov and ClinicalTrialsRegister.eu
were investigated for unpublished studies. In case of missing data,
authors and patent owners were contacted. Cochrane risk of bias tool
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was used for assessing the quality of each RCT and the GRADE tool
was used for the meta‐analysis' overall quality. Heterogeneity
between studies was assessed by the Cochran Q test and the I2 index.
The pooled relative risks (RR) and their 95% confidence intervals (95%
CI) were calculated for each study and pooled using inverse of vari-
ance method (fixed‐effects or random effects models if Q test
p < 0.10). Prospero registration number CRD420180938100.
Results: No observational studies were found. Of 53 eligible RCTs 42
studies had not outcome data. Thus, eleven RCT (75% industry
funded) were included in the main analysis and comprised a total of
61,900 patients with 1,441 bradyarrhythmia. Significant increased risk
of bradyarrhythmia (RR 1.14 [IC95% 1.04 to 1.26]) and severe
bradyarrhythmia (RR 1.42 [1.08 to 1.86]) was found, without any evi-
dence of heterogeneity. Concerning severe bradyarrhythmia this
increased risk was found to be due to ventricular pauses >2.5 s (RR
1.65 [1.23 to 2.22]). A trend for dose‐dependent risk was observed
and the risks appeared to be reduced patients at risk of
bradyarrhythmia were excluded. The overall quality of the meta‐anal-
ysis was judged as “moderate”.
Conclusions: This meta‐analysis suggests the presence of a risk of
bradyarrhythmia or severe bradyarrhythmia (ventricular pauses
>2.5 s) related to ticagrelor use. Its use in patients without risk factors
of bradyarrhythmia seems effective for reducing this risk. The evi-
dence coming from this meta‐analysis was moderate because the
presence of a huge reporting bias, due to the missing outcome data
in 2/3 of eligible studies. Real‐world evidences on the risk of
bradyarrhythmia related to ticagrelor are also needed to further eval-
uate this risk.
1163 | Use of Pregabalin and worsening
heart failure: A Nationwide cohort study
Marie Lund1; Gry Juul Poulsen1; Björn Pasternak1,2;
Niklas Worm Andersson1,3; Mads Melbye1,4,5; Henrik Svanström1
1Statens Serum Institut, Copenhagen, Denmark; 2Karolinska Institutet,
Stockholm, Sweden; 3Bispebjerg and Frederiksberg University Hospital,
Copenhagen, Denmark; 4University of Copenhagen, Copenhagen,
Denmark; 5Stanford University School of Medicine, Stanford, CA
Background: Pregabalin is a gamma‐aminobutyric acid (GABA) ana-
logue approved for the treatment of neuropathic pain, epilepsy and
generalized anxiety disorder and has been increasingly prescribed in
recent years. Concerns of increased risk of worsening heart failure
with use of pregabalin have been raised.
Objectives: To assess the association between use of pregabalin and
risk of worsening heart failure in routine clinical practice.
Methods: We conducted a population based cohort study in Denmark
using data from nationwide health and administrative registers, Janu-
ary 1, 2008, to December 31, 2017. The study population consisted
of patients 50 years or older with a diagnosis of heart failure who
were new users of pregabalin or gabapentin. In a sensitivity analysis,
we compared pregabalin with duloxetine. We matched both cohorts
in a ratio 1:1 on the propensity score. Using proportional hazards
regression, we estimated hazard ratios (HRs) for worsening heart fail-
ure, defined as hospitalization with or death from heart failure within
90 days of start of treatment.
Results: 1415 new users of pregabalin were matched to 1415 new
users of gabapentin. We observed 35 individuals with worsening heart
failure among users of pregabalin (incidence rate [IR], 110.5 per 1000
person‐years) vs. 44 individuals among users of gabapentin (IR 135.6
per 1000 person‐years) corresponding to a HR of 0.81 (95% confi-
dence interval [CI] 0.52–1.27). The corresponding absolute risk differ-
ence was −25 (95% CI ‐65 to 36) per 1000 person‐years. Results of
the sensitivity analysis, comparing 847 new users of pregabalin vs.
847 new users of duloxetine, provided similar results (HR 1.05, 95%
CI 0.59–1.89).
Conclusions: The present study does not provide evidence to support
an association between use of pregabalin and an increased risk of
worsening heart failure.
1164 | DPP‐4 inhibitors and risk of venous
thromboembolism: Analysis of the FDA
adverse event reporting system database
Wenchao Lu1,2; Dandan Li3; Jingkai Wei4; Lulu Sun2;
Tiansheng Wang4
1School of Pharmaceutical Sciences, Peking University, Beijing, China;
2Peking University Ninth School of Clinical Medicine (Beijing Shijitan
Hospital, Capital Medical University), Beijing, China; 3Beijing Friendship
Hospital, Capital Medical University, Beijing, China; 4Department of
Epidemiology, Gillings School of Global Public Health, University of North
Carolina at Chapel Hill, Chapel Hill, NC
Background: Dipeptidylpeptidase‐4 inhibitors (DPP4i) are widely used
for treating type 2 diabetes. A recent pharmacovigilance study using
French national healthcare insurance system database have showed
DPP4i may be associated with venous thromboembolism (VTE).
Objectives: To assess the association between DPP4i and VTE using
US Food and Drug Administration Adverse Event Reporting System
(FAERS) database.
Methods: By running a query on AERSMINE (an open access web data
mining tool of FAERS) from 2004 Q1 to 2018 Q1, we obtained the VTE
cases related to DPP4i (sitagliptin, saxagliptin, linagliptin, alogliptin,
vildagliptin) and comparator drugs. The VTE events were identified by
MedDRA v21.0 and include the following: 1) deep vein thrombosis
(DVT); 2) Pulmonary embolism (PE); 3) VTE at gastrointestinal level
(GIVTE). We conducted three mutually exclusive comparisons: 1) com-
pared DPP4i to all other glucose lowering drugs (GLDs) excluding insu-
lins; 2) compared DPP4i to two classes of therapeutics alternatives:
sulfonylureas and sodium‐glucose cotransporter 2 inhibitors (SGLT2i);
3) compared DPP4i to SGLT2i only, as SGLT2i is a new class of GLDs
with more similar reporting rates to DPP4i than other GLDs. In each
comparison, we calculated proportional rate ratio (PRR) and 95% CI
using 2 × 2 tables by SAS 9.4. A signal is defined as PRR more than 2.
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Results: A total of 571 DPP4i associated VTE events were identified,
393 cases(68.8%) were DVT, 2 cases(0.35%) were PE,129 cases
(22.6%) were GIVTE, including portal vein thrombosis (n = 76), splenic
vein thrombosis (n = 33) and mesenteric vein thrombosis (n = 20).
Compared to all other antidiabetic drugs excluding insulins, the PRR
for overall VTE, DVT, GIVTE was 1.06 (0.97–1.16), 0.91 (0.8–1.01),
and 4.87(3.86–6.13), respectively. Compared to sulfonylureas and
SGLT2i, the PRR for overall VTE, DVT, and GIVTE was 0.93 (0.83–
1.03), 0.74 (0.65–0.84), and 5.10 (3.73–6.99), respectively; The PRR
for overall VTE and DVT was 3.54 (2.69–4.64) and 2.87 (2.12–3.87),
respectively, when compared to SGLT2i only. Similarly, in the most
analyses stratified by individual DPP4i, consistent results were seen
with the primary analysis.
Conclusions: Our analysis using FAERS database found signals of VTE
at gastrointestinal level for DPP4i. However, this study is limited by
reporting bias, lack of denominator data, and FAERS cannot be used
to assess the incidence. Thus, further studies are warranted to assess
the potential VTE risk associated with DPP4i.
1165 | Major cardiovascular events in adults
on antiretroviral therapy in a South African
HIV Management Programme
Johannes P. Mouton; Reneé de Waal; Morna Cornell; Gary Maartens;
Karen Cohen
University of Cape Town, Cape Town, South Africa
Background: Studies from high‐income settings found increased risk
of cardiovascular events (CVEs) in people living with HIV (PLWH).
Data on CVE incidence in PLWH in Africa are limited.
Objectives: To describe incidence of and risk factors for major CVEs
leading to hospitalization in PLWH on antiretroviral therapy (ART) in
the Aid for AIDS (AfA) private sector cohort.
Methods: We included adults (≥18 years) starting ART through AfA
from 1 Jan 2011 to 30 Jun 2017. We extracted demographic and lab-
oratory variables and ART regimen at first AfA ART claim. We defined
major CVE as hospitalization for stroke, acute coronary syndrome, or
coronary revascularization procedure, as coded in claims data. We cal-
culated crude CVE incidence stratified by HIV viral load (VL) suppres-
sion at first AfA ART claim. We explored associations with major CVE
with Cox regression.
Results: We studied 110,932 patients: median [IQR] follow‐up 25
[10 to 48] months, total follow‐up 275,191 person‐years, median
[IQR] age 38 [33 to 45] years, median [IQR] CD4 count 277 [150
to 437] cells/μL, and 67,079 (60%) women. At first AfA ART claim,
VL was suppressed in 29,866 (27%), suggesting that these patients
were already taking ART. Median [IQR] VL in those unsuppressed
at first claim was 4.8 [4.1 to 5.3] log10 copies/mL. 85,145/110,932
(77%) commenced tenofovir, emtricitabine/lamivudine, and efavirenz;
5,123 (4.6%) commenced a protease inhibitor. There were 911
patients with major CVE: 555 (61%) strokes, 317 (35%) acute coro-
nary syndromes, and 39 (4.3%) revascularization procedures. 7,134
patients (6.4%) died. Crude incidence of major CVE was 3.3 events
per 1,000 person‐years follow‐up (PYFU). Incidence in the first
6 months was 3 times higher in the unsuppressed than in the sup-
pressed (5.1 vs 1.7 per 1,000 PYFU, incidence rate ratio 2.9, 95%
CI 1.9 to 4.7). Major CVE in the first 6 months was associated with
older age, male sex, lower CD4 count and unsuppressed VL:
adjusted hazard ratios (95% CI) were 1.8 (1.5 to 2.0) per 10 year
age increase; 1.3 (1.0 to 1.8) for male vs female; 4.2 (2.6 to 6.9)
for <50 cells/μL, 2.1 (1.3 to 3.3) for 50 to 199 cells/μL, 1.4 (0.9 to
2.3) for 200 to 349 cells/μL, vs ≥350 cells/μL; 1.9 (1.2 to 3.0) for
unsuppressed vs unsuppressed. Associations remained significant
for the follow‐up duration.
Conclusions: Our crude incidence of major CVE is lower than that
found in a D:A:D cohort analysis of patients from Europe, USA and
Australia (5.3 events per 1,000 PYFU). Strokes were the predominant
CVE in our cohort, in contrast to D:A:D. Immune reconstitution may
explain the higher incidence of major CVEs soon after ART initiation
in the unsuppressed group.
1166 | Antiplatelet agents and risk of stroke
Lamiae Grimaldi‐Bensouda1,2; Nicolas Morisot3;
Pegdwende O. Dialla3; Clémentine Nordon3,4; Lucien Abenhaim5,6
1University of Versailles Saint‐Quentin en Yvelines, Versailles, France;
2Ambroise Pare Hospital, Boulogne‐Billancourt, France; 3Laser Core,
Paris, France; 4Maison Blanche Public Hospital, Paris, France; 5 LA Risk
Research, London, UK; 6London School of Hygiene & Tropical Medicine,
London, UK
Background: Publications have reported controversial results about
the role of antiplatelet agents (APA) in the prevention of stroke
and with little consideration for confounding by indication and the
type of stroke to be prevented.
Objectives: To assess the preventive effect of antiplatelet agents on
the occurrence of ischemic or hemorrhagic stroke in patients with
previous history of cardiac diseases.
Methods: From two systematic national registries, patients with pre-
vious history of cardiac diseases defined as ischemic coronary heart
disease, peripheral arteriopathy or carotid stenosis were identified.
Atrial fibrillation (AF) was confirmed with an EKG. Stroke cases were
identified among these registries and documented by CT scan or
MRI and matched to patients without stroke on age, gender, index
date (date of stroke diagnosis for cases and date of recruitment
for non‐cases). All treatments received in the previous 12 months
before index date were documented (mostly from medical records).
APA were considered in two categories, i.e. aspirin used alone and
P2Y12 inhibitors (namely clopidogrel, ticagrelor and prasugrel). Asso-
ciations with the occurrence of stroke vs no APA use, were assessed
with multivariable conditional logistic regression models controlled
for anticoagulants use, diabetes, history of other cardiovascular dis-
eases, hyperlipidemia, renal impairment, liver disease, hemorrhagic
disorder, alcoholism or their indicators in the databases.
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Results: Among patients with history of cardiac diseases in the regis-
tries, 676 stroke cases were matched to 676 randomly selected
patients without stroke at the index date. The adjusted odds ratio
(OR) for the association between any stroke and use of aspirin alone
was 0.89; 95%CI[0.69–1.16] while it was 0.48; 95%CI[0.34–0.69] for
P2Y12 inhibitors. Similar results were found when the analysis was
restricted to ischemic stroke: OR = 0.82; 95%CI[0.62–1.10] and
0.40; 95%CI[0.27–0.59] for aspirin alone and P2Y12 inhibitors respec-
tively. In hemorrhagic stroke, the OR for aspirin alone was 1.34;
95%CI[0.62–2.90], and 1.04; 95%CI[0.35–3.03] for P2Y12 inhibitors.
Conclusions: In patients with a previous history of cardiac diseases,
P2Y12 inhibitors significantly decreased the risk of ischemic stroke
and show no association with hemorrhagic stroke. Results for aspirin
need to be confirmed.
1167 | A plausible causal link between
antiretroviral therapy and increased blood
pressure in patients on highly active
antiretroviral therapy‐ a propensity score‐
matched analysis
Edmund T. Nartey1; Raymond A. Tetteh2
1University of Ghana School of Medicine and Dentistry, Accra, Ghana;
2Korle‐Bu Teaching Hospital, Accra, Ghana
Background: Two Decades into the highly active antiretroviral therapy
(ART) era, there has been improvement in the management of HIV/
AIDS. Persons living with HIV (PLHIV) in sub‐Saharan Africa are how-
ever faced with an epidemiological transition of an increasing burden
of non‐communicable diseases.
Objectives: This study aimed to determine the prevalence of hyper-
tension and associated factors and also estimate the average treat-
ment effect on the treated (ATT) of ART on hypertension/blood
pressure among patients attending HIV clinic at the Korle‐BuTeaching
Hospital (KBTH).
Methods: The study design was cross sectional involving 311 ran-
domly selected PLHIV. The WHO STEPwise Approach to Chronic Dis-
ease Risk Factor Surveillance instrument was modified and used for
data collection. Factors associated with hypertension were deter-
mined by logistic regression modeling using purposeful selection of
covariates method. Propensity score matching (PSM) analysis was
used to determine the ATT of ART on hypertension/blood pressure
values using kernel weighting method with a bandwidth of 0.06.
Results: Study participants on ART had a significantly higher preva-
lence of hypertension (41.3% [95% CI, 35.2–47.3]) compared with
their ART‐naive counterparts (16.9%, [95% CI, 7.4–26.5]). Regression
modeling indicated factors associated with hypertension were,
increasing age, family history of cardiovascular disease, inadequate
exercising, a BMI ≥25.0 kg/m2, abdominal obesity, hypercholesterol-
emia and exposure to ART. Post‐estimation analysis indicated the gen-
erated logistic model was “good” on “discrimination” with an AUROCC
of 0.81 (95% CI, 0.75–0.85; p < 0.001) and on “calibration”, with a
Hosmer‐Lemeshow goodness‐of‐fit test χ2 value of 4.49 (p = 0.810).
The estimated ATT of ART on systolic blood pressure (12.0 mmHg,
[95% CI, 5.7–18.3]; p < 0.001), diastolic blood pressure (6.1 mmHg,
[95% CI, 1.3–10.82]; p = 0.012) and hypertension (26.2%, [95% CI,
13.3–39.1]; p < 0.001) were significant indicating a high possibility
that the epidemiological association between ART and hypertension/
increased blood pressure may be causal in nature.
Conclusions: This study showed that hypertension is prevalent among
patients on ART attending KBTH HIV clinic and also established a
plausible causal relation between ART and hypertension/increased
blood pressure.
1168 | Pharmacogenetic modeling of
metformin on stroke, myocardial infarction
and cardiovascular mortality
Marten E. Van den Berg; Katia M.C. Verhamme; Bruno H. Stricker
Erasmus MC, Rotterdam, Netherlands
Background: Detailed pharmacodynamic (PD) modeling is usually not
possible in large population‐based cohorts. However, it is possible to
use genetic variants that modify the PD of drugs to model clinical
outcomes.
Objectives: To evaluate candidate genetic variants that influence the
PD of Metformin, notably on intermediate endpoints such as glucose
and HbA1c. Variants that were significantly associated were subse-
quently assessed for possible effects on stroke, myocardial infarction
(MI) and cardiovascular mortality.
Methods: The setting was the population‐based Rotterdam Study.
HbA1c measurements were taken as part of routine care in the
Stichting Trombosedienst en Artsenlaboratorium Rijnmond‐Medisch
Diagnostisch Centrum (STAR‐MDC). We used linear mixed models
to study the change in glucose or HbA1c between two measure-
ments, where the first measurement was without metformin use,
and the second measurement was during metformin use. We
adjusted for the time between measurements. We tested 23 genetic
variants known to influence the pharmacodynamics of metformin.
The analysis was first performed stratified on each allele, after that,
an interaction with treatment and genetic variants was tested. After
the confirmation of previous SNPs, we took the SNPs that were sig-
nificant, and tested them in three different Cox’ models with use of
Metformin as time‐dependent covariable. In the first model, the out-
come was stroke, in the second one it was MI and in the third one it
was cardiovascular mortality.
Results: Of the 14,926 participants of the Rotterdam Study, there
were 5644 participants with both glucose measurements and genetic
data, and 2988 participants with both HbA1c measurements and
genetic data. There were 39,094 measurements of glucose and
31,629 measurements of HbA1c. There was a significant interaction
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between the variant and change in glucose in starters with metfor-
min for rs3013105, rs6867983, rs11212617, rs11231159, and
rs4787778. There was a significant interaction between the variant
and change in HbA1c in starters with metformin for rs2457574
and rs11231159. These variants were tested in the Cox regression
models for stroke, MI, and coronary heart disease (CHD) mortality.
Metformin use was significantly protective for MI and CHD mortal-
ity, but there was no significant interaction between use of metfor-
min and any of the SNPs on these three endpoints.
Conclusions: The protective effect of metformin could be explained
by confounding by indication. The seven SNPs found to modify
the effect of metformin on glucose and HbA1c might be tested in
other cohorts for their risk of cardiovascular mortality.
1169 | Association between the risk of
venous thrombosis and antidepressants: A
meta‐analysis
Kiyon Rhew1,2; Victoria Z. Reams1; Joshua D. Brown1;
Almut G. Winterstein1,3
1University of Florida, Gainesville, FL; 2Dongduk Women's University,
Seoul, Korea, Republic of; 3University of Florida, Gainesville, FL
Background: Venous thromboembolism (VTE) is a major adverse
event associated with exposure to select medications. Previous
research provides conflicting evidence regarding the use of antide-
pressants and risk of VTE.
Objectives: The objective of this study was to synthesize published
literature that aimed to evaluate the association of antidepressants
with VTE.
Methods: Medline, Embase, and Web of Science were searched for
relevant studies up to August 2018. All controlled studies that for-
mally evaluated the relationship between antidepressants and VTE
were included. Pooled relative risk (RR) and 95% confidence inter-
vals (CIs) were calculated using random effects models. We used
univariate meta‐regression to explore reasons for between‐study
heterogeneity including: minimum duration of antidepressant treat-
ment, % of female sex, mean age of subjects, study design, published
year, NOS quality score, and sample size.
Results: Ten studies were included in the meta‐analysis. Antidepres-
sants were associated with increased VTE risk overall (RR = 1.17,
95% CI, 1.03, 1.32; P = 0.02) which was driven by an increase in
VTE risk associated with tricyclic antidepressants (TCAs) (RR = 1.29,
95% CI 1.03, 1.60; P = 0.03). Selective serotonin reuptake inhibitors
(SSRIs) and monoamine oxidase inhibitors (MAOIs) did not signifi-
cantly increase the VTE risk. Meta‐regression did not reveal system-
atic associations between study features and reported results.
Conclusions: Pooled literature estimates suggested TCAs but not
SSRIs or MAOIs increased the risk of VTE.
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1171 | Spironolactone reduces the risk of
mortality and hospitalization in veterans with
heart failure with preserved ejection fraction
Katherine E. Kurgansky1; Rachel Parker1; Luc Djousse1,2;
Jacob Joseph1,2; David Gagnon1,3
1US Department of Veteran Affairs, Boston, MA; 2Brigham and Women's
Hospital, Harvard Medical School, Boston, MA; 3Boston University School
of Public Health, Boston, MA
Background: Results from the Treatment of Preserved Cardiac Func-
tion Heart Failure with an Aldosterone Antagonist (TOPCAT) trial sug-
gested that spironolactone reduced the risk of the composite primary
outcome (cardiovascular death, aborted cardiac arrest, or heart failure
hospitalization), however results were inconclusive and varied by
region. Mechanistically, spironolactone has been shown to decrease
the interstitial fibrotic process, which is common in heart failure with
preserved ejection fraction (HFpEF).
Objectives: To determine if spironolactone is associated with lower
risk of all‐cause mortality, all‐cause and heart failure hospitalizations
in a cohort of veterans with HFpEF.
Methods: We used a validated algorithm to identify HFpEF patients
diagnosed between 2002–2012 in the Veterans Affairs healthcare
system. Patients were followed from 1 year after HFpEF diagnosis
(or 1 year after start of first spironolactone prescription, if it occurred
after diagnosis) until death or censoring at their last VA visit or the end
of their last spironolactone prescription. Patients were classified as
spironolactone users if they had at least 80% compliance for at least
a year after initiation and HFpEF diagnosis. Controls were HFpEF
patients without spironolactone use. We also did sensitivity analyses
extending follow‐up by 30‐day increments through 180 days past
the end of the last spironolactone prescription. All‐cause mortality
and hospitalizations, for any cause or heart failure, were assessed
using Poisson and negative binomial generalized estimating equation
models, respectively. Inverse probability weights were calculated for
age and multivariable adjustment.
Results: In 53,705 HFpEF patients (96% male; 84% white; mean age
83 ± 12 years), 4,060 used spironolactone. Over follow‐up (median of
3.2 years), 1,844 spironolactone users and 26,657 non‐users died.Mor-
tality rates were 43% (95%CI: 36–49%) lower and all‐cause hospitaliza-
tion rates were 41% (95% CI: 30–51%) lower for spironolactone users
compared to non‐users. Sensitivity analyses showed that when censor-
ing 180 days after the end of the last prescription, mortality rates were
still 8% (95% CI: 0–16%) lower and all‐cause hospitalization rates were
still 25% (95% CI: 12–35%) lower for spironolactone users compared to
non‐users. No significant association was observed between
spironolactone use and heart failure hospitalization rates.
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Conclusions: Spironolactone use among HFpEF patients is associated
with a lower rate of mortality and all‐cause hospitalization compared
to those who did not take the drug.
1172 | Antidepressants use and the risk of
brain hemorrhage
Seonji Kim1; Young‐Jin Ko1; Bo Ram Yang2; Kyounghoon Park1;
Mi‐sook Kim1; Byung‐Joo Park1
1Seoul National University College of Medicine, Seoul, Korea, Republic of;
2Medical Research Collaborating Center, Seoul National University
Hospital and Seoul National University College of Medicine, Seoul, Korea,
Republic of
Background: The use of antidepressants has been steadily increasing.
However antidepressants may have an impact on hemostasis and thus
may increase the risk of hemorrhages related to antidepressive
psychopharmacotherapy. A number of cerebral hemorrhage have been
reported, however, study results have not been consistent on their
association.
Objectives: To investigate causality between the risk of brain hemor-
rhage and use of antidepressant drugs by therapeutic class in Korean
patients.
Methods: The patients (>18 years old) having first hospitalization or
visiting emergency department for brain hemorrhage in the Health
Insurance Review and Assessment (HIRA) database from January
2009 to July 2017. The patients diagnosed brain hemorrhage and
cerebrovascular diseases in 2009, any head injury before event date,
and did not prescribed antidepressants within 8‐month before brain
hemorrhage were excluded. Antidepressant drugs were classified as
TCAs, SSRIs, SNRIs, and Others. Hazard period and control period
were matched by 1:4. Characteristics of this study subjects were ana-
lyzed by age group, gender, and charlson comorbidity index. Statistical
analysis was calculated by odds ratios for brain hemorrhage associated
with the use of antidepressants and their 95% confidence intervals
using conditional logistic regression with adjusting for confounders
including antipsychotics, antithrombotic agents, antidiabetes agents,
antihypertensive drugs, lipid modifying agents, and NSAIDs. Sensitiv-
ity analyses were conducted using two time window periods.
Results: A total of 2,589 patients with brain hemorrhage, who
received antidepressant drugs were included in this study (31.02%
male, 68.98% female). The greatest number of these patients were
60 to 79 years old group (54.67%), followed by 40 to 59 years old
group (25.34%). Compared with control periods, adjusted ORs were
1.39 (95% CI, 1.20–1.61) in total antidepressant groups, 1.04 (95%
CI, 0.68–1.24) in TCA, 1.49 (95% CI, 1.26–1.77) in SSRI, 1.38 (95%
CI, 1.03–1.85) in SNRI, and 1.37 (95% CI, 1.15–1.63) in Others group.
Conclusions: Antidepressant use was associated with an increased risk
of brain hemorrhage, particularly SSRI, SNRI, and Other antidepres-
sants. For patients with a high risk of brain hemorrhage, close monitor-
ing is needed when prescribing antidepressants.
1173 | The association between direct Oral
anticoagulants and gynecological bleeding in
women v. standard therapy: A systematic
review
Sandeep Dhanda1,2; Vicki Osborne1,3; Saad Shakir1,3
1Drug Safety Research Unit, Southampton, UK; 2London School Of
Hygiene & Tropical Medicine, London, UK; 3University of Portsmouth,
Portsmouth, UK
Background: Women receiving anticoagulation are susceptible to the
added risk of gynecological bleeding (GB). This may occur in premen-
opausal women who experience physiological bleeding related to the
ovulatory cycle and for whom the risk is greater, or postmenopausal
women. Thus, the use of anticoagulation in women requires special
consideration in terms of GB risk. It may be that DOACs overall or a
particular DOAC are the wrong choice of treatment for women at risk.
Objectives: To examine the association between DOACs and GB in
women, by comparing risk in users of DOACs to users of standard
anticoagulant (AC) therapy (e.g. vitamin K antagonists (VKAs)).
Methods: 4 databases were searched (July 2018) for clinical trials
(CTs) and observational studies (OS) reporting GB in women taking
DOACs or a comparator of standard AC therapy for any indication.
Abstracts were screened followed by full review of a subset for eligi-
bility. Studies reporting GB with DOACs but with no standard AC
comparator were excluded. Due to a high degree of heterogeneity
between studies in terms of study design, indications, outcome mea-
sures and use of different denominators, a meta‐analysis was not
performed.
Results: Records identified n = 594; 16 eligible for inclusion (CTs n = 7,
OS n = 9). Of the 6 studies specifically designed to evaluate GB in
women with DOACs v. standard AC, 3 reported a significantly
increased risk of this outcome with DOACs v. standard AC
(rivaroxaban (riva) n = 2 (HR 2.13; 95% CI [1.57, 2.89], risk ratio 2.3;
p = 0.009), and edoxaban (edox) n = 1 (HR 1.7; 95% CI [1.1, 2.5])). Con-
versely, no significant difference for 2 studies (riva n = 1, apixaban
(apix) n = 1) and a lower risk for 1 (dabigatran (dabi)) was observed
(OR 0.59; 95% CI [0.30, 0.90]). The remaining 10 studies were not
designed to evaluate GB with DOACs but reported this within study
results; 1 reported a higher risk of GB with dabi v. standard AC (HR
2.27; 95% CI [1.32, 3.90]), and for the remaining 9, results were incon-
clusive due to non‐significant/lack of hypothesis test results.
Conclusions: Gynecological bleeding appears to be a common compli-
cation of DOACs, however, there is variability between DOACs. More
evidence is available for riva, in which the risk of GB appears to be
higher than with standard AC. Although limited, evidence suggests a
higher risk with edox, lower risk with dabi and no difference with apix
v. standard AC. Further research including head‐to‐head CTs and OS
specifically investigating GB is needed to draw firm conclusions on
which class of ACs (VKAs v. DOACs) are more favorable for women
and the difference in risk between individual DOACs.
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1174 | Adverse drug reactions of
antihypertensive products
Matveev Alexandr1,2; Krasheninnikov Anatoly2; Egorova Elena1;
Dormidor Arthur3
1Crimea Medical Academy named after S.I.Georgievsky, Simferopol,
Russian Federation; 2National Scientific Center of Pharmacovigilance,
Moscow, Russian Federation; 3Centre of Blood Circulation Pathology,
Moscow, Russian Federation
Background: Arterial hypertension (AH) is one of the leading causes of
mortality in world. Patients with AH need life long therapy and in most
cases take a few antihypertensive medicines.
Objectives: The aim of this work was to study the patterns and pecu-
liarities of use of following groups of drugs, which are considered as
first‐line therapy of AH: ACE inhibitors (ACEI) and angiotensin recep-
tors antagonists (ARA), beta‐adrenoblockers (BAB), diuretics and cal-
cium channel blockers (CaCB).
Methods: We analyzed records about adverse drug reactions (ADR) in
local pharmacovigilance database ARCADe, which contains data of
individual case safety reports spontaneously sent by Crimean doctors
to local pharmacovigilance office. We restricted our search to 2011–
2016 period.
Results: Totally 211 ADR reports were found. More than half of ADR
were caused by ACEI (125 cases, 59.2%). Enalapril and Captopril were
“leaders” in this pharmacotherapeutic group and provoked 37 and 31
reactions (respectively). 51 (24.2%) patient had ADR caused by CaCB,
mainly by third generation drug Amlodipine (36 records, 70.6%). BAB
and ARAwere suspected reason of ADR in 19 (9%) and 16 (7.6%) cases,
respectively. More often ADR were reported for female patients (152
records, 72%) than for male patients (59 reports, 28%), and in age group
51–60 y.o. (73 episodes, 34.6%) and 61–70 y.o. (51 case, 24.1%). There
were no reports about ADR caused by diuretic drugs. No lethal ADR
were reported. Allergic reactions were registered in 1/3 of cases (70
reports). 13 reactions were life threating due to severe laryngeal
oedema. In 64 cases a dyspnoea, rales, bronchoconstriction and dry
cough were reported. Rhythm disorders and hypotension were men-
tioned in 29 reports. Complains on headache, dizziness and vertigowere
found in 13 reports. In 86 cases (41%) additinal medicines were pre-
scribed for ADR correction.
Conclusions: Our analysis has shown that allergic reactions is the
leading cause of ADR in patients with AH. Nevertheless well‐studied
safety of first line therapy antihypertensives and long history of their
use in medical practice, doctors should pay attention for ADR of
them, especially during first days of therapy. ADR of drugs pre-
scribed for AH may negatively affect quality of patient's life and
compliance, therefore effectiveness of treatment.
1175 | Comparative effects of sodium‐
glucose cotransporter 2 inhibitors on serum
electrolyte levels in patients with type 2
diabetes: A network meta‐analysis of
randomized controlled trials
Huilin Tang1; Qi Dai2; Jingjing Zhang3; Yiqing Song1
1 Indian University, Indianapolis, IN; 2Vanderbilt University, Nashville, TN;
3Sidney Kimmel Medical College at Thomas Jefferson University,
Philadelphia, PA
Background: Previous studies have reported that sodium‐glucose
cotransporter 2 (SGLT2) inhibitors affect serum electrolytes levels,
especially magnesium.
Objectives: This study aimed to integrate direct and indirect trial evi-
dence to evaluate the relative effects of all SGLT2 inhibitors against
each other on electrolyte levels in patients with type 2 diabetes
(T2D).
Methods: Electronic databases were systematically searched through
December 2018 to identify eligible randomized controlled trials
(RCTs) that reported the mean changes in serum electrolyte, includ-
ing magnesium, sodium, potassium, phosphate, and calcium. Ran-
dom‐effects pairwise and network meta‐analyses were performed
to calculate the weighted mean difference (WMD).
Results: Twenty‐five RCTs involving 17,446 patients with five
SGLT2 inhibitors were included. Compared with placebo, SGLT2
inhibitors were significantly associated with elevations in serum
magnesium by 0.08 mmol/L and serum phosphate by 0.03 mmol/L.
Overall, there was no evidence for the changes of serum sodium,
potassium, and calcium levels by SGLT2 inhibitors compared to the
placebo. Our network meta‐analysis showed significant increases in
serum magnesium among the patients taking canagliflozin
(WMD = 0.08 mmol/L), dapagliflozin (WMD = 0.15 mmol/L), and
empagliflozin (WMD = 0.06 mmol/L) compared to their respective
controls. Similarly, dapagliflozin (WMD = 0.04 mmol/L), ertugliflozin
(WMD = 0.06 mmol/L), and ipragliflozin (0.09 mmol/L) were signifi-
cantly associated with increases in serum phosphate. Empagliflozin
significantly increased serum sodium by 0.28 mmol/L. No statistically
detectable differences were evident between any two of SGLT2
inhibitors but between dapagliflozin and empagliflozin in serum mag-
nesium (WMD = 0.09 mmol/L).
Conclusions: SGLT2 inhibitors could significantly increase serum
magnesium and phosphate, indicating a potentially similar class‐
effect. However, more data for long‐term efficacy and safety of rais-
ing serum magnesium and phosphate in T2D patients with
different clinical phenotypes are needed for further investigation.
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1176 | Antipsychotic dose and weight gain:
Long‐term evidence from a retrospective
study using electronic health records
Juan Carlos Bazo‐Alvarez1,2; Tim P. Morris1; James R. Carpenter1,3;
Joseph F. Hayes1; Irene Petersen1
1University College London, London, UK; 2Universidad Católica Los
Angeles de Chimbote, Chimbote, Peru; 3London School of Hygiene and
Tropical Medicine, London, UK
Background: Short‐term weight gain, approximately over the first
6 weeks, is a known problem among patients treated with antipsy-
chotics. Nevertheless, further assessment over long term periods and
on dose differences is necessary, especially from real‐life contexts.
Electronic health records obtained from general medical practice are
useful sources of this type of information.
Objectives: To describe the short and long‐term change in body
weight of people with psychotic disorders initiated on high or low
doses of the three most commonly prescribed second‐generation anti-
psychotics (olanzapine, quetiapine or risperidone).
Methods: We performed a retrospective cohort study using The
Health Improvement Network, a primary care database representative
of the UK. In total, 38 865 individuals with a diagnosed psychotic dis-
order and at least two consecutive antipsychotic prescriptions were
observed. The main outcome was change in body weight four years
before and four years after initiation of antipsychotic treatment (one
cohort per drug), stratified on ‘low’ or ‘high’ dose. We modeled weight
change over time using continuous linear splines with mixed effect
models, from which three slopes of weight change were estimated
for: i) pre‐treatment (−4 years to baseline), ii) short‐term (baseline to
6 weeks), iii) long‐term (6 weeks to 4 years).
Results: In total, 22 306 women and 16 559 men were included in
the study. Olanzapine treatment was associated with the highest
change in weight, with higher doses resulting in more weight gain.
Thus, after 4 years, given a high dose of olanzapine (>5 mg), women
gained on average 6.1 kg; whereas given a low dose (≤5 mg), they
gained 4.4 kg. During the first 6 weeks of olanzapine treatment, they
gained on average 3.2 kg on high dose and 1.9 kg on low dose. The
trends were similar for men. Individuals prescribed risperidone and
quetiapine experienced less weight gain in both the short and
long‐term and by high and low dose. In general, individuals did not
lose the weight gained during the first 6 weeks of treatment. Pre‐
treatment weight change was negligible or slightly negative across
all cohorts. Individuals with lower weight before initiation of
olanzapine gained more weight in the short term than individuals
with higher weight.
Conclusions: Olanzapine treatment was associated with the highest
increase in weight with around 6 kg for individuals on high dose and
4.5 kg for individuals on low dose over 4 years. The weight gain was
less dramatic for those treated with quetiapine and risperidone. In
general, individuals did not lose the weight gained during the first
6 weeks of treatment.
1177 | Comparative risk of poly‐cystic ovary
syndrome in young female patients newly
initiating anti‐psychotic medications
Ying‐Shan Chung
Chang Gung Memorial Hospital, Chiayi, Taiwan
Background: Antipsychotic medications are commonly used for young
females with psychiatric disorders. Recent reports indicated young
females receiving antipsychotic medications were at increasing risk
of polycystic ovary syndrome (PCOS). However, not all antipsychotics
pose identical risk profiles of PCOS.
Objectives: To compare the risk of PCOS in young females newly
receiving antipsychotic medications.
Methods:We conducted a retrospective cohort study by usingTaiwan
National Health Insurance Research Database. We included patients
aged 18–30, diagnosed with mental disorders and newly prescribed
with antipsychotic medications, including haloperidol, sulpiride,
olanzapine, quetiapine, risperidone, amisulpride, aripiprazole,
paliperidone and ziprasidone, between years 2004 and 2012. We
defined the event of PCOS by two or more diagnosis records of
patients. We followed patients until discontinuation, switching, add‐
on of antipsychotic medications or the occurrence of PCOS. We used
multivariate Cox regression hazard models considering patients' age,
mental conditions, and concomitant psychotropic drugs to evaluate
the risk of PCOS among different antipsychotic medications.
Results: We included a total of 22,586 female patients with a mean age
of 24.9 ± 3.4 years.Most of patientswere diagnosedwith anxiety (54%),
major depression disorders (24%), schizophrenia (20%) and bipolar dis-
order (19%). The most used antipsychotic medications were sulpiride
(45%), quetiapine (18%) and risperidone (15%). We found the incidence
rates were higher in ziprasidone (105.2 per 1,000 person year), follow-
ing by haloperidol (51.7 per 1,000 person year) and paliperidone (32.4
per 1,000 person year), compared to risperidone (18.5 per 1,000 person
year), quetiapine (17.1 per 1,000 person year) and olanzapine (14.7 per
1,000 person year). The risk of PCOS was higher in patients receiving
haloperidol (hazard ratio [HR], 1.86; 95% CI, 1.00–3.44), ziprasidone
(HR, 4.65; 95% CI, 1.94–11.16) and paliperidone (HR, 1.12; 95% CI,
0.15–8.25), compared with risperidone.
Conclusions: The findings indicated different antipsychotic medica-
tions posed various risk profiles of PCOS. We suggest clinicians should
pay attention on PCOS for young female patients receiving antipsy-
chotics especially for those with high risk.
1178 | Impact of Levothyrox formulation
change on health and healthcare use in
France
Sandrine Colas1; Marion Bertrand1; Clara Bouche2; Lise Duranteau3;
Mathilde Francois4; Vanessa Pauly5; Elisabeth Polard6;
Mahmoud Zureik1,4; Rosemary Dray‐Spira1
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Kremlin‐Bicetre, France; 4Versailles Saint‐Quentin‐en‐Yvelines University,
Montigny le Bretonneux, France; 5AP‐, HM, Marseille, France; 6CHU
Rennes, Rennes, France
Background: An unprecedented number of pharmacovigilance notifi-
cations were reported in France following the introduction in
2017 of a new formulation of Levothyrox (the only levothyroxine
product available in France by then), giving rise to a high media cov-
erage. A toxicity of this new formulation was suspected.
Objectives: To measure the impact of Levothyrox new formulation
(NF) on health and healthcare use, based on data of the French
national healthcare databases.
Methods: The whole population aged 18–85 years treated with
Levothyrox in 2016 and/or 2017 was randomly split into two inde-
pendent groups. Patients of the ‘2017’ group, who initiated
Levothyrox NF in April, May or June 2017, were individually
matched to patients treated with Levothyrox old formulation (OF)
in 2016 (‘2016’ group). Levothyrox NF first dispensing date was con-
sidered as the index date. Matching criteria included
sociodemographic characteristics, characteristics of the thyroid treat-
ment, and Levothyrox dispensing date. Patients were followed from
the index date up to December, 31 of the same year. Risks of hos-
pitalization or death, sick leaves of ≥7 days among working‐aged
patients (<65 years), outpatient visits to general practitioners (GP)
and specialists, and various medications consumption were com-
pared in 2017 versus 2016, using conditional Cox models adjusted
for baseline health status indicators. Patients treated with oral anti-
diabetic drugs (OAD) in 2016–2017 were considered as a control
population.
Results: A total of 2,075,106 patients treated with Levothyrox were
included (1,037,553 treated with Levothyrox NF in 2017 and
1,037,553 treated with Levothyrox OF in 2016) and followed during
7.5 months in mean. Patients were predominantly women (85.7%),
aged 61.6 years in mean. Compared to 2016, in 2017 the risk of
all‐cause hospitalization was lower (aHR 0.95, 95% confidence inter-
val [0.94–0.96]) and the risk of death was similar (aHR 0.98 [0.94–
1.02]). The risk of sick leave was 2% higher in 2017 compared to
2016 (aHR 1.02 [1.01–1.04]); a similar increase was observed in
patients with OAD. The mean number of outpatient visits increased
by 2%, from 6.08 in 2016 to 6.20 in 2017 (P < 0.0001); this increase
was limited to visits to GP and endocrinologists and to the period
from August to October 2017. Renewals of chronic treatments
including psychotropic, anti‐hypertensive and lipid‐lowering drugs
were slightly more frequent in 2017.
Conclusions: Our results do not provide evidence of increased risks of
serious health concerns associated with Levothyrox NF. Though, they
show a substantial increase in healthcare use following Levothyrox
formulation change.
1179 | The association between receptor
affinity and metabolic side effects profile of
antipsychotics and major adverse cardiac and
cerebrovascular events: A case/non‐case
study in VigiBase
João Pedro Aguiar1; Filipa Alves da Costa1,2; Ana Paula Martins1;
Toine Egberts3,4; Hubert G.M. Leufkens3; Patrick Souverein3
1Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; 2 Instituto
Universitário Egas Moniz, Caparica, Lisbon, Portugal; 3Utrecht Institute
for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands;
4University Medical Centre Utrecht, Utrecht, Netherlands
Background: The association between antipsychotics (APs) use and the
occurrence of major adverse cardiac and cerebrovascular events
(MACCE) is well established. However, the underlying pharmacological
mechanisms by which APs may cause those events are still speculative.
Objectives: Our aim was to elucidate the role of possible pharmaco-
logical mechanisms (i.e. the degree of receptor affinity and metabolic
side effects profile) in the reporting of MACCE in AP users.
Methods: A case/non‐case study was undertaken using data (1968–
10/2017) from theWorld Health Organization (WHO) global Individual
Case Safety Report (ICSR) database, VigiBase, among all reports associ-
ated with an AP as suspected drugs. Cases were defined as all ICSRs of
MACCE (included cerebrovascular events, myocardial infarction, and
cardiovascular death) and non‐cases all the other reported suspected
Adverse Drug Reactions (ADRs). APs were classified by AP group (typi-
cal vs atypical), the degree of receptor affinity for adrenergic, dopami-
nergic, muscarinic, histaminic, and serotoninergic receptors (low‐:
>1,000 nM; intermediate‐: 10–1,000 nM; and high‐affinity: < 10 nM)
and metabolic side effects profile (low‐, intermediate‐ and high‐risk).
The strength of the association was estimated with logistic regression
and expressed as crude and adjusted reporting odds ratios (aRORs) with
a corresponding 95% confidence intervals (95%CIs).
Results: By October 2017, there were 333,894 ICSRs concerning only
APs and MACCE was reported in 1.5% (n = 4,987) ICSRs, the rest
being other ADRs. Atypical APs (aROR 2.41; 95%CI 2.15–2.69) were
significantly more frequently associated with the reporting of MACCE
compared to typical ones. APs with high affinity for alfa1 (aROR 2.77;
95%CI 1.80–4.27), H1 (aROR 2.24; 95%CI 1.93–2.60), M1 (aROR 1.79;
95%CI 1.66–1.92), and 5‐HT2A (aROR 2.97; 95%CI 1.93–4.58) recep-
tors were associated with a higher frequency of MACCE compared to
low affinity. APs associated with higher‐risk of metabolic side effects
(aROR 1.80; 95%CI 1.65–1.96) were associated with higher reporting
of MACCE compared to those with a low‐risk.
Conclusions: Data confirm the association between atypical APs and
MACCE. Our findings also showed that APs with high‐affinity for α1,
H1, M1, and 5‐HT2A receptors and high‐risk of metabolic side effects
may be pathways to explain the occurrence of MACCE.
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1180 | Identifying type 2 diabetes patients at
risk for hypoglycemic events: Dealing with
class imbalance
Stijn Crutzen1; Sunil Belur Nagaraj1; Katja Taxis2; Petra Denig1
1UMCG, Groningen, Netherlands; 2RUG, Groningen, Netherlands
Background: Between 5–15% of patients with type 2 diabetes (T2D)
experience hypoglycemic events in need of a healthcare provider's
attention. To give better support and prevent hypoglycemic events,
patients at risk need to be identified using routine care data.
Objectives: To test the impact of class imbalance when developing an
algorithm for identifying T2D patients at risk for hypoglycemic events.
Methods: A retrospective cohort study was conducted using data from
the Groningen Initiative to AnalyzeType 2 Diabetes treatment (GIANTT)
database.GIANTTcontains longitudinal data fromgeneral practices in the
northern part of the Netherlands. T2D patients using a glucose lowering
drugwere included. The primary binary outcomewas having≥1 glycemic
event or no event in 1 calendar year. To deal with expected class imbal-
ance in this outcome, an undersampling strategy was used to balance
the data in which patients without an event were split in random equal
groups of the same size as patientwith an event. These groupswere com-
pared to the patients with an event. Univariate analyses were performed
to select predictors from a range of routinely available clinical and medi-
cation variables.Multivariate logisticmodelswere compared onaccuracy,
specificity and sensitivity at a prediction probability cut‐off point of 0.5
and on area under the curve (AUC).
Results: The following variables were included in the multivariate
models: insulin use, sex, non‐chronic infections, glucose variability,
diabetes duration, HbA1c, diastolic blood pressure, drug count, non‐
selective beta‐blocker use, anti‐depressant use, liver disease and
eGFR. The unbalanced model had an AUC of 0.70, an accuracy of
88.2% with a specificity of 99.8% and a sensitivity of 1.0%. The bal-
anced model had an AUC of 0.71, an accuracy of 66.8% with a spec-
ificity of 72.7% and a sensitivity of 61.8%.
Conclusions: To develop an algorithm for identifying patients at risk for
hypoglycemic events class imbalance should be taken into account. The
balanced model showed an improved sensitivity with an acceptable
specificity.More advanced feature selection techniques, such as LASSO
and elastic net, can be tested to further improve the model.
1181 | Abstract Withdrawn
1182 | Antidepressant‐induced
hyponatremia: A Pharmacoepidemiological‐
Pharmacodynamic analysis of suspected
adverse drug reactions reported to the US
FAERS database
Faizan Mazhar1; Marco Pozzi2; Marta Gentili1; Emilio Clementi1;
Sonia Radice1; Carla Carnovale1
1University of Milan, Milan, Italy; 2University of Milan, Bosisio Parini LC,
Italy
Background: Hyponatraemia induced by antidepressant drugs is a rare
but potentially life‐threatening adverse reaction. Whether it is associ-
ated with all or only some antidepressant drugs is still unclear.
Objectives: To quantify the strength of association between the use
of different a antidepressant drugs and hyponatraemia by using infor-
mation reported to the Food and Drug Administration (FDA) Adverse
Event Reporting System (FAERS). The secondary objective was to
investigate the putative relationship between different antidepressant
pharmacological targets and the risks of hyponatraemia induced by
antidepressant drugs using the ‘pharmacoepidemiological‐pharmaco-
dynamic’ method.
Methods: A case‐noncase analysis was used using spontaneous
reports from the FAERS database to measure the risk of reporting
between suspected antidepressant and hyponatraemia with all other
ADRs [expressed as a reporting odds ratio (ROR) while adjusting for
gender, age, and concomitant medications associated with
hyponatremia]. We assessed to what extent the receptor binding
properties of antidepressants could associate to the RORs of
hyponatraemia/SIADH of antidepressants, building a linear regression
model that included as independent variables the binding affinities
(pKi) to the serotonin transporter (SERT), dopamine transporter, nor-
epinephrine transporter, and 5‐HT2C, 5‐HT2A, 5‐HT1A, α1 and α2
adrenergic receptors].
Results: 2,233 reports were identified. The adjusted ROR for the asso-
ciation between antidepressant drugs use and hyponatraemia was of
1.91 [95%CI 1.83, 2.00]. The association was strongest for mirtazapine,
followed by selective serotonin reuptake inhibitors (SSRIs), and lowest
with serotonin modulating antidepressant drugs. A significant linear
correlation was found between the adjusted RORs for
hyponatraemia/SIADH and pKi for the adrenergic receptors α1and α2.
Conclusions: Hyponatraemia/SIADH is reported at a disproportion-
ately higher rate with classes of antidepressant drugs (NaSSAs and
serotonin modulators) that are in general considered to have a better
profile of tolerability in terms of hyponatraemia. The risk of
hyponatraemia with mirtazapine appears to be greater than what
was reported in the literature. Our PE‐PD analysis indicates also that
inhibition of SERT may not be involved in the hyponatraemia linked
to the use of antidepressant drugs.
1183 | Hyperkalemia risk with
spironolactone in patients with heart failure
using loop diuretics
Alex Secora; Jung‐Im Shin; Yao Qiao; G. Caleb Alexander;
Josef Coresh; Morgan Grams
Johns Hopkins University, Baltimore, MD
Background: There are a paucity of real‐world clinical data on the risk
of hyperkalemia when adding spironolactone to loop diuretics in
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patients with heart failure, and it is also unclear whether risk differs by
kidney function.
Objectives: To measure the absolute and relative risks of
hyperkalemia associated with adding spironolactone to loop diuretics
among patients with heart failure.
Methods: Patients with heart failure and loop diuretic use were iden-
tified in MarketScan commercial claims data (MS) from 2010–15
(N = 5448), and the Geisinger Health System (GHS) from 2004–16
(N = 7448). Medication use was determined through dispensing data
(MS) and prescription orders (GHS). We quantified the incidence of
hyperkalemia, defined as inpatient encounters with hyperkalemia diag-
nosis codes, comparing rates on treatment (from spironolactone initia-
tion among initiators) with those on control (from a randomly selected
loop diuretic prescription among those not using spironolactone). We
evaluated whether spironolactone use was associated with higher risk
of hyperkalemia in patients with estimated glomerular filtration rate
(eGFR) <60 ml/min/1.73m2 compared to ≥60 ml/min/1.73m2 using
negative binomial regression. All models were adjusted for baseline
serum potassium, demographics, comorbidities, and medication use
and, in sensitivity analyses, we repeated the analysis matching treat-
ment 1:1 to controls using propensity scores.
Results: Among individuals with incident heart failure (MS: treatment
n = 759 and control n = 4689; GHS treatment n = 1242 and control
n = 6206), the treatment groups were younger, and more likely to be
male, have liver disease, and take cardiovascular medications (all
p < 0.05). Baseline mean potassium was lower (−0.06 mEq/L) and
eGFR was higher (+2.6 ml/min/1.73m2) in the treatment group in
GHS. Overall, there were 68 hyperkalemia events [4.6 vs 2.5 per
1000 person‐months in treatment and controls, respectively] in MS,
and 208 (3.4 vs 1.4) in GHS. In adjusted analyses, treatment was asso-
ciated with an incidence rate ratio of 1.95 [95% confidence interval
(CI): 1.05–3.64] and 2.90 (CI: 1.95–4.33) for hyperkalemia events in
MS and GHS, respectively. There were no differences in hyperkalemia
risk by level of kidney function in either cohort (p for interaction
between treatment status and kidney function ‐ MS: 0.89; GHS:
0.64). Results were similar in propensity score matched analyses.
Conclusions: The initiation of spironolactone among loop diuretic
users with heart failure was associated with a greater risk of
hyperkalemia, but the risk did not differ by baseline level of kidney
function.
1184 | Monitoring the safety of Exenatide
once‐weekly (Bydureon®) in primary Care in
England: Results from a PASS
Sandeep Dhanda1,2; Vicki Osborne1,2; Debabrata Roy1,2;
Saad Shakir1,2
1Drug Safety Research Unit, Southampton, UK; 2University of
Portsmouth, Portsmouth, UK
Background: Clinical trials have reported specific safety concerns such
as acute pancreatitis (AP) in patients (pts) taking Bydureon®
(exenatide once‐weekly) for type 2 diabetes mellitus (T2DM). A
Post‐Authorisation Safety Study (PASS) was conducted to monitor
the real‐world safety of Bydureon® in primary (1o) care in England.
Objectives: To estimate the incidence of targeted safety outcomes in
pts prescribed Bydureon® in 1o care.
Methods: Pts identified from dispensed Bydureon® prescriptions in
England (2012–2016). Questionnaires sent to prescribing general
practitioners (GPs) at ≥12‐months observation collected event infor-
mation. Events of interest included AP, pancreatic cancer (PC), thyroid
neoplasm (TN), gallstones, biliary colic or cholecystitis (GBC), acute
renal failure (ARF), type 1 hypersensitivity (T1H), and cardiac events
(CE). 12‐month incidence estimates (on Bydureon® or ≤ 10 weeks
after stopping) were calculated; results were stratified according to
prior exenatide use (i.e. Byetta®).
Results: Questionnaire response rate = 37.2% (7752/20860). Total
cohort = 6294 pts prescribed Bydureon® for T2DM (median age
57 years [IQR 50, 65]; 55.2% male). Exenatide naïve n = 4556
(72.4%), previous Byetta® users n = 1629 (25.9%), previous Byetta®
use unknown n = 109 (1.7%). Risk of AP in total cohort 0.2% (95%
CI [0.1, 0.4]; n = 14). 2 pts had a prior history. Risk of AP was similar
for exenatide naïve (0.2% (95% CI [0.1, 0.4]; n = 10) and previous
Byetta® users (0.2% (95% CI [0.0, 0.5]; n = 3). Rate of AP in total
cohort was 2.5/1000 person‐years (95% CI [1.5, 4.3]) and no statisti-
cally significant difference was observed between the 2 user groups.
Time‐to‐event analyses suggested no clear pattern in the hazard func-
tion of AP over time. For 12 of the 14 pts, Bydureon® was stopped
due to AP. AP complications; necrosis/pseudocyst n = 1, fatal outcome
n = 1. PC 0.1% (n = 4); a fatal outcome was reported in 3 of these pts.
TN 0.0% (n = 0). GBC 0.6% (95% CI [0.4, 0.8]; n = 38); 15 of which had
a prior history of GBC. ARF 0.5% (95% CI [0.3, 0.7]; n = 29). T1H 0.7%
(95% CI [0.5, 0.9]; n = 44). CE 3.6% (95% CI [3.2, 4.1]; n = 227). No sta-
tistically significant differences in risk between the 2 user groups were
observed.
Conclusions: Incidence of AP was low in Bydureon® users and consis-
tent with prior clinical trial/observational data. No unexpected find-
ings were identified. This study has unique strengths, including
collection of timely, granular real‐world data from GPs, facilitating
accurate estimates. The study is part of a broader literature on the
safety of Bydureon® and conclusions should be made in context with
other post‐marketing findings.
1185 | Incidence and risk factors for
hypoglycemia in patients with diabetes
hospitalized in a quaternary Care Centre in
South India
Jeeva Joseph; Suja Abraham
Nirmala College of Pharmacy, Muvattupuzha, Ernakulam District, Kerala,
India
Background: Hypoglycemia occurs in 8% of hospital admissions and is
an important complication of type 2 diabetes that can have a major
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impact on health outcomes. The 2017 Standards of Medical Care high-
light renal insufficiency and cognitive dysfunction as important risk fac-
tors for hypoglycemia but other risk factors remain less documented.
Objectives: To identify potential risk factors in the development of
hypoglycemia in hospitalized diabetic patients and to evaluate their
influence in patients admitted to critical care and non‐critical care units.
Methods: In this prospective, non‐randomized study a number of
potential risk factors for the development of hypoglycemia in hospital-
ized patients such as clinical condition of the patient, duration of dia-
betes, blood sugar level at the time of admission, type of feed and
surgical status were predefined based on the literature. The influence
of these factors were then evaluated in patients admitted to critical
and non‐critical care units. Blood glucose measurement was done by
point‐of‐care testing. All Type II diabetic patients admitted to the hos-
pital (>18 years) were included and Type 1 diabetic patients and
hyperglycemia without a history of diabetes were excluded. The influ-
ence of risk factors in the development of hypoglycemia were ana-
lyzed and compared the data of critical and non critical care units
using chi square method with p < 0.05 to be significant.
Results: The study revealed that 14.3% of the diabetic patients devel-
oped hypoglycemia and the incidence of events was found to be
31.25%. There was no significant difference in age (65 ± 9.5 vs
64.5 ± 9.6 p = 0.764) and time of hypoglycemic attack (46% vs
54.5% p = 0.344) in patients admitted to critical and non critical care
units whereas duration of diabetes (44% vs 6% p = 0.000), blood sugar
at the time of admission (30.5% vs 47% p = 0.000), surgical status (5%
vs 30% p = 0.000) significantly differed. There was also significant dif-
ference in the incidence of hypoglycemia based on the type of feed in
both groups; normal intake (15% vs 50.5% p = 0.05), decreased intake
(6.8% vs 30% p = 0.05), RT feed (40.7% vs 6% p = 0.05). Terminal ill-
ness was considered a major risk factor for hypoglycemia and the rela-
tionship between hypoglycemia and mortality(10% vs 1.5% p = 0.001)
was stronger among patients who had multiple events of moderate
hypoglycemia(40–60 mg/dl) during their hospital stay.
Conclusions: Hypoglycemia is a common problem in hospitalized dia-
betic patients and the influence of these risk factors should be consid-
ered in hypoglycemic risk assessment when individualizing diabetes
care for older patients.
1186 | Incretin mimetic drugs (GLP‐1
receptor agonists and DPP‐4 inhibitors) and
associated adverse events and renal
outcomes: A Pharmacoepidemiologic analysis
using the FAERS database
Hamza Alshannaq; Jeff Jianfei Guo
University of Cincinnati, Cincinnati, OH
Background: Clinical studies demonstrated the efficacy and safety of
incretin memetic drugs among patients with diabetes, however, the
impact of these drugs on renal function is still not settled.
Objectives: 1) To identify potential signals of adverse events that are
frequently reported but not currently stated on drug labels. 2) To
explore the potential impact of incretin mimetic drugs on renal out-
comes using a real world data.
Methods: Retrospective descriptive analysis of adverse events
reported to the US Food and Drug Administration Adverse Events
Reporting System (FAERS) database from quarter 1, 2012 to quarter
2, 2018. Our Analysis focused on three drugs of the incretin mimetic
class resulted in a postmarket safety communications by the FDA,
namely Exenatide, Sitagliptin and Saxagliptin. The most common
adverse events (AEs) were compared with the current warnings on
each drug label. Renal adverse event reports AE reports were identi-
fied using text string search queries of preferred terms related to the
renal system.
Results: A total of 72,035 AEs were identified for the study drugs
(Exenatide, 41,089, Sitagliptin, 25,091, Saxagliptin, 5,855). The most
common AEs that are not posted on label N(%) were: For Exenatide,
Hypertension 317(1.26%), Bladder Cancer 234 (0.93%), Anxiety
230(0.92%), Depression 181 (0.72%), Myocardial Infarction 159
(0.63%), and Pneumonia 142 (0.57%); For Sitagliptin, Pneumonia
1127(2.74%), Asthenia 1015 (2.47%), Hypertension 889(2.16%), Ane-
mia 857(2.09%), Bladder Cancer 847(2.06%); For Saxagliptin, Hyper-
glycemia 424 (7.24%), Diarrhea 279 (4.77%), Nausea 233 (3.98%),
fatigue 231(3.95%), weight reduction 233 (3.81%). The most common
renal AEs for Exenatide were: Acute Kidney Injury 217 (0.86%), Renal
failure 213 (0.85%), Urinary Tract Infections 112 (0.45%); for
Sitagliptin were: Renal failure 907 (2.21%), Acute Kidney Injury 768
(1.87%), and Urinary Tract Infection 705 (1.72%); and for Saxagliptin:
Urinary Tract Infections 123 (2.1%), Renal Failure 115 (1.96%), Acute
Kidney Injury 80 (1.37%).
Conclusions: Renal adverse events seem more commonly reported for
Sitagliptin and Saxagliptin compared with Exenatide. Hypertension,
myocardial infarction and pneumonia were identified for all drugs
and not currently addressed on drug labels and need further
assessment.
1187 | Diabetes management protocol:
Impact in the incidence of hypoglycemia
Suja Abraham
Nirmala College of Pharmacy, Muvattupuzha, Ernakulam, Kerala, India
Background: Hypoglycemia occurs in 7.7%of hospital admissions and is
associated with increased length of stay and increased mortality. It is
suboptimally treated and has severe consequences. There remains a
need for the development, implementation and adherence to a diabetes
management protocol that reduces the incidence of hypoglycemia.
Objectives: To develop a protocol in the management of hospitalized
diabetic patients and to evaluate its impact during post interventional
phase.
Methods: In this prospective, interventional, non randomized study,
diabetes management protocol was developed according to ADA
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guidelines. All Type II diabetic patients admitted in a Quaternary Care
Centre in South India in the age group≥18 years of either sex irrespec-
tive of comorbidities and medications were included in the study and
those with gestational diabetes or hyperglycemia without a history of
diabetes were excluded. Blood glucose measurement was done by
point‐of‐care testing. The impact of protocol in reducing hypoglycemic
events were analyzed and compared the data of pre intervention with
post intervention using chi square method with p < 0.05 to be
significant.
Results: Pre intervention data showed 85 hypoglycemic events (15.8%)
in 535 diabetic patients and in post intervention phase,57 (14.3%)
events were observed in 400 patients. Therewas statistically significant
reduction in the severity of hypoglycemia (23.5% vs 6.4%, P = 0.035),
incidence in patients with normal diet (73.3% vs 43.2%, p = 0.00) and
an increase in referral to specialist(30.6% vs 43.2%, P = 0.000) and reg-
ular monitoring (47.1% vs 94.4%, P = 0.001) after implementing the
protocol.
Conclusions: Development and implementation of a diabetes manage-
ment protocol, significantly reduces the incidence and severity of hypo-
glycemia. Adherence to protocol, regular monitoring, proper feed and
early referral to specialists may help to reduce the hypoglycemic
episodes.
1188 | Risk and signals of ketoacidosis
among sodium‐glucose Cotransporter‐2
(SGLT2) inhibitors: Analysis of post marketing
FDA adverse event reporting system (FAERS)
database, 2013–2018
Thamir M. Alshammari1,2; Maram A. Al‐Otaiby3; Fatemah A. Anofal2;
Khaledah A. Alenazi4
1Medication Safety Research Chair, King Saud University, Riyadh, Saudi
Arabia; 2Saudi Food and Drug Authority, Riyadh, Saudi Arabia;
3Pathology department, College of Medicine, King Saud University,
Riyadh, Saudi Arabia; 4Ministry of Health, Riyadh, Saudi Arabia
Background: Sodium‐glucose Cotransporter‐2 (SGLT2) Inhibitors are
considered a novel treatment option for patients with diabetes, due
in part to their cardiovascular protective effects and their availability
as oral medications. However, the risk of ketoacidosis has substan-
tially increased in par with reports concerning the health effects of this
group of medication, as regarded by health institutions and regulatory
authorities.
Objectives: To analyze and compare the risks of ketoacidosis among
Sodium‐glucose Cotransporter‐2 (SGLT2) Inhibitors in the FDA
Adverse Event Reporting System (FAERS) database over 5 years.
Methods: Reports of ketoacidosis and related terms events (e.g. dia-
betic ketoacidosis) submitted to FAERS in the period between March
2013 and March 2018 were retrieved and analyzed by the reporting
odds ratio (ROR). Using FAERS database, the ROR of case/non‐case
reports of ketoacidosis and its related terms associated with SGLT2
inhibitors was compared. All data were analyzed by using the Statisti-
cal Analysis Software (SAS), version 9.4.
Results: 6,809 reports of ketoacidosis were reported during the study
period in FAERS database among the total of 6,583,341 unique
reports. Majority of reports of ketoacidosis during the study periods
were linked to SGLT2 inhibitors (73%). Around 2,692 reports linked
canagliflozin to ketoacidosis and the proportion of ketoacidosis
reports with canagliflozin—among all canagliflozin reports—was
11.5%. There were 1,217 reports linked dapagliflozin to ketoacidosis,
and the proportion of this was 12.2%, while it was 13.2% for
empagliflozin with 1,064 reports connected to ketoacidosis. The
annual number of reports increased yearly (2013 to 2018) with a high
spike in 2015. The association between ketoacidosis and its related
terms was statistically significant with the use of all three medications
with different with the degree of association. ROR was 162 [95% CI
152–173]) with dapagliflozin, ROR 173 [95% CI 161–186] with
empagliflozin, and ROR 205 [95% CI 195–216] with canagliflozin.
Conclusions: There is a significant risk of ketoacidosis with the use of
the SGLT2 inhibitors. However, the risk varies within SGLT2 inhibi-
tors, with an increase among canagliflozin and a decrease with
dapagliflozin.
1189 | Pancreatic safety of sodium‐glucose
co‐transporter 2 inhibitors in patients with
type 2 diabetes: A systematic review and
meta‐analysis
Huilin Tang1; Keming Yang1; Aihua Wang2; Xin Li1; Yiqing Song1;
Jiali Han1
1 Indian University, Indianapolis, IN; 2Beijing Obstetrics and Gynecology
Hospital, Beijing, China
Background: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, a
novel class of oral antidiabetic drugs, have been suggested a potential
risk of acute pancreatitis in patients with type 2 diabetes (T2D). How-
ever, the pancreatic safety of SGLT2 inhibitors in patients with T2D is
not well known.
Objectives: This study aimed to systematically evaluate the associa-
tion between SGLT2 inhibitors and pancreatic safety in patients with
T2D.
Methods: We systematically searched PubMed, EMBASE, the
Cochrane Central Register of Controlled Trials (CENTRAL), and
ClinicalTrials.gov through May 2018 to identify randomized controlled
trials that reported adverse events on acute pancreatitis, pancreatitis,
or pancreatic cancer among the adults with T2D treated with SGLT2
inhibitors compared with placebo or other active antidiabetic drugs.
Peto odds ratio (OR) with 95% confidence interval (CI) was used to
pool the data. The GRADE framework was introduced to assess the
quality of evidence.
Results: Thirty‐one trials involving 39,002 patients with T2D, with a
median duration of 52 weeks were included. Meta‐analysis of 16 trials
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(37 acute pancreatitis events among 27,301 patients) did not find an
increased risk of acute pancreatitis with SGLT2 inhibitors compared
to controls (Peto OR, 0.80; 95% CI, 0.41 to 1.57; I2 = 0%; moderate
quality evidence). A similar result was found for risk of pancreatitis
(Peto OR, 0.79; 95% CI, 0.47 to 1.34; I2 = 0%; moderate quality evi-
dence). When pooling the data from seventeen trials (14 pancreatic
cancers among 17,664 patients), SGLT2 inhibitors were significantly
associated with increased risk of pancreatic cancer (Peto OR, 3.74;
95% CI, 1.25 to 11.21; I2 = 0%; very low quality evidence).
Conclusions: Our comprehensive analysis of randomized trial data
suggests that SGLT2 inhibitors are not associated with increased risk
of acute pancreatitis but with an increased risk of pancreatic cancer
among patients withT2D. Despite suggestive evidence, these findings
call for future safety monitoring in trial participants and in real‐world
settings.
1190 | Acute pancreatitis associated with
opioid use: A nested case–control study
Iris Pujade1; Francesco Salvo1; Anne‐Marie Castilloux2,3;
Audrey Béliveau2; Yola Moride2,3
1University Hospital of Bordeaux, Bordeaux, France; 2University of
Montreal, Montréal, QC, Canada; 3YolaRx, Consultants, Montréal, QC,
Canada
Background: The annual incidence of acute pancreatitis (AP) in the
general population ranges from 1.3 to 4.5/10,000 persons and drugs
are responsible for 0.1% to 2% of cases. Opioids are among the
suspected agents as they may induce spasms of the sphincter of Oddi
(SSO), which can reduce biliary secretion, disrupt the enzyme's excre-
tion from the pancreas and thus, lead to AP. In France the regulatory
Agency considers opioid‐induced pancreatitis as an emerging signal
requiring additional data.
Objectives: i)To estimate the incidence of AP in adults (aged ≥18)
who have initiated an opioid; ii)To identify the characteristics of opioid
treatment and of patients that are associated with an increased risk of
AP.
Methods:We conducted a nested case–control study within a random
sample of adults who initiated an opioid between January 1, 2014 and
December 31, 2016, identified in the administrative claims databases
of Quebec (RAMQ). Cases were patients with a claims diagnosis of
AP and/or SSO during the 12 months following the first opioid fill.
Index date was the date of first diagnosis. For each case, 4 controls
were identified through incidence density sampling and matched on
age group (5‐year intervals), gender and calendar date of cohort entry
(± 6 months). Suspected risk factors were treatment characteristics
(type of opioid, dose in MME and duration). Covariables included: his-
tory of AP, gallstones, alcoholism, hypertriglyceridemia, cholecystec-
tomy, immune‐related comorbidities and use of drugs known to
increase the risk of pancreatitis. The incidence rate of AP in the cohort
was estimated along with 95% confidence interval (95% CI). The asso-
ciation with treatment and individual patient characteristics was
assessed through conditional logistic regression analysis. Risk modi-
fiers were assessed using interaction terms in the model.
Results: The cohort included 84,825 new opioid users and the inci-
dence of AP was estimated at 27.0/10,000 person‐years (95% CI 2.4
to 3.1). The mean time to event was 141 days (median 108) for PA
and 74 days (median 14) for SSO. Overall, 233 cases (229 PA, 4
SSO) were matched with 932 controls. Cases were more likely to have
initiated an opioid treatment with morphine than controls (40.3% vs
32.3%), but less likely with codeine (38.2% vs 43.9%). Only 8 cases
(4.4%) were long‐term opioid users (≥90 days) compared to 21 con-
trols (2.2%).
Conclusions: According to the standard threshold of 0.1%, acute pan-
creatitis is not a rare event in the population of opioid users. The iden-
tification of at‐risk patients may be useful to minimize or mitigate the
risk and therefore improve the follow‐up care of patients initiating
opioids.
1191 | Cinacalcet use and risk of
gastrointestinal bleeding in secondary
hyperparathyroidism patients receiving
maintenance hemodialysis
Tzu‐Chieh Lin1; Haifeng Guo2; Paul Dluzniewski1; Yi Peng2;
Dave Gilbertson2; Brian Bradbury1; Kimberly Nieman2;
Michael Sprafka3; Jiannong Liu2
1Amgen Inc., Thousand Oaks, CA; 2Chronic Disease Research Group,
Hennepin Healthcare Research Institute, Minneapolis, MN; 3 Independent,
Thousand Oaks, CA
Background: Gastrointestinal (GI) bleeding is a frequent complication
among hemodialysis (HD) patients. It has been hypothesized that
cinacalcet use increases GI bleeding risk in HD patients with second-
ary hyperparathyroidism (SHPT).
Objectives: To assess the potential association between cinacalcet use
and risk of GI bleeding in HD patients with SHPT.
Methods: We conducted a case–control study nested within a cohort
of adult Medicare patients with SHPT who received chronic HD in a
large dialysis provider in the US between 2007 and 2010. We excluded
patients with evidence of cinacalcet use or a GI bleeding event in the
year before cohort entry. Patients were followed from cohort entry to
the earliest of death, parathyroidectomy, GI bleeding event, loss of
Medicare coverage, change to peritoneal dialysis, transplant, or 12/
31/2010. We defined a case who experienced a fatal or non‐fatal GI
bleeding event during follow‐up. We matched up to four controls to
each case based on age, race, sex, time on dialysis, and PTH level using
incidence density sampling. The date of case event andmatched control
date were assigned as the index date. Exposure to cinacalcet preceding
the index date was defined as any use (yes/no) and recency of use
(within 61 days preceding index [current], more than 61 days preceding
index [past], and no use). Multivariable conditional logistic regression
was used to estimate the OR and the corresponding 95% CI for the
association between cinacalcet use and risk of fatal and non‐fatal GI
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bleeding adjusting for potential confounders. Subgroup analyses were
conducted by age, sex, race, time on dialysis and PTH levels groups.
Results: Among 51,007 patients, we identified 2570 cases, and of
those, 2465 (96%) could be matched to 9400 controls. Matched cases
and controls were on average 66 years, 48% were female, and 19%
had PTH ≥600 pg/mL. Comorbid conditions were generally more
prevalent in cases than controls, such as hepatitis (36% vs. 30%),
COPD (27% vs. 20%), coronary artery diseases (50% vs. 42%) and
upper GI diseases (31% vs. 22%). Cinacalcet use at any time before
the index date was similar among cases and controls, 17.2% and
15.8%, respectively. The adjusted ORs and associated 95% CI's for
the association between any use, current use and past use and GI
bleeding were 1.04 (0.9–1.2), 0.97 (0.8–1.1), 1.22 (0.99–1.5), respec-
tively. Results were consistent across subgroups.
Conclusions: In this study over 50,000 patients receiving HD, we
found no evidence of an increased risk of GI bleeding associated with
cinacalcet use, a treatment commonly used to manage SHPT.
1192 | Measuring the risk of liver injury in
UK primary care patients prescribed a second
course of Flucloxacillin: A cohort study using
the clinical practice research datalink (CPRD)
Patrick Bidulka1; Ian Douglas1; Louise Pealing2; Kevin Wing1
1London School of Hygiene & Tropical Medicine, London, UK; 2University
of Oxford, Oxford, UK
Background: First‐time users of flucloxacillin are at an increased risk
of serious liver injury. It is currently unknown, however, whether peo-
ple with previous flucloxacillin exposure remain at‐risk during subse-
quent courses of flucloxacillin therapy. Increasing rates of
flucloxacillin prescriptions in the UK, particularly in the elderly, war-
rant further investigation into the side effects of this drug.
Objectives: To calculate the absolute and relative risks of drug‐
induced liver injury (DILI) during a second course of flucloxacillin and
identify risk factors for second course DILI.
Methods: We used data from the UK Clinical Practice Research
Datalink (CPRD) (1 January 2000 to 1 January 2012) to conduct a
cohort study comparing the risk of DILI in patients prescribed a sec-
ond course of flucloxacillin with patients prescribed a first course of
oxytetracycline. Outcomes were (i) symptom‐defined and (ii) labora-
tory‐confirmed DILI within 1–45 days of second course initiation.
Absolute 1–45 day risks were estimated, before applying multivariable
logistic regression to calculate the relative risks. Secondary analyses
were stratified by age, sex, and number of flucloxacillin prescriptions.
Results: There were 259,395 patients prescribed a second course of
flucloxacillin (25 symptom‐defined cases, 10 lab‐confirmed) and
184,737 patients prescribed a first course of oxytetracycline (10
symptom‐defined cases, <5 lab‐confirmed). The 1–45 day adjusted
risk ratio of symptom‐defined DILI for flucloxacillin compared to oxy-
tetracycline was 2.09 (95% CI 0.90–4.85). The absolute risk of symp-
tom‐defined DILI during the second course of flucloxacillin was 9.64
per 100,000 patients (95% CI 6.24–14.23), compared to 3.79 per
100,000 patients (95% CI 1.52–7.81) for the first course of oxytetra-
cycline. Patients 80 years‐of‐age or older had 8 times the risk of symp-
tom‐defined DILI compared to those aged 18–49 (RR 7.99, 95% CI
2.44–26.15), and those with repeat flucloxacillin prescriptions within
the second course had 2.4 times the risk compared to those with only
one (RR 2.39, 95% CI 0.99–5.75).
Conclusions: There was weak evidence suggesting patients remain at
an elevated risk of DILI during a second course of flucloxacillin; how-
ever, the risk appears to be lower when compared to a previous anal-
ysis of the risk in first‐time users (14.15 per 100,000 during the first
course vs. 9.64 per 100,000 during the second). Second‐course DILI
risk factors include older age and repeat prescriptions. Further work
is ongoing to increase the sample size of this cohort.
1193 | Main drug classes dispensed prior to
hospital admission for acute liver injury
Adeline Grolleau; Stephanie Duret; Nicolas Thurin; Mai Duong;
Regis Lassalle; Patrick Blin; Sinem‐Ezgi Gulmez; Nicholas Moore
Bordeaux PharmacoEpi, Bordeaux, France
Background: Hepatic injury is a major safety issue. Most drugs and
drug classes have been associated with liver toxicity.
Objectives: To quantify exposure to different drug classes prior to
hospital admission for acute liver injury (ALI) in the French National
healthcare systems database, SNDS.
Methods: All hospital admissions for acute liver injury (K71.1,.2,.6,.9,
K72.0) over 2009–2014 were identified in SNDS (66 million persons).
Previous diagnoses of liver disease/liver injury were excluded. Expo-
sures of interest were all drug classes at the highest ATC level, dis-
pensed from 7 to 60 days before hospital admission. Reference
populations were a) the French population over the study period,
extrapolated from the 1/97thpermanent representative sample, EGB
in a case‐population analysis. b) 5 controls/case from EGB, matched
on age, gender, and index date, for case–control analysis. Results are
provided as a) number of cases per million users (MPt) or ten thousand
patient‐years (TPY), with 95% confidence intervals [95%CI]; b) Odds
Ratios [95% CI], compared to non‐exposure.
Results: 4807 ALI were matched to 24035 controls, with 3619 cases
and 12793 controls exposed (OR 3.1 [2.9–3.4]). The greatest number
of cases was exposed to analgesics (1954) followed by cardiovascular
drugs (1858), the smallest was antimycobacterial (AMB, 86 cases). On
the other hand, AMB were associated with by far the highest rates per
MPt (399.9) and per MPY (909) and OR (72 [31–1646]) Second worst
per million patients were antithrombotics (mostly aspirin) (86/MPt,
33/MPY, OR 1.54 [1.42–1.6], then cardiovascular drugs (74/MPt,
11/MPY, OR 1.8[1.66–1.94]. Analgesics including paracetamol were
at 36/MPt, 88/MPY, OR 2.04 [1.91–2.18], and NSAIDs at 18.3/MPt,
77/MPY, OR 1.4[1.28–1.52]. Drugs for functional gastrointestinal dis-
order and antiemetics had OR above 3, maybe reflecting protopathic
bias rather than actual risk. Risk per patient increased and risk per
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MPY decreased with increasing average duration of treatment up to
one year, then became very similar and stable for treatment dispensed
for more than one year on average, in this five‐year study.
Conclusions: The apparent risk of hospital admission for hepatic injury
with previous exposure to drugs was probably increased by the ICD10
codes chosen, which selected for toxic liver injury, with a three times
higher exposure to any drugs in cases than in controls.
Antimycobacterial had by far the highest risk of hepatotoxicity, and
NSAIDs among the lowest. Data was collected for over 200 drugs.
1194 | Antibiotic exposure prior to hospital
admission for acute liver injury
Adeline Grolleau; Stephanie Duret; Nicolas Thurin; Mai Duong;
Regis Lassalle; Patrick Blin; Cecile Droz; Sinem‐Ezgi Gulmez;
Nicholas Moore
Bordeaux PharmacoEpi, Bordeaux, France
Background: Hepatic injury is a major safety issue. Several antibiotics
(AB) have been concerned. Antimycobacterials (AMB) are known hep-
atotoxic drugs.
Objectives: To quantify exposure to AB or AMB prior to hospital
admission for acute liver injury (ALI) in the French National healthcare
systems database, SNDS.
Methods: All hospital admissions for acute liver injury (K71.1,.2,.6,.9,
K72.0) over 2009–2014 were identified in SNDS (66 million persons).
Previous diagnoses of liver disease/liver injury were excluded. Expo-
sures of interest were AB (ATC codes J01AA to J01MA) and AMB
(J04) dispensed from 7 to 60 days before hospital admission. Refer-
ence populations were a) the French population over the study period,
extrapolated from the 1/97thpermanent representative sample, EGB in
a case‐population analysis. b) 5 controls/case from EGB, matched on
age, gender, and index date, for case–control analysis. Results are pro-
vided as a) number of cases per million users (MPt) or ten thousand
patient‐years (TPY), with 95% confidence intervals [95%CI]; b) Odds
Ratios [95% CI], compared to non‐exposure.
Results: 4807 ALI were matched to 24035 controls, with 3619 cases
and 12793 controls exposed (OR 3.1 [2.9–3.4]). 1108 cases had been
exposed to at least one AB, vs. 2606 controls (OR 2.47 [2.29–2.68]).
All AB together had 1.3 [1.2–1.5] cases per TPY, 22.7 [20.2–25.2]
per MPt. Individual drugs ranged per TPY from erythromycin 28.8
[21.8–37.5] to Doxycycline 0.4 [0.2–0.6]. Other commonly used drugs
were amoxicillin 0.9 [0.8–1.0], co‐amoxiclav 1.5 [1.3–1.7],
clarithromycin 1.9 [1.5–2.5] /TPY. Per MPt rates were erythromycin
189 [141–242], clindamycin 31 [15–58], cotrimoxazole 26 [20–34],
Co‐amoxiclav 15 [13–18]. Odds ratios ranged from 93 [29–298] for
erythromycin to 1.36 [0.85–2.18] for roxithromycin. Co‐amoxiclav's
OR was 3.55 [3.05–4.13], amoxicillin 1.76 [1.5–2.1].AMB ranged from
108/TPY for the triple association isoniazid, rifampicin, ethambutol to
17/TPY for isoniazid alone; per patient rates were 1728/MPt for the
triple association, to 780 for isoniazid. The OR for all AMB pooled
was 73 [31–164]. Many Individual AMB had no exposed controls.
Estimated OR went from 174 for triple therapy, ethambutol 125, iso-
niazid 35.
Conclusions: The risk of hospital admission for hepatic injury with AB
was similar for most AB, with some outliers: in addition to AMB, eryth-
romycin was associated with a clearly much higher risk of admission
for hepatic injury.
1195 | Antidepressant and anxiolytic‐
hypnotic exposure prior to hospital admission
for acute liver injury
Adeline Grolleau; Stephanie Duret; Nicolas Thurin; Mai Duong;
Regis Lassalle; Patrick Blin; Cecile Droz; SinemEzgi Gulmez;
Nicholas Moore
Bordeaux PharmacoEpi, Bordeaux, France
Background: Acute liver injury (ALI) is a major drug safety issues. Sev-
eral antidepressant (AD) and anxiolytic‐hypnotic (BZ) drugs have been
associated with ALI.
Objectives: To quantify exposure to AD/BZ prior to hospital admis-
sion for acute liver injury (ALI) in the French National healthcare sys-
tems database SNDS (66 million persons).
Methods: All hospital admissions for ALI (K71.1,.2,.6,.9, K72.0) over
2010–2014 were identified in SNDS. Cases with diagnoses of liver
disease/injury were excluded. Exposures of interest were BZ (ATC
codes N05B, N05C) and AD (N06A) dispensed from 7 to 60 days
before hospital admission to avoid indication and protopathic biases.
Reference populations were a) the whole French population over the
study period extrapolated from the 1/97thpermanent representative
sample EGB, in a case‐population analysis: b) 5 controls/case from
the same database matched on age and gender using the same index
date for the case–control analysis:. Results are provided as a) number
of cases per million users (MPt) or patient‐years (MPY) with 95% con-
fidence intervals [95%CI] b) Odds Ratios (OR) [95% CI] compared to
non‐exposure.
Results: 4807 cases with hospital admission for ALI were identified
matched to 24035 controls. 3619 cases and 12796 controls had been
exposed to any drug within 7–60 days preadmission (OR 3.1 [2.9–
3.4]). 914 cases were exposed to at least one anxiolytic BZ and 495
to at least one hypnotic (vs. 2289 and 1207 controls (OR 2.3 [2.1–
2.5] and 2.2 [2.0–2.5])): ranging from 244 cases for zolpidem to 5 for
estazolam. Rates of ALI was 43 [37–47]/MPY for all BZ with individual
drugs risk from 132 for clotiazepam [62–244] or hydroxyzine [113–
153] to 32 [18–51] for loprazolam. Zolpidem was associated with 55
[47–62] cases/MPY. Per MPt rate was 45 [41–51] for all BZ, ranging
from clorazepate 68 [49–94] to prazepam 26 [21–33]. Zolpidem was
associated with 36 [31–41] cases/MPt, alprazolam 28 [24–32],
bromazepam 30 [26–35]. OR ranged from 7.5 [1.2–45] for
flunitrazepam to 1.5 [1.2–1.9] for lorazepam, with 2.1 [1.8–2.5] for
zolpidem and 1.7 [1.5–2.0] for bromazepam 732 cases were exposed
to AD vs. 1809 controls (OR 2.3 [2.1–2.5]) from 137 for escitalopram
to 5 for fluvoxamine. Event rates/MPY ranged from 115 [88–146] for
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mianserin to 32 [26–40] for escitalopram; per MPt from 118 [38–275]
(fluvoxamine) to 31 [26–37] (escitalopram). OR ranged from
moclobemide 7.5 [1.2–45] or agomelatine 6.36 [2.9–14] to
escitalopram 1.8 [1.5–2.2].
Conclusions: Risks associated with most BZ or AD were within the
same order of magnitude within each class, with a few outliers, none
unexpected.
1196 | Liver enzymes during and after
antimalarial therapy in Nigerian children with
uncomplicated Plasmodium falciparum
infection
Zacchaeus F. Olofin1; Adebola E. Orimadegun1; Catherine O. Falade1,2
1University of Ibadan, Ibadan, Nigeria; 2University College Hospital,
Ibadan, Nigeria
Background: Derangement of liver enzymes could occur during anti-
malarial treatment according to literature and this has been attributed
to drug‐induced liver toxicity. However, it remains unclear whether
these changes in liver enzyme levels persist following the completion
of antimalarial therapy.
Objectives: To determine the effect of artemether‐lumefantrine on
plasma levels of four liver enzymes, namely; alanine aminotransferase
[ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP]
and gamma glutamyl transpeptidase [GGT] in children with uncompli-
cated Plasmodium falciparum infection.
Methods: We reviewed the records of all children who participated in
a clinical trial of antimalarial drug in Ibadan, Nigeria and a sample of
102 children who met eligible criteria and with microscopically‐proven
Plasmodium falciparum infection treated with artemether‐lumefantrine
at recommended age‐specific doses for 3 days. Study participants
were followed up on days 3, 7, 14, 21, and 28 according to the World
Health Organization recommendation for treatment of malaria
research participants. Inclusion criteria included symptoms attuned
with acute uncomplicated malaria, including parasite density of at least
1000/μL and absence of chronic illness or danger signs of severe
malaria. The results of ALT (U/L), AST (U/L), ALP (U/L) and GGT (U/
L) at baseline (day 0), on day 3, and day 28 post‐treatments were
extracted and compared using Friedman tests.
Results: The median age of participants was 25 months (range = 3 to
119), and 49% were male. The mean values of ALT and AST did not
change significantly over the course of the 28‐day follow‐up from
baseline (25.8–19.1 U/L p = 0.0984 and 50.4–52.2 U/L p = 0.1943
respectively). GGT decreased substantially between baseline 17.0 U/
L (11.0–22.5) and day 28 15.0 U/L (10.5–21.5) p = 0.0010 while
ALP increased over time (baseline: 305.0 U/L (216.0–403.5); day 28:
345.0 U/L (241.0–492.5) p = 0.0303. Elevated ALT, AST, ALP and
GGT were observed in 8.5%, 20.0%, 20.9%, and 14.8% of participants,
respectively.
Conclusions: Considerable rise in plasma levels occurred in ALP which
could be indicative of liver injury occurring during antimalarial
treatment among Nigerian children. Further research is needed to
identify the underlying mechanism responsible for this drug‐induced
liver toxicity.
1197 | Drug‐induced liver injury associated
with Antituberculosis and/or antiretroviral
therapy: A case series from a prospective
registry in the Western cape, South Africa
Hannah M. Gunter1; Shaazia Allie1; Annemie Stewart1;
Munir Pirmohamed2; Karen Cohen1
1University of Cape Town, Cape Town, South Africa; 2 Institute of
Translational Medicine, University of Liverpool, Liverpool, UK
Background: Drug‐induced liver injury (DILI) is one of the most com-
mon adverse drug reactions resulting in hospital admission and death
in South Africa. Antituberculosis therapy (ATT) and antiretroviral ther-
apy (ART) are frequently implicated. We established a prospective reg-
istry of cases of liver injury that were suspected to have been caused
by ATT and/or ART.
Objectives: To describe participant characteristics, liver injury presen-
tation, potentially implicated drugs and outcome for DILI cases
enrolled during the first 12 months after establishing the registry.
Methods: We enrolled adults (≥18 years) admitted to three Cape
Town hospitals with a liver injury suspected to be due to ATT and/
or ART, who fulfilled American Thoracic Society criteria for tuberculo-
sis treatment interruption: ALT≥5 times ULN with no symptoms/
ALT≥3 times ULN with symptoms/total bilirubin≥1.5 times ULN).
We also enrolled patients meeting these criteria who developed a DILI
during admission. Participants were followed until DILI resolution and
drug rechallenge completion.
Results: We enrolled 48 patients with a median age of 38 years (inter-
quartile range [IQR] 32 to 46), of which 25 (52%) were women. Forty‐
seven (98%) were HIV positive with a median CD4 count of 88 cells/
mm3 (IQR 31 to 302). DILI presentation was hepatocellular in 19
(40%), mixed in 8 (17%), cholestatic in 17 (35%), and uncategorized
in 4 (8%). There was a median of 4 suspect drugs per case (range 1
to 7). ATT was potentially implicated in 38 cases (isoniazid in 38,
rifampicin in 34, pyrazinamide in 31), ART in 36 cases (efavirenz in
34, ritonavir‐boosted lopinavir in 2) and cotrimoxazole in 16 cases.
Other potentially implicated drugs were carbapenems (3 cases), flu-
conazole (3 cases), amoxicillin‐clavulanate (1 case) and paracetamol
(1 case). Median hospital admission duration was 17 days (IQR 10 to
28). Rechallenge with ATT and/or ART was attempted in 30 partici-
pants, and was successful in 21. In 9/30 rechallenged participants
the liver injury recurred, of which 3 died. In total 8/48 patients died
(17%).
Conclusions: Patients with liver injury in this case series were
receiving multiple concomitant potentially implicated drugs, which
complicates causality assessment. Hospital admissions were
prolonged, and mortality was high. Drug rechallenge is frequently
attempted in liver injury due to ATT and/or ART because of limited
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alternative treatment options, which resulted in DILI recurrence in
30% of rechallenged patients in this case series, and should be
attempted with caution.
1198 | A multifactorial algorithm to
automate screening of drug‐induced liver
injury cases in clinical and post‐marketing
settings
Osman Turkoglu; Ritu Gupta; Alvin Estilo; Liliam Pineda Salgado;
Rajesh Pandey; Mirza Rahman
Otsuka Pharmaceutical Development and Commercialization Inc.,
Princeton, NJ
Background: Hepatotoxicity can be linked to many different clinical
symptoms and histopathological signs, making the surveillance of the
suspected drug‐induced liver injury (DILI) cases in the safety database
a huge challenge. Additionally, a majority of the cases are rare, idiosyn-
cratic, highly unpredictable, and with unique individual susceptibility.
This ultimately makes the pharmacovigilance monitoring tedious and
time‐consuming.
Objectives: Develop a multifactorial algorithm to help identify high‐
risk hepatotoxicity cases from the safety database that lead to DILI.
Methods: Multifactorial selection criteria were established using a
combination of word fragments, wildcard strings, and mathematical
constructs based on Hy's law and pattern of injury (R‐Value) for
excluding non‐eligible cases from monthly line listings. The capabilities
and limitations of these criteria were verified by comparing a manual
review of all monthly cases with system generated monthly listings
over 11 months.
Results: The algorithm was easily programmable and could success-
fully identify 80–90% of non‐eligible cases in both clinical and post‐
marketing settings. The automated process could easily compare
enzyme elevations with baseline values, which reduced screening
activity time to under 10 minutes. Approximately 25% of the monthly
cases required manual reviews, as the algorithm could not screen them
due to a non‐standard laboratory test, naming conventions, and
incomplete or incorrectly processed laboratory values, suggesting a
partial elimination of the manual review process.
Conclusions: This multifactorial algorithm proved to be useful for the
early detection of DILI cases before it leads to a Hy's Law case that
might get missed by conventional methods. It also has the potential
for universal application, due to its product‐agnostic data and keyword
mining features.
1199 | Analysis of 172 cases with drug‐
induced liver injury between 2017 and 2018
in a general Hospital in Central China
Hong Cheng; Wanni Yan
Zhongnan Hospital, Wuhan University, Wuhan, China
Background: Drug‐induced liver injury (DILI) is a rare clinical event, it
carries significant morbidity and mortality. The causes and features
of DILI vary in different regions.
Objectives: The main objective is to provide detailed description and
characterization of DILI in a general hospital in Central China.
Methods: This study was conducted in a general hospital in Central
China. In this retrospetive study, we collecting data on individuals
with suspected DILI admitted from January 1, 2017 to December 31,
2018. Criteria for enrollment included alanine aminotransferase (ALT)
level > 5 times the upper limit of normal (ULN), or alkaline phosphatase
level > 2 times ULN, or (ALT>3 times ULN and total bilirubin >2
times ULN). Descriptive statistics were used to describe the features
of the patients. Between group difference was tested using the x2test
for categorical variables and Wilcoxon/Kruskal‐Wallis test for the con-
tinuous variables. A P value <0.05 was considered statistically
significant.
Results: Of the 172 cases, 44.8% were males, the mean age was
51 years. 55.2%ofDILI cases occurredwithin 30 days and 76.6%ofDILI
cases occurred within 90 days after starting drug administration. 19.8%
of patients had allergic history. 76.2% of patients received combined
medication before admission. Leading causes for liver injurywere herbal
medicinal products (40.7%), antineoplastic drugs (15.1%) and antimicro-
bials (11.6%). The pattern of liver injury was hepatocellular in 57.6%,
mixed in 27.3% and cholestatic in 15.1%. There were no differences in
latency and severity of liver injury among different patterns of liver
injury. In 60 patients with pre‐existing liver disease, age is younger
(46.7 years vs 53.3 years, P = 0.006) and proportion of hepatocellular
type is higher than in those without liver disease (73.3% vs 49.1%,
P < 0.01). Compared with liver injury caused by antineoplastic agents,
liver injury induced by herbal medicinal products has shorter latency
(P = 0.04), is more likely to be hepatocellular injury (P = 0.006), appeared
to be more severe (P < 0.001), peak values of ALT and total bilirubin are
higher (P < 0.001).
Conclusions: Leading causes for 172 DILI cases were herbal medicinal
products, antineoplastic drugs and antimicrobials. In patients with pre‐
existing liver disease, age is younger and proportion of hepatocellular
type is higher than in those without liver disease. Compared with anti-
neoplastic agents, liver injury induced by herbal medicinal products
has shorter latency, is more likely to be hepatocellular type injury,
appeared to be more severe.
1200 | Proton pump inhibitors vs Histamine‐
2 receptor antagonists and risk of mortality in
critically ill patients ‐ a pilot analysis of multi‐
institutional study
Hsing‐Chun Hsieh1; Tsung‐Hsuan Lin1; Mei‐Chuan Lee1;
Hui‐Chen Su1; Shih‐Chieh Shao2; Chien‐Chou Su3;
Edward Chia‐Cheng Lai3
1Chi Mei Medical Center, Tainan, Taiwan; 2Keelung Chang Gung
Memorial Hospital, Keelung, Taiwan; 3 Institute of Clinical Pharmacy and
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Pharmaceutical Sciences, College of Medicine, National Cheng Kung
University, Tainan, Taiwan
Background: Proton pump inhibitors (PPIs) and histamine‐2 receptor
antagonists (H2RAs) are commonly used for stress ulcer prophylaxis
in intensive care units (ICUs). PPIs might possess higher potency in
suppressing acid secretion to prevent gastrointestinal bleeding (GIB)
than H2RAs; however concerns of adverse events such as Clostridium
difficile infection and pneumonia limit the use of PPIs. The use of PPIs
vs H2RAs to the overall survival and GI outcome for ICU patients
remains controversial.
Objectives: To compare the risk of mortality and gastrointestinal
bleeding between PPIs versus H2RAs in ICU patients.
Methods: We conducted a retrospective cohort study using medical
records from two hospitals in Taiwan. We included ICU patients
receiving either a PPI or a H2RA for prophylaxis of stress ulcer in
2018. We included patients' demographics and factors associated
with GIB in the analysis, including use of invasive ventilator, shock,
trauma, surgery, kidney and liver injury, coagulopathy, head injury,
concurrent use of steroids or antithrombotic agents and hospital
level. To reduce selection bias, we used propensity score methods
to balance patients' characteristics between PPI and H2RA groups.
We compared the risk of in‐hospital mortality and GIB between
two groups by using conditional logistic regression. We compared
length of hospital stay between two groups by using generalized lin-
ear model.
Results: We included 89 PPI and 87 H2RA users with age of
61 ± 17 (mean ± SD) and 69 ± 17 (mean ± SD) years, respectively.
We found PPI users with higher proportion of ventilator use (69%
vs 36%), shock status (35% vs 17%), use of steroids (51% vs 13%)
and antiplatelets (25% vs 15%) compared with H2RA users. The risk
of in‐hospital mortality was higher in PPI than in H2RA group
(21.8% vs 12.6%; adjusted OR, 2.18; 95% CI, 0.59–8.02). PPI group
had slightly lower risk of GIB than H2RA (adjusted OR, 0.83; 95%
CI, 0.10–6.65), although no statistical significance. We found PPI
and H2RA group had similar length of hospital stay (beta value,
0.97 days; 95% CI 0.65–1.47).
Conclusions: Although PPIs could possibly pose favorable effect
in preventing GIB for ICU patients, it caused a higher risk of in‐
hospital mortality compared to H2RAs. This pilot study provides a
fundamental ground for future multi‐institutional study to confirm
this finding.
1201 | Nsaid and analgesic exposure prior to
hospital admission for acute liver injury
Nicholas Moore; Adeline Grolleau; Stephanie Duret; Nicolas Thurin;
Mai Duong; Regis Lassalle; Patrick Blin; Sinem Ezgi Gulmez;
Cecile Droz‐Perroteau
Bordeaux PharmacoEpi, Bordeaux, France
Background: Hepatic injury is one of the major drug safety issues.
Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been associated
with liver injury.
Objectives: To quantify exposure to NSAIDs/analgesics prior to hospi-
tal admission for acute liver injury (ALI) in the French National
healthcare systems database, SNDS.
Methods: All hospital admissions for ALI (K71.1,.2,.6,.9, K72.0) over
2010–2014 were identified in SNDS (66 million persons). Previous
diagnoses of liver disease/liver injury were excluded. Exposures of
interest were systemic NSAIDs (ATC codes M01A), non‐overdose
paracetamol (N02AA, N02BE) and tramadol (N02AX02) dispensed
from 7 to 60 days before hospital admission, to avoid indication and
protopathic biases. Reference populations were a) the whole French
population over the study period, extrapolated from the 1/
97thpermanent representative sample, EGB in a case‐population anal-
ysis; b) 5 controls/case from EGB, matched on age and gender, using
the same index date for the case–control analysis. Results are pro-
vided as a) number of cases per million users (MPt) or patient‐years
(MPY) with 95% confidence interval [95%CI], b) Odds Ratios (OR)
[95% CI], compared to non‐exposure.
Results: 4807 ALI were matched to 24035 controls. 3619 cases and
12793 controls had been dispensed any drug within 7–60 days
before admission (OR 3.1 [2.9–3.4]. 815 cases had been exposed
to an NSAID (from 228 for ibuprofen to 5 for nimesulide, among
18 NSAIDs with at least 5 exposed cases); 1698 cases had been
exposed to paracetamol, 162 to tramadol. Rates of Hospital admis-
sion were 75/MPY or 18/MPt [16–20] for any NSAID, and ranged
from 299/MPY [120–616] for mefenamic acid to 37.9/MPY [11–
88] for nimesulide, or from 14/MPt [1.5–19] for celecoxib to 2.7/
MPt [0.9–6.3] for nimesulide. Other individual NSAIDs were ibupro-
fen 8.9/MPt [7.6–10.2], diclofenac 8.7/Mpt [7.6–10.2].
Paracetamol (alone or in combination) association with ALI was
105/MPY [95–117], 32/MPt. [28–35], tramadol used alone 91/
MPY [77–106], 19/MPt [16–22].OR from the case–control analysis
were 1.4 [1.3–1.5] for any NSAID, from 3.5 [1.3–9.2] for mefenamic
acid, to 0.6 [0.25–1.6] for nimesulide, 1.4 [1.2–1.6] for ibuprofen,
diclofenac 1.5 [1.3–1.9], celecoxib 2.1 [1.4–3.2], etoricoxib 2.1
[1.1–4.2]; OR for paracetamol was 1.95 [1.8–2.1], tramadol 2.3
[1.9–2.8].
Conclusions: The risk of hospital admission for hepatic injury was
lower for NSAIDs than analgesics. There were no striking differences
between NSAIDs. Risk of ALI after NSAIDs was generally lower that
for all drugs combined.
1202 | Rates and predictors of post‐surgical
infections for common surgical approaches
Abhishek S. Chitnis1; Katherine Corso1; Zhenna Huang1;
Piyush Nandwani2; Chantal E. Holy1
1 Johnson and Johnson, New Brunswick, NJ; 2Mu Sigma, Bangalore, India
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Background: More than 10 million patients undergo surgical proce-
dures each year. The most common types of inpatient surgical proce-
dures include cesarean section (CS), hysterectomy (HT), primary and
revision total hip/knee replacement (P_THR, R_THR, P_TKR, R_TKR),
spinal surgery (SS) and colorectal surgery (CRS). Post‐surgical infection
(PSI) are a significant cause of hospital readmissions,morbidity andmor-
tality after surgery.
Objectives: To evaluate the rates of PSI by types, deep, superficial and
organ/space for different surgical approaches (CS, HT, P_THR, R_THR,
P_TKR, R_TKR, SS and CRS). This study also evaluated the risk factors
for any PSI by surgical approaches.
Methods: This was a retrospective study of patients undergoing sur-
gery (CS, HT, P_THR, R_THR, P_TKR, R_TKR, SS AND CRS) between
2014 and 2017 using IBM® MarketScan® Commercial, Multi‐State
Medicaid and Medicare Supplemental databases. Separate cohorts
were created based on the surgical approach. The rates for new diagno-
ses of PSI, categorized as deep, superficial and organ/space within
6 months of surgery were calculated. Logistic regression models were
evaluated to examine patient demographic and clinical comorbidities
associated with any PSI.
Results: A total of 362,132 CS, 150,000 HT, 92,029 P_THR, 6,298
R_THR, 153,335 P_TKR, 10,429 R_TKR, 31,416 SS and 83,691
CRS patients were included in the analysis. For CS, PSI included
0.3% deep, 3.5% superficial, 0.9% organ/space and 0.04% both
organ/space and deep cases with payer type and obesity as key risk
factors associated with PSI. For HT, PSI included 0.5% deep, 4.7%
superficial, 1.7% organ/space, and 0.1% organ/space and deep cases
with cancer and renal failure as key risk factors associated with PSI.
Overall 6.1% P_THR and 14.9% R_THR patients developed any PSI
(deep infection: 2.7% in P_THR and 11.0% in R_THR) with obesity,
liver disease and fluid/electrolyte disorders as key variables associ-
ated with PSI. Overall 5.9% P_TKR and 16.4% R_TKR patients
developed any PSI (deep infection: 2.2% in P_TKR and 11.4% in
R_TKR) with age, psychoses and cancer as key variables associated
with PSI. For SS, PSI included 3.9% deep infection and 4.6% super-
ficial cases with paralysis and blood loss anemia as the key factors
associated with PSI. For CRS, PSI included 1.0% deep, 10.4% super-
ficial, 9.0% organ/space and 0.8% both organ/space and deep cases
with weight loss and fluid and electrolyte disorder as key factors for
PSI.
Conclusions: The rate of any PSI was high for all common surgical pro-
cedures and ranged from 4.7% for CS to 21.2% for CRS. The risk fac-
tors identified differed by surgical approaches.
1203 | The role of sleeping pills in the
development of shingles in veterans
Pragati Ghimire‐Aryal1; Skai W. Schwartz1; Darren Scheer1;
Kenneth Taylor1; Yuri Sebastião2; W. McDowell Anderson3,4;
Philip R. Foulis4
1University of South Florida College of Public Health, Tampa, FL;
2Nationwide Children's Hospital, Columbus, OH; 3University of South
Florida College of Medicine, Tampa, FL; 4 James A. Haley VA Hospital,
Tampa, FL
Background: There is continuing evidence that the chronic use of
sleeping pills may be a risk factor for infection. One infection of con-
cern in the aging veteran population is Herpes Zoster (HZ). Veterans
are commonly prescribed sedative‐hypnotics (sleeping pills) for
chronic conditions such as insomnia, generalized anxiety disorders,
mood disorders, alcohol withdrawal, seizures, panic attacks.
Objectives: To study the role of chronic use of commonly prescribed
sedative‐hypnotics in the development of shingles.
Methods: We studied the relationship between commonly pre-
scribed sedative‐hypnotics (benzodiazepines and Z‐drugs) and inci-
dent HZ among veterans who received care at the James A. Haley
Veteran's Hospital. A total of 22,000 veterans were randomly
selected from each quarter year from 2007–2011 from CPRS/VISTA
Patient Record System. All outpatient diagnoses, procedures and
pharmacy data between 2006–2015 were then drawn from this
cohort. To eliminate confounding by calendar date, patients without
HZ were frequency matched on a visit date that was close to a HZ
diagnosis date in the patients with HZ. Hypnotic use was examined
in the 365 days prior to the HZ diagnosis date or a matching control
date. Patients who had an acute hypnotic use (e.g. for a medical pro-
cedure) prior to the 90 days of HZ diagnosis date were excluded
from that analysis. Logistic regression was used to calculate odds
ratios (OR).
Results: Of 3522 patients on sedative‐hypnotics, 200 (5.7%) devel-
oped HZ; out of the 18422 patients with no prescription for hyp-
notics, 741 (4.0%) developed HZ (OR = 1.437, 95%CI = 1.224,
1.687). The association remained significant (OR = 1.22, 95%CI
=1.024,1.453) after adjusting for age, sex, BMI, Charlson comorbidity
index, race, Hispanic ethnicity, marital status, combat status, opioid
use.
Conclusions: Chronic use of sleeping pills is associated with later devel-
opment of HZ. This supports a premise that long‐term use of sleeping
pills lowers immune status.
1204 | Medication related problems and
associated risk factors among HIV/AIDS
patients on antiretroviral therapy at a
National Referral Hospital in Kenya: A cross‐
sectional study
Sylvia Opanga; Peris W. Thuo
School of Pharmacy, University of Nairobi, Nairobi, Kenya
Background: Medication Related Problems (MRPs) are untoward
events or circumstances that occur during drug therapy and interfere
with desired therapeutic outcomes. HIV/AIDS patients on complex
antiretroviral drug regimens are predisposed to medication related
problems and associated morbidity and mortality.
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Objectives: To evaluate the prevalence and risk factors of MRPs
among adult HIV/AIDS patients on antiretroviral therapy at Kenyatta
National Hospital (KNH).
Methods: A cross‐sectional study was conducted in July and August
2018, at the Comprehensive Care Center at KNH, where patients on
antiretroviral drugs are seen. Adults 18 years old and over were
recruited, regardless of the antiretroviral regimen they were on. Data
was collected prospectively through patient interviews and evaluation
of patient records. A pharmacotherapy work up form developed by
Cipolle, Morley and Strand was used as an interview guide. MRPs
were identified and classified according to the Hepler‐Strand classifi-
cation. Descriptive and bi‐variable data analysis was conducted using
STATA (v.13).
Results: A total of 248 patients, of whom 62.0% were female were
recruited into the study. MRPs were present in 118 (47.6%) patients.
MRPs included: sub‐therapeutic dosage (31.9%); untreated indication
(21.3%); adverse drug reactions (17.9%); failure to receive drugs
(15.5%); drug interactions (5.3%); overdose (4.4%); improper drug
selection (2.4%); and drug use without indication (1.5%). The risk fac-
tors for sub‐therapeutic dosage were poor adherence (p = <0.001), on
transit patients (p = <0.001), and social/marital problems (p = 0.0001).
For untreated indication, risk factors were clinician error (p = <0.001),
financial constraints (p = <0.001), and stigma (p = 0.0002). Confusion
due to complex regimens (p = 0.001) was the main risk factor for
adverse drug reactions.
Conclusions: The prevalence of MRPs among adult HIV/AIDS patients
in a single Kenyan referral hospital was high. The most prevalent
MRPs were sub‐therapeutic dosage, untreated indication and adverse
drug reactions. Comprehensive pharmaceutical care is required to
reduce the high prevalence of MRPs.
1205 | Medication related problems among
HIV/AIDS patients on antiretroviral therapy
at a National Referral Hospital in Kenya
Sylvia Opanga; Peris Wambui Thuo
University of Nairobi, Nairobi, Kenya
Background: Medication Related Problems (MRPs) are untoward
events or circumstances that occur during drug therapy and interfere
with desired therapeutic outcomes. HIV/AIDS patients on complex
antiretroviral drug regimens are predisposed to medication related
problems and associated morbidity and mortality.
Objectives: To evaluate the prevalence and risk factors of MRPs
among adult HIV/AIDS patients on antiretroviral therapy at Kenyatta
National Hospital (KNH).
Methods: A cross‐sectional study was carried out at the Comprehen-
sive Care Center (CCC) at KNH, where patients on antiretroviral drugs
are seen. Adult patients over 18 years old were recruited. Data was
collected through patient interviews and evaluation of patient records,
over a period of two months. A pharmacotherapy work up form devel-
oped by Cipolle, Morley and Strand was used as an interview guide.
MRPs were identified and classified according to the Hepler‐Strand
classification. Descriptive and bi‐variable data analysis was conducted
using STATA version 13 software. The level of significance was set at
0.05.
Results: A total of 248 patients, on different antiretroviral regimens
were recruited in the study, of which 62% were female and 38% male.
MRPs were present in 118 (47.58%) of the 248 patients. MRPs iden-
tified were sub‐therapeutic dosage (31.88%), untreated indication
(21.26%), adverse drug reactions (17.87%), failure to receive drugs
(15.46%), drug interactions (5.31%), overdose (4.35%), improper drug
selection (2.42%) and drug use without indication (1.45%). The risk
factors for sub‐therapeutic dosage were poor adherence
(p = <0.001), on transit patients (p = <0.001) and social/marital prob-
lems (p = 0.0001). For untreated indication, risk factors were clinician
error (p = <0.001), financial constraints (p = <0.001) and stigma
(p = 0.0002). Mix up due to complex regimens (p = 0.001) was the
main risk factor for adverse drug reactions.
Conclusions: The prevalence of MRPs in adult HIV/AIDS patients was
high (47.58%). The most prevalent MRPs were sub‐therapeutic dos-
age, untreated indication and adverse drug reactions. There were no
documented interventions by a pharmacist.
1206 | Rare adverse effects analysis of new
generation hepatitis C medications using EMR
and FAERS data
Chongliang Luo1; Xinyuan Zhang2; Liu Yang3; Jingcheng Du2;
Jiayi Tong1; Jing Huang1; Cui Tao2; Yong Chen1
1University of Pennsylvania, Philadelphia, PA; 2University of Texas Health
Science Center at Houston, Houston, TX; 3Mayo Clinic, Jacksonville, FL
Background: New generation drugs for treating Hepatitis C have been
introduced to the market in 2014, including Harvoni, Sovaldi, Olysio,
Mavyret, Vosevi and Epclusa. The new treatments have been proven
to be more effective and better tolerated, compared to the old inter-
feron based treatments. However, the rare adverse effects of these
drugs are largely unknown, due to the limited sample size of the clin-
ical trials and lack of post‐marketing evidence of these drugs.
Objectives: In this paper, we conduct a comparative study of the drug
safety of the old and new generation Hepatitis C medications, aiming
to find some important rare adverse effects, especially for the new
medication.
Methods: We use the data from the post market spontaneous
reporting systems such as the FDA/CDC Adverse Event Reporting
System (FAERS), as well as health system data such as electronic med-
ical record (EMR) data. For FAERS data, we search over 6,000,000
reports between 2004 to 2015 and extractthe AEs for both the old
and new medications. For EMR data, we define a selection window
from the medication started date to 180 days after the medication
stopped date for any patient that ever had old or new Hepatitis C
medication. The diagnosis code of any encounter during the selection
window are extracted and mapped to the MedDRA terms. Rare AEs
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that happen only for new medications are identified and their risk
rates are calculated.
Results: For the new drug‐specific rare AEs, the number of total
encounters and risk rates are calculated and ranked, using both FAERS
and EMR data sets. For example, using EMR data the identified AEs
include toxoplasmosis (1.1%, [0.9%, 1.3%]), meningitis due to other
organisms (1%, [0.8%, 1.2%]), malignant neoplasm of rectum (0.9%,
[0.7%, 1.1%]) and slow virus infection of central nervous system
(0.7%, [0.5%, 0.8%]).
Conclusions: The two data sources, FAERS and EMR, agree on some
identified AEs but are not consistent on some others. We interpret
the importance of the identified AEs from the clinical perspective.
We also discuss the strengths and limitations of the two data sources
in post‐marketing pharmacovigilance research and the need for novel
data integration methods that can effectively combine the strengths
of these two data sources.
1207 | Tenofovir‐associated renal toxicity in
a cohort of HIV‐infected patients in Ghana
Edmund T. Nartey1; Raymond A. Tetteh2
1University of Ghana School of Medicine and Dentistry, Accra, Ghana;
2Korle‐Bu Teaching Hospital, Accra, Ghana
Background: Tenofovir disoproxil fumarate (TDF) is a nucleotide ana-
logue recommended in international HIV treatment guidelines. The
association of TDF with renal dysfunction has remained an area of
interest due the structural similarity between tenofovir and the neph-
rotoxic acyclic nucleotide analogues adefovir and cidofovir.
Objectives: Purpose of study was to estimate the long term effects of
TDF on renal profile in a cohort of HIV patients in Ghana.
Methods: We selected 300 consecutive HIV‐positive patients (with
baseline creatinine clearance ≥50 mL/min) who initiated TDF‐based
antiretroviral treatment in 2008 from a database of patients on antire-
troviral therapy at the Korle‐Bu Teaching Hospital. Socio‐demo-
graphic, clinical and laboratory details were extracted from patients'
medical records. Creatinine clearance (CrCl) was calculated using the
Cockcroft‐Gault equation at baseline and renal impairment was
defined as CrCl values of 30.0–49.9 mL/min (moderate renal impair-
ment) and < 30 mL/min (severe renal impairment) as per institutional
guidelines for renal function test. The proportion of patients with
moderate or severe renal impairment was calculated. Relative risks
(RRs) and 95% confidence intervals (CIs) were calculated for factors
associated with renal impairment.
Results: Median follow up time was 2.9 years (IQR 2.3–3.4 years).
Females were dominant (n = 213, 71.1%) and the mean age of study
participants was 39.1 ± 11.1 years. The median CrCl rate at initiation
of TDF‐containing ART was 76.8 mL/min [IQR 58.3–105.4]. At study
endpoint, 63 participants (21.0% [95% CI: 6.5–26.1]) recorded CrCl
rate below 50 ml/min indicating incident renal impairment, made up
of 18.3% moderate renal impairment and 2.3% severe renal impair-
ment. Factors associated with the incidence of renal impairment were
increasing age (RR = 1.04 [95% CI, 1.03–1.06] per year), decrease in
creatinine clearance rate at baseline (RR = 1.05 [95% CI, 1.04–1.08]
per every 1 mL decrease), WHO HIV stage III (RR = 3.78 [95% CI,
1.42–10.06]) or Stage IV (RR = 3.42 [95% CI, 1.16–10.09]) compared
with stage I and participants with BMI of <18.5 kg/m2 underweight
(RR = 3.87; 95% CI, 2.49–6.03) compared with patients with BMI of
>18.5–24.9 kg/m2 (normal weight).
Conclusions: The use of TDF based regimen led to 18.3% developing
moderate renal impairment and 2.3%, severe renal impairment.
Patients with identified renal impairment risk factors at ART initiation
should be targeted and monitored effectively to prevent renal injury.
1208 | The effects of amoxicillin on acute
COPD exacerbations in the outpatient
setting: A retrospective cohort study based
on real‐world data
Yuanyuan Wang; Jens H. Bos; Catharina C.M. Schuiling‐Veninga;
Bob Wilffert; Eelko Hak
Department of PharmacoTherapy, Epidemiology & Economics, Groningen
Research Institute of Pharmacy, University of Groningen, Groningen,
Netherlands
Background: Previously the effects of antibiotics for COPD exacer-
bation were only established in ICU patients. Recent updated
Cochrane review (Vollenweider et al., 2018) shows a significant
effect of antibiotics in treating COPD exacerbations in the outpa-
tient setting. However, effects have not been established using
real‐world data.
Objectives: To assess both the short‐term and long‐term effects of
amoxicillin on the prognosis of COPD exacerbation in outpatients.
Methods: We conducted a retrospective inception cohort study using
the widely researched University of Groningen prescription database
IADB.nl. Eligible patients had a first exacerbation treatment with or
without amoxicillin to exclude the influence of prior exacerbation his-
tory. The main outcome was treatment failure, which was defined as a
new prescription of prednisone/prednisolone or antibiotics between
15 to 30 days after the first exacerbation. A secondary outcome was
the time to second exacerbation within 12 months.
Results: In all, we identified 4,775 eligible COPD patients. Among
these patients, 736 (15%) were treated with combined treatment
of amoxicillin plus prednisone/prednisolone, while 4039 (85%) were
given only prednisolone/prednisone. We did not observe a signifi-
cant difference in rates of treatment failure between amoxicillin
and comparison group (relative risk (RR) of treatment failure: 0.96
[95%CI: 0.78–1.20]). After adjustments for differences in age, gen-
der, drug use for COPD and other comorbidities, the adjusted RR
indicated a small non‐statistically significant effect (RR 0.91
[95%CI: 0.73, 1.13]). Median time to 2nd exacerbation was 174 days
[95% CI 151–197]) in amoxicillin group compared with 180 days
[95% CI 169–191] in the control group (hazard ratio: 1.07 [0.97–
1.17], p = 0.17).
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Conclusions: The data were compatible with a potential small effect of
amoxicillin added to oral corticosteroids in acute COPD exacerbations
treated in an outpatient setting. However, unmeasured confounding
by indication should in future studies be quantified to confirm or
refute this finding.
1209 | Risk of interstitial lung disease among
patients treated for atrial fibrillation with
selected anti‐arrhythmic drugs in two
healthcare databases
Arlene K. Tave1; Earl Goehring Jr1; Vibha Desai2; Chuntao Wu3;
Rhonda Bohn4; Sally Tamayo5; Nicholas Sicignano6; Juhaeri Juhaeri3;
Judith K. Jones1; Sheila Weiss1
1PharmaLex US Corporation, Fairfax, VA; 2HealthCore, Andover, MA;
3Sanofi Pharmaceuticals, Inc., Bridgewater, NJ; 4Bohn Epidemiology,
Boston, MA; 5Naval Medical Center, Portsmouth, VA; 6Health Research
Tx, Portsmouth, VA
Background: Dronedarone is an anti‐arrhythmic drug (AAD) indicated
to reduce risk of hospitalization for atrial fibrillation (AF) among
patients in sinus rhythm with a history of paroxysmal or persistent
AF. Interstitial lung disease (ILD) is an identified risk for dronedarone,
and ILD is also related to other AADs, notably amiodarone.
Objectives: To investigate if there is an increased ILD risk with
dronedarone when compared to amiodarone and other anti‐
arrhythmics.
Methods: Retrospective cohort studies were conducted using records
from two healthcare databases, the US Department of Defense Mili-
tary Health System (MHS) and HealthCore Integrated Research Data-
base (HIRD), for services from 7/20/2008 to 9/30/2014. Eligibility
criteria were an AF diagnosis and new prescription for dronedarone,
amiodarone, sotalol or flecainide. Prevalent cases of ILD were
excluded. Propensity scores were used to adjust for confounding
and potential selection factors associated with dronedarone treatment
relative to the three comparator treatment groups.
Incident ILD cases were identified from inpatient ICD‐9‐CM diagnosis
codes 515, 516.3–516.37, 516.8 or 516.9. An expanded definition of
ILD, used for sensitivity analysis, added ICD‐9‐CM codes 495.9 and
518.82. Cases were adjudicated by expert pulmonologists and only
confirmed cases were retained.
Separate Cox proportional hazards models were used to compare the
hazard of ILD for each comparator to that of dronedarone (reference).
Results: Following adjudication there were 72 ILD cases (52 in the
MHS and 20 in the HIRD). Risk of ILD in the MHS was elevated for
amiodarone when compared to dronedarone (HR 2.5; 95% CI 1.1–
5.3; p < 0.05). No significant differences were seen with any of the
other AADs in either database.
Conclusions: Dronedarone was not associated with an increased risk
of ILD when compared to other AADs, while patients prescribed ami-
odarone were at an increased risk for ILD compared to dronedarone in
the MHS. Despite propensity score matching, the potential for
residual confounding, selecting older and sicker patients for treatment
with amiodarone, is an important limitation to these findings.
1210 | Risk of developing chronic
obstructive pulmonary disease or lung cancer
in smokers taking enzyme‐inducing
antiepileptic drugs
Daphne Reinau1; Anne Leuppi‐Taegtmeyer1; Susan S. Jick2;
Christoph R. Meier1
1University Hospital Basel, Basel, Switzerland; 2Boston Collaborative
Drug Surveillance Program, Lexington, MA
Background: Enzyme‐inducing antiepileptic drugs (AEDs) can
increase the activity of pulmonary enzymes involved in the bio‐acti-
vation and metabolism of toxic chemicals in tobacco smoke. Smokers
who take these drugs may therefore have an altered risk of develop-
ing chronic obstructive pulmonary disease (COPD) or lung cancer
(LC).
Objectives: To determine whether enzyme‐inducing AEDs affect the
risk of developing COPD or LC in people who smoke.
Methods: We conducted a matched case–control study using UK
primary care data from the Clinical Practice Research Datalink. We
performed multivariate logistic regression analyses to compare prior
exposure to enzyme‐inducing AEDs between cases with incident
COPD or LC and controls without these lung diseases among
smokers having ≥1 prescription for any type of AED (enzyme‐ or
non‐enzyme‐inducing) before the index date. We stratified analyses
by duration of enzyme‐inducing AED use and level of tobacco
exposure.
Results: We identified 5952 incident COPD and 1373 incident LC
cases, and 59 328 and 13 681 matching controls, respectively,
between 1995 and 2016. Overall, compared with never use, ever
use of enzyme‐inducing AEDs was associated with a slightly
decreased risk of COPD (adjusted odds ratio [aOR]: 0.84, 95% CI:
0.80–0.89) and LC (aOR: 0.82, 95% CI: 0.73–0.92). However,
the risk of COPD and LC was not altered among medium‐ and
long‐term users of enzyme‐inducing AEDs who were moderate or
heavy smokers, which argues against a consistent protective effect
of enzyme induction in preventing these smoking‐related lung
diseases.
Conclusions: We did not find robust evidence for an association
between the use of enzyme‐inducing AEDs and the development of
COPD or LC in people who smoke.
1211 | A comparison of outcome‐related
diagnostics for propensity scores
Emily Granger; Jamie C. Sergeant; Mark Lunt
The University of Manchester, Manchester, UK
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Background: Propensity scores are commonly used to reduce con-
founding bias in observational data by balancing covariate distribu-
tions between exposure groups. However, it is unclear how best to
assess their performance. Outcome‐related diagnostics which priori-
tize balance on covariates strongly associated with outcome would
be of value, since these covariates contribute most towards
confounding bias. One idea is to calculate a weighted average of bal-
ance across all covariates. Alternatively, we could use the standard-
ized mean difference in prognostic scores (i.e. predicted outcome
under the control condition) between exposure groups. There is little
research available comparing the performance of these diagnostics.
Objectives: To compare seven outcome‐related diagnostics in terms
of their correlation with bias in a simulation study.
Methods: Diagnostics included the standardized difference in prog-
nostic scores and six weighted averages of balance across covariates.
Weighted averages were defined by the combinations of three bal-
ance metrics (standardized difference, Kolmogorov–Smirnov statistic
and overlapping coefficient) and two weighting methods. For covari-
ate X, Weights 1 and 2 were defined as the coefficient for X obtained
after regressing the outcome on X and all covariates respectively, mul-
tiplied by the standard deviation of X.
Results: Using the Kolmogorov–Smirnov statistic or overlapping
coefficient led to negligible correlation with bias in all scenarios.
For scenarios with independent covariates and linear outcomes,
prognostic scores and weighted standardized differences (using
either weights) performed well (all correlations above 0.9). When
covariates were correlated, the correlation between bias and
weighted standardized differences using Weights 1 decreased to
0.4, but remained high for prognostic scores and weighted standard-
ized differences using Weights 2. For nonlinear outcomes, weighted
standardized differences and prognostic scores estimated using a lin-
ear model demonstrated poorer performance. For example, in sce-
narios with moderate nonlinearity in the outcome, using Weights 1,
2 and linear prognostic scores obtained correlations of 0.2, 0.3 and
0.4 respectively. Only prognostic scores estimated using the cor-
rectly specified model performed consistently well across all
scenarios.
Conclusions: A correctly estimated prognostic score would be a useful
diagnostic for assessing how well propensity scores have removed
confounding bias. In real data however, the true prognostic
scores are unknown and it is unclear what the best estimation strategy
would be.
1212 | A systematic review of the use of
propensity scores in cardiovascular literature
Julie Rouette1,2; Michelle Samuel1,3; Brice Batomen1; Joanne Kim1;
Robert W. Platt1,2; James Brophy1,3; Jay S. Kaufman1
1McGill University, Montreal, QC, Canada; 2 Jewish General Hospital,
Montreal, QC, Canada; 3McGill University Health Centre Research
Institute, Montreal, QC, Canada
Background: Previous assessments have found that propensity score
(PS) methods are implemented and reported inadequately in clinical lit-
erature. As cardiovascular studies increasingly use these methods, a
comprehensive review of their reporting and use in cardiovascular lit-
erature is needed.
Objectives: To conduct a systematic review of the use, reporting, and
interpretation of PS methods in cardiovascular publications.
Methods: Articles using PS methods, published between 2010–2017
in high‐impact medical (5) and cardiovascular (3) journals and focusing
on cardiovascular drugs, devices, diseases, and outcomes, were identi-
fied. Keywords included propensity, inverse probability weighting (IPW),
marginal structural models, targeted maximum likelihood estimation, and
doubly robust. Elements for data extraction were based on PS litera-
ture, with an additional focus on causal interpretations and target pop-
ulation. Data collection form was reviewed by all investigators and
pilot tested. Each article was assessed independently by two
reviewers.
Results: A total of 296 articles were included. The most commonly
used PS method was matching (53% of studies), followed by more
than one method (19%), direct adjustment (13%), IPW (12%), and
stratification (3%). In almost half (48%) of reviewed articles, interpre-
tations of the effect estimates (average treatment effect (ATE),
average treatment effect in the treated (ATT), average treatment
effect in the untreated (ATU)) did not correspond to the PS method
conducted. Whereas a priori identification of confounders or predic-
tors of the outcome is preferred, 17% of publications used statistical
testing to identify variables for the PS model. Assessment of
balance, a critical step in the appropriate use of PS methods, was
not assessed in 16% of articles. Of those who assessed balance,
55% reported standardized differences, the recommended measure
for assessing balance, and 45% reported other measures. Among
articles that used PS matching, 21% did not describe their matching
strategy and 8% did not describe the post‐match balance of covari-
ates. Furthermore, 17% of studies matched fewer than half of the
available treated (or untreated, based on targeted parameter)
subjects.
Conclusions: Detailed reporting of PS methods provides transpar-
ency and helps accurately evaluate the results and the population
to which the results apply. This systematic review shows that
details of PS methods in cardiovascular studies were generally well
reported in high‐impact cardiovascular journals. In almost half of
the studies, however, the interpretation of the effect estimates
was inaccurate.
1213 | Comparisons of propensity score‐
based estimates in the presence of treatment
effect modification
M. Sanni Ali1; Daniel Prieto‐Alhambra2; Ian Douglas1; Liam Smeeth1
1London School of Hygiene and Tropical Medicine, London, UK;
2University of Oxford, Oxford, UK
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Background: Clinical studies using both PS based methods (matching,
stratification, covariate adjustment, weighting) and conventional
regression have compared estimates from both approaches. Although
each of the methods provides different estimand particularly in the
presence of treatment effect modification, differences or similarities
in the treatment effect estimates have been misinterpreted as limita-
tions of the methods per se.
Objectives: To describe different PS‐based estimates in the presence
of treatment effect modification using a clinical example.
Methods: We used the UK Clinical Practice Record Datalink (CPRD)
data to evaluate the association between bariatric surgery (BS) on
the risk of type‐2 diabetes mellitus (T2DM) as an example. We
followed patients from index date until T2DM, death, loss‐to
follow‐up or end of study (31‐December‐2014), whichever came
first. We fitted DRS in the patient groups without the exposure
(Bariatric Surgery) and predicted baseline risk of T2DM for the entire
cohort using logistic regression. We then applied 1:1 PSM with
caliper width of 0.20 standard deviation on the logit of the PSto
estimate the treatment effect in the Bariatric surgery groups (ATT),
non‐surgery group (ATU), and the total population (ATE). In
addition, we used inverse probability of treatment weighting (IPTW)
and conventional Cox model to estimate ATE. We evaluated
covariate balance using absolute standardized mean difference
(ASMD) in the PSmatched dataset. We estimated hazard ratios and
95% confidence intervals (95%CI) using Cox proportional hazards
models.
Results: In total, we had 17030 patients with 1596 developing T2DM
during follow‐up and after PSM, 5,132 patients with 406 developing
T2DM during follow‐up to estimate ATT and 5134 patients with
439 developing T2DM during follow‐up to estimate ATU. In both
PSM, all patients in the bariatric surgery group were retained. Bariatric
surgery reduced the risk of T2DM, the PSM estimated ATT was 0.57
[95%CI; 0.47, 0.70] compared to the ATU 0.58 [0.48, 0.71]. Both esti-
mates were similar to the ATE estimated using IPTW, 0.57 [0.47,
0.69], and conventional Cox models, 0.56 [0.47, 0.66].
Conclusions: We observed similar results among PS methods even in
the presence of treatment effect modification. This could partly be
explained by retention of the patients in the treatment group after
PSM. Specifications of treatment effect estimands are important when
patients from one treatment groups are excluded due to matching par-
ticularly in studies using combinations of methods.
1214 | Propensity score matching with
bootstrapping and “divide and recombine”
approaches in huge data
Gabriela Lima Borges1; M. Sanni Ali2,1; Mauricio L. Barreto1,3;
Liam Smeeth2; Rosemeire Leovigildo Fiaccone4,1
1Center for Integration of Data and Health Knowledge, Salvador, Brazil;
2 London School of Hygiene and Tropical Medicine, London, UK; 3Oswaldo
Cruz Institute, Salvador, Brazil; 4 Federal University of Bahia, Salvador,
Brazil
Background: Propensity score matching has been a popular
approach in pharmacoepidemiology; however, the computational
load associated with propensity score matching in huge data such
as “the 100 Million Brazilian Cohort” pose a big challenge. Several
alternatives such as bootstrap sampling and “Divide and Recombine”
(R&D) using parallelization have been suggested as ways to
increase the procedure speed by utilizing multiple processors/cores
simultaneously. However, the performance of these approaches has
not been evaluated.
Objectives: To evaluate the performance of PSM using bootstrap
sampling and “D&R” approaches in huge data.
Methods: We used Monte Carlo simulations to generate datasets of
5 million and 10 million records. Covariates were created using bino-
mial, normal and multinomial distributions. Treatment was generated
using binomial logistic regression model conditional on covariate and
outcome data was generated using the Poisson model conditional on
treatment and covariates. PSM was performed: 1) in each of 500
bootstrap samples from the full data; and 2) with D&R approach,
in each of the k‐sample data after the full dataset was split into
k‐samples, all being parallelized. PSM was performed with and
without caliper and covariate balance was assessed using absolute
standardized mean difference (ASMD). Afterwards, treatment
effect estimates were recombined using weighted average and). In
addition, inverse probability weighting and PS stratification were
used to estimate treatment effect on the entire sample. The
performance was evaluated using percentage bias and coverage
probability.
Results: PSM based approaches (both bootstrapping and D&R) and
IPTW gave similar treatment effect estimate with an average percent-
age bias close to 2%. However, PSM approaches resulted in improved
covariate balance (SMD for all covariates <2.5%) and high coverage
probability (100%) compared to IPTW methods (ASMD for some
covariates was as big as 15%). On the other hand, PS stratification
with five quintiles resulted in a greater bias in the treatment effect
estimate, up to 8%.
Conclusions: PSM using bootstrap sampling and D&R approaches are
efficient alternatives to IPTW approaches with huge data when full
sample PSM cannot be conducted.
1215 | Improving confounder adjustment:
Translating high‐dimensional propensity
score principles to United Kingdom electronic
health records
JohnTazare; Liam Smeeth; Stephen J.W. Evans; Elizabeth Williamson;
Ian J. Douglas
London School of Hygiene & Tropical Medicine, London, UK
Background: A recent United Kingdom (UK) electronic health
record (EHR) study found that among clopidogrel users, co‐use of
a proton pump inhibitor (PPI) was associated with an increased
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risk of myocar‐dial infarction (MI). However, the study authors
highlighted evidence suggesting that this finding was driven by
unmeasured confounding. In situations like this, use of the high‐
dimensional propensity score (hd‐PS) algorithm has become
increasingly popular amid evidence in US claims data suggesting
it improves adjustment for confounding. Despite this enthusiasm,
it is unclear how best to adapt hd‐PS principles outside its
original setting, especially given the potential disparity between
databases.
Objectives: To adapt the hd‐PS algorithm in the setting of UK EHRs.
Methods: A cohort of clopidogrel users was derived from the
UK Clinical Practice Research Datalink linked with the Myocardial
Ischaemia National Audit Project. All analyses estimated the
hazard ratio of MI comparing PPI users with non‐users using a Cox
model adjusting for confounders via propensity scores. We con-
ducted hd‐PS analyses incrementally applying modifications that
included varying the coding system and adapting the existing assess-
ment of code recurrence to reflect recording practice in UK EHRs.
Results were compared to an analysis incorporating only the original
confounders. Sensitivity analyses investigated the impact of varying
the number of covariates selected for inclusion in our adapted hd‐
PS model.
Results: 24471 patients took clopidogrel, of whom 9111 were
prescribed a PPI. Of PPI users, 313 (3.4%) had an incident MI versus
421 (2.7%) in non‐users. Including the original confounders via
propensity scores obtained a HR for the association between
PPI use and MI of 1.17 (95% CI: 1.01–1.36). Standard implementa-
tion of the hd‐PS algorithm obtained a HR of 1.10 (95% CI: 0.88–
1.36), while applying our modifications resulted in effect estimates
closer to the expected null result (HR 0.99; 95% CI: 0.79–1.24). Sen-
sitivity analyses found that selecting fewer than 500 variables
improved the precision of effect estimates (HR 1.00; 95% CI:
0.86–1.18).
Conclusions: Use of hd‐PS provided improved adjustment for con-
founding compared with non‐hd approaches, suggesting hd‐PS
methods can be usefully applied in UK EHR data.
1216 | Evaluation of observational study
data with multi‐level propensity scores: The
planning process
Mary E. Ritchey1; Mary Anne Armstrong2; Shannon Hunter1;
Jiaxiao M. Shi3; Darios T. Getahun3; Fagen Xie3; Christoph Dierig4
1RTI Health Solutions, Research Triangle Park, NC; 2Kaiser Permanente
Northern California, Oakland, CA; 3Kaiser Permanente Southern
California, Pasadena, CA; 4Bayer AG, Berlin, Germany
Background: Pharmacoepidemiology database studies often utilize
propensity scores (PS) to adjust for confounding between two expo-
sure groups while reducing dimensionality by including fewer indepen-
dent variables within outcome models. A multi‐database study was
originally planned with a binary exposure, but then modified to 4
exposure levels at FDA request.
Objectives: To codify a process for shifting the design from a binary to
4‐level exposure, highlight considerations for discussion.
Methods: Three distinct parts of PS model development were
discussed in considering the change from binary to 4‐level exposure:
(1) determine the model to develop the PS, (2) assess balance in the
PS model, and (3) decide on whether and how to do trimming. The
FDA requested specific documentation of how covariate balance
would be assessed and achieved and how the 4‐level PS would be
incorporated into outcome models.
Results: After deciding that PS was still appropriate for the study, PS
model development was discussed. (1) Exposure levels could be
treated as ordinal or nominal; nominal and multinomial logistic regres-
sion models were chosen. (2) Balance could be assessed using stan-
dardized bias assessment (e.g., absolute standardized differences
[ASD]) either as summary measures or via pairwise comparisons
between all pairs of exposure levels (n = 6 comparisons) or as compar-
ison versus a single referent (n = 3 comparisons). Summary measures
could be created via averages, min/max of pairwise comparisons, or
as a composite score accounting for distance between all 4 levels
simultaneously. Pairwise comparisons versus the referent category of
ASD for all variables included in the PS model was chosen. If any
ASD was above 0.2, further refinement of the PS model would be
used. (3) Overlap could be considered as the range of PS covered by
any pair of exposure levels, the coverage between the referent and
each of the other 3 levels, or the coverage only for the range of PS
occurring in all 4 levels of the exposure. “Fully overlapping” regions
would be ideal for interpretation but would narrow the range of PS.
A broader PS range of any overlapping may be more robust analyti-
cally and was deemed appropriate for the primary analysis, with the
caveat that this would be revisited after examination of the data.
Conclusions: This process allowed the study team to discuss and
decide upon changes to PS model development to address regulatory
research questions.
1217 | Deep learning‐based propensity score
computation: Cohort study in second line
treated advanced non‐small cell lung cancer
(aNSCLC) patients
Janick Weberpals1; Tim Becker1; Fabian Schmich1;
Dominik Rüttinger1; Fabian Theis2,3; Anna Bauer‐Mehren1
1Roche Innovation Center Munich (RICM), Penzberg, Germany;
2Helmholtz Center Munich, Munich, Germany; 3Technical University of
Munich (TUM), Munich, Germany
Background: Autoencoders are unsupervised deep learning encoder‐
decoder architectures which learn a nonlinear lower‐dimensional fea-
ture representation from unlabelled data. Propensity score (PS) com-
putation utilizing autoencoder‐learned patient representations might
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be an attractive alternative to manual variable selection in
pharmacoepidemiology.
Objectives: To investigate and compare PS balancing and adjustment
generated from manual variable selection versus autoencoder‐derived
PS. To this end, both approaches were applied to replicate the result
of a meta‐analysis of randomized trials (RCTs) investigating the com-
parative effectiveness of checkpoint inhibitors (CPIs) versus docetaxel
as second line (2 L) treatment in aNSCLC patients.
Methods: Within the Flatiron Health EHR‐derived database, aNSCLC
patients were identified who initiated either CPI or docetaxel as 2 L
treatment. In a first approach, PS were computed using logistic
regression with manually selected variables. In a second approach,
representation learning among all 2 L treated patients was employed
using a 7‐layer symmetric autoencoder architecture with all available
baseline covariates as input vector. The learned patient embeddings
in the 64‐dimensional bottleneck layer were used within the
eligible aNSCLC study population to compute the PS via logistic
regression. In the final outcome model, overall survival (OS) was esti-
mated using Cox proportional hazards regression with trimmed and
stabilized PS weights. Balance in PS distributions for both settings
was graphically examined by plotting density functions before and
after weighting.
Results: The study population comprised 4,781 CPI and 900
docetaxel initiators. Kaplan–Meier analysis suggested a significant
survival benefit for CPI initiators with a median OS of 9.1 (95% CI
8.6–9.6) months compared to 6.1 (95% CI 5.5–6.6) months among
docetaxel initiators (p < .0001). Graphical comparison of PS overlap
between CPI and docetaxel initiators indicated well‐balanced cohorts
for both settings after PS weighting. In the adjusted analysis, both
approaches led to similar results with hazard ratios (HR) of 0.72
(95% CI 0.65–0.80) with manual variable selection and 0.75 (95%
CI 0.69–0.81) in the autoencoder setting. In comparison, the
meta‐analysis of RCTs resulted in an estimate of HR 0.69 (95% CI
0.63–0.75).
Conclusions: In line with RCTs, both PS computation approaches sim-
ilarly suggest a significantly enhanced OS among patients receiving 2 L
CPI therapy. Autoencoders might be alternatively used to derive PS in
a more automated way.
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